<SEC-DOCUMENT>0001554855-25-002032.txt : 20251113
<SEC-HEADER>0001554855-25-002032.hdr.sgml : 20251113
<ACCEPTANCE-DATETIME>20251113133101
ACCESSION NUMBER:		0001554855-25-002032
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		68
CONFORMED PERIOD OF REPORT:	20250930
FILED AS OF DATE:		20251113
DATE AS OF CHANGE:		20251113

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			60 DEGREES PHARMACEUTICALS, INC.
		CENTRAL INDEX KEY:			0001946563
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				452406880
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-41719
		FILM NUMBER:		251477100

	BUSINESS ADDRESS:	
		STREET 1:		1025 CONNECTICUT AVENUE NW
		STREET 2:		SUITE 1000
		CITY:			WASHINGTON
		STATE:			DC
		ZIP:			20036
		BUSINESS PHONE:		202-327-5422

	MAIL ADDRESS:	
		STREET 1:		1025 CONNECTICUT AVENUE NW
		STREET 2:		SUITE 1000
		CITY:			WASHINGTON
		STATE:			DC
		ZIP:			20036
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>sxtp-20250930.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--Created by IRIS Business Services_Direct, Powered by IRIS Carbon, Unique Code 691618107ea6641f94c6a05b, Generated At Thu, 13 Nov 2025 17:41:17 GMT-->
<html xmlns:srt="http://fasb.org/srt/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:ecd="http://xbrl.sec.gov/ecd/2025" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:currency="http://xbrl.sec.gov/currency/2025" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2024-01-31" xmlns:sxtp="http://60degreespharma.com/20250930" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns="http://www.w3.org/1999/xhtml"><head><title>sxtp-20250930.htm</title><meta http-equiv="Content-Type" content="text/html"/></head><body>
<div style="display: none;">
<ix:header>
<ix:hidden>












<ix:nonNumeric name="dei:DocumentFiscalYearFocus" contextRef="D20250930_1" id="Tag1004">2025</ix:nonNumeric>
<ix:nonNumeric name="dei:DocumentFiscalPeriodFocus" contextRef="D20250930_1" id="Tag1005">Q3</ix:nonNumeric>
<ix:nonNumeric name="dei:CurrentFiscalYearEndDate" contextRef="D20250930_1" id="Tag1006">--12-31</ix:nonNumeric>
<ix:nonNumeric name="dei:EntityCentralIndexKey" contextRef="D20250930_1" id="Tag1007">0001946563</ix:nonNumeric>
<ix:nonNumeric name="dei:AmendmentFlag" contextRef="D20250930_1" id="Tag1008">false</ix:nonNumeric>




<ix:nonNumeric name="us-gaap:LesseeOperatingLeaseRenewalTerm" contextRef="I20250930" format="ixt-sec:durwordsen" id="Tag1013">one year</ix:nonNumeric>
<ix:nonNumeric name="ecd:Rule10b51ArrAdoptedFlag" contextRef="D20250930" escape="false" id="Tag1014">false</ix:nonNumeric>
<ix:nonNumeric name="ecd:NonRule10b51ArrAdoptedFlag" contextRef="D20250930" escape="false" id="Tag1015">false</ix:nonNumeric>
<ix:nonNumeric name="ecd:Rule10b51ArrTrmntdFlag" contextRef="D20250930" escape="false" id="Tag1016">false</ix:nonNumeric>
<ix:nonNumeric name="ecd:NonRule10b51ArrTrmntdFlag" contextRef="D20250930" escape="false" id="Tag1017">false</ix:nonNumeric>


















<ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="D20250930_1" id="Tag1036">DC</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:href="sxtp-20250930.xsd" xlink:type="simple"/></ix:references><ix:resources><xbrli:context id="D20250331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="D20240331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="D20250930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="D20240930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="D20250930_1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="D20240930_1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="I20250930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="I20241231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="I20250930_SeriesAPreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="I20241231_SeriesAPreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="I20250930_LabEquipmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sxtp:LabEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="I20250930_MachineryAndEquipmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="I20250930_ComputerEquipmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="I20250930_FurnitureAndFixturesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="I20241231_LabEquipmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sxtp:LabEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="I20241231_MachineryAndEquipmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="I20241231_ComputerEquipmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="I20241231_FurnitureAndFixturesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="I20240930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="I20231231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="I20250930_PatentsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="I20250930_SoftwareAndSoftwareDevelopmentCostsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="D20240930_ResearchAndDevelopmentExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="D20250930_ResearchAndDevelopmentExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="D20250930_ResearchAndDevelopmentExpenseMember_1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="D20240930_ResearchAndDevelopmentExpenseMember_1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="D20250930_GeneralAndAdministrativeExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="D20250930_GeneralAndAdministrativeExpenseMember_1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="D20240930_GeneralAndAdministrativeExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="D20240930_GeneralAndAdministrativeExpenseMember_1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="I20250930_TwoThousandTwentyTwoEquityIncentivePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sxtp:TwoThousandTwentyTwoEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="I20250930_BoardOfDirectorsChairmanMember_StephenTooveyMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sxtp:StephenTooveyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="I20250930_PaulFieldMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sxtp:PaulFieldMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="I20250930_CharlesAllenMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sxtp:CharlesAllenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="I20250930_IPOMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="D20150715"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2015-07-15</xbrli:startDate><xbrli:endDate>2015-07-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="D20150715_BoardOfDirectorsChairmanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-07-15</xbrli:startDate><xbrli:endDate>2015-07-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="D20150715_USGovernmentSalesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sxtp:USGovernmentSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-07-15</xbrli:startDate><xbrli:endDate>2015-07-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="D20150715_USArmyAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sxtp:USArmyAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-07-15</xbrli:startDate><xbrli:endDate>2015-07-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="D20241220"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-12-20</xbrli:startDate><xbrli:endDate>2024-12-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="D20241220_MinimumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-12-20</xbrli:startDate><xbrli:endDate>2024-12-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="I20241220"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-12-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="D20241220_MaximumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-12-20</xbrli:startDate><xbrli:endDate>2024-12-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="D20250930_ShareBasedCompensationAwardTrancheOneMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="D20250930_CommonStockMember_RestrictedStockUnitsRSUMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="D20240930_CommonStockMember_RestrictedStockUnitsRSUMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="D20250930_RestrictedStockUnitsRSUMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="D20240930_RestrictedStockUnitsRSUMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="D20250120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-20</xbrli:startDate><xbrli:endDate>2025-01-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="D20241231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="I20200514_SmallBusinessAdministrationMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sxtp:SmallBusinessAdministrationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="I20200514_BalloonPaymentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sxtp:BalloonPaymentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="D20200514_SBAMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sxtp:SBAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-14</xbrli:startDate><xbrli:endDate>2020-05-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="D20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-31</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="I20220331_SeriesANonVotingConvertiblePreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sxtp:SeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="I20241231_FairValueMeasurementsRecurringMember_ContingentMilestonePaymentMember_FairValueInputsLevel3Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">sxtp:ContingentMilestonePaymentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="I20231231_FairValueMeasurementsRecurringMember_FairValueInputsLevel3Member_ContingentMilestonePaymentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">sxtp:ContingentMilestonePaymentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="D20240331_FairValueMeasurementsRecurringMember_ContingentMilestonePaymentMember_FairValueInputsLevel3Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">sxtp:ContingentMilestonePaymentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="I20240331_FairValueMeasurementsRecurringMember_ContingentMilestonePaymentMember_FairValueInputsLevel3Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">sxtp:ContingentMilestonePaymentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="I20241231_WarrantMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="D20250930_FairValueMeasurementsRecurringMember_ContingentMilestonePaymentMember_FairValueInputsLevel3Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">sxtp:ContingentMilestonePaymentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="D20250331_WarrantMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="I20250331_WarrantMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="I20250930_FairValueMeasurementsRecurringMember_ContingentMilestonePaymentMember_FairValueInputsLevel3Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">sxtp:ContingentMilestonePaymentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="I20240930_FairValueMeasurementsRecurringMember_ContingentMilestonePaymentMember_FairValueInputsLevel3Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">sxtp:ContingentMilestonePaymentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="D20250930_WarrantMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="I20250930_WarrantMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="D20240930_FairValueMeasurementsRecurringMember_ContingentMilestonePaymentMember_FairValueInputsLevel3Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">sxtp:ContingentMilestonePaymentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="I20231231_WarrantMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="D20240331_WarrantMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="I20240331_WarrantMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="D20240930_WarrantMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="D20250331_FairValueMeasurementsRecurringMember_ContingentMilestonePaymentMember_FairValueInputsLevel3Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">sxtp:ContingentMilestonePaymentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="I20240930_WarrantMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="I20250331_FairValueMeasurementsRecurringMember_ContingentMilestonePaymentMember_FairValueInputsLevel3Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">sxtp:ContingentMilestonePaymentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="I20250930_SeriesANonVotingConvertiblePreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sxtp:SeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="D20250218"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-02-18</xbrli:startDate><xbrli:endDate>2025-02-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="D20250128"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-28</xbrli:startDate><xbrli:endDate>2025-01-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="I20250128"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-01-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="D20250130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-30</xbrli:startDate><xbrli:endDate>2025-01-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="I20250131_PlacementAgentWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sxtp:PlacementAgentWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="D20250205"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-02-05</xbrli:startDate><xbrli:endDate>2025-02-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="I20250205"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-02-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="D20250205_CommonStockMember_WarrantMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-02-05</xbrli:startDate><xbrli:endDate>2025-02-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="I20250205_WarrantMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-02-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="D20250206"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-02-06</xbrli:startDate><xbrli:endDate>2025-02-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="I20250205_PlacementAgentWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sxtp:PlacementAgentWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-02-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="I20250930_CommonStockMember_1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="I20240930_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="D20240930_SeriesAPreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="D20250930_SeriesAPreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="I20250331_PreferredStockMember_SeriesAPreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="I20241231_PreferredStockMember_SeriesAPreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="I20250930_PreferredStockMember_SeriesAPreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="D20250331_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="I20241231_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="I20250331_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="D20250331_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="I20250331_RetainedEarningsUnappropriatedMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsUnappropriatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="D20250331_RetainedEarningsUnappropriatedMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsUnappropriatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="I20250331_AccumulatedOtherComprehensiveIncomeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="D20250331_AccumulatedOtherComprehensiveIncomeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="I20250331_ParentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="D20250331_ParentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="I20250331_NoncontrollingInterestMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="D20250331_NoncontrollingInterestMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="I20250331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="I20241231_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="I20241231_RetainedEarningsUnappropriatedMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsUnappropriatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="I20241231_AccumulatedOtherComprehensiveIncomeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="I20241231_ParentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="I20241231_NoncontrollingInterestMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="D20250930_CommonStockMember_3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="D20250930_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="I20250930_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="D20250930_RetainedEarningsUnappropriatedMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsUnappropriatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="I20250930_RetainedEarningsUnappropriatedMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsUnappropriatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="D20250930_AccumulatedOtherComprehensiveIncomeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="I20250930_AccumulatedOtherComprehensiveIncomeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="D20250930_ParentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="I20250930_ParentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="D20250930_NoncontrollingInterestMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="I20250930_NoncontrollingInterestMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="I20240930_PreferredStockMember_SeriesAPreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="I20240331_PreferredStockMember_SeriesAPreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="I20240331_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="D20240331_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="I20240331_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="D20240331_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="I20240331_RetainedEarningsUnappropriatedMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsUnappropriatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="D20240331_RetainedEarningsUnappropriatedMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsUnappropriatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="I20240331_AccumulatedOtherComprehensiveIncomeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="D20240331_AccumulatedOtherComprehensiveIncomeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="I20240331_ParentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="D20240331_ParentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="I20240331_NoncontrollingInterestMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="D20240331_NoncontrollingInterestMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="I20240331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="D20240930_PreferredStockMember_SeriesAPreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="D20240930_CommonStockMember_3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="D20240930_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="I20240930_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="D20240930_RetainedEarningsUnappropriatedMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsUnappropriatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="I20240930_RetainedEarningsUnappropriatedMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsUnappropriatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="D20240930_AccumulatedOtherComprehensiveIncomeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="I20240930_AccumulatedOtherComprehensiveIncomeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="D20240930_ParentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="I20240930_ParentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="D20240930_NoncontrollingInterestMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="I20240930_NoncontrollingInterestMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="D20241231_CustomerConcentrationRiskMember_SignificantCustomersMember_AccountsReceivableMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">sxtp:SignificantCustomersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-12-31</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="D20250930_CustomerConcentrationRiskMember_SignificantCustomersMember_SalesRevenueNetMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">sxtp:SignificantCustomersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="D20240930_CustomerConcentrationRiskMember_SignificantCustomersMember_SalesRevenueNetMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">sxtp:SignificantCustomersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="D20250930_CustomerConcentrationRiskMember_SignificantCustomersMember_SalesRevenueNetMember_1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">sxtp:SignificantCustomersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="D20240930_CustomerConcentrationRiskMember_SignificantCustomersMember_SalesRevenueNetMember_1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">sxtp:SignificantCustomersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="D20250930_USD"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="D20250930_USD_1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="I20250930_USD"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="D20240930_USD"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="D20240930_USD_1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="I20241231_USD"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="I20250930_FairValueInputsLevel1Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="I20250930_FairValueInputsLevel2Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="I20250930_FairValueInputsLevel3Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="I20250930_FairValueInputsLevel1Member_DerivativeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DerivativeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="I20250930_DerivativeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DerivativeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="I20250930_FairValueInputsLevel2Member_DerivativeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DerivativeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="I20250930_FairValueInputsLevel3Member_DerivativeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DerivativeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="I20241231_DerivativeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DerivativeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="I20241231_DerivativeMember_FairValueInputsLevel1Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DerivativeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="I20241231_DerivativeMember_FairValueInputsLevel2Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DerivativeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="I20241231_DerivativeMember_FairValueInputsLevel3Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DerivativeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="D20250930_RestrictedStockUnitsRSUMember_1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="I20250930_PreFundedWarrantMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sxtp:PreFundedWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="I20240930_PreFundedWarrantMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sxtp:PreFundedWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="D20250930_SeriesAPreferredStockMember_1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="D20240930_SeriesAPreferredStockMember_1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="I20231231_PreferredStockMember_SeriesAPreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="I20231231_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="I20231231_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="I20231231_RetainedEarningsUnappropriatedMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsUnappropriatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="I20231231_AccumulatedOtherComprehensiveIncomeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="I20231231_ParentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="I20231231_NoncontrollingInterestMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="I20241231_FairValueInputsLevel3Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="I20250331_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="D20231231_WarrantMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="I20241231_FairValueInputsLevel1Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="I20241231_FairValueInputsLevel2Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="D20250930_CustomerConcentrationRiskMember_SignificantCustomerOneMember_SalesRevenueNetMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">sxtp:SignificantCustomerOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="D20241231_WarrantMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="D20250930_CommonStockMember_5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="D20250930_WarrantMember_3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="D20241106"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-11-06</xbrli:startDate><xbrli:endDate>2024-11-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="D20250210"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-02-10</xbrli:startDate><xbrli:endDate>2025-02-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="D20250930_CustomerConcentrationRiskMember_SalesRevenueNetMember_SignificantCustomerOneMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">sxtp:SignificantCustomerOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="D20250930_CustomerConcentrationRiskMember_SalesRevenueNetMember_SignificantCustomerTwoMember_1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">sxtp:SignificantCustomerTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="D20250716_July2025OfferingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">sxtp:July2025OfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-16</xbrli:startDate><xbrli:endDate>2025-07-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="D20250930_CommonStockMember_RestrictedStockUnitsRSUMember_1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="D20240930_CommonStockMember_RestrictedStockUnitsRSUMember_1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="D20240930_RestrictedStockUnitsRSUMember_1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="D20240731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="D20240930_CommonStockMember_RestrictedStockUnitsRSUMember_3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="D20250930_CommonStockMember_RestrictedStockUnitsRSUMember_3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="D20250930_StockOptionsMember_1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sxtp:StockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="D20250930_CommonStockMember_RestrictedStockUnitsRSUMember_4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="D20240930_CommonStockMember_RestrictedStockUnitsRSUMember_4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="D20250930_CustomerConcentrationRiskMember_SignificantCustomersMember_AccountsReceivableMember_1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">sxtp:SignificantCustomersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-09-30</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="D20250930_CustomerConcentrationRiskMember_AccountsReceivableMember_SignificantCustomerOneMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">sxtp:SignificantCustomerOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-09-30</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="D20250930_CustomerConcentrationRiskMember_AccountsReceivableMember_SignificantCustomerTwoMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">sxtp:SignificantCustomerTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-09-30</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="D20250630_FairValueMeasurementsRecurringMember_ContingentMilestonePaymentMember_FairValueInputsLevel3Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">sxtp:ContingentMilestonePaymentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="I20240630_FairValueMeasurementsRecurringMember_ContingentMilestonePaymentMember_FairValueInputsLevel3Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">sxtp:ContingentMilestonePaymentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="D20240630_FairValueMeasurementsRecurringMember_ContingentMilestonePaymentMember_FairValueInputsLevel3Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">sxtp:ContingentMilestonePaymentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="I20250630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="D20250630_WarrantMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="I20250630_WarrantMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="D20250630_18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="D20240630_WarrantMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="I20240630_WarrantMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="D20240630_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="I20240630_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="D20240630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="I20240630_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="I20240630_RetainedEarningsUnappropriatedMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsUnappropriatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="I20240630_AccumulatedOtherComprehensiveIncomeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="I20240630_ParentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="I20240630_NoncontrollingInterestMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="I20240630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="D20240630_RetainedEarningsUnappropriatedMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsUnappropriatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="D20240630_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="D20240630_AccumulatedOtherComprehensiveIncomeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="D20240630_ParentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="D20240630_NoncontrollingInterestMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="D20250630_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="D20250630_RetainedEarningsUnappropriatedMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsUnappropriatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="I20250630_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="I20250630_RetainedEarningsUnappropriatedMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsUnappropriatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="D20250630_AccumulatedOtherComprehensiveIncomeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="I20250630_AccumulatedOtherComprehensiveIncomeMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="D20250630_ParentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="I20250630_ParentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="D20250630_NoncontrollingInterestMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="I20250630_NoncontrollingInterestMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="I20250630_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="I20250630_PreferredStockMember_SeriesAPreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="I20250630_FairValueMeasurementsRecurringMember_ContingentMilestonePaymentMember_FairValueInputsLevel3Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">sxtp:ContingentMilestonePaymentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="D20250715_July2025OfferingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">sxtp:July2025OfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-15</xbrli:startDate><xbrli:endDate>2025-07-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="I20250715_July2025OfferingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">sxtp:July2025OfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-07-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="I20250715_PreFundedWarrantMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sxtp:PreFundedWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-07-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="D20250715_PreFundedWarrantMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sxtp:PreFundedWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-15</xbrli:startDate><xbrli:endDate>2025-07-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="I20250715_JulyTwoThousandTwentyFivePreFundedWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sxtp:JulyTwoThousandTwentyFivePreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-07-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="I20250715_JulyTwoThousandTwentyFiveAOneWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sxtp:JulyTwoThousandTwentyFiveAOneWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-07-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="I20250715_JulyTwoThousandTwentyFiveATwoWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sxtp:JulyTwoThousandTwentyFiveATwoWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-07-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="D20250120_CommonStockMember_3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-20</xbrli:startDate><xbrli:endDate>2025-01-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="I20240630_PreferredStockMember_SeriesAPreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="I20240722_SeriesAPreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-07-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="I20240726_SeriesAPreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-07-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="D20240726_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-26</xbrli:startDate><xbrli:endDate>2024-07-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="D20240722_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-22</xbrli:startDate><xbrli:endDate>2024-07-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="I20240930_SeriesBWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sxtp:SeriesBWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="I20240930_SeriesAPreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="I20250930_ConvertibleCommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertibleCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="I20240930_ConvertibleCommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertibleCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="D20251008_SubsequentEventMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-10-08</xbrli:startDate><xbrli:endDate>2025-10-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="I20251008_SubsequentEventMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-10-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="D20250715_JulyTwoThousandTwentyFivePreFundedWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sxtp:JulyTwoThousandTwentyFivePreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-15</xbrli:startDate><xbrli:endDate>2025-07-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="D20250715_JulyTwoThousandTwentyFiveAOneWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sxtp:JulyTwoThousandTwentyFiveAOneWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-15</xbrli:startDate><xbrli:endDate>2025-07-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="D20240712_WallachBethCapitalLLCMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sxtp:WallachBethCapitalLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-12</xbrli:startDate><xbrli:endDate>2024-07-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="D20240801_WallachBethCapitalLLCMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sxtp:WallachBethCapitalLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-19</xbrli:startDate><xbrli:endDate>2024-08-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="I20250930_HCWainwrightAndCoLLCMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sxtp:HCWainwrightAndCoLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="D20240930_PreFundedWarrantMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sxtp:PreFundedWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-09-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="D20250930_PreFundedWarrantMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sxtp:PreFundedWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="I20250930_DirectorMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="D20250930_DirectorMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="D20250930_TuftsMedicalCenterAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sxtp:TuftsMedicalCenterAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="D20250731_PreFundedWarrantMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sxtp:PreFundedWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="D20250930_PreFundedWarrantMember_1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sxtp:PreFundedWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="D20240930_PreFundedWarrantMember_1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sxtp:PreFundedWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="I20250903_HCWainwrightAndCoLLCMember_AtTheMarket2025AgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sxtp:HCWainwrightAndCoLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">sxtp:AtTheMarket2025AgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="D20250930_HCWainwrightAndCoLLCMember_AtTheMarket2025AgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sxtp:HCWainwrightAndCoLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">sxtp:AtTheMarket2025AgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-09-30</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="D20251021_SubsequentEventMember_StockOptionsMember_DirectorMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sxtp:StockOptionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-10-21</xbrli:startDate><xbrli:endDate>2025-10-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="I20251021_SubsequentEventMember_StockOptionsMember_DirectorMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sxtp:StockOptionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-10-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="D20251021_SubsequentEventMember_StockOptionsMember_DirectorOneMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sxtp:StockOptionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">sxtp:DirectorOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-10-21</xbrli:startDate><xbrli:endDate>2025-10-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="D20240930_PreFundedWarrantMember_3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sxtp:PreFundedWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="D20240930_WarrantMember_1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="I20250715_JulyTwoThousandTwentyFivePlacementAgentWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sxtp:JulyTwoThousandTwentyFivePlacementAgentWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-07-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="D20250715_MaximumMember_JulyTwoThousandTwentyFivePlacementAgentWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sxtp:JulyTwoThousandTwentyFivePlacementAgentWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-15</xbrli:startDate><xbrli:endDate>2025-07-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="D20250715_JulyTwoThousandTwentyFiveATwoWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sxtp:JulyTwoThousandTwentyFiveATwoWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-15</xbrli:startDate><xbrli:endDate>2025-07-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="D20250715_JulyTwoThousandTwentyFivePlacementAgentWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sxtp:JulyTwoThousandTwentyFivePlacementAgentWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-15</xbrli:startDate><xbrli:endDate>2025-07-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="D20240930_SeriesAWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sxtp:SeriesAWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-09-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="D20240930_SeptemberTwoThousandTwentyFourAgentWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sxtp:SeptemberTwoThousandTwentyFourAgentWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-09-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="D20240930_SeriesBWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sxtp:SeriesBWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-09-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="I20250331_PreFundedWarrantMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sxtp:PreFundedWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="I20250630_PreFundedWarrantMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sxtp:PreFundedWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="D20250930_CustomerConcentrationRiskMember_SignificantCustomersMember_AccountsReceivableOrSalesRevenueNetMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">sxtp:SignificantCustomersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">sxtp:AccountsReceivableOrSalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="D20250224"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-02-24</xbrli:startDate><xbrli:endDate>2025-02-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="I20251113"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-11-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="D20251113_SubsequentEventMember_HCWainwrightAndCoLLCMember_AtTheMarket2025AgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sxtp:HCWainwrightAndCoLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">sxtp:AtTheMarket2025AgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-10-16</xbrli:startDate><xbrli:endDate>2025-11-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="D20250903_WallachBethCapitalLLCMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001946563</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sxtp:WallachBethCapitalLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-09-03</xbrli:startDate><xbrli:endDate>2025-09-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="Shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="Pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="USDPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="Number"><xbrli:measure>sxtp:Number</xbrli:measure></xbrli:unit><xbrli:unit id="Director"><xbrli:measure>sxtp:Director</xbrli:measure></xbrli:unit>
<ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tag996" toRefs="footnote0"/>
<ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tag997" toRefs="footnote0"/>
<ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tag998" toRefs="footnote0"/>
<ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tag1000" toRefs="footnote1"/>
<ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tag1001" toRefs="footnote1"/>
<ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tag1002" toRefs="footnote1"/>
<ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tag1003" toRefs="footnote1"/>
<ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tag1009" toRefs="footnote0"/>
<ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tag241" toRefs="footnote0"/>
<ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tag242" toRefs="footnote0"/>
<ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tag243" toRefs="footnote0"/>
<ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tag244" toRefs="footnote0"/>
<ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tag433" toRefs="footnote0"/>
<ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tag434" toRefs="footnote0"/>
<ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tag431" toRefs="footnote0"/>
<ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tag432" toRefs="footnote0"/>
<ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tag520" toRefs="footnote1"/>
<ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tag521" toRefs="footnote1"/>
<ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tag522" toRefs="footnote1"/>
<ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tag523" toRefs="footnote1"/>
<ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tag232" toRefs="footnote2"/>
<ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tag233" toRefs="footnote2"/>
<ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tag234" toRefs="footnote2"/>
<ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tag226" toRefs="footnote3"/>
<ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tag227" toRefs="footnote3"/>
<ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tag228" toRefs="footnote3"/>
<ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tag216" toRefs="footnote4"/>
<ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tag215" toRefs="footnote4"/>
<ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tag217" toRefs="footnote4"/>
<ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tag231" toRefs="footnote5"/>
<ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tag230" toRefs="footnote5"/>
<ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tag229" toRefs="footnote5"/></ix:resources></ix:header></div><div class="content_container" style="font-family:'Times New Roman' !important; font-size:12pt"><div class="Section_1"><table cellspacing="0" cellpadding="0" style="width:100%; border-collapse:collapse"><tbody><tr style="height:1pt"><td style="width:100%; border-top:1.5pt solid #000000; border-bottom:0.75pt solid #000000; vertical-align:top; -aw-border-bottom:0.5pt single"><p style="margin-top:0pt; margin-bottom:0pt; font-size:1pt"><span id="EXH_68a5582bc0bf431834c5ad8f"></span><span style="font-weight:bold; -aw-import:ignore">&#160;</span></p></td></tr></tbody></table><p style="margin-top:10pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold">UNITED STATES</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold">SECURITIES AND EXCHANGE COMMISSION</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold">WASHINGTON, D.C. 20549</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-variant:small-caps">Form </span><span style="-aw-sdt-tag:'c51083aa65211e63d713'"><span style="font-weight:bold; font-family: 'Times New Roman'"><ix:nonNumeric name="dei:DocumentType" contextRef="D20250930_1" id="Tag923">10-Q</ix:nonNumeric></span></span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold">(Mark One)</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="-aw-sdt-tag:'c6a2fff4fc67a03c5d3c'"><span style="font-family:'Segoe UI Symbol'"><ix:nonNumeric name="dei:DocumentQuarterlyReport" contextRef="D20250930_1" format="ixt-sec:boolballotbox" id="Tag932">&#9746;</ix:nonNumeric></span></span><span> </span><span style="font-weight:bold">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold">FOR THE QUARTERLY PERIOD ENDED </span><span style="-aw-sdt-tag:'547-f12-35e-9f8-6830'; -aw-sdt-title:'Current_Period_P38'"><span style="font-weight:bold; font-family: 'Times New Roman'"><ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="D20250930_1" format="ixt:date-monthname-day-year-en" id="Tag949">September 30, 2025</ix:nonNumeric></span></span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold">or</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="-aw-sdt-tag:'c86605ae33c3f13f0c7e'"><span style="font-family:'Segoe UI Symbol'"><ix:nonNumeric name="dei:DocumentTransitionReport" contextRef="D20250930_1" format="ixt-sec:boolballotbox" id="Tag933">&#9744;</ix:nonNumeric></span></span><span> </span><span style="font-weight:bold">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold">FOR THE TRANSITION PERIOD FROM _________ to __________</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold">COMMISSION FILE NUMBER </span><span style="-aw-sdt-tag:'ca4889229b908d09601d'"><span style="font-weight:bold; font-family: 'Times New Roman'"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="D20250930_1" id="Tag924">001-41719</ix:nonNumeric></span></span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold">&#160;</span></p><div style="-aw-sdt-tag:'c2da3069359df88e7d98'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'"><ix:nonNumeric name="dei:EntityRegistrantName" contextRef="D20250930_1" id="Tag969">60 DEGREES PHARMACEUTICALS, INC.</ix:nonNumeric></span></p></div><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span>(Exact name of registrant as specified in its charter)</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span>&#160;</span></p><table cellspacing="0" cellpadding="0" style="width:100%; border-collapse:collapse"><tbody><tr><td style="width:49%; border-bottom:1.5pt solid #000000; vertical-align:bottom"><div style="-aw-sdt-tag:'c5d4237aa656591afc7f'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="D20250930_1" format="ixt-sec:stateprovnameen" id="Tag709">Delaware</ix:nonNumeric></span></p></div></td><td style="width:2%; vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span>&#160;</span></p></td><td style="width:49%; border-bottom:1.5pt solid #000000; vertical-align:bottom"><div style="-aw-sdt-tag:'c66e4dcfd81989b5d525'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="D20250930_1" id="Tag710">45-2406880</ix:nonNumeric></span></p></div></td></tr><tr><td style="border-top:1.5pt solid #000000; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span>(State or other jurisdiction of</span><br/><span>incorporation or organization) </span></p></td><td style="vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span>&#160;</span></p></td><td style="border-top:1.5pt solid #000000; vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span>(I.R.S. Employer</span><br/><span>Identification No.)</span></p></td></tr></tbody></table><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span>&#160;</span></p><table cellspacing="0" cellpadding="0" style="width:100%; border-collapse:collapse"><tbody><tr><td style="width:49%; border-bottom:1.5pt solid #000000; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="-aw-sdt-tag:'c76c9fc96e87bc545609'"><span style="font-weight:bold; font-family: 'Times New Roman'"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="D20250930_1" id="Tag443">1025 Connecticut Avenue</ix:nonNumeric></span></span><span style="font-weight:bold"> </span><span style="-aw-sdt-tag:'c60f1744a79446451553'"><span style="font-weight:bold; font-family: 'Times New Roman'"><ix:nonNumeric name="dei:EntityAddressAddressLine2" contextRef="D20250930_1" id="Tag444">NW Suite 1000</ix:nonNumeric></span></span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="-aw-sdt-tag:'38b-435-98b-4aa-ca77'"><span style="font-weight:bold; font-family: 'Times New Roman'"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="D20250930_1" id="Tag708">Washington</ix:nonNumeric></span></span><span style="font-weight:bold">, </span><span style="-sec-ix-hidden:Tag1036;-aw-sdt-tag:'e78-61c-91f-f3f-bd38';"><span style="font-weight:bold; font-family: 'Times New Roman'">D.C.</span></span><span style="font-weight:bold"> </span><span style="-aw-sdt-tag:'c397ac6e42322bf3b0f9'"><span style="font-weight:bold; font-family: 'Times New Roman'"><ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="D20250930_1" id="Tag445">20036</ix:nonNumeric></span></span></p></td><td style="width:2%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span>&#160;</span></p></td><td style="width:49%; border-bottom:1.5pt solid #000000; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold">(</span><span style="-aw-sdt-tag:'c0f2de670bd3a1c54156'"><span style="font-weight:bold; font-family: 'Times New Roman'"><ix:nonNumeric name="dei:CityAreaCode" contextRef="D20250930_1" id="Tag446">202</ix:nonNumeric></span></span><span style="font-weight:bold">) </span><span style="-aw-sdt-tag:'cdf49510fe80e6f8888e'"><span style="font-weight:bold; font-family: 'Times New Roman'"><ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="D20250930_1" id="Tag447">327-5422</ix:nonNumeric></span></span></p></td></tr><tr><td style="border-top:1.5pt solid #000000; vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span>(Address of principal executive offices) (Zip Code)</span></p></td><td style="vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span>&#160;</span></p></td><td style="border-top:1.5pt solid #000000; vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span>(Registrant&#8217;s telephone number, including area code)</span></p></td></tr></tbody></table><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span>&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span>Securities registered pursuant to Section 12(b) of the Act:</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span>&#160;</span></p><table cellspacing="0" cellpadding="0" style="width:100%; border-collapse:collapse"><tbody><tr><td style="width:32%; border-bottom:1.5pt solid #000000; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold">Title of each class</span></p></td><td style="width:2%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span>&#160;</span></p></td><td style="width:32%; border-bottom:1.5pt solid #000000; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold">Trading Symbol(s)</span></p></td><td style="width:2%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span>&#160;</span></p></td><td style="width:32%; border-bottom:1.5pt solid #000000; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold">Name of each exchange on which registered</span></p></td></tr><tr><td style="border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-tag:'c1fa18e38496c91f5cf2'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonNumeric name="dei:Security12bTitle" contextRef="D20250930_CommonStockMember_5" id="Tag714">Common Stock, par value $0.0001 per share</ix:nonNumeric></span></p></div></td><td style="vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span>&#160;</span></p></td><td style="border-top:1.5pt solid #000000; vertical-align:top; background-color:#cceeff"><div style="-aw-sdt-tag:'ccef664db2b0437e2559'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonNumeric name="dei:TradingSymbol" contextRef="D20250930_CommonStockMember_5" id="Tag715">SXTP</ix:nonNumeric></span></p></div></td><td style="vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span>&#160;</span></p></td><td style="border-top:1.5pt solid #000000; vertical-align:top; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span>The </span><span style="-aw-sdt-tag:'c4b3e0e03b729b53a9e9'"><span style="font-family: 'Times New Roman';"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="D20250930_CommonStockMember_5" format="ixt-sec:exchnameen" id="Tag484">Nasdaq</ix:nonNumeric></span></span><span> Stock Market LLC</span></p></td></tr><tr><td style="vertical-align:bottom"><div style="-aw-sdt-tag:'c04ec91df0cedabbae76'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonNumeric name="dei:Security12bTitle" contextRef="D20250930_WarrantMember_3" id="Tag716">Warrants, each warrant to purchase one share of Common Stock</ix:nonNumeric></span></p></div></td><td style="vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span>&#160;</span></p></td><td style="vertical-align:top"><div style="-aw-sdt-tag:'cb41e4afe6c6be82c77b'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonNumeric name="dei:TradingSymbol" contextRef="D20250930_WarrantMember_3" id="Tag717">SXTPW</ix:nonNumeric></span></p></div></td><td style="vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span>&#160;</span></p></td><td style="vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span>The </span><span style="-aw-sdt-tag:'cbd4aca687b914bd4d27'"><span style="font-family: 'Times New Roman';"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="D20250930_WarrantMember_3" format="ixt-sec:exchnameen" id="Tag485">Nasdaq</ix:nonNumeric></span></span><span> Stock Market LLC</span></p></td></tr></tbody></table><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes </span><span style="-aw-sdt-tag:'c96e992ce1670a4fdf4e'"><span style="font-family:'Segoe UI Symbol'"><ix:nonNumeric name="dei:EntityCurrentReportingStatus" contextRef="D20250930_1" format="ixt-sec:yesnoballotbox" id="Tag925">&#9746;</ix:nonNumeric></span></span><span> No </span><span style="font-family:'Segoe UI Symbol'">&#9744;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes </span><span style="-aw-sdt-tag:'ce22a1248f7ff4c4445e'"><span style="font-family:'Segoe UI Symbol'"><ix:nonNumeric name="dei:EntityInteractiveDataCurrent" contextRef="D20250930_1" format="ixt-sec:yesnoballotbox" id="Tag926">&#9746;</ix:nonNumeric></span></span><span> No </span><span style="font-family:'Segoe UI Symbol'">&#9744;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>&#160;</span></p><table cellspacing="0" cellpadding="0" style="width:100%; border-collapse:collapse"><tbody><tr><td style="width:25%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span>Large accelerated filer</span></p></td><td style="width:5%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family:'Segoe UI Symbol'">&#9744;</span></p></td><td style="width:40%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span>&#160;</span></p></td><td style="width:25%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span>Accelerated filer</span></p></td><td style="width:5%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family:'Segoe UI Symbol'">&#9744;</span></p></td></tr><tr style="height:4.55pt"><td style="vertical-align:bottom"><div style="-aw-sdt-tag:'ce7652ce3b06eb4f7f79'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonNumeric name="dei:EntityFilerCategory" contextRef="D20250930_1" format="ixt-sec:entityfilercategoryen" id="Tag711">Non-accelerated filer</ix:nonNumeric></span></p></div></td><td style="vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family:'Segoe UI Symbol'">&#9746;</span></p></td><td style="vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span>&#160;</span></p></td><td style="vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span>Smaller reporting company</span></p></td><td style="vertical-align:bottom"><div style="-aw-sdt-tag:'cdf7fce6299c91ac30d9'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family:'Segoe UI Symbol'"><ix:nonNumeric name="dei:EntitySmallBusiness" contextRef="D20250930_1" format="ixt-sec:boolballotbox" id="Tag712">&#9746;</ix:nonNumeric></span></p></div></td></tr><tr><td style="vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span>&#160;</span></p></td><td style="vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span>&#160;</span></p></td><td style="vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span>&#160;</span></p></td><td style="vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span>Emerging growth company</span></p></td><td style="vertical-align:bottom"><div style="-aw-sdt-tag:'c923ae758678a29b18f2'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family:'Segoe UI Symbol'"><ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="D20250930_1" format="ixt-sec:boolballotbox" id="Tag713">&#9746;</ix:nonNumeric></span></p></div></td></tr></tbody></table><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="-aw-sdt-tag:'689-8a0-0a5-d78-f005'"><span style="font-family:'Segoe UI Symbol'"><ix:nonNumeric name="dei:EntityExTransitionPeriod" contextRef="D20250930_1" format="ixt-sec:boolballotbox" id="Tag951">&#9744;</ix:nonNumeric></span></span></p><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span>&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act) Yes </span><span style="-aw-sdt-tag:'c18a08bc7f1e26ab2a7f'"><span style="font-family:'Segoe UI Symbol'"><ix:nonNumeric name="dei:EntityShellCompany" contextRef="D20250930_1" format="ixt-sec:boolballotbox" id="Tag927">&#9744;</ix:nonNumeric></span></span><span> No </span><span style="font-family:'Segoe UI Symbol'">&#9746;</span></p><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span>&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>As of </span><span style="-aw-sdt-tag:'c27e973d191bf1670586'; -aw-sdt-title:'Shares_Outstanding_Date_P1'"><span style="font-family: 'Times New Roman';">November 13, 2025</span></span><span> the registrant had a total of </span><span style="-aw-sdt-tag:'ce5-12a-99e-b9f-68e6'; -aw-sdt-title:'Shares Outstanding at FS Issuance'"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" contextRef="I20251113" unitRef="Shares" decimals="0" format="ixt:num-dot-decimal" id="Tag962">4,230,448</ix:nonFraction></span></span><span> shares of its common stock, par value $0.0001 per share, issued and shares outstanding.</span></p><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore">&#160;</span></p><table cellspacing="0" cellpadding="0" style="width:99.9%; border-collapse:collapse"><tbody><tr style="height:1pt"><td style="width:100%; border-top:0.75pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:top; -aw-border-top:0.5pt single"><p style="margin-top:0pt; margin-bottom:0pt; font-size:1pt"><span style="-aw-import:ignore">&#160;</span></p></td></tr></tbody></table><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="-aw-import:ignore">&#160;</span></p><div><hr style="width: 100%; color: #000000; background-color: #000000; margin: 1rem 0;"/></div><p style="margin-top:0pt; margin-bottom:0pt"><span style="-aw-import:spaces">&#160;</span></p></div><div class="Section_2"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold">INDEX</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold">&#160;</span></p><table cellspacing="0" cellpadding="0" style="width:100%; border-collapse:collapse"><tbody><tr><td colspan="2" style="vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span id="TOC_TableofContent"><span>&#160;</span></span></p></td><td style="border-bottom:1.5pt solid #000000; vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold">Page</span></p></td></tr><tr><td colspan="2" style="vertical-align:top; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center"><a href="#TOC_c05d4a0c45d7836a5c8b" style="text-decoration:none"><span style="font-size:10pt; text-decoration:underline; color:#0000ff">PART I. FINANCIAL INFORMATION</span></a></p></td><td style="vertical-align:top; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'TPG-TOC_c05d4a0c45d7836a5c8b'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-family: 'Times New Roman';">1</span></p></div></td></tr><tr><td style="width:9%; vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span>Item 1.</span></p></td><td style="width:82%; padding-left:9.5pt; vertical-align:top"><p style="margin-top:0pt; margin-left:9pt; margin-bottom:0pt; text-indent:-9pt"><a href="#TOC_c0f8866b9a43f79d5200" style="text-decoration:none"><span style="font-size:10pt; text-decoration:underline; color:#0000ff">Consolidated Condensed Financial Statements (unaudited)</span></a></p></td><td style="width:9%; vertical-align:top"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'TPG-TOC_c0f8866b9a43f79d5200'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-family: 'Times New Roman';">1</span></p></div></td></tr><tr><td style="vertical-align:top; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span>&#160;</span></p></td><td style="padding-left:9.5pt; vertical-align:top; background-color:#cceeff"><p style="margin-top:0pt; margin-left:9pt; margin-bottom:0pt; text-indent:-9pt"><a href="#TOC_cb14c1d383054445acd2" style="text-decoration:none"><span style="font-size:10pt; text-decoration:underline; color:#0000ff">Consolidated Condensed Balance Sheets </span></a></p></td><td style="vertical-align:top; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'TPG-TOC_cb14c1d383054445acd2'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-family: 'Times New Roman';">1</span></p></div></td></tr><tr><td style="vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span>&#160;</span></p></td><td style="padding-left:9.5pt; vertical-align:top"><div style="-aw-sdt-tag:'fd4-06b-935-04d-5e4a'"><p style="margin-top:0pt; margin-left:9pt; margin-bottom:0pt; text-indent:-9pt"><a href="#TOC_c5a6f75c3f8d1a4a4c18" style="text-decoration:none"><span style="font-size:10pt; text-decoration:underline; color:#0000ff; font-family: 'Times New Roman'">Consolidated Condensed Statements of Operations and Comprehensive Loss</span></a></p></div></td><td style="vertical-align:top"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'TPG-TOC_c5a6f75c3f8d1a4a4c18'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-family: 'Times New Roman';">2</span></p></div></td></tr><tr><td style="vertical-align:top; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span>&#160;</span></p></td><td style="padding-left:9.5pt; vertical-align:top; background-color:#cceeff"><p style="margin-top:0pt; margin-left:9pt; margin-bottom:0pt; text-indent:-9pt"><a href="#TOC_cc19643ebb8455de0f81" style="text-decoration:none"><span style="font-size:10pt; text-decoration:underline; color:#0000ff">Consolidated Condensed Statements of Shareholders&#8217; Equity </span></a></p></td><td style="vertical-align:top; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'TPG-TOC_cc19643ebb8455de0f81'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-family: 'Times New Roman';">3</span></p></div></td></tr><tr><td style="vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span>&#160;</span></p></td><td style="padding-left:9.5pt; vertical-align:top"><p style="margin-top:0pt; margin-left:9pt; margin-bottom:0pt; text-indent:-9pt"><a href="#TOC_c4ba879b2cbf15949667" style="text-decoration:none"><span style="font-size:10pt; text-decoration:underline; color:#0000ff">Consolidated Condensed Statements of Cash Flows</span></a></p></td><td style="vertical-align:top"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'TPG-TOC_c4ba879b2cbf15949667'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-family: 'Times New Roman';">5</span></p></div></td></tr><tr><td style="vertical-align:top; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span>&#160;</span></p></td><td style="padding-left:9.5pt; vertical-align:top; background-color:#cceeff"><p style="margin-top:0pt; margin-left:9pt; margin-bottom:0pt; text-indent:-9pt"><a href="#TOC_c2ad382b9a9434be612a" style="text-decoration:none"><span style="font-size:10pt; text-decoration:underline; color:#0000ff">Notes to Consolidated Condensed Financial Statements </span></a></p></td><td style="vertical-align:top; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'TPG-TOC_c2ad382b9a9434be612a'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-family: 'Times New Roman';">6</span></p></div></td></tr><tr><td style="vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span>Item 2.</span></p></td><td style="padding-left:9.5pt; vertical-align:top"><p style="margin-top:0pt; margin-left:9pt; margin-bottom:0pt; text-indent:-9pt"><a href="#TOC_cf05ecac3ce0c1336e68" style="text-decoration:none"><span style="font-size:10pt; text-decoration:underline; color:#0000ff">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations </span></a></p></td><td style="vertical-align:top"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'TPG-TOC_cf05ecac3ce0c1336e68'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-family: 'Times New Roman';">25</span></p></div></td></tr><tr><td style="vertical-align:top; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span>Item 3.</span></p></td><td style="padding-left:9.5pt; vertical-align:top; background-color:#cceeff"><p style="margin-top:0pt; margin-left:9pt; margin-bottom:0pt; text-indent:-9pt"><a href="#TOC_c048e7bcdce9d8c360e2" style="text-decoration:none"><span style="font-size:10pt; text-decoration:underline; color:#0000ff">Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td><td style="vertical-align:top; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'TPG-TOC_c048e7bcdce9d8c360e2'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-family: 'Times New Roman';">38</span></p></div></td></tr><tr><td style="vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span>Item 4.</span></p></td><td style="padding-left:9.5pt; vertical-align:top"><p style="margin-top:0pt; margin-left:9pt; margin-bottom:0pt; text-indent:-9pt"><a href="#TOC_c44a338213ccfed10dc0" style="text-decoration:none"><span style="font-size:10pt; text-decoration:underline; color:#0000ff">Controls and Procedures</span></a></p></td><td style="vertical-align:top"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'TPG-TOC_c44a338213ccfed10dc0'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-family: 'Times New Roman';">38</span></p></div></td></tr><tr><td colspan="2" style="vertical-align:top; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center"><a href="#TOC_c3d00586ee10cdb846f0" style="text-decoration:none"><span style="font-size:10pt; text-decoration:underline; color:#0000ff">PART II. OTHER INFORMATION</span></a></p></td><td style="vertical-align:top; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'TPG-TOC_c3d00586ee10cdb846f0'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-family: 'Times New Roman';">39</span></p></div></td></tr><tr><td style="vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span>Item 1.</span></p></td><td style="padding-left:9.5pt; vertical-align:top"><p style="margin-top:0pt; margin-left:9pt; margin-bottom:0pt; text-indent:-9pt"><a href="#TOC_ccead316ceadde1ebbd5" style="text-decoration:none"><span style="font-size:10pt; text-decoration:underline; color:#0000ff">Legal Proceedings</span></a></p></td><td style="vertical-align:top"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'TPG-TOC_ccead316ceadde1ebbd5'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-family: 'Times New Roman';">39</span></p></div></td></tr><tr><td style="vertical-align:top; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span>Item 1A.</span></p></td><td style="padding-left:9.5pt; vertical-align:top; background-color:#cceeff"><p style="margin-top:0pt; margin-left:9pt; margin-bottom:0pt; text-indent:-9pt"><a href="#TOC_c340f91f4051b8348248" style="text-decoration:none"><span style="font-size:10pt; text-decoration:underline; color:#0000ff">Risk Factors</span></a></p></td><td style="vertical-align:top; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'TPG-TOC_c340f91f4051b8348248'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-family: 'Times New Roman';">39</span></p></div></td></tr><tr><td style="vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span>Item 2.</span></p></td><td style="padding-left:9.5pt; vertical-align:top"><p style="margin-top:0pt; margin-left:9pt; margin-bottom:0pt; text-indent:-9pt"><a href="#TOC_c97dbd053b8428a29933" style="text-decoration:none"><span style="font-size:10pt; text-decoration:underline; color:#0000ff">Unregistered Sales of Equity Securities and Use of Proceeds</span></a></p></td><td style="vertical-align:top"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'TPG-TOC_c97dbd053b8428a29933'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-family: 'Times New Roman';">39</span></p></div></td></tr><tr><td style="vertical-align:top; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span>Item 3.</span></p></td><td style="padding-left:9.5pt; vertical-align:top; background-color:#cceeff"><p style="margin-top:0pt; margin-left:9pt; margin-bottom:0pt; text-indent:-9pt"><a href="#TOC_c30ae60e8b69047e149e" style="text-decoration:none"><span style="font-size:10pt; text-decoration:underline; color:#0000ff">Defaults Upon Senior Securities</span></a></p></td><td style="vertical-align:top; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'TPG-TOC_c30ae60e8b69047e149e'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-family: 'Times New Roman';">41</span></p></div></td></tr><tr><td style="vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span>Item 4.</span></p></td><td style="padding-left:9.5pt; vertical-align:top"><p style="margin-top:0pt; margin-left:9pt; margin-bottom:0pt; text-indent:-9pt"><a href="#TOC_c111a0a3b652434a3acf" style="text-decoration:none"><span style="font-size:10pt; text-decoration:underline; color:#0000ff">Mine Safety Disclosures</span></a></p></td><td style="vertical-align:top"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'TPG-TOC_c111a0a3b652434a3acf'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-family: 'Times New Roman';">41</span></p></div></td></tr><tr><td style="vertical-align:top; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span>Item 5.</span></p></td><td style="padding-left:9.5pt; vertical-align:top; background-color:#cceeff"><p style="margin-top:0pt; margin-left:9pt; margin-bottom:0pt; text-indent:-9pt"><a href="#TOC_c8282f48d1dc5f58e236" style="text-decoration:none"><span style="font-size:10pt; text-decoration:underline; color:#0000ff">Other Information</span></a></p></td><td style="vertical-align:top; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'TPG-TOC_c8282f48d1dc5f58e236'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-family: 'Times New Roman';">41</span></p></div></td></tr><tr><td style="vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span>Item 6.</span></p></td><td style="padding-left:9.5pt; vertical-align:top"><p style="margin-top:0pt; margin-left:9pt; margin-bottom:0pt; text-indent:-9pt"><a href="#TOC_cc8115f676224bc17698" style="text-decoration:none"><span style="font-size:10pt; text-decoration:underline; color:#0000ff">Exhibits</span></a></p></td><td style="vertical-align:top"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'TPG-TOC_cc8115f676224bc17698'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-family: 'Times New Roman';">42</span></p></div></td></tr><tr><td colspan="2" style="vertical-align:top; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt"><a href="#TOC_c410221d0afbca7d34bd" style="text-decoration:none"><span style="font-size:10pt; text-decoration:underline; color:#0000ff">SIGNATURES</span></a></p></td><td style="vertical-align:top; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'TPG-TOC_c410221d0afbca7d34bd'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-family: 'Times New Roman';">43</span></p></div></td></tr></tbody></table><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-bookmark-end:TOC_TableofContent"></span><span>&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span>i</span></p><div><hr style="width: 100%; color: #000000; background-color: #000000; margin: 1rem 0;"/></div><p style="margin-top:0pt; margin-bottom:0pt"><span style="-aw-import:spaces">&#160;</span></p></div><div class="Section_3"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold">CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>This Quarterly Report on Form 10-Q (this &#8220;Quarterly Report&#8221;) contains &#8220;forward-looking statements&#8221; within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), and Section 21E of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;). We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends impacting the financial condition of our business. Forward-looking statements should not be read as a guarantee of future performance or results and will not necessarily be accurate indications of the times at, or by, which such performance or results will be achieved. Forward-looking statements are based on information available at the time those statements are made and/or management&#8217;s good faith belief as of that time with respect to future events and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-indent:18pt; text-align:justify; font-size:10pt"><span>&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>Forward-looking statements include all statements that are not historical facts. In some cases, you can identify forward-looking statements by terms such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;could,&#8221; &#8220;would,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;seek,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;project,&#8221; &#8220;predict,&#8221; &#8220;potential,&#8221; &#8220;might,&#8221; &#8220;forecast,&#8221; &#8220;continue,&#8221; or the negative of those terms, and similar expressions and comparable terminology intended to reference future periods. Forward-looking statements include, but are not limited to, statements about:</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-indent:18pt; text-align:justify; font-size:10pt"><span>&#160;</span></p><table cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="width:18pt; vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-import:ignore">&#160;</span></p></td><td style="width:18pt; vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span>&#9679;</span></p></td><td style="vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>Our ability to effectively operate our business segment;</span></p></td></tr></tbody></table><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span>&#160;</span></p><table cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="width:18pt; vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-import:ignore">&#160;</span></p></td><td style="width:18pt; vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span>&#9679;</span></p></td><td style="vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>Our ability to manage our research, development, expansion, growth and operating expenses;</span></p></td></tr></tbody></table><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span>&#160;</span></p><table cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="width:18pt; vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-import:ignore">&#160;</span></p></td><td style="width:18pt; vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span>&#9679;</span></p></td><td style="vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>Our ability to evaluate and measure our business, prospects and performance metrics;</span></p></td></tr></tbody></table><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span>&#160;</span></p><table cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="width:18pt; vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-import:ignore">&#160;</span></p></td><td style="width:18pt; vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span>&#9679;</span></p></td><td style="vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>Our ability to compete, directly and indirectly, and succeed in a highly competitive and evolving industry;</span></p></td></tr></tbody></table><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span>&#160;</span></p><table cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="width:18pt; vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-import:ignore">&#160;</span></p></td><td style="width:18pt; vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span>&#9679;</span></p></td><td style="vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>Our ability to respond and adapt to changes in technology and customer behavior; and</span></p></td></tr></tbody></table><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span>&#160;</span></p><table cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="width:18pt; vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-import:ignore">&#160;</span></p></td><td style="width:18pt; vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span>&#9679;</span></p></td><td style="vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>Our ability to protect our intellectual property and to develop, maintain and enhance a strong brand.</span></p></td></tr></tbody></table><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span>&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>Should one or more of these risks or uncertainties materialize, or should the underlying assumptions prove incorrect, actual results may differ significantly from those anticipated, believed, estimated, expected, intended or planned.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-indent:18pt; text-align:justify; font-size:10pt"><span>&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We cannot guarantee future results, levels of activity, performance or achievements. Accordingly, the forward-looking statements in this Quarterly Report should not be regarded as representations that the results or conditions described in such statements will occur or that our objectives and plans will be achieved, and we do not assume any responsibility for the accuracy or completeness of any of these forward-looking statements.</span></p><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span>ii</span></p><div><hr style="width: 100%; color: #000000; background-color: #000000; margin: 1rem 0;"/></div><p style="margin-top:0pt; margin-bottom:0pt"><span style="-aw-import:spaces">&#160;</span></p></div><div class="Section_4"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span id="TOC_c05d4a0c45d7836a5c8b"><span style="font-weight:bold">PART I - FINANCIAL INFORMATION</span></span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="-aw-bookmark-end:TOC_c05d4a0c45d7836a5c8b"></span><span style="font-weight:bold">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span id="TOC_c0f8866b9a43f79d5200"><span style="font-weight:bold">ITEM 1. Consolidated Condensed Financial Statements</span></span></p><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-bookmark-end:TOC_c0f8866b9a43f79d5200"></span><span>&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold">60 DEGREES PHARMACEUTICALS, INC.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span id="TOC_cb14c1d383054445acd2"><span style="font-weight:bold">CONSOLIDATED CONDENSED BALANCE SHEETS</span></span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="-aw-bookmark-end:TOC_cb14c1d383054445acd2"></span><span>&#160;</span></p><div style="-aw-sdt-tag:'c4543a0cd0cf3e45c087'; -aw-sdt-title:'Balance sheet'"><table cellspacing="0" cellpadding="0" style="width:100%; border-collapse:collapse"><tbody><tr style="height:13.15pt"><td style="width:77%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="2" style="vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_7dc998ed26534cec8cffd3361a8d1c49'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">September 30, 2025</span></p></div></td><td style="width:1%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="2" style="vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_2f79ab0123194875a701bce36948f4c7'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">December 31,</span></p></div></td></tr><tr style="height:13.15pt"><td style="width:77%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="2" style="border-bottom:1.5pt solid #000000; padding-right:5.4pt; padding-left:5.4pt; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_c6e339e19a864f64996f01cdabb3c392'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">(Unaudited)</span></p></div></td><td style="width:1%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="2" style="border-bottom:1.5pt solid #000000; padding-right:5.4pt; padding-left:5.4pt; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_ad07fcab9a0045f18ce14eb031a2f5f2'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">2024</span></p></div></td></tr><tr style="height:13.15pt"><td style="width:77%; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_c4b2c94a730744ef9558932f62161d35'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">ASSETS:</span></p></div></td><td style="width:1%; border-top:1.5pt solid #000000; padding-right:5.4pt; padding-left:5.4pt; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:1.5pt solid #000000; padding-right:5.4pt; padding-left:5.4pt; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; padding-right:5.4pt; padding-left:5.4pt; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:1.5pt solid #000000; padding-right:5.4pt; padding-left:5.4pt; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td></tr><tr style="height:13.15pt"><td style="width:77%; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_d475e26201d04ca29e6cd3f26b9cf5d0'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Current Assets:</span></p></div></td><td style="width:1%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td></tr><tr style="height:3pt"><td style="width:77%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_367337c139d34ce6b51f4feab694a680'"><p style="margin-top:0pt; margin-left:9.35pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Cash and Cash Equivalents</span></p></div></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_142ed3feba3c47c890b36e7eb3daddaf'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_01e328f90f1e4de58788b06c5abd08da'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="I20250930" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag388">4,115,779</ix:nonFraction></span></p></div></td><td style="width:1%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_e81d6665effe4b18bc4cfe54916b3f13'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_49aebaff164c4e5082494c760ed8ea02'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="I20241231" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag408">1,659,353</ix:nonFraction></span></p></div></td></tr><tr style="height:3pt"><td style="width:77%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_9f2b747fe3e34434889d8d2b9e36673d'"><p style="margin-top:0pt; margin-left:9pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Accounts Receivable</span></p></div></td><td style="width:1%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_ff4471fd58564de894989c377afe6377'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="I20250930" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag389">674,036</ix:nonFraction></span></p></div></td><td style="width:1%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_60d8f87b8fef4b4fa9f1a98086cfa0ad'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="I20241231" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag409">486,748</ix:nonFraction></span></p></div></td></tr><tr style="height:3pt"><td style="width:77%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_ee77cc065e09475092eba9c6be63a4c6'"><p style="margin-top:0pt; margin-left:9pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Prepaid and Other Assets</span></p></div></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_22b1e956063f403f8e5c4302e828187d'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="I20250930" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag390">992,390</ix:nonFraction></span></p></div></td><td style="width:1%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_b42657feb1064b3abb97710e73b8bb87'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="I20241231" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag410">1,068,940</ix:nonFraction></span></p></div></td></tr><tr style="height:3pt"><td style="width:77%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_9e0dc0be4749419aa5cfe6023cbb7caf'"><p style="margin-top:0pt; margin-left:9pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Short-Term Investments</span></p></div></td><td style="width:1%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-tag:'C_fad8e891ca4a4167ba62b746b80218a7'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:ShortTermInvestments" contextRef="I20250930" unitRef="USD" decimals="0" format="ixt:fixed-zero" id="Tag525">-</ix:nonFraction></span></p></div></td><td style="width:1%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_704d1163f08a4903b19434262335d41b'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:ShortTermInvestments" contextRef="I20241231" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag411">1,728,472</ix:nonFraction></span></p></div></td></tr><tr style="height:9.9pt"><td style="width:77%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_d3e675fec8294b48a88ea4498327dfa0'"><p style="margin-top:0pt; margin-left:9pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Inventory (Note 3)</span></p></div></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_e303fdb83aeb468fb3e71fe10303a3f1'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="I20250930" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag391">527,004</ix:nonFraction></span></p></div></td><td style="width:1%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_46839c9454534850b315e713d01aaec9'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="I20241231" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag412">442,764</ix:nonFraction></span></p></div></td></tr><tr style="height:1.5pt"><td style="width:77%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_f8fda292367644978f5b461d25e08463'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">Total Current Assets</span></p></div></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_1701679d057f4ebeae90ffe8fe222010'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="I20250930" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag392">6,309,209</ix:nonFraction></span></p></div></td><td style="width:1%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_58a77bc4745d4046a2b5f06713543fe5'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="I20241231" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag413">5,386,277</ix:nonFraction></span></p></div></td></tr><tr style="height:1.5pt"><td style="width:77%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_366b2775853f4d38ae9179090dca6b12'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Property and Equipment, net (Note 4)</span></p></div></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_f153f39e7c8940caba2956a927ced78a'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="I20250930" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag393">227,752</ix:nonFraction></span></p></div></td><td style="width:1%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_add021f2fbdf4d9380593eefb6876ed3'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="I20241231" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag414">149,808</ix:nonFraction></span></p></div></td></tr><tr style="height:3.6pt"><td style="width:77%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_80c4c498f82f45759d56935f7ada03b8'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Other Assets:</span></p></div></td><td style="width:1%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td></tr><tr style="height:3pt"><td style="width:77%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_bb2fde20db6645e39a2c48af266aec3c'"><p style="margin-top:0pt; margin-left:9pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Long-Term Prepaid Expense</span></p></div></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-tag:'C_b79ce1955bfa4b88afc4abe1f828f3a5'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:PrepaidExpenseNoncurrent" contextRef="I20250930" unitRef="USD" decimals="0" format="ixt:fixed-zero" id="Tag524">-</ix:nonFraction></span></p></div></td><td style="width:1%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_f116187d104d4707bdeecd2c1c37e997'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:PrepaidExpenseNoncurrent" contextRef="I20241231" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag415">66,176</ix:nonFraction></span></p></div></td></tr><tr style="height:3pt"><td style="width:77%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_98541cf88fd5485b913d7bfd37dc45e7'"><p style="margin-top:0pt; margin-left:9pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Intangible Assets, net (Note 5)</span></p></div></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_05c7ac9bfaf84108ac3bec59ad4d9008'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="I20250930" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag394">152,383</ix:nonFraction></span></p></div></td><td style="width:1%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_9c9508b9acd7423186a55b93d4aa71cd'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="I20241231" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag416">157,084</ix:nonFraction></span></p></div></td></tr><tr style="height:1.5pt"><td style="width:77%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_b1133cd6343e4c4c91e59f5d5a5085e3'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">Total Other Assets</span></p></div></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_d3e37b3a601b411e9f6e38bc00090f80'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'"><ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" contextRef="I20250930" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag395">152,383</ix:nonFraction></span></p></div></td><td style="width:1%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_6b9f9946a7144f56a549e0a3c8f3f5dc'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'"><ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" contextRef="I20241231" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag417">223,260</ix:nonFraction></span></p></div></td></tr><tr style="height:1.5pt"><td style="width:77%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_335e8fe16d134da59afc1ddd5e3e2c42'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">Total Assets</span></p></div></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_8eba47e621314fbfb3b893b149f22eb2'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">$</span></p></div></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_73d4e96fdd8040089e454ce281d34817'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'"><ix:nonFraction name="us-gaap:Assets" contextRef="I20250930" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag396">6,689,344</ix:nonFraction></span></p></div></td><td style="width:1%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_70e9b4b80106458eaddb3154ca852ccf'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">$</span></p></div></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_1b5569477e2c49b582d9a64bea9efa92'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'"><ix:nonFraction name="us-gaap:Assets" contextRef="I20241231" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag418">5,759,345</ix:nonFraction></span></p></div></td></tr><tr style="height:1pt"><td style="width:77%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_8a359875d2ec48ed8efe5b34b45e0507'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">LIABILITIES AND SHAREHOLDERS' EQUITY:</span></p></div></td><td style="width:1%; border-top:4.5pt double #000000; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:4.5pt double #000000; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:4.5pt double #000000; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:4.5pt double #000000; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td></tr><tr style="height:8.55pt"><td style="width:77%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_ad8db2b765604ab382eee423feb4cf85'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Current Liabilities:</span></p></div></td><td style="width:1%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td></tr><tr style="height:9.45pt"><td style="width:77%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_3bae410c3ed2442e9c1f072e86c4afdb'"><p style="margin-top:0pt; margin-left:9pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Accounts Payable and Accrued Expenses</span></p></div></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_17b031bfce68492cb314a1b2b12134f6'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_9b25ce26816f487d9d424d51da980b0c'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" contextRef="I20250930" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag397">1,391,347</ix:nonFraction></span></p></div></td><td style="width:1%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_889524b5950049449abde9662f2fec51'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_91ef28ef7e71413e8d8927a7ba26ea68'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" contextRef="I20241231" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag419">1,007,618</ix:nonFraction></span></p></div></td></tr><tr style="height:10.8pt"><td style="width:77%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_679763c8f6ca4c7b81d01736b9adddc3'"><p style="margin-top:0pt; margin-left:9pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">SBA EIDL (including accrued interest) (Note 7)</span></p></div></td><td style="width:1%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_f929dedc27ca4c17be5dbe76b8ee2807'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="sxtp:SBAEIDLincludingAccruedInterestCurrent" contextRef="I20250930" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag398">8,772</ix:nonFraction></span></p></div></td><td style="width:1%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_78963660ffa842b3b2ae37e476c23ccd'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="sxtp:SBAEIDLincludingAccruedInterestCurrent" contextRef="I20241231" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag420">8,772</ix:nonFraction></span></p></div></td></tr><tr style="height:7.65pt"><td style="width:77%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_992053b1df26464f9e56b5c10dbd996d'"><p style="margin-top:0pt; margin-left:9pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Derivative Liabilities (Note 8)</span></p></div></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_61f4821a08e446adb6a290081cc91a7d'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="I20250930" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag399">797,275</ix:nonFraction></span></p></div></td><td style="width:1%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_7430b25a886945eb8b9e13be0bf5705e'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="I20241231" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag421">640,830</ix:nonFraction></span></p></div></td></tr><tr style="height:1.5pt"><td style="width:77%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_cac3d8569c4d4731b414ff8e8a4eb582'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">Total Current Liabilities</span></p></div></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_2073016521ac432bbed167669abc9dfc'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="I20250930" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag400">2,197,394</ix:nonFraction></span></p></div></td><td style="width:1%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_9cb0300197cc453a81d0a244655f98de'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="I20241231" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag422">1,657,220</ix:nonFraction></span></p></div></td></tr><tr style="height:9.3pt"><td style="width:77%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_8a6c79783aa14cd296784f89515ca6b8'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Long-Term Liabilities:</span></p></div></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td></tr><tr style="height:6.75pt"><td style="width:77%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_a23f4ef4c0634c3494413f84d50b4c0b'"><p style="margin-top:0pt; margin-left:9pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">SBA EIDL (including accrued interest) (Note 7)</span></p></div></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_24c0b4d6875f4517ae86928914774306'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="sxtp:SBAEIDLincludingAccruedInterestNonCurrent" contextRef="I20250930" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag637">144,992</ix:nonFraction></span></p></div></td><td style="width:1%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_077f690c09a54047b792c9e4c5700ea5'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="sxtp:SBAEIDLincludingAccruedInterestNonCurrent" contextRef="I20241231" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag423">147,119</ix:nonFraction></span></p></div></td></tr><tr style="height:1.5pt"><td style="width:77%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_f8961b542f32414598ea395cd6e1472b'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">Total Long-Term Liabilities</span></p></div></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_aec0ca0a1a9f4999b60303bba11da999'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'"><ix:nonFraction name="us-gaap:LiabilitiesNoncurrent" contextRef="I20250930" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag401">144,992</ix:nonFraction></span></p></div></td><td style="width:1%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_fdfbd9492ea648dd86e2cc0b34050544'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'"><ix:nonFraction name="us-gaap:LiabilitiesNoncurrent" contextRef="I20241231" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag424">147,119</ix:nonFraction></span></p></div></td></tr><tr style="height:7.5pt"><td style="width:77%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_21226787a3f843e2b3bad5ed75bf1e70'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">Total Liabilities</span></p></div></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_1485ea9013ee444d96e54c57b4cdd66a'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'"><ix:nonFraction name="us-gaap:Liabilities" contextRef="I20250930" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag402">2,342,386</ix:nonFraction></span></p></div></td><td style="width:1%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_28d9737614014bdc82ae4764fc07d3ae'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'"><ix:nonFraction name="us-gaap:Liabilities" contextRef="I20241231" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag425">1,804,339</ix:nonFraction></span></p></div></td></tr><tr style="height:7.95pt"><td style="width:77%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_9b8d81f8fb2e4b3ca986584dbb279b8f'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Commitments and Contingencies (Note 11)</span></p></div></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td></tr><tr style="height:3pt"><td style="width:77%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_c0d0e4b02962466d9573770bc0dff295'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">SHAREHOLDERS' EQUITY:</span></p></div></td><td style="width:1%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td></tr><tr style="height:4.95pt"><td style="width:77%; vertical-align:top; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_8111c02e3c064e76a7fb58d54c8165b1'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Series A Preferred Stock, $</span><span style="-aw-sdt-tag:'ecc-1c7-74a-123-ce79'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="I20241231_SeriesAPreferredStockMember" unitRef="USDPerShare" decimals="4" format="ixt:num-dot-decimal" id="Tag992"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="I20250930_SeriesAPreferredStockMember" unitRef="USDPerShare" decimals="4" format="ixt:num-dot-decimal" id="Tag237">0.0001</ix:nonFraction></ix:nonFraction></span></span><span style="font-family: 'Times New Roman';"> par value, </span><span style="-aw-sdt-tag:'9a1-f81-a5c-082-073c'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="I20241231_SeriesAPreferredStockMember" unitRef="Shares" decimals="0" format="ixt:num-dot-decimal" id="Tag993"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="I20250930_SeriesAPreferredStockMember" unitRef="Shares" decimals="0" format="ixt:num-dot-decimal" id="Tag238">1,000,000</ix:nonFraction></ix:nonFraction></span></span><span style="font-family: 'Times New Roman';"> shares authorized&#894; </span><span style="-aw-sdt-tag:'667-eb0-57f-409-1218'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="I20250930_SeriesAPreferredStockMember" unitRef="Shares" decimals="0" format="ixt:num-dot-decimal" id="Tag994"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="I20250930_SeriesAPreferredStockMember" unitRef="Shares" decimals="0" format="ixt:num-dot-decimal" id="Tag239">76,480</ix:nonFraction></ix:nonFraction></span></span><span style="font-family: 'Times New Roman';"> and </span><span style="-aw-sdt-tag:'d75-3ae-8cf-9c7-d1b8'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="I20241231_SeriesAPreferredStockMember" unitRef="Shares" decimals="0" format="ixt:num-dot-decimal" id="Tag995"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="I20241231_SeriesAPreferredStockMember" unitRef="Shares" decimals="0" format="ixt:num-dot-decimal" id="Tag240">76,480</ix:nonFraction></ix:nonFraction></span></span><span style="font-family: 'Times New Roman';"> shares issued and outstanding as of September 30, 2025 and December 31, 2024, respectively (Note 6)</span></p></div></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_d6a141d1be664b7584b26d78d106636a'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="I20250930" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag403">9,567,439</ix:nonFraction></span></p></div></td><td style="width:1%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_bfdaa4c1104d49ceb5cc29321e0201c5'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="I20241231" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag426">9,567,439</ix:nonFraction></span></p></div></td></tr><tr style="height:9pt"><td style="width:77%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_c18177941f2e4fa49560bb9440e41b35'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Common Stock, $</span><span style="-aw-sdt-tag:'2a3-c1d-0a8-c29-ca8e'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="I20241231" unitRef="USDPerShare" decimals="4" format="ixt:num-dot-decimal" id="Tag996"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="I20250930" unitRef="USDPerShare" decimals="4" format="ixt:num-dot-decimal" id="Tag241">0.0001</ix:nonFraction></ix:nonFraction></span></span><span style="font-family: 'Times New Roman';"> par value, </span><span style="-aw-sdt-tag:'663-955-b64-cb4-419d'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="I20241231" unitRef="Shares" decimals="0" format="ixt:num-dot-decimal" id="Tag997"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="I20250930" unitRef="Shares" decimals="0" format="ixt:num-dot-decimal" id="Tag242">150,000,000</ix:nonFraction></ix:nonFraction></span></span><span style="font-family: 'Times New Roman';"> shares authorized&#894; </span><span style="-aw-sdt-tag:'7f8-3e5-771-bce-5086'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="I20250930" unitRef="Shares" decimals="0" format="ixt:num-dot-decimal" id="Tag998"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="I20250930" unitRef="Shares" decimals="0" format="ixt:num-dot-decimal" id="Tag243">4,104,469</ix:nonFraction></ix:nonFraction></span></span><span style="font-family: 'Times New Roman';"> and </span><span style="-aw-sdt-tag:'1ad-ab6-dce-86b-78f8'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="I20241231" unitRef="Shares" decimals="0" format="ixt:num-dot-decimal" id="Tag1009"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="I20241231" unitRef="Shares" decimals="0" format="ixt:num-dot-decimal" id="Tag244">566,908</ix:nonFraction></ix:nonFraction></span></span><span style="font-family: 'Times New Roman';"> shares issued and outstanding as of September 30, 2025 and December 31, 2024, respectively</span><span style="font-size:6.67pt; vertical-align:super; font-family: 'Times New Roman'">(1)</span><span style="font-family: 'Times New Roman';"> (Note 6)</span></p></div></td><td style="width:1%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_5ad93988adcf4d1b99afcb1a7d90b6ba'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="I20250930" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag433">410</ix:nonFraction></span></p></div></td><td style="width:1%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_907f90d26e974768a207beea084a8ddb'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="I20241231" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag434">57</ix:nonFraction></span></p></div></td></tr><tr style="height:8.55pt"><td style="width:77%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_af879db2798c4f81a5b65f967da1c188'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Additional Paid-in Capital</span><span style="font-size:6.67pt; vertical-align:super; font-family: 'Times New Roman'">(1)</span></p></div></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_ddd278c96fa84be095b02b00d6f21b1d'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="I20250930" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag431">41,172,888</ix:nonFraction></span></p></div></td><td style="width:1%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_62c096bda9a44d16ab7e4f70c52b0286'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="I20241231" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag432">34,860,590</ix:nonFraction></span></p></div></td></tr><tr style="height:6.3pt"><td style="width:77%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_9d3983abec7348f787b60986700ec5f4'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Accumulated Other Comprehensive Income</span></p></div></td><td style="width:1%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_ee8851e7c1cd41328ca3c06d94cdaa9d'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="I20250930" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag404">144,039</ix:nonFraction></span></p></div></td><td style="width:1%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_8bb1b0539905413db247686c8e701099'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="I20241231" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag427">135,471</ix:nonFraction></span></p></div></td></tr><tr style="height:7.65pt"><td style="width:77%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_8d43b2ac41964308a8eca3b04d20036f'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Accumulated Deficit</span></p></div></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_42e25df6f2be42f6acf200d6ffe11510'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="I20250930" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" sign="-" id="Tag247">46,454,556</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">)</span></p></td><td style="width:1%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_9f3e1d8d852a454680b3fe6fa5854f57'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="I20241231" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" sign="-" id="Tag249">40,527,957</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">)</span></p></td></tr><tr style="height:1.5pt"><td style="width:77%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_cee7a31b2c1140e9a4c146ef66f2a27f'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">60P Shareholders&#8217; Equity:</span></p></div></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_abe7833489d441e98815373cca216762'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="I20250930" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag405">4,430,220</ix:nonFraction></span></p></div></td><td style="width:1%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_b0ea094bdeaa410d97fd7e5bb8704109'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="I20241231" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag428">4,035,600</ix:nonFraction></span></p></div></td></tr><tr style="height:3pt"><td style="width:77%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_56babad8099c4233b6592ce7f9220e3b'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Noncontrolling Interest</span></p></div></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_8093f51a2b67474789638b7beb8dab65'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:MinorityInterest" contextRef="I20250930" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" sign="-" id="Tag248">83,262</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">)</span></p></td><td style="width:1%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_d0428597f0e24de8a3308d96ebfa5b1a'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:MinorityInterest" contextRef="I20241231" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" sign="-" id="Tag250">80,594</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">)</span></p></td></tr><tr style="height:1.5pt"><td style="width:77%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_a7ba411cba7b44d185c479625ea6030a'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">Total Shareholders' Equity </span></p></div></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_a92111cc2ae34e22a7f065ca7a306f3d'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="I20250930" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag406">4,346,958</ix:nonFraction></span></p></div></td><td style="width:1%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_af8d24c4d9254399944d96e7d8763fbf'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="I20241231" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag429">3,955,006</ix:nonFraction></span></p></div></td></tr><tr style="height:1.5pt"><td style="width:77%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_aba44c9f03a84e988edb8327905b43b3'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">Total Liabilities and Shareholders' Equity</span></p></div></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_0bc8634e8ddc42278cf8d65aaeea20aa'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">$</span></p></div></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_a17a15e8da78424c97a66299e4bfc8b1'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="I20250930" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag407">6,689,344</ix:nonFraction></span></p></div></td><td style="width:1%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_c7d348769ecc4c6382d1f9480a994240'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">$</span></p></div></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_4e4b231c14ea48169011c21713cb33e9'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="I20241231" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag430">5,759,345</ix:nonFraction></span></p></div></td></tr></tbody></table></div><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span>&#160;</span></p><table cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="width:18pt; vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span>(1)</span></p></td><td style="vertical-align:top"><ix:footnote xml:lang="en-US" footnoteRole="http://www.xbrl.org/2003/role/footnote" id="footnote0"><div style="-aw-sdt-tag:'c13961dbf06a06abf874'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">Prior periods presented have been adjusted to reflect the 1:5 reverse stock split on February 24, 2025.</span></p></div></ix:footnote></td></tr></tbody></table><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span>&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-style:italic">The accompanying notes are an integral part of these unaudited consolidated condensed financial statements.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span>&#160;</span></p><div style="-aw-sdt-tag:'PG_c444835fd0ba971a2688'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-family: 'Times New Roman';">1</span></p><div><hr style="width: 100%; color: #000000; background-color: #000000; margin: 1rem 0;"/></div></div></div><div class="Section_5"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold">60 DEGREES PHARMACEUTICALS, INC.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span id="TOC_c5a6f75c3f8d1a4a4c18"><span style="font-weight:bold">CONSOLIDATED CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS </span></span><span style="font-weight:bold">(UNAUDITED)</span></p><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span>&#160;</span></p><div style="-aw-sdt-tag:'ce97d0061a0694a0835a'; -aw-sdt-title:'Income Statement'"><table cellspacing="0" cellpadding="0" style="width:100%; border-collapse:collapse"><tbody><tr style="height:11.5pt"><td style="width:53%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="5" style="border-bottom:1.5pt solid #000000; padding-right:3.6pt; padding-left:3.6pt; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_d02a2568bb9e4f14a2033de0488dadec'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">For the Three Months Ended September 30,</span></p></div></td><td style="width:1%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="5" style="border-bottom:1.5pt solid #000000; padding-right:3.6pt; padding-left:3.6pt; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_f1a0c3656a4d4876b195eeac36b3695c'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">For the Nine Months Ended September 30,</span></p></div></td></tr><tr style="height:11.5pt"><td style="width:53%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="2" style="border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_4d1dd205676d44c18a83317eb5afb2b1'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">2025</span></p></div></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="2" style="border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_494c51932f0e4a99b15376646d505028'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">2024</span></p></div></td><td style="width:1%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="2" style="border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_9be2563d368248db9c1e4061bfe58dec'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">2025</span></p></div></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="2" style="border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_30ef1db69d4a4e4bb3362489d5728d27'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">2024</span></p></div></td></tr><tr style="height:11.5pt"><td style="width:53%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_af28824987a5400f9741f9726ab327a4'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Product Revenues &#8211; net of Discounts and Rebates</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_acd0a623decd40418700f536131d6c78'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_2ee95d141c85485b81a7b10dbc5a0300'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:Revenues" contextRef="D20250930" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag435">437,602</ix:nonFraction></span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_cb40214119f74340ab6f81a9241fc0fb'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_bc97b340c6aa48c9b1043470f18ba739'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:Revenues" contextRef="D20240930" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag436">135,293</ix:nonFraction></span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_7137ce06829d4e4ca17799f1f9bd68e3'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_835ff6af42bd4029abb9b86bc49b3434'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:Revenues" contextRef="D20250930_1" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag437">702,086</ix:nonFraction></span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_36cf82d56c064a668b38271711b22fc8'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:9%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_5026899662a14b2ba8340cedd40829e0'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:Revenues" contextRef="D20240930_1" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag438">365,939</ix:nonFraction></span></p></div></td></tr><tr style="height:11.5pt"><td style="width:53%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_327e3199dd3b44588a15ff5bfb2649b7'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Cost of Revenues</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_60d914b6438d4f3482c43c44c6ee11aa'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="D20250930" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag517">537,690</ix:nonFraction></span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_b53ddf3dc68941ba896460a67b2a69bb'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="D20240930" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag518">111,687</ix:nonFraction></span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_3d38ee27147e4cdfa5bdd2652e6d6784'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="D20250930_1" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag519">661,013</ix:nonFraction></span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:9%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_4910bdfd461146f0bb2fec787aefa7c9'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:CostOfRevenue" contextRef="D20240930_1" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag508">266,688</ix:nonFraction></span></p></div></td></tr><tr style="height:11.5pt"><td style="width:53%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_c8fab3ec6012474cbf96703e6b53273a'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Gross (Loss) Profit</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_daeeab22053e4436b8022bffe8202e35'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:GrossProfit" contextRef="D20250930" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" sign="-" id="Tag377">100,088</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">)</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_e5472c86e60845a48c084d944d27f2ef'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="D20240930" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag492">23,606</ix:nonFraction></span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_b3ab704f18a245beaf95e91e48bf3458'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="D20250930_1" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag500">41,073</ix:nonFraction></span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:9%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_90613506194c4b759090cc021b71ad18'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:GrossProfit" contextRef="D20240930_1" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag509">99,251</ix:nonFraction></span></p></div></td></tr><tr style="height:11.5pt"><td style="width:53%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_ee375448749342bbb887ad60e6f6f829'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Research Revenues</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_8445eceb1b10433da1624a9d7a1cc6a9'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:RevenueNotFromContractWithCustomerOther" contextRef="D20250930" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag615">90,960</ix:nonFraction></span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_5dc5745d88b34a76865bbc6ec833d108'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:RevenueNotFromContractWithCustomerOther" contextRef="D20240930" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag616">12,818</ix:nonFraction></span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_5ddeb80e400949b0b06d35cfe6afdd70'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:RevenueNotFromContractWithCustomerOther" contextRef="D20250930_1" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag617">390,630</ix:nonFraction></span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:9%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_abf6d909647247c99b8766bd8337187d'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:RevenueNotFromContractWithCustomerOther" contextRef="D20240930_1" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag618">43,177</ix:nonFraction></span></p></div></td></tr><tr style="height:11.5pt"><td style="width:53%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_b741d418b96d49cfadf913b207243038'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Net (Loss) Revenue</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_035299d45ae04eec97a472130bcb183d'; font-family: 'Times New Roman'"><span><ix:nonFraction name="sxtp:NetRevenueLoss" contextRef="D20250930" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" sign="-" id="Tag376">9,128</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">)</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_572425430c2d43d2b2afd113ca92824e'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="sxtp:NetRevenueLoss" contextRef="D20240930" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag493">36,424</ix:nonFraction></span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_4fca60bb57714e2e9b806709521fb2c8'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="sxtp:NetRevenueLoss" contextRef="D20250930_1" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag501">431,703</ix:nonFraction></span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:9%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_c54805ff6c3f469bb1c44bf2fd8f3be2'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="sxtp:NetRevenueLoss" contextRef="D20240930_1" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag510">142,428</ix:nonFraction></span></p></div></td></tr><tr style="height:11.5pt"><td style="width:53%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:9%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td></tr><tr style="height:11.5pt"><td style="width:53%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_b5176b9a2efc4e4da40b6fd0060da0a9'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Operating Expenses:</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:9%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td></tr><tr style="height:11.5pt"><td style="width:53%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_53a1f500007146cf80847bfc79b9680b'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Research and Development</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_096c8538d461440e93152208270f7263'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="D20250930" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag486">809,777</ix:nonFraction></span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_21775a8a5d3645cc9adfaafae3753b95'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="D20240930" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag494">940,063</ix:nonFraction></span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_c275eeb1079845619154e1f7059822b0'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="D20250930_1" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag502">1,467,283</ix:nonFraction></span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:9%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_101ed580cee44283899dfa06a8819381'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="D20240930_1" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag511">4,372,571</ix:nonFraction></span></p></div></td></tr><tr style="height:11.5pt"><td style="width:53%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_6a9ee104afb5425599c28f0f3e9011c9'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">General and Administrative Expenses</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_543cc035fa29459db126e004036d23e5'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="D20250930" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag487">1,506,620</ix:nonFraction></span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_44fc1902e6bf42a6a4c35cfc260bef8a'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="D20240930" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag495">1,215,053</ix:nonFraction></span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_32ebee46e1394238a4a673192143a102'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="D20250930_1" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag503">4,805,648</ix:nonFraction></span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:9%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_1f954973a8db4c18967cd97c4c26a569'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="D20240930_1" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag512">3,419,747</ix:nonFraction></span></p></div></td></tr><tr style="height:11.5pt"><td style="width:53%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_4c1863e8c56345e0b7ec282c3a47fcb4'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Total Operating Expenses</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_ead39aced53b4756b2ae737aebc54069'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="D20250930" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag488">2,316,397</ix:nonFraction></span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_ce4979ab874e4ac3a1a9bd5148120bf0'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="D20240930" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag496">2,155,116</ix:nonFraction></span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_8478893fbdb746e28791877ae00a79cb'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="D20250930_1" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag504">6,272,931</ix:nonFraction></span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:9%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_f52ff1b940a244e29512f14fd4d84a77'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="D20240930_1" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag513">7,792,318</ix:nonFraction></span></p></div></td></tr><tr style="height:11.5pt"><td style="width:53%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:9%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td></tr><tr style="height:11.5pt"><td style="width:53%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_fe19abcfa27741798672e6db6d0632f1'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Loss from Operations</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_8aa9e232b55b4458ac903e3670ca216d'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="D20250930" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" sign="-" id="Tag298">2,325,525</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">)</span></p></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_ca9d4764d90e438d8aa14d7d8cad16f5'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="D20240930" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" sign="-" id="Tag299">2,118,692</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">)</span></p></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_e67ab15e88164d659564c7ae1aafdc1e'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="D20250930_1" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" sign="-" id="Tag300">5,841,228</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">)</span></p></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:9%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_008ab58664cd47d89afc2f67fd703a9e'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="D20240930_1" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" sign="-" id="Tag301">7,649,890</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">)</span></p></td></tr><tr style="height:11.5pt"><td style="width:53%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:9%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td></tr><tr style="height:11.5pt"><td style="width:53%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_88b99dedf4eb46d9838a0df37d88ba1f'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Interest Expense</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_3252e46302974bdfa4006ca264790161'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:InterestExpenseNonoperating" contextRef="D20250930" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag302">1,708</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">)</span></p></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_51a01684c0b24f7eb5124e9ef99a73cd'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:InterestExpenseNonoperating" contextRef="D20240930" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag303">1,467</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">)</span></p></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_b05606638bdb4862a8f2cb54a661c547'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:InterestExpenseNonoperating" contextRef="D20250930_1" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag304">4,719</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">)</span></p></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:9%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_ebc3ffef35b941c99909ffa51d61dc02'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:InterestExpenseNonoperating" contextRef="D20240930_1" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag305">6,490</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">)</span></p></td></tr><tr style="height:11.5pt"><td style="width:53%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_86722de910064fc0abd3d7c09056df32'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Change in Fair Value of Derivative Liabilities</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_aee0257ab19e48b88ab8dbcd5040430a'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="D20250930" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag378">21,103</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">)</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_48d07e3ef86e409b81a9d1e2080d25a3'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="D20240930" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag379">56,712</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">)</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_d6b6477de67f4eac8cf32f6bb312366b'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="D20250930_1" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag380">156,445</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">)</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:9%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_667310e498d442598320ea4abe1ee63e'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="D20240930_1" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" sign="-" id="Tag619">1,683,034</ix:nonFraction></span></p></div></td></tr><tr style="height:11.5pt"><td style="width:53%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_0647eeb4c4ae4142b7b250c6502110c6'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Other Income, net</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_a6851bf0125346fd8ede0686212b4acc'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="D20250930" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag489">31,550</ix:nonFraction></span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_02a7ffb94c694e8488e1eef44878d583'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="D20240930" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag497">16,623</ix:nonFraction></span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_c513626005434fdbab1b339ad4c2011c'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="D20250930_1" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag505">74,938</ix:nonFraction></span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:9%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_79fc5efc86504320b088863ed2a1edbb'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="D20240930_1" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag514">67,358</ix:nonFraction></span></p></div></td></tr><tr style="height:11.5pt"><td style="width:53%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_7a9f31480e314300ba7ec51e7fd5bb0c'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Total Interest and Other Income (Expense), net</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_85f89fa8ec3541e594108a228222effe'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:InterestIncomeExpenseNonoperatingNet" contextRef="D20250930" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag614">8,739</ix:nonFraction></span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_f973b6f34f1940b39c3864fe54d23983'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:InterestIncomeExpenseNonoperatingNet" contextRef="D20240930" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" sign="-" id="Tag375">41,556</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">)</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_0c4cb2d0b41b4869a522f8ae50a9dc62'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:InterestIncomeExpenseNonoperatingNet" contextRef="D20250930_1" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" sign="-" id="Tag279">86,226</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">)</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:9%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_2325a90d4f8446e5a09853b80d479f9e'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:InterestIncomeExpenseNonoperatingNet" contextRef="D20240930_1" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag516">1,743,902</ix:nonFraction></span></p></div></td></tr><tr style="height:11.5pt"><td style="width:53%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_003ca49045304cf5b18caa2ee7182158'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Loss from Operations before Provision for Income Taxes</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_2313472188684444bfd47cfdfc043bb2'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="D20250930" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" sign="-" id="Tag306">2,316,786</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">)</span></p></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_4ca7449c6945420299a7125cb23e92f1'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="D20240930" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" sign="-" id="Tag307">2,160,248</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">)</span></p></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_658abbd080e849b8ae239f88b83d6831'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="D20250930_1" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" sign="-" id="Tag308">5,927,454</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">)</span></p></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:9%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_d0163904e72243e19f53fd11261fdcdd'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="D20240930_1" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" sign="-" id="Tag309">5,905,988</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">)</span></p></td></tr><tr style="height:11.5pt"><td style="width:53%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_6856a0d9b4fc438a80c010fb92b2c5a1'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Provision for Income Taxes (Note 9)</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_5f48320d7d934b55b687f0d10a5dee48'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="D20250930" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag490">250</ix:nonFraction></span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_247bb714b34d47ad95b060d6b4be7e82'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="D20240930" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag498">250</ix:nonFraction></span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_f491fdf5472f4fd3bd8f9d5cc3add8d5'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="D20250930_1" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag506">1,813</ix:nonFraction></span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:9%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_62d41da4811442748f8d8e1934ce5f99'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="D20240930_1" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag515">751</ix:nonFraction></span></p></div></td></tr><tr style="height:11.5pt"><td style="width:53%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_c6b86e80b8c540cb9c937fa33e3519b1'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Net Loss including Noncontrolling Interest</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_eece01a79e11456299023ed7d1212f07'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="D20250930" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" sign="-" id="Tag372">2,317,036</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">)</span></p></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_71ebd7e73a94483d9dd59c86d51b839c'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="D20240930" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" sign="-" id="Tag310">2,160,498</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">)</span></p></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_390a5d1f417e48f49dd1ae9cb64df878'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="D20250930_1" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" sign="-" id="Tag280">5,929,267</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">)</span></p></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:9%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_adbfe19bb114448aa87e356ad389f4de'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="D20240930_1" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" sign="-" id="Tag311">5,906,739</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">)</span></p></td></tr><tr style="height:11.5pt"><td style="width:53%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_e3b2fb904a17401e9eb8cdb809333e28'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Net Loss &#8211; Noncontrolling Interest</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_73f8ec6fd2564ca2848c07481efe3cc0'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextRef="D20250930" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" sign="-" id="Tag321">712</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">)</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_854a5e7261c846939de639bb07997c1f'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextRef="D20240930" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" sign="-" id="Tag322">713</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">)</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_ff17db9d3bb34477a37518ed10dcc535'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextRef="D20250930_1" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" sign="-" id="Tag323">2,668</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">)</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:9%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_486eb6b642bb4191816eba0c797240dc'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextRef="D20240930_1" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" sign="-" id="Tag324">4,669</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">)</span></p></td></tr><tr style="height:11.5pt"><td style="width:53%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_1ec1d04deade47e59dcd9e418a566504'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Net Loss &#8211; attributed to 60 Degrees Pharmaceuticals, Inc.</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_1bb95ef0eb1949f5b9e3d33620c9e57f'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="D20250930" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" sign="-" id="Tag271">2,316,324</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">)</span></p></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_0ad07816ee8b4e83af5ceaabf32fa2df'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="D20240930" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" sign="-" id="Tag312">2,159,785</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">)</span></p></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_671d4309dfd44157a2486c075f2a5276'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="D20250930_1" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" sign="-" id="Tag281">5,926,599</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">)</span></p></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:9%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_505a2ad809b44a6db2cfc99fd2afa9e7'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="D20240930_1" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" sign="-" id="Tag313">5,902,070</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">)</span></p></td></tr><tr style="height:8.1pt"><td style="width:53%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:4.5pt double #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:4.5pt double #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:4.5pt double #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:4.5pt double #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:4.5pt double #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:4.5pt double #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:4.5pt double #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:9%; border-top:4.5pt double #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td></tr><tr style="height:11.5pt"><td style="width:53%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_ad0dcee691f24bb09cff4cdbcf6a03c7'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Comprehensive Loss:</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:9%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td></tr><tr style="height:11.5pt"><td style="width:53%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_72e6e93ff4394755918074cf9e511982'"><p style="margin-top:0pt; margin-left:9.35pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Net Loss</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_eb75148ffa7e42068c1cb3ee260bc4a4'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="D20250930" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" sign="-" id="Tag373">2,317,036</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">)</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_f96ba2034af1452b85a8ef95d3552a11'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="D20240930" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" sign="-" id="Tag314">2,160,498</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">)</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_58081da8bef94c388a261729c052e580'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="D20250930_1" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" sign="-" id="Tag315">5,929,267</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">)</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:9%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_d671595cafbf4389bfd52b4c9542c75e'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="D20240930_1" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" sign="-" id="Tag316">5,906,739</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">)</span></p></td></tr><tr style="height:11.5pt"><td style="width:53%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_bf8ffe1e414b4bd58de21fb59bfb7a93'"><p style="margin-top:0pt; margin-left:9.35pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Unrealized Foreign Currency Translation Gain</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_b933416046a0429aa169be306704c61f'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossUnrealizedAfterTax" contextRef="D20250930" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag491">1,230</ix:nonFraction></span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_4864727a1de94d80b5e07d5a0da81714'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossUnrealizedAfterTax" contextRef="D20240930" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag499">4,403</ix:nonFraction></span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_0d990035fc4d4196b90a93e791ae9224'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossUnrealizedAfterTax" contextRef="D20250930_1" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag507">8,568</ix:nonFraction></span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:9%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_8a73149f09e041cf8043461ad0da0ce7'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:ForeignCurrencyTransactionGainLossUnrealizedAfterTax" contextRef="D20240930_1" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag613">3,646</ix:nonFraction></span></p></div></td></tr><tr style="height:11.5pt"><td style="width:53%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_807368b29a9043109b7940702fb73e71'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Total Comprehensive Loss</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_4024c65c85b948f9988ca2ff63b43b0a'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" contextRef="D20250930" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" sign="-" id="Tag272">2,315,806</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">)</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_d3ccaaa1a65943d2b95a3989080fcc3c'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" contextRef="D20240930" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" sign="-" id="Tag288">2,156,095</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">)</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_b2f1a335fd6e4a3faf28cca3e188e918'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" contextRef="D20250930_1" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" sign="-" id="Tag282">5,920,699</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">)</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:9%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_993a80cdfdf74f87a10f706044666bc2'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" contextRef="D20240930_1" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" sign="-" id="Tag289">5,903,093</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">)</span></p></td></tr><tr style="height:9.9pt"><td style="width:53%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-left:9pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:4.5pt double #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:4.5pt double #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:4.5pt double #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:4.5pt double #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:4.5pt double #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:4.5pt double #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:4.5pt double #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:9%; border-top:4.5pt double #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td></tr><tr style="height:11.5pt"><td style="width:53%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_eaab6ab83ac6419f96a586cbf1e257ed'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Net Loss &#8211; Noncontrolling Interest</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_f7cc44ce277f4435a0c28721c1d6d2dc'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" contextRef="D20250930" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" sign="-" id="Tag273">712</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">)</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_2e8e356122e14033b0404f56c2d818ca'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" contextRef="D20240930" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" sign="-" id="Tag317">713</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">)</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_33a19f0780cb4f0698fa9c25e7bce70e'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" contextRef="D20250930_1" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" sign="-" id="Tag283">2,668</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">)</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:9%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_e5d81b82086347d097b31031ebff0a90'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" contextRef="D20240930_1" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" sign="-" id="Tag318">4,669</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">)</span></p></td></tr><tr style="height:2.5pt"><td style="width:53%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_41d4712c4a9649a18f7a4b2b7d304aff'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Comprehensive Loss &#8211; attributed to 60 Degrees Pharmaceuticals, Inc.</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_aa189d0ee21d495eb25b5a05a6f25c25'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="D20250930" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" sign="-" id="Tag291">2,315,094</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">)</span></p></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_89dc56ef32df472da29f7bb25262ea0b'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="D20240930" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" sign="-" id="Tag290">2,155,382</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">)</span></p></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_4c9d4b139c2b4476b558741b8040981e'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="D20250930_1" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" sign="-" id="Tag292">5,918,031</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">)</span></p></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:9%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_cda051782bd0409aabb3938f3756882e'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="D20240930_1" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" sign="-" id="Tag293">5,898,424</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">)</span></p></td></tr><tr style="height:11.5pt"><td style="width:53%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:9%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td></tr><tr style="height:11.5pt"><td style="width:53%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_023469904fe84852a88c16e08d765b97'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Cumulative Dividends on Series A Preferred Stock</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_cb6d7e83b6914d99942832fcb66874a7'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:PreferredStockDividendsAndOtherAdjustments" contextRef="D20250930" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag319">128,097</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">)</span></p></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_76dac8ecfb574b34b4b379df9897ac0e'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:PreferredStockDividendsAndOtherAdjustments" contextRef="D20240930" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag278">116,571</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">)</span></p></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_9d307ca98fe74298a10c151e161570e4'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:PreferredStockDividendsAndOtherAdjustments" contextRef="D20250930_1" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag320">372,960</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">)</span></p></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:9%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_2f0839a2c4c94614adce9b6d0286f09b'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:PreferredStockDividendsAndOtherAdjustments" contextRef="D20240930_1" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag284">352,333</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">)</span></p></td></tr><tr style="height:11.5pt"><td style="width:53%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_5a73c6ca121a4cb486796be786ab0215'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">Net Loss - attributed to common stockholders</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_bbe08139318c4eba802bf7d3e514fa70'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">$</span></p></div></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">(</span><span style="-aw-sdt-tag:'C_2e1a53ebee4f493bbf2876c15889905f'; font-family: 'Times New Roman'"><span style="font-weight:bold"><ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="D20250930" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" sign="-" id="Tag294">2,443,191</ix:nonFraction></span></span><span style="font-weight:bold; font-family: 'Times New Roman'">)</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_82a8eb7d8ab5405882bc1d245aeaeaab'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">$</span></p></div></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">(</span><span style="-aw-sdt-tag:'C_fc94ec6fc2ff4eeda1c176004fde57ca'; font-family: 'Times New Roman'"><span style="font-weight:bold"><ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="D20240930" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" sign="-" id="Tag295">2,271,953</ix:nonFraction></span></span><span style="font-weight:bold; font-family: 'Times New Roman'">)</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_3b407458a1c94f78b04b559f9777c0bb'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">$</span></p></div></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">(</span><span style="-aw-sdt-tag:'C_a160c07361c94ec58e7f0da5b067303d'; font-family: 'Times New Roman'"><span style="font-weight:bold"><ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="D20250930_1" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" sign="-" id="Tag296">6,290,991</ix:nonFraction></span></span><span style="font-weight:bold; font-family: 'Times New Roman'">)</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_c0d26146726c4f5b832ff51c1f38fed9'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">$</span></p></div></td><td style="width:9%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">(</span><span style="-aw-sdt-tag:'C_d17456eedd8e478f9beda071afad65e5'; font-family: 'Times New Roman'"><span style="font-weight:bold"><ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="D20240930_1" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" sign="-" id="Tag297">6,250,757</ix:nonFraction></span></span><span style="font-weight:bold; font-family: 'Times New Roman'">)</span></p></td></tr><tr style="height:8.1pt"><td style="width:53%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:4.5pt double #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:4.5pt double #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:4.5pt double #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:4.5pt double #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:4.5pt double #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:4.5pt double #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:4.5pt double #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:9%; border-top:4.5pt double #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td></tr><tr style="height:11.5pt"><td style="width:53%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_96a8dc90493c45098a794937c3858331'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Net Loss per Common Share:</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:9%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td></tr><tr style="height:11.5pt"><td style="width:53%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_513b092dfa23436f9e1ee94eb2a8e1ab'"><p style="margin-top:0pt; margin-left:9.35pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Basic and Diluted</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_35709724e6584ba6b0ed7da970272791'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_949c16f38014413e93e61f5052a1c598'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="D20250930" unitRef="USDPerShare" decimals="2" format="ixt:num-dot-decimal" sign="-" id="Tag999"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="D20250930" unitRef="USDPerShare" decimals="2" format="ixt:num-dot-decimal" sign="-" id="Tag274">0.66</ix:nonFraction></ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">)</span></p></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_f9ec5f8618d34b879f4077db519352e2'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_8941edd61d5241f1908f77e0affaed98'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="D20250930_1" unitRef="USDPerShare" decimals="2" format="ixt:num-dot-decimal" sign="-" id="Tag1011"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="D20240930" unitRef="USDPerShare" decimals="2" format="ixt:num-dot-decimal" sign="-" id="Tag275">4.65</ix:nonFraction></ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">)</span></p></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_3029cf281b864f20aeb3d5d78cba027a'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_84cc8e5b5a2b44f88e18c393fba796df'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="D20240930" unitRef="USDPerShare" decimals="2" format="ixt:num-dot-decimal" sign="-" id="Tag1010"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="D20250930_1" unitRef="USDPerShare" decimals="2" format="ixt:num-dot-decimal" sign="-" id="Tag276">2.92</ix:nonFraction></ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">)</span></p></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_a8319ac8c4604cd5b96f0e6e35b6e275'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:9%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_487be7a7b4104f2ea3f1ee3538b2239f'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="D20240930_1" unitRef="USDPerShare" decimals="2" format="ixt:num-dot-decimal" sign="-" id="Tag1012"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="D20240930_1" unitRef="USDPerShare" decimals="2" format="ixt:num-dot-decimal" sign="-" id="Tag277">21.74</ix:nonFraction></ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">)</span></p></td></tr><tr style="height:11.5pt"><td style="width:53%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_f47db5d587314b768ace883347a918fe'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Weighted Average Number of Common Shares Outstanding</span><span style="font-size:6.67pt; vertical-align:super; font-family: 'Times New Roman'">(1)</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:9%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td></tr><tr style="height:11.5pt"><td style="width:53%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_5f990d5a64af41138833f57b0d67d9c5'"><p style="margin-top:0pt; margin-left:9pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Basic and Diluted</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_23ffc3a8cdc14eb7adc428c4500d1966'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="D20250930" unitRef="Shares" decimals="0" format="ixt:num-dot-decimal" id="Tag1003"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="D20250930" unitRef="Shares" decimals="0" format="ixt:num-dot-decimal" id="Tag520">3,675,407</ix:nonFraction></ix:nonFraction></span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_5ca6d5be4871464faae20583d1dfcce5'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="D20250930_1" unitRef="Shares" decimals="0" format="ixt:num-dot-decimal" id="Tag1001"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="D20240930" unitRef="Shares" decimals="0" format="ixt:num-dot-decimal" id="Tag521">488,654</ix:nonFraction></ix:nonFraction></span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_0e6ab255637a4a88b37457503131feca'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="D20240930" unitRef="Shares" decimals="0" format="ixt:num-dot-decimal" id="Tag1002"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="D20250930_1" unitRef="Shares" decimals="0" format="ixt:num-dot-decimal" id="Tag522">2,152,682</ix:nonFraction></ix:nonFraction></span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:9%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_51c50bdec9d84687807e42bc665cd9a2'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="D20240930_1" unitRef="Shares" decimals="0" format="ixt:num-dot-decimal" id="Tag1000"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="D20240930_1" unitRef="Shares" decimals="0" format="ixt:num-dot-decimal" id="Tag523">287,529</ix:nonFraction></ix:nonFraction></span></p></div></td></tr></tbody></table></div><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore">&#160;</span></p><table cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="width:18pt; vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span>(1)</span></p></td><td style="vertical-align:top"><ix:footnote xml:lang="en-US" footnoteRole="http://www.xbrl.org/2003/role/footnote" id="footnote1"><div style="-aw-sdt-tag:'c734aea3392f6a6b2ec2'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">Prior periods presented have been adjusted to reflect the 1:5 reverse stock split on February 24, 2025.</span></p></div></ix:footnote></td></tr></tbody></table><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span>&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-style:italic">The accompanying notes are an integral part of these unaudited consolidated condensed financial statements.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-style:italic">&#160;</span></p><div style="-aw-sdt-tag:'PG_cc78cafbb8a43f7e62df'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-family: 'Times New Roman';">2</span></p><div><hr style="width: 100%; color: #000000; background-color: #000000; margin: 1rem 0;"/></div></div></div><div class="Section_6"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="width:36pt; font-weight:bold; display:inline-block">&#160;</span><span style="font-weight:bold">60 DEGREES PHARMACEUTICALS, INC.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span id="TOC_cc19643ebb8455de0f81"><span style="font-weight:bold">CONSOLIDATED CONDENSED STATEMENTS OF SHAREHOLDERS&#8217; EQUITY </span></span><span style="font-weight:bold">(UNAUDITED)</span></p><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore">&#160;</span></p><div style="-aw-sdt-tag:'cec18f5285db5cf58056'; -aw-sdt-title:'SHAREHOLDERS&#8217; EQUITY_Table 1'"><table cellspacing="0" cellpadding="0" style="width:100%; border-collapse:collapse"><tbody><tr style="height:11.5pt"><td style="width:18%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="27" style="border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_e80577e10f1046ee9ed713a2e74e9050'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">For the Three and Nine Months Ended September 30, 2025</span></p></div></td></tr><tr style="height:11.5pt"><td style="width:18%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="4" style="border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_d3caecc105aa4010b214c9f4d92510ea'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">Series A Preferred Stock</span></p></div></td><td style="width:0.5%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:8pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="4" style="border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_014c841991b74a37920934d0783b4cbf'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">Common Stock</span><span style="font-size:5.33pt; font-weight:bold; vertical-align:super; font-family: 'Times New Roman'">(1)</span></p></div></td><td style="width:0.5%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:8pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="2" rowspan="2" style="border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_0273cb34e38b4effad7bc20e2def7531'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">Additional Paid-In Capital</span><span style="font-size:5.33pt; font-weight:bold; vertical-align:super; font-family: 'Times New Roman'">(1)</span></p></div></td><td style="width:0.5%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:8pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="2" rowspan="2" style="border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_6bb57fc4de8345dcb23aa07756d7dae1'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">Accumulated Deficit</span></p></div></td><td style="width:0.5%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:8pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="2" rowspan="2" style="border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_ae25fd483c8941c0aa607bcc13648c03'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">Accumulated Other Comprehensive Income (Loss)</span></p></div></td><td style="width:0.5%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:8pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="2" rowspan="2" style="border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_c548ef617e9a4b8f8cee4903730c0461'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">Total Shareholders&#8217; Equity Attributable to 60P</span></p></div></td><td style="width:0.5%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:8pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="2" rowspan="2" style="border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_85ed5d17b2524939a86e31fcb66046ad'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">Noncontrolling Interest on Shareholders</span></p></div></td><td style="width:0.5%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:8pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="2" rowspan="2" style="border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_40b111b65aee4c9992f00ee1c553d57f'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">Total Shareholders' Equity</span></p></div></td></tr><tr style="height:11.5pt"><td style="width:18%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:8pt"><span style="font-family: 'Times New Roman';">&#160;</span></p></td><td style="width:6%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_1e742792617a4ed2b63384db306504f7'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">Shares</span></p></div></td><td style="width:0.5%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="2" style="border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_e4318a33673645678e9428af56b57959'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">Amount</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:7.5%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_fd337498ce3545adbf390aae0cc9da1f'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">Shares</span></p></div></td><td style="width:0.5%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="2" style="border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; padding-right:0.7pt; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_c75810abef8b4e5da63a71d7a2d8e64e'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">Amount</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">&#160;</span></p></td></tr><tr style="height:11.5pt"><td style="width:18%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_408dfc0ccc8440c68833e5aa4c76457e'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">Balance&#8212;December 31, 2024</span></p></div></td><td style="width:6%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_8bf2dae62b2a42098a0be469ccd7de94'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="I20241231_PreferredStockMember_SeriesAPreferredStockMember" unitRef="Shares" decimals="0" format="ixt:num-dot-decimal" id="Tag460">76,480</ix:nonFraction></span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_c027e4c8701c4a7190210f102486df8a'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">$</span></p></div></td><td style="width:7%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_3b5812c8571c4b348f26d58581e941d3'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="I20241231_PreferredStockMember_SeriesAPreferredStockMember" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag461">9,567,439</ix:nonFraction></span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:7.5%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_511deaa6cd254ebeb9ad132f6d6c4cff'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="I20241231_CommonStockMember" unitRef="Shares" decimals="0" format="ixt:num-dot-decimal" id="Tag643">566,908</ix:nonFraction></span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_e6c336a706664e0ab6423d49d27965d8'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">$</span></p></div></td><td style="width:6%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_e55d20ce5e7b40bcb7d4f7db0b990df2'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="I20241231_CommonStockMember" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag651">57</ix:nonFraction></span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_368b7fc78830455fab93dd233cdef3b2'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">$</span></p></div></td><td style="width:7.5%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_c64a864c088149d695cc362e9276b70f'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="I20241231_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag659">34,860,590</ix:nonFraction></span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_fbac0f7f71624816a6429215c40be1a7'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">$</span></p></div></td><td style="width:8.5%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">(</span><span style="-aw-sdt-tag:'C_731df13856844fc58dfdfb443391c0dc'; font-family: 'Times New Roman'"><span style="font-weight:bold"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="I20241231_RetainedEarningsUnappropriatedMember" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" sign="-" id="Tag267">40,527,957</ix:nonFraction></span></span><span style="font-weight:bold; font-family: 'Times New Roman'">)</span></p></td><td style="width:0.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_aedcae35f4e0486c9b96451deabb54bb'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">$</span></p></div></td><td style="width:6%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_57adaa4a59324c80b15ef5090d1bfe95'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="I20241231_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag479">135,471</ix:nonFraction></span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_ec909a37bcde45fc87bccb8a52e10323'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">$</span></p></div></td><td style="width:7.5%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_14da8fb1fe2746c7b57bb210a9be4ba1'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="I20241231_ParentMember" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag480">4,035,600</ix:nonFraction></span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_25f03d3286d24d649bfe2b4ebe2e8661'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">$</span></p></div></td><td style="width:6%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">(</span><span style="-aw-sdt-tag:'C_1f11ce4e7b6b4062ba91f7af2b93f7d3'; font-family: 'Times New Roman'"><span style="font-weight:bold"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="I20241231_NoncontrollingInterestMember" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" sign="-" id="Tag268">80,594</ix:nonFraction></span></span><span style="font-weight:bold; font-family: 'Times New Roman'">)</span></p></td><td style="width:0.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_e3d2816827c14dc093ed931e3df489b8'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">$</span></p></div></td><td style="width:7.5%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_c4f444301951412a9d33f644e1a9921a'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="I20241231" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag481">3,955,006</ix:nonFraction></span></p></div></td></tr><tr style="height:11.5pt"><td style="width:18%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_a80672b96c3e49ef807c02d89d8048e3'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-family: 'Times New Roman';">Issuance of common stock and warrants pursuant to January 2025 Offering, net of offering costs paid at closing and deferred offering costs (Note 6)</span></p></div></td><td style="width:6%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-tag:'C_7f40ba2f1ae048b4b9ea383cd19e114e'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-family: 'Times New Roman';">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-family: 'Times New Roman';">&#160;</span></p></td><td style="width:7%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-tag:'C_9a7198921e4949b59eee3a19567dbb99'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-family: 'Times New Roman';">&#160;</span></p></td><td style="width:7.5%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_9930bc5b5037490aadd3fb7d4e5c4efb'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="sxtp:StockIssuedDuringPeriodIssuanceOfCommonStockAndWarrantsPursuantToJanuary2025OfferingNetOfOfferingCosts" contextRef="D20250331_CommonStockMember" unitRef="Shares" decimals="0" format="ixt:num-dot-decimal" id="Tag639">204,312</ix:nonFraction></span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-family: 'Times New Roman';">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-family: 'Times New Roman';">&#160;</span></p></td><td style="width:6%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_5526099bd8b04b24b273c1c278210a8d'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="sxtp:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPursuantToJanuary2025OfferingNetOfOfferingCosts" contextRef="D20250331_CommonStockMember" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag658">20</ix:nonFraction></span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-family: 'Times New Roman';">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-family: 'Times New Roman';">&#160;</span></p></td><td style="width:7.5%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_2c69ed8bb5834ec7adfdbb750be47cb3'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="sxtp:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPursuantToJanuary2025OfferingNetOfOfferingCosts" contextRef="D20250331_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag662">804,326</ix:nonFraction></span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-family: 'Times New Roman';">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-family: 'Times New Roman';">&#160;</span></p></td><td style="width:8.5%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-tag:'C_cdf0ba99260c43dda5d4399bdb72335c'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-family: 'Times New Roman';">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-family: 'Times New Roman';">&#160;</span></p></td><td style="width:6%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-tag:'C_8992f19e6dc245a79c1bc1df89e7dad6'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-family: 'Times New Roman';">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-family: 'Times New Roman';">&#160;</span></p></td><td style="width:7.5%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_569e8002f5f4442e8d416bf981a28d3d'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="sxtp:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPursuantToJanuary2025OfferingNetOfOfferingCosts" contextRef="D20250331_ParentMember" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag463">804,346</ix:nonFraction></span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-family: 'Times New Roman';">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-family: 'Times New Roman';">&#160;</span></p></td><td style="width:6%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-tag:'C_ee68ec52c1e649778afb3c3d8db94813'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-family: 'Times New Roman';">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-family: 'Times New Roman';">&#160;</span></p></td><td style="width:7.5%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_4d6083a1b9f24243ac08dc2d9def39fa'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="sxtp:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPursuantToJanuary2025OfferingNetOfOfferingCosts" contextRef="D20250331" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag455">804,346</ix:nonFraction></span></p></div></td></tr><tr style="height:11.5pt"><td style="width:18%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_af750210c8bf4ba7a8f0c9f74d6e2ccb'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-family: 'Times New Roman';">Issuance of common stock and warrants pursuant to February 2025 Offering, net of offering costs paid at closing and deferred offering costs (Note 6)</span></p></div></td><td style="width:6%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-tag:'C_0aebebb9c57d4f5bb91d2d14aa295940'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-family: 'Times New Roman';">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-family: 'Times New Roman';">&#160;</span></p></td><td style="width:7%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-tag:'C_316838e62b6745d48672cc931be620c7'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-family: 'Times New Roman';">&#160;</span></p></td><td style="width:7.5%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_753254f2177a406394cc7331d7fd605c'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="sxtp:StockIssuedDuringPeriodIssuanceOfCommonStockAndWarrantsPursuantToFebruary2025OfferingNetOfOfferingCosts" contextRef="D20250331_CommonStockMember" unitRef="Shares" decimals="0" format="ixt:num-dot-decimal" id="Tag640">300,700</ix:nonFraction></span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-family: 'Times New Roman';">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-family: 'Times New Roman';">&#160;</span></p></td><td style="width:6%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_95e4ec328b514d07a06dd6c745cdf9c1'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="sxtp:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPursuantToFebruary2025OfferingNetOfOfferingCosts" contextRef="D20250331_CommonStockMember" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag649">30</ix:nonFraction></span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-family: 'Times New Roman';">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:7.5%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_7eb092eae7c94b849af9d9f758cd6f0e'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="sxtp:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPursuantToFebruary2025OfferingNetOfOfferingCosts" contextRef="D20250331_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag663">908,597</ix:nonFraction></span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-family: 'Times New Roman';">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-family: 'Times New Roman';">&#160;</span></p></td><td style="width:8.5%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-tag:'C_1e8e797c893748cbb083938f53b3fb42'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-family: 'Times New Roman';">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-family: 'Times New Roman';">&#160;</span></p></td><td style="width:6%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-tag:'C_422c82e9e60b4af89d4273951da0d4ed'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-family: 'Times New Roman';">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-family: 'Times New Roman';">&#160;</span></p></td><td style="width:7.5%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_3ba1067f975c426488810df873811e7a'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="sxtp:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPursuantToFebruary2025OfferingNetOfOfferingCosts" contextRef="D20250331_ParentMember" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag464">908,627</ix:nonFraction></span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-family: 'Times New Roman';">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-family: 'Times New Roman';">&#160;</span></p></td><td style="width:6%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-tag:'C_ab522fd9bb21415b8cd2721b6346d722'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-family: 'Times New Roman';">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-family: 'Times New Roman';">&#160;</span></p></td><td style="width:7.5%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_f68a425df2eb483ca74f8b82ac4dec8d'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="sxtp:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPursuantToFebruary2025OfferingNetOfOfferingCosts" contextRef="D20250331" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag454">908,627</ix:nonFraction></span></p></div></td></tr><tr style="height:11.5pt"><td style="width:18%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_bd313e0be35e4d14a5b51babd9594f07'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-family: 'Times New Roman';">Issuance of common stock upon exercise of Pre-Funded Warrants</span></p></div></td><td style="width:6%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-tag:'C_8648121c32a04ee3a51ca24afb6fa5b9'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-family: 'Times New Roman';">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-family: 'Times New Roman';">&#160;</span></p></td><td style="width:7%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-tag:'C_494a878a03a3492fb16493e9e9b7dd0c'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-family: 'Times New Roman';">&#160;</span></p></td><td style="width:7.5%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_f4e4c31f5f2349e9a01675e68e795e95'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="sxtp:StockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfPreFundedWarrantsinShares" contextRef="D20250331_CommonStockMember" unitRef="Shares" decimals="0" format="ixt:num-dot-decimal" id="Tag641">385,200</ix:nonFraction></span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-family: 'Times New Roman';">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-family: 'Times New Roman';">&#160;</span></p></td><td style="width:6%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_011a1947567244dbaeb5a9b05ce67924'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="sxtp:StockIssuedDuringPeriodValueStockIssuanceOfCommonStockUponExerciseOfPreFundedWarrants" contextRef="D20250331_CommonStockMember" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag652">38</ix:nonFraction></span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-family: 'Times New Roman';">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:7.5%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_8cfe42eba7454b608be23292a80e0f0e'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="sxtp:StockIssuedDuringPeriodValueStockIssuanceOfCommonStockUponExerciseOfPreFundedWarrants" contextRef="D20250331_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag664">1,888</ix:nonFraction></span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-family: 'Times New Roman';">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-family: 'Times New Roman';">&#160;</span></p></td><td style="width:8.5%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-tag:'C_d6e9481708d34352b06ff6e697143329'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-family: 'Times New Roman';">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-family: 'Times New Roman';">&#160;</span></p></td><td style="width:6%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-tag:'C_191fd1444fd545b481a2e471fbd291c7'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-family: 'Times New Roman';">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-family: 'Times New Roman';">&#160;</span></p></td><td style="width:7.5%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_4f86cd2937b9421da0b73ef3fa730b84'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="sxtp:StockIssuedDuringPeriodValueStockIssuanceOfCommonStockUponExerciseOfPreFundedWarrants" contextRef="D20250331_ParentMember" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag465">1,926</ix:nonFraction></span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-family: 'Times New Roman';">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-family: 'Times New Roman';">&#160;</span></p></td><td style="width:6%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-tag:'C_9d4d2c70c5664b9fb9ac7ac40ec0451b'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-family: 'Times New Roman';">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-family: 'Times New Roman';">&#160;</span></p></td><td style="width:7.5%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_4ce7800216164372baa68d3eb0d72819'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="sxtp:StockIssuedDuringPeriodValueStockIssuanceOfCommonStockUponExerciseOfPreFundedWarrants" contextRef="D20250331" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag456">1,926</ix:nonFraction></span></p></div></td></tr><tr style="height:11.5pt"><td style="width:18%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_617f94068b9a4097ab0c32b1dd772952'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-family: 'Times New Roman';">Issuance of shares for annual performance bonuses, net of shares withheld for taxes</span></p></div></td><td style="width:6%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-tag:'C_3688aa971b0e4fb3880e82eee8898266'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-family: 'Times New Roman';">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-family: 'Times New Roman';">&#160;</span></p></td><td style="width:7%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-tag:'C_4e30cb19559745749e8d2e0a63a4fb67'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-family: 'Times New Roman';">&#160;</span></p></td><td style="width:7.5%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_00f40defe85f4313b2d1d7b5d5ce43b9'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="sxtp:StockIssuedDuringPeriodIssuanceOfSharesForAnnualPerformanceBonusesNetOfSharesWithheldForTaxesinShares" contextRef="D20250331_CommonStockMember" unitRef="Shares" decimals="0" format="ixt:num-dot-decimal" id="Tag642">15,809</ix:nonFraction></span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-family: 'Times New Roman';">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-family: 'Times New Roman';">&#160;</span></p></td><td style="width:6%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_ddc68ecc56b3496abb82c56be62f1757'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="sxtp:StockIssuedDuringPeriodValueIssuanceOfSharesForAnnualPerformanceBonusesNetOfSharesWithheldForTaxes" contextRef="D20250331_CommonStockMember" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag653">2</ix:nonFraction></span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-family: 'Times New Roman';">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-family: 'Times New Roman';">&#160;</span></p></td><td style="width:7.5%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_6a4d0ff21fd647dc9c8810118f584da1'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="sxtp:StockIssuedDuringPeriodValueIssuanceOfSharesForAnnualPerformanceBonusesNetOfSharesWithheldForTaxes" contextRef="D20250331_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag665">103,542</ix:nonFraction></span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-family: 'Times New Roman';">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-family: 'Times New Roman';">&#160;</span></p></td><td style="width:8.5%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-tag:'C_4f3086bbff2c42579dca3f3ebe73134a'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-family: 'Times New Roman';">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-family: 'Times New Roman';">&#160;</span></p></td><td style="width:6%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-tag:'C_a38da4b0d1734d4e9ee4ea240070cadf'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-family: 'Times New Roman';">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-family: 'Times New Roman';">&#160;</span></p></td><td style="width:7.5%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_f579b60169bd4b82955463ee276e154d'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="sxtp:StockIssuedDuringPeriodValueIssuanceOfSharesForAnnualPerformanceBonusesNetOfSharesWithheldForTaxes" contextRef="D20250331_ParentMember" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag466">103,544</ix:nonFraction></span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-family: 'Times New Roman';">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-family: 'Times New Roman';">&#160;</span></p></td><td style="width:6%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-tag:'C_b948fd0e37404d4295b8e611745a9c29'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-family: 'Times New Roman';">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-family: 'Times New Roman';">&#160;</span></p></td><td style="width:7.5%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_bdd08faadfc84e73818f35790e6215bd'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="sxtp:StockIssuedDuringPeriodValueIssuanceOfSharesForAnnualPerformanceBonusesNetOfSharesWithheldForTaxes" contextRef="D20250331" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag457">103,544</ix:nonFraction></span></p></div></td></tr><tr style="height:11.5pt"><td style="width:18%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_072649fe125e4344ade23f2e398b5944'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-family: 'Times New Roman';">Share-based compensation expense</span></p></div></td><td style="width:6%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-tag:'C_dd9dbcdef5b44537a0a6ad0a5304c212'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-family: 'Times New Roman';">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-family: 'Times New Roman';">&#160;</span></p></td><td style="width:7%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-tag:'C_73ac28f2d0164b12ab09fb5ab301f9e6'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-family: 'Times New Roman';">&#160;</span></p></td><td style="width:7.5%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-tag:'C_9fd7f2a12f1f40bcacabbc2ddb913bc8'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-family: 'Times New Roman';">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-family: 'Times New Roman';">&#160;</span></p></td><td style="width:6%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-tag:'C_89abf1b122ee4f2ba96f3e1f01672027'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-family: 'Times New Roman';">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-family: 'Times New Roman';">&#160;</span></p></td><td style="width:7.5%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_924b7ae2cf5846209d83346b0426abdc'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="D20250331_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag666">142,645</ix:nonFraction></span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-family: 'Times New Roman';">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-family: 'Times New Roman';">&#160;</span></p></td><td style="width:8.5%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-tag:'C_4f49667667f14746b4d4d36bdaf5a73d'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-family: 'Times New Roman';">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-family: 'Times New Roman';">&#160;</span></p></td><td style="width:6%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-tag:'C_af3b1999f3144d8b85d7f3409a24c836'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-family: 'Times New Roman';">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-family: 'Times New Roman';">&#160;</span></p></td><td style="width:7.5%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_d0bda1f402ed4fca960d9cb8eedb832a'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="D20250331_ParentMember" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag467">142,645</ix:nonFraction></span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-family: 'Times New Roman';">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-family: 'Times New Roman';">&#160;</span></p></td><td style="width:6%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-tag:'C_d7022451f0b441d296ccb67019549a8e'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-family: 'Times New Roman';">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-family: 'Times New Roman';">&#160;</span></p></td><td style="width:7.5%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_51d384f42b7547bab73bdecbe385d54e'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="D20250331" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag458">142,645</ix:nonFraction></span></p></div></td></tr><tr style="height:11.5pt"><td style="width:18%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_d6a9b62568fc4785b95b22372540ec3e'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-family: 'Times New Roman';">Net foreign translation loss</span></p></div></td><td style="width:6%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-tag:'C_5096462c59ef4bbba3f46420c62012f9'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-family: 'Times New Roman';">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-family: 'Times New Roman';">&#160;</span></p></td><td style="width:7%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-tag:'C_520b44ffb0294e47819366052d8b64e9'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-family: 'Times New Roman';">&#160;</span></p></td><td style="width:7.5%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-tag:'C_56a8a9d2f19447578f279b8c1c0c7c50'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-family: 'Times New Roman';">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-family: 'Times New Roman';">&#160;</span></p></td><td style="width:6%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-tag:'C_b6cf00446bcc41638cac95198c38dcb2'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-family: 'Times New Roman';">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-family: 'Times New Roman';">&#160;</span></p></td><td style="width:7.5%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-tag:'C_c74301a5e5be4027a5686173a3839361'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-family: 'Times New Roman';">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-family: 'Times New Roman';">&#160;</span></p></td><td style="width:8.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">&#160;</span></p></td><td style="width:0.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-family: 'Times New Roman';">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-family: 'Times New Roman';">&#160;</span></p></td><td style="width:6%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_8026ca22634e4a49b53077e657f3a859'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="D20250331_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" sign="-" id="Tag381">9,904</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">)</span></p></td><td style="width:0.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-family: 'Times New Roman';">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-family: 'Times New Roman';">&#160;</span></p></td><td style="width:7.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_56135012a2e144eabd1c811420d1469c'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="D20250331_ParentMember" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" sign="-" id="Tag382">9,904</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">)</span></p></td><td style="width:0.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-family: 'Times New Roman';">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-family: 'Times New Roman';">&#160;</span></p></td><td style="width:6%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-tag:'C_d3e8ad2571cf46cb806e02dd7a154946'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-family: 'Times New Roman';">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-family: 'Times New Roman';">&#160;</span></p></td><td style="width:7.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_25fc69d43b2341f28c9fc71dd6b780d2'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="D20250331" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" sign="-" id="Tag383">9,904</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">)</span></p></td></tr><tr style="height:11.5pt"><td style="width:18%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_3a0ce0c2ce4d42279560c27dc25982c8'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-family: 'Times New Roman';">Net loss</span></p></div></td><td style="width:6%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-tag:'C_c4cb34b3eaa04462be48f036e2afb619'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-family: 'Times New Roman';">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-family: 'Times New Roman';">&#160;</span></p></td><td style="width:7%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-tag:'C_ec9735f8997c4b54b2be55446590efcf'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-family: 'Times New Roman';">&#160;</span></p></td><td style="width:7.5%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-tag:'C_73e34007d3fe4bbe9f72c0abbb2e0231'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-family: 'Times New Roman';">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-family: 'Times New Roman';">&#160;</span></p></td><td style="width:6%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-tag:'C_c235b63c429c4df5bb1974f05df9fc3b'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-family: 'Times New Roman';">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-family: 'Times New Roman';">&#160;</span></p></td><td style="width:7.5%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-tag:'C_f60e7ba414f446e98265303e4b911cc9'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-family: 'Times New Roman';">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-family: 'Times New Roman';">&#160;</span></p></td><td style="width:8.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_18326ce0d14840e0b3d4f1278d9abe9d'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="D20250331_RetainedEarningsUnappropriatedMember" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" sign="-" id="Tag257">1,876,549</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">)</span></p></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-family: 'Times New Roman';">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-family: 'Times New Roman';">&#160;</span></p></td><td style="width:6%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-tag:'C_e772961809444da093abc36af6f33ac4'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-family: 'Times New Roman';">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-family: 'Times New Roman';">&#160;</span></p></td><td style="width:7.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_a3693802c15d4d66a19c9bd9bd6663d2'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="D20250331_ParentMember" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" sign="-" id="Tag258">1,876,549</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">)</span></p></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-family: 'Times New Roman';">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-family: 'Times New Roman';">&#160;</span></p></td><td style="width:6%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_f569df3f970f4e9598726088de103823'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="D20250331_NoncontrollingInterestMember" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" sign="-" id="Tag259">752</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">)</span></p></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-family: 'Times New Roman';">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-family: 'Times New Roman';">&#160;</span></p></td><td style="width:7.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_b4427fb7e49d4e6597aaf28ffbdfa151'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="D20250331" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" sign="-" id="Tag260">1,877,301</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">)</span></p></td></tr><tr style="height:11.5pt"><td style="width:18%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_277dd939a743483dab893c9c5c6ea177'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-family: 'Times New Roman';">Share rounding adjustment for reverse stock split</span></p></div></td><td style="width:6%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-tag:'C_a3916987a1424c6aa22cc988c102a9f9'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-family: 'Times New Roman';">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-family: 'Times New Roman';">&#160;</span></p></td><td style="width:7%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-tag:'C_c365f83c74e5455c8270f3f506e69e48'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-family: 'Times New Roman';">&#160;</span></p></td><td style="width:7.5%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_04ac5121f07d4a9481533a3a93f6685f'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits" contextRef="D20250331_CommonStockMember" unitRef="Shares" decimals="0" format="ixt:num-dot-decimal" id="Tag385">38</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">)</span></p></td><td style="width:0.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-family: 'Times New Roman';">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-family: 'Times New Roman';">&#160;</span></p></td><td style="width:6%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-tag:'C_dfcb1604e88e45319f18503aaa05858f'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-family: 'Times New Roman';">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-family: 'Times New Roman';">&#160;</span></p></td><td style="width:7.5%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-tag:'C_0e42428ddb7d49c5b629b68fe97c55de'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-family: 'Times New Roman';">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-family: 'Times New Roman';">&#160;</span></p></td><td style="width:8.5%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">&#160;</span></p></td><td style="width:0.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-family: 'Times New Roman';">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-family: 'Times New Roman';">&#160;</span></p></td><td style="width:6%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-tag:'C_442099f5a18b4426b56e279e8e8ee3a5'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-family: 'Times New Roman';">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-family: 'Times New Roman';">&#160;</span></p></td><td style="width:7.5%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-tag:'C_4b8b36fef6fe4972bc15cf15e134d463'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-family: 'Times New Roman';">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-family: 'Times New Roman';">&#160;</span></p></td><td style="width:6%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-tag:'C_c8d3b567080c4d789e32df44037bedd4'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-family: 'Times New Roman';">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-family: 'Times New Roman';">&#160;</span></p></td><td style="width:7.5%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-tag:'C_402d9da801074d209ffa3a3a58b3d1e3'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td></tr><tr style="height:11.5pt"><td style="width:18%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_454053df4d7749cca63be7d63eb66231'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">Balance&#8212; March 31, 2025 (unaudited)</span></p></div></td><td style="width:6%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_234f71fac72c4c7ea800d8e2653979c0'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="I20250331_PreferredStockMember_SeriesAPreferredStockMember" unitRef="Shares" decimals="0" format="ixt:num-dot-decimal" id="Tag483">76,480</ix:nonFraction></span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_622defd26a8546cc85d6359bd370010f'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">$</span></p></div></td><td style="width:7%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_d959d2b367c14570a2894db50e72c8d2'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="I20250331_PreferredStockMember_SeriesAPreferredStockMember" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag482">9,567,439</ix:nonFraction></span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:7.5%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_4c278bfa54044a61956d192166f0f1da'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="I20250331_CommonStockMember" unitRef="Shares" decimals="0" format="ixt:num-dot-decimal" id="Tag644">1,472,891</ix:nonFraction></span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_900f386d1c854c87a4dd7f61010a5333'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">$</span></p></div></td><td style="width:6%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_be109758a2cc4accbf6acd02125f21b0'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="I20250331_CommonStockMember" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag650">147</ix:nonFraction></span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_da3cdd3e084e42a6a8f7b540951cf32d'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">$</span></p></div></td><td style="width:7.5%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_de760d3b56554f8b8b82ef9abc02455e'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="I20250331_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag667">36,821,588</ix:nonFraction></span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_f0d11bea339c4df2898498e9dacc1412'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">$</span></p></div></td><td style="width:8.5%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">(</span><span style="-aw-sdt-tag:'C_5fce9cc758fe47359cac0e681257a807'; font-family: 'Times New Roman'"><span style="font-weight:bold"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="I20250331_RetainedEarningsUnappropriatedMember" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" sign="-" id="Tag261">42,404,506</ix:nonFraction></span></span><span style="font-weight:bold; font-family: 'Times New Roman'">)</span></p></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_4b9b4086723b46a6af25bdbaf48b62b7'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">$</span></p></div></td><td style="width:6%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_56598a81f58847a7b85a7ed1e5f86da8'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="I20250331_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag462">125,567</ix:nonFraction></span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_9829072446f24f4c94f07004b69a30f4'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">$</span></p></div></td><td style="width:7.5%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_39b363ee7f0a4ebf8ca2f802e9758d04'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="I20250331_ParentMember" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag468">4,110,235</ix:nonFraction></span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_94f2ba910f674f9fa7eb1d1ec20285ad'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">$</span></p></div></td><td style="width:6%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">(</span><span style="-aw-sdt-tag:'C_1803dff2570546a882c0e0584e770b1c'; font-family: 'Times New Roman'"><span style="font-weight:bold"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="I20250331_NoncontrollingInterestMember" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" sign="-" id="Tag262">81,346</ix:nonFraction></span></span><span style="font-weight:bold; font-family: 'Times New Roman'">)</span></p></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_be9f195f888c425a8d7c43afe22603f9'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">$</span></p></div></td><td style="width:7.5%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_de14bea35b224765b02c7afea3074f37'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="I20250331" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag459">4,028,889</ix:nonFraction></span></p></div></td></tr><tr style="height:11.5pt"><td style="width:18%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_403785419d4b43a99a19545e5711a5f9'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-family: 'Times New Roman';">Share-based compensation expense</span></p></div></td><td style="width:6%; border-top:4.5pt double #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-tag:'C_d667fad10133481584c189c0e5ab3b1c'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:4.5pt double #000000; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:7%; border-top:4.5pt double #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-tag:'C_509e23d59bc140689d038021b8752b4f'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:7.5%; border-top:4.5pt double #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-tag:'C_496cfb51aa784a939e1d0f7d68c9ef8c'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:4.5pt double #000000; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:6%; border-top:4.5pt double #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-tag:'C_9afd1e31ea7f42d78ef498a38eadfbbe'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:4.5pt double #000000; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:7.5%; border-top:4.5pt double #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_f8b5cf90c1474193bff5f850e167caeb'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="D20250630_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag661">34,503</ix:nonFraction></span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:4.5pt double #000000; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:8.5%; border-top:4.5pt double #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-tag:'C_d05c32e8d54e448ab3cf4b44e99210f7'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:4.5pt double #000000; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:6%; border-top:4.5pt double #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-tag:'C_f9ff59f26bad4e71bb54622f70ee1342'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:4.5pt double #000000; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:7.5%; border-top:4.5pt double #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_8a8e355b3a2946819065d28e192d1aaf'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="D20250630_ParentMember" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag553">34,503</ix:nonFraction></span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:4.5pt double #000000; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:6%; border-top:4.5pt double #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-tag:'C_bc4fa54d7e1c447a9bc567b7955ff141'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:4.5pt double #000000; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:7.5%; border-top:4.5pt double #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_eba820ca06674889bf6519efab6a76b7'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="D20250630_18" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag556">34,503</ix:nonFraction></span></p></div></td></tr><tr style="height:11.5pt"><td style="width:18%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_79187ebcd54048eca8f3c7cdb48d78d9'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-family: 'Times New Roman';">Net foreign translation gain</span></p></div></td><td style="width:6%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-tag:'C_ae49b729c00945e691973290116f306d'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:7%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-tag:'C_a9cd35c0d6ed4f438bde85e6e5cefabd'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:7.5%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-tag:'C_c4925ce13d354f7396a94cb7cf9952cd'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:6%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-tag:'C_2d95e434e547432e82cb66338ee52888'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:7.5%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-tag:'C_b5370f33c91847f3bbfff257bda56d11'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:8.5%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-tag:'C_838b2ff906db4ccf972739b4075c8155'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:6%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_0624533fac914b5c81fb6ca6d2fdd8da'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="D20250630_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag626">17,242</ix:nonFraction></span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:7.5%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_ef1078f8a4bd4f77b8cba67644105ea4'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="D20250630_ParentMember" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag628">17,242</ix:nonFraction></span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:6%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-tag:'C_a8749b8980c347bca5e80821f67459cc'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:7.5%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_0ee92dae6c9a417fa8b3dd4632c165d5'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="D20250630_18" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag627">17,242</ix:nonFraction></span></p></div></td></tr><tr style="height:11.5pt"><td style="width:18%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_58454fb4c4fc417680adba5a6066b126'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-family: 'Times New Roman';">Net loss</span></p></div></td><td style="width:6%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-tag:'C_6f2d6f878b2c4eb4916247597b9772ae'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:7%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-tag:'C_53d78911213242ae819eb54bb0c968d8'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:7.5%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-tag:'C_3bb5b87a85614cb3b545daa0bc1ce66f'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:6%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-tag:'C_d56d49276da54775bda3c7c63a166aa7'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:7.5%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-tag:'C_d8999f7d2e30468c89652481a855c1e4'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:8.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_037346e930d24e31bc46cfdade27c464'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="D20250630_RetainedEarningsUnappropriatedMember" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" sign="-" id="Tag346">1,733,726</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">)</span></p></td><td style="width:0.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:6%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-tag:'C_4f047596fccd4311846ad4996bc19763'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:7.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_e55580a7339e4f889da5afe5e03d0a0e'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="D20250630_ParentMember" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" sign="-" id="Tag347">1,733,726</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">)</span></p></td><td style="width:0.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:6%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_cefbb52a2b1e426fbf7e8b2778a04219'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="D20250630_NoncontrollingInterestMember" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" sign="-" id="Tag349">1,204</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">)</span></p></td><td style="width:0.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:7.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_a9b5dbb3ee7342aebcc1dd864dd98375'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="D20250630_18" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" sign="-" id="Tag348">1,734,930</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">)</span></p></td></tr><tr style="height:11.5pt"><td style="width:18%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_3bf09e815baf4dcd99348c6b34c75fec'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">Balance&#8212; June 30, 2025 (unaudited)</span></p></div></td><td style="width:6%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_5a1669a8fe714a598d2ff0bbfde3df3b'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="I20250630_PreferredStockMember_SeriesAPreferredStockMember" unitRef="Shares" decimals="0" format="ixt:num-dot-decimal" id="Tag558">76,480</ix:nonFraction></span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_9f472305bf444348a7618b1582d4b45b'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">$</span></p></div></td><td style="width:7%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_11908f8a4aa44ec4a03708c84f8ed442'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="I20250630_PreferredStockMember_SeriesAPreferredStockMember" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag557">9,567,439</ix:nonFraction></span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:7.5%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_033d585f3f144843964fa0e11a3a3f86'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="I20250630_CommonStockMember" unitRef="Shares" decimals="0" format="ixt:num-dot-decimal" id="Tag645">1,472,891</ix:nonFraction></span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_7c755288a80d44df807bb43b7c3d69aa'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">$</span></p></div></td><td style="width:6%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_460e355e9379435b9e34a3ad0e79b1f2'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="I20250630_CommonStockMember" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag654">147</ix:nonFraction></span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_5c182fd7943d4e958b54b24914cbfdea'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">$</span></p></div></td><td style="width:7.5%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_dfae731f0cfd4c19b3b363c18035f902'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="I20250630_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag668">36,856,091</ix:nonFraction></span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_40051311d86644c2a9ef73006efd69a5'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">$</span></p></div></td><td style="width:8.5%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">(</span><span style="-aw-sdt-tag:'C_ad1f998b25ac4b849b83818096181a4d'; font-family: 'Times New Roman'"><span style="font-weight:bold"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="I20250630_RetainedEarningsUnappropriatedMember" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" sign="-" id="Tag344">44,138,232</ix:nonFraction></span></span><span style="font-weight:bold; font-family: 'Times New Roman'">)</span></p></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_d62b21036bcf4961ada9918e3d003003'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">$</span></p></div></td><td style="width:6%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_8b3c1f7e88244757a7be372ec4a3eb0d'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="I20250630_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag552">142,809</ix:nonFraction></span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_d1529eddec46494cb68aac2c7043bb3e'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">$</span></p></div></td><td style="width:7.5%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_e102d24101fb4c1594da9a116b78c135'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="I20250630_ParentMember" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag554">2,428,254</ix:nonFraction></span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_4ae04495ca14436c880e5cd7810611f0'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">$</span></p></div></td><td style="width:6%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">(</span><span style="-aw-sdt-tag:'C_f579d47ec2534deeb5e47ace4d10809b'; font-family: 'Times New Roman'"><span style="font-weight:bold"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="I20250630_NoncontrollingInterestMember" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" sign="-" id="Tag345">82,550</ix:nonFraction></span></span><span style="font-weight:bold; font-family: 'Times New Roman'">)</span></p></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_d871b3d4a4e249e880f275b5f2f4492f'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">$</span></p></div></td><td style="width:7.5%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_fa94c727bf1b44d6b03ff57d07f5ff6d'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="I20250630" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag555">2,345,704</ix:nonFraction></span></p></div></td></tr><tr style="height:11.5pt"><td style="width:18%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_4e97ea9480db41a68f73b90226fe6b57'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-family: 'Times New Roman';">Issuance of common stock and warrants pursuant to July 2025 Offering, net of offering costs paid at closing and deferred offering costs (Note 6)</span></p></div></td><td style="width:6%; border-top:4.5pt double #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-tag:'C_240e29b078a0443c8b352a3c88b85cc4'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:4.5pt double #000000; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:7%; border-top:4.5pt double #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-tag:'C_f62aacba946548b99da5af64639dd453'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:7.5%; border-top:4.5pt double #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_27cc74e6b52f49f79c7517d8d8f71173'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="sxtp:StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsPursuantToJuly2025OfferingNetOfOfferingCosts" contextRef="D20250930_CommonStockMember_3" unitRef="Shares" decimals="0" format="ixt:num-dot-decimal" id="Tag648">1,753,314</ix:nonFraction></span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:4.5pt double #000000; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:6%; border-top:4.5pt double #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_ba1dd0733d224a5ea56a7c5152b2bb23'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="sxtp:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPursuantToJuly2025OfferingNetOfOfferingCosts" contextRef="D20250930_CommonStockMember_3" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag657">175</ix:nonFraction></span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:4.5pt double #000000; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:7.5%; border-top:4.5pt double #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_9d44be8e79544c06a01e79f8f202929d'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="sxtp:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPursuantToJuly2025OfferingNetOfOfferingCosts" contextRef="D20250930_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag671">4,281,125</ix:nonFraction></span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:4.5pt double #000000; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:8.5%; border-top:4.5pt double #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-tag:'C_f3b9c4d1ca0348979ec818ebef800511'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:4.5pt double #000000; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:6%; border-top:4.5pt double #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-tag:'C_d281829cd45a4201862c02b569d8d4b9'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:4.5pt double #000000; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:7.5%; border-top:4.5pt double #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_531c30b823da408f92b687fd652f34a6'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="sxtp:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPursuantToJuly2025OfferingNetOfOfferingCosts" contextRef="D20250930_ParentMember" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag622">4,281,300</ix:nonFraction></span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:4.5pt double #000000; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:6%; border-top:4.5pt double #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-tag:'C_95883561ddf342098f6955ba08d7541d'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:4.5pt double #000000; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:7.5%; border-top:4.5pt double #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_a1eee482c6f84c5eb8f47e1ba12ef36e'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="sxtp:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPursuantToJuly2025OfferingNetOfOfferingCosts" contextRef="D20250930" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag623">4,281,300</ix:nonFraction></span></p></div></td></tr><tr style="height:11.5pt"><td style="width:18%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_5a855389cceb4575be2dc32b28ca6bfa'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-family: 'Times New Roman';">Issuance of common stock upon exercise of Pre-Funded Warrants</span></p></div></td><td style="width:6%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-tag:'C_89e0b40396a4450e8802c48bd0c6ac5b'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:7%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-tag:'C_f4bef8e8242340708ae532704b9a9d63'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:7.5%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_2a8dcaa400034886b27de176f541fa9b'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="sxtp:StockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfPreFundedWarrantsinShares" contextRef="D20250930_CommonStockMember_3" unitRef="Shares" decimals="0" format="ixt:num-dot-decimal" id="Tag647">878,264</ix:nonFraction></span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:6%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_b8123a43ce5a4e6ebfa0f460da21460b'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="sxtp:StockIssuedDuringPeriodValueStockIssuanceOfCommonStockUponExerciseOfPreFundedWarrants" contextRef="D20250930_CommonStockMember_3" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag656">88</ix:nonFraction></span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:7.5%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_ee83554c5237407794475ed82eccad39'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="sxtp:StockIssuedDuringPeriodValueStockIssuanceOfCommonStockUponExerciseOfPreFundedWarrants" contextRef="D20250930_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag670">790</ix:nonFraction></span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:8.5%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-tag:'C_f7740ba075eb4aa59b03a1c0926adf04'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:6%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-tag:'C_7eeb832088b946dcb4ff3ed95c38b617'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:7.5%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_054c293260ef49aa9088dfeda6a9fa88'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="sxtp:StockIssuedDuringPeriodValueStockIssuanceOfCommonStockUponExerciseOfPreFundedWarrants" contextRef="D20250930_ParentMember" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag564">878</ix:nonFraction></span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:6%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-tag:'C_825dd14373eb48f49f19f0bf78ba08b4'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:7.5%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_e07df580cf994731a49e63f4ccfcbb4c'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="sxtp:StockIssuedDuringPeriodValueStockIssuanceOfCommonStockUponExerciseOfPreFundedWarrants" contextRef="D20250930" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag563">878</ix:nonFraction></span></p></div></td></tr><tr style="height:11.5pt"><td style="width:18%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_940fbd38cc08487481b538ddfa60082d'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-family: 'Times New Roman';">Share-based compensation expense</span></p></div></td><td style="width:6%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-tag:'C_0a00e43cedef4c1c86bc2f704406f8ef'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:7%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-tag:'C_4954a2284eab497d8aaed119e6ba6599'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:7.5%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-tag:'C_0ddab18dbc1e4c39af0fd5bc5a8eb3b6'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:6%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-tag:'C_12630d4f579142628ce2f959eaf2f3fb'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:7.5%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_b1d90be1a9f24e07a0b42a4e4f21b036'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="D20250930_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag660">34,882</ix:nonFraction></span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:8.5%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-tag:'C_458de83c62e04250b79eb4850a5f31a9'"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="D20250930_RetainedEarningsUnappropriatedMember" xsi:nil="true" unitRef="USD" id="Tag612"></ix:nonFraction><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:6%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-tag:'C_367e62cc26434565bbf3d0523130c3f1'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:7.5%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_a754c3f915654d96b0bc274478f1e844'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="D20250930_ParentMember" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag562">34,882</ix:nonFraction></span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:6%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-tag:'C_27e1d0e40c97400cb2fa14673ec77c7e'"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="D20250930_NoncontrollingInterestMember" xsi:nil="true" unitRef="USD" id="Tag611"></ix:nonFraction><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:7.5%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_b8e9870179d54cdd8d6b70f86e16ee66'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="D20250930" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag561">34,882</ix:nonFraction></span></p></div></td></tr><tr style="height:11.5pt"><td style="width:18%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_161d04679acd4e318afaf35ff9d62d60'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-family: 'Times New Roman';">Net foreign translation gain</span></p></div></td><td style="width:6%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-tag:'C_d441352c4123489e9d925fbe5d8866a6'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:7%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-tag:'C_705d44532a874c519664d0238f199b4f'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:7.5%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-tag:'C_689de796128d413ab5421a6b21e8b5fa'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:6%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-tag:'C_ae39ee830a294439865e2ede8bf5e2ba'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:7.5%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-tag:'C_b4fc5d0f62f349428a19ab8fb92c3d39'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:8.5%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-tag:'C_1bfdf304f02e430dba476d81a7723b25'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:6%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_a30d0e1524c9433ca52a0700d2f3766b'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="D20250930_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag629">1,230</ix:nonFraction></span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:7.5%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_64cbe8ad26e84c74b5da683d6a802f9c'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="D20250930_ParentMember" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag630">1,230</ix:nonFraction></span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:6%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-tag:'C_9048f219d79542319bca1e10bd1cf14c'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:7.5%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_bc7592bc95f64457b8984c69015ab09a'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="D20250930" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag631">1,230</ix:nonFraction></span></p></div></td></tr><tr style="height:11.5pt"><td style="width:18%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_e948d0b737b4409ba615933ef9685ec8'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-family: 'Times New Roman';">Net loss</span></p></div></td><td style="width:6%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-tag:'C_d9156f4f2d5547dabc1a2faa79eecf77'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:7%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-tag:'C_eda1961f198d4c62a69f161285a14e84'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:7.5%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-tag:'C_d317637ab7ef4c5c8d33e5184c5986e0'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:6%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-tag:'C_6902cd1b79564ea18906f9f9699aa670'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:7.5%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-tag:'C_bfe40843cf064ae7943f2dd35262625a'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:8.5%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_cd3537b63d4a41e9882f0a84ceeb5b6e'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="D20250930_RetainedEarningsUnappropriatedMember" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" sign="-" id="Tag350">2,316,324</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">)</span></p></td><td style="width:0.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:6%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-tag:'C_a08d59115e2d434a8c5f3f7b53da1ca8'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:7.5%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_9e2a22415b294315a0068e05bacb6ed1'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="D20250930_ParentMember" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" sign="-" id="Tag351">2,316,324</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">)</span></p></td><td style="width:0.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:6%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_9588ff373e9b4a8ab3e4c3b57bc5a1f6'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="D20250930_NoncontrollingInterestMember" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" sign="-" id="Tag352">712</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">)</span></p></td><td style="width:0.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:7.5%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_187edcc75d264889b46290d2d5115681'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="D20250930" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" sign="-" id="Tag371">2,317,036</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">)</span></p></td></tr><tr style="height:11.5pt"><td style="width:18%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_b8c49cc0e74948b287efa78cda0b175e'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">Balance&#8212; September 30, 2025 (unaudited)</span></p></div></td><td style="width:6%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_5ab592e704684f00a1c1a83bcedd2eb6'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="I20250930_PreferredStockMember_SeriesAPreferredStockMember" unitRef="Shares" decimals="0" format="ixt:num-dot-decimal" id="Tag548">76,480</ix:nonFraction></span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_689be7593c0b4d70a7d305cdf6c126a4'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">$</span></p></div></td><td style="width:7%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_52fc601f4bde495c90f079c03ac80f48'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="I20250930_PreferredStockMember_SeriesAPreferredStockMember" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag549">9,567,439</ix:nonFraction></span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:7.5%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_edfaca3914574418890c35588f8449a7'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="I20250930_CommonStockMember_1" unitRef="Shares" decimals="0" format="ixt:num-dot-decimal" id="Tag646">4,104,469</ix:nonFraction></span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_6f769292af6f416dbe08d6282e0fcd49'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">$</span></p></div></td><td style="width:6%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_b1079aa78ab34e7a8f0bfb5fb1e201d2'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="I20250930_CommonStockMember_1" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag655">410</ix:nonFraction></span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_a59c12cbb53649dc97768f8fd8d46da5'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">$</span></p></div></td><td style="width:7.5%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_d83eaf5f105a4a29863b1b123eece8d4'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="I20250930_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag669">41,172,888</ix:nonFraction></span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_3501bdaf47bc417facb54a2893ff46b3'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">$</span></p></div></td><td style="width:8.5%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">(</span><span style="-aw-sdt-tag:'C_d9b5c0515f1744b6957dffeda8f098cb'; font-family: 'Times New Roman'"><span style="font-weight:bold"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="I20250930_RetainedEarningsUnappropriatedMember" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" sign="-" id="Tag343">46,454,556</ix:nonFraction></span></span><span style="font-weight:bold; font-family: 'Times New Roman'">)</span></p></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_77fb789859104a609efb26cd4947b8dc'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">$</span></p></div></td><td style="width:6%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_0ae60d0ee08a4f1a827ebc6c4c4ef066'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="I20250930_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag636">144,039</ix:nonFraction></span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_99b8b4fa61774c25b6714d9545289097'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">$</span></p></div></td><td style="width:7.5%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_ad4629c5816e4a25a53e79b3e4a28c78'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="I20250930_ParentMember" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag550">4,430,220</ix:nonFraction></span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_cc184fb4a9d84dfaaf0be55a6f81ae86'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">$</span></p></div></td><td style="width:6%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">(</span><span style="-aw-sdt-tag:'C_f7eabea45e3148cf966171e0871f6c99'; font-family: 'Times New Roman'"><span style="font-weight:bold"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="I20250930_NoncontrollingInterestMember" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" sign="-" id="Tag342">83,262</ix:nonFraction></span></span><span style="font-weight:bold; font-family: 'Times New Roman'">)</span></p></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_329a254002ce463aa09d994015807e90'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">$</span></p></div></td><td style="width:7.5%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_d99e9a3d8c09432389e9b89c7bf39b55'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="I20250930" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag551">4,346,958</ix:nonFraction></span></p></div></td></tr></tbody></table></div><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="-aw-import:ignore">&#160;</span></p><table cellspacing="0" cellpadding="0" style="width:97.44%"><tbody><tr><td style="vertical-align:top"><div style="-aw-sdt-tag:'a21-dce-86e-c9f-48a8'; -aw-sdt-title:'STATEMENTS OF SHAREHOLDERS\' EQUITY_T1F1'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-size:6.67pt; vertical-align:super; font-family: 'Times New Roman'">(1)</span><span style="font-family: 'Times New Roman';"> </span><span style="-aw-sdt-tag:'547-3fc-aef-70b-eb6d'; font-family: 'Times New Roman'"><span>Prior periods presented have been adjusted to reflect the 1:5 reverse stock split on February 24, 2025.</span></span></p></div></td></tr></tbody></table><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-style:italic">The accompanying notes are an integral part of these unaudited consolidated condensed financial statements.</span></p><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore">&#160;</span></p><div style="-aw-sdt-tag:'PG_c85f491779f5c668df68'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-family: 'Times New Roman';">3</span></p><div><hr style="width: 100%; color: #000000; background-color: #000000; margin: 1rem 0;"/></div></div></div><div class="Section_7"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold">60 DEGREES PHARMACEUTICALS, INC.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold">CONSOLIDATED CONDENSED STATEMENTS OF SHAREHOLDERS&#8217; EQUITY (UNAUDITED)</span></p><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore">&#160;</span></p><div style="-aw-sdt-tag:'c0b30333621c599836cf'; -aw-sdt-title:'STATEMENTS OF SHAREHOLDERS&#8217; EQUITY_T2'"><table cellspacing="0" cellpadding="0" style="width:100%; border-collapse:collapse"><tbody><tr style="height:11.5pt"><td style="width:18%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="27" style="border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_36e13cca6a97453f8a9952fd238ca91b'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">For the Three and Nine Months Ended September 30, 2024</span></p></div></td></tr><tr style="height:11.5pt"><td style="width:18%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="4" style="border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_cf0e042c816049e89573873852d4d563'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">Series A Preferred Stock</span></p></div></td><td style="width:0.5%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="4" style="border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; padding-right:5.4pt; padding-left:5.4pt; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_16c5fbef0d634b00b5ee2b5aa99d9eb2'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">Common Stock</span><span style="font-size:5.33pt; font-weight:bold; vertical-align:super; font-family: 'Times New Roman'">(1)</span></p></div></td><td style="width:0.5%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="2" rowspan="2" style="border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_53ca7a5d65e244558fb4b3076b891c6c'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">Additional Paid-In Capital</span><span style="font-size:5.33pt; font-weight:bold; vertical-align:super; font-family: 'Times New Roman'">(1)</span></p></div></td><td style="width:0.5%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="2" rowspan="2" style="border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_32ca995833fd4d4799e6f4639b569e6a'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">Accumulated Deficit</span></p></div></td><td style="width:0.5%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="2" rowspan="2" style="border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_d05e5c7255d7476aafb5aff3872c8fdd'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">Accumulated Other Comprehensive Income (Loss)</span></p></div></td><td style="width:0.5%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="2" rowspan="2" style="border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_d650a8011cdb4b3b92d488230b7af987'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">Total Shareholders&#8217; Equity Attributable to 60P</span></p></div></td><td style="width:0.5%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="2" rowspan="2" style="border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_534232efccee48dca9c40341c3bd61f0'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">Noncontrolling Interest on Shareholders</span></p></div></td><td style="width:0.5%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="2" rowspan="2" style="border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_c91b5c3cfc9a429cba35602d6dafd540'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">Total Shareholders' Equity</span></p></div></td></tr><tr style="height:11.5pt"><td style="width:18%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:6%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_b2f5e6bd83004e72b1040d702f5335e2'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">Shares</span></p></div></td><td style="width:0.5%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="2" style="border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_066f77e851ff4c1f9979b1bf9332738f'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">Amount</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:7.5%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_6b8cf226396248b689fc06d414371a03'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">Shares</span></p></div></td><td style="width:0.5%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="2" style="border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_5d935ea3572344e083b9dcf833100f1c'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">Amount</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td></tr><tr style="height:11.5pt"><td style="width:18%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_67353c50079e491caffaeabc35a635ab'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">Balance&#8212;December 31, 2023</span></p></div></td><td style="width:6%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_27ebf755bc384141a13fcf50360f838d'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="I20231231_PreferredStockMember_SeriesAPreferredStockMember" unitRef="Shares" decimals="0" format="ixt:num-dot-decimal" id="Tag449">78,803</ix:nonFraction></span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_ebbf8e50bcd7473196bd399311793b46'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">$</span></p></div></td><td style="width:7%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_70ea9f13e1974af7819789412c0e359a'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="I20231231_PreferredStockMember_SeriesAPreferredStockMember" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag450">9,858,040</ix:nonFraction></span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:7.5%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_090bcc3efac84b5589672333ac186f76'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="I20231231_CommonStockMember" unitRef="Shares" decimals="0" format="ixt:num-dot-decimal" id="Tag672">96,847</ix:nonFraction></span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_6c4c7eac48f74f34a4fa5f9809525a0e'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">$</span></p></div></td><td style="width:6%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_75691fdff56f4b10b5215c40cae67dd2'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="I20231231_CommonStockMember" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag684">10</ix:nonFraction></span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_7bc3dd40bcc144f1bca551778b44bd1e'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">$</span></p></div></td><td style="width:7.5%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_5483014963134c3faad64c8b71dfc239'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="I20231231_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag694">27,457,373</ix:nonFraction></span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_192b37d841a54506a9a18d16909741e8'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">$</span></p></div></td><td style="width:8.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">(</span><span style="-aw-sdt-tag:'C_3631d234d7e046e9b83e97870242bd6d'; font-family: 'Times New Roman'"><span style="font-weight:bold"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="I20231231_RetainedEarningsUnappropriatedMember" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" sign="-" id="Tag269">32,580,850</ix:nonFraction></span></span><span style="font-weight:bold; font-family: 'Times New Roman'">)</span></p></td><td style="width:0.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_8decdd382b174cb086c2055b5ace033b'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">$</span></p></div></td><td style="width:6%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_cbf07df56a7941ed883d55bc8b889ee9'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="I20231231_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag476">135,561</ix:nonFraction></span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_47e2db2d393849a69cbe880cd4ba0d30'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">$</span></p></div></td><td style="width:7.5%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_0de0892dc3eb4489ae4400f713697949'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="I20231231_ParentMember" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag477">4,870,134</ix:nonFraction></span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_021a7fdb21f7471798d01929ebe15b36'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">$</span></p></div></td><td style="width:6%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">(</span><span style="-aw-sdt-tag:'C_44eaa70e56874831a089611d202acf4d'; font-family: 'Times New Roman'"><span style="font-weight:bold"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="I20231231_NoncontrollingInterestMember" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" sign="-" id="Tag270">72,038</ix:nonFraction></span></span><span style="font-weight:bold; font-family: 'Times New Roman'">)</span></p></td><td style="width:0.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_18785658991a4296a69b196de247298e'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">$</span></p></div></td><td style="width:7.5%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_0ac78b74bbba431ab30ca573d17939df'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="I20231231" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag478">4,798,096</ix:nonFraction></span></p></div></td></tr><tr style="height:11.5pt"><td style="width:18%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_91b3a8aca87f4c18b465b7a288a68fe4'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-family: 'Times New Roman';">Issuance of common stock and warrants, net of underwriting discounts and offering costs paid at closing and deferred offering costs (Note 6)</span></p></div></td><td style="width:6%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-tag:'C_28f4c4ed87944743b13adc6a9a259a85'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:7%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-tag:'C_2a535d8135eb4799879c28b57c984ade'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:7.5%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_4baeae963c684ab689cb84b2f526cca4'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="sxtp:StockIssuedDuringPeriodSharesOfCommonStockAndWarrantsOfUnderwritingDiscountsAndOfferingCostsPaidAtClosingAndDeferredOfferingCosts" contextRef="D20240331_CommonStockMember" unitRef="Shares" decimals="0" format="ixt:num-dot-decimal" id="Tag673">87,683</ix:nonFraction></span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:6%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_fb5b70f6207f43abab89caa7a1afa198'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="sxtp:IssuanceOfCommonStockAndWarrantsOfUnderwritingDiscountsAndOfferingCostsPaidAtClosingAndDeferredOfferingCosts" contextRef="D20240331_CommonStockMember" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag685">9</ix:nonFraction></span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:7.5%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_c93f57a7eeea4ecc9c87aea58dc5441d'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="sxtp:IssuanceOfCommonStockAndWarrantsOfUnderwritingDiscountsAndOfferingCostsPaidAtClosingAndDeferredOfferingCosts" contextRef="D20240331_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag695">1,898,287</ix:nonFraction></span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:8.5%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-tag:'C_7703eafbad4a4fac9b2307db139efbc6'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:6%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-tag:'C_e83bc2229a264cecb528dd6be3efafdd'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:7.5%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_304afd719ac144828f2480a6228c2103'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="sxtp:IssuanceOfCommonStockAndWarrantsOfUnderwritingDiscountsAndOfferingCostsPaidAtClosingAndDeferredOfferingCosts" contextRef="D20240331_ParentMember" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag451">1,898,296</ix:nonFraction></span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:6%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-tag:'C_6784c9b6a38c4db89db997df1d3f2a67'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:7.5%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_0dcd441daf374fcd85563b006ab16914'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="sxtp:IssuanceOfCommonStockAndWarrantsOfUnderwritingDiscountsAndOfferingCostsPaidAtClosingAndDeferredOfferingCosts" contextRef="D20240331" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag469">1,898,296</ix:nonFraction></span></p></div></td></tr><tr style="height:11.5pt"><td style="width:18%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_0775f93a74554829a35e26d83d239fff'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-family: 'Times New Roman';">Issuance of common stock upon exercise of Pre-Funded Warrants</span></p></div></td><td style="width:6%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-tag:'C_e153f5ff9f2e4532b891778a74f48a71'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:7%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-tag:'C_e0361da9c0ce43239b0b888c70512735'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:7.5%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_1d2968b208444e84b23be0cbf4656672'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="sxtp:StockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfPreFundedWarrantsinShares" contextRef="D20240331_CommonStockMember" unitRef="Shares" decimals="0" format="ixt:num-dot-decimal" id="Tag681">8,326</ix:nonFraction></span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:6%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_2e40d8b22f4a40588305b2cdf7202ddb'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="sxtp:StockIssuedDuringPeriodValueStockIssuanceOfCommonStockUponExerciseOfPreFundedWarrants" contextRef="D20240331_CommonStockMember" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag686">1</ix:nonFraction></span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:7.5%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_9424145021404bb093f9345b8f26e829'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="sxtp:StockIssuedDuringPeriodValueStockIssuanceOfCommonStockUponExerciseOfPreFundedWarrants" contextRef="D20240331_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag696">4,994</ix:nonFraction></span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:8.5%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-tag:'C_85fb2270638645ff83e50a2162e9c4ad'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:6%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-tag:'C_262c9b5f82ce4550866897dda28e7679'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:7.5%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_03e1ee4f75ac4f9e934a09867f70acca'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="sxtp:StockIssuedDuringPeriodValueStockIssuanceOfCommonStockUponExerciseOfPreFundedWarrants" contextRef="D20240331_ParentMember" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag472">4,995</ix:nonFraction></span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:6%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-tag:'C_37b517dc3c11434abd2d5b45874481bd'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:7.5%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_edf2f9e97978429499344af804770f63'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="sxtp:StockIssuedDuringPeriodValueStockIssuanceOfCommonStockUponExerciseOfPreFundedWarrants" contextRef="D20240331" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag470">4,995</ix:nonFraction></span></p></div></td></tr><tr style="height:11.5pt"><td style="width:18%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_c21106b0457948cdb25b093ff06cbdbc'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-family: 'Times New Roman';">Issuance of shares for RSUs</span></p></div></td><td style="width:6%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-tag:'C_3bfa3486f67248588964953d7d8ec095'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:7%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-tag:'C_ed60a5974f404164a1317d80684b8538'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:7.5%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_8ccea6722a084728a6deb7ff4c09ab2d'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" contextRef="D20240331_CommonStockMember" unitRef="Shares" decimals="0" format="ixt:num-dot-decimal" id="Tag674">3,201</ix:nonFraction></span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:6%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-tag:'C_42b4b974799a4edd9b6380f030bd909a'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:7.5%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-tag:'C_ca33e8fbf8fd4cafb8dac92ca73b24e3'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:8.5%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-tag:'C_422ce27f78624d54a05fe7791e6e6a61'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:6%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-tag:'C_0ee2490be0c94457a163ed3a3c748239'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:7.5%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-tag:'C_82221a60a8e04bf3ab00e850b552e3fc'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:6%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-tag:'C_c2f55ee32eef433580cc15d0be09d74b'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:7.5%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-tag:'C_549b16fe97db4e659595c397012dca0b'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td></tr><tr style="height:11.5pt"><td style="width:18%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_b17fd3b126dc48f186e1f8f2829a9b0a'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-family: 'Times New Roman';">Net foreign translation loss</span><span style="width:21.13pt; display:inline-block; font-family: 'Times New Roman'">&#160;</span></p></div></td><td style="width:6%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-tag:'C_b0a9df5b345a49c7bdfa42a6da2adf1f'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:7%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-tag:'C_b47c59447e174091977586735c58d80c'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:7.5%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-tag:'C_4b25474bdc5e44d38a91f6b0de5e9b66'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:6%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-tag:'C_eef489b158c84d208ede9b21f2954ea6'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:7.5%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-tag:'C_1f85c9cc96104e0184e8112393acd7c5'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:8.5%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-tag:'C_1152725d13aa47fdaff7c4095b275a29'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:6%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_d56aa415acdd41dba68982143686fbe3'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="D20240331_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" sign="-" id="Tag264">3,894</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">)</span></p></td><td style="width:0.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:7.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_99d0820e6e23407ba123676faa6f9fa8'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="D20240331_ParentMember" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" sign="-" id="Tag265">3,894</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">)</span></p></td><td style="width:0.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:6%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-tag:'C_667a8d9ee09249bc8ff30a2d3f7c6c36'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:7.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_06df0f69fce24290b97cbf3a3b88e13f'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="D20240331" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" sign="-" id="Tag263">3,894</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">)</span></p></td></tr><tr style="height:11.5pt"><td style="width:18%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_a292ea5ec02248f79e3c03fec957a80d'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-family: 'Times New Roman';">Net income (loss)</span></p></div></td><td style="width:6%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-tag:'C_2e6a8f71a01d4c46a98e68358541b5fa'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:7%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-tag:'C_b4484f2eb2aa4963a8c418bfd10468d5'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:7.5%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-tag:'C_ecd16e2c30a648c6a96e3e618e74f2bc'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:6%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-tag:'C_cc9461309f714c0685c0bd5b7caafba0'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:7.5%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-tag:'C_b03ad95f3f1f42599846e0765f701442'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:8.5%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_709d98da547c487aad995b99cabcbaca'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="D20240331_RetainedEarningsUnappropriatedMember" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag473">430,470</ix:nonFraction></span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:6%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-tag:'C_676fed00dcfd41df9df5ef9ff599ce14'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:7.5%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_6fa353bfc558417a95931543514d099d'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="D20240331_ParentMember" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag474">430,470</ix:nonFraction></span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:6%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_bdafc2d5d67e48fb8990e7c98cbcb7ba'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="D20240331_NoncontrollingInterestMember" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" sign="-" id="Tag266">2,485</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">)</span></p></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:7.5%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_8909856a1b3d4304ac12dd52ecf88cd9'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="D20240331" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag471">427,985</ix:nonFraction></span></p></div></td></tr><tr style="height:11.5pt"><td style="width:18%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_f79621ec1ac34efabc22837e6dd5ff8d'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">Balance&#8212; March 31, 2024 (unaudited)</span></p></div></td><td style="width:6%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_fcd5d45f0268451d95b106ea2e0bc653'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="I20240331_PreferredStockMember_SeriesAPreferredStockMember" unitRef="Shares" decimals="0" format="ixt:num-dot-decimal" id="Tag475">78,803</ix:nonFraction></span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_26ffa6ec210a47c89c743e325994a15a'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">$</span></p></div></td><td style="width:7%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-tag:'9a8-8f2-1be-e07-0d4d'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="I20240331_PreferredStockMember_SeriesAPreferredStockMember" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag635">9,858,040</ix:nonFraction></span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:7.5%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_08e64aa3bff24bae975ec8863d2c1ae7'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="I20240331_CommonStockMember" unitRef="Shares" decimals="0" format="ixt:num-dot-decimal" id="Tag675">196,057</ix:nonFraction></span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_7d7be030f44c4643a9e2963d9c6fc116'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">$</span></p></div></td><td style="width:6%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_7534b2b63f2443c095b9443e3f094a33'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="I20240331_CommonStockMember" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag687">20</ix:nonFraction></span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_ea6dacb4df3940dabc253823f9ce3810'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">$</span></p></div></td><td style="width:7.5%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_92eb10fe7ade410aa3b3c4bdd001c261'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="I20240331_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag704">29,360,654</ix:nonFraction></span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_468de40946c942cd8b83bc9439ca0534'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">$</span></p></div></td><td style="width:8.5%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">(</span><span style="-aw-sdt-tag:'C_bf9993a8ce05413fa1750ee99d353578'; font-family: 'Times New Roman'"><span style="font-weight:bold"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="I20240331_RetainedEarningsUnappropriatedMember" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" sign="-" id="Tag256">32,150,380</ix:nonFraction></span></span><span style="font-weight:bold; font-family: 'Times New Roman'">)</span></p></td><td style="width:0.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_61d488becafb408287c4fe0cd92fcf0b'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">$</span></p></div></td><td style="width:6%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_cd9cd15699b94b0fbc2c03a9f5783348'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="I20240331_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag453">131,667</ix:nonFraction></span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_42d6b5c556b8425381c5ec1295ed2b64'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">$</span></p></div></td><td style="width:7.5%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_f918ff2301284a12a6960a64967ac966'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="I20240331_ParentMember" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag452">7,200,001</ix:nonFraction></span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_a5f64e47351b41c08ba4de48ad51e955'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">$</span></p></div></td><td style="width:6%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">(</span><span style="-aw-sdt-tag:'C_04640a1742a7402eb7a8fb61c24f8287'; font-family: 'Times New Roman'"><span style="font-weight:bold"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="I20240331_NoncontrollingInterestMember" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" sign="-" id="Tag255">74,523</ix:nonFraction></span></span><span style="font-weight:bold; font-family: 'Times New Roman'">)</span></p></td><td style="width:0.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_4ef319bd24884e60be08d0325ec483f2'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">$</span></p></div></td><td style="width:7.5%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_76821b1335dc43d4b7e3934132b292ef'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="I20240331" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag448">7,125,478</ix:nonFraction></span></p></div></td></tr><tr style="height:11.5pt"><td style="width:18%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_28047325b97b48bb8b2f9107c172ed76'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-family: 'Times New Roman';">Issuance of common stock upon exercise of Pre-Funded Warrants</span></p></div></td><td style="width:6%; border-top:4.5pt double #000000; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-tag:'C_ba003622862f46fc8f35fcd0de33c0d3'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:4.5pt double #000000; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:7%; border-top:4.5pt double #000000; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-tag:'C_da9105a01a694733837df0bb04011f4a'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:7.5%; border-top:4.5pt double #000000; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_e3b2c38d13fd413db6305119ecfe8f25'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="sxtp:StockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfPreFundedWarrantsinShares" contextRef="D20240630_CommonStockMember" unitRef="Shares" decimals="0" format="ixt:num-dot-decimal" id="Tag676">8,326</ix:nonFraction></span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:4.5pt double #000000; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:6%; border-top:4.5pt double #000000; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_cd4eab31b2894e488f18e2d2783e7b99'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="sxtp:StockIssuedDuringPeriodValueStockIssuanceOfCommonStockUponExerciseOfPreFundedWarrants" contextRef="D20240630_CommonStockMember" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag689">1</ix:nonFraction></span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:4.5pt double #000000; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:7.5%; border-top:4.5pt double #000000; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_0b804545b4404ed09b2778cd5fcd7c04'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="sxtp:StockIssuedDuringPeriodValueStockIssuanceOfCommonStockUponExerciseOfPreFundedWarrants" contextRef="D20240630_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag698">4,994</ix:nonFraction></span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:4.5pt double #000000; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:8.5%; border-top:4.5pt double #000000; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-tag:'C_54970ba4a6a44f20902be8d1e99dc392'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:4.5pt double #000000; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:6%; border-top:4.5pt double #000000; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-tag:'C_af93c85cf17644d59d380e7756c536d2'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:4.5pt double #000000; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:7.5%; border-top:4.5pt double #000000; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_319b3fe2f72f4c268194738c961a1c75'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="sxtp:StockIssuedDuringPeriodValueStockIssuanceOfCommonStockUponExerciseOfPreFundedWarrants" contextRef="D20240630_ParentMember" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag530">4,995</ix:nonFraction></span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:4.5pt double #000000; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:6%; border-top:4.5pt double #000000; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-tag:'C_1c348cbca21f40be81626e8d97ea3c52'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:4.5pt double #000000; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:7.5%; border-top:4.5pt double #000000; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_5a76ac9ab6184ff49374deaa260d3d29'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="sxtp:StockIssuedDuringPeriodValueStockIssuanceOfCommonStockUponExerciseOfPreFundedWarrants" contextRef="D20240630" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag533">4,995</ix:nonFraction></span></p></div></td></tr><tr style="height:11.5pt"><td style="width:18%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_765110d0cc764f30bfbcc9156420e18d'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-family: 'Times New Roman';">Issuance of shares for RSUs</span></p></div></td><td style="width:6%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-tag:'C_9b5443ac302e436a8b9b11da79bf6282'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:7%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-tag:'C_9de84e5fe05845688ca333c2f695153c'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:7.5%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_0e011b822a8348a6813c0392b9c6439d'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" contextRef="D20240630_CommonStockMember" unitRef="Shares" decimals="0" format="ixt:num-dot-decimal" id="Tag677">1,069</ix:nonFraction></span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:6%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-tag:'C_30ef09ba226f42e28675d5581d9c8a3f'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:7.5%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-tag:'C_db390133443f44859bfa84a819d27953'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:8.5%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-tag:'C_1c596aeb3bb842c7bf4ef102f1f78cc0'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:6%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-tag:'C_b626276e09a345c5bfa4237dc1cb5614'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:7.5%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-tag:'C_352b307b1b2d4c429a56e268cd8659ae'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:6%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-tag:'C_ddf789fdcd8946179f278d9efb13e619'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:7.5%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-tag:'C_e7f441f9954a4fe79942b953bae12aca'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td></tr><tr style="height:11.5pt"><td style="width:18%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_b381f661803f4b409a9e33723f59a2b2'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-family: 'Times New Roman';">Voluntary return of shares issued to vendor for services</span></p></div></td><td style="width:6%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-tag:'C_0ee3f5238dc544adbee6406e51705b96'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:7%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-tag:'C_3dbd417de47345329af44912feb3f1ae'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:7.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_e14dc3f28d984fb3b0dc52b62d709f8a'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="D20240630_CommonStockMember" unitRef="Shares" decimals="0" format="ixt:num-dot-decimal" id="Tag386">2,000</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">)</span></p></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:6%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-tag:'C_f7d442fbc973421aa89c4d1102291dd2'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:7.5%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-tag:'C_3fcd8fc1924a4782aad37045caacc138'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:8.5%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-tag:'C_07f38e5bddd14b2c8b07780f29109513'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:6%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-tag:'C_dfa9e92220a241a0a649bd59bc7599e0'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:7.5%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-tag:'C_7d838d3663044bed8c32b5713155ed04'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:6%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-tag:'C_1a3052e011ab414799bef4ba77de662b'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:7.5%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-tag:'C_8ba81070767446179c7f54a6d9137c74'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td></tr><tr style="height:11.5pt"><td style="width:18%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_5da3e50d4917489ea866404fd64cd69d'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-family: 'Times New Roman';">Net foreign translation gain</span></p></div></td><td style="width:6%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-tag:'C_6512ff0d71d3452cb2b6ffa208dbf431'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:7%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-tag:'C_d623bf58c2694e249d5ff6d0e91e3b96'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:7.5%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-tag:'C_2d95195518af48dcae7d84c330f1d034'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:6%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-tag:'C_e5ea536317804e289969e70ee40713d9'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:7.5%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-tag:'C_594fa68e669e48f88a2073a6d6ef8cd6'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:8.5%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-tag:'C_764d65515e244c35bc75cbb90e32779e'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:6%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_49bb5749ec9a4899bbfa98f55cbac8f3'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="D20240630_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag529">3,137</ix:nonFraction></span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:7.5%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_d3711bae9b5f4835b3651ac67d8e9de5'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="D20240630_ParentMember" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag531">3,137</ix:nonFraction></span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:6%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-tag:'C_881d649f14564711b910427d6562d56d'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:7.5%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_26456125b1fb4b27845f30e290cc745b'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="D20240630" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag532">3,137</ix:nonFraction></span></p></div></td></tr><tr style="height:11.5pt"><td style="width:18%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_cc6a5c94fb5f46f294886980c7bf5d9b'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-family: 'Times New Roman';">Net loss</span></p></div></td><td style="width:6%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-tag:'C_92dbba6721054e32a0b3cc0c8c13c128'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:7%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-tag:'C_9334a1e8d8cd4eb8b01111a7093e940b'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:7.5%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-tag:'C_fb111159dc014d77a975c1746c442c56'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:6%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-tag:'C_54da9b65744e4852bf2fff430c622b76'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:7.5%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-tag:'C_0d105e82c48b4326ae3dde3dd1351424'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:8.5%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_493457dbca164611afe496a260e300d6'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="D20240630_RetainedEarningsUnappropriatedMember" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" sign="-" id="Tag330">4,172,755</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">)</span></p></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:6%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-tag:'C_e576c16cf3294f10ba2b0e2e480f8122'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:7.5%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_f9b474f161174a80b906541d0a32d407'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="D20240630_ParentMember" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" sign="-" id="Tag331">4,172,755</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">)</span></p></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:6%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_bcd2ec7b0c9e470cb227ecfc7afbbe2f'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="D20240630_NoncontrollingInterestMember" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" sign="-" id="Tag332">1,471</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">)</span></p></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:7.5%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_e95c75c9badd4abe9b0e0322ce391620'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="D20240630" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" sign="-" id="Tag333">4,174,226</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">)</span></p></td></tr><tr style="height:11.5pt"><td style="width:18%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_db4b8c63a2184c98af8702a45e64cf5b'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">Balance&#8212; June 30, 2024 (unaudited)</span></p></div></td><td style="width:6%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_6853bb0bd3f443a68fd954c96cfa2c81'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="I20240630_PreferredStockMember_SeriesAPreferredStockMember" unitRef="Shares" decimals="0" format="ixt:num-dot-decimal" id="Tag560">78,803</ix:nonFraction></span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_c63e116cdce243d4906a8e50be4122d1'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">$</span></p></div></td><td style="width:7%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_c2e5da1492be462682222b94bbc9693c'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="I20240630_PreferredStockMember_SeriesAPreferredStockMember" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag559">9,858,040</ix:nonFraction></span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:7.5%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_ea58f02ac6064637850734d7268ea29b'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="I20240630_CommonStockMember" unitRef="Shares" decimals="0" format="ixt:num-dot-decimal" id="Tag678">203,452</ix:nonFraction></span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_468b29f446504fb39c4102525dc2d9d6'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">$</span></p></div></td><td style="width:6%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_340f5ca567c048cf931db876b7ca11a8'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="I20240630_CommonStockMember" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag688">21</ix:nonFraction></span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_dd774317f7004eb6ad8d85a54cc7fc30'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">$</span></p></div></td><td style="width:7.5%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_b6c5b209fa5d4a2dad5027af953eccb2'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="I20240630_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag697">29,365,648</ix:nonFraction></span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_66f17264e59d4ad49be51790d8ea139d'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">$</span></p></div></td><td style="width:8.5%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">(</span><span style="-aw-sdt-tag:'C_fbb95fc19e3d4a16b7baaeeccaa956a0'; font-family: 'Times New Roman'"><span style="font-weight:bold"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="I20240630_RetainedEarningsUnappropriatedMember" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" sign="-" id="Tag328">36,323,135</ix:nonFraction></span></span><span style="font-weight:bold; font-family: 'Times New Roman'">)</span></p></td><td style="width:0.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_6bfeae32711e44449e8b1c6648311fd5'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">$</span></p></div></td><td style="width:6%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_80340405a18b426b91cce42517fa39f4'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="I20240630_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag526">134,804</ix:nonFraction></span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_9e1d22add52b48afb790e4396511c59b'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">$</span></p></div></td><td style="width:7.5%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_c59e55234ec24b999f97e760d58f2fb7'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="I20240630_ParentMember" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag527">3,035,378</ix:nonFraction></span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_96d3a9d65d584336909161b12c91c134'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">$</span></p></div></td><td style="width:6%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">(</span><span style="-aw-sdt-tag:'C_8445aabb87b340d5a40f4dc1bf34a924'; font-family: 'Times New Roman'"><span style="font-weight:bold"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="I20240630_NoncontrollingInterestMember" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" sign="-" id="Tag329">75,994</ix:nonFraction></span></span><span style="font-weight:bold; font-family: 'Times New Roman'">)</span></p></td><td style="width:0.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_15b3f335b8cf4ede90c18cf64c3b774b'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">$</span></p></div></td><td style="width:7.5%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_9661ffed772a4edfab8b73db44c2301b'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="I20240630" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag528">2,959,384</ix:nonFraction></span></p></div></td></tr><tr style="height:11.5pt"><td style="width:18%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_72d07acddcfb423e928b0e2b6fab69f7'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-family: 'Times New Roman';">Voluntary conversion of Series A Preferred Stock into common stock</span></p></div></td><td style="width:6%; border-top:4.5pt double #000000; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_988490f1e37242a780150f3e98d293fc'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesOther" contextRef="D20240930_PreferredStockMember_SeriesAPreferredStockMember" unitRef="Shares" decimals="0" format="ixt:num-dot-decimal" sign="-" id="Tag341">2,323</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">)</span></p></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:4.5pt double #000000; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:7%; border-top:4.5pt double #000000; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_2ae6393d81a1455b95a718e813a68d8d'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:ConversionOfStockAmountConverted1" contextRef="D20240930_PreferredStockMember_SeriesAPreferredStockMember" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" sign="-" id="Tag340">290,601</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">)</span></p></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:7.5%; border-top:4.5pt double #000000; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_20526ff79dc74463896595420f78e6a5'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesOther" contextRef="D20240930_CommonStockMember_3" unitRef="Shares" decimals="0" format="ixt:num-dot-decimal" id="Tag679">14,667</ix:nonFraction></span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:4.5pt double #000000; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:6%; border-top:4.5pt double #000000; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_5b8a972c60e044ccb4b103fdfb2ee467'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:ConversionOfStockAmountConverted1" contextRef="D20240930_CommonStockMember_3" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag690">1</ix:nonFraction></span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:4.5pt double #000000; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:7.5%; border-top:4.5pt double #000000; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_a07f0e42e7d74632bd72312b2a16a31d'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:ConversionOfStockAmountConverted1" contextRef="D20240930_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag699">290,600</ix:nonFraction></span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:4.5pt double #000000; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:8.5%; border-top:4.5pt double #000000; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-tag:'C_d23c7007074a42b69c28f397d090b1bf'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:4.5pt double #000000; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:6%; border-top:4.5pt double #000000; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-tag:'C_cb93b7874fb24379a5089dc4e52a0868'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:4.5pt double #000000; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:7.5%; border-top:4.5pt double #000000; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-tag:'C_291816d476974b02a5ebeefe874d46e0'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:4.5pt double #000000; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:6%; border-top:4.5pt double #000000; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-tag:'C_e85f0e3d61624679bf521f703057ade1'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:4.5pt double #000000; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:7.5%; border-top:4.5pt double #000000; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-tag:'C_bc9b132361da4ffc8ad0f0c628da3360'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td></tr><tr style="height:11.5pt"><td style="width:18%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_c229bb5f9a5e4c958a9f8ffb24196911'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-family: 'Times New Roman';">Issuance of common stock pursuant to ATM Offering, net of offering costs paid at closing and deferred offering costs (Note 6)</span></p></div></td><td style="width:6%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-tag:'C_a3afdc04d907432a9d5ec97cba8eea71'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:7%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-tag:'C_64ea237507234fe9ae2c848468cf1374'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:7.5%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_4625326e663145b6831e1901c736ec6d'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="sxtp:IssuanceOfCommonStockPursuantToATMOfferingNetOfOfferingCostsPaid" contextRef="D20240930_CommonStockMember_3" unitRef="Shares" decimals="0" format="ixt:num-dot-decimal" id="Tag682">135,568</ix:nonFraction></span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:6%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_e2dba1022898452bbaeaf8aa45ec82cc'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="sxtp:StockIssuedDuringPeriodValueIssuanceOfCommonStockPursuantToATMOfferingNetOfOfferingCosts" contextRef="D20240930_CommonStockMember_3" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag691">14</ix:nonFraction></span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:7.5%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_2c9cd3473a6e433590f1f46d867016fa'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="sxtp:StockIssuedDuringPeriodValueIssuanceOfCommonStockPursuantToATMOfferingNetOfOfferingCosts" contextRef="D20240930_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag700">1,729,796</ix:nonFraction></span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:8.5%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-tag:'C_97489db0014848b18facc358ef304a9e'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:6%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-tag:'C_69b9c35f8aa54202a901e566ed152a25'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:7.5%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_aeebc2e98d7a4c349f56cb29ab9ab2f3'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="sxtp:StockIssuedDuringPeriodValueIssuanceOfCommonStockPursuantToATMOfferingNetOfOfferingCosts" contextRef="D20240930_ParentMember" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag541">1,729,810</ix:nonFraction></span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:6%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-tag:'C_1b43447d8561434fa321df1f0067e993'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:7.5%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_932ee5441f2941669ed88b17b1ed909b'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="sxtp:StockIssuedDuringPeriodValueIssuanceOfCommonStockPursuantToATMOfferingNetOfOfferingCosts" contextRef="D20240930" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag534">1,729,810</ix:nonFraction></span></p></div></td></tr><tr style="height:11.5pt"><td style="width:18%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_c415fe4269b84375891bc85473556c92'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-family: 'Times New Roman';">Issuance of warrants in Private Placement, net of offering costs paid at closing and deferred offering costs (Note 6)</span></p></div></td><td style="width:6%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-tag:'C_b946917d589344a2971194debb4b52e8'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:7%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-tag:'C_374317f1a2cc47938d1c4fc1c0ebf7be'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:7.5%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-tag:'C_ad9f74580ef54f7f8627e92330d688d0'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:6%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-tag:'C_772ffe758d234f8e972a012b618ff72b'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:7.5%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_23954e6bcc684630b56f168dad1c93fc'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="D20240930_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag703">3,414,502</ix:nonFraction></span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:8.5%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-tag:'C_a4f7cf8c955a4914b4f2eb059c56a2bd'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:6%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-tag:'C_eb771324cf1b4c8e928a60666373415c'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:7.5%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_7ba9842393f44fc984171e9694393501'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="D20240930_ParentMember" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag542">3,414,502</ix:nonFraction></span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:6%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-tag:'C_a0f84cb8a2384db79cb619ed7d8c7d92'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:7.5%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_72cf8180ea764c7bb0c7e406332f9141'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="D20240930" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag535">3,414,502</ix:nonFraction></span></p></div></td></tr><tr style="height:11.5pt"><td style="width:18%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_68ee6760de434f88a5d5f34fee041008'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-family: 'Times New Roman';">Issuance of common stock for fractional shares pursuant to Reverse Stock Split rounding adjustment</span></p></div></td><td style="width:6%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-tag:'C_9759f123b7c14afead2247d817b7de42'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:7%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-tag:'C_6124a543845448f4b7edadc4636184b6'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:7.5%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_57a35135537247d298c4b374005771a1'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits" contextRef="D20240930_CommonStockMember_3" unitRef="Shares" decimals="0" format="ixt:num-dot-decimal" id="Tag683">18,710</ix:nonFraction></span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:6%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_ac99377064384d50a9e7854700975d33'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="sxtp:StockIssuedDuringPeriodValueIssuanceOfCommonStockForFractionalSharesPursuantToReverseStockSplitRoundingAdjustment" contextRef="D20240930_CommonStockMember_3" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag693">2</ix:nonFraction></span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:7.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_802a53fd87d3430181ef3de0d319844b'; font-family: 'Times New Roman'"><span><ix:nonFraction name="sxtp:StockIssuedDuringPeriodValueIssuanceOfCommonStockForFractionalSharesPursuantToReverseStockSplitRoundingAdjustment" contextRef="D20240930_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" sign="-" id="Tag387">2</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">)</span></p></td><td style="width:0.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:8.5%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-tag:'C_5f4a4f69ead24d25a73f88a9abb0aeaa'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:6%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-tag:'C_ac7cf4ed1b7343178f49de223ce1563f'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:7.5%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-tag:'C_6b973b02aff84eafb471ba061bce4378'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:6%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-tag:'C_58c5790158ad47759bb79dc290c73e6e'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:7.5%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-tag:'C_b906507387ac4edb8a3e16271d48b119'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td></tr><tr style="height:11.5pt"><td style="width:18%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_72f472dabd51468c9ad9cf36343e2210'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-family: 'Times New Roman';">Share-based compensation expense</span></p></div></td><td style="width:6%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-tag:'C_adb82ba1fb364fb099258a4d5ab89136'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:7%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-tag:'C_6eb9be94433846debf54f1c5ce4c1430'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:7.5%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-tag:'C_3e1e4444bf5e4d69b42a13270fd2df7d'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:6%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-tag:'C_4af38f7b552946f9a13040add6c8932b'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:7.5%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_1f7bf68b849f4afb829c2413607c4be0'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="D20240930_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag702">15,246</ix:nonFraction></span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:8.5%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-tag:'C_9af8e797ad1c436cb8e746f266e1b78d'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:6%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-tag:'C_8585cf2070634c55992678ee75f32c29'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:7.5%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_70b93b945305467ebc9876198c34f618'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="D20240930_ParentMember" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag543">15,246</ix:nonFraction></span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:6%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-tag:'C_265b2401adf547e1afd4bbbf44f44a0f'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:7.5%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_fbc882e3fb76432aa481833c990cdbc9'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="D20240930" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag536">15,246</ix:nonFraction></span></p></div></td></tr><tr style="height:11.5pt"><td style="width:18%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_7139bcbeb24840988f1172c36662511e'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-family: 'Times New Roman';">Net foreign translation gain</span></p></div></td><td style="width:6%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-tag:'C_aa2fb513ca7d4bdb82eba36cac62f60f'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:7%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-tag:'C_ed86de2221c246868b88b1b3252e8b25'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:7.5%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-tag:'C_df7fee031de346e583a6933cadbb5622'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:6%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-tag:'C_5ec71e5cd9cf48ebbaf5b85e76cdf701'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:7.5%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-tag:'C_842a67c63372415c995deaa0bf3def11'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:8.5%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-tag:'C_49a53a6cfa0e487bbe04a9b79307e4d1'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:6%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_a805d83a02c74990b0b0c721d0a7e3dd'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="D20240930_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag539">4,403</ix:nonFraction></span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:7.5%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_fdc1e2cf0419425bb951aaadaf41e2b2'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="D20240930_ParentMember" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag544">4,403</ix:nonFraction></span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:6%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-tag:'C_ab5dd91c626e442b9971d23433627dec'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:7.5%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_5ef7a4b228264e998a96928e7432200d'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="D20240930" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag537">4,403</ix:nonFraction></span></p></div></td></tr><tr style="height:11.5pt"><td style="width:18%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_398ca612334547c2a0de807fbff85d38'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-family: 'Times New Roman';">Net loss</span></p></div></td><td style="width:6%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-tag:'C_2bf8f5d8884d4936908e85e9c9a92aa3'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:7%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-tag:'C_7e3ccbf521614c0488285e17a97d6087'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:7.5%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-tag:'C_29c96fe7e57243429f1627f97f020432'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:6%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-tag:'C_3c6a4df6c09645fa958795238166d29a'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:7.5%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-tag:'C_e8e7f5ed32a74899b5fac9826845f079'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:8.5%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_ab432b0c8a9c4d33b25ae15b0cc090f9'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="D20240930_RetainedEarningsUnappropriatedMember" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" sign="-" id="Tag335">2,159,785</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">)</span></p></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:6%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-tag:'C_a9be9a2613604fad87599abdc4ec4269'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:7.5%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_8f4eeda66eb649b5853c2c005f81c5fc'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="D20240930_ParentMember" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" sign="-" id="Tag337">2,159,785</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">)</span></p></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:6%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_024f5302949143fe8f50754b18cec9f9'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="D20240930_NoncontrollingInterestMember" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" sign="-" id="Tag338">713</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">)</span></p></td><td style="width:0.5%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:7.5%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_d0cf163bdbaa419ea63cacd25a6705fc'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="D20240930" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" sign="-" id="Tag334">2,160,498</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">)</span></p></td></tr><tr style="height:11.5pt"><td style="width:18%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_81a3d64287464dc0ae5962997877c6de'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">Balance&#8212; September 30, 2024 (unaudited)</span></p></div></td><td style="width:6%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_0d7a03831f0b4b6fa85dfa10dcc9193a'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="I20240930_PreferredStockMember_SeriesAPreferredStockMember" unitRef="Shares" decimals="0" format="ixt:num-dot-decimal" id="Tag547">76,480</ix:nonFraction></span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_da5d32515c2e4a439a70fb7451d91c15'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">$</span></p></div></td><td style="width:7%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_330a5783ac5246a79ed5ecd8f052a2a1'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="I20240930_PreferredStockMember_SeriesAPreferredStockMember" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag546">9,567,439</ix:nonFraction></span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:7.5%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_7cd0224d789c4c5fb042d4cefa926963'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="I20240930_CommonStockMember" unitRef="Shares" decimals="0" format="ixt:num-dot-decimal" id="Tag680">372,397</ix:nonFraction></span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_52c3fcc6abdf4f2a96a53f715f433e6a'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">$</span></p></div></td><td style="width:6%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_9dbfe56c482f43a8b45eb97df7da690c'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="I20240930_CommonStockMember" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag692">38</ix:nonFraction></span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_fdd9aa8a19344bdf8a83f5faca39e1ad'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">$</span></p></div></td><td style="width:7.5%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_33218341da7a46e196aa443b33b5a1a8'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="I20240930_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag701">34,815,790</ix:nonFraction></span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_e09718cdc088430ba587d4e0f348648a'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">$</span></p></div></td><td style="width:8.5%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">(</span><span style="-aw-sdt-tag:'C_afbd4763670d49eaa0ccb64cf41acf58'; font-family: 'Times New Roman'"><span style="font-weight:bold"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="I20240930_RetainedEarningsUnappropriatedMember" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" sign="-" id="Tag336">38,482,920</ix:nonFraction></span></span><span style="font-weight:bold; font-family: 'Times New Roman'">)</span></p></td><td style="width:0.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_f9124b51fe1e4d1980c1dc59ed7f0f35'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">$</span></p></div></td><td style="width:6%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_7494708f2c7541ffb9f5f33749b1ae00'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="I20240930_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag540">139,207</ix:nonFraction></span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_fb5d78ecbd134d3dbad11ca9b31eb74f'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">$</span></p></div></td><td style="width:7.5%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_dae6ac3b3a12403cb0284c499228a8ea'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="I20240930_ParentMember" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag545">6,039,554</ix:nonFraction></span></p></div></td><td style="width:0.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_037fcc8b9a6049fb84ca0296d158ddf6'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">$</span></p></div></td><td style="width:6%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">(</span><span style="-aw-sdt-tag:'C_b3e3ebc85b644a19a0c92501ba15f6fd'; font-family: 'Times New Roman'"><span style="font-weight:bold"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="I20240930_NoncontrollingInterestMember" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" sign="-" id="Tag339">76,707</ix:nonFraction></span></span><span style="font-weight:bold; font-family: 'Times New Roman'">)</span></p></td><td style="width:0.5%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_54c5589d7d354f229e97f4d22e24a96e'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'">$</span></p></div></td><td style="width:7.5%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_8548bdede2cc44d5a28dd5189434df7d'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:8pt"><span style="font-weight:bold; font-family: 'Times New Roman'"><ix:nonFraction name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="I20240930" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag538">5,962,847</ix:nonFraction></span></p></div></td></tr></tbody></table></div><p style="margin-top:0pt; margin-bottom:0pt"><span style="-aw-import:ignore">&#160;</span></p><table cellspacing="0" cellpadding="0" style="width:100%; border-collapse:collapse"><tbody><tr style="height:13.15pt"><td style="width:59.15pt; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-size:6.67pt; vertical-align:super">(1)</span><span> Prior periods presented have been adjusted to reflect the 1:5 reverse stock split on February 24, 2025.</span></p></td></tr></tbody></table><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span>&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-style:italic">The accompanying notes are an integral part of these unaudited consolidated condensed financial statements.</span></p><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span>&#160;</span></p><div style="-aw-sdt-tag:'PG_c10fdf0d3da33f2cb4c3'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-family: 'Times New Roman';">4</span></p><div><hr style="width: 100%; color: #000000; background-color: #000000; margin: 1rem 0;"/></div></div></div><div class="Section_8"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold">60 DEGREES PHARMACEUTICALS, INC.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span id="TOC_c4ba879b2cbf15949667"><span style="font-weight:bold">CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED)</span></span></p><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-bookmark-end:TOC_c4ba879b2cbf15949667"></span><span>&#160;</span></p><div style="-aw-sdt-tag:'c30a1bb88863d1703f07'; -aw-sdt-title:'Cash Flow'"><table cellspacing="0" cellpadding="0" style="width:100%; border-collapse:collapse"><tbody><tr style="height:13.8pt"><td style="width:74%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_ae754b2ef8bc47599ab6950fa6f076aa'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">For the Nine Months Ended September 30,</span></p></div></td><td style="width:1%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="2" style="border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_67d8daacd1554980aad16e2b2dd8f017'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">2025</span></p></div></td><td style="width:1%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="2" style="border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_d6e942bb89c14d0ba5962d4110b6539b'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">2024</span></p></div></td></tr><tr style="height:13.2pt"><td style="width:74%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_75e1c32cb4d9474fbce60a993fa4c4eb'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">CASH FLOWS FROM OPERATING ACTIVITIES</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:11%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:11%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td></tr><tr style="height:13.2pt"><td style="width:74%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_01fb4c06a98d46d8b9b629889e508d4f'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Net Loss</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_acfae004dd0c462c950459884b71c449'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:11%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_081ab814859c4a3bb4328a51da84d1ce'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="D20250930_1" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" sign="-" id="Tag251">5,929,267</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">)</span></p></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_3d7305a9279f4562951ccdf06cb8954b'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:11%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_f16410c8f3b246f3bce65726afead617'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:ProfitLoss" contextRef="D20240930_1" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" sign="-" id="Tag356">5,906,739</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">)</span></p></td></tr><tr style="height:13.2pt"><td style="width:74%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_e0a205f040b84b6b913af10d9f894ea3'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Adjustments to Reconcile Net Loss to Net Cash Used in Operating Activities:</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:11%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:11%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td></tr><tr style="height:13.2pt"><td style="width:74%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_16d2eceda62f42dfb785d5ad3481d898'"><p style="margin-top:0pt; margin-left:9pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Depreciation</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:11%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_cef973ae6805440f9531e545f701d9bb'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:Depreciation" contextRef="D20250930_1" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag439">28,155</ix:nonFraction></span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:11%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_346c9c7ec3c44eea8a71649acc85e601'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:Depreciation" contextRef="D20240930_1" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag579">6,277</ix:nonFraction></span></p></div></td></tr><tr style="height:13.2pt"><td style="width:74%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_3e47d7e8354b492cb4641ff04e83c804'"><p style="margin-top:0pt; margin-left:9pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Amortization</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:11%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_e53fc533ccfa49589fd975e261d209b6'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:AdjustmentForAmortization" contextRef="D20250930_1" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag440">31,150</ix:nonFraction></span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:11%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_6beaa0a8e33d4b2b9635350ad1b04bf3'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:AdjustmentForAmortization" contextRef="D20240930_1" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag580">28,004</ix:nonFraction></span></p></div></td></tr><tr style="height:13.2pt"><td style="width:74%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_58f453c1d5be4317b531ba426aab5fd8'"><p style="margin-top:0pt; margin-left:9pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Amortization of ROU Asset</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:11%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-tag:'C_0fdaab6870e3418496ffa085b48ba746'"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" contextRef="D20250930_1" xsi:nil="true" unitRef="USD" id="Tag602"></ix:nonFraction><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:11%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_ff93584816424eecb099cc7b6c530f80'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" contextRef="D20240930_1" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag624">13,517</ix:nonFraction></span></p></div></td></tr><tr style="height:14.4pt"><td style="width:74%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_d98e3168ba1f484ab9d0425da7a1036a'"><p style="margin-top:0pt; margin-left:9pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Amortization of Capitalized Share-Based Payments</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:11%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_5fc2e3bab2a04ca18a459710e9086f83'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="sxtp:AmortizationOfCapitalizedShareBasedPayments" contextRef="D20250930_1" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag441">132,353</ix:nonFraction></span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:11%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_9f241d9d4f504885907d806c5b7dba03'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="sxtp:AmortizationOfCapitalizedShareBasedPayments" contextRef="D20240930_1" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag581">3,531,763</ix:nonFraction></span></p></div></td></tr><tr style="height:14.4pt"><td style="width:74%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_89d4c40dca9c46d1846acc0b746dcc68'"><p style="margin-top:0pt; margin-left:9pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Share-Based Compensation under Equity Incentive Plan</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:11%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_6d15ac296f754e65a1e33b513bfa3d39'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:EmployeeBenefitsAndShareBasedCompensation" contextRef="D20250930_1" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag442">212,030</ix:nonFraction></span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:11%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_cbae83ff975847939a263efe3bcdc8fe'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:EmployeeBenefitsAndShareBasedCompensation" contextRef="D20240930_1" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag625">15,246</ix:nonFraction></span></p></div></td></tr><tr style="height:13.2pt"><td style="width:74%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_c37158b212874542add6276e0e431451'"><p style="margin-top:0pt; margin-left:9pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Change in Fair Value of Derivative Liabilities</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:11%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_9f4274c7fe84498bb8998f2b54013e1b'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="D20250930_1" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" sign="-" id="Tag569">156,445</ix:nonFraction></span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:11%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_a78199cea26d4712befcbb18601be0d2'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="D20240930_1" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag357">1,683,034</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">)</span></p></td></tr><tr style="height:13.2pt"><td style="width:74%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_30b4380f76964154a91218a7744e93c0'"><p style="margin-top:0pt; margin-left:9pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Write-offs of Capitalized Patents</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:11%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-tag:'C_45a4e89a6fcb412dbb97291deac480a3'"><ix:nonFraction name="sxtp:WriteoffsOfCapitalizedPatents" contextRef="D20250930_1" xsi:nil="true" unitRef="USD" id="Tag603"></ix:nonFraction><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:11%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_6933259daf7b49688a5ec564ff533165'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="sxtp:WriteoffsOfCapitalizedPatents" contextRef="D20240930_1" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag582">11,300</ix:nonFraction></span></p></div></td></tr><tr style="height:13.2pt"><td style="width:74%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_0bfec080f24c47b1b4589017400f7073'"><p style="margin-top:0pt; margin-left:9pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Change in Inventory Reserve</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:11%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_5e7b7a6b07204549a52994eceb734d29'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:InventoryLIFOReservePeriodCharge" contextRef="D20250930_1" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag610">244,682</ix:nonFraction></span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:11%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-tag:'C_3c77a4368af342d39e54d3ba5312d9f1'"><ix:nonFraction name="us-gaap:InventoryLIFOReservePeriodCharge" contextRef="D20240930_1" xsi:nil="true" unitRef="USD" id="Tag609"></ix:nonFraction><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td></tr><tr style="height:13.2pt"><td style="width:74%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_90893a7c6842466d83ebb813a4fc52e6'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Changes in Operating Assets and Liabilities:</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:11%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:11%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td></tr><tr style="height:13.2pt"><td style="width:74%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_e1702504f40340de8a24f7f3a06a333a'"><p style="margin-top:0pt; margin-left:9pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Accounts Receivable</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:11%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_0eec5a1bbd8d411b9121004cf532d08e'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="D20250930_1" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag360">187,288</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">)</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:11%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_4e55fe1145674792ac1378a318d1e9a9'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="D20240930_1" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag361">92,490</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">)</span></p></td></tr><tr style="height:13.2pt"><td style="width:74%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_b12986f5496b454f87df0f8b98dc05e5'"><p style="margin-top:0pt; margin-left:9pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Prepaid and Other Assets</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:11%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_2d42d63e833c41069342668b01c61515'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="D20250930_1" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" sign="-" id="Tag567">10,373</ix:nonFraction></span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:11%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_d2e2cd90ac6c454c9d7612d564c2161c'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="D20240930_1" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag362">99,756</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">)</span></p></td></tr><tr style="height:13.2pt"><td style="width:74%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_2c25d8cf59a746858ffa02f0231f7b5d'"><p style="margin-top:0pt; margin-left:9pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Inventory</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:11%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_e59840f09a2a41278aa5b6c9492428e6'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:IncreaseDecreaseInInventories" contextRef="D20250930_1" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag353">328,922</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">)</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:11%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_87d0682150e1416595fe0e6260d26970'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:IncreaseDecreaseInInventories" contextRef="D20240930_1" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" sign="-" id="Tag583">14,133</ix:nonFraction></span></p></div></td></tr><tr style="height:13.2pt"><td style="width:74%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_7fcb444c93e945c8b27561725e588a70'"><p style="margin-top:0pt; margin-left:9pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Accounts Payable and Accrued Liabilities</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:11%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_454589b7ff4640ada8aedcf6f603cfb1'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="D20250930_1" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag607">455,378</ix:nonFraction></span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:11%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_708cf2cdd9454d3680d55d28f02de826'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="D20240930_1" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag584">171,411</ix:nonFraction></span></p></div></td></tr><tr style="height:13.2pt"><td style="width:74%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_d235e75a9db64576b56f5b2018840f68'"><p style="margin-top:0pt; margin-left:9pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Accrued Interest, net</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:11%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_dc939468fd7e4b72af8d35a09179edc6'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet" contextRef="D20250930_1" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" sign="-" id="Tag568">18,345</ix:nonFraction></span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:11%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_4423ff0dcd134283a48f24874dcee502'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet" contextRef="D20240930_1" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag363">5,853</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">)</span></p></td></tr><tr style="height:13.8pt"><td style="width:74%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_7d32ae26dfd84a5681c459f40b399cb4'"><p style="margin-top:0pt; margin-left:9pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Reduction of Lease Liability</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:11%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-tag:'C_9d908008b9694b2f87bedde90d09567e'"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" contextRef="D20250930_1" xsi:nil="true" unitRef="USD" id="Tag601"></ix:nonFraction><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:11%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_98f9430a4c644350be15fd42beb90909'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" contextRef="D20240930_1" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" sign="-" id="Tag374">13,650</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">)</span></p></td></tr><tr style="height:13.2pt"><td style="width:74%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_fff419f1cb8b4401b3597afe5eb29032'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">Net Cash Used in Operating Activities</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:11%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">(</span><span style="-aw-sdt-tag:'C_dc964a9527a6490b8025f8ba4d5257ec'; font-family: 'Times New Roman'"><span style="font-weight:bold"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="D20250930_1" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" sign="-" id="Tag369">5,156,566</ix:nonFraction></span></span><span style="font-weight:bold; font-family: 'Times New Roman'">)</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:11%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">(</span><span style="-aw-sdt-tag:'C_55825319cb934afda5e79e0720e4dfad'; font-family: 'Times New Roman'"><span style="font-weight:bold"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="D20240930_1" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" sign="-" id="Tag370">4,009,871</ix:nonFraction></span></span><span style="font-weight:bold; font-family: 'Times New Roman'">)</span></p></td></tr><tr style="height:13.2pt"><td style="width:74%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:11%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:11%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td></tr><tr style="height:13.2pt"><td style="width:74%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_ae39da29854e41b6afd8a6dd9d55b97b'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">CASH FLOWS FROM INVESTING ACTIVITIES</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:11%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:11%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td></tr><tr style="height:13.2pt"><td style="width:74%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_85776245a2f44baa821b7968a881f0ee'"><p style="margin-top:0pt; margin-left:9pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Capitalization of Patents</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:11%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_cbeef95af0d24ef09e8ee568ed67d8cd'; font-family: 'Times New Roman'"><span><ix:nonFraction name="sxtp:PaymentOfCapitalizationOfPatents" contextRef="D20250930_1" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag354">20,868</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">)</span></p></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:11%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_1100c08659424065b1cca6effbf596af'; font-family: 'Times New Roman'"><span><ix:nonFraction name="sxtp:PaymentOfCapitalizationOfPatents" contextRef="D20240930_1" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag358">49,869</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">)</span></p></td></tr><tr style="height:13.2pt"><td style="width:74%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_0446d02f50a94d50aa2684ed7737b67f'"><p style="margin-top:0pt; margin-left:9pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Purchases of Fixed Assets</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:11%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_7a622adb92e64dc6ac32fa4ea69edd9c'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="D20250930_1" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag364">60,000</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">)</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:11%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_2571690347bc412490605b0444d028f5'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="D20240930_1" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag359">103,773</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">)</span></p></td></tr><tr style="height:13.2pt"><td style="width:74%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_7382b3d275094ab480ad33e0a6bee84c'"><p style="margin-top:0pt; margin-left:9pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Acquisition of Intangibles</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:11%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_1ae16232150444ac87cd891f77f7b560'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:PaymentsToAcquireIntangibleAssets" contextRef="D20250930_1" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag365">1,785</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">)</span></p></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:11%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_0870021ae97d4d39a200b02cf45388d0'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:PaymentsToAcquireIntangibleAssets" contextRef="D20240930_1" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag366">25,374</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">)</span></p></td></tr><tr style="height:13.2pt"><td style="width:74%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_a53768030cfb4670bc4e948d635eb0b3'"><p style="margin-top:0pt; margin-left:9pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Purchase of Short-Term Investments</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:11%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-tag:'C_8b8b80233c924700bc7be0d647474c6c'"><ix:nonFraction name="us-gaap:PaymentsToAcquireShortTermInvestments" contextRef="D20250930_1" xsi:nil="true" unitRef="USD" id="Tag599"></ix:nonFraction><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:11%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_963b871b98844a9b822985549cfbe18e'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:PaymentsToAcquireShortTermInvestments" contextRef="D20240930_1" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag367">1,708,000</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">)</span></p></td></tr><tr style="height:13.8pt"><td style="width:74%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_b9fcc59e628a44b28d64352fb6ff62b3'"><p style="margin-top:0pt; margin-left:9pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Maturities of Short-Term Investments</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:11%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_fc27d59c6f4f4e0394aa8c2f8e416112'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" contextRef="D20250930_1" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag565">1,708,000</ix:nonFraction></span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:11%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-tag:'C_1c7448260fae42b596570fe51c0f0cf5'"><ix:nonFraction name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" contextRef="D20240930_1" xsi:nil="true" unitRef="USD" id="Tag600"></ix:nonFraction><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td></tr><tr style="height:13.2pt"><td style="width:74%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_c44b38a5c3c14197bcd91f2a55abfa8e'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">Net Cash Provided by (Used in) Investing Activities</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:11%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_8a425e9f7f1b481bb703453682ef3232'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="D20250930_1" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag566">1,625,347</ix:nonFraction></span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:11%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">(</span><span style="-aw-sdt-tag:'C_27627ec7352c4e968f8669cd2e02ca6f'; font-family: 'Times New Roman'"><span style="font-weight:bold"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="D20240930_1" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" sign="-" id="Tag368">1,887,016</ix:nonFraction></span></span><span style="font-weight:bold; font-family: 'Times New Roman'">)</span></p></td></tr><tr style="height:13.2pt"><td style="width:74%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:11%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:11%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td></tr><tr style="height:13.2pt"><td style="width:74%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_f7bbe70c48d943c78798a94519e696d3'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">CASH FLOWS FROM FINANCING ACTIVITIES</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:11%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:11%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td></tr><tr style="height:13.2pt"><td style="width:74%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_d2f525e29e1f4321ab7bfa51b100a6a5'"><p style="margin-top:0pt; margin-left:9pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Net Proceeds from January 2024 Offering</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:11%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-tag:'C_88df963721a24936bf8426f4b956134d'"><ix:nonFraction name="sxtp:NetProceedsFromSharesAndWarrantsOffering" contextRef="D20250930_1" xsi:nil="true" unitRef="USD" id="Tag592"></ix:nonFraction><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:11%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_2a4dada68ab342c5b8519ce8b70d3692'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="sxtp:NetProceedsFromSharesAndWarrantsOffering" contextRef="D20240930_1" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag604">1,898,296</ix:nonFraction></span></p></div></td></tr><tr style="height:13.2pt"><td style="width:74%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_0ea87b19fb5a4f21ac218746f3d77e2b'"><p style="margin-top:0pt; margin-left:9pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Net Proceeds from January 2025 Offering</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:11%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_0ef5e9cc308e408d8f732d417634c504'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="sxtp:NetProceedsFromJanuary2025Offering" contextRef="D20250930_1" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag605">804,346</ix:nonFraction></span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:11%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-tag:'C_1c86f3a48d22491f9beb1aae1341ada5'"><ix:nonFraction name="sxtp:NetProceedsFromJanuary2025Offering" contextRef="D20240930_1" xsi:nil="true" unitRef="USD" id="Tag593"></ix:nonFraction><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td></tr><tr style="height:13.2pt"><td style="width:74%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_2cc77e6b4ee6443ba64f676ff333b2eb'"><p style="margin-top:0pt; margin-left:9pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Net Proceeds from February 2025 Offering</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:11%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_52afede0a383415eb6c55d6528a37f24'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="sxtp:NetProceedsFromFebruary2025Offering" contextRef="D20250930_1" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag606">908,627</ix:nonFraction></span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:11%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-tag:'C_307aab856e9d488ebfc4f0b3dbf75f3c'"><ix:nonFraction name="sxtp:NetProceedsFromFebruary2025Offering" contextRef="D20240930_1" xsi:nil="true" unitRef="USD" id="Tag634"></ix:nonFraction><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td></tr><tr style="height:13.2pt"><td style="width:74%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_00dedf6ff0f24fb2ac5171163805a81f'"><p style="margin-top:0pt; margin-left:9pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Net Proceeds from July 2025 Offering</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:11%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_8b1ab7e1e2764ca49690949ccd7e58a8'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="sxtp:NetProceedsFromJuly2025Offering" contextRef="D20250930_1" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag620">4,281,300</ix:nonFraction></span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:11%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-tag:'C_6023f452d51145e28600edac3c76d1f3'"><ix:nonFraction name="sxtp:NetProceedsFromJuly2025Offering" contextRef="D20240930_1" xsi:nil="true" unitRef="USD" id="Tag621"></ix:nonFraction><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td></tr><tr style="height:13.2pt"><td style="width:74%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_72f58ca488564e56b10deb1640de8221'"><p style="margin-top:0pt; margin-left:9pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Shares Withheld for Net Share Settlement of Performance Bonuses</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:11%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_d9581a72539e42729d486576cda81dee'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" contextRef="D20250930_1" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag355">18,000</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">)</span></p></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:11%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-tag:'C_db9e1ed278774510b8e5da989e8d2b3e'"><ix:nonFraction name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" contextRef="D20240930_1" xsi:nil="true" unitRef="USD" id="Tag594"></ix:nonFraction><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td></tr><tr style="height:13.2pt"><td style="width:74%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_cecb11c169e14406b718f3bee55f0d0f'"><p style="margin-top:0pt; margin-left:9pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Net proceeds from ATM Offering</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:11%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-tag:'C_080bbf124f88410e8faaf4d48c9d568e'"><ix:nonFraction name="sxtp:ProceedsFromIssuanceATMOfferingCosts" contextRef="D20250930_1" xsi:nil="true" unitRef="USD" id="Tag595"></ix:nonFraction><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:11%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_ad561fbe290a42659d6c080ba8d691c1'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="sxtp:ProceedsFromIssuanceATMOfferingCosts" contextRef="D20240930_1" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag585">1,729,810</ix:nonFraction></span></p></div></td></tr><tr style="height:13.2pt"><td style="width:74%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_3fd247922fdc4abdab86b71fb8503369'"><p style="margin-top:0pt; margin-left:9pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Net proceeds from Private Placement</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:11%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-tag:'C_a19a4203ff5a400cb532e2cbca7716e6'"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" contextRef="D20250930_1" xsi:nil="true" unitRef="USD" id="Tag596"></ix:nonFraction><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:11%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_3447168b5fa842779e270d38ec068c97'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" contextRef="D20240930_1" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag586">3,414,502</ix:nonFraction></span></p></div></td></tr><tr style="height:13.8pt"><td style="width:74%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_4a61bad6757144878ad345acb31864b1'"><p style="margin-top:0pt; margin-left:9pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Proceeds from Exercise of Pre-Funded Warrants</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:11%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_e3235c21f3484b56bff7b080a06482c4'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="sxtp:ProceedsFromExerciseOfPreFundedWarrants" contextRef="D20250930_1" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag570">2,804</ix:nonFraction></span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:11%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_2cd924e1e6844060b293c1cf321ba5da'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="sxtp:ProceedsFromExerciseOfPreFundedWarrants" contextRef="D20240930_1" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag587">9,990</ix:nonFraction></span></p></div></td></tr><tr style="height:13.2pt"><td style="width:74%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_7340b0cce2ed495fae3e58f51a99067f'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">Net Cash Provided by Financing Activities</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:11%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_751659127b904d08a7a542634b6312fa'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="D20250930_1" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag571">5,979,077</ix:nonFraction></span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:11%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_040dedacdfb64c7183799f7cf9a35c1d'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="D20240930_1" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag588">7,052,598</ix:nonFraction></span></p></div></td></tr><tr style="height:13.2pt"><td style="width:74%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:11%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:11%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td></tr><tr style="height:13.2pt"><td style="width:74%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_a3df1a6fd5b14cfb927a9ddd20a3c64a'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Effect of Exchange Rate Changes on Cash</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:11%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_a0cea6733d3346d298c5bebc2c73aed1'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="D20250930_1" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag572">8,568</ix:nonFraction></span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:11%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_afbb2f96180a4151afae332f4601873f'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="D20240930_1" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag589">2,492</ix:nonFraction></span></p></div></td></tr><tr style="height:14.4pt"><td style="width:74%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:11%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:11%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td></tr><tr style="height:13.2pt"><td style="width:74%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_2f2963c2d43c47a198a011ea6fe4cec6'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Change in Cash and Cash Equivalents</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:11%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_fbf20003b7e545299cd83e9091088364'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="D20250930_1" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag573">2,456,426</ix:nonFraction></span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:11%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_c0cf3ae5f31447a8af951bbb5b49c10f'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="D20240930_1" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag590">1,158,203</ix:nonFraction></span></p></div></td></tr><tr style="height:13.8pt"><td style="width:74%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_202ef93524f843b4850e4dab002226fe'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Cash and Cash Equivalents&#8212;Beginning of Period</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:11%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_e78a4bae7009476ca49da1d1165ff9fd'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="I20241231" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag574">1,659,353</ix:nonFraction></span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:11%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_bb6a7a8cb92b4283a028d5dbfe97d98a'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="I20231231" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag575">2,142,485</ix:nonFraction></span></p></div></td></tr><tr style="height:13.8pt"><td style="width:74%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_b46ddaf602d84f8b8c405e5031ab8c53'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">Cash and Cash Equivalents&#8212;End of Period</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_fd6e00bd09c944c3ae4fed9e5a941b82'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">$</span></p></div></td><td style="width:11%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_b53696459db04f8db776a37b0cafab38'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="I20250930" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag576">4,115,779</ix:nonFraction></span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_5c6e38c28ce048799b41ff0ff01f7b3c'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">$</span></p></div></td><td style="width:11%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_1d4e2eb67a964a739e89d5abffd5581e'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="I20240930" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag577">3,300,688</ix:nonFraction></span></p></div></td></tr><tr style="height:2.25pt"><td style="width:74%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:4.5pt double #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:11%; border-top:4.5pt double #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:4.5pt double #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:11%; border-top:4.5pt double #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td></tr><tr style="height:13.8pt"><td style="width:74%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_a61d03f2dcd84375b5b20c1b918dfca8'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">NONCASH INVESTING/FINANCING ACTIVITIES</span></p></div></td><td style="width:1%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:11%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:11%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td></tr><tr style="height:13.2pt"><td style="width:74%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_97b20f82356748248eb3cc3155f8cc18'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Fair Value of Warrants Issued to Underwriters</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_0fb6c56712b94e51a71cea8f09e56c8f'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:11%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-tag:'C_4fb82987906a443fb524b5d74e750bbf'"><ix:nonFraction name="sxtp:FairValueOfWarrantsIssuedToUnderwriters" contextRef="D20250930_1" xsi:nil="true" unitRef="USD" id="Tag597"></ix:nonFraction><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_317a05d5377e449ca29f6efdc8cd8612'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:11%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_a86ebd2181d841e99ee35a3e761139e0'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="sxtp:FairValueOfWarrantsIssuedToUnderwriters" contextRef="D20240930_1" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag591">71,364</ix:nonFraction></span></p></div></td></tr><tr style="height:13.2pt"><td style="width:74%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_a965d81094834244a7820af353054c5f'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Purchases of Fixed Assets included in Accounts Payable</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_af49e944a4b542ae876a975bd37f4a28'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:11%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_6b97a5c6d47a4e00a46ffddf9f5d713d'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1" contextRef="D20250930_1" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag608">46,099</ix:nonFraction></span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_cc70482fbd51497883338da0d77c76b6'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:11%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-tag:'C_1b58abe1a06a4c45b886457ccb630649'"><ix:nonFraction name="us-gaap:NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1" contextRef="D20240930_1" xsi:nil="true" unitRef="USD" id="Tag707"></ix:nonFraction><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td></tr><tr style="height:13.2pt"><td style="width:74%; vertical-align:middle; background-color:#ccecff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_fae084e2fa7944aa9de4cbc8ecc48b00'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Conversion of Series A Preferred Stock into Common Stock</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ccecff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#ccecff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_18f8420571aa42b3a48230fd855657cf'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:11%; vertical-align:middle; background-color:#ccecff"><div style="-aw-sdt-tag:'C_8212667179ea454da3019e6b3dfdcb76'"><ix:nonFraction name="sxtp:ConversionOfSeriesAPreferredStockIntoCommonStock" contextRef="D20250930_1" xsi:nil="true" unitRef="USD" id="Tag706"></ix:nonFraction><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ccecff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#ccecff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_0adc873a412b48e39e855715332ff0dc'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:11%; vertical-align:middle; background-color:#ccecff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_c6d6a653c04544f8b49b4d25254ad535'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="sxtp:ConversionOfSeriesAPreferredStockIntoCommonStock" contextRef="D20240930_1" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag705">290,601</ix:nonFraction></span></p></div></td></tr><tr style="height:13.2pt"><td style="width:74%; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_c0dbf5afccb94c63932e74ca9164a98b'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Capitalized Patent Costs included in Accounts Payable</span></p></div></td><td style="width:1%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_34fd9cdfa23540ff82c7bef98bfab1f6'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:11%; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_d0c80cec06914caaac7a1a056fb9c456'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1" contextRef="D20250930_1" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag632">3,796</ix:nonFraction></span></p></div></td><td style="width:1%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_f1407abb30844502b5d58c7a4892c5f7'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:11%; vertical-align:middle"><div style="-aw-sdt-tag:'C_660a9c16fbc94b1eb5be3a5e5efea640'"><ix:nonFraction name="us-gaap:NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1" contextRef="D20240930_1" xsi:nil="true" unitRef="USD" id="Tag633"></ix:nonFraction><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td></tr><tr style="height:13.2pt"><td style="width:74%; vertical-align:bottom; background-color:#ccecff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_d763f35729df4601a8bed1ff61bc018e'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Gross Shares Issued for Annual Performance Bonuses</span></p></div></td><td style="width:1%; vertical-align:bottom; background-color:#ccecff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#ccecff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_a81064717a784ef783d95c1131aa4180'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:11%; vertical-align:middle; background-color:#ccecff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_4d0a05a8fdd14423bf2fd0f80a3dc9c4'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="sxtp:GrossSharesIssuedForAnnualPerformanceBonuses" contextRef="D20250930_1" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag578">121,544</ix:nonFraction></span></p></div></td><td style="width:1%; vertical-align:bottom; background-color:#ccecff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#ccecff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_f7e29856720d4962882ca320b7349a7e'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:11%; vertical-align:middle; background-color:#ccecff"><div style="-aw-sdt-tag:'C_681cb3641f2c48ba86819ca785655f59'"><ix:nonFraction name="sxtp:GrossSharesIssuedForAnnualPerformanceBonuses" contextRef="D20240930_1" xsi:nil="true" unitRef="USD" id="Tag598"></ix:nonFraction><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td></tr></tbody></table></div><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-style:italic">The accompanying notes are an integral part of these unaudited consolidated condensed financial statements.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span>&#160;</span></p><div style="-aw-sdt-tag:'PG_c9a19faecdf5326caab0'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-family: 'Times New Roman';">5</span></p><div><hr style="width: 100%; color: #000000; background-color: #000000; margin: 1rem 0;"/></div></div></div><div class="Section_9"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold">60 DEGREES PHARMACEUTICALS, INC.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span id="TOC_c2ad382b9a9434be612a"><span style="font-weight:bold">NOTES TO UNAUDITED CONSOLIDATED CONDENSED FINANCIAL STATEMENTS</span></span></p><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-bookmark-end:TOC_c2ad382b9a9434be612a"></span><span>&#160;</span></p><div style="-aw-sdt-tag:'133-036-ea5-2f3-449d'"><ix:nonNumeric name="us-gaap:NatureOfOperations" contextRef="D20250930_1" escape="true" id="Tag981" continuedAt="c9539acd963a415503a5"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">1. NATURE OF OPERATIONS</span></p><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">60 Degrees Pharmaceuticals, Inc. was incorporated in Delaware on June 1, </span><span style="-aw-sdt-tag:'c270bf7cd5ba984b5e1c'; font-family: 'Times New Roman'"><span>2022</span></span><span style="font-family: 'Times New Roman';"> and merged on the same day with </span><span style="-aw-sdt-tag:'c657950d5b1564663aa5'; font-family: 'Times New Roman'"><span>60</span></span><span style="font-family: 'Times New Roman';"> Degrees Pharmaceuticals, LLC, a District of Columbia limited liability company organized on September </span><span style="-aw-sdt-tag:'c1c7e4992ee8ee67833d'; font-family: 'Times New Roman'"><span>9</span></span><span style="font-family: 'Times New Roman';">, </span><span style="-aw-sdt-tag:'ca396d6e4d1f987f4646'; font-family: 'Times New Roman'"><span>2010</span></span><span style="font-family: 'Times New Roman';"> (&#8220;</span><span style="-aw-sdt-tag:'ccbaaf62d4129f0282b6'; font-family: 'Times New Roman'"><span>60</span></span><span style="font-family: 'Times New Roman';">P LLC&#8221;). </span><span style="-aw-sdt-tag:'cba51fa10334af688698'; font-family: 'Times New Roman'"><span>60</span></span><span style="font-family: 'Times New Roman';"> Degrees Pharmaceuticals, Inc. and its subsidiary (referred to collectively as the &#8220;Company&#8221;, &#8220;</span><span style="-aw-sdt-tag:'c5523ac12e81e3a392be'; font-family: 'Times New Roman'"><span>60</span></span><span style="font-family: 'Times New Roman';">P&#8221;, or &#8220;</span><span style="-aw-sdt-tag:'c784671fbd07bf0d40cf'; font-family: 'Times New Roman'"><span>60</span></span><span style="font-family: 'Times New Roman';"> Degrees Pharmaceuticals&#8221;) is a specialty pharmaceutical company that specializes in the development and marketing of new medicines for the treatment and prevention of infectious diseases. </span><span style="-aw-sdt-tag:'c834b08102bb9356bc64'; font-family: 'Times New Roman'"><span>60</span></span><span style="font-family: 'Times New Roman';">P achieved FDA approval of its lead product, ARAKODA&#174; (tafenoquine), for malaria prevention, in </span><span style="-aw-sdt-tag:'ce4eef3e3aca50301650'; font-family: 'Times New Roman'"><span>2018</span></span><span style="font-family: 'Times New Roman';">. Currently, </span><span style="-aw-sdt-tag:'c93fc95f7e4cdd4f571a'; font-family: 'Times New Roman'"><span>60</span></span><span style="font-family: 'Times New Roman';">P&#8217;s pipeline under development covers development programs for tick-borne fungal and other viral diseases utilizing three of the Company&#8217;s future products: (i) new products that contain the Arakoda regimen of tafenoquine; (ii) new products that contain tafenoquine; and (iii) celgosivir and/or botanical extracts from Australian Chestnut Trees. The Company&#8217;s headquarters are located in Washington, D.C., with a majority-owned subsidiary in Australia.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; text-decoration:underline; font-family: 'Times New Roman'">Risks and Uncertainties</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">The Company is subject to risks common to companies in the biopharmaceutical industry including, but not limited to, the risks associated with developing product candidates and successfully launching and commercializing its drug/device combination products, the Company&#8217;s ability to obtain regulatory approval of such products in the United States and other geography markets, the uncertainty of the broad adoption of its approved products by physicians and consumers, and significant competition.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">In addition, higher rates of inflation have resulted in the U.S. Federal Reserve raising interest rates. Increases in interest rates, especially if coupled with reduced government spending and volatility in financial markets, may further increase economic uncertainty and heighten these risks. Furthermore, if additional banks and financial institutions enter receivership or become insolvent in the future in response to financial conditions affecting the banking system and financial markets, the Company or its partners&#8217; ability to access existing cash, cash equivalents and investments may be threatened and could have a material adverse effect on the Company&#8217;s business and financial condition, including the Company&#8217;s ability to access additional capital on favorable terms, or at all, which could in the future negatively affect the Company&#8217;s ability to pursue its business strategy.</span><span style="font-weight:bold; font-family: 'Times New Roman'">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; text-decoration:underline; font-family: 'Times New Roman'">Going Concern</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">The Company&#8217;s future results are subject to substantial risks and uncertainties. Since its inception, the Company has not demonstrated the ability to generate enough revenues to date to cover operating expenses and has accumulated losses to date. At </span><span style="-aw-sdt-tag:'c6621e838f6e2797b148'; -aw-sdt-title:'Current_Period_P26'; font-family: 'Times New Roman'"><span>September 30, 2025</span></span><span style="font-family: 'Times New Roman';">, the Company had cash and cash equivalents totaling $</span><span style="-aw-sdt-tag:'ccf01eed229ee36500f5'; -aw-sdt-title:'cash and cash equivalents_CP'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="I20250930" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag740">4,115,779</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">, as compared to cash and cash equivalents totaling $</span><span style="-aw-sdt-tag:'c9861c7425fd7e3efbf3'; -aw-sdt-title:'cash and cash equivalents_PY'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="I20241231" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag741">1,659,353</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';"> at </span><span style="-aw-sdt-tag:'c3b49d62cc46a9e3bf26'; -aw-sdt-title:'Previous_Year_End_P19'; font-family: 'Times New Roman'"><span>December 31, 2024</span></span><span style="font-family: 'Times New Roman';">. During the </span><span style="-aw-sdt-tag:'c1d42859dfcea9ae8a6a'; -aw-sdt-title:'Current_YTD_P3'; font-family: 'Times New Roman'"><span>nine months ended September 30, 2025</span></span><span style="font-family: 'Times New Roman';"> the Company used cash of $</span><span style="-aw-sdt-tag:'c1c30bf00acb9628ea81'; -aw-sdt-title:'Operating activities_CYTD'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="D20250930_1" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" sign="-" id="Tag743">5,156,566</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';"> in its operating activities. The Company&#8217;s capital commitments over the next twelve months include interest payments on the Company&#8217;s debt arrangement of $</span><span style="-aw-sdt-tag:'c7df475d3e16907ec478'; -aw-sdt-title:'Next 12M Debt Payments'; font-family: 'Times New Roman'"><span><ix:nonFraction name="sxtp:SBAEIDLincludingAccruedInterestCurrent" contextRef="I20250930" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag742">8,772</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';"> and $</span><span style="-aw-sdt-tag:'bbd-7d3-a59-176-8056'; -aw-sdt-title:'Next 12M AP and Accruals'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" contextRef="I20250930" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag813">1,391,347</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';"> to satisfy accounts payable and accrued expenses.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">To date, the Company has funded its operations primarily with proceeds from sales of common stock and warrants for the purchase of common stock, sales of preferred stock, proceeds from the issuance of convertible debt and borrowings under loan and security agreements.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">Continuation as a going concern is dependent upon the Company&#8217;s ability to meet its financial requirements, raise additional capital, and achieve gross profitability from the Company&#8217;s single marketed product. To achieve profitability, the Company expects it will need to raise additional capital to fund its activities relating to commercial support for its existing product and any future clinical research trials and operating activities. However, there can be no assurance that it will ever achieve or maintain profitability. These conditions, among others, raise substantial doubt about the ability of the Company to continue as a going concern for one year from the date these consolidated condensed financial statements are issued.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><div style="-aw-sdt-tag:'PG_c12ebe76f85b70d02c5e'"><ix:exclude><ix:exclude><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-family: 'Times New Roman'; z-index: 100;">6</span></p><div><hr style="width: 100%; color: #000000; background-color: #000000; margin: 1rem 0;"/></div></ix:exclude></ix:exclude></div></ix:nonNumeric></div></div><div class="Section_10"><div style="-aw-sdt-tag:'133-036-ea5-2f3-449d'"><ix:continuation id="c9539acd963a415503a5"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">Management plans to fund operations of the Company through third party and related party debt/advances, private placement of restricted securities and the issuance of stock in a subsequent offering until such a time as the business achieves profitability or a business combination may be achieved. However, there can be no assurance that the Company will be successful in raising additional capital or that such capital, if available, will be on terms that are favorable to the Company. Debt financing and equity financing, if available, may involve agreements that include covenants limiting or restricting the Company&#8217;s ability to take specific actions, such as incurring additional debt, making capital expenditures, or declaring dividends. If the Company raises funds through collaborations, or other similar arrangements with third parties, it may have to relinquish valuable rights to its technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to the Company and/or may reduce the value of its common stock. If the Company is unable to raise additional funds through equity or debt financings when needed, it may be required to delay, limit, reduce or terminate its product development or future commercialization efforts or grant rights to develop and market its product candidates even if the Company would otherwise prefer to develop and market such product candidates itself.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">As such, management concluded that such plans do not alleviate the substantial doubt about the ability of the Company to continue as a going concern for one year from the date these consolidated condensed financial statements are issued.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">The consolidated condensed financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of obligations in the normal course of business, and do not include any adjustments to the amount and classification of assets and liabilities that may be necessary should the Company be unable to continue as a going concern.</span><span style="font-family: 'Times New Roman';">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </span><span style="font-family: 'Times New Roman';">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </span></p></ix:continuation></div><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore">&#160;</span></p><div style="-aw-sdt-tag:'d52-b02-e2a-ceb-f6c1'"><ix:nonNumeric name="us-gaap:SignificantAccountingPoliciesTextBlock" contextRef="D20250930_1" escape="true" id="Tag974" continuedAt="c053c4981011054c2133"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-import:spaces; font-family: 'Times New Roman'">&#160;</span></p><div style="-aw-sdt-tag:'cdb505dc74cc1259e26b'"><ix:nonNumeric name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" contextRef="D20250930_1" escape="true" id="Tag954"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; text-decoration:underline; font-family: 'Times New Roman'">Basis of Presentation</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">The financial statements of </span><span style="-aw-sdt-tag:'ce903abe84353d2391d6'; font-family: 'Times New Roman'"><span>60</span></span><span style="font-family: 'Times New Roman';">P are prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;). The Company has prepared the accompanying consolidated condensed financial statements pursuant to the instructions to Form </span><span style="-aw-sdt-tag:'c90d6f77918f6efd358d'; font-family: 'Times New Roman'"><span>10</span></span><span style="font-family: 'Times New Roman';">-Q and Article </span><span style="-aw-sdt-tag:'c8389d80e96daea9720b'; font-family: 'Times New Roman'"><span>8</span></span><span style="font-family: 'Times New Roman';"> of Regulation S-X of the Securities and Exchange Commission (&#8220;SEC&#8221;). These financial statements are unaudited and, in the opinion of management, all adjustments considered necessary for a fair presentation of the Company&#8217;s financial position, results of operations, and cash flows have been included and are of a normal and recurring nature. Operating results for the periods presented are not necessarily indicative of the results that may be expected for the year ending </span><span style="-aw-sdt-tag:'c0c7176b5bdb194bfddc'; -aw-sdt-title:'Current_Year_End_P1'; font-family: 'Times New Roman'"><span>December 31, 2025</span></span><span style="font-family: 'Times New Roman';"> due to various factors. These consolidated condensed financial statements should be read in conjunction with the audited consolidated financial statements and related notes thereto as of and for the years ended </span><span style="-aw-sdt-tag:'c18cdcd3e90810c9b66a'; -aw-sdt-title:'Previous_Year_End_P6'; font-family: 'Times New Roman'"><span>December 31, 2024</span></span><span style="font-family: 'Times New Roman';"> and </span><span style="-aw-sdt-tag:'c81138fdfee9b110fdf9'; font-family: 'Times New Roman'"><span>2023</span></span><span style="font-family: 'Times New Roman';">, included in the Company&#8217;s annual report on Form </span><span style="-aw-sdt-tag:'c4c00800b9e2d5f1439e'; font-family: 'Times New Roman'"><span>10</span></span><span style="font-family: 'Times New Roman';">-K, as filed with the SEC on March </span><span style="-aw-sdt-tag:'c48ed363e59cdbbb1e8b'; font-family: 'Times New Roman'"><span>27</span></span><span style="font-family: 'Times New Roman';">, </span><span style="-aw-sdt-tag:'c7da1b0fe69d8d60fb79'; font-family: 'Times New Roman'"><span>2025</span></span><span style="font-family: 'Times New Roman';"> (the &#8220;Annual Report&#8221;). Certain information, footnote disclosures, and significant accounting policies that would substantially duplicate the disclosures contained in the Annual Report have been omitted.</span></p></ix:nonNumeric></div><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p><div style="-aw-sdt-tag:'d24-ead-d5b-0d7-fd95'"><ix:nonNumeric name="us-gaap:UseOfEstimates" contextRef="D20250930_1" escape="true" id="Tag959"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; text-decoration:underline; font-family: 'Times New Roman'">Use of Estimates</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates, and those estimates may be material. Significant estimates include the reserve for inventory, the fair value of derivative liabilities, and stock-based compensation.</span></p></ix:nonNumeric></div><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p><div style="-aw-sdt-tag:'PG_c5050bfc508bd0645091'"><ix:exclude><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-family: 'Times New Roman'; z-index: 100;">7</span></p><div><hr style="width: 100%; color: #000000; background-color: #000000; margin: 1rem 0;"/></div></ix:exclude></div></ix:nonNumeric></div></div><div class="Section_11"><div style="-aw-sdt-tag:'d52-b02-e2a-ceb-f6c1'"><ix:continuation id="c053c4981011054c2133" continuedAt="cf42cc39c75d2de59f74"><div style="-aw-sdt-tag:'c6fb7024e47107499fcb'"><ix:nonNumeric name="us-gaap:StockholdersEquityPolicyTextBlock" contextRef="D20250930_1" escape="true" id="Tag936"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; text-decoration:underline; font-family: 'Times New Roman'">Reverse Stock Splits</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-sdt-tag:'dac-e32-fd4-981-41a6'; font-family: 'Times New Roman'"><ix:nonNumeric name="us-gaap:StockholdersEquityReverseStockSplit" contextRef="D20240731" escape="false" id="Tag739"><span>Following stockholder approval in July 2024, the Company effected a reverse stock split at a ratio of 1:12, which was effective as of August 12, 2024 (the &#8220;1:12 Reverse Stock Split&#8221;).</span></ix:nonNumeric></span><span style="font-family: 'Times New Roman';"> </span><span style="-aw-sdt-tag:'731-9b8-7ee-b5e-cc0f'; font-family: 'Times New Roman'"><ix:nonNumeric name="us-gaap:StockholdersEquityReverseStockSplit" contextRef="D20241106" escape="false" id="Tag723"><span>On November 6, 2024, a majority of the Company&#8217;s stockholders approved an additional reverse stock split at a split ratio ranging between 1:3 and 1:5, as determined by the Board of Directors in its sole discretion.</span></ix:nonNumeric></span><span style="font-family: 'Times New Roman';"> </span><span style="-aw-sdt-tag:'013-0eb-6cc-bc0-02a0'; font-family: 'Times New Roman'"><ix:nonNumeric name="us-gaap:StockholdersEquityReverseStockSplit" contextRef="D20250210" escape="false" id="Tag724"><span>On February 10, 2025, the Board of Directors approved a 1:5 reverse split ratio. On February 24, 2025, the Company effected the 1:5 reverse stock split (the &#8220;1:5 Reverse Stock Split&#8221;, and together with the 1:12 Reverse Stock Split, the &#8220;Reverse Stock Splits&#8221;).</span></ix:nonNumeric></span><span style="font-family: 'Times New Roman';"> Beginning February </span><span style="-aw-sdt-tag:'c26c29b86737c43d1066'; font-family: 'Times New Roman'"><span>24</span></span><span style="font-family: 'Times New Roman';">, </span><span style="-aw-sdt-tag:'c7cca48741fbb787a7db'; font-family: 'Times New Roman'"><span>2025</span></span><span style="font-family: 'Times New Roman';">, the common stock traded on The Nasdaq Capital Market on a split adjusted basis.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">Proportional adjustments were made to the number of shares of common stock issuable upon exercise or conversion of the Company&#8217;s equity awards, warrants, and other equity instruments convertible into common stock, as well as the respective exercise prices, if applicable, in accordance with the terms of the instruments. Unless otherwise noted, all references to numbers of shares of the Company&#8217;s common stock and per share information presented in these consolidated condensed financial statements have been retroactively adjusted, as appropriate, to reflect the Reverse Stock Splits, including reclassifying an amount equal to the reduction in par value of common stock to additional paid-in capital.</span></p></ix:nonNumeric></div><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><div style="-aw-sdt-tag:'ce4d5252ffc132995fd3'"><ix:nonNumeric name="us-gaap:ConcentrationRiskCreditRisk" contextRef="D20250930_1" escape="true" id="Tag937"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; text-decoration:underline; font-family: 'Times New Roman'">Concentrations</span></p><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents, short-term investments, accounts receivable, inventory purchases, and borrowings.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">Significant customers represent any customer whose business makes up </span><span style="-aw-sdt-tag:'c38d441a704cc0769f2e'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="D20250930_CustomerConcentrationRiskMember_SignificantCustomersMember_AccountsReceivableOrSalesRevenueNetMember" unitRef="Pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="Tag737">10</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">% of receivables or revenues. At </span><span style="-aw-sdt-tag:'c8aefa95b7837b6c59db'; -aw-sdt-title:'Current_Period_P1'; font-family: 'Times New Roman'"><span>September 30, 2025</span></span><span style="font-family: 'Times New Roman';">, significant customers represented </span><span style="-aw-sdt-tag:'c7d0ee37bbed719c14fb'; -aw-sdt-title:'Current_Sig. Cust AR Percent'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="D20250930_CustomerConcentrationRiskMember_SignificantCustomersMember_AccountsReceivableMember_1" unitRef="Pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="Tag734">89</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">% of receivables (consisting of </span><span style="-aw-sdt-tag:'efa-f25-b7a-0c0-3393'; -aw-sdt-title:'Current_Total Customers in AR'; font-family: 'Times New Roman'"><span>six</span></span><span style="font-family: 'Times New Roman';"> total customers and </span><span style="-aw-sdt-tag:'6bd-f9c-095-2b1-0b97'; -aw-sdt-title:'Current_Sigificant Customers in AR'; font-family: 'Times New Roman'"><span>two</span></span><span style="font-family: 'Times New Roman';"> significant customers at </span><span style="-aw-sdt-tag:'757-b3e-309-2f1-7957'; -aw-sdt-title:'AR Sig Customer 1 _Current'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="D20250930_CustomerConcentrationRiskMember_AccountsReceivableMember_SignificantCustomerOneMember" unitRef="Pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="Tag735">75</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">% and </span><span style="-aw-sdt-tag:'053-64b-d59-480-934c'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="D20250930_CustomerConcentrationRiskMember_AccountsReceivableMember_SignificantCustomerTwoMember" unitRef="Pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="Tag736">13</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">%, respectively), and </span><span style="-aw-sdt-tag:'c8865edd41199200cda9'; -aw-sdt-title:'Prior_Sig. Cust AR Percent'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="D20241231_CustomerConcentrationRiskMember_SignificantCustomersMember_AccountsReceivableMember" unitRef="Pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="Tag720">95</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">% of receivables at </span><span style="-aw-sdt-tag:'c612e322ca6f5a44144a'; -aw-sdt-title:'Previous_Year_End_P7'; font-family: 'Times New Roman'"><span>December 31, 2024</span></span><span style="font-family: 'Times New Roman';"> (consisting of </span><span style="-aw-sdt-tag:'58c-1fd-4c8-cbc-24e3'; -aw-sdt-title:'Prior_Total Customers in AR'; font-family: 'Times New Roman'"><span>three</span></span><span style="font-family: 'Times New Roman';"> total customers and </span><span style="-aw-sdt-tag:'0cd-eb1-27d-ce1-d261'; -aw-sdt-title:'Prior_Sigificant Customers in AR'; font-family: 'Times New Roman'"><span>one</span></span><span style="font-family: 'Times New Roman';"> significant customer). For the </span><span style="-aw-sdt-tag:'ca0e62e990a606583b94'; -aw-sdt-title:'Current_Quarter_P14'; font-family: 'Times New Roman'"><span>three months ended September 30, 2025</span></span><span style="font-family: 'Times New Roman';">, significant customers comprised </span><span style="-aw-sdt-tag:'c610c2cb61e4f95ffd6c'; -aw-sdt-title:'CQTD_Sig.Cust Percent Net Revenue'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="D20250930_CustomerConcentrationRiskMember_SignificantCustomersMember_SalesRevenueNetMember" unitRef="Pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="Tag732">80</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">% of total net product revenues (consisting of </span><span style="-aw-sdt-tag:'7ac-793-8fb-7b6-6b7e'; -aw-sdt-title:'CQTD_Total Customers'; font-family: 'Times New Roman'"><span>four</span></span><span style="font-family: 'Times New Roman';"> total customers and </span><span style="-aw-sdt-tag:'935-1d8-24e-b55-3697'; -aw-sdt-title:'CWTD_Significant Customers'; font-family: 'Times New Roman'"><span>one</span></span><span style="font-family: 'Times New Roman';"> significant customer at </span><span style="-aw-sdt-tag:'fd4-598-fc6-c55-b5b3'; -aw-sdt-title:'CQTD_Sig Customer 1 Percent'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="D20250930_CustomerConcentrationRiskMember_SignificantCustomerOneMember_SalesRevenueNetMember" unitRef="Pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="Tag733">80</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">%). For the </span><span style="-aw-sdt-tag:'c89b221bf86e60e80aee'; -aw-sdt-title:'Previous_Quarter_P5'; font-family: 'Times New Roman'"><span>three months ended September 30, 2024</span></span><span style="font-family: 'Times New Roman';">, </span><span style="-aw-sdt-tag:'c4871e9ed0486ef91d28'; -aw-sdt-title:'PQTD_Sig.Cust Percent Net Revenue'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="D20240930_CustomerConcentrationRiskMember_SignificantCustomersMember_SalesRevenueNetMember" unitRef="Pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="Tag726">92</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">% of total net product revenues (consisting of </span><span style="-aw-sdt-tag:'92a-ab1-dc7-7a9-7dd3'; -aw-sdt-title:'PQTD_Total Customers'; font-family: 'Times New Roman'"><span>two</span></span><span style="font-family: 'Times New Roman';"> total customers and </span><span style="-aw-sdt-tag:'813-a74-d78-4e2-d0ec'; -aw-sdt-title:'PQTD_Significant Customers'; font-family: 'Times New Roman'"><span>one</span></span><span style="font-family: 'Times New Roman';"> significant customer) were generated from significant customers. For the </span><span style="-aw-sdt-tag:'c71fb825a8fc9183fba4'; -aw-sdt-title:'Current_YTD_P9'; font-family: 'Times New Roman'"><span>nine months ended September 30, 2025</span></span><span style="font-family: 'Times New Roman';">,</span><span style="font-family: 'Times New Roman';">&#160;</span><span style="-aw-sdt-tag:'cd703ca85832d9e6ccd9'; -aw-sdt-title:'CYTD_Sig.Cust Percent Net Revenue'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="D20250930_CustomerConcentrationRiskMember_SignificantCustomersMember_SalesRevenueNetMember_1" unitRef="Pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="Tag721">91</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">% of total net product revenues (consisting of </span><span style="-aw-sdt-tag:'d25-e87-6c3-44b-77b8'; -aw-sdt-title:'CYTD_Total Customers'; font-family: 'Times New Roman'"><span>four</span></span><span style="font-family: 'Times New Roman';"> total customers and </span><span style="-aw-sdt-tag:'623-163-567-ed7-13d7'; -aw-sdt-title:'CYTD_Significant Customers'; font-family: 'Times New Roman'"><span>two</span></span><span style="font-family: 'Times New Roman';"> significant customers at </span><span style="-aw-sdt-tag:'fd4-589-ac0-f12-5f6a'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="D20250930_CustomerConcentrationRiskMember_SalesRevenueNetMember_SignificantCustomerOneMember" unitRef="Pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="Tag725">73</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">% and </span><span style="-aw-sdt-tag:'aa0-f10-986-33c-5f25'; -aw-sdt-title:'CYTD_Sig Customer 2 Percent'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="D20250930_CustomerConcentrationRiskMember_SalesRevenueNetMember_SignificantCustomerTwoMember_1" unitRef="Pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="Tag727">18</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">%, respectively) were generated from significant customers. For the </span><span style="-aw-sdt-tag:'cd6d62b9c3ce9b21e230'; -aw-sdt-title:'Previous_YTD_P4'; font-family: 'Times New Roman'"><span>nine months ended September 30, 2024</span></span><span style="font-family: 'Times New Roman';">,</span><span style="font-family: 'Times New Roman';">&#160;</span><span style="-aw-sdt-tag:'c34cf87b1815b4a11766'; -aw-sdt-title:'PYTD_Sig.Cust Percent Net Revenue'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" contextRef="D20240930_CustomerConcentrationRiskMember_SignificantCustomersMember_SalesRevenueNetMember_1" unitRef="Pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="Tag722">94</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">% of total net product revenues (consisting of </span><span style="-aw-sdt-tag:'f2f-f63-4d3-652-810a'; -aw-sdt-title:'PYTD_Total Customers'; font-family: 'Times New Roman'"><span>three</span></span><span style="font-family: 'Times New Roman';"> total customers and </span><span style="-aw-sdt-tag:'20a-b2d-e5b-ae2-0417'; -aw-sdt-title:'PYTD_Significant Customers'; font-family: 'Times New Roman'"><span>one</span></span><span style="font-family: 'Times New Roman';"> significant customer) were generated from significant customers.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">Currently, the Company has exclusive relationships with distributors in Australia and Europe. A failure to perform by any of our current distributors would create disruption for patients in those markets.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">Since the Company first started working on tafenoquine, all inventory has been acquired in a collaborative relationship from a sole vendor. Should the vendor cease to supply tafenoquine, it would take significant costs and efforts to rebuild the supply chain with a new sole vendor sourcing the active pharmaceutical ingredient (&#8220;API&#8221;).</span></p></ix:nonNumeric></div><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><div style="-aw-sdt-tag:'cb21377b78bedc008a21'"><ix:nonNumeric name="us-gaap:SegmentReportingPolicyPolicyTextBlock" contextRef="D20250930_1" escape="true" id="Tag938" continuedAt="c8194bbbf07be6a81c78"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; text-decoration:underline; font-family: 'Times New Roman'">Segment Information</span></p><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">Since its inception, the Company operates and manages its business as a single identifiable segment, focused on the development and marketing of new medicines for the treatment and prevention of infectious diseases. The determination of a single business segment is consistent with the consolidated financial information regularly provided to the Company&#8217;s chief operating decision maker (&#8220;CODM&#8221;).</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:10pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">The Company&#8217;s CODM is its Chief Executive Officer, who reviews and evaluates consolidated net income or loss for purposes of evaluating performance, making operating decisions, allocating resources, and planning and forecasting for future periods. The significant components of consolidated net income or loss regularly provided to the CODM include net product revenues and the significant expense categories presented in the accompanying </span><span style="-aw-sdt-tag:'40d-f92-19d-c95-c73e'; -aw-sdt-title:'PandL_title_P2'; font-family: 'Times New Roman'"><span>consolidated condensed statements of operations and comprehensive loss</span></span><span style="font-family: 'Times New Roman';"> (cost of revenues, research and development, and general and administrative expenses). These are presented at the consolidated level and used by the CODM to monitor budgeted versus actual results to make key operating decisions. The information and operating expense categories presented in the accompanying </span><span style="-aw-sdt-tag:'253-c33-1cd-8c6-3ae5'; -aw-sdt-title:'PandL_title_P3'; font-family: 'Times New Roman'"><span>consolidated condensed statements of operations and comprehensive loss</span></span><span style="font-family: 'Times New Roman';"> are fully reflective of the significant expense categories and amounts that are regularly provided to the CODM.</span></p><div style="-aw-sdt-tag:'PG_c24bb3258a68b0280db8'"><ix:exclude><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-family: 'Times New Roman'; z-index: 100;">8</span></p><div><hr style="width: 100%; color: #000000; background-color: #000000; margin: 1rem 0;"/></div></ix:exclude></div></ix:nonNumeric></div></ix:continuation></div></div><div class="Section_12"><div style="-aw-sdt-tag:'d52-b02-e2a-ceb-f6c1'"><ix:continuation id="cf42cc39c75d2de59f74" continuedAt="c8c66f33053658861626"><div style="-aw-sdt-tag:'cb21377b78bedc008a21'"><ix:continuation id="c8194bbbf07be6a81c78"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">The measure of segment assets that is regularly reported to the CODM includes cash and cash equivalents and short-term investments, each as reported on the </span><span style="-aw-sdt-tag:'139-b42-89d-4af-5020'; -aw-sdt-title:'Balance_Sheet_Title_P1'; font-family: 'Times New Roman'"><span>consolidated condensed balance sheets</span></span><span style="font-family: 'Times New Roman';">. Total consolidated cash and cash equivalents and short-term investments were $</span><span style="-aw-sdt-tag:'c26449208c3edf5c7aa8'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:CashCashEquivalentsAndShortTermInvestments" contextRef="I20250930" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag718">4,115,779</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';"> and $</span><span style="-aw-sdt-tag:'cdccccade90e66a13fb9'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:CashCashEquivalentsAndShortTermInvestments" contextRef="I20241231" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag719">3,387,825</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';"> as of </span><span style="-aw-sdt-tag:'c7407e74fc85ec3ccdfe'; -aw-sdt-title:'Current_Period_P2'; font-family: 'Times New Roman'"><span>September 30, 2025</span></span><span style="font-family: 'Times New Roman';"> and </span><span style="-aw-sdt-tag:'c00bf74fe48b3c64541d'; -aw-sdt-title:'Previous_Year_End_P12'; font-family: 'Times New Roman'"><span>December 31, 2024</span></span><span style="font-family: 'Times New Roman';">, respectively.</span></p></ix:continuation></div><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p><div style="-aw-sdt-tag:'aed-ca6-c7c-350-2bc6'"><ix:nonNumeric name="us-gaap:DerivativesPolicyTextBlock" contextRef="D20250930_1" escape="true" id="Tag950"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; text-decoration:underline; font-family: 'Times New Roman'">Derivative Liabilities</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">The Company analyzes all financial instruments with features of both liabilities and equity under FASB ASC Topic No. </span><span style="-aw-sdt-tag:'c4a98c0f9c305eb9ad0a'; font-family: 'Times New Roman'"><span>480</span></span><span style="font-family: 'Times New Roman';">, </span><span style="font-style:italic; font-family: 'Times New Roman'">Distinguishing Liabilities from Equity</span><span style="font-family: 'Times New Roman';"> (&#8220;ASC </span><span style="-aw-sdt-tag:'ce2b75a3274a6a43e17f'; font-family: 'Times New Roman'"><span>480</span></span><span style="font-family: 'Times New Roman';">&#8221;), and FASB ASC Topic No. </span><span style="-aw-sdt-tag:'ced90c7d41ecdbd49877'; font-family: 'Times New Roman'"><span>815</span></span><span style="font-family: 'Times New Roman';">, </span><span style="font-style:italic; font-family: 'Times New Roman'">Derivatives and Hedging</span><span style="font-family: 'Times New Roman';"> (&#8220;ASC </span><span style="-aw-sdt-tag:'ccd1349dccf1b3e1afae'; font-family: 'Times New Roman'"><span>815</span></span><span style="font-family: 'Times New Roman';">&#8221;). The classification of derivative financial instruments is reassessed each reporting period. Derivative liabilities are adjusted to reflect fair value at each reporting period, with any increase or decrease in the fair value recorded in the results of operations, as a component of other income or expense as change in fair value of derivative liabilities. As of </span><span style="-aw-sdt-tag:'c1af92d97c032e45d07a'; -aw-sdt-title:'Current_Period_P14'; font-family: 'Times New Roman'"><span>September 30, 2025</span></span><span style="font-family: 'Times New Roman';">, derivative liabilities consist of contingent payment arrangements. The Company uses a probability-weighted expected return method to determine the fair value of these instruments.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">Upon conversion or repayment of a debt or equity instrument in exchange for equity shares, where the embedded conversion option has been bifurcated and accounted for as a derivative liability (generally convertible debt and warrants), the Company records the equity shares at fair value on the date of conversion, relieves all related debt, derivative liabilities, and unamortized debt discounts, and recognizes a net gain or loss on debt extinguishment, if any.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">Equity or liability instruments that become subject to reclassification under ASC Topic </span><span style="-aw-sdt-tag:'ce08ae8c5268be0628c7'; font-family: 'Times New Roman'"><span>815</span></span><span style="font-family: 'Times New Roman';"> are reclassified at the fair value of the instrument on the reclassification date.</span></p></ix:nonNumeric></div><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p><div style="-aw-sdt-tag:'c263c163ec50c04829df'"><ix:nonNumeric name="sxtp:EquityClassifiedWarrantsPolicyTextBlock" contextRef="D20250930_1" escape="true" id="Tag940"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; text-decoration:underline; font-family: 'Times New Roman'">Equity-Classified Warrants</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">As of </span><span style="-aw-sdt-tag:'c7bcd8e778eedd1caaab'; -aw-sdt-title:'Current_Period_P11'; font-family: 'Times New Roman'"><span>September 30, 2025</span></span><span style="font-family: 'Times New Roman';">, the Company accounts for all outstanding warrants to purchase common stock as equity-classified instruments based on an assessment of the warrants&#8217; specific terms and applicable authoritative guidance in ASC </span><span style="-aw-sdt-tag:'cdb856b4f4bde6d47eab'; font-family: 'Times New Roman'"><span>480</span></span><span style="font-family: 'Times New Roman';"> and ASC </span><span style="-aw-sdt-tag:'cd5e76a6a6ce96ef7c87'; font-family: 'Times New Roman'"><span>815</span></span><span style="font-family: 'Times New Roman';">. This assessment considers whether the warrants are freestanding financial instruments pursuant to ASC </span><span style="-aw-sdt-tag:'cd481df4cd7bb454097c'; font-family: 'Times New Roman'"><span>480</span></span><span style="font-family: 'Times New Roman';">, meet the definition of a liability pursuant to ASC </span><span style="-aw-sdt-tag:'c75d25a4963187f34a5b'; font-family: 'Times New Roman'"><span>480</span></span><span style="font-family: 'Times New Roman';">, whether the warrants meet all of the requirements for equity classification under ASC </span><span style="-aw-sdt-tag:'c8f59ed9b1458f19f86f'; font-family: 'Times New Roman'"><span>815</span></span><span style="font-family: 'Times New Roman';">, including whether the warrants are indexed to the Company&#8217;s own common stock and whether the warrant holders could potentially require &#8220;net cash settlement&#8221; in a circumstance outside of the Company&#8217;s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the respective issuance dates and as of each subsequent reporting period while the warrants are outstanding.</span></p></ix:nonNumeric></div><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><div style="-aw-sdt-tag:'cd350ef809c535d516f7'"><ix:nonNumeric name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" contextRef="D20250930_1" escape="true" id="Tag941" continuedAt="c485acd2b6d1a9c8093a"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; text-decoration:underline; font-family: 'Times New Roman'">Revenue Recognition</span></p><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">The Company recognizes revenue in accordance with FASB ASC Topic No. </span><span style="-aw-sdt-tag:'c1024005423a4297ddef'; font-family: 'Times New Roman'"><span>606</span></span><span style="font-family: 'Times New Roman';">, </span><span style="font-style:italic; font-family: 'Times New Roman'">Revenue from Contracts with Customers</span><span style="font-family: 'Times New Roman';"> (&#8220;ASC </span><span style="-aw-sdt-tag:'c01990ecd114b774522a'; font-family: 'Times New Roman'"><span>606</span></span><span style="font-family: 'Times New Roman';">&#8221;). Revenues are recognized when control is transferred to customers in amounts that reflect the consideration the Company expects to be entitled to receive in exchange for those goods. Revenue recognition is evaluated through the following five steps: (i) identification of the contract, or contracts, with a customer; (ii) identification of the performance obligations in the contract; (iii) determination of the transaction price; (iv) allocation of the transaction price to the performance obligations in the contract; and (v) recognition of revenue when or as a performance obligation is satisfied. As part of the accounting for these arrangements, the Company may be required to make significant judgments, including identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each performance obligation.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">Revenues from product sales are recorded at the net sales price, or &#8220;transaction price,&#8221; which may include estimates of variable consideration that result from product returns. The Company determines the amount of variable consideration by using either the expected value method or the most-likely-amount method. The Company includes the unconstrained amount of estimated variable consideration in the transaction price, which reflects the amount for which it is probable that a significant reversal of cumulative revenue recognized will not occur. At the end of each subsequent reporting period, the Company re-evaluates the estimated variable consideration included in the transaction price and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis in the period of adjustment. Reserves are established for the estimates of variable consideration based on the amounts the Company expects to be earned or to be claimed on the related sales.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p><div style="-aw-sdt-tag:'PG_c6053e6c5f792d82acc2'"><ix:exclude><ix:exclude><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-family: 'Times New Roman'; z-index: 100;">9</span></p><div><hr style="width: 100%; color: #000000; background-color: #000000; margin: 1rem 0;"/></div></ix:exclude></ix:exclude></div></ix:nonNumeric></div></ix:continuation></div></div><div class="Section_13"><div style="-aw-sdt-tag:'d52-b02-e2a-ceb-f6c1'"><ix:continuation id="c8c66f33053658861626" continuedAt="c7f86c73a4193aa2bc27"><div style="-aw-sdt-tag:'cd350ef809c535d516f7'"><ix:continuation id="c485acd2b6d1a9c8093a"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">The Company receives the majority of its revenues from sales of its Arakoda product to resellers in the US and abroad. The Company records US commercial revenues as a receivable when our American distributor transfers shipped product to their title model for </span><span style="-aw-sdt-tag:'cfae9bd6533b6134b81a'; font-family: 'Times New Roman'"><span>60</span></span><span style="font-family: 'Times New Roman';">P. Foreign sales to both Australia and Europe are recognized as a receivable at the point product is shipped to distributor. The shipments to Australia and Europe are further subject to profit sharing agreements for boxes sold to customers.</span></p></ix:continuation></div><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span><span style="font-family: 'Times New Roman';">&#160;</span></p><div style="-aw-sdt-tag:'c84f7303a81bfc500dea'"><ix:nonNumeric name="us-gaap:ResearchAndDevelopmentExpensePolicy" contextRef="D20250930_1" escape="true" id="Tag943"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; text-decoration:underline; font-family: 'Times New Roman'">Research and Development Costs </span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">The Company accounts for research and development costs in accordance with FASB ASC Subtopic No. </span><span style="-aw-sdt-tag:'cbc781f7013a6eaa59f8'; font-family: 'Times New Roman'"><span>730</span></span><span style="font-family: 'Times New Roman';">-</span><span style="-aw-sdt-tag:'c82ed5ff78a1295bb276'; font-family: 'Times New Roman'"><span>10</span></span><span style="font-family: 'Times New Roman';">, Research and Development (&#8220;ASC </span><span style="-aw-sdt-tag:'c8d16d1806c924bd6931'; font-family: 'Times New Roman'"><span>730</span></span><span style="font-family: 'Times New Roman';">-</span><span style="-aw-sdt-tag:'ca09ffaa8d3135cb1e6b'; font-family: 'Times New Roman'"><span>10</span></span><span style="font-family: 'Times New Roman';">&#8221;). Under ASC </span><span style="-aw-sdt-tag:'c9a334fab141f1bfcaaa'; font-family: 'Times New Roman'"><span>730</span></span><span style="font-family: 'Times New Roman';">-</span><span style="-aw-sdt-tag:'cd9c059505344e7aa50b'; font-family: 'Times New Roman'"><span>10</span></span><span style="font-family: 'Times New Roman';">, research and development costs are expensed as incurred. Accordingly, internal research and development costs are expensed as incurred. Prepayments for research and development services are deferred and amortized over the service period as the services are provided. Advance payments for specific materials, equipment, or facilities determined to have no alternative future use are initially deferred and recognized as research and development expense when the related goods are delivered.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">The Company recorded $</span><span style="-aw-sdt-tag:'c0cae7d3178274b183f7'; -aw-sdt-title:'CQTD_RandD Expense'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="D20250930" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag728">809,777</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">&#160;</span><span style="font-family: 'Times New Roman';">and $</span><span style="-aw-sdt-tag:'c819708eba76301c2ea4'; -aw-sdt-title:'PQTD_RandD Expense'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="D20240930" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag729">940,063</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">&#160;</span><span style="font-family: 'Times New Roman';">in research and development expense during the </span><span style="-aw-sdt-tag:'cc1e5d1af75cc719a927'; -aw-sdt-title:'Current_Quarter_P15'; font-family: 'Times New Roman'"><span>three months ended September 30, 2025</span></span><span style="font-family: 'Times New Roman';"> and </span><span style="-aw-sdt-tag:'cc35a31294de2fb9966a'; -aw-sdt-title:'Previous_Year_P29'; font-family: 'Times New Roman'"><span>2024</span></span><span style="font-family: 'Times New Roman';">, respectively, ($</span><span style="-aw-sdt-tag:'c0a12c3296b44a12831e'; -aw-sdt-title:'CYTD_RandD Expense'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="D20250930_1" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag730">1,467,283</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';"> and $</span><span style="-aw-sdt-tag:'c0c5d0d81b151b0a0872'; -aw-sdt-title:'PYTD_RandD Expense'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="D20240930_1" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag731">4,372,571</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';"> for the </span><span style="-aw-sdt-tag:'c14bc5f963419ab2aed9'; -aw-sdt-title:'Current_YTD_P12'; font-family: 'Times New Roman'"><span>nine months ended September 30, 2025</span></span><span style="font-family: 'Times New Roman';"> and </span><span style="-aw-sdt-tag:'c141bbe47f263859b34f'; -aw-sdt-title:'Previous_Year_P30'; font-family: 'Times New Roman'"><span>2024</span></span><span style="font-family: 'Times New Roman';">, respectively). The Company has also issued shares of common stock to nonemployees in exchange for research and development services. The Company recognizes prepaid research and development costs on the grant date, as defined in FASB ASC Subtopic No. </span><span style="-aw-sdt-tag:'c5f925ba06665ac933a5'; font-family: 'Times New Roman'"><span>718</span></span><span style="font-family: 'Times New Roman';">, </span><span style="font-style:italic; font-family: 'Times New Roman'">Compensation - Stock Compensation</span><span style="font-family: 'Times New Roman';">. See Note </span><span style="-aw-sdt-tag:'cd731d5a4723c771d07e'; font-family: 'Times New Roman'"><span>10</span></span><span style="font-family: 'Times New Roman';"> for further details.</span></p></ix:nonNumeric></div><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><div style="-aw-sdt-tag:'c8e2e451fcc7fadfeb42'"><ix:nonNumeric name="us-gaap:FairValueOfFinancialInstrumentsPolicy" contextRef="D20250930_1" escape="true" id="Tag944" continuedAt="cd5ca7905abea41419f9"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; text-decoration:underline; font-family: 'Times New Roman'">Fair Value of Financial Instruments</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">The carrying value of the Company&#8217;s financial instruments included in current assets and current liabilities (such as cash and cash equivalents, accounts receivable, accounts payable, and accrued expenses) approximate their fair value due to the short-term nature of such instruments.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">The inputs used to measure fair value are based on a hierarchy that prioritizes observable and unobservable inputs used in valuation techniques. These levels, in order of highest to lowest priority, are described below:</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><table cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="width:36pt; vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">Level </span><span style="-aw-sdt-tag:'c10a34efbf72f35b33de'; font-family: 'Times New Roman'"><span style="font-weight:bold">1</span></span></p></td><td style="width:18pt; vertical-align:top"><div style="-aw-sdt-tag:'c574d522f70efd479dc3'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">Quoted prices (unadjusted) in active markets that are accessible at the measurement date for identical assets or liabilities.</span></p></td></tr><tr><td style="vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p></td><td style="vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p></td><td style="vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p></td></tr><tr><td style="vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">Level </span><span style="-aw-sdt-tag:'c152bc38d599e5fa0056'; font-family: 'Times New Roman'"><span style="font-weight:bold">2</span></span></p></td><td style="vertical-align:top"><div style="-aw-sdt-tag:'c41453b900cbc0348861'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">Observable prices that are based on inputs not quoted on active markets but corroborated by market data.</span></p></td></tr><tr><td style="vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p></td><td style="vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p></td><td style="vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p></td></tr><tr><td style="vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">Level </span><span style="-aw-sdt-tag:'cae8e9dbfa205b2e8396'; font-family: 'Times New Roman'"><span style="font-weight:bold">3</span></span></p></td><td style="vertical-align:top"><div style="-aw-sdt-tag:'c38191d9430425b3ee7b'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">Unobservable inputs reflecting the Company&#8217;s assumptions, consistent with reasonably available assumptions made by other market participants. These valuations require significant judgment.</span></p></td></tr></tbody></table><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">The Company&#8217;s financial instruments recorded at fair value on a recurring basis at </span><span style="-aw-sdt-tag:'ccb07ec5194190047e9d'; -aw-sdt-title:'Current_Period_P12'; font-family: 'Times New Roman'"><span>September 30, 2025</span></span><span style="font-family: 'Times New Roman';">, and </span><span style="-aw-sdt-tag:'c12a3919fe92233b9c27'; -aw-sdt-title:'Previous_Year_End_P13'; font-family: 'Times New Roman'"><span>December 31, 2024</span></span><span style="font-family: 'Times New Roman';"> include the derivative liability associated with the contingent milestone payment due to Knight upon a future sale of Arakoda or a Change of Control, which is carried at fair value based on Level </span><span style="-aw-sdt-tag:'cf44dbdc1b5a3adb8e5d'; font-family: 'Times New Roman'"><span>3</span></span><span style="font-family: 'Times New Roman';"> inputs. The Company uses a probability-weighted expected return method to determine the fair value of the contingent milestone payment using significant inputs such as the timing and probability of discrete potential exit scenarios, forward interest rate curves, and discount rates based on implied and market yields. See Note </span><span style="-aw-sdt-tag:'c607a69561493866770f'; font-family: 'Times New Roman'"><span>8</span></span><span style="font-family: 'Times New Roman';"> for more information on Derivative Liabilities.</span><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p><div style="-aw-sdt-tag:'PG_c0c20bca974f854c1494'"><ix:exclude><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-family: 'Times New Roman'; z-index: 100;">10</span></p><div><hr style="width: 100%; color: #000000; background-color: #000000; margin: 1rem 0;"/></div></ix:exclude></div></ix:nonNumeric></div></ix:continuation></div></div><div class="Section_14"><div style="-aw-sdt-tag:'d52-b02-e2a-ceb-f6c1'"><ix:continuation id="c7f86c73a4193aa2bc27" continuedAt="c05865b0d2f332fc8a7c"><div style="-aw-sdt-tag:'c8e2e451fcc7fadfeb42'"><ix:continuation id="cd5ca7905abea41419f9"><div style="-aw-sdt-tag:'ce01f1bed3993d32f2f9'"><ix:nonNumeric name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" contextRef="D20250930_1" escape="true" id="Tag810"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Liabilities measured at fair value at </span><span style="-aw-sdt-tag:'c0bf68fbeefde243c15a'; -aw-sdt-title:'Current_Period_P15'; font-family: 'Times New Roman'"><span>September 30, 2025</span></span><span style="font-family: 'Times New Roman';"> and </span><span style="-aw-sdt-tag:'c732f17c4f405be7abd5'; -aw-sdt-title:'Previous_Year_End_P15'; font-family: 'Times New Roman'"><span>December 31, 2024</span></span><span style="font-family: 'Times New Roman';"> are as follows:</span></p><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p><div style="-aw-sdt-tag:'cf921e92f02c49f734d5'; -aw-sdt-title:'SIGNIFICANT ACCOUNTING POLICIES T1'"><table cellspacing="0" cellpadding="0" style="width:100%; border-collapse:collapse"><tbody><tr style="height:11.5pt"><td style="width:53%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:spaces; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="11" style="border-bottom:1.5pt solid #000000; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_1f865470141349c9b37ae84a55aacecc'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">September 30, 2025</span></p></div></td></tr><tr style="height:11.5pt"><td style="width:53%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="2" style="border-top:1.5pt solid #000000; border-bottom:1pt solid #000000; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_a9a7008663a046198bc1b79f62990348'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; -aw-import:spaces; font-family: 'Times New Roman'">&#160;</span><span style="font-weight:bold; font-family: 'Times New Roman'">Level 1</span></p></div></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="2" style="border-top:1.5pt solid #000000; border-bottom:1pt solid #000000; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_81f8a817fe384b62ae7dcf394585ad13'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; -aw-import:spaces; font-family: 'Times New Roman'">&#160;</span><span style="font-weight:bold; font-family: 'Times New Roman'">Level 2</span></p></div></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="2" style="border-top:1.5pt solid #000000; border-bottom:1pt solid #000000; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_0f2ddb2f4dea4255b9372b845c3d8cf9'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; -aw-import:spaces; font-family: 'Times New Roman'">&#160;</span><span style="font-weight:bold; font-family: 'Times New Roman'">Level 3</span></p></div></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="2" style="border-top:1.5pt solid #000000; border-bottom:1pt solid #000000; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_5169a80e4244429fb7957e47ebcd8580'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; -aw-import:spaces; font-family: 'Times New Roman'">&#160;</span><span style="font-weight:bold; font-family: 'Times New Roman'">Total</span></p></div></td></tr><tr style="height:11.5pt"><td style="width:53%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_c3fe79fa6419450bb2de75dc0fbcb8e0'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:spaces; font-family: 'Times New Roman'">&#160;</span><span style="font-family: 'Times New Roman';">Liabilities:</span></p></div></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td></tr><tr style="height:11.5pt"><td style="width:53%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_37594b78a4ff46fda8c7c6c31dda2819'"><p style="margin-top:0pt; margin-left:5.4pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:spaces; font-family: 'Times New Roman'">&#160;</span><span style="font-family: 'Times New Roman';">Derivative Liabilities</span></p></div></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_7f6e995134194c1f85dce5bf4027caab'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-tag:'C_1ebf3664e1d74ad8aa7a5f6f86bcafc6'"><ix:nonFraction name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="I20250930_FairValueInputsLevel1Member_DerivativeMember" xsi:nil="true" unitRef="USD" id="Tag29"></ix:nonFraction><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_2f314ddebd474b209bfcbd65835b25ed'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-tag:'C_ab7845e24d35492db1dd11a0aaa21e2e'"><ix:nonFraction name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="I20250930_FairValueInputsLevel2Member_DerivativeMember" xsi:nil="true" unitRef="USD" id="Tag32"></ix:nonFraction><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_e71039cd49df4ed0a91d801f3eecd241'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_c478d60eaf6f4ba79d74d84f29ff1501'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="I20250930_FairValueInputsLevel3Member_DerivativeMember" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag7">797,275</ix:nonFraction></span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_d7e156ea5a164ce28ac588dac4d1a77f'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_706a282cea3b4dce906d3c671c501ff6'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="I20250930_DerivativeMember" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag6">797,275</ix:nonFraction></span></p></div></td></tr><tr style="height:11.5pt"><td style="width:53%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_e3a4e18287cc4026a749060e1e8fb5a9'"><p style="margin-top:0pt; margin-left:5.4pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:spaces; font-family: 'Times New Roman'">&#160;</span><span style="font-family: 'Times New Roman';">Total</span></p></div></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_105c7afdf9de422991cf5a00287ac307'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-tag:'C_7d18406ed78f4c4f8c3bb851f3c5e787'"><ix:nonFraction name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="I20250930_FairValueInputsLevel1Member" xsi:nil="true" unitRef="USD" id="Tag31"></ix:nonFraction><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_49026756b4a640278f43ece44be0ab14'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-tag:'C_a3c7a3645b97455cade875ff7e738781'"><ix:nonFraction name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="I20250930_FairValueInputsLevel2Member" xsi:nil="true" unitRef="USD" id="Tag30"></ix:nonFraction><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_8bbc20c75ef0447fa466d4bfaafb8f5f'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_62a7e9f4e692400483031bb740e41569'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="I20250930_FairValueInputsLevel3Member" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag8">797,275</ix:nonFraction></span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_07827564eb61499086af507f234ed67f'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_1600b9fa42ba44889bf927265c22067e'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="I20250930" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag9">797,275</ix:nonFraction></span></p></div></td></tr></tbody></table></div><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p><div style="-aw-sdt-tag:'cb468fdcd6e0460b0777'; -aw-sdt-title:'SIGNIFICANT ACCOUNTING POLICIES T2'"><table cellspacing="0" cellpadding="0" style="width:100%; border-collapse:collapse"><tbody><tr style="height:11.5pt"><td style="width:53%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:spaces; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="11" style="border-bottom:1pt solid #000000; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_4b44e1528e8c4f3cbca59f75d6bdc366'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">December 31, 2024</span></p></div></td></tr><tr style="height:11.5pt"><td style="width:53%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="2" style="border-top:1.5pt solid #000000; border-bottom:1pt solid #000000; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_63bb47cb4152462c97cb5bc1a070ad98'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; -aw-import:spaces; font-family: 'Times New Roman'">&#160;</span><span style="font-weight:bold; font-family: 'Times New Roman'">Level 1</span></p></div></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="2" style="border-top:1.5pt solid #000000; border-bottom:1pt solid #000000; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_b9e93ac9d9e9420ea54dc08f973671b4'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; -aw-import:spaces; font-family: 'Times New Roman'">&#160;</span><span style="font-weight:bold; font-family: 'Times New Roman'">Level 2</span></p></div></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="2" style="border-top:1.5pt solid #000000; border-bottom:1pt solid #000000; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_6cfd423b093941b7a426daca9a7c4fd9'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; -aw-import:spaces; font-family: 'Times New Roman'">&#160;</span><span style="font-weight:bold; font-family: 'Times New Roman'">Level 3</span></p></div></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="2" style="border-top:1.5pt solid #000000; border-bottom:1pt solid #000000; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_ba6b2c8ff28f4584a84bb8a1cf763836'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; -aw-import:spaces; font-family: 'Times New Roman'">&#160;</span><span style="font-weight:bold; font-family: 'Times New Roman'">Total</span></p></div></td></tr><tr style="height:11.5pt"><td style="width:53%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_a6ef2c6558264f7ca0c50be6c5f2e477'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:spaces; font-family: 'Times New Roman'">&#160;</span><span style="font-family: 'Times New Roman';">Liabilities:</span></p></div></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td></tr><tr style="height:11.5pt"><td style="width:53%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_1ad21d4a0f664c76a8a1de7dc61969e3'"><p style="margin-top:0pt; margin-left:5.4pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:spaces; font-family: 'Times New Roman'">&#160;</span><span style="font-family: 'Times New Roman';">Derivative Liabilities</span></p></div></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_0c00d5728d434da99efe8bee0a732f0f'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-tag:'C_38b73fa55f154f55af3cfbeff629bf16'"><ix:nonFraction name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="I20241231_DerivativeMember_FairValueInputsLevel1Member" xsi:nil="true" unitRef="USD" id="Tag14"></ix:nonFraction><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_e025b21daccb422bbc8f2753e7ae30b9'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-tag:'C_333fc1e0c3f6433084115dd2779c80c0'"><ix:nonFraction name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="I20241231_DerivativeMember_FairValueInputsLevel2Member" xsi:nil="true" unitRef="USD" id="Tag16"></ix:nonFraction><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_ccf3e162c56f48aabe5b242a8d57684f'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_fda27296d6fe4023a90164878a00a1d8'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="I20241231_DerivativeMember_FairValueInputsLevel3Member" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag11">640,830</ix:nonFraction></span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_121a4a1679bd49579650a47153a7674a'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_8c697e7693374899bebfc6db6f39b905'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="I20241231_DerivativeMember" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag10">640,830</ix:nonFraction></span></p></div></td></tr><tr style="height:11.5pt"><td style="width:53%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_cb56be67da024df7ab547d83c57f3594'"><p style="margin-top:0pt; margin-left:5.4pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:spaces; font-family: 'Times New Roman'">&#160;</span><span style="font-family: 'Times New Roman';">Total</span></p></div></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_1d0941b2301d4640a725a3c444db0b29'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-tag:'C_34e9411fc246454890a3839765ba75c7'"><ix:nonFraction name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="I20241231_FairValueInputsLevel1Member" xsi:nil="true" unitRef="USD" id="Tag15"></ix:nonFraction><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_5c011b0873844cb68a8ad4cfa194d590'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-tag:'C_59708d0fdeda4619aa91fe10eff71319'"><ix:nonFraction name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="I20241231_FairValueInputsLevel2Member" xsi:nil="true" unitRef="USD" id="Tag17"></ix:nonFraction><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_fcc1b7589a9c4ce3859c970a7eb6b9c6'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_712785fcd2f54bfb89d8883eed8aebd5'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="I20241231_FairValueInputsLevel3Member" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag12">640,830</ix:nonFraction></span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_e0ed0ee91ac4479e99c9a1322299ae2a'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_a4fc6be6554e49b0832d0ac5c0e1c4d7'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="I20241231" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag13">640,830</ix:nonFraction></span></p></div></td></tr></tbody></table></div></ix:nonNumeric></div><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">There were no transfers of financial instruments between Level </span><span style="-aw-sdt-tag:'c512200b7f4efb193a74'; font-family: 'Times New Roman'"><span>1</span></span><span style="font-family: 'Times New Roman';">, Level </span><span style="-aw-sdt-tag:'cc88af1c10b9095520b3'; font-family: 'Times New Roman'"><span>2</span></span><span style="font-family: 'Times New Roman';">, and Level </span><span style="-aw-sdt-tag:'c28cda9bda6d116b1482'; font-family: 'Times New Roman'"><span>3</span></span><span style="font-family: 'Times New Roman';"> during the periods presented.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">A rollforward of liabilities measured at fair value using Level </span><span style="-aw-sdt-tag:'c3417e051371b629cb2b'; font-family: 'Times New Roman'"><span>3</span></span><span style="font-family: 'Times New Roman';"> inputs for the </span><span style="-aw-sdt-tag:'c07ff2f3886b9784d3b4'; -aw-sdt-title:'Current_Quarter_and_YTD_P9'; font-family: 'Times New Roman'"><span>three and nine months ended September 30, 2025</span></span><span style="font-family: 'Times New Roman';"> and </span><span style="-aw-sdt-tag:'ce922678da5c46f0ab60'; font-family: 'Times New Roman'"><span>2024</span></span><span style="font-family: 'Times New Roman';"> is presented in Note </span><span style="-aw-sdt-tag:'cb6b017f206e8e342188'; font-family: 'Times New Roman'"><span>8</span></span><span style="font-family: 'Times New Roman';"> &#8211; Derivative Liabilities.</span><span style="font-family: 'Times New Roman';">&#160;</span></p></ix:continuation></div><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><div style="-aw-sdt-tag:'ce957af50e61212b40ab'"><ix:nonNumeric name="sxtp:AssetsAndLiabilitiesNotMeasuredAtFairValueOnARecurringBasisPolicyTextBlock" contextRef="D20250930_1" escape="true" id="Tag946"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; text-decoration:underline; font-family: 'Times New Roman'">Assets and Liabilities Not Measured at Fair Value on a Recurring Basis</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">In addition to assets and liabilities that are measured at fair value on a recurring basis, the Company also measures certain assets and liabilities at fair value on a nonrecurring basis. The Company&#8217;s non-financial assets, including Intangible Assets and Property and Equipment, are measured at fair value when there is an indication of impairment and the carrying amount exceeds the asset&#8217;s projected undiscounted cash flows. These assets are recorded at fair value only when an impairment charge is recognized.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">Certificates of deposit, classified as cash equivalents or short-term investments depending on the instrument&#8217;s original time to maturity, are measured at amortized cost, which approximates fair value as of </span><span style="-aw-sdt-tag:'cbcda125eaa60887c6fa'; -aw-sdt-title:'Current_Period_P21'; font-family: 'Times New Roman'"><span>September 30, 2025</span></span><span style="font-family: 'Times New Roman';"> and </span><span style="-aw-sdt-tag:'c1cb724ff032da6352c4'; -aw-sdt-title:'Previous_Year_End_P18'; font-family: 'Times New Roman'"><span>December 31, 2024</span></span><span style="font-family: 'Times New Roman';">.</span></p></ix:nonNumeric></div><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><div style="-aw-sdt-tag:'856-502-b92-78d-804f'"><ix:nonNumeric name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" contextRef="D20250930_1" escape="true" id="Tag957" continuedAt="ce02a5f6e20976c86564"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; text-decoration:underline; font-family: 'Times New Roman'">Foreign Currency Transactions and Translation</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">The individual financial statements of each group entity are measured and presented in the currency of the primary economic environment in which the entity operates (its functional currency). The consolidated condensed financial statements of the Company are presented in United States dollars, which is the functional currency of the Company and the presentation currency for the consolidated condensed financial statements.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">For the purpose of presenting consolidated condensed financial statements, the assets and liabilities of the Company&#8217;s foreign operations are mostly translated at exchange rates prevailing on the reporting date. Income and expense items are translated at the average exchange rates for the period, unless exchange rates fluctuate significantly during that period, in which case the exchange rates at the dates of the transactions are used. Exchange differences arising, if any, are recognized as a component of other comprehensive income (loss) as unrealized foreign currency translation gain (loss).</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p><div style="-aw-sdt-tag:'PG_c0a5df5ef4dd14c932ff'"><ix:exclude><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-family: 'Times New Roman'; z-index: 100;">11</span></p><div><hr style="width: 100%; color: #000000; background-color: #000000; margin: 1rem 0;"/></div></ix:exclude></div></ix:nonNumeric></div></ix:continuation></div></div><div class="Section_15"><div style="-aw-sdt-tag:'d52-b02-e2a-ceb-f6c1'"><ix:continuation id="c05865b0d2f332fc8a7c" continuedAt="cc433944165ef4a5be05"><div style="-aw-sdt-tag:'856-502-b92-78d-804f'"><ix:continuation id="ce02a5f6e20976c86564"><div style="-aw-sdt-tag:'c777f028f5d92d4cc514'"><ix:nonNumeric name="us-gaap:ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock" contextRef="D20250930_1" escape="true" id="Tag904"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">Exchange rates along with historical rates used in these financial statements are as follows:</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p><div style="-aw-sdt-tag:'549-6dd-c75-531-a655'; -aw-sdt-title:'SIGNIFICANT ACCOUNTING POLICIES T3'"><table cellspacing="0" cellpadding="0" style="width:100%; border-collapse:collapse"><tbody><tr style="height:11.5pt"><td style="width:34%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="17" style="border-bottom:1.5pt solid #000000; padding:0.75pt; vertical-align:bottom; -aw-padding-bottom:0.75pt"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_9482da9e9ef24112bed6d94f9f662d7c'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">Average Exchange Rate</span></p></div></td></tr><tr style="height:11.5pt"><td style="width:34%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="5" style="border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; padding:0.75pt; vertical-align:bottom; -aw-padding-bottom:0.75pt; -aw-padding-top:0.75pt"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_659f3565fccf471d885d5bbcc6f23513'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">Three Months Ended September 30,</span></p></div></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="5" style="border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_af26db9d568a41c18f4404ac7ead58b6'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">Nine Months Ended September 30,</span></p></div></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="5" style="border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_cf885fb35a704f019f0cad0d5795b8d8'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">As of</span></p></div></td></tr><tr style="height:11.5pt"><td style="width:34%; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_973ee19447724c17b71b4faa457b2249'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">Currency</span></p></div></td><td style="width:1%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="2" style="border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; padding:0.75pt; vertical-align:bottom; -aw-padding-bottom:0.75pt; -aw-padding-top:0.75pt"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_e3e1c97c5b854e929dfeef87960bfbc4'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">2025</span></p></div></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="2" style="border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_91424ca5026c4cce945405cc6ea74a81'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">2024</span></p></div></td><td style="width:1%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="2" style="border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_791c5860584c493ba5598384cfdde256'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">2025</span></p></div></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="2" style="border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_fd4986cad1d4488da73173ef15330bc0'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">2024</span></p></div></td><td style="width:1%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="2" style="border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_63ce180cbb5d445f83c9530d4f721062'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">September 30, 2025</span></p></div></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="2" style="border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_d9d1430a9c7a400390a13074b0c685af'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">December 31, 2024</span></p></div></td></tr><tr style="height:11.5pt"><td style="width:34%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_dde09534ca0e4664b9e7a6dbce09d46b'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">1 AUD =</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:6%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_7254928b2f564e559f8c533598d728fb'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="sxtp:AverageExchangeRate" contextRef="D20250930_USD" unitRef="Pure" decimals="2" format="ixt:num-dot-decimal" id="Tag18">0.65</ix:nonFraction></span></p></div></td><td style="width:4%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_01fc1cc76a7d496482338117b041e5d7'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">USD</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:6%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_0dd2b89b644c47918dd20e0ae4036641'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="sxtp:AverageExchangeRate" contextRef="D20240930_USD" unitRef="Pure" decimals="2" format="ixt:num-dot-decimal" id="Tag19">0.67</ix:nonFraction></span></p></div></td><td style="width:4%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_60bc7b550ded4fd0b8454a10aff9f2b9'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">USD</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:6%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_39890b79d6d94e83bbb6512adb82089c'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="sxtp:AverageExchangeRate" contextRef="D20250930_USD_1" unitRef="Pure" decimals="2" format="ixt:num-dot-decimal" id="Tag20">0.64</ix:nonFraction></span></p></div></td><td style="width:4%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_bcf46b0b9cd64fa28023abd0bd2f9eeb'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">USD</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:4%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_ffd190f4cb644fdc858572d0e04df5bc'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="sxtp:AverageExchangeRate" contextRef="D20240930_USD_1" unitRef="Pure" decimals="2" format="ixt:num-dot-decimal" id="Tag21">0.66</ix:nonFraction></span></p></div></td><td style="width:4%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_2ed4c46e122f4c9388749a2785a69bc5'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">USD</span></p></div></td><td style="width:1%; vertical-align:bottom; background-color:#ccecff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:6%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_deaa0fa001c447fa9db5c11c7e69f76e'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:ForeignCurrencyExchangeRateTranslation1" contextRef="I20250930_USD" unitRef="Pure" decimals="2" format="ixt:num-dot-decimal" id="Tag22">0.66</ix:nonFraction></span></p></div></td><td style="width:4%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_4ed3d209ddad4027b90139f12205d725'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">USD</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:6%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_f1dbbad2340443dba35674893ccabab6'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:ForeignCurrencyExchangeRateTranslation1" contextRef="I20241231_USD" unitRef="Pure" decimals="2" format="ixt:num-dot-decimal" id="Tag23">0.62</ix:nonFraction></span></p></div></td><td style="width:4%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'0b4-c37-b49-3e0-c6cf'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">USD</span></p></div></td></tr></tbody></table></div></ix:nonNumeric></div></ix:continuation></div><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p><div style="-aw-sdt-tag:'cfbab6fdada9c08626e2'"><ix:nonNumeric name="us-gaap:PriorPeriodReclassificationAdjustmentDescription" contextRef="D20250930_1" escape="true" id="Tag947"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; text-decoration:underline; font-family: 'Times New Roman'">Reclassifications</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">Certain prior period interim amounts have been reclassified for consistency with the current period presentation. These reclassifications had no material effect on the consolidated condensed results of operations and comprehensive loss, shareholders&#8217; equity, or cash flows.</span></p></ix:nonNumeric></div><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><div style="-aw-sdt-tag:'c5ae9390f02706bea469'"><ix:nonNumeric name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" contextRef="D20250930_1" escape="true" id="Tag953"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; text-decoration:underline; font-family: 'Times New Roman'">Share-Based Payments</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">On November </span><span style="-aw-sdt-tag:'cb8e4cad4e4d214394a1'; font-family: 'Times New Roman'"><span>22</span></span><span style="font-family: 'Times New Roman';">, </span><span style="-aw-sdt-tag:'c07fc0c7362febea5ed1'; font-family: 'Times New Roman'"><span>2022</span></span><span style="font-family: 'Times New Roman';">, the Company adopted the </span><span style="-aw-sdt-tag:'c82523a8da0311b6da03'; font-family: 'Times New Roman'"><span>2022</span></span><span style="font-family: 'Times New Roman';"> Equity Incentive Plan also referred to as (&#8220;</span><span style="-aw-sdt-tag:'c84ff39eab4b2b69d4e5'; font-family: 'Times New Roman'"><span>2022</span></span><span style="font-family: 'Times New Roman';"> Plan&#8221;). The </span><span style="-aw-sdt-tag:'c77a8fd767458ed89fe9'; font-family: 'Times New Roman'"><span>2022</span></span><span style="font-family: 'Times New Roman';"> Plan and related share-based awards are discussed more fully in Note </span><span style="-aw-sdt-tag:'c89592db43d1d0460416'; font-family: 'Times New Roman'"><span>10</span></span><span style="font-family: 'Times New Roman';">.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">The Company accounts for share-based payments in accordance with ASC Subtopic </span><span style="-aw-sdt-tag:'cfb759d6c4e98b9f102c'; font-family: 'Times New Roman'"><span>718</span></span><span style="font-family: 'Times New Roman';">, </span><span style="font-style:italic; font-family: 'Times New Roman'">Compensation - Stock Compensation </span><span style="font-family: 'Times New Roman';">(&#8220;ASC </span><span style="-aw-sdt-tag:'c28e007bf795e0cf0e4d'; font-family: 'Times New Roman'"><span>718</span></span><span style="font-family: 'Times New Roman';">&#8221;). The Company measures compensation for all share-based payment awards granted to employees, directors, and nonemployees, based on the estimated fair value of the awards on the date of grant. For awards that vest based on continued service, the service-based compensation cost is recognized on a straight-line basis over the requisite service period, which is generally the vesting period of the awards. For service vesting awards with compensation expense recognized on a straight-line basis, at no point in time does the cumulative grant date value of vested awards exceed the cumulative amount of compensation expense recognized. The grant date is determined based on the date when a mutual understanding of the key terms of the share-based awards is established. The Company accounts for forfeitures as they occur.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">The Company estimates the fair value of all stock option awards as of the grant date by applying the Black-Scholes option pricing model. The application of this valuation model involves assumptions, including the fair value of the common stock, expected volatility, risk-free interest rate, expected dividends and the expected term of the option. Due to the lack of a public market for the Company&#8217;s common stock prior to the IPO and lack of company-specific historical implied volatility data, the Company has based its computations of expected volatility on the historical volatility of a representative group of public companies with similar characteristics of the Company, including stage of development and industry focus. The historical volatility is calculated based on a period of time commensurate with the expected term assumption. The Company generally uses the simplified method as prescribed by the SEC Staff Accounting Bulletin Topic </span><span style="-aw-sdt-tag:'cdc65a3ad6830dc2131f'; font-family: 'Times New Roman'"><span>14</span></span><span style="font-family: 'Times New Roman';">, </span><span style="font-style:italic; font-family: 'Times New Roman'">Share-Based Payment</span><span style="font-family: 'Times New Roman';">, to estimate the expected term for stock options, whereby, the expected term equals the midpoint of the weighted average remaining time to vest, vesting period and the contractual term of the options due to its lack of historical exercise data. For certain options granted out-of-the-money, the Company&#8217;s best estimate of the expected term is the contractual term of the award. The risk-free interest rate is based on U.S. Treasury securities with a maturity date commensurate with the expected term of the associated award. The expected dividend yield is assumed to be zero as the Company has never paid dividends and has no current plans to pay any dividends on its common stock. The assumptions used in calculating the fair value of share-based awards represent management&#8217;s best estimates and involve inherent uncertainties and the application of significant judgment.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">Compensation expense for restricted stock units (&#8220;RSUs&#8221;) with only service-based vesting conditions is recognized on a straight-line basis over the vesting period. Compensation cost for service-based RSUs is based on the grant date fair value of the award, which is the closing market price of the Company&#8217;s common stock on the grant date multiplied by the number of shares awarded.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">For awards that vest upon a liquidity event or a change in control, the performance condition is not probable of being achieved until the event occurs. As a result, no compensation expense is recognized until the performance-based vesting condition is achieved, at which time the cumulative compensation expense is recognized. Compensation cost related to any remaining time-based service for share-based awards after the liquidity-based event is recognized on a straight-line basis over the remaining service period.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">For fully vested, nonforfeitable equity instruments that are granted at the date the Company and a nonemployee enter into an agreement for goods or services, the Company recognizes the fair value of the equity instruments on the grant date. The corresponding cost is recognized as an immediate expense or a prepaid asset and expensed over the service period depending on the specific facts and circumstances of the agreement with the nonemployee. See Note </span><span style="-aw-sdt-tag:'c7c93237c1946f635b03'; font-family: 'Times New Roman'"><span>10</span></span><span style="font-family: 'Times New Roman';"> for further details.</span></p></ix:nonNumeric></div><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p><div style="-aw-sdt-tag:'PG_c8b1ac81b7bf3b856ef3'"><ix:exclude><ix:exclude><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-family: 'Times New Roman'; z-index: 100;">12</span></p><div><hr style="width: 100%; color: #000000; background-color: #000000; margin: 1rem 0;"/></div></ix:exclude></ix:exclude></div></ix:continuation></div></div><div class="Section_16"><div style="-aw-sdt-tag:'d52-b02-e2a-ceb-f6c1'"><ix:continuation id="cc433944165ef4a5be05"><div style="-aw-sdt-tag:'c37c1b3b29bcf7d9b9ab'"><ix:nonNumeric name="us-gaap:EarningsPerSharePolicyTextBlock" contextRef="D20250930_1" escape="true" id="Tag960"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; text-decoration:underline; font-family: 'Times New Roman'">Net Loss per Common Share</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-sdt-tag:'a31-2b2-f34-82d-cfe6'; -aw-sdt-title:'Net_(Loss)_Income_Title_P2'; font-family: 'Times New Roman'"><span>Net Loss</span></span><span style="font-family: 'Times New Roman';"> per Common Share is computed by dividing </span><span style="-aw-sdt-tag:'a78-fb5-6f5-642-14ce'; -aw-sdt-title:'Net_(Loss)_Income_Title___Lower_P1'; font-family: 'Times New Roman'"><span>net loss</span></span><span style="font-family: 'Times New Roman';"> attributable to common shareholders by the weighted average number of common shares outstanding during each period. The Company includes pre-funded warrants, which carry a nominal exercise price per share, in its computation of basic and diluted net loss per share beginning on the date of issuance. The cumulative dividends accrued on the Series A Preferred Stock during the period are reflected as an increase to net loss or a reduction of net income in determining basic and diluted </span><span style="-aw-sdt-tag:'31c-481-9ce-577-2088'; -aw-sdt-title:'Net_(Loss)_Income_Title___Lower_P2'; font-family: 'Times New Roman'"><span>net loss</span></span><span style="font-family: 'Times New Roman';"> attributable to common stockholders.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">As the Company reported a net loss for all periods presented, the calculation of diluted net loss per common share is the same as basic net loss per common share. </span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">As a result of the </span><span style="-aw-sdt-tag:'5f0-31e-83e-591-f354'; font-family: 'Times New Roman'"><ix:nonNumeric name="us-gaap:StockholdersEquityReverseStockSplit" contextRef="D20250224" escape="false" id="Tag738"><span>1:5</span></ix:nonNumeric></span><span style="font-family: 'Times New Roman';"> Reverse Stock Split, which was effective as of February 24, 2025, all shares of outstanding common stock and net loss per common share calculations have been retroactively adjusted for all periods presented.</span></p></ix:nonNumeric></div><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p><div style="-aw-sdt-tag:'c5700c4a179318bf9512'"><ix:nonNumeric name="us-gaap:CompensationRelatedCostsPolicyTextBlock" contextRef="D20250930_1" escape="true" id="Tag961"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; text-decoration:underline; font-family: 'Times New Roman'">Related Parties</span></p><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">Parties are considered to be related to the Company if the parties, directly or indirectly, through one or more intermediaries, control, are controlled by, or are under common control with the Company. Related parties also include principal owners of the Company, its management, members of the immediate families of principal owners of the Company and its management and other parties with which the Company may deal with if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.</span></p></ix:nonNumeric></div><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span><span style="font-family: 'Times New Roman';">&#160;</span></p><div style="-aw-sdt-tag:'c49a2178ae9eff53812a'"><ix:nonNumeric name="us-gaap:SubsequentEventsPolicyPolicyTextBlock" contextRef="D20250930_1" escape="true" id="Tag948"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; text-decoration:underline; font-family: 'Times New Roman'">Subsequent Events</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">The Company considers events or transactions that occur after the balance sheet date, but prior to the issuance of the financial statements to provide additional evidence relative to certain estimates or to identify matters that require additional disclosure. Subsequent events have been evaluated through </span><span style="-aw-sdt-tag:'cb270f797852c1e1f2a5'; -aw-sdt-title:'Current_Period_Date_FS_Issued_P1'; font-family: 'Times New Roman'"><span>November 13, 2025</span></span><span style="font-family: 'Times New Roman';">, which is the date the financial statements were issued. See Note </span><span style="-aw-sdt-tag:'c8dbf1260408b95c5a15'; font-family: 'Times New Roman'"><span>12</span></span><span style="font-family: 'Times New Roman';">.</span></p></ix:nonNumeric></div><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><div style="-aw-sdt-tag:'b58-716-f7b-33e-6c0c'"><ix:nonNumeric name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" contextRef="D20250930_1" escape="true" id="Tag952"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; text-decoration:underline; font-family: 'Times New Roman'">Recently Adopted and Issued Accounting Pronouncements</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">From time to time, the FASB issues Accounting Standards Updates (&#8220;ASU&#8221;) to amend the authoritative literature in the ASC. The Company regularly evaluates new ASUs to determine the impact that these pronouncements may have on the consolidated condensed financial statements. Other than the pronouncements listed below, the Company believes that those issued to date either (i) provide supplemental guidance, (ii) are technical corrections, or (iii) are not applicable to the Company&#8217;s consolidated condensed financial statements or related disclosures.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">In November </span><span style="-aw-sdt-tag:'c40fc8bff493befc18d6'; font-family: 'Times New Roman'"><span>2023</span></span><span style="font-family: 'Times New Roman';">, the FASB issued ASU </span><span style="-aw-sdt-tag:'c0a6b49074383096c882'; font-family: 'Times New Roman'"><span>2023</span></span><span style="font-family: 'Times New Roman';">-</span><span style="-aw-sdt-tag:'cd25ae9feb1743719bb1'; font-family: 'Times New Roman'"><span>07</span></span><span style="font-family: 'Times New Roman';">, </span><span style="font-style:italic; font-family: 'Times New Roman'">Segment Reporting (Topic </span><span style="-aw-sdt-tag:'c48474e3644a54930dfc'; font-family: 'Times New Roman'"><span style="font-style:italic">280</span></span><span style="font-style:italic; font-family: 'Times New Roman'">): Improvements to Reportable Segment Disclosures</span><span style="font-family: 'Times New Roman';"> (&#8220;ASU </span><span style="-aw-sdt-tag:'c731ea50ea67c7e4b420'; font-family: 'Times New Roman'"><span>2023</span></span><span style="font-family: 'Times New Roman';">-</span><span style="-aw-sdt-tag:'cce9c44e2351f5ac2796'; font-family: 'Times New Roman'"><span>07</span></span><span style="font-family: 'Times New Roman';">&#8221;) which expands annual and interim disclosure requirements for reportable segments, primarily through enhanced disclosures about significant segment expenses and segment profit or loss. ASU </span><span style="-aw-sdt-tag:'c7a9ce0a0ac8993d0acf'; font-family: 'Times New Roman'"><span>2023</span></span><span style="font-family: 'Times New Roman';">-</span><span style="-aw-sdt-tag:'cdd16562ce807243ed58'; font-family: 'Times New Roman'"><span>07</span></span><span style="font-family: 'Times New Roman';"> also requires entities with a single reportable segment to provide all segment disclosures under ASC </span><span style="-aw-sdt-tag:'cf6e9777e809f25e1b07'; font-family: 'Times New Roman'"><span>280</span></span><span style="font-family: 'Times New Roman';">, including the new required disclosures under the ASU. The Company adopted ASU </span><span style="-aw-sdt-tag:'cc9be51d0fa22b72f687'; font-family: 'Times New Roman'"><span>2023</span></span><span style="font-family: 'Times New Roman';">-</span><span style="-aw-sdt-tag:'cc2f4662055f1cf358a4'; font-family: 'Times New Roman'"><span>07</span></span><span style="font-family: 'Times New Roman';"> on a retrospective basis for the </span><span style="-aw-sdt-tag:'c304e39ce5549b67326b'; font-family: 'Times New Roman'"><span>2024</span></span><span style="font-family: 'Times New Roman';"> annual period, and for interim periods beginning in </span><span style="-aw-sdt-tag:'c50e039416b6752cbc9e'; font-family: 'Times New Roman'"><span>2025</span></span><span style="font-family: 'Times New Roman';">. The impact is limited to the Company&#8217;s financial statement disclosures, which are presented in the Segment Information section above.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">In December </span><span style="-aw-sdt-tag:'cf066c3ed14287513469'; font-family: 'Times New Roman'"><span>2023</span></span><span style="font-family: 'Times New Roman';">, the FASB issued ASU </span><span style="-aw-sdt-tag:'c0565bc7ca2af95b4c7c'; font-family: 'Times New Roman'"><span>2023</span></span><span style="font-family: 'Times New Roman';">-</span><span style="-aw-sdt-tag:'ceb96c9259852308d896'; font-family: 'Times New Roman'"><span>09</span></span><span style="font-family: 'Times New Roman';">, </span><span style="font-style:italic; font-family: 'Times New Roman'">Income Taxes (ASC </span><span style="-aw-sdt-tag:'c0282851b575f38250ce'; font-family: 'Times New Roman'"><span style="font-style:italic">740</span></span><span style="font-style:italic; font-family: 'Times New Roman'">): Improvements to Income Tax Disclosures</span><span style="font-family: 'Times New Roman';"> (&#8220;ASU </span><span style="-aw-sdt-tag:'c397c2576fab14a6843a'; font-family: 'Times New Roman'"><span>2023</span></span><span style="font-family: 'Times New Roman';">-</span><span style="-aw-sdt-tag:'c43ea664edca3b7d1221'; font-family: 'Times New Roman'"><span>09</span></span><span style="font-family: 'Times New Roman';">&#8221;) which requires disaggregated information about a reporting entity&#8217;s effective tax rate reconciliation as well as information on income taxes paid. ASU </span><span style="-aw-sdt-tag:'ced6791b435360aa514d'; font-family: 'Times New Roman'"><span>2023</span></span><span style="font-family: 'Times New Roman';">-</span><span style="-aw-sdt-tag:'c152d39afa37813cff35'; font-family: 'Times New Roman'"><span>09</span></span><span style="font-family: 'Times New Roman';"> is effective for annual periods beginning after December </span><span style="-aw-sdt-tag:'c65d60af908ae022a7fb'; font-family: 'Times New Roman'"><span>15</span></span><span style="font-family: 'Times New Roman';">, </span><span style="-aw-sdt-tag:'c9d2f568ca33a0e3ddc2'; font-family: 'Times New Roman'"><span>2024</span></span><span style="font-family: 'Times New Roman';">. The Company will adopt this standard for the annual period ending December 31, 2025. The impact of ASU 2023-09 will be limited to the Company&#8217;s financial statement disclosures.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">In November </span><span style="-aw-sdt-tag:'cb06da4c60c3ed718870'; font-family: 'Times New Roman'"><span>2024</span></span><span style="font-family: 'Times New Roman';">, the FASB issued ASU </span><span style="-aw-sdt-tag:'c5896724f85326b5cf6c'; font-family: 'Times New Roman'"><span>2024</span></span><span style="font-family: 'Times New Roman';">-</span><span style="-aw-sdt-tag:'c5ee0130675746e94982'; font-family: 'Times New Roman'"><span>03</span></span><span style="font-family: 'Times New Roman';">, </span><span style="font-style:italic; font-family: 'Times New Roman'">Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic </span><span style="-aw-sdt-tag:'c686357b9151070c0b80'; font-family: 'Times New Roman'"><span style="font-style:italic">220</span></span><span style="font-style:italic; font-family: 'Times New Roman'">-</span><span style="-aw-sdt-tag:'ccb37deca24433c43642'; font-family: 'Times New Roman'"><span style="font-style:italic">40</span></span><span style="font-style:italic; font-family: 'Times New Roman'">): Disaggregation of Income Statement Expenses </span><span style="font-family: 'Times New Roman';">(&#8220;ASU </span><span style="-aw-sdt-tag:'c82c510f162b91f255e5'; font-family: 'Times New Roman'"><span>2024</span></span><span style="font-family: 'Times New Roman';">-</span><span style="-aw-sdt-tag:'c9b3edff03a8224442ee'; font-family: 'Times New Roman'"><span>03</span></span><span style="font-family: 'Times New Roman';">&#8221;), which applies to all public business entities that file financial statements with the SEC. The amendments in this ASU require public business entities to disclose on an annual and interim basis, disaggregated information about certain income statement expense line items. The new standard is effective for fiscal years beginning after December </span><span style="-aw-sdt-tag:'c4227d4f684c80f6fc7b'; font-family: 'Times New Roman'"><span>15</span></span><span style="font-family: 'Times New Roman';">, </span><span style="-aw-sdt-tag:'cdb1897f2589fc5290f5'; font-family: 'Times New Roman'"><span>2026</span></span><span style="font-family: 'Times New Roman';">, with early adoption permitted. The Company is currently evaluating the impact that ASU </span><span style="-aw-sdt-tag:'cd9fcbee88c447594d3d'; font-family: 'Times New Roman'"><span>2024</span></span><span style="font-family: 'Times New Roman';">-</span><span style="-aw-sdt-tag:'cea1fdf602d68e8ea393'; font-family: 'Times New Roman'"><span>03</span></span><span style="font-family: 'Times New Roman';"> will have on its financial statement disclosures.</span><span style="font-family: 'Times New Roman';">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </span></p></ix:nonNumeric></div></ix:continuation></div><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore">&#160;</span></p><div style="-aw-sdt-tag:'c51d122b5f22834151d0'"><ix:nonNumeric name="us-gaap:InventoryDisclosureTextBlock" contextRef="D20250930_1" escape="true" id="Tag965"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">3. INVENTORY</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><div style="-aw-sdt-tag:'c4b64ef482d85585ddef'"><ix:nonNumeric name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" contextRef="D20250930_1" escape="true" id="Tag928"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">Inventory consists of the following major classes:</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><div style="-aw-sdt-tag:'c3ad763587e21d5ec175'; -aw-sdt-title:'INVENTORY T1'"><table cellspacing="0" cellpadding="0" style="width:100%; margin-right:auto; margin-left:auto; border-collapse:collapse"><tbody><tr style="height:11.5pt"><td style="width:77%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="2" style="border-bottom:1.5pt solid #000000; padding-right:5.75pt; padding-left:5.75pt; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_8c78ee49c91e44ce918f2ebd1b7927a2'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">September 30, 2025</span></p></div></td><td style="width:1%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="2" style="border-bottom:1.5pt solid #000000; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_eb198c15a0e04e4e8352b8854a5daadc'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">December 31, 2024</span></p></div></td></tr><tr style="height:11.5pt"><td style="width:77%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_9f6e148ddfbd43bd85c0bd773b3ebd5b'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Raw Material (API)</span></p></div></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_00a19566ed1c43f99c98897b148d8d2a'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_f16c7a3406eb4165a5632f4b2432cc52'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:InventoryRawMaterials" contextRef="I20250930" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag61">345,195</ix:nonFraction></span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_97a890fb4676459799df39011e8dd53c'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-tag:'C_ab71897d07ac40d28dfd83405a9dfafe'"><ix:nonFraction name="us-gaap:InventoryRawMaterials" contextRef="I20241231" xsi:nil="true" unitRef="USD" id="Tag65"></ix:nonFraction><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td></tr><tr style="height:11.5pt"><td style="width:77%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_aeef74c84e0f4d1f96536ddc357d7064'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Work in Process</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-tag:'C_6a3655bdab5d48dd86ca61227681b415'"><ix:nonFraction name="us-gaap:InventoryWorkInProcess" contextRef="I20250930" xsi:nil="true" unitRef="USD" id="Tag190"></ix:nonFraction><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_ef00ca8ecef947d48a2392dce651f727'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:InventoryWorkInProcess" contextRef="I20241231" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag63">284,883</ix:nonFraction></span></p></div></td></tr><tr style="height:11.5pt"><td style="width:77%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_d5d56b1ac61047c8bb2cd738f043bffa'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Finished Goods</span></p></div></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_5b0903d97dea4325b613f810a8c5eaf2'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:InventoryFinishedGoods" contextRef="I20250930" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag62">426,491</ix:nonFraction></span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_36ca9b2fc2674b1b9e7c5ee6ac7b2cc2'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:InventoryFinishedGoods" contextRef="I20241231" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag64">157,881</ix:nonFraction></span></p></div></td></tr><tr style="height:11.5pt"><td style="width:77%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_be61fc4bb0cc4c4ba6288d79409b3e45'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Total Inventory</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_83e5c4c46f15469f98bfb74b9c0152cc'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:InventoryGross" contextRef="I20250930" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag187">771,686</ix:nonFraction></span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_a90105c86d004c7988263596647fb77a'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:InventoryGross" contextRef="I20241231" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag189">442,764</ix:nonFraction></span></p></div></td></tr><tr style="height:11.5pt"><td style="width:77%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_4beb2619f3b64a17be38dcd2cbe156d3'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Reserve for Expiring Inventory</span></p></div></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_93d116c0bb494287916a99a01a7fd59c'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:InventoryAdjustments" contextRef="I20250930" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag27">244,682</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">)</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-tag:'C_dee47b6fa0dc487eba64f4acdf903ada'"><ix:nonFraction name="us-gaap:InventoryAdjustments" contextRef="I20241231" xsi:nil="true" unitRef="USD" id="Tag191"></ix:nonFraction><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td></tr><tr style="height:11.5pt"><td style="width:77%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_73dc86a2354c42c5af659415f686502c'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">Inventory</span></p></div></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_18ec2a0d235e48ca8dccc53077caf073'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">$</span></p></div></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_352a37dac1dc493db25e225319ba1514'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="I20250930" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag188">527,004</ix:nonFraction></span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_14f157594d2f42b2a8d7ac54924f20bb'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">$</span></p></div></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'d7b-8b1-5fc-6b2-f7e6'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="I20241231" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag224">442,764</ix:nonFraction></span></p></div></td></tr></tbody></table></div></ix:nonNumeric></div><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">The Company regularly monitors its inventory levels to identify inventory that may expire or has a cost basis in excess of its estimated net realizable value, and records write-downs for inventory that has expired, inventory that has a cost basis in excess of its expected net realizable value, and inventory in excess of expected sales requirements. Any write-downs of inventories are charged to cost of revenues in the </span><span style="-aw-sdt-tag:'ffb-eda-e3e-f96-f173'; -aw-sdt-title:'PandL_title_P4'; font-family: 'Times New Roman'"><span>consolidated condensed statements of operations and comprehensive loss</span></span><span style="font-family: 'Times New Roman';">. During the </span><span style="-aw-sdt-tag:'b1e-16f-504-955-dd45'; -aw-sdt-title:'Current_Quarter_P48'; font-family: 'Times New Roman'"><span>three months ended September 30, 2025</span></span><span style="font-family: 'Times New Roman';"> and </span><span style="-aw-sdt-tag:'19f-9c4-d3b-e65-dd8f'; -aw-sdt-title:'Previous_Year_P54'; font-family: 'Times New Roman'"><span>2024</span></span><span style="font-family: 'Times New Roman';">, write downs for expired inventory were $</span><span style="-aw-sdt-tag:'8c7-42a-927-d0d-4aae'; -aw-sdt-title:'Inventory Write-downs CQ'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:InventoryWriteDown" contextRef="D20250930" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag839">436,561</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';"> and $</span><span style="-aw-sdt-tag:'dc4-345-946-2cb-8a9f'; -aw-sdt-title:'Inventory Write-downs PQ'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:InventoryWriteDown" contextRef="D20240930" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag831">1,165</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">, respectively ($</span><span style="-aw-sdt-tag:'1ec-156-b10-d9c-e801'; -aw-sdt-title:'Inventory Write-downs CYTD'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:InventoryWriteDown" contextRef="D20250930_1" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag832">436,596</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';"> and $</span><span style="-aw-sdt-tag:'acd-db4-0d0-210-5cfb'; -aw-sdt-title:'Inventory Write-downs PYTD'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:InventoryWriteDown" contextRef="D20240930_1" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag821">18,490</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';"> for the </span><span style="-aw-sdt-tag:'497-514-bce-6c1-7d4b'; -aw-sdt-title:'Current_YTD_P56'; font-family: 'Times New Roman'"><span>nine months ended September 30, 2025</span></span><span style="font-family: 'Times New Roman';"> and </span><span style="-aw-sdt-tag:'860-e12-55e-aec-5da2'; -aw-sdt-title:'Previous_Year_P55'; font-family: 'Times New Roman'"><span>2024</span></span><span style="font-family: 'Times New Roman';">, respectively).</span></p></ix:nonNumeric></div><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="-aw-import:ignore">&#160;</span></p><div style="-aw-sdt-tag:'PG_4f931f9db43aea7b'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-family: 'Times New Roman';">13</span></p><div><hr style="width: 100%; color: #000000; background-color: #000000; margin: 1rem 0;"/></div></div></div><div class="Section_17"><div style="-aw-sdt-tag:'743-968-85c-946-476b'"><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" contextRef="D20250930_1" escape="true" id="Tag970"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-sdt-tag:'362-52b-f94-e85-08c1'; font-family: 'Times New Roman'"><span style="font-weight:bold">4</span></span><span style="font-weight:bold; font-family: 'Times New Roman'">. PROPERTY AND EQUIPMENT</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><div style="-aw-sdt-tag:'c3328980f611b2c2c18e'"><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentTextBlock" contextRef="D20250930_1" escape="true" id="Tag929"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">Property and Equipment, net consists of:</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><div style="-aw-sdt-tag:'c585e2b6503490e35b6e'; -aw-sdt-title:'PROPERTY AND EQUIPMENT T1'"><table cellspacing="0" cellpadding="0" style="width:100%; border-collapse:collapse"><tbody><tr style="height:11.5pt"><td style="width:77%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="2" style="border-bottom:1.5pt solid #000000; padding-right:5.75pt; padding-left:5.75pt; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_d243be9044f94e5789d1c03995fef724'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">September 30, 2025</span></p></div></td><td style="width:1%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="2" style="border-bottom:1.5pt solid #000000; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_cdf2c2bb81134c98a67579ef3ca9e8ac'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">December 31, 2024</span></p></div></td></tr><tr style="height:11.5pt"><td style="width:77%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_210216e127fe482781b410d7ec74a0b8'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Lab Equipment</span></p></div></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_53af035c51d0478aa394754c413e6ffb'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_9328eadfcc594ac596b0acc136f7b8f0'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="I20250930_LabEquipmentMember" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag66">333,010</ix:nonFraction></span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_e940a18328bb4ad9bea7def38d0d559f'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_2329b86c972f422ba404be9dd3277495'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="I20241231_LabEquipmentMember" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag72">233,411</ix:nonFraction></span></p></div></td></tr><tr style="height:11.5pt"><td style="width:77%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_0319c462920c42afa0d3176c000bd9f7'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Machinery</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_ef8d24443e6e4e8cb5980f37db5e774c'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="I20250930_MachineryAndEquipmentMember" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag67">55,800</ix:nonFraction></span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_c8ff641cd4744c44a8ca4ea45f4e85c8'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="I20241231_MachineryAndEquipmentMember" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag73">55,800</ix:nonFraction></span></p></div></td></tr><tr style="height:11.5pt"><td style="width:77%; vertical-align:middle; background-color:#ccecff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_6249934fa3de4adaa792e486a851badc'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Computer Equipment</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ccecff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:middle; background-color:#ccecff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_aca3f556efe04148b984c56098021a99'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="I20250930_ComputerEquipmentMember" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag68">11,597</ix:nonFraction></span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ccecff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#ccecff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:middle; background-color:#ccecff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_a531e0c254db4110ad34d073164553f9'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="I20241231_ComputerEquipmentMember" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag74">7,000</ix:nonFraction></span></p></div></td></tr><tr style="height:11.5pt"><td style="width:77%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_aebc173cb2c8413fa5fcf35341f8657a'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Furniture</span></p></div></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_b504fb680d844731bb0cd3fabd739eac'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="I20250930_FurnitureAndFixturesMember" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag69">3,030</ix:nonFraction></span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_6e01e63464c941e29d2034653b8107e5'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="I20241231_FurnitureAndFixturesMember" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag75">3,030</ix:nonFraction></span></p></div></td></tr><tr style="height:11.5pt"><td style="width:77%; vertical-align:middle; background-color:#ccecff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_8a33d8c7b8f447cf9991bc44f6e506d2'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Property and Equipment, at cost</span></p></div></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ccecff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ccecff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_7e9128e9f9104afc873f970c6a9135ce'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="I20250930" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag70">403,437</ix:nonFraction></span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ccecff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ccecff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ccecff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_0083050d4387424b9262c3e3b6a9fee5'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="I20241231" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag76">299,241</ix:nonFraction></span></p></div></td></tr><tr style="height:11.5pt"><td style="width:77%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_b6b62697f29548dbaf51d4cf72f0c5f7'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Accumulated Depreciation</span></p></div></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_d1d3c66b3b5440948d85580b0ecb68ec'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="I20250930" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag1">175,685</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">)</span></p></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_6e53c81a6ded46cca2cd24a44cf411d0'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="I20241231" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag2">149,433</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">)</span></p></td></tr><tr style="height:11.5pt"><td style="width:77%; vertical-align:middle; background-color:#ccecff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_11c099461546454a8d4b17afa85db567'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">Property and Equipment, net</span></p></div></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ccecff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_e7ec042f6b194d6a858be22c9a1b091a'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">$</span></p></div></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ccecff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_2faa5c0453e4450596c4956cffc1df1e'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="I20250930" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag71">227,752</ix:nonFraction></span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ccecff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ccecff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_05cfb6f1de00493d99ff10680b286a1a'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">$</span></p></div></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ccecff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_519d7c2bff0c454799f8e791a58c7103'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="I20241231" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag77">149,808</ix:nonFraction></span></p></div></td></tr></tbody></table></div></ix:nonNumeric></div><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">Depreciation expense for the </span><span style="-aw-sdt-tag:'3df-38b-a90-624-8e5d'; -aw-sdt-title:'Current_Quarter_P44'; font-family: 'Times New Roman'"><span>three months ended September 30, 2025</span></span><span style="font-family: 'Times New Roman';"> and </span><span style="-aw-sdt-tag:'382-eed-505-ecf-e5da'; -aw-sdt-title:'Previous_Year_P47'; font-family: 'Times New Roman'"><span>2024</span></span><span style="font-family: 'Times New Roman';"> was in the amount of $</span><span style="-aw-sdt-tag:'c6f-708-7ed-a12-e87f'; -aw-sdt-title:'Depreciation expense_CQTD'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="D20250930" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag811">12,225</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';"> and $</span><span style="-aw-sdt-tag:'05d-cb7-531-47b-40f1'; -aw-sdt-title:'Depreciation expense_PYQTD'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="D20240930" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag812">4,334</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">, respectively ($</span><span style="-aw-sdt-tag:'cd782fa2db2ddfc0ea5e'; -aw-sdt-title:'Depreciation expense_CYTD'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="D20250930_1" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag744">28,155</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';"> and $</span><span style="-aw-sdt-tag:'c3e71056f41b8e6237d0'; -aw-sdt-title:'Depreciation expense_PYTD'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="D20240930_1" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag745">6,277</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';"> for the </span><span style="-aw-sdt-tag:'cecb412e14ad226c62ea'; -aw-sdt-title:'Current_YTD_P4'; font-family: 'Times New Roman'"><span>nine months ended September 30, 2025</span></span><span style="font-family: 'Times New Roman';"> and </span><span style="-aw-sdt-tag:'cd2da8121dd3f61410cb'; -aw-sdt-title:'Previous_Year_P6'; font-family: 'Times New Roman'"><span>2024</span></span><span style="font-family: 'Times New Roman';">, respectively).</span><span style="font-family: 'Times New Roman';">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </span></p></ix:nonNumeric></div><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore">&#160;</span></p><div style="-aw-sdt-tag:'263-14a-043-4c3-6544'"><ix:nonNumeric name="us-gaap:IntangibleAssetsDisclosureTextBlock" contextRef="D20250930_1" escape="true" id="Tag991"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">5. INTANGIBLE ASSETS</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><div style="-aw-sdt-tag:'ce139b5a70e6301672f2'"><ix:nonNumeric name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" contextRef="D20250930_1" escape="true" id="Tag930"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">Intangible Assets, net consists of:</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><div style="-aw-sdt-tag:'c07707b83cb3f173b9aa'; -aw-sdt-title:'INTANGIBLE ASSETS T1'"><table cellspacing="0" cellpadding="0" style="width:100%; border-collapse:collapse"><tbody><tr style="height:11.5pt"><td style="width:76%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="2" style="border-bottom:1.5pt solid #000000; padding-right:5.75pt; padding-left:5.75pt; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_e87ec5587e3840c4a97f2064f2104ed4'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">September 30, 2025</span></p></div></td><td style="width:1%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="2" style="border-bottom:1.5pt solid #000000; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_6084f1e1489b48879fcbbe5600141f97'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">December 31, 2024</span></p></div></td></tr><tr style="height:11.5pt"><td style="width:76%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_a974f35cc65443269ff066743129189d'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Patents</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_d202bcb88b044d028a4bbb28f6a6e8b0'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_11b78614bac54ef0a49e4b893a15b1d0'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:FiniteLivedPatentsGross" contextRef="I20250930" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag78">152,267</ix:nonFraction></span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_51a78629619a4b75ba95f8f8f4f7ec7b'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_860e11faa60f4e3cb17c35e447e6d321'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:FiniteLivedPatentsGross" contextRef="I20241231" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag82">127,603</ix:nonFraction></span></p></div></td></tr><tr style="height:11.5pt"><td style="width:76%; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_f612ea6912ea4de8936ab11fa94001b2'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Website Development Costs</span></p></div></td><td style="width:1%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_bd5beeeb98654d3cb378b1f150cf237e'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="sxtp:FiniteLivedWebsiteDevelopmentCostsGross" contextRef="I20250930" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag79">106,407</ix:nonFraction></span></p></div></td><td style="width:1%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_0297394f2e174985a9011e14c17a1c32'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="sxtp:FiniteLivedWebsiteDevelopmentCostsGross" contextRef="I20241231" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag83">104,622</ix:nonFraction></span></p></div></td></tr><tr style="height:11.5pt"><td style="width:76%; vertical-align:middle; background-color:#ccecff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_69283753d7194d8481cb58344618da62'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Intangible Assets, at cost</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ccecff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ccecff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ccecff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_67428270244741e190f4ba5b6f6c89a4'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="I20250930" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag80">258,674</ix:nonFraction></span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ccecff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ccecff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ccecff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_ce68356243274a62b8341406f23e7284'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="I20241231" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag84">232,225</ix:nonFraction></span></p></div></td></tr><tr style="height:11.5pt"><td style="width:76%; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_5ec84ad9cbbb4a728206c96fd6d9a6ac'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Accumulated Amortization</span></p></div></td><td style="width:1%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_a4c0c57793a24539a911c71110c0a6db'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="I20250930" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag3">106,291</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">)</span></p></td><td style="width:1%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_ba8b1931203d40b8b853f7cd33fb68a0'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="I20241231" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag4">75,141</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">)</span></p></td></tr><tr style="height:11.5pt"><td style="width:76%; vertical-align:middle; background-color:#ccecff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_609bae755e8b4231bb1d4b943acee2ff'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">Intangible Assets, net</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ccecff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ccecff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_bbacba70555c4d44a3ed2b95ac3cb5f3'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">$</span></p></div></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ccecff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_2fda802cc17945c78daa21dc34cb0e8e'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'"><ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="I20250930" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag81">152,383</ix:nonFraction></span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ccecff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ccecff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_0f46f04104944ac794c1fcc3501b0184'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">$</span></p></div></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ccecff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_01b52cfeb567443aae2cc897f6e6903c'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'"><ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="I20241231" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag85">157,084</ix:nonFraction></span></p></div></td></tr></tbody></table></div></ix:nonNumeric></div><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">During the </span><span style="-aw-sdt-tag:'cfddb1f69b08f6739761'; -aw-sdt-title:'Current_Quarter_P8'; font-family: 'Times New Roman'"><span>three months ended September 30, 2025</span></span><span style="font-family: 'Times New Roman';"> and </span><span style="-aw-sdt-tag:'c29e36ff587f2ca8119a'; -aw-sdt-title:'Previous_Year_P7'; font-family: 'Times New Roman'"><span>2024</span></span><span style="font-family: 'Times New Roman';">, the Company capitalized website development related costs of $</span><span style="-aw-sdt-tag:'c2a1e8afbb1fb6a25958'; -aw-sdt-title:'Capitalized website cost_CQ'; font-family: 'Times New Roman'"><span><ix:nonFraction name="sxtp:CapitalizedWebsiteDevelopmentrelatedCosts" contextRef="D20250930" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag817">1,785</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';"> and $</span><span style="-aw-sdt-tag:'cda0d70b09d724d001f4'; -aw-sdt-title:'Capitalized website cost_PQ'; font-family: 'Times New Roman'"><span><ix:nonFraction name="sxtp:CapitalizedWebsiteDevelopmentrelatedCosts" contextRef="D20240930" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag747">3,299</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">, respectively, in connection with the upgrade and enhancement of functionality of the corporate website at www.60degreespharma.com</span><span style="-aw-import:spaces; font-family: 'Times New Roman'">&#160; </span><span style="font-family: 'Times New Roman';">($</span><span style="-aw-sdt-tag:'c3dc95a82a1b1e546d01'; -aw-sdt-title:'Capitalized website cost_CYTD'; font-family: 'Times New Roman'"><span><ix:nonFraction name="sxtp:CapitalizedWebsiteDevelopmentrelatedCosts" contextRef="D20250930_1" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag748">1,785</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">&#160;</span><span style="font-family: 'Times New Roman';">and $</span><span style="-aw-sdt-tag:'cf4550241ecb006a41f6'; -aw-sdt-title:'Capitalized website cost_PYTD'; font-family: 'Times New Roman'"><span><ix:nonFraction name="sxtp:CapitalizedWebsiteDevelopmentrelatedCosts" contextRef="D20240930_1" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag749">25,374</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">&#160;</span><span style="font-family: 'Times New Roman';">for the </span><span style="-aw-sdt-tag:'c33b8fe0f39e14089973'; -aw-sdt-title:'Current_YTD_P5'; font-family: 'Times New Roman'"><span>nine months ended September 30, 2025</span></span><span style="font-family: 'Times New Roman';"> and </span><span style="-aw-sdt-tag:'ce5f4b2075d79cc2478c'; -aw-sdt-title:'Previous_Year_P8'; font-family: 'Times New Roman'"><span>2024</span></span><span style="font-family: 'Times New Roman';">, respectively). Amortization expense for the </span><span style="-aw-sdt-tag:'c44e3479c6cf2fd17b26'; -aw-sdt-title:'Current_Quarter_P9'; font-family: 'Times New Roman'"><span>three months ended September 30, 2025</span></span><span style="font-family: 'Times New Roman';"> and </span><span style="-aw-sdt-tag:'c17bd43eeffe59b5f10e'; -aw-sdt-title:'Previous_Year_P9'; font-family: 'Times New Roman'"><span>2024</span></span><span style="font-family: 'Times New Roman';">, was in the amount of $</span><span style="-aw-sdt-tag:'cdf9166bedebda2ed9aa'; -aw-sdt-title:'Amortization expense_CQ'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="D20250930" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag750">10,605</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';"> and $</span><span style="-aw-sdt-tag:'ca20761b02425983f940'; -aw-sdt-title:'Amortization expense_PQ'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="D20240930" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag751">10,325</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">, respectively ($</span><span style="-aw-sdt-tag:'c8ce6837087c033d4286'; -aw-sdt-title:'Amortization expense_CYTD'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="D20250930_1" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag752">31,150</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">&#160;</span><span style="font-family: 'Times New Roman';">and $</span><span style="-aw-sdt-tag:'cc44d6d5241d199376d1'; -aw-sdt-title:'Amortization expense_PYTD'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="D20240930_1" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag753">28,004</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">&#160;</span><span style="font-family: 'Times New Roman';">for the </span><span style="-aw-sdt-tag:'ce158ad54306c4664c5b'; -aw-sdt-title:'Current_YTD_P6'; font-family: 'Times New Roman'"><span>nine months ended September 30, 2025</span></span><span style="font-family: 'Times New Roman';"> and </span><span style="-aw-sdt-tag:'c4c2c545f5f21414391e'; -aw-sdt-title:'Previous_Year_P10'; font-family: 'Times New Roman'"><span>2024</span></span><span style="font-family: 'Times New Roman';">, respectively). During the </span><span style="-aw-sdt-tag:'c457dc719db4eca31b2a'; -aw-sdt-title:'Current_Quarter_P10'; font-family: 'Times New Roman'"><span>three months ended September 30, 2025</span></span><span style="font-family: 'Times New Roman';"> and </span><span style="-aw-sdt-tag:'cdc79815474d680ddd9e'; -aw-sdt-title:'Previous_Year_P45'; font-family: 'Times New Roman'"><span>2024</span></span><span style="font-family: 'Times New Roman';"> write-downs for expired or obsolete patents totaled $</span><span style="-aw-sdt-tag:'7d9-88c-e97-7af-e31e'; -aw-sdt-title:'Write-downs CQ'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" contextRef="D20250930" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag833">0</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';"> and $</span><span style="-aw-sdt-tag:'283-f1b-606-cfc-9b44'; -aw-sdt-title:'Write-downs PQ'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" contextRef="D20240930" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag834">2,922</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">, respectively ($</span><span style="-aw-sdt-tag:'e6c-293-14b-bb4-26d0'; -aw-sdt-title:'Write downs_CYTD'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" contextRef="D20250930_1" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag820">0</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';"> and</span><span style="font-family: 'Times New Roman';">&#160;</span><span style="font-family: 'Times New Roman';">$</span><span style="-aw-sdt-tag:'cac27d69e412e4ba21e5'; -aw-sdt-title:'Write-downs_PYTD'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" contextRef="D20240930_1" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag754">11,300</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">&#160;</span><span style="font-family: 'Times New Roman';">for the </span><span style="-aw-sdt-tag:'c72938f4a0ec43514747'; -aw-sdt-title:'Current_YTD_P7'; font-family: 'Times New Roman'"><span>nine months ended September 30, 2025</span></span><span style="font-family: 'Times New Roman';"> and </span><span style="-aw-sdt-tag:'cbbf9cb9616e40a9b45a'; -aw-sdt-title:'Previous_Year_P11'; font-family: 'Times New Roman'"><span>2024</span></span><span style="font-family: 'Times New Roman';">, respectively).</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><div style="-aw-sdt-tag:'c3bc236d7ffc1c5b8cde'"><ix:nonNumeric name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" contextRef="D20250930_1" escape="true" id="Tag931"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">The following table summarizes the estimated future amortization expense for our patents and website development costs as of </span><span style="-aw-sdt-tag:'ce96f421a46d06d458b3'; -aw-sdt-title:'Current_Period_P7'; font-family: 'Times New Roman'"><span>September 30, 2025</span></span><span style="font-family: 'Times New Roman';">:</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><div style="-aw-sdt-tag:'c0f2fdd191b23a42f69c'; -aw-sdt-title:'INTANGIBLE ASSETS T2'"><table cellspacing="0" cellpadding="0" style="width:100%; border-collapse:collapse"><tbody><tr style="height:11.5pt"><td style="width:76%; border-bottom:1.5pt solid #000000; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_174dcc19aadc45dcbec245e8e5590546'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">Period</span></p></div></td><td style="width:1%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="2" style="border-bottom:1.5pt solid #000000; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_2b4fd151a35e427f81944ed4aef3cd03'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">Patents</span></p></div></td><td style="width:1%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="2" style="border-bottom:1.5pt solid #000000; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_eac02702a1b6481292e04477eabff1f5'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">Website Development Costs</span></p></div></td></tr><tr style="height:11.5pt"><td style="width:76%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_bed21abb624848b39d25a0e5198a3eea'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">2025 (remaining three months)</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_0628bafa871b46b6b23c7839bac84a2b'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; border-top:1.5pt solid #000000; padding-right:0.7pt; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_9ed72b1fc9a841678c6414ffa9250716'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" contextRef="I20250930_PatentsMember" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag86">1,816</ix:nonFraction></span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_9971da9e37cf45c6965a560295ce2ee3'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_b86b8d6612d346b299a1f4e8b716937d'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" contextRef="I20250930_SoftwareAndSoftwareDevelopmentCostsMember" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag93">5,754</ix:nonFraction></span></p></div></td></tr><tr style="height:11.5pt"><td style="width:76%; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_98ee970e69c748c69cc8bbd0ed8e7995'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">2026</span></p></div></td><td style="width:1%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; padding-right:0.7pt; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_29d81502a5fc40d6b3b22b749ae8c2cc'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" contextRef="I20250930_PatentsMember" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag87">7,264</ix:nonFraction></span></p></div></td><td style="width:1%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_d2022197ea7e432dad2b843e2cba5634'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" contextRef="I20250930_SoftwareAndSoftwareDevelopmentCostsMember" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag94">13,027</ix:nonFraction></span></p></div></td></tr><tr style="height:11.5pt"><td style="width:76%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_4130c067c39a40829ddaa2a81e97ae4b'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">2027</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; padding-right:0.7pt; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_4d3a475d713840deb210ba44e18e1f33'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" contextRef="I20250930_PatentsMember" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag88">7,264</ix:nonFraction></span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_5fd36d2d7338473a98e0eaca4c3bb72e'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" contextRef="I20250930_SoftwareAndSoftwareDevelopmentCostsMember" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag95">3,689</ix:nonFraction></span></p></div></td></tr><tr style="height:11.5pt"><td style="width:76%; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_313ade7de15848e1805861fa9d495eb2'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">2028</span></p></div></td><td style="width:1%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; padding-right:0.7pt; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_9a518cad7b5f4600b17899e4df170f7e'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" contextRef="I20250930_PatentsMember" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag89">7,264</ix:nonFraction></span></p></div></td><td style="width:1%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_ba37da8a5d21434286c58831bdac112f'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" contextRef="I20250930_SoftwareAndSoftwareDevelopmentCostsMember" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag235">397</ix:nonFraction></span></p></div></td></tr><tr style="height:11.5pt"><td style="width:76%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_faf1ce39ee004fdbacf45816b0cd8e1b'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">2029</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; padding-right:0.7pt; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_1dbfcb6bede14893b1d590e5550007a7'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" contextRef="I20250930_PatentsMember" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag90">7,264</ix:nonFraction></span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-tag:'C_4124ac0cb341498b8445cea7bd35d757'"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" contextRef="I20250930_SoftwareAndSoftwareDevelopmentCostsMember" xsi:nil="true" unitRef="USD" id="Tag96"></ix:nonFraction><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td></tr><tr style="height:11.5pt"><td style="width:76%; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_a93ca8f84d704c2685aef38dd6e616fb'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Thereafter</span></p></div></td><td style="width:1%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-bottom:1.5pt solid #000000; padding-right:0.7pt; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_6321783027ee42c18b71f36dd0941a2f'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" contextRef="I20250930_PatentsMember" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag91">38,435</ix:nonFraction></span></p></div></td><td style="width:1%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle"><div style="-aw-sdt-tag:'C_257cb67d346b4113ac890add634412f6'"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" contextRef="I20250930_SoftwareAndSoftwareDevelopmentCostsMember" xsi:nil="true" unitRef="USD" id="Tag97"></ix:nonFraction><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td></tr><tr style="height:11.5pt"><td style="width:76%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_d7c76dd6b9cc422d8a6b884dacaa3365'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">Total</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_75767eb28a1d449ab596ff84732f7256'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">$</span></p></div></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; padding-right:0.7pt; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_2ee72c55a7204d64a57ac09c73611a03'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="I20250930_PatentsMember" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag92">69,307</ix:nonFraction></span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_6779a62c90a14cb8b35f588ce92d9296'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">$</span></p></div></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'e65-d56-30f-2c3-e9f3'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="I20250930_SoftwareAndSoftwareDevelopmentCostsMember" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag199">22,867</ix:nonFraction></span></p></div></td></tr></tbody></table></div></ix:nonNumeric></div><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">The Company has recorded $</span><span style="-aw-sdt-tag:'cbd86a35bd29e0f037ae'; -aw-sdt-title:'capitalized patent expenses'; font-family: 'Times New Roman'"><span><ix:nonFraction name="sxtp:CapitalizedPatentExpenses" contextRef="D20250930_1" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag746">60,209</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';"> in capitalized patent expenses that will become amortizable as the patents they are associated with are awarded.</span></p></ix:nonNumeric></div><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore">&#160;</span></p><div style="-aw-sdt-tag:'PG_d5f4daba08a3b704'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-family: 'Times New Roman';">14</span></p><div><hr style="width: 100%; color: #000000; background-color: #000000; margin: 1rem 0;"/></div></div></div><div class="Section_18"><div style="-aw-sdt-tag:'ae6-f22-934-ddc-59fc'"><ix:nonNumeric name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" contextRef="D20250930_1" escape="true" id="Tag983" continuedAt="c72e0545e151ecc20163"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">6. STOCKHOLDERS&#8217; EQUITY</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">Pursuant to the Certificate of Incorporation of </span><span style="-aw-sdt-tag:'c00395ab615233e65b60'; font-family: 'Times New Roman'"><span>60</span></span><span style="font-family: 'Times New Roman';"> Degrees Pharmaceuticals, Inc., the Company&#8217;s authorized shares consist of (a) </span><span style="-aw-sdt-tag:'c8256dca101917b93f72'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="I20250930" unitRef="Shares" decimals="0" format="ixt:num-dot-decimal" id="Tag780">150,000,000</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';"> shares of common stock, par value $</span><span style="-aw-sdt-tag:'c3bf7f20ec7068739bfa'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="I20250930" unitRef="USDPerShare" decimals="4" format="ixt:num-dot-decimal" id="Tag781">0.0001</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';"> per share and (b) </span><span style="-aw-sdt-tag:'c047a66335e6c7190382'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="I20250930_SeriesAPreferredStockMember" unitRef="Shares" decimals="0" format="ixt:num-dot-decimal" id="Tag808">1,000,000</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';"> shares of preferred stock, par value $</span><span style="-aw-sdt-tag:'c911e740c0eb8459e49a'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="I20250930_SeriesAPreferredStockMember" unitRef="USDPerShare" decimals="4" format="ixt:num-dot-decimal" id="Tag782">0.0001</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';"> per share, of which </span><span style="-aw-sdt-tag:'c8d91dff0ef3b8a20008'; -aw-sdt-title:'Series A Designated Shares'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:ExcessStockSharesAuthorized" contextRef="I20250930_SeriesANonVotingConvertiblePreferredStockMember" unitRef="Shares" decimals="0" format="ixt:num-dot-decimal" id="Tag783">80,965</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';"> have been designated as Series A Non-Voting Convertible Preferred Stock (&#8220;Series A Preferred Stock&#8221;). As of </span><span style="-aw-sdt-tag:'c34ccecbf9d8ef0f5dec'; -aw-sdt-title:'Current_Period_P29'; font-family: 'Times New Roman'"><span>September 30, 2025</span></span><span style="font-family: 'Times New Roman';">, </span><span style="-aw-sdt-tag:'cf2aa1a6a0c77e7c2fd3'; -aw-sdt-title:'Current Common Shares Outstanding'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="I20250930" unitRef="Shares" decimals="0" format="ixt:num-dot-decimal" id="Tag903">4,104,469</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';"> shares of Common Stock and </span><span style="-aw-sdt-tag:'ca0007fd29b564fc54fa'; -aw-sdt-title:'Current Series A Shares Outstanding'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="I20250930_SeriesAPreferredStockMember" unitRef="Shares" decimals="0" format="ixt:num-dot-decimal" id="Tag902">76,480</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';"> shares of Series A Preferred Stock are issued and outstanding.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">Following stockholder approval in November </span><span style="-aw-sdt-tag:'ce5446ee6a7ba063dc41'; font-family: 'Times New Roman'"><span>2024</span></span><span style="font-family: 'Times New Roman';">, on February </span><span style="-aw-sdt-tag:'c208cdf92af8907a4aa6'; font-family: 'Times New Roman'"><span>18</span></span><span style="font-family: 'Times New Roman';">, </span><span style="-aw-sdt-tag:'c37dc585619006d80d82'; font-family: 'Times New Roman'"><span>2025</span></span><span style="font-family: 'Times New Roman';">, the Company filed an additional Amendment to the Certificate of Incorporation with the Secretary of State of Delaware to effect the </span><span style="-aw-sdt-tag:'c81652786d96c9a5557d'; font-family: 'Times New Roman'"><ix:nonNumeric name="us-gaap:StockholdersEquityReverseStockSplit" contextRef="D20250218" escape="false" id="Tag784"><span>1:5</span></ix:nonNumeric></span><span style="font-family: 'Times New Roman';"> Reverse Stock Split of the issued and outstanding shares of the Company&#8217;s common stock, which was effective as of February </span><span style="-aw-sdt-tag:'cb3826fdc552899bbbcd'; font-family: 'Times New Roman'"><span>24</span></span><span style="font-family: 'Times New Roman';">, </span><span style="-aw-sdt-tag:'cbb3cb20b9a2ea915ff9'; font-family: 'Times New Roman'"><span>2025</span></span><span style="font-family: 'Times New Roman';">. As of the effective time of the </span><span style="-aw-sdt-tag:'c0fc832f2594da84f996'; font-family: 'Times New Roman'"><ix:nonNumeric name="us-gaap:StockholdersEquityReverseStockSplit" contextRef="D20250930_1" escape="false" id="Tag785"><span>1:5</span></ix:nonNumeric></span><span style="font-family: 'Times New Roman';"> Reverse Stock Split, every five (</span><span style="-aw-sdt-tag:'c5da0431da494b8ec1a4'; font-family: 'Times New Roman'"><span>5</span></span><span style="font-family: 'Times New Roman';">) issued and outstanding shares of the Company&#8217;s common stock were automatically combined and converted into one (</span><span style="-aw-sdt-tag:'c6f015b36370d0756173'; font-family: 'Times New Roman'"><span>1</span></span><span style="font-family: 'Times New Roman';">) issued and outstanding share of the Company&#8217;s common stock. </span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">No fractional shares of common stock were issued in connection with the Reverse Stock Splits. All fractional shares were rounded up to the nearest whole share with respect to outstanding shares of common stock. The Reverse Stock Splits did not change the authorized number of shares of common stock or preferred stock, the par value of the common stock, or the number of issued and outstanding shares of Series A Preferred Stock. All references to numbers of shares of the Company&#8217;s common stock and per share information in these consolidated condensed financial statements have been retroactively adjusted, as appropriate, to reflect the Reverse Stock Splits, including reclassifying an amount equal to the reduction in par value of common stock to additional paid-in capital.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; text-decoration:underline; font-family: 'Times New Roman'">Common Stock</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-style:italic; font-family: 'Times New Roman'">January </span><span style="-aw-sdt-tag:'c766051bc4fd2494d06a'; font-family: 'Times New Roman'"><span style="font-style:italic">2025</span></span><span style="font-style:italic; font-family: 'Times New Roman'"> Offering</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-style:italic; font-family: 'Times New Roman'">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">On January </span><span style="-aw-sdt-tag:'c4b9a9512956ad47ecaf'; font-family: 'Times New Roman'"><span>28</span></span><span style="font-family: 'Times New Roman';">, </span><span style="-aw-sdt-tag:'c6f16f1df2bab72eed3c'; font-family: 'Times New Roman'"><span>2025</span></span><span style="font-family: 'Times New Roman';">, the Company entered into a securities purchase agreement with certain institutional investors pursuant to which the Company sold, in a registered direct offering priced at-the-market under the rules of Nasdaq, an aggregate of </span><span style="-aw-sdt-tag:'34f-dfe-350-c12-0797'; -aw-sdt-title:'January 2025_Shares Sold'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" contextRef="D20250128" unitRef="Shares" decimals="0" format="ixt:num-dot-decimal" id="Tag856">204,312</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';"> shares of common stock at a purchase price of $</span><span style="-aw-sdt-tag:'c1872eac4741b1175066'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="I20250128" unitRef="USDPerShare" decimals="3" format="ixt:num-dot-decimal" id="Tag786">5.105</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';"> per share. The shares were offered pursuant to a &#8220;shelf&#8221; registration statement on Form S-</span><span style="-aw-sdt-tag:'cac83fd442a049f28577'; font-family: 'Times New Roman'"><span>3</span></span><span style="font-family: 'Times New Roman';"> (Registration No. </span><span style="-aw-sdt-tag:'c202eae5d68d3a899c77'; font-family: 'Times New Roman'"><span>333</span></span><span style="font-family: 'Times New Roman';">-</span><span style="-aw-sdt-tag:'c9a4b74ad6cb16c00e24'; font-family: 'Times New Roman'"><span>280796</span></span><span style="font-family: 'Times New Roman';">). In a concurrent private placement, the Company also issued to the investors unregistered warrants (the &#8220;January </span><span style="-aw-sdt-tag:'c0d7448c7d769ad24bc4'; font-family: 'Times New Roman'"><span>2025</span></span><span style="font-family: 'Times New Roman';"> Warrants&#8221;) to purchase up to an aggregate of </span><span style="-aw-sdt-tag:'c906142c107a5541bca4'; -aw-sdt-title:'January 2025 Common Warrants'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="I20250128" unitRef="Shares" decimals="0" format="ixt:num-dot-decimal" id="Tag787">408,621</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';"> shares of common stock at an exercise price of $</span><span style="-aw-sdt-tag:'c3c56402ae377ab0a7f9'; -aw-sdt-title:'January 2025 Common Warrants_Ex.Price'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="I20250128" unitRef="USDPerShare" decimals="3" format="ixt:num-dot-decimal" id="Tag788">3.855</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';"> per share. The January </span><span style="-aw-sdt-tag:'cfa07e0e67817e897454'; font-family: 'Times New Roman'"><span>2025</span></span><span style="font-family: 'Times New Roman';"> Warrants are exercisable upon issuance, or January </span><span style="-aw-sdt-tag:'c7e84c25b2f65bdff56b'; font-family: 'Times New Roman'"><span>30</span></span><span style="font-family: 'Times New Roman';">, </span><span style="-aw-sdt-tag:'cce83998a76b653b7691'; font-family: 'Times New Roman'"><span>2025</span></span><span style="font-family: 'Times New Roman';">, and expire twenty-four months from the date of issuance, or January </span><span style="-aw-sdt-tag:'c57fd77fa1237d600805'; font-family: 'Times New Roman'"><span>30</span></span><span style="font-family: 'Times New Roman';">, </span><span style="-aw-sdt-tag:'c7aaa60fc0eec6a0fd8c'; font-family: 'Times New Roman'"><span>2027</span></span><span style="font-family: 'Times New Roman';">. The registered direct offering and concurrent private placement (together, the &#8220;January </span><span style="-aw-sdt-tag:'cd52d29afd3f5d2eccf7'; font-family: 'Times New Roman'"><span>2025</span></span><span style="font-family: 'Times New Roman';"> Offering&#8221;) closed on January </span><span style="-aw-sdt-tag:'c494798979cbe56b695a'; font-family: 'Times New Roman'"><span>30</span></span><span style="font-family: 'Times New Roman';">, </span><span style="-aw-sdt-tag:'c4016c0efa1198b21f27'; font-family: 'Times New Roman'"><span>2025</span></span><span style="font-family: 'Times New Roman';">, resulting in net proceeds to the Company of approximately $</span><span style="-aw-sdt-tag:'c580de3ddd57ac018e42'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" contextRef="D20250130" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag789">804,346</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">, after deducting the placement agent fees and other offering expenses paid by the Company.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">As compensation for acting as the placement agent for the January </span><span style="-aw-sdt-tag:'cee7ccbe0d04fba82a6c'; font-family: 'Times New Roman'"><span>2025</span></span><span style="font-family: 'Times New Roman';"> Offering, in addition to certain cash fees, the Company issued H.C. Wainwright &amp; Co., LLC (the &#8220;Placement Agent&#8221;) warrants to purchase up to </span><span style="-aw-sdt-tag:'c0f8089b6089330b6b04'; -aw-sdt-title:'January 2025 Agent Warrants'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="I20250131_PlacementAgentWarrantsMember" unitRef="Shares" decimals="0" format="ixt:num-dot-decimal" id="Tag917">15,325</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';"> shares of common stock at an exercise price of $</span><span style="-aw-sdt-tag:'c37edb8ca4f2c575ae63'; -aw-sdt-title:'January 2025 Agent Warrants_Ex.Price'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="I20250131_PlacementAgentWarrantsMember" unitRef="USDPerShare" decimals="3" format="ixt:num-dot-decimal" id="Tag790">6.382</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';"> (the &#8220;January </span><span style="-aw-sdt-tag:'cf18e7f7a6818d437bb7'; font-family: 'Times New Roman'"><span>2025</span></span><span style="font-family: 'Times New Roman';"> Agent Warrants&#8221;). The January </span><span style="-aw-sdt-tag:'c31825f688b0d9e23238'; font-family: 'Times New Roman'"><span>2025</span></span><span style="font-family: 'Times New Roman';"> Agent Warrants were exercisable upon issuance and expire twenty-four months from the date of issuance.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-style:italic; font-family: 'Times New Roman'">February </span><span style="-aw-sdt-tag:'c5b0aa4c07ace5151d7d'; font-family: 'Times New Roman'"><span style="font-style:italic">2025</span></span><span style="font-style:italic; font-family: 'Times New Roman'"> Offering</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-style:italic; font-family: 'Times New Roman'">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">On February </span><span style="-aw-sdt-tag:'c72b369793d8cb0663de'; font-family: 'Times New Roman'"><span>5</span></span><span style="font-family: 'Times New Roman';">, </span><span style="-aw-sdt-tag:'ccfae45335d3132329d8'; font-family: 'Times New Roman'"><span>2025</span></span><span style="font-family: 'Times New Roman';">, the Company entered into a securities purchase agreement with certain institutional investors pursuant to which the Company sold, in a registered direct offering priced at-the-market under the rules of Nasdaq, an aggregate of </span><span style="-aw-sdt-tag:'c7a47a1b4a61568a79ee'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="D20250205" unitRef="Shares" decimals="0" format="ixt:num-dot-decimal" id="Tag791">300,700</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';"> shares of the Company&#8217;s common stock at a purchase price of $</span><span style="-aw-sdt-tag:'cd40fa8984cf91955d65'; -aw-sdt-title:'February 2025_Purchase Price'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="I20250205" unitRef="USDPerShare" decimals="3" format="ixt:num-dot-decimal" id="Tag792">3.575</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';"> per share. In a concurrent private placement, the Company separately issued to the investors unregistered warrants to purchase up to an aggregate of </span><span style="-aw-sdt-tag:'c70410176c474a809bb6'; -aw-sdt-title:'February 2025 Warrants'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="D20250205_CommonStockMember_WarrantMember" unitRef="Shares" decimals="0" format="ixt:num-dot-decimal" id="Tag793">300,700</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';"> shares of common stock at an exercise price of $</span><span style="-aw-sdt-tag:'c9ab699f16e4535f6559'; -aw-sdt-title:'February 2025 Warrants_Ex.Price'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="I20250205_WarrantMember" unitRef="USDPerShare" decimals="2" format="ixt:num-dot-decimal" id="Tag794">2.95</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';"> per share (the &#8220;February </span><span style="-aw-sdt-tag:'ce612c83cf1f52410608'; font-family: 'Times New Roman'"><span>2025</span></span><span style="font-family: 'Times New Roman';"> Warrants&#8221;). The February </span><span style="-aw-sdt-tag:'c94c89dae7699225143d'; font-family: 'Times New Roman'"><span>2025</span></span><span style="font-family: 'Times New Roman';"> Warrants were immediately exercisable upon issuance and expire twenty-four months from the date of issuance. The registered direct offering and concurrent private placement (together, the &#8220;February </span><span style="-aw-sdt-tag:'cb9faf62303c5603f05f'; font-family: 'Times New Roman'"><span>2025</span></span><span style="font-family: 'Times New Roman';"> Offering&#8221;) closed on February </span><span style="-aw-sdt-tag:'cab9c9f59f2aa9bdd2ea'; font-family: 'Times New Roman'"><span>6</span></span><span style="font-family: 'Times New Roman';">, </span><span style="-aw-sdt-tag:'c02d9a9c7a98c7cb6b11'; font-family: 'Times New Roman'"><span>2025</span></span><span style="font-family: 'Times New Roman';">, resulting in net proceeds to the Company of approximately $</span><span style="-aw-sdt-tag:'cae17f4b26b5215dec57'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" contextRef="D20250206" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag795">908,627</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">, after deducting the placement agent fees and other offering expenses paid by the Company.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">As compensation for acting as the placement agent for the February </span><span style="-aw-sdt-tag:'ca49d3c0f55aa58250b8'; font-family: 'Times New Roman'"><span>2025</span></span><span style="font-family: 'Times New Roman';"> Offering, in addition to certain cash fees, the Company issued the Placement Agent warrants to purchase up to </span><span style="-aw-sdt-tag:'cdaf4a5d62e024e6958a'; -aw-sdt-title:'February 2025 Agent Warrants'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="I20250205_PlacementAgentWarrantsMember" unitRef="Shares" decimals="0" format="ixt:num-dot-decimal" id="Tag796">22,554</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';"> shares of common stock at an exercise price of $</span><span style="-aw-sdt-tag:'ca55514cbc775909ead5'; -aw-sdt-title:'February 2025 Agent Warrants_Ex.Price'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="I20250205_PlacementAgentWarrantsMember" unitRef="USDPerShare" decimals="3" format="ixt:num-dot-decimal" id="Tag809">4.469</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';"> (the &#8220;February </span><span style="-aw-sdt-tag:'c33357b171c6a2bbe58b'; font-family: 'Times New Roman'"><span>2025</span></span><span style="font-family: 'Times New Roman';"> Agent Warrants&#8221;). The February </span><span style="-aw-sdt-tag:'cb0e922589e5ea34bfd9'; font-family: 'Times New Roman'"><span>2025</span></span><span style="font-family: 'Times New Roman';"> Agent Warrants were exercisable upon issuance and expire twenty-four months from the date of issuance.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-style:italic; font-family: 'Times New Roman'">July 2025 Offering</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">On July 15, 2025, the Company entered into a securities purchase agreement with certain institutional investors pursuant to which the Company sold, in a registered direct offering (the &#8220;July 2025 Offering&#8221;), </span><span style="-aw-sdt-tag:'963-08e-7a4-81c-04b1'; -aw-sdt-title:'July 2025_Common Units'; font-family: 'Times New Roman'"><span><ix:nonFraction name="sxtp:UnitsIssuedDuringPeriodSharesNewIssues" contextRef="D20250715_July2025OfferingMember" unitRef="Shares" decimals="0" format="ixt:num-dot-decimal" id="Tag822">1,753,314</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';"> units at an offering price of $</span><span style="-aw-sdt-tag:'35d-504-224-bc2-70b0'; -aw-sdt-title:'July 2025_Common Units Price'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="I20250715_July2025OfferingMember" unitRef="USDPerShare" decimals="2" format="ixt:num-dot-decimal" id="Tag823">1.90</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';"> per unit and </span><span style="-aw-sdt-tag:'0de-3a9-e49-e5f-bc0e'; -aw-sdt-title:'July 2025_Pre Funded Units'; font-family: 'Times New Roman'"><span><ix:nonFraction name="sxtp:UnitsIssuedDuringPeriodSharesNewIssues" contextRef="D20250715_PreFundedWarrantMember" unitRef="Shares" decimals="0" format="ixt:num-dot-decimal" id="Tag824">878,264</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';"> pre-funded units at an offering price of $</span><span style="-aw-sdt-tag:'31f-af2-e74-9f4-4be5'; -aw-sdt-title:'July 2025_Pre Funded Units Price'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="I20250715_PreFundedWarrantMember" unitRef="USDPerShare" decimals="3" format="ixt:num-dot-decimal" id="Tag825">1.899</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';"> per pre-funded unit. Each unit consisted of (i) one share of common stock, (ii) one series A-1 warrant exercisable for one share of common stock (the &#8220;July 2025 A-1 Warrants&#8221;), and (iii) one series A-2 warrant exercisable for one share of common stock (the &#8220;July 2025 A-2 Warrants&#8221; and together with the July 2025 A-1 Warrants, the &#8220;July 2025 Warrants&#8221;). Each pre-funded unit consists of one pre-funded warrant exercisable for one share of common stock (the &#8220;July 2025 Pre-Funded Warrants&#8221;) and warrants identical to the July 2025 Warrants included in the units. The July 2025 Pre-Funded Warrants have an exercise price of $</span><span style="-aw-sdt-tag:'2e3-1e4-caf-c40-41a1'; -aw-sdt-title:'July 2025_Pre Funded Units Exercise Price'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="I20250715_JulyTwoThousandTwentyFivePreFundedWarrantsMember" unitRef="USDPerShare" decimals="3" format="ixt:num-dot-decimal" id="Tag826">0.001</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';"> per share, and were immediately exercisable beginning on </span><span style="-aw-sdt-tag:'270-92e-ea6-8c6-95e7'; -aw-sdt-title:'July 2025_Pre Funded Units Issue Date'; font-family: 'Times New Roman'"><span><ix:nonNumeric name="us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" contextRef="D20250715_JulyTwoThousandTwentyFivePreFundedWarrantsMember" format="ixt:date-monthname-day-year-en" id="Tag828">July 16, 2025</ix:nonNumeric></span></span><span style="font-family: 'Times New Roman';"> until exercised in full. The July 2025 A-1 Warrants have an exercise price of $</span><span style="-aw-sdt-tag:'85a-9a8-4d9-ee9-1793'; -aw-sdt-title:'July 2025_A-1 Exercise Price'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="I20250715_JulyTwoThousandTwentyFiveAOneWarrantsMember" unitRef="USDPerShare" decimals="2" format="ixt:num-dot-decimal" id="Tag827">1.90</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';"> per share and are exercisable beginning on </span><span style="-aw-sdt-tag:'745-2b8-404-908-2d8c'; -aw-sdt-title:'July 2025_A-1 Issue Date'; font-family: 'Times New Roman'"><span><ix:nonNumeric name="us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" contextRef="D20250715_JulyTwoThousandTwentyFiveAOneWarrantsMember" format="ixt:date-monthname-day-year-en" id="Tag829">July 16, 2025</ix:nonNumeric></span></span><span style="font-family: 'Times New Roman';"> until </span><span style="-aw-sdt-tag:'303-107-340-789-0138'; -aw-sdt-title:'July 2025_A-1 Expiry Date'; font-family: 'Times New Roman'"><span><ix:nonNumeric name="us-gaap:WarrantsAndRightsOutstandingMaturityDate" contextRef="I20250715_JulyTwoThousandTwentyFiveAOneWarrantsMember" format="ixt:date-monthname-day-year-en" id="Tag830">July 15, 2030</ix:nonNumeric></span></span><span style="font-family: 'Times New Roman';">. The July 2025 A-2 Warrants have an exercise price of $</span><span style="-aw-sdt-tag:'7d7-395-569-007-7e21'; -aw-sdt-title:'July 2025_A-2 Exercise Price'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="I20250715_JulyTwoThousandTwentyFiveATwoWarrantsMember" unitRef="USDPerShare" decimals="2" format="ixt:num-dot-decimal" id="Tag900">1.90</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';"> per share and are exercisable beginning on </span><span style="-aw-sdt-tag:'926-d02-8ee-91c-294d'; -aw-sdt-title:'July 2025_A-2 Issue Date'; font-family: 'Times New Roman'"><span><ix:nonNumeric name="us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" contextRef="D20250715_JulyTwoThousandTwentyFiveATwoWarrantsMember" format="ixt:date-monthname-day-year-en" id="Tag897">July 16, 2025</ix:nonNumeric></span></span><span style="font-family: 'Times New Roman';"> until </span><span style="-aw-sdt-tag:'73a-95e-768-9a2-c4cc'; -aw-sdt-title:'July 2025_A-2 Expiry Date'; font-family: 'Times New Roman'"><span><ix:nonNumeric name="us-gaap:WarrantsAndRightsOutstandingMaturityDate" contextRef="I20250715_JulyTwoThousandTwentyFiveATwoWarrantsMember" format="ixt:date-monthname-day-year-en" id="Tag898">January 15, 2027</ix:nonNumeric></span></span><span style="font-family: 'Times New Roman';">.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">As compensation for acting as the placement agent for the July 2025 Offering, the Company also issued to H.C. Wainwright &amp; Co., LLC warrants (the &#8220;July 2025 Placement Agent Warrants&#8221;) to purchase up to </span><span style="-aw-sdt-tag:'0b5-721-1f3-439-eaf1'; -aw-sdt-title:'July 2025 Placement Agent Warrants'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="D20250715_MaximumMember_JulyTwoThousandTwentyFivePlacementAgentWarrantsMember" unitRef="Shares" decimals="0" format="ixt:num-dot-decimal" id="Tag894">197,368</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';"> shares of common stock. The July 2025 Placement Agent Warrants have an exercise price equal to $</span><span style="-aw-sdt-tag:'8d1-309-84e-2ab-e8ac'; -aw-sdt-title:'July 2025_Agent Warrants Exercise Price'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="I20250715_JulyTwoThousandTwentyFivePlacementAgentWarrantsMember" unitRef="USDPerShare" decimals="3" format="ixt:num-dot-decimal" id="Tag895">2.375</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';"> per share and are exercisable upon issuance, or </span><span style="-aw-sdt-tag:'960-754-5c2-f81-ad5e'; -aw-sdt-title:'July 2025_Agent Warrants Issue Date'; font-family: 'Times New Roman'"><span><ix:nonNumeric name="us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" contextRef="D20250715_JulyTwoThousandTwentyFivePlacementAgentWarrantsMember" format="ixt:date-monthname-day-year-en" id="Tag899">July 16, 2025</ix:nonNumeric></span></span><span style="font-family: 'Times New Roman';">, and expire </span><span style="-aw-sdt-tag:'295-24e-c09-37d-52db'; font-family: 'Times New Roman'"><span><ix:nonNumeric name="us-gaap:WarrantsAndRightsOutstandingTerm" contextRef="I20250715_JulyTwoThousandTwentyFivePlacementAgentWarrantsMember" format="ixt-sec:durwordsen" id="Tag893">five years</ix:nonNumeric></span></span><span style="font-family: 'Times New Roman';"> from the date of issuance, or </span><span style="-aw-sdt-tag:'663-3e7-37e-91f-6134'; -aw-sdt-title:'July 2025_Agent Warrants Expiry Date'; font-family: 'Times New Roman'"><span><ix:nonNumeric name="us-gaap:WarrantsAndRightsOutstandingMaturityDate" contextRef="I20250715_JulyTwoThousandTwentyFivePlacementAgentWarrantsMember" format="ixt:date-monthname-day-year-en" id="Tag896">July 15, 2030</ix:nonNumeric></span></span><span style="font-family: 'Times New Roman';">.</span><span style="-aw-import:spaces; font-family: 'Times New Roman'">&#160; </span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p><div style="-aw-sdt-tag:'PG_6327b60d7f0da94a'"><ix:exclude><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-family: 'Times New Roman'; z-index: 100;">15</span></p><div><hr style="width: 100%; color: #000000; background-color: #000000; margin: 1rem 0;"/></div></ix:exclude></div></ix:nonNumeric></div></div><div class="Section_19"><div style="-aw-sdt-tag:'ae6-f22-934-ddc-59fc'"><ix:continuation id="c72e0545e151ecc20163" continuedAt="c09c7d793ca4e63faeaf"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">The July 2025 Offering was made pursuant to the Company&#8217;s registration statement on Form S-1 (File No. 333-288550), which was declared effective by the Securities and Exchange Commission (the &#8220;SEC&#8221;) on July 15, 2025, and the final prospectus, which was filed with the SEC on July 16, 2025. The Offering closed on July 16, 2025, resulting in net proceeds to the Company of approximately $</span><span style="-aw-sdt-tag:'1ea-cd6-103-d88-c43a'; -aw-sdt-title:'July 2025_Net Proceeds'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" contextRef="D20250716_July2025OfferingMember" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag816">4,281,300</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">, after deducting placement agent fees and other offering expenses paid by the Company. </span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-style:italic; font-family: 'Times New Roman'">2025 ATM Agreement</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-import:spaces; font-family: 'Times New Roman'">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">On September 5, 2025, the Company entered into an At-The-Market Sales Agreement (the &#8220;2025 ATM Agreement&#8221;) with H.C. Wainwright &amp; Co., LLC (&#8220;Wainwright&#8221;) pursuant to which the Company may, from time to time, offer and sell shares of its common stock, having aggregate gross sales proceeds of up to $</span><span style="-aw-sdt-tag:'5e1-86e-ff2-592-8db0'; font-family: 'Times New Roman'"><span><ix:nonFraction name="sxtp:CommonStockAggregateGrossSalesProceedAuthorized" contextRef="I20250903_HCWainwrightAndCoLLCMember_AtTheMarket2025AgreementMember" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag886">1,397,532</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';"> (the &#8220;2025 ATM Offering&#8221;). As compensation for acting as the sales agent for the 2025 ATM Offering, Wainwright will be entitled to a commission of </span><span style="-aw-sdt-tag:'ec6-04e-04d-299-5b8e'; font-family: 'Times New Roman'"><span><ix:nonFraction name="sxtp:SalesAgentCommissionPercentage" contextRef="I20250903_HCWainwrightAndCoLLCMember_AtTheMarket2025AgreementMember" unitRef="Pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="Tag885">3.0</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">% of the gross proceeds from sales of shares in the 2025 ATM Offering. </span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">The common stock to be sold under the 2025 ATM Agreement, if any, will be issued and sold pursuant to the Company&#8217;s shelf registration statement on Form S-3 and accompanying base prospectus (Registration Statement No. 333-280796), which was declared effective by the SEC on July 18, 2024, and a prospectus supplement dated September 5, 2025 relating to the offer and sale of the shares pursuant to the 2025 ATM Agreement. As of </span><span style="-aw-sdt-tag:'1dd-95e-3f2-a00-31c0'; -aw-sdt-title:'Current_Period_P44'; font-family: 'Times New Roman'"><span>September 30, 2025</span></span><span style="font-family: 'Times New Roman';">, </span><span style="-aw-sdt-tag:'d31-fbf-141-727-882c'; font-family: 'Times New Roman'"><span><ix:nonFraction name="sxtp:ATMOfferingShares" contextRef="D20250930_HCWainwrightAndCoLLCMember_AtTheMarket2025AgreementMember" unitRef="Shares" decimals="0" format="ixt-sec:numwordsen" id="Tag887">no</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';"> shares had been sold pursuant to the 2025 ATM Agreement. See Note 12 &#8211; Subsequent Events. </span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-style:italic; font-family: 'Times New Roman'">2024 ATM Offering</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-style:italic; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">On July 12, 2024, the Company entered into an At-the-Market Issuance Sales Agreement (the &#8220;2024 ATM Agreement&#8221;) with WallachBeth Capital LLC as sales agent, to sell shares of common stock having an aggregate offering price of up to $</span><span style="-aw-sdt-tag:'f78-d1a-df1-988-f9d9'; font-family: 'Times New Roman'"><span><ix:nonFraction name="sxtp:CommonStockAggregateOfferingPrice" contextRef="D20240712_WallachBethCapitalLLCMember" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag848">1,253,603</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';"> from time to time, through an &#8220;at the market offering&#8221; program (the &#8220;2024 ATM Offering&#8221;). The offer and sale of shares of common stock from the ATM Offering were made pursuant to the Company&#8217;s shelf registration statement on Form S-3 and accompanying base prospectus (Registration Statement No. 333-280796) contained therein which became effective on July 18, 2024. The prospectus supplement was subsequently amended four times to increase the maximum aggregate offering price under the ATM Agreement. From July 19, 2024 to August 1, 2024, the Company sold a total of </span><span style="-aw-sdt-tag:'215-287-a05-1c1-a884'; font-family: 'Times New Roman'"><span><ix:nonFraction name="sxtp:ATMOfferingShares" contextRef="D20240801_WallachBethCapitalLLCMember" unitRef="Shares" decimals="0" format="ixt:num-dot-decimal" id="Tag849">135,568</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';"> shares in the ATM Offering for gross proceeds of $</span><span style="-aw-sdt-tag:'596-827-921-65f-fb9d'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:ProceedsFromOtherEquity" contextRef="D20240801_WallachBethCapitalLLCMember" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag850">1,994,583</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">. </span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">On September 3, 2025, the Company and Wallachbeth Capital LLC entered into a Waiver and Termination Agreement, agreeing to terminate the 2024 ATM Agreement effective as of </span><span style="-aw-sdt-tag:'613-61b-e90-595-df3c'; font-family: 'Times New Roman'"><span><ix:nonNumeric name="sxtp:SalesAgreementTerminationDate" contextRef="D20250903_WallachBethCapitalLLCMember" format="ixt:date-monthname-day-year-en" id="Tag921">September 3, 2025</ix:nonNumeric></span></span><span style="font-family: 'Times New Roman';">.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-style:italic; font-family: 'Times New Roman'">Preferred Stock Conversions</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-style:italic; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">On July 22, 2024 and July 26, 2024, the Company converted </span><span style="-aw-sdt-tag:'ce3-ac4-d73-7d2-12d8'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" contextRef="I20240722_SeriesAPreferredStockMember" unitRef="Shares" decimals="0" format="ixt:num-dot-decimal" id="Tag851">1,291</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';"> and </span><span style="-aw-sdt-tag:'9a0-00a-e5a-a76-32bc'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" contextRef="I20240726_SeriesAPreferredStockMember" unitRef="Shares" decimals="0" format="ixt:num-dot-decimal" id="Tag840">1,032</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';"> shares of Series A Preferred Stock, respectively, held by Knight Therapeutics Inc. into </span><span style="-aw-sdt-tag:'93a-f5c-959-7bf-1e56'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:ConversionOfStockSharesConverted1" contextRef="D20240722_CommonStockMember" unitRef="Shares" decimals="0" format="ixt:num-dot-decimal" id="Tag853">8,000</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';"> shares and </span><span style="-aw-sdt-tag:'562-eef-59d-7f7-d8f5'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:ConversionOfStockSharesConverted1" contextRef="D20240726_CommonStockMember" unitRef="Shares" decimals="0" format="ixt:num-dot-decimal" id="Tag852">6,667</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';"> shares of common stock, respectively.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-style:italic; font-family: 'Times New Roman'">Warrant Exercises</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-style:italic; font-family: 'Times New Roman'">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">During the </span><span style="-aw-sdt-tag:'841-1ba-bd6-f3b-ce0b'; -aw-sdt-title:'Current_Quarter_P47'; font-family: 'Times New Roman'"><span>three months ended September 30, 2025</span></span><span style="font-family: 'Times New Roman';"> and </span><span style="-aw-sdt-tag:'91c-dae-554-39a-2bb2'; -aw-sdt-title:'Previous_Year_P51'; font-family: 'Times New Roman'"><span>2024</span></span><span style="font-family: 'Times New Roman';"> the Company issued </span><span style="-aw-sdt-tag:'645-280-92b-f86-2352'; -aw-sdt-title:'CQTD_Shares Issued for Warrant Exercises'; font-family: 'Times New Roman'"><span><ix:nonFraction name="sxtp:StockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfPreFundedWarrantsinShares" contextRef="D20250930_PreFundedWarrantMember" unitRef="Shares" decimals="0" format="ixt:num-dot-decimal" id="Tag905">878,264</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';"> and </span><span style="-aw-sdt-tag:'d79-532-1f1-c9c-9b2d'; font-family: 'Times New Roman'"><span><ix:nonFraction name="sxtp:StockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfPreFundedWarrantsinShares" contextRef="D20240930_PreFundedWarrantMember_3" unitRef="Shares" decimals="0" format="ixt:num-dot-decimal" id="Tag906">0</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';"> shares of common stock upon the exercise of </span><span style="-aw-sdt-tag:'7c5-227-e1d-0f7-eb4e'; -aw-sdt-title:'CQTD_Warrants Exercised'; font-family: 'Times New Roman'"><span><ix:nonFraction name="sxtp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfWarrantsExercised" contextRef="D20250930_PreFundedWarrantMember" unitRef="Shares" decimals="0" format="ixt:num-dot-decimal" id="Tag909">878,264</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';"> and </span><span style="-aw-sdt-tag:'67f-ac0-19d-0e1-1c4f'; font-family: 'Times New Roman'"><span><ix:nonFraction name="sxtp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfWarrantsExercised" contextRef="D20240930_PreFundedWarrantMember_3" unitRef="Shares" decimals="0" format="ixt:num-dot-decimal" id="Tag916">0</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';"> pre-funded warrants, respectively, resulting in proceeds to the Company of $</span><span style="-aw-sdt-tag:'2bc-7cc-b50-b2e-86ef'; -aw-sdt-title:'CQTD_Warrant Exercise Proceeds'; font-family: 'Times New Roman'"><span><ix:nonFraction name="sxtp:ProceedsFromExerciseOfPreFundedWarrants" contextRef="D20250930_PreFundedWarrantMember" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag912">878</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';"> and $</span><span style="-aw-sdt-tag:'adb-c80-e7b-bbe-6898'; font-family: 'Times New Roman'"><span><ix:nonFraction name="sxtp:ProceedsFromExerciseOfPreFundedWarrants" contextRef="D20240930_PreFundedWarrantMember_3" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag913">0</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">, respectively. During the </span><span style="-aw-sdt-tag:'7e7-2e9-110-4e9-daa7'; -aw-sdt-title:'Current_YTD_P55'; font-family: 'Times New Roman'"><span>nine months ended September 30, 2025</span></span><span style="font-family: 'Times New Roman';"> and </span><span style="-aw-sdt-tag:'12b-9be-73b-065-6355'; -aw-sdt-title:'Previous_Year_P52'; font-family: 'Times New Roman'"><span>2024</span></span><span style="font-family: 'Times New Roman';"> the Company issued </span><span style="-aw-sdt-tag:'bd7-fd5-83b-da2-1fa0'; font-family: 'Times New Roman'"><span><ix:nonFraction name="sxtp:StockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfPreFundedWarrantsinShares" contextRef="D20250930_PreFundedWarrantMember_1" unitRef="Shares" decimals="0" format="ixt:num-dot-decimal" id="Tag907">1,263,464</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';"> and </span><span style="-aw-sdt-tag:'cf9c544cf94ba4b58a99'; -aw-sdt-title:'PYTD_CS issued for warrants'; font-family: 'Times New Roman'"><span><ix:nonFraction name="sxtp:StockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfPreFundedWarrantsinShares" contextRef="D20240930_PreFundedWarrantMember_1" unitRef="Shares" decimals="0" format="ixt:num-dot-decimal" id="Tag908">16,652</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';"> shares of common stock upon the exercise of </span><span style="-aw-sdt-tag:'0ba-275-7d5-d83-6d9c'; font-family: 'Times New Roman'"><span><ix:nonFraction name="sxtp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfWarrantsExercised" contextRef="D20250930_PreFundedWarrantMember_1" unitRef="Shares" decimals="0" format="ixt:num-dot-decimal" id="Tag914">1,263,464</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';"> and </span><span style="-aw-sdt-tag:'c38e9982b4c14bef4cf7'; -aw-sdt-title:'PYTD_PFW Exercises'; font-family: 'Times New Roman'"><span><ix:nonFraction name="sxtp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfWarrantsExercised" contextRef="D20240930_PreFundedWarrantMember_1" unitRef="Shares" decimals="0" format="ixt:num-dot-decimal" id="Tag915">16,652</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';"> pre-funded warrants, respectively, resulting in proceeds to the Company of $</span><span style="-aw-sdt-tag:'687-1b4-df6-4c3-39b0'; -aw-sdt-title:'CYTD_Warrant exercise proceeds'; font-family: 'Times New Roman'"><span><ix:nonFraction name="sxtp:ProceedsFromExerciseOfPreFundedWarrants" contextRef="D20250930_PreFundedWarrantMember_1" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag910">2,804</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';"> and $</span><span style="-aw-sdt-tag:'cb9d9b63f679ae3cb8e1'; -aw-sdt-title:'PYTD_Warrant exercise proceeds'; font-family: 'Times New Roman'"><span><ix:nonFraction name="sxtp:ProceedsFromExerciseOfPreFundedWarrants" contextRef="D20240930_PreFundedWarrantMember_1" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag911">9,990</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">, respectively.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; text-decoration:underline; font-family: 'Times New Roman'">Common Stock Warrants</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">As of </span><span style="-aw-sdt-tag:'c97818c1951368fe0e26'; -aw-sdt-title:'Current_Period_P19'; font-family: 'Times New Roman'"><span>September 30, 2025</span></span><span style="font-family: 'Times New Roman';">, the Company accounts for all issued and outstanding warrants to purchase common stock as equity-classified instruments based on the guidance in ASC </span><span style="-aw-sdt-tag:'c0eabc92e2fa2c832655'; font-family: 'Times New Roman'"><span>480</span></span><span style="font-family: 'Times New Roman';"> and ASC </span><span style="-aw-sdt-tag:'c064d77ec2d1f973d46b'; font-family: 'Times New Roman'"><span>815</span></span><span style="font-family: 'Times New Roman';">.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">As compensation for acting as the placement agent for the Private Placement, the Company issued to H.C. Wainwright &amp; Co., LLC warrants to purchase up to </span><span style="-aw-sdt-tag:'cdf-796-b0c-6e9-ff08'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" contextRef="I20250930_HCWainwrightAndCoLLCMember" unitRef="Shares" decimals="0" format="ixt:num-dot-decimal" id="Tag854">43,479</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';"> shares of stock (the &#8220;September 2024 Agent Warrants&#8221;). The September 2024 Agent Warrants have substantially the same terms as the Series A Warrants, except that the September 2024 Agent Warrants have an exercise price equal to $</span><span style="-aw-sdt-tag:'398-324-697-f50-ef44'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="I20250930_HCWainwrightAndCoLLCMember" unitRef="USDPerShare" decimals="2" format="ixt:num-dot-decimal" id="Tag855">8.63</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';"> per share.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p><div style="-aw-sdt-tag:'PG_79108baa3f2dac7d'"><ix:exclude><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-family: 'Times New Roman'; z-index: 100;">16</span></p><div><hr style="width: 100%; color: #000000; background-color: #000000; margin: 1rem 0;"/></div></ix:exclude></div></ix:continuation></div></div><div class="Section_20"><div style="-aw-sdt-tag:'ae6-f22-934-ddc-59fc'"><ix:continuation id="c09c7d793ca4e63faeaf" continuedAt="c07490d7c3e9a412b584"><div style="-aw-sdt-tag:'0b9-32d-758-bbb-7d61'"><ix:nonNumeric name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" contextRef="D20250930_1" escape="true" id="Tag963" continuedAt="c07397913793c6902f7d"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">The following table presents a summary of the activity for the Company&#8217;s equity-classified warrants during the </span><span style="-aw-sdt-tag:'c564d7f6835302971ae2'; -aw-sdt-title:'Current_Quarter_and_YTD_P11'; font-family: 'Times New Roman'"><span>three and nine months ended September 30, 2025</span></span><span style="font-family: 'Times New Roman';">:</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><div style="-aw-sdt-tag:'c03fb2d1c9552e699f9f'; -aw-sdt-title:'STOCKHOLDERS EQUITY T1'"><table cellspacing="0" cellpadding="0" style="width:100%; border-collapse:collapse"><tbody><tr style="height:51pt"><td style="width:65.32%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1.02%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10.2%; border-bottom:1.5pt solid #000000; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_255042d0e6a541a388b409c03b69aa6a'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">Number of Warrants</span></p></div></td><td style="width:1.02%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="2" style="border-bottom:1.5pt solid #000000; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_1d3baab02d8c401b900003c44b2c7c3f'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">Weighted Average Exercise Price</span></p></div></td><td style="width:1.02%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10.2%; border-bottom:1.5pt solid #000000; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_d9d36dc13cae43cf8b651c83ff0751cb'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">Weighted Average Remaining Contractual Life (Years)</span></p></div></td></tr><tr style="height:12.75pt"><td style="width:65.32%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_0df67d8471e9467a89ff88e0439581e5'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Total outstanding, December 31, 2024</span><span style="font-size:6.67pt; vertical-align:super; font-family: 'Times New Roman'">(1)</span></p></div></td><td style="width:1.02%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10.2%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_cfd86fffd9a24a8681860699bbc5835a'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="I20241231_WarrantMember" unitRef="Shares" decimals="0" format="ixt:num-dot-decimal" id="Tag232">1,765,070</ix:nonFraction></span></p></div></td><td style="width:1.02%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1.02%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_018f691c6c554fcd9f2ea902cef36ea6'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10.2%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_401143ee48e043d3b3536cd6cdf9c432'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="I20241231_WarrantMember" unitRef="USDPerShare" decimals="2" format="ixt:num-dot-decimal" id="Tag233">17.59</ix:nonFraction></span></p></div></td><td style="width:1.02%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10.2%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_b26821ca78ac44ef92c209c2bc9c966d'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" contextRef="D20241231_WarrantMember" format="ixt-sec:duryear" id="Tag234">3.26</ix:nonNumeric></span></p></div></td></tr><tr style="height:12.75pt"><td style="width:65.32%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_56484066bcc74bf8b3793fd9b87e4059'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Granted</span></p></div></td><td style="width:1.02%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10.2%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_1e370c5c9b7142789405b4714e344dcf'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="D20250331_WarrantMember" unitRef="Shares" decimals="0" format="ixt:num-dot-decimal" id="Tag106">747,200</ix:nonFraction></span></p></div></td><td style="width:1.02%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1.02%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10.2%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_49bb5b90dc4242be96236f035345724d'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="D20250331_WarrantMember" unitRef="USDPerShare" decimals="2" format="ixt:num-dot-decimal" id="Tag108">3.56</ix:nonFraction></span></p></div></td><td style="width:1.02%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10.2%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_a636cf72eae548238b35fe47161c70e0'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonNumeric name="sxtp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsGranted" contextRef="D20250331_WarrantMember" format="ixt-sec:duryear" id="Tag112">2.00</ix:nonNumeric></span></p></div></td></tr><tr style="height:12.75pt"><td style="width:65.32%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_092740af605f4bc4a7ada8bdf5055958'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Exercised</span></p></div></td><td style="width:1.02%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10.2%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_be464264c8194207a861f4cab206040c'; font-family: 'Times New Roman'"><span><ix:nonFraction name="sxtp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfWarrantsExercised" contextRef="D20250331_WarrantMember" unitRef="Shares" decimals="0" format="ixt:num-dot-decimal" sign="-" id="Tag40">385,200</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">)</span></p></td><td style="width:1.02%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1.02%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10.2%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_9014c8bd62e048859509a2426149ef61'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="sxtp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExercised" contextRef="D20250331_WarrantMember" unitRef="USDPerShare" decimals="2" format="ixt:num-dot-decimal" id="Tag109">0.01</ix:nonFraction></span></p></div></td><td style="width:1.02%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10.2%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_99814e762c194b82bf77fe18e9120666'"><ix:nonNumeric name="sxtp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsExercised" contextRef="D20250331_WarrantMember" escape="false" id="Tag111"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:spaces; font-family: 'Times New Roman'">&#160;</span><span style="font-family: 'Times New Roman';">Indefinite </span></p></ix:nonNumeric></div></td></tr><tr style="height:12.75pt"><td style="width:65.32%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_96b027d191d3489eb4634d84c32b33bb'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Forfeited</span></p></div></td><td style="width:1.02%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10.2%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-tag:'C_ebc58888ed7e443eb0bed3fbb4e296cd'"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" contextRef="D20250331_WarrantMember" xsi:nil="true" unitRef="Shares" id="Tag116"></ix:nonFraction><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:1.02%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1.02%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10.2%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-tag:'C_1cbf9c8fae99456bb1db09f419f10e3b'"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" contextRef="D20250331_WarrantMember" xsi:nil="true" unitRef="USDPerShare" id="Tag117"></ix:nonFraction><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:1.02%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10.2%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-tag:'C_023e956011684a2e8efc0a2c95e7aafa'"><ix:nonNumeric name="sxtp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsForfeited" contextRef="D20250331_WarrantMember" xsi:nil="true" escape="false" id="Tag118"></ix:nonNumeric><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td></tr><tr style="height:12.75pt"><td style="width:65.32%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_3a9cd327c03648eabee6def9efeb8a16'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Expired</span></p></div></td><td style="width:1.02%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10.2%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-tag:'C_1b9506549baa4d28b730114acf607f9d'"><ix:nonFraction name="sxtp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfWarrantsExpired" contextRef="D20250331_WarrantMember" xsi:nil="true" unitRef="Shares" id="Tag119"></ix:nonFraction><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:1.02%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1.02%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10.2%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-tag:'C_ceb7f15a6ff64d289ae12ddbd0b82690'"><ix:nonFraction name="sxtp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExpired" contextRef="D20250331_WarrantMember" xsi:nil="true" unitRef="USDPerShare" id="Tag120"></ix:nonFraction><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:1.02%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10.2%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-tag:'C_28fd827460b74eed914d939d69a18b99'"><ix:nonNumeric name="sxtp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsExpired" contextRef="D20250331" xsi:nil="true" escape="false" id="Tag236"></ix:nonNumeric><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td></tr><tr style="height:8.4pt"><td style="width:65.32%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_940a2249f6b3409bbd4cf1fd3bfef304'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Total outstanding, March 31, 2025</span></p></div></td><td style="width:1.02%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10.2%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_dc623020fea849eba11ebc4bfb2db46b'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="I20250331_WarrantMember" unitRef="Shares" decimals="0" format="ixt:num-dot-decimal" id="Tag107">2,127,070</ix:nonFraction></span></p></div></td><td style="width:1.02%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1.02%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_4a782ea234b64abda040b2705b8054db'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10.2%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_6c6bbe87d4d04a50ba3802b29e13ca71'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="I20250331_WarrantMember" unitRef="USDPerShare" decimals="2" format="ixt:num-dot-decimal" id="Tag110">15.85</ix:nonFraction></span></p></div></td><td style="width:1.02%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10.2%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_13fb13eaf08b49a2b57074280816ad0b'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonNumeric name="sxtp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms1" contextRef="D20250331_WarrantMember" format="ixt-sec:duryear" id="Tag113">2.60</ix:nonNumeric></span></p></div></td></tr><tr style="height:12.75pt"><td style="width:65.32%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_ea5e3e245b884185986e713469cfdfa7'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Granted</span></p></div></td><td style="width:1.02%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10.2%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-tag:'C_57e1c8a9723f46f5b83a7dc55783fee9'"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="D20250630_WarrantMember" xsi:nil="true" unitRef="Shares" id="Tag145"></ix:nonFraction><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:1.02%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1.02%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10.2%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-tag:'C_243d18f890714f9fa13c4b72d28af692'"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="D20250630_WarrantMember" xsi:nil="true" unitRef="USDPerShare" id="Tag155"></ix:nonFraction><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:1.02%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10.2%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-tag:'C_f31c5abd07e34d559789feb6be7b30a9'"><ix:nonNumeric name="sxtp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsGranted" contextRef="D20250630_WarrantMember" xsi:nil="true" escape="false" id="Tag156"></ix:nonNumeric><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td></tr><tr style="height:12.75pt"><td style="width:65.32%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_5f1d9b909eb24eac860bae5956db20ff'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Exercised</span></p></div></td><td style="width:1.02%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10.2%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-tag:'C_c4963ba6c9714c2b848973d90745bbe7'"><ix:nonFraction name="sxtp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfWarrantsExercised" contextRef="D20250630_WarrantMember" xsi:nil="true" unitRef="Shares" id="Tag146"></ix:nonFraction><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:1.02%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1.02%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10.2%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-tag:'C_00ce71b2c5d1489abe5ef8882e6eb43b'"><ix:nonFraction name="sxtp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExercised" contextRef="D20250630_WarrantMember" xsi:nil="true" unitRef="USDPerShare" id="Tag154"></ix:nonFraction><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:1.02%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10.2%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-tag:'C_87370543a6f5422cb31f728fb2213f65'"><ix:nonNumeric name="sxtp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsExercised" contextRef="D20250630_WarrantMember" xsi:nil="true" escape="false" id="Tag157"></ix:nonNumeric><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td></tr><tr style="height:12.75pt"><td style="width:65.32%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_de6f15e3ec76429fb39fe3cc06dcd0b4'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Forfeited</span></p></div></td><td style="width:1.02%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10.2%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-tag:'C_1226676f1bf44f8197d4965d8019abfa'"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" contextRef="D20250630_WarrantMember" xsi:nil="true" unitRef="Shares" id="Tag147"></ix:nonFraction><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:1.02%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1.02%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10.2%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-tag:'C_38dc8b6b23e14f2fb10ac0aab43b0957'"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" contextRef="D20250630_WarrantMember" xsi:nil="true" unitRef="USDPerShare" id="Tag153"></ix:nonFraction><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:1.02%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10.2%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-tag:'C_71849749deae49b1affc3ffaa76a7bf6'"><ix:nonNumeric name="sxtp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsForfeited" contextRef="D20250630_WarrantMember" xsi:nil="true" escape="false" id="Tag158"></ix:nonNumeric><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td></tr><tr style="height:12.75pt"><td style="width:65.32%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_8cdb6926b5124838a53f846006ffe4d5'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Expired</span></p></div></td><td style="width:1.02%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10.2%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-tag:'C_85eba8ce16524c9c992ae58a76b43a52'"><ix:nonFraction name="sxtp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfWarrantsExpired" contextRef="D20250630_WarrantMember" xsi:nil="true" unitRef="Shares" id="Tag148"></ix:nonFraction><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:1.02%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1.02%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10.2%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-tag:'C_3fa373d813a84ebaac3667eead34d3c5'"><ix:nonFraction name="sxtp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExpired" contextRef="D20250630_WarrantMember" xsi:nil="true" unitRef="USDPerShare" id="Tag152"></ix:nonFraction><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:1.02%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10.2%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-tag:'C_b9f06ff4ca7a45779ddab62a866d8364'"><ix:nonNumeric name="sxtp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsExpired" contextRef="D20250630_WarrantMember" xsi:nil="true" escape="false" id="Tag198"></ix:nonNumeric><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td></tr><tr style="height:13.5pt"><td style="width:65.32%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_c764316e0a5941d382adb9acefbbf02d'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Total outstanding, June 30, 2025</span></p></div></td><td style="width:1.02%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10.2%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_bd4af9854bee45f4a6e8551c9ffeab14'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="I20250630_WarrantMember" unitRef="Shares" decimals="0" format="ixt:num-dot-decimal" id="Tag149">2,127,070</ix:nonFraction></span></p></div></td><td style="width:1.02%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1.02%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_06b30492d24443dea9f922ac7c5991eb'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10.2%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_dd5b51e6504c4fe485896034c4ab5aaf'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="I20250630_WarrantMember" unitRef="USDPerShare" decimals="2" format="ixt:num-dot-decimal" id="Tag150">15.85</ix:nonFraction></span></p></div></td><td style="width:1.02%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10.2%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_8c4c3f1235014bbd826251d11d481ada'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonNumeric name="sxtp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms1" contextRef="D20250630_WarrantMember" format="ixt-sec:duryear" id="Tag151">2.10</ix:nonNumeric></span></p></div></td></tr><tr style="height:1.3pt"><td style="width:65.32%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_c64851bf815b4da8863747dd5755f707'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Granted</span><span style="font-size:6.67pt; vertical-align:super; font-family: 'Times New Roman'">(2)</span></p></div></td><td style="width:1.02%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10.2%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_807950b3ae924a2f975de95c2d052326'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="D20250930_WarrantMember" unitRef="Shares" decimals="0" format="ixt:num-dot-decimal" id="Tag226">6,338,788</ix:nonFraction></span></p></div></td><td style="width:1.02%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1.02%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10.2%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_4fd32df330bb4ce6a8e82401cf8bfee9'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="D20250930_WarrantMember" unitRef="USDPerShare" decimals="2" format="ixt:num-dot-decimal" id="Tag227">1.65</ix:nonFraction></span></p></div></td><td style="width:1.02%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10.2%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_ed4130eba4504c2992f76b5ad495c647'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonNumeric name="sxtp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsGranted" contextRef="D20250930_WarrantMember" format="ixt-sec:duryear" id="Tag228">3.31</ix:nonNumeric></span></p></div></td></tr><tr style="height:13.5pt"><td style="width:65.32%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_d9b5d3e46cf0480dbe71aa1b85fd2730'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Exercised</span></p></div></td><td style="width:1.02%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10.2%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_453fa426afc145e39bde490d351be1d5'; font-family: 'Times New Roman'"><span><ix:nonFraction name="sxtp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfWarrantsExercised" contextRef="D20250930_WarrantMember" unitRef="Shares" decimals="0" format="ixt:num-dot-decimal" id="Tag25">878,264</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">)</span></p></td><td style="width:1.02%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1.02%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10.2%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_b3cd337ad3c643b98646dee9eafdf4db'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="sxtp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExercised" contextRef="D20250930_WarrantMember" unitRef="USDPerShare" decimals="3" format="ixt:num-dot-decimal" id="Tag142">0.001</ix:nonFraction></span></p></div></td><td style="width:1.02%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10.2%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_ebf6d0f4a79044b1a96cec392910afa3'"><ix:nonNumeric name="sxtp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsExercised" contextRef="D20250930_WarrantMember" escape="false" id="Tag144"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:spaces; font-family: 'Times New Roman'">&#160;</span><span style="font-family: 'Times New Roman';">Indefinite </span></p></ix:nonNumeric></div></td></tr><tr style="height:13.5pt"><td style="width:65.32%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_9941868f9f2b4eeb9ad1e9a0ec7731e5'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Forfeited</span></p></div></td><td style="width:1.02%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10.2%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-tag:'C_f6c86e35bf8044009a4b4a9ffa2be0b9'"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" contextRef="D20250930_WarrantMember" xsi:nil="true" unitRef="Shares" id="Tag192"></ix:nonFraction><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:1.02%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1.02%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10.2%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-tag:'C_5120de4eb07c46d1a887d6f33993bd48'"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" contextRef="D20250930_WarrantMember" xsi:nil="true" unitRef="USDPerShare" id="Tag193"></ix:nonFraction><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:1.02%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10.2%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-tag:'C_d16cd40451854e3c9422892d316527ed'"><ix:nonNumeric name="sxtp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsForfeited" contextRef="D20250930_WarrantMember" xsi:nil="true" escape="false" id="Tag194"></ix:nonNumeric><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td></tr><tr style="height:13.5pt"><td style="width:65.32%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_d493e9ce3b6e44bcb5f236c8e5cf90bc'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Expired</span></p></div></td><td style="width:1.02%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10.2%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-tag:'C_5eee2f2968084f68bd96a105a2a456ba'"><ix:nonFraction name="sxtp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfWarrantsExpired" contextRef="D20250930_WarrantMember" xsi:nil="true" unitRef="Shares" id="Tag195"></ix:nonFraction><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:1.02%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1.02%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10.2%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-tag:'C_351547f4bdc341548bd95be3a56c990b'"><ix:nonFraction name="sxtp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExpired" contextRef="D20250930_WarrantMember" xsi:nil="true" unitRef="USDPerShare" id="Tag196"></ix:nonFraction><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:1.02%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10.2%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-tag:'C_e5c3e7a2d1ea48788874fe6f1aaa160e'"><ix:nonNumeric name="sxtp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsExpired" contextRef="D20250930_WarrantMember" xsi:nil="true" escape="false" id="Tag197"></ix:nonNumeric><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td></tr><tr style="height:13.5pt"><td style="width:65.32%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_a711a12f9677437590c66b5950b17bd5'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Total outstanding, September 30, 2025</span></p></div></td><td style="width:1.02%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10.2%; border-top:0.75pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#ffffff; -aw-border-top:0.5pt single"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_8ea7f7a4e1d24d429c6f06db22b55e6d'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="I20250930_WarrantMember" unitRef="Shares" decimals="0" format="ixt:num-dot-decimal" id="Tag141">7,587,594</ix:nonFraction></span></p></div></td><td style="width:1.02%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1.02%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_2d3b290467d343018ea51921f595758a'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10.2%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_7047b295f89941d1bdfff27a2c97d2f6'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="I20250930_WarrantMember" unitRef="USDPerShare" decimals="2" format="ixt:num-dot-decimal" id="Tag143">5.82</ix:nonFraction></span></p></div></td><td style="width:1.02%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10.2%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_01e4caaff41844e1ae7feb1c2ae66d69'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonNumeric name="sxtp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms1" contextRef="D20250930_WarrantMember" format="ixt-sec:duryear" id="Tag245">2.82</ix:nonNumeric></span></p></div></td></tr><tr style="height:13.5pt"><td style="width:65.32%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_d51b62342edd4404956c0bf1cb0b2079'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Total exercisable, September 30, 2025</span></p></div></td><td style="width:1.02%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10.2%; border-top:4.5pt double #000000; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_7b1ea82a944942ceb4546250d540a297'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="sxtp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable" contextRef="I20250930_WarrantMember" unitRef="Shares" decimals="0" format="ixt:num-dot-decimal" id="Tag219">7,587,594</ix:nonFraction></span></p></div></td><td style="width:1.02%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1.02%; border-top:4.5pt double #000000; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_f78db16daa4a48f09d41316116f43005'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10.2%; border-top:4.5pt double #000000; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_f6c5be1b8d51432b8279c89401af163b'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="sxtp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageGrantDateFairValue" contextRef="I20250930_WarrantMember" unitRef="USDPerShare" decimals="2" format="ixt:num-dot-decimal" id="Tag218">5.82</ix:nonFraction></span></p></div></td><td style="width:1.02%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10.2%; border-top:4.5pt double #000000; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_28a537d0722b41f7ba4474c4041f1592'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonNumeric name="sxtp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableOutstandingWeightedAverageRemainingContractualTerms" contextRef="D20250930_WarrantMember" format="ixt-sec:duryear" id="Tag246">2.82</ix:nonNumeric></span></p></div></td></tr></tbody></table></div><p style="margin-top:0pt; margin-bottom:0pt"><span style="-aw-import:ignore; font-family: 'Times New Roman';  font-size: 12pt;">&#160;</span></p><table cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="width:3.3%; vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; font-size:12.5pt"><span style="font-size:8.33pt; vertical-align:super; font-family: 'Times New Roman'">(1)</span></p></td><td style="width:96.7%; vertical-align:top"><ix:footnote xml:lang="en-US" footnoteRole="http://www.xbrl.org/2003/role/footnote" id="footnote2"><div style="-aw-sdt-tag:'cc60b45585da36d079a6'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">Weighted average remaining contractual life at </span><span style="-aw-sdt-tag:'cb7acd8bf727a3348920'; -aw-sdt-title:'Previous_Year_End_P16'; font-family: 'Times New Roman'"><span>December 31, 2024</span></span><span style="font-family: 'Times New Roman';"> excludes </span><span style="-aw-sdt-tag:'c9eaac2b3a02e0ecbfed'; font-family: 'Times New Roman'"><span><ix:nonFraction name="sxtp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable" contextRef="I20240930_PreFundedWarrantMember" unitRef="Shares" decimals="0" format="ixt:num-dot-decimal" id="Tag41">385,200</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';"> Pre-Funded Warrants issued September </span><span style="-aw-sdt-tag:'c084844e24a211ebd242'; font-family: 'Times New Roman'"><span>2024</span></span><span style="font-family: 'Times New Roman';"> that do not have a contractual expiration date, for which </span><span style="-aw-sdt-tag:'c6c65c3f0bb7343724f4'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="I20250630_PreFundedWarrantMember" unitRef="Shares" decimals="0" format="ixt:num-dot-decimal" id="Tag1034"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="I20250930_PreFundedWarrantMember" unitRef="Shares" decimals="0" format="ixt:num-dot-decimal" id="Tag1035"><ix:nonFraction name="sxtp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable" contextRef="I20250331_PreFundedWarrantMember" unitRef="Shares" decimals="0" format="ixt:num-dot-decimal" id="Tag1030"><ix:nonFraction name="sxtp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable" contextRef="I20250630_PreFundedWarrantMember" unitRef="Shares" decimals="0" format="ixt:num-dot-decimal" id="Tag1031"><ix:nonFraction name="sxtp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable" contextRef="I20250930_PreFundedWarrantMember" unitRef="Shares" decimals="0" format="ixt:num-dot-decimal" id="Tag1032"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="I20250331_PreFundedWarrantMember" unitRef="Shares" decimals="0" format="ixt:num-dot-decimal" id="Tag46">0</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span></span><span style="font-family: 'Times New Roman';"> warrants remain outstanding and exercisable at March 31, 2025, June 30, 2025 and </span><span style="-aw-sdt-tag:'c3f8bf32fba6f0a28902'; -aw-sdt-title:'Current_Period_P16'; font-family: 'Times New Roman'"><span>September 30, 2025</span></span><span style="font-family: 'Times New Roman';">.</span></p></div></ix:footnote></td></tr></tbody></table><table cellspacing="0" cellpadding="0" style="width:100%; border-collapse:collapse"><tbody><tr><td style="width:3.3%; vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:12.5pt"><span style="font-size:8.33pt; vertical-align:super; font-family: 'Times New Roman'">(2)</span></p></td><td style="width:96.7%; vertical-align:top"><ix:footnote xml:lang="en-US" footnoteRole="http://www.xbrl.org/2003/role/footnote" id="footnote3"><div style="-aw-sdt-tag:'4e2-557-131-530-ea28'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">Weighted average remaining contractual life excludes </span><span style="-aw-sdt-tag:'155-a3e-4e3-421-5e47'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="D20250731_PreFundedWarrantMember" unitRef="Shares" decimals="0" format="ixt:num-dot-decimal" id="Tag42">878,264</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';"> Pre-Funded Warrants issued July 2025 that do not have a contractual expiration date, for which </span><span style="-aw-sdt-tag:'cfe-9a0-ea6-43f-4379'; font-family: 'Times New Roman'"><span><ix:nonFraction name="sxtp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable" contextRef="I20250930_PreFundedWarrantMember" unitRef="Shares" decimals="0" format="ixt:num-dot-decimal" id="Tag1033"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" contextRef="I20250930_PreFundedWarrantMember" unitRef="Shares" decimals="0" format="ixt:num-dot-decimal" id="Tag47">0</ix:nonFraction></ix:nonFraction></span></span><span style="font-family: 'Times New Roman';"> warrants remain outstanding and exercisable at </span><span style="-aw-sdt-tag:'b56-24f-fd5-c1f-b53f'; -aw-sdt-title:'Current_Period_P43'; font-family: 'Times New Roman'"><span>September 30, 2025</span></span><span style="font-family: 'Times New Roman';">.</span></p></div></ix:footnote></td></tr><tr><td style="width:3.3%; vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:5pt"><span style="font-size:3.33pt; vertical-align:super; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:96.7%; vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:5pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td></tr></tbody></table><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-import:spaces; font-family: 'Times New Roman'">&#160;</span></p><div style="-aw-sdt-tag:'PG_2924caba445ee74c'"><ix:exclude><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-family: 'Times New Roman'; z-index: 100;">17</span></p><div><hr style="width: 100%; color: #000000; background-color: #000000; margin: 1rem 0;"/></div></ix:exclude></div></ix:nonNumeric></div></ix:continuation></div></div><div class="Section_21"><div style="-aw-sdt-tag:'ae6-f22-934-ddc-59fc'"><ix:continuation id="c07490d7c3e9a412b584" continuedAt="cf471ae84d476702bea4"><div style="-aw-sdt-tag:'0b9-32d-758-bbb-7d61'"><ix:continuation id="c07397913793c6902f7d"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">The following table presents a summary of the activity for the Company&#8217;s equity-classified warrants during the </span><span style="-aw-sdt-tag:'cb837e6a667bb2d8e81a'; -aw-sdt-title:'Previous_Quarter_and_YTD_P4'; font-family: 'Times New Roman'"><span>three and nine months ended September 30, 2024</span></span><span style="font-family: 'Times New Roman';">:</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p><div style="-aw-sdt-tag:'5ef-bd1-660-949-dac4'; -aw-sdt-title:'PYTD Warrant Activity Table'"><table cellspacing="0" cellpadding="0" style="width:100%; border-collapse:collapse"><tbody><tr style="height:66pt"><td style="width:66%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_2fe24833a44b41479778dfa15ea39d75'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">Number of Warrants</span></p></div></td><td style="width:1%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="2" style="border-bottom:1.5pt solid #000000; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_f18fecd537364a0f93431550cd6beb89'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">Weighted Average Exercise Price</span></p></div></td><td style="width:1%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_46e2237dbc934f6b9426112c9d46cff7'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">Weighted Average Remaining Contractual Life (Years)</span></p></div></td></tr><tr style="height:13.2pt"><td style="width:66%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_e3159a48c35a441588285bc5f08adbb5'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Total outstanding, December 31, 2023</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_26c6e8ba5c4f437b898bce96847ea990'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="I20231231_WarrantMember" unitRef="Shares" decimals="0" format="ixt:num-dot-decimal" id="Tag122">52,737</ix:nonFraction></span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_7932e86b6155416a856e4b9e3135e6a0'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_1e1cfe2fee02428fb18bed385db26f5b'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="I20231231_WarrantMember" unitRef="USDPerShare" decimals="2" format="ixt:num-dot-decimal" id="Tag124">369.98</ix:nonFraction></span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_0fdf3faee9384a09b6fb1053d73cd117'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" contextRef="D20231231_WarrantMember" format="ixt-sec:duryear" id="Tag136">4.47</ix:nonNumeric></span></p></div></td></tr><tr style="height:13.2pt"><td style="width:66%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_d2f19f5220f34a67a6cf0ad536ecceaf'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Granted</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_ca72a78fc17a4df2b8b050de41cb1fb2'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="D20240331_WarrantMember" unitRef="Shares" decimals="0" format="ixt:num-dot-decimal" id="Tag123">140,884</ix:nonFraction></span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_03da05c614d4494ab5a425272003c87d'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="D20240331_WarrantMember" unitRef="USDPerShare" decimals="2" format="ixt:num-dot-decimal" id="Tag125">22.48</ix:nonFraction></span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_1e23442a8f184d09a6640f316b286c13'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonNumeric name="sxtp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsGranted" contextRef="D20240331_WarrantMember" format="ixt-sec:duryear" id="Tag137">5.00</ix:nonNumeric></span></p></div></td></tr><tr style="height:13.2pt"><td style="width:66%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_5bc3ca100224454db31571d2f7b1902d'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Exercised</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_947713b195ad4820bbb30058fc78b8f8'; font-family: 'Times New Roman'"><span><ix:nonFraction name="sxtp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfWarrantsExercised" contextRef="D20240331_WarrantMember" unitRef="Shares" decimals="0" format="ixt:num-dot-decimal" sign="-" id="Tag24">8,326</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">)</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_6653a7d365a745d882b7652b6ee003cf'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="sxtp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExercised" contextRef="D20240331_WarrantMember" unitRef="USDPerShare" decimals="2" format="ixt:num-dot-decimal" id="Tag126">0.60</ix:nonFraction></span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_d11cc3479bef4b49bb34a26fb81a3dab'"><ix:nonNumeric name="sxtp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsExercised" contextRef="D20240331_WarrantMember" escape="false" id="Tag138"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:spaces; font-family: 'Times New Roman'">&#160;</span><span style="font-family: 'Times New Roman';">Indefinite </span></p></ix:nonNumeric></div></td></tr><tr style="height:13.2pt"><td style="width:66%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_036865088ae34687ad76ec0118f6c13a'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Forfeited</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-tag:'C_0b98733a323540198451b82d59cb06fc'"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" contextRef="D20240331_WarrantMember" xsi:nil="true" unitRef="Shares" id="Tag128"></ix:nonFraction><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-tag:'C_b095fd6b9be94bbc8c5bffe34783b7e9'"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" contextRef="D20240331_WarrantMember" xsi:nil="true" unitRef="USDPerShare" id="Tag130"></ix:nonFraction><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-tag:'C_62e43591234846379c4d980c1b569ce5'"><ix:nonNumeric name="sxtp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsForfeited" contextRef="D20240331_WarrantMember" xsi:nil="true" escape="false" id="Tag132"></ix:nonNumeric><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td></tr><tr style="height:13.2pt"><td style="width:66%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_ed4f3a89e25f4188a6c83db8976197d5'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Expired</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-tag:'C_e3ce5466c2be49d1857c06466db44631'"><ix:nonFraction name="sxtp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfWarrantsExpired" contextRef="D20240331_WarrantMember" xsi:nil="true" unitRef="Shares" id="Tag134"></ix:nonFraction><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-tag:'C_dfdbdd8338f8414d8f83aae99237906a'"><ix:nonFraction name="sxtp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExpired" contextRef="D20240331_WarrantMember" xsi:nil="true" unitRef="USDPerShare" id="Tag129"></ix:nonFraction><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-tag:'C_fe44fba7b4ea4e7aa0021a9bccd19da2'"><ix:nonNumeric name="sxtp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsExpired" contextRef="D20240331_WarrantMember" xsi:nil="true" escape="false" id="Tag133"></ix:nonNumeric><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td></tr><tr style="height:13.8pt"><td style="width:66%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_3d817872bae142abb1bdde9aec1609a3'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Total outstanding, March 31, 2024</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_c163a2b7f7f04b69b4d13a118cc458f9'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="I20240331_WarrantMember" unitRef="Shares" decimals="0" format="ixt:num-dot-decimal" id="Tag131">185,295</ix:nonFraction></span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_2b8349367e4e49bd8341592d5d525a88'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_f13c7faf7831462aab2cb911bc2f0dd6'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="I20240331_WarrantMember" unitRef="USDPerShare" decimals="2" format="ixt:num-dot-decimal" id="Tag127">122.36</ix:nonFraction></span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_0005a1e335884fc7ac7b8d95109bce26'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonNumeric name="sxtp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms1" contextRef="D20240331_WarrantMember" format="ixt-sec:duryear" id="Tag135">4.67</ix:nonNumeric></span></p></div></td></tr><tr style="height:13.8pt"><td style="width:66%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_dcc561ad8f5141e9ad4b5045a2890934'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Granted</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-tag:'C_88de1f197d034065b9cd32ef1dcd9706'"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="D20240630_WarrantMember" xsi:nil="true" unitRef="Shares" id="Tag172"></ix:nonFraction><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-tag:'C_f73d194d7c854624909dcf76b8ba5ce8'"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="D20240630_WarrantMember" xsi:nil="true" unitRef="USDPerShare" id="Tag171"></ix:nonFraction><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-tag:'C_fb1a4c504f914dc289bb53a1b30080ae'"><ix:nonNumeric name="sxtp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsGranted" contextRef="D20240630_WarrantMember" xsi:nil="true" escape="false" id="Tag170"></ix:nonNumeric><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td></tr><tr style="height:13.2pt"><td style="width:66%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_a977d41b2c174189a08b961656853a60'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Exercised</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_79bdaacfa9994fb2b69b6344f572705f'; font-family: 'Times New Roman'"><span><ix:nonFraction name="sxtp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfWarrantsExercised" contextRef="D20240630_WarrantMember" unitRef="Shares" decimals="0" format="ixt:num-dot-decimal" sign="-" id="Tag26">8,326</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">)</span></p></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_31638e6c276c4f2fa99250fcb9843150'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="sxtp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExercised" contextRef="D20240630_WarrantMember" unitRef="USDPerShare" decimals="2" format="ixt:num-dot-decimal" id="Tag159">0.60</ix:nonFraction></span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_f5cdcd321c28407aa89715dc54333513'"><ix:nonNumeric name="sxtp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsExercised" contextRef="D20240630_WarrantMember" escape="false" id="Tag160"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:spaces; font-family: 'Times New Roman'">&#160;</span><span style="font-family: 'Times New Roman';">Indefinite </span></p></ix:nonNumeric></div></td></tr><tr style="height:13.2pt"><td style="width:66%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_fa7dd320f8ff4aac96b933a7fbc11384'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Forfeited</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-tag:'C_110cf5dfc8bd4bc080a6b64cb16f3187'"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" contextRef="D20240630_WarrantMember" xsi:nil="true" unitRef="Shares" id="Tag164"></ix:nonFraction><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-tag:'C_4a2d3439c11443f6b2da01418ec74397'"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" contextRef="D20240630_WarrantMember" xsi:nil="true" unitRef="USDPerShare" id="Tag166"></ix:nonFraction><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-tag:'C_0da9202225b040e19c3d69fa37a95f80'"><ix:nonNumeric name="sxtp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsForfeited" contextRef="D20240630_WarrantMember" xsi:nil="true" escape="false" id="Tag168"></ix:nonNumeric><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td></tr><tr style="height:13.2pt"><td style="width:66%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_59813ff6f1844a788243218269af1e79'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Expired</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-tag:'C_9b5fd3e6aa1b4e4cb21d298ea65de0ea'"><ix:nonFraction name="sxtp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfWarrantsExpired" contextRef="D20240630_WarrantMember" xsi:nil="true" unitRef="Shares" id="Tag165"></ix:nonFraction><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-tag:'C_f2ddee167a494c22b7bd797d8ae1c6c2'"><ix:nonFraction name="sxtp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExpired" contextRef="D20240630_WarrantMember" xsi:nil="true" unitRef="USDPerShare" id="Tag167"></ix:nonFraction><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-tag:'C_7a4c7af18d3f4f77813081f40c1d117a'"><ix:nonNumeric name="sxtp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsExpired" contextRef="D20240630_WarrantMember" xsi:nil="true" escape="false" id="Tag169"></ix:nonNumeric><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td></tr><tr style="height:13.8pt"><td style="width:66%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_a82321d8724e48d9a9d4e5fea605470a'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Total outstanding, June 30, 2024</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_2a6ee883b436439caf9659428ef1344a'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="I20240630_WarrantMember" unitRef="Shares" decimals="0" format="ixt:num-dot-decimal" id="Tag163">176,969</ix:nonFraction></span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_aa95f7f315f940a2a5739ae21aafd495'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_dedfd6de48f64fde8de26755f4cdd4e4'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="I20240630_WarrantMember" unitRef="USDPerShare" decimals="2" format="ixt:num-dot-decimal" id="Tag162">128.09</ix:nonFraction></span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_79c28b5186b7430280974bffea1c6e69'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonNumeric name="sxtp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms1" contextRef="D20240630_WarrantMember" format="ixt-sec:duryear" id="Tag161">4.41</ix:nonNumeric></span></p></div></td></tr><tr style="height:4.05pt"><td style="width:66%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_1e54e27571a64e8887f09b7346aff7c4'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Granted</span><span style="font-size:6.67pt; vertical-align:super; font-family: 'Times New Roman'">(1)</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_adfe2fb2d65545cba64b8094d9c2cc08'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="D20240930_WarrantMember" unitRef="Shares" decimals="0" format="ixt:num-dot-decimal" id="Tag183">1,782,612</ix:nonFraction></span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_b0770c488b2d44c0b74d38914ce1a1f4'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="D20240930_WarrantMember" unitRef="USDPerShare" decimals="2" format="ixt:num-dot-decimal" id="Tag181">4.70</ix:nonFraction></span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-tag:'C_8a1c8815f35841ef9b2cf22465a70cbd'"><ix:nonNumeric name="sxtp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsGranted" contextRef="D20240930_WarrantMember" xsi:nil="true" escape="false" id="Tag180"></ix:nonNumeric><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td></tr><tr style="height:4.05pt"><td style="width:66%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_e4111cde5ebf4e2db2c6ef266cda76df'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Exercised</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-tag:'C_667abf06483d4e4aab4ecd254ca4fb4d'"><ix:nonFraction name="sxtp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfWarrantsExercised" contextRef="D20240930_WarrantMember" xsi:nil="true" unitRef="Shares" id="Tag182"></ix:nonFraction><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-tag:'C_1b9a47ca596e4271804077a0fce457bd'"><ix:nonFraction name="sxtp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExercised" contextRef="D20240930_WarrantMember" xsi:nil="true" unitRef="USDPerShare" id="Tag174"></ix:nonFraction><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-tag:'C_c7fead391f1c4bedaf8cbd7c73bfcbf9'"><ix:nonNumeric name="sxtp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsExercised" contextRef="D20240930_WarrantMember" xsi:nil="true" escape="false" id="Tag177"></ix:nonNumeric><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td></tr><tr style="height:4.05pt"><td style="width:66%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_19cb9448efb54e7e898444eb0f2563a8'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Forfeited</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-tag:'C_60dcc17070434c6ab1cafb9462e1e3d6'"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" contextRef="D20240930_WarrantMember" xsi:nil="true" unitRef="Shares" id="Tag184"></ix:nonFraction><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-tag:'C_ba07f171b24f486fa792b6c7c3444cc7'"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" contextRef="D20240930_WarrantMember" xsi:nil="true" unitRef="USDPerShare" id="Tag175"></ix:nonFraction><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-tag:'C_1e57ce7e25864bb89046552a08c0e3fc'"><ix:nonNumeric name="sxtp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsForfeited" contextRef="D20240930_WarrantMember" xsi:nil="true" escape="false" id="Tag178"></ix:nonNumeric><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td></tr><tr style="height:4.05pt"><td style="width:66%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_350af71c0b4948a6a77dfcd4075ad433'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Expired</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-tag:'C_aedbe4e189824914abc8f3a4b2bda114'"><ix:nonFraction name="sxtp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfWarrantsExpired" contextRef="D20240930_WarrantMember" xsi:nil="true" unitRef="Shares" id="Tag185"></ix:nonFraction><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-tag:'C_9d6d068f7ee644de9a393925a4cbfc15'"><ix:nonFraction name="sxtp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExpired" contextRef="D20240930_WarrantMember" xsi:nil="true" unitRef="USDPerShare" id="Tag176"></ix:nonFraction><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-tag:'C_bfabe0e863a542ac80153555a0367873'"><ix:nonNumeric name="sxtp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsExpired" contextRef="D20240930_WarrantMember" xsi:nil="true" escape="false" id="Tag179"></ix:nonNumeric><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td></tr><tr style="height:4.05pt"><td style="width:66%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_1de26c9af20040a29472d2ca9138d19f'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Total outstanding, September 30, 2024</span><span style="font-size:6.67pt; vertical-align:super; font-family: 'Times New Roman'">(1)</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_f4d9856e21884f16b54c37b835a9f33a'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="I20240930_WarrantMember" unitRef="Shares" decimals="0" format="ixt:num-dot-decimal" id="Tag216">1,959,581</ix:nonFraction></span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_f8d0824dee194343b9daffd0ef500eda'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_2419a538771d4014a0aa04299e82b736'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="I20240930_WarrantMember" unitRef="USDPerShare" decimals="2" format="ixt:num-dot-decimal" id="Tag215">15.84</ix:nonFraction></span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_7ddd3f67b2d74622afae5bc4f4059994'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonNumeric name="sxtp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms1" contextRef="D20240930_WarrantMember" format="ixt-sec:duryear" id="Tag217">4.16</ix:nonNumeric></span></p></div></td></tr><tr style="height:4.05pt"><td style="width:66%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_db4c1fd8ae924d69b46bdc6baf2841b1'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Total exercisable, September 30, 2024</span><span style="font-size:6.67pt; vertical-align:super; font-family: 'Times New Roman'">(2)</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:4.5pt double #000000; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_8f538a18dc5c4b0789915e07028c8a3b'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="sxtp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable" contextRef="I20240930_WarrantMember" unitRef="Shares" decimals="0" format="ixt:num-dot-decimal" id="Tag231">756,680</ix:nonFraction></span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:4.5pt double #000000; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_b445e814ada34f288326ca954e930c27'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; border-top:4.5pt double #000000; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_e1118852385841f19496c5a949e0e0bb'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="sxtp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageGrantDateFairValue" contextRef="I20240930_WarrantMember" unitRef="USDPerShare" decimals="2" format="ixt:num-dot-decimal" id="Tag230">29.96</ix:nonFraction></span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:4.5pt double #000000; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'a4f-f6d-3a4-587-6f95'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonNumeric name="sxtp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableOutstandingWeightedAverageRemainingContractualTerms" contextRef="D20240930_WarrantMember_1" format="ixt-sec:duryear" id="Tag229">4.16</ix:nonNumeric></span></p></div></td></tr></tbody></table></div><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p><table cellspacing="0" cellpadding="0" style="width:100%; border-collapse:collapse"><tbody><tr style="height:11.5pt"><td style="width:3.3%; vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; font-size:12.5pt"><span style="font-size:8.33pt; vertical-align:super; font-family: 'Times New Roman'">(1)</span></p></td><td style="width:96.7%; vertical-align:top"><ix:footnote xml:lang="en-US" footnoteRole="http://www.xbrl.org/2003/role/footnote" id="footnote4"><div style="-aw-sdt-tag:'54e-de6-a74-b52-df70'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">Weighted average remaining contractual life calculations exclude (i) </span><span style="-aw-sdt-tag:'732-da0-de5-bf5-8dbb'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="D20240930_PreFundedWarrantMember" unitRef="Shares" decimals="0" format="ixt:num-dot-decimal" id="Tag33">579,711</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';"> Pre-Funded Warrants issued September 2024 that do not have a contractual expiration date, (ii) </span><span style="-aw-sdt-tag:'f2c-5f7-8bf-af8-594f'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="D20240930_SeptemberTwoThousandTwentyFourAgentWarrantsMember" unitRef="Shares" decimals="0" format="ixt:num-dot-decimal" id="Tag44">43,479</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';"> September 2024 Agent Warrants and </span><span style="-aw-sdt-tag:'e8a-7d2-dd0-c63-800f'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="D20240930_SeriesAWarrantsMember" unitRef="Shares" decimals="0" format="ixt:num-dot-decimal" id="Tag43">579,711</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';"> Series A Warrants issued September 2024 that expire </span><span style="-aw-sdt-tag:'316-f81-d28-80c-a600'; font-family: 'Times New Roman'"><span><ix:nonNumeric name="us-gaap:WarrantsAndRightsOutstandingTerm" contextRef="I20240930_SeriesAPreferredStockMember" format="ixt-sec:durwordsen" id="Tag48">five years</ix:nonNumeric></span></span><span style="font-family: 'Times New Roman';"> from the Stockholder Approval Date, defined above, and (iii) </span><span style="-aw-sdt-tag:'051-85c-a14-d67-3f56'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="D20240930_SeriesBWarrantsMember" unitRef="Shares" decimals="0" format="ixt:num-dot-decimal" id="Tag45">579,711</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';"> Series B Warrants issued September 2024 that expire </span><span style="-aw-sdt-tag:'5a3-db5-072-293-bc68'; font-family: 'Times New Roman'"><span><ix:nonNumeric name="us-gaap:WarrantsAndRightsOutstandingTerm" contextRef="I20240930_SeriesBWarrantsMember" format="ixt-sec:durwordsen" id="Tag28">eighteen months</ix:nonNumeric></span></span><span style="font-family: 'Times New Roman';"> from the Stockholder Approval Date, which had not yet occurred as of September 30, 2024.</span></p></div></ix:footnote></td></tr><tr style="height:11.5pt"><td style="width:3.3%; vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; font-size:12.5pt"><span style="font-size:8.33pt; vertical-align:super; font-family: 'Times New Roman'">(2)</span></p></td><td style="width:96.7%; vertical-align:top"><ix:footnote xml:lang="en-US" footnoteRole="http://www.xbrl.org/2003/role/footnote" id="footnote5"><div style="-aw-sdt-tag:'f6b-c28-fc7-73a-bf3d'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">Weighted average remaining contractual life calculation excludes </span><span style="-aw-sdt-tag:'789-7d3-dde-216-e566'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="D20240930_PreFundedWarrantMember" unitRef="Shares" decimals="0" format="ixt:num-dot-decimal" id="Tag34">579,711</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';"> exercisable Pre-Funded Warrants issued September 2024 that do not have a contractual expiration date.</span></p></div></ix:footnote></td></tr></tbody></table></ix:continuation></div><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p><div style="-aw-sdt-tag:'PG_c093876e3a43e140a243'"><ix:exclude><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-family: 'Times New Roman'; z-index: 100;">18</span></p><div><hr style="width: 100%; color: #000000; background-color: #000000; margin: 1rem 0;"/></div></ix:exclude></div></ix:continuation></div></div><div class="Section_22"><div style="-aw-sdt-tag:'ae6-f22-934-ddc-59fc'"><ix:continuation id="cf471ae84d476702bea4"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; text-decoration:underline; font-family: 'Times New Roman'">Series A Preferred Stock</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">During the </span><span style="-aw-sdt-tag:'5c9-2a4-edd-9b2-9f2b'; -aw-sdt-title:'Current_Quarter_and_YTD_P14'; font-family: 'Times New Roman'"><span>three and nine months ended September 30, 2025</span></span><span style="font-family: 'Times New Roman';"> and </span><span style="-aw-sdt-tag:'30c-b61-ed7-5bc-836f'; -aw-sdt-title:'Previous_Year_P53'; font-family: 'Times New Roman'"><span>2024</span></span><span style="font-family: 'Times New Roman';">, the Company converted </span><span style="-aw-sdt-tag:'26e-8f7-c03-a34-5fdd'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:PreferredStockConvertibleSharesIssuable" contextRef="I20250930_SeriesAPreferredStockMember" unitRef="Shares" decimals="0" format="ixt:num-dot-decimal" id="Tag841">0</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';"> and </span><span style="-aw-sdt-tag:'c8c-9b4-436-87f-0fad'; -aw-sdt-title:'PY_Preferred Shares Converted'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:PreferredStockConvertibleSharesIssuable" contextRef="I20240930_SeriesAPreferredStockMember" unitRef="Shares" decimals="0" format="ixt:num-dot-decimal" id="Tag842">2,323</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';"> shares of Series A Preferred Stock, respectively, held by Knight Therapeutics Inc. into </span><span style="-aw-sdt-tag:'46f-111-ec1-a22-3bfa'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="I20250930_ConvertibleCommonStockMember" unitRef="Shares" decimals="0" format="ixt:num-dot-decimal" id="Tag843">0</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';"> shares and </span><span style="-aw-sdt-tag:'5d3-ac8-a1a-288-a527'; -aw-sdt-title:'PY_CS Issued for Preferred'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="I20240930_ConvertibleCommonStockMember" unitRef="Shares" decimals="0" format="ixt:num-dot-decimal" id="Tag844">14,667</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';"> shares of common stock, respectively.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">The holders of shares of Series A Preferred Stock have the rights, preferences, powers, restrictions, and limitations as set forth below.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-style:italic; font-family: 'Times New Roman'">Voting Rights</span><span style="font-family: 'Times New Roman';"> - The holders of shares of Series A Preferred Stock are not entitled to any voting rights.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-style:italic; font-family: 'Times New Roman'">Dividends</span><span style="font-family: 'Times New Roman';"> - From and after the date of issuance of any share of Series A Preferred Stock, cumulative dividends shall accrue, whether or not declared by the Board and whether or not there are funds legally available for the payment of dividends, on a daily basis in arrears at the rate of </span><span style="-aw-sdt-tag:'c892c80e3878c0cecf8e'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:PreferredStockDividendRatePercentage" contextRef="D20241231" unitRef="Pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="Tag797">6.0</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">% per annum on the sum of the Liquidation Value (as defined below). Accrued dividends shall be paid in cash only when, as and if declared by the Board out of funds legally available therefor or upon a liquidation or redemption of the Series A Preferred Stock. On March 31 of each calendar year, any accrued and unpaid dividends shall accumulate and compound on such date, and are cumulative until paid or converted. Holders of shares of Series A Preferred Stock are entitled to receive accrued and accumulated dividends prior to and in preference to any dividend, distribution, or redemption on shares of Common Stock or any other class of securities that is designated as junior to the Series A Preferred Stock. During the </span><span style="-aw-sdt-tag:'cc911d4ba3e887d4a594'; -aw-sdt-title:'Current_Quarter_and_YTD_P12'; font-family: 'Times New Roman'"><span>three and nine months ended September 30, 2025</span></span><span style="font-family: 'Times New Roman';">, dividends in the amount of $</span><span style="-aw-sdt-tag:'c5d01b9ca1ecc7a2ced3'; -aw-sdt-title:'CQTD_Preferred Dividends Accrued'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:DividendsPreferredStock" contextRef="D20250930_SeriesAPreferredStockMember_1" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag802">128,097</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';"> and $</span><span style="-aw-sdt-tag:'c4dc3d0e64763e414812'; -aw-sdt-title:'CYTD_Preferred Dividends Accrued'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:DividendsPreferredStock" contextRef="D20250930_SeriesAPreferredStockMember" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag803">372,960</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';"> accrued on outstanding shares of Series A Preferred Stock ($</span><span style="-aw-sdt-tag:'cea75396bb906943a436'; -aw-sdt-title:'PQTD_Preferred Dividends Accrued'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:DividendsPreferredStock" contextRef="D20240930_SeriesAPreferredStockMember_1" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag804">116,571</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';"> and $</span><span style="-aw-sdt-tag:'ca40e5f7b0254ff2f7e6'; -aw-sdt-title:'PYTD_Preferred Dividends Accrued'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:DividendsPreferredStock" contextRef="D20240930_SeriesAPreferredStockMember" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag805">352,333</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';"> during the </span><span style="-aw-sdt-tag:'c3c0fdc97672faa58e7e'; -aw-sdt-title:'Previous_Quarter_and_YTD_P5'; font-family: 'Times New Roman'"><span>three and nine months ended September 30, 2024</span></span><span style="font-family: 'Times New Roman';">). As of </span><span style="-aw-sdt-tag:'c2299401c4c85264b52f'; -aw-sdt-title:'Current_Period_P18'; font-family: 'Times New Roman'"><span>September 30, 2025</span></span><span style="font-family: 'Times New Roman';">, cumulative dividends on outstanding shares of Series A Preferred Stock amount to $</span><span style="-aw-sdt-tag:'c813e72b0da56ce25468'; -aw-sdt-title:'Cumulative Preferred Dividends'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:DividendsPreferredStock" contextRef="D20250930_1" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag798">1,076,975</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">. To date, the Company has not declared or paid any dividends.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-style:italic; font-family: 'Times New Roman'">Liquidation Rights - </span><span style="font-family: 'Times New Roman';">In the event of any voluntary or involuntary liquidation, dissolution or winding up of the Company, the holders of shares of Series A Preferred Stock then outstanding will share ratably in any distribution of the remaining assets and funds of the Company with all other stockholders as if each share of Series A Preferred Stock had been converted by the Company to Common Stock as described below.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-style:italic; font-family: 'Times New Roman'">Conversion Rights </span><span style="font-family: 'Times New Roman';">- The Company has the right, in its sole discretion, to convert all or any portion of the outstanding shares of Series A Preferred Stock (including any fraction of a share), plus the aggregate accrued or accumulated and unpaid dividends thereon into a number of shares of Common Stock determined by (i) multiplying the number of shares to be converted by $</span><span style="-aw-sdt-tag:'c6021622cfc46b68553d'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:CommonStockConvertibleConversionPriceIncrease" contextRef="D20250930_SeriesAPreferredStockMember" unitRef="USDPerShare" decimals="0" format="ixt:num-dot-decimal" id="Tag799">100</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';"> per share, as adjusted for any stock splits, stock dividends, recapitalizations or similar transactions with respect to the Series A Preferred Stock (but unchanged as a result of the Reverse Stock Splits impacting the common stock on August </span><span style="-aw-sdt-tag:'cf52d7caefe8194001c1'; font-family: 'Times New Roman'"><span>12</span></span><span style="font-family: 'Times New Roman';">, </span><span style="-aw-sdt-tag:'c75ba405cdf0dec60ee5'; font-family: 'Times New Roman'"><span>2024</span></span><span style="font-family: 'Times New Roman';"> and February </span><span style="-aw-sdt-tag:'cc9a608cfc1faa48bbb2'; font-family: 'Times New Roman'"><span>24</span></span><span style="font-family: 'Times New Roman';">, </span><span style="-aw-sdt-tag:'cad67accf5f2bbc138d0'; font-family: 'Times New Roman'"><span>2025</span></span><span style="font-family: 'Times New Roman';">) (the &#8220;Liquidation Value&#8221;), (ii) plus all accrued and accumulated and unpaid dividends on such shares to be converted, and then (ii) dividing the result by the then-effective Conversion Price in effect, provided that such conversion would not result in the holders of shares of Series A Preferred Stock owning more than </span><span style="-aw-sdt-tag:'c6205514cffce1e92bc3'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:PreferredStockDividendRatePercentage" contextRef="D20250930_SeriesAPreferredStockMember" unitRef="Pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="Tag800">19.9</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">% of the outstanding shares of common stock on an as-converted basis. The &#8220;Conversion Price&#8221; is equal to the lesser of (a) the Liquidation Value, (b) the offering price per share of Common Stock in the Company&#8217;s IPO, </span><span style="-aw-sdt-tag:'fc2-007-c74-683-0eb3'; font-family: 'Times New Roman'"><ix:nonNumeric name="us-gaap:StockholdersEquityReverseStockSplit" contextRef="D20250930_SeriesAPreferredStockMember" escape="false" id="Tag819"><span>as adjusted for the 1:12 Reverse Stock Split after August 12, 2024 and the 1:5 Reverse Stock Split after February 24, 2025</span></ix:nonNumeric></span><span style="font-family: 'Times New Roman';">, or $</span><span style="-aw-sdt-tag:'c941adacc45bab52df52'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="I20250930_IPOMember" unitRef="USDPerShare" decimals="0" format="ixt:num-dot-decimal" id="Tag801">300</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';"> per share, or (c) the </span><span style="-aw-sdt-tag:'c0d54e0a97864e25394d'; font-family: 'Times New Roman'"><span>10</span></span><span style="font-family: 'Times New Roman';">-day volume weighted average price per share of Common Stock, as reasonably determined by the Company.</span></p></ix:continuation></div><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore">&#160;</span></p><div style="-aw-sdt-tag:'cff412ba9bf5310b0f59'"><ix:nonNumeric name="us-gaap:DebtDisclosureTextBlock" contextRef="D20250930_1" escape="true" id="Tag967" continuedAt="cf9ff54c552fbe4e64f3"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">7. DEBT</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">On May 14, 2020, the Company received COVID-19 EIDL lending from the U.S. Small Business Administration (SBA) in the amount of $</span><span style="-aw-sdt-tag:'c48cb4c9162d422015d4'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="I20200514_SmallBusinessAdministrationMember" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag770">150,000</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">. The loan bears interest at an annual rate of </span><span style="-aw-sdt-tag:'c6f785f17e52ccfa7dc3'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" contextRef="I20200514_SmallBusinessAdministrationMember" unitRef="Pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="Tag771">3.75</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">% calculated on a monthly basis. Monthly payments of $</span><span style="-aw-sdt-tag:'ce8d5e1c3a4b0eab7645'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" contextRef="I20200514_BalloonPaymentMember" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag772">731</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';"> were required beginning in November 2022, with a final balloon payment equal to the remaining principal due at the maturity date of </span><span style="-aw-sdt-tag:'cc3ad40f0dbc4577a481'; font-family: 'Times New Roman'"><span><ix:nonNumeric name="us-gaap:DebtInstrumentMaturityDate" contextRef="D20200514_SBAMember" format="ixt:date-monthname-day-year-en" id="Tag773">October 12, 2050</ix:nonNumeric></span></span><span style="font-family: 'Times New Roman';">. The balance as of </span><span style="-aw-sdt-tag:'cd38c0f163fbd87499cc'; -aw-sdt-title:'Current_Period_P8'; font-family: 'Times New Roman'"><span>September 30, 2025</span></span><span style="font-family: 'Times New Roman';"> and </span><span style="-aw-sdt-tag:'c5acf3df8535129173ae'; -aw-sdt-title:'Previous_Year_End_P10'; font-family: 'Times New Roman'"><span>December 31, 2024</span></span><span style="font-family: 'Times New Roman';"> was $</span><span style="-aw-sdt-tag:'c87f7d68622df072b284'; -aw-sdt-title:'Total Maturity_CP'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" contextRef="D20250930_1" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag774">153,764</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';"> and $</span><span style="-aw-sdt-tag:'cc7ee715ff42ce67d2e4'; -aw-sdt-title:'Total Maturity_PY'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" contextRef="D20241231" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag775">155,891</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">, respectively. The current maturity at </span><span style="-aw-sdt-tag:'c5a0ccdcf213162f587b'; -aw-sdt-title:'Current_Period_P9'; font-family: 'Times New Roman'"><span>September 30, 2025</span></span><span style="font-family: 'Times New Roman';"> is $</span><span style="-aw-sdt-tag:'ce635aff7ad263800b94'; -aw-sdt-title:'Current maturity of SBA loan_CP'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:LongTermDebtCurrent" contextRef="I20250930" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag776">8,772</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';"> and the long-term liability is $</span><span style="-aw-sdt-tag:'cfdb6cde5a192d0a563f'; -aw-sdt-title:'Long-term maturity of SBA loan_CP'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:LiabilitiesNoncurrent" contextRef="I20250930" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag777">144,992</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';"> ($</span><span style="-aw-sdt-tag:'ce15e0c8eedcfdb512e2'; -aw-sdt-title:'Current maturity of SBA loan_PY'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:LongTermDebtCurrent" contextRef="I20241231" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag778">8,772</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';"> and $</span><span style="-aw-sdt-tag:'c6ea72e7c7e452607500'; -aw-sdt-title:'Long-term maturity of SBA loan_PY'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:LiabilitiesNoncurrent" contextRef="I20241231" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag779">147,119</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';"> at </span><span style="-aw-sdt-tag:'ce2f78b521ed062187e6'; -aw-sdt-title:'Previous_Year_End_P11'; font-family: 'Times New Roman'"><span>December 31, 2024</span></span><span style="font-family: 'Times New Roman';">, respectively). The loan is collateralized by all tangible and intangible personal property of the Company. The Company is prohibited from accepting future advances under any superior liens on the collateral without the prior consent of SBA.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p><div style="-aw-sdt-tag:'PG_c57a1a7c3051a319b430'"><ix:exclude><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-family: 'Times New Roman'; z-index: 100;">19</span></p><div><hr style="width: 100%; color: #000000; background-color: #000000; margin: 1rem 0;"/></div></ix:exclude></div></ix:nonNumeric></div></div><div class="Section_23"><div style="-aw-sdt-tag:'cff412ba9bf5310b0f59'"><ix:continuation id="cf9ff54c552fbe4e64f3"><div style="-aw-sdt-tag:'cd9aa1ed7e4867c19560'"><ix:nonNumeric name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" contextRef="D20250930_1" escape="true" id="Tag922"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">The current future payment obligations of the principal are as follows:</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><div style="-aw-sdt-tag:'c317e04dae973ecfbe43'; -aw-sdt-title:'DEBT T1'"><table cellspacing="0" cellpadding="0" style="width:100%; border-collapse:collapse"><tbody><tr style="height:11.5pt"><td style="width:88%; border-bottom:1.5pt solid #000000; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_5c968b0016b149cfb1f12fa47b1bca41'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">Period</span></p></div></td><td style="width:1%; padding-bottom:1.75pt; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="2" style="border-bottom:1.5pt solid #000000; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_5c764bbf41d64098a324b0fa0eee9c97'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">Principal Payments</span></p></div></td></tr><tr style="height:11.5pt"><td style="width:88%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_0bb61a42b37543a7b09da928c987f7ac'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">2025 (remaining three months)</span></p></div></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_ed70aeb871a64cbcae4e1e638cd44d8c'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-tag:'C_9cc5803ea7e44342b95a83be6a937207'"><ix:nonFraction name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" contextRef="I20250930" xsi:nil="true" unitRef="USD" id="Tag104"></ix:nonFraction><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td></tr><tr style="height:11.5pt"><td style="width:88%; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_897e8cb5c5764f54bf36adbea961583d'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">2026</span></p></div></td><td style="width:1%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p></td><td style="width:1%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p></td><td style="width:10%; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_11851a9e806d4f58b44ce574ad2a99ae'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" contextRef="I20250930" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag98">465</ix:nonFraction></span></p></div></td></tr><tr style="height:11.5pt"><td style="width:88%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_bd218f23a8534654beb35d354f005013'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">2027</span></p></div></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p></td><td style="width:10%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_9e76a127fe434806b75dd7251717545a'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" contextRef="I20250930" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag99">3,220</ix:nonFraction></span></p></div></td></tr><tr style="height:11.5pt"><td style="width:88%; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_5f57e987c26c48cb8368c698d86412c7'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">2028</span></p></div></td><td style="width:1%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p></td><td style="width:1%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p></td><td style="width:10%; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_a641af32d4f142d4896d4e72026bfbf6'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" contextRef="I20250930" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag100">3,333</ix:nonFraction></span></p></div></td></tr><tr style="height:11.5pt"><td style="width:88%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_39e1010cfe6e4fc0b5e28f5cfced0432'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">2029</span></p></div></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p></td><td style="width:10%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_b3e786a7693a420dbcb23ba7b9111b35'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" contextRef="I20250930" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag101">3,470</ix:nonFraction></span></p></div></td></tr><tr style="height:11.5pt"><td style="width:88%; padding-bottom:1.75pt; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_61dc3ec600314411bf83aaf42b0afb2c'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Thereafter</span></p></div></td><td style="width:1%; padding-bottom:1.75pt; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_d9ea3ec1cd2f4f809bcc21cdbccf2901'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" contextRef="I20250930" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag102">139,512</ix:nonFraction></span></p></div></td></tr><tr style="height:11.5pt"><td style="width:88%; padding-bottom:4.25pt; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_5b82b081b0cd4cd7810fcd446de801b1'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">Total</span></p></div></td><td style="width:1%; padding-bottom:4.25pt; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_0749ec546c48465eb63ec47c309b1dfa'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">$</span></p></div></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_cfd83dce046d4d62badcc6025377dc63'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'"><ix:nonFraction name="us-gaap:LongTermDebt" contextRef="I20250930" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag103">150,000</ix:nonFraction></span></p></div></td></tr></tbody></table></div></ix:nonNumeric></div></ix:continuation></div><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt"><span style="-aw-import:ignore">&#160;</span></p><div style="-aw-sdt-tag:'403-72f-b35-61e-66ce'"><ix:nonNumeric name="us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" contextRef="D20250930_1" escape="true" id="Tag971" continuedAt="c02650d6c8f489166c71"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">8. DERIVATIVE LIABILITIES</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">In accordance with the provisions of ASC 815, derivative liabilities are initially measured at fair value at the commitment date and subsequently remeasured at each reporting period, with any increase or decrease in the fair value recorded in the results of operations within other income/expense as the change in fair value of derivative liabilities.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">As of </span><span style="-aw-sdt-tag:'c5350c81469bdad05f66'; -aw-sdt-title:'Current_Period_P3'; font-family: 'Times New Roman'"><span>September 30, 2025</span></span><span style="font-family: 'Times New Roman';"> and </span><span style="-aw-sdt-tag:'cc24fc16174c59980f1b'; -aw-sdt-title:'Previous_Year_End_P5'; font-family: 'Times New Roman'"><span>December 31, 2024</span></span><span style="font-family: 'Times New Roman';">, derivative liabilities consist of the contingent milestone payment due to Knight Therapeutics, Inc. (&#8220;Knight&#8221;), a former lender of the Company, as required by the Debt Conversion Agreement executed between the Company and Knight on January 9, 2023, as subsequently amended (the &#8220;Knight Debt Conversion Agreement&#8221;). Key points of this agreement were as follows:</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><table cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="width:18pt; vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:18pt; vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">&#9679;</span></p></td><td style="vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">The Parties agreed to fix Knight&#8217;s cumulative debt to the value as it stood on March 31, 2022, which consisted of</span><span style="font-family: 'Times New Roman';">&#160;</span><span style="font-family: 'Times New Roman';">principal and accumulated interest. As a result of the completion of the IPO, the cumulative outstanding principal as of March 31, 2022 converted to </span><span style="-aw-sdt-tag:'fae-f38-9d2-e8b-9372'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:ConversionOfStockSharesConverted1" contextRef="D20220331" unitRef="Shares" decimals="0" format="ixt:num-dot-decimal" id="Tag286">18,473</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';"> shares of common stock (representing </span><span style="-aw-sdt-tag:'c9be0aef95d1594431cf'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:SaleOfStockPercentageOfOwnershipAfterTransaction" contextRef="D20220331" unitRef="Pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="Tag252">19.9</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">% ownership of the Company&#8217;s common stock after giving effect to the IPO), and the entirety of the accumulated interest as of March 31, 2022 converted into </span><span style="-aw-sdt-tag:'b9a-c0f-a3d-679-5200'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:ExcessStockSharesAuthorized" contextRef="I20220331_SeriesANonVotingConvertiblePreferredStockMember" unitRef="Shares" decimals="0" format="ixt:num-dot-decimal" id="Tag287">80,965</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';"> shares of Series A Preferred Stock, in full satisfaction of the Company&#8217;s obligations with respect to the outstanding principal and accumulated interest.</span></p></td></tr></tbody></table><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span><span style="font-family: 'Times New Roman';">&#160;</span></p><table cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="width:18pt; vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:18pt; vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">&#9679;</span></p></td><td style="vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">The Parties agreed that the Company will make a milestone payment of $</span><span style="-aw-sdt-tag:'327-c72-933-ea9-2221'; font-family: 'Times New Roman'"><span><ix:nonFraction name="sxtp:MilestonePayment" contextRef="D20250930_1" unitRef="USD" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Tag285">10</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';"> million to Knight if, after the IPO, the Company sells Arakoda&#8482; or if a Change of Control (as per the definition included in the original loan agreement dated on December 10, 2015) occurs, provided that the purchaser of Arakoda&#8482; or individual or entity gaining control of the Borrower is not the Lender or an affiliate of the Lender.</span></p></td></tr></tbody></table><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><table cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="width:18pt; vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:18pt; vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">&#9679;</span></p></td><td style="vertical-align:top"><div style="-aw-sdt-tag:'675-b6d-46f-99f-ad14'"><ix:nonNumeric name="us-gaap:PreferredStockRedemptionTerms" contextRef="D20250930_1" escape="false" id="Tag638"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">For the period ending upon the earlier of (i) </span><span style="-aw-sdt-tag:'550-977-3ca-73c-4910'; font-family: 'Times New Roman'"><span>10 years</span></span><span style="font-family: 'Times New Roman';"> after the closing of the IPO, or (ii) the conversion or redemption in full of the Series A Preferred Stock, the Company will pay to Knight a royalty equal to </span><span style="-aw-sdt-tag:'c0b4d8ca01f4210c3db8'; font-family: 'Times New Roman'"><span><ix:nonFraction name="sxtp:RoyaltyPercentage" contextRef="D20250930_1" unitRef="Pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="Tag105">3.5</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">% of the Company&#8217;s net sales (the &#8220;Royalty&#8221;) on a quarterly basis, where &#8220;Net Sales&#8221; has the same meaning as in the Company&#8217;s license agreement with the U.S. Army for tafenoquine.</span></p></ix:nonNumeric></div></td></tr></tbody></table><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">Upon consummation of the IPO, the Company concluded that the contingent milestone payment is a freestanding financial instrument that meets the definition of a derivative under ASC 815, and accordingly, the fair value of the derivative liability is marked to market each reporting period until settled. The Royalty due to Knight was determined to be an embedded component of the Series A Preferred Stock, however, is exempt from derivative accounting under the ASC 815 scope exception for specified volumes of sales or service revenues. Therefore, the Company accrues a royalty expense as sales are made.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">The valuation of the contingent milestone payment includes significant unobservable inputs such as the timing and probability of discrete potential exit scenarios, forward interest rate curves, and discount rates based on implied and market yields.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><div style="-aw-sdt-tag:'c06f707a4f647dbf011d'"><ix:nonNumeric name="us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" contextRef="D20250930_1" escape="true" id="Tag934" continuedAt="cded1f4d79e481f8ea1b"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">A reconciliation of the beginning and ending balances for the derivative liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) is as follows for the </span><span style="-aw-sdt-tag:'ca75fd2c5ebfac9ccdc1'; -aw-sdt-title:'Current_Quarter_and_YTD_P7'; font-family: 'Times New Roman'"><span>three and nine months ended September 30, 2025</span></span><span style="font-family: 'Times New Roman';">:</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p><div style="-aw-sdt-tag:'c6639d815e653fadd5ae'; -aw-sdt-title:'DERIVATIVE LIABILITIES T1'"><table cellspacing="0" cellpadding="0" style="width:100%; border-collapse:collapse"><tbody><tr style="height:11.5pt"><td style="width:88%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1.14%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="2" style="border-bottom:1.5pt solid #000000; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_fd577863c4914b8ea632e84e6f1d9eec'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">Contingent Milestone Payment</span></p></div></td></tr><tr style="height:11.5pt"><td style="width:88%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_ff0051b243e64116bbf90efbe05a88e3'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Derivative</span><span style="font-family: 'Times New Roman';">&#160;</span><span style="font-family: 'Times New Roman';">liabilities - December 31, 2024</span></p></div></td><td style="width:1.14%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_ef378dbe0e17475fa21c77879bdff28f'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_c7aae7bfd1584e14a5a3a5d58fab1fd6'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="I20241231_FairValueMeasurementsRecurringMember_ContingentMilestonePaymentMember_FairValueInputsLevel3Member" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag114">640,830</ix:nonFraction></span></p></div></td></tr><tr style="height:11.5pt"><td style="width:88%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_4377246d44bb4cfc863de19c989a5202'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Change in fair value</span></p></div></td><td style="width:1.14%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_c327358aecad485cba82f75897b00fec'; font-family: 'Times New Roman'"><span><ix:nonFraction name="sxtp:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisMarkToMarketAdjustment" contextRef="D20250331_FairValueMeasurementsRecurringMember_ContingentMilestonePaymentMember_FairValueInputsLevel3Member" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" sign="-" id="Tag5">5,105</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">)</span></p></td></tr><tr style="height:11.5pt"><td style="width:88%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_5a97f90a3edd45afa8a36844a79b2ea4'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Derivative</span><span style="font-family: 'Times New Roman';">&#160;</span><span style="font-family: 'Times New Roman';">liabilities - March 31, 2025</span></p></div></td><td style="width:1.14%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_9f633fdc6b9242d381ac51540e4153ee'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="I20250331_FairValueMeasurementsRecurringMember_ContingentMilestonePaymentMember_FairValueInputsLevel3Member" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag115">635,725</ix:nonFraction></span></p></div></td></tr><tr style="height:11.5pt"><td style="width:88%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_078e4af6f8af42d295052694ed2c2427'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Change in fair value</span></p></div></td><td style="width:1.14%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_23198fd411e74a64b8eeef85300e3dcf'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="sxtp:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisMarkToMarketAdjustment" contextRef="D20250630_FairValueMeasurementsRecurringMember_ContingentMilestonePaymentMember_FairValueInputsLevel3Member" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag140">140,447</ix:nonFraction></span></p></div></td></tr><tr style="height:11.5pt"><td style="width:88%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_9462c6e0577448ed88294c1d0aae294c'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Derivative</span><span style="font-family: 'Times New Roman';">&#160;</span><span style="font-family: 'Times New Roman';">liabilities - June 30, 2025</span></p></div></td><td style="width:1.14%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_a0832472ffb74935b23fb706f1e8f50b'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="I20250630_FairValueMeasurementsRecurringMember_ContingentMilestonePaymentMember_FairValueInputsLevel3Member" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag173">776,172</ix:nonFraction></span></p></div></td></tr><tr style="height:11.5pt"><td style="width:88%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_2150e1d56b154f04bf9d302078fa6006'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Change in fair value</span></p></div></td><td style="width:1.14%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_ae80a322a7494033b888a0b4927f3dcd'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="sxtp:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisMarkToMarketAdjustment" contextRef="D20250930_FairValueMeasurementsRecurringMember_ContingentMilestonePaymentMember_FairValueInputsLevel3Member" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag186">21,103</ix:nonFraction></span></p></div></td></tr><tr style="height:11.5pt"><td style="width:88%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_adfe59ed6a5b4ce1ad247b7d83b2b16e'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Derivative</span><span style="font-family: 'Times New Roman';">&#160;</span><span style="font-family: 'Times New Roman';">liabilities - September 30, 2025</span></p></div></td><td style="width:1.14%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_fc90d64ea50e4c308d229a9c947721a7'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_8c7042f142d54906ae51e9d2fb2300b4'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="I20250930_FairValueMeasurementsRecurringMember_ContingentMilestonePaymentMember_FairValueInputsLevel3Member" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag139">797,275</ix:nonFraction></span></p></div></td></tr></tbody></table></div><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p><div style="-aw-sdt-tag:'PG_c50ece2c23a2dc4329b4'"><ix:exclude><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-family: 'Times New Roman'; z-index: 100;">20</span></p><div><hr style="width: 100%; color: #000000; background-color: #000000; margin: 1rem 0;"/></div></ix:exclude></div></ix:nonNumeric></div></ix:nonNumeric></div></div><div class="Section_24"><div style="-aw-sdt-tag:'403-72f-b35-61e-66ce'"><ix:continuation id="c02650d6c8f489166c71"><div style="-aw-sdt-tag:'c06f707a4f647dbf011d'"><ix:continuation id="cded1f4d79e481f8ea1b"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">A reconciliation of the beginning and ending balances for the derivative liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) is as follows for the </span><span style="-aw-sdt-tag:'cd848d58778f479d6fa9'; -aw-sdt-title:'Previous_Quarter_and_YTD_P3'; font-family: 'Times New Roman'"><span>three and nine months ended September 30, 2024</span></span><span style="font-family: 'Times New Roman';">:</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><table cellspacing="0" cellpadding="0" style="width:100%; border-collapse:collapse"><tbody><tr style="height:11.5pt"><td style="width:88%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1.14%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="2" style="border-bottom:1.5pt solid #000000; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_9b7bbdd2b0ad450593bb39fcb5204a2d'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">Contingent Milestone Payment</span></p></div></td></tr><tr style="height:11.5pt"><td style="width:88%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_349fc0c506ae466a8afcdbfdf7eb138c'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Derivative</span><span style="font-family: 'Times New Roman';">&#160;</span><span style="font-family: 'Times New Roman';">liabilities - December 31, 2023</span></p></div></td><td style="width:1.14%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_e6028efd12ee4fa482ca3e0bf101af8e'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_7ab6157566fd406ba29b6922a10b9ec9'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="I20231231_FairValueMeasurementsRecurringMember_FairValueInputsLevel3Member_ContingentMilestonePaymentMember" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag253">2,306,796</ix:nonFraction></span></p></div></td></tr><tr style="height:11.5pt"><td style="width:88%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_c6bf1ed06ead4adf9f2296394e5d94fe'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Change in fair value</span></p></div></td><td style="width:1.14%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_fd1f212ea84445ea8753de1b222fe7fa'; font-family: 'Times New Roman'"><span><ix:nonFraction name="sxtp:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisMarkToMarketAdjustment" contextRef="D20240331_FairValueMeasurementsRecurringMember_ContingentMilestonePaymentMember_FairValueInputsLevel3Member" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" sign="-" id="Tag121">1,740,847</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">)</span></p></td></tr><tr style="height:11.5pt"><td style="width:88%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_ebba7a73ac5447149cff86376061747e'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Derivative</span><span style="font-family: 'Times New Roman';">&#160;</span><span style="font-family: 'Times New Roman';">liabilities - March 31, 2024</span></p></div></td><td style="width:1.14%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_6c58f57330b54183b08d956ee1ecbd60'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="I20240331_FairValueMeasurementsRecurringMember_ContingentMilestonePaymentMember_FairValueInputsLevel3Member" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag254">565,949</ix:nonFraction></span></p></div></td></tr><tr style="height:11.5pt"><td style="width:88%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_a251d932ed0f4f349433c36d59e8d1c5'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Change in fair value</span></p></div></td><td style="width:1.14%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_f59f8bc8d656446584c1334e2dc483b9'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="sxtp:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisMarkToMarketAdjustment" contextRef="D20240630_FairValueMeasurementsRecurringMember_ContingentMilestonePaymentMember_FairValueInputsLevel3Member" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag327">1,101</ix:nonFraction></span></p></div></td></tr><tr style="height:11.5pt"><td style="width:88%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_a2f0ff1379314111b76e648c5de945d5'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Derivative</span><span style="font-family: 'Times New Roman';">&#160;</span><span style="font-family: 'Times New Roman';">liabilities - June 30, 2024</span></p></div></td><td style="width:1.14%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_2dbbcbe08cd646c49d4ad4090192625e'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="I20240630_FairValueMeasurementsRecurringMember_ContingentMilestonePaymentMember_FairValueInputsLevel3Member" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag326">567,050</ix:nonFraction></span></p></div></td></tr><tr style="height:11.5pt"><td style="width:88%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_97ca7a3e4491452f85dadb11644bd7ed'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Change in fair value</span></p></div></td><td style="width:1.14%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_b81e163c70f24c44b27596e3b6f00f4d'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="sxtp:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisMarkToMarketAdjustment" contextRef="D20240930_FairValueMeasurementsRecurringMember_ContingentMilestonePaymentMember_FairValueInputsLevel3Member" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag325">56,712</ix:nonFraction></span></p></div></td></tr><tr style="height:11.5pt"><td style="width:88%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_2d719b55a9614add8a41b0e7dc9bd875'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Derivative</span><span style="font-family: 'Times New Roman';">&#160;</span><span style="font-family: 'Times New Roman';">liabilities - September 30, 2024</span></p></div></td><td style="width:1.14%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_28189adff441454eb8ae6052808da967'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_1e958d79d6f442799205fed39a546989'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="I20240930_FairValueMeasurementsRecurringMember_ContingentMilestonePaymentMember_FairValueInputsLevel3Member" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag384">623,762</ix:nonFraction></span></p></div></td></tr></tbody></table></ix:continuation></div><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">Changes in the fair value of derivative liabilities are included in </span><span style="-aw-sdt-tag:'336-1f6-b4d-7ae-89fc'; -aw-sdt-title:'Other_income_(expense)_P1'; font-family: 'Times New Roman'"><span>other income (expense)</span></span><span style="font-family: 'Times New Roman';"> in the accompanying consolidated condensed statements of operations and comprehensive loss. During the </span><span style="-aw-sdt-tag:'c7a870c15245e746541a'; -aw-sdt-title:'Current_YTD_P10'; font-family: 'Times New Roman'"><span>nine months ended September 30, 2025</span></span><span style="font-family: 'Times New Roman';"> and </span><span style="-aw-sdt-tag:'c515be331bb8d4793eb8'; -aw-sdt-title:'Previous_Year_P12'; font-family: 'Times New Roman'"><span>2024</span></span><span style="font-family: 'Times New Roman';">, the Company recorded a net (loss) gain on the change in the fair value of derivative liabilities of ($</span><span style="-aw-sdt-tag:'c77e4e2e8d34f16dd511'; -aw-sdt-title:'CYTD_Change in FV Derivatives'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="D20250930_1" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" sign="-" id="Tag815">156,445</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">) and $</span><span style="-aw-sdt-tag:'c93e5c070ddcafae864d'; -aw-sdt-title:'PYTD_Change in FV Derivatives'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="D20240930_1" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag814">1,683,034</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">, respectively.</span></p></ix:continuation></div><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore">&#160;</span></p><div style="-aw-sdt-tag:'c8e567fe883129accdb7'"><ix:nonNumeric name="us-gaap:IncomeTaxDisclosureTextBlock" contextRef="D20250930_1" escape="true" id="Tag966"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">9. INCOME TAXES</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">The Company did not record a federal income tax provision or benefit for the </span><span style="-aw-sdt-tag:'cd80ebf44dd4a49459a3'; -aw-sdt-title:'Current_Quarter_and_YTD_P8'; font-family: 'Times New Roman'"><span>three and nine months ended September 30, 2025</span></span><span style="font-family: 'Times New Roman';"> and </span><span style="-aw-sdt-tag:'ca9a1d3291cee7dfe7d3'; -aw-sdt-title:'Previous_Year_P22'; font-family: 'Times New Roman'"><span>2024</span></span><span style="font-family: 'Times New Roman';"> due to taxable losses. The Company recorded a provision for income taxes for the District of Columbia of $</span><span style="-aw-sdt-tag:'908-1ae-370-c57-56fb'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="D20250930" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag835">250</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">&#160;</span><span style="font-family: 'Times New Roman';">and $</span><span style="-aw-sdt-tag:'6f4-8fe-bb5-dd0-f075'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="D20240930" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag836">250</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">&#160;</span><span style="font-family: 'Times New Roman';">for the </span><span style="-aw-sdt-tag:'24f-910-caa-173-01a4'; -aw-sdt-title:'Current_Quarter_P45'; font-family: 'Times New Roman'"><span>three months ended September 30, 2025</span></span><span style="font-family: 'Times New Roman';"> and </span><span style="-aw-sdt-tag:'1e7-2ec-a39-80f-df36'; -aw-sdt-title:'Previous_Year_P48'; font-family: 'Times New Roman'"><span>2024</span></span><span style="font-family: 'Times New Roman';">, respectively, thereby reflecting the minimum statutory tax due ($</span><span style="-aw-sdt-tag:'02d-fa8-465-f09-3ba2'; -aw-sdt-title:'DC_Taxes_CY_YTD'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="D20250930_1" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag837">1,813</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">&#160;</span><span style="font-family: 'Times New Roman';">and $</span><span style="-aw-sdt-tag:'d32-f75-fc1-36a-e6f0'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="D20240930_1" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag838">751</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">&#160;</span><span style="font-family: 'Times New Roman';">for the </span><span style="-aw-sdt-tag:'65b-b80-259-dec-ff1c'; -aw-sdt-title:'Current_YTD_P54'; font-family: 'Times New Roman'"><span>nine months ended September 30, 2025</span></span><span style="font-family: 'Times New Roman';"> and </span><span style="-aw-sdt-tag:'679-3d3-4cd-809-ad81'; -aw-sdt-title:'Previous_Year_P49'; font-family: 'Times New Roman'"><span>2024</span></span><span style="font-family: 'Times New Roman';">, respectively). </span></p></ix:nonNumeric></div><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore">&#160;</span></p><div style="-aw-sdt-tag:'c68ff7a85c1746c9c97e'"><ix:nonNumeric name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" contextRef="D20250930_1" escape="true" id="Tag988" continuedAt="c6f2d5d271f35dec7ce3"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">10. SHARE-BASED COMPENSATION</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><div style="-aw-sdt-tag:'c037fface987eb1f9566'"><ix:nonNumeric name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" contextRef="D20250930_1" escape="true" id="Tag955"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">The following is a summary of share-based compensation expenses reported in the </span><span style="-aw-sdt-tag:'928-fd0-43f-33f-a583'; -aw-sdt-title:'PandL_title_P1'; font-family: 'Times New Roman'"><span>consolidated condensed statements of operations and comprehensive loss</span></span><span style="font-family: 'Times New Roman';"> for the </span><span style="-aw-sdt-tag:'ce72a01889339805360e'; -aw-sdt-title:'Current_Quarter_and_YTD_P1'; font-family: 'Times New Roman'"><span>three and nine months ended September 30, 2025</span></span><span style="font-family: 'Times New Roman';"> and </span><span style="-aw-sdt-tag:'cb6dccf48217e97e781f'; -aw-sdt-title:'Previous_Year_P14'; font-family: 'Times New Roman'"><span>2024</span></span><span style="font-family: 'Times New Roman';">:</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><div style="-aw-sdt-tag:'c13275b5451f7f9fa78e'; -aw-sdt-title:'SHARE-BASED COMPENSATION T1'"><table cellspacing="0" cellpadding="0" style="width:100%; border-collapse:collapse"><tbody><tr style="height:11.5pt"><td style="width:52%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="5" style="border-bottom:1.5pt solid #000000; padding-right:3.6pt; padding-left:3.6pt; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_b793b7deaa5f4e1d950f54932847ec4e'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">For the Three Months Ended September 30,</span></p></div></td><td style="width:1%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="5" style="border-bottom:1.5pt solid #000000; padding-left:11.5pt; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_537410e7812d486a9a1750abab377793'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">For the Nine Months Ended September 30,</span></p></div></td></tr><tr style="height:11.5pt"><td style="width:52%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="2" style="border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_1c65bd1b721f4fdbb0598ff8d89de949'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">2025</span></p></div></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="2" style="border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_e80ebe59c55b4da093ced29e2c908199'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">2024</span></p></div></td><td style="width:1%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="2" style="border-bottom:1.5pt solid #000000; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_91ed7e22685d417984396bafa04be366'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">2025</span></p></div></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="2" style="border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_df669bbe060d4fb4868590c39a9103dd'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">2024</span></p></div></td></tr><tr style="height:11.5pt"><td style="width:52%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_1f65a7c0fbbf45a68b9646858ce371ce'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Research and Development</span></p></div></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_23d3849a725541999e62bbfea44aac84'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-tag:'C_11384fc8b65f4d7db353787823d55423'"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="D20250930_ResearchAndDevelopmentExpenseMember" xsi:nil="true" unitRef="USD" id="Tag212"></ix:nonFraction><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_025187fdcd654094abb16118f061da90'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_2b22ee8f24c54fa896add2668695efcb'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="D20240930_ResearchAndDevelopmentExpenseMember" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag202">600,000</ix:nonFraction></span></p></div></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_b4c10c58c0314c169080c9c8b8fcbf8e'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-tag:'C_a08e3c8a4c6f4085aa8a9d31befcd057'"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="D20250930_ResearchAndDevelopmentExpenseMember_1" xsi:nil="true" unitRef="USD" id="Tag207"></ix:nonFraction><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_78842318fd574561a2884382a7738a2b'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_35eff82596e143da87976fe2e081d8ab'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="D20240930_ResearchAndDevelopmentExpenseMember_1" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag203">3,227,300</ix:nonFraction></span></p></div></td></tr><tr style="height:11.5pt"><td style="width:52%; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_61c64308dfc6458ea1fbb4a8c7b703f2'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">General and Administrative Expenses</span></p></div></td><td style="width:1%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_ddd5fe7024e34d6d8b4886992b4b418e'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="D20250930_GeneralAndAdministrativeExpenseMember" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag208">79,000</ix:nonFraction></span></p></div></td><td style="width:1%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_b1923603f0314dcc9f9dff054d6a03da'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="D20240930_GeneralAndAdministrativeExpenseMember_1" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag206">68,974</ix:nonFraction></span></p></div></td><td style="width:1%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_be2f81c4d0954142a92c2d69272f7316'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="D20250930_GeneralAndAdministrativeExpenseMember_1" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag204">344,383</ix:nonFraction></span></p></div></td><td style="width:1%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_62aa8b68d8d0491db7039e6b80dd5e0e'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="D20240930_GeneralAndAdministrativeExpenseMember" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag205">319,709</ix:nonFraction></span></p></div></td></tr><tr style="height:11.5pt"><td style="width:52%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_bfa6fe246dec48e885d05f0057213748'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Total Share-Based Compensation Expense Included in Operating Expenses</span></p></div></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_f745775470c94315af299adf55367ded'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_74b13f97c0cf48dab5e62d86746dd071'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="D20250930" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag209">79,000</ix:nonFraction></span></p></div></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_f2f730e985d34774bbed0f63d2691b9d'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_40018e5c15e74eda9b9f7804866b0d19'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="D20240930" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag200">668,974</ix:nonFraction></span></p></div></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_6d7a61fde61344dc8721193a9a15d53c'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_04eded1abc4d4ad9aef27f111b48a590'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="D20250930_1" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag201">344,383</ix:nonFraction></span></p></div></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_9c2d8eda549747ef9ba345afb4170af9'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'761-c75-0e8-f8a-eee2'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="D20240930_1" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag225">3,547,009</ix:nonFraction></span></p></div></td></tr></tbody></table></div></ix:nonNumeric></div><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; text-decoration:underline; font-family: 'Times New Roman'">Share-Based Compensation under </span><span style="-aw-sdt-tag:'c2cce9b34b4cce207dc3'; font-family: 'Times New Roman'"><span style="font-weight:bold; text-decoration:underline">2022</span></span><span style="font-weight:bold; text-decoration:underline; font-family: 'Times New Roman'"> Equity Incentive Plan</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">On November </span><span style="-aw-sdt-tag:'ce33ff49852d9b6cc9af'; font-family: 'Times New Roman'"><span>22</span></span><span style="font-family: 'Times New Roman';">, </span><span style="-aw-sdt-tag:'cd04e73f864219172e17'; font-family: 'Times New Roman'"><span>2022</span></span><span style="font-family: 'Times New Roman';">, the Company adopted the </span><span style="-aw-sdt-tag:'cc81a70adfa65fd8fe85'; font-family: 'Times New Roman'"><span>2022</span></span><span style="font-family: 'Times New Roman';"> Equity Incentive Plan (the &#8220;</span><span style="-aw-sdt-tag:'c84237e68151d396e260'; font-family: 'Times New Roman'"><span>2022</span></span><span style="font-family: 'Times New Roman';"> Plan&#8221;), which provides for the grant of stock options, stock appreciation rights, restricted stock, restricted stock units and performance awards to eligible employees, directors and consultants, to be granted from time to time by the Board of Directors of the Company. To date, the Company has granted shares of common stock, restricted stock units, stock options to employees, non-employees, and directors under the </span><span style="-aw-sdt-tag:'c6469f80875469d8dcaa'; font-family: 'Times New Roman'"><span>2022</span></span><span style="font-family: 'Times New Roman';"> Plan. As of </span><span style="-aw-sdt-tag:'c119f5f4ee3e094a8aad'; -aw-sdt-title:'Current_Period_P17'; font-family: 'Times New Roman'"><span>September 30, 2025</span></span><span style="font-family: 'Times New Roman';">, the number of remaining shares available for issuance under the 2022 Plan is equal to </span><span style="-aw-sdt-tag:'c0d4a4d9d67084ea6d66'; -aw-sdt-title:'2022 Plan _Shares Available for Issuance'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="I20250930_TwoThousandTwentyTwoEquityIncentivePlanMember" unitRef="Shares" decimals="0" format="ixt:num-dot-decimal" id="Tag861">57,068</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-style:italic; font-family: 'Times New Roman'">Stock Options</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-style:italic; font-family: 'Times New Roman'">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">The Company grants stock options to employees, non-employees, and directors with exercise prices equal to the closing price of the underlying shares of the Company&#8217;s common stock on the Nasdaq Capital Market on the date that the options are granted. Options granted generally have a </span><span style="-aw-sdt-tag:'e63-273-caa-f00-1383'; font-family: 'Times New Roman'"><ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" contextRef="D20250930_StockOptionsMember_1" escape="false" id="Tag875"><span>term of five to ten years</span></ix:nonNumeric></span><span style="font-family: 'Times New Roman';"> from the grant date and are subject to vesting as determined in the individual award agreement. The Company estimates the fair value of stock options on the grant date by applying the Black-Scholes option pricing valuation model.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><div style="-aw-sdt-tag:'PG_ccc01229426adb7fbfee'"><ix:exclude><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-family: 'Times New Roman'; z-index: 100;">21</span></p><div><hr style="width: 100%; color: #000000; background-color: #000000; margin: 1rem 0;"/></div></ix:exclude></div></ix:nonNumeric></div></div><div class="Section_25"><div style="-aw-sdt-tag:'c68ff7a85c1746c9c97e'"><ix:continuation id="c6f2d5d271f35dec7ce3"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">There were </span><span style="-aw-sdt-tag:'5f1-2bf-683-a23-2ca7'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="D20250930" unitRef="Shares" decimals="0" format="ixt-sec:numwordsen" id="Tag872">no</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';"> stock options granted during the </span><span style="-aw-sdt-tag:'9f5-d6b-c4e-520-d6a5'; -aw-sdt-title:'Current_Quarter_P46'; font-family: 'Times New Roman'"><span>three months ended September 30, 2025</span></span><span style="font-family: 'Times New Roman';">. During the </span><span style="-aw-sdt-tag:'918-ef8-5a7-218-1704'; -aw-sdt-title:'Current_YTD_P53'; font-family: 'Times New Roman'"><span>nine months ended September 30, 2025</span></span><span style="font-family: 'Times New Roman';">, the Company granted a total of </span><span style="-aw-sdt-tag:'cc4f82113885d00917ff'; -aw-sdt-title:'CYTD_Stock Options Granted'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="D20250930_1" unitRef="Shares" decimals="0" format="ixt:num-dot-decimal" id="Tag873">120,000</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';"> stock options to </span><span style="-aw-sdt-tag:'2e4-092-32a-f6f-c96e'; font-family: 'Times New Roman'"><span><ix:nonFraction name="sxtp:NumberOfExecutives" contextRef="I20250930" unitRef="Number" decimals="0" format="ixt-sec:numwordsen" id="Tag871">two</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';"> executives at a per share exercise price of $</span><span style="-aw-sdt-tag:'c8fe171f9f46a4304c75'; -aw-sdt-title:'CYTD_Stock Options Ex.Price'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="D20250930_1" unitRef="USDPerShare" decimals="2" format="ixt:num-dot-decimal" id="Tag862">6.55</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">. These options are subject to vesting annually in five equal tranches, with the first </span><span style="-aw-sdt-tag:'cbd22998573814036f2e'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" contextRef="D20250930_ShareBasedCompensationAwardTrancheOneMember" unitRef="Pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="Tag883">20</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">% tranche fully vested on the date of grant and thereafter, vest on the last date of each fiscal year beginning December 31, 2025. The weighted average grant date fair value of options granted during the </span><span style="-aw-sdt-tag:'c6aa6012cf7103ba2a01'; -aw-sdt-title:'Current_YTD_P2'; font-family: 'Times New Roman'"><span>nine months ended September 30, 2025</span></span><span style="font-family: 'Times New Roman';"> was $</span><span style="-aw-sdt-tag:'c2ff4eac22c6343b6acb'; -aw-sdt-title:'CYTD_Stock Options WA Grant Date FV'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" contextRef="D20250930_1" unitRef="USDPerShare" decimals="2" format="ixt:num-dot-decimal" id="Tag863">4.55</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">. </span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">During the </span><span style="-aw-sdt-tag:'0e2-2b6-e25-ec0-511e'; -aw-sdt-title:'Previous_Quarter_and_YTD_P6'; font-family: 'Times New Roman'"><span>three and nine months ended September 30, 2024</span></span><span style="font-family: 'Times New Roman';">, Company granted a total of </span><span style="-aw-sdt-tag:'844-d69-61d-665-d9fe'; -aw-sdt-title:'PYTD_Stock Options Granted'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="D20240930" unitRef="Shares" decimals="0" format="ixt:num-dot-decimal" id="Tag1027"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="D20240930_1" unitRef="Shares" decimals="0" format="ixt:num-dot-decimal" id="Tag879">17,005</ix:nonFraction></ix:nonFraction></span></span><span style="font-family: 'Times New Roman';"> stock options at a weighted average per share exercise price of $</span><span style="-aw-sdt-tag:'266-3e1-8af-307-25b7'; -aw-sdt-title:'PYTD_Stock Options_Avg Ex Price'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="D20240930" unitRef="USDPerShare" decimals="2" format="ixt:num-dot-decimal" id="Tag1028"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="D20240930_1" unitRef="USDPerShare" decimals="2" format="ixt:num-dot-decimal" id="Tag880">54.62</ix:nonFraction></ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">. The weighted average grant date fair value of options granted during the </span><span style="-aw-sdt-tag:'27d-ea8-614-ca9-2785'; -aw-sdt-title:'Previous_Quarter_and_YTD_P9'; font-family: 'Times New Roman'"><span>three and nine months ended September 30, 2024</span></span><span style="font-family: 'Times New Roman';"> was $</span><span style="-aw-sdt-tag:'4bf-904-a4c-ccb-354e'; -aw-sdt-title:'PYTD_Options Granted_Avg. Grant Date Fair Value'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" contextRef="D20240930" unitRef="USDPerShare" decimals="2" format="ixt:num-dot-decimal" id="Tag1029"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" contextRef="D20240930_1" unitRef="USDPerShare" decimals="2" format="ixt:num-dot-decimal" id="Tag881">8.78</ix:nonFraction></ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><div style="-aw-sdt-tag:'2b8-829-358-045-27fb'"><ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock" contextRef="D20250930_1" escape="true" id="Tag956"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">The following table summarizes the significant assumptions used in determining the fair value of options granted during the </span><span style="-aw-sdt-tag:'cb926b1bec8a5c9d7e88'; -aw-sdt-title:'Current_Quarter_and_YTD_P3'; font-family: 'Times New Roman'"><span>three and nine months ended September 30, 2025</span></span><span style="font-family: 'Times New Roman';"> and </span><span style="-aw-sdt-tag:'c208469c38a8aafffc4c'; -aw-sdt-title:'Previous_Year_P15'; font-family: 'Times New Roman'"><span>2024</span></span><span style="font-family: 'Times New Roman';">:</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p><div style="-aw-sdt-tag:'c6b82afc388c401d9e30'; -aw-sdt-title:'SBC Table FMV Assumptions'"><table cellspacing="0" cellpadding="0" style="width:100%; border-collapse:collapse"><tbody><tr style="height:11.5pt"><td style="width:53%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="5" style="border-bottom:1.5pt solid #000000; padding-right:3.6pt; padding-left:3.6pt; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_371d5f2bfb054b0e8460d09bb59858a9'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">For the Three Months Ended September 30,</span></p></div></td><td style="width:0.86%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="5" style="border-bottom:1.5pt solid #000000; padding-left:18.7pt; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_e2d4b0f5404c484680abbbec2fbb1cd5'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">For the Nine Months Ended September 30,</span></p></div></td></tr><tr style="height:11.5pt"><td style="width:53%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="2" style="border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_58cd0c9841254a3dac116deef4bcbc41'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">2025</span></p></div></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="2" style="border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_78c64d6266234af3b75e0972a6752883'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">2024</span></p></div></td><td style="width:0.86%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="2" style="border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_4b5707f7e1f340fabeba896192704cbf'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">2025</span></p></div></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="2" style="border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_c0b54a2289c946b5b7a0a1ca7a79bae1'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">2024</span></p></div></td></tr><tr style="height:11.5pt"><td style="width:53%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_bdbe21d861f54e598b6c2ebeaf8c95fe'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Weighted-average grant date fair value</span></p></div></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_7890dccaab874e7d92cb7b0e72fc317f'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_22b11df71f0d47098e6e2bded099c637'"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="D20250930" xsi:nil="true" unitRef="USDPerShare" id="Tag220"></ix:nonFraction><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:spaces; font-family: 'Times New Roman'">&#160;</span><span style="font-family: 'Times New Roman';">N/A </span></p></div></td><td style="width:1%; padding-right:1.45pt; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_0a2dcde2664d42579b74f707d6505d93'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_37a0df27750945fc9b6899c1a6a047ca'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="D20240930" unitRef="USDPerShare" decimals="2" format="ixt:num-dot-decimal" id="Tag213">8.78</ix:nonFraction></span></p></div></td><td style="width:0.86%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_f54f277a21d94c4cacdd010927e3433e'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_61461e1150e24180814adbbea8f0035f'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="D20250930_1" unitRef="USDPerShare" decimals="2" format="ixt:num-dot-decimal" id="Tag210">4.55</ix:nonFraction></span></p></div></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_7ea73308c7384caa83280f67a66a433e'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_2e5e3ada99254986ae82736208308e85'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="D20240930_1" unitRef="USDPerShare" decimals="2" format="ixt:num-dot-decimal" id="Tag214">8.78</ix:nonFraction></span></p></div></td></tr><tr style="height:11.5pt"><td style="width:53%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_a86fcbd02d504a77b42500289cd5f9c5'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Risk-free interest rate</span></p></div></td><td style="width:1%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_422b919e53604b4d9b01e6a4ff8ae470'"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="D20250930" xsi:nil="true" unitRef="Pure" id="Tag221"></ix:nonFraction><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:spaces; font-family: 'Times New Roman'">&#160;</span><span style="font-family: 'Times New Roman';">N/A </span></p></div></td><td style="width:1%; padding-right:1.45pt; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-sdt-tag:'5c3-4af-63f-0a8-8170'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" contextRef="D20240930" unitRef="Pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="Tag49">3.62</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">% - </span><span style="-aw-sdt-tag:'f97-3e4-a51-d60-5557'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" contextRef="D20240930" unitRef="Pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="Tag50">4.17</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">%</span></p></td><td style="width:0.86%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-sdt-tag:'C_a0a8c0c2864a4afbb105903f2b68b28b'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="D20250930_1" unitRef="Pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="Tag35">4.36</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">%</span></p></td><td style="width:1%; padding-right:1.45pt; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-sdt-tag:'30e-490-8f8-814-d30e'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" contextRef="D20240930_1" unitRef="Pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="Tag53">3.62</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">% - </span><span style="-aw-sdt-tag:'ee3-181-3dc-e8f-312d'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" contextRef="D20240930_1" unitRef="Pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="Tag54">4.17</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">%</span></p></td></tr><tr style="height:11.5pt"><td style="width:53%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_5fe58341b1494de19749b138fb5378ee'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Expected volatility</span></p></div></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_0c331ee129f64ed1b9fa50dc73136fcd'"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="D20250930" xsi:nil="true" unitRef="Pure" id="Tag222"></ix:nonFraction><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:spaces; font-family: 'Times New Roman'">&#160;</span><span style="font-family: 'Times New Roman';">N/A </span></p></div></td><td style="width:1%; padding-right:1.45pt; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-sdt-tag:'bda-6e1-a52-5f0-7b06'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" contextRef="D20240930" unitRef="Pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="Tag51">86.00</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">% - </span><span style="-aw-sdt-tag:'07d-67f-348-6f7-ba1e'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" contextRef="D20240930" unitRef="Pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="Tag52">87.00</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">%</span></p></td><td style="width:0.86%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-sdt-tag:'C_3c6e0737f3d74b34934c2901d877dee2'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="D20250930_1" unitRef="Pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="Tag36">90.00</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">%</span></p></td><td style="width:1%; padding-right:1.45pt; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-sdt-tag:'64f-7fb-a1f-61b-8c23'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" contextRef="D20240930_1" unitRef="Pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="Tag55">86.00</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">% - </span><span style="-aw-sdt-tag:'163-d0d-e3e-4ea-7923'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" contextRef="D20240930_1" unitRef="Pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="Tag56">87.00</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">%</span></p></td></tr><tr style="height:11.5pt"><td style="width:53%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_f98e805c00b14edb84da40ce6346c721'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Expected term (years)</span></p></div></td><td style="width:1%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_e4b5461f1a1746da98b836b10b7a794a'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:spaces; font-family: 'Times New Roman'">&#160;</span><span style="font-family: 'Times New Roman';">N/A </span></p></div></td><td style="width:1%; padding-right:1.45pt; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-sdt-tag:'9fd-a7d-dce-aee-b8d3'; font-family: 'Times New Roman'"><span><ix:nonNumeric name="sxtp:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1Minimum" contextRef="D20240930" format="ixt-sec:duryear" id="Tag59">6.41</ix:nonNumeric></span></span><span style="font-family: 'Times New Roman';"> - </span><span style="-aw-sdt-tag:'922-43a-fd5-af0-7c6d'; font-family: 'Times New Roman'"><span><ix:nonNumeric name="sxtp:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1Maximum" contextRef="D20240930" format="ixt-sec:duryear" id="Tag60">10.00</ix:nonNumeric></span></span></p></td><td style="width:0.86%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_67fa179582ea40ab85e70f2d97a7168b'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="D20250930_1" format="ixt-sec:duryear" id="Tag211">4.50</ix:nonNumeric></span></p></div></td><td style="width:1%; padding-right:1.45pt; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-sdt-tag:'39b-8fc-eba-917-6b4f'; font-family: 'Times New Roman'"><span><ix:nonNumeric name="sxtp:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1Minimum" contextRef="D20240930_1" format="ixt-sec:duryear" id="Tag57">6.41</ix:nonNumeric></span></span><span style="font-family: 'Times New Roman';"> - </span><span style="-aw-sdt-tag:'c62-ee5-3a2-e98-0fdf'; font-family: 'Times New Roman'"><span><ix:nonNumeric name="sxtp:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1Maximum" contextRef="D20240930_1" format="ixt-sec:duryear" id="Tag58">10.00</ix:nonNumeric></span></span></p></td></tr><tr style="height:11.5pt"><td style="width:53%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_04267cb0abf54990bdf4b71fb0d4b3f1'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Expected dividend yield</span></p></div></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_3310313796d64fcca52c3a9e78c2bec2'"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="D20250930" xsi:nil="true" unitRef="Pure" id="Tag223"></ix:nonFraction><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:spaces; font-family: 'Times New Roman'">&#160;</span><span style="font-family: 'Times New Roman';">N/A </span></p></div></td><td style="width:1%; padding-right:1.45pt; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-sdt-tag:'C_d9ef82eb21d54263b8ca618d8d975456'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="D20240930" unitRef="Pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="Tag38">0.00</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">%</span></p></td><td style="width:0.86%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-sdt-tag:'C_555c1c1a0720497ba6cdc1357d20b8ce'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="D20250930_1" unitRef="Pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="Tag37">0.00</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">%</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-sdt-tag:'bd0-9dc-c14-a77-e224'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="D20240930_1" unitRef="Pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="Tag39">0.00</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">%</span></p></td></tr></tbody></table></div></ix:nonNumeric></div><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">For the </span><span style="-aw-sdt-tag:'e0c-27a-82f-8b3-9fea'; -aw-sdt-title:'Current_Quarter_P50'; font-family: 'Times New Roman'"><span>three months ended September 30, 2025</span></span><span style="font-family: 'Times New Roman';"> and </span><span style="-aw-sdt-tag:'88b-dd6-6a9-1fd-8fb5'; -aw-sdt-title:'Previous_Year_P56'; font-family: 'Times New Roman'"><span>2024</span></span><span style="font-family: 'Times New Roman';">, the Company recognized $</span><span style="-aw-sdt-tag:'cfbc46a1a35c78396973'; -aw-sdt-title:'Option Expense CQ'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="D20250930" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag864">34,882</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';"> and $</span><span style="-aw-sdt-tag:'49b-c31-e1c-ca4-3665'; -aw-sdt-title:'Option Expense PQ'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="D20240930" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag901">15,246</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';"> of compensation expense related to stock option awards, respectively ($</span><span style="-aw-sdt-tag:'04d-477-46c-4d6-fb29'; -aw-sdt-title:'Option Expenses CYTD'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="D20250930_1" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag884">212,030</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';"> and $</span><span style="-aw-sdt-tag:'b15-7a6-d2f-027-2572'; -aw-sdt-title:'Option Expense PYTD'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" contextRef="D20240930_1" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag882">15,246</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';"> for the </span><span style="-aw-sdt-tag:'d56-222-98b-71d-4fce'; -aw-sdt-title:'Current_YTD_P58'; font-family: 'Times New Roman'"><span>nine months ended September 30, 2025</span></span><span style="font-family: 'Times New Roman';"> and </span><span style="-aw-sdt-tag:'147-551-d96-263-b55d'; -aw-sdt-title:'Previous_Year_P57'; font-family: 'Times New Roman'"><span>2024</span></span><span style="font-family: 'Times New Roman';">, respectively). </span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-style:italic; font-family: 'Times New Roman'">Restricted Stock Units</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-style:italic; font-family: 'Times New Roman'">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">Compensation cost for service-based RSUs is based on the grant date fair value of the award, which is the closing market price of the Company&#8217;s common stock on the grant date multiplied by the number of shares awarded.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">During the </span><span style="-aw-sdt-tag:'c8156768d3ede0db34bd'; -aw-sdt-title:'Current_Quarter_and_YTD_P5'; font-family: 'Times New Roman'"><span>three and nine months ended September 30, 2025</span></span><span style="font-family: 'Times New Roman';"> and </span><span style="-aw-sdt-tag:'cf953a8ed1d8c57cfe06'; -aw-sdt-title:'Previous_Year_P16'; font-family: 'Times New Roman'"><span>2024</span></span><span style="font-family: 'Times New Roman';">, </span><span style="-aw-sdt-tag:'c2d498a80f581c1e21a0'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" contextRef="D20240930_CommonStockMember_RestrictedStockUnitsRSUMember" unitRef="Shares" decimals="0" format="ixt:num-dot-decimal" id="Tag1018"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" contextRef="D20250930_CommonStockMember_RestrictedStockUnitsRSUMember_1" unitRef="Shares" decimals="0" format="ixt:num-dot-decimal" id="Tag1020"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" contextRef="D20240930_CommonStockMember_RestrictedStockUnitsRSUMember_1" unitRef="Shares" decimals="0" format="ixt:num-dot-decimal" id="Tag1021"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" contextRef="D20250930_CommonStockMember_RestrictedStockUnitsRSUMember" unitRef="Shares" decimals="0" format="ixt:num-dot-decimal" id="Tag865">0</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span></span><span style="font-family: 'Times New Roman';"> shares of common stock underlying RSUs vested and </span><span style="-aw-sdt-tag:'f83-1f3-cda-5bd-ab74'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="D20240930_CommonStockMember_RestrictedStockUnitsRSUMember_4" unitRef="Shares" decimals="0" format="ixt-sec:numwordsen" id="Tag1026"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="D20240930_CommonStockMember_RestrictedStockUnitsRSUMember_3" unitRef="Shares" decimals="0" format="ixt-sec:numwordsen" id="Tag1024"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="D20250930_CommonStockMember_RestrictedStockUnitsRSUMember_3" unitRef="Shares" decimals="0" format="ixt-sec:numwordsen" id="Tag1025"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="D20250930_CommonStockMember_RestrictedStockUnitsRSUMember_4" unitRef="Shares" decimals="0" format="ixt-sec:numwordsen" id="Tag876">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span></span><span style="font-family: 'Times New Roman';"> RSUs were granted. The Company recognized $</span><span style="-aw-sdt-tag:'cd379d5b42a143859706'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="D20240930_RestrictedStockUnitsRSUMember" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag1019"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="D20250930_RestrictedStockUnitsRSUMember_1" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag1022"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="D20240930_RestrictedStockUnitsRSUMember_1" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag1023"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="D20250930_RestrictedStockUnitsRSUMember" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag874">0</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span></span><span style="font-family: 'Times New Roman';"> of compensation expense related to vested RSUs for the </span><span style="-aw-sdt-tag:'c9e6e47e8d91295983e5'; -aw-sdt-title:'Current_Quarter_and_YTD_P6'; font-family: 'Times New Roman'"><span>three and nine months ended September 30, 2025</span></span><span style="font-family: 'Times New Roman';"> and </span><span style="-aw-sdt-tag:'c4363c78014d853fb341'; -aw-sdt-title:'Previous_Year_P17'; font-family: 'Times New Roman'"><span>2024</span></span><span style="font-family: 'Times New Roman';">.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; text-decoration:underline; font-family: 'Times New Roman'">Annual Performance Bonus</span></p><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span><span style="width:360pt; display:inline-block; -aw-tabstop-align:left; -aw-tabstop-pos:362.5pt; font-family: 'Times New Roman'">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">In December </span><span style="-aw-sdt-tag:'ca6d224b0a30d2bead97'; font-family: 'Times New Roman'"><span>2024</span></span><span style="font-family: 'Times New Roman';">, the Board approved the payment of </span><span style="-aw-sdt-tag:'cf9ad02c046ec83aca33'; font-family: 'Times New Roman'"><span>2024</span></span><span style="font-family: 'Times New Roman';"> performance bonuses to executives of the Company. Each executive was provided the option of receiving up to $</span><span style="-aw-sdt-tag:'c4ee71f3aad053507c7f'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:Cash" contextRef="I20241231" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag866">20,000</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';"> in cash, with the remainder paid in shares of common stock determined based on the closing market price on January </span><span style="-aw-sdt-tag:'ce3e6a83235437c0275c'; font-family: 'Times New Roman'"><span>2</span></span><span style="font-family: 'Times New Roman';">, </span><span style="-aw-sdt-tag:'c1824d9e08acec6d5251'; font-family: 'Times New Roman'"><span>2025</span></span><span style="font-family: 'Times New Roman';">. On January </span><span style="-aw-sdt-tag:'c8530f88525131331e3a'; font-family: 'Times New Roman'"><span>20</span></span><span style="font-family: 'Times New Roman';">, </span><span style="-aw-sdt-tag:'c599c9f4b2e63ebb486c'; font-family: 'Times New Roman'"><span>2025</span></span><span style="font-family: 'Times New Roman';">, the Company issued a total of </span><span style="-aw-sdt-tag:'cfc988ccd41d40490852'; font-family: 'Times New Roman'"><span><ix:nonFraction name="sxtp:StockIssuedDuringPeriodIssuanceOfSharesForAnnualPerformanceBonusesNetOfSharesWithheldForTaxesinShares" contextRef="D20250120_CommonStockMember_3" unitRef="Shares" decimals="0" format="ixt:num-dot-decimal" id="Tag878">15,809</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';"> shares of common stock to the executives in settlement of the share-based portion of the </span><span style="-aw-sdt-tag:'cfa3618d6dccb054d4d7'; font-family: 'Times New Roman'"><span>2024</span></span><span style="font-family: 'Times New Roman';"> performance bonuses. Approximately </span><span style="-aw-sdt-tag:'c85caee2925573fd285e'; font-family: 'Times New Roman'"><span><ix:nonFraction name="sxtp:SharesIssuedPayrollTaxesWithholdings" contextRef="D20250120" unitRef="Shares" decimals="0" format="ixt:num-dot-decimal" id="Tag867">2,748</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';"> shares were withheld to cover payroll tax withholdings.</span><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; text-decoration:underline; font-family: 'Times New Roman'">Share-Based Payments to Vendors for Services</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">In </span><span style="-aw-sdt-tag:'c70630d4e04440e9a333'; font-family: 'Times New Roman'"><span>2023</span></span><span style="font-family: 'Times New Roman';">, the Company issued shares of common stock as share-based payments to certain vendors in exchange for services to be rendered to the Company in the future. For fully vested, nonforfeitable equity instruments that are granted at the date the Company and a nonemployee enter into an agreement for goods or services, the Company recognizes the fair value of the equity instruments as a prepaid asset on the grant date, as defined in ASC </span><span style="-aw-sdt-tag:'c7013a8e8550887fe160'; font-family: 'Times New Roman'"><span>718</span></span><span style="font-family: 'Times New Roman';">. The corresponding cost is expensed over the service period depending on the specific facts and circumstances of the agreement with the nonemployee. As of </span><span style="-aw-sdt-tag:'c237df05d38456da6ce7'; -aw-sdt-title:'Current_Period_P6'; font-family: 'Times New Roman'"><span>September 30, 2025</span></span><span style="font-family: 'Times New Roman';">, the remaining unamortized balance of prepaid assets related to these share-based payments for which the grant date criteria has been met and the services are expected to be rendered within one year is $</span><span style="-aw-sdt-tag:'c3aab794da6a33ebaf3d'; -aw-sdt-title:'Current Unamortized Vendor SBC'; font-family: 'Times New Roman'"><span><ix:nonFraction name="sxtp:UnamortizedBalance" contextRef="D20250930_1" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag868">240,004</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';"> ($</span><span style="-aw-sdt-tag:'cf8ef19d090c64e5bbab'; -aw-sdt-title:'Prior Period Unamortized Vendor SBC'; font-family: 'Times New Roman'"><span><ix:nonFraction name="sxtp:UnamortizedBalance" contextRef="D20241231" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag869">306,181</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';"> at </span><span style="-aw-sdt-tag:'c26c82bd0ee1b08b856a'; -aw-sdt-title:'Previous_Year_End_P8'; font-family: 'Times New Roman'"><span>December 31, 2024</span></span><span style="font-family: 'Times New Roman';">), which is presented as a component of prepaid and other assets on the accompanying </span><span style="-aw-sdt-tag:'be6-d2e-cb9-321-e328'; -aw-sdt-title:'Balance_Sheet_Title_P2'; font-family: 'Times New Roman'"><span>consolidated condensed balance sheets</span></span><span style="font-family: 'Times New Roman';">. The unamortized balance of noncurrent prepaid assets related to these share-based payments for which the services are expected to be rendered beyond one year is $</span><span style="-aw-sdt-tag:'c4028fc370a9695f41ea'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:PrepaidExpenseNoncurrent" contextRef="I20250930" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag877">0</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';"> ($</span><span style="-aw-sdt-tag:'c8c2a095517ee623341c'; -aw-sdt-title:'Prior Period Long Term Unamortized Vendor SBC'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:PrepaidExpenseNoncurrent" contextRef="I20241231" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag870">66,176</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';"> at </span><span style="-aw-sdt-tag:'c43649c75076a44f9e67'; -aw-sdt-title:'Previous_Year_End_P9'; font-family: 'Times New Roman'"><span>December 31, 2024</span></span><span style="font-family: 'Times New Roman';">), reported in long-term prepaid expense on the accompanying </span><span style="-aw-sdt-tag:'8d3-6a2-4c1-ed7-7507'; -aw-sdt-title:'Balance_Sheet_Title_P3'; font-family: 'Times New Roman'"><span>consolidated condensed balance sheets</span></span><span style="font-family: 'Times New Roman';">.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">The agreements with the nonemployees do not include any provisions to claw back the share-based payments in the event of nonperformance by the nonemployees. Subject to applicable federal and state securities laws, the nonemployees can sell the received equity instruments.</span></p></ix:continuation></div><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="width:380.25pt; font-weight:bold; display:inline-block; -aw-tabstop-align:left; -aw-tabstop-pos:380.25pt">&#160;</span></p><div style="-aw-sdt-tag:'PG_c52d425eff546406e8d1'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-family: 'Times New Roman';">22</span></p><div><hr style="width: 100%; color: #000000; background-color: #000000; margin: 1rem 0;"/></div></div></div><div class="Section_26"><div style="-aw-sdt-tag:'a45-221-8c3-a62-cf49'"><ix:nonNumeric name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" contextRef="D20250930_1" escape="true" id="Tag973"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-sdt-tag:'c7916e61a7bda9b51eb5'; font-family: 'Times New Roman'"><span style="font-weight:bold">11</span></span><span style="font-weight:bold; font-family: 'Times New Roman'">. COMMITMENTS AND CONTINGENCIES</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; text-decoration:underline; font-family: 'Times New Roman'">Leases</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">The Company is a party to a single lease for its office space located in Washington, DC, which was most recently renewed for an additional </span><span style="-sec-ix-hidden:Tag1013;-aw-sdt-tag:'471-47d-78e-0c2-c68d'; font-family: 'Times New Roman';"><span>one-year</span></span><span style="font-family: 'Times New Roman';"> term that expires March </span><span style="-aw-sdt-tag:'c8d35c399c9a3442b96c'; font-family: 'Times New Roman'"><span>31</span></span><span style="font-family: 'Times New Roman';">, </span><span style="-aw-sdt-tag:'ceb220ef0c9941bd9af2'; font-family: 'Times New Roman'"><span>2026</span></span><span style="font-family: 'Times New Roman';">. As the term of the office lease is </span><span style="-aw-sdt-tag:'cd0fb876e27f05507c99'; font-family: 'Times New Roman'"><span>12</span></span><span style="font-family: 'Times New Roman';"> months, the lease is not recorded on the balance sheet. The Company recognizes lease expense on this lease as short-term lease costs. Operating lease costs, including short-term leases, were in the amount of $</span><span style="-aw-sdt-tag:'cd5c94b9c313d289b382'; -aw-sdt-title:'Operating lease costs_CQ'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:OperatingLeaseCost" contextRef="D20250930" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag807">5,573</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">&#160;</span><span style="font-family: 'Times New Roman';">and $</span><span style="-aw-sdt-tag:'c0db659496b5badf8a70'; -aw-sdt-title:'Operating lease costs_PQ'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:OperatingLeaseCost" contextRef="D20240930" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag755">4,938</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">&#160;</span><span style="font-family: 'Times New Roman';">for the </span><span style="-aw-sdt-tag:'c00f68e43fb81f0a3a6f'; -aw-sdt-title:'Current_Quarter_P18'; font-family: 'Times New Roman'"><span>three months ended September 30, 2025</span></span><span style="font-family: 'Times New Roman';"> and </span><span style="-aw-sdt-tag:'c0544c7e1d672dd6a524'; -aw-sdt-title:'Previous_Year_P39'; font-family: 'Times New Roman'"><span>2024</span></span><span style="font-family: 'Times New Roman';">, respectively ($</span><span style="-aw-sdt-tag:'c19f05d774f689867aee'; -aw-sdt-title:'Operating lease costs_CYTD'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:OperatingLeaseCost" contextRef="D20250930_1" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag806">15,340</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">&#160;</span><span style="font-family: 'Times New Roman';">and $</span><span style="-aw-sdt-tag:'c323f9f24f97d741bebf'; -aw-sdt-title:'Operating lease costs_PYTD'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:OperatingLeaseCost" contextRef="D20240930_1" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag756">24,067</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">&#160;</span><span style="font-family: 'Times New Roman';">for the </span><span style="-aw-sdt-tag:'c3eaf105153db479206c'; -aw-sdt-title:'Current_YTD_P17'; font-family: 'Times New Roman'"><span>nine months ended September 30, 2025</span></span><span style="font-family: 'Times New Roman';"> and </span><span style="-aw-sdt-tag:'ccde6b94d63a3ed0d73b'; -aw-sdt-title:'Previous_Year_P40'; font-family: 'Times New Roman'"><span>2024</span></span><span style="font-family: 'Times New Roman';">, respectively).</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; text-decoration:underline; font-family: 'Times New Roman'">Board of Directors</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">In November and December </span><span style="-aw-sdt-tag:'ceded28c546cdff3103d'; font-family: 'Times New Roman'"><span>2022</span></span><span style="font-family: 'Times New Roman';">, the Company signed agreements with </span><span style="-aw-sdt-tag:'047-f50-789-ede-ed65'; font-family: 'Times New Roman'"><span><ix:nonFraction name="sxtp:NumberOfDirectors" contextRef="I20250930_DirectorMember" unitRef="Director" decimals="0" format="ixt-sec:numwordsen" id="Tag857">four</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';"> director nominees (Cheryl Xu, Paul Field, Charles Allen, and Stephen Toovey) which came into effect on July </span><span style="-aw-sdt-tag:'c5ebe60d064ae023bc98'; font-family: 'Times New Roman'"><span>11</span></span><span style="font-family: 'Times New Roman';">, </span><span style="-aw-sdt-tag:'c0db6f79eaa785e55516'; font-family: 'Times New Roman'"><span>2023</span></span><span style="font-family: 'Times New Roman';">, the date the Company&#8217;s Registration Statement was declared effective. Each director is entitled to receive cash compensation of $</span><span style="-aw-sdt-tag:'cead4e48e0e3dfb38324'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:CompensationAndBenefitsTrust" contextRef="I20250930_BoardOfDirectorsChairmanMember_StephenTooveyMember" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag757">11,250</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';"> quarterly. In addition, the </span><span style="-aw-sdt-tag:'c2b8816960a856041d4d'; font-family: 'Times New Roman'"><span><ix:nonFraction name="sxtp:NumberOfNonAuditCommitteeChairs" contextRef="I20250930" unitRef="Pure" decimals="0" format="ixt-sec:numwordsen" id="Tag758">two</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';"> non-audit committee chairs (Toovey, Field) will receive $</span><span style="-aw-sdt-tag:'cf60737ac055ebc86af7'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:CompensationAndBenefitsTrust" contextRef="I20250930_PaulFieldMember" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag759">1,250</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';"> per quarter and the audit committee chair (Allen) will receive an additional $</span><span style="-aw-sdt-tag:'c678970b8b9f3d32b9e0'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:CompensationAndBenefitsTrust" contextRef="I20250930_CharlesAllenMember" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag760">2,000</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';"> per quarter. In addition, each director is entitled to receive </span><span style="-aw-sdt-tag:'c45-3ff-244-abc-9e9e'; font-family: 'Times New Roman'"><ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" contextRef="D20250930_DirectorMember" escape="false" id="Tag858"><span>annual</span></ix:nonNumeric></span><span style="font-family: 'Times New Roman';"> equity-based compensation awards, with the amounts and terms to be determined by the Compensation Committee.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; text-decoration:underline; font-family: 'Times New Roman'">Contingencies</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">The Company&#8217;s operations are subject to a variety of local and state regulations. Failure to comply with one or more of those regulations could result in fines, restrictions on its operations, or losses of permits that could result in the Company ceasing operations.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; text-decoration:underline; font-family: 'Times New Roman'">Contingent Compensation </span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">Following the Company&#8217;s IPO and the conversion of the outstanding debt pursuant to the Knight Debt Conversion Agreement as discussed in Note </span><span style="-aw-sdt-tag:'cb6de7e290230b8a811a'; font-family: 'Times New Roman'"><span>8</span></span><span style="font-family: 'Times New Roman';">, the Company is obligated to pay Knight a contingent milestone payment of $</span><span style="-aw-sdt-tag:'c55651d68ed1749336c5'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="I20250930_IPOMember" unitRef="USD" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Tag818">10</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';"> million if the Company sells Arakoda or if a Change of Control occurs. The Company accounts for the contingent milestone payment as a derivative liability (See Note </span><span style="-aw-sdt-tag:'cb46d3d5eed43a8991ab'; font-family: 'Times New Roman'"><span>8</span></span><span style="font-family: 'Times New Roman';">).</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">On July </span><span style="-aw-sdt-tag:'c9ddb49ff306b2e819bc'; font-family: 'Times New Roman'"><span>15</span></span><span style="font-family: 'Times New Roman';">, </span><span style="-aw-sdt-tag:'c62eea5dde02cf11a936'; font-family: 'Times New Roman'"><span>2015</span></span><span style="font-family: 'Times New Roman';">, the Company entered into the Exclusive License Agreement with the U.S. Army Medical Materiel Development Activity (the &#8220;U.S. Army&#8221;), which was subsequently amended (the &#8220;U.S. Army Agreement&#8221;), in which the Company obtained a license to develop and commercialize the licensed technology with respect to all therapeutic applications and uses excluding radical cure of symptomatic vivax malaria. The term of the U.S. Army Agreement will continue until the expiration of the last to expire of the patent application or valid claim of the licensed technology, or </span><span style="-aw-sdt-tag:'cbf97d3e60b36d2a50b8'; font-family: 'Times New Roman'"><span><ix:nonNumeric name="sxtp:LicensedTechnologyTerm" contextRef="D20150715" format="ixt-sec:duryear" id="Tag761">20</ix:nonNumeric></span></span><span style="font-family: 'Times New Roman';"> years from the start date of the U.S. Army Agreement, unless terminated earlier by the parties. The Company must make a minimum annual royalty payment of </span><span style="-aw-sdt-tag:'c0743d438ddf722d27fc'; font-family: 'Times New Roman'"><span><ix:nonFraction name="sxtp:AnnualRoyaltyPaymentPercentage" contextRef="D20150715_BoardOfDirectorsChairmanMember" unitRef="Pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="Tag762">3</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">% of Net Sales (as defined in the U.S. Army Agreement) for Net Sales less than $</span><span style="-aw-sdt-tag:'cf2e115de1723a0ed45f'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:RoyaltyExpense" contextRef="D20150715_USGovernmentSalesMember" unitRef="USD" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Tag763">35</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';"> million, and </span><span style="-aw-sdt-tag:'c4481b3b4d4093d568f0'; font-family: 'Times New Roman'"><span><ix:nonFraction name="sxtp:AnnualRoyaltyPaymentPercentage" contextRef="D20150715" unitRef="Pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="Tag764">5</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">% of Net Sales greater than $</span><span style="-aw-sdt-tag:'cc31fd6e0a8dcfc322fa'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:RoyaltyExpense" contextRef="D20150715_USArmyAgreementMember" unitRef="USD" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="Tag765">35</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';"> million, with US government sales excluded from the definition of Net Sales. In addition, the Company must pay fees upon the achievement of certain milestones. The Company accrues the minimum annual royalty when the related sales occur. The achievement of the remaining milestones under the U.S. Army Agreement are not considered probable and thus no accruals for the related milestone payments have been made.</span></p><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">On December </span><span style="-aw-sdt-tag:'cbb240240b052d6f8172'; font-family: 'Times New Roman'"><span>20</span></span><span style="font-family: 'Times New Roman';">, </span><span style="-aw-sdt-tag:'c027369bd0398d6eba8f'; font-family: 'Times New Roman'"><span>2024</span></span><span style="font-family: 'Times New Roman';">, the Company entered into a Patent License Agreement with Tufts Medical Center (&#8220;Tufts MC&#8221;), in which the Company obtained a license to research and commercialize the licensed technology with respect to the use of tafenoquine for treatment and/or prevention of babesiosis (the &#8220;Tufts MC Agreement&#8221;). The term of the Tufts MC Agreement will continue until the expiration or final abandonment of the last patent application or issued patent for the use of tafenoquine for treatment and/or prevention of babesiosis, unless terminated earlier by the parties. On the earlier of (x) the date of patent issuance or (y) the date of regulatory approval for the use of tafenoquine product in treatment of babesiosis, the Company must make royalty payments equal to </span><span style="-aw-sdt-tag:'c54edac88924604315c8'; font-family: 'Times New Roman'"><span><ix:nonFraction name="sxtp:PercentageOfRoyaltyPaymentsOfNetSales" contextRef="D20241220" unitRef="Pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="Tag766">4</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">% of Net Sales (as defined in the Tufts MC Agreement) for tafenoquine sold in a format labeled for use in the treatment of babesiosis or </span><span style="-aw-sdt-tag:'cf88cbfc1ea21062cba6'; font-family: 'Times New Roman'"><span><ix:nonFraction name="sxtp:PercentageOfTreatmentOfBabesiosis" contextRef="D20241220_MinimumMember" unitRef="Pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="Tag767">2</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">% of Net Sales for </span><span style="-aw-sdt-tag:'c074caac69bf4612113a'; font-family: 'Times New Roman'"><span>60</span></span><span style="font-family: 'Times New Roman';">P products that are not sold in a format labeled for use in the treatment of babesiosis. In addition, for all sublicense revenue received by </span><span style="-aw-sdt-tag:'c86ede9c1c4a486b5149'; font-family: 'Times New Roman'"><span>60</span></span><span style="font-family: 'Times New Roman';">P from sales of sublicensed products, the Company must make royalty payments equal to </span><span style="-aw-sdt-tag:'c636764bc4488d0fba9e'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:RevenueRemainingPerformanceObligationPercentage" contextRef="I20241220" unitRef="Pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="Tag768">20</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">% of the revenue received by the Company for sales of tafenoquine sold in a format labeled for use in the treatment of babesiosis or </span><span style="-aw-sdt-tag:'cb710989fdd28cf064c7'; font-family: 'Times New Roman'"><span><ix:nonFraction name="sxtp:PercentageOfTreatmentOfBabesiosis" contextRef="D20241220_MaximumMember" unitRef="Pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="Tag769">10</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">% for sales of tafenoquine that are not sold in a format labeled for use in the treatment of babesiosis. As of </span><span style="-aw-sdt-tag:'cce588c7b78411dd262d'; -aw-sdt-title:'Current_Period_P24'; font-family: 'Times New Roman'"><span>September 30, 2025</span></span><span style="font-family: 'Times New Roman';">, the royalty period has not commenced, thus </span><span style="-aw-sdt-tag:'1dc-6d9-7b7-ffb-8c04'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:RoyaltyExpense" contextRef="D20250930_TuftsMedicalCenterAgreementMember" unitRef="USD" decimals="0" format="ixt-sec:numwordsen" id="Tag860">no</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';"> accruals have been made.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; text-decoration:underline; font-family: 'Times New Roman'">Litigation, Claims and Assessments</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">From time to time, the Company may be involved in litigation relating to claims arising out of operations in the normal course of business. As of </span><span style="-aw-sdt-tag:'c68a81d7a6d5e41ec529'; -aw-sdt-title:'Current_Period_P23'; font-family: 'Times New Roman'"><span>September 30, 2025</span></span><span style="font-family: 'Times New Roman';">, there were </span><span style="-aw-sdt-tag:'493-5d4-85c-584-67d2'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:LossContingencyPendingClaimsNumber" contextRef="I20250930" unitRef="USD" decimals="0" format="ixt-sec:numwordsen" id="Tag859">no</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';"> pending or threatened lawsuits that could reasonably be expected to have a material effect on the results of the Company&#8217;s operations.</span></p></ix:nonNumeric></div><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore">&#160;</span></p><div style="-aw-sdt-tag:'PG_a5a69d49d606c7a1'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-family: 'Times New Roman';">23</span></p><div><hr style="width: 100%; color: #000000; background-color: #000000; margin: 1rem 0;"/></div></div></div><div class="Section_27"><div style="-aw-sdt-tag:'453-9ae-4b1-135-a0b8'"><ix:nonNumeric name="us-gaap:SubsequentEventsTextBlock" contextRef="D20250930_1" escape="true" id="Tag990"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">12. SUBSEQUENT EVENTS</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span><span style="width:104.75pt; display:inline-block; -aw-tabstop-align:left; -aw-tabstop-pos:107.25pt; font-family: 'Times New Roman'">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">The Company has evaluated subsequent events through </span><span style="-aw-sdt-tag:'e16-1c0-097-c46-bd43'; -aw-sdt-title:'Current_Period_Date_FS_Issued_P2'; font-family: 'Times New Roman'"><span>November 13, 2025</span></span><span style="font-family: 'Times New Roman';">, which is the date the financial statements were issued. </span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-style:italic; font-family: 'Times New Roman'">2025 Annual Meeting of Stockholders</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">On October 8, 2025, the Company conducted its virtual 2025 Annual Meeting of Stockholders (the &#8220;2025 Annual Meeting&#8221;). The Company&#8217;s stockholders of record at the close of business on August 29, 2025, the record date for the determination of stockholders entitled to vote at the 2025 Annual Meeting, approved the proposals to (1) elect </span><span style="-aw-sdt-tag:'454-79f-b5b-ad3-7921'; font-family: 'Times New Roman'"><span><ix:nonFraction name="sxtp:NumberOfDirectors" contextRef="I20251008_SubsequentEventMember" unitRef="Number" decimals="0" format="ixt-sec:numwordsen" id="Tag846">five</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';"> directors to serve until the 2026 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified&#894; (2) approve an amendment to the 2022 Plan to increase the number of shares of common stock available for issuance by </span><span style="-aw-sdt-tag:'ad1-9b9-eb6-e8c-4870'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="I20251008_SubsequentEventMember" unitRef="Shares" decimals="0" format="ixt:num-dot-decimal" id="Tag845">250,000</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';"> shares&#894; (3) approve an amendment to the Company&#8217;s Certificate of Incorporation, to effect a reverse stock split of the common stock at a reverse stock split ratio ranging from </span><span style="-aw-sdt-tag:'6e9-6db-b5f-c60-506b'; font-family: 'Times New Roman'"><ix:nonNumeric name="us-gaap:StockholdersEquityReverseStockSplit" contextRef="D20251008_SubsequentEventMember" escape="false" id="Tag847"><span>1:3 to 1:10</span></ix:nonNumeric></span><span style="font-family: 'Times New Roman';"> inclusive, as may be determined at the appropriate time by the Board of Directors, in its sole discretion&#894; and (4) ratify the selection of RBSM LLP by the Board of Directors as the Company&#8217;s independent registered public accounting firm for the fiscal year ending December 31, 2025.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-style:italic; font-family: 'Times New Roman'">Option Grant</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">On October 21, 2025, the Company&#8217;s Board of Directors approved the grant of </span><span style="-aw-sdt-tag:'df3-cbb-b07-8bb-c693'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="D20251021_SubsequentEventMember_StockOptionsMember_DirectorMember" unitRef="Shares" decimals="0" format="ixt:num-dot-decimal" id="Tag888">32,000</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';"> stock options to each of the </span><span style="-aw-sdt-tag:'705-e1a-464-35f-5940'; font-family: 'Times New Roman'"><span><ix:nonFraction name="sxtp:NumberOfDirectors" contextRef="I20251021_SubsequentEventMember_StockOptionsMember_DirectorMember" unitRef="Number" decimals="0" format="ixt-sec:numwordsen" id="Tag889">four</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';"> directors (</span><span style="-aw-sdt-tag:'50a-16a-20d-537-e8de'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="D20251021_SubsequentEventMember_StockOptionsMember_DirectorOneMember" unitRef="Shares" decimals="0" format="ixt:num-dot-decimal" id="Tag890">8,000</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';"> per director) at a per share exercise price of $</span><span style="-aw-sdt-tag:'1ec-25c-5ee-eca-013d'; font-family: 'Times New Roman'"><span><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="D20251021_SubsequentEventMember_StockOptionsMember_DirectorMember" unitRef="USDPerShare" decimals="2" format="ixt:num-dot-decimal" id="Tag891">1.46</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">. These stock options were fully vested on the date of grant and have a term of </span><span style="-aw-sdt-tag:'71a-74e-77b-7dc-6383'; font-family: 'Times New Roman'"><span><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="D20251021_SubsequentEventMember_StockOptionsMember_DirectorMember" format="ixt-sec:durwordsen" id="Tag892">seven years</ix:nonNumeric></span></span><span style="font-family: 'Times New Roman';">. </span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-style:italic; font-family: 'Times New Roman'">2025 ATM Agreement</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">Pursuant to the 2025 ATM Agreement described in Note 6, between </span><span style="-aw-sdt-tag:'075-02e-67e-8cb-173b'; -aw-sdt-title:'ATM_Sales_Start Date'; font-family: 'Times New Roman'"><span>October 16, 2025</span></span><span style="font-family: 'Times New Roman';"> and </span><span style="-aw-sdt-tag:'9c6-a68-8ff-273-4e9d'; -aw-sdt-title:'Signature_Date_P8'; font-family: 'Times New Roman'"><span>November 13, 2025</span></span><span style="font-family: 'Times New Roman';">, the Company sold an aggregate of </span><span style="-aw-sdt-tag:'3bd-c63-bbc-85b-e9a5'; -aw-sdt-title:'ATM_Shares_Sold'; font-family: 'Times New Roman'"><span><ix:nonFraction name="sxtp:ATMOfferingShares" contextRef="D20251113_SubsequentEventMember_HCWainwrightAndCoLLCMember_AtTheMarket2025AgreementMember" unitRef="Shares" decimals="0" format="ixt:num-dot-decimal" id="Tag918">125,979</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';"> shares at a weighted average price per share of $</span><span style="-aw-sdt-tag:'88e-ea0-f71-977-3a31'; -aw-sdt-title:'ATM_Sales_WeightedAvgPrice'; font-family: 'Times New Roman'"><span><ix:nonFraction name="sxtp:CommonStockSalesAgreementWeightedAveragePricePerShare" contextRef="D20251113_SubsequentEventMember_HCWainwrightAndCoLLCMember_AtTheMarket2025AgreementMember" unitRef="USDPerShare" decimals="2" format="ixt:num-dot-decimal" id="Tag919">1.62</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">, generating net proceeds to the Company of $</span><span style="-aw-sdt-tag:'63a-f84-1ca-24b-ad31'; -aw-sdt-title:'ATM_Sales_NetProceeds'; font-family: 'Times New Roman'"><span><ix:nonFraction name="sxtp:ProceedsFromCommonStockSalesAgreementNet" contextRef="D20251113_SubsequentEventMember_HCWainwrightAndCoLLCMember_AtTheMarket2025AgreementMember" unitRef="USD" decimals="0" format="ixt:num-dot-decimal" id="Tag920">196,356</ix:nonFraction></span></span><span style="font-family: 'Times New Roman';">, after deducting commissions and certain other offering expenses. </span><span style="-aw-import:spaces; font-family: 'Times New Roman'">&#160; </span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">There have been no other events or transactions during this time which would have a material effect on these consolidated condensed financial statements.</span></p></ix:nonNumeric></div><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span>&#160;</span></p><div style="-aw-sdt-tag:'PG_c1927fc58aae31ed2f84'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-family: 'Times New Roman';">24</span></p><div><hr style="width: 100%; color: #000000; background-color: #000000; margin: 1rem 0;"/></div></div></div><div class="Section_28"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span id="TOC_cf05ecac3ce0c1336e68"><span style="font-weight:bold">ITEM 2. MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-bookmark-end:TOC_cf05ecac3ce0c1336e68"></span><span>&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>The following discussion and analysis is intended as a review of significant factors affecting our financial condition and results of operations for the periods indicated. The discussion should be read in conjunction with our unaudited consolidated condensed financial statements and the related notes included elsewhere in this Quarterly Report on Form 10-Q and the audited financial statements and the other information set forth in certain of our filings with the SEC, including our Annual Report on Form 10-K for the year ended </span><span style="-aw-sdt-tag:'ca889c1abbdf5490243a'; -aw-sdt-title:'Previous_Year_End_P1'"><span style="font-family: 'Times New Roman';">December 31, 2024</span></span><span> filed with the SEC on March 27, 2025. In addition to historical information, the following Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations contains forward-looking statements that involve risks and uncertainties. Our actual results could differ significantly from those anticipated in these forward-looking statements as a result of certain factors discussed herein and any other periodic reports filed and to be filed with the SEC.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-weight:bold">Overview</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>We are a specialty pharmaceutical company with a goal of using cutting-edge biological science and applied research to further develop and commercialize new therapies for the prevention and treatment of infectious diseases. We have successfully achieved regulatory approval of Arakoda&#174; (&#8220;Arakoda&#8221;), a malaria preventative treatment that has been on the market since late 2019. Currently, 60P&#8217;s pipeline under development covers development programs for vector-borne, fungal, and viral diseases utilizing three of the Company&#8217;s future products: (i) new products that contain the Arakoda regimen of Tafenoquine; (ii) new products that contain Tafenoquine; and (iii) Celgosivir and/or botanical extracts from Australian Chestnut Trees.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-weight:bold">Business Developments</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>The following highlights significant business developments in our business during the quarter ended </span><span style="-aw-sdt-tag:'c5daa9a9e7a611524f85'; -aw-sdt-title:'Current_Period_P5'"><span style="font-family: 'Times New Roman';">September 30, 2025</span></span><span>.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>&#160;</span></p><table cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr style="height:11.5pt"><td style="width:3.34%; vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore">&#160;</span></p></td><td style="width:3.34%; vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span>&#9679;</span></p></td><td style="width:93.34%; vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>On July 14, 2025, we announced our intent to seek a Minor Use Minor Species (MUMS) designation from the United States Food and Drug Administration (FDA) for the treatment of acute canine babesiosis upon completing a gap analysis of our existing data.</span></p></td></tr></tbody></table><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore">&#160;</span></p><table cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr style="height:11.5pt"><td style="width:3.34%; vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore">&#160;</span></p></td><td style="width:3.34%; vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span>&#9679;</span></p></td><td style="width:93.34%; vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>After completing a 6,000 nationwide patient survey and quantitative research study, on July 15, 2025, we announced that we had determined the total addressable market (TAM) for Babesiosis treatment to be $1.1 billion through patent expiration in 2035.</span></p></td></tr></tbody></table><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore">&#160;</span></p><table cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr style="height:11.5pt"><td style="width:3.34%; vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore">&#160;</span></p></td><td style="width:3.34%; vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span>&#9679;</span></p></td><td style="width:93.34%; vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>On July 17, 2025, we announced our entry into a sponsored research agreement with Tulane University to evaluate activity of tafenoquine against lyme and bartonella bacteria.</span></p></td></tr></tbody></table><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore">&#160;</span></p><table cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr style="height:11.5pt"><td style="width:3.34%; vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore">&#160;</span></p></td><td style="width:3.34%; vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span>&#9679;</span></p></td><td style="width:93.34%; vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>On August 19, 2025, we announced our partnership with the Icahn School of Medicine at Mount Sinai for our planned Phase II clinical study of tafenoquine in treating chronic babesiosis.</span></p></td></tr></tbody></table><p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt"><span style="-aw-import:ignore">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-style:italic">July 2025 Offering</span></p><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>On July 15, 2025, we entered into a securities purchase agreement with certain institutional investors pursuant to which we sold, in a registered direct offering (the &#8220;July 2025 Offering&#8221;), </span><span style="-aw-sdt-tag:'b54-dde-b60-721-9596'; -aw-sdt-title:'MDA_July2025_Common Units Sold'"><span style="font-family: 'Times New Roman';">1,753,314</span></span><span> units at an offering price of $</span><span style="-aw-sdt-tag:'59b-6a7-d65-24e-3dd5'; -aw-sdt-title:'MDA_July2025_Common Unit Price'"><span style="font-family: 'Times New Roman';">1.90</span></span><span> per unit and </span><span style="-aw-sdt-tag:'780-89f-ab8-9c6-ca3a'; -aw-sdt-title:'MDA_July2025_PreFunded Units Sold'"><span style="font-family: 'Times New Roman';">878,264</span></span><span> pre-funded units at an offering price of $</span><span style="-aw-sdt-tag:'7df-977-51f-d6a-03b0'; -aw-sdt-title:'MDA_July2025_PreFunded Unit Price'"><span style="font-family: 'Times New Roman';">1.899</span></span><span> per pre-funded unit. Each unit consisted of (i) one share of common stock, (ii) one series A-1 warrant exercisable for one share of common stock (the &#8220;July 2025 A-1 Warrants&#8221;), and (iii) one series A-2 warrant exercisable for one share of common stock (the &#8220;July 2025 A-2 Warrants&#8221; and together with the July 2025 A-1 Warrants, the &#8220;July 2025 Warrants&#8221;). Each pre-funded unit consists of one pre-funded warrant exercisable for one share of common stock (the &#8220;July 2025 Pre-Funded Warrants&#8221;) and warrants identical to the July 2025 Warrants included in the units. The July 2025 Pre-Funded Warrants have an exercise price of $</span><span style="-aw-sdt-tag:'c46-b5b-9d0-6c1-7cdc'; -aw-sdt-title:'MDA_July2025_PreFundedExPrice'"><span style="font-family: 'Times New Roman';">0.001</span></span><span> per share, and were immediately exercisable beginning on </span><span style="-aw-sdt-tag:'eff-a47-97f-241-0e7f'; -aw-sdt-title:'MDA_July2025_PreFunded_InitialExerciseDate'"><span style="font-family: 'Times New Roman';">July 16, 2025</span></span><span> until exercised in full. The July 2025 A-1 Warrants have an exercise price of $</span><span style="-aw-sdt-tag:'91a-490-5d2-33b-bed8'; -aw-sdt-title:'MDA_July2025_A-1ExPrice'"><span style="font-family: 'Times New Roman';">1.90</span></span><span> per share and are exercisable beginning on July 16, 2025 until </span><span style="-aw-sdt-tag:'fec-be4-4f1-367-2fbf'; -aw-sdt-title:'MDA_July2025_A-1TermDate'"><span style="font-family: 'Times New Roman';">July 15, 2030</span></span><span>. The July 2025 A-2 Warrants have an exercise price of $</span><span style="-aw-sdt-tag:'623-434-b48-784-a533'; -aw-sdt-title:'MDA_July2025_A-2ExPrice'"><span style="font-family: 'Times New Roman';">1.90</span></span><span> per share and are exercisable beginning on July 16, 2025 until </span><span style="-aw-sdt-tag:'098-fbe-e62-8d9-2c63'; -aw-sdt-title:'MDA_July2025_A-2TermDate'"><span style="font-family: 'Times New Roman';">January 15, 2027</span></span><span>.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-import:ignore">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>As compensation for acting as the placement agent for the July 2025 Offering, we also issued to H.C. Wainwright &amp; Co., LLC warrants (the &#8220;July 2025 Placement Agent Warrants&#8221;) to purchase up to </span><span style="-aw-sdt-tag:'00a-755-360-d7a-9f1a'; -aw-sdt-title:'MDA_July2025_AgentWarrantsNo'"><span style="font-family: 'Times New Roman';">197,368</span></span><span> shares of common stock. The July 2025 Placement Agent Warrants have an exercise price equal to $</span><span style="-aw-sdt-tag:'cc6-6e7-c8c-988-c4f7'; -aw-sdt-title:'MDA_July2025_AgentWarrants_ExPrice'"><span style="font-family: 'Times New Roman';">2.375</span></span><span> per share and are exercisable upon issuance, or July 16, 2025, and expire five years from the date of issuance, or </span><span style="-aw-sdt-tag:'15f-a48-8bd-62c-2e09'; -aw-sdt-title:'MDA_July2025_AgentWarrantsTermDate'"><span style="font-family: 'Times New Roman';">July 15, 2030</span></span><span>. </span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-import:ignore">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>The July 2025 Offering was made pursuant to our registration statement on Form S-1 (File No. 333-288550), which was declared effective by the Securities and Exchange Commission (the &#8220;SEC&#8221;) on July 15, 2025, and the final prospectus, which we filed with the SEC on July 16, 2025. The Offering closed on July 16, 2025, resulting in net proceeds of approximately $</span><span style="-aw-sdt-tag:'073-2d6-403-526-7952'; -aw-sdt-title:'MDA_July2025_NetProceeds'"><span style="font-family: 'Times New Roman';">4,281,300</span></span><span>, after deducting placement agent fees and other offering expenses paid by us. </span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-import:ignore">&#160;</span></p><div style="-aw-sdt-tag:'PG_add1b4605d9ef6ce'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-family: 'Times New Roman';">25</span></p><div><hr style="width: 100%; color: #000000; background-color: #000000; margin: 1rem 0;"/></div></div></div><div class="Section_29"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-style:italic">2025 ATM Agreement</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-style:italic; -aw-import:ignore">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>On September 5, 2025, we entered into an At-The-Market Sales Agreement (the &#8220;2025 ATM Agreement&#8221;) with H.C. Wainwright &amp; Co., LLC (&#8220;Wainwright&#8221;) pursuant to which we may, from time to time, offer and sell shares of our common stock, having aggregate gross sales proceeds of up to $1,397,532 (the &#8220;2025 ATM Offering&#8221;). As compensation for acting as the sales agent for the 2025 ATM Offering, Wainwright will be entitled to a commission of 3.0% of the gross proceeds from sales of shares in the 2025 ATM Offering. The common stock to be sold under the 2025 ATM Agreement, if any, will be issued and sold pursuant to our shelf registration statement on Form S-3 and accompanying base prospectus (Registration Statement No. 333-280796), which was declared effective by the SEC on July 18, 2024, and our prospectus supplement dated September 5, 2025 relating to the offer and sale of the shares pursuant to the 2025 ATM Agreement. Between </span><span style="-aw-sdt-tag:'0c6-117-dcd-78c-c6e9'; -aw-sdt-title:'ATM_Sales_Start'"><span style="font-family: 'Times New Roman';">October 16, 2025</span></span><span> and </span><span style="-aw-sdt-tag:'752-c73-b71-88b-b9e5'; -aw-sdt-title:'Signature_Date_P7'"><span style="font-family: 'Times New Roman';">November 13, 2025</span></span><span>, we sold an aggregate of </span><span style="-aw-sdt-tag:'24f-93b-fa0-af4-250c'; -aw-sdt-title:'Cummulative ATM Shares Sold'"><span style="font-family: 'Times New Roman';">125,979</span></span><span> shares at a weighted average price per share of $</span><span style="-aw-sdt-tag:'06e-546-6c5-0f5-c8c2'; -aw-sdt-title:'Cummulative Share Price'"><span style="font-family: 'Times New Roman';">1.62</span></span><span>, generating net proceeds of $</span><span style="-aw-sdt-tag:'164-472-09d-be9-04cd'; -aw-sdt-title:'Cummualtive ATM Proceeds'"><span style="font-family: 'Times New Roman';">196,356</span></span><span>, after deducting commissions and certain other offering expenses.</span></p><p style="margin-top:0pt; margin-bottom:0pt"><span style="font-style:italic; -aw-import:ignore">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold">Liquidity and Capital Resources</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>As of </span><span style="-aw-sdt-tag:'c5d89a292184b57f52a1'; -aw-sdt-title:'Current_Period_P10'"><span style="font-family: 'Times New Roman';">September 30, 2025</span></span><span>, we had cash and cash equivalents of $</span><span style="-aw-sdt-tag:'cd4a2b609697f7644d09'; -aw-sdt-title:'cash and cash equivalents_CP 2'"><span style="font-family: 'Times New Roman';">4,115,779</span></span><span> ($</span><span style="-aw-sdt-tag:'c92061b51c8d94d66ab2'; -aw-sdt-title:'cash and cash equivalents_PY 2'"><span style="font-family: 'Times New Roman';">1,659,353</span></span><span> as of </span><span style="-aw-sdt-tag:'c5d5a250c86435e71fe0'; -aw-sdt-title:'Previous_Year_End_P3'"><span style="font-family: 'Times New Roman';">December 31, 2024</span></span><span>). For the </span><span style="-aw-sdt-tag:'cd73ca23f076ac04d615'; -aw-sdt-title:'Current_YTD_P11'"><span style="font-family: 'Times New Roman';">nine months ended September 30, 2025</span></span><span> and </span><span style="-aw-sdt-tag:'c48163b6dd1dcf636af2'; -aw-sdt-title:'Previous_Year_P28'"><span style="font-family: 'Times New Roman';">2024</span></span><span>, our net cash used in operating activities was $</span><span style="-aw-sdt-tag:'c05dce6f37f89a916302'; -aw-sdt-title:'Net cash used in operating activities_CYTD'"><span style="font-family: 'Times New Roman';">5,156,566</span></span><span> and $</span><span style="-aw-sdt-tag:'cf26143ed8cfad0dcf63'; -aw-sdt-title:'Net cash used in operating activities_PYTD'"><span style="font-family: 'Times New Roman';">4,009,871</span></span><span>, respectively. To date, we have financed our operations primarily through the issuance of common stock, warrants to purchase common stock, and proceeds from the issuance of convertible debt and promissory notes. Based on current internal projections, taking into consideration the net proceeds of approximately $</span><span style="-aw-sdt-tag:'ac8-1f8-059-523-7541'; -aw-sdt-title:'July 2025_ Offering proceeds'"><span style="font-family: 'Times New Roman';">4.3</span></span><span> million received from the July 2025 public offering and an additional $</span><span style="-aw-sdt-tag:'e16-433-1ae-709-b4fd'; -aw-sdt-title:'MDA_ATMProceeds'"><span style="font-family: 'Times New Roman';">196</span></span><span> thousand received through the 2025 ATM Agreement, we estimate that we will have sufficient funds to remain viable through March 31, 2026, assuming no additional capital raises. We cannot give assurance that we can increase our cash balances or limit our cash consumption and thus maintain sufficient cash balances for our planned operations or future acquisitions. Future business demands may lead to cash utilization at levels greater than recently experienced. We may need to raise additional capital in the future. However, we cannot assure you that we will be able to raise additional capital on acceptable terms, or at all.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-weight:bold; font-style:italic">Going Concern</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>In their audit report for the fiscal year ended </span><span style="-aw-sdt-tag:'c09b1b589036e366f299'; -aw-sdt-title:'Previous_Year_End_P14'"><span style="font-family: 'Times New Roman';">December 31, 2024</span></span><span>, our auditors have expressed their concern as to our ability to continue as a going concern. Our ability to continue as a going concern is dependent upon our ability to generate cash flows from operations and obtain financing. The audited consolidated financial statements for the year ended </span><span style="-aw-sdt-tag:'c942778edf937be03f7e'; -aw-sdt-title:'Previous_Year_End_P20'"><span style="font-family: 'Times New Roman';">December 31, 2024</span></span><span> included an explanatory note referring to our recurring operating losses and expressing substantial doubt in our ability to continue as a going concern. </span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>Our future results are subject to substantial risks and uncertainties. Since our inception, we have not demonstrated the ability to generate enough revenues to date to cover operating expenses and we have accumulated losses to date. To date, we have funded our operations primarily with proceeds from sales of common stock and warrants for the purchase of common stock, sales of preferred stock, proceeds from the issuance of convertible debt and borrowings under loan and </span><span style="-aw-sdt-tag:'c26a0ebb37b60e736288'; -aw-sdt-title:'Current_period_P1'"><span style="font-family: 'Times New Roman';">security</span></span><span> agreements.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>Continuation as a going concern is dependent upon our ability to meet our financial requirements, raise additional capital, and achieve gross profitability from our single marketed product. To achieve profitability, we expect we will need to raise additional capital to fund our activities relating to commercial support for our existing product and any future clinical research trials and operating activities. However, there can be no assurance that we will ever achieve or maintain profitability. These conditions, among others, raise substantial doubt about our ability to continue as a going concern for one year from the date these financial statements are issued.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>We plan to fund our operations through third party and related party debt/advances, private placement of restricted securities and the issuance of stock in a subsequent offering until such a time as the business achieves profitability or a business combination may be achieved. However, there can be no assurance that we will be successful in raising additional capital or that such capital, if available, will be on terms that are favorable to us. Debt financing and equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise funds through collaborations, or other similar arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us and/or may reduce the value of our common stock. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market our product candidates even if we would otherwise prefer to develop and market such product candidates ourselves.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>As such, we have concluded that such plans do not alleviate the substantial doubt about our ability to continue as a going concern for one year from the date the accompanying financial statements are issued.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>The accompanying consolidated condensed financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of obligations in the normal course of business, and do not include any adjustments to the amount and classification of assets and liabilities that may be necessary should we be unable to continue as a going concern.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-import:ignore">&#160;</span></p><div style="-aw-sdt-tag:'PG_f3fef19916f69e37'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-family: 'Times New Roman';">26</span></p><div><hr style="width: 100%; color: #000000; background-color: #000000; margin: 1rem 0;"/></div></div></div><div class="Section_30"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>&#160;</span><span style="font-weight:bold; font-style:italic">Contractual Obligations</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>The following table summarizes our contractual obligations as of </span><span style="-aw-sdt-tag:'c54df7f5adda2e4f4f83'; -aw-sdt-title:'Current_Period_P13'"><span style="font-family: 'Times New Roman';">September 30, 2025</span></span><span>:</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-import:ignore">&#160;</span></p><div style="-aw-sdt-tag:'ca379082c4a7f6013636'; -aw-sdt-title:'ITEM 2, 3 and 4_T1'"><table cellspacing="0" cellpadding="0" style="width:100%; border-collapse:collapse"><tbody><tr style="height:11.5pt"><td style="width:40%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="11" style="border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_59c161f1a76c4011868a0f808b00e212'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">Payments Due By Period</span></p></div></td></tr><tr style="height:11.5pt"><td style="width:40%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="2" style="border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_e8de4f3c5128469f82a79ac8f847ca00'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">Total</span></p></div></td><td style="width:1%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="2" style="border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_1d7245007b5949c5937037404fb00ad7'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">Less than 1 year</span></p></div></td><td style="width:1%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="2" style="border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_9d345ec2ec854cd49d1960155bfe0bbd'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">1-3 years</span></p></div></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="2" style="border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_964c4af4318f4c0a9746724b98e14cb1'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">4-5 years</span></p></div></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="2" style="border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_45cf24f6f540426a81cb0d82fd08b23a'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">More than 5 Years</span></p></div></td></tr><tr style="height:11.5pt"><td style="width:40%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_2c628ba63a25420e8b74a85359c3a1e3'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Principal obligations on the debt arrangements</span></p></div></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_e2a599034833424da103df7ded38fce1'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_b94ce693d9fa4ca5891fcbcc2eb293ed'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">150,000</span></p></div></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_bb5887633fd140328414e6cbc06a9427'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-tag:'C_315760fa380441379495c521bf4d2c8a'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_00d3a0f29ef74192bd1318278f77c19f'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_014fca075c6f44e2853ef5f31b3978da'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">6,167</span></p></div></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_58a2155b20a345c7b0a17086d0075e37'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_535f6d4427e847e69d23f5f34e6de2c7'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">7,007</span></p></div></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_38ab00c5af424432b80baebce578ed11'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_88503e58eb5744b2af6a84651781041b'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">136,826</span></p></div></td></tr><tr style="height:11.5pt"><td style="width:40%; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_614ea500167440be9244596178aaab79'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Interest obligations on the debt arrangements</span></p></div></td><td style="width:1%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_a1f82dba01cd4f10882a08558fc001cc'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">98,068</span></p></div></td><td style="width:1%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_bb6eefce324d49ada7f482e093146f27'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">8,772</span></p></div></td><td style="width:1%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_ac8b68a7db3348e9a3da5bdce3857688'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">11,377</span></p></div></td><td style="width:1%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_fa3e7acfb8124dbbaaae813300f6b437'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">10,537</span></p></div></td><td style="width:1%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_22bb59d2d73e4ac6bccc6b67851be0f6'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">67,382</span></p></div></td></tr><tr style="height:11.5pt"><td style="width:40%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_4a29f145e67c4d23bb8cd8b4d4d9cda3'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Accounts payable and accrued expenses</span></p></div></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_e3fd3455ee924ca59b87751ac58edc39'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">1,391,347</span></p></div></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_7bf40e7c1e5c4680a7ee8321dc0096bd'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">1,391,347</span></p></div></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-tag:'C_ad82a9ddca6543ff8e0b38373158fa9e'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-tag:'C_0769b0f6b8964a2689ec136b6b36de82'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-tag:'C_0faccc36da3c4544ac92d9f7ad978227'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td></tr><tr style="height:11.5pt"><td style="width:40%; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_11aaaf6ff24340a1b40e4fcc1ff8f1fe'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Total</span></p></div></td><td style="width:1%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_87271920601f4cc9877d697c2c6b2f14'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_d4b8ff74a04e43258bc1a9662fc9c8aa'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">1,639,415</span></p></div></td><td style="width:1%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_85d6bf52b9354e1e9144568c76d1fc5d'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_b42d4bb6dd4c4db69c52ecc168405cee'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">1,400,119</span></p></div></td><td style="width:1%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_af936fcbf5da484c8fdae1ed93267511'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_31567253a9ca456bb293942133568711'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">17,544</span></p></div></td><td style="width:1%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_356156cccbc64a79914462a3cb8154aa'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_7a999008e9b245398d302f2320823c6a'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">17,544</span></p></div></td><td style="width:1%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_8ad1fde9337244aa93bc8dce54dfa059'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_acff072292834ef09d57cd607c86eb00'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">204,208</span></p></div></td></tr></tbody></table></div><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>&#160;</span><span>&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>Amounts related to contingent milestone payments are not considered contractual obligations as they are contingent on the achievement of certain milestones. These contingent milestones may or may not be achieved. We have not included any of these amounts in the table above as we cannot estimate or predict when, or if, these amounts will become due.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-weight:bold">Components of Results of Operations</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-weight:bold; font-style:italic">Product Revenues - net of Discounts and Rebates</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>We receive the majority of our product revenues from sales of our Arakoda product to resellers in the U.S. and abroad. Foreign sales to both Australia and Europe are further subject to profit sharing agreements for boxes sold to customers. Sales to resellers in the US are subject to considerable discounts and rebates for services provided by our third-party logistics (&#8220;3PL&#8221;) partner and wholesalers and pharmacy benefit managers (&#8220;PBMs&#8221;).</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-weight:bold; font-style:italic">Cost of Revenues, Gross Profit, and Gross Margin</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>Cost of revenues associated with our products is primarily comprised of direct materials, shipping, manufacturing-related costs incurred in the production process, serialization costs, and inventory write-downs due to expiration.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-weight:bold; font-style:italic">Other Operating Revenues</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>Other operating revenues for the periods presented include research revenue earned from the Australian Tax Authority for research activities conducted in Australia. Beginning in the third quarter of 2024, we began to recognize research revenues associated with our new contract with the United States Army Medical Material Development Activity (USAMMDA) for Arakoda supply chain upgrade support. Research revenue under this contract is recognized when we incur the direct costs eligible for reimbursement, up to the maximum allowable amount.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-weight:bold; font-style:italic">Operating Expenses</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-style:italic">Research and Development</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>Research and development costs for the periods presented primarily consist of contracted research and development services and costs associated with preparation for and conducting our Babesiosis trial. We expense all research and development costs in the period in which they are incurred. Payments made prior to the receipt of goods or services to be used in research and development are recognized as prepaid assets and expensed over the service period as the services are provided. We have also issued shares of our common stock to vendors in exchange for research and development services.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-style:italic">General and Administrative Expenses</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>Our general and administrative expenses primarily consist of salaries, advertising and promotion expenses, professional services fees, such as consulting, audit, accounting and legal fees, general corporate costs and allocated costs, including facilities, information technology and amortization of intangibles.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-weight:bold; font-style:italic">Interest and Other Income (Expense), Net</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>We earn interest income from cash invested in interest-bearing accounts, as well as cash equivalents and short-term investments consisting of certificates of deposits with original maturities ranging from three to six months. Interest expense for the periods presented is limited to a single $150,000 SBA loan that bears interest at 3.75%. Other components of </span><span style="-aw-sdt-tag:'160-669-eb4-cf4-eadf'; -aw-sdt-title:'Other_income_(expense)_P2'"><span style="font-family: 'Times New Roman';">other income (expense)</span></span><span> include changes in the fair value of derivative liabilities and other miscellaneous income or expenses.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>&#160;</span></p><div style="-aw-sdt-tag:'PG_cc0093e570255c4c9632'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-family: 'Times New Roman';">27</span></p><div><hr style="width: 100%; color: #000000; background-color: #000000; margin: 1rem 0;"/></div></div></div><div class="Section_31"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-weight:bold">Results of Operations </span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>The following table sets forth our results of operations for the periods presented:</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-import:ignore">&#160;</span></p><div style="-aw-sdt-tag:'c62327f85cc17164e60e'; -aw-sdt-title:'ITEM 2, 3 and 4_T2'"><table cellspacing="0" cellpadding="0" style="width:100%; border-collapse:collapse"><tbody><tr style="height:11.5pt"><td style="width:52%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="5" style="border-bottom:1.5pt solid #000000; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_a74fbc3ef80d4430bc3922b7da772686'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">For the Three Months Ended September 30,</span></p></div></td><td style="width:1%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="5" style="border-bottom:1.5pt solid #000000; padding-left:11.5pt; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_10e8acbffde9440682a63f8b9847db15'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">For the Nine Months Ended September 30,</span></p></div></td></tr><tr style="height:11.5pt"><td style="width:52%; border-bottom:1.5pt solid #000000; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_ef214b3d959b4a0da048a70451502792'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">Consolidated Statements of Operations Data:</span></p></div></td><td style="width:1%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="2" style="border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_7075fea7067345efa076eb7b3a40b0c6'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">2025</span></p></div></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="2" style="border-bottom:1.5pt solid #000000; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_33411610dc5e49079c760db9d0dc752c'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">2024</span></p></div></td><td style="width:1%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="2" style="border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_ac9dafcc85b64487ae88dfb3abb5e4fc'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">2025</span></p></div></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="2" style="border-bottom:1.5pt solid #000000; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_bd0b494c1a73478696aa2818c527e2ac'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">2024</span></p></div></td></tr><tr style="height:11.5pt"><td style="width:52%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_21e1950ec6264eb49b4436eab5550ba0'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Product Revenues &#8211; net of Discounts and Rebates</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_856b016610824639a5970776314e6d04'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_fb7a1cfb1241435b90489cf891e9ed41'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">437,602</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_ddbc825a60cc4188922a1f05164f0826'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_279a670396b141afa5c7af3cfd4e29db'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">135,293</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_55a43c428e144dcc995255e16999615c'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_1b7a2697ec3e4801bd523d4b2ea34e5b'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">702,086</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_e5db6205891044a9a38678521dd83f18'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_d84cd50888714f458545c1b42d1c154f'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">365,939</span></p></div></td></tr><tr style="height:11.5pt"><td style="width:52%; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_04bd3cdad58b4c2ea6abf59d47843358'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Cost of Revenues</span></p></div></td><td style="width:1%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_04e49aa7ef5242ceb0b16139c9f5f3e0'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">537,690</span></p></div></td><td style="width:1%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_fc9780e70d5e41888cd86f2f0c253755'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">111,687</span></p></div></td><td style="width:1%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_d0205435466347878b98ba976fdfc4d5'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">661,013</span></p></div></td><td style="width:1%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_66fa5035b8dc4b5592e681ec7c7dfeeb'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">266,688</span></p></div></td></tr><tr style="height:11.5pt"><td style="width:52%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_59708218ab9945808854155b5ecc4a03'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Gross (Loss) Profit</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_513f3e638815467db9245aa596cdeb6a'; font-family: 'Times New Roman'"><span>100,088</span></span><span style="font-family: 'Times New Roman';">)</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_1f4a8e7ac1924c93b96740b8fa8cf612'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">23,606</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_74c7c169f98a4dcfa82cf17f6e83330c'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">41,073</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_526d7e43e358403db7f502940b4099a6'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">99,251</span></p></div></td></tr><tr style="height:11.5pt"><td style="width:52%; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_a13f90f258dd4e779da53be6bf96fba0'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Research Revenues</span></p></div></td><td style="width:1%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_47ad5c01f91143deaefa2b6afb361520'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">90,960</span></p></div></td><td style="width:1%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_5c34e488347a45be994656d36c02c247'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">12,818</span></p></div></td><td style="width:1%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_d18e6ab84b774b409afba77ad9fdbccd'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">390,630</span></p></div></td><td style="width:1%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_ae776304e298486fbc5fe946e9f51243'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">43,177</span></p></div></td></tr><tr style="height:11.5pt"><td style="width:52%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_4f3141bc1ffb42788e522092b12e699f'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Net (Loss) Revenue</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_0f02b26c96464ddebf1949efc2a07975'; font-family: 'Times New Roman'"><span>9,128</span></span><span style="font-family: 'Times New Roman';">)</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_ad3ae3c3cfe7421e8c69e86cc9079dee'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">36,424</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_1da3cca7afe140bea8f621b04f27bf42'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">431,703</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_9902c4b6465b43ac97b2245f46a579f8'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">142,428</span></p></div></td></tr><tr style="height:11.5pt"><td style="width:52%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td></tr><tr style="height:11.5pt"><td style="width:52%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_f69db1f1224d48fca0de51e8e95cc019'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Operating Expenses:</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td></tr><tr style="height:11.5pt"><td style="width:52%; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_95547d6728804d8f9ff7aed1db466e14'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Research and Development</span></p></div></td><td style="width:1%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_b2701d5dacf745d28aec57064b935f19'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">809,777</span></p></div></td><td style="width:1%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_815f39a61a80465da0e6a8e5719fc0ba'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">940,063</span></p></div></td><td style="width:1%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_64d3b6eb77144b338f9494e332fa5cb5'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">1,467,283</span></p></div></td><td style="width:1%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_9d37ac5532084b12a075ce49f57d8957'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">4,372,571</span></p></div></td></tr><tr style="height:11.5pt"><td style="width:52%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_84e24dc82ec74447a678afeb46b8d3a6'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">General and Administrative Expenses</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_63480ea0326343819626ad49b78580ce'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">1,506,620</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_d81a07fe81cb4053b05838a5a22a93b5'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">1,215,053</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_1efe4611ebac481d8410a515bcf5d671'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">4,805,648</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_0d1764d4eeab441aa47829656db26d0d'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">3,419,747</span></p></div></td></tr><tr style="height:11.5pt"><td style="width:52%; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_11d740d71f5b41258bc89508e1c25e99'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Total Operating Expenses</span></p></div></td><td style="width:1%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_30874cd7d0c5454eba07a022b2ec430e'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">2,316,397</span></p></div></td><td style="width:1%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_6bcfab4978544c47882ec6e932e87488'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">2,155,116</span></p></div></td><td style="width:1%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_ad0ffcb5fb5f419b99c32c5333ced4c9'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">6,272,931</span></p></div></td><td style="width:1%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_f23b90c186134b1da396921302178273'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">7,792,318</span></p></div></td></tr><tr style="height:11.5pt"><td style="width:52%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td></tr><tr style="height:11.5pt"><td style="width:52%; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_8344d4ebf4674aac8e71462f83e8c23a'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Loss from Operations</span></p></div></td><td style="width:1%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_8fe649e93743426e88d4840d4b1a22a2'; font-family: 'Times New Roman'"><span>2,325,525</span></span><span style="font-family: 'Times New Roman';">)</span></p></td><td style="width:1%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_439cfc9c2f324578832d90e50610fb68'; font-family: 'Times New Roman'"><span>2,118,692</span></span><span style="font-family: 'Times New Roman';">)</span></p></td><td style="width:1%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_11b7c925da134a1eac1c1215a34e664b'; font-family: 'Times New Roman'"><span>5,841,228</span></span><span style="font-family: 'Times New Roman';">)</span></p></td><td style="width:1%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_36e91eae652a42269f540d9e0629bce6'; font-family: 'Times New Roman'"><span>7,649,890</span></span><span style="font-family: 'Times New Roman';">)</span></p></td></tr><tr style="height:11.5pt"><td style="width:52%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td></tr><tr style="height:11.5pt"><td style="width:52%; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_aff3a465e943476586db8ac1e53a5b42'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Interest Expense</span></p></div></td><td style="width:1%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_8f129a2b3d914bccb0acc88f025c08d7'; font-family: 'Times New Roman'"><span>1,708</span></span><span style="font-family: 'Times New Roman';">)</span></p></td><td style="width:1%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_bfa4ee4c34f94cf8af205a574127862f'; font-family: 'Times New Roman'"><span>1,467</span></span><span style="font-family: 'Times New Roman';">)</span></p></td><td style="width:1%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_18939f22c7dd4d86a496d4175ec113f3'; font-family: 'Times New Roman'"><span>4,719</span></span><span style="font-family: 'Times New Roman';">)</span></p></td><td style="width:1%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_9ad452fea4b6419f92e85f0f9516659e'; font-family: 'Times New Roman'"><span>6,490</span></span><span style="font-family: 'Times New Roman';">)</span></p></td></tr><tr style="height:11.5pt"><td style="width:52%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_9cf2c80e4eb748479147c8cbc88083d9'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Change in Fair Value of Derivative Liabilities</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_32ea1df23eac4f7ca848a56e5293d0bd'; font-family: 'Times New Roman'"><span>21,103</span></span><span style="font-family: 'Times New Roman';">)</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_6a057cc9bc0f4cf1bfee51d972adb580'; font-family: 'Times New Roman'"><span>56,712</span></span><span style="font-family: 'Times New Roman';">)</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_aa6fc167136e42639707e686d4240178'; font-family: 'Times New Roman'"><span>156,445</span></span><span style="font-family: 'Times New Roman';">)</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_23fb9990a5da4d6ca6e6530271cd156c'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">1,683,034</span></p></div></td></tr><tr style="height:11.5pt"><td style="width:52%; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_da0b3d32a12045e8936e8fd5e393adae'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Other Income, net</span></p></div></td><td style="width:1%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_61a629ef9c554b53ad2def757af67a22'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">31,550</span></p></div></td><td style="width:1%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_e1bfb7e342cf49caa1606c8450fcf591'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">16,623</span></p></div></td><td style="width:1%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_4a69cff225ba4da5b8e9ac03d62ac8dc'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">74,938</span></p></div></td><td style="width:1%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_6ccd6c2c37a8455b8d73bd36277a1c55'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">67,358</span></p></div></td></tr><tr style="height:11.5pt"><td style="width:52%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_405bef55fad143b68c44e434e391a27d'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Total Interest and Other Income (Expense), net</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_2d42c7732e014481be0088222f02c1b5'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">8,739</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_d128784fff0f443f9569118af3b4088e'; font-family: 'Times New Roman'"><span>41,556</span></span><span style="font-family: 'Times New Roman';">)</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_a95e07289c01403bbfdf5a17176794de'; font-family: 'Times New Roman'"><span>86,226</span></span><span style="font-family: 'Times New Roman';">)</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_91c6d7e6044841868f74dfa84582fc74'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">1,743,902</span></p></div></td></tr><tr style="height:11.5pt"><td style="width:52%; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_cb2df2aac713448a8c1edd0f364d201f'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Loss from Operations before Provision for Income Taxes</span></p></div></td><td style="width:1%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_0979baade5f44dabbfa195144f54dcaa'; font-family: 'Times New Roman'"><span>2,316,786</span></span><span style="font-family: 'Times New Roman';">)</span></p></td><td style="width:1%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_8353ce21446a4ff780ab56ae948730bd'; font-family: 'Times New Roman'"><span>2,160,248</span></span><span style="font-family: 'Times New Roman';">)</span></p></td><td style="width:1%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_e573ff2a362f46b5856e7932f6d1bcf8'; font-family: 'Times New Roman'"><span>5,927,454</span></span><span style="font-family: 'Times New Roman';">)</span></p></td><td style="width:1%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_95dbb8a9c64d44b2986d44a82bd7619b'; font-family: 'Times New Roman'"><span>5,905,988</span></span><span style="font-family: 'Times New Roman';">)</span></p></td></tr><tr style="height:11.5pt"><td style="width:52%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_b1a10c83c8604820bcc7ef6424f19dcc'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Provision for Income Taxes</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_a0cce687e4e14a4986bef5038c7f3b03'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">250</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_b46d27456e26414cba39081649833589'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">250</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_3ac26ffd01c4472b90273980e9f0c66a'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">1,813</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_f15d178a58d84b6bb7d992f11d0f91bc'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">751</span></p></div></td></tr><tr style="height:11.5pt"><td style="width:52%; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_1646e65455804ab39d28a5b198422e9f'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Net Loss including Noncontrolling Interest</span></p></div></td><td style="width:1%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_7219fcea15b646aa8f090ccd8cd26413'; font-family: 'Times New Roman'"><span>2,317,036</span></span><span style="font-family: 'Times New Roman';">)</span></p></td><td style="width:1%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_2ffa42f480a64f1aa2e8ed20c7b5bded'; font-family: 'Times New Roman'"><span>2,160,498</span></span><span style="font-family: 'Times New Roman';">)</span></p></td><td style="width:1%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_c7412b70fef64e0e9e0267662e74a752'; font-family: 'Times New Roman'"><span>5,929,267</span></span><span style="font-family: 'Times New Roman';">)</span></p></td><td style="width:1%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_d8aa057f7fd5485da5520de4d77034ce'; font-family: 'Times New Roman'"><span>5,906,739</span></span><span style="font-family: 'Times New Roman';">)</span></p></td></tr><tr style="height:11.5pt"><td style="width:52%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_7a209ebff47c4a6ab5f13bc656c9695f'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Net Loss &#8211; Noncontrolling Interest</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_92fc6d1e9465486a99a03e0b4b77fae7'; font-family: 'Times New Roman'"><span>712</span></span><span style="font-family: 'Times New Roman';">)</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_519263c0c0f6401292c955318637fd44'; font-family: 'Times New Roman'"><span>713</span></span><span style="font-family: 'Times New Roman';">)</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_1eeb46ba8c8949fda7fb9b752adb022c'; font-family: 'Times New Roman'"><span>2,668</span></span><span style="font-family: 'Times New Roman';">)</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_c93f0bd0ea0f408588cfe693cb27257f'; font-family: 'Times New Roman'"><span>4,669</span></span><span style="font-family: 'Times New Roman';">)</span></p></td></tr><tr style="height:11.5pt"><td style="width:52%; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_ddd5f1ed42b64fde9251170d52be40e3'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Net Loss &#8211; attributed to 60 Degrees Pharmaceuticals, Inc.</span></p></div></td><td style="width:1%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_194a9a7104cb473f993a93f98f277a7b'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_6c5fb339bdff45808981251641cb44ee'; font-family: 'Times New Roman'"><span>2,316,324</span></span><span style="font-family: 'Times New Roman';">)</span></p></td><td style="width:1%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_196a9d0000c9406eacc527ff3ddc5e45'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_f5973115ae744982b4e99da211dab73b'; font-family: 'Times New Roman'"><span>2,159,785</span></span><span style="font-family: 'Times New Roman';">)</span></p></td><td style="width:1%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_35e9c18572174af3bf01b86ce8065998'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_eff56bb3944e488aa003ec1948782c74'; font-family: 'Times New Roman'"><span>5,926,599</span></span><span style="font-family: 'Times New Roman';">)</span></p></td><td style="width:1%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_1335b70d4ddc40d98dbff6192f9506b0'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_281272668d8c4650ba8142232cbbd377'; font-family: 'Times New Roman'"><span>5,902,070</span></span><span style="font-family: 'Times New Roman';">)</span></p></td></tr></tbody></table></div><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-import:ignore">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>The following table sets forth our results of operations as a percentage of revenue:</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>&#160;</span></p><div style="-aw-sdt-tag:'c2dd7e1f4573d311a01f'; -aw-sdt-title:'ITEM 2, 3 and 4_T3'"><table cellspacing="0" cellpadding="0" style="width:100%; border-collapse:collapse"><tbody><tr style="height:11.5pt"><td style="width:51.88%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:0.52%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="4" style="border-bottom:1.5pt solid #000000; padding-right:3.6pt; padding-left:3.6pt; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_26f31078858d4b34916481c54670951f'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">For the Three Months Ended September 30,</span></p></div></td><td style="width:1.54%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:0.76%; border-bottom:1.5pt solid #000000; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="4" style="border-bottom:1.5pt solid #000000; padding-left:5.75pt; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_53aa00cc75bd48baa14abfa4095b498b'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">For the Nine Months Ended September 30,</span></p></div></td><td style="width:1.54%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td></tr><tr style="height:11.5pt"><td style="width:51.88%; border-bottom:1.5pt solid #000000; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_4be331def61e4946b7c15e9829f4e98d'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">Consolidated Statements of Operations Data:</span></p></div></td><td style="width:0.52%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:9.78%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_b79aa43fe1bc411eb404bcc7eb5cc93b'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">2025</span></p></div></td><td style="width:1.54%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:0.76%; border-top:1.5pt solid #000000; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:9.78%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_89b3f8b0e2994395a538ff9d91cc88f7'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">2024</span></p></div></td><td style="width:1.54%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:0.76%; border-top:1.5pt solid #000000; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:9.78%; border-bottom:1.5pt solid #000000; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_7b7449b2d18f408fb7d12ea61ae3ce75'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">2025</span></p></div></td><td style="width:1.54%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:0.76%; border-top:1.5pt solid #000000; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:9.78%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_00562b8bb41e4636b897b5558ffbc733'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">2025</span></p></div></td><td style="width:1.54%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td></tr><tr style="height:11.5pt"><td style="width:51.88%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_18c75e0c95b247a9b639cf57caf89fcf'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Product Revenues &#8211; net of Discounts and Rebates</span></p></div></td><td style="width:0.52%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:9.78%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_1bb3761b569a4e928b6abf7c4e251cf4'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">100.00</span></p></div></td><td style="width:1.54%; vertical-align:top; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_fb20eb25afd54c14a1ab8b8a7594958b'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">%</span></p></div></td><td style="width:0.76%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:9.78%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_7879e6bb34f847df9d254f807cab7a2c'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">100.00</span></p></div></td><td style="width:1.54%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_804356fc30c441228ad988d83236a810'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">%</span></p></div></td><td style="width:0.76%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:9.78%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_6a2e3c163f1a44a9aea05996dcce23cc'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">100.00</span></p></div></td><td style="width:1.54%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_0f535f2834f943d38a4f1158bf68385d'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">%</span></p></div></td><td style="width:0.76%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:9.78%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_4cdf2fbb5717461dbb36d5addc927a0a'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">100.00</span></p></div></td><td style="width:1.54%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_65108e0c03bd47e58a22282b73977f1c'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">%</span></p></div></td></tr><tr style="height:11.5pt"><td style="width:51.88%; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_f98fc8035adb443abbb7bb02122f72e7'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Cost of Revenues</span></p></div></td><td style="width:0.52%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:9.78%; border-bottom:1.5pt solid #000000; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_08f1df713b3140f0b4c111be96150261'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">122.87</span></p></div></td><td style="width:1.54%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:0.76%; border-bottom:1.5pt solid #000000; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:9.78%; border-bottom:1.5pt solid #000000; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_961adf7591d542ea80287aa65102f8ec'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">82.55</span></p></div></td><td style="width:1.54%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:0.76%; border-bottom:1.5pt solid #000000; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:9.78%; border-bottom:1.5pt solid #000000; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_d64e9df1f5a948eabec5064e51059145'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">94.15</span></p></div></td><td style="width:1.54%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:0.76%; border-bottom:1.5pt solid #000000; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:9.78%; border-bottom:1.5pt solid #000000; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_30ff159ed0f84b2a92408ae260340498'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">72.88</span></p></div></td><td style="width:1.54%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td></tr><tr style="height:11.5pt"><td style="width:51.88%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_45cca6e906d942cc94275a6b3456d1e2'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Gross (Loss) Profit</span></p></div></td><td style="width:0.52%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:9.78%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_3de14092004443ff8fd73f149429bcd6'; font-family: 'Times New Roman'"><span>22.87</span></span><span style="font-family: 'Times New Roman';">)</span></p></td><td style="width:1.54%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:0.76%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:9.78%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_91fa66b0381049f1ac86f622c9c44306'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">17.45</span></p></div></td><td style="width:1.54%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:0.76%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:9.78%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_746a0a73adc94d099050fc029a7d0484'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">5.85</span></p></div></td><td style="width:1.54%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:0.76%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:9.78%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_79738ba3643b4903bc7f27c3edce1d50'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">27.12</span></p></div></td><td style="width:1.54%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td></tr><tr style="height:11.5pt"><td style="width:51.88%; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_e0dcf9219c27441a8a7d292db5743932'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Research Revenues</span></p></div></td><td style="width:0.52%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:9.78%; border-bottom:1.5pt solid #000000; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_defd857dc8d841e19954f20ba15845a3'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">20.79</span></p></div></td><td style="width:1.54%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:0.76%; border-bottom:1.5pt solid #000000; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:9.78%; border-bottom:1.5pt solid #000000; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_cf19d8633ebc44e09fab28eacc89bc70'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">9.47</span></p></div></td><td style="width:1.54%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:0.76%; border-bottom:1.5pt solid #000000; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:9.78%; border-bottom:1.5pt solid #000000; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_912b57fbd44f4d98a13a996115804395'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">55.64</span></p></div></td><td style="width:1.54%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:0.76%; border-bottom:1.5pt solid #000000; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:9.78%; border-bottom:1.5pt solid #000000; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_86084c9127e24f9d8024cc4913aadc43'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">11.80</span></p></div></td><td style="width:1.54%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td></tr><tr style="height:11.5pt"><td style="width:51.88%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_7ef7c667614244de8b8e619dcf7763d5'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Net (Loss) Revenue</span></p></div></td><td style="width:0.52%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:9.78%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_a51de745ec3f4972a1c6fc6adc3384c1'; font-family: 'Times New Roman'"><span>2.09</span></span><span style="font-family: 'Times New Roman';">)</span></p></td><td style="width:1.54%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:0.76%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:9.78%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_f7d664213f114d0abf29a1036192adf0'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">26.92</span></p></div></td><td style="width:1.54%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:0.76%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:9.78%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_df29e6be1ce746ce8defdd5db8a097c5'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">61.49</span></p></div></td><td style="width:1.54%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:0.76%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:9.78%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_15f998d0730548e1bc931f27bb2f6d61'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">38.92</span></p></div></td><td style="width:1.54%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td></tr><tr style="height:11.5pt"><td style="width:51.88%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:0.52%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:9.78%; border-top:1.5pt solid #000000; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1.54%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:0.76%; border-top:1.5pt solid #000000; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:9.78%; border-top:1.5pt solid #000000; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1.54%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:0.76%; border-top:1.5pt solid #000000; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:9.78%; border-top:1.5pt solid #000000; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1.54%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:0.76%; border-top:1.5pt solid #000000; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:9.78%; border-top:1.5pt solid #000000; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1.54%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td></tr><tr style="height:11.5pt"><td style="width:51.88%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_8cd2a0b8fe474ceeb5ec4229ddee0dbd'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Operating Expenses:</span></p></div></td><td style="width:0.52%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:9.78%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1.54%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:0.76%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:9.78%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1.54%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:0.76%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:9.78%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1.54%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:0.76%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:9.78%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1.54%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td></tr><tr style="height:11.5pt"><td style="width:51.88%; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_330624cda8a44f08932e1a015eca005c'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Research and Development</span></p></div></td><td style="width:0.52%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:9.78%; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_3dff4f406c3348799c172136eeab4610'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">185.05</span></p></div></td><td style="width:1.54%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:0.76%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:9.78%; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_0400e0de4ef849279063c381ee7bcf3e'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">694.83</span></p></div></td><td style="width:1.54%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:0.76%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:9.78%; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_0c0b6406206242878b22f343136695b4'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">208.99</span></p></div></td><td style="width:1.54%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:0.76%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:9.78%; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_423b01c4a0ac4fa1a5b506591dd1a962'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">1,194.89</span></p></div></td><td style="width:1.54%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td></tr><tr style="height:11.5pt"><td style="width:51.88%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_b3873d732fed4f90a4f8ae8ae13693c9'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">General and Administrative Expenses</span></p></div></td><td style="width:0.52%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:9.78%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_72a117e5f255486583e993c72baa551e'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">344.29</span></p></div></td><td style="width:1.54%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:0.76%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:9.78%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_6bbb08951a364d9e817c9587aa02d65b'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">898.09</span></p></div></td><td style="width:1.54%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:0.76%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:9.78%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_63b19ebbf38b4e828f70dfda2325da53'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">684.48</span></p></div></td><td style="width:1.54%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:0.76%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:9.78%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_f5cc2d5f9eb541038b919647f453942b'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">934.51</span></p></div></td><td style="width:1.54%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td></tr><tr style="height:11.5pt"><td style="width:51.88%; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_3de7c5aa1d524fbcabb841b04e5ee01e'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Total Operating Expenses</span></p></div></td><td style="width:0.52%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:9.78%; border-top:1.5pt solid #000000; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_56f80b74cd2742bc9b434f5b76882a4d'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">529.34</span></p></div></td><td style="width:1.54%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:0.76%; border-top:1.5pt solid #000000; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:9.78%; border-top:1.5pt solid #000000; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_bd6f4e4ae2f84861b191b8c1403e7c2a'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">1,592.92</span></p></div></td><td style="width:1.54%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:0.76%; border-top:1.5pt solid #000000; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:9.78%; border-top:1.5pt solid #000000; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_d8386b6dd2834d7d8fbab89d1fd2d911'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">893.47</span></p></div></td><td style="width:1.54%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:0.76%; border-top:1.5pt solid #000000; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:9.78%; border-top:1.5pt solid #000000; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_eb7e57ee61bd40f38c0919dc67fb4e2f'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">2,129.40</span></p></div></td><td style="width:1.54%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td></tr><tr style="height:11.5pt"><td style="width:51.88%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:0.52%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:9.78%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1.54%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:0.76%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:9.78%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1.54%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:0.76%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:9.78%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1.54%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:0.76%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:9.78%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1.54%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td></tr><tr style="height:11.5pt"><td style="width:51.88%; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_4a871d96799d4e1aaf8c05864d064eaf'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Loss from Operations</span></p></div></td><td style="width:0.52%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:9.78%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_4dfe33c4b7b44866bbcc14871b06178c'; font-family: 'Times New Roman'"><span>531.42</span></span><span style="font-family: 'Times New Roman';">)</span></p></td><td style="width:1.54%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:0.76%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:9.78%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_d788778bd59c46f0afa564c7f1b8d540'; font-family: 'Times New Roman'"><span>1,566.00</span></span><span style="font-family: 'Times New Roman';">)</span></p></td><td style="width:1.54%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:0.76%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:9.78%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_3d139dec9857426b8cd79cbe7f5d4d19'; font-family: 'Times New Roman'"><span>831.98</span></span><span style="font-family: 'Times New Roman';">)</span></p></td><td style="width:1.54%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:0.76%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:9.78%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_58e089b7283344f2af36a66f6dd5daa4'; font-family: 'Times New Roman'"><span>2,090.48</span></span><span style="font-family: 'Times New Roman';">)</span></p></td><td style="width:1.54%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td></tr><tr style="height:11.5pt"><td style="width:51.88%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:0.52%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:9.78%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1.54%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:0.76%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:9.78%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1.54%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:0.76%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:9.78%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1.54%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:0.76%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:9.78%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1.54%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td></tr><tr style="height:11.5pt"><td style="width:51.88%; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_7f67e315bdcc48edb676ef4768b72d0e'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Interest Expense</span></p></div></td><td style="width:0.52%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:9.78%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_f9700f1f697d443393861b02f59b5d9f'; font-family: 'Times New Roman'"><span>0.39</span></span><span style="font-family: 'Times New Roman';">)</span></p></td><td style="width:1.54%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:0.76%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:9.78%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_b939c9471b7c4ca4bdb735cee75ab744'; font-family: 'Times New Roman'"><span>1.08</span></span><span style="font-family: 'Times New Roman';">)</span></p></td><td style="width:1.54%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:0.76%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:9.78%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_99f2636647ae4cb4bb8e361a46742c37'; font-family: 'Times New Roman'"><span>0.67</span></span><span style="font-family: 'Times New Roman';">)</span></p></td><td style="width:1.54%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:0.76%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:9.78%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_89b397a1bf8941a49ab517dd2b62e98f'; font-family: 'Times New Roman'"><span>1.77</span></span><span style="font-family: 'Times New Roman';">)</span></p></td><td style="width:1.54%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td></tr><tr style="height:11.5pt"><td style="width:51.88%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_a654eec01d5e4f40955b57deeac750c7'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Change in Fair Value of Derivative Liabilities</span></p></div></td><td style="width:0.52%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:9.78%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_01013b57291347d39c088bb25e9f68aa'; font-family: 'Times New Roman'"><span>4.82</span></span><span style="font-family: 'Times New Roman';">)</span></p></td><td style="width:1.54%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:0.76%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:9.78%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_d2ce0c04c8b345edb0ca2dbe53eb767b'; font-family: 'Times New Roman'"><span>41.92</span></span><span style="font-family: 'Times New Roman';">)</span></p></td><td style="width:1.54%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:0.76%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:9.78%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_7715b86b81a648438e0946c78100679b'; font-family: 'Times New Roman'"><span>22.28</span></span><span style="font-family: 'Times New Roman';">)</span></p></td><td style="width:1.54%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:0.76%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:9.78%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_fb6c7863f0d74715a8e56a9415b37cc8'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">459.92</span></p></div></td><td style="width:1.54%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td></tr><tr style="height:11.5pt"><td style="width:51.88%; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_c61c48b7f8c24e93941ceebb6edcea34'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Other Income, net</span></p></div></td><td style="width:0.52%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:9.78%; border-bottom:1.5pt solid #000000; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_83d3f4706acc42a6b1a6cc1485ba4e28'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">7.21</span></p></div></td><td style="width:1.54%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:0.76%; border-bottom:1.5pt solid #000000; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:9.78%; border-bottom:1.5pt solid #000000; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_7529d1412ddb43b686559594ac719dec'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">12.29</span></p></div></td><td style="width:1.54%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:0.76%; border-bottom:1.5pt solid #000000; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:9.78%; border-bottom:1.5pt solid #000000; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_7e2285c14a994d58b673677b2a338c70'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">10.67</span></p></div></td><td style="width:1.54%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:0.76%; border-bottom:1.5pt solid #000000; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:9.78%; border-bottom:1.5pt solid #000000; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_e794f42ffa6a4683af49afc9187b8386'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">18.41</span></p></div></td><td style="width:1.54%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td></tr><tr style="height:11.5pt"><td style="width:51.88%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_ff1509353edf456d8d0a1140c217cee5'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Total Interest and Other Income (Expense), net</span></p></div></td><td style="width:0.52%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:9.78%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_da3dc5dc49234eefa30cbdebddb1c835'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">2.00</span></p></div></td><td style="width:1.54%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:0.76%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:9.78%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_234395b212f747249c328ebcc928dba4'; font-family: 'Times New Roman'"><span>30.72</span></span><span style="font-family: 'Times New Roman';">)</span></p></td><td style="width:1.54%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:0.76%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:9.78%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_1ef39fce55d140069d48a7222ee3d43e'; font-family: 'Times New Roman'"><span>12.28</span></span><span style="font-family: 'Times New Roman';">)</span></p></td><td style="width:1.54%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:0.76%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:9.78%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_9861954f53e04b81a7577197a2b25dfd'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">476.56</span></p></div></td><td style="width:1.54%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td></tr><tr style="height:11.5pt"><td style="width:51.88%; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_5e053f1c05cc45dba60e9eca540497dc'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Loss from Operations before Provision for Income Taxes</span></p></div></td><td style="width:0.52%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:9.78%; border-bottom:1.5pt solid #000000; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_1174d53bfb354cbe974b5dd6aed6b2b8'; font-family: 'Times New Roman'"><span>529.43</span></span><span style="font-family: 'Times New Roman';">)</span></p></td><td style="width:1.54%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:0.76%; border-bottom:1.5pt solid #000000; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:9.78%; border-bottom:1.5pt solid #000000; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_131b5d795c904819b09ee27628492814'; font-family: 'Times New Roman'"><span>1,596.72</span></span><span style="font-family: 'Times New Roman';">)</span></p></td><td style="width:1.54%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:0.76%; border-bottom:1.5pt solid #000000; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:9.78%; border-bottom:1.5pt solid #000000; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_02fce9bcdf3b4ea1b9a11a122d06a9ae'; font-family: 'Times New Roman'"><span>844.26</span></span><span style="font-family: 'Times New Roman';">)</span></p></td><td style="width:1.54%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:0.76%; border-bottom:1.5pt solid #000000; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:9.78%; border-bottom:1.5pt solid #000000; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_2b5d8da834fa4af6b787ccc69088ecbb'; font-family: 'Times New Roman'"><span>1,613.93</span></span><span style="font-family: 'Times New Roman';">)</span></p></td><td style="width:1.54%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td></tr><tr style="height:11.5pt"><td style="width:51.88%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_0f2b50710b0d47f0893d8b7b8f9738bc'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Provision for Income Taxes</span></p></div></td><td style="width:0.52%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:9.78%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_701a62d7cec54eb3b210b32b8961acfc'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">0.06</span></p></div></td><td style="width:1.54%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:0.76%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:9.78%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_a2d74dafce2d4f7ba7536865d57b1c78'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">0.18</span></p></div></td><td style="width:1.54%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:0.76%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:9.78%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_52db1f831df44d0c8994c0eee986379c'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">0.26</span></p></div></td><td style="width:1.54%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:0.76%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:9.78%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_36d054b9fc39459e918586f5817174f2'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">0.21</span></p></div></td><td style="width:1.54%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td></tr><tr style="height:11.5pt"><td style="width:51.88%; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_afc20edd5c7647b3add88917074b3376'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Net Loss including Noncontrolling Interest</span></p></div></td><td style="width:0.52%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:9.78%; border-top:1.5pt solid #000000; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_f6c9884f2db04666b2923a72e099498a'; font-family: 'Times New Roman'"><span>529.48</span></span><span style="font-family: 'Times New Roman';">)</span></p></td><td style="width:1.54%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:0.76%; border-top:1.5pt solid #000000; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:9.78%; border-top:1.5pt solid #000000; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_7cc2a033ac9b42c187e118772d72a235'; font-family: 'Times New Roman'"><span>1,596.90</span></span><span style="font-family: 'Times New Roman';">)</span></p></td><td style="width:1.54%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:0.76%; border-top:1.5pt solid #000000; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:9.78%; border-top:1.5pt solid #000000; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_fa3c2536061543248b136f3d5776e153'; font-family: 'Times New Roman'"><span>844.52</span></span><span style="font-family: 'Times New Roman';">)</span></p></td><td style="width:1.54%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:0.76%; border-top:1.5pt solid #000000; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:9.78%; border-top:1.5pt solid #000000; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_bbab19c982e34f8a9859297c4f348c54'; font-family: 'Times New Roman'"><span>1,614.13</span></span><span style="font-family: 'Times New Roman';">)</span></p></td><td style="width:1.54%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td></tr><tr style="height:11.5pt"><td style="width:51.88%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_0df8be4934434bbd90040ad298b270c2'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Net Loss &#8211; Noncontrolling Interest</span></p></div></td><td style="width:0.52%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:9.78%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_d96a2b1fd7e34535b38e185b30d0f2c2'; font-family: 'Times New Roman'"><span>0.16</span></span><span style="font-family: 'Times New Roman';">)</span></p></td><td style="width:1.54%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:0.76%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:9.78%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_bfd36a61357d42f29f649605baa000ea'; font-family: 'Times New Roman'"><span>0.53</span></span><span style="font-family: 'Times New Roman';">)</span></p></td><td style="width:1.54%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:0.76%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:9.78%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_f099040693e244a5bb44612201ca9fbe'; font-family: 'Times New Roman'"><span>0.38</span></span><span style="font-family: 'Times New Roman';">)</span></p></td><td style="width:1.54%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:0.76%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:9.78%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_d40719f4cdc342e68206e5b1de344112'; font-family: 'Times New Roman'"><span>1.28</span></span><span style="font-family: 'Times New Roman';">)</span></p></td><td style="width:1.54%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td></tr><tr style="height:11.5pt"><td style="width:51.88%; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_c453ca6f28e34462bb76415d9ecfd31b'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Net Loss &#8211; attributed to 60 Degrees Pharmaceuticals, Inc.</span></p></div></td><td style="width:0.52%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:9.78%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_4d5b546692c24cb4abe55a339730f5e6'; font-family: 'Times New Roman'"><span>529.32</span></span><span style="font-family: 'Times New Roman';">)</span></p></td><td style="width:1.54%; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_ae1b1c8a913f48cebe7983d0aa790bb5'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">%</span></p></div></td><td style="width:0.76%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:9.78%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_88bc47207b6442ec9b49e8fe2b016082'; font-family: 'Times New Roman'"><span>1,596.38</span></span><span style="font-family: 'Times New Roman';">)</span></p></td><td style="width:1.54%; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_55ec3d45cd56425ba46339506e6551df'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">%</span></p></div></td><td style="width:0.76%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:9.78%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_5e6969d626824d83b9eae93d23507bec'; font-family: 'Times New Roman'"><span>844.14</span></span><span style="font-family: 'Times New Roman';">)</span></p></td><td style="width:1.54%; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_d43afc9058594c1a9c575986ff2b825f'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">%</span></p></div></td><td style="width:0.76%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:9.78%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_86029cd25e384aca9cdc41caeedc6611'; font-family: 'Times New Roman'"><span>1,612.86</span></span><span style="font-family: 'Times New Roman';">)</span></p></td><td style="width:1.54%; vertical-align:middle"><div style="-aw-sdt-tag:'C_b17572ef515d4fb385c6dfb2902dd198'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">%</span></p></div></td></tr></tbody></table></div><div style="-aw-sdt-tag:'PG_c5a6c6a115d074b7aefa'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center"><span style="-aw-import:ignore; font-family: 'Times New Roman';  font-size: 12pt;">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-family: 'Times New Roman';">28</span></p><div><hr style="width: 100%; color: #000000; background-color: #000000; margin: 1rem 0;"/></div></div></div><div class="Section_32"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold">Comparison of the Three Months Ended </span><span style="-aw-sdt-tag:'ceebd38ab10bd456e61a'; -aw-sdt-title:'Current_Period_P22'"><span style="font-weight:bold; font-family: 'Times New Roman'">September 30, 2025</span></span><span style="font-weight:bold"> and </span><span style="-aw-sdt-tag:'c503a3512de11da56a4e'; -aw-sdt-title:'Previous_Year_P38'"><span style="font-weight:bold; font-family: 'Times New Roman'">2024</span></span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-weight:bold; font-style:italic">Product Revenues - net of Discounts and Rebates, Cost of Revenues, Gross (Loss) Profit, and Gross Margin</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-import:ignore">&#160;</span></p><div style="-aw-sdt-tag:'cf0b01186f23d76abef9'; -aw-sdt-title:'ITEM 2, 3 and 4_T4'"><table cellspacing="0" cellpadding="0" style="width:100%; border-collapse:collapse"><tbody><tr style="height:11.5pt"><td style="width:51.72%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:0.72%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="5" style="border-bottom:1.5pt solid #000000; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_5bab565e4a654204bb3c41629d039dba'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">For the Three Months Ended September 30,</span></p></div></td><td style="width:1%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:0.74%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10.16%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td></tr><tr style="height:11.5pt"><td style="width:51.72%; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_d4b785a58f20460082fe67f89e3e6caa'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">Consolidated Statements of Operations Data:</span></p></div></td><td style="width:0.72%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="2" style="border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_b03228ce7e294eb5af453bf4300e733f'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">2025</span></p></div></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="2" style="border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_ba78d428a70f47828449aea07ba6144c'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">2024</span></p></div></td><td style="width:1%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="2" style="border-bottom:1.5pt solid #000000; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_211b95ea4b34469b9fe998d60c0626e2'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">$ Change</span></p></div></td><td style="width:0.74%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10.16%; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_40ecb95449b6496eab9ddb08b7919420'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">% Change</span></p></div></td><td style="width:1%; padding:0.75pt; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td></tr><tr style="height:11.5pt"><td style="width:51.72%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_926c5ffe481d45618a1798d9e2ca5039'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Product Revenues &#8211; net of Discounts and Rebates</span></p></div></td><td style="width:0.72%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_f0eac5980b0c479b91d6dfc249c54918'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_ab5269de8d214f8f8c439a62644c9e6d'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">437,602</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ccecff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_3eb82d4d60ef4f48b69dd5f2d30940d6'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_15672c7530994371befe0b96abee3ada'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">135,293</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ccecff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#ccecff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_de4401e188c544b6a6b605014ecc4c73'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#ccecff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_d615d132f60e486383b0e8b18421aa26'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">302,309</span></p></div></td><td style="width:0.74%; vertical-align:bottom; background-color:#ccecff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10.16%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#ccecff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_1410dfe880df42e0a558f91a5a62eace'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">223.45</span></p></div></td><td style="width:1%; vertical-align:bottom; background-color:#ccecff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_61b5a154b92349bdbdc484f4c65f4a88'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">%</span></p></div></td></tr><tr style="height:11.5pt"><td style="width:51.72%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_cbdd8851db6049f8807f1fce7cba9b43'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Cost of Revenues</span></p></div></td><td style="width:0.72%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_91b6bf4972964785883e58fb1f997037'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">537,690</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_58611a28f3ae4f17a8ce0345e3afee99'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">111,687</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_b298da0f7ec14611866ede69a6e71c0d'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">426,003</span></p></div></td><td style="width:0.74%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10.16%; border-bottom:1.5pt solid #000000; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_321544d0ebe541239c35de03df20e113'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">381.43</span></p></div></td><td style="width:1%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td></tr><tr style="height:11.5pt"><td style="width:51.72%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_45998fdf9b444332a470c5f45521e353'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Gross (Loss) Profit</span></p></div></td><td style="width:0.72%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_f21107d52cc24ff394c784f8017bd437'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_56e9715785b549f4a51c9e91d232885a'; font-family: 'Times New Roman'"><span>100,088</span></span><span style="font-family: 'Times New Roman';">)</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ccecff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_5ce77431c0a443d7be28cabdb5eca8cc'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ccecff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_8828fd65d260419bb8b8e442450d0c19'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">23,606</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ccecff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#ccecff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_82683214fff942f29a38ac68866a117e'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#ccecff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_c08b511cc4b1456fac7f2330de3c8269'; font-family: 'Times New Roman'"><span>123,694</span></span><span style="font-family: 'Times New Roman';">)</span></p></td><td style="width:0.74%; vertical-align:bottom; background-color:#ccecff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10.16%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#ccecff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_dc949355279e4fcb8fbc67876498484c'; font-family: 'Times New Roman'"><span>523.99</span></span><span style="font-family: 'Times New Roman';">)</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#ccecff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_6532aad500804adeae452a9490eb11f3'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">%</span></p></div></td></tr><tr style="height:11.5pt"><td style="width:51.72%; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_2bd1e920acbe4147bfa9c6a7e43b7a65'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">Gross Margin %</span></p></div></td><td style="width:0.72%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:4.5pt double #000000; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:4.5pt double #000000; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">(</span><span style="-aw-sdt-tag:'C_0b6e850d05a34515a6ba9b7580252a11'; font-family: 'Times New Roman'"><span style="font-weight:bold">22.87</span></span><span style="font-weight:bold; font-family: 'Times New Roman'">)</span></p></td><td style="width:1%; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_9fa212789a8e489e80773248f3b5c305'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">%</span></p></div></td><td style="width:1%; border-top:4.5pt double #000000; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:4.5pt double #000000; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_8ba7cd68c2ba4634b2899dbbcb5ceefd'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">17.45</span></p></div></td><td style="width:1%; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_508daee205324ce99b5a05d93951e4d4'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">%</span></p></div></td><td style="width:1%; border-top:4.5pt double #000000; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:4.5pt double #000000; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:0.74%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10.16%; border-top:4.5pt double #000000; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td></tr></tbody></table></div><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span>&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-style:italic">Product Revenues - net of Discounts and Rebates</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>Our product revenues - net of discounts and rebates were $</span><span style="-aw-sdt-tag:'c9ea875d0467efbdb8bb'; -aw-sdt-title:'Product revenues_CQ'"><span style="font-family: 'Times New Roman';">437,602</span></span><span> for the </span><span style="-aw-sdt-tag:'cf131d736ab7db545e7d'; -aw-sdt-title:'Current_Quarter_P19'"><span style="font-family: 'Times New Roman';">three months ended September 30, 2025</span></span><span>, as compared to $</span><span style="-aw-sdt-tag:'cde83ecf3670913406b5'; -aw-sdt-title:'Product revenues_PQ'"><span style="font-family: 'Times New Roman';">135,293</span></span><span> for the </span><span style="-aw-sdt-tag:'c34d1ea015b0ed90107f'; -aw-sdt-title:'Previous_Quarter_P6'"><span style="font-family: 'Times New Roman';">three months ended September 30, 2024</span></span><span>. For the </span><span style="-aw-sdt-tag:'cbc4078838eca41f10cf'; -aw-sdt-title:'Current_Quarter_P20'"><span style="font-family: 'Times New Roman';">three months ended September 30, 2025</span></span><span>, our U.S. pharmaceutical distributor and Infuserve America accounted for </span><span style="-aw-sdt-tag:'16b-ea4-8bb-667-c157'; -aw-sdt-title:'Current_Year_3M_ICS_PCT'"><span style="font-family: 'Times New Roman';">80</span></span><span>% and </span><span style="-aw-sdt-tag:'d28-ef3-a66-921-7a7c'; -aw-sdt-title:'Current_Year_Infuserve_PCT'"><span style="font-family: 'Times New Roman';">8</span></span><span>% of our total net product sales of Arakoda, respectively, and Kodatef sales to our Australian distributor accounted for </span><span style="-aw-sdt-tag:'fad-26f-d47-33c-5000'; -aw-sdt-title:'Current_Year_CQ_Biocelect_PCT'"><span style="font-family: 'Times New Roman';">7</span></span><span>% of total net product sales (</span><span style="-aw-sdt-tag:'d2b-c47-1fe-3b4-dc5d'; -aw-sdt-title:'Prior_Year_CQ_ICS_PCT'"><span style="font-family: 'Times New Roman';">92</span></span><span>%, </span><span style="-aw-sdt-tag:'2b8-e3f-aee-ef8-1e33'; -aw-sdt-title:'Prior_Year_CQ_Infuserve_PCT'"><span style="font-family: 'Times New Roman';">0</span></span><span>% and </span><span style="-aw-sdt-tag:'df6-03b-d43-dcc-6fe2'; -aw-sdt-title:'Prior_Year_CQ_Biocelect_PCT'"><span style="font-family: 'Times New Roman';">8</span></span><span>% for the </span><span style="-aw-sdt-tag:'c57762756b1b7af4521b'; -aw-sdt-title:'Previous_Quarter_P7'"><span style="font-family: 'Times New Roman';">three months ended September 30, 2024</span></span><span>, respectively). Domestic, commercial product sales increased substantially in the period due to refilling the supply chain after stocking out in Q2 2025. </span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>We offer discounts and rebates to the civilian U.S. supply chain distribution channel. We record sales when our 3PL partner transfers boxes into their title model. Discounts and rebates offered to our 3PL partner amount to 12% (lower rates available upon reaching larger revenue tiers) along with a $5,500 fixed monthly fee. The product is then transferred usually to one of the three large U.S. pharmaceutical distributors where rebates are 10%. Lastly, we have relationships with several large pharmacy benefit managers (&#8220;PBMs&#8221;) that allow patients to purchase Arakoda at a discount. The rebate associated with PBMs ranges from 30% to 41.25% depending on the amount of coverage provided. For the </span><span style="-aw-sdt-tag:'c1d4ca77779523cbc55d'; -aw-sdt-title:'Current_Quarter_P21'"><span style="font-family: 'Times New Roman';">three months ended September 30, 2025</span></span><span>, discounts and rebates were $</span><span style="-aw-sdt-tag:'867-63a-8ad-ed7-85d0'; -aw-sdt-title:'Disc and Rebates_CY3M'"><span style="font-family: 'Times New Roman';">150,532</span></span><span> compared to $</span><span style="-aw-sdt-tag:'929-2b8-bc0-6f4-197c'; -aw-sdt-title:'Disc and Rebates_PY3M'"><span style="font-family: 'Times New Roman';">122,862</span></span><span> for the </span><span style="-aw-sdt-tag:'c9b92d53e74b1e3be6a9'; -aw-sdt-title:'Previous_Quarter_P8'"><span style="font-family: 'Times New Roman';">three months ended September 30, 2024</span></span><span>. The rebate on Kodatef sales was only 10% and there were no PBM-related discounts on sales of Kodatef.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>Arakoda entered the U.S. civilian supply chain in the third quarter of 2019. Since the introduction of the new 8-ct bottle in June 2025, we will be reporting Arakoda unit sales in terms of 16-ct box equivalents. For the </span><span style="-aw-sdt-tag:'c7503f27114676dcddd9'; -aw-sdt-title:'Current_Quarter_P22'"><span style="font-family: 'Times New Roman';">three months ended September 30, 2025</span></span><span>, the equivalent of </span><span style="-aw-sdt-tag:'c0d2578eecf297de0d63'; -aw-sdt-title:'Boxes sold to pharmacies and dispensaries_CQ'"><span style="font-family: 'Times New Roman';">1,505</span></span><span> 16-ct boxes were sold to pharmacies and dispensaries. Sales volume </span><span style="-aw-sdt-tag:'faa-ff4-864-130-a719'; -aw-sdt-title:'Qtr_Direction_of_US_Pharmacies'"><span style="font-family: 'Times New Roman';">increased</span></span><span> by </span><span style="-aw-sdt-tag:'cd76347f1d988764afdf'; -aw-sdt-title:'Boxes sold Change Perc_Q'"><span style="font-family: 'Times New Roman';">14</span></span><span>% from </span><span style="-aw-sdt-tag:'7d3-3e1-832-43e-ff50'; -aw-sdt-title:'LastYr_Qtr_US_Boxes_Pharmacies'"><span style="font-family: 'Times New Roman';">1,319</span></span><span> 16-ct box equivalents sold to pharmacies and dispensaries for the </span><span style="-aw-sdt-tag:'c8edc03aab86ed895290'; -aw-sdt-title:'Previous_Quarter_P9'"><span style="font-family: 'Times New Roman';">three months ended September 30, 2024</span></span><span>. </span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-import:ignore">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>Kodatef sales to our distributor Biocelect in Australia for the </span><span style="-aw-sdt-tag:'c968b7b0dee2c7456a19'; -aw-sdt-title:'Current_Quarter_P23'"><span style="font-family: 'Times New Roman';">three months ended September 30, 2025</span></span><span> were $</span><span style="-aw-sdt-tag:'dc1-70b-f2e-def-af78'; -aw-sdt-title:'Kodatef Sales_CY3M'"><span style="font-family: 'Times New Roman';">29,490</span></span><span> ($</span><span style="-aw-sdt-tag:'5e0-668-4cf-7dd-7a98'; -aw-sdt-title:'Kodatef Sales_PY3M'"><span style="font-family: 'Times New Roman';">10,691</span></span><span> for the </span><span style="-aw-sdt-tag:'cb1e01808aa854933eb1'; -aw-sdt-title:'Previous_Quarter_P10'"><span style="font-family: 'Times New Roman';">three months ended September 30, 2024</span></span><span>). A historical portion of sales to Biocelect remained subject to a profit share distribution once the original transfer price has been recouped. Biocelect, which acts as a distributor in the Australian and New Zealand markets, reported a </span><span style="-aw-sdt-tag:'531-cbb-ce0-5ec-1903'; -aw-sdt-title:'AU_Box_Sales_PCT_Change_3M'"><span style="font-family: 'Times New Roman';">33</span></span><span>% quarter-over-quarter </span><span style="-aw-sdt-tag:'a93-72e-388-633-e090'; -aw-sdt-title:'AU_Box_Sales_3M_Direction'"><span style="font-family: 'Times New Roman';">increase</span></span><span>, with </span><span style="-aw-sdt-tag:'f4f-6d4-602-99b-8729'; -aw-sdt-title:'AU Box Sales_CY3M'"><span style="font-family: 'Times New Roman';">552</span></span><span> boxes sold for the </span><span style="-aw-sdt-tag:'cdde081e389c95e97c34'; -aw-sdt-title:'Current_Quarter_P24'"><span style="font-family: 'Times New Roman';">three months ended September 30, 2025</span></span><span>, compared to </span><span style="-aw-sdt-tag:'409-7f4-30a-771-f311'; -aw-sdt-title:'Prior_3M_AU_Boxes_Sold'"><span style="font-family: 'Times New Roman';">414</span></span><span> boxes for the </span><span style="-aw-sdt-tag:'c12dce5ccd57183f92ad'; -aw-sdt-title:'Previous_Quarter_P11'"><span style="font-family: 'Times New Roman';">three months ended September 30, 2024</span></span><span>. As of </span><span style="-aw-sdt-tag:'cad09a0f1b366c255e1a'; -aw-sdt-title:'Current_Period_P25'"><span style="font-family: 'Times New Roman';">September 30, 2025</span></span><span>, Biocelect has no inventory left that remains subject to profit share. Additionally, under a new agreement executed during the second quarter, Biocelect began to purchase from the latest manufactured lot of Kodatef at $49.50 AUD per box which are not subject to historical profit share. For the quarter ended </span><span style="-aw-sdt-tag:'ce885f2087da5aa2649e'; -aw-sdt-title:'Current_Period_P27'"><span style="font-family: 'Times New Roman';">September 30, 2025</span></span><span>, </span><span style="-aw-sdt-tag:'797-78e-20a-8f3-fceb'; -aw-sdt-title:'Kodatef Boxes Sold_CY3M'"><span style="font-family: 'Times New Roman';">900</span></span><span> boxes of Kodatef were sold to Biocelect (none for the quarter ended September 30, 2024). As of </span><span style="-aw-sdt-tag:'c38868c526bdc93020b9'; -aw-sdt-title:'Current_Period_P28'"><span style="font-family: 'Times New Roman';">September 30, 2025</span></span><span>, $</span><span style="-aw-sdt-tag:'c3e-3a3-a97-048-f513'; -aw-sdt-title:'Kodatef Profit Share_CY3M'"><span style="font-family: 'Times New Roman';">16,331</span></span><span> of receivables were due to us ($</span><span style="-aw-sdt-tag:'5e9-b15-39e-8a2-32d0'; -aw-sdt-title:'Dec 2024_Kodatef Profit Share Receivable (QTD)'"><span style="font-family: 'Times New Roman';">9,444</span></span><span> as of </span><span style="-aw-sdt-tag:'2db-044-943-5bd-ea3f'; -aw-sdt-title:'Previous_Year_End_P21'"><span style="font-family: 'Times New Roman';">December 31, 2024</span></span><span>). </span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>Arakoda sales volume in Europe continues to grow. We first shipped Arakoda to our distributor Scandinavian Biopharma (&#8220;SB&#8221;) in September 2022. SB reported </span><span style="-aw-sdt-tag:'d30-82b-eef-a75-05b6'; -aw-sdt-title:'EU_3M_Boxes_Sold'"><span style="font-family: 'Times New Roman';">66</span></span><span> boxes sold during the </span><span style="-aw-sdt-tag:'c258ab74d10e054a9830'; -aw-sdt-title:'Current_Quarter_P25'"><span style="font-family: 'Times New Roman';">three months ended September 30, 2025</span></span><span>, representing a </span><span style="-aw-sdt-tag:'ad9-09a-8b6-8a8-0618'; -aw-sdt-title:'EU_3M_PCT_Change'"><span style="font-family: 'Times New Roman';">22</span></span><span>% </span><span style="-aw-sdt-tag:'8e1-5c0-0aa-7ef-6494'; -aw-sdt-title:'EU_Direction_3M'"><span style="font-family: 'Times New Roman';">increase from</span></span><span> the </span><span style="-aw-sdt-tag:'12d-113-4ad-ff3-f18a'; -aw-sdt-title:'SB_Boxes_Sold_PreviousQuarter'"><span style="font-family: 'Times New Roman';">54</span></span><span> boxes sold during the </span><span style="-aw-sdt-tag:'c6590171a59c87c6b468'; -aw-sdt-title:'Previous_Quarter_P12'"><span style="font-family: 'Times New Roman';">three months ended September 30, 2024</span></span><span>. According to our distributor, the stock out experienced in the US during the second quarter of 2025 also negatively impacted sales for the quarter in Europe. This only became rectified in late August when we sent 1,000 bottles of Arakoda to Europe.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>&#160;</span></p><div style="-aw-sdt-tag:'PG_c3827ead24cfc5a30d01'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-family: 'Times New Roman';">29</span></p><div><hr style="width: 100%; color: #000000; background-color: #000000; margin: 1rem 0;"/></div></div></div><div class="Section_33"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-style:italic">Cost of Revenues, Gross (Loss) Profit, and Gross Margin</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-style:italic">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>Cost of revenues was $</span><span style="-aw-sdt-tag:'c8b5c864ebee40f3f3ac'; -aw-sdt-title:'Cost of revenues_CQ'"><span style="font-family: 'Times New Roman';">537,690</span></span><span> for the </span><span style="-aw-sdt-tag:'c2d65c00d8b084c02d79'; -aw-sdt-title:'Current_Quarter_P26'"><span style="font-family: 'Times New Roman';">three months ended September 30, 2025</span></span><span>, as compared to $</span><span style="-aw-sdt-tag:'c058b6133bcc17759654'; -aw-sdt-title:'Cost of revenues_PQ'"><span style="font-family: 'Times New Roman';">111,687</span></span><span> for the </span><span style="-aw-sdt-tag:'c01605e805ab052a75b9'; -aw-sdt-title:'Previous_Quarter_P13'"><span style="font-family: 'Times New Roman';">three months ended September 30, 2024</span></span><span>. </span><span style="-aw-import:spaces">&#160;</span><span>The significant increase in cost of goods sold was primarily due to higher write-offs of inventory not expected to be sold prior to its expiration date. Write-offs of expiring inventory were $</span><span style="-aw-sdt-tag:'120-dcb-877-81f-868b'; -aw-sdt-title:'Inventory_WriteOffs_CQTD'"><span style="font-family: 'Times New Roman';">436,561</span></span><span> for the </span><span style="-aw-sdt-tag:'85a-946-260-b90-df04'; -aw-sdt-title:'Current_Quarter_P49'"><span style="font-family: 'Times New Roman';">three months ended September 30, 2025</span></span><span>, as compared to $</span><span style="-aw-sdt-tag:'5a7-abc-5e5-901-bfaa'; -aw-sdt-title:'Inventory_WriteOffs_PQTD'"><span style="font-family: 'Times New Roman';">1,165</span></span><span> for the </span><span style="-aw-sdt-tag:'f3c-a87-0f2-f4d-75e2'; -aw-sdt-title:'Previous_Quarter_P33'"><span style="font-family: 'Times New Roman';">three months ended September 30, 2024</span></span><span>. The excess inventory resulted from our strategic decision to validate a new, larger-scale production method with then soon to be expiring raw materials (API), with the offsetting assistance from our USAMMDA grant. The development proved successful but the dating on the produced inventory is already considered in the industry to be short-dated and will have to be replaced by the beginning of the second quarter of 2026. The temporary increase in inventory write-offs was a necessary step in scaling our operations and is not expected to be recurring. Our new larger-scale production processes are expected to help keep inventory costs lower than otherwise. As a result of these factors, the Gross Margin % decreased from </span><span style="-aw-sdt-tag:'c1454b5e44e0b8028059'; -aw-sdt-title:'Gross Margin Perc_PQ'"><span style="font-family: 'Times New Roman';">17.45</span></span><span>% for the </span><span style="-aw-sdt-tag:'cf78eb2c0558623d905e'; -aw-sdt-title:'Previous_Quarter_P14'"><span style="font-family: 'Times New Roman';">three months ended September 30, 2024</span></span><span> to a Gross Loss % of </span><span style="-aw-sdt-tag:'cd152b28b051547d634a'; -aw-sdt-title:'Gross Margin Perc_CQ'"><span style="font-family: 'Times New Roman';">22.87</span></span><span>% for the </span><span style="-aw-sdt-tag:'c9ced6e95acc599a7384'; -aw-sdt-title:'Current_Quarter_P27'"><span style="font-family: 'Times New Roman';">three months ended September 30, 2025</span></span><span>. </span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-weight:bold; font-style:italic">Other Operating Revenues</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-import:ignore">&#160;</span></p><div style="-aw-sdt-tag:'c16886f9029926f8ef2d'; -aw-sdt-title:'ITEM 2, 3 and 4_T5'"><table cellspacing="0" cellpadding="0" style="width:100%; border-collapse:collapse"><tbody><tr style="height:11.5pt"><td style="width:51.92%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:0.92%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="5" style="border-bottom:1.5pt solid #000000; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_c25513f92d88415999828d3758711a6b'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">For the Three Months Ended September 30,</span></p></div></td><td style="width:0.92%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:0.94%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:9.92%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:0.94%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10.26%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1.54%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td></tr><tr style="height:11.5pt"><td style="width:51.92%; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_79ad476b0c844defa540b6989b2c408d'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">Consolidated Statements of Operations Data:</span></p></div></td><td style="width:0.92%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="2" style="border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_69ea355010694f6e8778e7c360bf980a'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">2025</span></p></div></td><td style="width:0.92%; border-top:1.5pt solid #000000; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="2" style="border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_19d895402f934753be4c0f6ff6fe3af7'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">2024</span></p></div></td><td style="width:0.92%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="2" style="border-bottom:1.5pt solid #000000; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_01ed2916c0324f64b16bb719ff9edb26'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">$ Change</span></p></div></td><td style="width:0.94%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10.26%; border-bottom:1.5pt solid #000000; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_df177747d42d465e84fb4ad5e8e43339'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">% Change</span></p></div></td><td style="width:1.54%; padding:0.75pt; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td></tr><tr style="height:11.5pt"><td style="width:51.92%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ccecff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_20c35c4571144155bfb2ce5846335b7f'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Research Revenues</span></p></div></td><td style="width:0.92%; vertical-align:middle; background-color:#ccecff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:0.92%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_5c490201f42b4659817f25ecf213d764'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:9.92%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_faeaacfff6d74ae5be6f6da915de2bfe'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">90,960</span></p></div></td><td style="width:0.92%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:0.92%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_3dd5c1998ad742a4bab6f875e1450f8a'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:9.92%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_bba3988027ab47a9ab28569dc9be26e4'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">12,818</span></p></div></td><td style="width:0.92%; vertical-align:middle; background-color:#ccecff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:0.94%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ccecff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_512bc2f0b46845b89c03985d7867afcf'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:9.92%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#ccecff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_d75bb8d9c6304c8b848feab9a245b619'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">78,142</span></p></div></td><td style="width:0.94%; vertical-align:bottom; background-color:#ccecff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10.26%; vertical-align:bottom; background-color:#ccecff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_6ea0e512e8d8402bbfac10effddd8800'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">609.63</span></p></div></td><td style="width:1.54%; vertical-align:bottom; background-color:#ccecff"><div style="-aw-sdt-tag:'C_68602525c3d84ec1a6c5e383111c441b'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">%</span></p></div></td></tr></tbody></table></div><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>The research revenues earned by us were $</span><span style="-aw-sdt-tag:'c56e0243295b4abf8b65'; -aw-sdt-title:'Research revenues_CQ'"><span style="font-family: 'Times New Roman';">90,960</span></span><span> for the </span><span style="-aw-sdt-tag:'ce2a300cc925950c9fc0'; -aw-sdt-title:'Current_Quarter_P28'"><span style="font-family: 'Times New Roman';">three months ended September 30, 2025</span></span><span>, as compared to $</span><span style="-aw-sdt-tag:'caf5cf1475a943eaccb3'; -aw-sdt-title:'Research revenues_PQ'"><span style="font-family: 'Times New Roman';">12,818</span></span><span> for the </span><span style="-aw-sdt-tag:'cdd6a07fd0baf739e161'; -aw-sdt-title:'Previous_Quarter_P15'"><span style="font-family: 'Times New Roman';">three months ended September 30, 2024</span></span><span>. </span><span><span>The increase in research revenues is due to the new USAMMDA contract we were awarded in July 2024 to facilitate commercial validation of a new bottle and replacement blister packaging of Arakoda. We recognized research revenues of $</span><span style="-aw-sdt-tag:'4ea-a55-973-f27-1897'; -aw-sdt-title:'USAMMDA Arakoda_CQ Research Revenue'"><span style="font-family: 'Times New Roman';">90,960</span></span><span> related to the USAMMDA grant for the </span><span style="-aw-sdt-tag:'c98a64b2135d239b9850'; -aw-sdt-title:'Current_Quarter_P29'"><span style="font-family: 'Times New Roman';">three months ended September 30, 2025</span></span><span> ($</span><span style="-aw-sdt-tag:'b50-a8b-a9e-5bb-2450'; -aw-sdt-title:'USAMMDA Arakoda_PQ Research Revenue'"><span style="font-family: 'Times New Roman';">12,994</span></span><span> for the </span><span style="-aw-sdt-tag:'cd05fee480bb9d859255'; -aw-sdt-title:'Previous_Quarter_P16'"><span style="font-family: 'Times New Roman';">three months ended September 30, 2024</span></span><span>). </span></span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-weight:bold; font-style:italic">Operating Expenses</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-weight:bold; font-style:italic">&#160;</span></p><div style="-aw-sdt-tag:'c7d4d52d6f51514f0cd9'; -aw-sdt-title:'ITEM 2, 3 and 4_T6'"><table cellspacing="0" cellpadding="0" style="width:100%; border-collapse:collapse"><tbody><tr style="height:11.5pt"><td style="width:51.92%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:0.92%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="5" style="border-bottom:1.5pt solid #000000; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_5a84ba8bba9848618883ef32ea907432'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">For the Three Months Ended September 30,</span></p></div></td><td style="width:0.92%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:0.92%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:9.94%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:0.94%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10.26%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1.54%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td></tr><tr style="height:11.5pt"><td style="width:51.92%; border-bottom:1.5pt solid #000000; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_5394a8c05d9c41ed963cdb1a76131095'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">Consolidated Statements of Operations Data:</span></p></div></td><td style="width:0.92%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="2" style="border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_6f7c66d415cd481a8638b148fd118b08'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">2025</span></p></div></td><td style="width:0.92%; border-top:1.5pt solid #000000; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="2" style="border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_44157a049d7847cb90914671ead32775'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">2024</span></p></div></td><td style="width:0.92%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="2" style="border-bottom:1.5pt solid #000000; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_f4f8202d77924b7db1d3befcf3c1b176'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">$ Change</span></p></div></td><td style="width:0.94%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10.26%; border-bottom:1.5pt solid #000000; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_30a051069b8a4c8c9b4e434dc14f6610'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">% Change</span></p></div></td><td style="width:1.54%; padding:0.75pt; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td></tr><tr style="height:11.5pt"><td style="width:51.92%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ccecff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_92350ef51fb44538bb94621ea9edf0b3'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Research and Development</span></p></div></td><td style="width:0.92%; vertical-align:middle; background-color:#ccecff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:0.92%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ccecff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_aeee8ae84ce9417fa67d2f7ab6b30b7b'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:9.92%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ccecff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_cfd3dfb406234cb1a20a50b5a6c84fb3'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">809,777</span></p></div></td><td style="width:0.92%; vertical-align:middle; background-color:#ccecff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:0.92%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ccecff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_7baaa02ecb064e46b9f35fef6f4978e8'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:9.92%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ccecff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_a0814b16444747d6b2a4c7341c914809'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">940,063</span></p></div></td><td style="width:0.92%; vertical-align:middle; background-color:#ccecff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:0.92%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ccecff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_c85b3135f74140d9a666ef8e8a448a04'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:9.94%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#ccecff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_bc4a19e6c92f40b3813667e63e257d41'; font-family: 'Times New Roman'"><span>130,286</span></span><span style="font-family: 'Times New Roman';">)</span></p></td><td style="width:0.94%; vertical-align:bottom; background-color:#ccecff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10.26%; vertical-align:bottom; background-color:#ccecff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_4ef83c275d18469d92e5b01a9eda5f52'; font-family: 'Times New Roman'"><span>13.86</span></span><span style="font-family: 'Times New Roman';">)</span></p></td><td style="width:1.54%; vertical-align:bottom; background-color:#ccecff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_bea7f1bf0fce47e59c39d246ff646682'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">%</span></p></div></td></tr><tr style="height:11.5pt"><td style="width:51.92%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_4854a11a28e8433ba0d17745d49319ba'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">General and Administrative Expenses</span></p></div></td><td style="width:0.92%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:0.92%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:9.92%; border-bottom:1.5pt solid #000000; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_ac580a9ed87b4473a32e9ec829cdf570'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">1,506,620</span></p></div></td><td style="width:0.92%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:0.92%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:9.92%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_9cebd579efab4ff7a5e849bdb9c8699c'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">1,215,053</span></p></div></td><td style="width:0.92%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:0.92%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:9.94%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_88107cddc89349f4abf4861818b4bfb4'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">291,567</span></p></div></td><td style="width:0.94%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10.26%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_4703b5772d4346afac6e596096e04729'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">24.00</span></p></div></td><td style="width:1.54%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td></tr><tr style="height:11.5pt"><td style="width:51.92%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_a4af437b552f4178a62bcb06d8f5f187'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Total Operating Expenses</span></p></div></td><td style="width:0.92%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:0.92%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_e438005dd0534f2e83c26a8f8e4c927d'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:9.92%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_cb55a038aaa448e881711b1e49a758f3'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">2,316,397</span></p></div></td><td style="width:0.92%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:0.92%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_320421626d4b48c584fcd46fcac68bb2'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:9.92%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_a801e09b040948e682ced0405238ec65'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">2,155,116</span></p></div></td><td style="width:0.92%; vertical-align:middle; background-color:#ccecff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:0.92%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_8b069779692c4ca0bb3584a3a058c23e'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:9.94%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#ccecff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_28d664a998b04404a6ef7f8365e22d0e'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">161,281</span></p></div></td><td style="width:0.94%; vertical-align:bottom; background-color:#ccecff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10.26%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#ccecff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_bea1f10e4b284debb7e1750d5880531b'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">7.48</span></p></div></td><td style="width:1.54%; vertical-align:bottom; background-color:#ccecff"><div style="-aw-sdt-tag:'C_0274b292dd23456ab70d8eaab9b868f9'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">%</span></p></div></td></tr></tbody></table></div><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-style:italic">Research and Development </span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-style:italic">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>Research and development costs </span><span style="-aw-sdt-tag:'cc32232b97f48e1efa88'; -aw-sdt-title:'Research and development Direction_Q'"><span style="font-family: 'Times New Roman';">decreased</span></span><span> by $</span><span style="-aw-sdt-tag:'cb623176115ecdce8394'; -aw-sdt-title:'Research and development Change Amt_Q'"><span style="font-family: 'Times New Roman';">130,286</span></span><span> for the </span><span style="-aw-sdt-tag:'c4e807d4b3bdd567bbce'; -aw-sdt-title:'Current_Quarter_P31'"><span style="font-family: 'Times New Roman';">three months ended September 30, 2025</span></span><span> when compared to the </span><span style="-aw-sdt-tag:'cc16618cef58596d6443'; -aw-sdt-title:'Previous_Quarter_P18'"><span style="font-family: 'Times New Roman';">three months ended September 30, 2024</span></span><span>. The decline is partially attributable to a non-cash charge of $</span><span style="-aw-sdt-tag:'424-e43-c58-a94-01e8'; -aw-sdt-title:'Trevally_RDCharge_Q324'"><span style="font-family: 'Times New Roman';">600,000</span></span><span> recognized during the </span><span style="-aw-sdt-tag:'cad-818-c09-a71-a96b'; -aw-sdt-title:'Previous_Quarter_P31'"><span style="font-family: 'Times New Roman';">three months ended September 30, 2024</span></span><span> upon the delivery from Trevally of 8.8 kilograms of castanospermine, for which we had previously issued fully vested shares as advance consideration for the research materials. Otherwise, research and development costs incurred for the </span><span style="-aw-sdt-tag:'c4ab4e54b988ce0e86be'; -aw-sdt-title:'Current_Quarter_P32'"><span style="font-family: 'Times New Roman';">three months ended September 30, 2025</span></span><span> and </span><span style="-aw-sdt-tag:'cd77538e6cc36c6a5890'; -aw-sdt-title:'Previous_Year_P42'"><span style="font-family: 'Times New Roman';">2024</span></span><span> primarily consisted of costs related to our babesiosis trials for tafenoquine. Direct trial-related costs represent </span><span style="-aw-sdt-tag:'b72-2df-7de-3fb-5af3'; -aw-sdt-title:'Babesia PCT RandDExp_CQ'"><span style="font-family: 'Times New Roman';">81</span></span><span>% of the total research and development costs at $</span><span style="-aw-sdt-tag:'f09-3b6-d93-57e-edf2'; -aw-sdt-title:'Babesia Amount RandDExp_CYQTD'"><span style="font-family: 'Times New Roman';">656,754</span></span><span> for the </span><span style="-aw-sdt-tag:'c6790582a545eb13e78d'; -aw-sdt-title:'Current_Quarter_P33'"><span style="font-family: 'Times New Roman';">three months ended September 30, 2025</span></span><span>, compared to </span><span style="-aw-sdt-tag:'371-862-8f8-31a-8084'; -aw-sdt-title:'Babesia Pct RandDExp_PYQTD'"><span style="font-family: 'Times New Roman';">29</span></span><span>% of the costs at $</span><span style="-aw-sdt-tag:'313-52f-ff7-f0e-828e'; -aw-sdt-title:'Babesia Amount RandDExp_PYQTD'"><span style="font-family: 'Times New Roman';">270,497</span></span><span> for the </span><span style="-aw-sdt-tag:'c796c768d8c8abd07196'; -aw-sdt-title:'Previous_Quarter_P19'"><span style="font-family: 'Times New Roman';">three months ended September 30, 2024</span></span><span>.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-import:ignore">&#160;</span></p><div style="-aw-sdt-tag:'PG_cc51820e94dc310c10d8'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-family: 'Times New Roman';">30</span></p><div><hr style="width: 100%; color: #000000; background-color: #000000; margin: 1rem 0;"/></div></div></div><div class="Section_34"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-style:italic">General and Administrative Expenses</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>For the </span><span style="-aw-sdt-tag:'c2f41a0e0f84bf1b6577'; -aw-sdt-title:'Current_Quarter_P34'"><span style="font-family: 'Times New Roman';">three months ended September 30, 2025</span></span><span>, our general and administrative expenses </span><span style="-aw-sdt-tag:'c5d7cefcbf32532344ec'; -aw-sdt-title:'General and administrative exp Direction_Q'"><span style="font-family: 'Times New Roman';">increased</span></span><span> by approximately </span><span style="-aw-sdt-tag:'cfa1d736b28c6f62b345'; -aw-sdt-title:'General and administrative exp Change Perc_Q'"><span style="font-family: 'Times New Roman';">24.00</span></span><span>% or $</span><span style="-aw-sdt-tag:'ce61fc34b777a4efeb1b'; -aw-sdt-title:'General and Administrative Exp Change Amt_Q'"><span style="font-family: 'Times New Roman';">291,567</span></span><span> from the </span><span style="-aw-sdt-tag:'c650d4dc43f979f29442'; -aw-sdt-title:'Previous_Quarter_P20'"><span style="font-family: 'Times New Roman';">three months ended September 30, 2024</span></span><span>. For the </span><span style="-aw-sdt-tag:'ca63ed483fa6a27e778e'; -aw-sdt-title:'Current_Quarter_P35'"><span style="font-family: 'Times New Roman';">three months ended September 30, 2025</span></span><span>, we incurred higher sales, advertising and promotion expenses at $</span><span style="-aw-sdt-tag:'c9b-7d9-c79-c44-d1f7'; -aw-sdt-title:'SalesADVPromo Expense_CYQTD'"><span style="font-family: 'Times New Roman';">414,718</span></span><span>, up from $</span><span style="-aw-sdt-tag:'6ed-f5e-44c-f6d-df98'; -aw-sdt-title:'SalesADVPromo Expense_PYQTD'"><span style="font-family: 'Times New Roman';">47,645</span></span><span> for the </span><span style="-aw-sdt-tag:'cbbae37111d886aad67c'; -aw-sdt-title:'Previous_Quarter_P21'"><span style="font-family: 'Times New Roman';">three months ended September 30, 2024</span></span><span>. Additionally, for the </span><span style="-aw-sdt-tag:'c499ff687aed6f31fb15'; -aw-sdt-title:'Current_Quarter_P37'"><span style="font-family: 'Times New Roman';">three months ended September 30, 2025</span></span><span>, we incurred higher legal and professional fees at $</span><span style="-aw-sdt-tag:'f17-0bf-bfe-731-32d4'; -aw-sdt-title:'Legal_ProfessionalFees_CQTD'"><span style="font-family: 'Times New Roman';">177,401</span></span><span> ($</span><span style="-aw-sdt-tag:'c30-024-6c9-0b6-6c3a'; -aw-sdt-title:'Legal_ProfessionalFees_PQTD'"><span style="font-family: 'Times New Roman';">86,335</span></span><span> for the </span><span style="-aw-sdt-tag:'c57a5c3454a72317a144'; -aw-sdt-title:'Previous_Quarter_P22'"><span style="font-family: 'Times New Roman';">three months ended September 30, 2024</span></span><span>). </span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-weight:bold; font-style:italic">Interest and Other Income, net</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>&#160;</span></p><div style="-aw-sdt-tag:'cea7a432325a81233a6e'; -aw-sdt-title:'ITEM 2, 3 and 4_T7'"><table cellspacing="0" cellpadding="0" style="width:100%; border-collapse:collapse"><tbody><tr style="height:11.5pt"><td style="width:51.92%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:0.92%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="5" style="border-bottom:1.5pt solid #000000; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_1b3dd09b8d2f4fcea2d124787d958fa0'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">For the Three Months Ended September 30,</span></p></div></td><td style="width:0.92%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:0.92%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:9.94%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:0.94%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10.26%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1.54%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td></tr><tr style="height:11.5pt"><td style="width:51.92%; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_7b5e4ea38c734e24be6fc2205313beb5'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">Consolidated Statements of Operations Data:</span></p></div></td><td style="width:0.92%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="2" style="border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_8ebe9ea5760940f2ab250e7a67f1bd55'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">2025</span></p></div></td><td style="width:0.92%; border-top:1.5pt solid #000000; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="2" style="border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_5ad83e9100d246508cde0e95261217c2'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">2024</span></p></div></td><td style="width:0.92%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="2" style="border-bottom:1.5pt solid #000000; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_96bc853089af4182b09f8e218e92c07f'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">$ Change</span></p></div></td><td style="width:0.94%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10.26%; border-bottom:1.5pt solid #000000; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_88983e4b04614724a83f35abffd55c30'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">% Change</span></p></div></td><td style="width:1.54%; padding:0.75pt; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td></tr><tr style="height:11.5pt"><td style="width:51.92%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_1669215540b445fa99032a99f1c49969'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Interest Expense</span></p></div></td><td style="width:0.92%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:0.92%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_e97d81037fc64d8188155b67f280bbcf'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:9.92%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_2d0484da84b847e6ab9b8807b009d100'; font-family: 'Times New Roman'"><span>1,708</span></span><span style="font-family: 'Times New Roman';">)</span></p></td><td style="width:0.92%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:0.92%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_9603d6bd87624b528a6ec4c8d55b14c2'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:9.92%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_1a439526d3054f52b1e5475f5a7dd80c'; font-family: 'Times New Roman'"><span>1,467</span></span><span style="font-family: 'Times New Roman';">)</span></p></td><td style="width:0.92%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:0.92%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_1998016540624f33bf9ad451ee8c455c'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:9.94%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_dd0e55caa5504e80b062416c554919f2'; font-family: 'Times New Roman'"><span>241</span></span><span style="font-family: 'Times New Roman';">)</span></p></td><td style="width:0.94%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10.26%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_3c7bd13642e442a8aa0d8c9957298e69'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">16.43</span></p></div></td><td style="width:1.54%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_2240a750f5f545a88d3d3ec79f8042e4'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">%</span></p></div></td></tr><tr style="height:11.5pt"><td style="width:51.92%; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_8b30f6bf35604096b8b95d842c65beb5'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Change in Fair Value of Derivative Liabilities</span></p></div></td><td style="width:0.92%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:0.92%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:9.92%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_c66613cd0d1849c9a801d62e5f0b0b9e'; font-family: 'Times New Roman'"><span>21,103</span></span><span style="font-family: 'Times New Roman';">)</span></p></td><td style="width:0.92%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:0.92%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:9.92%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_64d18c3ef79b4b2ba6e496072c189ccb'; font-family: 'Times New Roman'"><span>56,712</span></span><span style="font-family: 'Times New Roman';">)</span></p></td><td style="width:0.92%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:0.92%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:9.94%; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_3ecc446354ef4aed9269732b291c0068'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">35,609</span></p></div></td><td style="width:0.94%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10.26%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_1e5c6ee87fd84ac085edfbcdfb0ac5fd'; font-family: 'Times New Roman'"><span>62.79</span></span><span style="font-family: 'Times New Roman';">)</span></p></td><td style="width:1.54%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td></tr><tr style="height:11.5pt"><td style="width:51.92%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_9f709282223a4534901712807edbdfdd'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Other Income, net</span></p></div></td><td style="width:0.92%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:0.92%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:9.92%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_270e54c7cc38479482a5f8c23853ad70'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">31,550</span></p></div></td><td style="width:0.92%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:0.92%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:9.92%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_c2059390eb3a4e0b95e133d912c2cef3'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">16,623</span></p></div></td><td style="width:0.92%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:0.92%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:9.94%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_a49758562c8841b18ef2d33657546064'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">14,927</span></p></div></td><td style="width:0.94%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10.26%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_859db08a9fdf465588306e79aa55291d'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">89.80</span></p></div></td><td style="width:1.54%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td></tr><tr style="height:11.5pt"><td style="width:51.92%; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_ea5183c1a93c4b2c84c625e3494448a9'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Total Interest and Other Income (Expense), net</span></p></div></td><td style="width:0.92%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:0.92%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_b5cacb235e534598ad23f64b70f40fd6'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:9.92%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_3f63812cf95a4753b8165d9fedd74326'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">8,739</span></p></div></td><td style="width:0.92%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:0.92%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_d6a011cc2ef94b35bb8b067a8f3b2fbc'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:9.92%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_ade035f31f154777bc04eae174aea8b1'; font-family: 'Times New Roman'"><span>41,556</span></span><span style="font-family: 'Times New Roman';">)</span></p></td><td style="width:0.92%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:0.92%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_92bc8332fb834962ac019f4f9e80c73c'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:9.94%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_ee0cc04a9a4a4500924d1d600e279554'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">50,295</span></p></div></td><td style="width:0.94%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10.26%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_2dcda71df9d44817b04b16833ddab276'; font-family: 'Times New Roman'"><span>121.03</span></span><span style="font-family: 'Times New Roman';">)</span></p></td><td style="width:1.54%; vertical-align:bottom"><div style="-aw-sdt-tag:'C_4b502e37ab6b43259c2041a73f64408d'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">%</span></p></div></td></tr></tbody></table></div><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-style:italic">Interest Expense</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-style:italic">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>For the </span><span style="-aw-sdt-tag:'c853f4a6b24d6fe95f36'; -aw-sdt-title:'Current_Quarter_P38'"><span style="font-family: 'Times New Roman';">three months ended September 30, 2025</span></span><span>, we recognized $</span><span style="-aw-sdt-tag:'855-f78-aff-105-bb36'; -aw-sdt-title:'Interest Expense_CQ'"><span style="font-family: 'Times New Roman';">1,708</span></span><span> of interest expense ($</span><span style="-aw-sdt-tag:'c7301e6b6d51dc1a71f2'; -aw-sdt-title:'Interest Expense_PQ'"><span style="font-family: 'Times New Roman';">1,467</span></span><span> for the </span><span style="-aw-sdt-tag:'c033f01e2ce9ab1b66d6'; -aw-sdt-title:'Previous_Quarter_P23'"><span style="font-family: 'Times New Roman';">three months ended September 30, 2024</span></span><span>). Our interest expense for the periods presented primarily relates to our single outstanding loan from the SBA. Cash paid for interest expense was $</span><span style="-aw-sdt-tag:'c465e037713f9452688a'"><span style="font-family: 'Times New Roman';">2,193</span></span><span> and $</span><span style="-aw-sdt-tag:'cbce0f8f4d6a39f4f02a'"><span style="font-family: 'Times New Roman';">2,193</span></span><span> for the </span><span style="-aw-sdt-tag:'c3c7631d4946573bdd92'; -aw-sdt-title:'Current_Quarter_P39'"><span style="font-family: 'Times New Roman';">three months ended September 30, 2025</span></span><span> and </span><span style="-aw-sdt-tag:'678-d66-c4a-68b-cc26'; -aw-sdt-title:'Previous_Period_P2'"><span style="font-family: 'Times New Roman';">September 30, 2024</span></span><span>, respectively.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-style:italic">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-style:italic">Change in Fair Value of Derivative Liabilities</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-style:italic">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>For the </span><span style="-aw-sdt-tag:'c6338aeb4da0491de354'; -aw-sdt-title:'Current_Quarter_P40'"><span style="font-family: 'Times New Roman';">three months ended September 30, 2025</span></span><span>, we recognized a loss on the change in fair value of derivative liabilities of $</span><span style="-aw-sdt-tag:'c3fee56fcaba3b01c3ff'; -aw-sdt-title:'fair value of derivative liabilities_CQ'"><span style="font-family: 'Times New Roman';">21,103</span></span><span> compared to the loss of $</span><span style="-aw-sdt-tag:'c1489a173d6393485069'; -aw-sdt-title:'fair value of derivative liabilities_PQ'"><span style="font-family: 'Times New Roman';">56,712</span></span><span> for the </span><span style="-aw-sdt-tag:'cc5f188fbc2f8bce7b31'; -aw-sdt-title:'Previous_Quarter_P24'"><span style="font-family: 'Times New Roman';">three months ended September 30, 2024</span></span><span>. During the periods presented, derivative liabilities include the contingent milestone payment due to Knight upon a future sale of Arakoda or a Change of Control. We use a probability-weighted expected return method to estimate the fair value of this derivative liability.</span><span style="-aw-import:spaces">&#160; </span><span>Generally in the valuation model as we get closer to potential milestones the value of the derivative increases.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-style:italic">Other Income, net </span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-style:italic">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>For the </span><span style="-aw-sdt-tag:'c40a1c6f99c990b60124'; -aw-sdt-title:'Current_Quarter_P41'"><span style="font-family: 'Times New Roman';">three months ended September 30, 2025</span></span><span>, we recognized $</span><span style="-aw-sdt-tag:'ce5806d6a32e9cb53ae3'; -aw-sdt-title:'Other Income_CQ'"><span style="font-family: 'Times New Roman';">31,550</span></span><span> in other income compared to $</span><span style="-aw-sdt-tag:'c2673795c5c57a6b83c9'; -aw-sdt-title:'Other Income_PQ'"><span style="font-family: 'Times New Roman';">16,623</span></span><span> for the </span><span style="-aw-sdt-tag:'c8b841d83cfc2f94ba4c'; -aw-sdt-title:'Previous_Quarter_P25'"><span style="font-family: 'Times New Roman';">three months ended September 30, 2024</span></span><span>. For the </span><span style="-aw-sdt-tag:'c2d14123ca9b62af9903'; -aw-sdt-title:'Current_Quarter_P42'"><span style="font-family: 'Times New Roman';">three months ended September 30, 2025</span></span><span>, we recognized interest income from cash invested in interest-bearing accounts and investments in certificates of deposit of $</span><span style="-aw-sdt-tag:'aa3-24a-00e-72c-c889'; -aw-sdt-title:'Interest Income Inv_CQ'"><span style="font-family: 'Times New Roman';">32,566</span></span><span> ($</span><span style="-aw-sdt-tag:'48c-652-d07-5cb-33da'; -aw-sdt-title:'Interest Income Inv_PQ'"><span style="font-family: 'Times New Roman';">16,635</span></span><span> for the </span><span style="-aw-sdt-tag:'c38e2e1116191ca95941'; -aw-sdt-title:'Previous_Quarter_P26'"><span style="font-family: 'Times New Roman';">three months ended September 30, 2024</span></span><span>).</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-import:ignore">&#160;</span></p><div style="-aw-sdt-tag:'PG_cd766339c09669c765ed'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-family: 'Times New Roman';">31</span></p><div><hr style="width: 100%; color: #000000; background-color: #000000; margin: 1rem 0;"/></div></div></div><div class="Section_35"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-weight:bold">Comparison of the Nine Months Ended September 30, 2025, and </span><span style="-aw-sdt-tag:'073-7e0-932-674-e092'; -aw-sdt-title:'Previous_Year_P46'"><span style="font-weight:bold; font-family: 'Times New Roman'">2024</span></span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-import:ignore">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-weight:bold; font-style:italic">Product Revenues - net of Discounts and Rebates, Cost of Revenues, Gross Profit, and Gross Margin</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-import:ignore">&#160;</span></p><div style="-aw-sdt-tag:'c026f0bad07c4e3def02'; -aw-sdt-title:'ITEM 2, 3 and 4_T8'"><table cellspacing="0" cellpadding="0" style="width:100%; border-collapse:collapse"><tbody><tr style="height:11.5pt"><td style="width:52%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:0.7%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="5" style="border-bottom:1.5pt solid #000000; padding-left:12.25pt; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_4cb7386484424af6a52461fbe2968688'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">For the Nine Months Ended September 30,</span></p></div></td><td style="width:1%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:0.74%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10.14%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td></tr><tr style="height:11.5pt"><td style="width:52%; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_6ade69b76b964497b54ed408dfd90451'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">Consolidated Statements of Operations Data:</span></p></div></td><td style="width:0.7%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="2" style="border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_a9b9b99acd334bb8a76013885cc29c77'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">2025</span></p></div></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="2" style="border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_529149042b6b4839915180c34b848620'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">2024</span></p></div></td><td style="width:1%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="2" style="border-bottom:1.5pt solid #000000; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_e1e564b952024f7eaf32bb65fb58f307'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">$ Change</span></p></div></td><td style="width:0.74%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10.14%; border-bottom:1.5pt solid #000000; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_fcb0bbae2ab24bac860134fdb9a29558'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">% Change</span></p></div></td><td style="width:1%; padding:0.75pt; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td></tr><tr style="height:11.5pt"><td style="width:52%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_d7410c42f01846e48628282bc6b378bc'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Product Revenues &#8211; net of Discounts and Rebates</span></p></div></td><td style="width:0.7%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_aa640fd67f814815889cd37521d4cc3d'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_ce00fdffcb714adf8ceead29df9aa15f'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">702,086</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ccecff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_1ab3be99931f43dca644c2584fc0d0f8'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_eee8f9f2b18f4946a8a6852485acb582'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">365,939</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ccecff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#ccecff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_f72ce8cbe8564644a11d50976d5dfcfe'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#ccecff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_e3b6928002014668b91c6b27cd799aa6'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">336,147</span></p></div></td><td style="width:0.74%; vertical-align:bottom; background-color:#ccecff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10.14%; vertical-align:bottom; background-color:#ccecff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_30ced4622cfc4c15a91925b1c4a930ca'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">91.86</span></p></div></td><td style="width:1%; vertical-align:bottom; background-color:#ccecff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_80b06195ea774730a28f8b8e24716462'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">%</span></p></div></td></tr><tr style="height:11.5pt"><td style="width:52%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_55e30be7a5da47b181ddbd2142e9ff37'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Cost of Revenues</span></p></div></td><td style="width:0.7%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_f5220a29cdb04afda86d3635d6e44608'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">661,013</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_9cc7455adc964004a141ac28e54bb335'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">266,688</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_568568d5ef504603b2b32c082a27776f'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">394,325</span></p></div></td><td style="width:0.74%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10.14%; border-bottom:1.5pt solid #000000; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_03954540e5fa41cba414e28a1eceb752'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">147.86</span></p></div></td><td style="width:1%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td></tr><tr style="height:11.5pt"><td style="width:52%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_0cf00c1f57b641e49b0dd4dd84c77125'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Gross Profit</span></p></div></td><td style="width:0.7%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_beac9fc33ce84d6d95c581095acb9fb3'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_a8805c514122417491a0ff7797afd3e7'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">41,073</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ccecff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_e9f987836661458791b495d6029f3aa2'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ccecff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_9b741a50a15a4fa39f64e47bde73acc4'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">99,251</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ccecff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#ccecff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_6f2d2c28856a4fc3be0652f73a03cca9'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#ccecff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_d81dc35e595f4d4c85bfe6faab68fd9e'; font-family: 'Times New Roman'"><span>58,178</span></span><span style="font-family: 'Times New Roman';">)</span></p></td><td style="width:0.74%; vertical-align:bottom; background-color:#ccecff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10.14%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#ccecff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_861a6260f9e74cc180bc606c32aef9f0'; font-family: 'Times New Roman'"><span>58.62</span></span><span style="font-family: 'Times New Roman';">)</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#ccecff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_d108dcec43054afc99e436648be08975'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">%</span></p></div></td></tr><tr style="height:11.5pt"><td style="width:52%; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_8f052ea97fef4faeb46d22fb5885f4c3'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">Gross Margin %</span></p></div></td><td style="width:0.7%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:4.5pt double #000000; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:4.5pt double #000000; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_e87aa43ef2534942a600ea6b1f3bd3e8'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">5.85</span></p></div></td><td style="width:1%; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_8d60243a1939473e921ee477df2c4365'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">%</span></p></div></td><td style="width:1%; border-top:4.5pt double #000000; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:4.5pt double #000000; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_3f888d24c02641fbaf523697c17b6d42'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">27.12</span></p></div></td><td style="width:1%; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_733cf4c6a4a64ecea2b3643503fea9d5'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">%</span></p></div></td><td style="width:1%; border-top:4.5pt double #000000; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:4.5pt double #000000; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:0.74%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10.14%; border-top:4.5pt double #000000; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td></tr></tbody></table></div><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-style:italic; -aw-import:ignore">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-style:italic">Product Revenues - net of Discounts and Rebates</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>Our product revenues - net of discounts and rebates were $</span><span style="-aw-sdt-tag:'c57301edad4295b9fcf3'; -aw-sdt-title:'Product revenues_CYTD'"><span style="font-family: 'Times New Roman';">702,086</span></span><span> for the </span><span style="-aw-sdt-tag:'c08c547b0559fb17b571'; -aw-sdt-title:'Current_YTD_P16'"><span style="font-family: 'Times New Roman';">nine months ended September 30, 2025</span></span><span>, as compared to $</span><span style="-aw-sdt-tag:'c7db57d2b3428035f3c8'; -aw-sdt-title:'Product revenues_PYTD'"><span style="font-family: 'Times New Roman';">365,939</span></span><span> for the </span><span style="-aw-sdt-tag:'c202a798b1bc3ec3650f'; -aw-sdt-title:'Previous_YTD_P5'"><span style="font-family: 'Times New Roman';">nine months ended September 30, 2024</span></span><span>. For the </span><span style="-aw-sdt-tag:'c9c4b4e3205143749605'; -aw-sdt-title:'Current_YTD_P18'"><span style="font-family: 'Times New Roman';">nine months ended September 30, 2025</span></span><span>, our U.S. pharmaceutical distributor and Infuserve America accounted for </span><span style="-aw-sdt-tag:'b23-0fe-ef8-7a3-1b22'; -aw-sdt-title:'Distributor1_CY_PCT'"><span style="font-family: 'Times New Roman';">73</span></span><span>% and </span><span style="-aw-sdt-tag:'a69-4bd-da5-561-eb36'"><span style="font-family: 'Times New Roman';">18</span></span><span>% of our total net product sales of Arakoda, respectively, and Kodatef sales to our Australian distributor accounted for </span><span style="-aw-sdt-tag:'c29-928-2be-a40-41bc'; -aw-sdt-title:'Distributor3 (AUS)_CYPCT'"><span style="font-family: 'Times New Roman';">6</span></span><span>% of total net product sales (</span><span style="-aw-sdt-tag:'77a-72e-1f4-749-b5c0'; -aw-sdt-title:'Distributor1_PYPCT'"><span style="font-family: 'Times New Roman';">94</span></span><span>%, </span><span style="-aw-sdt-tag:'74a-a30-9a4-a7d-a40a'; -aw-sdt-title:'Distributor2_PYPCT'"><span style="font-family: 'Times New Roman';">0</span></span><span>%, and </span><span style="-aw-sdt-tag:'d26-6ef-4ba-72d-1552'; -aw-sdt-title:'Distributor3(AU)_PYPCT'"><span style="font-family: 'Times New Roman';">6</span></span><span>% for the </span><span style="-aw-sdt-tag:'c08774017e7673f1efa8'; -aw-sdt-title:'Previous_YTD_P6'"><span style="font-family: 'Times New Roman';">nine months ended September 30, 2024</span></span><span>, respectively). Despite a shortage of Arakoda 16-ct boxes starting in April 2025, which resulted from a delay in completing commercial validation of a new packaging format, domestic, commercial product sales increased during the period, primarily due to the combination of rising sales, price increases and fewer returns. </span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>We offer discounts and rebates to the civilian U.S. supply chain distribution channel. We record sales when our 3PL partner transfers boxes into their title model. Discounts and rebates offered to our 3PL partner amount to 12% (lower rates available upon reaching larger revenue tiers) along with a $5,500 fixed monthly fee. The product is then transferred usually to one of the three large U.S. pharmaceutical distributors where rebates are 10%. Lastly, we have relationships with several large pharmacy benefit managers (&#8220;PBMs&#8221;) that allow patients to purchase Arakoda at a discount. The rebate associated with PBMs ranges from 30% to 41.25% depending on the amount of coverage provided. For the </span><span style="-aw-sdt-tag:'ce2-370-85c-8f8-85a2'; -aw-sdt-title:'Current_YTD_P51'"><span style="font-family: 'Times New Roman';">nine months ended September 30, 2025</span></span><span>, discounts and rebates were $</span><span style="-aw-sdt-tag:'a98-757-e1d-122-aadd'; -aw-sdt-title:'Disc and Rebates_CYTD'"><span style="font-family: 'Times New Roman';">324,948</span></span><span> compared to $</span><span style="-aw-sdt-tag:'c52-09c-9ac-a8e-858a'; -aw-sdt-title:'Disc and Rebates_PYTD'"><span style="font-family: 'Times New Roman';">324,486</span></span><span> for the </span><span style="-aw-sdt-tag:'d42-146-aaa-496-08bb'; -aw-sdt-title:'Previous_YTD_P38'"><span style="font-family: 'Times New Roman';">nine months ended September 30, 2024</span></span><span>.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>Arakoda entered the U.S. civilian supply chain in the third quarter of 2019. Since the introduction of the new 8-ct bottle in June 2025, we will be reporting Arakoda unit sales in terms of 16-ct box equivalents. For the </span><span style="-aw-sdt-tag:'c44a71d8881d958039e2'; -aw-sdt-title:'Previous_YTD_P25'"><span style="font-family: 'Times New Roman';">nine months ended September 30, 2024</span></span><span>, </span><span style="-aw-sdt-tag:'c3239b0a9c77700d0a70'; -aw-sdt-title:'Boxes sold to pharmacies_PYTD'"><span style="font-family: 'Times New Roman';">3,642</span></span><span> 16-ct box equivalents were sold to pharmacies and dispensaries. Sales volume </span><span style="-aw-sdt-tag:'c25b6a3f6cdb885384f2'; -aw-sdt-title:'Boxes sold to pharmacies Direction_CYTD'"><span style="font-family: 'Times New Roman';">increased</span></span><span> by </span><span style="-aw-sdt-tag:'cd5570c0fd970b5f7930'; -aw-sdt-title:'Boxes sold to pharmacies Change Perc_CYTD'"><span style="font-family: 'Times New Roman';">14</span></span><span>% to </span><span style="-aw-sdt-tag:'c692bb0a95ec25d0d842'; -aw-sdt-title:'Boxes sold to pharmacies_CYTD'"><span style="font-family: 'Times New Roman';">4,166</span></span><span> 16-ct box equivalents sold to pharmacies and dispensaries for the </span><span style="-aw-sdt-tag:'c39f32ebd17a6945c364'; -aw-sdt-title:'Current_YTD_P39'"><span style="font-family: 'Times New Roman';">nine months ended September 30, 2025</span></span><span>. </span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>Kodatef sales to our distributor Biocelect in Australia for the </span><span style="-aw-sdt-tag:'cda73d6aff779359362d'; -aw-sdt-title:'Current_YTD_P19'"><span style="font-family: 'Times New Roman';">nine months ended September 30, 2025</span></span><span> were $</span><span style="-aw-sdt-tag:'63e-239-884-1bc-b148'; -aw-sdt-title:'AUKodatef Sales Dollar Amount_CYTD'"><span style="font-family: 'Times New Roman';">42,775</span></span><span> ($</span><span style="-aw-sdt-tag:'e48-3ae-b63-fc3-e95b'; -aw-sdt-title:'AUKodatef Sales Dollar Amount_PYTD'"><span style="font-family: 'Times New Roman';">20,697</span></span><span> for the </span><span style="-aw-sdt-tag:'cea4e8d2497a407b686d'; -aw-sdt-title:'Previous_YTD_P7'"><span style="font-family: 'Times New Roman';">nine months ended September 30, 2024</span></span><span>). A historical portion of sales to Biocelect remained subject to a profit share distribution once the original transfer price has been recouped. Biocelect, which acts as a distributor in the Australian and New Zealand market, reported </span><span style="-aw-sdt-tag:'4a8-740-a2a-3c6-788f'; -aw-sdt-title:'AUKodated Boxes PCT Change_YTD'"><span style="font-family: 'Times New Roman';">10</span></span><span>% year-over-year decline, the equivalent of </span><span style="-aw-sdt-tag:'115-530-19e-8f9-0c3e'; -aw-sdt-title:'AUKodated Boxes Change_YTD'"><span style="font-family: 'Times New Roman';">1,334</span></span><span> boxes sold for the </span><span style="-aw-sdt-tag:'c7684bbb8f9220160361'; -aw-sdt-title:'Current_YTD_P20'"><span style="font-family: 'Times New Roman';">nine months ended September 30, 2025</span></span><span>, compared to </span><span style="-aw-sdt-tag:'ee0-77b-5a4-812-b6fa'; -aw-sdt-title:'AUKodated Boxes_PYTD'"><span style="font-family: 'Times New Roman';">1,489</span></span><span> boxes for the </span><span style="-aw-sdt-tag:'cab9df7ecea20edc57af'; -aw-sdt-title:'Previous_YTD_P8'"><span style="font-family: 'Times New Roman';">nine months ended September 30, 2024</span></span><span>. As of </span><span style="-aw-sdt-tag:'cb9ece85a88523e670d0'; -aw-sdt-title:'Current_Period_P30'"><span style="font-family: 'Times New Roman';">September 30, 2025</span></span><span>, Biocelect has no inventory left that remains subject to profit share. Additionally, under a new agreement executed during the period, Biocelect began to purchase from the latest manufactured lot of Kodatef at $49.50 AUD per box which are not subject to historical profit share. For the nine months ended </span><span style="-aw-sdt-tag:'cc4eeb6be8a9f788f6f2'; -aw-sdt-title:'Current_Period_P31'"><span style="font-family: 'Times New Roman';">September 30, 2025</span></span><span>, </span><span style="-aw-sdt-tag:'8ab-c4c-d2b-9e9-46d6'; -aw-sdt-title:'AUKodatef Boxes2Biocelet CY YTD'"><span style="font-family: 'Times New Roman';">1,100</span></span><span> boxes of Kodatef were sold to Biocelect (</span><span style="-aw-sdt-tag:'9fc-605-84d-a4b-8c37'; -aw-sdt-title:'AUKodatef Boxes2Biocelet PY YTD'"><span style="font-family: 'Times New Roman';">None</span></span><span> for the </span><span style="-aw-sdt-tag:'bb9-263-9b0-2d9-00d5'; -aw-sdt-title:'Previous_YTD_P41'"><span style="font-family: 'Times New Roman';">nine months ended September 30, 2024</span></span><span>). As of </span><span style="-aw-sdt-tag:'cfd14d8e044b0629a24f'; -aw-sdt-title:'Current_Period_P32'"><span style="font-family: 'Times New Roman';">September 30, 2025</span></span><span>, $</span><span style="-aw-sdt-tag:'73c-83e-362-048-f0e3'; -aw-sdt-title:'Current Period_Kodatef Profit Share Receivable'"><span style="font-family: 'Times New Roman';">16,331</span></span><span> of receivables was due to us ($</span><span style="-aw-sdt-tag:'1f2-165-2a2-e6d-d66d'; -aw-sdt-title:'Dec 2024 _Kodatef Profit Share Receivable'"><span style="font-family: 'Times New Roman';">9,444</span></span><span> as of </span><span style="-aw-sdt-tag:'6b2-89c-cac-2bf-d4b2'; -aw-sdt-title:'Previous_Year_End_P22'"><span style="font-family: 'Times New Roman';">December 31, 2024</span></span><span>).</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>Arakoda sales volume in Europe continues to grow. We first shipped Arakoda to our distributor Scandinavian Biopharma (&#8220;SB&#8221;) in September 2022. For the </span><span style="-aw-sdt-tag:'ce825b2565a8d1275aaf'; -aw-sdt-title:'Current_YTD_P21'"><span style="font-family: 'Times New Roman';">nine months ended September 30, 2025</span></span><span>, SB reported </span><span style="-aw-sdt-tag:'a63-cf2-7d6-b1a-4fe9'; -aw-sdt-title:'SB Arakoda Boxes Sold _CYTD'"><span style="font-family: 'Times New Roman';">249</span></span><span> boxes sold (</span><span style="-aw-sdt-tag:'ea8-55e-ff5-d4c-b4a1'; -aw-sdt-title:'SB Arakoda Boxes Sold _PYTD'"><span style="font-family: 'Times New Roman';">109</span></span><span> boxes sold for the </span><span style="-aw-sdt-tag:'ce9f39a119a02d44e67f'; -aw-sdt-title:'Previous_YTD_P9'"><span style="font-family: 'Times New Roman';">nine months ended September 30, 2024</span></span><span>). According to our distributor, this is due to greater interest in treating babesiosis. Additionally, we received another purchase order of product from Europe and shipped 1,000 bottles towards the end of August 2025.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-import:ignore">&#160;</span></p><div style="-aw-sdt-tag:'PG_c74846914a599b296bc9'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-family: 'Times New Roman';">32</span></p><div><hr style="width: 100%; color: #000000; background-color: #000000; margin: 1rem 0;"/></div></div></div><div class="Section_36"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-style:italic">Cost of Revenues, Gross Profit, and Gross Margin</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-style:italic">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>Cost of revenues was $</span><span style="-aw-sdt-tag:'c08ce5917c450f6f01fc'; -aw-sdt-title:'Cost of revenues_CYTD'"><span style="font-family: 'Times New Roman';">661,013</span></span><span> for the </span><span style="-aw-sdt-tag:'cc75dd775d5c8f5fa557'; -aw-sdt-title:'Current_YTD_P22'"><span style="font-family: 'Times New Roman';">nine months ended September 30, 2025</span></span><span>, as compared to $</span><span style="-aw-sdt-tag:'c245edcb01bbc402a342'; -aw-sdt-title:'Cost of revenues_PYTD'"><span style="font-family: 'Times New Roman';">266,688</span></span><span> for the </span><span style="-aw-sdt-tag:'c13c0a6f7192212af6ae'; -aw-sdt-title:'Previous_YTD_P10'"><span style="font-family: 'Times New Roman';">nine months ended September 30, 2024</span></span><span>. The significant increase in cost of goods sold was primarily due to higher write-offs of inventory not expected to be sold prior to its expiration date. Write-offs of expiring inventory were $</span><span style="-aw-sdt-tag:'a8d-2cd-b02-cb7-652d'; -aw-sdt-title:'Inventory_Writeoffs_CYTD'"><span style="font-family: 'Times New Roman';">436,596</span></span><span> for the </span><span style="-aw-sdt-tag:'457-650-107-b77-c56d'; -aw-sdt-title:'Current_YTD_P57'"><span style="font-family: 'Times New Roman';">nine months ended September 30, 2025</span></span><span>, as compared to $</span><span style="-aw-sdt-tag:'091-c11-e1e-a35-eab0'; -aw-sdt-title:'Inventory_Writeoffs_PYTD'"><span style="font-family: 'Times New Roman';">18,490</span></span><span> for the </span><span style="-aw-sdt-tag:'fcb-23c-9db-f7a-062d'; -aw-sdt-title:'Previous_YTD_P42'"><span style="font-family: 'Times New Roman';">nine months ended September 30, 2024</span></span><span>. The excess inventory resulted from our strategic decision to validate a new, larger-scale production method with then soon to be expiring raw materials (API), with the offsetting assistance from our USAMMDA grant. The development proved successful but the dating on the produced inventory is already considered in the industry to be short-dated and will have to be replaced by the beginning of the second quarter 2026. The temporary increase in inventory writeoffs was a necessary step in scaling our operations and is not expected to be recurring. Our new larger-scale production processes are expected to help keep inventory costs lower than otherwise. Due to these factors, the Gross Margin % decreased from </span><span style="-aw-sdt-tag:'953-5ee-8b4-030-8f62'; -aw-sdt-title:'Gross Margin_PYTD'"><span style="font-family: 'Times New Roman';">27.12</span></span><span>% for the </span><span style="-aw-sdt-tag:'c6b1a142cce8eb9d1604'; -aw-sdt-title:'Previous_YTD_P11'"><span style="font-family: 'Times New Roman';">nine months ended September 30, 2024</span></span><span> to </span><span style="-aw-sdt-tag:'a3f-6dd-b94-7f8-cf22'; -aw-sdt-title:'Gross Margin_CYTD'"><span style="font-family: 'Times New Roman';">5.85</span></span><span>% for the </span><span style="-aw-sdt-tag:'c9332186436d1133d689'; -aw-sdt-title:'Current_YTD_P23'"><span style="font-family: 'Times New Roman';">nine months ended September 30, 2025</span></span><span>. </span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-import:ignore">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-weight:bold; font-style:italic">Other Operating Revenues</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-import:ignore">&#160;</span></p><div style="-aw-sdt-tag:'c5142a14d34326ce6e4d'; -aw-sdt-title:'ITEM 2, 3 and 4_T9'"><table cellspacing="0" cellpadding="0" style="width:100%; border-collapse:collapse"><tbody><tr style="height:11.5pt"><td style="width:51.92%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:0.92%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="5" style="border-bottom:1.5pt solid #000000; padding-left:10.1pt; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_9f2ae9d8185240f799c2af3566826ec4'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">For the Nine Months Ended September 30,</span></p></div></td><td style="width:0.92%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:0.92%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:9.94%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:0.94%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10.26%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1.54%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td></tr><tr style="height:11.5pt"><td style="width:51.92%; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_ca8519ceb14942b6995e98582cff7310'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">Consolidated Statements of Operations Data:</span></p></div></td><td style="width:0.92%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="2" style="border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_94bb28efabb843c897ea7b7603604cbf'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">2025</span></p></div></td><td style="width:0.92%; border-top:1.5pt solid #000000; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="2" style="border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_10a8ee0a2017473dae372943c15d6cbc'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">2024</span></p></div></td><td style="width:0.92%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="2" style="border-bottom:1.5pt solid #000000; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_3f5362c121d8405799e3b4574bc8cafb'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">$ Change</span></p></div></td><td style="width:0.94%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10.26%; border-bottom:1.5pt solid #000000; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_ea32100214a14e1d8216bbd56f50897c'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">% Change</span></p></div></td><td style="width:1.54%; padding:0.75pt; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td></tr><tr style="height:11.5pt"><td style="width:51.92%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#ccecff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_804c6085f75e4aabbffc88be1bc4c75f'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Research Revenues</span></p></div></td><td style="width:0.92%; vertical-align:bottom; background-color:#ccecff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:0.92%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_d4b668fd4dbb4bcb8e4f716b6ce36923'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:9.92%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_271bfb44680541ecb6564929f2e51f2a'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">390,630</span></p></div></td><td style="width:0.92%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:0.92%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_5453ff9c37fc4a6bb05df248fde3ad02'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:9.92%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_0af87108350b4907b947cb8f5be8a4df'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">43,177</span></p></div></td><td style="width:0.92%; vertical-align:bottom; background-color:#ccecff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:0.92%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#ccecff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_a98e19e839874d84b2bfe7700a5264aa'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:9.94%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#ccecff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_ec41c4537e9b49a58962cf14d67b8bfb'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">347,453</span></p></div></td><td style="width:0.94%; vertical-align:bottom; background-color:#ccecff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10.26%; vertical-align:bottom; background-color:#ccecff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_d98dfcb9e10b4b75b85f6f482243a2c9'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">804.72</span></p></div></td><td style="width:1.54%; vertical-align:bottom; background-color:#ccecff"><div style="-aw-sdt-tag:'C_8d29c563782c4696bcff7080a771bda2'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">%</span></p></div></td></tr></tbody></table></div><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-import:spaces">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>The research revenues earned by us were $</span><span style="-aw-sdt-tag:'c05d91ef8280ed79cde3'; -aw-sdt-title:'Research revenues_CYTD'"><span style="font-family: 'Times New Roman';">390,630</span></span><span> for the </span><span style="-aw-sdt-tag:'c6ab5dc56f0ef8ec53e0'; -aw-sdt-title:'Current_YTD_P24'"><span style="font-family: 'Times New Roman';">nine months ended September 30, 2025</span></span><span>, as compared to $</span><span style="-aw-sdt-tag:'c95e1c8fabc2babd47ce'; -aw-sdt-title:'Research revenues_PYTD'"><span style="font-family: 'Times New Roman';">43,177</span></span><span> for the </span><span style="-aw-sdt-tag:'cfe6ab18c4b13d610a8e'; -aw-sdt-title:'Previous_YTD_P12'"><span style="font-family: 'Times New Roman';">nine months ended September 30, 2024</span></span><span>. The increase in research revenues is primarily due to the new USAMMDA contract we were awarded in July 2024 to facilitate commercial validation of a new bottle and replacement blister packaging of Arakoda and the contract we signed with the University of Kentucky for tafenoquine clinical trial supply. We recognized research revenues of $</span><span style="-aw-sdt-tag:'585-122-45a-712-1b00'; -aw-sdt-title:'USAMMDAResearch Rev_CYTD'"><span style="font-family: 'Times New Roman';">285,874</span></span><span> related to the USAMMDA grant for the </span><span style="-aw-sdt-tag:'c1ff85296debe8d11235'; -aw-sdt-title:'Current_YTD_P25'"><span style="font-family: 'Times New Roman';">nine months ended September 30, 2025</span></span><span> ($</span><span style="-aw-sdt-tag:'847-fe7-e9d-ad1-e255'; -aw-sdt-title:'RandDRev_USAMMDA_LYCP'"><span style="font-family: 'Times New Roman';">12,994</span></span><span> for the </span><span style="-aw-sdt-tag:'ccafbb81b3f7cf59441c'; -aw-sdt-title:'Previous_YTD_P13'"><span style="font-family: 'Times New Roman';">nine months ended September 30, 2024</span></span><span>). We recognized research revenues of $</span><span style="-aw-sdt-tag:'b6a-8f7-153-a7b-85f7'; -aw-sdt-title:'RandDRev_UK_CYCP'"><span style="font-family: 'Times New Roman';">89,302</span></span><span> from the University of Kentucky for the </span><span style="-aw-sdt-tag:'0b3-5bd-7bf-41c-1bba'; -aw-sdt-title:'Current_YTD_P52'"><span style="font-family: 'Times New Roman';">nine months ended September 30, 2025</span></span><span> ($</span><span style="-aw-sdt-tag:'616-398-7a8-8de-476c'; -aw-sdt-title:'RandDRev_UK_LYCP'"><span style="font-family: 'Times New Roman';">0</span></span><span> for the </span><span style="-aw-sdt-tag:'57a-def-5ba-157-71ab'; -aw-sdt-title:'Previous_YTD_P37'"><span style="font-family: 'Times New Roman';">nine months ended September 30, 2024</span></span><span>). Other research revenues were $</span><span style="-aw-sdt-tag:'f15-ab4-928-408-62a1'; -aw-sdt-title:'Australia Research Rev_CYTD'"><span style="font-family: 'Times New Roman';">15,454</span></span><span> for the </span><span style="-aw-sdt-tag:'c0ecb5e04c0af120962b'; -aw-sdt-title:'Current_YTD_P26'"><span style="font-family: 'Times New Roman';">nine months ended September 30, 2025</span></span><span> ($</span><span style="-aw-sdt-tag:'d86-4c6-334-a67-eb8f'; -aw-sdt-title:'Australia Research Rev_PYTD'"><span style="font-family: 'Times New Roman';">30,183</span></span><span> for the </span><span style="-aw-sdt-tag:'c9a9ee1039d8c7893a76'; -aw-sdt-title:'Previous_YTD_P14'"><span style="font-family: 'Times New Roman';">nine months ended September 30, 2024</span></span><span>).</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-import:ignore">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-weight:bold; font-style:italic">Operating Expenses</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-weight:bold; font-style:italic; -aw-import:ignore">&#160;</span></p><div style="-aw-sdt-tag:'c6cb993aa29960a0d686'; -aw-sdt-title:'ITEM 2, 3 and 4_T10'"><table cellspacing="0" cellpadding="0" style="width:100%; border-collapse:collapse"><tbody><tr style="height:11.5pt"><td style="width:51.9%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:0.9%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="5" style="border-bottom:1.5pt solid #000000; padding-left:10.8pt; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_f41bd65d300b4323a3cb546fc180b198'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">For the Nine Months Ended September 30,</span></p></div></td><td style="width:0.92%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:0.92%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:9.94%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:0.94%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10.26%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1.54%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td></tr><tr style="height:11.5pt"><td style="width:51.9%; border-bottom:1.5pt solid #000000; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_dccb9543e98840f4aee4e822f84dde61'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">Consolidated Statements of Operations Data:</span></p></div></td><td style="width:0.9%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="2" style="border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_f651536ccb344117aba2a728224c7710'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">2025</span></p></div></td><td style="width:0.92%; border-top:1.5pt solid #000000; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="2" style="border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_b3c88045c8144be3be7e0eae43942dd8'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">2024</span></p></div></td><td style="width:0.92%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="2" style="border-bottom:1.5pt solid #000000; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_822df11773c94af3a74218b20155056c'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">$ Change</span></p></div></td><td style="width:0.94%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10.26%; border-bottom:1.5pt solid #000000; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_ce01dcaa0a644a34952b563ad855bcb6'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">% Change</span></p></div></td><td style="width:1.54%; padding-top:0.75pt; padding-bottom:0.75pt; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td></tr><tr style="height:11.5pt"><td style="width:51.9%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#ccecff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_a15be2f587e54bb89490881891a03902'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Research and Development</span></p></div></td><td style="width:0.9%; vertical-align:bottom; background-color:#ccecff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:0.92%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#ccecff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_89b7968467e74f95b4a52e609dbb21f0'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:9.94%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#ccecff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_5c71d8f1d4db4b5b885f3902e03d87a4'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">1,467,283</span></p></div></td><td style="width:0.92%; vertical-align:bottom; background-color:#ccecff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:0.92%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#ccecff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_981888dcfa99404ab6c9dca7e1ef623b'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:9.94%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#ccecff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_851704f295a0489f9220b32cda6acf22'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">4,372,571</span></p></div></td><td style="width:0.92%; vertical-align:bottom; background-color:#ccecff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:0.92%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#ccecff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_6f5fab4037b84f5eadcb104ee349e55b'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:9.94%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#ccecff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_bdd3ec40c9ce4b589ab840bee7682857'; font-family: 'Times New Roman'"><span>2,905,288</span></span><span style="font-family: 'Times New Roman';">)</span></p></td><td style="width:0.94%; vertical-align:bottom; background-color:#ccecff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10.26%; vertical-align:bottom; background-color:#ccecff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_a3ebcd6cc93540e78b1d526099558924'; font-family: 'Times New Roman'"><span>66.44</span></span><span style="font-family: 'Times New Roman';">)</span></p></td><td style="width:1.54%; vertical-align:bottom; background-color:#ccecff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_85976cef99134635b103a0831763dada'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">%</span></p></div></td></tr><tr style="height:11.5pt"><td style="width:51.9%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_d43a45f3b7fc4aebb7681b3c5b88ed1e'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">General and Administrative Expenses</span></p></div></td><td style="width:0.9%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:0.92%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:9.94%; border-bottom:1.5pt solid #000000; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_bb00d1cad306475dbd2febd2f044f60c'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">4,805,648</span></p></div></td><td style="width:0.92%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:0.92%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:9.94%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_c1b772485ed148ca9a103b6aaf681aaf'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">3,419,747</span></p></div></td><td style="width:0.92%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:0.92%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:9.94%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_6ad308d10f624603a92a7896ac451dbd'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">1,385,901</span></p></div></td><td style="width:0.94%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10.26%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_486ca159a8a041609831d34e2b667f24'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">40.53</span></p></div></td><td style="width:1.54%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td></tr><tr style="height:11.5pt"><td style="width:51.9%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_bd8aca04efa8492a8c23d93c49cb66b3'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Total Operating Expenses</span></p></div></td><td style="width:0.9%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:0.92%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_975f1a4a66954d8dbe937787364b29ef'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:9.94%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_240c809010f546c8860aa069818ead25'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">6,272,931</span></p></div></td><td style="width:0.92%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:0.92%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_9a63f94f6e93441b9053bff4f50052ef'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:9.94%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_af31144f40d4443198c3f55481d51864'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">7,792,318</span></p></div></td><td style="width:0.92%; vertical-align:bottom; background-color:#ccecff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:0.92%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_f662013b4e8c4a198afc0a0b972a53a7'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:9.94%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#ccecff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_c02075c81fb04ff9a8d403feecc68296'; font-family: 'Times New Roman'"><span>1,519,387</span></span><span style="font-family: 'Times New Roman';">)</span></p></td><td style="width:0.94%; vertical-align:bottom; background-color:#ccecff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10.26%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#ccecff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_708117ffc5fe410a897344cc581e5a43'; font-family: 'Times New Roman'"><span>19.50</span></span><span style="font-family: 'Times New Roman';">)</span></p></td><td style="width:1.54%; vertical-align:bottom; background-color:#ccecff"><div style="-aw-sdt-tag:'C_32327b5703c743ffbbbfedef53a8c7a6'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">%</span></p></div></td></tr></tbody></table></div><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-weight:bold; font-style:italic; -aw-import:ignore">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-style:italic">Research and Development </span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-style:italic">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>Research and development costs </span><span style="-aw-sdt-tag:'caa2723b96ab76a60935'; -aw-sdt-title:'RD Cost direction_CYTD'"><span style="font-family: 'Times New Roman';">decreased</span></span><span> by $</span><span style="-aw-sdt-tag:'5a1-8b2-0a3-383-36de'; -aw-sdt-title:'RD Change Amt_YTD'"><span style="font-family: 'Times New Roman';">2,905,288</span></span><span> for the </span><span style="-aw-sdt-tag:'c251e300e0cb6b1a460c'; -aw-sdt-title:'Current_YTD_P27'"><span style="font-family: 'Times New Roman';">nine months ended September 30, 2025</span></span><span> when compared to the </span><span style="-aw-sdt-tag:'c0529328df1290533b04'; -aw-sdt-title:'Previous_YTD_P15'"><span style="font-family: 'Times New Roman';">nine months ended September 30, 2024</span></span><span>. The decline is primarily attributable to a non-cash charge of $3,225,000 recognized during the </span><span style="-aw-sdt-tag:'2da-184-159-192-6a65'; -aw-sdt-title:'Previous_YTD_P36'"><span style="font-family: 'Times New Roman';">nine months ended September 30, 2024</span></span><span> related to share-based payments issued to vendors in January 2023 as advance consideration, which payments were initially deferred and capitalized. Kentucky Technology, Inc. delivered us a report on the potential development of SJ733 + tafenoquine in the second quarter of 2024 and Trevally completed the synthesis of 8.8 kilograms of castanospermine in the third quarter of 2024, resulting in $2,625,000 and $600,000, respectively, of research and development expense recognized for the </span><span style="-aw-sdt-tag:'9a8-cad-d5c-92a-98ba'; -aw-sdt-title:'Previous_YTD_P43'"><span style="font-family: 'Times New Roman';">nine months ended September 30, 2024</span></span><span>. Otherwise, research and development costs incurred for the </span><span style="-aw-sdt-tag:'c65aa8cfb1f08a5a4974'; -aw-sdt-title:'Current_YTD_P28'"><span style="font-family: 'Times New Roman';">nine months ended September 30, 2025</span></span><span> and </span><span style="-aw-sdt-tag:'c7933a7155b937919aa0'; -aw-sdt-title:'Previous_Year_P43'"><span style="font-family: 'Times New Roman';">2024</span></span><span> primarily consisted of costs related to our babesiosis trial for tafenoquine. Direct trial-related costs represent </span><span style="-aw-sdt-tag:'8f4-632-3d5-a01-170c'; -aw-sdt-title:'RandDExpense Babesia PCT_ CYTD'"><span style="font-family: 'Times New Roman';">76</span></span><span>% of the total research and development costs at $</span><span style="-aw-sdt-tag:'0d6-12a-c92-203-c40f'; -aw-sdt-title:'RandDExpense Babesia Amount_CYTD'"><span style="font-family: 'Times New Roman';">1,109,279</span></span><span> for the </span><span style="-aw-sdt-tag:'c01a94015a2cd976fec7'; -aw-sdt-title:'Current_YTD_P29'"><span style="font-family: 'Times New Roman';">nine months ended September 30, 2025</span></span><span>, compared to </span><span style="-aw-sdt-tag:'795-519-7c8-47f-af33'; -aw-sdt-title:'RandDExpense Babesia PCT _PYTD'"><span style="font-family: 'Times New Roman';">19</span></span><span>% of the costs at $</span><span style="-aw-sdt-tag:'a07-087-5c4-948-3140'; -aw-sdt-title:'RandDExpense Babesia Amount_PYTD'"><span style="font-family: 'Times New Roman';">846,323</span></span><span> for the </span><span style="-aw-sdt-tag:'c6707842246d293a63a2'; -aw-sdt-title:'Previous_YTD_P16'"><span style="font-family: 'Times New Roman';">nine months ended September 30, 2024</span></span><span>. We also recorded $</span><span style="-aw-sdt-tag:'cb4-532-989-e3f-a87f'"><span style="font-family: 'Times New Roman';">204,112</span></span><span> in research and development expenses related to commercial validation and packaging of Arakoda, for which a majority qualifies for reimbursement under the USAMMDA grant discussed above.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-import:ignore">&#160;</span></p><div style="-aw-sdt-tag:'PG_c4645f1609632a4fae95'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-family: 'Times New Roman';">33</span></p><div><hr style="width: 100%; color: #000000; background-color: #000000; margin: 1rem 0;"/></div></div></div><div class="Section_37"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-style:italic">General and Administrative Expenses</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>For the </span><span style="-aw-sdt-tag:'c0ca342fc590888c4246'; -aw-sdt-title:'Current_YTD_P30'"><span style="font-family: 'Times New Roman';">nine months ended September 30, 2025</span></span><span>, our general and administrative expenses </span><span style="-aw-sdt-tag:'c333a723c4ff4827487b'; -aw-sdt-title:'GA expenses direction_YTD'"><span style="font-family: 'Times New Roman';">increased</span></span><span> by approximately </span><span style="-aw-sdt-tag:'cb17bf418663c161b583'; -aw-sdt-title:'GA expenses Perc_YTD'"><span style="font-family: 'Times New Roman';">40.53</span></span><span>% or $</span><span style="-aw-sdt-tag:'cb530bf27910b21b7276'; -aw-sdt-title:'GA expenses change Amt_YTD'"><span style="font-family: 'Times New Roman';">1,385,901</span></span><span> from the </span><span style="-aw-sdt-tag:'c727bad0fe0b498335bc'; -aw-sdt-title:'Previous_YTD_P17'"><span style="font-family: 'Times New Roman';">nine months ended September 30, 2024</span></span><span>. For the </span><span style="-aw-sdt-tag:'c9c4390b3920abc7f774'; -aw-sdt-title:'Current_YTD_P31'"><span style="font-family: 'Times New Roman';">nine months ended September 30, 2025</span></span><span>, we incurred significantly higher sales, advertising and promotion expenses and investor outreach expenses at $</span><span style="-aw-sdt-tag:'578-005-001-b34-c703'; -aw-sdt-title:'Sales Adv Promo_CYTD'"><span style="font-family: 'Times New Roman';">1,095,102</span></span><span> and $</span><span style="-aw-sdt-tag:'41c-e36-006-fdc-cd33'; -aw-sdt-title:'Investor Outreach_CYTD'"><span style="font-family: 'Times New Roman';">992,044</span></span><span>, up from $</span><span style="-aw-sdt-tag:'a5e-fb7-f7d-639-66c3'; -aw-sdt-title:'Sales Adv Promo_PYTD'"><span style="font-family: 'Times New Roman';">226,024</span></span><span> and $</span><span style="-aw-sdt-tag:'baf-193-ad3-631-3b02'; -aw-sdt-title:'Investor Outreach_PYTD'"><span style="font-family: 'Times New Roman';">684,808</span></span><span> for the </span><span style="-aw-sdt-tag:'c83d161443c83bfd5f2e'; -aw-sdt-title:'Previous_YTD_P18'"><span style="font-family: 'Times New Roman';">nine months ended September 30, 2024</span></span><span>, respectively. Additionally, for the </span><span style="-aw-sdt-tag:'cc9cdf77e77323b24982'; -aw-sdt-title:'Current_YTD_P33'"><span style="font-family: 'Times New Roman';">nine months ended September 30, 2025</span></span><span>, we recognized $</span><span style="-aw-sdt-tag:'77f-34b-cbb-337-1648'; -aw-sdt-title:'SBC_CYTD'"><span style="font-family: 'Times New Roman';">212,030</span></span><span> in stock-based compensation expense ($</span><span style="-aw-sdt-tag:'08d-c4d-2e0-2e9-907b'; -aw-sdt-title:'SBC_PYTD'"><span style="font-family: 'Times New Roman';">15,246</span></span><span> for the </span><span style="-aw-sdt-tag:'c815531e22823dd07b5f'; -aw-sdt-title:'Previous_YTD_P19'"><span style="font-family: 'Times New Roman';">nine months ended September 30, 2024</span></span><span>). This increase was in part due to new partially vested option grants awarded to two executives in January 2025, as well as the ongoing quarterly expense recognized for additional stock options granted in the third quarter of 2024.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-import:ignore">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-weight:bold; font-style:italic">Interest and Other (Expense) Income, net</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-weight:bold; font-style:italic; -aw-import:ignore">&#160;</span></p><div style="-aw-sdt-tag:'c141614dd2d44965089e'; -aw-sdt-title:'ITEM 2, 3 and 4_T11'"><table cellspacing="0" cellpadding="0" style="width:100%; border-collapse:collapse"><tbody><tr style="height:11.5pt"><td style="width:51.92%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:0.92%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="5" style="border-bottom:1.5pt solid #000000; padding-left:10.8pt; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_8573d320bd6a47ffb12d5d16ecd65046'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">For the Nine Months Ended September 30,</span></p></div></td><td style="width:0.92%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:0.92%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:9.94%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:0.94%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10.26%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1.54%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td></tr><tr style="height:11.5pt"><td style="width:51.92%; border-bottom:1.5pt solid #000000; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_b0a48cba291945fb993172aa47ac57ae'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">Consolidated Statements of Operations Data:</span></p></div></td><td style="width:0.92%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="2" style="border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_229623be5d774437b19b0cf2e415c5fa'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">2025</span></p></div></td><td style="width:0.92%; border-top:1.5pt solid #000000; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="2" style="border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_40a99a892c51470db3b8427a0fa5ad70'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">2024</span></p></div></td><td style="width:0.92%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="2" style="border-bottom:1.5pt solid #000000; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_5ea85d46956f4dd090b6e7bafafacfcf'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">$ Change</span></p></div></td><td style="width:0.94%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10.26%; border-bottom:1.5pt solid #000000; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_4a677750ec364ffb9171f862b11d9196'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">% Change</span></p></div></td><td style="width:1.54%; padding:0.75pt; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td></tr><tr style="height:11.5pt"><td style="width:51.92%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_45e6340694294710acebb30d28864d14'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Interest Expense</span></p></div></td><td style="width:0.92%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:0.92%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_aa7a765c33214fd294a19bea011e3555'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:9.92%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_cfd7b582d7db420daecac291e6143681'; font-family: 'Times New Roman'"><span>4,719</span></span><span style="font-family: 'Times New Roman';">)</span></p></td><td style="width:0.92%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:0.92%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_c281329fac5a437da15f9266b47328a5'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:9.92%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_736d0dc78c144bb687c94ff898aa1ab9'; font-family: 'Times New Roman'"><span>6,490</span></span><span style="font-family: 'Times New Roman';">)</span></p></td><td style="width:0.92%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:0.92%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_8a44607cb2e24e458275840c02b4bfc0'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:9.94%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_3f6c4733bc9e489e961916bdebfc48e7'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">1,771</span></p></div></td><td style="width:0.94%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10.26%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_8cf9c3b5018142d6b680ff11a89bbd35'; font-family: 'Times New Roman'"><span>27.29</span></span><span style="font-family: 'Times New Roman';">)</span></p></td><td style="width:1.54%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_5909ced5f7704a5ca125c553443d363f'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">%</span></p></div></td></tr><tr style="height:11.5pt"><td style="width:51.92%; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_7340fbc184b6462a8c0e0c558020e467'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Change in Fair Value of Derivative Liabilities</span></p></div></td><td style="width:0.92%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:0.92%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:9.92%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_5993c54e3c3a4cab8683308d0037f621'; font-family: 'Times New Roman'"><span>156,445</span></span><span style="font-family: 'Times New Roman';">)</span></p></td><td style="width:0.92%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:0.92%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:9.92%; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_039b60631ce84bdba4801bac1af6b2a8'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">1,683,034</span></p></div></td><td style="width:0.92%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:0.92%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:9.94%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_1452aa7357d74a77b140dd8e890e087b'; font-family: 'Times New Roman'"><span>1,839,479</span></span><span style="font-family: 'Times New Roman';">)</span></p></td><td style="width:0.94%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10.26%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_9bda8daec5f2424ca35f095beba6e58e'; font-family: 'Times New Roman'"><span>109.30</span></span><span style="font-family: 'Times New Roman';">)</span></p></td><td style="width:1.54%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td></tr><tr style="height:11.5pt"><td style="width:51.92%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_a7bcb99114c14665857f8347c89bea31'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Other Income, net</span></p></div></td><td style="width:0.92%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:0.92%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:9.92%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_c185e6b1f2c745bfafd23ff278ff41ac'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">74,938</span></p></div></td><td style="width:0.92%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:0.92%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:9.92%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_a6259949c225417fa7805d53cf4b3415'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">67,358</span></p></div></td><td style="width:0.92%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:0.92%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:9.94%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_8b5d950746814c9396c79adf383ac27b'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">7,580</span></p></div></td><td style="width:0.94%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10.26%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_772d948d36d64215a149f1f96e4a7c6e'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">11.25</span></p></div></td><td style="width:1.54%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td></tr><tr style="height:11.5pt"><td style="width:51.92%; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_de493e1f2784490ea5f025573949aaf6'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Total Interest and Other Income (Expense), net</span></p></div></td><td style="width:0.92%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:0.92%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_90a1f32e36b1402e822b617fd3ba12a9'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:9.92%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_06076b0df611479ab387c7896882a098'; font-family: 'Times New Roman'"><span>86,226</span></span><span style="font-family: 'Times New Roman';">)</span></p></td><td style="width:0.92%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:0.92%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_6db5db8887dc4e2c9cb00e56676c8bbf'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:9.92%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_b3d510eb1e3f4fd0b1f1eaaad954f8cf'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">1,743,902</span></p></div></td><td style="width:0.92%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:0.92%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_b46962422e1847c187be0e3ff5f5fe7f'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:9.94%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_c8f49e6e37594f76b56a0364a8573806'; font-family: 'Times New Roman'"><span>1,830,128</span></span><span style="font-family: 'Times New Roman';">)</span></p></td><td style="width:0.94%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10.26%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_8f7765321fa74c05ba0e4f87574013cf'; font-family: 'Times New Roman'"><span>104.94</span></span><span style="font-family: 'Times New Roman';">)</span></p></td><td style="width:1.54%; vertical-align:bottom"><div style="-aw-sdt-tag:'C_b2f76186b7264ce3ac9bb8d97495e4ea'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">%</span></p></div></td></tr></tbody></table></div><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-import:ignore">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-style:italic">Interest Expense</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-style:italic">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>For the </span><span style="-aw-sdt-tag:'c54d60f36e6621d96c70'; -aw-sdt-title:'Current_YTD_P34'"><span style="font-family: 'Times New Roman';">nine months ended September 30, 2025</span></span><span>, we recognized $</span><span style="-aw-sdt-tag:'c554475ec7dd1526e52a'; -aw-sdt-title:'Interest expense_CYTD'"><span style="font-family: 'Times New Roman';">4,719</span></span><span> of interest expense ($</span><span style="-aw-sdt-tag:'c0074d08e4b552851aab'; -aw-sdt-title:'Interest expense_PYTD'"><span style="font-family: 'Times New Roman';">6,490</span></span><span> for the </span><span style="-aw-sdt-tag:'c50d9e4eb3ecd5715963'; -aw-sdt-title:'Previous_YTD_P20'"><span style="font-family: 'Times New Roman';">nine months ended September 30, 2024</span></span><span>). Our interest expense for the periods presented relates primarily to our single outstanding loan from the SBA. Cash paid for interest expense was $</span><span style="-aw-sdt-tag:'5eb-50d-5f2-b50-71bd'; -aw-sdt-title:'Cash Paid for SBA Int_CYTD'"><span style="font-family: 'Times New Roman';">6,579</span></span><span> and $</span><span style="-aw-sdt-tag:'679-cb3-0de-e6e-0e4c'; -aw-sdt-title:'Cash Paid for SBA Int_PYTD'"><span style="font-family: 'Times New Roman';">6,579</span></span><span> for the </span><span style="-aw-sdt-tag:'c670c25a642090c0d20f'; -aw-sdt-title:'Current_YTD_P35'"><span style="font-family: 'Times New Roman';">nine months ended September 30, 2025</span></span><span> and </span><span style="-aw-sdt-tag:'cfe4cd253259b8e9d65d'; -aw-sdt-title:'Previous_Year_P44'"><span style="font-family: 'Times New Roman';">2024</span></span><span>, respectively.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-style:italic">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-style:italic">Change in Fair Value of Derivative Liabilities</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-style:italic">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>For the </span><span style="-aw-sdt-tag:'c8a4e72defa9ac7d2485'; -aw-sdt-title:'Current_YTD_P36'"><span style="font-family: 'Times New Roman';">nine months ended September 30, 2025</span></span><span>, we recognized a loss on the change in fair value of derivative liabilities of $</span><span style="-aw-sdt-tag:'cfeeebaeb5e917cf11bf'; -aw-sdt-title:'Change in fair value of DL_CYTD'"><span style="font-family: 'Times New Roman';">156,445</span></span><span> compared to the gain of $</span><span style="-aw-sdt-tag:'ce85f611b71cc849f292'; -aw-sdt-title:'Change in fair value of DL_PYTD'"><span style="font-family: 'Times New Roman';">1,683,034</span></span><span> for the </span><span style="-aw-sdt-tag:'ca213b32fb766021c4ea'; -aw-sdt-title:'Previous_YTD_P21'"><span style="font-family: 'Times New Roman';">nine months ended September 30, 2024</span></span><span>. During the periods presented, derivative liabilities include the contingent milestone payment due to Knight upon a future sale of Arakoda or a Change of Control. We use a probability-weighted expected return method to estimate the fair value of this derivative liability.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-style:italic">Other Income, net </span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-style:italic">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>For the </span><span style="-aw-sdt-tag:'c86b682fe7c2cae73672'; -aw-sdt-title:'Current_YTD_P37'"><span style="font-family: 'Times New Roman';">nine months ended September 30, 2025</span></span><span>, we recognized $</span><span style="-aw-sdt-tag:'cb7d8d6ae00969f74ea0'; -aw-sdt-title:'Other Income_CYTD'"><span style="font-family: 'Times New Roman';">74,938</span></span><span> in other income compared to $</span><span style="-aw-sdt-tag:'cdecccd238faff643b4d'; -aw-sdt-title:'Other Income_PYTD'"><span style="font-family: 'Times New Roman';">67,358</span></span><span> for the </span><span style="-aw-sdt-tag:'c2ba1f4a3ba499e01990'; -aw-sdt-title:'Previous_YTD_P22'"><span style="font-family: 'Times New Roman';">nine months ended September 30, 2024</span></span><span>. For the </span><span style="-aw-sdt-tag:'c363289fb4f9e7c29d01'; -aw-sdt-title:'Current_YTD_P38'"><span style="font-family: 'Times New Roman';">nine months ended September 30, 2025</span></span><span>, we recognized interest income from cash invested in interest-bearing accounts and investments in certificates of deposit of $</span><span style="-aw-sdt-tag:'7a4-9ad-2e3-d65-3f61'; -aw-sdt-title:'Interest Income Investments_CYTD'"><span style="font-family: 'Times New Roman';">80,150</span></span><span> ($</span><span style="-aw-sdt-tag:'489-e15-5ec-ecc-db22'; -aw-sdt-title:'Interest Income Investments_PYTD'"><span style="font-family: 'Times New Roman';">59,192</span></span><span> for the </span><span style="-aw-sdt-tag:'cfee4cdc5f9ec03054bf'; -aw-sdt-title:'Previous_YTD_P23'"><span style="font-family: 'Times New Roman';">nine months ended September 30, 2024</span></span><span>). Other income for the </span><span style="-aw-sdt-tag:'cd1feb37e96010772be0'; -aw-sdt-title:'Previous_YTD_P24'"><span style="font-family: 'Times New Roman';">nine months ended September 30, 2024</span></span><span> also included $</span><span style="-aw-sdt-tag:'6b8-60b-7d3-fcd-657e'; -aw-sdt-title:'Other Income Storage_PYTD'"><span style="font-family: 'Times New Roman';">10,789</span></span><span> of storage revenue recognized in association with final payment under the legacy contract with the USAMMDA for storing Arakoda purchases. We did not recognize storage revenue for the nine months ended September 30, 2025.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-import:spaces">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-weight:bold">Cash Flows</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>&#160;</span></p><div style="-aw-sdt-tag:'c7ad624d452eea5704a6'; -aw-sdt-title:'ITEM 2, 3 and 4_T12'"><table cellspacing="0" cellpadding="0" style="width:100%; border-collapse:collapse"><tbody><tr style="height:13pt"><td style="width:14.98%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="5" style="border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_5bb10258dc5e4e7b8a505abb398dcedc'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">For the Nine Months Ended September 30,</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="2" style="vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td></tr><tr style="height:13pt"><td style="width:14.98%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="2" style="border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_4ea5115bc21a4ef1bd228846414669a5'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">2025</span></p></div></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="2" style="border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_fd1f0e57b4de4c3aaf3e457eafd5f282'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">2024</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="2" style="border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_08a9601f7c864f2fb1a85806f50ba761'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">$ Change</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_e24e83878aa14c3981044ba6608e5c9f'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">% Change</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td></tr><tr style="height:13pt"><td style="width:14.98%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_742e17f2fc6c49b8b510964818666386'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Net Cash (Used In) Provided By :</span></p></div></td><td style="width:1%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td></tr><tr style="height:13pt"><td style="width:51%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_f46278d7cff94776b8131e405c6cedc5'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Operating Activities</span></p></div></td><td style="width:1%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_d7c4db5e2db24ea2a3c737371ee2524e'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_83364de6c835484a8c632f83e9a72e6f'; font-family: 'Times New Roman'"><span>5,156,566</span></span><span style="font-family: 'Times New Roman';">)</span></p></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_644b4067d18b40908c3772c1e277a015'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_f0ef6c2221c14c1c9da8fddbe69afe1d'; font-family: 'Times New Roman'"><span>4,009,871</span></span><span style="font-family: 'Times New Roman';">)</span></p></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_6125a8f13b764f909b5c7509d631e226'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_f233fa741976496b81793f191e503e45'; font-family: 'Times New Roman'"><span>1,146,695</span></span><span style="font-family: 'Times New Roman';">)</span></p></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_6b3f8b6cc22842c7897edf08d0690339'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">28.60</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_3e9bac29b25d43b4a243336dd95453b2'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">%</span></p></div></td></tr><tr style="height:13pt"><td style="width:51%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_641eca7fb87447f69f6ebf1c9bac8270'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Investing Activities</span></p></div></td><td style="width:1%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_407188e3830a482a89eef4e72a6b6a62'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">1,625,347</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_0a47f744888a420a85e7e88c482bfe56'; font-family: 'Times New Roman'"><span>1,887,016</span></span><span style="font-family: 'Times New Roman';">)</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_d02da95d57fc40fea91fc240d76b3814'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">3,512,363</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_05d1e166debd46c58caa3a97b2a38860'; font-family: 'Times New Roman'"><span>186.13</span></span><span style="font-family: 'Times New Roman';">)</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td></tr><tr style="height:13pt"><td style="width:51%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_76024dd73f9549f7853809edfd6c8bd6'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Financing Activities</span></p></div></td><td style="width:1%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_5530c0f7c17a4e4ebfabe7140f08c19e'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">5,979,077</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_bd3d019039cd4f53aa082e5e28982fa5'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">7,052,598</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_489b801d32ed4a538972bb3ac911a27a'; font-family: 'Times New Roman'"><span>1,073,521</span></span><span style="font-family: 'Times New Roman';">)</span></p></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_f57154a32883405793974fcdfe6beb9e'; font-family: 'Times New Roman'"><span>15.22</span></span><span style="font-family: 'Times New Roman';">)</span></p></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td></tr><tr style="height:13pt"><td style="width:51%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_1022020d3aa34618bf08578520a2621f'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Effect of Foreign Currency Translation on Cash Flow</span></p></div></td><td style="width:1%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_ab16aafe91a64941b213ff61d7441170'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">8,568</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_4cdf6e5be85f4497823c12b93bab4e5e'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">2,492</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_3df1890393d24515b003a6ffef1fd285'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">6,076</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_467cf241afb34ee3aa83fff0b98c6d70'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">243.82</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td></tr><tr style="height:13.5pt"><td style="width:51%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_573b9dc0f4fd4c229c87aeee954e16df'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Net Increase (Decrease) in Cash and Cash Equivalents</span></p></div></td><td style="width:1%; padding-right:5.4pt; padding-left:5.4pt; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_ac976fec2d6145b1b1a34ebbf05dc3b1'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_9ba485c52f754f6e914da324d6030da4'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">2,456,426</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_f32df987defe47c6ae24311016bb5887'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_7807c90398ca46af85d9d7309449e034'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">1,158,203</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_45cb1556b0434e2cbd1371d30d1e48b9'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_f4c58e59ac894b059e433f5c661f98d7'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">1,298,223</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_7e8d1ac6bf004b1f9baaf066ec66cf2a'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">112.09</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-tag:'C_c8b32e282eb24ea1bfed165668d6ba58'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">%</span></p></div></td></tr></tbody></table></div><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore">&#160;</span></p><div style="-aw-sdt-tag:'PG_c17c66e28bf3e5e34d34'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-family: 'Times New Roman';">34</span></p><div><hr style="width: 100%; color: #000000; background-color: #000000; margin: 1rem 0;"/></div></div></div><div class="Section_38"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-style:italic">Cash Used in Operating Activities</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-style:italic">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>Net cash used in operating activities was $</span><span style="-aw-sdt-tag:'c93fb89ecfd931519985'; -aw-sdt-title:'Net cash used in operating activities_CYTD 2'"><span style="font-family: 'Times New Roman';">5,156,566</span></span><span> for the </span><span style="-aw-sdt-tag:'c7353d25782663ff5eb2'; -aw-sdt-title:'Current_YTD_P40'"><span style="font-family: 'Times New Roman';">nine months ended September 30, 2025</span></span><span>, as compared to $</span><span style="-aw-sdt-tag:'c8c04a21ca2068daba02'; -aw-sdt-title:'Net cash used in operating activities_PYTD 2'"><span style="font-family: 'Times New Roman';">4,009,871</span></span><span> for the </span><span style="-aw-sdt-tag:'ca53ca8215b6d1bebd65'; -aw-sdt-title:'Previous_YTD_P26'"><span style="font-family: 'Times New Roman';">nine months ended September 30, 2024</span></span><span>. Our net cash used in operating activities increased primarily due to </span><span style="-aw-sdt-tag:'b8e-01e-7b1-6f9-6ded'; -aw-sdt-title:'GandA Expense_Trend'"><span style="font-family: 'Times New Roman';">higher</span></span><span> general and administrative expenses at $</span><span style="-aw-sdt-tag:'4fb-3c3-815-540-a3bc'; -aw-sdt-title:'GandA Expense_CYTD'"><span style="font-family: 'Times New Roman';">4,805,648</span></span><span> for the </span><span style="-aw-sdt-tag:'cd4a4a7e55ab370d4c9f'; -aw-sdt-title:'Current_YTD_P41'"><span style="font-family: 'Times New Roman';">nine months ended September 30, 2025</span></span><span> ($</span><span style="-aw-sdt-tag:'074-0be-5f5-f27-6012'; -aw-sdt-title:'GandA Expense_PYTD'"><span style="font-family: 'Times New Roman';">3,419,747</span></span><span> for the </span><span style="-aw-sdt-tag:'c05953fc24aa24a75ddc'; -aw-sdt-title:'Previous_YTD_P27'"><span style="font-family: 'Times New Roman';">nine months ended September 30, 2024</span></span><span>), as a result of higher sales, advertising and promotion costs and investor outreach expenses, as discussed above, and higher research and development costs for our babesiosis trial at $</span><span style="-aw-sdt-tag:'017-b06-a90-015-bd44'; -aw-sdt-title:'Babesiosis trial costs_CYTD'"><span style="font-family: 'Times New Roman';">1,109,279</span></span><span> for the </span><span style="-aw-sdt-tag:'c82938d5faf6a82e3de4'; -aw-sdt-title:'Current_YTD_P42'"><span style="font-family: 'Times New Roman';">nine months ended September 30, 2025</span></span><span> ($</span><span style="-aw-sdt-tag:'a2f-035-46e-b4b-07bc'; -aw-sdt-title:'Babesiosis trial costs_PYTD'"><span style="font-family: 'Times New Roman';">846,323</span></span><span> for the </span><span style="-aw-sdt-tag:'ce08a19d58bd201cfe20'; -aw-sdt-title:'Previous_YTD_P28'"><span style="font-family: 'Times New Roman';">nine months ended September 30, 2024</span></span><span>).</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-style:italic">Cash Provided by (Used in) Investing Activities</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-style:italic">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>Net cash provided by investing activities was $</span><span style="-aw-sdt-tag:'c60ccaed7b21bc4ef624'; -aw-sdt-title:'Net cash provided by investing activities_CYTD'"><span style="font-family: 'Times New Roman';">1,625,347</span></span><span> for the </span><span style="-aw-sdt-tag:'c30fadbead918c9d3806'; -aw-sdt-title:'Current_YTD_P43'"><span style="font-family: 'Times New Roman';">nine months ended September 30, 2025</span></span><span>, as compared to net cash used in investing activities of $</span><span style="-aw-sdt-tag:'ce206dfc1d02aa0b4734'; -aw-sdt-title:'Net cash provided by investing activities_PYTD'"><span style="font-family: 'Times New Roman';">1,887,016</span></span><span> for the </span><span style="-aw-sdt-tag:'cdb69a0b4d714c7a6a43'; -aw-sdt-title:'Previous_YTD_P29'"><span style="font-family: 'Times New Roman';">nine months ended September 30, 2024</span></span><span>. For the </span><span style="-aw-sdt-tag:'ce7a95917f80aa8f0181'; -aw-sdt-title:'Current_YTD_P44'"><span style="font-family: 'Times New Roman';">nine months ended September 30, 2025</span></span><span>, we received proceeds of $</span><span style="-aw-sdt-tag:'167-705-ec9-46f-d016'; -aw-sdt-title:'Proceeds from Inv Mat_CYTD'"><span style="font-family: 'Times New Roman';">1,708,000</span></span><span> from maturities of certain short-term investments in certificates of deposit ($</span><span style="-aw-sdt-tag:'74a-55d-f97-fd2-a580'; -aw-sdt-title:'Proceeds from Inv Mat_PYTD'"><span style="font-family: 'Times New Roman';">0</span></span><span> for the </span><span style="-aw-sdt-tag:'c7259ad4cb6c027bf48a'; -aw-sdt-title:'Previous_YTD_P30'"><span style="font-family: 'Times New Roman';">nine months ended September 30, 2024</span></span><span>). The cash proceeds are partially offset by capitalized patent costs of $</span><span style="-aw-sdt-tag:'144-2de-36d-98e-c5e9'; -aw-sdt-title:'Patent Costs_CYTD'"><span style="font-family: 'Times New Roman';">20,868</span></span><span> and fixed asset purchases of $</span><span style="-aw-sdt-tag:'c24-ad7-2ff-86f-1153'; -aw-sdt-title:'PPE Purchases_CYTD'"><span style="font-family: 'Times New Roman';">60,000</span></span><span> for the </span><span style="-aw-sdt-tag:'cf6ba6a2635fa640f843'; -aw-sdt-title:'Current_YTD_P45'"><span style="font-family: 'Times New Roman';">nine months ended September 30, 2025</span></span><span> ($</span><span style="-aw-sdt-tag:'478-d3d-c2d-94b-dfac'; -aw-sdt-title:'Patent Costs_PYTD'"><span style="font-family: 'Times New Roman';">49,869</span></span><span> and $</span><span style="-aw-sdt-tag:'75f-0b7-44a-2c3-123b'; -aw-sdt-title:'PPE Purchases_PYTD'"><span style="font-family: 'Times New Roman';">103,773</span></span><span> for the </span><span style="-aw-sdt-tag:'ce2641778b048af2c12c'; -aw-sdt-title:'Previous_YTD_P31'"><span style="font-family: 'Times New Roman';">nine months ended September 30, 2024</span></span><span>, respectively). Additionally, we capitalized less website development costs for the </span><span style="-aw-sdt-tag:'c06d2e8bcfcad651f390'; -aw-sdt-title:'Current_YTD_P46'"><span style="font-family: 'Times New Roman';">nine months ended September 30, 2025</span></span><span> at $</span><span style="-aw-sdt-tag:'1bc-c13-a4d-159-5c48'; -aw-sdt-title:'Cap WebDev Costs_CYTD'"><span style="font-family: 'Times New Roman';">1,785</span></span><span> ($</span><span style="-aw-sdt-tag:'4ce-8f4-12b-8a6-8996'; -aw-sdt-title:'Capitalized Web Costs_PYTD'"><span style="font-family: 'Times New Roman';">25,374</span></span><span> capitalized for the </span><span style="-aw-sdt-tag:'ccfaac8350b5a0dac74b'; -aw-sdt-title:'Previous_YTD_P32'"><span style="font-family: 'Times New Roman';">nine months ended September 30, 2024</span></span><span>) associated with enhancements to the functionality of our corporate website.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-style:italic">Cash Provided by Financing Activities</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>Net cash provided by financing activities was $</span><span style="-aw-sdt-tag:'c37c2db1ad85495e96db'; -aw-sdt-title:'Net cash provided by financing activities_CYTD'"><span style="font-family: 'Times New Roman';">5,979,077</span></span><span> for the </span><span style="-aw-sdt-tag:'cc59bd92f966afef67ff'; -aw-sdt-title:'Current_YTD_P47'"><span style="font-family: 'Times New Roman';">nine months ended September 30, 2025</span></span><span>, as compared to $</span><span style="-aw-sdt-tag:'c9c727fff88fe94dedb6'; -aw-sdt-title:'Net cash provided by financing activities_PYTD'"><span style="font-family: 'Times New Roman';">7,052,598</span></span><span> for the </span><span style="-aw-sdt-tag:'c883c1e203460ab32509'; -aw-sdt-title:'Previous_YTD_P33'"><span style="font-family: 'Times New Roman';">nine months ended September 30, 2024</span></span><span>. The </span><span style="-aw-sdt-tag:'c59b7037d2c60fddf9b9'; -aw-sdt-title:'financing activities Direction'"><span style="font-family: 'Times New Roman';">decrease</span></span><span> in net cash provided by financing activities is mainly attributable to net proceeds aggregating to $</span><span style="-aw-sdt-tag:'66c-7c3-550-258-99e6'; -aw-sdt-title:'MDA_2024 Offering Proceeds_Aggregate'"><span style="font-family: 'Times New Roman';">7,042,608</span></span><span> received in connection with (i) our common stock and warrant offering in January 2024, (ii) the sale of common stock pursuant to the At-the-Market Sales Agreement in July and August 2024, and (iii) the sale of warrants in our Private Placement offering that closed in September 2024, which exceeded the aggregate net proceeds of $</span><span style="-aw-sdt-tag:'0a1-798-b16-25d-52f8'; -aw-sdt-title:'YTD 2025 Offering Proceeds SCF'"><span style="font-family: 'Times New Roman';">5,994,273</span></span><span> received in connection with our common stock and warrant offerings completed in January, February, and July 2025. </span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-import:ignore">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>We also received lower proceeds from the exercise of warrants at $</span><span style="-aw-sdt-tag:'ae6-101-a5d-1d6-cfb3'; -aw-sdt-title:'2025 Warrant Proceeds_SCF'"><span style="font-family: 'Times New Roman';">2,804</span></span><span> for the </span><span style="-aw-sdt-tag:'cb7bee36903057f67fc2'; -aw-sdt-title:'Current_YTD_P48'"><span style="font-family: 'Times New Roman';">nine months ended September 30, 2025</span></span><span>, compared to $</span><span style="-aw-sdt-tag:'678-582-a50-438-4213'; -aw-sdt-title:'2024 Warrant Proceeds_SCF'"><span style="font-family: 'Times New Roman';">9,990</span></span><span> for the </span><span style="-aw-sdt-tag:'c5be0befd84cfd940279'; -aw-sdt-title:'Previous_YTD_P34'"><span style="font-family: 'Times New Roman';">nine months ended September 30, 2024</span></span><span>. Additionally, for the </span><span style="-aw-sdt-tag:'c1baa1e646b390cc3645'; -aw-sdt-title:'Current_YTD_P49'"><span style="font-family: 'Times New Roman';">nine months ended September 30, 2025</span></span><span>, we withheld shares valued at $</span><span style="-aw-sdt-tag:'a24-3f9-085-3b2-5616'; -aw-sdt-title:'Share Settled Bonus CYTD_SCF'"><span style="font-family: 'Times New Roman';">18,000</span></span><span> to cover tax withholdings for net share settlement of certain 2024 performance bonuses awarded to our executives ($0 for the </span><span style="-aw-sdt-tag:'c5dd2b4338a0af5c7aba'; -aw-sdt-title:'Previous_YTD_P35'"><span style="font-family: 'Times New Roman';">nine months ended September 30, 2024</span></span><span>).</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-style:italic">Effect of Foreign Currency Translation on Cash </span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-style:italic">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>Our foreign operations were small relative to U.S. operations for the </span><span style="-aw-sdt-tag:'c9e1684ce3fbb1eb992a'; -aw-sdt-title:'Current_YTD_P50'"><span style="font-family: 'Times New Roman';">nine months ended September 30, 2025</span></span><span> and </span><span style="-aw-sdt-tag:'c4eee3a6d3a250762eb0'; -aw-sdt-title:'Previous_Period_P4'"><span style="font-family: 'Times New Roman';">September 30, 2024</span></span><span>, thus effects of foreign currency translation have been minor.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-weight:bold">Critical Accounting Policies, Significant Judgments, and Use of Estimates</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-import:spaces">&#160;</span><span>&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-weight:bold; font-style:italic">Revenue Recognition </span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-weight:bold; font-style:italic">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>We recognize revenue in accordance with FASB ASC Topic No. 606, </span><span style="font-style:italic">Revenue from Contracts with Customers</span><span> (&#8220;ASC 606&#8221;). Revenues are recognized when control is transferred to customers in amounts that reflect the consideration we expect to be entitled to receive in exchange for those goods. Revenue recognition is evaluated through the following five steps: (i) identification of the contract, or contracts, with a customer; (ii) identification of the performance obligations in the contract; (iii) determination of the transaction price; (iv) allocation of the transaction price to the performance obligations in the contract; and (v) recognition of revenue when or as a performance obligation is satisfied. As part of the accounting for these arrangements, we may be required to make significant judgments, including identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each performance obligation.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-import:ignore">&#160;</span></p><div style="-aw-sdt-tag:'PG_c201c8d26e01a0f0276b'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-family: 'Times New Roman';">35</span></p><div><hr style="width: 100%; color: #000000; background-color: #000000; margin: 1rem 0;"/></div></div></div><div class="Section_39"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>Revenues from product sales are recorded at the net sales price, or &#8220;transaction price,&#8221; which may include estimates of variable consideration that result from product returns. We determine the amount of variable consideration by using either the expected value method or the most-likely-amount method. We include the unconstrained amount of estimated variable consideration in the transaction price, which reflects the amount for which it is probable that a significant reversal of cumulative revenue recognized will not occur. At the end of each subsequent reporting period, we re-evaluate the estimated variable consideration included in the transaction price and any related constraint, and if necessary, adjust our estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis in the period of adjustment. Reserves are established for the estimates of variable consideration based on the amounts we expect to be earned or to be claimed on the related sales.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>We record U.S. commercial revenues as a receivable when our American distributor transfers shipped product to their title model for 60P. Foreign sales to both Australia and Europe are recognized as a receivable at the point product is shipped to distributor. The shipments to Australia and Europe are further subject to profit sharing agreements for boxes sold to customers.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-weight:bold; font-style:italic">Share-Based Payments</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>We account for share-based payments in accordance with ASC Subtopic 718, </span><span style="font-style:italic">Compensation - Stock Compensation</span><span> (&#8220;ASC 718&#8221;). We measure compensation for all share-based payment awards granted to employees, directors, and nonemployees, based on the estimated fair value of the awards on the date of grant. For awards that vest based on continued service, the service-based compensation cost is recognized on a straight-line basis over the requisite service period, which is generally the vesting period of the awards. For service vesting awards with compensation expense recognized on a straight-line basis, at no point in time does the cumulative grant date value of vested awards exceed the cumulative amount of compensation expense recognized. The grant date is determined based on the date when a mutual understanding of the key terms of the share-based awards is established. We account for forfeitures as they occur.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>We estimate the fair value of all stock option awards as of the grant date by applying the Black-Scholes option pricing model. The application of this valuation model involves assumptions, including the fair value of the common stock, expected volatility, risk-free interest rate, expected dividends and the expected term of the option. Due to the lack of a public market for our common stock prior to the IPO and lack of company-specific historical implied volatility data, we base our computations of expected volatility on the historical volatility of a representative group of public companies with similar characteristics of the Company, including stage of development and industry focus. The historical volatility is calculated based on a period of time commensurate with the expected term assumption. We generally use the simplified method as prescribed by the SEC Staff Accounting Bulletin Topic 14, </span><span style="font-style:italic">Share-Based Payment</span><span>, to estimate the expected term for stock options, whereby, the expected term equals the midpoint of the weighted average remaining time to vest, vesting period and the contractual term of the options due to our lack of historical exercise data. For certain options granted out-of-the-money, our best estimate of the expected term is the contractual term of the award. The risk-free interest rate is based on U.S. Treasury securities with a maturity date commensurate with the expected term of the associated award. The expected dividend yield is assumed to be zero as we have never paid dividends and have no current plans to pay any dividends on our common stock. The assumptions used in calculating the fair value of share-based awards represent our best estimates and involve inherent uncertainties and the application of significant judgment.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>We recognize compensation expense for restricted stock units (&#8220;RSUs&#8221;) with only service-based vesting conditions on a straight-line basis over the vesting period. Compensation cost for service-based RSUs is based on the grant date fair value of the award, which is the closing market price of our common stock on the grant date multiplied by the number of shares awarded.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>For awards that vest upon a liquidity event or a change in control, the performance condition is not probable of being achieved until the event occurs. As a result, no compensation expense is recognized until the performance-based vesting condition is achieved, at which time the cumulative compensation expense is recognized. Compensation cost related to any remaining time-based service for share-based awards after the liquidity-based event is recognized on a straight-line basis over the remaining service period.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>&#160;</span></p><div style="-aw-sdt-tag:'PG_cf64678e6607e55488a8'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-family: 'Times New Roman';">36</span></p><div><hr style="width: 100%; color: #000000; background-color: #000000; margin: 1rem 0;"/></div></div></div><div class="Section_40"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>For fully vested, nonforfeitable equity instruments that are granted at the date we enter into an agreement for goods or services with a nonemployee, we recognize the fair value of the equity instruments on the grant date. The corresponding cost is recognized as an immediate expense or a prepaid asset and expensed over the service period depending on the specific facts and circumstances of the agreement with the nonemployee.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-weight:bold; font-style:italic">Derivative Liabilities</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>We analyze all financial instruments with features of both liabilities and equity under ASC Topic 480, </span><span style="font-style:italic">Distinguishing Liabilities from Equity</span><span> (&#8220;ASC 480&#8221;) and ASC Topic 815, </span><span style="font-style:italic">Derivatives and Hedging</span><span> (&#8220;ASC 815&#8221;). The classification of derivative financial instruments is reassessed each reporting period. Derivative liabilities are adjusted to reflect fair value at each reporting period, with any increase or decrease in the fair value recorded in the results of operations (other income/expense) as change in fair value of derivative liabilities. As of </span><span style="-aw-sdt-tag:'c47da0b90c9365950a78'; -aw-sdt-title:'Current_Period_P36'"><span style="font-family: 'Times New Roman';">September 30, 2025</span></span><span>, derivative liabilities consist of contingent payment arrangements. We use a probability-weighted expected return method to determine the fair value of these instruments.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>Upon conversion or repayment of a debt or equity instrument in exchange for equity shares, where the embedded conversion option has been bifurcated and accounted for as a derivative liability (generally convertible debt and warrants), we record the equity shares at fair value on the date of conversion, relieve all related debt, derivative liabilities, and unamortized debt discounts, and recognize a net gain or loss on debt extinguishment, if any.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>Equity or liability instruments that become subject to reclassification under ASC Topic 815 are reclassified at the fair value of the instrument on the reclassification date.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-weight:bold; font-style:italic">Off-Balance Sheet Arrangements</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>During 2025 and 2024, we did not have any relationships with unconsolidated organizations or financial partnerships, such as structured finance or special purpose entities that would have been established for the purpose of facilitating off-balance sheet arrangements or other contractually narrow or limited purposes.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-weight:bold; font-style:italic">JOBS Act Accounting Election</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>In April 2012, the JOBS Act was enacted. Section 107(b) of the JOBS Act provides that an &#8220;emerging growth company&#8221; can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act for complying with new or revised accounting standards. Thus, an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have elected to avail ourselves of this exemption and, therefore, we will not be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-weight:bold; font-style:italic">Recent Accounting Pronouncements</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>From time to time, the FASB issues Accounting Standards Updates (&#8220;ASU&#8221;) to amend the authoritative literature in the ASC. The Company regularly evaluates new ASUs to determine the impact that these pronouncements may have on the consolidated condensed financial statements. Other than the pronouncements listed below, management believes that those issued to date either (i) provide supplemental guidance, (ii) are technical corrections, or (iii) are not applicable to the Company&#8217;s consolidated condensed financial statements or related disclosures.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>In November 2023, the FASB issued ASU 2023-07, </span><span style="font-style:italic">Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures</span><span> (&#8220;ASU 2023-07&#8221;) which expands annual and interim disclosure requirements for reportable segments, primarily through enhanced disclosures about significant segment expenses and segment profit or loss. ASU 2023-07 also requires entities with a single reportable segment to provide all segment disclosures under ASC 280, including the new required disclosures under the ASU. We adopted ASU 2023-07 on a retrospective basis for the 2024 annual period, and for interim periods beginning in 2025. The impact is limited to our financial statement disclosures, which are presented in Note 2 to the accompanying consolidated condensed financial statements.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>&#160;</span></p><div style="-aw-sdt-tag:'PG_cdb14d6e35d84660165b'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-family: 'Times New Roman';">37</span></p><div><hr style="width: 100%; color: #000000; background-color: #000000; margin: 1rem 0;"/></div></div></div><div class="Section_41"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>In December 2023, the FASB issued ASU 2023-09, Income Taxes (ASC 740): </span><span style="font-style:italic">Improvements to Income Tax Disclosures</span><span> (&#8220;ASU 2023-09&#8221;) which requires disaggregated information about a reporting entity&#8217;s effective tax rate reconciliation as well as information on income taxes paid. ASU 2023-09 is effective for annual periods beginning after December 15, 2024. We will adopt this standard for the annual period ending December 31, 2025. The impact of ASU 2023-09 will be limited to our financial statement disclosures.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>In November 2024, the FASB issued ASU 2024-03, </span><span style="font-style:italic">Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses</span><span> (&#8220;ASU 2024-03&#8221;), which applies to all public business entities that file financial statements with the SEC. The amendments in this ASU require public business entities to disclose on an annual and interim basis, disaggregated information about certain income statement expense line items. The new standard is effective for fiscal years beginning after December 15, 2026, with early adoption permitted. We are currently evaluating the impact that ASU 2024-03 will have on our financial statement disclosures.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-weight:bold">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span id="TOC_c048e7bcdce9d8c360e2"><span style="font-weight:bold">ITEM 3. Quantitative and Qualitative Disclosures about Market Risk</span></span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-bookmark-end:TOC_c048e7bcdce9d8c360e2"></span><span>&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>As a smaller reporting company as defined by Rule 12b-2 of the Exchange Act of 1934, as amended and in Item 10(f)(1) of Regulation S-K, we are electing scaled disclosure reporting obligations and therefore are not required to provide the information requested by this item.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span id="TOC_c44a338213ccfed10dc0"><span style="font-weight:bold">ITEM 4. Controls and Procedures. Disclosure Controls and Procedures </span></span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-bookmark-end:TOC_c44a338213ccfed10dc0"></span><span style="font-weight:bold">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-style:italic">Evaluation of Disclosure Controls and Procedures </span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>The Company&#8217;s management, with the participation of the Company&#8217;s Chief Executive Officer and Chief Financial Officer, have evaluated the effectiveness of the Company&#8217;s disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of </span><span style="-aw-sdt-tag:'cd1dab4fa21277f32620'; -aw-sdt-title:'Current_Period_P34'"><span style="font-family: 'Times New Roman';">September 30, 2025</span></span><span>. Based on that evaluation, the Company&#8217;s Chief Executive Officer and the Company&#8217;s Chief Financial Officer have concluded that as of </span><span style="-aw-sdt-tag:'c8278e2de05d7e0fa07a'; -aw-sdt-title:'Current_Period_P35'"><span style="font-family: 'Times New Roman';">September 30, 2025</span></span><span>, due to the existence of the material weakness in the Company&#8217;s internal control over financial reporting described below, the Company&#8217;s disclosure controls and procedures were not effective.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>Management is responsible for establishing and maintaining adequate internal control over our financial reporting, as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act. Under the supervision and with the participation of our management, including our Chief Executive Officer and our Chief Financial Officer, we conducted an evaluation of the effectiveness of our internal control over financial reporting. Management has used the framework set forth in the report entitled &#8220;Internal Control-Integrated Framework (2013)&#8221; published by the Committee of Sponsoring Organizations of the Treadway Commission to evaluate the effectiveness of our internal control over financial reporting. Based on that assessment, our management has identified certain material weaknesses in our internal control over financial reporting.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>Our management concluded that as of </span><span style="-aw-sdt-tag:'c52cb02cdd6098cc3f36'; -aw-sdt-title:'Current_Period_P33'"><span style="font-family: 'Times New Roman';">September 30, 2025</span></span><span>, our internal control over financial reporting was not effective, and that material weaknesses existed in the following areas:</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>&#160;</span></p><table cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="width:18pt; vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-import:ignore">&#160;</span></p></td><td style="width:18pt; vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span>(1)</span></p></td><td style="vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>we do not employ full time in-house personnel with the technical knowledge to identify and address some of the reporting issues surrounding certain complex or non-routine transactions. With respect to material, complex and non-routine transactions, management has and will continue to seek guidance from third-party experts and/or consultants to gain a thorough understanding of these transactions&#894;</span></p></td></tr></tbody></table><p style="margin-top:0pt; margin-left:36pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>&#160;</span></p><table cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="width:18pt; vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-import:ignore">&#160;</span></p></td><td style="width:18pt; vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span>(2)</span></p></td><td style="vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>we have inadequate segregation of duties consistent with the control objectives including but not limited to the disbursement process, transaction or account changes, and the performance of account reconciliations and approval&#894; and</span></p></td></tr></tbody></table><p style="margin-top:0pt; margin-left:36pt; margin-bottom:0pt; font-size:10pt"><span>&#160;</span></p><table cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="width:18pt; vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-import:ignore">&#160;</span></p></td><td style="width:18pt; vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span>(3)</span></p></td><td style="vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>we have ineffective controls over the period end financial disclosure and reporting process caused by insufficient accounting staff.</span></p></td></tr></tbody></table><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-style:italic">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-style:italic">Limitations on Effectiveness of Controls and Procedures</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-style:italic">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>In designing and evaluating the disclosure controls and procedures and internal control over financial reporting, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures and internal control over financial reporting must reflect the fact that there are resource constraints and that management is required to apply judgment in evaluating the benefits of possible controls and procedures relative to their costs.</span><span>&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-style:italic">Changes in Internal Control over Financial Reporting</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>There were no changes in our internal control over financial reporting that occurred during our most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</span></p><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span>&#160;</span></p><div style="-aw-sdt-tag:'PG_cd714c397cae9a21d2b8'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-family: 'Times New Roman';">38</span></p><div><hr style="width: 100%; color: #000000; background-color: #000000; margin: 1rem 0;"/></div></div></div><div class="Section_42"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span id="TOC_c3d00586ee10cdb846f0"><span style="font-weight:bold">PART II. OTHER INFORMATION</span></span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span id="TOC_ccead316ceadde1ebbd5"><span style="font-weight:bold">ITEM 1. LEGAL PROCEDINGS</span></span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-bookmark-end:TOC_ccead316ceadde1ebbd5"></span><span>&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>From time to time, claims are made against us in the ordinary course of business, which could result in litigation. Claims and associated litigation are subject to inherent uncertainties and unfavorable outcomes could occur, such as monetary damages, fines, penalties or injunctions prohibiting us from selling one or more products or engaging in other activities. There were no reportable litigation events during the quarter ended </span><span style="-aw-sdt-tag:'c32e3e444820965d147f'; -aw-sdt-title:'Current_Period_P37'"><span style="font-family: 'Times New Roman';">September 30, 2025</span></span><span>.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span id="TOC_c340f91f4051b8348248"><span style="font-weight:bold">ITEM 1A. RISK FACTORS</span></span></p><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-bookmark-end:TOC_c340f91f4051b8348248"></span><span style="font-weight:bold">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>As a smaller reporting company as defined by Rule 12b-2 of the Securities Exchange Act of 1934, as amended, and in item 10(f)(1) of Regulation S-K, we are electing scaled disclosure reporting obligations and therefore are not required to provide the information requested by this item. In any event, there have been no material changes in our risk factors as previously disclosed in our Registration Statement.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-import:ignore">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-weight:bold; font-style:italic">We may issue a substantial number of shares of common stock upon exercise of the warrants issued in our July 2025 Offering, which would cause dilution to our stockholders and may affect the market price of our common stock. </span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-import:ignore">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>In connection with our July 2025 Offering, we issued (i) </span><span style="-aw-sdt-tag:'5ed-214-d76-f27-0989'; -aw-sdt-title:'July Offering PFW'"><span style="font-family: 'Times New Roman';">878,264</span></span><span> pre-funded warrants, (ii) Series A-1 warrants to purchase up to </span><span style="-aw-sdt-tag:'c14-a93-a08-d41-49cc'; -aw-sdt-title:'July Offering A-1 Warrants'"><span style="font-family: 'Times New Roman';">2,631,578</span></span><span> shares of common stock, and (iii) Series A-2 warrants to purchase up to </span><span style="-aw-sdt-tag:'d9f-595-7e9-597-e33e'; -aw-sdt-title:'July Offering A-2 Warrants'"><span style="font-family: 'Times New Roman';">2,631,578</span></span><span> shares of common stock. We also issued placement agent warrants to purchase up to </span><span style="-aw-sdt-tag:'2eb-218-16c-241-239a'; -aw-sdt-title:'July Offering Agent Warrants'"><span style="font-family: 'Times New Roman';">197,368</span></span><span> shares of common stock. The exercise of these warrants will results in the issuance of a substantial number of additional shares of common stock, which will dilute the ownership interests of existing stockholders. The sale of such shares, or the perception that such sales could occur, could also cause the market price of our common stock to decline.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-import:ignore">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-weight:bold; font-style:italic">If we fail to maintain compliance with Nasdaq&#8217;s continued listing requirements, including the minimum bid price rule, our common stock could be delisted, which would adversely affect the liquidity and market price of our shares.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-import:ignore">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>In February 2025, we effected a 1-for-5 reverse stock split in order to regain compliance with Nasdaq&#8217;s $1.00 minimum bid price requirement. There can be no assurance that we will be able to maintain compliance with Nasdaq&#8217;s continued listing standards in the future. A Delisting of our common stock from The Nasdaq Capital Market would likely result in decreased liquidity for our stockholders. Could make it more difficult for us to raise additional capital, and might adversely affect the market price of our common stock. </span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-import:ignore">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span id="TOC_c97dbd053b8428a29933"><span style="font-weight:bold">ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</span></span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-bookmark-end:TOC_c97dbd053b8428a29933"></span><span style="font-weight:bold">&#160;</span></p><table cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="width:18pt; vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore">&#160;</span></p></td><td style="width:18pt; vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-style:italic">(A)</span></p></td><td style="vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-style:italic">Unregistered Sales of Equity Securities</span></p></td></tr></tbody></table><p style="margin-top:0pt; margin-left:36pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-style:italic">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-weight:bold; font-style:italic">January 2025 Securities Purchase Agreement</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>On January 28, 2025, the Company entered into a securities purchase agreement (the &#8220;January 2025 Securities Purchase Agreement&#8221;) with certain institutional investors (the &#8220;January 2025 Purchasers&#8221;) pursuant to which the Company sold an aggregate of 204,312 shares of common stock at a purchase price of $5.105 per share in a registered direct offering priced at-the-market under the rules of The Nasdaq Stock Market LLC.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>The shares were offered pursuant to a &#8220;shelf&#8221; registration statement on Form S-3 (Registration No. 333-280796), which was declared effective by SEC on July 18, 2024 as supplemented by a prospectus supplement dated January 28, 2025, filed with the SEC on January 30, 2025, and accompanying base prospectus, pursuant to Rule 424(b)(5) promulgated under the Securities Act.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>In a concurrent private placement, the Company also issued to the January 2025 Purchasers unregistered warrants (the &#8220;January 2025 Warrants&#8221;) to purchase up to an aggregate of 408,621 shares of common stock at an exercise price of $3.855 per share. The January 2025 Warrants are exercisable upon issuance and expire twenty-four months from the date of issuance.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>Any holder will not have the right to exercise any portion of the January 2025 Warrants if the holder (together with its affiliates) would beneficially own more than 4.99% (or, upon the election of the holder, 9.99%) of the number of shares of the common stock outstanding immediately after giving effect to the exercise, as such percentage ownership is determined in accordance with the terms of the warrants. However, any holder may increase or decrease such percentage, provided that any increase will not be effective until the 61st day after such election.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>The exercise price of the January 2025 Warrants is subject to customary adjustment in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events affecting the common stock and also upon any distributions of assets, including cash, stock or other property to the stockholders of the Company.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>The issuance of the January 2025 Warrants pursuant to the January 2025 Securities Purchase Agreement and issuance of the January 2025 Placement Agent Warrants, as defined below, and the shares of common stock issuable thereunder were made pursuant to the exemption from the registration requirements under the Securities Act, available to the Company under Section 4(a)(2) promulgated thereunder and Rule 506 of Regulation D promulgated under the Securities Act due to the fact that the offering of the January 2025 Warrants and the January 2025 Placement Agent Warrants thereunder did not involve a public offering of securities.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>The January 2025 Securities Purchase Agreement contained customary representations and warranties. The offering closed on January 30, 2025.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>Pursuant to an engagement letter agreement between the Company and the Placement Agent dated August 30, 2024, as amended on September 3, 2024 and January 24, 2025 (the &#8220;Engagement Agreement&#8221;), the Placement Agent acted as the Company&#8217;s exclusive placement agent in connection with the offering.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-import:ignore">&#160;</span></p><div style="-aw-sdt-tag:'PG_c2113f0aa564460fe422'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-family: 'Times New Roman';">39</span></p><div><hr style="width: 100%; color: #000000; background-color: #000000; margin: 1rem 0;"/></div></div></div><div class="Section_43"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>Pursuant to the terms of the Engagement Agreement, the Company paid the Placement Agent a cash transaction fee equal to 7.5% of the aggregate gross cash proceeds in the offering and a management fee equal to 1.0% of the aggregate gross cash proceeds in the offering. In addition, the Company paid for certain non-accountable expenses in the amount of $15,000 and a clearing fee in the amount of $10,000. The Company also issued to the Placement Agent (or its designees) warrants (the &#8220;January 2025 Placement Agent Warrants&#8221;) to purchase up to 15,325 shares of common stock. The January 2025 Placement Agent Warrants have an exercise price equal to $6.382 per share and are exercisable upon issuance and expire twenty-four months from the date of issuance.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>The Company received net proceeds of approximately $804,346 from the offering, after deducting estimated offering expenses paid by the Company, including the Placement Agent fees. The Company intends to use the net proceeds from the offering for general corporate purposes, including working capital.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-weight:bold; font-style:italic">February 2025 Securities Purchase Agreement</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-weight:bold; font-style:italic">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>On February 5, 2025, the Company entered into a securities purchase agreement (the &#8220;February 2025 Securities Purchase Agreement&#8221;) with certain institutional investors (the &#8220;February 2025 Purchasers&#8221;) pursuant to which the Company sold an aggregate of 300,700 shares of common stock at a purchase price of $3.575 per share in a registered direct offering priced at-the-market under the rules of The Nasdaq Stock Market LLC.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>The shares were offered pursuant to a &#8220;shelf&#8221; registration statement on Form S-3 (Registration No. 333-280796), which was declared effective by the Securities and Exchange Commission (the &#8220;SEC&#8221;) on July 18, 2024 as supplemented by a prospectus supplement dated February 5, 2025, filed with the SEC on February 6, 2025, and accompanying base prospectus, pursuant to Rule 424(b)(5) promulgated under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;).</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>In a concurrent private placement, the Company also issued to the February 2025 Purchasers unregistered warrants (the &#8220;February 2025 Warrants&#8221;) to purchase up to an aggregate of 300,700 shares of common stock at an exercise price of $2.95 per share. The February 2025 Warrants are exercisable upon issuance and expire twenty-four months from the date of issuance.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>Any holder will not have the right to exercise any portion of the February 2025 Warrants if the holder (together with its affiliates) would beneficially own more than 4.99% (or, upon the election of the holder, 9.99%) of the number of shares of the common stock outstanding immediately after giving effect to the exercise, as such percentage ownership is determined in accordance with the terms of the warrants. However, any holder may increase or decrease such percentage, provided that any increase will not be effective until the 61st day after such election.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>The exercise price of the February 2025 Warrants is subject to customary adjustment in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events affecting the Common Stock and also upon any distributions of assets, including cash, stock or other property to the stockholders of the Company.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>The issuance of the February 2025 Warrants pursuant to the February 2025 Securities Purchase Agreement and the issuance of the February 2025 Placement Agent Warrants, as defined below, and the shares of common stock issuable thereunder, were made pursuant to the exemption from the registration requirements under the Securities Act, available to the Company under Section 4(a)(2) promulgated thereunder and Rule 506 of Regulation D promulgated under the Securities Act due to the fact that the offering of the February 2025 Warrants and the February 2025 Placement Agent Warrants thereunder did not involve a public offering of securities.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>The February 2025 Securities Purchase Agreement contained customary representations and warranties. The offering closed on February 6, 2025.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-import:ignore">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>Pursuant to the Engagement Agreement between the Company and the Placement Agent dated August 30, 2024, as amended on September 3, 2024 and January 24, 2025, the Placement Agent acted as the Company&#8217;s exclusive placement agent in connection with the offering.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>Pursuant to the terms of the Engagement Agreement, the Company paid the Placement Agent a cash transaction fee equal to 7.5% of the aggregate gross cash proceeds in the offering and a management fee equal to 1.0% of the aggregate gross cash proceeds in the offering. In addition, the Company paid for certain non-accountable expenses in the amount of $15,000 and a clearing fee in the amount of $10,000. The Company also issued to the Placement Agent (or its designees) warrants (the &#8220;February 2025 Placement Agent Warrants&#8221;) to purchase up to 22,554 shares of common stock. The February 2025 Placement Agent Warrants have an exercise price equal to $4.469 per share and are exercisable upon issuance and expire twenty-four months from the date of issuance.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>The Company received net proceeds of approximately $908,627 from the offering, after deducting estimated offering expenses paid by the Company, including the Placement Agent fees. The Company intends to use the net proceeds from the offering for general corporate purposes, including working capital.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-import:ignore">&#160;</span></p><div style="-aw-sdt-tag:'PG_885ea259eb17e1d5'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-family: 'Times New Roman';">40</span></p><div><hr style="width: 100%; color: #000000; background-color: #000000; margin: 1rem 0;"/></div></div></div><div class="Section_44"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-weight:bold; font-style:italic">Registration of the Shares of Common Stock Underlying Warrants</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>Pursuant to the January and February 2025 Securities Purchase Agreements, the Company was required to file a registration statement with the SEC within 45 days after the date of the respective Securities Purchase Agreements to register the shares underlying the warrants under the Securities Act. The Company agreed to use commercially reasonable efforts to cause such registration statement to become effective within 75 days following the respective closing dates, and to keep such registration statement effective at all times until no purchaser owns any warrants or warrant shares issuable upon exercise thereof. Subsequently, the Company filed a registration statement on Form S-1 (File No. 333-284983) on February 14, 2025, which was declared effective by the Securities and Exchange Commission on April 2, 2025 (the &#8220;Registration Statement&#8221;).</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>The Registration Statement covered the resale of: (i) 408,621 shares of our common stock issuable upon exercise of the January 2025 Warrants at an exercise price of $3.855 per share; (ii) 300,700 shares of our common stock issuable upon exercise of the February 2025 Warrants at an exercise price of $2.95 per share; (iii) 15,325 shares of our common stock issuable upon exercise of the January 2025 Placement Agent Warrants at an exercise price of $6.382 per share; and (iv) 22,554 shares of our common stock issuable upon exercise of the February 2025 Placement Agent Warrants at an exercise price of $4.469 per share.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-style:italic">(B) Use of Proceeds</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>None.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-style:italic">(C) Issuer Purchases of Equity Securities</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>None.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span id="TOC_c30ae60e8b69047e149e"><span style="font-weight:bold">ITEM 3. DEFAULTS UPON SENIOR SECURITIES</span></span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-bookmark-end:TOC_c30ae60e8b69047e149e"></span><span style="font-weight:bold">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>None.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span id="TOC_c111a0a3b652434a3acf"><span style="font-weight:bold">ITEM 4. MINE SAFETY DISCLOSURES</span></span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-bookmark-end:TOC_c111a0a3b652434a3acf"></span><span style="font-weight:bold">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>Not Applicable.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span>&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span id="TOC_c8282f48d1dc5f58e236"><span style="font-weight:bold">ITEM 5. OTHER INFORMATION</span></span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-bookmark-end:TOC_c8282f48d1dc5f58e236"></span><span style="font-weight:bold">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-weight:bold">Securities Trading Plans</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>During the three months ended September 30, 2025, </span><span style="-aw-sdt-tag:'ecd-6d2-602-8fa-2c60'"><span style="font-family: 'Times New Roman';">no</span></span><span style="-aw-sdt-tag:'d78-1fd-a69-ba6-aeb3'"><span style="font-family: 'Times New Roman';">ne</span></span><span> of our Section 16 officers or directors (as defined in Rule 16a-1(f) of the Exchange Act) </span><span style="-sec-ix-hidden:Tag1014;-aw-sdt-tag:'88e-402-f79-843-99df';"><span style="font-family: 'Times New Roman';">adopted</span></span><span> or </span><span style="-sec-ix-hidden:Tag1016;-aw-sdt-tag:'692-05c-846-67d-d471';"><span style="font-family: 'Times New Roman';">terminated</span></span><span> any contract, instruction or written plan for the purchase or sale of our securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) of the Exchange Act or any &#8220;</span><span style="-sec-ix-hidden:Tag1015;-aw-sdt-tag:'6a8-202-91f-701-53c3';"><span style="font-family: 'Times New Roman';">non-Rule</span></span><span> </span><span style="-sec-ix-hidden:Tag1017;-aw-sdt-tag:'573-333-c1e-c7e-d3c3';"><span style="font-family: 'Times New Roman';">10b5-1</span></span><span> trading arrangement&#8221; (as defined in Section 408(c) of Regulation S-K).</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-import:ignore">&#160;</span></p><div style="-aw-sdt-tag:'PG_cdfc3cd36413a96a7604'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-family: 'Times New Roman';">41</span></p><div><hr style="width: 100%; color: #000000; background-color: #000000; margin: 1rem 0;"/></div></div></div><div class="Section_45"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span id="TOC_cc8115f676224bc17698"><span style="font-weight:bold">ITEM 6. EXHIBITS</span></span></p><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-bookmark-end:TOC_cc8115f676224bc17698"></span><span>&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold">EXHIBIT INDEX</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold">&#160;</span></p><table cellspacing="0" cellpadding="0" style="width:100%; border-collapse:collapse"><tbody><tr><td style="width:9%; border-bottom:1.5pt solid #000000; vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold">Exhibit No.</span></p></td><td style="width:1%; vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span>&#160;</span></p></td><td style="width:90%; border-bottom:1.5pt solid #000000; vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold">Description</span></p></td></tr><tr><td style="vertical-align:top; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>1.1</span></p></td><td style="vertical-align:top; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>&#160;</span></p></td><td style="vertical-align:top; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify"><a href="https://www.sec.gov/Archives/edgar/data/1946563/000121390025008463/ea022931001ex1-1_60degrees.htm" style="-sec-extract:exhibit"><span style="font-size:10pt; text-decoration:underline; color:#0000ff">Engagement Agreement (incorporated by reference to Exhibit 1.1 of the Company&#8217;s Current Report on Form 8-K filed on January 30, 2025</span></a><span style="font-size:10pt; text-decoration:underline; color:#0000ee">)</span></p></td></tr><tr><td style="vertical-align:top; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>1.2</span></p></td><td style="vertical-align:top; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>&#160;</span></p></td><td style="vertical-align:top; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify"><a href="https://www.sec.gov/Archives/edgar/data/1946563/000121390025008463/ea022931001ex1-2_60degrees.htm" style="-sec-extract:exhibit"><span style="font-size:10pt; text-decoration:underline; color:#0000ff">Amendment to Engagement Agreement (incorporated by reference to Exhibit 1.2 of the Company&#8217;s Current Report on Form 8-K filed on January 30, 2025)</span></a></p></td></tr><tr><td style="vertical-align:top; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>1.3</span></p></td><td style="vertical-align:top; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>&#160;</span></p></td><td style="vertical-align:top; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify"><a href="https://www.sec.gov/Archives/edgar/data/1946563/000121390025008463/ea022931001ex1-3_60degrees.htm" style="-sec-extract:exhibit"><span style="font-size:10pt; text-decoration:underline; color:#0000ff">Extension to Engagement Agreement (incorporated by reference to Exhibit 1.3 of the Company&#8217;s Current Report on Form 8-K filed on January 30, 2025)</span></a></p></td></tr><tr><td style="vertical-align:top; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>1.4 </span></p></td><td style="vertical-align:top; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-import:ignore">&#160;</span></p></td><td style="vertical-align:top; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify"><a href="https://www.sec.gov/Archives/edgar/data/1946563/000121390025065718/ea024943801ex10-1_60degrees.htm" style="-sec-extract:exhibit"><span style="font-size:10pt; text-decoration:underline; color:#0000ff">Form of Securities Purchase Agreement (incorporated by reference to Exhibit 10.1 of the Company&#8217;s Current Report on Form 8-K filed July 18, 2025)</span></a></p></td></tr><tr><td style="vertical-align:top; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>1.5 </span></p></td><td style="vertical-align:top; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-import:ignore">&#160;</span></p></td><td style="vertical-align:top; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify"><a href="https://www.sec.gov/Archives/edgar/data/1946563/000121390025065718/ea024943801ex4-4_60degrees.htm" style="-sec-extract:exhibit"><span style="font-size:10pt; text-decoration:underline; color:#0000ff">Form of Placement Agent Warrant (incorporated by reference to Exhibit 4.4 of the Company&#8217;s Current Report on Form 8-K filed July 18, 2025)</span></a></p></td></tr><tr><td style="vertical-align:top; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>1.6</span></p></td><td style="vertical-align:top; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-import:ignore">&#160;</span></p></td><td style="vertical-align:top; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify"><a href="https://www.sec.gov/Archives/edgar/data/1946563/000121390025085040/ea025591601ex1-1_60degrees.htm" style="-sec-extract:exhibit"><span style="font-size:10pt; text-decoration:underline; color:#0000ff">At-The-Market Sales Agreement (incorporated by reference to Exhibit 1.1 of the Company&#8217;s Current Report on Form 8-K filed September 5, 2025)</span></a></p></td></tr><tr><td style="vertical-align:top; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>4.1</span></p></td><td style="vertical-align:top; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>&#160;</span></p></td><td style="vertical-align:top; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify"><a href="https://www.sec.gov/Archives/edgar/data/1946563/000121390025008463/ea022931001ex4-1_60degrees.htm" style="-sec-extract:exhibit"><span style="font-size:10pt; text-decoration:underline; color:#0000ff">Form of Warrant (incorporated by reference to Exhibit 4.1 of the Company&#8217;s Current Report on Form 8-K filed on January 30, 2025)</span></a></p></td></tr><tr><td style="vertical-align:top; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>4.2</span></p></td><td style="vertical-align:top; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>&#160;</span></p></td><td style="vertical-align:top; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify"><a href="https://www.sec.gov/Archives/edgar/data/1946563/000121390025008463/ea022931001ex4-2_60degrees.htm" style="-sec-extract:exhibit"><span style="font-size:10pt; text-decoration:underline; color:#0000ff">Form of Placement Agent Warrant (incorporated by reference to Exhibit 4.2 of the Company&#8217;s Current Report on Form 8-K filed on January 30, 2025)</span></a></p></td></tr><tr><td style="vertical-align:top; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>4.3</span></p></td><td style="vertical-align:top; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>&#160;</span></p></td><td style="vertical-align:top; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify"><a href="https://www.sec.gov/Archives/edgar/data/1946563/000121390025010962/ea023022801ex4-1_60degrees.htm" style="-sec-extract:exhibit"><span style="font-size:10pt; text-decoration:underline; color:#0000ff">Form of Warrant (incorporated by reference to Exhibit 4.1 of the Company&#8217;s Current Report on Form 8-K filed on February 6, 2025)</span></a></p></td></tr><tr><td style="vertical-align:top; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>4.4</span></p></td><td style="vertical-align:top; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>&#160;</span></p></td><td style="vertical-align:top; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify"><a href="https://www.sec.gov/Archives/edgar/data/1946563/000121390025010962/ea023022801ex4-2_60degrees.htm" style="-sec-extract:exhibit"><span style="font-size:10pt; text-decoration:underline; color:#0000ff">Form of Placement Agent Warrant (incorporated by reference to Exhibit 4.2 of the Company&#8217;s Current Report on Form 8-K filed on February 6, 2025)</span></a></p></td></tr><tr><td style="vertical-align:top; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>10.1</span></p></td><td style="vertical-align:top; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>&#160;</span></p></td><td style="vertical-align:top; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify"><a href="https://www.sec.gov/Archives/edgar/data/1946563/000121390025008463/ea022931001ex10-1_60degrees.htm" style="-sec-extract:exhibit"><span style="font-size:10pt; text-decoration:underline; color:#0000ff">Form of Securities Purchase Agreement (incorporated by reference to Exhibit 10.1 of the Company&#8217;s Current Report on Form 8-K filed on January 30, 2025)</span></a></p></td></tr><tr><td style="vertical-align:top; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>10.2</span></p></td><td style="vertical-align:top; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>&#160;</span></p></td><td style="vertical-align:top; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify"><a href="https://www.sec.gov/Archives/edgar/data/1946563/000121390025010962/ea023022801ex10-1_60degrees.htm" style="-sec-extract:exhibit"><span style="font-size:10pt; text-decoration:underline; color:#0000ff">Form of Securities Purchase Agreement (incorporated by reference to Exhibit 10.1 of the Company&#8217;s Current Report on Form 8-K filed on February 6, 2025)</span></a></p></td></tr><tr><td style="vertical-align:top; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>31.1*</span></p></td><td style="vertical-align:top; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>&#160;</span></p></td><td style="vertical-align:top; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify"><a href="ex311_1.htm" style="-sec-extract:exhibit"><span style="font-size:10pt; text-decoration:underline; color:#0000ff">Rule 13a-14(a)/15d-14(a) Certification of the President and Chief Executive Officer of 60 Degrees Pharmaceuticals, Inc.</span></a></p></td></tr><tr><td style="vertical-align:top; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>31.2*</span></p></td><td style="vertical-align:top; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>&#160;</span></p></td><td style="vertical-align:top; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify"><a href="ex312_2.htm" style="-sec-extract:exhibit"><span style="font-size:10pt; text-decoration:underline; color:#0000ff">Rule 13a-14(a)/15d-14(a) Certification of the Chief Financial Officer of 60 Degrees Pharmaceuticals, Inc.</span></a></p></td></tr><tr><td style="vertical-align:top; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>32.1**</span></p></td><td style="vertical-align:top; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>&#160;</span></p></td><td style="vertical-align:top; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify"><a href="ex321_3.htm" style="-sec-extract:exhibit"><span style="font-size:10pt; text-decoration:underline; color:#0000ff">Section 1350 Certification of the President and Chief Executive Officer of 60 Degrees Pharmaceuticals, Inc.</span></a></p></td></tr><tr><td style="vertical-align:top; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>32.2**</span></p></td><td style="vertical-align:top; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>&#160;</span></p></td><td style="vertical-align:top; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify"><a href="ex322_4.htm" style="-sec-extract:exhibit"><span style="font-size:10pt; text-decoration:underline; color:#0000ff">Section 1350 Certification of the Chief Financial Officer of 60 Degrees Pharmaceuticals, Inc.</span></a></p></td></tr><tr><td style="vertical-align:top; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>101.INS*</span></p></td><td style="vertical-align:top; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>&#160;</span></p></td><td style="vertical-align:top; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>Inline XBRL Instance Document</span></p></td></tr><tr><td style="vertical-align:top; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>101.SCH*</span></p></td><td style="vertical-align:top; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>&#160;</span></p></td><td style="vertical-align:top; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>Inline XBRL Taxonomy Extension Schema Document</span></p></td></tr><tr><td style="vertical-align:top; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>101.CAL*</span></p></td><td style="vertical-align:top; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>&#160;</span></p></td><td style="vertical-align:top; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></p></td></tr><tr><td style="vertical-align:top; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>101.DEF*</span></p></td><td style="vertical-align:top; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>&#160;</span></p></td><td style="vertical-align:top; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>Inline XBRL Taxonomy Extension Definition Linkbase Document</span></p></td></tr><tr><td style="vertical-align:top; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>101.LAB*</span></p></td><td style="vertical-align:top; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>&#160;</span></p></td><td style="vertical-align:top; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>Inline XBRL Taxonomy Extension Label Linkbase Document</span></p></td></tr><tr><td style="vertical-align:top; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>101.PRE*</span></p></td><td style="vertical-align:top; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>&#160;</span></p></td><td style="vertical-align:top; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></p></td></tr><tr><td style="vertical-align:top; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>104*</span></p></td><td style="vertical-align:top; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>&#160;</span></p></td><td style="vertical-align:top; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></p></td></tr></tbody></table><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span>&#160;</span></p><table cellspacing="0" cellpadding="0" style="width:100%; border-collapse:collapse"><tbody><tr><td style="width:18.5pt; vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span>*</span></p></td><td style="vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>Filed herewith.</span></p></td></tr></tbody></table><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span>&#160;</span></p><table cellspacing="0" cellpadding="0" style="width:100%; border-collapse:collapse"><tbody><tr><td style="width:18.5pt; vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span>**</span></p></td><td style="vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>Exhibits 32.1 and 32.2 are being furnished and shall not be deemed to be &#8220;filed&#8221; for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of that section, nor shall such exhibits be deemed to be incorporated by reference in any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise specifically stated in such filing.</span></p></td></tr></tbody></table><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore">&#160;</span></p><div style="-aw-sdt-tag:'PG_c0cc6a384b1e8125cf74'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-family: 'Times New Roman';">42</span></p><div><hr style="width: 100%; color: #000000; background-color: #000000; margin: 1rem 0;"/></div></div></div><div class="Section_46"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span id="TOC_c410221d0afbca7d34bd"><span style="font-weight:bold">SIGNATURES</span></span></p><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-bookmark-end:TOC_c410221d0afbca7d34bd"></span><span>&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span>Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-indent:18pt; font-size:10pt"><span>&#160;</span></p><table cellspacing="0" cellpadding="0" style="width:100%; border-collapse:collapse"><tbody><tr><td style="width:60%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span>&#160;</span></p></td><td style="width:40%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold">60 DEGREES PHARMACEUTICALS, INC.</span></p></td></tr><tr><td style="vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span>&#160;</span></p></td><td style="vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span>&#160;</span></p></td></tr><tr><td style="vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span>Dated: </span><span style="-aw-sdt-tag:'ccccb477a1a846ad2513'; -aw-sdt-title:'Signature_Date_P1'"><span style="font-family: 'Times New Roman';">November 13, 2025</span></span></p></td><td style="border-bottom:1.5pt solid #000000; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-style:italic">/s/ Geoffrey Dow</span></p></td></tr><tr><td style="vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span>&#160;</span></p></td><td style="border-top:1.5pt solid #000000; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span>Geoffrey Dow</span></p></td></tr><tr><td style="vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span>&#160;</span></p></td><td style="vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span>Chief Executive Officer and President, Director</span></p><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span>(Principal Executive Officer)</span></p></td></tr><tr><td style="vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span>&#160;</span></p></td><td style="vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span>&#160;</span></p></td></tr><tr><td style="vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span>Dated: </span><span style="-aw-sdt-tag:'c753809477fa9b69285e'; -aw-sdt-title:'Signature_Date_P2'"><span style="font-family: 'Times New Roman';">November 13, 2025</span></span></p></td><td style="border-bottom:1.5pt solid #000000; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-style:italic">/s/ Tyrone Miller</span></p></td></tr><tr><td style="vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span>&#160;</span></p></td><td style="border-top:1.5pt solid #000000; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span>Tyrone Miller</span></p></td></tr><tr><td style="vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span>&#160;</span></p></td><td style="vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span>Chief Financial Officer</span></p><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span>(Principal Financial and Accounting Officer)</span></p></td></tr></tbody></table><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span>&#160;</span></p><div style="-aw-sdt-tag:'PG_c041a03986e47abe6287'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-family: 'Times New Roman';">43</span></p><div><hr style="width: 100%; color: #000000; background-color: #000000; margin: 1rem 0;"/></div></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>2
<FILENAME>sxtp-20250930_def.xml
<DESCRIPTION>DEFINITION
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!--Created by IRIS Business Services_Direct, Powered by IRIS Carbon, Unique Code 691618107ea6641f94c6a05b, Generated At Thu, 13 Nov 2025 17:41:17 GMT-->
<link:linkbase xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
  <link:roleRef roleURI="http://60degreespharma.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails" xlink:type="simple" xlink:href="sxtp-20250930.xsd#PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails" />
  <link:roleRef roleURI="http://60degreespharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofExchangeRatesalongwithHistoricalRatesDetails" xlink:type="simple" xlink:href="sxtp-20250930.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofExchangeRatesalongwithHistoricalRatesDetails" />
  <link:roleRef roleURI="http://60degreespharma.com/role/sxtp_r_ConsolidatedBalanceSheet_Parentheticals" xlink:type="simple" xlink:href="sxtp-20250930.xsd#sxtp_r_ConsolidatedBalanceSheet_Parentheticals" />
  <link:roleRef roleURI="http://60degreespharma.com/role/DocumentAndEntityInformation" xlink:type="simple" xlink:href="sxtp-20250930.xsd#DocumentAndEntityInformation" />
  <link:roleRef roleURI="http://60degreespharma.com/role/NATUREOFOPERATIONSDetails" xlink:type="simple" xlink:href="sxtp-20250930.xsd#NATUREOFOPERATIONSDetails" />
  <link:roleRef roleURI="http://60degreespharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofLiabilitiesMeasuredatFairValueDetails" xlink:type="simple" xlink:href="sxtp-20250930.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofLiabilitiesMeasuredatFairValueDetails" />
  <link:roleRef roleURI="http://60degreespharma.com/role/INTANGIBLEASSETSScheduleofEstimatedFutureAmortizationExpenseforOurPatentsandWebsiteDevelopmentCostsDetails" xlink:type="simple" xlink:href="sxtp-20250930.xsd#INTANGIBLEASSETSScheduleofEstimatedFutureAmortizationExpenseforOurPatentsandWebsiteDevelopmentCostsDetails" />
  <link:roleRef roleURI="http://60degreespharma.com/role/DEBTDetails" xlink:type="simple" xlink:href="sxtp-20250930.xsd#DEBTDetails" />
  <link:roleRef roleURI="http://60degreespharma.com/role/DERIVATIVELIABILITIESDetails" xlink:type="simple" xlink:href="sxtp-20250930.xsd#DERIVATIVELIABILITIESDetails" />
  <link:roleRef roleURI="http://60degreespharma.com/role/SHAREBASEDCOMPENSATIONScheduleofShareBasedCompensationExpensesDetails" xlink:type="simple" xlink:href="sxtp-20250930.xsd#SHAREBASEDCOMPENSATIONScheduleofShareBasedCompensationExpensesDetails" />
  <link:roleRef roleURI="http://60degreespharma.com/role/DERIVATIVELIABILITIESScheduleofDerivativeLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="simple" xlink:href="sxtp-20250930.xsd#DERIVATIVELIABILITIESScheduleofDerivativeLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" />
  <link:roleRef roleURI="http://60degreespharma.com/role/COMMITMENTSANDCONTINGENCIESDetails" xlink:type="simple" xlink:href="sxtp-20250930.xsd#COMMITMENTSANDCONTINGENCIESDetails" />
  <link:roleRef roleURI="http://60degreespharma.com/role/SHAREBASEDCOMPENSATIONDetails" xlink:type="simple" xlink:href="sxtp-20250930.xsd#SHAREBASEDCOMPENSATIONDetails" />
  <link:roleRef roleURI="http://60degreespharma.com/role/SUBSEQUENTEVENTSDetails" xlink:type="simple" xlink:href="sxtp-20250930.xsd#SUBSEQUENTEVENTSDetails" />
  <link:roleRef roleURI="http://60degreespharma.com/role/STOCKHOLDERSEQUITYScheduleofEquityClassifiedWarrantsDetails" xlink:type="simple" xlink:href="sxtp-20250930.xsd#STOCKHOLDERSEQUITYScheduleofEquityClassifiedWarrantsDetails" />
  <link:roleRef roleURI="http://60degreespharma.com/role/STOCKHOLDERSEQUITYDetails" xlink:type="simple" xlink:href="sxtp-20250930.xsd#STOCKHOLDERSEQUITYDetails" />
  <link:roleRef roleURI="http://60degreespharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails" xlink:type="simple" xlink:href="sxtp-20250930.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails" />
  <link:roleRef roleURI="http://60degreespharma.com/role/ConsolidatedCondensedStatementsofShareholdersEquityUnaudited" xlink:type="simple" xlink:href="sxtp-20250930.xsd#ConsolidatedCondensedStatementsofShareholdersEquityUnaudited" />
  <link:roleRef roleURI="http://60degreespharma.com/role/sxtp_r_ConsolidatedBalanceSheet" xlink:type="simple" xlink:href="sxtp-20250930.xsd#sxtp_r_ConsolidatedBalanceSheet" />
  <link:roleRef roleURI="http://60degreespharma.com/role/sxtp_r_ConsolidatedIncomeStatement" xlink:type="simple" xlink:href="sxtp-20250930.xsd#sxtp_r_ConsolidatedIncomeStatement" />
  <link:roleRef roleURI="http://60degreespharma.com/role/ConsolidatedCondensedStatementsofOperationsandComprehensiveLossIncomeUnauditedCalc2" xlink:type="simple" xlink:href="sxtp-20250930.xsd#ConsolidatedCondensedStatementsofOperationsandComprehensiveLossIncomeUnauditedCalc2" />
  <link:roleRef roleURI="http://60degreespharma.com/role/ConsolidatedCondensedStatementsofShareholdersEquityDeficitUnauditedParentheticals" xlink:type="simple" xlink:href="sxtp-20250930.xsd#ConsolidatedCondensedStatementsofShareholdersEquityDeficitUnauditedParentheticals" />
  <link:roleRef roleURI="http://60degreespharma.com/role/sxtp_r_ConsolidatedCashFlow" xlink:type="simple" xlink:href="sxtp-20250930.xsd#sxtp_r_ConsolidatedCashFlow" />
  <link:roleRef roleURI="http://60degreespharma.com/role/ConsolidatedCondensedStatementsofCashFlowsUnauditedParentheticals" xlink:type="simple" xlink:href="sxtp-20250930.xsd#ConsolidatedCondensedStatementsofCashFlowsUnauditedParentheticals" />
  <link:roleRef roleURI="http://60degreespharma.com/role/NATUREOFOPERATIONS" xlink:type="simple" xlink:href="sxtp-20250930.xsd#NATUREOFOPERATIONS" />
  <link:roleRef roleURI="http://60degreespharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="simple" xlink:href="sxtp-20250930.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" />
  <link:roleRef roleURI="http://60degreespharma.com/role/INVENTORY" xlink:type="simple" xlink:href="sxtp-20250930.xsd#INVENTORY" />
  <link:roleRef roleURI="http://60degreespharma.com/role/PROPERTYANDEQUIPMENT" xlink:type="simple" xlink:href="sxtp-20250930.xsd#PROPERTYANDEQUIPMENT" />
  <link:roleRef roleURI="http://60degreespharma.com/role/INTANGIBLEASSETS" xlink:type="simple" xlink:href="sxtp-20250930.xsd#INTANGIBLEASSETS" />
  <link:roleRef roleURI="http://60degreespharma.com/role/STOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="sxtp-20250930.xsd#STOCKHOLDERSEQUITY" />
  <link:roleRef roleURI="http://60degreespharma.com/role/DEBT" xlink:type="simple" xlink:href="sxtp-20250930.xsd#DEBT" />
  <link:roleRef roleURI="http://60degreespharma.com/role/DERIVATIVELIABILITIES" xlink:type="simple" xlink:href="sxtp-20250930.xsd#DERIVATIVELIABILITIES" />
  <link:roleRef roleURI="http://60degreespharma.com/role/INCOMETAXES" xlink:type="simple" xlink:href="sxtp-20250930.xsd#INCOMETAXES" />
  <link:roleRef roleURI="http://60degreespharma.com/role/SHAREBASEDCOMPENSATION" xlink:type="simple" xlink:href="sxtp-20250930.xsd#SHAREBASEDCOMPENSATION" />
  <link:roleRef roleURI="http://60degreespharma.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="simple" xlink:href="sxtp-20250930.xsd#COMMITMENTSANDCONTINGENCIES" />
  <link:roleRef roleURI="http://60degreespharma.com/role/SUBSEQUENTEVENTS" xlink:type="simple" xlink:href="sxtp-20250930.xsd#SUBSEQUENTEVENTS" />
  <link:roleRef roleURI="http://60degreespharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="simple" xlink:href="sxtp-20250930.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" />
  <link:roleRef roleURI="http://60degreespharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" xlink:type="simple" xlink:href="sxtp-20250930.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" />
  <link:roleRef roleURI="http://60degreespharma.com/role/INVENTORYTables" xlink:type="simple" xlink:href="sxtp-20250930.xsd#INVENTORYTables" />
  <link:roleRef roleURI="http://60degreespharma.com/role/PROPERTYANDEQUIPMENTTables" xlink:type="simple" xlink:href="sxtp-20250930.xsd#PROPERTYANDEQUIPMENTTables" />
  <link:roleRef roleURI="http://60degreespharma.com/role/INTANGIBLEASSETSTables" xlink:type="simple" xlink:href="sxtp-20250930.xsd#INTANGIBLEASSETSTables" />
  <link:roleRef roleURI="http://60degreespharma.com/role/STOCKHOLDERSEQUITYTables" xlink:type="simple" xlink:href="sxtp-20250930.xsd#STOCKHOLDERSEQUITYTables" />
  <link:roleRef roleURI="http://60degreespharma.com/role/DEBTTables" xlink:type="simple" xlink:href="sxtp-20250930.xsd#DEBTTables" />
  <link:roleRef roleURI="http://60degreespharma.com/role/DERIVATIVELIABILITIESTables" xlink:type="simple" xlink:href="sxtp-20250930.xsd#DERIVATIVELIABILITIESTables" />
  <link:roleRef roleURI="http://60degreespharma.com/role/SHAREBASEDCOMPENSATIONTables" xlink:type="simple" xlink:href="sxtp-20250930.xsd#SHAREBASEDCOMPENSATIONTables" />
  <link:roleRef roleURI="http://60degreespharma.com/role/INVENTORYScheduleofInventoryDetails" xlink:type="simple" xlink:href="sxtp-20250930.xsd#INVENTORYScheduleofInventoryDetails" />
  <link:roleRef roleURI="http://60degreespharma.com/role/INVENTORYDetails" xlink:type="simple" xlink:href="sxtp-20250930.xsd#INVENTORYDetails" />
  <link:roleRef roleURI="http://60degreespharma.com/role/PROPERTYANDEQUIPMENTDetails" xlink:type="simple" xlink:href="sxtp-20250930.xsd#PROPERTYANDEQUIPMENTDetails" />
  <link:roleRef roleURI="http://60degreespharma.com/role/INTANGIBLEASSETSDetails" xlink:type="simple" xlink:href="sxtp-20250930.xsd#INTANGIBLEASSETSDetails" />
  <link:roleRef roleURI="http://60degreespharma.com/role/INTANGIBLEASSETSScheduleofIntangibleAssetsDetails" xlink:type="simple" xlink:href="sxtp-20250930.xsd#INTANGIBLEASSETSScheduleofIntangibleAssetsDetails" />
  <link:roleRef roleURI="http://60degreespharma.com/role/DEBTScheduleoftheCurrentFuturePaymentObligationsDetails" xlink:type="simple" xlink:href="sxtp-20250930.xsd#DEBTScheduleoftheCurrentFuturePaymentObligationsDetails" />
  <link:roleRef roleURI="http://60degreespharma.com/role/INCOMETAXESDetails" xlink:type="simple" xlink:href="sxtp-20250930.xsd#INCOMETAXESDetails" />
  <link:roleRef roleURI="http://60degreespharma.com/role/SHAREBASEDCOMPENSATIONScheduleofFairValueofOptionsGrantedDetails" xlink:type="simple" xlink:href="sxtp-20250930.xsd#SHAREBASEDCOMPENSATIONScheduleofFairValueofOptionsGrantedDetails" />
  <link:definitionLink xlink:type="extended" xlink:role="http://60degreespharma.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:title="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:title="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" xlink:title="Definition : us-gaap_PropertyPlantAndEquipmentLineItems to us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" use="optional" order="0" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:title="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:title="Definition : us-gaap_PropertyPlantAndEquipmentLineItems to us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" use="optional" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:title="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" xlink:title="Definition : us-gaap_PropertyPlantAndEquipmentLineItems to us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" use="optional" order="2" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:title="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:title="Definition : us-gaap_PropertyPlantAndEquipmentLineItems to us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="3" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:title="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:title="Definition : us-gaap_ScheduleOfPropertyPlantAndEquipmentTable to us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" use="optional" order="0" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:title="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:title="Definition : us-gaap_PropertyPlantAndEquipmentByTypeAxis to us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" use="optional" order="0" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_LabEquipmentMember" xlink:label="sxtp_LabEquipmentMember" xlink:title="sxtp_LabEquipmentMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="sxtp_LabEquipmentMember" xlink:title="Definition : us-gaap_PropertyPlantAndEquipmentTypeDomain to sxtp_LabEquipmentMember" xlink:type="arc" use="optional" order="0" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="us-gaap_MachineryAndEquipmentMember" xlink:title="us-gaap_MachineryAndEquipmentMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_MachineryAndEquipmentMember" xlink:title="Definition : us-gaap_PropertyPlantAndEquipmentTypeDomain to us-gaap_MachineryAndEquipmentMember" xlink:type="arc" use="optional" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" xlink:title="us-gaap_ComputerEquipmentMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" xlink:title="Definition : us-gaap_PropertyPlantAndEquipmentTypeDomain to us-gaap_ComputerEquipmentMember" xlink:type="arc" use="optional" order="2" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:title="us-gaap_FurnitureAndFixturesMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" xlink:title="Definition : us-gaap_PropertyPlantAndEquipmentTypeDomain to us-gaap_FurnitureAndFixturesMember" xlink:type="arc" use="optional" order="3" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" xlink:title="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" xlink:title="Definition : us-gaap_PropertyPlantAndEquipmentByTypeAxis to us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1" xbrldt:closed="false" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://60degreespharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofExchangeRatesalongwithHistoricalRatesDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntercompanyForeignCurrencyBalanceLineItems" xlink:label="us-gaap_IntercompanyForeignCurrencyBalanceLineItems" xlink:title="us-gaap_IntercompanyForeignCurrencyBalanceLineItems" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_AverageExchangeRate" xlink:label="sxtp_AverageExchangeRate" xlink:title="sxtp_AverageExchangeRate" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IntercompanyForeignCurrencyBalanceLineItems" xlink:to="sxtp_AverageExchangeRate" xlink:title="Definition : us-gaap_IntercompanyForeignCurrencyBalanceLineItems to sxtp_AverageExchangeRate" xlink:type="arc" use="optional" order="0" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCurrencyExchangeRateTranslation1" xlink:label="us-gaap_ForeignCurrencyExchangeRateTranslation1" xlink:title="us-gaap_ForeignCurrencyExchangeRateTranslation1" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IntercompanyForeignCurrencyBalanceLineItems" xlink:to="us-gaap_ForeignCurrencyExchangeRateTranslation1" xlink:title="Definition : us-gaap_IntercompanyForeignCurrencyBalanceLineItems to us-gaap_ForeignCurrencyExchangeRateTranslation1" xlink:type="arc" use="optional" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_SummaryofSignificantAccountingPoliciesScheduleofExchangeRatesalongwithHistoricalRatesDetailsTable" xlink:label="sxtp_SummaryofSignificantAccountingPoliciesScheduleofExchangeRatesalongwithHistoricalRatesDetailsTable" xlink:title="sxtp_SummaryofSignificantAccountingPoliciesScheduleofExchangeRatesalongwithHistoricalRatesDetailsTable" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_IntercompanyForeignCurrencyBalanceLineItems" xlink:to="sxtp_SummaryofSignificantAccountingPoliciesScheduleofExchangeRatesalongwithHistoricalRatesDetailsTable" xlink:title="Definition : us-gaap_IntercompanyForeignCurrencyBalanceLineItems to sxtp_SummaryofSignificantAccountingPoliciesScheduleofExchangeRatesalongwithHistoricalRatesDetailsTable" xlink:type="arc" order="2" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CurrencyAxis" xlink:label="srt_CurrencyAxis" xlink:title="srt_CurrencyAxis" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sxtp_SummaryofSignificantAccountingPoliciesScheduleofExchangeRatesalongwithHistoricalRatesDetailsTable" xlink:to="srt_CurrencyAxis" xlink:title="Definition : sxtp_SummaryofSignificantAccountingPoliciesScheduleofExchangeRatesalongwithHistoricalRatesDetailsTable to srt_CurrencyAxis" xlink:type="arc" use="optional" order="0" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2025/currency-2025.xsd#currency_AllCurrenciesDomain" xlink:label="currency_AllCurrenciesDomain" xlink:title="currency_AllCurrenciesDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CurrencyAxis" xlink:to="currency_AllCurrenciesDomain" xlink:title="Definition : srt_CurrencyAxis to currency_AllCurrenciesDomain" xlink:type="arc" use="optional" order="0" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2025/currency-2025.xsd#currency_USD" xlink:label="currency_USD" xlink:title="currency_USD" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="currency_AllCurrenciesDomain" xlink:to="currency_USD" xlink:title="Definition : currency_AllCurrenciesDomain to currency_USD" xlink:type="arc" use="optional" order="0" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2025/currency-2025.xsd#currency_AllCurrenciesDomain" xlink:label="currency_AllCurrenciesDomain_1" xlink:title="currency_AllCurrenciesDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CurrencyAxis" xlink:to="currency_AllCurrenciesDomain_1" xlink:title="Definition : srt_CurrencyAxis to currency_AllCurrenciesDomain" xlink:type="arc" order="1" xbrldt:closed="false" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://60degreespharma.com/role/sxtp_r_ConsolidatedBalanceSheet_Parentheticals">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:title="us-gaap_StatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:title="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:title="Definition : us-gaap_StatementLineItems to us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" use="optional" order="0" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:title="us-gaap_PreferredStockSharesAuthorized" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" xlink:title="Definition : us-gaap_StatementLineItems to us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" use="optional" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:title="us-gaap_PreferredStockSharesIssued" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" xlink:title="Definition : us-gaap_StatementLineItems to us-gaap_PreferredStockSharesIssued" xlink:type="arc" use="optional" order="2" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:title="us-gaap_PreferredStockSharesOutstanding" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" xlink:title="Definition : us-gaap_StatementLineItems to us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" use="optional" order="3" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:title="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" xlink:title="Definition : us-gaap_StatementLineItems to us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" use="optional" order="4" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:title="us-gaap_CommonStockSharesAuthorized" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" xlink:title="Definition : us-gaap_StatementLineItems to us-gaap_CommonStockSharesAuthorized" xlink:type="arc" use="optional" order="5" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xlink:title="us-gaap_CommonStockSharesIssued" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" xlink:title="Definition : us-gaap_StatementLineItems to us-gaap_CommonStockSharesIssued" xlink:type="arc" use="optional" order="6" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:title="us-gaap_CommonStockSharesOutstanding" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" xlink:title="Definition : us-gaap_StatementLineItems to us-gaap_CommonStockSharesOutstanding" xlink:type="arc" use="optional" order="7" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:title="us-gaap_StatementTable" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:title="Definition : us-gaap_StatementLineItems to us-gaap_StatementTable" xlink:type="arc" order="8" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:title="us-gaap_StatementClassOfStockAxis" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" xlink:title="Definition : us-gaap_StatementTable to us-gaap_StatementClassOfStockAxis" xlink:type="arc" use="optional" order="0" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xlink:title="us-gaap_ClassOfStockDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" xlink:title="Definition : us-gaap_StatementClassOfStockAxis to us-gaap_ClassOfStockDomain" xlink:type="arc" use="optional" order="0" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:title="us-gaap_SeriesAPreferredStockMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" xlink:title="Definition : us-gaap_ClassOfStockDomain to us-gaap_SeriesAPreferredStockMember" xlink:type="arc" use="optional" order="0" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_1" xlink:title="us-gaap_ClassOfStockDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_1" xlink:title="Definition : us-gaap_StatementClassOfStockAxis to us-gaap_ClassOfStockDomain" xlink:type="arc" order="1" xbrldt:closed="false" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://60degreespharma.com/role/DocumentAndEntityInformation">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:title="dei_DocumentInformationLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:title="dei_EntityRegistrantName" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" xlink:title="Definition : dei_DocumentInformationLineItems to dei_EntityRegistrantName" xlink:type="arc" use="optional" order="0" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:title="dei_DocumentType" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" xlink:title="Definition : dei_DocumentInformationLineItems to dei_DocumentType" xlink:type="arc" use="optional" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:title="dei_AmendmentFlag" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" xlink:title="Definition : dei_DocumentInformationLineItems to dei_AmendmentFlag" xlink:type="arc" use="optional" order="2" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:title="dei_EntityCentralIndexKey" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" xlink:title="Definition : dei_DocumentInformationLineItems to dei_EntityCentralIndexKey" xlink:type="arc" use="optional" order="3" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:title="dei_DocumentPeriodEndDate" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" xlink:title="Definition : dei_DocumentInformationLineItems to dei_DocumentPeriodEndDate" xlink:type="arc" use="optional" order="4" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xlink:title="dei_CurrentFiscalYearEndDate" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" xlink:title="Definition : dei_DocumentInformationLineItems to dei_CurrentFiscalYearEndDate" xlink:type="arc" use="optional" order="5" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xlink:title="dei_DocumentFiscalYearFocus" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" xlink:title="Definition : dei_DocumentInformationLineItems to dei_DocumentFiscalYearFocus" xlink:type="arc" use="optional" order="6" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:title="dei_DocumentFiscalPeriodFocus" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" xlink:title="Definition : dei_DocumentInformationLineItems to dei_DocumentFiscalPeriodFocus" xlink:type="arc" use="optional" order="7" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" xlink:title="dei_DocumentQuarterlyReport" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentQuarterlyReport" xlink:title="Definition : dei_DocumentInformationLineItems to dei_DocumentQuarterlyReport" xlink:type="arc" use="optional" order="8" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" xlink:title="dei_DocumentTransitionReport" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentTransitionReport" xlink:title="Definition : dei_DocumentInformationLineItems to dei_DocumentTransitionReport" xlink:type="arc" use="optional" order="9" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xlink:title="dei_EntityFileNumber" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" xlink:title="Definition : dei_DocumentInformationLineItems to dei_EntityFileNumber" xlink:type="arc" use="optional" order="10" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:title="dei_EntityIncorporationStateCountryCode" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" xlink:title="Definition : dei_DocumentInformationLineItems to dei_EntityIncorporationStateCountryCode" xlink:type="arc" use="optional" order="11" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xlink:title="dei_EntityTaxIdentificationNumber" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" xlink:title="Definition : dei_DocumentInformationLineItems to dei_EntityTaxIdentificationNumber" xlink:type="arc" use="optional" order="12" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:title="dei_EntityAddressAddressLine1" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" xlink:title="Definition : dei_DocumentInformationLineItems to dei_EntityAddressAddressLine1" xlink:type="arc" use="optional" order="13" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" xlink:title="dei_EntityAddressAddressLine2" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine2" xlink:title="Definition : dei_DocumentInformationLineItems to dei_EntityAddressAddressLine2" xlink:type="arc" use="optional" order="14" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:title="dei_EntityAddressCityOrTown" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" xlink:title="Definition : dei_DocumentInformationLineItems to dei_EntityAddressCityOrTown" xlink:type="arc" use="optional" order="15" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:title="dei_EntityAddressStateOrProvince" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" xlink:title="Definition : dei_DocumentInformationLineItems to dei_EntityAddressStateOrProvince" xlink:type="arc" use="optional" order="16" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:title="dei_EntityAddressPostalZipCode" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" xlink:title="Definition : dei_DocumentInformationLineItems to dei_EntityAddressPostalZipCode" xlink:type="arc" use="optional" order="17" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xlink:title="dei_CityAreaCode" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" xlink:title="Definition : dei_DocumentInformationLineItems to dei_CityAreaCode" xlink:type="arc" use="optional" order="18" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xlink:title="dei_LocalPhoneNumber" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" xlink:title="Definition : dei_DocumentInformationLineItems to dei_LocalPhoneNumber" xlink:type="arc" use="optional" order="19" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xlink:title="dei_Security12bTitle" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" xlink:title="Definition : dei_DocumentInformationLineItems to dei_Security12bTitle" xlink:type="arc" use="optional" order="20" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:title="dei_TradingSymbol" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" xlink:title="Definition : dei_DocumentInformationLineItems to dei_TradingSymbol" xlink:type="arc" use="optional" order="21" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xlink:title="dei_SecurityExchangeName" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" xlink:title="Definition : dei_DocumentInformationLineItems to dei_SecurityExchangeName" xlink:type="arc" use="optional" order="22" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xlink:title="dei_EntityCurrentReportingStatus" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" xlink:title="Definition : dei_DocumentInformationLineItems to dei_EntityCurrentReportingStatus" xlink:type="arc" use="optional" order="23" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" xlink:title="dei_EntityInteractiveDataCurrent" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" xlink:title="Definition : dei_DocumentInformationLineItems to dei_EntityInteractiveDataCurrent" xlink:type="arc" use="optional" order="24" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xlink:title="dei_EntityFilerCategory" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" xlink:title="Definition : dei_DocumentInformationLineItems to dei_EntityFilerCategory" xlink:type="arc" use="optional" order="25" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" xlink:title="dei_EntitySmallBusiness" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitySmallBusiness" xlink:title="Definition : dei_DocumentInformationLineItems to dei_EntitySmallBusiness" xlink:type="arc" use="optional" order="26" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:title="dei_EntityEmergingGrowthCompany" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" xlink:title="Definition : dei_DocumentInformationLineItems to dei_EntityEmergingGrowthCompany" xlink:type="arc" use="optional" order="27" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" xlink:title="dei_EntityExTransitionPeriod" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityExTransitionPeriod" xlink:title="Definition : dei_DocumentInformationLineItems to dei_EntityExTransitionPeriod" xlink:type="arc" use="optional" order="28" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" xlink:title="dei_EntityShellCompany" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" xlink:title="Definition : dei_DocumentInformationLineItems to dei_EntityShellCompany" xlink:type="arc" use="optional" order="29" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:title="dei_EntityCommonStockSharesOutstanding" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" xlink:title="Definition : dei_DocumentInformationLineItems to dei_EntityCommonStockSharesOutstanding" xlink:type="arc" use="optional" order="30" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitiesTable" xlink:label="dei_EntitiesTable" xlink:title="dei_EntitiesTable" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitiesTable" xlink:title="Definition : dei_DocumentInformationLineItems to dei_EntitiesTable" xlink:type="arc" order="31" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:title="us-gaap_StatementClassOfStockAxis" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dei_EntitiesTable" xlink:to="us-gaap_StatementClassOfStockAxis" xlink:title="Definition : dei_EntitiesTable to us-gaap_StatementClassOfStockAxis" xlink:type="arc" use="optional" order="0" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xlink:title="us-gaap_ClassOfStockDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" xlink:title="Definition : us-gaap_StatementClassOfStockAxis to us-gaap_ClassOfStockDomain" xlink:type="arc" use="optional" order="0" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:title="us-gaap_CommonStockMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonStockMember" xlink:title="Definition : us-gaap_ClassOfStockDomain to us-gaap_CommonStockMember" xlink:type="arc" use="optional" order="0" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" xlink:title="us-gaap_WarrantMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_WarrantMember" xlink:title="Definition : us-gaap_ClassOfStockDomain to us-gaap_WarrantMember" xlink:type="arc" use="optional" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_1" xlink:title="us-gaap_ClassOfStockDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_1" xlink:title="Definition : us-gaap_StatementClassOfStockAxis to us-gaap_ClassOfStockDomain" xlink:type="arc" order="1" xbrldt:closed="false" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://60degreespharma.com/role/NATUREOFOPERATIONSDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:title="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:title="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:title="Definition : us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" use="optional" order="0" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:title="us-gaap_SharesIssuedPricePerShare" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" xlink:title="Definition : us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to us-gaap_SharesIssuedPricePerShare" xlink:type="arc" use="optional" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:title="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:title="Definition : us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:type="arc" use="optional" order="2" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:title="us-gaap_WarrantsAndRightsOutstandingTerm" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:title="Definition : us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to us-gaap_WarrantsAndRightsOutstandingTerm" xlink:type="arc" use="optional" order="3" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:title="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:title="Definition : us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" use="optional" order="4" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:title="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:title="Definition : us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" use="optional" order="5" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_SBAEIDLincludingAccruedInterestCurrent" xlink:label="sxtp_SBAEIDLincludingAccruedInterestCurrent" xlink:title="sxtp_SBAEIDLincludingAccruedInterestCurrent" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="sxtp_SBAEIDLincludingAccruedInterestCurrent" xlink:title="Definition : us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to sxtp_SBAEIDLincludingAccruedInterestCurrent" xlink:type="arc" use="optional" order="6" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:title="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:title="Definition : us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc" use="optional" order="7" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_NatureofOperationsDetailsTable" xlink:label="sxtp_NatureofOperationsDetailsTable" xlink:title="sxtp_NatureofOperationsDetailsTable" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="sxtp_NatureofOperationsDetailsTable" xlink:title="Definition : us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to sxtp_NatureofOperationsDetailsTable" xlink:type="arc" use="optional" order="8" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:title="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sxtp_NatureofOperationsDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:title="Definition : sxtp_NatureofOperationsDetailsTable to us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" use="optional" order="0" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:title="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:title="Definition : us-gaap_SubsidiarySaleOfStockAxis to us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" use="optional" order="0" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember" xlink:title="us-gaap_IPOMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" xlink:title="Definition : us-gaap_SaleOfStockNameOfTransactionDomain to us-gaap_IPOMember" xlink:type="arc" use="optional" order="0" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_TradeableWarrantsMember" xlink:label="sxtp_TradeableWarrantsMember" xlink:title="sxtp_TradeableWarrantsMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="sxtp_TradeableWarrantsMember" xlink:title="Definition : us-gaap_SaleOfStockNameOfTransactionDomain to sxtp_TradeableWarrantsMember" xlink:type="arc" use="optional" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_NontradeableWarrantsMember" xlink:label="sxtp_NontradeableWarrantsMember" xlink:title="sxtp_NontradeableWarrantsMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="sxtp_NontradeableWarrantsMember" xlink:title="Definition : us-gaap_SaleOfStockNameOfTransactionDomain to sxtp_NontradeableWarrantsMember" xlink:type="arc" use="optional" order="2" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_TradeableAndNonTradeableWarrantsMember" xlink:label="sxtp_TradeableAndNonTradeableWarrantsMember" xlink:title="sxtp_TradeableAndNonTradeableWarrantsMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="sxtp_TradeableAndNonTradeableWarrantsMember" xlink:title="Definition : us-gaap_SaleOfStockNameOfTransactionDomain to sxtp_TradeableAndNonTradeableWarrantsMember" xlink:type="arc" use="optional" order="3" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_1" xlink:title="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_1" xlink:title="Definition : us-gaap_SubsidiarySaleOfStockAxis to us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" use="optional" order="1" xbrldt:closed="false" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://60degreespharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofLiabilitiesMeasuredatFairValueDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:title="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="us-gaap_DerivativeLiabilitiesCurrent" xlink:title="us-gaap_DerivativeLiabilitiesCurrent" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_DerivativeLiabilitiesCurrent" xlink:title="Definition : us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to us-gaap_DerivativeLiabilitiesCurrent" xlink:type="arc" use="optional" order="0" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_SummaryofSignificantAccountingPoliciesScheduleofLiabilitiesMeasuredatFairValueDetailsTable" xlink:label="sxtp_SummaryofSignificantAccountingPoliciesScheduleofLiabilitiesMeasuredatFairValueDetailsTable" xlink:title="sxtp_SummaryofSignificantAccountingPoliciesScheduleofLiabilitiesMeasuredatFairValueDetailsTable" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="sxtp_SummaryofSignificantAccountingPoliciesScheduleofLiabilitiesMeasuredatFairValueDetailsTable" xlink:title="Definition : us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to sxtp_SummaryofSignificantAccountingPoliciesScheduleofLiabilitiesMeasuredatFairValueDetailsTable" xlink:type="arc" use="optional" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" xlink:title="us-gaap_FinancialInstrumentAxis" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sxtp_SummaryofSignificantAccountingPoliciesScheduleofLiabilitiesMeasuredatFairValueDetailsTable" xlink:to="us-gaap_FinancialInstrumentAxis" xlink:title="Definition : sxtp_SummaryofSignificantAccountingPoliciesScheduleofLiabilitiesMeasuredatFairValueDetailsTable to us-gaap_FinancialInstrumentAxis" xlink:type="arc" use="optional" order="0" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:title="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:title="Definition : us-gaap_FinancialInstrumentAxis to us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" use="optional" order="0" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeMember" xlink:label="us-gaap_DerivativeMember" xlink:title="us-gaap_DerivativeMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_DerivativeMember" xlink:title="Definition : us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain to us-gaap_DerivativeMember" xlink:type="arc" use="optional" order="0" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" xlink:title="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" xlink:title="Definition : us-gaap_FinancialInstrumentAxis to us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" use="optional" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:title="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sxtp_SummaryofSignificantAccountingPoliciesScheduleofLiabilitiesMeasuredatFairValueDetailsTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:title="Definition : sxtp_SummaryofSignificantAccountingPoliciesScheduleofLiabilitiesMeasuredatFairValueDetailsTable to us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" use="optional" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:title="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:title="Definition : us-gaap_FairValueByFairValueHierarchyLevelAxis to us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" use="optional" order="0" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" xlink:title="us-gaap_FairValueInputsLevel1Member" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" xlink:title="Definition : us-gaap_FairValueMeasurementsFairValueHierarchyDomain to us-gaap_FairValueInputsLevel1Member" xlink:type="arc" use="optional" order="0" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:title="us-gaap_FairValueInputsLevel2Member" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" xlink:title="Definition : us-gaap_FairValueMeasurementsFairValueHierarchyDomain to us-gaap_FairValueInputsLevel2Member" xlink:type="arc" use="optional" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" xlink:title="us-gaap_FairValueInputsLevel3Member" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" xlink:title="Definition : us-gaap_FairValueMeasurementsFairValueHierarchyDomain to us-gaap_FairValueInputsLevel3Member" xlink:type="arc" use="optional" order="2" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" xlink:title="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" xlink:title="Definition : us-gaap_FairValueByFairValueHierarchyLevelAxis to us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" use="optional" order="1" xbrldt:closed="false" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://60degreespharma.com/role/INTANGIBLEASSETSScheduleofEstimatedFutureAmortizationExpenseforOurPatentsandWebsiteDevelopmentCostsDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:title="us-gaap_FiniteLivedIntangibleAssetsLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:title="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:title="Definition : us-gaap_FiniteLivedIntangibleAssetsLineItems to us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:type="arc" use="optional" order="0" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:title="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:title="Definition : us-gaap_FiniteLivedIntangibleAssetsLineItems to us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" use="optional" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:title="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:title="Definition : us-gaap_FiniteLivedIntangibleAssetsLineItems to us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" use="optional" order="2" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:title="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:title="Definition : us-gaap_FiniteLivedIntangibleAssetsLineItems to us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" use="optional" order="3" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:title="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:title="Definition : us-gaap_FiniteLivedIntangibleAssetsLineItems to us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" use="optional" order="4" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:title="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:title="Definition : us-gaap_FiniteLivedIntangibleAssetsLineItems to us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:type="arc" use="optional" order="5" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:title="us-gaap_FiniteLivedIntangibleAssetsNet" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:title="Definition : us-gaap_FiniteLivedIntangibleAssetsLineItems to us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" use="optional" order="6" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_IntangibleAssetsScheduleofEstimatedFutureAmortizationExpenseforOurPatentsandWebsiteDevelopmentCostsDetailsTable" xlink:label="sxtp_IntangibleAssetsScheduleofEstimatedFutureAmortizationExpenseforOurPatentsandWebsiteDevelopmentCostsDetailsTable" xlink:title="sxtp_IntangibleAssetsScheduleofEstimatedFutureAmortizationExpenseforOurPatentsandWebsiteDevelopmentCostsDetailsTable" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="sxtp_IntangibleAssetsScheduleofEstimatedFutureAmortizationExpenseforOurPatentsandWebsiteDevelopmentCostsDetailsTable" xlink:title="Definition : us-gaap_FiniteLivedIntangibleAssetsLineItems to sxtp_IntangibleAssetsScheduleofEstimatedFutureAmortizationExpenseforOurPatentsandWebsiteDevelopmentCostsDetailsTable" xlink:type="arc" use="optional" order="7" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:title="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sxtp_IntangibleAssetsScheduleofEstimatedFutureAmortizationExpenseforOurPatentsandWebsiteDevelopmentCostsDetailsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:title="Definition : sxtp_IntangibleAssetsScheduleofEstimatedFutureAmortizationExpenseforOurPatentsandWebsiteDevelopmentCostsDetailsTable to us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" use="optional" order="0" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:title="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:title="Definition : us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis to us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" use="optional" order="0" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PatentsMember" xlink:label="us-gaap_PatentsMember" xlink:title="us-gaap_PatentsMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_PatentsMember" xlink:title="Definition : us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain to us-gaap_PatentsMember" xlink:type="arc" use="optional" order="0" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:title="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:title="Definition : us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain to us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:type="arc" use="optional" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1" xlink:title="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1" xlink:title="Definition : us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis to us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" use="optional" order="1" xbrldt:closed="false" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://60degreespharma.com/role/DEBTDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems" xlink:title="us-gaap_DebtInstrumentLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" xlink:title="us-gaap_DebtInstrumentFaceAmount" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" xlink:title="Definition : us-gaap_DebtInstrumentLineItems to us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" use="optional" order="0" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:title="us-gaap_DebtInstrumentInterestRateEffectivePercentage" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:title="Definition : us-gaap_DebtInstrumentLineItems to us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:type="arc" use="optional" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" xlink:label="us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" xlink:title="us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" xlink:title="Definition : us-gaap_DebtInstrumentLineItems to us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" xlink:type="arc" use="optional" order="2" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate" xlink:title="us-gaap_DebtInstrumentMaturityDate" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" xlink:title="Definition : us-gaap_DebtInstrumentLineItems to us-gaap_DebtInstrumentMaturityDate" xlink:type="arc" use="optional" order="3" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:title="us-gaap_AmortizationOfFinancingCostsAndDiscounts" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:title="Definition : us-gaap_DebtInstrumentLineItems to us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:type="arc" use="optional" order="4" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtCurrent" xlink:label="us-gaap_LongTermDebtCurrent" xlink:title="us-gaap_LongTermDebtCurrent" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebtCurrent" xlink:title="Definition : us-gaap_DebtInstrumentLineItems to us-gaap_LongTermDebtCurrent" xlink:type="arc" use="optional" order="5" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent" xlink:title="us-gaap_LiabilitiesNoncurrent" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LiabilitiesNoncurrent" xlink:title="Definition : us-gaap_DebtInstrumentLineItems to us-gaap_LiabilitiesNoncurrent" xlink:type="arc" use="optional" order="6" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_DebtDetailsTable" xlink:label="sxtp_DebtDetailsTable" xlink:title="sxtp_DebtDetailsTable" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="sxtp_DebtDetailsTable" xlink:title="Definition : us-gaap_DebtInstrumentLineItems to sxtp_DebtDetailsTable" xlink:type="arc" use="optional" order="7" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:title="us-gaap_DebtInstrumentAxis" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sxtp_DebtDetailsTable" xlink:to="us-gaap_DebtInstrumentAxis" xlink:title="Definition : sxtp_DebtDetailsTable to us-gaap_DebtInstrumentAxis" xlink:type="arc" use="optional" order="0" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:title="us-gaap_DebtInstrumentNameDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" xlink:title="Definition : us-gaap_DebtInstrumentAxis to us-gaap_DebtInstrumentNameDomain" xlink:type="arc" use="optional" order="0" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_SmallBusinessAdministrationMember" xlink:label="sxtp_SmallBusinessAdministrationMember" xlink:title="sxtp_SmallBusinessAdministrationMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="sxtp_SmallBusinessAdministrationMember" xlink:title="Definition : us-gaap_DebtInstrumentNameDomain to sxtp_SmallBusinessAdministrationMember" xlink:type="arc" use="optional" order="0" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_BalloonPaymentMember" xlink:label="sxtp_BalloonPaymentMember" xlink:title="sxtp_BalloonPaymentMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="sxtp_BalloonPaymentMember" xlink:title="Definition : us-gaap_DebtInstrumentNameDomain to sxtp_BalloonPaymentMember" xlink:type="arc" use="optional" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_SBAMember" xlink:label="sxtp_SBAMember" xlink:title="sxtp_SBAMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="sxtp_SBAMember" xlink:title="Definition : us-gaap_DebtInstrumentNameDomain to sxtp_SBAMember" xlink:type="arc" use="optional" order="2" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_1" xlink:title="us-gaap_DebtInstrumentNameDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain_1" xlink:title="Definition : us-gaap_DebtInstrumentAxis to us-gaap_DebtInstrumentNameDomain" xlink:type="arc" use="optional" order="1" xbrldt:closed="false" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://60degreespharma.com/role/DERIVATIVELIABILITIESDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems" xlink:label="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems" xlink:title="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1" xlink:title="us-gaap_ConversionOfStockSharesConverted1" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" xlink:title="Definition : us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems to us-gaap_ConversionOfStockSharesConverted1" xlink:type="arc" use="optional" order="0" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction" xlink:label="us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction" xlink:title="us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems" xlink:to="us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction" xlink:title="Definition : us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems to us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction" xlink:type="arc" use="optional" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ExcessStockSharesAuthorized" xlink:label="us-gaap_ExcessStockSharesAuthorized" xlink:title="us-gaap_ExcessStockSharesAuthorized" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems" xlink:to="us-gaap_ExcessStockSharesAuthorized" xlink:title="Definition : us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems to us-gaap_ExcessStockSharesAuthorized" xlink:type="arc" use="optional" order="2" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_MilestonePayment" xlink:label="sxtp_MilestonePayment" xlink:title="sxtp_MilestonePayment" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems" xlink:to="sxtp_MilestonePayment" xlink:title="Definition : us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems to sxtp_MilestonePayment" xlink:type="arc" use="optional" order="3" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockRedemptionTerms" xlink:label="us-gaap_PreferredStockRedemptionTerms" xlink:title="us-gaap_PreferredStockRedemptionTerms" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems" xlink:to="us-gaap_PreferredStockRedemptionTerms" xlink:title="Definition : us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems to us-gaap_PreferredStockRedemptionTerms" xlink:type="arc" use="optional" order="4" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_RoyaltyPercentage" xlink:label="sxtp_RoyaltyPercentage" xlink:title="sxtp_RoyaltyPercentage" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems" xlink:to="sxtp_RoyaltyPercentage" xlink:title="Definition : us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems to sxtp_RoyaltyPercentage" xlink:type="arc" use="optional" order="5" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet" xlink:title="us-gaap_DerivativeGainLossOnDerivativeNet" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet" xlink:title="Definition : us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems to us-gaap_DerivativeGainLossOnDerivativeNet" xlink:type="arc" use="optional" order="6" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_DerivativeLiabilitiesDetailsTable" xlink:label="sxtp_DerivativeLiabilitiesDetailsTable" xlink:title="sxtp_DerivativeLiabilitiesDetailsTable" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems" xlink:to="sxtp_DerivativeLiabilitiesDetailsTable" xlink:title="Definition : us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems to sxtp_DerivativeLiabilitiesDetailsTable" xlink:type="arc" use="optional" order="7" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:title="us-gaap_StatementClassOfStockAxis" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sxtp_DerivativeLiabilitiesDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" xlink:title="Definition : sxtp_DerivativeLiabilitiesDetailsTable to us-gaap_StatementClassOfStockAxis" xlink:type="arc" use="optional" order="0" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xlink:title="us-gaap_ClassOfStockDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" xlink:title="Definition : us-gaap_StatementClassOfStockAxis to us-gaap_ClassOfStockDomain" xlink:type="arc" use="optional" order="0" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_SeriesANonVotingConvertiblePreferredStockMember" xlink:label="sxtp_SeriesANonVotingConvertiblePreferredStockMember" xlink:title="sxtp_SeriesANonVotingConvertiblePreferredStockMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="sxtp_SeriesANonVotingConvertiblePreferredStockMember" xlink:title="Definition : us-gaap_ClassOfStockDomain to sxtp_SeriesANonVotingConvertiblePreferredStockMember" xlink:type="arc" use="optional" order="0" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_1" xlink:title="us-gaap_ClassOfStockDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_1" xlink:title="Definition : us-gaap_StatementClassOfStockAxis to us-gaap_ClassOfStockDomain" xlink:type="arc" use="optional" order="1" xbrldt:closed="false" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://60degreespharma.com/role/SHAREBASEDCOMPENSATIONScheduleofShareBasedCompensationExpensesDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:title="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:title="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" xlink:title="Definition : us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems to us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" use="optional" order="0" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:title="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:title="Definition : us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems to us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" use="optional" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:title="us-gaap_IncomeStatementLocationAxis" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" xlink:title="Definition : us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable to us-gaap_IncomeStatementLocationAxis" xlink:type="arc" use="optional" order="0" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:title="us-gaap_IncomeStatementLocationDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" xlink:title="Definition : us-gaap_IncomeStatementLocationAxis to us-gaap_IncomeStatementLocationDomain" xlink:type="arc" use="optional" order="0" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:title="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:title="Definition : us-gaap_IncomeStatementLocationDomain to us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" use="optional" order="0" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:title="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:title="Definition : us-gaap_IncomeStatementLocationDomain to us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" use="optional" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_1" xlink:title="us-gaap_IncomeStatementLocationDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_1" xlink:title="Definition : us-gaap_IncomeStatementLocationAxis to us-gaap_IncomeStatementLocationDomain" xlink:type="arc" use="optional" order="1" xbrldt:closed="false" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://60degreespharma.com/role/DERIVATIVELIABILITIESScheduleofDerivativeLiabilitiesMeasuredatFairValueonaRecurringBasisDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:title="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="us-gaap_DerivativeLiabilitiesCurrent" xlink:title="us-gaap_DerivativeLiabilitiesCurrent" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_DerivativeLiabilitiesCurrent" xlink:title="Definition : us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems to us-gaap_DerivativeLiabilitiesCurrent" xlink:type="arc" use="optional" order="0" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisMarkToMarketAdjustment" xlink:label="sxtp_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisMarkToMarketAdjustment" xlink:title="sxtp_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisMarkToMarketAdjustment" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="sxtp_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisMarkToMarketAdjustment" xlink:title="Definition : us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems to sxtp_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisMarkToMarketAdjustment" xlink:type="arc" use="optional" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_DerivativeLiabilitiesScheduleofDerivativeLiabilitiesMeasuredatFairValueonaRecurringBasisDetailsTable" xlink:label="sxtp_DerivativeLiabilitiesScheduleofDerivativeLiabilitiesMeasuredatFairValueonaRecurringBasisDetailsTable" xlink:title="sxtp_DerivativeLiabilitiesScheduleofDerivativeLiabilitiesMeasuredatFairValueonaRecurringBasisDetailsTable" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="sxtp_DerivativeLiabilitiesScheduleofDerivativeLiabilitiesMeasuredatFairValueonaRecurringBasisDetailsTable" xlink:title="Definition : us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems to sxtp_DerivativeLiabilitiesScheduleofDerivativeLiabilitiesMeasuredatFairValueonaRecurringBasisDetailsTable" xlink:type="arc" order="3" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:title="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sxtp_DerivativeLiabilitiesScheduleofDerivativeLiabilitiesMeasuredatFairValueonaRecurringBasisDetailsTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:title="Definition : sxtp_DerivativeLiabilitiesScheduleofDerivativeLiabilitiesMeasuredatFairValueonaRecurringBasisDetailsTable to us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" use="optional" order="0" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" xlink:title="us-gaap_FairValueMeasurementFrequencyDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" xlink:title="Definition : us-gaap_FairValueByMeasurementFrequencyAxis to us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" use="optional" order="0" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" xlink:title="us-gaap_FairValueMeasurementsRecurringMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" xlink:title="Definition : us-gaap_FairValueMeasurementFrequencyDomain to us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" use="optional" order="0" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_1" xlink:title="us-gaap_FairValueMeasurementFrequencyDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_1" xlink:title="Definition : us-gaap_FairValueByMeasurementFrequencyAxis to us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:title="us-gaap_DerivativeInstrumentRiskAxis" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sxtp_DerivativeLiabilitiesScheduleofDerivativeLiabilitiesMeasuredatFairValueonaRecurringBasisDetailsTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" xlink:title="Definition : sxtp_DerivativeLiabilitiesScheduleofDerivativeLiabilitiesMeasuredatFairValueonaRecurringBasisDetailsTable to us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc" use="optional" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain" xlink:title="us-gaap_DerivativeContractTypeDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain" xlink:title="Definition : us-gaap_DerivativeInstrumentRiskAxis to us-gaap_DerivativeContractTypeDomain" xlink:type="arc" use="optional" order="0" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_ContingentMilestonePaymentMember" xlink:label="sxtp_ContingentMilestonePaymentMember" xlink:title="sxtp_ContingentMilestonePaymentMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="sxtp_ContingentMilestonePaymentMember" xlink:title="Definition : us-gaap_DerivativeContractTypeDomain to sxtp_ContingentMilestonePaymentMember" xlink:type="arc" use="optional" order="0" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_BridgeSharesMember" xlink:label="sxtp_BridgeSharesMember" xlink:title="sxtp_BridgeSharesMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="sxtp_BridgeSharesMember" xlink:title="Definition : us-gaap_DerivativeContractTypeDomain to sxtp_BridgeSharesMember" xlink:type="arc" use="optional" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" xlink:title="us-gaap_WarrantMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="us-gaap_WarrantMember" xlink:title="Definition : us-gaap_DerivativeContractTypeDomain to us-gaap_WarrantMember" xlink:type="arc" use="optional" order="2" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain_1" xlink:title="us-gaap_DerivativeContractTypeDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain_1" xlink:title="Definition : us-gaap_DerivativeInstrumentRiskAxis to us-gaap_DerivativeContractTypeDomain" xlink:type="arc" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:title="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sxtp_DerivativeLiabilitiesScheduleofDerivativeLiabilitiesMeasuredatFairValueonaRecurringBasisDetailsTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:title="Definition : sxtp_DerivativeLiabilitiesScheduleofDerivativeLiabilitiesMeasuredatFairValueonaRecurringBasisDetailsTable to us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" use="optional" order="2" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:title="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:title="Definition : us-gaap_FairValueByFairValueHierarchyLevelAxis to us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" use="optional" order="0" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" xlink:title="us-gaap_FairValueInputsLevel3Member" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" xlink:title="Definition : us-gaap_FairValueMeasurementsFairValueHierarchyDomain to us-gaap_FairValueInputsLevel3Member" xlink:type="arc" use="optional" order="0" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" xlink:title="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" xlink:title="Definition : us-gaap_FairValueByFairValueHierarchyLevelAxis to us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1" xbrldt:closed="false" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://60degreespharma.com/role/COMMITMENTSANDCONTINGENCIESDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="us-gaap_OtherCommitmentsLineItems" xlink:title="us-gaap_OtherCommitmentsLineItems" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_NumberOfDirectors" xlink:label="sxtp_NumberOfDirectors" xlink:title="sxtp_NumberOfDirectors" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="sxtp_NumberOfDirectors" xlink:title="Definition : us-gaap_OtherCommitmentsLineItems to sxtp_NumberOfDirectors" xlink:type="arc" order="0" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" xlink:title="Definition : us-gaap_OtherCommitmentsLineItems to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" xlink:type="arc" use="optional" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingencyPendingClaimsNumber" xlink:label="us-gaap_LossContingencyPendingClaimsNumber" xlink:title="us-gaap_LossContingencyPendingClaimsNumber" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_LossContingencyPendingClaimsNumber" xlink:title="Definition : us-gaap_OtherCommitmentsLineItems to us-gaap_LossContingencyPendingClaimsNumber" xlink:type="arc" use="optional" order="2" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:title="us-gaap_LesseeOperatingLeaseRenewalTerm" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:title="Definition : us-gaap_OtherCommitmentsLineItems to us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="arc" use="optional" order="3" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost" xlink:title="us-gaap_OperatingLeaseCost" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OperatingLeaseCost" xlink:title="Definition : us-gaap_OtherCommitmentsLineItems to us-gaap_OperatingLeaseCost" xlink:type="arc" use="optional" order="4" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CompensationAndBenefitsTrust" xlink:label="us-gaap_CompensationAndBenefitsTrust" xlink:title="us-gaap_CompensationAndBenefitsTrust" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_CompensationAndBenefitsTrust" xlink:title="Definition : us-gaap_OtherCommitmentsLineItems to us-gaap_CompensationAndBenefitsTrust" xlink:type="arc" use="optional" order="5" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_NumberOfNonAuditCommitteeChairs" xlink:label="sxtp_NumberOfNonAuditCommitteeChairs" xlink:title="sxtp_NumberOfNonAuditCommitteeChairs" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="sxtp_NumberOfNonAuditCommitteeChairs" xlink:title="Definition : us-gaap_OtherCommitmentsLineItems to sxtp_NumberOfNonAuditCommitteeChairs" xlink:type="arc" use="optional" order="6" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:title="us-gaap_BusinessCombinationContingentConsiderationLiability" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:title="Definition : us-gaap_OtherCommitmentsLineItems to us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="arc" use="optional" order="7" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_LicensedTechnologyTerm" xlink:label="sxtp_LicensedTechnologyTerm" xlink:title="sxtp_LicensedTechnologyTerm" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="sxtp_LicensedTechnologyTerm" xlink:title="Definition : us-gaap_OtherCommitmentsLineItems to sxtp_LicensedTechnologyTerm" xlink:type="arc" use="optional" order="8" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_AnnualRoyaltyPaymentPercentage" xlink:label="sxtp_AnnualRoyaltyPaymentPercentage" xlink:title="sxtp_AnnualRoyaltyPaymentPercentage" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="sxtp_AnnualRoyaltyPaymentPercentage" xlink:title="Definition : us-gaap_OtherCommitmentsLineItems to sxtp_AnnualRoyaltyPaymentPercentage" xlink:type="arc" use="optional" order="9" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RoyaltyExpense" xlink:label="us-gaap_RoyaltyExpense" xlink:title="us-gaap_RoyaltyExpense" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_RoyaltyExpense" xlink:title="Definition : us-gaap_OtherCommitmentsLineItems to us-gaap_RoyaltyExpense" xlink:type="arc" use="optional" order="10" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_PercentageOfRoyaltyPaymentsOfNetSales" xlink:label="sxtp_PercentageOfRoyaltyPaymentsOfNetSales" xlink:title="sxtp_PercentageOfRoyaltyPaymentsOfNetSales" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="sxtp_PercentageOfRoyaltyPaymentsOfNetSales" xlink:title="Definition : us-gaap_OtherCommitmentsLineItems to sxtp_PercentageOfRoyaltyPaymentsOfNetSales" xlink:type="arc" use="optional" order="11" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_PercentageOfTreatmentOfBabesiosis" xlink:label="sxtp_PercentageOfTreatmentOfBabesiosis" xlink:title="sxtp_PercentageOfTreatmentOfBabesiosis" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="sxtp_PercentageOfTreatmentOfBabesiosis" xlink:title="Definition : us-gaap_OtherCommitmentsLineItems to sxtp_PercentageOfTreatmentOfBabesiosis" xlink:type="arc" use="optional" order="12" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueRemainingPerformanceObligationPercentage" xlink:label="us-gaap_RevenueRemainingPerformanceObligationPercentage" xlink:title="us-gaap_RevenueRemainingPerformanceObligationPercentage" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligationPercentage" xlink:title="Definition : us-gaap_OtherCommitmentsLineItems to us-gaap_RevenueRemainingPerformanceObligationPercentage" xlink:type="arc" use="optional" order="13" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_CommitmentsandContingenciesDetailsTable" xlink:label="sxtp_CommitmentsandContingenciesDetailsTable" xlink:title="sxtp_CommitmentsandContingenciesDetailsTable" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="sxtp_CommitmentsandContingenciesDetailsTable" xlink:title="Definition : us-gaap_OtherCommitmentsLineItems to sxtp_CommitmentsandContingenciesDetailsTable" xlink:type="arc" order="14" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:title="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sxtp_CommitmentsandContingenciesDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:title="Definition : sxtp_CommitmentsandContingenciesDetailsTable to us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" use="optional" order="0" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:title="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:title="Definition : us-gaap_SubsidiarySaleOfStockAxis to us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" use="optional" order="0" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember" xlink:title="us-gaap_IPOMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" xlink:title="Definition : us-gaap_SaleOfStockNameOfTransactionDomain to us-gaap_IPOMember" xlink:type="arc" use="optional" order="0" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_1" xlink:title="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_1" xlink:title="Definition : us-gaap_SubsidiarySaleOfStockAxis to us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:title="srt_RangeAxis" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sxtp_CommitmentsandContingenciesDetailsTable" xlink:to="srt_RangeAxis" xlink:title="Definition : sxtp_CommitmentsandContingenciesDetailsTable to srt_RangeAxis" xlink:type="arc" use="optional" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:title="srt_RangeMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:title="Definition : srt_RangeAxis to srt_RangeMember" xlink:type="arc" use="optional" order="0" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:title="srt_MinimumMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" xlink:title="Definition : srt_RangeMember to srt_MinimumMember" xlink:type="arc" use="optional" order="0" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:title="srt_MaximumMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" xlink:title="Definition : srt_RangeMember to srt_MaximumMember" xlink:type="arc" use="optional" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember_1" xlink:title="srt_RangeMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_1" xlink:title="Definition : srt_RangeAxis to srt_RangeMember" xlink:type="arc" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" xlink:title="srt_TitleOfIndividualAxis" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sxtp_CommitmentsandContingenciesDetailsTable" xlink:to="srt_TitleOfIndividualAxis" xlink:title="Definition : sxtp_CommitmentsandContingenciesDetailsTable to srt_TitleOfIndividualAxis" xlink:type="arc" use="optional" order="2" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="Definition : srt_TitleOfIndividualAxis to srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" use="optional" order="0" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_BoardOfDirectorsChairmanMember" xlink:label="srt_BoardOfDirectorsChairmanMember" xlink:title="srt_BoardOfDirectorsChairmanMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_BoardOfDirectorsChairmanMember" xlink:title="Definition : srt_TitleOfIndividualWithRelationshipToEntityDomain to srt_BoardOfDirectorsChairmanMember" xlink:type="arc" use="optional" order="0" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember" xlink:title="srt_DirectorMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_DirectorMember" xlink:title="Definition : srt_TitleOfIndividualWithRelationshipToEntityDomain to srt_DirectorMember" xlink:type="arc" use="optional" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_1" xlink:title="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_1" xlink:title="Definition : srt_TitleOfIndividualAxis to srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:title="us-gaap_RelatedPartyTransactionAxis" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sxtp_CommitmentsandContingenciesDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" xlink:title="Definition : sxtp_CommitmentsandContingenciesDetailsTable to us-gaap_RelatedPartyTransactionAxis" xlink:type="arc" use="optional" order="3" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:title="us-gaap_RelatedPartyTransactionDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" xlink:title="Definition : us-gaap_RelatedPartyTransactionAxis to us-gaap_RelatedPartyTransactionDomain" xlink:type="arc" use="optional" order="0" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_CherylXuMember" xlink:label="sxtp_CherylXuMember" xlink:title="sxtp_CherylXuMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="sxtp_CherylXuMember" xlink:title="Definition : us-gaap_RelatedPartyTransactionDomain to sxtp_CherylXuMember" xlink:type="arc" use="optional" order="0" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_PaulFieldMember" xlink:label="sxtp_PaulFieldMember" xlink:title="sxtp_PaulFieldMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="sxtp_PaulFieldMember" xlink:title="Definition : us-gaap_RelatedPartyTransactionDomain to sxtp_PaulFieldMember" xlink:type="arc" use="optional" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_CharlesAllenMember" xlink:label="sxtp_CharlesAllenMember" xlink:title="sxtp_CharlesAllenMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="sxtp_CharlesAllenMember" xlink:title="Definition : us-gaap_RelatedPartyTransactionDomain to sxtp_CharlesAllenMember" xlink:type="arc" use="optional" order="2" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_StephenTooveyMember" xlink:label="sxtp_StephenTooveyMember" xlink:title="sxtp_StephenTooveyMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="sxtp_StephenTooveyMember" xlink:title="Definition : us-gaap_RelatedPartyTransactionDomain to sxtp_StephenTooveyMember" xlink:type="arc" use="optional" order="3" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_USGovernmentSalesMember" xlink:label="sxtp_USGovernmentSalesMember" xlink:title="sxtp_USGovernmentSalesMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="sxtp_USGovernmentSalesMember" xlink:title="Definition : us-gaap_RelatedPartyTransactionDomain to sxtp_USGovernmentSalesMember" xlink:type="arc" use="optional" order="4" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_USArmyAgreementMember" xlink:label="sxtp_USArmyAgreementMember" xlink:title="sxtp_USArmyAgreementMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="sxtp_USArmyAgreementMember" xlink:title="Definition : us-gaap_RelatedPartyTransactionDomain to sxtp_USArmyAgreementMember" xlink:type="arc" use="optional" order="5" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_TuftsMedicalCenterAgreementMember" xlink:label="sxtp_TuftsMedicalCenterAgreementMember" xlink:title="sxtp_TuftsMedicalCenterAgreementMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="sxtp_TuftsMedicalCenterAgreementMember" xlink:title="Definition : us-gaap_RelatedPartyTransactionDomain to sxtp_TuftsMedicalCenterAgreementMember" xlink:type="arc" order="6" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain_1" xlink:title="us-gaap_RelatedPartyTransactionDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain_1" xlink:title="Definition : us-gaap_RelatedPartyTransactionAxis to us-gaap_RelatedPartyTransactionDomain" xlink:type="arc" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sxtp_CommitmentsandContingenciesDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="Definition : sxtp_CommitmentsandContingenciesDetailsTable to us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" use="optional" order="4" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" xlink:title="us-gaap_RelatedPartyDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" xlink:title="Definition : us-gaap_RelatedPartyTransactionsByRelatedPartyAxis to us-gaap_RelatedPartyDomain" xlink:type="arc" use="optional" order="0" xbrldt:closed="false" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="sxtp_CharlesAllenMember" xlink:title="Definition : us-gaap_RelatedPartyDomain to sxtp_CharlesAllenMember" xlink:type="arc" use="optional" order="0" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_1" xlink:title="us-gaap_RelatedPartyDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_1" xlink:title="Definition : us-gaap_RelatedPartyTransactionsByRelatedPartyAxis to us-gaap_RelatedPartyDomain" xlink:type="arc" order="1" xbrldt:closed="false" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://60degreespharma.com/role/SHAREBASEDCOMPENSATIONDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:title="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:title="Definition : us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" use="optional" order="0" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:title="Definition : us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems to us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" use="optional" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:title="Definition : us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems to us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="arc" use="optional" order="2" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:title="Definition : us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems to us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:type="arc" use="optional" order="3" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:title="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:title="Definition : us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems to us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:type="arc" use="optional" order="4" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:title="Definition : us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems to us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:type="arc" use="optional" order="5" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:title="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" xlink:title="Definition : us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems to us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" use="optional" order="6" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash" xlink:title="us-gaap_Cash" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_Cash" xlink:title="Definition : us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems to us-gaap_Cash" xlink:type="arc" use="optional" order="7" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_SharesIssuedPayrollTaxesWithholdings" xlink:label="sxtp_SharesIssuedPayrollTaxesWithholdings" xlink:title="sxtp_SharesIssuedPayrollTaxesWithholdings" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="sxtp_SharesIssuedPayrollTaxesWithholdings" xlink:title="Definition : us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems to sxtp_SharesIssuedPayrollTaxesWithholdings" xlink:type="arc" use="optional" order="8" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_UnamortizedBalance" xlink:label="sxtp_UnamortizedBalance" xlink:title="sxtp_UnamortizedBalance" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="sxtp_UnamortizedBalance" xlink:title="Definition : us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems to sxtp_UnamortizedBalance" xlink:type="arc" use="optional" order="9" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseNoncurrent" xlink:label="us-gaap_PrepaidExpenseNoncurrent" xlink:title="us-gaap_PrepaidExpenseNoncurrent" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_PrepaidExpenseNoncurrent" xlink:title="Definition : us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems to us-gaap_PrepaidExpenseNoncurrent" xlink:type="arc" use="optional" order="10" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_NumberOfExecutives" xlink:label="sxtp_NumberOfExecutives" xlink:title="sxtp_NumberOfExecutives" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="sxtp_NumberOfExecutives" xlink:title="Definition : us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems to sxtp_NumberOfExecutives" xlink:type="arc" order="11" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="Definition : us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" use="optional" order="12" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" xlink:title="Definition : us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" xlink:type="arc" use="optional" order="13" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_StockIssuedDuringPeriodIssuanceOfSharesForAnnualPerformanceBonusesNetOfSharesWithheldForTaxesinShares" xlink:label="sxtp_StockIssuedDuringPeriodIssuanceOfSharesForAnnualPerformanceBonusesNetOfSharesWithheldForTaxesinShares" xlink:title="sxtp_StockIssuedDuringPeriodIssuanceOfSharesForAnnualPerformanceBonusesNetOfSharesWithheldForTaxesinShares" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="sxtp_StockIssuedDuringPeriodIssuanceOfSharesForAnnualPerformanceBonusesNetOfSharesWithheldForTaxesinShares" xlink:title="Definition : us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems to sxtp_StockIssuedDuringPeriodIssuanceOfSharesForAnnualPerformanceBonusesNetOfSharesWithheldForTaxesinShares" xlink:type="arc" use="optional" order="14" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_ShareBasedCompensationDetailsTable" xlink:label="sxtp_ShareBasedCompensationDetailsTable" xlink:title="sxtp_ShareBasedCompensationDetailsTable" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="sxtp_ShareBasedCompensationDetailsTable" xlink:title="Definition : us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems to sxtp_ShareBasedCompensationDetailsTable" xlink:type="arc" order="15" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:title="us-gaap_PlanNameAxis" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sxtp_ShareBasedCompensationDetailsTable" xlink:to="us-gaap_PlanNameAxis" xlink:title="Definition : sxtp_ShareBasedCompensationDetailsTable to us-gaap_PlanNameAxis" xlink:type="arc" use="optional" order="0" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:title="us-gaap_PlanNameDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:title="Definition : us-gaap_PlanNameAxis to us-gaap_PlanNameDomain" xlink:type="arc" use="optional" order="0" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_TwoThousandTwentyTwoEquityIncentivePlanMember" xlink:label="sxtp_TwoThousandTwentyTwoEquityIncentivePlanMember" xlink:title="sxtp_TwoThousandTwentyTwoEquityIncentivePlanMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="sxtp_TwoThousandTwentyTwoEquityIncentivePlanMember" xlink:title="Definition : us-gaap_PlanNameDomain to sxtp_TwoThousandTwentyTwoEquityIncentivePlanMember" xlink:type="arc" use="optional" order="0" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_1" xlink:title="us-gaap_PlanNameDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_1" xlink:title="Definition : us-gaap_PlanNameAxis to us-gaap_PlanNameDomain" xlink:type="arc" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:title="us-gaap_StatementEquityComponentsAxis" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sxtp_ShareBasedCompensationDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" xlink:title="Definition : sxtp_ShareBasedCompensationDetailsTable to us-gaap_StatementEquityComponentsAxis" xlink:type="arc" use="optional" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:title="us-gaap_EquityComponentDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" xlink:title="Definition : us-gaap_StatementEquityComponentsAxis to us-gaap_EquityComponentDomain" xlink:type="arc" use="optional" order="0" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:title="us-gaap_CommonStockMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" xlink:title="Definition : us-gaap_EquityComponentDomain to us-gaap_CommonStockMember" xlink:type="arc" use="optional" order="0" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_1" xlink:title="us-gaap_EquityComponentDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_1" xlink:title="Definition : us-gaap_StatementEquityComponentsAxis to us-gaap_EquityComponentDomain" xlink:type="arc" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:title="us-gaap_StatementClassOfStockAxis" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sxtp_ShareBasedCompensationDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" xlink:title="Definition : sxtp_ShareBasedCompensationDetailsTable to us-gaap_StatementClassOfStockAxis" xlink:type="arc" use="optional" order="2" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xlink:title="us-gaap_ClassOfStockDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" xlink:title="Definition : us-gaap_StatementClassOfStockAxis to us-gaap_ClassOfStockDomain" xlink:type="arc" use="optional" order="0" xbrldt:closed="false" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonStockMember" xlink:title="Definition : us-gaap_ClassOfStockDomain to us-gaap_CommonStockMember" xlink:type="arc" use="optional" order="0" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_1" xlink:title="us-gaap_ClassOfStockDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_1" xlink:title="Definition : us-gaap_StatementClassOfStockAxis to us-gaap_ClassOfStockDomain" xlink:type="arc" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" xlink:title="us-gaap_VestingAxis" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sxtp_ShareBasedCompensationDetailsTable" xlink:to="us-gaap_VestingAxis" xlink:title="Definition : sxtp_ShareBasedCompensationDetailsTable to us-gaap_VestingAxis" xlink:type="arc" use="optional" order="3" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" xlink:title="us-gaap_VestingDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" xlink:title="Definition : us-gaap_VestingAxis to us-gaap_VestingDomain" xlink:type="arc" use="optional" order="0" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:title="us-gaap_ShareBasedCompensationAwardTrancheOneMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:title="Definition : us-gaap_VestingDomain to us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="arc" use="optional" order="0" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain_1" xlink:title="us-gaap_VestingDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain_1" xlink:title="Definition : us-gaap_VestingAxis to us-gaap_VestingDomain" xlink:type="arc" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:title="us-gaap_AwardTypeAxis" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sxtp_ShareBasedCompensationDetailsTable" xlink:to="us-gaap_AwardTypeAxis" xlink:title="Definition : sxtp_ShareBasedCompensationDetailsTable to us-gaap_AwardTypeAxis" xlink:type="arc" use="optional" order="4" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="Definition : us-gaap_AwardTypeAxis to us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" use="optional" order="0" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_StockOptionsMember" xlink:label="sxtp_StockOptionsMember" xlink:title="sxtp_StockOptionsMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="sxtp_StockOptionsMember" xlink:title="Definition : us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to sxtp_StockOptionsMember" xlink:type="arc" use="optional" order="0" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:title="us-gaap_RestrictedStockUnitsRSUMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" xlink:title="Definition : us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" use="optional" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" xlink:title="Definition : us-gaap_AwardTypeAxis to us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1" xbrldt:closed="false" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://60degreespharma.com/role/SUBSEQUENTEVENTSDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" xlink:title="us-gaap_SubsequentEventLineItems" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_NumberOfDirectors" xlink:label="sxtp_NumberOfDirectors" xlink:title="sxtp_NumberOfDirectors" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="sxtp_NumberOfDirectors" xlink:title="Definition : us-gaap_SubsequentEventLineItems to sxtp_NumberOfDirectors" xlink:type="arc" order="0" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:title="Definition : us-gaap_SubsequentEventLineItems to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" use="optional" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" xlink:title="us-gaap_StockholdersEquityReverseStockSplit" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" xlink:title="Definition : us-gaap_SubsequentEventLineItems to us-gaap_StockholdersEquityReverseStockSplit" xlink:type="arc" use="optional" order="2" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_ProceedsFromCommonStockSalesAgreementNet" xlink:label="sxtp_ProceedsFromCommonStockSalesAgreementNet" xlink:title="sxtp_ProceedsFromCommonStockSalesAgreementNet" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="sxtp_ProceedsFromCommonStockSalesAgreementNet" xlink:title="Definition : us-gaap_SubsequentEventLineItems to sxtp_ProceedsFromCommonStockSalesAgreementNet" xlink:type="arc" order="3" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_CommonStockSalesAgreementWeightedAveragePricePerShare" xlink:label="sxtp_CommonStockSalesAgreementWeightedAveragePricePerShare" xlink:title="sxtp_CommonStockSalesAgreementWeightedAveragePricePerShare" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="sxtp_CommonStockSalesAgreementWeightedAveragePricePerShare" xlink:title="Definition : us-gaap_SubsequentEventLineItems to sxtp_CommonStockSalesAgreementWeightedAveragePricePerShare" xlink:type="arc" order="4" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_ATMOfferingShares" xlink:label="sxtp_ATMOfferingShares" xlink:title="sxtp_ATMOfferingShares" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="sxtp_ATMOfferingShares" xlink:title="Definition : us-gaap_SubsequentEventLineItems to sxtp_ATMOfferingShares" xlink:type="arc" order="5" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:title="Definition : us-gaap_SubsequentEventLineItems to us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" use="optional" order="6" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:title="Definition : us-gaap_SubsequentEventLineItems to us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" use="optional" order="7" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="Definition : us-gaap_SubsequentEventLineItems to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" use="optional" order="8" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" xlink:title="us-gaap_SubsequentEventTable" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventTable" xlink:title="Definition : us-gaap_SubsequentEventLineItems to us-gaap_SubsequentEventTable" xlink:type="arc" order="9" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:title="us-gaap_SubsequentEventTypeAxis" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:title="Definition : us-gaap_SubsequentEventTable to us-gaap_SubsequentEventTypeAxis" xlink:type="arc" use="optional" order="0" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:title="us-gaap_SubsequentEventTypeDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:title="Definition : us-gaap_SubsequentEventTypeAxis to us-gaap_SubsequentEventTypeDomain" xlink:type="arc" use="optional" order="0" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:title="us-gaap_SubsequentEventMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" xlink:title="Definition : us-gaap_SubsequentEventTypeDomain to us-gaap_SubsequentEventMember" xlink:type="arc" use="optional" order="0" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_1" xlink:title="us-gaap_SubsequentEventTypeDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_1" xlink:title="Definition : us-gaap_SubsequentEventTypeAxis to us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:title="srt_RangeAxis" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="srt_RangeAxis" xlink:title="Definition : us-gaap_SubsequentEventTable to srt_RangeAxis" xlink:type="arc" use="optional" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:title="srt_RangeMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:title="Definition : srt_RangeAxis to srt_RangeMember" xlink:type="arc" use="optional" order="0" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:title="srt_MaximumMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" xlink:title="Definition : srt_RangeMember to srt_MaximumMember" xlink:type="arc" use="optional" order="0" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember_1" xlink:title="srt_RangeMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_1" xlink:title="Definition : srt_RangeAxis to srt_RangeMember" xlink:type="arc" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" xlink:title="srt_TitleOfIndividualAxis" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="srt_TitleOfIndividualAxis" xlink:title="Definition : us-gaap_SubsequentEventTable to srt_TitleOfIndividualAxis" xlink:type="arc" use="optional" order="2" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="Definition : srt_TitleOfIndividualAxis to srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" use="optional" order="0" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember" xlink:title="srt_DirectorMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_DirectorMember" xlink:title="Definition : srt_TitleOfIndividualWithRelationshipToEntityDomain to srt_DirectorMember" xlink:type="arc" use="optional" order="0" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_DirectorOneMember" xlink:label="sxtp_DirectorOneMember" xlink:title="sxtp_DirectorOneMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="sxtp_DirectorOneMember" xlink:title="Definition : srt_TitleOfIndividualWithRelationshipToEntityDomain to sxtp_DirectorOneMember" xlink:type="arc" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_1" xlink:title="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_1" xlink:title="Definition : srt_TitleOfIndividualAxis to srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" use="optional" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:title="us-gaap_AwardTypeAxis" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_AwardTypeAxis" xlink:title="Definition : us-gaap_SubsequentEventTable to us-gaap_AwardTypeAxis" xlink:type="arc" use="optional" order="3" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="Definition : us-gaap_AwardTypeAxis to us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" use="optional" order="0" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_StockOptionsMember" xlink:label="sxtp_StockOptionsMember" xlink:title="sxtp_StockOptionsMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="sxtp_StockOptionsMember" xlink:title="Definition : us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to sxtp_StockOptionsMember" xlink:type="arc" order="0" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" xlink:title="Definition : us-gaap_AwardTypeAxis to us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" use="optional" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardDateAxis" xlink:label="us-gaap_AwardDateAxis" xlink:title="us-gaap_AwardDateAxis" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_AwardDateAxis" xlink:title="Definition : us-gaap_SubsequentEventTable to us-gaap_AwardDateAxis" xlink:type="arc" use="optional" order="4" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardDateDomain" xlink:label="us-gaap_AwardDateDomain" xlink:title="us-gaap_AwardDateDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateDomain" xlink:title="Definition : us-gaap_AwardDateAxis to us-gaap_AwardDateDomain" xlink:type="arc" use="optional" order="0" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_AtTheMarket2025AgreementMember" xlink:label="sxtp_AtTheMarket2025AgreementMember" xlink:title="sxtp_AtTheMarket2025AgreementMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AwardDateDomain" xlink:to="sxtp_AtTheMarket2025AgreementMember" xlink:title="Definition : us-gaap_AwardDateDomain to sxtp_AtTheMarket2025AgreementMember" xlink:type="arc" order="0" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardDateDomain" xlink:label="us-gaap_AwardDateDomain_1" xlink:title="us-gaap_AwardDateDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateDomain_1" xlink:title="Definition : us-gaap_AwardDateAxis to us-gaap_AwardDateDomain" xlink:type="arc" use="optional" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:title="us-gaap_RelatedPartyTransactionAxis" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" xlink:title="Definition : us-gaap_SubsequentEventTable to us-gaap_RelatedPartyTransactionAxis" xlink:type="arc" use="optional" order="5" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:title="us-gaap_RelatedPartyTransactionDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" xlink:title="Definition : us-gaap_RelatedPartyTransactionAxis to us-gaap_RelatedPartyTransactionDomain" xlink:type="arc" use="optional" order="0" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_HCWainwrightAndCoLLCMember" xlink:label="sxtp_HCWainwrightAndCoLLCMember" xlink:title="sxtp_HCWainwrightAndCoLLCMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="sxtp_HCWainwrightAndCoLLCMember" xlink:title="Definition : us-gaap_RelatedPartyTransactionDomain to sxtp_HCWainwrightAndCoLLCMember" xlink:type="arc" order="0" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain_1" xlink:title="us-gaap_RelatedPartyTransactionDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain_1" xlink:title="Definition : us-gaap_RelatedPartyTransactionAxis to us-gaap_RelatedPartyTransactionDomain" xlink:type="arc" use="optional" order="1" xbrldt:closed="false" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://60degreespharma.com/role/STOCKHOLDERSEQUITYScheduleofEquityClassifiedWarrantsDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" xlink:title="us-gaap_ClassOfWarrantOrRightLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:title="Definition : us-gaap_ClassOfWarrantOrRightLineItems to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" use="optional" order="0" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:title="Definition : us-gaap_ClassOfWarrantOrRightLineItems to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" use="optional" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:title="Definition : us-gaap_ClassOfWarrantOrRightLineItems to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:type="arc" use="optional" order="2" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:title="Definition : us-gaap_ClassOfWarrantOrRightLineItems to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" use="optional" order="3" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:title="Definition : us-gaap_ClassOfWarrantOrRightLineItems to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" use="optional" order="4" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsGranted" xlink:label="sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsGranted" xlink:title="sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsGranted" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsGranted" xlink:title="Definition : us-gaap_ClassOfWarrantOrRightLineItems to sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsGranted" xlink:type="arc" use="optional" order="5" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfWarrantsExercised" xlink:label="sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfWarrantsExercised" xlink:title="sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfWarrantsExercised" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfWarrantsExercised" xlink:title="Definition : us-gaap_ClassOfWarrantOrRightLineItems to sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfWarrantsExercised" xlink:type="arc" use="optional" order="6" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExercised" xlink:label="sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExercised" xlink:title="sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExercised" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExercised" xlink:title="Definition : us-gaap_ClassOfWarrantOrRightLineItems to sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExercised" xlink:type="arc" use="optional" order="7" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsExercised" xlink:label="sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsExercised" xlink:title="sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsExercised" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsExercised" xlink:title="Definition : us-gaap_ClassOfWarrantOrRightLineItems to sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsExercised" xlink:type="arc" use="optional" order="8" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:title="Definition : us-gaap_ClassOfWarrantOrRightLineItems to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" use="optional" order="9" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:title="Definition : us-gaap_ClassOfWarrantOrRightLineItems to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" use="optional" order="10" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsForfeited" xlink:label="sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsForfeited" xlink:title="sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsForfeited" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsForfeited" xlink:title="Definition : us-gaap_ClassOfWarrantOrRightLineItems to sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsForfeited" xlink:type="arc" use="optional" order="11" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfWarrantsExpired" xlink:label="sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfWarrantsExpired" xlink:title="sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfWarrantsExpired" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfWarrantsExpired" xlink:title="Definition : us-gaap_ClassOfWarrantOrRightLineItems to sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfWarrantsExpired" xlink:type="arc" use="optional" order="12" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExpired" xlink:label="sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExpired" xlink:title="sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExpired" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExpired" xlink:title="Definition : us-gaap_ClassOfWarrantOrRightLineItems to sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExpired" xlink:type="arc" use="optional" order="13" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsExpired" xlink:label="sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsExpired" xlink:title="sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsExpired" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsExpired" xlink:title="Definition : us-gaap_ClassOfWarrantOrRightLineItems to sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsExpired" xlink:type="arc" use="optional" order="14" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms1" xlink:label="sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms1" xlink:title="sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms1" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms1" xlink:title="Definition : us-gaap_ClassOfWarrantOrRightLineItems to sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms1" xlink:type="arc" use="optional" order="17" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable" xlink:label="sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable" xlink:title="sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable" xlink:title="Definition : us-gaap_ClassOfWarrantOrRightLineItems to sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable" xlink:type="arc" use="optional" order="18" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageGrantDateFairValue" xlink:label="sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageGrantDateFairValue" xlink:title="sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageGrantDateFairValue" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageGrantDateFairValue" xlink:title="Definition : us-gaap_ClassOfWarrantOrRightLineItems to sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageGrantDateFairValue" xlink:type="arc" use="optional" order="19" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableOutstandingWeightedAverageRemainingContractualTerms" xlink:label="sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableOutstandingWeightedAverageRemainingContractualTerms" xlink:title="sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableOutstandingWeightedAverageRemainingContractualTerms" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableOutstandingWeightedAverageRemainingContractualTerms" xlink:title="Definition : us-gaap_ClassOfWarrantOrRightLineItems to sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableOutstandingWeightedAverageRemainingContractualTerms" xlink:type="arc" use="optional" order="20" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable" xlink:title="us-gaap_ClassOfWarrantOrRightTable" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightTable" xlink:title="Definition : us-gaap_ClassOfWarrantOrRightLineItems to us-gaap_ClassOfWarrantOrRightTable" xlink:type="arc" order="21" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:title="us-gaap_ClassOfWarrantOrRightAxis" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:title="Definition : us-gaap_ClassOfWarrantOrRightTable to us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc" use="optional" order="0" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:title="us-gaap_ClassOfWarrantOrRightDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:title="Definition : us-gaap_ClassOfWarrantOrRightAxis to us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc" use="optional" order="0" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" xlink:title="us-gaap_WarrantMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_WarrantMember" xlink:title="Definition : us-gaap_ClassOfWarrantOrRightDomain to us-gaap_WarrantMember" xlink:type="arc" use="optional" order="0" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_1" xlink:title="us-gaap_ClassOfWarrantOrRightDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_1" xlink:title="Definition : us-gaap_ClassOfWarrantOrRightAxis to us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc" order="1" xbrldt:closed="false" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://60degreespharma.com/role/STOCKHOLDERSEQUITYDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" xlink:title="us-gaap_ClassOfStockLineItems" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExercised" xlink:label="sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExercised" xlink:title="sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExercised" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExercised" xlink:title="Definition : us-gaap_ClassOfStockLineItems to sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExercised" xlink:type="arc" use="optional" order="0" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_StockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfPreFundedWarrantsinShares" xlink:label="sxtp_StockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfPreFundedWarrantsinShares" xlink:title="sxtp_StockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfPreFundedWarrantsinShares" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="sxtp_StockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfPreFundedWarrantsinShares" xlink:title="Definition : us-gaap_ClassOfStockLineItems to sxtp_StockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfPreFundedWarrantsinShares" xlink:type="arc" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable" xlink:label="sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable" xlink:title="sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable" xlink:title="Definition : us-gaap_ClassOfStockLineItems to sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable" xlink:type="arc" use="optional" order="2" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:title="Definition : us-gaap_ClassOfStockLineItems to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" use="optional" order="3" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:title="us-gaap_CommonStockSharesAuthorized" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" xlink:title="Definition : us-gaap_ClassOfStockLineItems to us-gaap_CommonStockSharesAuthorized" xlink:type="arc" use="optional" order="4" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:title="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" xlink:title="Definition : us-gaap_ClassOfStockLineItems to us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" use="optional" order="5" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:title="us-gaap_PreferredStockSharesAuthorized" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" xlink:title="Definition : us-gaap_ClassOfStockLineItems to us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" use="optional" order="6" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:title="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:title="Definition : us-gaap_ClassOfStockLineItems to us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" use="optional" order="7" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ExcessStockSharesAuthorized" xlink:label="us-gaap_ExcessStockSharesAuthorized" xlink:title="us-gaap_ExcessStockSharesAuthorized" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ExcessStockSharesAuthorized" xlink:title="Definition : us-gaap_ClassOfStockLineItems to us-gaap_ExcessStockSharesAuthorized" xlink:type="arc" use="optional" order="8" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xlink:title="us-gaap_CommonStockSharesIssued" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesIssued" xlink:title="Definition : us-gaap_ClassOfStockLineItems to us-gaap_CommonStockSharesIssued" xlink:type="arc" use="optional" order="9" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:title="us-gaap_CommonStockSharesOutstanding" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" xlink:title="Definition : us-gaap_ClassOfStockLineItems to us-gaap_CommonStockSharesOutstanding" xlink:type="arc" use="optional" order="10" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:title="us-gaap_PreferredStockSharesIssued" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" xlink:title="Definition : us-gaap_ClassOfStockLineItems to us-gaap_PreferredStockSharesIssued" xlink:type="arc" use="optional" order="11" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:title="us-gaap_PreferredStockSharesOutstanding" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" xlink:title="Definition : us-gaap_ClassOfStockLineItems to us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" use="optional" order="12" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" xlink:title="us-gaap_StockholdersEquityReverseStockSplit" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" xlink:title="Definition : us-gaap_ClassOfStockLineItems to us-gaap_StockholdersEquityReverseStockSplit" xlink:type="arc" use="optional" order="13" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:title="Definition : us-gaap_ClassOfStockLineItems to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="arc" use="optional" order="14" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare" xlink:title="us-gaap_SaleOfStockPricePerShare" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" xlink:title="Definition : us-gaap_ClassOfStockLineItems to us-gaap_SaleOfStockPricePerShare" xlink:type="arc" use="optional" order="15" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:title="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:title="Definition : us-gaap_ClassOfStockLineItems to us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" use="optional" order="16" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:title="us-gaap_WarrantsAndRightsOutstandingTerm" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:title="Definition : us-gaap_ClassOfStockLineItems to us-gaap_WarrantsAndRightsOutstandingTerm" xlink:type="arc" use="optional" order="17" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding" xlink:title="us-gaap_WarrantsAndRightsOutstanding" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstanding" xlink:title="Definition : us-gaap_ClassOfStockLineItems to us-gaap_WarrantsAndRightsOutstanding" xlink:type="arc" use="optional" order="18" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:title="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:title="Definition : us-gaap_ClassOfStockLineItems to us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" use="optional" order="19" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:title="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:title="Definition : us-gaap_ClassOfStockLineItems to us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:type="arc" use="optional" order="20" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:title="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:title="Definition : us-gaap_ClassOfStockLineItems to us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" use="optional" order="21" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_UnitsIssuedDuringPeriodSharesNewIssues" xlink:label="sxtp_UnitsIssuedDuringPeriodSharesNewIssues" xlink:title="sxtp_UnitsIssuedDuringPeriodSharesNewIssues" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="sxtp_UnitsIssuedDuringPeriodSharesNewIssues" xlink:title="Definition : us-gaap_ClassOfStockLineItems to sxtp_UnitsIssuedDuringPeriodSharesNewIssues" xlink:type="arc" use="optional" order="22" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:title="us-gaap_ClassOfWarrantOrRightOutstanding" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:title="Definition : us-gaap_ClassOfStockLineItems to us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="arc" use="optional" order="23" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:title="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:title="Definition : us-gaap_ClassOfStockLineItems to us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:type="arc" use="optional" order="24" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested" xlink:label="us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested" xlink:title="us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested" xlink:title="Definition : us-gaap_ClassOfStockLineItems to us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested" xlink:type="arc" use="optional" order="25" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_OtherOfferingExpensesPaid" xlink:label="sxtp_OtherOfferingExpensesPaid" xlink:title="sxtp_OtherOfferingExpensesPaid" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="sxtp_OtherOfferingExpensesPaid" xlink:title="Definition : us-gaap_ClassOfStockLineItems to sxtp_OtherOfferingExpensesPaid" xlink:type="arc" use="optional" order="26" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_SharesOfWarrants" xlink:label="sxtp_SharesOfWarrants" xlink:title="sxtp_SharesOfWarrants" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="sxtp_SharesOfWarrants" xlink:title="Definition : us-gaap_ClassOfStockLineItems to sxtp_SharesOfWarrants" xlink:type="arc" use="optional" order="27" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:title="us-gaap_StockIssuedDuringPeriodSharesOther" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:title="Definition : us-gaap_ClassOfStockLineItems to us-gaap_StockIssuedDuringPeriodSharesOther" xlink:type="arc" use="optional" order="28" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantExercisePriceIncrease" xlink:label="us-gaap_WarrantExercisePriceIncrease" xlink:title="us-gaap_WarrantExercisePriceIncrease" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_WarrantExercisePriceIncrease" xlink:title="Definition : us-gaap_ClassOfStockLineItems to us-gaap_WarrantExercisePriceIncrease" xlink:type="arc" use="optional" order="29" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_NumberofWarrantExercisable" xlink:label="sxtp_NumberofWarrantExercisable" xlink:title="sxtp_NumberofWarrantExercisable" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="sxtp_NumberofWarrantExercisable" xlink:title="Definition : us-gaap_ClassOfStockLineItems to sxtp_NumberofWarrantExercisable" xlink:type="arc" use="optional" order="30" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_NumberOfShares" xlink:label="sxtp_NumberOfShares" xlink:title="sxtp_NumberOfShares" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="sxtp_NumberOfShares" xlink:title="Definition : us-gaap_ClassOfStockLineItems to sxtp_NumberOfShares" xlink:type="arc" use="optional" order="31" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:title="us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:title="Definition : us-gaap_ClassOfStockLineItems to us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:type="arc" use="optional" order="32" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="us-gaap_PreferredStockDividendRatePercentage" xlink:title="us-gaap_PreferredStockDividendRatePercentage" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockDividendRatePercentage" xlink:title="Definition : us-gaap_ClassOfStockLineItems to us-gaap_PreferredStockDividendRatePercentage" xlink:type="arc" use="optional" order="33" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DividendsPreferredStock" xlink:label="us-gaap_DividendsPreferredStock" xlink:title="us-gaap_DividendsPreferredStock" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_DividendsPreferredStock" xlink:title="Definition : us-gaap_ClassOfStockLineItems to us-gaap_DividendsPreferredStock" xlink:type="arc" use="optional" order="34" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockConvertibleConversionPriceIncrease" xlink:label="us-gaap_CommonStockConvertibleConversionPriceIncrease" xlink:title="us-gaap_CommonStockConvertibleConversionPriceIncrease" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockConvertibleConversionPriceIncrease" xlink:title="Definition : us-gaap_ClassOfStockLineItems to us-gaap_CommonStockConvertibleConversionPriceIncrease" xlink:type="arc" use="optional" order="35" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:title="Definition : us-gaap_ClassOfStockLineItems to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" use="optional" order="36" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_AgreedToReturnShares" xlink:label="sxtp_AgreedToReturnShares" xlink:title="sxtp_AgreedToReturnShares" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="sxtp_AgreedToReturnShares" xlink:title="Definition : us-gaap_ClassOfStockLineItems to sxtp_AgreedToReturnShares" xlink:type="arc" order="37" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" xlink:title="us-gaap_ProceedsFromWarrantExercises" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromWarrantExercises" xlink:title="Definition : us-gaap_ClassOfStockLineItems to us-gaap_ProceedsFromWarrantExercises" xlink:type="arc" use="optional" order="38" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_CommonStockAggregateOfferingPrice" xlink:label="sxtp_CommonStockAggregateOfferingPrice" xlink:title="sxtp_CommonStockAggregateOfferingPrice" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="sxtp_CommonStockAggregateOfferingPrice" xlink:title="Definition : us-gaap_ClassOfStockLineItems to sxtp_CommonStockAggregateOfferingPrice" xlink:type="arc" order="39" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_ATMOfferingShares" xlink:label="sxtp_ATMOfferingShares" xlink:title="sxtp_ATMOfferingShares" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="sxtp_ATMOfferingShares" xlink:title="Definition : us-gaap_ClassOfStockLineItems to sxtp_ATMOfferingShares" xlink:type="arc" order="40" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromOtherEquity" xlink:label="us-gaap_ProceedsFromOtherEquity" xlink:title="us-gaap_ProceedsFromOtherEquity" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromOtherEquity" xlink:title="Definition : us-gaap_ClassOfStockLineItems to us-gaap_ProceedsFromOtherEquity" xlink:type="arc" use="optional" order="41" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:title="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:title="Definition : us-gaap_ClassOfStockLineItems to us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:type="arc" use="optional" order="42" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1" xlink:title="us-gaap_ConversionOfStockSharesConverted1" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" xlink:title="Definition : us-gaap_ClassOfStockLineItems to us-gaap_ConversionOfStockSharesConverted1" xlink:type="arc" use="optional" order="43" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantExercisePriceDecrease" xlink:label="us-gaap_WarrantExercisePriceDecrease" xlink:title="us-gaap_WarrantExercisePriceDecrease" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_WarrantExercisePriceDecrease" xlink:title="Definition : us-gaap_ClassOfStockLineItems to us-gaap_WarrantExercisePriceDecrease" xlink:type="arc" use="optional" order="44" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockConvertibleSharesIssuable" xlink:label="us-gaap_PreferredStockConvertibleSharesIssuable" xlink:title="us-gaap_PreferredStockConvertibleSharesIssuable" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockConvertibleSharesIssuable" xlink:title="Definition : us-gaap_ClassOfStockLineItems to us-gaap_PreferredStockConvertibleSharesIssuable" xlink:type="arc" use="optional" order="45" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:title="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:title="Definition : us-gaap_ClassOfStockLineItems to us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:type="arc" use="optional" order="46" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:title="us-gaap_WarrantsAndRightsOutstandingMaturityDate" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:title="Definition : us-gaap_ClassOfStockLineItems to us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:type="arc" use="optional" order="47" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_SalesAgreementTerminationDate" xlink:label="sxtp_SalesAgreementTerminationDate" xlink:title="sxtp_SalesAgreementTerminationDate" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="sxtp_SalesAgreementTerminationDate" xlink:title="Definition : us-gaap_ClassOfStockLineItems to sxtp_SalesAgreementTerminationDate" xlink:type="arc" order="48" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_CommonStockAggregateGrossSalesProceedAuthorized" xlink:label="sxtp_CommonStockAggregateGrossSalesProceedAuthorized" xlink:title="sxtp_CommonStockAggregateGrossSalesProceedAuthorized" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="sxtp_CommonStockAggregateGrossSalesProceedAuthorized" xlink:title="Definition : us-gaap_ClassOfStockLineItems to sxtp_CommonStockAggregateGrossSalesProceedAuthorized" xlink:type="arc" order="49" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_SalesAgentCommissionPercentage" xlink:label="sxtp_SalesAgentCommissionPercentage" xlink:title="sxtp_SalesAgentCommissionPercentage" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="sxtp_SalesAgentCommissionPercentage" xlink:title="Definition : us-gaap_ClassOfStockLineItems to sxtp_SalesAgentCommissionPercentage" xlink:type="arc" order="50" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfWarrantsExercised" xlink:label="sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfWarrantsExercised" xlink:title="sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfWarrantsExercised" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfWarrantsExercised" xlink:title="Definition : us-gaap_ClassOfStockLineItems to sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfWarrantsExercised" xlink:type="arc" use="optional" order="51" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_ProceedsFromExerciseOfPreFundedWarrants" xlink:label="sxtp_ProceedsFromExerciseOfPreFundedWarrants" xlink:title="sxtp_ProceedsFromExerciseOfPreFundedWarrants" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="sxtp_ProceedsFromExerciseOfPreFundedWarrants" xlink:title="Definition : us-gaap_ClassOfStockLineItems to sxtp_ProceedsFromExerciseOfPreFundedWarrants" xlink:type="arc" use="optional" order="52" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_StockholdersEquityDetailsTable" xlink:label="sxtp_StockholdersEquityDetailsTable" xlink:title="sxtp_StockholdersEquityDetailsTable" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="sxtp_StockholdersEquityDetailsTable" xlink:title="Definition : us-gaap_ClassOfStockLineItems to sxtp_StockholdersEquityDetailsTable" xlink:type="arc" order="53" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:title="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sxtp_StockholdersEquityDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:title="Definition : sxtp_StockholdersEquityDetailsTable to us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" use="optional" order="0" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:title="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:title="Definition : us-gaap_SubsidiarySaleOfStockAxis to us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" use="optional" order="0" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember" xlink:title="us-gaap_OverAllotmentOptionMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" xlink:title="Definition : us-gaap_SaleOfStockNameOfTransactionDomain to us-gaap_OverAllotmentOptionMember" xlink:type="arc" use="optional" order="0" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember" xlink:title="us-gaap_IPOMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" xlink:title="Definition : us-gaap_SaleOfStockNameOfTransactionDomain to us-gaap_IPOMember" xlink:type="arc" use="optional" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_1" xlink:title="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_1" xlink:title="Definition : us-gaap_SubsidiarySaleOfStockAxis to us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:title="us-gaap_StatementClassOfStockAxis" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sxtp_StockholdersEquityDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" xlink:title="Definition : sxtp_StockholdersEquityDetailsTable to us-gaap_StatementClassOfStockAxis" xlink:type="arc" use="optional" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xlink:title="us-gaap_ClassOfStockDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" xlink:title="Definition : us-gaap_StatementClassOfStockAxis to us-gaap_ClassOfStockDomain" xlink:type="arc" use="optional" order="0" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:title="us-gaap_SeriesAPreferredStockMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" xlink:title="Definition : us-gaap_ClassOfStockDomain to us-gaap_SeriesAPreferredStockMember" xlink:type="arc" use="optional" order="0" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_SeriesANonVotingConvertiblePreferredStockMember" xlink:label="sxtp_SeriesANonVotingConvertiblePreferredStockMember" xlink:title="sxtp_SeriesANonVotingConvertiblePreferredStockMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="sxtp_SeriesANonVotingConvertiblePreferredStockMember" xlink:title="Definition : us-gaap_ClassOfStockDomain to sxtp_SeriesANonVotingConvertiblePreferredStockMember" xlink:type="arc" use="optional" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:title="us-gaap_CommonStockMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonStockMember" xlink:title="Definition : us-gaap_ClassOfStockDomain to us-gaap_CommonStockMember" xlink:type="arc" use="optional" order="2" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleCommonStockMember" xlink:label="us-gaap_ConvertibleCommonStockMember" xlink:title="us-gaap_ConvertibleCommonStockMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertibleCommonStockMember" xlink:title="Definition : us-gaap_ClassOfStockDomain to us-gaap_ConvertibleCommonStockMember" xlink:type="arc" use="optional" order="3" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_1" xlink:title="us-gaap_ClassOfStockDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_1" xlink:title="Definition : us-gaap_StatementClassOfStockAxis to us-gaap_ClassOfStockDomain" xlink:type="arc" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:title="us-gaap_RelatedPartyTransactionAxis" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sxtp_StockholdersEquityDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" xlink:title="Definition : sxtp_StockholdersEquityDetailsTable to us-gaap_RelatedPartyTransactionAxis" xlink:type="arc" use="optional" order="2" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:title="us-gaap_RelatedPartyTransactionDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" xlink:title="Definition : us-gaap_RelatedPartyTransactionAxis to us-gaap_RelatedPartyTransactionDomain" xlink:type="arc" use="optional" order="0" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_WallachBethCapitalLLCMember" xlink:label="sxtp_WallachBethCapitalLLCMember" xlink:title="sxtp_WallachBethCapitalLLCMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="sxtp_WallachBethCapitalLLCMember" xlink:title="Definition : us-gaap_RelatedPartyTransactionDomain to sxtp_WallachBethCapitalLLCMember" xlink:type="arc" use="optional" order="0" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_TrevallyLLCMember" xlink:label="sxtp_TrevallyLLCMember" xlink:title="sxtp_TrevallyLLCMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="sxtp_TrevallyLLCMember" xlink:title="Definition : us-gaap_RelatedPartyTransactionDomain to sxtp_TrevallyLLCMember" xlink:type="arc" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_HCWainwrightAndCoLLCMember" xlink:label="sxtp_HCWainwrightAndCoLLCMember" xlink:title="sxtp_HCWainwrightAndCoLLCMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="sxtp_HCWainwrightAndCoLLCMember" xlink:title="Definition : us-gaap_RelatedPartyTransactionDomain to sxtp_HCWainwrightAndCoLLCMember" xlink:type="arc" order="2" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain_1" xlink:title="us-gaap_RelatedPartyTransactionDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain_1" xlink:title="Definition : us-gaap_RelatedPartyTransactionAxis to us-gaap_RelatedPartyTransactionDomain" xlink:type="arc" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sxtp_StockholdersEquityDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="Definition : sxtp_StockholdersEquityDetailsTable to us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" use="optional" order="3" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" xlink:title="us-gaap_RelatedPartyDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" xlink:title="Definition : us-gaap_RelatedPartyTransactionsByRelatedPartyAxis to us-gaap_RelatedPartyDomain" xlink:type="arc" use="optional" order="0" xbrldt:closed="false" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="sxtp_WallachBethCapitalLLCMember" xlink:title="Definition : us-gaap_RelatedPartyDomain to sxtp_WallachBethCapitalLLCMember" xlink:type="arc" use="optional" order="0" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_1" xlink:title="us-gaap_RelatedPartyDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_1" xlink:title="Definition : us-gaap_RelatedPartyTransactionsByRelatedPartyAxis to us-gaap_RelatedPartyDomain" xlink:type="arc" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:title="us-gaap_StatementEquityComponentsAxis" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sxtp_StockholdersEquityDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" xlink:title="Definition : sxtp_StockholdersEquityDetailsTable to us-gaap_StatementEquityComponentsAxis" xlink:type="arc" use="optional" order="4" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:title="us-gaap_EquityComponentDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" xlink:title="Definition : us-gaap_StatementEquityComponentsAxis to us-gaap_EquityComponentDomain" xlink:type="arc" use="optional" order="0" xbrldt:closed="false" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" xlink:title="Definition : us-gaap_EquityComponentDomain to us-gaap_CommonStockMember" xlink:type="arc" use="optional" order="0" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_1" xlink:title="us-gaap_EquityComponentDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_1" xlink:title="Definition : us-gaap_StatementEquityComponentsAxis to us-gaap_EquityComponentDomain" xlink:type="arc" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardDateAxis" xlink:label="us-gaap_AwardDateAxis" xlink:title="us-gaap_AwardDateAxis" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sxtp_StockholdersEquityDetailsTable" xlink:to="us-gaap_AwardDateAxis" xlink:title="Definition : sxtp_StockholdersEquityDetailsTable to us-gaap_AwardDateAxis" xlink:type="arc" use="optional" order="5" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardDateDomain" xlink:label="us-gaap_AwardDateDomain" xlink:title="us-gaap_AwardDateDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateDomain" xlink:title="Definition : us-gaap_AwardDateAxis to us-gaap_AwardDateDomain" xlink:type="arc" use="optional" order="0" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_January2024OfferingMember" xlink:label="sxtp_January2024OfferingMember" xlink:title="sxtp_January2024OfferingMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AwardDateDomain" xlink:to="sxtp_January2024OfferingMember" xlink:title="Definition : us-gaap_AwardDateDomain to sxtp_January2024OfferingMember" xlink:type="arc" use="optional" order="0" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_July2025OfferingMember" xlink:label="sxtp_July2025OfferingMember" xlink:title="sxtp_July2025OfferingMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AwardDateDomain" xlink:to="sxtp_July2025OfferingMember" xlink:title="Definition : us-gaap_AwardDateDomain to sxtp_July2025OfferingMember" xlink:type="arc" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_AtTheMarket2025AgreementMember" xlink:label="sxtp_AtTheMarket2025AgreementMember" xlink:title="sxtp_AtTheMarket2025AgreementMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AwardDateDomain" xlink:to="sxtp_AtTheMarket2025AgreementMember" xlink:title="Definition : us-gaap_AwardDateDomain to sxtp_AtTheMarket2025AgreementMember" xlink:type="arc" order="2" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardDateDomain" xlink:label="us-gaap_AwardDateDomain_1" xlink:title="us-gaap_AwardDateDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateDomain_1" xlink:title="Definition : us-gaap_AwardDateAxis to us-gaap_AwardDateDomain" xlink:type="arc" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:title="us-gaap_ClassOfWarrantOrRightAxis" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sxtp_StockholdersEquityDetailsTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:title="Definition : sxtp_StockholdersEquityDetailsTable to us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc" use="optional" order="6" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:title="us-gaap_ClassOfWarrantOrRightDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:title="Definition : us-gaap_ClassOfWarrantOrRightAxis to us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc" use="optional" order="0" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_PlacementAgentWarrantsMember" xlink:label="sxtp_PlacementAgentWarrantsMember" xlink:title="sxtp_PlacementAgentWarrantsMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="sxtp_PlacementAgentWarrantsMember" xlink:title="Definition : us-gaap_ClassOfWarrantOrRightDomain to sxtp_PlacementAgentWarrantsMember" xlink:type="arc" use="optional" order="0" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" xlink:title="us-gaap_WarrantMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_WarrantMember" xlink:title="Definition : us-gaap_ClassOfWarrantOrRightDomain to us-gaap_WarrantMember" xlink:type="arc" use="optional" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_PreFundedWarrantMember" xlink:label="sxtp_PreFundedWarrantMember" xlink:title="sxtp_PreFundedWarrantMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="sxtp_PreFundedWarrantMember" xlink:title="Definition : us-gaap_ClassOfWarrantOrRightDomain to sxtp_PreFundedWarrantMember" xlink:type="arc" use="optional" order="2" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_JanuaryTwoThousandTwentyFourPreFundedWarrantsMember" xlink:label="sxtp_JanuaryTwoThousandTwentyFourPreFundedWarrantsMember" xlink:title="sxtp_JanuaryTwoThousandTwentyFourPreFundedWarrantsMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="sxtp_JanuaryTwoThousandTwentyFourPreFundedWarrantsMember" xlink:title="Definition : us-gaap_ClassOfWarrantOrRightDomain to sxtp_JanuaryTwoThousandTwentyFourPreFundedWarrantsMember" xlink:type="arc" use="optional" order="3" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_JanuaryTwoThousandTwentyFourWarrantMember" xlink:label="sxtp_JanuaryTwoThousandTwentyFourWarrantMember" xlink:title="sxtp_JanuaryTwoThousandTwentyFourWarrantMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="sxtp_JanuaryTwoThousandTwentyFourWarrantMember" xlink:title="Definition : us-gaap_ClassOfWarrantOrRightDomain to sxtp_JanuaryTwoThousandTwentyFourWarrantMember" xlink:type="arc" use="optional" order="4" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_JanuaryRepresentativeWarrantsMember" xlink:label="sxtp_JanuaryRepresentativeWarrantsMember" xlink:title="sxtp_JanuaryRepresentativeWarrantsMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="sxtp_JanuaryRepresentativeWarrantsMember" xlink:title="Definition : us-gaap_ClassOfWarrantOrRightDomain to sxtp_JanuaryRepresentativeWarrantsMember" xlink:type="arc" use="optional" order="5" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_SeriesAWarrantsMember" xlink:label="sxtp_SeriesAWarrantsMember" xlink:title="sxtp_SeriesAWarrantsMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="sxtp_SeriesAWarrantsMember" xlink:title="Definition : us-gaap_ClassOfWarrantOrRightDomain to sxtp_SeriesAWarrantsMember" xlink:type="arc" order="6" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_SeriesBWarrantsMember" xlink:label="sxtp_SeriesBWarrantsMember" xlink:title="sxtp_SeriesBWarrantsMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="sxtp_SeriesBWarrantsMember" xlink:title="Definition : us-gaap_ClassOfWarrantOrRightDomain to sxtp_SeriesBWarrantsMember" xlink:type="arc" order="7" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_SeptemberTwoThousandTwentyFourAgentWarrantsMember" xlink:label="sxtp_SeptemberTwoThousandTwentyFourAgentWarrantsMember" xlink:title="sxtp_SeptemberTwoThousandTwentyFourAgentWarrantsMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="sxtp_SeptemberTwoThousandTwentyFourAgentWarrantsMember" xlink:title="Definition : us-gaap_ClassOfWarrantOrRightDomain to sxtp_SeptemberTwoThousandTwentyFourAgentWarrantsMember" xlink:type="arc" order="8" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_SeriesAAndSeriesBWarrantsMember" xlink:label="sxtp_SeriesAAndSeriesBWarrantsMember" xlink:title="sxtp_SeriesAAndSeriesBWarrantsMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="sxtp_SeriesAAndSeriesBWarrantsMember" xlink:title="Definition : us-gaap_ClassOfWarrantOrRightDomain to sxtp_SeriesAAndSeriesBWarrantsMember" xlink:type="arc" order="9" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_JulyTwoThousandTwentyFivePreFundedWarrantsMember" xlink:label="sxtp_JulyTwoThousandTwentyFivePreFundedWarrantsMember" xlink:title="sxtp_JulyTwoThousandTwentyFivePreFundedWarrantsMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="sxtp_JulyTwoThousandTwentyFivePreFundedWarrantsMember" xlink:title="Definition : us-gaap_ClassOfWarrantOrRightDomain to sxtp_JulyTwoThousandTwentyFivePreFundedWarrantsMember" xlink:type="arc" order="10" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_JulyTwoThousandTwentyFiveAOneWarrantsMember" xlink:label="sxtp_JulyTwoThousandTwentyFiveAOneWarrantsMember" xlink:title="sxtp_JulyTwoThousandTwentyFiveAOneWarrantsMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="sxtp_JulyTwoThousandTwentyFiveAOneWarrantsMember" xlink:title="Definition : us-gaap_ClassOfWarrantOrRightDomain to sxtp_JulyTwoThousandTwentyFiveAOneWarrantsMember" xlink:type="arc" order="11" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_JulyTwoThousandTwentyFiveATwoWarrantsMember" xlink:label="sxtp_JulyTwoThousandTwentyFiveATwoWarrantsMember" xlink:title="sxtp_JulyTwoThousandTwentyFiveATwoWarrantsMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="sxtp_JulyTwoThousandTwentyFiveATwoWarrantsMember" xlink:title="Definition : us-gaap_ClassOfWarrantOrRightDomain to sxtp_JulyTwoThousandTwentyFiveATwoWarrantsMember" xlink:type="arc" order="12" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_JulyTwoThousandTwentyFivePlacementAgentWarrantsMember" xlink:label="sxtp_JulyTwoThousandTwentyFivePlacementAgentWarrantsMember" xlink:title="sxtp_JulyTwoThousandTwentyFivePlacementAgentWarrantsMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="sxtp_JulyTwoThousandTwentyFivePlacementAgentWarrantsMember" xlink:title="Definition : us-gaap_ClassOfWarrantOrRightDomain to sxtp_JulyTwoThousandTwentyFivePlacementAgentWarrantsMember" xlink:type="arc" order="13" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_1" xlink:title="us-gaap_ClassOfWarrantOrRightDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_1" xlink:title="Definition : us-gaap_ClassOfWarrantOrRightAxis to us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:title="srt_RangeAxis" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sxtp_StockholdersEquityDetailsTable" xlink:to="srt_RangeAxis" xlink:title="Definition : sxtp_StockholdersEquityDetailsTable to srt_RangeAxis" xlink:type="arc" use="optional" order="7" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:title="srt_RangeMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:title="Definition : srt_RangeAxis to srt_RangeMember" xlink:type="arc" use="optional" order="0" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:title="srt_MaximumMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" xlink:title="Definition : srt_RangeMember to srt_MaximumMember" xlink:type="arc" use="optional" order="0" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember_1" xlink:title="srt_RangeMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_1" xlink:title="Definition : srt_RangeAxis to srt_RangeMember" xlink:type="arc" order="1" xbrldt:closed="false" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://60degreespharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ChangeInAccountingEstimateLineItems" xlink:label="us-gaap_ChangeInAccountingEstimateLineItems" xlink:title="us-gaap_ChangeInAccountingEstimateLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" xlink:title="us-gaap_StockholdersEquityReverseStockSplit" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ChangeInAccountingEstimateLineItems" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" xlink:title="Definition : us-gaap_ChangeInAccountingEstimateLineItems to us-gaap_StockholdersEquityReverseStockSplit" xlink:type="arc" use="optional" order="0" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1" xlink:title="us-gaap_ConcentrationRiskPercentage1" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ChangeInAccountingEstimateLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" xlink:title="Definition : us-gaap_ChangeInAccountingEstimateLineItems to us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" use="optional" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:title="us-gaap_CashCashEquivalentsAndShortTermInvestments" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ChangeInAccountingEstimateLineItems" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:title="Definition : us-gaap_ChangeInAccountingEstimateLineItems to us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:type="arc" use="optional" order="2" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:title="us-gaap_ResearchAndDevelopmentExpense" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ChangeInAccountingEstimateLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" xlink:title="Definition : us-gaap_ChangeInAccountingEstimateLineItems to us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" use="optional" order="3" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:label="sxtp_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:title="sxtp_SummaryofSignificantAccountingPoliciesDetailsTable" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ChangeInAccountingEstimateLineItems" xlink:to="sxtp_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:title="Definition : us-gaap_ChangeInAccountingEstimateLineItems to sxtp_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:type="arc" order="4" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:title="us-gaap_StatementEquityComponentsAxis" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sxtp_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" xlink:title="Definition : sxtp_SummaryofSignificantAccountingPoliciesDetailsTable to us-gaap_StatementEquityComponentsAxis" xlink:type="arc" use="optional" order="0" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:title="us-gaap_EquityComponentDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" xlink:title="Definition : us-gaap_StatementEquityComponentsAxis to us-gaap_EquityComponentDomain" xlink:type="arc" use="optional" order="0" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_ReverseStockSplitsMember" xlink:label="sxtp_ReverseStockSplitsMember" xlink:title="sxtp_ReverseStockSplitsMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="sxtp_ReverseStockSplitsMember" xlink:title="Definition : us-gaap_EquityComponentDomain to sxtp_ReverseStockSplitsMember" xlink:type="arc" use="optional" order="0" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_NetLossPerCommonShareMember" xlink:label="sxtp_NetLossPerCommonShareMember" xlink:title="sxtp_NetLossPerCommonShareMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="sxtp_NetLossPerCommonShareMember" xlink:title="Definition : us-gaap_EquityComponentDomain to sxtp_NetLossPerCommonShareMember" xlink:type="arc" use="optional" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_1" xlink:title="us-gaap_EquityComponentDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_1" xlink:title="Definition : us-gaap_StatementEquityComponentsAxis to us-gaap_EquityComponentDomain" xlink:type="arc" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" xlink:title="us-gaap_ConcentrationRiskByTypeAxis" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sxtp_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" xlink:title="Definition : sxtp_SummaryofSignificantAccountingPoliciesDetailsTable to us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" use="optional" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain" xlink:title="us-gaap_ConcentrationRiskTypeDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" xlink:title="Definition : us-gaap_ConcentrationRiskByTypeAxis to us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" use="optional" order="0" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember" xlink:title="us-gaap_CustomerConcentrationRiskMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_CustomerConcentrationRiskMember" xlink:title="Definition : us-gaap_ConcentrationRiskTypeDomain to us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" use="optional" order="0" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain_1" xlink:title="us-gaap_ConcentrationRiskTypeDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain_1" xlink:title="Definition : us-gaap_ConcentrationRiskByTypeAxis to us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis" xlink:title="srt_MajorCustomersAxis" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sxtp_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="srt_MajorCustomersAxis" xlink:title="Definition : sxtp_SummaryofSignificantAccountingPoliciesDetailsTable to srt_MajorCustomersAxis" xlink:type="arc" use="optional" order="2" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain" xlink:title="srt_NameOfMajorCustomerDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain" xlink:title="Definition : srt_MajorCustomersAxis to srt_NameOfMajorCustomerDomain" xlink:type="arc" use="optional" order="0" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_SignificantCustomersMember" xlink:label="sxtp_SignificantCustomersMember" xlink:title="sxtp_SignificantCustomersMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="sxtp_SignificantCustomersMember" xlink:title="Definition : srt_NameOfMajorCustomerDomain to sxtp_SignificantCustomersMember" xlink:type="arc" use="optional" order="0" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_CustomerTwoMember" xlink:label="sxtp_CustomerTwoMember" xlink:title="sxtp_CustomerTwoMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="sxtp_CustomerTwoMember" xlink:title="Definition : srt_NameOfMajorCustomerDomain to sxtp_CustomerTwoMember" xlink:type="arc" use="optional" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_CustomerThreeMember" xlink:label="sxtp_CustomerThreeMember" xlink:title="sxtp_CustomerThreeMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="sxtp_CustomerThreeMember" xlink:title="Definition : srt_NameOfMajorCustomerDomain to sxtp_CustomerThreeMember" xlink:type="arc" use="optional" order="2" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_SignificantCustomerOneMember" xlink:label="sxtp_SignificantCustomerOneMember" xlink:title="sxtp_SignificantCustomerOneMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="sxtp_SignificantCustomerOneMember" xlink:title="Definition : srt_NameOfMajorCustomerDomain to sxtp_SignificantCustomerOneMember" xlink:type="arc" use="optional" order="3" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_SignificantCustomerTwoMember" xlink:label="sxtp_SignificantCustomerTwoMember" xlink:title="sxtp_SignificantCustomerTwoMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="sxtp_SignificantCustomerTwoMember" xlink:title="Definition : srt_NameOfMajorCustomerDomain to sxtp_SignificantCustomerTwoMember" xlink:type="arc" order="4" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_SignificantCustomerThreeMember" xlink:label="sxtp_SignificantCustomerThreeMember" xlink:title="sxtp_SignificantCustomerThreeMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="sxtp_SignificantCustomerThreeMember" xlink:title="Definition : srt_NameOfMajorCustomerDomain to sxtp_SignificantCustomerThreeMember" xlink:type="arc" order="5" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain_1" xlink:title="srt_NameOfMajorCustomerDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain_1" xlink:title="Definition : srt_MajorCustomersAxis to srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:title="us-gaap_ConcentrationRiskByBenchmarkAxis" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sxtp_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:title="Definition : sxtp_SummaryofSignificantAccountingPoliciesDetailsTable to us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" use="optional" order="3" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:title="us-gaap_ConcentrationRiskBenchmarkDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:title="Definition : us-gaap_ConcentrationRiskByBenchmarkAxis to us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" use="optional" order="0" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableMember" xlink:label="us-gaap_AccountsReceivableMember" xlink:title="us-gaap_AccountsReceivableMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_AccountsReceivableMember" xlink:title="Definition : us-gaap_ConcentrationRiskBenchmarkDomain to us-gaap_AccountsReceivableMember" xlink:type="arc" use="optional" order="0" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SalesRevenueNetMember" xlink:label="us-gaap_SalesRevenueNetMember" xlink:title="us-gaap_SalesRevenueNetMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_SalesRevenueNetMember" xlink:title="Definition : us-gaap_ConcentrationRiskBenchmarkDomain to us-gaap_SalesRevenueNetMember" xlink:type="arc" use="optional" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_AccountsReceivableOrSalesRevenueNetMember" xlink:label="sxtp_AccountsReceivableOrSalesRevenueNetMember" xlink:title="sxtp_AccountsReceivableOrSalesRevenueNetMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="sxtp_AccountsReceivableOrSalesRevenueNetMember" xlink:title="Definition : us-gaap_ConcentrationRiskBenchmarkDomain to sxtp_AccountsReceivableOrSalesRevenueNetMember" xlink:type="arc" order="2" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_1" xlink:title="us-gaap_ConcentrationRiskBenchmarkDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_1" xlink:title="Definition : us-gaap_ConcentrationRiskByBenchmarkAxis to us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1" xbrldt:closed="false" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://60degreespharma.com/role/ConsolidatedCondensedStatementsofShareholdersEquityUnaudited">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:title="us-gaap_StatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="us-gaap_ConversionOfStockAmountConverted1" xlink:title="us-gaap_ConversionOfStockAmountConverted1" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConversionOfStockAmountConverted1" xlink:title="Definition : us-gaap_StatementLineItems to us-gaap_ConversionOfStockAmountConverted1" xlink:type="arc" use="optional" order="0" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:title="us-gaap_StockIssuedDuringPeriodSharesOther" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:title="Definition : us-gaap_StatementLineItems to us-gaap_StockIssuedDuringPeriodSharesOther" xlink:type="arc" use="optional" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_StockIssuedDuringPeriodValueIssuanceOfCommonStockPursuantToATMOfferingNetOfOfferingCosts" xlink:label="sxtp_StockIssuedDuringPeriodValueIssuanceOfCommonStockPursuantToATMOfferingNetOfOfferingCosts" xlink:title="sxtp_StockIssuedDuringPeriodValueIssuanceOfCommonStockPursuantToATMOfferingNetOfOfferingCosts" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sxtp_StockIssuedDuringPeriodValueIssuanceOfCommonStockPursuantToATMOfferingNetOfOfferingCosts" xlink:title="Definition : us-gaap_StatementLineItems to sxtp_StockIssuedDuringPeriodValueIssuanceOfCommonStockPursuantToATMOfferingNetOfOfferingCosts" xlink:type="arc" order="2" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_IssuanceOfCommonStockPursuantToATMOfferingNetOfOfferingCostsPaid" xlink:label="sxtp_IssuanceOfCommonStockPursuantToATMOfferingNetOfOfferingCostsPaid" xlink:title="sxtp_IssuanceOfCommonStockPursuantToATMOfferingNetOfOfferingCostsPaid" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sxtp_IssuanceOfCommonStockPursuantToATMOfferingNetOfOfferingCostsPaid" xlink:title="Definition : us-gaap_StatementLineItems to sxtp_IssuanceOfCommonStockPursuantToATMOfferingNetOfOfferingCostsPaid" xlink:type="arc" order="3" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:title="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:title="Definition : us-gaap_StatementLineItems to us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" use="optional" order="4" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsNetOfOfferingCostsPaidAtClosingAndDeferredOfferingCosts" xlink:label="sxtp_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsNetOfOfferingCostsPaidAtClosingAndDeferredOfferingCosts" xlink:title="sxtp_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsNetOfOfferingCostsPaidAtClosingAndDeferredOfferingCosts" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sxtp_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsNetOfOfferingCostsPaidAtClosingAndDeferredOfferingCosts" xlink:title="Definition : us-gaap_StatementLineItems to sxtp_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsNetOfOfferingCostsPaidAtClosingAndDeferredOfferingCosts" xlink:type="arc" order="5" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsNetOfOfferingCostsPaidAtClosingAndDeferredOfferingCosts" xlink:label="sxtp_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsNetOfOfferingCostsPaidAtClosingAndDeferredOfferingCosts" xlink:title="sxtp_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsNetOfOfferingCostsPaidAtClosingAndDeferredOfferingCosts" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sxtp_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsNetOfOfferingCostsPaidAtClosingAndDeferredOfferingCosts" xlink:title="Definition : us-gaap_StatementLineItems to sxtp_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsNetOfOfferingCostsPaidAtClosingAndDeferredOfferingCosts" xlink:type="arc" order="6" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPursuantToJanuary2025OfferingNetOfOfferingCosts" xlink:label="sxtp_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPursuantToJanuary2025OfferingNetOfOfferingCosts" xlink:title="sxtp_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPursuantToJanuary2025OfferingNetOfOfferingCosts" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sxtp_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPursuantToJanuary2025OfferingNetOfOfferingCosts" xlink:title="Definition : us-gaap_StatementLineItems to sxtp_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPursuantToJanuary2025OfferingNetOfOfferingCosts" xlink:type="arc" use="optional" order="7" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_StockIssuedDuringPeriodIssuanceOfCommonStockAndWarrantsPursuantToJanuary2025OfferingNetOfOfferingCosts" xlink:label="sxtp_StockIssuedDuringPeriodIssuanceOfCommonStockAndWarrantsPursuantToJanuary2025OfferingNetOfOfferingCosts" xlink:title="sxtp_StockIssuedDuringPeriodIssuanceOfCommonStockAndWarrantsPursuantToJanuary2025OfferingNetOfOfferingCosts" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sxtp_StockIssuedDuringPeriodIssuanceOfCommonStockAndWarrantsPursuantToJanuary2025OfferingNetOfOfferingCosts" xlink:title="Definition : us-gaap_StatementLineItems to sxtp_StockIssuedDuringPeriodIssuanceOfCommonStockAndWarrantsPursuantToJanuary2025OfferingNetOfOfferingCosts" xlink:type="arc" use="optional" order="8" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPursuantToFebruary2025OfferingNetOfOfferingCosts" xlink:label="sxtp_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPursuantToFebruary2025OfferingNetOfOfferingCosts" xlink:title="sxtp_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPursuantToFebruary2025OfferingNetOfOfferingCosts" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sxtp_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPursuantToFebruary2025OfferingNetOfOfferingCosts" xlink:title="Definition : us-gaap_StatementLineItems to sxtp_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPursuantToFebruary2025OfferingNetOfOfferingCosts" xlink:type="arc" use="optional" order="9" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_StockIssuedDuringPeriodIssuanceOfCommonStockAndWarrantsPursuantToFebruary2025OfferingNetOfOfferingCosts" xlink:label="sxtp_StockIssuedDuringPeriodIssuanceOfCommonStockAndWarrantsPursuantToFebruary2025OfferingNetOfOfferingCosts" xlink:title="sxtp_StockIssuedDuringPeriodIssuanceOfCommonStockAndWarrantsPursuantToFebruary2025OfferingNetOfOfferingCosts" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sxtp_StockIssuedDuringPeriodIssuanceOfCommonStockAndWarrantsPursuantToFebruary2025OfferingNetOfOfferingCosts" xlink:title="Definition : us-gaap_StatementLineItems to sxtp_StockIssuedDuringPeriodIssuanceOfCommonStockAndWarrantsPursuantToFebruary2025OfferingNetOfOfferingCosts" xlink:type="arc" use="optional" order="10" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPursuantToJuly2025OfferingNetOfOfferingCosts" xlink:label="sxtp_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPursuantToJuly2025OfferingNetOfOfferingCosts" xlink:title="sxtp_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPursuantToJuly2025OfferingNetOfOfferingCosts" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sxtp_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPursuantToJuly2025OfferingNetOfOfferingCosts" xlink:title="Definition : us-gaap_StatementLineItems to sxtp_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPursuantToJuly2025OfferingNetOfOfferingCosts" xlink:type="arc" order="11" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsPursuantToJuly2025OfferingNetOfOfferingCosts" xlink:label="sxtp_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsPursuantToJuly2025OfferingNetOfOfferingCosts" xlink:title="sxtp_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsPursuantToJuly2025OfferingNetOfOfferingCosts" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sxtp_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsPursuantToJuly2025OfferingNetOfOfferingCosts" xlink:title="Definition : us-gaap_StatementLineItems to sxtp_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsPursuantToJuly2025OfferingNetOfOfferingCosts" xlink:type="arc" order="12" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_IssuanceOfCommonStockAndWarrantsOfUnderwritingDiscountsAndOfferingCostsPaidAtClosingAndDeferredOfferingCosts" xlink:label="sxtp_IssuanceOfCommonStockAndWarrantsOfUnderwritingDiscountsAndOfferingCostsPaidAtClosingAndDeferredOfferingCosts" xlink:title="sxtp_IssuanceOfCommonStockAndWarrantsOfUnderwritingDiscountsAndOfferingCostsPaidAtClosingAndDeferredOfferingCosts" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sxtp_IssuanceOfCommonStockAndWarrantsOfUnderwritingDiscountsAndOfferingCostsPaidAtClosingAndDeferredOfferingCosts" xlink:title="Definition : us-gaap_StatementLineItems to sxtp_IssuanceOfCommonStockAndWarrantsOfUnderwritingDiscountsAndOfferingCostsPaidAtClosingAndDeferredOfferingCosts" xlink:type="arc" use="optional" order="13" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_StockIssuedDuringPeriodSharesOfCommonStockAndWarrantsOfUnderwritingDiscountsAndOfferingCostsPaidAtClosingAndDeferredOfferingCosts" xlink:label="sxtp_StockIssuedDuringPeriodSharesOfCommonStockAndWarrantsOfUnderwritingDiscountsAndOfferingCostsPaidAtClosingAndDeferredOfferingCosts" xlink:title="sxtp_StockIssuedDuringPeriodSharesOfCommonStockAndWarrantsOfUnderwritingDiscountsAndOfferingCostsPaidAtClosingAndDeferredOfferingCosts" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sxtp_StockIssuedDuringPeriodSharesOfCommonStockAndWarrantsOfUnderwritingDiscountsAndOfferingCostsPaidAtClosingAndDeferredOfferingCosts" xlink:title="Definition : us-gaap_StatementLineItems to sxtp_StockIssuedDuringPeriodSharesOfCommonStockAndWarrantsOfUnderwritingDiscountsAndOfferingCostsPaidAtClosingAndDeferredOfferingCosts" xlink:type="arc" use="optional" order="14" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_StockIssuedDuringPeriodValueStockIssuanceOfCommonStockUponExerciseOfPreFundedWarrants" xlink:label="sxtp_StockIssuedDuringPeriodValueStockIssuanceOfCommonStockUponExerciseOfPreFundedWarrants" xlink:title="sxtp_StockIssuedDuringPeriodValueStockIssuanceOfCommonStockUponExerciseOfPreFundedWarrants" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sxtp_StockIssuedDuringPeriodValueStockIssuanceOfCommonStockUponExerciseOfPreFundedWarrants" xlink:title="Definition : us-gaap_StatementLineItems to sxtp_StockIssuedDuringPeriodValueStockIssuanceOfCommonStockUponExerciseOfPreFundedWarrants" xlink:type="arc" use="optional" order="15" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_StockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfPreFundedWarrantsinShares" xlink:label="sxtp_StockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfPreFundedWarrantsinShares" xlink:title="sxtp_StockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfPreFundedWarrantsinShares" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sxtp_StockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfPreFundedWarrantsinShares" xlink:title="Definition : us-gaap_StatementLineItems to sxtp_StockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfPreFundedWarrantsinShares" xlink:type="arc" use="optional" order="16" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:title="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:title="Definition : us-gaap_StatementLineItems to us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:type="arc" use="optional" order="17" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:title="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:title="Definition : us-gaap_StatementLineItems to us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:type="arc" use="optional" order="18" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_StockIssuedDuringPeriodValueIssuanceOfSharesForAnnualPerformanceBonusesNetOfSharesWithheldForTaxes" xlink:label="sxtp_StockIssuedDuringPeriodValueIssuanceOfSharesForAnnualPerformanceBonusesNetOfSharesWithheldForTaxes" xlink:title="sxtp_StockIssuedDuringPeriodValueIssuanceOfSharesForAnnualPerformanceBonusesNetOfSharesWithheldForTaxes" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sxtp_StockIssuedDuringPeriodValueIssuanceOfSharesForAnnualPerformanceBonusesNetOfSharesWithheldForTaxes" xlink:title="Definition : us-gaap_StatementLineItems to sxtp_StockIssuedDuringPeriodValueIssuanceOfSharesForAnnualPerformanceBonusesNetOfSharesWithheldForTaxes" xlink:type="arc" use="optional" order="19" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_StockIssuedDuringPeriodIssuanceOfSharesForAnnualPerformanceBonusesNetOfSharesWithheldForTaxesinShares" xlink:label="sxtp_StockIssuedDuringPeriodIssuanceOfSharesForAnnualPerformanceBonusesNetOfSharesWithheldForTaxesinShares" xlink:title="sxtp_StockIssuedDuringPeriodIssuanceOfSharesForAnnualPerformanceBonusesNetOfSharesWithheldForTaxesinShares" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sxtp_StockIssuedDuringPeriodIssuanceOfSharesForAnnualPerformanceBonusesNetOfSharesWithheldForTaxesinShares" xlink:title="Definition : us-gaap_StatementLineItems to sxtp_StockIssuedDuringPeriodIssuanceOfSharesForAnnualPerformanceBonusesNetOfSharesWithheldForTaxesinShares" xlink:type="arc" use="optional" order="20" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:title="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:title="Definition : us-gaap_StatementLineItems to us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:type="arc" use="optional" order="21" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:title="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:title="Definition : us-gaap_StatementLineItems to us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:type="arc" use="optional" order="22" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:title="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:title="Definition : us-gaap_StatementLineItems to us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:type="arc" use="optional" order="23" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:title="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:title="Definition : us-gaap_StatementLineItems to us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" use="optional" order="24" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" xlink:title="us-gaap_ProfitLoss" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProfitLoss" xlink:title="Definition : us-gaap_StatementLineItems to us-gaap_ProfitLoss" xlink:type="arc" use="optional" order="25" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_StockIssuedDuringPeriodValueIssuanceOfCommonStockForFractionalSharesPursuantToReverseStockSplitRoundingAdjustment" xlink:label="sxtp_StockIssuedDuringPeriodValueIssuanceOfCommonStockForFractionalSharesPursuantToReverseStockSplitRoundingAdjustment" xlink:title="sxtp_StockIssuedDuringPeriodValueIssuanceOfCommonStockForFractionalSharesPursuantToReverseStockSplitRoundingAdjustment" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sxtp_StockIssuedDuringPeriodValueIssuanceOfCommonStockForFractionalSharesPursuantToReverseStockSplitRoundingAdjustment" xlink:title="Definition : us-gaap_StatementLineItems to sxtp_StockIssuedDuringPeriodValueIssuanceOfCommonStockForFractionalSharesPursuantToReverseStockSplitRoundingAdjustment" xlink:type="arc" use="optional" order="26" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:title="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:title="Definition : us-gaap_StatementLineItems to us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" use="optional" order="27" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_ShareRoundingAdjustmentForReverseStockSplit" xlink:label="sxtp_ShareRoundingAdjustmentForReverseStockSplit" xlink:title="sxtp_ShareRoundingAdjustmentForReverseStockSplit" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sxtp_ShareRoundingAdjustmentForReverseStockSplit" xlink:title="Definition : us-gaap_StatementLineItems to sxtp_ShareRoundingAdjustmentForReverseStockSplit" xlink:type="arc" order="28" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:label="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:title="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:title="Definition : us-gaap_StatementLineItems to us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:type="arc" use="optional" order="29" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" xlink:title="us-gaap_SharesOutstanding" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" xlink:title="Definition : us-gaap_StatementLineItems to us-gaap_SharesOutstanding" xlink:type="arc" use="optional" order="30" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:title="us-gaap_StatementTable" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:title="Definition : us-gaap_StatementLineItems to us-gaap_StatementTable" xlink:type="arc" order="31" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:title="us-gaap_StatementEquityComponentsAxis" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" xlink:title="Definition : us-gaap_StatementTable to us-gaap_StatementEquityComponentsAxis" xlink:type="arc" use="optional" order="0" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:title="us-gaap_EquityComponentDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" xlink:title="Definition : us-gaap_StatementEquityComponentsAxis to us-gaap_EquityComponentDomain" xlink:type="arc" use="optional" order="0" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember" xlink:title="us-gaap_PreferredStockMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_PreferredStockMember" xlink:title="Definition : us-gaap_EquityComponentDomain to us-gaap_PreferredStockMember" xlink:type="arc" use="optional" order="0" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:title="us-gaap_CommonStockMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" xlink:title="Definition : us-gaap_EquityComponentDomain to us-gaap_CommonStockMember" xlink:type="arc" use="optional" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:title="us-gaap_AdditionalPaidInCapitalMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" xlink:title="Definition : us-gaap_EquityComponentDomain to us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" use="optional" order="2" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsUnappropriatedMember" xlink:label="us-gaap_RetainedEarningsUnappropriatedMember" xlink:title="us-gaap_RetainedEarningsUnappropriatedMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsUnappropriatedMember" xlink:title="Definition : us-gaap_EquityComponentDomain to us-gaap_RetainedEarningsUnappropriatedMember" xlink:type="arc" use="optional" order="3" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:title="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:title="Definition : us-gaap_EquityComponentDomain to us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" use="optional" order="4" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ParentMember" xlink:label="us-gaap_ParentMember" xlink:title="us-gaap_ParentMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_ParentMember" xlink:title="Definition : us-gaap_EquityComponentDomain to us-gaap_ParentMember" xlink:type="arc" use="optional" order="5" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="us-gaap_NoncontrollingInterestMember" xlink:title="us-gaap_NoncontrollingInterestMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_NoncontrollingInterestMember" xlink:title="Definition : us-gaap_EquityComponentDomain to us-gaap_NoncontrollingInterestMember" xlink:type="arc" use="optional" order="6" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_1" xlink:title="us-gaap_EquityComponentDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_1" xlink:title="Definition : us-gaap_StatementEquityComponentsAxis to us-gaap_EquityComponentDomain" xlink:type="arc" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:title="us-gaap_StatementClassOfStockAxis" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" xlink:title="Definition : us-gaap_StatementTable to us-gaap_StatementClassOfStockAxis" xlink:type="arc" use="optional" order="1" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xlink:title="us-gaap_ClassOfStockDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" xlink:title="Definition : us-gaap_StatementClassOfStockAxis to us-gaap_ClassOfStockDomain" xlink:type="arc" use="optional" order="0" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:title="us-gaap_SeriesAPreferredStockMember" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" xlink:title="Definition : us-gaap_ClassOfStockDomain to us-gaap_SeriesAPreferredStockMember" xlink:type="arc" use="optional" order="0" xbrldt:closed="false" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_1" xlink:title="us-gaap_ClassOfStockDomain" />
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_1" xlink:title="Definition : us-gaap_StatementClassOfStockAxis to us-gaap_ClassOfStockDomain" xlink:type="arc" order="1" xbrldt:closed="false" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://60degreespharma.com/role/sxtp_r_ConsolidatedBalanceSheet" />
  <link:definitionLink xlink:type="extended" xlink:role="http://60degreespharma.com/role/sxtp_r_ConsolidatedIncomeStatement" />
  <link:definitionLink xlink:type="extended" xlink:role="http://60degreespharma.com/role/ConsolidatedCondensedStatementsofOperationsandComprehensiveLossIncomeUnauditedCalc2" />
  <link:definitionLink xlink:type="extended" xlink:role="http://60degreespharma.com/role/ConsolidatedCondensedStatementsofShareholdersEquityDeficitUnauditedParentheticals" />
  <link:definitionLink xlink:type="extended" xlink:role="http://60degreespharma.com/role/sxtp_r_ConsolidatedCashFlow" />
  <link:definitionLink xlink:type="extended" xlink:role="http://60degreespharma.com/role/ConsolidatedCondensedStatementsofCashFlowsUnauditedParentheticals" />
  <link:definitionLink xlink:type="extended" xlink:role="http://60degreespharma.com/role/NATUREOFOPERATIONS" />
  <link:definitionLink xlink:type="extended" xlink:role="http://60degreespharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" />
  <link:definitionLink xlink:type="extended" xlink:role="http://60degreespharma.com/role/INVENTORY" />
  <link:definitionLink xlink:type="extended" xlink:role="http://60degreespharma.com/role/PROPERTYANDEQUIPMENT" />
  <link:definitionLink xlink:type="extended" xlink:role="http://60degreespharma.com/role/INTANGIBLEASSETS" />
  <link:definitionLink xlink:type="extended" xlink:role="http://60degreespharma.com/role/STOCKHOLDERSEQUITY" />
  <link:definitionLink xlink:type="extended" xlink:role="http://60degreespharma.com/role/DEBT" />
  <link:definitionLink xlink:type="extended" xlink:role="http://60degreespharma.com/role/DERIVATIVELIABILITIES" />
  <link:definitionLink xlink:type="extended" xlink:role="http://60degreespharma.com/role/INCOMETAXES" />
  <link:definitionLink xlink:type="extended" xlink:role="http://60degreespharma.com/role/SHAREBASEDCOMPENSATION" />
  <link:definitionLink xlink:type="extended" xlink:role="http://60degreespharma.com/role/COMMITMENTSANDCONTINGENCIES" />
  <link:definitionLink xlink:type="extended" xlink:role="http://60degreespharma.com/role/SUBSEQUENTEVENTS" />
  <link:definitionLink xlink:type="extended" xlink:role="http://60degreespharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" />
  <link:definitionLink xlink:type="extended" xlink:role="http://60degreespharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" />
  <link:definitionLink xlink:type="extended" xlink:role="http://60degreespharma.com/role/INVENTORYTables" />
  <link:definitionLink xlink:type="extended" xlink:role="http://60degreespharma.com/role/PROPERTYANDEQUIPMENTTables" />
  <link:definitionLink xlink:type="extended" xlink:role="http://60degreespharma.com/role/INTANGIBLEASSETSTables" />
  <link:definitionLink xlink:type="extended" xlink:role="http://60degreespharma.com/role/STOCKHOLDERSEQUITYTables" />
  <link:definitionLink xlink:type="extended" xlink:role="http://60degreespharma.com/role/DEBTTables" />
  <link:definitionLink xlink:type="extended" xlink:role="http://60degreespharma.com/role/DERIVATIVELIABILITIESTables" />
  <link:definitionLink xlink:type="extended" xlink:role="http://60degreespharma.com/role/SHAREBASEDCOMPENSATIONTables" />
  <link:definitionLink xlink:type="extended" xlink:role="http://60degreespharma.com/role/INVENTORYScheduleofInventoryDetails" />
  <link:definitionLink xlink:type="extended" xlink:role="http://60degreespharma.com/role/INVENTORYDetails" />
  <link:definitionLink xlink:type="extended" xlink:role="http://60degreespharma.com/role/PROPERTYANDEQUIPMENTDetails" />
  <link:definitionLink xlink:type="extended" xlink:role="http://60degreespharma.com/role/INTANGIBLEASSETSDetails" />
  <link:definitionLink xlink:type="extended" xlink:role="http://60degreespharma.com/role/INTANGIBLEASSETSScheduleofIntangibleAssetsDetails" />
  <link:definitionLink xlink:type="extended" xlink:role="http://60degreespharma.com/role/DEBTScheduleoftheCurrentFuturePaymentObligationsDetails" />
  <link:definitionLink xlink:type="extended" xlink:role="http://60degreespharma.com/role/INCOMETAXESDetails" />
  <link:definitionLink xlink:type="extended" xlink:role="http://60degreespharma.com/role/SHAREBASEDCOMPENSATIONScheduleofFairValueofOptionsGrantedDetails" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>3
<FILENAME>sxtp-20250930_pre.xml
<DESCRIPTION>PRESENTATION
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!--Created by IRIS Business Services_Direct, Powered by IRIS Carbon, Unique Code 691618107ea6641f94c6a05b, Generated At Thu, 13 Nov 2025 17:41:17 GMT-->
<link:linkbase xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://60degreespharma.com/role/NATUREOFOPERATIONS" xlink:type="simple" xlink:href="sxtp-20250930.xsd#NATUREOFOPERATIONS" />
  <link:roleRef roleURI="http://60degreespharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="simple" xlink:href="sxtp-20250930.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" />
  <link:roleRef roleURI="http://60degreespharma.com/role/INVENTORY" xlink:type="simple" xlink:href="sxtp-20250930.xsd#INVENTORY" />
  <link:roleRef roleURI="http://60degreespharma.com/role/PROPERTYANDEQUIPMENT" xlink:type="simple" xlink:href="sxtp-20250930.xsd#PROPERTYANDEQUIPMENT" />
  <link:roleRef roleURI="http://60degreespharma.com/role/INTANGIBLEASSETS" xlink:type="simple" xlink:href="sxtp-20250930.xsd#INTANGIBLEASSETS" />
  <link:roleRef roleURI="http://60degreespharma.com/role/STOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="sxtp-20250930.xsd#STOCKHOLDERSEQUITY" />
  <link:roleRef roleURI="http://60degreespharma.com/role/DEBT" xlink:type="simple" xlink:href="sxtp-20250930.xsd#DEBT" />
  <link:roleRef roleURI="http://60degreespharma.com/role/DERIVATIVELIABILITIES" xlink:type="simple" xlink:href="sxtp-20250930.xsd#DERIVATIVELIABILITIES" />
  <link:roleRef roleURI="http://60degreespharma.com/role/INCOMETAXES" xlink:type="simple" xlink:href="sxtp-20250930.xsd#INCOMETAXES" />
  <link:roleRef roleURI="http://60degreespharma.com/role/SHAREBASEDCOMPENSATION" xlink:type="simple" xlink:href="sxtp-20250930.xsd#SHAREBASEDCOMPENSATION" />
  <link:roleRef roleURI="http://60degreespharma.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="simple" xlink:href="sxtp-20250930.xsd#COMMITMENTSANDCONTINGENCIES" />
  <link:roleRef roleURI="http://60degreespharma.com/role/SUBSEQUENTEVENTS" xlink:type="simple" xlink:href="sxtp-20250930.xsd#SUBSEQUENTEVENTS" />
  <link:roleRef roleURI="http://60degreespharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="simple" xlink:href="sxtp-20250930.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" />
  <link:roleRef roleURI="http://60degreespharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" xlink:type="simple" xlink:href="sxtp-20250930.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" />
  <link:roleRef roleURI="http://60degreespharma.com/role/INVENTORYTables" xlink:type="simple" xlink:href="sxtp-20250930.xsd#INVENTORYTables" />
  <link:roleRef roleURI="http://60degreespharma.com/role/PROPERTYANDEQUIPMENTTables" xlink:type="simple" xlink:href="sxtp-20250930.xsd#PROPERTYANDEQUIPMENTTables" />
  <link:roleRef roleURI="http://60degreespharma.com/role/INTANGIBLEASSETSTables" xlink:type="simple" xlink:href="sxtp-20250930.xsd#INTANGIBLEASSETSTables" />
  <link:roleRef roleURI="http://60degreespharma.com/role/STOCKHOLDERSEQUITYTables" xlink:type="simple" xlink:href="sxtp-20250930.xsd#STOCKHOLDERSEQUITYTables" />
  <link:roleRef roleURI="http://60degreespharma.com/role/DEBTTables" xlink:type="simple" xlink:href="sxtp-20250930.xsd#DEBTTables" />
  <link:roleRef roleURI="http://60degreespharma.com/role/DERIVATIVELIABILITIESTables" xlink:type="simple" xlink:href="sxtp-20250930.xsd#DERIVATIVELIABILITIESTables" />
  <link:roleRef roleURI="http://60degreespharma.com/role/SHAREBASEDCOMPENSATIONTables" xlink:type="simple" xlink:href="sxtp-20250930.xsd#SHAREBASEDCOMPENSATIONTables" />
  <link:roleRef roleURI="http://60degreespharma.com/role/INTANGIBLEASSETSDetails" xlink:type="simple" xlink:href="sxtp-20250930.xsd#INTANGIBLEASSETSDetails" />
  <link:roleRef roleURI="http://60degreespharma.com/role/INTANGIBLEASSETSScheduleofIntangibleAssetsDetails" xlink:type="simple" xlink:href="sxtp-20250930.xsd#INTANGIBLEASSETSScheduleofIntangibleAssetsDetails" />
  <link:roleRef roleURI="http://60degreespharma.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails" xlink:type="simple" xlink:href="sxtp-20250930.xsd#PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails" />
  <link:roleRef roleURI="http://60degreespharma.com/role/DEBTScheduleoftheCurrentFuturePaymentObligationsDetails" xlink:type="simple" xlink:href="sxtp-20250930.xsd#DEBTScheduleoftheCurrentFuturePaymentObligationsDetails" />
  <link:roleRef roleURI="http://60degreespharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofExchangeRatesalongwithHistoricalRatesDetails" xlink:type="simple" xlink:href="sxtp-20250930.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofExchangeRatesalongwithHistoricalRatesDetails" />
  <link:roleRef roleURI="http://60degreespharma.com/role/sxtp_r_ConsolidatedBalanceSheet_Parentheticals" xlink:type="simple" xlink:href="sxtp-20250930.xsd#sxtp_r_ConsolidatedBalanceSheet_Parentheticals" />
  <link:roleRef roleURI="http://60degreespharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofLiabilitiesMeasuredatFairValueDetails" xlink:type="simple" xlink:href="sxtp-20250930.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofLiabilitiesMeasuredatFairValueDetails" />
  <link:roleRef roleURI="http://60degreespharma.com/role/DocumentAndEntityInformation" xlink:type="simple" xlink:href="sxtp-20250930.xsd#DocumentAndEntityInformation" />
  <link:roleRef roleURI="http://60degreespharma.com/role/sxtp_r_ConsolidatedIncomeStatement" xlink:type="simple" xlink:href="sxtp-20250930.xsd#sxtp_r_ConsolidatedIncomeStatement" />
  <link:roleRef roleURI="http://60degreespharma.com/role/INVENTORYDetails" xlink:type="simple" xlink:href="sxtp-20250930.xsd#INVENTORYDetails" />
  <link:roleRef roleURI="http://60degreespharma.com/role/sxtp_r_ConsolidatedBalanceSheet" xlink:type="simple" xlink:href="sxtp-20250930.xsd#sxtp_r_ConsolidatedBalanceSheet" />
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#InsiderTradingArrangements" />
  <link:roleRef roleURI="http://60degreespharma.com/role/NATUREOFOPERATIONSDetails" xlink:type="simple" xlink:href="sxtp-20250930.xsd#NATUREOFOPERATIONSDetails" />
  <link:roleRef roleURI="http://60degreespharma.com/role/INTANGIBLEASSETSScheduleofEstimatedFutureAmortizationExpenseforOurPatentsandWebsiteDevelopmentCostsDetails" xlink:type="simple" xlink:href="sxtp-20250930.xsd#INTANGIBLEASSETSScheduleofEstimatedFutureAmortizationExpenseforOurPatentsandWebsiteDevelopmentCostsDetails" />
  <link:roleRef roleURI="http://60degreespharma.com/role/DEBTDetails" xlink:type="simple" xlink:href="sxtp-20250930.xsd#DEBTDetails" />
  <link:roleRef roleURI="http://60degreespharma.com/role/DERIVATIVELIABILITIESDetails" xlink:type="simple" xlink:href="sxtp-20250930.xsd#DERIVATIVELIABILITIESDetails" />
  <link:roleRef roleURI="http://60degreespharma.com/role/SHAREBASEDCOMPENSATIONScheduleofShareBasedCompensationExpensesDetails" xlink:type="simple" xlink:href="sxtp-20250930.xsd#SHAREBASEDCOMPENSATIONScheduleofShareBasedCompensationExpensesDetails" />
  <link:roleRef roleURI="http://60degreespharma.com/role/INVENTORYScheduleofInventoryDetails" xlink:type="simple" xlink:href="sxtp-20250930.xsd#INVENTORYScheduleofInventoryDetails" />
  <link:roleRef roleURI="http://60degreespharma.com/role/INCOMETAXESDetails" xlink:type="simple" xlink:href="sxtp-20250930.xsd#INCOMETAXESDetails" />
  <link:roleRef roleURI="http://60degreespharma.com/role/DERIVATIVELIABILITIESScheduleofDerivativeLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="simple" xlink:href="sxtp-20250930.xsd#DERIVATIVELIABILITIESScheduleofDerivativeLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" />
  <link:roleRef roleURI="http://60degreespharma.com/role/COMMITMENTSANDCONTINGENCIESDetails" xlink:type="simple" xlink:href="sxtp-20250930.xsd#COMMITMENTSANDCONTINGENCIESDetails" />
  <link:roleRef roleURI="http://60degreespharma.com/role/ConsolidatedCondensedStatementsofCashFlowsUnauditedParentheticals" xlink:type="simple" xlink:href="sxtp-20250930.xsd#ConsolidatedCondensedStatementsofCashFlowsUnauditedParentheticals" />
  <link:roleRef roleURI="http://60degreespharma.com/role/ConsolidatedCondensedStatementsofShareholdersEquityDeficitUnauditedParentheticals" xlink:type="simple" xlink:href="sxtp-20250930.xsd#ConsolidatedCondensedStatementsofShareholdersEquityDeficitUnauditedParentheticals" />
  <link:roleRef roleURI="http://60degreespharma.com/role/SHAREBASEDCOMPENSATIONScheduleofFairValueofOptionsGrantedDetails" xlink:type="simple" xlink:href="sxtp-20250930.xsd#SHAREBASEDCOMPENSATIONScheduleofFairValueofOptionsGrantedDetails" />
  <link:roleRef roleURI="http://60degreespharma.com/role/SHAREBASEDCOMPENSATIONDetails" xlink:type="simple" xlink:href="sxtp-20250930.xsd#SHAREBASEDCOMPENSATIONDetails" />
  <link:roleRef roleURI="http://60degreespharma.com/role/SUBSEQUENTEVENTSDetails" xlink:type="simple" xlink:href="sxtp-20250930.xsd#SUBSEQUENTEVENTSDetails" />
  <link:roleRef roleURI="http://60degreespharma.com/role/STOCKHOLDERSEQUITYScheduleofEquityClassifiedWarrantsDetails" xlink:type="simple" xlink:href="sxtp-20250930.xsd#STOCKHOLDERSEQUITYScheduleofEquityClassifiedWarrantsDetails" />
  <link:roleRef roleURI="http://60degreespharma.com/role/STOCKHOLDERSEQUITYDetails" xlink:type="simple" xlink:href="sxtp-20250930.xsd#STOCKHOLDERSEQUITYDetails" />
  <link:roleRef roleURI="http://60degreespharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails" xlink:type="simple" xlink:href="sxtp-20250930.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails" />
  <link:roleRef roleURI="http://60degreespharma.com/role/PROPERTYANDEQUIPMENTDetails" xlink:type="simple" xlink:href="sxtp-20250930.xsd#PROPERTYANDEQUIPMENTDetails" />
  <link:roleRef roleURI="http://60degreespharma.com/role/ConsolidatedCondensedStatementsofShareholdersEquityUnaudited" xlink:type="simple" xlink:href="sxtp-20250930.xsd#ConsolidatedCondensedStatementsofShareholdersEquityUnaudited" />
  <link:roleRef roleURI="http://60degreespharma.com/role/sxtp_r_ConsolidatedCashFlow" xlink:type="simple" xlink:href="sxtp-20250930.xsd#sxtp_r_ConsolidatedCashFlow" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" />
  <link:presentationLink xlink:type="extended" xlink:role="http://60degreespharma.com/role/NATUREOFOPERATIONS">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:title="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations" xlink:title="us-gaap_NatureOfOperations" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_NatureOfOperations" xlink:title="Presentation : us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to us-gaap_NatureOfOperations" use="optional" priority="0" order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://60degreespharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:title="us-gaap_AccountingPoliciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:title="us-gaap_SignificantAccountingPoliciesTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:title="Presentation : us-gaap_AccountingPoliciesAbstract to us-gaap_SignificantAccountingPoliciesTextBlock" use="optional" priority="0" order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://60degreespharma.com/role/INVENTORY">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="us-gaap_InventoryDisclosureAbstract" xlink:title="us-gaap_InventoryDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="us-gaap_InventoryDisclosureTextBlock" xlink:title="us-gaap_InventoryDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryDisclosureTextBlock" xlink:title="Presentation : us-gaap_InventoryDisclosureAbstract to us-gaap_InventoryDisclosureTextBlock" use="optional" priority="0" order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://60degreespharma.com/role/PROPERTYANDEQUIPMENT">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:title="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:title="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:title="Presentation : us-gaap_PropertyPlantAndEquipmentAbstract to us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" use="optional" priority="0" order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://60degreespharma.com/role/INTANGIBLEASSETS">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:title="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:title="us-gaap_IntangibleAssetsDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:title="Presentation : us-gaap_FiniteLivedIntangibleAssetsNetAbstract to us-gaap_IntangibleAssetsDisclosureTextBlock" use="optional" priority="0" order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://60degreespharma.com/role/STOCKHOLDERSEQUITY">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" xlink:title="us-gaap_EquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:title="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:title="Presentation : us-gaap_EquityAbstract to us-gaap_StockholdersEquityNoteDisclosureTextBlock" use="optional" priority="0" order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://60degreespharma.com/role/DEBT">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:title="us-gaap_DebtDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock" xlink:title="us-gaap_DebtDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock" xlink:title="Presentation : us-gaap_DebtDisclosureAbstract to us-gaap_DebtDisclosureTextBlock" use="optional" priority="0" order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://60degreespharma.com/role/DERIVATIVELIABILITIES">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:title="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:label="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:title="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:title="Presentation : us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract to us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" use="optional" priority="0" order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://60degreespharma.com/role/INCOMETAXES">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:title="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:title="us-gaap_IncomeTaxDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" xlink:title="Presentation : us-gaap_IncomeTaxDisclosureAbstract to us-gaap_IncomeTaxDisclosureTextBlock" use="optional" priority="0" order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://60degreespharma.com/role/SHAREBASEDCOMPENSATION">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:title="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:title="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:title="Presentation : us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" use="optional" priority="0" order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://60degreespharma.com/role/COMMITMENTSANDCONTINGENCIES">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:title="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:title="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:title="Presentation : us-gaap_CommitmentsAndContingenciesDisclosureAbstract to us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" use="optional" priority="0" order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://60degreespharma.com/role/SUBSEQUENTEVENTS">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:title="us-gaap_SubsequentEventsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:title="us-gaap_SubsequentEventsTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" xlink:title="Presentation : us-gaap_SubsequentEventsAbstract to us-gaap_SubsequentEventsTextBlock" use="optional" priority="0" order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://60degreespharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:title="us-gaap_AccountingPoliciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:title="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:title="Presentation : us-gaap_AccountingPoliciesAbstract to us-gaap_BasisOfAccountingPolicyPolicyTextBlock" use="optional" priority="0" order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xlink:title="us-gaap_UseOfEstimates" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" xlink:title="Presentation : us-gaap_AccountingPoliciesAbstract to us-gaap_UseOfEstimates" use="optional" priority="0" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityPolicyTextBlock" xlink:label="us-gaap_StockholdersEquityPolicyTextBlock" xlink:title="us-gaap_StockholdersEquityPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_StockholdersEquityPolicyTextBlock" xlink:title="Presentation : us-gaap_AccountingPoliciesAbstract to us-gaap_StockholdersEquityPolicyTextBlock" use="optional" priority="0" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:title="us-gaap_ConcentrationRiskCreditRisk" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" xlink:title="Presentation : us-gaap_AccountingPoliciesAbstract to us-gaap_ConcentrationRiskCreditRisk" use="optional" priority="0" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:title="us-gaap_SegmentReportingPolicyPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:title="Presentation : us-gaap_AccountingPoliciesAbstract to us-gaap_SegmentReportingPolicyPolicyTextBlock" use="optional" priority="0" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="us-gaap_DerivativesPolicyTextBlock" xlink:title="us-gaap_DerivativesPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DerivativesPolicyTextBlock" xlink:title="Presentation : us-gaap_AccountingPoliciesAbstract to us-gaap_DerivativesPolicyTextBlock" use="optional" priority="0" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_EquityClassifiedWarrantsPolicyTextBlock" xlink:label="sxtp_EquityClassifiedWarrantsPolicyTextBlock" xlink:title="sxtp_EquityClassifiedWarrantsPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="sxtp_EquityClassifiedWarrantsPolicyTextBlock" xlink:title="Presentation : us-gaap_AccountingPoliciesAbstract to sxtp_EquityClassifiedWarrantsPolicyTextBlock" use="optional" priority="0" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:title="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:title="Presentation : us-gaap_AccountingPoliciesAbstract to us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" use="optional" priority="0" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:title="us-gaap_ResearchAndDevelopmentExpensePolicy" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:title="Presentation : us-gaap_AccountingPoliciesAbstract to us-gaap_ResearchAndDevelopmentExpensePolicy" use="optional" priority="0" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:title="us-gaap_FairValueOfFinancialInstrumentsPolicy" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:title="Presentation : us-gaap_AccountingPoliciesAbstract to us-gaap_FairValueOfFinancialInstrumentsPolicy" use="optional" priority="0" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_AssetsAndLiabilitiesNotMeasuredAtFairValueOnARecurringBasisPolicyTextBlock" xlink:label="sxtp_AssetsAndLiabilitiesNotMeasuredAtFairValueOnARecurringBasisPolicyTextBlock" xlink:title="sxtp_AssetsAndLiabilitiesNotMeasuredAtFairValueOnARecurringBasisPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="sxtp_AssetsAndLiabilitiesNotMeasuredAtFairValueOnARecurringBasisPolicyTextBlock" xlink:title="Presentation : us-gaap_AccountingPoliciesAbstract to sxtp_AssetsAndLiabilitiesNotMeasuredAtFairValueOnARecurringBasisPolicyTextBlock" use="optional" priority="0" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:title="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:title="Presentation : us-gaap_AccountingPoliciesAbstract to us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" use="optional" priority="0" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:title="us-gaap_PriorPeriodReclassificationAdjustmentDescription" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:title="Presentation : us-gaap_AccountingPoliciesAbstract to us-gaap_PriorPeriodReclassificationAdjustmentDescription" use="optional" priority="0" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:title="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:title="Presentation : us-gaap_AccountingPoliciesAbstract to us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" use="optional" priority="0" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:title="us-gaap_EarningsPerSharePolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" xlink:title="Presentation : us-gaap_AccountingPoliciesAbstract to us-gaap_EarningsPerSharePolicyTextBlock" use="optional" priority="0" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:title="us-gaap_CompensationRelatedCostsPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:title="Presentation : us-gaap_AccountingPoliciesAbstract to us-gaap_CompensationRelatedCostsPolicyTextBlock" use="optional" priority="0" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsPolicyPolicyTextBlock" xlink:label="us-gaap_SubsequentEventsPolicyPolicyTextBlock" xlink:title="us-gaap_SubsequentEventsPolicyPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SubsequentEventsPolicyPolicyTextBlock" xlink:title="Presentation : us-gaap_AccountingPoliciesAbstract to us-gaap_SubsequentEventsPolicyPolicyTextBlock" use="optional" priority="0" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:title="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:title="Presentation : us-gaap_AccountingPoliciesAbstract to us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" use="optional" priority="0" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://60degreespharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:title="us-gaap_AccountingPoliciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:title="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:title="Presentation : us-gaap_AccountingPoliciesAbstract to us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" use="optional" priority="0" order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock" xlink:label="us-gaap_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock" xlink:title="us-gaap_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock" xlink:title="Presentation : us-gaap_AccountingPoliciesAbstract to us-gaap_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock" use="optional" priority="0" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://60degreespharma.com/role/INVENTORYTables">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="us-gaap_InventoryDisclosureAbstract" xlink:title="us-gaap_InventoryDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:title="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:title="Presentation : us-gaap_InventoryDisclosureAbstract to us-gaap_ScheduleOfInventoryCurrentTableTextBlock" use="optional" priority="0" order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://60degreespharma.com/role/PROPERTYANDEQUIPMENTTables">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:title="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:title="us-gaap_PropertyPlantAndEquipmentTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:title="Presentation : us-gaap_PropertyPlantAndEquipmentAbstract to us-gaap_PropertyPlantAndEquipmentTextBlock" use="optional" priority="0" order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://60degreespharma.com/role/INTANGIBLEASSETSTables">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:title="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:title="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:title="Presentation : us-gaap_FiniteLivedIntangibleAssetsNetAbstract to us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" use="optional" priority="0" order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:title="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:title="Presentation : us-gaap_FiniteLivedIntangibleAssetsNetAbstract to us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" use="optional" priority="0" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://60degreespharma.com/role/STOCKHOLDERSEQUITYTables">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" xlink:title="us-gaap_EquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:title="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:title="Presentation : us-gaap_EquityAbstract to us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" use="optional" priority="0" order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://60degreespharma.com/role/DEBTTables">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:title="us-gaap_DebtDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:title="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:title="Presentation : us-gaap_DebtDisclosureAbstract to us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" use="optional" priority="0" order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://60degreespharma.com/role/DERIVATIVELIABILITIESTables">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:title="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:label="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:title="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:title="Presentation : us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract to us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" use="optional" priority="0" order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://60degreespharma.com/role/SHAREBASEDCOMPENSATIONTables">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:title="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:title="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:title="Presentation : us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" use="optional" priority="0" order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock" xlink:title="Presentation : us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock" use="optional" priority="0" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://60degreespharma.com/role/INTANGIBLEASSETSDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:title="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_CapitalizedWebsiteDevelopmentrelatedCosts" xlink:label="sxtp_CapitalizedWebsiteDevelopmentrelatedCosts" xlink:title="sxtp_CapitalizedWebsiteDevelopmentrelatedCosts" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:to="sxtp_CapitalizedWebsiteDevelopmentrelatedCosts" xlink:title="Presentation : us-gaap_FiniteLivedIntangibleAssetsNetAbstract to sxtp_CapitalizedWebsiteDevelopmentrelatedCosts" use="optional" priority="0" order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets" xlink:title="us-gaap_AmortizationOfIntangibleAssets" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:to="us-gaap_AmortizationOfIntangibleAssets" xlink:title="Presentation : us-gaap_FiniteLivedIntangibleAssetsNetAbstract to us-gaap_AmortizationOfIntangibleAssets" use="optional" priority="0" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:title="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:title="Presentation : us-gaap_FiniteLivedIntangibleAssetsNetAbstract to us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" use="optional" priority="0" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_CapitalizedPatentExpenses" xlink:label="sxtp_CapitalizedPatentExpenses" xlink:title="sxtp_CapitalizedPatentExpenses" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:to="sxtp_CapitalizedPatentExpenses" xlink:title="Presentation : us-gaap_FiniteLivedIntangibleAssetsNetAbstract to sxtp_CapitalizedPatentExpenses" use="optional" priority="0" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://60degreespharma.com/role/INTANGIBLEASSETSScheduleofIntangibleAssetsDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:title="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedPatentsGross" xlink:label="us-gaap_FiniteLivedPatentsGross" xlink:title="us-gaap_FiniteLivedPatentsGross" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:to="us-gaap_FiniteLivedPatentsGross" xlink:title="Presentation : us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract to us-gaap_FiniteLivedPatentsGross" use="optional" priority="0" order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_FiniteLivedWebsiteDevelopmentCostsGross" xlink:label="sxtp_FiniteLivedWebsiteDevelopmentCostsGross" xlink:title="sxtp_FiniteLivedWebsiteDevelopmentCostsGross" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:to="sxtp_FiniteLivedWebsiteDevelopmentCostsGross" xlink:title="Presentation : us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract to sxtp_FiniteLivedWebsiteDevelopmentCostsGross" use="optional" priority="0" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:title="us-gaap_FiniteLivedIntangibleAssetsGross" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:title="Presentation : us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract to us-gaap_FiniteLivedIntangibleAssetsGross" use="optional" priority="0" order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:title="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:title="Presentation : us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract to us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" use="optional" priority="0" order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:title="us-gaap_IntangibleAssetsNetExcludingGoodwill" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:title="Presentation : us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract to us-gaap_IntangibleAssetsNetExcludingGoodwill" use="optional" priority="0" order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://60degreespharma.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails">
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_ScheduleOfPropertyAndEquipmentAbstract" xlink:label="sxtp_ScheduleOfPropertyAndEquipmentAbstract" xlink:title="sxtp_ScheduleOfPropertyAndEquipmentAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:title="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sxtp_ScheduleOfPropertyAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:title="Presentation : sxtp_ScheduleOfPropertyAndEquipmentAbstract to us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" use="optional" priority="0" order="0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:title="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:title="Presentation : us-gaap_ScheduleOfPropertyPlantAndEquipmentTable to us-gaap_PropertyPlantAndEquipmentByTypeAxis" use="optional" priority="0" order="0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:title="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:title="Presentation : us-gaap_PropertyPlantAndEquipmentByTypeAxis to us-gaap_PropertyPlantAndEquipmentTypeDomain" use="optional" priority="0" order="0" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_LabEquipmentMember" xlink:label="sxtp_LabEquipmentMember" xlink:title="sxtp_LabEquipmentMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="sxtp_LabEquipmentMember" xlink:title="Presentation : us-gaap_PropertyPlantAndEquipmentTypeDomain to sxtp_LabEquipmentMember" use="optional" priority="0" order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="us-gaap_MachineryAndEquipmentMember" xlink:title="us-gaap_MachineryAndEquipmentMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_MachineryAndEquipmentMember" xlink:title="Presentation : us-gaap_PropertyPlantAndEquipmentTypeDomain to us-gaap_MachineryAndEquipmentMember" use="optional" priority="0" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" xlink:title="us-gaap_ComputerEquipmentMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" xlink:title="Presentation : us-gaap_PropertyPlantAndEquipmentTypeDomain to us-gaap_ComputerEquipmentMember" use="optional" priority="0" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:title="us-gaap_FurnitureAndFixturesMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" xlink:title="Presentation : us-gaap_PropertyPlantAndEquipmentTypeDomain to us-gaap_FurnitureAndFixturesMember" use="optional" priority="0" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:title="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:title="Presentation : us-gaap_ScheduleOfPropertyPlantAndEquipmentTable to us-gaap_PropertyPlantAndEquipmentLineItems" use="optional" priority="0" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:title="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" xlink:title="Presentation : us-gaap_PropertyPlantAndEquipmentLineItems to us-gaap_PropertyPlantAndEquipmentGross" use="optional" priority="0" order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:title="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:title="Presentation : us-gaap_PropertyPlantAndEquipmentLineItems to us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" use="optional" priority="0" order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:title="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" xlink:title="Presentation : us-gaap_PropertyPlantAndEquipmentLineItems to us-gaap_PropertyPlantAndEquipmentNet" use="optional" priority="0" order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://60degreespharma.com/role/DEBTScheduleoftheCurrentFuturePaymentObligationsDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtByMaturityAbstract" xlink:label="us-gaap_LongTermDebtByMaturityAbstract" xlink:title="us-gaap_LongTermDebtByMaturityAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:title="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermDebtByMaturityAbstract" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:title="Presentation : us-gaap_LongTermDebtByMaturityAbstract to us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" use="optional" priority="0" order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:title="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermDebtByMaturityAbstract" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:title="Presentation : us-gaap_LongTermDebtByMaturityAbstract to us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" use="optional" priority="0" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:title="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermDebtByMaturityAbstract" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:title="Presentation : us-gaap_LongTermDebtByMaturityAbstract to us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" use="optional" priority="0" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:title="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermDebtByMaturityAbstract" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:title="Presentation : us-gaap_LongTermDebtByMaturityAbstract to us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" use="optional" priority="0" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:title="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermDebtByMaturityAbstract" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:title="Presentation : us-gaap_LongTermDebtByMaturityAbstract to us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" use="optional" priority="0" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:title="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermDebtByMaturityAbstract" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:title="Presentation : us-gaap_LongTermDebtByMaturityAbstract to us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" use="optional" priority="0" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt" xlink:title="us-gaap_LongTermDebt" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermDebtByMaturityAbstract" xlink:to="us-gaap_LongTermDebt" xlink:title="Presentation : us-gaap_LongTermDebtByMaturityAbstract to us-gaap_LongTermDebt" use="optional" priority="0" order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://60degreespharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofExchangeRatesalongwithHistoricalRatesDetails">
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_ScheduleOfExchangeRatesAlongWithHistoricalRatesAbstract" xlink:label="sxtp_ScheduleOfExchangeRatesAlongWithHistoricalRatesAbstract" xlink:title="sxtp_ScheduleOfExchangeRatesAlongWithHistoricalRatesAbstract" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_SummaryofSignificantAccountingPoliciesScheduleofExchangeRatesalongwithHistoricalRatesDetailsTable" xlink:label="sxtp_SummaryofSignificantAccountingPoliciesScheduleofExchangeRatesalongwithHistoricalRatesDetailsTable" xlink:title="sxtp_SummaryofSignificantAccountingPoliciesScheduleofExchangeRatesalongwithHistoricalRatesDetailsTable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sxtp_ScheduleOfExchangeRatesAlongWithHistoricalRatesAbstract" xlink:to="sxtp_SummaryofSignificantAccountingPoliciesScheduleofExchangeRatesalongwithHistoricalRatesDetailsTable" xlink:title="Presentation : sxtp_ScheduleOfExchangeRatesAlongWithHistoricalRatesAbstract to sxtp_SummaryofSignificantAccountingPoliciesScheduleofExchangeRatesalongwithHistoricalRatesDetailsTable" use="optional" priority="0" order="0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CurrencyAxis" xlink:label="srt_CurrencyAxis" xlink:title="srt_CurrencyAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sxtp_SummaryofSignificantAccountingPoliciesScheduleofExchangeRatesalongwithHistoricalRatesDetailsTable" xlink:to="srt_CurrencyAxis" xlink:title="Presentation : sxtp_SummaryofSignificantAccountingPoliciesScheduleofExchangeRatesalongwithHistoricalRatesDetailsTable to srt_CurrencyAxis" use="optional" priority="0" order="0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2025/currency-2025.xsd#currency_AllCurrenciesDomain" xlink:label="currency_AllCurrenciesDomain" xlink:title="currency_AllCurrenciesDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CurrencyAxis" xlink:to="currency_AllCurrenciesDomain" xlink:title="Presentation : srt_CurrencyAxis to currency_AllCurrenciesDomain" use="optional" priority="0" order="0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2025/currency-2025.xsd#currency_USD" xlink:label="currency_USD" xlink:title="currency_USD" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="currency_AllCurrenciesDomain" xlink:to="currency_USD" xlink:title="Presentation : currency_AllCurrenciesDomain to currency_USD" use="optional" priority="0" order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntercompanyForeignCurrencyBalanceLineItems" xlink:label="us-gaap_IntercompanyForeignCurrencyBalanceLineItems" xlink:title="us-gaap_IntercompanyForeignCurrencyBalanceLineItems" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sxtp_SummaryofSignificantAccountingPoliciesScheduleofExchangeRatesalongwithHistoricalRatesDetailsTable" xlink:to="us-gaap_IntercompanyForeignCurrencyBalanceLineItems" xlink:title="Presentation : sxtp_SummaryofSignificantAccountingPoliciesScheduleofExchangeRatesalongwithHistoricalRatesDetailsTable to us-gaap_IntercompanyForeignCurrencyBalanceLineItems" use="optional" priority="0" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_AverageExchangeRate" xlink:label="sxtp_AverageExchangeRate" xlink:title="sxtp_AverageExchangeRate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IntercompanyForeignCurrencyBalanceLineItems" xlink:to="sxtp_AverageExchangeRate" xlink:title="Presentation : us-gaap_IntercompanyForeignCurrencyBalanceLineItems to sxtp_AverageExchangeRate" use="optional" priority="0" order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCurrencyExchangeRateTranslation1" xlink:label="us-gaap_ForeignCurrencyExchangeRateTranslation1" xlink:title="us-gaap_ForeignCurrencyExchangeRateTranslation1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IntercompanyForeignCurrencyBalanceLineItems" xlink:to="us-gaap_ForeignCurrencyExchangeRateTranslation1" xlink:title="Presentation : us-gaap_IntercompanyForeignCurrencyBalanceLineItems to us-gaap_ForeignCurrencyExchangeRateTranslation1" use="optional" priority="0" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://60degreespharma.com/role/sxtp_r_ConsolidatedBalanceSheet_Parentheticals">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:title="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:title="us-gaap_StatementTable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" xlink:title="Presentation : us-gaap_StatementOfFinancialPositionAbstract to us-gaap_StatementTable" use="optional" priority="0" order="0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:title="us-gaap_StatementClassOfStockAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" xlink:title="Presentation : us-gaap_StatementTable to us-gaap_StatementClassOfStockAxis" use="optional" priority="0" order="0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xlink:title="us-gaap_ClassOfStockDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" xlink:title="Presentation : us-gaap_StatementClassOfStockAxis to us-gaap_ClassOfStockDomain" use="optional" priority="0" order="0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:title="us-gaap_SeriesAPreferredStockMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" xlink:title="Presentation : us-gaap_ClassOfStockDomain to us-gaap_SeriesAPreferredStockMember" use="optional" priority="0" order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:title="us-gaap_StatementLineItems" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:title="Presentation : us-gaap_StatementTable to us-gaap_StatementLineItems" use="optional" priority="0" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:title="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:title="Presentation : us-gaap_StatementLineItems to us-gaap_PreferredStockParOrStatedValuePerShare" use="optional" priority="0" order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:title="us-gaap_PreferredStockSharesAuthorized" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" xlink:title="Presentation : us-gaap_StatementLineItems to us-gaap_PreferredStockSharesAuthorized" use="optional" priority="0" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:title="us-gaap_PreferredStockSharesIssued" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" xlink:title="Presentation : us-gaap_StatementLineItems to us-gaap_PreferredStockSharesIssued" use="optional" priority="0" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:title="us-gaap_PreferredStockSharesOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" xlink:title="Presentation : us-gaap_StatementLineItems to us-gaap_PreferredStockSharesOutstanding" use="optional" priority="0" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:title="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" xlink:title="Presentation : us-gaap_StatementLineItems to us-gaap_CommonStockParOrStatedValuePerShare" use="optional" priority="0" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:title="us-gaap_CommonStockSharesAuthorized" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" xlink:title="Presentation : us-gaap_StatementLineItems to us-gaap_CommonStockSharesAuthorized" use="optional" priority="0" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xlink:title="us-gaap_CommonStockSharesIssued" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" xlink:title="Presentation : us-gaap_StatementLineItems to us-gaap_CommonStockSharesIssued" use="optional" priority="0" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:title="us-gaap_CommonStockSharesOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" xlink:title="Presentation : us-gaap_StatementLineItems to us-gaap_CommonStockSharesOutstanding" use="optional" priority="0" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://60degreespharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofLiabilitiesMeasuredatFairValueDetails">
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_ScheduleOfLiabilitiesMeasuredAtFairValueAbstract" xlink:label="sxtp_ScheduleOfLiabilitiesMeasuredAtFairValueAbstract" xlink:title="sxtp_ScheduleOfLiabilitiesMeasuredAtFairValueAbstract" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_SummaryofSignificantAccountingPoliciesScheduleofLiabilitiesMeasuredatFairValueDetailsTable" xlink:label="sxtp_SummaryofSignificantAccountingPoliciesScheduleofLiabilitiesMeasuredatFairValueDetailsTable" xlink:title="sxtp_SummaryofSignificantAccountingPoliciesScheduleofLiabilitiesMeasuredatFairValueDetailsTable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sxtp_ScheduleOfLiabilitiesMeasuredAtFairValueAbstract" xlink:to="sxtp_SummaryofSignificantAccountingPoliciesScheduleofLiabilitiesMeasuredatFairValueDetailsTable" xlink:title="Presentation : sxtp_ScheduleOfLiabilitiesMeasuredAtFairValueAbstract to sxtp_SummaryofSignificantAccountingPoliciesScheduleofLiabilitiesMeasuredatFairValueDetailsTable" use="optional" priority="0" order="0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" xlink:title="us-gaap_FinancialInstrumentAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sxtp_SummaryofSignificantAccountingPoliciesScheduleofLiabilitiesMeasuredatFairValueDetailsTable" xlink:to="us-gaap_FinancialInstrumentAxis" xlink:title="Presentation : sxtp_SummaryofSignificantAccountingPoliciesScheduleofLiabilitiesMeasuredatFairValueDetailsTable to us-gaap_FinancialInstrumentAxis" use="optional" priority="0" order="0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:title="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:title="Presentation : us-gaap_FinancialInstrumentAxis to us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" use="optional" priority="0" order="0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeMember" xlink:label="us-gaap_DerivativeMember" xlink:title="us-gaap_DerivativeMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_DerivativeMember" xlink:title="Presentation : us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain to us-gaap_DerivativeMember" use="optional" priority="0" order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:title="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sxtp_SummaryofSignificantAccountingPoliciesScheduleofLiabilitiesMeasuredatFairValueDetailsTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:title="Presentation : sxtp_SummaryofSignificantAccountingPoliciesScheduleofLiabilitiesMeasuredatFairValueDetailsTable to us-gaap_FairValueByFairValueHierarchyLevelAxis" use="optional" priority="0" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:title="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:title="Presentation : us-gaap_FairValueByFairValueHierarchyLevelAxis to us-gaap_FairValueMeasurementsFairValueHierarchyDomain" use="optional" priority="0" order="0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" xlink:title="us-gaap_FairValueInputsLevel1Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" xlink:title="Presentation : us-gaap_FairValueMeasurementsFairValueHierarchyDomain to us-gaap_FairValueInputsLevel1Member" use="optional" priority="0" order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:title="us-gaap_FairValueInputsLevel2Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" xlink:title="Presentation : us-gaap_FairValueMeasurementsFairValueHierarchyDomain to us-gaap_FairValueInputsLevel2Member" use="optional" priority="0" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" xlink:title="us-gaap_FairValueInputsLevel3Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" xlink:title="Presentation : us-gaap_FairValueMeasurementsFairValueHierarchyDomain to us-gaap_FairValueInputsLevel3Member" use="optional" priority="0" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:title="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sxtp_SummaryofSignificantAccountingPoliciesScheduleofLiabilitiesMeasuredatFairValueDetailsTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:title="Presentation : sxtp_SummaryofSignificantAccountingPoliciesScheduleofLiabilitiesMeasuredatFairValueDetailsTable to us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" use="optional" priority="0" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="us-gaap_DerivativeLiabilitiesCurrent" xlink:title="us-gaap_DerivativeLiabilitiesCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_DerivativeLiabilitiesCurrent" xlink:title="Presentation : us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to us-gaap_DerivativeLiabilitiesCurrent" use="optional" priority="0" order="0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://60degreespharma.com/role/DocumentAndEntityInformation">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" xlink:title="dei_CoverAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitiesTable" xlink:label="dei_EntitiesTable" xlink:title="dei_EntitiesTable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitiesTable" xlink:title="Presentation : dei_CoverAbstract to dei_EntitiesTable" use="optional" priority="9" order="0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:title="us-gaap_StatementClassOfStockAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntitiesTable" xlink:to="us-gaap_StatementClassOfStockAxis" xlink:title="Presentation : dei_EntitiesTable to us-gaap_StatementClassOfStockAxis" use="optional" priority="0" order="0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xlink:title="us-gaap_ClassOfStockDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" xlink:title="Presentation : us-gaap_StatementClassOfStockAxis to us-gaap_ClassOfStockDomain" use="optional" priority="0" order="0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:title="us-gaap_CommonStockMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonStockMember" xlink:title="Presentation : us-gaap_ClassOfStockDomain to us-gaap_CommonStockMember" use="optional" priority="0" order="0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" xlink:title="us-gaap_WarrantMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_WarrantMember" xlink:title="Presentation : us-gaap_ClassOfStockDomain to us-gaap_WarrantMember" use="optional" priority="0" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:title="dei_DocumentInformationLineItems" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntitiesTable" xlink:to="dei_DocumentInformationLineItems" xlink:title="Presentation : dei_EntitiesTable to dei_DocumentInformationLineItems" use="optional" priority="9" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:title="dei_EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" xlink:title="Presentation : dei_DocumentInformationLineItems to dei_EntityRegistrantName" use="optional" priority="9" order="0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:title="dei_DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" xlink:title="Presentation : dei_DocumentInformationLineItems to dei_DocumentType" use="optional" priority="9" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:title="dei_AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" xlink:title="Presentation : dei_DocumentInformationLineItems to dei_AmendmentFlag" use="optional" priority="9" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:title="dei_EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" xlink:title="Presentation : dei_DocumentInformationLineItems to dei_EntityCentralIndexKey" use="optional" priority="9" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:title="dei_DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" xlink:title="Presentation : dei_DocumentInformationLineItems to dei_DocumentPeriodEndDate" use="optional" priority="9" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xlink:title="dei_CurrentFiscalYearEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" xlink:title="Presentation : dei_DocumentInformationLineItems to dei_CurrentFiscalYearEndDate" use="optional" priority="9" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xlink:title="dei_DocumentFiscalYearFocus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" xlink:title="Presentation : dei_DocumentInformationLineItems to dei_DocumentFiscalYearFocus" use="optional" priority="9" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:title="dei_DocumentFiscalPeriodFocus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" xlink:title="Presentation : dei_DocumentInformationLineItems to dei_DocumentFiscalPeriodFocus" use="optional" priority="9" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" xlink:title="dei_DocumentQuarterlyReport" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentQuarterlyReport" xlink:title="Presentation : dei_DocumentInformationLineItems to dei_DocumentQuarterlyReport" use="optional" priority="9" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" xlink:title="dei_DocumentTransitionReport" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentTransitionReport" xlink:title="Presentation : dei_DocumentInformationLineItems to dei_DocumentTransitionReport" use="optional" priority="9" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xlink:title="dei_EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" xlink:title="Presentation : dei_DocumentInformationLineItems to dei_EntityFileNumber" use="optional" priority="9" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:title="dei_EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" xlink:title="Presentation : dei_DocumentInformationLineItems to dei_EntityIncorporationStateCountryCode" use="optional" priority="9" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xlink:title="dei_EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" xlink:title="Presentation : dei_DocumentInformationLineItems to dei_EntityTaxIdentificationNumber" use="optional" priority="9" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:title="dei_EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" xlink:title="Presentation : dei_DocumentInformationLineItems to dei_EntityAddressAddressLine1" use="optional" priority="9" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" xlink:title="dei_EntityAddressAddressLine2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine2" xlink:title="Presentation : dei_DocumentInformationLineItems to dei_EntityAddressAddressLine2" use="optional" priority="9" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:title="dei_EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" xlink:title="Presentation : dei_DocumentInformationLineItems to dei_EntityAddressCityOrTown" use="optional" priority="9" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:title="dei_EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" xlink:title="Presentation : dei_DocumentInformationLineItems to dei_EntityAddressStateOrProvince" use="optional" priority="9" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:title="dei_EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" xlink:title="Presentation : dei_DocumentInformationLineItems to dei_EntityAddressPostalZipCode" use="optional" priority="9" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xlink:title="dei_CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" xlink:title="Presentation : dei_DocumentInformationLineItems to dei_CityAreaCode" use="optional" priority="9" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xlink:title="dei_LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" xlink:title="Presentation : dei_DocumentInformationLineItems to dei_LocalPhoneNumber" use="optional" priority="9" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xlink:title="dei_Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" xlink:title="Presentation : dei_DocumentInformationLineItems to dei_Security12bTitle" use="optional" priority="9" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:title="dei_TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" xlink:title="Presentation : dei_DocumentInformationLineItems to dei_TradingSymbol" use="optional" priority="9" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xlink:title="dei_SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" xlink:title="Presentation : dei_DocumentInformationLineItems to dei_SecurityExchangeName" use="optional" priority="9" order="22" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xlink:title="dei_EntityCurrentReportingStatus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" xlink:title="Presentation : dei_DocumentInformationLineItems to dei_EntityCurrentReportingStatus" use="optional" priority="9" order="23" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" xlink:title="dei_EntityInteractiveDataCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" xlink:title="Presentation : dei_DocumentInformationLineItems to dei_EntityInteractiveDataCurrent" use="optional" priority="9" order="24" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xlink:title="dei_EntityFilerCategory" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" xlink:title="Presentation : dei_DocumentInformationLineItems to dei_EntityFilerCategory" use="optional" priority="9" order="25" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" xlink:title="dei_EntitySmallBusiness" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitySmallBusiness" xlink:title="Presentation : dei_DocumentInformationLineItems to dei_EntitySmallBusiness" use="optional" priority="9" order="26" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:title="dei_EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" xlink:title="Presentation : dei_DocumentInformationLineItems to dei_EntityEmergingGrowthCompany" use="optional" priority="9" order="27" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" xlink:title="dei_EntityExTransitionPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityExTransitionPeriod" xlink:title="Presentation : dei_DocumentInformationLineItems to dei_EntityExTransitionPeriod" use="optional" priority="9" order="28" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" xlink:title="dei_EntityShellCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" xlink:title="Presentation : dei_DocumentInformationLineItems to dei_EntityShellCompany" use="optional" priority="9" order="29" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:title="dei_EntityCommonStockSharesOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" xlink:title="Presentation : dei_DocumentInformationLineItems to dei_EntityCommonStockSharesOutstanding" use="optional" priority="9" order="30" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://60degreespharma.com/role/sxtp_r_ConsolidatedIncomeStatement">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xlink:title="us-gaap_IncomeStatementAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" xlink:title="us-gaap_Revenues" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_Revenues" xlink:title="Presentation : us-gaap_IncomeStatementAbstract to us-gaap_Revenues" use="optional" priority="0" order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue" xlink:title="us-gaap_CostOfRevenue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_CostOfRevenue" xlink:title="Presentation : us-gaap_IncomeStatementAbstract to us-gaap_CostOfRevenue" use="optional" priority="0" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit" xlink:title="us-gaap_GrossProfit" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_GrossProfit" xlink:title="Presentation : us-gaap_IncomeStatementAbstract to us-gaap_GrossProfit" use="optional" priority="0" order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueNotFromContractWithCustomerOther" xlink:label="us-gaap_RevenueNotFromContractWithCustomerOther" xlink:title="us-gaap_RevenueNotFromContractWithCustomerOther" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_RevenueNotFromContractWithCustomerOther" xlink:title="Presentation : us-gaap_IncomeStatementAbstract to us-gaap_RevenueNotFromContractWithCustomerOther" use="optional" priority="0" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_NetRevenueLoss" xlink:label="sxtp_NetRevenueLoss" xlink:title="sxtp_NetRevenueLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="sxtp_NetRevenueLoss" xlink:title="Presentation : us-gaap_IncomeStatementAbstract to sxtp_NetRevenueLoss" use="optional" priority="0" order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:title="us-gaap_OperatingExpensesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" xlink:title="Presentation : us-gaap_IncomeStatementAbstract to us-gaap_OperatingExpensesAbstract" use="optional" priority="0" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:title="us-gaap_ResearchAndDevelopmentExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" xlink:title="Presentation : us-gaap_OperatingExpensesAbstract to us-gaap_ResearchAndDevelopmentExpense" use="optional" priority="0" order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:title="us-gaap_GeneralAndAdministrativeExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" xlink:title="Presentation : us-gaap_OperatingExpensesAbstract to us-gaap_GeneralAndAdministrativeExpense" use="optional" priority="0" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" xlink:title="us-gaap_OperatingExpenses" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" xlink:title="Presentation : us-gaap_OperatingExpensesAbstract to us-gaap_OperatingExpenses" use="optional" priority="0" order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xlink:title="us-gaap_OperatingIncomeLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" xlink:title="Presentation : us-gaap_IncomeStatementAbstract to us-gaap_OperatingIncomeLoss" use="optional" priority="0" order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseNonoperating" xlink:label="us-gaap_InterestExpenseNonoperating" xlink:title="us-gaap_InterestExpenseNonoperating" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_InterestExpenseNonoperating" xlink:title="Presentation : us-gaap_IncomeStatementAbstract to us-gaap_InterestExpenseNonoperating" use="optional" priority="0" order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" xlink:title="us-gaap_FairValueAdjustmentOfWarrants" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" xlink:title="Presentation : us-gaap_IncomeStatementAbstract to us-gaap_FairValueAdjustmentOfWarrants" use="optional" priority="0" order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:title="us-gaap_OtherNonoperatingIncomeExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" xlink:title="Presentation : us-gaap_IncomeStatementAbstract to us-gaap_OtherNonoperatingIncomeExpense" use="optional" priority="0" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:title="us-gaap_InterestIncomeExpenseNonoperatingNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:title="Presentation : us-gaap_IncomeStatementAbstract to us-gaap_InterestIncomeExpenseNonoperatingNet" use="optional" priority="0" order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:title="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:title="Presentation : us-gaap_IncomeStatementAbstract to us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" use="optional" priority="0" order="11" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:title="us-gaap_IncomeTaxExpenseBenefit" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" xlink:title="Presentation : us-gaap_IncomeStatementAbstract to us-gaap_IncomeTaxExpenseBenefit" use="optional" priority="0" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" xlink:title="us-gaap_ProfitLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ProfitLoss" xlink:title="Presentation : us-gaap_IncomeStatementAbstract to us-gaap_ProfitLoss" use="optional" priority="0" order="13" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:title="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:title="Presentation : us-gaap_IncomeStatementAbstract to us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" use="optional" priority="0" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:title="us-gaap_NetIncomeLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" xlink:title="Presentation : us-gaap_IncomeStatementAbstract to us-gaap_NetIncomeLoss" use="optional" priority="0" order="15" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:title="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:title="Presentation : us-gaap_IncomeStatementAbstract to us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" use="optional" priority="0" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_1" xlink:title="us-gaap_ProfitLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_ProfitLoss_1" xlink:title="Presentation : us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract to us-gaap_ProfitLoss" use="optional" priority="0" order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealizedAfterTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealizedAfterTax" xlink:title="us-gaap_ForeignCurrencyTransactionGainLossUnrealizedAfterTax" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossUnrealizedAfterTax" xlink:title="Presentation : us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract to us-gaap_ForeignCurrencyTransactionGainLossUnrealizedAfterTax" use="optional" priority="0" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:title="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:title="Presentation : us-gaap_IncomeStatementAbstract to us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" use="optional" priority="0" order="17" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:title="us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:title="Presentation : us-gaap_IncomeStatementAbstract to us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" use="optional" priority="0" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:title="us-gaap_ComprehensiveIncomeNetOfTax" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" xlink:title="Presentation : us-gaap_IncomeStatementAbstract to us-gaap_ComprehensiveIncomeNetOfTax" use="optional" priority="0" order="19" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockDividendsAndOtherAdjustments" xlink:label="us-gaap_PreferredStockDividendsAndOtherAdjustments" xlink:title="us-gaap_PreferredStockDividendsAndOtherAdjustments" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_PreferredStockDividendsAndOtherAdjustments" xlink:title="Presentation : us-gaap_IncomeStatementAbstract to us-gaap_PreferredStockDividendsAndOtherAdjustments" use="optional" priority="0" order="20" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:title="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:title="Presentation : us-gaap_IncomeStatementAbstract to us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" use="optional" priority="0" order="21" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:title="us-gaap_EarningsPerShareAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareAbstract" xlink:title="Presentation : us-gaap_IncomeStatementAbstract to us-gaap_EarningsPerShareAbstract" use="optional" priority="0" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" xlink:title="us-gaap_EarningsPerShareBasic" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasic" xlink:title="Presentation : us-gaap_EarningsPerShareAbstract to us-gaap_EarningsPerShareBasic" use="optional" priority="0" order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:title="us-gaap_EarningsPerShareDiluted" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" xlink:title="Presentation : us-gaap_EarningsPerShareAbstract to us-gaap_EarningsPerShareDiluted" use="optional" priority="0" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:title="us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:title="Presentation : us-gaap_IncomeStatementAbstract to us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" use="optional" priority="0" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:title="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:title="Presentation : us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract to us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" use="optional" priority="0" order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:title="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:title="Presentation : us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract to us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" use="optional" priority="0" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://60degreespharma.com/role/INVENTORYDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="us-gaap_InventoryDisclosureAbstract" xlink:title="us-gaap_InventoryDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryWriteDown" xlink:label="us-gaap_InventoryWriteDown" xlink:title="us-gaap_InventoryWriteDown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryWriteDown" xlink:title="Presentation : us-gaap_InventoryDisclosureAbstract to us-gaap_InventoryWriteDown" use="optional" priority="0" order="0" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://60degreespharma.com/role/sxtp_r_ConsolidatedBalanceSheet">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:title="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" xlink:title="us-gaap_AssetsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract" xlink:title="Presentation : us-gaap_StatementOfFinancialPositionAbstract to us-gaap_AssetsAbstract" use="optional" priority="0" order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:title="us-gaap_AssetsCurrentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" xlink:title="Presentation : us-gaap_AssetsAbstract to us-gaap_AssetsCurrentAbstract" use="optional" priority="0" order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:title="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:title="Presentation : us-gaap_AssetsCurrentAbstract to us-gaap_CashAndCashEquivalentsAtCarryingValue" use="optional" priority="0" order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:title="us-gaap_AccountsReceivableNetCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" xlink:title="Presentation : us-gaap_AssetsCurrentAbstract to us-gaap_AccountsReceivableNetCurrent" use="optional" priority="0" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:title="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:title="Presentation : us-gaap_AssetsCurrentAbstract to us-gaap_PrepaidExpenseAndOtherAssetsCurrent" use="optional" priority="0" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments" xlink:title="us-gaap_ShortTermInvestments" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_ShortTermInvestments" xlink:title="Presentation : us-gaap_AssetsCurrentAbstract to us-gaap_ShortTermInvestments" use="optional" priority="0" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" xlink:title="us-gaap_InventoryNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_InventoryNet" xlink:title="Presentation : us-gaap_AssetsCurrentAbstract to us-gaap_InventoryNet" use="optional" priority="0" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xlink:title="us-gaap_AssetsCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" xlink:title="Presentation : us-gaap_AssetsCurrentAbstract to us-gaap_AssetsCurrent" use="optional" priority="0" order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:title="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" xlink:title="Presentation : us-gaap_AssetsCurrentAbstract to us-gaap_PropertyPlantAndEquipmentNet" use="optional" priority="0" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsAbstract" xlink:label="us-gaap_OtherAssetsAbstract" xlink:title="us-gaap_OtherAssetsAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OtherAssetsAbstract" xlink:title="Presentation : us-gaap_AssetsCurrentAbstract to us-gaap_OtherAssetsAbstract" use="optional" priority="0" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseNoncurrent" xlink:label="us-gaap_PrepaidExpenseNoncurrent" xlink:title="us-gaap_PrepaidExpenseNoncurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherAssetsAbstract" xlink:to="us-gaap_PrepaidExpenseNoncurrent" xlink:title="Presentation : us-gaap_OtherAssetsAbstract to us-gaap_PrepaidExpenseNoncurrent" use="optional" priority="0" order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:title="us-gaap_IntangibleAssetsNetExcludingGoodwill" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherAssetsAbstract" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:title="Presentation : us-gaap_OtherAssetsAbstract to us-gaap_IntangibleAssetsNetExcludingGoodwill" use="optional" priority="0" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:title="us-gaap_OtherAssetsNoncurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherAssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" xlink:title="Presentation : us-gaap_OtherAssetsAbstract to us-gaap_OtherAssetsNoncurrent" use="optional" priority="0" order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xlink:title="us-gaap_Assets" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_Assets" xlink:title="Presentation : us-gaap_AssetsCurrentAbstract to us-gaap_Assets" use="optional" priority="0" order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:title="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:title="Presentation : us-gaap_StatementOfFinancialPositionAbstract to us-gaap_LiabilitiesAndStockholdersEquityAbstract" use="optional" priority="0" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:title="us-gaap_LiabilitiesCurrentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" xlink:title="Presentation : us-gaap_LiabilitiesAndStockholdersEquityAbstract to us-gaap_LiabilitiesCurrentAbstract" use="optional" priority="0" order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:title="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:title="Presentation : us-gaap_LiabilitiesCurrentAbstract to us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" use="optional" priority="0" order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_SBAEIDLincludingAccruedInterestCurrent" xlink:label="sxtp_SBAEIDLincludingAccruedInterestCurrent" xlink:title="sxtp_SBAEIDLincludingAccruedInterestCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="sxtp_SBAEIDLincludingAccruedInterestCurrent" xlink:title="Presentation : us-gaap_LiabilitiesCurrentAbstract to sxtp_SBAEIDLincludingAccruedInterestCurrent" use="optional" priority="0" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="us-gaap_DerivativeLiabilitiesCurrent" xlink:title="us-gaap_DerivativeLiabilitiesCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DerivativeLiabilitiesCurrent" xlink:title="Presentation : us-gaap_LiabilitiesCurrentAbstract to us-gaap_DerivativeLiabilitiesCurrent" use="optional" priority="0" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xlink:title="us-gaap_LiabilitiesCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" xlink:title="Presentation : us-gaap_LiabilitiesCurrentAbstract to us-gaap_LiabilitiesCurrent" use="optional" priority="0" order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" xlink:title="us-gaap_LiabilitiesNoncurrentAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract" xlink:title="Presentation : us-gaap_StatementOfFinancialPositionAbstract to us-gaap_LiabilitiesNoncurrentAbstract" use="optional" priority="0" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_SBAEIDLincludingAccruedInterestNonCurrent" xlink:label="sxtp_SBAEIDLincludingAccruedInterestNonCurrent" xlink:title="sxtp_SBAEIDLincludingAccruedInterestNonCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="sxtp_SBAEIDLincludingAccruedInterestNonCurrent" xlink:title="Presentation : us-gaap_LiabilitiesNoncurrentAbstract to sxtp_SBAEIDLincludingAccruedInterestNonCurrent" use="optional" priority="0" order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent" xlink:title="us-gaap_LiabilitiesNoncurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrent" xlink:title="Presentation : us-gaap_LiabilitiesNoncurrentAbstract to us-gaap_LiabilitiesNoncurrent" use="optional" priority="0" order="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" xlink:title="us-gaap_Liabilities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_Liabilities" xlink:title="Presentation : us-gaap_StatementOfFinancialPositionAbstract to us-gaap_Liabilities" use="optional" priority="0" order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:title="us-gaap_CommitmentsAndContingencies" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" xlink:title="Presentation : us-gaap_StatementOfFinancialPositionAbstract to us-gaap_CommitmentsAndContingencies" use="optional" priority="0" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:title="us-gaap_StockholdersEquityAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" xlink:title="Presentation : us-gaap_StatementOfFinancialPositionAbstract to us-gaap_StockholdersEquityAbstract" use="optional" priority="0" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" xlink:title="us-gaap_PreferredStockValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" xlink:title="Presentation : us-gaap_StockholdersEquityAbstract to us-gaap_PreferredStockValue" use="optional" priority="0" order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:title="us-gaap_CommonStockValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" xlink:title="Presentation : us-gaap_StockholdersEquityAbstract to us-gaap_CommonStockValue" use="optional" priority="0" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:title="us-gaap_AdditionalPaidInCapital" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" xlink:title="Presentation : us-gaap_StockholdersEquityAbstract to us-gaap_AdditionalPaidInCapital" use="optional" priority="0" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:title="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:title="Presentation : us-gaap_StockholdersEquityAbstract to us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" use="optional" priority="0" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:title="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:title="Presentation : us-gaap_StockholdersEquityAbstract to us-gaap_RetainedEarningsAccumulatedDeficit" use="optional" priority="0" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:title="us-gaap_StockholdersEquity" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" xlink:title="Presentation : us-gaap_StockholdersEquityAbstract to us-gaap_StockholdersEquity" use="optional" priority="0" order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MinorityInterest" xlink:label="us-gaap_MinorityInterest" xlink:title="us-gaap_MinorityInterest" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_MinorityInterest" xlink:title="Presentation : us-gaap_StockholdersEquityAbstract to us-gaap_MinorityInterest" use="optional" priority="0" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:title="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:title="Presentation : us-gaap_StockholdersEquityAbstract to us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" use="optional" priority="0" order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:title="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" xlink:title="Presentation : us-gaap_StockholdersEquityAbstract to us-gaap_LiabilitiesAndStockholdersEquity" use="optional" priority="0" order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingArrLineItems" xlink:label="ecd_InsiderTradingArrLineItems" xlink:title="ecd_InsiderTradingArrLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrAdoptedFlag" xlink:label="ecd_Rule10b51ArrAdoptedFlag" xlink:title="ecd_Rule10b51ArrAdoptedFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_InsiderTradingArrLineItems" xlink:to="ecd_Rule10b51ArrAdoptedFlag" xlink:title="Presentation : ecd_InsiderTradingArrLineItems to ecd_Rule10b51ArrAdoptedFlag" use="optional" priority="9" order="0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrAdoptedFlag" xlink:label="ecd_NonRule10b51ArrAdoptedFlag" xlink:title="ecd_NonRule10b51ArrAdoptedFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_InsiderTradingArrLineItems" xlink:to="ecd_NonRule10b51ArrAdoptedFlag" xlink:title="Presentation : ecd_InsiderTradingArrLineItems to ecd_NonRule10b51ArrAdoptedFlag" use="optional" priority="9" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrTrmntdFlag" xlink:label="ecd_Rule10b51ArrTrmntdFlag" xlink:title="ecd_Rule10b51ArrTrmntdFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_InsiderTradingArrLineItems" xlink:to="ecd_Rule10b51ArrTrmntdFlag" xlink:title="Presentation : ecd_InsiderTradingArrLineItems to ecd_Rule10b51ArrTrmntdFlag" use="optional" priority="9" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrTrmntdFlag" xlink:label="ecd_NonRule10b51ArrTrmntdFlag" xlink:title="ecd_NonRule10b51ArrTrmntdFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ecd_InsiderTradingArrLineItems" xlink:to="ecd_NonRule10b51ArrTrmntdFlag" xlink:title="Presentation : ecd_InsiderTradingArrLineItems to ecd_NonRule10b51ArrTrmntdFlag" use="optional" priority="9" order="3" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://60degreespharma.com/role/NATUREOFOPERATIONSDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:title="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_NatureofOperationsDetailsTable" xlink:label="sxtp_NatureofOperationsDetailsTable" xlink:title="sxtp_NatureofOperationsDetailsTable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="sxtp_NatureofOperationsDetailsTable" xlink:title="Presentation : us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to sxtp_NatureofOperationsDetailsTable" use="optional" priority="0" order="0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:title="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sxtp_NatureofOperationsDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:title="Presentation : sxtp_NatureofOperationsDetailsTable to us-gaap_SubsidiarySaleOfStockAxis" use="optional" priority="0" order="0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:title="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:title="Presentation : us-gaap_SubsidiarySaleOfStockAxis to us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" priority="0" order="0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember" xlink:title="us-gaap_IPOMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" xlink:title="Presentation : us-gaap_SaleOfStockNameOfTransactionDomain to us-gaap_IPOMember" use="optional" priority="0" order="0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_TradeableWarrantsMember" xlink:label="sxtp_TradeableWarrantsMember" xlink:title="sxtp_TradeableWarrantsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="sxtp_TradeableWarrantsMember" xlink:title="Presentation : us-gaap_SaleOfStockNameOfTransactionDomain to sxtp_TradeableWarrantsMember" use="optional" priority="0" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_NontradeableWarrantsMember" xlink:label="sxtp_NontradeableWarrantsMember" xlink:title="sxtp_NontradeableWarrantsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="sxtp_NontradeableWarrantsMember" xlink:title="Presentation : us-gaap_SaleOfStockNameOfTransactionDomain to sxtp_NontradeableWarrantsMember" use="optional" priority="0" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_TradeableAndNonTradeableWarrantsMember" xlink:label="sxtp_TradeableAndNonTradeableWarrantsMember" xlink:title="sxtp_TradeableAndNonTradeableWarrantsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="sxtp_TradeableAndNonTradeableWarrantsMember" xlink:title="Presentation : us-gaap_SaleOfStockNameOfTransactionDomain to sxtp_TradeableAndNonTradeableWarrantsMember" use="optional" priority="0" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:title="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sxtp_NatureofOperationsDetailsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:title="Presentation : sxtp_NatureofOperationsDetailsTable to us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" use="optional" priority="0" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:title="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:title="Presentation : us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to us-gaap_StockIssuedDuringPeriodSharesNewIssues" use="optional" priority="0" order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:title="us-gaap_SharesIssuedPricePerShare" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" xlink:title="Presentation : us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to us-gaap_SharesIssuedPricePerShare" use="optional" priority="0" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:title="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:title="Presentation : us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to us-gaap_ProceedsFromIssuanceInitialPublicOffering" use="optional" priority="0" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:title="us-gaap_WarrantsAndRightsOutstandingTerm" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:title="Presentation : us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to us-gaap_WarrantsAndRightsOutstandingTerm" use="optional" priority="0" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:title="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:title="Presentation : us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to us-gaap_CashAndCashEquivalentsAtCarryingValue" use="optional" priority="0" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:title="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:title="Presentation : us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to us-gaap_NetCashProvidedByUsedInOperatingActivities" use="optional" priority="0" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_SBAEIDLincludingAccruedInterestCurrent" xlink:label="sxtp_SBAEIDLincludingAccruedInterestCurrent" xlink:title="sxtp_SBAEIDLincludingAccruedInterestCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="sxtp_SBAEIDLincludingAccruedInterestCurrent" xlink:title="Presentation : us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to sxtp_SBAEIDLincludingAccruedInterestCurrent" use="optional" priority="0" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:title="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:title="Presentation : us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" use="optional" priority="0" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://60degreespharma.com/role/INTANGIBLEASSETSScheduleofEstimatedFutureAmortizationExpenseforOurPatentsandWebsiteDevelopmentCostsDetails">
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_ScheduleOfEstimatedFutureAmortizationExpenseForOurPatentsAndWebsiteDevelopmentCostsAbstract" xlink:label="sxtp_ScheduleOfEstimatedFutureAmortizationExpenseForOurPatentsAndWebsiteDevelopmentCostsAbstract" xlink:title="sxtp_ScheduleOfEstimatedFutureAmortizationExpenseForOurPatentsAndWebsiteDevelopmentCostsAbstract" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_IntangibleAssetsScheduleofEstimatedFutureAmortizationExpenseforOurPatentsandWebsiteDevelopmentCostsDetailsTable" xlink:label="sxtp_IntangibleAssetsScheduleofEstimatedFutureAmortizationExpenseforOurPatentsandWebsiteDevelopmentCostsDetailsTable" xlink:title="sxtp_IntangibleAssetsScheduleofEstimatedFutureAmortizationExpenseforOurPatentsandWebsiteDevelopmentCostsDetailsTable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sxtp_ScheduleOfEstimatedFutureAmortizationExpenseForOurPatentsAndWebsiteDevelopmentCostsAbstract" xlink:to="sxtp_IntangibleAssetsScheduleofEstimatedFutureAmortizationExpenseforOurPatentsandWebsiteDevelopmentCostsDetailsTable" xlink:title="Presentation : sxtp_ScheduleOfEstimatedFutureAmortizationExpenseForOurPatentsAndWebsiteDevelopmentCostsAbstract to sxtp_IntangibleAssetsScheduleofEstimatedFutureAmortizationExpenseforOurPatentsandWebsiteDevelopmentCostsDetailsTable" use="optional" priority="0" order="0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:title="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sxtp_IntangibleAssetsScheduleofEstimatedFutureAmortizationExpenseforOurPatentsandWebsiteDevelopmentCostsDetailsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:title="Presentation : sxtp_IntangibleAssetsScheduleofEstimatedFutureAmortizationExpenseforOurPatentsandWebsiteDevelopmentCostsDetailsTable to us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" use="optional" priority="0" order="0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:title="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:title="Presentation : us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis to us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" use="optional" priority="0" order="0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PatentsMember" xlink:label="us-gaap_PatentsMember" xlink:title="us-gaap_PatentsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_PatentsMember" xlink:title="Presentation : us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain to us-gaap_PatentsMember" use="optional" priority="0" order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:title="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:title="Presentation : us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain to us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" use="optional" priority="0" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:title="us-gaap_FiniteLivedIntangibleAssetsLineItems" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sxtp_IntangibleAssetsScheduleofEstimatedFutureAmortizationExpenseforOurPatentsandWebsiteDevelopmentCostsDetailsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:title="Presentation : sxtp_IntangibleAssetsScheduleofEstimatedFutureAmortizationExpenseforOurPatentsandWebsiteDevelopmentCostsDetailsTable to us-gaap_FiniteLivedIntangibleAssetsLineItems" use="optional" priority="0" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:title="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:title="Presentation : us-gaap_FiniteLivedIntangibleAssetsLineItems to us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" use="optional" priority="0" order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:title="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:title="Presentation : us-gaap_FiniteLivedIntangibleAssetsLineItems to us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" use="optional" priority="0" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:title="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:title="Presentation : us-gaap_FiniteLivedIntangibleAssetsLineItems to us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" use="optional" priority="0" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:title="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:title="Presentation : us-gaap_FiniteLivedIntangibleAssetsLineItems to us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" use="optional" priority="0" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:title="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:title="Presentation : us-gaap_FiniteLivedIntangibleAssetsLineItems to us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" use="optional" priority="0" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:title="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:title="Presentation : us-gaap_FiniteLivedIntangibleAssetsLineItems to us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" use="optional" priority="0" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:title="us-gaap_FiniteLivedIntangibleAssetsNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:title="Presentation : us-gaap_FiniteLivedIntangibleAssetsLineItems to us-gaap_FiniteLivedIntangibleAssetsNet" use="optional" priority="0" order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://60degreespharma.com/role/DEBTDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:title="us-gaap_DebtDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_DebtDetailsTable" xlink:label="sxtp_DebtDetailsTable" xlink:title="sxtp_DebtDetailsTable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="sxtp_DebtDetailsTable" xlink:title="Presentation : us-gaap_DebtDisclosureAbstract to sxtp_DebtDetailsTable" use="optional" priority="0" order="0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:title="us-gaap_DebtInstrumentAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sxtp_DebtDetailsTable" xlink:to="us-gaap_DebtInstrumentAxis" xlink:title="Presentation : sxtp_DebtDetailsTable to us-gaap_DebtInstrumentAxis" use="optional" priority="0" order="0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:title="us-gaap_DebtInstrumentNameDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" xlink:title="Presentation : us-gaap_DebtInstrumentAxis to us-gaap_DebtInstrumentNameDomain" use="optional" priority="0" order="0" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_SmallBusinessAdministrationMember" xlink:label="sxtp_SmallBusinessAdministrationMember" xlink:title="sxtp_SmallBusinessAdministrationMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="sxtp_SmallBusinessAdministrationMember" xlink:title="Presentation : us-gaap_DebtInstrumentNameDomain to sxtp_SmallBusinessAdministrationMember" use="optional" priority="0" order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_BalloonPaymentMember" xlink:label="sxtp_BalloonPaymentMember" xlink:title="sxtp_BalloonPaymentMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="sxtp_BalloonPaymentMember" xlink:title="Presentation : us-gaap_DebtInstrumentNameDomain to sxtp_BalloonPaymentMember" use="optional" priority="0" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_SBAMember" xlink:label="sxtp_SBAMember" xlink:title="sxtp_SBAMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="sxtp_SBAMember" xlink:title="Presentation : us-gaap_DebtInstrumentNameDomain to sxtp_SBAMember" use="optional" priority="0" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems" xlink:title="us-gaap_DebtInstrumentLineItems" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sxtp_DebtDetailsTable" xlink:to="us-gaap_DebtInstrumentLineItems" xlink:title="Presentation : sxtp_DebtDetailsTable to us-gaap_DebtInstrumentLineItems" use="optional" priority="0" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" xlink:title="us-gaap_DebtInstrumentFaceAmount" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" xlink:title="Presentation : us-gaap_DebtInstrumentLineItems to us-gaap_DebtInstrumentFaceAmount" use="optional" priority="0" order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:title="us-gaap_DebtInstrumentInterestRateEffectivePercentage" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:title="Presentation : us-gaap_DebtInstrumentLineItems to us-gaap_DebtInstrumentInterestRateEffectivePercentage" use="optional" priority="0" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" xlink:label="us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" xlink:title="us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" xlink:title="Presentation : us-gaap_DebtInstrumentLineItems to us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" use="optional" priority="0" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate" xlink:title="us-gaap_DebtInstrumentMaturityDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" xlink:title="Presentation : us-gaap_DebtInstrumentLineItems to us-gaap_DebtInstrumentMaturityDate" use="optional" priority="0" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:title="us-gaap_AmortizationOfFinancingCostsAndDiscounts" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:title="Presentation : us-gaap_DebtInstrumentLineItems to us-gaap_AmortizationOfFinancingCostsAndDiscounts" use="optional" priority="0" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtCurrent" xlink:label="us-gaap_LongTermDebtCurrent" xlink:title="us-gaap_LongTermDebtCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebtCurrent" xlink:title="Presentation : us-gaap_DebtInstrumentLineItems to us-gaap_LongTermDebtCurrent" use="optional" priority="0" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent" xlink:title="us-gaap_LiabilitiesNoncurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LiabilitiesNoncurrent" xlink:title="Presentation : us-gaap_DebtInstrumentLineItems to us-gaap_LiabilitiesNoncurrent" use="optional" priority="0" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://60degreespharma.com/role/DERIVATIVELIABILITIESDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:title="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_DerivativeLiabilitiesDetailsTable" xlink:label="sxtp_DerivativeLiabilitiesDetailsTable" xlink:title="sxtp_DerivativeLiabilitiesDetailsTable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="sxtp_DerivativeLiabilitiesDetailsTable" xlink:title="Presentation : us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract to sxtp_DerivativeLiabilitiesDetailsTable" use="optional" priority="0" order="0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:title="us-gaap_StatementClassOfStockAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sxtp_DerivativeLiabilitiesDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" xlink:title="Presentation : sxtp_DerivativeLiabilitiesDetailsTable to us-gaap_StatementClassOfStockAxis" use="optional" priority="0" order="0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xlink:title="us-gaap_ClassOfStockDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" xlink:title="Presentation : us-gaap_StatementClassOfStockAxis to us-gaap_ClassOfStockDomain" use="optional" priority="0" order="0" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_SeriesANonVotingConvertiblePreferredStockMember" xlink:label="sxtp_SeriesANonVotingConvertiblePreferredStockMember" xlink:title="sxtp_SeriesANonVotingConvertiblePreferredStockMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="sxtp_SeriesANonVotingConvertiblePreferredStockMember" xlink:title="Presentation : us-gaap_ClassOfStockDomain to sxtp_SeriesANonVotingConvertiblePreferredStockMember" use="optional" priority="0" order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems" xlink:label="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems" xlink:title="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sxtp_DerivativeLiabilitiesDetailsTable" xlink:to="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems" xlink:title="Presentation : sxtp_DerivativeLiabilitiesDetailsTable to us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems" use="optional" priority="0" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1" xlink:title="us-gaap_ConversionOfStockSharesConverted1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" xlink:title="Presentation : us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems to us-gaap_ConversionOfStockSharesConverted1" use="optional" priority="0" order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction" xlink:label="us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction" xlink:title="us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems" xlink:to="us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction" xlink:title="Presentation : us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems to us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction" use="optional" priority="0" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ExcessStockSharesAuthorized" xlink:label="us-gaap_ExcessStockSharesAuthorized" xlink:title="us-gaap_ExcessStockSharesAuthorized" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems" xlink:to="us-gaap_ExcessStockSharesAuthorized" xlink:title="Presentation : us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems to us-gaap_ExcessStockSharesAuthorized" use="optional" priority="0" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_MilestonePayment" xlink:label="sxtp_MilestonePayment" xlink:title="sxtp_MilestonePayment" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems" xlink:to="sxtp_MilestonePayment" xlink:title="Presentation : us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems to sxtp_MilestonePayment" use="optional" priority="0" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockRedemptionTerms" xlink:label="us-gaap_PreferredStockRedemptionTerms" xlink:title="us-gaap_PreferredStockRedemptionTerms" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems" xlink:to="us-gaap_PreferredStockRedemptionTerms" xlink:title="Presentation : us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems to us-gaap_PreferredStockRedemptionTerms" use="optional" priority="0" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_RoyaltyPercentage" xlink:label="sxtp_RoyaltyPercentage" xlink:title="sxtp_RoyaltyPercentage" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems" xlink:to="sxtp_RoyaltyPercentage" xlink:title="Presentation : us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems to sxtp_RoyaltyPercentage" use="optional" priority="0" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet" xlink:title="us-gaap_DerivativeGainLossOnDerivativeNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet" xlink:title="Presentation : us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems to us-gaap_DerivativeGainLossOnDerivativeNet" use="optional" priority="0" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://60degreespharma.com/role/SHAREBASEDCOMPENSATIONScheduleofShareBasedCompensationExpensesDetails">
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_ScheduleOfShareBasedCompensationExpensesAbstract" xlink:label="sxtp_ScheduleOfShareBasedCompensationExpensesAbstract" xlink:title="sxtp_ScheduleOfShareBasedCompensationExpensesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:title="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sxtp_ScheduleOfShareBasedCompensationExpensesAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:title="Presentation : sxtp_ScheduleOfShareBasedCompensationExpensesAbstract to us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" use="optional" priority="0" order="0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:title="us-gaap_IncomeStatementLocationAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" xlink:title="Presentation : us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable to us-gaap_IncomeStatementLocationAxis" use="optional" priority="0" order="0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:title="us-gaap_IncomeStatementLocationDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" xlink:title="Presentation : us-gaap_IncomeStatementLocationAxis to us-gaap_IncomeStatementLocationDomain" use="optional" priority="0" order="0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:title="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:title="Presentation : us-gaap_IncomeStatementLocationDomain to us-gaap_ResearchAndDevelopmentExpenseMember" use="optional" priority="0" order="0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:title="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:title="Presentation : us-gaap_IncomeStatementLocationDomain to us-gaap_GeneralAndAdministrativeExpenseMember" use="optional" priority="0" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:title="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:title="Presentation : us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable to us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" use="optional" priority="0" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:title="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" xlink:title="Presentation : us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems to us-gaap_AllocatedShareBasedCompensationExpense" use="optional" priority="0" order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://60degreespharma.com/role/INVENTORYScheduleofInventoryDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryNetAbstract" xlink:label="us-gaap_InventoryNetAbstract" xlink:title="us-gaap_InventoryNetAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryRawMaterials" xlink:label="us-gaap_InventoryRawMaterials" xlink:title="us-gaap_InventoryRawMaterials" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryNetAbstract" xlink:to="us-gaap_InventoryRawMaterials" xlink:title="Presentation : us-gaap_InventoryNetAbstract to us-gaap_InventoryRawMaterials" use="optional" priority="0" order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryWorkInProcess" xlink:label="us-gaap_InventoryWorkInProcess" xlink:title="us-gaap_InventoryWorkInProcess" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryNetAbstract" xlink:to="us-gaap_InventoryWorkInProcess" xlink:title="Presentation : us-gaap_InventoryNetAbstract to us-gaap_InventoryWorkInProcess" use="optional" priority="0" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryFinishedGoods" xlink:label="us-gaap_InventoryFinishedGoods" xlink:title="us-gaap_InventoryFinishedGoods" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryNetAbstract" xlink:to="us-gaap_InventoryFinishedGoods" xlink:title="Presentation : us-gaap_InventoryNetAbstract to us-gaap_InventoryFinishedGoods" use="optional" priority="0" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryGross" xlink:label="us-gaap_InventoryGross" xlink:title="us-gaap_InventoryGross" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryNetAbstract" xlink:to="us-gaap_InventoryGross" xlink:title="Presentation : us-gaap_InventoryNetAbstract to us-gaap_InventoryGross" use="optional" priority="0" order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryAdjustments" xlink:label="us-gaap_InventoryAdjustments" xlink:title="us-gaap_InventoryAdjustments" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryNetAbstract" xlink:to="us-gaap_InventoryAdjustments" xlink:title="Presentation : us-gaap_InventoryNetAbstract to us-gaap_InventoryAdjustments" use="optional" priority="0" order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" xlink:title="us-gaap_InventoryNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InventoryNetAbstract" xlink:to="us-gaap_InventoryNet" xlink:title="Presentation : us-gaap_InventoryNetAbstract to us-gaap_InventoryNet" use="optional" priority="0" order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://60degreespharma.com/role/INCOMETAXESDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:title="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FederalStateAndLocalIncomeTaxExpenseBenefitContinuingOperations" xlink:label="us-gaap_FederalStateAndLocalIncomeTaxExpenseBenefitContinuingOperations" xlink:title="us-gaap_FederalStateAndLocalIncomeTaxExpenseBenefitContinuingOperations" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_FederalStateAndLocalIncomeTaxExpenseBenefitContinuingOperations" xlink:title="Presentation : us-gaap_IncomeTaxDisclosureAbstract to us-gaap_FederalStateAndLocalIncomeTaxExpenseBenefitContinuingOperations" use="optional" priority="0" order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:title="us-gaap_IncomeTaxExpenseBenefit" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" xlink:title="Presentation : us-gaap_IncomeTaxDisclosureAbstract to us-gaap_IncomeTaxExpenseBenefit" use="optional" priority="0" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:title="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:title="Presentation : us-gaap_IncomeTaxDisclosureAbstract to us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" use="optional" priority="0" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther" xlink:title="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther" xlink:title="Presentation : us-gaap_IncomeTaxDisclosureAbstract to us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther" use="optional" priority="0" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://60degreespharma.com/role/DERIVATIVELIABILITIESScheduleofDerivativeLiabilitiesMeasuredatFairValueonaRecurringBasisDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:title="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_ScheduleOfDerivativeLiabilitiesMeasuredAtFairValueOnARecurringBasisAbstract" xlink:label="sxtp_ScheduleOfDerivativeLiabilitiesMeasuredAtFairValueOnARecurringBasisAbstract" xlink:title="sxtp_ScheduleOfDerivativeLiabilitiesMeasuredAtFairValueOnARecurringBasisAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="sxtp_ScheduleOfDerivativeLiabilitiesMeasuredAtFairValueOnARecurringBasisAbstract" xlink:title="Presentation : us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract to sxtp_ScheduleOfDerivativeLiabilitiesMeasuredAtFairValueOnARecurringBasisAbstract" order="0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_DerivativeLiabilitiesScheduleofDerivativeLiabilitiesMeasuredatFairValueonaRecurringBasisDetailsTable" xlink:label="sxtp_DerivativeLiabilitiesScheduleofDerivativeLiabilitiesMeasuredatFairValueonaRecurringBasisDetailsTable" xlink:title="sxtp_DerivativeLiabilitiesScheduleofDerivativeLiabilitiesMeasuredatFairValueonaRecurringBasisDetailsTable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sxtp_ScheduleOfDerivativeLiabilitiesMeasuredAtFairValueOnARecurringBasisAbstract" xlink:to="sxtp_DerivativeLiabilitiesScheduleofDerivativeLiabilitiesMeasuredatFairValueonaRecurringBasisDetailsTable" xlink:title="Presentation : sxtp_ScheduleOfDerivativeLiabilitiesMeasuredAtFairValueOnARecurringBasisAbstract to sxtp_DerivativeLiabilitiesScheduleofDerivativeLiabilitiesMeasuredatFairValueonaRecurringBasisDetailsTable" use="optional" priority="0" order="0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:title="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sxtp_DerivativeLiabilitiesScheduleofDerivativeLiabilitiesMeasuredatFairValueonaRecurringBasisDetailsTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:title="Presentation : sxtp_DerivativeLiabilitiesScheduleofDerivativeLiabilitiesMeasuredatFairValueonaRecurringBasisDetailsTable to us-gaap_FairValueByMeasurementFrequencyAxis" use="optional" priority="0" order="0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" xlink:title="us-gaap_FairValueMeasurementFrequencyDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" xlink:title="Presentation : us-gaap_FairValueByMeasurementFrequencyAxis to us-gaap_FairValueMeasurementFrequencyDomain" use="optional" priority="0" order="0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" xlink:title="us-gaap_FairValueMeasurementsRecurringMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" xlink:title="Presentation : us-gaap_FairValueMeasurementFrequencyDomain to us-gaap_FairValueMeasurementsRecurringMember" use="optional" priority="0" order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" xlink:title="us-gaap_DerivativeInstrumentRiskAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sxtp_DerivativeLiabilitiesScheduleofDerivativeLiabilitiesMeasuredatFairValueonaRecurringBasisDetailsTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" xlink:title="Presentation : sxtp_DerivativeLiabilitiesScheduleofDerivativeLiabilitiesMeasuredatFairValueonaRecurringBasisDetailsTable to us-gaap_DerivativeInstrumentRiskAxis" use="optional" priority="0" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain" xlink:title="us-gaap_DerivativeContractTypeDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain" xlink:title="Presentation : us-gaap_DerivativeInstrumentRiskAxis to us-gaap_DerivativeContractTypeDomain" use="optional" priority="0" order="0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_ContingentMilestonePaymentMember" xlink:label="sxtp_ContingentMilestonePaymentMember" xlink:title="sxtp_ContingentMilestonePaymentMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="sxtp_ContingentMilestonePaymentMember" xlink:title="Presentation : us-gaap_DerivativeContractTypeDomain to sxtp_ContingentMilestonePaymentMember" use="optional" priority="0" order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_BridgeSharesMember" xlink:label="sxtp_BridgeSharesMember" xlink:title="sxtp_BridgeSharesMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="sxtp_BridgeSharesMember" xlink:title="Presentation : us-gaap_DerivativeContractTypeDomain to sxtp_BridgeSharesMember" use="optional" priority="0" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" xlink:title="us-gaap_WarrantMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="us-gaap_WarrantMember" xlink:title="Presentation : us-gaap_DerivativeContractTypeDomain to us-gaap_WarrantMember" use="optional" priority="0" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:title="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sxtp_DerivativeLiabilitiesScheduleofDerivativeLiabilitiesMeasuredatFairValueonaRecurringBasisDetailsTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:title="Presentation : sxtp_DerivativeLiabilitiesScheduleofDerivativeLiabilitiesMeasuredatFairValueonaRecurringBasisDetailsTable to us-gaap_FairValueByFairValueHierarchyLevelAxis" use="optional" priority="0" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:title="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:title="Presentation : us-gaap_FairValueByFairValueHierarchyLevelAxis to us-gaap_FairValueMeasurementsFairValueHierarchyDomain" use="optional" priority="0" order="0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" xlink:title="us-gaap_FairValueInputsLevel3Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" xlink:title="Presentation : us-gaap_FairValueMeasurementsFairValueHierarchyDomain to us-gaap_FairValueInputsLevel3Member" use="optional" priority="0" order="0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:title="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sxtp_DerivativeLiabilitiesScheduleofDerivativeLiabilitiesMeasuredatFairValueonaRecurringBasisDetailsTable" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:title="Presentation : sxtp_DerivativeLiabilitiesScheduleofDerivativeLiabilitiesMeasuredatFairValueonaRecurringBasisDetailsTable to us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" use="optional" priority="0" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="us-gaap_DerivativeLiabilitiesCurrent" xlink:title="us-gaap_DerivativeLiabilitiesCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_DerivativeLiabilitiesCurrent" xlink:title="Presentation : us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems to us-gaap_DerivativeLiabilitiesCurrent" use="optional" priority="0" order="0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisMarkToMarketAdjustment" xlink:label="sxtp_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisMarkToMarketAdjustment" xlink:title="sxtp_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisMarkToMarketAdjustment" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="sxtp_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisMarkToMarketAdjustment" xlink:title="Presentation : us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems to sxtp_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisMarkToMarketAdjustment" use="optional" priority="0" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="us-gaap_DerivativeLiabilitiesCurrent_1" xlink:title="us-gaap_DerivativeLiabilitiesCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_DerivativeLiabilitiesCurrent_1" xlink:title="Presentation : us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems to us-gaap_DerivativeLiabilitiesCurrent" use="optional" priority="0" order="2" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://60degreespharma.com/role/COMMITMENTSANDCONTINGENCIESDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:title="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_CommitmentsandContingenciesDetailsTable" xlink:label="sxtp_CommitmentsandContingenciesDetailsTable" xlink:title="sxtp_CommitmentsandContingenciesDetailsTable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="sxtp_CommitmentsandContingenciesDetailsTable" xlink:title="Presentation : us-gaap_CommitmentsAndContingenciesDisclosureAbstract to sxtp_CommitmentsandContingenciesDetailsTable" use="optional" priority="0" order="0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:title="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sxtp_CommitmentsandContingenciesDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:title="Presentation : sxtp_CommitmentsandContingenciesDetailsTable to us-gaap_SubsidiarySaleOfStockAxis" use="optional" priority="0" order="0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:title="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:title="Presentation : us-gaap_SubsidiarySaleOfStockAxis to us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" priority="0" order="0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember" xlink:title="us-gaap_IPOMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" xlink:title="Presentation : us-gaap_SaleOfStockNameOfTransactionDomain to us-gaap_IPOMember" use="optional" priority="0" order="0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:title="srt_RangeAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sxtp_CommitmentsandContingenciesDetailsTable" xlink:to="srt_RangeAxis" xlink:title="Presentation : sxtp_CommitmentsandContingenciesDetailsTable to srt_RangeAxis" use="optional" priority="0" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:title="srt_RangeMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:title="Presentation : srt_RangeAxis to srt_RangeMember" use="optional" priority="0" order="0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:title="srt_MinimumMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" xlink:title="Presentation : srt_RangeMember to srt_MinimumMember" use="optional" priority="0" order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:title="srt_MaximumMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" xlink:title="Presentation : srt_RangeMember to srt_MaximumMember" use="optional" priority="0" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" xlink:title="srt_TitleOfIndividualAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sxtp_CommitmentsandContingenciesDetailsTable" xlink:to="srt_TitleOfIndividualAxis" xlink:title="Presentation : sxtp_CommitmentsandContingenciesDetailsTable to srt_TitleOfIndividualAxis" use="optional" priority="0" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="Presentation : srt_TitleOfIndividualAxis to srt_TitleOfIndividualWithRelationshipToEntityDomain" use="optional" priority="0" order="0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_BoardOfDirectorsChairmanMember" xlink:label="srt_BoardOfDirectorsChairmanMember" xlink:title="srt_BoardOfDirectorsChairmanMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_BoardOfDirectorsChairmanMember" xlink:title="Presentation : srt_TitleOfIndividualWithRelationshipToEntityDomain to srt_BoardOfDirectorsChairmanMember" use="optional" priority="0" order="0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember" xlink:title="srt_DirectorMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_DirectorMember" xlink:title="Presentation : srt_TitleOfIndividualWithRelationshipToEntityDomain to srt_DirectorMember" use="optional" priority="0" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:title="us-gaap_RelatedPartyTransactionAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sxtp_CommitmentsandContingenciesDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" xlink:title="Presentation : sxtp_CommitmentsandContingenciesDetailsTable to us-gaap_RelatedPartyTransactionAxis" use="optional" priority="0" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:title="us-gaap_RelatedPartyTransactionDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" xlink:title="Presentation : us-gaap_RelatedPartyTransactionAxis to us-gaap_RelatedPartyTransactionDomain" use="optional" priority="0" order="0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_CherylXuMember" xlink:label="sxtp_CherylXuMember" xlink:title="sxtp_CherylXuMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="sxtp_CherylXuMember" xlink:title="Presentation : us-gaap_RelatedPartyTransactionDomain to sxtp_CherylXuMember" use="optional" priority="0" order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_PaulFieldMember" xlink:label="sxtp_PaulFieldMember" xlink:title="sxtp_PaulFieldMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="sxtp_PaulFieldMember" xlink:title="Presentation : us-gaap_RelatedPartyTransactionDomain to sxtp_PaulFieldMember" use="optional" priority="0" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_CharlesAllenMember" xlink:label="sxtp_CharlesAllenMember" xlink:title="sxtp_CharlesAllenMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="sxtp_CharlesAllenMember" xlink:title="Presentation : us-gaap_RelatedPartyTransactionDomain to sxtp_CharlesAllenMember" use="optional" priority="0" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_StephenTooveyMember" xlink:label="sxtp_StephenTooveyMember" xlink:title="sxtp_StephenTooveyMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="sxtp_StephenTooveyMember" xlink:title="Presentation : us-gaap_RelatedPartyTransactionDomain to sxtp_StephenTooveyMember" use="optional" priority="0" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_USGovernmentSalesMember" xlink:label="sxtp_USGovernmentSalesMember" xlink:title="sxtp_USGovernmentSalesMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="sxtp_USGovernmentSalesMember" xlink:title="Presentation : us-gaap_RelatedPartyTransactionDomain to sxtp_USGovernmentSalesMember" use="optional" priority="0" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_USArmyAgreementMember" xlink:label="sxtp_USArmyAgreementMember" xlink:title="sxtp_USArmyAgreementMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="sxtp_USArmyAgreementMember" xlink:title="Presentation : us-gaap_RelatedPartyTransactionDomain to sxtp_USArmyAgreementMember" use="optional" priority="0" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_TuftsMedicalCenterAgreementMember" xlink:label="sxtp_TuftsMedicalCenterAgreementMember" xlink:title="sxtp_TuftsMedicalCenterAgreementMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="sxtp_TuftsMedicalCenterAgreementMember" xlink:title="Presentation : us-gaap_RelatedPartyTransactionDomain to sxtp_TuftsMedicalCenterAgreementMember" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sxtp_CommitmentsandContingenciesDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="Presentation : sxtp_CommitmentsandContingenciesDetailsTable to us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" use="optional" priority="0" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" xlink:title="us-gaap_RelatedPartyDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" xlink:title="Presentation : us-gaap_RelatedPartyTransactionsByRelatedPartyAxis to us-gaap_RelatedPartyDomain" use="optional" priority="0" order="0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="sxtp_CharlesAllenMember" xlink:title="Presentation : us-gaap_RelatedPartyDomain to sxtp_CharlesAllenMember" use="optional" priority="0" order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="us-gaap_OtherCommitmentsLineItems" xlink:title="us-gaap_OtherCommitmentsLineItems" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sxtp_CommitmentsandContingenciesDetailsTable" xlink:to="us-gaap_OtherCommitmentsLineItems" xlink:title="Presentation : sxtp_CommitmentsandContingenciesDetailsTable to us-gaap_OtherCommitmentsLineItems" use="optional" priority="0" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_NumberOfDirectors" xlink:label="sxtp_NumberOfDirectors" xlink:title="sxtp_NumberOfDirectors" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="sxtp_NumberOfDirectors" xlink:title="Presentation : us-gaap_OtherCommitmentsLineItems to sxtp_NumberOfDirectors" order="0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" xlink:title="Presentation : us-gaap_OtherCommitmentsLineItems to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" use="optional" priority="0" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingencyPendingClaimsNumber" xlink:label="us-gaap_LossContingencyPendingClaimsNumber" xlink:title="us-gaap_LossContingencyPendingClaimsNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_LossContingencyPendingClaimsNumber" xlink:title="Presentation : us-gaap_OtherCommitmentsLineItems to us-gaap_LossContingencyPendingClaimsNumber" use="optional" priority="0" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:title="us-gaap_LesseeOperatingLeaseRenewalTerm" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:title="Presentation : us-gaap_OtherCommitmentsLineItems to us-gaap_LesseeOperatingLeaseRenewalTerm" use="optional" priority="0" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost" xlink:title="us-gaap_OperatingLeaseCost" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_OperatingLeaseCost" xlink:title="Presentation : us-gaap_OtherCommitmentsLineItems to us-gaap_OperatingLeaseCost" use="optional" priority="0" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CompensationAndBenefitsTrust" xlink:label="us-gaap_CompensationAndBenefitsTrust" xlink:title="us-gaap_CompensationAndBenefitsTrust" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_CompensationAndBenefitsTrust" xlink:title="Presentation : us-gaap_OtherCommitmentsLineItems to us-gaap_CompensationAndBenefitsTrust" use="optional" priority="0" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_NumberOfNonAuditCommitteeChairs" xlink:label="sxtp_NumberOfNonAuditCommitteeChairs" xlink:title="sxtp_NumberOfNonAuditCommitteeChairs" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="sxtp_NumberOfNonAuditCommitteeChairs" xlink:title="Presentation : us-gaap_OtherCommitmentsLineItems to sxtp_NumberOfNonAuditCommitteeChairs" use="optional" priority="0" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:title="us-gaap_BusinessCombinationContingentConsiderationLiability" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:title="Presentation : us-gaap_OtherCommitmentsLineItems to us-gaap_BusinessCombinationContingentConsiderationLiability" use="optional" priority="0" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_LicensedTechnologyTerm" xlink:label="sxtp_LicensedTechnologyTerm" xlink:title="sxtp_LicensedTechnologyTerm" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="sxtp_LicensedTechnologyTerm" xlink:title="Presentation : us-gaap_OtherCommitmentsLineItems to sxtp_LicensedTechnologyTerm" use="optional" priority="0" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_AnnualRoyaltyPaymentPercentage" xlink:label="sxtp_AnnualRoyaltyPaymentPercentage" xlink:title="sxtp_AnnualRoyaltyPaymentPercentage" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="sxtp_AnnualRoyaltyPaymentPercentage" xlink:title="Presentation : us-gaap_OtherCommitmentsLineItems to sxtp_AnnualRoyaltyPaymentPercentage" use="optional" priority="0" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RoyaltyExpense" xlink:label="us-gaap_RoyaltyExpense" xlink:title="us-gaap_RoyaltyExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_RoyaltyExpense" xlink:title="Presentation : us-gaap_OtherCommitmentsLineItems to us-gaap_RoyaltyExpense" use="optional" priority="0" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_PercentageOfRoyaltyPaymentsOfNetSales" xlink:label="sxtp_PercentageOfRoyaltyPaymentsOfNetSales" xlink:title="sxtp_PercentageOfRoyaltyPaymentsOfNetSales" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="sxtp_PercentageOfRoyaltyPaymentsOfNetSales" xlink:title="Presentation : us-gaap_OtherCommitmentsLineItems to sxtp_PercentageOfRoyaltyPaymentsOfNetSales" use="optional" priority="0" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_PercentageOfTreatmentOfBabesiosis" xlink:label="sxtp_PercentageOfTreatmentOfBabesiosis" xlink:title="sxtp_PercentageOfTreatmentOfBabesiosis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="sxtp_PercentageOfTreatmentOfBabesiosis" xlink:title="Presentation : us-gaap_OtherCommitmentsLineItems to sxtp_PercentageOfTreatmentOfBabesiosis" use="optional" priority="0" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueRemainingPerformanceObligationPercentage" xlink:label="us-gaap_RevenueRemainingPerformanceObligationPercentage" xlink:title="us-gaap_RevenueRemainingPerformanceObligationPercentage" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligationPercentage" xlink:title="Presentation : us-gaap_OtherCommitmentsLineItems to us-gaap_RevenueRemainingPerformanceObligationPercentage" use="optional" priority="0" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://60degreespharma.com/role/ConsolidatedCondensedStatementsofCashFlowsUnauditedParentheticals">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:title="us-gaap_StatementOfCashFlowsAbstract" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_ATMOfferingNetOfOfferingCostsPaid" xlink:label="sxtp_ATMOfferingNetOfOfferingCostsPaid" xlink:title="sxtp_ATMOfferingNetOfOfferingCostsPaid" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="sxtp_ATMOfferingNetOfOfferingCostsPaid" xlink:title="Presentation : us-gaap_StatementOfCashFlowsAbstract to sxtp_ATMOfferingNetOfOfferingCostsPaid" order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://60degreespharma.com/role/ConsolidatedCondensedStatementsofShareholdersEquityDeficitUnauditedParentheticals">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:title="us-gaap_StatementOfStockholdersEquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:title="us-gaap_StatementLineItems" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementLineItems" xlink:title="Presentation : us-gaap_StatementOfStockholdersEquityAbstract to us-gaap_StatementLineItems" use="optional" priority="0" order="0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://60degreespharma.com/role/SHAREBASEDCOMPENSATIONScheduleofFairValueofOptionsGrantedDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" use="optional" priority="0" order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" use="optional" priority="0" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" use="optional" priority="0" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" use="optional" priority="0" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" use="optional" priority="0" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" use="optional" priority="0" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" use="optional" priority="0" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract to us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" use="optional" priority="0" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1Minimum" xlink:label="sxtp_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1Minimum" xlink:title="sxtp_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1Minimum" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="sxtp_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1Minimum" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract to sxtp_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1Minimum" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1Maximum" xlink:label="sxtp_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1Maximum" xlink:title="sxtp_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1Maximum" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="sxtp_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1Maximum" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract to sxtp_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1Maximum" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" use="optional" priority="0" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://60degreespharma.com/role/SHAREBASEDCOMPENSATIONDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:title="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_ShareBasedCompensationDetailsTable" xlink:label="sxtp_ShareBasedCompensationDetailsTable" xlink:title="sxtp_ShareBasedCompensationDetailsTable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="sxtp_ShareBasedCompensationDetailsTable" xlink:title="Presentation : us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to sxtp_ShareBasedCompensationDetailsTable" use="optional" priority="0" order="0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:title="us-gaap_PlanNameAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sxtp_ShareBasedCompensationDetailsTable" xlink:to="us-gaap_PlanNameAxis" xlink:title="Presentation : sxtp_ShareBasedCompensationDetailsTable to us-gaap_PlanNameAxis" use="optional" priority="0" order="0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:title="us-gaap_PlanNameDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:title="Presentation : us-gaap_PlanNameAxis to us-gaap_PlanNameDomain" use="optional" priority="0" order="0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_TwoThousandTwentyTwoEquityIncentivePlanMember" xlink:label="sxtp_TwoThousandTwentyTwoEquityIncentivePlanMember" xlink:title="sxtp_TwoThousandTwentyTwoEquityIncentivePlanMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="sxtp_TwoThousandTwentyTwoEquityIncentivePlanMember" xlink:title="Presentation : us-gaap_PlanNameDomain to sxtp_TwoThousandTwentyTwoEquityIncentivePlanMember" use="optional" priority="0" order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:title="us-gaap_StatementEquityComponentsAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sxtp_ShareBasedCompensationDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" xlink:title="Presentation : sxtp_ShareBasedCompensationDetailsTable to us-gaap_StatementEquityComponentsAxis" use="optional" priority="0" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:title="us-gaap_EquityComponentDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" xlink:title="Presentation : us-gaap_StatementEquityComponentsAxis to us-gaap_EquityComponentDomain" use="optional" priority="0" order="0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:title="us-gaap_CommonStockMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" xlink:title="Presentation : us-gaap_EquityComponentDomain to us-gaap_CommonStockMember" use="optional" priority="0" order="0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:title="us-gaap_StatementClassOfStockAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sxtp_ShareBasedCompensationDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" xlink:title="Presentation : sxtp_ShareBasedCompensationDetailsTable to us-gaap_StatementClassOfStockAxis" use="optional" priority="0" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xlink:title="us-gaap_ClassOfStockDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" xlink:title="Presentation : us-gaap_StatementClassOfStockAxis to us-gaap_ClassOfStockDomain" use="optional" priority="0" order="0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonStockMember" xlink:title="Presentation : us-gaap_ClassOfStockDomain to us-gaap_CommonStockMember" use="optional" priority="0" order="0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" xlink:title="us-gaap_VestingAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sxtp_ShareBasedCompensationDetailsTable" xlink:to="us-gaap_VestingAxis" xlink:title="Presentation : sxtp_ShareBasedCompensationDetailsTable to us-gaap_VestingAxis" use="optional" priority="0" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" xlink:title="us-gaap_VestingDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" xlink:title="Presentation : us-gaap_VestingAxis to us-gaap_VestingDomain" use="optional" priority="0" order="0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:title="us-gaap_ShareBasedCompensationAwardTrancheOneMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:title="Presentation : us-gaap_VestingDomain to us-gaap_ShareBasedCompensationAwardTrancheOneMember" use="optional" priority="0" order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:title="us-gaap_AwardTypeAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sxtp_ShareBasedCompensationDetailsTable" xlink:to="us-gaap_AwardTypeAxis" xlink:title="Presentation : sxtp_ShareBasedCompensationDetailsTable to us-gaap_AwardTypeAxis" use="optional" priority="0" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="Presentation : us-gaap_AwardTypeAxis to us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" priority="0" order="0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_StockOptionsMember" xlink:label="sxtp_StockOptionsMember" xlink:title="sxtp_StockOptionsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="sxtp_StockOptionsMember" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to sxtp_StockOptionsMember" use="optional" priority="0" order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:title="us-gaap_RestrictedStockUnitsRSUMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to us-gaap_RestrictedStockUnitsRSUMember" use="optional" priority="0" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:title="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sxtp_ShareBasedCompensationDetailsTable" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:title="Presentation : sxtp_ShareBasedCompensationDetailsTable to us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" use="optional" priority="0" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:title="Presentation : us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" use="optional" priority="0" order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:title="Presentation : us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems to us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" use="optional" priority="0" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:title="Presentation : us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems to us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" use="optional" priority="0" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:title="Presentation : us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems to us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" use="optional" priority="0" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:title="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:title="Presentation : us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems to us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" use="optional" priority="0" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:title="Presentation : us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems to us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" use="optional" priority="0" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:title="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" xlink:title="Presentation : us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems to us-gaap_AllocatedShareBasedCompensationExpense" use="optional" priority="0" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash" xlink:title="us-gaap_Cash" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_Cash" xlink:title="Presentation : us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems to us-gaap_Cash" use="optional" priority="0" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_SharesIssuedPayrollTaxesWithholdings" xlink:label="sxtp_SharesIssuedPayrollTaxesWithholdings" xlink:title="sxtp_SharesIssuedPayrollTaxesWithholdings" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="sxtp_SharesIssuedPayrollTaxesWithholdings" xlink:title="Presentation : us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems to sxtp_SharesIssuedPayrollTaxesWithholdings" use="optional" priority="0" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_UnamortizedBalance" xlink:label="sxtp_UnamortizedBalance" xlink:title="sxtp_UnamortizedBalance" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="sxtp_UnamortizedBalance" xlink:title="Presentation : us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems to sxtp_UnamortizedBalance" use="optional" priority="0" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseNoncurrent" xlink:label="us-gaap_PrepaidExpenseNoncurrent" xlink:title="us-gaap_PrepaidExpenseNoncurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_PrepaidExpenseNoncurrent" xlink:title="Presentation : us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems to us-gaap_PrepaidExpenseNoncurrent" use="optional" priority="0" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_NumberOfExecutives" xlink:label="sxtp_NumberOfExecutives" xlink:title="sxtp_NumberOfExecutives" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="sxtp_NumberOfExecutives" xlink:title="Presentation : us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems to sxtp_NumberOfExecutives" priority="0" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="Presentation : us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" use="optional" priority="0" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" xlink:title="Presentation : us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" use="optional" priority="0" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_StockIssuedDuringPeriodIssuanceOfSharesForAnnualPerformanceBonusesNetOfSharesWithheldForTaxesinShares" xlink:label="sxtp_StockIssuedDuringPeriodIssuanceOfSharesForAnnualPerformanceBonusesNetOfSharesWithheldForTaxesinShares" xlink:title="sxtp_StockIssuedDuringPeriodIssuanceOfSharesForAnnualPerformanceBonusesNetOfSharesWithheldForTaxesinShares" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="sxtp_StockIssuedDuringPeriodIssuanceOfSharesForAnnualPerformanceBonusesNetOfSharesWithheldForTaxesinShares" xlink:title="Presentation : us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems to sxtp_StockIssuedDuringPeriodIssuanceOfSharesForAnnualPerformanceBonusesNetOfSharesWithheldForTaxesinShares" use="optional" priority="0" order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://60degreespharma.com/role/SUBSEQUENTEVENTSDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:title="us-gaap_SubsequentEventsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" xlink:title="us-gaap_SubsequentEventTable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventTable" xlink:title="Presentation : us-gaap_SubsequentEventsAbstract to us-gaap_SubsequentEventTable" use="optional" priority="0" order="0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:title="us-gaap_SubsequentEventTypeAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:title="Presentation : us-gaap_SubsequentEventTable to us-gaap_SubsequentEventTypeAxis" use="optional" priority="0" order="0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:title="us-gaap_SubsequentEventTypeDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:title="Presentation : us-gaap_SubsequentEventTypeAxis to us-gaap_SubsequentEventTypeDomain" use="optional" priority="0" order="0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:title="us-gaap_SubsequentEventMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" xlink:title="Presentation : us-gaap_SubsequentEventTypeDomain to us-gaap_SubsequentEventMember" use="optional" priority="0" order="0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:title="us-gaap_RelatedPartyTransactionAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" xlink:title="Presentation : us-gaap_SubsequentEventTable to us-gaap_RelatedPartyTransactionAxis" use="optional" priority="0" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:title="us-gaap_RelatedPartyTransactionDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" xlink:title="Presentation : us-gaap_RelatedPartyTransactionAxis to us-gaap_RelatedPartyTransactionDomain" use="optional" priority="0" order="0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_HCWainwrightAndCoLLCMember" xlink:label="sxtp_HCWainwrightAndCoLLCMember" xlink:title="sxtp_HCWainwrightAndCoLLCMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="sxtp_HCWainwrightAndCoLLCMember" xlink:title="Presentation : us-gaap_RelatedPartyTransactionDomain to sxtp_HCWainwrightAndCoLLCMember" priority="0" order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardDateAxis" xlink:label="us-gaap_AwardDateAxis" xlink:title="us-gaap_AwardDateAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_AwardDateAxis" xlink:title="Presentation : us-gaap_SubsequentEventTable to us-gaap_AwardDateAxis" use="optional" priority="0" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardDateDomain" xlink:label="us-gaap_AwardDateDomain" xlink:title="us-gaap_AwardDateDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateDomain" xlink:title="Presentation : us-gaap_AwardDateAxis to us-gaap_AwardDateDomain" use="optional" priority="0" order="0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_AtTheMarket2025AgreementMember" xlink:label="sxtp_AtTheMarket2025AgreementMember" xlink:title="sxtp_AtTheMarket2025AgreementMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateDomain" xlink:to="sxtp_AtTheMarket2025AgreementMember" xlink:title="Presentation : us-gaap_AwardDateDomain to sxtp_AtTheMarket2025AgreementMember" priority="0" order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:title="srt_RangeAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="srt_RangeAxis" xlink:title="Presentation : us-gaap_SubsequentEventTable to srt_RangeAxis" use="optional" priority="0" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:title="srt_RangeMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:title="Presentation : srt_RangeAxis to srt_RangeMember" use="optional" priority="0" order="0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:title="srt_MaximumMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" xlink:title="Presentation : srt_RangeMember to srt_MaximumMember" use="optional" priority="0" order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:title="us-gaap_AwardTypeAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_AwardTypeAxis" xlink:title="Presentation : us-gaap_SubsequentEventTable to us-gaap_AwardTypeAxis" use="optional" priority="0" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="Presentation : us-gaap_AwardTypeAxis to us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" priority="0" order="0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_StockOptionsMember" xlink:label="sxtp_StockOptionsMember" xlink:title="sxtp_StockOptionsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="sxtp_StockOptionsMember" xlink:title="Presentation : us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to sxtp_StockOptionsMember" priority="0" order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" xlink:title="srt_TitleOfIndividualAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="srt_TitleOfIndividualAxis" xlink:title="Presentation : us-gaap_SubsequentEventTable to srt_TitleOfIndividualAxis" use="optional" priority="0" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="Presentation : srt_TitleOfIndividualAxis to srt_TitleOfIndividualWithRelationshipToEntityDomain" use="optional" priority="0" order="0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember" xlink:title="srt_DirectorMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_DirectorMember" xlink:title="Presentation : srt_TitleOfIndividualWithRelationshipToEntityDomain to srt_DirectorMember" use="optional" priority="0" order="0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_DirectorOneMember" xlink:label="sxtp_DirectorOneMember" xlink:title="sxtp_DirectorOneMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="sxtp_DirectorOneMember" xlink:title="Presentation : srt_TitleOfIndividualWithRelationshipToEntityDomain to sxtp_DirectorOneMember" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" xlink:title="us-gaap_SubsequentEventLineItems" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventLineItems" xlink:title="Presentation : us-gaap_SubsequentEventTable to us-gaap_SubsequentEventLineItems" use="optional" priority="0" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_NumberOfDirectors" xlink:label="sxtp_NumberOfDirectors" xlink:title="sxtp_NumberOfDirectors" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="sxtp_NumberOfDirectors" xlink:title="Presentation : us-gaap_SubsequentEventLineItems to sxtp_NumberOfDirectors" order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:title="Presentation : us-gaap_SubsequentEventLineItems to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" use="optional" priority="0" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" xlink:title="us-gaap_StockholdersEquityReverseStockSplit" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" xlink:title="Presentation : us-gaap_SubsequentEventLineItems to us-gaap_StockholdersEquityReverseStockSplit" use="optional" priority="0" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="Presentation : us-gaap_SubsequentEventLineItems to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" use="optional" priority="0" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:title="Presentation : us-gaap_SubsequentEventLineItems to us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" use="optional" priority="0" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:title="Presentation : us-gaap_SubsequentEventLineItems to us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" use="optional" priority="0" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_ATMOfferingShares" xlink:label="sxtp_ATMOfferingShares" xlink:title="sxtp_ATMOfferingShares" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="sxtp_ATMOfferingShares" xlink:title="Presentation : us-gaap_SubsequentEventLineItems to sxtp_ATMOfferingShares" priority="0" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_CommonStockSalesAgreementWeightedAveragePricePerShare" xlink:label="sxtp_CommonStockSalesAgreementWeightedAveragePricePerShare" xlink:title="sxtp_CommonStockSalesAgreementWeightedAveragePricePerShare" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="sxtp_CommonStockSalesAgreementWeightedAveragePricePerShare" xlink:title="Presentation : us-gaap_SubsequentEventLineItems to sxtp_CommonStockSalesAgreementWeightedAveragePricePerShare" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_ProceedsFromCommonStockSalesAgreementNet" xlink:label="sxtp_ProceedsFromCommonStockSalesAgreementNet" xlink:title="sxtp_ProceedsFromCommonStockSalesAgreementNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="sxtp_ProceedsFromCommonStockSalesAgreementNet" xlink:title="Presentation : us-gaap_SubsequentEventLineItems to sxtp_ProceedsFromCommonStockSalesAgreementNet" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://60degreespharma.com/role/STOCKHOLDERSEQUITYScheduleofEquityClassifiedWarrantsDetails">
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_ScheduleOfEquityClassifiedWarrantsAbstract" xlink:label="sxtp_ScheduleOfEquityClassifiedWarrantsAbstract" xlink:title="sxtp_ScheduleOfEquityClassifiedWarrantsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable" xlink:title="us-gaap_ClassOfWarrantOrRightTable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sxtp_ScheduleOfEquityClassifiedWarrantsAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightTable" xlink:title="Presentation : sxtp_ScheduleOfEquityClassifiedWarrantsAbstract to us-gaap_ClassOfWarrantOrRightTable" use="optional" priority="0" order="0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:title="us-gaap_ClassOfWarrantOrRightAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:title="Presentation : us-gaap_ClassOfWarrantOrRightTable to us-gaap_ClassOfWarrantOrRightAxis" use="optional" priority="0" order="0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:title="us-gaap_ClassOfWarrantOrRightDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:title="Presentation : us-gaap_ClassOfWarrantOrRightAxis to us-gaap_ClassOfWarrantOrRightDomain" use="optional" priority="0" order="0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" xlink:title="us-gaap_WarrantMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_WarrantMember" xlink:title="Presentation : us-gaap_ClassOfWarrantOrRightDomain to us-gaap_WarrantMember" use="optional" priority="0" order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" xlink:title="us-gaap_ClassOfWarrantOrRightLineItems" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems" xlink:title="Presentation : us-gaap_ClassOfWarrantOrRightTable to us-gaap_ClassOfWarrantOrRightLineItems" use="optional" priority="0" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:title="Presentation : us-gaap_ClassOfWarrantOrRightLineItems to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" use="optional" priority="0" order="0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:title="Presentation : us-gaap_ClassOfWarrantOrRightLineItems to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" use="optional" priority="0" order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:title="Presentation : us-gaap_ClassOfWarrantOrRightLineItems to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" use="optional" priority="0" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:title="Presentation : us-gaap_ClassOfWarrantOrRightLineItems to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" use="optional" priority="0" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:title="Presentation : us-gaap_ClassOfWarrantOrRightLineItems to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" use="optional" priority="0" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsGranted" xlink:label="sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsGranted" xlink:title="sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsGranted" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsGranted" xlink:title="Presentation : us-gaap_ClassOfWarrantOrRightLineItems to sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsGranted" use="optional" priority="0" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfWarrantsExercised" xlink:label="sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfWarrantsExercised" xlink:title="sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfWarrantsExercised" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfWarrantsExercised" xlink:title="Presentation : us-gaap_ClassOfWarrantOrRightLineItems to sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfWarrantsExercised" use="optional" priority="0" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExercised" xlink:label="sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExercised" xlink:title="sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExercised" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExercised" xlink:title="Presentation : us-gaap_ClassOfWarrantOrRightLineItems to sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExercised" use="optional" priority="0" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsExercised" xlink:label="sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsExercised" xlink:title="sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsExercised" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsExercised" xlink:title="Presentation : us-gaap_ClassOfWarrantOrRightLineItems to sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsExercised" use="optional" priority="0" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:title="Presentation : us-gaap_ClassOfWarrantOrRightLineItems to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" use="optional" priority="0" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:title="Presentation : us-gaap_ClassOfWarrantOrRightLineItems to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" use="optional" priority="0" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsForfeited" xlink:label="sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsForfeited" xlink:title="sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsForfeited" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsForfeited" xlink:title="Presentation : us-gaap_ClassOfWarrantOrRightLineItems to sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsForfeited" use="optional" priority="0" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfWarrantsExpired" xlink:label="sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfWarrantsExpired" xlink:title="sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfWarrantsExpired" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfWarrantsExpired" xlink:title="Presentation : us-gaap_ClassOfWarrantOrRightLineItems to sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfWarrantsExpired" use="optional" priority="0" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExpired" xlink:label="sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExpired" xlink:title="sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExpired" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExpired" xlink:title="Presentation : us-gaap_ClassOfWarrantOrRightLineItems to sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExpired" use="optional" priority="0" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsExpired" xlink:label="sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsExpired" xlink:title="sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsExpired" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsExpired" xlink:title="Presentation : us-gaap_ClassOfWarrantOrRightLineItems to sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsExpired" use="optional" priority="0" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1" xlink:title="Presentation : us-gaap_ClassOfWarrantOrRightLineItems to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" use="optional" priority="0" order="15" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_1" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_1" xlink:title="Presentation : us-gaap_ClassOfWarrantOrRightLineItems to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" use="optional" priority="0" order="16" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms1" xlink:label="sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms1" xlink:title="sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms1" xlink:title="Presentation : us-gaap_ClassOfWarrantOrRightLineItems to sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms1" use="optional" priority="0" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable" xlink:label="sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable" xlink:title="sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable" xlink:title="Presentation : us-gaap_ClassOfWarrantOrRightLineItems to sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable" use="optional" priority="0" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageGrantDateFairValue" xlink:label="sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageGrantDateFairValue" xlink:title="sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageGrantDateFairValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageGrantDateFairValue" xlink:title="Presentation : us-gaap_ClassOfWarrantOrRightLineItems to sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageGrantDateFairValue" use="optional" priority="0" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableOutstandingWeightedAverageRemainingContractualTerms" xlink:label="sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableOutstandingWeightedAverageRemainingContractualTerms" xlink:title="sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableOutstandingWeightedAverageRemainingContractualTerms" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableOutstandingWeightedAverageRemainingContractualTerms" xlink:title="Presentation : us-gaap_ClassOfWarrantOrRightLineItems to sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableOutstandingWeightedAverageRemainingContractualTerms" use="optional" priority="0" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://60degreespharma.com/role/STOCKHOLDERSEQUITYDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" xlink:title="us-gaap_EquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_StockholdersEquityDetailsTable" xlink:label="sxtp_StockholdersEquityDetailsTable" xlink:title="sxtp_StockholdersEquityDetailsTable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="sxtp_StockholdersEquityDetailsTable" xlink:title="Presentation : us-gaap_EquityAbstract to sxtp_StockholdersEquityDetailsTable" use="optional" priority="0" order="0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:title="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sxtp_StockholdersEquityDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:title="Presentation : sxtp_StockholdersEquityDetailsTable to us-gaap_SubsidiarySaleOfStockAxis" use="optional" priority="0" order="0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:title="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:title="Presentation : us-gaap_SubsidiarySaleOfStockAxis to us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" priority="0" order="0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember" xlink:title="us-gaap_OverAllotmentOptionMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" xlink:title="Presentation : us-gaap_SaleOfStockNameOfTransactionDomain to us-gaap_OverAllotmentOptionMember" use="optional" priority="0" order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember" xlink:title="us-gaap_IPOMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" xlink:title="Presentation : us-gaap_SaleOfStockNameOfTransactionDomain to us-gaap_IPOMember" use="optional" priority="0" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:title="us-gaap_StatementClassOfStockAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sxtp_StockholdersEquityDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" xlink:title="Presentation : sxtp_StockholdersEquityDetailsTable to us-gaap_StatementClassOfStockAxis" use="optional" priority="0" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xlink:title="us-gaap_ClassOfStockDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" xlink:title="Presentation : us-gaap_StatementClassOfStockAxis to us-gaap_ClassOfStockDomain" use="optional" priority="0" order="0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:title="us-gaap_SeriesAPreferredStockMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" xlink:title="Presentation : us-gaap_ClassOfStockDomain to us-gaap_SeriesAPreferredStockMember" use="optional" priority="0" order="0" preferredLabel="http://www.xbrl.org/2009/role/netLabel" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_SeriesANonVotingConvertiblePreferredStockMember" xlink:label="sxtp_SeriesANonVotingConvertiblePreferredStockMember" xlink:title="sxtp_SeriesANonVotingConvertiblePreferredStockMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="sxtp_SeriesANonVotingConvertiblePreferredStockMember" xlink:title="Presentation : us-gaap_ClassOfStockDomain to sxtp_SeriesANonVotingConvertiblePreferredStockMember" use="optional" priority="0" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:title="us-gaap_CommonStockMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonStockMember" xlink:title="Presentation : us-gaap_ClassOfStockDomain to us-gaap_CommonStockMember" use="optional" priority="0" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleCommonStockMember" xlink:label="us-gaap_ConvertibleCommonStockMember" xlink:title="us-gaap_ConvertibleCommonStockMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ConvertibleCommonStockMember" xlink:title="Presentation : us-gaap_ClassOfStockDomain to us-gaap_ConvertibleCommonStockMember" use="optional" priority="0" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:title="us-gaap_RelatedPartyTransactionAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sxtp_StockholdersEquityDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" xlink:title="Presentation : sxtp_StockholdersEquityDetailsTable to us-gaap_RelatedPartyTransactionAxis" use="optional" priority="0" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:title="us-gaap_RelatedPartyTransactionDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" xlink:title="Presentation : us-gaap_RelatedPartyTransactionAxis to us-gaap_RelatedPartyTransactionDomain" use="optional" priority="0" order="0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_WallachBethCapitalLLCMember" xlink:label="sxtp_WallachBethCapitalLLCMember" xlink:title="sxtp_WallachBethCapitalLLCMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="sxtp_WallachBethCapitalLLCMember" xlink:title="Presentation : us-gaap_RelatedPartyTransactionDomain to sxtp_WallachBethCapitalLLCMember" use="optional" priority="0" order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_TrevallyLLCMember" xlink:label="sxtp_TrevallyLLCMember" xlink:title="sxtp_TrevallyLLCMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="sxtp_TrevallyLLCMember" xlink:title="Presentation : us-gaap_RelatedPartyTransactionDomain to sxtp_TrevallyLLCMember" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_HCWainwrightAndCoLLCMember" xlink:label="sxtp_HCWainwrightAndCoLLCMember" xlink:title="sxtp_HCWainwrightAndCoLLCMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="sxtp_HCWainwrightAndCoLLCMember" xlink:title="Presentation : us-gaap_RelatedPartyTransactionDomain to sxtp_HCWainwrightAndCoLLCMember" priority="0" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sxtp_StockholdersEquityDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="Presentation : sxtp_StockholdersEquityDetailsTable to us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" use="optional" priority="0" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" xlink:title="us-gaap_RelatedPartyDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" xlink:title="Presentation : us-gaap_RelatedPartyTransactionsByRelatedPartyAxis to us-gaap_RelatedPartyDomain" use="optional" priority="0" order="0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="sxtp_WallachBethCapitalLLCMember" xlink:title="Presentation : us-gaap_RelatedPartyDomain to sxtp_WallachBethCapitalLLCMember" use="optional" priority="0" order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:title="us-gaap_StatementEquityComponentsAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sxtp_StockholdersEquityDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" xlink:title="Presentation : sxtp_StockholdersEquityDetailsTable to us-gaap_StatementEquityComponentsAxis" use="optional" priority="0" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:title="us-gaap_EquityComponentDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" xlink:title="Presentation : us-gaap_StatementEquityComponentsAxis to us-gaap_EquityComponentDomain" use="optional" priority="0" order="0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" xlink:title="Presentation : us-gaap_EquityComponentDomain to us-gaap_CommonStockMember" use="optional" priority="0" order="0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardDateAxis" xlink:label="us-gaap_AwardDateAxis" xlink:title="us-gaap_AwardDateAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sxtp_StockholdersEquityDetailsTable" xlink:to="us-gaap_AwardDateAxis" xlink:title="Presentation : sxtp_StockholdersEquityDetailsTable to us-gaap_AwardDateAxis" use="optional" priority="0" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardDateDomain" xlink:label="us-gaap_AwardDateDomain" xlink:title="us-gaap_AwardDateDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateDomain" xlink:title="Presentation : us-gaap_AwardDateAxis to us-gaap_AwardDateDomain" use="optional" priority="0" order="0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_January2024OfferingMember" xlink:label="sxtp_January2024OfferingMember" xlink:title="sxtp_January2024OfferingMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateDomain" xlink:to="sxtp_January2024OfferingMember" xlink:title="Presentation : us-gaap_AwardDateDomain to sxtp_January2024OfferingMember" use="optional" priority="0" order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_July2025OfferingMember" xlink:label="sxtp_July2025OfferingMember" xlink:title="sxtp_July2025OfferingMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateDomain" xlink:to="sxtp_July2025OfferingMember" xlink:title="Presentation : us-gaap_AwardDateDomain to sxtp_July2025OfferingMember" priority="0" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_AtTheMarket2025AgreementMember" xlink:label="sxtp_AtTheMarket2025AgreementMember" xlink:title="sxtp_AtTheMarket2025AgreementMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateDomain" xlink:to="sxtp_AtTheMarket2025AgreementMember" xlink:title="Presentation : us-gaap_AwardDateDomain to sxtp_AtTheMarket2025AgreementMember" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:title="us-gaap_ClassOfWarrantOrRightAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sxtp_StockholdersEquityDetailsTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:title="Presentation : sxtp_StockholdersEquityDetailsTable to us-gaap_ClassOfWarrantOrRightAxis" use="optional" priority="0" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:title="us-gaap_ClassOfWarrantOrRightDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:title="Presentation : us-gaap_ClassOfWarrantOrRightAxis to us-gaap_ClassOfWarrantOrRightDomain" use="optional" priority="0" order="0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_PlacementAgentWarrantsMember" xlink:label="sxtp_PlacementAgentWarrantsMember" xlink:title="sxtp_PlacementAgentWarrantsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="sxtp_PlacementAgentWarrantsMember" xlink:title="Presentation : us-gaap_ClassOfWarrantOrRightDomain to sxtp_PlacementAgentWarrantsMember" use="optional" priority="0" order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" xlink:title="us-gaap_WarrantMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_WarrantMember" xlink:title="Presentation : us-gaap_ClassOfWarrantOrRightDomain to us-gaap_WarrantMember" use="optional" priority="0" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_PreFundedWarrantMember" xlink:label="sxtp_PreFundedWarrantMember" xlink:title="sxtp_PreFundedWarrantMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="sxtp_PreFundedWarrantMember" xlink:title="Presentation : us-gaap_ClassOfWarrantOrRightDomain to sxtp_PreFundedWarrantMember" use="optional" priority="0" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_JanuaryTwoThousandTwentyFourPreFundedWarrantsMember" xlink:label="sxtp_JanuaryTwoThousandTwentyFourPreFundedWarrantsMember" xlink:title="sxtp_JanuaryTwoThousandTwentyFourPreFundedWarrantsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="sxtp_JanuaryTwoThousandTwentyFourPreFundedWarrantsMember" xlink:title="Presentation : us-gaap_ClassOfWarrantOrRightDomain to sxtp_JanuaryTwoThousandTwentyFourPreFundedWarrantsMember" use="optional" priority="0" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_JanuaryTwoThousandTwentyFourWarrantMember" xlink:label="sxtp_JanuaryTwoThousandTwentyFourWarrantMember" xlink:title="sxtp_JanuaryTwoThousandTwentyFourWarrantMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="sxtp_JanuaryTwoThousandTwentyFourWarrantMember" xlink:title="Presentation : us-gaap_ClassOfWarrantOrRightDomain to sxtp_JanuaryTwoThousandTwentyFourWarrantMember" use="optional" priority="0" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_JanuaryRepresentativeWarrantsMember" xlink:label="sxtp_JanuaryRepresentativeWarrantsMember" xlink:title="sxtp_JanuaryRepresentativeWarrantsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="sxtp_JanuaryRepresentativeWarrantsMember" xlink:title="Presentation : us-gaap_ClassOfWarrantOrRightDomain to sxtp_JanuaryRepresentativeWarrantsMember" use="optional" priority="0" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_SeriesAWarrantsMember" xlink:label="sxtp_SeriesAWarrantsMember" xlink:title="sxtp_SeriesAWarrantsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="sxtp_SeriesAWarrantsMember" xlink:title="Presentation : us-gaap_ClassOfWarrantOrRightDomain to sxtp_SeriesAWarrantsMember" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_SeriesBWarrantsMember" xlink:label="sxtp_SeriesBWarrantsMember" xlink:title="sxtp_SeriesBWarrantsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="sxtp_SeriesBWarrantsMember" xlink:title="Presentation : us-gaap_ClassOfWarrantOrRightDomain to sxtp_SeriesBWarrantsMember" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_SeptemberTwoThousandTwentyFourAgentWarrantsMember" xlink:label="sxtp_SeptemberTwoThousandTwentyFourAgentWarrantsMember" xlink:title="sxtp_SeptemberTwoThousandTwentyFourAgentWarrantsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="sxtp_SeptemberTwoThousandTwentyFourAgentWarrantsMember" xlink:title="Presentation : us-gaap_ClassOfWarrantOrRightDomain to sxtp_SeptemberTwoThousandTwentyFourAgentWarrantsMember" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_SeriesAAndSeriesBWarrantsMember" xlink:label="sxtp_SeriesAAndSeriesBWarrantsMember" xlink:title="sxtp_SeriesAAndSeriesBWarrantsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="sxtp_SeriesAAndSeriesBWarrantsMember" xlink:title="Presentation : us-gaap_ClassOfWarrantOrRightDomain to sxtp_SeriesAAndSeriesBWarrantsMember" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_JulyTwoThousandTwentyFivePreFundedWarrantsMember" xlink:label="sxtp_JulyTwoThousandTwentyFivePreFundedWarrantsMember" xlink:title="sxtp_JulyTwoThousandTwentyFivePreFundedWarrantsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="sxtp_JulyTwoThousandTwentyFivePreFundedWarrantsMember" xlink:title="Presentation : us-gaap_ClassOfWarrantOrRightDomain to sxtp_JulyTwoThousandTwentyFivePreFundedWarrantsMember" priority="0" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_JulyTwoThousandTwentyFiveAOneWarrantsMember" xlink:label="sxtp_JulyTwoThousandTwentyFiveAOneWarrantsMember" xlink:title="sxtp_JulyTwoThousandTwentyFiveAOneWarrantsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="sxtp_JulyTwoThousandTwentyFiveAOneWarrantsMember" xlink:title="Presentation : us-gaap_ClassOfWarrantOrRightDomain to sxtp_JulyTwoThousandTwentyFiveAOneWarrantsMember" priority="0" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_JulyTwoThousandTwentyFiveATwoWarrantsMember" xlink:label="sxtp_JulyTwoThousandTwentyFiveATwoWarrantsMember" xlink:title="sxtp_JulyTwoThousandTwentyFiveATwoWarrantsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="sxtp_JulyTwoThousandTwentyFiveATwoWarrantsMember" xlink:title="Presentation : us-gaap_ClassOfWarrantOrRightDomain to sxtp_JulyTwoThousandTwentyFiveATwoWarrantsMember" priority="0" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_JulyTwoThousandTwentyFivePlacementAgentWarrantsMember" xlink:label="sxtp_JulyTwoThousandTwentyFivePlacementAgentWarrantsMember" xlink:title="sxtp_JulyTwoThousandTwentyFivePlacementAgentWarrantsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="sxtp_JulyTwoThousandTwentyFivePlacementAgentWarrantsMember" xlink:title="Presentation : us-gaap_ClassOfWarrantOrRightDomain to sxtp_JulyTwoThousandTwentyFivePlacementAgentWarrantsMember" priority="0" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:title="srt_RangeAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sxtp_StockholdersEquityDetailsTable" xlink:to="srt_RangeAxis" xlink:title="Presentation : sxtp_StockholdersEquityDetailsTable to srt_RangeAxis" use="optional" priority="0" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:title="srt_RangeMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:title="Presentation : srt_RangeAxis to srt_RangeMember" use="optional" priority="0" order="0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:title="srt_MaximumMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" xlink:title="Presentation : srt_RangeMember to srt_MaximumMember" use="optional" priority="0" order="0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" xlink:title="us-gaap_ClassOfStockLineItems" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sxtp_StockholdersEquityDetailsTable" xlink:to="us-gaap_ClassOfStockLineItems" xlink:title="Presentation : sxtp_StockholdersEquityDetailsTable to us-gaap_ClassOfStockLineItems" use="optional" priority="0" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:title="us-gaap_CommonStockSharesAuthorized" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" xlink:title="Presentation : us-gaap_ClassOfStockLineItems to us-gaap_CommonStockSharesAuthorized" use="optional" priority="0" order="0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:title="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" xlink:title="Presentation : us-gaap_ClassOfStockLineItems to us-gaap_CommonStockParOrStatedValuePerShare" use="optional" priority="0" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:title="us-gaap_PreferredStockSharesAuthorized" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" xlink:title="Presentation : us-gaap_ClassOfStockLineItems to us-gaap_PreferredStockSharesAuthorized" use="optional" priority="0" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:title="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:title="Presentation : us-gaap_ClassOfStockLineItems to us-gaap_PreferredStockParOrStatedValuePerShare" use="optional" priority="0" order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ExcessStockSharesAuthorized" xlink:label="us-gaap_ExcessStockSharesAuthorized" xlink:title="us-gaap_ExcessStockSharesAuthorized" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ExcessStockSharesAuthorized" xlink:title="Presentation : us-gaap_ClassOfStockLineItems to us-gaap_ExcessStockSharesAuthorized" use="optional" priority="0" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xlink:title="us-gaap_CommonStockSharesIssued" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesIssued" xlink:title="Presentation : us-gaap_ClassOfStockLineItems to us-gaap_CommonStockSharesIssued" use="optional" priority="0" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:title="us-gaap_CommonStockSharesOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" xlink:title="Presentation : us-gaap_ClassOfStockLineItems to us-gaap_CommonStockSharesOutstanding" use="optional" priority="0" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:title="us-gaap_PreferredStockSharesIssued" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" xlink:title="Presentation : us-gaap_ClassOfStockLineItems to us-gaap_PreferredStockSharesIssued" use="optional" priority="0" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:title="us-gaap_PreferredStockSharesOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" xlink:title="Presentation : us-gaap_ClassOfStockLineItems to us-gaap_PreferredStockSharesOutstanding" use="optional" priority="0" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" xlink:title="us-gaap_StockholdersEquityReverseStockSplit" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" xlink:title="Presentation : us-gaap_ClassOfStockLineItems to us-gaap_StockholdersEquityReverseStockSplit" use="optional" priority="0" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:title="Presentation : us-gaap_ClassOfStockLineItems to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" use="optional" priority="0" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare" xlink:title="us-gaap_SaleOfStockPricePerShare" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" xlink:title="Presentation : us-gaap_ClassOfStockLineItems to us-gaap_SaleOfStockPricePerShare" use="optional" priority="0" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:title="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:title="Presentation : us-gaap_ClassOfStockLineItems to us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" use="optional" priority="0" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:title="us-gaap_WarrantsAndRightsOutstandingTerm" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:title="Presentation : us-gaap_ClassOfStockLineItems to us-gaap_WarrantsAndRightsOutstandingTerm" use="optional" priority="0" order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding" xlink:title="us-gaap_WarrantsAndRightsOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstanding" xlink:title="Presentation : us-gaap_ClassOfStockLineItems to us-gaap_WarrantsAndRightsOutstanding" use="optional" priority="0" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:title="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:title="Presentation : us-gaap_ClassOfStockLineItems to us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" use="optional" priority="0" order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:title="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:title="Presentation : us-gaap_ClassOfStockLineItems to us-gaap_ProceedsFromIssuanceOfPrivatePlacement" use="optional" priority="0" order="16" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:title="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:title="Presentation : us-gaap_ClassOfStockLineItems to us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" use="optional" priority="0" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_UnitsIssuedDuringPeriodSharesNewIssues" xlink:label="sxtp_UnitsIssuedDuringPeriodSharesNewIssues" xlink:title="sxtp_UnitsIssuedDuringPeriodSharesNewIssues" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="sxtp_UnitsIssuedDuringPeriodSharesNewIssues" xlink:title="Presentation : us-gaap_ClassOfStockLineItems to sxtp_UnitsIssuedDuringPeriodSharesNewIssues" use="optional" priority="0" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:title="us-gaap_ClassOfWarrantOrRightOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:title="Presentation : us-gaap_ClassOfStockLineItems to us-gaap_ClassOfWarrantOrRightOutstanding" use="optional" priority="0" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:label="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:title="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:title="Presentation : us-gaap_ClassOfStockLineItems to us-gaap_ProceedsFromDebtNetOfIssuanceCosts" use="optional" priority="0" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested" xlink:label="us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested" xlink:title="us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested" xlink:title="Presentation : us-gaap_ClassOfStockLineItems to us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested" use="optional" priority="0" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_OtherOfferingExpensesPaid" xlink:label="sxtp_OtherOfferingExpensesPaid" xlink:title="sxtp_OtherOfferingExpensesPaid" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="sxtp_OtherOfferingExpensesPaid" xlink:title="Presentation : us-gaap_ClassOfStockLineItems to sxtp_OtherOfferingExpensesPaid" use="optional" priority="0" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_SharesOfWarrants" xlink:label="sxtp_SharesOfWarrants" xlink:title="sxtp_SharesOfWarrants" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="sxtp_SharesOfWarrants" xlink:title="Presentation : us-gaap_ClassOfStockLineItems to sxtp_SharesOfWarrants" use="optional" priority="0" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:title="us-gaap_StockIssuedDuringPeriodSharesOther" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:title="Presentation : us-gaap_ClassOfStockLineItems to us-gaap_StockIssuedDuringPeriodSharesOther" use="optional" priority="0" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantExercisePriceIncrease" xlink:label="us-gaap_WarrantExercisePriceIncrease" xlink:title="us-gaap_WarrantExercisePriceIncrease" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_WarrantExercisePriceIncrease" xlink:title="Presentation : us-gaap_ClassOfStockLineItems to us-gaap_WarrantExercisePriceIncrease" use="optional" priority="0" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_NumberofWarrantExercisable" xlink:label="sxtp_NumberofWarrantExercisable" xlink:title="sxtp_NumberofWarrantExercisable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="sxtp_NumberofWarrantExercisable" xlink:title="Presentation : us-gaap_ClassOfStockLineItems to sxtp_NumberofWarrantExercisable" use="optional" priority="0" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_NumberOfShares" xlink:label="sxtp_NumberOfShares" xlink:title="sxtp_NumberOfShares" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="sxtp_NumberOfShares" xlink:title="Presentation : us-gaap_ClassOfStockLineItems to sxtp_NumberOfShares" use="optional" priority="0" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:title="us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:title="Presentation : us-gaap_ClassOfStockLineItems to us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" use="optional" priority="0" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="us-gaap_PreferredStockDividendRatePercentage" xlink:title="us-gaap_PreferredStockDividendRatePercentage" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockDividendRatePercentage" xlink:title="Presentation : us-gaap_ClassOfStockLineItems to us-gaap_PreferredStockDividendRatePercentage" use="optional" priority="0" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DividendsPreferredStock" xlink:label="us-gaap_DividendsPreferredStock" xlink:title="us-gaap_DividendsPreferredStock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_DividendsPreferredStock" xlink:title="Presentation : us-gaap_ClassOfStockLineItems to us-gaap_DividendsPreferredStock" use="optional" priority="0" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockConvertibleConversionPriceIncrease" xlink:label="us-gaap_CommonStockConvertibleConversionPriceIncrease" xlink:title="us-gaap_CommonStockConvertibleConversionPriceIncrease" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockConvertibleConversionPriceIncrease" xlink:title="Presentation : us-gaap_ClassOfStockLineItems to us-gaap_CommonStockConvertibleConversionPriceIncrease" use="optional" priority="0" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:title="Presentation : us-gaap_ClassOfStockLineItems to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" use="optional" priority="0" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_AgreedToReturnShares" xlink:label="sxtp_AgreedToReturnShares" xlink:title="sxtp_AgreedToReturnShares" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="sxtp_AgreedToReturnShares" xlink:title="Presentation : us-gaap_ClassOfStockLineItems to sxtp_AgreedToReturnShares" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" xlink:title="us-gaap_ProceedsFromWarrantExercises" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromWarrantExercises" xlink:title="Presentation : us-gaap_ClassOfStockLineItems to us-gaap_ProceedsFromWarrantExercises" use="optional" priority="0" order="34" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_CommonStockAggregateOfferingPrice" xlink:label="sxtp_CommonStockAggregateOfferingPrice" xlink:title="sxtp_CommonStockAggregateOfferingPrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="sxtp_CommonStockAggregateOfferingPrice" xlink:title="Presentation : us-gaap_ClassOfStockLineItems to sxtp_CommonStockAggregateOfferingPrice" order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_ATMOfferingShares" xlink:label="sxtp_ATMOfferingShares" xlink:title="sxtp_ATMOfferingShares" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="sxtp_ATMOfferingShares" xlink:title="Presentation : us-gaap_ClassOfStockLineItems to sxtp_ATMOfferingShares" order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromOtherEquity" xlink:label="us-gaap_ProceedsFromOtherEquity" xlink:title="us-gaap_ProceedsFromOtherEquity" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromOtherEquity" xlink:title="Presentation : us-gaap_ClassOfStockLineItems to us-gaap_ProceedsFromOtherEquity" use="optional" priority="0" order="37" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:title="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:title="Presentation : us-gaap_ClassOfStockLineItems to us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" use="optional" priority="0" order="38" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1" xlink:title="us-gaap_ConversionOfStockSharesConverted1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" xlink:title="Presentation : us-gaap_ClassOfStockLineItems to us-gaap_ConversionOfStockSharesConverted1" use="optional" priority="0" order="39" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantExercisePriceDecrease" xlink:label="us-gaap_WarrantExercisePriceDecrease" xlink:title="us-gaap_WarrantExercisePriceDecrease" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_WarrantExercisePriceDecrease" xlink:title="Presentation : us-gaap_ClassOfStockLineItems to us-gaap_WarrantExercisePriceDecrease" use="optional" priority="0" order="40" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockConvertibleSharesIssuable" xlink:label="us-gaap_PreferredStockConvertibleSharesIssuable" xlink:title="us-gaap_PreferredStockConvertibleSharesIssuable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PreferredStockConvertibleSharesIssuable" xlink:title="Presentation : us-gaap_ClassOfStockLineItems to us-gaap_PreferredStockConvertibleSharesIssuable" use="optional" priority="0" order="41" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:title="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:title="Presentation : us-gaap_ClassOfStockLineItems to us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" use="optional" priority="0" order="42" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:title="us-gaap_WarrantsAndRightsOutstandingMaturityDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:title="Presentation : us-gaap_ClassOfStockLineItems to us-gaap_WarrantsAndRightsOutstandingMaturityDate" use="optional" priority="0" order="43" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_SalesAgreementTerminationDate" xlink:label="sxtp_SalesAgreementTerminationDate" xlink:title="sxtp_SalesAgreementTerminationDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="sxtp_SalesAgreementTerminationDate" xlink:title="Presentation : us-gaap_ClassOfStockLineItems to sxtp_SalesAgreementTerminationDate" order="44" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_CommonStockAggregateGrossSalesProceedAuthorized" xlink:label="sxtp_CommonStockAggregateGrossSalesProceedAuthorized" xlink:title="sxtp_CommonStockAggregateGrossSalesProceedAuthorized" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="sxtp_CommonStockAggregateGrossSalesProceedAuthorized" xlink:title="Presentation : us-gaap_ClassOfStockLineItems to sxtp_CommonStockAggregateGrossSalesProceedAuthorized" order="45" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_SalesAgentCommissionPercentage" xlink:label="sxtp_SalesAgentCommissionPercentage" xlink:title="sxtp_SalesAgentCommissionPercentage" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="sxtp_SalesAgentCommissionPercentage" xlink:title="Presentation : us-gaap_ClassOfStockLineItems to sxtp_SalesAgentCommissionPercentage" order="46" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfWarrantsExercised" xlink:label="sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfWarrantsExercised" xlink:title="sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfWarrantsExercised" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfWarrantsExercised" xlink:title="Presentation : us-gaap_ClassOfStockLineItems to sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfWarrantsExercised" use="optional" priority="0" order="47" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_ProceedsFromExerciseOfPreFundedWarrants" xlink:label="sxtp_ProceedsFromExerciseOfPreFundedWarrants" xlink:title="sxtp_ProceedsFromExerciseOfPreFundedWarrants" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="sxtp_ProceedsFromExerciseOfPreFundedWarrants" xlink:title="Presentation : us-gaap_ClassOfStockLineItems to sxtp_ProceedsFromExerciseOfPreFundedWarrants" use="optional" priority="0" order="48" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:title="Presentation : us-gaap_ClassOfStockLineItems to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" use="optional" priority="0" order="49" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable" xlink:label="sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable" xlink:title="sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable" xlink:title="Presentation : us-gaap_ClassOfStockLineItems to sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable" use="optional" priority="0" order="50" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_StockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfPreFundedWarrantsinShares" xlink:label="sxtp_StockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfPreFundedWarrantsinShares" xlink:title="sxtp_StockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfPreFundedWarrantsinShares" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="sxtp_StockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfPreFundedWarrantsinShares" xlink:title="Presentation : us-gaap_ClassOfStockLineItems to sxtp_StockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfPreFundedWarrantsinShares" priority="0" order="51" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExercised" xlink:label="sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExercised" xlink:title="sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExercised" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExercised" xlink:title="Presentation : us-gaap_ClassOfStockLineItems to sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExercised" use="optional" priority="0" order="52" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_1" xlink:title="us-gaap_ClassOfWarrantOrRightOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_1" xlink:title="Presentation : us-gaap_ClassOfStockLineItems to us-gaap_ClassOfWarrantOrRightOutstanding" use="optional" priority="0" order="53" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://60degreespharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:title="us-gaap_AccountingPoliciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:label="sxtp_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:title="sxtp_SummaryofSignificantAccountingPoliciesDetailsTable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="sxtp_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:title="Presentation : us-gaap_AccountingPoliciesAbstract to sxtp_SummaryofSignificantAccountingPoliciesDetailsTable" use="optional" priority="0" order="0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:title="us-gaap_StatementEquityComponentsAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sxtp_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" xlink:title="Presentation : sxtp_SummaryofSignificantAccountingPoliciesDetailsTable to us-gaap_StatementEquityComponentsAxis" use="optional" priority="0" order="0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:title="us-gaap_EquityComponentDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" xlink:title="Presentation : us-gaap_StatementEquityComponentsAxis to us-gaap_EquityComponentDomain" use="optional" priority="0" order="0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_ReverseStockSplitsMember" xlink:label="sxtp_ReverseStockSplitsMember" xlink:title="sxtp_ReverseStockSplitsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="sxtp_ReverseStockSplitsMember" xlink:title="Presentation : us-gaap_EquityComponentDomain to sxtp_ReverseStockSplitsMember" use="optional" priority="0" order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_NetLossPerCommonShareMember" xlink:label="sxtp_NetLossPerCommonShareMember" xlink:title="sxtp_NetLossPerCommonShareMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="sxtp_NetLossPerCommonShareMember" xlink:title="Presentation : us-gaap_EquityComponentDomain to sxtp_NetLossPerCommonShareMember" use="optional" priority="0" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" xlink:title="us-gaap_ConcentrationRiskByTypeAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sxtp_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" xlink:title="Presentation : sxtp_SummaryofSignificantAccountingPoliciesDetailsTable to us-gaap_ConcentrationRiskByTypeAxis" use="optional" priority="0" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain" xlink:title="us-gaap_ConcentrationRiskTypeDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" xlink:title="Presentation : us-gaap_ConcentrationRiskByTypeAxis to us-gaap_ConcentrationRiskTypeDomain" use="optional" priority="0" order="0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember" xlink:title="us-gaap_CustomerConcentrationRiskMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_CustomerConcentrationRiskMember" xlink:title="Presentation : us-gaap_ConcentrationRiskTypeDomain to us-gaap_CustomerConcentrationRiskMember" use="optional" priority="0" order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis" xlink:title="srt_MajorCustomersAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sxtp_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="srt_MajorCustomersAxis" xlink:title="Presentation : sxtp_SummaryofSignificantAccountingPoliciesDetailsTable to srt_MajorCustomersAxis" use="optional" priority="0" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain" xlink:title="srt_NameOfMajorCustomerDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain" xlink:title="Presentation : srt_MajorCustomersAxis to srt_NameOfMajorCustomerDomain" use="optional" priority="0" order="0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_SignificantCustomersMember" xlink:label="sxtp_SignificantCustomersMember" xlink:title="sxtp_SignificantCustomersMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="sxtp_SignificantCustomersMember" xlink:title="Presentation : srt_NameOfMajorCustomerDomain to sxtp_SignificantCustomersMember" use="optional" priority="0" order="0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_CustomerTwoMember" xlink:label="sxtp_CustomerTwoMember" xlink:title="sxtp_CustomerTwoMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="sxtp_CustomerTwoMember" xlink:title="Presentation : srt_NameOfMajorCustomerDomain to sxtp_CustomerTwoMember" use="optional" priority="0" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_CustomerThreeMember" xlink:label="sxtp_CustomerThreeMember" xlink:title="sxtp_CustomerThreeMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="sxtp_CustomerThreeMember" xlink:title="Presentation : srt_NameOfMajorCustomerDomain to sxtp_CustomerThreeMember" use="optional" priority="0" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_SignificantCustomerOneMember" xlink:label="sxtp_SignificantCustomerOneMember" xlink:title="sxtp_SignificantCustomerOneMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="sxtp_SignificantCustomerOneMember" xlink:title="Presentation : srt_NameOfMajorCustomerDomain to sxtp_SignificantCustomerOneMember" use="optional" priority="0" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_SignificantCustomerTwoMember" xlink:label="sxtp_SignificantCustomerTwoMember" xlink:title="sxtp_SignificantCustomerTwoMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="sxtp_SignificantCustomerTwoMember" xlink:title="Presentation : srt_NameOfMajorCustomerDomain to sxtp_SignificantCustomerTwoMember" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_SignificantCustomerThreeMember" xlink:label="sxtp_SignificantCustomerThreeMember" xlink:title="sxtp_SignificantCustomerThreeMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="sxtp_SignificantCustomerThreeMember" xlink:title="Presentation : srt_NameOfMajorCustomerDomain to sxtp_SignificantCustomerThreeMember" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:title="us-gaap_ConcentrationRiskByBenchmarkAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sxtp_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:title="Presentation : sxtp_SummaryofSignificantAccountingPoliciesDetailsTable to us-gaap_ConcentrationRiskByBenchmarkAxis" use="optional" priority="0" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:title="us-gaap_ConcentrationRiskBenchmarkDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:title="Presentation : us-gaap_ConcentrationRiskByBenchmarkAxis to us-gaap_ConcentrationRiskBenchmarkDomain" use="optional" priority="0" order="0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableMember" xlink:label="us-gaap_AccountsReceivableMember" xlink:title="us-gaap_AccountsReceivableMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_AccountsReceivableMember" xlink:title="Presentation : us-gaap_ConcentrationRiskBenchmarkDomain to us-gaap_AccountsReceivableMember" use="optional" priority="0" order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SalesRevenueNetMember" xlink:label="us-gaap_SalesRevenueNetMember" xlink:title="us-gaap_SalesRevenueNetMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_SalesRevenueNetMember" xlink:title="Presentation : us-gaap_ConcentrationRiskBenchmarkDomain to us-gaap_SalesRevenueNetMember" use="optional" priority="0" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_AccountsReceivableOrSalesRevenueNetMember" xlink:label="sxtp_AccountsReceivableOrSalesRevenueNetMember" xlink:title="sxtp_AccountsReceivableOrSalesRevenueNetMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="sxtp_AccountsReceivableOrSalesRevenueNetMember" xlink:title="Presentation : us-gaap_ConcentrationRiskBenchmarkDomain to sxtp_AccountsReceivableOrSalesRevenueNetMember" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ChangeInAccountingEstimateLineItems" xlink:label="us-gaap_ChangeInAccountingEstimateLineItems" xlink:title="us-gaap_ChangeInAccountingEstimateLineItems" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sxtp_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_ChangeInAccountingEstimateLineItems" xlink:title="Presentation : sxtp_SummaryofSignificantAccountingPoliciesDetailsTable to us-gaap_ChangeInAccountingEstimateLineItems" use="optional" priority="0" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit" xlink:title="us-gaap_StockholdersEquityReverseStockSplit" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ChangeInAccountingEstimateLineItems" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" xlink:title="Presentation : us-gaap_ChangeInAccountingEstimateLineItems to us-gaap_StockholdersEquityReverseStockSplit" use="optional" priority="0" order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1" xlink:title="us-gaap_ConcentrationRiskPercentage1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ChangeInAccountingEstimateLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" xlink:title="Presentation : us-gaap_ChangeInAccountingEstimateLineItems to us-gaap_ConcentrationRiskPercentage1" use="optional" priority="0" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:title="us-gaap_CashCashEquivalentsAndShortTermInvestments" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ChangeInAccountingEstimateLineItems" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:title="Presentation : us-gaap_ChangeInAccountingEstimateLineItems to us-gaap_CashCashEquivalentsAndShortTermInvestments" use="optional" priority="0" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:title="us-gaap_ResearchAndDevelopmentExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ChangeInAccountingEstimateLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" xlink:title="Presentation : us-gaap_ChangeInAccountingEstimateLineItems to us-gaap_ResearchAndDevelopmentExpense" use="optional" priority="0" order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://60degreespharma.com/role/PROPERTYANDEQUIPMENTDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:title="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:title="us-gaap_DepreciationDepletionAndAmortization" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" xlink:title="Presentation : us-gaap_PropertyPlantAndEquipmentAbstract to us-gaap_DepreciationDepletionAndAmortization" use="optional" priority="0" order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://60degreespharma.com/role/ConsolidatedCondensedStatementsofShareholdersEquityUnaudited">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:title="us-gaap_StatementOfStockholdersEquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:title="us-gaap_StatementTable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" xlink:title="Presentation : us-gaap_StatementOfStockholdersEquityAbstract to us-gaap_StatementTable" use="optional" priority="0" order="0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:title="us-gaap_StatementEquityComponentsAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" xlink:title="Presentation : us-gaap_StatementTable to us-gaap_StatementEquityComponentsAxis" use="optional" priority="0" order="0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:title="us-gaap_EquityComponentDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" xlink:title="Presentation : us-gaap_StatementEquityComponentsAxis to us-gaap_EquityComponentDomain" use="optional" priority="0" order="0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember" xlink:title="us-gaap_PreferredStockMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_PreferredStockMember" xlink:title="Presentation : us-gaap_EquityComponentDomain to us-gaap_PreferredStockMember" use="optional" priority="0" order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:title="us-gaap_CommonStockMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" xlink:title="Presentation : us-gaap_EquityComponentDomain to us-gaap_CommonStockMember" use="optional" priority="0" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:title="us-gaap_AdditionalPaidInCapitalMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" xlink:title="Presentation : us-gaap_EquityComponentDomain to us-gaap_AdditionalPaidInCapitalMember" use="optional" priority="0" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsUnappropriatedMember" xlink:label="us-gaap_RetainedEarningsUnappropriatedMember" xlink:title="us-gaap_RetainedEarningsUnappropriatedMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsUnappropriatedMember" xlink:title="Presentation : us-gaap_EquityComponentDomain to us-gaap_RetainedEarningsUnappropriatedMember" use="optional" priority="0" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:title="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:title="Presentation : us-gaap_EquityComponentDomain to us-gaap_AccumulatedOtherComprehensiveIncomeMember" use="optional" priority="0" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ParentMember" xlink:label="us-gaap_ParentMember" xlink:title="us-gaap_ParentMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_ParentMember" xlink:title="Presentation : us-gaap_EquityComponentDomain to us-gaap_ParentMember" use="optional" priority="0" order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="us-gaap_NoncontrollingInterestMember" xlink:title="us-gaap_NoncontrollingInterestMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_NoncontrollingInterestMember" xlink:title="Presentation : us-gaap_EquityComponentDomain to us-gaap_NoncontrollingInterestMember" use="optional" priority="0" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:title="us-gaap_StatementClassOfStockAxis" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" xlink:title="Presentation : us-gaap_StatementTable to us-gaap_StatementClassOfStockAxis" use="optional" priority="0" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xlink:title="us-gaap_ClassOfStockDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" xlink:title="Presentation : us-gaap_StatementClassOfStockAxis to us-gaap_ClassOfStockDomain" use="optional" priority="0" order="0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:title="us-gaap_SeriesAPreferredStockMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" xlink:title="Presentation : us-gaap_ClassOfStockDomain to us-gaap_SeriesAPreferredStockMember" use="optional" priority="0" order="0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:title="us-gaap_StatementLineItems" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:title="Presentation : us-gaap_StatementTable to us-gaap_StatementLineItems" use="optional" priority="0" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:title="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:title="Presentation : us-gaap_StatementLineItems to us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" use="optional" priority="0" order="0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" xlink:title="us-gaap_SharesOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" xlink:title="Presentation : us-gaap_StatementLineItems to us-gaap_SharesOutstanding" use="optional" priority="0" order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="us-gaap_ConversionOfStockAmountConverted1" xlink:title="us-gaap_ConversionOfStockAmountConverted1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConversionOfStockAmountConverted1" xlink:title="Presentation : us-gaap_StatementLineItems to us-gaap_ConversionOfStockAmountConverted1" use="optional" priority="0" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:title="us-gaap_StockIssuedDuringPeriodSharesOther" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:title="Presentation : us-gaap_StatementLineItems to us-gaap_StockIssuedDuringPeriodSharesOther" use="optional" priority="0" order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_StockIssuedDuringPeriodValueIssuanceOfCommonStockPursuantToATMOfferingNetOfOfferingCosts" xlink:label="sxtp_StockIssuedDuringPeriodValueIssuanceOfCommonStockPursuantToATMOfferingNetOfOfferingCosts" xlink:title="sxtp_StockIssuedDuringPeriodValueIssuanceOfCommonStockPursuantToATMOfferingNetOfOfferingCosts" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sxtp_StockIssuedDuringPeriodValueIssuanceOfCommonStockPursuantToATMOfferingNetOfOfferingCosts" xlink:title="Presentation : us-gaap_StatementLineItems to sxtp_StockIssuedDuringPeriodValueIssuanceOfCommonStockPursuantToATMOfferingNetOfOfferingCosts" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_IssuanceOfCommonStockPursuantToATMOfferingNetOfOfferingCostsPaid" xlink:label="sxtp_IssuanceOfCommonStockPursuantToATMOfferingNetOfOfferingCostsPaid" xlink:title="sxtp_IssuanceOfCommonStockPursuantToATMOfferingNetOfOfferingCostsPaid" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sxtp_IssuanceOfCommonStockPursuantToATMOfferingNetOfOfferingCostsPaid" xlink:title="Presentation : us-gaap_StatementLineItems to sxtp_IssuanceOfCommonStockPursuantToATMOfferingNetOfOfferingCostsPaid" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:title="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:title="Presentation : us-gaap_StatementLineItems to us-gaap_StockIssuedDuringPeriodValueNewIssues" use="optional" priority="0" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPursuantToJanuary2025OfferingNetOfOfferingCosts" xlink:label="sxtp_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPursuantToJanuary2025OfferingNetOfOfferingCosts" xlink:title="sxtp_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPursuantToJanuary2025OfferingNetOfOfferingCosts" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sxtp_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPursuantToJanuary2025OfferingNetOfOfferingCosts" xlink:title="Presentation : us-gaap_StatementLineItems to sxtp_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPursuantToJanuary2025OfferingNetOfOfferingCosts" use="optional" priority="0" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_StockIssuedDuringPeriodIssuanceOfCommonStockAndWarrantsPursuantToJanuary2025OfferingNetOfOfferingCosts" xlink:label="sxtp_StockIssuedDuringPeriodIssuanceOfCommonStockAndWarrantsPursuantToJanuary2025OfferingNetOfOfferingCosts" xlink:title="sxtp_StockIssuedDuringPeriodIssuanceOfCommonStockAndWarrantsPursuantToJanuary2025OfferingNetOfOfferingCosts" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sxtp_StockIssuedDuringPeriodIssuanceOfCommonStockAndWarrantsPursuantToJanuary2025OfferingNetOfOfferingCosts" xlink:title="Presentation : us-gaap_StatementLineItems to sxtp_StockIssuedDuringPeriodIssuanceOfCommonStockAndWarrantsPursuantToJanuary2025OfferingNetOfOfferingCosts" use="optional" priority="0" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPursuantToFebruary2025OfferingNetOfOfferingCosts" xlink:label="sxtp_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPursuantToFebruary2025OfferingNetOfOfferingCosts" xlink:title="sxtp_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPursuantToFebruary2025OfferingNetOfOfferingCosts" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sxtp_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPursuantToFebruary2025OfferingNetOfOfferingCosts" xlink:title="Presentation : us-gaap_StatementLineItems to sxtp_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPursuantToFebruary2025OfferingNetOfOfferingCosts" use="optional" priority="0" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_StockIssuedDuringPeriodIssuanceOfCommonStockAndWarrantsPursuantToFebruary2025OfferingNetOfOfferingCosts" xlink:label="sxtp_StockIssuedDuringPeriodIssuanceOfCommonStockAndWarrantsPursuantToFebruary2025OfferingNetOfOfferingCosts" xlink:title="sxtp_StockIssuedDuringPeriodIssuanceOfCommonStockAndWarrantsPursuantToFebruary2025OfferingNetOfOfferingCosts" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sxtp_StockIssuedDuringPeriodIssuanceOfCommonStockAndWarrantsPursuantToFebruary2025OfferingNetOfOfferingCosts" xlink:title="Presentation : us-gaap_StatementLineItems to sxtp_StockIssuedDuringPeriodIssuanceOfCommonStockAndWarrantsPursuantToFebruary2025OfferingNetOfOfferingCosts" use="optional" priority="0" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPursuantToJuly2025OfferingNetOfOfferingCosts" xlink:label="sxtp_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPursuantToJuly2025OfferingNetOfOfferingCosts" xlink:title="sxtp_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPursuantToJuly2025OfferingNetOfOfferingCosts" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sxtp_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPursuantToJuly2025OfferingNetOfOfferingCosts" xlink:title="Presentation : us-gaap_StatementLineItems to sxtp_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPursuantToJuly2025OfferingNetOfOfferingCosts" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsPursuantToJuly2025OfferingNetOfOfferingCosts" xlink:label="sxtp_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsPursuantToJuly2025OfferingNetOfOfferingCosts" xlink:title="sxtp_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsPursuantToJuly2025OfferingNetOfOfferingCosts" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sxtp_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsPursuantToJuly2025OfferingNetOfOfferingCosts" xlink:title="Presentation : us-gaap_StatementLineItems to sxtp_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsPursuantToJuly2025OfferingNetOfOfferingCosts" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_IssuanceOfCommonStockAndWarrantsOfUnderwritingDiscountsAndOfferingCostsPaidAtClosingAndDeferredOfferingCosts" xlink:label="sxtp_IssuanceOfCommonStockAndWarrantsOfUnderwritingDiscountsAndOfferingCostsPaidAtClosingAndDeferredOfferingCosts" xlink:title="sxtp_IssuanceOfCommonStockAndWarrantsOfUnderwritingDiscountsAndOfferingCostsPaidAtClosingAndDeferredOfferingCosts" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sxtp_IssuanceOfCommonStockAndWarrantsOfUnderwritingDiscountsAndOfferingCostsPaidAtClosingAndDeferredOfferingCosts" xlink:title="Presentation : us-gaap_StatementLineItems to sxtp_IssuanceOfCommonStockAndWarrantsOfUnderwritingDiscountsAndOfferingCostsPaidAtClosingAndDeferredOfferingCosts" use="optional" priority="0" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_StockIssuedDuringPeriodSharesOfCommonStockAndWarrantsOfUnderwritingDiscountsAndOfferingCostsPaidAtClosingAndDeferredOfferingCosts" xlink:label="sxtp_StockIssuedDuringPeriodSharesOfCommonStockAndWarrantsOfUnderwritingDiscountsAndOfferingCostsPaidAtClosingAndDeferredOfferingCosts" xlink:title="sxtp_StockIssuedDuringPeriodSharesOfCommonStockAndWarrantsOfUnderwritingDiscountsAndOfferingCostsPaidAtClosingAndDeferredOfferingCosts" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sxtp_StockIssuedDuringPeriodSharesOfCommonStockAndWarrantsOfUnderwritingDiscountsAndOfferingCostsPaidAtClosingAndDeferredOfferingCosts" xlink:title="Presentation : us-gaap_StatementLineItems to sxtp_StockIssuedDuringPeriodSharesOfCommonStockAndWarrantsOfUnderwritingDiscountsAndOfferingCostsPaidAtClosingAndDeferredOfferingCosts" use="optional" priority="0" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_StockIssuedDuringPeriodValueStockIssuanceOfCommonStockUponExerciseOfPreFundedWarrants" xlink:label="sxtp_StockIssuedDuringPeriodValueStockIssuanceOfCommonStockUponExerciseOfPreFundedWarrants" xlink:title="sxtp_StockIssuedDuringPeriodValueStockIssuanceOfCommonStockUponExerciseOfPreFundedWarrants" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sxtp_StockIssuedDuringPeriodValueStockIssuanceOfCommonStockUponExerciseOfPreFundedWarrants" xlink:title="Presentation : us-gaap_StatementLineItems to sxtp_StockIssuedDuringPeriodValueStockIssuanceOfCommonStockUponExerciseOfPreFundedWarrants" use="optional" priority="0" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_StockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfPreFundedWarrantsinShares" xlink:label="sxtp_StockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfPreFundedWarrantsinShares" xlink:title="sxtp_StockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfPreFundedWarrantsinShares" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sxtp_StockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfPreFundedWarrantsinShares" xlink:title="Presentation : us-gaap_StatementLineItems to sxtp_StockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfPreFundedWarrantsinShares" use="optional" priority="0" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:title="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:title="Presentation : us-gaap_StatementLineItems to us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" use="optional" priority="0" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_StockIssuedDuringPeriodValueIssuanceOfSharesForAnnualPerformanceBonusesNetOfSharesWithheldForTaxes" xlink:label="sxtp_StockIssuedDuringPeriodValueIssuanceOfSharesForAnnualPerformanceBonusesNetOfSharesWithheldForTaxes" xlink:title="sxtp_StockIssuedDuringPeriodValueIssuanceOfSharesForAnnualPerformanceBonusesNetOfSharesWithheldForTaxes" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sxtp_StockIssuedDuringPeriodValueIssuanceOfSharesForAnnualPerformanceBonusesNetOfSharesWithheldForTaxes" xlink:title="Presentation : us-gaap_StatementLineItems to sxtp_StockIssuedDuringPeriodValueIssuanceOfSharesForAnnualPerformanceBonusesNetOfSharesWithheldForTaxes" use="optional" priority="0" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_StockIssuedDuringPeriodIssuanceOfSharesForAnnualPerformanceBonusesNetOfSharesWithheldForTaxesinShares" xlink:label="sxtp_StockIssuedDuringPeriodIssuanceOfSharesForAnnualPerformanceBonusesNetOfSharesWithheldForTaxesinShares" xlink:title="sxtp_StockIssuedDuringPeriodIssuanceOfSharesForAnnualPerformanceBonusesNetOfSharesWithheldForTaxesinShares" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sxtp_StockIssuedDuringPeriodIssuanceOfSharesForAnnualPerformanceBonusesNetOfSharesWithheldForTaxesinShares" xlink:title="Presentation : us-gaap_StatementLineItems to sxtp_StockIssuedDuringPeriodIssuanceOfSharesForAnnualPerformanceBonusesNetOfSharesWithheldForTaxesinShares" use="optional" priority="0" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:title="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:title="Presentation : us-gaap_StatementLineItems to us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" use="optional" priority="0" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:title="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:title="Presentation : us-gaap_StatementLineItems to us-gaap_StockIssuedDuringPeriodValueIssuedForServices" use="optional" priority="0" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:title="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:title="Presentation : us-gaap_StatementLineItems to us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" use="optional" priority="0" order="22" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:title="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:title="Presentation : us-gaap_StatementLineItems to us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" use="optional" priority="0" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" xlink:title="us-gaap_ProfitLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProfitLoss" xlink:title="Presentation : us-gaap_StatementLineItems to us-gaap_ProfitLoss" use="optional" priority="0" order="24" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_StockIssuedDuringPeriodValueIssuanceOfCommonStockForFractionalSharesPursuantToReverseStockSplitRoundingAdjustment" xlink:label="sxtp_StockIssuedDuringPeriodValueIssuanceOfCommonStockForFractionalSharesPursuantToReverseStockSplitRoundingAdjustment" xlink:title="sxtp_StockIssuedDuringPeriodValueIssuanceOfCommonStockForFractionalSharesPursuantToReverseStockSplitRoundingAdjustment" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sxtp_StockIssuedDuringPeriodValueIssuanceOfCommonStockForFractionalSharesPursuantToReverseStockSplitRoundingAdjustment" xlink:title="Presentation : us-gaap_StatementLineItems to sxtp_StockIssuedDuringPeriodValueIssuanceOfCommonStockForFractionalSharesPursuantToReverseStockSplitRoundingAdjustment" use="optional" priority="0" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:label="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:title="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:title="Presentation : us-gaap_StatementLineItems to us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" use="optional" priority="0" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_1" xlink:title="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_1" xlink:title="Presentation : us-gaap_StatementLineItems to us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" use="optional" priority="0" order="27" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_1" xlink:title="us-gaap_SharesOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_1" xlink:title="Presentation : us-gaap_StatementLineItems to us-gaap_SharesOutstanding" use="optional" priority="0" order="28" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://60degreespharma.com/role/sxtp_r_ConsolidatedCashFlow">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:title="us-gaap_StatementOfCashFlowsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="Presentation : us-gaap_StatementOfCashFlowsAbstract to us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" use="optional" priority="0" order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" xlink:title="us-gaap_ProfitLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" xlink:title="Presentation : us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract to us-gaap_ProfitLoss" use="optional" priority="0" order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="Presentation : us-gaap_StatementOfCashFlowsAbstract to us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" use="optional" priority="0" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" xlink:title="us-gaap_Depreciation" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_Depreciation" xlink:title="Presentation : us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to us-gaap_Depreciation" use="optional" priority="0" order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentForAmortization" xlink:label="us-gaap_AdjustmentForAmortization" xlink:title="us-gaap_AdjustmentForAmortization" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentForAmortization" xlink:title="Presentation : us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to us-gaap_AdjustmentForAmortization" use="optional" priority="0" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:title="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:title="Presentation : us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" use="optional" priority="0" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_AmortizationOfCapitalizedShareBasedPayments" xlink:label="sxtp_AmortizationOfCapitalizedShareBasedPayments" xlink:title="sxtp_AmortizationOfCapitalizedShareBasedPayments" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="sxtp_AmortizationOfCapitalizedShareBasedPayments" xlink:title="Presentation : us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to sxtp_AmortizationOfCapitalizedShareBasedPayments" use="optional" priority="0" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:title="us-gaap_EmployeeBenefitsAndShareBasedCompensation" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:title="Presentation : us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to us-gaap_EmployeeBenefitsAndShareBasedCompensation" use="optional" priority="0" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet" xlink:title="us-gaap_DerivativeGainLossOnDerivativeNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet" xlink:title="Presentation : us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to us-gaap_DerivativeGainLossOnDerivativeNet" use="optional" priority="0" order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_WriteoffsOfCapitalizedPatents" xlink:label="sxtp_WriteoffsOfCapitalizedPatents" xlink:title="sxtp_WriteoffsOfCapitalizedPatents" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="sxtp_WriteoffsOfCapitalizedPatents" xlink:title="Presentation : us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to sxtp_WriteoffsOfCapitalizedPatents" use="optional" priority="0" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryLIFOReservePeriodCharge" xlink:label="us-gaap_InventoryLIFOReservePeriodCharge" xlink:title="us-gaap_InventoryLIFOReservePeriodCharge" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_InventoryLIFOReservePeriodCharge" xlink:title="Presentation : us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to us-gaap_InventoryLIFOReservePeriodCharge" use="optional" priority="0" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:title="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:title="Presentation : us-gaap_StatementOfCashFlowsAbstract to us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" use="optional" priority="0" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:title="us-gaap_IncreaseDecreaseInAccountsReceivable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:title="Presentation : us-gaap_IncreaseDecreaseInOperatingCapitalAbstract to us-gaap_IncreaseDecreaseInAccountsReceivable" use="optional" priority="0" order="0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:title="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:title="Presentation : us-gaap_IncreaseDecreaseInOperatingCapitalAbstract to us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" use="optional" priority="0" order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories" xlink:title="us-gaap_IncreaseDecreaseInInventories" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInInventories" xlink:title="Presentation : us-gaap_IncreaseDecreaseInOperatingCapitalAbstract to us-gaap_IncreaseDecreaseInInventories" use="optional" priority="0" order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:title="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:title="Presentation : us-gaap_IncreaseDecreaseInOperatingCapitalAbstract to us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" use="optional" priority="0" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:label="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:title="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:title="Presentation : us-gaap_IncreaseDecreaseInOperatingCapitalAbstract to us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" use="optional" priority="0" order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:title="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:title="Presentation : us-gaap_IncreaseDecreaseInOperatingCapitalAbstract to us-gaap_IncreaseDecreaseInOperatingLeaseLiability" use="optional" priority="0" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:title="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:title="Presentation : us-gaap_StatementOfCashFlowsAbstract to us-gaap_NetCashProvidedByUsedInOperatingActivities" use="optional" priority="0" order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:title="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:title="Presentation : us-gaap_StatementOfCashFlowsAbstract to us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" use="optional" priority="0" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_PaymentOfCapitalizationOfPatents" xlink:label="sxtp_PaymentOfCapitalizationOfPatents" xlink:title="sxtp_PaymentOfCapitalizationOfPatents" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="sxtp_PaymentOfCapitalizationOfPatents" xlink:title="Presentation : us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract to sxtp_PaymentOfCapitalizationOfPatents" use="optional" priority="0" order="0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:title="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:title="Presentation : us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract to us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" use="optional" priority="0" order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:title="us-gaap_PaymentsToAcquireIntangibleAssets" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:title="Presentation : us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract to us-gaap_PaymentsToAcquireIntangibleAssets" use="optional" priority="0" order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments" xlink:title="us-gaap_PaymentsToAcquireShortTermInvestments" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireShortTermInvestments" xlink:title="Presentation : us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract to us-gaap_PaymentsToAcquireShortTermInvestments" use="optional" priority="0" order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" xlink:title="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" xlink:title="Presentation : us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract to us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" use="optional" priority="0" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:title="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:title="Presentation : us-gaap_StatementOfCashFlowsAbstract to us-gaap_NetCashProvidedByUsedInInvestingActivities" use="optional" priority="0" order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:title="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:title="Presentation : us-gaap_StatementOfCashFlowsAbstract to us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" use="optional" priority="0" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_NetProceedsFromSharesAndWarrantsOffering" xlink:label="sxtp_NetProceedsFromSharesAndWarrantsOffering" xlink:title="sxtp_NetProceedsFromSharesAndWarrantsOffering" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="sxtp_NetProceedsFromSharesAndWarrantsOffering" xlink:title="Presentation : us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract to sxtp_NetProceedsFromSharesAndWarrantsOffering" use="optional" priority="0" order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_NetProceedsFromJanuary2025Offering" xlink:label="sxtp_NetProceedsFromJanuary2025Offering" xlink:title="sxtp_NetProceedsFromJanuary2025Offering" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="sxtp_NetProceedsFromJanuary2025Offering" xlink:title="Presentation : us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract to sxtp_NetProceedsFromJanuary2025Offering" use="optional" priority="0" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_NetProceedsFromFebruary2025Offering" xlink:label="sxtp_NetProceedsFromFebruary2025Offering" xlink:title="sxtp_NetProceedsFromFebruary2025Offering" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="sxtp_NetProceedsFromFebruary2025Offering" xlink:title="Presentation : us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract to sxtp_NetProceedsFromFebruary2025Offering" use="optional" priority="0" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_NetProceedsFromJuly2025Offering" xlink:label="sxtp_NetProceedsFromJuly2025Offering" xlink:title="sxtp_NetProceedsFromJuly2025Offering" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="sxtp_NetProceedsFromJuly2025Offering" xlink:title="Presentation : us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract to sxtp_NetProceedsFromJuly2025Offering" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:title="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:title="Presentation : us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract to us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" use="optional" priority="0" order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_ProceedsFromIssuanceATMOfferingCosts" xlink:label="sxtp_ProceedsFromIssuanceATMOfferingCosts" xlink:title="sxtp_ProceedsFromIssuanceATMOfferingCosts" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="sxtp_ProceedsFromIssuanceATMOfferingCosts" xlink:title="Presentation : us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract to sxtp_ProceedsFromIssuanceATMOfferingCosts" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:title="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:title="Presentation : us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract to us-gaap_ProceedsFromIssuanceOfPrivatePlacement" use="optional" priority="0" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_ProceedsFromExerciseOfPreFundedWarrants" xlink:label="sxtp_ProceedsFromExerciseOfPreFundedWarrants" xlink:title="sxtp_ProceedsFromExerciseOfPreFundedWarrants" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="sxtp_ProceedsFromExerciseOfPreFundedWarrants" xlink:title="Presentation : us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract to sxtp_ProceedsFromExerciseOfPreFundedWarrants" use="optional" priority="0" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:title="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:title="Presentation : us-gaap_StatementOfCashFlowsAbstract to us-gaap_NetCashProvidedByUsedInFinancingActivities" use="optional" priority="0" order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:title="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:title="Presentation : us-gaap_StatementOfCashFlowsAbstract to us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" use="optional" priority="0" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:title="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:title="Presentation : us-gaap_StatementOfCashFlowsAbstract to us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" use="optional" priority="0" order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:title="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:title="Presentation : us-gaap_StatementOfCashFlowsAbstract to us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" use="optional" priority="0" order="10" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1" xlink:title="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1" xlink:title="Presentation : us-gaap_StatementOfCashFlowsAbstract to us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" use="optional" priority="0" order="11" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:title="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:title="Presentation : us-gaap_StatementOfCashFlowsAbstract to us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" use="optional" priority="0" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_FairValueOfWarrantsIssuedToUnderwriters" xlink:label="sxtp_FairValueOfWarrantsIssuedToUnderwriters" xlink:title="sxtp_FairValueOfWarrantsIssuedToUnderwriters" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="sxtp_FairValueOfWarrantsIssuedToUnderwriters" xlink:title="Presentation : us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract to sxtp_FairValueOfWarrantsIssuedToUnderwriters" use="optional" priority="0" order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1" xlink:title="us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1" xlink:title="Presentation : us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract to us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1" use="optional" priority="0" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_ConversionOfSeriesAPreferredStockIntoCommonStock" xlink:label="sxtp_ConversionOfSeriesAPreferredStockIntoCommonStock" xlink:title="sxtp_ConversionOfSeriesAPreferredStockIntoCommonStock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="sxtp_ConversionOfSeriesAPreferredStockIntoCommonStock" xlink:title="Presentation : us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract to sxtp_ConversionOfSeriesAPreferredStockIntoCommonStock" priority="0" order="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1" xlink:label="us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1" xlink:title="us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1" xlink:title="Presentation : us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract to us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1" use="optional" priority="0" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_GrossSharesIssuedForAnnualPerformanceBonuses" xlink:label="sxtp_GrossSharesIssuedForAnnualPerformanceBonuses" xlink:title="sxtp_GrossSharesIssuedForAnnualPerformanceBonuses" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="sxtp_GrossSharesIssuedForAnnualPerformanceBonuses" xlink:title="Presentation : us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract to sxtp_GrossSharesIssuedForAnnualPerformanceBonuses" use="optional" priority="0" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>4
<FILENAME>sxtp-20250930_cal.xml
<DESCRIPTION>CALCULATION
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!--Created by IRIS Business Services_Direct, Powered by IRIS Carbon, Unique Code 691618107ea6641f94c6a05b, Generated At Thu, 13 Nov 2025 17:41:17 GMT-->
<link:linkbase xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://60degreespharma.com/role/sxtp_r_ConsolidatedBalanceSheet" xlink:type="simple" xlink:href="sxtp-20250930.xsd#sxtp_r_ConsolidatedBalanceSheet" />
  <link:roleRef roleURI="http://60degreespharma.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails" xlink:type="simple" xlink:href="sxtp-20250930.xsd#PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails" />
  <link:roleRef roleURI="http://60degreespharma.com/role/INTANGIBLEASSETSScheduleofIntangibleAssetsDetails" xlink:type="simple" xlink:href="sxtp-20250930.xsd#INTANGIBLEASSETSScheduleofIntangibleAssetsDetails" />
  <link:roleRef roleURI="http://60degreespharma.com/role/INTANGIBLEASSETSScheduleofEstimatedFutureAmortizationExpenseforOurPatentsandWebsiteDevelopmentCostsDetails" xlink:type="simple" xlink:href="sxtp-20250930.xsd#INTANGIBLEASSETSScheduleofEstimatedFutureAmortizationExpenseforOurPatentsandWebsiteDevelopmentCostsDetails" />
  <link:roleRef roleURI="http://60degreespharma.com/role/DEBTScheduleoftheCurrentFuturePaymentObligationsDetails" xlink:type="simple" xlink:href="sxtp-20250930.xsd#DEBTScheduleoftheCurrentFuturePaymentObligationsDetails" />
  <link:roleRef roleURI="http://60degreespharma.com/role/sxtp_r_ConsolidatedIncomeStatement" xlink:type="simple" xlink:href="sxtp-20250930.xsd#sxtp_r_ConsolidatedIncomeStatement" />
  <link:roleRef roleURI="http://60degreespharma.com/role/ConsolidatedCondensedStatementsofOperationsandComprehensiveLossIncomeUnauditedCalc2" xlink:type="simple" xlink:href="sxtp-20250930.xsd#ConsolidatedCondensedStatementsofOperationsandComprehensiveLossIncomeUnauditedCalc2" />
  <link:roleRef roleURI="http://60degreespharma.com/role/INVENTORYScheduleofInventoryDetails" xlink:type="simple" xlink:href="sxtp-20250930.xsd#INVENTORYScheduleofInventoryDetails" />
  <link:roleRef roleURI="http://60degreespharma.com/role/sxtp_r_ConsolidatedCashFlow" xlink:type="simple" xlink:href="sxtp-20250930.xsd#sxtp_r_ConsolidatedCashFlow" />
  <link:roleRef roleURI="http://60degreespharma.com/role/DocumentAndEntityInformation" xlink:type="simple" xlink:href="sxtp-20250930.xsd#DocumentAndEntityInformation" />
  <link:roleRef roleURI="http://60degreespharma.com/role/sxtp_r_ConsolidatedBalanceSheet_Parentheticals" xlink:type="simple" xlink:href="sxtp-20250930.xsd#sxtp_r_ConsolidatedBalanceSheet_Parentheticals" />
  <link:roleRef roleURI="http://60degreespharma.com/role/ConsolidatedCondensedStatementsofShareholdersEquityUnaudited" xlink:type="simple" xlink:href="sxtp-20250930.xsd#ConsolidatedCondensedStatementsofShareholdersEquityUnaudited" />
  <link:roleRef roleURI="http://60degreespharma.com/role/ConsolidatedCondensedStatementsofShareholdersEquityDeficitUnauditedParentheticals" xlink:type="simple" xlink:href="sxtp-20250930.xsd#ConsolidatedCondensedStatementsofShareholdersEquityDeficitUnauditedParentheticals" />
  <link:roleRef roleURI="http://60degreespharma.com/role/ConsolidatedCondensedStatementsofCashFlowsUnauditedParentheticals" xlink:type="simple" xlink:href="sxtp-20250930.xsd#ConsolidatedCondensedStatementsofCashFlowsUnauditedParentheticals" />
  <link:roleRef roleURI="http://60degreespharma.com/role/NATUREOFOPERATIONS" xlink:type="simple" xlink:href="sxtp-20250930.xsd#NATUREOFOPERATIONS" />
  <link:roleRef roleURI="http://60degreespharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="simple" xlink:href="sxtp-20250930.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" />
  <link:roleRef roleURI="http://60degreespharma.com/role/INVENTORY" xlink:type="simple" xlink:href="sxtp-20250930.xsd#INVENTORY" />
  <link:roleRef roleURI="http://60degreespharma.com/role/PROPERTYANDEQUIPMENT" xlink:type="simple" xlink:href="sxtp-20250930.xsd#PROPERTYANDEQUIPMENT" />
  <link:roleRef roleURI="http://60degreespharma.com/role/INTANGIBLEASSETS" xlink:type="simple" xlink:href="sxtp-20250930.xsd#INTANGIBLEASSETS" />
  <link:roleRef roleURI="http://60degreespharma.com/role/STOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="sxtp-20250930.xsd#STOCKHOLDERSEQUITY" />
  <link:roleRef roleURI="http://60degreespharma.com/role/DEBT" xlink:type="simple" xlink:href="sxtp-20250930.xsd#DEBT" />
  <link:roleRef roleURI="http://60degreespharma.com/role/DERIVATIVELIABILITIES" xlink:type="simple" xlink:href="sxtp-20250930.xsd#DERIVATIVELIABILITIES" />
  <link:roleRef roleURI="http://60degreespharma.com/role/INCOMETAXES" xlink:type="simple" xlink:href="sxtp-20250930.xsd#INCOMETAXES" />
  <link:roleRef roleURI="http://60degreespharma.com/role/SHAREBASEDCOMPENSATION" xlink:type="simple" xlink:href="sxtp-20250930.xsd#SHAREBASEDCOMPENSATION" />
  <link:roleRef roleURI="http://60degreespharma.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="simple" xlink:href="sxtp-20250930.xsd#COMMITMENTSANDCONTINGENCIES" />
  <link:roleRef roleURI="http://60degreespharma.com/role/SUBSEQUENTEVENTS" xlink:type="simple" xlink:href="sxtp-20250930.xsd#SUBSEQUENTEVENTS" />
  <link:roleRef roleURI="http://60degreespharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="simple" xlink:href="sxtp-20250930.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" />
  <link:roleRef roleURI="http://60degreespharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" xlink:type="simple" xlink:href="sxtp-20250930.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" />
  <link:roleRef roleURI="http://60degreespharma.com/role/INVENTORYTables" xlink:type="simple" xlink:href="sxtp-20250930.xsd#INVENTORYTables" />
  <link:roleRef roleURI="http://60degreespharma.com/role/PROPERTYANDEQUIPMENTTables" xlink:type="simple" xlink:href="sxtp-20250930.xsd#PROPERTYANDEQUIPMENTTables" />
  <link:roleRef roleURI="http://60degreespharma.com/role/INTANGIBLEASSETSTables" xlink:type="simple" xlink:href="sxtp-20250930.xsd#INTANGIBLEASSETSTables" />
  <link:roleRef roleURI="http://60degreespharma.com/role/STOCKHOLDERSEQUITYTables" xlink:type="simple" xlink:href="sxtp-20250930.xsd#STOCKHOLDERSEQUITYTables" />
  <link:roleRef roleURI="http://60degreespharma.com/role/DEBTTables" xlink:type="simple" xlink:href="sxtp-20250930.xsd#DEBTTables" />
  <link:roleRef roleURI="http://60degreespharma.com/role/DERIVATIVELIABILITIESTables" xlink:type="simple" xlink:href="sxtp-20250930.xsd#DERIVATIVELIABILITIESTables" />
  <link:roleRef roleURI="http://60degreespharma.com/role/SHAREBASEDCOMPENSATIONTables" xlink:type="simple" xlink:href="sxtp-20250930.xsd#SHAREBASEDCOMPENSATIONTables" />
  <link:roleRef roleURI="http://60degreespharma.com/role/NATUREOFOPERATIONSDetails" xlink:type="simple" xlink:href="sxtp-20250930.xsd#NATUREOFOPERATIONSDetails" />
  <link:roleRef roleURI="http://60degreespharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails" xlink:type="simple" xlink:href="sxtp-20250930.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails" />
  <link:roleRef roleURI="http://60degreespharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofLiabilitiesMeasuredatFairValueDetails" xlink:type="simple" xlink:href="sxtp-20250930.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofLiabilitiesMeasuredatFairValueDetails" />
  <link:roleRef roleURI="http://60degreespharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofExchangeRatesalongwithHistoricalRatesDetails" xlink:type="simple" xlink:href="sxtp-20250930.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofExchangeRatesalongwithHistoricalRatesDetails" />
  <link:roleRef roleURI="http://60degreespharma.com/role/INVENTORYDetails" xlink:type="simple" xlink:href="sxtp-20250930.xsd#INVENTORYDetails" />
  <link:roleRef roleURI="http://60degreespharma.com/role/PROPERTYANDEQUIPMENTDetails" xlink:type="simple" xlink:href="sxtp-20250930.xsd#PROPERTYANDEQUIPMENTDetails" />
  <link:roleRef roleURI="http://60degreespharma.com/role/INTANGIBLEASSETSDetails" xlink:type="simple" xlink:href="sxtp-20250930.xsd#INTANGIBLEASSETSDetails" />
  <link:roleRef roleURI="http://60degreespharma.com/role/STOCKHOLDERSEQUITYDetails" xlink:type="simple" xlink:href="sxtp-20250930.xsd#STOCKHOLDERSEQUITYDetails" />
  <link:roleRef roleURI="http://60degreespharma.com/role/STOCKHOLDERSEQUITYScheduleofEquityClassifiedWarrantsDetails" xlink:type="simple" xlink:href="sxtp-20250930.xsd#STOCKHOLDERSEQUITYScheduleofEquityClassifiedWarrantsDetails" />
  <link:roleRef roleURI="http://60degreespharma.com/role/DEBTDetails" xlink:type="simple" xlink:href="sxtp-20250930.xsd#DEBTDetails" />
  <link:roleRef roleURI="http://60degreespharma.com/role/DERIVATIVELIABILITIESDetails" xlink:type="simple" xlink:href="sxtp-20250930.xsd#DERIVATIVELIABILITIESDetails" />
  <link:roleRef roleURI="http://60degreespharma.com/role/DERIVATIVELIABILITIESScheduleofDerivativeLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" xlink:type="simple" xlink:href="sxtp-20250930.xsd#DERIVATIVELIABILITIESScheduleofDerivativeLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" />
  <link:roleRef roleURI="http://60degreespharma.com/role/INCOMETAXESDetails" xlink:type="simple" xlink:href="sxtp-20250930.xsd#INCOMETAXESDetails" />
  <link:roleRef roleURI="http://60degreespharma.com/role/SHAREBASEDCOMPENSATIONDetails" xlink:type="simple" xlink:href="sxtp-20250930.xsd#SHAREBASEDCOMPENSATIONDetails" />
  <link:roleRef roleURI="http://60degreespharma.com/role/SHAREBASEDCOMPENSATIONScheduleofShareBasedCompensationExpensesDetails" xlink:type="simple" xlink:href="sxtp-20250930.xsd#SHAREBASEDCOMPENSATIONScheduleofShareBasedCompensationExpensesDetails" />
  <link:roleRef roleURI="http://60degreespharma.com/role/SHAREBASEDCOMPENSATIONScheduleofFairValueofOptionsGrantedDetails" xlink:type="simple" xlink:href="sxtp-20250930.xsd#SHAREBASEDCOMPENSATIONScheduleofFairValueofOptionsGrantedDetails" />
  <link:roleRef roleURI="http://60degreespharma.com/role/COMMITMENTSANDCONTINGENCIESDetails" xlink:type="simple" xlink:href="sxtp-20250930.xsd#COMMITMENTSANDCONTINGENCIESDetails" />
  <link:roleRef roleURI="http://60degreespharma.com/role/SUBSEQUENTEVENTSDetails" xlink:type="simple" xlink:href="sxtp-20250930.xsd#SUBSEQUENTEVENTSDetails" />
  <link:calculationLink xlink:type="extended" xlink:role="http://60degreespharma.com/role/sxtp_r_ConsolidatedBalanceSheet">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xlink:title="us-gaap_Assets" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xlink:title="us-gaap_AssetsCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" xlink:title="Calculation : us-gaap_Assets to us-gaap_AssetsCurrent" order="0" weight="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:title="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:title="Calculation : us-gaap_AssetsCurrent to us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" weight="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:title="us-gaap_AccountsReceivableNetCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent" xlink:title="Calculation : us-gaap_AssetsCurrent to us-gaap_AccountsReceivableNetCurrent" order="1" weight="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:title="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:title="Calculation : us-gaap_AssetsCurrent to us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="2" weight="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments" xlink:title="us-gaap_ShortTermInvestments" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_ShortTermInvestments" xlink:title="Calculation : us-gaap_AssetsCurrent to us-gaap_ShortTermInvestments" order="3" weight="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" xlink:title="us-gaap_InventoryNet" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_InventoryNet" xlink:title="Calculation : us-gaap_AssetsCurrent to us-gaap_InventoryNet" order="4" weight="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:title="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" xlink:title="Calculation : us-gaap_Assets to us-gaap_PropertyPlantAndEquipmentNet" order="1" weight="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:title="us-gaap_OtherAssetsNoncurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" xlink:title="Calculation : us-gaap_Assets to us-gaap_OtherAssetsNoncurrent" order="2" weight="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseNoncurrent" xlink:label="us-gaap_PrepaidExpenseNoncurrent" xlink:title="us-gaap_PrepaidExpenseNoncurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_PrepaidExpenseNoncurrent" xlink:title="Calculation : us-gaap_OtherAssetsNoncurrent to us-gaap_PrepaidExpenseNoncurrent" order="0" weight="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:title="us-gaap_IntangibleAssetsNetExcludingGoodwill" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:title="Calculation : us-gaap_OtherAssetsNoncurrent to us-gaap_IntangibleAssetsNetExcludingGoodwill" order="1" weight="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:title="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" xlink:title="us-gaap_Liabilities" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" xlink:title="Calculation : us-gaap_LiabilitiesAndStockholdersEquity to us-gaap_Liabilities" order="0" weight="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xlink:title="us-gaap_LiabilitiesCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" xlink:title="Calculation : us-gaap_Liabilities to us-gaap_LiabilitiesCurrent" order="0" weight="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:title="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:title="Calculation : us-gaap_LiabilitiesCurrent to us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" order="0" weight="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_SBAEIDLincludingAccruedInterestCurrent" xlink:label="sxtp_SBAEIDLincludingAccruedInterestCurrent" xlink:title="sxtp_SBAEIDLincludingAccruedInterestCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="sxtp_SBAEIDLincludingAccruedInterestCurrent" xlink:title="Calculation : us-gaap_LiabilitiesCurrent to sxtp_SBAEIDLincludingAccruedInterestCurrent" order="1" weight="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="us-gaap_DerivativeLiabilitiesCurrent" xlink:title="us-gaap_DerivativeLiabilitiesCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_DerivativeLiabilitiesCurrent" xlink:title="Calculation : us-gaap_LiabilitiesCurrent to us-gaap_DerivativeLiabilitiesCurrent" order="2" weight="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent" xlink:title="us-gaap_LiabilitiesNoncurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesNoncurrent" xlink:title="Calculation : us-gaap_Liabilities to us-gaap_LiabilitiesNoncurrent" order="1" weight="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_SBAEIDLincludingAccruedInterestNonCurrent" xlink:label="sxtp_SBAEIDLincludingAccruedInterestNonCurrent" xlink:title="sxtp_SBAEIDLincludingAccruedInterestNonCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="sxtp_SBAEIDLincludingAccruedInterestNonCurrent" xlink:title="Calculation : us-gaap_LiabilitiesNoncurrent to sxtp_SBAEIDLincludingAccruedInterestNonCurrent" order="0" weight="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:title="us-gaap_CommitmentsAndContingencies" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" xlink:title="Calculation : us-gaap_LiabilitiesAndStockholdersEquity to us-gaap_CommitmentsAndContingencies" order="1" weight="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:title="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:title="Calculation : us-gaap_LiabilitiesAndStockholdersEquity to us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" order="2" weight="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:title="us-gaap_StockholdersEquity" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquity" xlink:title="Calculation : us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest to us-gaap_StockholdersEquity" order="0" weight="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" xlink:title="us-gaap_PreferredStockValue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" xlink:title="Calculation : us-gaap_StockholdersEquity to us-gaap_PreferredStockValue" order="0" weight="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:title="us-gaap_CommonStockValue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" xlink:title="Calculation : us-gaap_StockholdersEquity to us-gaap_CommonStockValue" order="1" weight="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:title="us-gaap_AdditionalPaidInCapital" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapital" xlink:title="Calculation : us-gaap_StockholdersEquity to us-gaap_AdditionalPaidInCapital" order="2" weight="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:title="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:title="Calculation : us-gaap_StockholdersEquity to us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="3" weight="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:title="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:title="Calculation : us-gaap_StockholdersEquity to us-gaap_RetainedEarningsAccumulatedDeficit" order="4" weight="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MinorityInterest" xlink:label="us-gaap_MinorityInterest" xlink:title="us-gaap_MinorityInterest" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_MinorityInterest" xlink:title="Calculation : us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest to us-gaap_MinorityInterest" order="1" weight="1" use="optional" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://60degreespharma.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:title="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:title="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" xlink:title="Calculation : us-gaap_PropertyPlantAndEquipmentNet to us-gaap_PropertyPlantAndEquipmentGross" order="0" weight="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:title="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:title="Calculation : us-gaap_PropertyPlantAndEquipmentNet to us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1" weight="-1" use="optional" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://60degreespharma.com/role/INTANGIBLEASSETSScheduleofIntangibleAssetsDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:title="us-gaap_IntangibleAssetsNetExcludingGoodwill" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:title="us-gaap_FiniteLivedIntangibleAssetsGross" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:title="Calculation : us-gaap_IntangibleAssetsNetExcludingGoodwill to us-gaap_FiniteLivedIntangibleAssetsGross" order="0" weight="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedPatentsGross" xlink:label="us-gaap_FiniteLivedPatentsGross" xlink:title="us-gaap_FiniteLivedPatentsGross" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="us-gaap_FiniteLivedPatentsGross" xlink:title="Calculation : us-gaap_FiniteLivedIntangibleAssetsGross to us-gaap_FiniteLivedPatentsGross" order="0" weight="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_FiniteLivedWebsiteDevelopmentCostsGross" xlink:label="sxtp_FiniteLivedWebsiteDevelopmentCostsGross" xlink:title="sxtp_FiniteLivedWebsiteDevelopmentCostsGross" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="sxtp_FiniteLivedWebsiteDevelopmentCostsGross" xlink:title="Calculation : us-gaap_FiniteLivedIntangibleAssetsGross to sxtp_FiniteLivedWebsiteDevelopmentCostsGross" order="1" weight="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:title="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:title="Calculation : us-gaap_IntangibleAssetsNetExcludingGoodwill to us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" order="1" weight="-1" use="optional" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://60degreespharma.com/role/INTANGIBLEASSETSScheduleofEstimatedFutureAmortizationExpenseforOurPatentsandWebsiteDevelopmentCostsDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:title="us-gaap_FiniteLivedIntangibleAssetsNet" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:title="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:title="Calculation : us-gaap_FiniteLivedIntangibleAssetsNet to us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" order="0" weight="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:title="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:title="Calculation : us-gaap_FiniteLivedIntangibleAssetsNet to us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" order="1" weight="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:title="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:title="Calculation : us-gaap_FiniteLivedIntangibleAssetsNet to us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" order="2" weight="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:title="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:title="Calculation : us-gaap_FiniteLivedIntangibleAssetsNet to us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" order="3" weight="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:title="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:title="Calculation : us-gaap_FiniteLivedIntangibleAssetsNet to us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" order="4" weight="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:title="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:title="Calculation : us-gaap_FiniteLivedIntangibleAssetsNet to us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" order="5" weight="1" use="optional" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://60degreespharma.com/role/DEBTScheduleoftheCurrentFuturePaymentObligationsDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt" xlink:title="us-gaap_LongTermDebt" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:title="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:title="Calculation : us-gaap_LongTermDebt to us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" order="0" weight="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:title="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:title="Calculation : us-gaap_LongTermDebt to us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" order="1" weight="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:title="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:title="Calculation : us-gaap_LongTermDebt to us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" order="2" weight="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:title="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:title="Calculation : us-gaap_LongTermDebt to us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" order="3" weight="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:title="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:title="Calculation : us-gaap_LongTermDebt to us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" order="4" weight="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:title="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:title="Calculation : us-gaap_LongTermDebt to us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" order="5" weight="1" use="optional" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://60degreespharma.com/role/sxtp_r_ConsolidatedIncomeStatement">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:title="us-gaap_NetIncomeLoss" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" xlink:title="us-gaap_ProfitLoss" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_ProfitLoss" xlink:title="Calculation : us-gaap_NetIncomeLoss to us-gaap_ProfitLoss" order="0" weight="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:title="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:title="Calculation : us-gaap_ProfitLoss to us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="0" weight="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xlink:title="us-gaap_OperatingIncomeLoss" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_OperatingIncomeLoss" xlink:title="Calculation : us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest to us-gaap_OperatingIncomeLoss" order="0" weight="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_NetRevenueLoss" xlink:label="sxtp_NetRevenueLoss" xlink:title="sxtp_NetRevenueLoss" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="sxtp_NetRevenueLoss" xlink:title="Calculation : us-gaap_OperatingIncomeLoss to sxtp_NetRevenueLoss" order="0" weight="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GrossProfit" xlink:label="us-gaap_GrossProfit" xlink:title="us-gaap_GrossProfit" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="sxtp_NetRevenueLoss" xlink:to="us-gaap_GrossProfit" xlink:title="Calculation : sxtp_NetRevenueLoss to us-gaap_GrossProfit" order="0" weight="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" xlink:title="us-gaap_Revenues" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_Revenues" xlink:title="Calculation : us-gaap_GrossProfit to us-gaap_Revenues" order="0" weight="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue" xlink:title="us-gaap_CostOfRevenue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_GrossProfit" xlink:to="us-gaap_CostOfRevenue" xlink:title="Calculation : us-gaap_GrossProfit to us-gaap_CostOfRevenue" order="1" weight="-1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueNotFromContractWithCustomerOther" xlink:label="us-gaap_RevenueNotFromContractWithCustomerOther" xlink:title="us-gaap_RevenueNotFromContractWithCustomerOther" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="sxtp_NetRevenueLoss" xlink:to="us-gaap_RevenueNotFromContractWithCustomerOther" xlink:title="Calculation : sxtp_NetRevenueLoss to us-gaap_RevenueNotFromContractWithCustomerOther" order="1" weight="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" xlink:title="us-gaap_OperatingExpenses" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" xlink:title="Calculation : us-gaap_OperatingIncomeLoss to us-gaap_OperatingExpenses" order="1" weight="-1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:title="us-gaap_ResearchAndDevelopmentExpense" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" xlink:title="Calculation : us-gaap_OperatingExpenses to us-gaap_ResearchAndDevelopmentExpense" order="0" weight="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:title="us-gaap_GeneralAndAdministrativeExpense" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" xlink:title="Calculation : us-gaap_OperatingExpenses to us-gaap_GeneralAndAdministrativeExpense" order="1" weight="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:title="us-gaap_InterestIncomeExpenseNonoperatingNet" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:title="Calculation : us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest to us-gaap_InterestIncomeExpenseNonoperatingNet" order="1" weight="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseNonoperating" xlink:label="us-gaap_InterestExpenseNonoperating" xlink:title="us-gaap_InterestExpenseNonoperating" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:to="us-gaap_InterestExpenseNonoperating" xlink:title="Calculation : us-gaap_InterestIncomeExpenseNonoperatingNet to us-gaap_InterestExpenseNonoperating" order="0" weight="-1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" xlink:title="us-gaap_FairValueAdjustmentOfWarrants" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" xlink:title="Calculation : us-gaap_InterestIncomeExpenseNonoperatingNet to us-gaap_FairValueAdjustmentOfWarrants" order="1" weight="-1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:title="us-gaap_OtherNonoperatingIncomeExpense" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" xlink:title="Calculation : us-gaap_InterestIncomeExpenseNonoperatingNet to us-gaap_OtherNonoperatingIncomeExpense" order="2" weight="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:title="us-gaap_IncomeTaxExpenseBenefit" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_IncomeTaxExpenseBenefit" xlink:title="Calculation : us-gaap_ProfitLoss to us-gaap_IncomeTaxExpenseBenefit" order="1" weight="-1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:title="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:title="Calculation : us-gaap_NetIncomeLoss to us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" order="1" weight="-1" use="optional" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://60degreespharma.com/role/ConsolidatedCondensedStatementsofOperationsandComprehensiveLossIncomeUnauditedCalc2">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:title="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:title="us-gaap_ComprehensiveIncomeNetOfTax" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" xlink:title="Calculation : us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic to us-gaap_ComprehensiveIncomeNetOfTax" order="0" weight="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:title="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:title="Calculation : us-gaap_ComprehensiveIncomeNetOfTax to us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" order="0" weight="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" xlink:title="us-gaap_ProfitLoss" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_ProfitLoss" xlink:title="Calculation : us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest to us-gaap_ProfitLoss" order="0" weight="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealizedAfterTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealizedAfterTax" xlink:title="us-gaap_ForeignCurrencyTransactionGainLossUnrealizedAfterTax" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossUnrealizedAfterTax" xlink:title="Calculation : us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest to us-gaap_ForeignCurrencyTransactionGainLossUnrealizedAfterTax" order="1" weight="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:title="us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:title="Calculation : us-gaap_ComprehensiveIncomeNetOfTax to us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" order="1" weight="-1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockDividendsAndOtherAdjustments" xlink:label="us-gaap_PreferredStockDividendsAndOtherAdjustments" xlink:title="us-gaap_PreferredStockDividendsAndOtherAdjustments" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_PreferredStockDividendsAndOtherAdjustments" xlink:title="Calculation : us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic to us-gaap_PreferredStockDividendsAndOtherAdjustments" order="1" weight="-1" use="optional" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://60degreespharma.com/role/INVENTORYScheduleofInventoryDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" xlink:title="us-gaap_InventoryNet" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryGross" xlink:label="us-gaap_InventoryGross" xlink:title="us-gaap_InventoryGross" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryGross" xlink:title="Calculation : us-gaap_InventoryNet to us-gaap_InventoryGross" order="0" weight="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryRawMaterials" xlink:label="us-gaap_InventoryRawMaterials" xlink:title="us-gaap_InventoryRawMaterials" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryGross" xlink:to="us-gaap_InventoryRawMaterials" xlink:title="Calculation : us-gaap_InventoryGross to us-gaap_InventoryRawMaterials" order="0" weight="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryWorkInProcess" xlink:label="us-gaap_InventoryWorkInProcess" xlink:title="us-gaap_InventoryWorkInProcess" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryGross" xlink:to="us-gaap_InventoryWorkInProcess" xlink:title="Calculation : us-gaap_InventoryGross to us-gaap_InventoryWorkInProcess" order="1" weight="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryFinishedGoods" xlink:label="us-gaap_InventoryFinishedGoods" xlink:title="us-gaap_InventoryFinishedGoods" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryGross" xlink:to="us-gaap_InventoryFinishedGoods" xlink:title="Calculation : us-gaap_InventoryGross to us-gaap_InventoryFinishedGoods" order="2" weight="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryAdjustments" xlink:label="us-gaap_InventoryAdjustments" xlink:title="us-gaap_InventoryAdjustments" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryAdjustments" xlink:title="Calculation : us-gaap_InventoryNet to us-gaap_InventoryAdjustments" order="1" weight="-1" use="optional" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://60degreespharma.com/role/sxtp_r_ConsolidatedCashFlow">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:title="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:title="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:title="Calculation : us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect to us-gaap_NetCashProvidedByUsedInOperatingActivities" order="0" weight="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" xlink:title="us-gaap_ProfitLoss" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProfitLoss" xlink:title="Calculation : us-gaap_NetCashProvidedByUsedInOperatingActivities to us-gaap_ProfitLoss" order="0" weight="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" xlink:title="us-gaap_Depreciation" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_Depreciation" xlink:title="Calculation : us-gaap_NetCashProvidedByUsedInOperatingActivities to us-gaap_Depreciation" order="1" weight="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentForAmortization" xlink:label="us-gaap_AdjustmentForAmortization" xlink:title="us-gaap_AdjustmentForAmortization" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AdjustmentForAmortization" xlink:title="Calculation : us-gaap_NetCashProvidedByUsedInOperatingActivities to us-gaap_AdjustmentForAmortization" order="2" weight="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:title="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:title="Calculation : us-gaap_NetCashProvidedByUsedInOperatingActivities to us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" order="3" weight="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_AmortizationOfCapitalizedShareBasedPayments" xlink:label="sxtp_AmortizationOfCapitalizedShareBasedPayments" xlink:title="sxtp_AmortizationOfCapitalizedShareBasedPayments" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="sxtp_AmortizationOfCapitalizedShareBasedPayments" xlink:title="Calculation : us-gaap_NetCashProvidedByUsedInOperatingActivities to sxtp_AmortizationOfCapitalizedShareBasedPayments" order="4" weight="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:title="us-gaap_EmployeeBenefitsAndShareBasedCompensation" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:title="Calculation : us-gaap_NetCashProvidedByUsedInOperatingActivities to us-gaap_EmployeeBenefitsAndShareBasedCompensation" order="5" weight="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_WriteoffsOfCapitalizedPatents" xlink:label="sxtp_WriteoffsOfCapitalizedPatents" xlink:title="sxtp_WriteoffsOfCapitalizedPatents" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="sxtp_WriteoffsOfCapitalizedPatents" xlink:title="Calculation : us-gaap_NetCashProvidedByUsedInOperatingActivities to sxtp_WriteoffsOfCapitalizedPatents" order="6" weight="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:title="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:title="Calculation : us-gaap_NetCashProvidedByUsedInOperatingActivities to us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="7" weight="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:title="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:title="Calculation : us-gaap_NetCashProvidedByUsedInOperatingActivities to us-gaap_IncreaseDecreaseInOperatingLeaseLiability" order="8" weight="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet" xlink:title="us-gaap_DerivativeGainLossOnDerivativeNet" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet" xlink:title="Calculation : us-gaap_NetCashProvidedByUsedInOperatingActivities to us-gaap_DerivativeGainLossOnDerivativeNet" order="9" weight="-1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:title="us-gaap_IncreaseDecreaseInAccountsReceivable" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:title="Calculation : us-gaap_NetCashProvidedByUsedInOperatingActivities to us-gaap_IncreaseDecreaseInAccountsReceivable" order="10" weight="-1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:title="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:title="Calculation : us-gaap_NetCashProvidedByUsedInOperatingActivities to us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="11" weight="-1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories" xlink:title="us-gaap_IncreaseDecreaseInInventories" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInInventories" xlink:title="Calculation : us-gaap_NetCashProvidedByUsedInOperatingActivities to us-gaap_IncreaseDecreaseInInventories" order="12" weight="-1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:label="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:title="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:title="Calculation : us-gaap_NetCashProvidedByUsedInOperatingActivities to us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" order="13" weight="-1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryLIFOReservePeriodCharge" xlink:label="us-gaap_InventoryLIFOReservePeriodCharge" xlink:title="us-gaap_InventoryLIFOReservePeriodCharge" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_InventoryLIFOReservePeriodCharge" xlink:title="Calculation : us-gaap_NetCashProvidedByUsedInOperatingActivities to us-gaap_InventoryLIFOReservePeriodCharge" order="14" weight="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:title="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:title="Calculation : us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect to us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1" weight="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" xlink:title="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" xlink:title="Calculation : us-gaap_NetCashProvidedByUsedInInvestingActivities to us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" order="0" weight="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_PaymentOfCapitalizationOfPatents" xlink:label="sxtp_PaymentOfCapitalizationOfPatents" xlink:title="sxtp_PaymentOfCapitalizationOfPatents" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="sxtp_PaymentOfCapitalizationOfPatents" xlink:title="Calculation : us-gaap_NetCashProvidedByUsedInInvestingActivities to sxtp_PaymentOfCapitalizationOfPatents" order="1" weight="-1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:title="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:title="Calculation : us-gaap_NetCashProvidedByUsedInInvestingActivities to us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="2" weight="-1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:title="us-gaap_PaymentsToAcquireIntangibleAssets" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:title="Calculation : us-gaap_NetCashProvidedByUsedInInvestingActivities to us-gaap_PaymentsToAcquireIntangibleAssets" order="3" weight="-1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments" xlink:title="us-gaap_PaymentsToAcquireShortTermInvestments" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireShortTermInvestments" xlink:title="Calculation : us-gaap_NetCashProvidedByUsedInInvestingActivities to us-gaap_PaymentsToAcquireShortTermInvestments" order="4" weight="-1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:title="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:title="Calculation : us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect to us-gaap_NetCashProvidedByUsedInFinancingActivities" order="2" weight="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_NetProceedsFromSharesAndWarrantsOffering" xlink:label="sxtp_NetProceedsFromSharesAndWarrantsOffering" xlink:title="sxtp_NetProceedsFromSharesAndWarrantsOffering" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="sxtp_NetProceedsFromSharesAndWarrantsOffering" xlink:title="Calculation : us-gaap_NetCashProvidedByUsedInFinancingActivities to sxtp_NetProceedsFromSharesAndWarrantsOffering" order="0" weight="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_NetProceedsFromJanuary2025Offering" xlink:label="sxtp_NetProceedsFromJanuary2025Offering" xlink:title="sxtp_NetProceedsFromJanuary2025Offering" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="sxtp_NetProceedsFromJanuary2025Offering" xlink:title="Calculation : us-gaap_NetCashProvidedByUsedInFinancingActivities to sxtp_NetProceedsFromJanuary2025Offering" order="1" weight="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_NetProceedsFromFebruary2025Offering" xlink:label="sxtp_NetProceedsFromFebruary2025Offering" xlink:title="sxtp_NetProceedsFromFebruary2025Offering" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="sxtp_NetProceedsFromFebruary2025Offering" xlink:title="Calculation : us-gaap_NetCashProvidedByUsedInFinancingActivities to sxtp_NetProceedsFromFebruary2025Offering" order="2" weight="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_NetProceedsFromJuly2025Offering" xlink:label="sxtp_NetProceedsFromJuly2025Offering" xlink:title="sxtp_NetProceedsFromJuly2025Offering" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="sxtp_NetProceedsFromJuly2025Offering" xlink:title="Calculation : us-gaap_NetCashProvidedByUsedInFinancingActivities to sxtp_NetProceedsFromJuly2025Offering" order="3" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:title="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:title="Calculation : us-gaap_NetCashProvidedByUsedInFinancingActivities to us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" order="4" weight="-1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_ProceedsFromIssuanceATMOfferingCosts" xlink:label="sxtp_ProceedsFromIssuanceATMOfferingCosts" xlink:title="sxtp_ProceedsFromIssuanceATMOfferingCosts" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="sxtp_ProceedsFromIssuanceATMOfferingCosts" xlink:title="Calculation : us-gaap_NetCashProvidedByUsedInFinancingActivities to sxtp_ProceedsFromIssuanceATMOfferingCosts" order="5" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:title="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:title="Calculation : us-gaap_NetCashProvidedByUsedInFinancingActivities to us-gaap_ProceedsFromIssuanceOfPrivatePlacement" order="6" weight="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_ProceedsFromExerciseOfPreFundedWarrants" xlink:label="sxtp_ProceedsFromExerciseOfPreFundedWarrants" xlink:title="sxtp_ProceedsFromExerciseOfPreFundedWarrants" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="sxtp_ProceedsFromExerciseOfPreFundedWarrants" xlink:title="Calculation : us-gaap_NetCashProvidedByUsedInFinancingActivities to sxtp_ProceedsFromExerciseOfPreFundedWarrants" order="7" weight="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:title="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:title="Calculation : us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect to us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="3" weight="1" use="optional" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://60degreespharma.com/role/DocumentAndEntityInformation" />
  <link:calculationLink xlink:type="extended" xlink:role="http://60degreespharma.com/role/sxtp_r_ConsolidatedBalanceSheet_Parentheticals" />
  <link:calculationLink xlink:type="extended" xlink:role="http://60degreespharma.com/role/ConsolidatedCondensedStatementsofShareholdersEquityUnaudited" />
  <link:calculationLink xlink:type="extended" xlink:role="http://60degreespharma.com/role/ConsolidatedCondensedStatementsofShareholdersEquityDeficitUnauditedParentheticals" />
  <link:calculationLink xlink:type="extended" xlink:role="http://60degreespharma.com/role/ConsolidatedCondensedStatementsofCashFlowsUnauditedParentheticals" />
  <link:calculationLink xlink:type="extended" xlink:role="http://60degreespharma.com/role/NATUREOFOPERATIONS" />
  <link:calculationLink xlink:type="extended" xlink:role="http://60degreespharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" />
  <link:calculationLink xlink:type="extended" xlink:role="http://60degreespharma.com/role/INVENTORY" />
  <link:calculationLink xlink:type="extended" xlink:role="http://60degreespharma.com/role/PROPERTYANDEQUIPMENT" />
  <link:calculationLink xlink:type="extended" xlink:role="http://60degreespharma.com/role/INTANGIBLEASSETS" />
  <link:calculationLink xlink:type="extended" xlink:role="http://60degreespharma.com/role/STOCKHOLDERSEQUITY" />
  <link:calculationLink xlink:type="extended" xlink:role="http://60degreespharma.com/role/DEBT" />
  <link:calculationLink xlink:type="extended" xlink:role="http://60degreespharma.com/role/DERIVATIVELIABILITIES" />
  <link:calculationLink xlink:type="extended" xlink:role="http://60degreespharma.com/role/INCOMETAXES" />
  <link:calculationLink xlink:type="extended" xlink:role="http://60degreespharma.com/role/SHAREBASEDCOMPENSATION" />
  <link:calculationLink xlink:type="extended" xlink:role="http://60degreespharma.com/role/COMMITMENTSANDCONTINGENCIES" />
  <link:calculationLink xlink:type="extended" xlink:role="http://60degreespharma.com/role/SUBSEQUENTEVENTS" />
  <link:calculationLink xlink:type="extended" xlink:role="http://60degreespharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" />
  <link:calculationLink xlink:type="extended" xlink:role="http://60degreespharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" />
  <link:calculationLink xlink:type="extended" xlink:role="http://60degreespharma.com/role/INVENTORYTables" />
  <link:calculationLink xlink:type="extended" xlink:role="http://60degreespharma.com/role/PROPERTYANDEQUIPMENTTables" />
  <link:calculationLink xlink:type="extended" xlink:role="http://60degreespharma.com/role/INTANGIBLEASSETSTables" />
  <link:calculationLink xlink:type="extended" xlink:role="http://60degreespharma.com/role/STOCKHOLDERSEQUITYTables" />
  <link:calculationLink xlink:type="extended" xlink:role="http://60degreespharma.com/role/DEBTTables" />
  <link:calculationLink xlink:type="extended" xlink:role="http://60degreespharma.com/role/DERIVATIVELIABILITIESTables" />
  <link:calculationLink xlink:type="extended" xlink:role="http://60degreespharma.com/role/SHAREBASEDCOMPENSATIONTables" />
  <link:calculationLink xlink:type="extended" xlink:role="http://60degreespharma.com/role/NATUREOFOPERATIONSDetails" />
  <link:calculationLink xlink:type="extended" xlink:role="http://60degreespharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails" />
  <link:calculationLink xlink:type="extended" xlink:role="http://60degreespharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofLiabilitiesMeasuredatFairValueDetails" />
  <link:calculationLink xlink:type="extended" xlink:role="http://60degreespharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofExchangeRatesalongwithHistoricalRatesDetails" />
  <link:calculationLink xlink:type="extended" xlink:role="http://60degreespharma.com/role/INVENTORYDetails" />
  <link:calculationLink xlink:type="extended" xlink:role="http://60degreespharma.com/role/PROPERTYANDEQUIPMENTDetails" />
  <link:calculationLink xlink:type="extended" xlink:role="http://60degreespharma.com/role/INTANGIBLEASSETSDetails" />
  <link:calculationLink xlink:type="extended" xlink:role="http://60degreespharma.com/role/STOCKHOLDERSEQUITYDetails" />
  <link:calculationLink xlink:type="extended" xlink:role="http://60degreespharma.com/role/STOCKHOLDERSEQUITYScheduleofEquityClassifiedWarrantsDetails" />
  <link:calculationLink xlink:type="extended" xlink:role="http://60degreespharma.com/role/DEBTDetails" />
  <link:calculationLink xlink:type="extended" xlink:role="http://60degreespharma.com/role/DERIVATIVELIABILITIESDetails" />
  <link:calculationLink xlink:type="extended" xlink:role="http://60degreespharma.com/role/DERIVATIVELIABILITIESScheduleofDerivativeLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" />
  <link:calculationLink xlink:type="extended" xlink:role="http://60degreespharma.com/role/INCOMETAXESDetails" />
  <link:calculationLink xlink:type="extended" xlink:role="http://60degreespharma.com/role/SHAREBASEDCOMPENSATIONDetails" />
  <link:calculationLink xlink:type="extended" xlink:role="http://60degreespharma.com/role/SHAREBASEDCOMPENSATIONScheduleofShareBasedCompensationExpensesDetails" />
  <link:calculationLink xlink:type="extended" xlink:role="http://60degreespharma.com/role/SHAREBASEDCOMPENSATIONScheduleofFairValueofOptionsGrantedDetails" />
  <link:calculationLink xlink:type="extended" xlink:role="http://60degreespharma.com/role/COMMITMENTSANDCONTINGENCIESDetails" />
  <link:calculationLink xlink:type="extended" xlink:role="http://60degreespharma.com/role/SUBSEQUENTEVENTSDetails" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>sxtp-20250930_lab.xml
<DESCRIPTION>LABEL
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!--Created by IRIS Business Services_Direct, Powered by IRIS Carbon, Unique Code 691618107ea6641f94c6a05b, Generated At Thu, 13 Nov 2025 17:41:17 GMT-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="StatementClassOfStockAxis" xlink:title="StatementClassOfStockAxis" />
    <link:label xlink:type="resource" xlink:label="label_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StatementClassOfStockAxis" xml:lang="en-US" id="label_StatementClassOfStockAxis">Class of Stock [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementClassOfStockAxis" xlink:to="label_StatementClassOfStockAxis" xlink:title="Label : StatementClassOfStockAxis to label_StatementClassOfStockAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="ClassOfStockDomain" xlink:title="ClassOfStockDomain" />
    <link:label xlink:type="resource" xlink:label="label_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ClassOfStockDomain" xml:lang="en-US" id="label_ClassOfStockDomain">Class of Stock [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfStockDomain" xlink:to="label_ClassOfStockDomain" xlink:title="Label : ClassOfStockDomain to label_ClassOfStockDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="StatementOfFinancialPositionAbstract" xlink:title="StatementOfFinancialPositionAbstract" />
    <link:label xlink:type="resource" xlink:label="label_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StatementOfFinancialPositionAbstract" xml:lang="en-US" id="label_StatementOfFinancialPositionAbstract">Statement of Financial Position [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="label_StatementOfFinancialPositionAbstract" xlink:title="Label : StatementOfFinancialPositionAbstract to label_StatementOfFinancialPositionAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="AssetsCurrentAbstract" xlink:title="AssetsCurrentAbstract" />
    <link:label xlink:type="resource" xlink:label="label_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_AssetsCurrentAbstract" xml:lang="en-US" id="label_AssetsCurrentAbstract">Current Assets:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsCurrentAbstract" xlink:to="label_AssetsCurrentAbstract" xlink:title="Label : AssetsCurrentAbstract to label_AssetsCurrentAbstract" />
    <link:label xlink:type="resource" xlink:label="label_AssetsCurrentAbstract_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AssetsCurrentAbstract_1" xml:lang="en-US" id="label_AssetsCurrentAbstract_1">Assets, Current [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsCurrentAbstract" xlink:to="label_AssetsCurrentAbstract_1" xlink:title="Label : AssetsCurrentAbstract to label_AssetsCurrentAbstract_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="CashAndCashEquivalentsAtCarryingValue" xlink:title="CashAndCashEquivalentsAtCarryingValue" />
    <link:label xlink:type="resource" xlink:label="label_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US" id="label_CashAndCashEquivalentsAtCarryingValue">Cash and Cash Equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashAndCashEquivalentsAtCarryingValue" xlink:to="label_CashAndCashEquivalentsAtCarryingValue" xlink:title="Label : CashAndCashEquivalentsAtCarryingValue to label_CashAndCashEquivalentsAtCarryingValue" />
    <link:label xlink:type="resource" xlink:label="label_CashAndCashEquivalentsAtCarryingValue_1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_CashAndCashEquivalentsAtCarryingValue_1" xml:lang="en-US" id="label_CashAndCashEquivalentsAtCarryingValue_1">Cash and cash equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashAndCashEquivalentsAtCarryingValue" xlink:to="label_CashAndCashEquivalentsAtCarryingValue_1" xlink:title="Label : CashAndCashEquivalentsAtCarryingValue to label_CashAndCashEquivalentsAtCarryingValue_1" />
    <link:label xlink:type="resource" xlink:label="label_CashAndCashEquivalentsAtCarryingValue_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_CashAndCashEquivalentsAtCarryingValue_2" xml:lang="en-US" id="label_CashAndCashEquivalentsAtCarryingValue_2">Cash and Cash Equivalent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashAndCashEquivalentsAtCarryingValue" xlink:to="label_CashAndCashEquivalentsAtCarryingValue_2" xlink:title="Label : CashAndCashEquivalentsAtCarryingValue to label_CashAndCashEquivalentsAtCarryingValue_2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="AccountsReceivableNetCurrent" xlink:title="AccountsReceivableNetCurrent" />
    <link:label xlink:type="resource" xlink:label="label_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_AccountsReceivableNetCurrent" xml:lang="en-US" id="label_AccountsReceivableNetCurrent">Accounts Receivable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccountsReceivableNetCurrent" xlink:to="label_AccountsReceivableNetCurrent" xlink:title="Label : AccountsReceivableNetCurrent to label_AccountsReceivableNetCurrent" />
    <link:label xlink:type="resource" xlink:label="label_AccountsReceivableNetCurrent_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AccountsReceivableNetCurrent_1" xml:lang="en-US" id="label_AccountsReceivableNetCurrent_1">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccountsReceivableNetCurrent" xlink:to="label_AccountsReceivableNetCurrent_1" xlink:title="Label : AccountsReceivableNetCurrent to label_AccountsReceivableNetCurrent_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="PrepaidExpenseAndOtherAssetsCurrent" xlink:title="PrepaidExpenseAndOtherAssetsCurrent" />
    <link:label xlink:type="resource" xlink:label="label_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_PrepaidExpenseAndOtherAssetsCurrent" xml:lang="en-US" id="label_PrepaidExpenseAndOtherAssetsCurrent">Prepaid and Other Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PrepaidExpenseAndOtherAssetsCurrent" xlink:to="label_PrepaidExpenseAndOtherAssetsCurrent" xlink:title="Label : PrepaidExpenseAndOtherAssetsCurrent to label_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:label xlink:type="resource" xlink:label="label_PrepaidExpenseAndOtherAssetsCurrent_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_PrepaidExpenseAndOtherAssetsCurrent_1" xml:lang="en-US" id="label_PrepaidExpenseAndOtherAssetsCurrent_1">Prepaid Expense and Other Assets, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PrepaidExpenseAndOtherAssetsCurrent" xlink:to="label_PrepaidExpenseAndOtherAssetsCurrent_1" xlink:title="Label : PrepaidExpenseAndOtherAssetsCurrent to label_PrepaidExpenseAndOtherAssetsCurrent_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermInvestments" xlink:label="ShortTermInvestments" xlink:title="ShortTermInvestments" />
    <link:label xlink:type="resource" xlink:label="label_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ShortTermInvestments" xml:lang="en-US" id="label_ShortTermInvestments">Short-Term Investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShortTermInvestments" xlink:to="label_ShortTermInvestments" xlink:title="Label : ShortTermInvestments to label_ShortTermInvestments" />
    <link:label xlink:type="resource" xlink:label="label_ShortTermInvestments_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ShortTermInvestments_1" xml:lang="en-US" id="label_ShortTermInvestments_1">Short-Term Investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShortTermInvestments" xlink:to="label_ShortTermInvestments_1" xlink:title="Label : ShortTermInvestments to label_ShortTermInvestments_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryNet" xlink:label="InventoryNet" xlink:title="InventoryNet" />
    <link:label xlink:type="resource" xlink:label="label_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_InventoryNet" xml:lang="en-US" id="label_InventoryNet">Inventory</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InventoryNet" xlink:to="label_InventoryNet" xlink:title="Label : InventoryNet to label_InventoryNet" />
    <link:label xlink:type="resource" xlink:label="label_InventoryNet_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_InventoryNet_1" xml:lang="en-US" id="label_InventoryNet_1">Inventory (Note 3)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InventoryNet" xlink:to="label_InventoryNet_1" xlink:title="Label : InventoryNet to label_InventoryNet_1" />
    <link:label xlink:type="resource" xlink:label="label_InventoryNet_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_InventoryNet_2" xml:lang="en-US" id="label_InventoryNet_2">Inventory, Net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InventoryNet" xlink:to="label_InventoryNet_2" xlink:title="Label : InventoryNet to label_InventoryNet_2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent" xlink:label="AssetsCurrent" xlink:title="AssetsCurrent" />
    <link:label xlink:type="resource" xlink:label="label_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_AssetsCurrent" xml:lang="en-US" id="label_AssetsCurrent">Total Current Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsCurrent" xlink:to="label_AssetsCurrent" xlink:title="Label : AssetsCurrent to label_AssetsCurrent" />
    <link:label xlink:type="resource" xlink:label="label_AssetsCurrent_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AssetsCurrent_1" xml:lang="en-US" id="label_AssetsCurrent_1">Assets, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsCurrent" xlink:to="label_AssetsCurrent_1" xlink:title="Label : AssetsCurrent to label_AssetsCurrent_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsAbstract" xlink:label="OtherAssetsAbstract" xlink:title="OtherAssetsAbstract" />
    <link:label xlink:type="resource" xlink:label="label_OtherAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_OtherAssetsAbstract" xml:lang="en-US" id="label_OtherAssetsAbstract">Other Assets:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherAssetsAbstract" xlink:to="label_OtherAssetsAbstract" xlink:title="Label : OtherAssetsAbstract to label_OtherAssetsAbstract" />
    <link:label xlink:type="resource" xlink:label="label_OtherAssetsAbstract_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_OtherAssetsAbstract_1" xml:lang="en-US" id="label_OtherAssetsAbstract_1">Other Assets [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherAssetsAbstract" xlink:to="label_OtherAssetsAbstract_1" xlink:title="Label : OtherAssetsAbstract to label_OtherAssetsAbstract_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseNoncurrent" xlink:label="PrepaidExpenseNoncurrent" xlink:title="PrepaidExpenseNoncurrent" />
    <link:label xlink:type="resource" xlink:label="label_PrepaidExpenseNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_PrepaidExpenseNoncurrent" xml:lang="en-US" id="label_PrepaidExpenseNoncurrent">Long-Term Prepaid Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PrepaidExpenseNoncurrent" xlink:to="label_PrepaidExpenseNoncurrent" xlink:title="Label : PrepaidExpenseNoncurrent to label_PrepaidExpenseNoncurrent" />
    <link:label xlink:type="resource" xlink:label="label_PrepaidExpenseNoncurrent_1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_PrepaidExpenseNoncurrent_1" xml:lang="en-US" id="label_PrepaidExpenseNoncurrent_1">Long-term prepaid expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PrepaidExpenseNoncurrent" xlink:to="label_PrepaidExpenseNoncurrent_1" xlink:title="Label : PrepaidExpenseNoncurrent to label_PrepaidExpenseNoncurrent_1" />
    <link:label xlink:type="resource" xlink:label="label_PrepaidExpenseNoncurrent_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_PrepaidExpenseNoncurrent_2" xml:lang="en-US" id="label_PrepaidExpenseNoncurrent_2">Prepaid Expense, Noncurrent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PrepaidExpenseNoncurrent" xlink:to="label_PrepaidExpenseNoncurrent_2" xlink:title="Label : PrepaidExpenseNoncurrent to label_PrepaidExpenseNoncurrent_2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="IntangibleAssetsNetExcludingGoodwill" xlink:title="IntangibleAssetsNetExcludingGoodwill" />
    <link:label xlink:type="resource" xlink:label="label_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_IntangibleAssetsNetExcludingGoodwill" xml:lang="en-US" id="label_IntangibleAssetsNetExcludingGoodwill">Intangible Assets, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IntangibleAssetsNetExcludingGoodwill" xlink:to="label_IntangibleAssetsNetExcludingGoodwill" xlink:title="Label : IntangibleAssetsNetExcludingGoodwill to label_IntangibleAssetsNetExcludingGoodwill" />
    <link:label xlink:type="resource" xlink:label="label_IntangibleAssetsNetExcludingGoodwill_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_IntangibleAssetsNetExcludingGoodwill_1" xml:lang="en-US" id="label_IntangibleAssetsNetExcludingGoodwill_1">Intangible Assets, net (Note 5)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IntangibleAssetsNetExcludingGoodwill" xlink:to="label_IntangibleAssetsNetExcludingGoodwill_1" xlink:title="Label : IntangibleAssetsNetExcludingGoodwill to label_IntangibleAssetsNetExcludingGoodwill_1" />
    <link:label xlink:type="resource" xlink:label="label_IntangibleAssetsNetExcludingGoodwill_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_IntangibleAssetsNetExcludingGoodwill_2" xml:lang="en-US" id="label_IntangibleAssetsNetExcludingGoodwill_2">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IntangibleAssetsNetExcludingGoodwill" xlink:to="label_IntangibleAssetsNetExcludingGoodwill_2" xlink:title="Label : IntangibleAssetsNetExcludingGoodwill to label_IntangibleAssetsNetExcludingGoodwill_2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="OtherAssetsNoncurrent" xlink:title="OtherAssetsNoncurrent" />
    <link:label xlink:type="resource" xlink:label="label_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_OtherAssetsNoncurrent" xml:lang="en-US" id="label_OtherAssetsNoncurrent">Total Other Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherAssetsNoncurrent" xlink:to="label_OtherAssetsNoncurrent" xlink:title="Label : OtherAssetsNoncurrent to label_OtherAssetsNoncurrent" />
    <link:label xlink:type="resource" xlink:label="label_OtherAssetsNoncurrent_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_OtherAssetsNoncurrent_1" xml:lang="en-US" id="label_OtherAssetsNoncurrent_1">Other Assets, Noncurrent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherAssetsNoncurrent" xlink:to="label_OtherAssetsNoncurrent_1" xlink:title="Label : OtherAssetsNoncurrent to label_OtherAssetsNoncurrent_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets" xlink:label="Assets" xlink:title="Assets" />
    <link:label xlink:type="resource" xlink:label="label_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_Assets" xml:lang="en-US" id="label_Assets">Total Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Assets" xlink:to="label_Assets" xlink:title="Label : Assets to label_Assets" />
    <link:label xlink:type="resource" xlink:label="label_Assets_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_Assets_1" xml:lang="en-US" id="label_Assets_1">Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Assets" xlink:to="label_Assets_1" xlink:title="Label : Assets to label_Assets_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="LiabilitiesCurrentAbstract" xlink:title="LiabilitiesCurrentAbstract" />
    <link:label xlink:type="resource" xlink:label="label_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_LiabilitiesCurrentAbstract" xml:lang="en-US" id="label_LiabilitiesCurrentAbstract">Current Liabilities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesCurrentAbstract" xlink:to="label_LiabilitiesCurrentAbstract" xlink:title="Label : LiabilitiesCurrentAbstract to label_LiabilitiesCurrentAbstract" />
    <link:label xlink:type="resource" xlink:label="label_LiabilitiesCurrentAbstract_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_LiabilitiesCurrentAbstract_1" xml:lang="en-US" id="label_LiabilitiesCurrentAbstract_1">Liabilities, Current [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesCurrentAbstract" xlink:to="label_LiabilitiesCurrentAbstract_1" xlink:title="Label : LiabilitiesCurrentAbstract to label_LiabilitiesCurrentAbstract_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="AccountsPayableAndAccruedLiabilitiesCurrent" xlink:title="AccountsPayableAndAccruedLiabilitiesCurrent" />
    <link:label xlink:type="resource" xlink:label="label_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_AccountsPayableAndAccruedLiabilitiesCurrent" xml:lang="en-US" id="label_AccountsPayableAndAccruedLiabilitiesCurrent">Accounts Payable and Accrued Expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="label_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:title="Label : AccountsPayableAndAccruedLiabilitiesCurrent to label_AccountsPayableAndAccruedLiabilitiesCurrent" />
    <link:label xlink:type="resource" xlink:label="label_AccountsPayableAndAccruedLiabilitiesCurrent_1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_AccountsPayableAndAccruedLiabilitiesCurrent_1" xml:lang="en-US" id="label_AccountsPayableAndAccruedLiabilitiesCurrent_1">Accounts payable and accrued expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="label_AccountsPayableAndAccruedLiabilitiesCurrent_1" xlink:title="Label : AccountsPayableAndAccruedLiabilitiesCurrent to label_AccountsPayableAndAccruedLiabilitiesCurrent_1" />
    <link:label xlink:type="resource" xlink:label="label_AccountsPayableAndAccruedLiabilitiesCurrent_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AccountsPayableAndAccruedLiabilitiesCurrent_2" xml:lang="en-US" id="label_AccountsPayableAndAccruedLiabilitiesCurrent_2">Accounts Payable and Accrued Liabilities, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="label_AccountsPayableAndAccruedLiabilitiesCurrent_2" xlink:title="Label : AccountsPayableAndAccruedLiabilitiesCurrent to label_AccountsPayableAndAccruedLiabilitiesCurrent_2" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_SBAEIDLincludingAccruedInterestCurrent" xlink:label="SBAEIDLincludingAccruedInterestCurrent" xlink:title="SBAEIDLincludingAccruedInterestCurrent" />
    <link:label xlink:type="resource" xlink:label="label_SBAEIDLincludingAccruedInterestCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_SBAEIDLincludingAccruedInterestCurrent" xml:lang="en-US" id="label_SBAEIDLincludingAccruedInterestCurrent">SBA EIDL (including accrued interest) (Note 7)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBAEIDLincludingAccruedInterestCurrent" xlink:to="label_SBAEIDLincludingAccruedInterestCurrent" xlink:title="Label : SBAEIDLincludingAccruedInterestCurrent to label_SBAEIDLincludingAccruedInterestCurrent" />
    <link:label xlink:type="resource" xlink:label="label_SBAEIDLincludingAccruedInterestCurrent_1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_SBAEIDLincludingAccruedInterestCurrent_1" xml:lang="en-US" id="label_SBAEIDLincludingAccruedInterestCurrent_1">Company&#x2019;s debt</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBAEIDLincludingAccruedInterestCurrent" xlink:to="label_SBAEIDLincludingAccruedInterestCurrent_1" xlink:title="Label : SBAEIDLincludingAccruedInterestCurrent to label_SBAEIDLincludingAccruedInterestCurrent_1" />
    <link:label xlink:type="resource" xlink:label="label_SBAEIDLincludingAccruedInterestCurrent_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_SBAEIDLincludingAccruedInterestCurrent_2" xml:lang="en-US" id="label_SBAEIDLincludingAccruedInterestCurrent_2">Represents the amount of SBA EIDL including accrued interest payable.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBAEIDLincludingAccruedInterestCurrent" xlink:to="label_SBAEIDLincludingAccruedInterestCurrent_2" xlink:title="Label : SBAEIDLincludingAccruedInterestCurrent to label_SBAEIDLincludingAccruedInterestCurrent_2" />
    <link:label xlink:type="resource" xlink:label="label_SBAEIDLincludingAccruedInterestCurrent_3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_SBAEIDLincludingAccruedInterestCurrent_3" xml:lang="en-US" id="label_SBAEIDLincludingAccruedInterestCurrent_3">SBAEIDLincluding Accrued Interest Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBAEIDLincludingAccruedInterestCurrent" xlink:to="label_SBAEIDLincludingAccruedInterestCurrent_3" xlink:title="Label : SBAEIDLincludingAccruedInterestCurrent to label_SBAEIDLincludingAccruedInterestCurrent_3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="DerivativeLiabilitiesCurrent" xlink:title="DerivativeLiabilitiesCurrent" />
    <link:label xlink:type="resource" xlink:label="label_DerivativeLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="label_DerivativeLiabilitiesCurrent" xml:lang="en-US" id="label_DerivativeLiabilitiesCurrent">Beginning balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DerivativeLiabilitiesCurrent" xlink:to="label_DerivativeLiabilitiesCurrent" xlink:title="Label : DerivativeLiabilitiesCurrent to label_DerivativeLiabilitiesCurrent" />
    <link:label xlink:type="resource" xlink:label="label_DerivativeLiabilitiesCurrent_1" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="label_DerivativeLiabilitiesCurrent_1" xml:lang="en-US" id="label_DerivativeLiabilitiesCurrent_1">Ending balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DerivativeLiabilitiesCurrent" xlink:to="label_DerivativeLiabilitiesCurrent_1" xlink:title="Label : DerivativeLiabilitiesCurrent to label_DerivativeLiabilitiesCurrent_1" />
    <link:label xlink:type="resource" xlink:label="label_DerivativeLiabilitiesCurrent_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_DerivativeLiabilitiesCurrent_2" xml:lang="en-US" id="label_DerivativeLiabilitiesCurrent_2">Derivative Liabilities (Note 8)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DerivativeLiabilitiesCurrent" xlink:to="label_DerivativeLiabilitiesCurrent_2" xlink:title="Label : DerivativeLiabilitiesCurrent to label_DerivativeLiabilitiesCurrent_2" />
    <link:label xlink:type="resource" xlink:label="label_DerivativeLiabilitiesCurrent_3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_DerivativeLiabilitiesCurrent_3" xml:lang="en-US" id="label_DerivativeLiabilitiesCurrent_3">Total derivative liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DerivativeLiabilitiesCurrent" xlink:to="label_DerivativeLiabilitiesCurrent_3" xlink:title="Label : DerivativeLiabilitiesCurrent to label_DerivativeLiabilitiesCurrent_3" />
    <link:label xlink:type="resource" xlink:label="label_DerivativeLiabilitiesCurrent_4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DerivativeLiabilitiesCurrent_4" xml:lang="en-US" id="label_DerivativeLiabilitiesCurrent_4">Derivative Liability, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DerivativeLiabilitiesCurrent" xlink:to="label_DerivativeLiabilitiesCurrent_4" xlink:title="Label : DerivativeLiabilitiesCurrent to label_DerivativeLiabilitiesCurrent_4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent" xlink:label="LiabilitiesCurrent" xlink:title="LiabilitiesCurrent" />
    <link:label xlink:type="resource" xlink:label="label_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_LiabilitiesCurrent" xml:lang="en-US" id="label_LiabilitiesCurrent">Total Current Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesCurrent" xlink:to="label_LiabilitiesCurrent" xlink:title="Label : LiabilitiesCurrent to label_LiabilitiesCurrent" />
    <link:label xlink:type="resource" xlink:label="label_LiabilitiesCurrent_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_LiabilitiesCurrent_1" xml:lang="en-US" id="label_LiabilitiesCurrent_1">Liabilities, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesCurrent" xlink:to="label_LiabilitiesCurrent_1" xlink:title="Label : LiabilitiesCurrent to label_LiabilitiesCurrent_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="LiabilitiesNoncurrentAbstract" xlink:title="LiabilitiesNoncurrentAbstract" />
    <link:label xlink:type="resource" xlink:label="label_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_LiabilitiesNoncurrentAbstract" xml:lang="en-US" id="label_LiabilitiesNoncurrentAbstract">Long-Term Liabilities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesNoncurrentAbstract" xlink:to="label_LiabilitiesNoncurrentAbstract" xlink:title="Label : LiabilitiesNoncurrentAbstract to label_LiabilitiesNoncurrentAbstract" />
    <link:label xlink:type="resource" xlink:label="label_LiabilitiesNoncurrentAbstract_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_LiabilitiesNoncurrentAbstract_1" xml:lang="en-US" id="label_LiabilitiesNoncurrentAbstract_1">Liabilities, Noncurrent [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesNoncurrentAbstract" xlink:to="label_LiabilitiesNoncurrentAbstract_1" xlink:title="Label : LiabilitiesNoncurrentAbstract to label_LiabilitiesNoncurrentAbstract_1" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_SBAEIDLincludingAccruedInterestNonCurrent" xlink:label="SBAEIDLincludingAccruedInterestNonCurrent" xlink:title="SBAEIDLincludingAccruedInterestNonCurrent" />
    <link:label xlink:type="resource" xlink:label="label_SBAEIDLincludingAccruedInterestNonCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_SBAEIDLincludingAccruedInterestNonCurrent" xml:lang="en-US" id="label_SBAEIDLincludingAccruedInterestNonCurrent">SBA EIDL (including accrued interest) (Note 7)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBAEIDLincludingAccruedInterestNonCurrent" xlink:to="label_SBAEIDLincludingAccruedInterestNonCurrent" xlink:title="Label : SBAEIDLincludingAccruedInterestNonCurrent to label_SBAEIDLincludingAccruedInterestNonCurrent" />
    <link:label xlink:type="resource" xlink:label="label_SBAEIDLincludingAccruedInterestNonCurrent_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_SBAEIDLincludingAccruedInterestNonCurrent_1" xml:lang="en-US" id="label_SBAEIDLincludingAccruedInterestNonCurrent_1">Represents the amount of SBA EIDL including accrued interest long-term debt payable.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBAEIDLincludingAccruedInterestNonCurrent" xlink:to="label_SBAEIDLincludingAccruedInterestNonCurrent_1" xlink:title="Label : SBAEIDLincludingAccruedInterestNonCurrent to label_SBAEIDLincludingAccruedInterestNonCurrent_1" />
    <link:label xlink:type="resource" xlink:label="label_SBAEIDLincludingAccruedInterestNonCurrent_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_SBAEIDLincludingAccruedInterestNonCurrent_2" xml:lang="en-US" id="label_SBAEIDLincludingAccruedInterestNonCurrent_2">SBAEIDLincluding Accrued Interest Non Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBAEIDLincludingAccruedInterestNonCurrent" xlink:to="label_SBAEIDLincludingAccruedInterestNonCurrent_2" xlink:title="Label : SBAEIDLincludingAccruedInterestNonCurrent to label_SBAEIDLincludingAccruedInterestNonCurrent_2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="LiabilitiesNoncurrent" xlink:title="LiabilitiesNoncurrent" />
    <link:label xlink:type="resource" xlink:label="label_LiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_LiabilitiesNoncurrent" xml:lang="en-US" id="label_LiabilitiesNoncurrent">Total Long-Term Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesNoncurrent" xlink:to="label_LiabilitiesNoncurrent" xlink:title="Label : LiabilitiesNoncurrent to label_LiabilitiesNoncurrent" />
    <link:label xlink:type="resource" xlink:label="label_LiabilitiesNoncurrent_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_LiabilitiesNoncurrent_1" xml:lang="en-US" id="label_LiabilitiesNoncurrent_1">Long-Term Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesNoncurrent" xlink:to="label_LiabilitiesNoncurrent_1" xlink:title="Label : LiabilitiesNoncurrent to label_LiabilitiesNoncurrent_1" />
    <link:label xlink:type="resource" xlink:label="label_LiabilitiesNoncurrent_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_LiabilitiesNoncurrent_2" xml:lang="en-US" id="label_LiabilitiesNoncurrent_2">Liabilities, Noncurrent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesNoncurrent" xlink:to="label_LiabilitiesNoncurrent_2" xlink:title="Label : LiabilitiesNoncurrent to label_LiabilitiesNoncurrent_2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities" xlink:label="Liabilities" xlink:title="Liabilities" />
    <link:label xlink:type="resource" xlink:label="label_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_Liabilities" xml:lang="en-US" id="label_Liabilities">Total Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Liabilities" xlink:to="label_Liabilities" xlink:title="Label : Liabilities to label_Liabilities" />
    <link:label xlink:type="resource" xlink:label="label_Liabilities_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_Liabilities_1" xml:lang="en-US" id="label_Liabilities_1">Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Liabilities" xlink:to="label_Liabilities_1" xlink:title="Label : Liabilities to label_Liabilities_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="CommitmentsAndContingencies" xlink:title="CommitmentsAndContingencies" />
    <link:label xlink:type="resource" xlink:label="label_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_CommitmentsAndContingencies" xml:lang="en-US" id="label_CommitmentsAndContingencies">Commitments and Contingencies (Note 11)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommitmentsAndContingencies" xlink:to="label_CommitmentsAndContingencies" xlink:title="Label : CommitmentsAndContingencies to label_CommitmentsAndContingencies" />
    <link:label xlink:type="resource" xlink:label="label_CommitmentsAndContingencies_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_CommitmentsAndContingencies_1" xml:lang="en-US" id="label_CommitmentsAndContingencies_1">Commitments and Contingencies</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommitmentsAndContingencies" xlink:to="label_CommitmentsAndContingencies_1" xlink:title="Label : CommitmentsAndContingencies to label_CommitmentsAndContingencies_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:title="AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <link:label xlink:type="resource" xlink:label="label_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xml:lang="en-US" id="label_AccumulatedOtherComprehensiveIncomeLossNetOfTax">Accumulated Other Comprehensive Income</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="label_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:title="Label : AccumulatedOtherComprehensiveIncomeLossNetOfTax to label_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <link:label xlink:type="resource" xlink:label="label_AccumulatedOtherComprehensiveIncomeLossNetOfTax_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AccumulatedOtherComprehensiveIncomeLossNetOfTax_1" xml:lang="en-US" id="label_AccumulatedOtherComprehensiveIncomeLossNetOfTax_1">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="label_AccumulatedOtherComprehensiveIncomeLossNetOfTax_1" xlink:title="Label : AccumulatedOtherComprehensiveIncomeLossNetOfTax to label_AccumulatedOtherComprehensiveIncomeLossNetOfTax_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="RetainedEarningsAccumulatedDeficit" xlink:title="RetainedEarningsAccumulatedDeficit" />
    <link:label xlink:type="resource" xlink:label="label_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_RetainedEarningsAccumulatedDeficit" xml:lang="en-US" id="label_RetainedEarningsAccumulatedDeficit">Accumulated Deficit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RetainedEarningsAccumulatedDeficit" xlink:to="label_RetainedEarningsAccumulatedDeficit" xlink:title="Label : RetainedEarningsAccumulatedDeficit to label_RetainedEarningsAccumulatedDeficit" />
    <link:label xlink:type="resource" xlink:label="label_RetainedEarningsAccumulatedDeficit_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_RetainedEarningsAccumulatedDeficit_1" xml:lang="en-US" id="label_RetainedEarningsAccumulatedDeficit_1">Retained Earnings (Accumulated Deficit)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RetainedEarningsAccumulatedDeficit" xlink:to="label_RetainedEarningsAccumulatedDeficit_1" xlink:title="Label : RetainedEarningsAccumulatedDeficit to label_RetainedEarningsAccumulatedDeficit_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="StockholdersEquity" xlink:title="StockholdersEquity" />
    <link:label xlink:type="resource" xlink:label="label_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_StockholdersEquity" xml:lang="en-US" id="label_StockholdersEquity">60P Shareholders&#x2019; Equity:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquity" xlink:to="label_StockholdersEquity" xlink:title="Label : StockholdersEquity to label_StockholdersEquity" />
    <link:label xlink:type="resource" xlink:label="label_StockholdersEquity_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StockholdersEquity_1" xml:lang="en-US" id="label_StockholdersEquity_1">Equity, Attributable to Parent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquity" xlink:to="label_StockholdersEquity_1" xlink:title="Label : StockholdersEquity to label_StockholdersEquity_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MinorityInterest" xlink:label="MinorityInterest" xlink:title="MinorityInterest" />
    <link:label xlink:type="resource" xlink:label="label_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_MinorityInterest" xml:lang="en-US" id="label_MinorityInterest">Noncontrolling Interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MinorityInterest" xlink:to="label_MinorityInterest" xlink:title="Label : MinorityInterest to label_MinorityInterest" />
    <link:label xlink:type="resource" xlink:label="label_MinorityInterest_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_MinorityInterest_1" xml:lang="en-US" id="label_MinorityInterest_1">Equity, Attributable to Noncontrolling Interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MinorityInterest" xlink:to="label_MinorityInterest_1" xlink:title="Label : MinorityInterest to label_MinorityInterest_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable" />
    <link:label xlink:type="resource" xlink:label="label_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StatementTable" xml:lang="en-US" id="label_StatementTable">Statement [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementTable" xlink:to="label_StatementTable" xlink:title="Label : StatementTable to label_StatementTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="SeriesAPreferredStockMember" xlink:title="SeriesAPreferredStockMember" />
    <link:label xlink:type="resource" xlink:label="label_SeriesAPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_SeriesAPreferredStockMember" xml:lang="en-US" id="label_SeriesAPreferredStockMember">Series A Preferred Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeriesAPreferredStockMember" xlink:to="label_SeriesAPreferredStockMember" xlink:title="Label : SeriesAPreferredStockMember to label_SeriesAPreferredStockMember" />
    <link:label xlink:type="resource" xlink:label="label_SeriesAPreferredStockMember_1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_SeriesAPreferredStockMember_1" xml:lang="en-US" id="label_SeriesAPreferredStockMember_1">Series A</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeriesAPreferredStockMember" xlink:to="label_SeriesAPreferredStockMember_1" xlink:title="Label : SeriesAPreferredStockMember to label_SeriesAPreferredStockMember_1" />
    <link:label xlink:type="resource" xlink:label="label_SeriesAPreferredStockMember_2" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:title="label_SeriesAPreferredStockMember_2" xml:lang="en-US" id="label_SeriesAPreferredStockMember_2">Series A Preferred Stock [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeriesAPreferredStockMember" xlink:to="label_SeriesAPreferredStockMember_2" xlink:title="Label : SeriesAPreferredStockMember to label_SeriesAPreferredStockMember_2" />
    <link:label xlink:type="resource" xlink:label="label_SeriesAPreferredStockMember_3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_SeriesAPreferredStockMember_3" xml:lang="en-US" id="label_SeriesAPreferredStockMember_3">Series A Preferred Stock [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeriesAPreferredStockMember" xlink:to="label_SeriesAPreferredStockMember_3" xlink:title="Label : SeriesAPreferredStockMember to label_SeriesAPreferredStockMember_3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems" />
    <link:label xlink:type="resource" xlink:label="label_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StatementLineItems" xml:lang="en-US" id="label_StatementLineItems">Statement [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementLineItems" xlink:to="label_StatementLineItems" xlink:title="Label : StatementLineItems to label_StatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="PreferredStockSharesAuthorized" xlink:title="PreferredStockSharesAuthorized" />
    <link:label xlink:type="resource" xlink:label="label_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_PreferredStockSharesAuthorized" xml:lang="en-US" id="label_PreferredStockSharesAuthorized">Preferred stock, shares authorized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockSharesAuthorized" xlink:to="label_PreferredStockSharesAuthorized" xlink:title="Label : PreferredStockSharesAuthorized to label_PreferredStockSharesAuthorized" />
    <link:label xlink:type="resource" xlink:label="label_PreferredStockSharesAuthorized_1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_PreferredStockSharesAuthorized_1" xml:lang="en-US" id="label_PreferredStockSharesAuthorized_1">Preferred stock shares authorized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockSharesAuthorized" xlink:to="label_PreferredStockSharesAuthorized_1" xlink:title="Label : PreferredStockSharesAuthorized to label_PreferredStockSharesAuthorized_1" />
    <link:label xlink:type="resource" xlink:label="label_PreferredStockSharesAuthorized_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_PreferredStockSharesAuthorized_2" xml:lang="en-US" id="label_PreferredStockSharesAuthorized_2">Preferred Stock, Shares Authorized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockSharesAuthorized" xlink:to="label_PreferredStockSharesAuthorized_2" xlink:title="Label : PreferredStockSharesAuthorized to label_PreferredStockSharesAuthorized_2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="PreferredStockSharesIssued" xlink:title="PreferredStockSharesIssued" />
    <link:label xlink:type="resource" xlink:label="label_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_PreferredStockSharesIssued" xml:lang="en-US" id="label_PreferredStockSharesIssued">Preferred stock, shares issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockSharesIssued" xlink:to="label_PreferredStockSharesIssued" xlink:title="Label : PreferredStockSharesIssued to label_PreferredStockSharesIssued" />
    <link:label xlink:type="resource" xlink:label="label_PreferredStockSharesIssued_1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_PreferredStockSharesIssued_1" xml:lang="en-US" id="label_PreferredStockSharesIssued_1">Preferred stock shares issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockSharesIssued" xlink:to="label_PreferredStockSharesIssued_1" xlink:title="Label : PreferredStockSharesIssued to label_PreferredStockSharesIssued_1" />
    <link:label xlink:type="resource" xlink:label="label_PreferredStockSharesIssued_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_PreferredStockSharesIssued_2" xml:lang="en-US" id="label_PreferredStockSharesIssued_2">Preferred Stock, Shares Issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockSharesIssued" xlink:to="label_PreferredStockSharesIssued_2" xlink:title="Label : PreferredStockSharesIssued to label_PreferredStockSharesIssued_2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="PreferredStockSharesOutstanding" xlink:title="PreferredStockSharesOutstanding" />
    <link:label xlink:type="resource" xlink:label="label_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_PreferredStockSharesOutstanding" xml:lang="en-US" id="label_PreferredStockSharesOutstanding">Preferred stock, shares outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockSharesOutstanding" xlink:to="label_PreferredStockSharesOutstanding" xlink:title="Label : PreferredStockSharesOutstanding to label_PreferredStockSharesOutstanding" />
    <link:label xlink:type="resource" xlink:label="label_PreferredStockSharesOutstanding_1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_PreferredStockSharesOutstanding_1" xml:lang="en-US" id="label_PreferredStockSharesOutstanding_1">Preferred stock shares outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockSharesOutstanding" xlink:to="label_PreferredStockSharesOutstanding_1" xlink:title="Label : PreferredStockSharesOutstanding to label_PreferredStockSharesOutstanding_1" />
    <link:label xlink:type="resource" xlink:label="label_PreferredStockSharesOutstanding_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_PreferredStockSharesOutstanding_2" xml:lang="en-US" id="label_PreferredStockSharesOutstanding_2">Preferred Stock, Shares Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockSharesOutstanding" xlink:to="label_PreferredStockSharesOutstanding_2" xlink:title="Label : PreferredStockSharesOutstanding to label_PreferredStockSharesOutstanding_2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="CommonStockSharesAuthorized" xlink:title="CommonStockSharesAuthorized" />
    <link:label xlink:type="resource" xlink:label="label_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_CommonStockSharesAuthorized" xml:lang="en-US" id="label_CommonStockSharesAuthorized">Common stock, shares authorized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockSharesAuthorized" xlink:to="label_CommonStockSharesAuthorized" xlink:title="Label : CommonStockSharesAuthorized to label_CommonStockSharesAuthorized" />
    <link:label xlink:type="resource" xlink:label="label_CommonStockSharesAuthorized_1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_CommonStockSharesAuthorized_1" xml:lang="en-US" id="label_CommonStockSharesAuthorized_1">Common stock shares authorized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockSharesAuthorized" xlink:to="label_CommonStockSharesAuthorized_1" xlink:title="Label : CommonStockSharesAuthorized to label_CommonStockSharesAuthorized_1" />
    <link:label xlink:type="resource" xlink:label="label_CommonStockSharesAuthorized_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_CommonStockSharesAuthorized_2" xml:lang="en-US" id="label_CommonStockSharesAuthorized_2">Common Stock, Shares Authorized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockSharesAuthorized" xlink:to="label_CommonStockSharesAuthorized_2" xlink:title="Label : CommonStockSharesAuthorized to label_CommonStockSharesAuthorized_2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued" xlink:label="CommonStockSharesIssued" xlink:title="CommonStockSharesIssued" />
    <link:label xlink:type="resource" xlink:label="label_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_CommonStockSharesIssued" xml:lang="en-US" id="label_CommonStockSharesIssued">Common stock, shares issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockSharesIssued" xlink:to="label_CommonStockSharesIssued" xlink:title="Label : CommonStockSharesIssued to label_CommonStockSharesIssued" />
    <link:label xlink:type="resource" xlink:label="label_CommonStockSharesIssued_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_CommonStockSharesIssued_1" xml:lang="en-US" id="label_CommonStockSharesIssued_1">Common Stock, Shares, Issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockSharesIssued" xlink:to="label_CommonStockSharesIssued_1" xlink:title="Label : CommonStockSharesIssued to label_CommonStockSharesIssued_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="CommonStockSharesOutstanding" xlink:title="CommonStockSharesOutstanding" />
    <link:label xlink:type="resource" xlink:label="label_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_CommonStockSharesOutstanding" xml:lang="en-US" id="label_CommonStockSharesOutstanding">Common stock, shares outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockSharesOutstanding" xlink:to="label_CommonStockSharesOutstanding" xlink:title="Label : CommonStockSharesOutstanding to label_CommonStockSharesOutstanding" />
    <link:label xlink:type="resource" xlink:label="label_CommonStockSharesOutstanding_1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_CommonStockSharesOutstanding_1" xml:lang="en-US" id="label_CommonStockSharesOutstanding_1">Common stock outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockSharesOutstanding" xlink:to="label_CommonStockSharesOutstanding_1" xlink:title="Label : CommonStockSharesOutstanding to label_CommonStockSharesOutstanding_1" />
    <link:label xlink:type="resource" xlink:label="label_CommonStockSharesOutstanding_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_CommonStockSharesOutstanding_2" xml:lang="en-US" id="label_CommonStockSharesOutstanding_2">Common Stock, Shares, Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockSharesOutstanding" xlink:to="label_CommonStockSharesOutstanding_2" xlink:title="Label : CommonStockSharesOutstanding to label_CommonStockSharesOutstanding_2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract" xlink:label="IncomeStatementAbstract" xlink:title="IncomeStatementAbstract" />
    <link:label xlink:type="resource" xlink:label="label_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_IncomeStatementAbstract" xml:lang="en-US" id="label_IncomeStatementAbstract">Income Statement [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeStatementAbstract" xlink:to="label_IncomeStatementAbstract" xlink:title="Label : IncomeStatementAbstract to label_IncomeStatementAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfRevenue" xlink:label="CostOfRevenue" xlink:title="CostOfRevenue" />
    <link:label xlink:type="resource" xlink:label="label_CostOfRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_CostOfRevenue" xml:lang="en-US" id="label_CostOfRevenue">Cost of Revenues</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CostOfRevenue" xlink:to="label_CostOfRevenue" xlink:title="Label : CostOfRevenue to label_CostOfRevenue" />
    <link:label xlink:type="resource" xlink:label="label_CostOfRevenue_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_CostOfRevenue_1" xml:lang="en-US" id="label_CostOfRevenue_1">Cost of Revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CostOfRevenue" xlink:to="label_CostOfRevenue_1" xlink:title="Label : CostOfRevenue to label_CostOfRevenue_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueNotFromContractWithCustomerOther" xlink:label="RevenueNotFromContractWithCustomerOther" xlink:title="RevenueNotFromContractWithCustomerOther" />
    <link:label xlink:type="resource" xlink:label="label_RevenueNotFromContractWithCustomerOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_RevenueNotFromContractWithCustomerOther" xml:lang="en-US" id="label_RevenueNotFromContractWithCustomerOther">Research Revenues</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RevenueNotFromContractWithCustomerOther" xlink:to="label_RevenueNotFromContractWithCustomerOther" xlink:title="Label : RevenueNotFromContractWithCustomerOther to label_RevenueNotFromContractWithCustomerOther" />
    <link:label xlink:type="resource" xlink:label="label_RevenueNotFromContractWithCustomerOther_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_RevenueNotFromContractWithCustomerOther_1" xml:lang="en-US" id="label_RevenueNotFromContractWithCustomerOther_1">Revenue Not from Contract with Customer, Other</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RevenueNotFromContractWithCustomerOther" xlink:to="label_RevenueNotFromContractWithCustomerOther_1" xlink:title="Label : RevenueNotFromContractWithCustomerOther to label_RevenueNotFromContractWithCustomerOther_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="OperatingExpensesAbstract" xlink:title="OperatingExpensesAbstract" />
    <link:label xlink:type="resource" xlink:label="label_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_OperatingExpensesAbstract" xml:lang="en-US" id="label_OperatingExpensesAbstract">Operating Expenses:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingExpensesAbstract" xlink:to="label_OperatingExpensesAbstract" xlink:title="Label : OperatingExpensesAbstract to label_OperatingExpensesAbstract" />
    <link:label xlink:type="resource" xlink:label="label_OperatingExpensesAbstract_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_OperatingExpensesAbstract_1" xml:lang="en-US" id="label_OperatingExpensesAbstract_1">Operating Expenses [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingExpensesAbstract" xlink:to="label_OperatingExpensesAbstract_1" xlink:title="Label : OperatingExpensesAbstract to label_OperatingExpensesAbstract_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="ResearchAndDevelopmentExpense" xlink:title="ResearchAndDevelopmentExpense" />
    <link:label xlink:type="resource" xlink:label="label_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ResearchAndDevelopmentExpense" xml:lang="en-US" id="label_ResearchAndDevelopmentExpense">Research and Development</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchAndDevelopmentExpense" xlink:to="label_ResearchAndDevelopmentExpense" xlink:title="Label : ResearchAndDevelopmentExpense to label_ResearchAndDevelopmentExpense" />
    <link:label xlink:type="resource" xlink:label="label_ResearchAndDevelopmentExpense_1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_ResearchAndDevelopmentExpense_1" xml:lang="en-US" id="label_ResearchAndDevelopmentExpense_1">Research and development (in Dollars)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchAndDevelopmentExpense" xlink:to="label_ResearchAndDevelopmentExpense_1" xlink:title="Label : ResearchAndDevelopmentExpense to label_ResearchAndDevelopmentExpense_1" />
    <link:label xlink:type="resource" xlink:label="label_ResearchAndDevelopmentExpense_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ResearchAndDevelopmentExpense_2" xml:lang="en-US" id="label_ResearchAndDevelopmentExpense_2">Research and Development Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchAndDevelopmentExpense" xlink:to="label_ResearchAndDevelopmentExpense_2" xlink:title="Label : ResearchAndDevelopmentExpense to label_ResearchAndDevelopmentExpense_2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="GeneralAndAdministrativeExpense" xlink:title="GeneralAndAdministrativeExpense" />
    <link:label xlink:type="resource" xlink:label="label_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_GeneralAndAdministrativeExpense" xml:lang="en-US" id="label_GeneralAndAdministrativeExpense">General and Administrative Expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GeneralAndAdministrativeExpense" xlink:to="label_GeneralAndAdministrativeExpense" xlink:title="Label : GeneralAndAdministrativeExpense to label_GeneralAndAdministrativeExpense" />
    <link:label xlink:type="resource" xlink:label="label_GeneralAndAdministrativeExpense_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_GeneralAndAdministrativeExpense_1" xml:lang="en-US" id="label_GeneralAndAdministrativeExpense_1">General and Administrative Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GeneralAndAdministrativeExpense" xlink:to="label_GeneralAndAdministrativeExpense_1" xlink:title="Label : GeneralAndAdministrativeExpense to label_GeneralAndAdministrativeExpense_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses" xlink:label="OperatingExpenses" xlink:title="OperatingExpenses" />
    <link:label xlink:type="resource" xlink:label="label_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_OperatingExpenses" xml:lang="en-US" id="label_OperatingExpenses">Total Operating Expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingExpenses" xlink:to="label_OperatingExpenses" xlink:title="Label : OperatingExpenses to label_OperatingExpenses" />
    <link:label xlink:type="resource" xlink:label="label_OperatingExpenses_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_OperatingExpenses_1" xml:lang="en-US" id="label_OperatingExpenses_1">Operating Expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingExpenses" xlink:to="label_OperatingExpenses_1" xlink:title="Label : OperatingExpenses to label_OperatingExpenses_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss" xlink:label="OperatingIncomeLoss" xlink:title="OperatingIncomeLoss" />
    <link:label xlink:type="resource" xlink:label="label_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_OperatingIncomeLoss" xml:lang="en-US" id="label_OperatingIncomeLoss">Loss from Operations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingIncomeLoss" xlink:to="label_OperatingIncomeLoss" xlink:title="Label : OperatingIncomeLoss to label_OperatingIncomeLoss" />
    <link:label xlink:type="resource" xlink:label="label_OperatingIncomeLoss_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_OperatingIncomeLoss_1" xml:lang="en-US" id="label_OperatingIncomeLoss_1">Operating Income (Loss)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingIncomeLoss" xlink:to="label_OperatingIncomeLoss_1" xlink:title="Label : OperatingIncomeLoss to label_OperatingIncomeLoss_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseNonoperating" xlink:label="InterestExpenseNonoperating" xlink:title="InterestExpenseNonoperating" />
    <link:label xlink:type="resource" xlink:label="label_InterestExpenseNonoperating" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_InterestExpenseNonoperating" xml:lang="en-US" id="label_InterestExpenseNonoperating">Interest Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InterestExpenseNonoperating" xlink:to="label_InterestExpenseNonoperating" xlink:title="Label : InterestExpenseNonoperating to label_InterestExpenseNonoperating" />
    <link:label xlink:type="resource" xlink:label="label_InterestExpenseNonoperating_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_InterestExpenseNonoperating_1" xml:lang="en-US" id="label_InterestExpenseNonoperating_1">Interest Expense, Nonoperating</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InterestExpenseNonoperating" xlink:to="label_InterestExpenseNonoperating_1" xlink:title="Label : InterestExpenseNonoperating to label_InterestExpenseNonoperating_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="FairValueAdjustmentOfWarrants" xlink:title="FairValueAdjustmentOfWarrants" />
    <link:label xlink:type="resource" xlink:label="label_FairValueAdjustmentOfWarrants" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_FairValueAdjustmentOfWarrants" xml:lang="en-US" id="label_FairValueAdjustmentOfWarrants">Change in Fair Value of Derivative Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueAdjustmentOfWarrants" xlink:to="label_FairValueAdjustmentOfWarrants" xlink:title="Label : FairValueAdjustmentOfWarrants to label_FairValueAdjustmentOfWarrants" />
    <link:label xlink:type="resource" xlink:label="label_FairValueAdjustmentOfWarrants_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FairValueAdjustmentOfWarrants_1" xml:lang="en-US" id="label_FairValueAdjustmentOfWarrants_1">Fair Value Adjustment of Warrants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueAdjustmentOfWarrants" xlink:to="label_FairValueAdjustmentOfWarrants_1" xlink:title="Label : FairValueAdjustmentOfWarrants to label_FairValueAdjustmentOfWarrants_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="OtherNonoperatingIncomeExpense" xlink:title="OtherNonoperatingIncomeExpense" />
    <link:label xlink:type="resource" xlink:label="label_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_OtherNonoperatingIncomeExpense" xml:lang="en-US" id="label_OtherNonoperatingIncomeExpense">Other Income, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherNonoperatingIncomeExpense" xlink:to="label_OtherNonoperatingIncomeExpense" xlink:title="Label : OtherNonoperatingIncomeExpense to label_OtherNonoperatingIncomeExpense" />
    <link:label xlink:type="resource" xlink:label="label_OtherNonoperatingIncomeExpense_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_OtherNonoperatingIncomeExpense_1" xml:lang="en-US" id="label_OtherNonoperatingIncomeExpense_1">Other Nonoperating Income (Expense)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherNonoperatingIncomeExpense" xlink:to="label_OtherNonoperatingIncomeExpense_1" xlink:title="Label : OtherNonoperatingIncomeExpense to label_OtherNonoperatingIncomeExpense_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:label="ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:title="ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" />
    <link:label xlink:type="resource" xlink:label="label_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xml:lang="en-US" id="label_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest">Net Loss &#x2013; Noncontrolling Interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:to="label_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:title="Label : ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest to label_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" />
    <link:label xlink:type="resource" xlink:label="label_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_1" xml:lang="en-US" id="label_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_1">Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:to="label_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_1" xlink:title="Label : ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest to label_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockDividendsAndOtherAdjustments" xlink:label="PreferredStockDividendsAndOtherAdjustments" xlink:title="PreferredStockDividendsAndOtherAdjustments" />
    <link:label xlink:type="resource" xlink:label="label_PreferredStockDividendsAndOtherAdjustments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_PreferredStockDividendsAndOtherAdjustments" xml:lang="en-US" id="label_PreferredStockDividendsAndOtherAdjustments">Cumulative Dividends on Series A Preferred Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockDividendsAndOtherAdjustments" xlink:to="label_PreferredStockDividendsAndOtherAdjustments" xlink:title="Label : PreferredStockDividendsAndOtherAdjustments to label_PreferredStockDividendsAndOtherAdjustments" />
    <link:label xlink:type="resource" xlink:label="label_PreferredStockDividendsAndOtherAdjustments_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_PreferredStockDividendsAndOtherAdjustments_1" xml:lang="en-US" id="label_PreferredStockDividendsAndOtherAdjustments_1">Preferred Stock Dividends and Other Adjustments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockDividendsAndOtherAdjustments" xlink:to="label_PreferredStockDividendsAndOtherAdjustments_1" xlink:title="Label : PreferredStockDividendsAndOtherAdjustments to label_PreferredStockDividendsAndOtherAdjustments_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic" xlink:label="EarningsPerShareBasic" xlink:title="EarningsPerShareBasic" />
    <link:label xlink:type="resource" xlink:label="label_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_EarningsPerShareBasic" xml:lang="en-US" id="label_EarningsPerShareBasic">Basic (in Dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarningsPerShareBasic" xlink:to="label_EarningsPerShareBasic" xlink:title="Label : EarningsPerShareBasic to label_EarningsPerShareBasic" />
    <link:label xlink:type="resource" xlink:label="label_EarningsPerShareBasic_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_EarningsPerShareBasic_1" xml:lang="en-US" id="label_EarningsPerShareBasic_1">Earnings Per Share, Basic</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarningsPerShareBasic" xlink:to="label_EarningsPerShareBasic_1" xlink:title="Label : EarningsPerShareBasic to label_EarningsPerShareBasic_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="EarningsPerShareDiluted" xlink:title="EarningsPerShareDiluted" />
    <link:label xlink:type="resource" xlink:label="label_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_EarningsPerShareDiluted" xml:lang="en-US" id="label_EarningsPerShareDiluted">Diluted (in Dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarningsPerShareDiluted" xlink:to="label_EarningsPerShareDiluted" xlink:title="Label : EarningsPerShareDiluted to label_EarningsPerShareDiluted" />
    <link:label xlink:type="resource" xlink:label="label_EarningsPerShareDiluted_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_EarningsPerShareDiluted_1" xml:lang="en-US" id="label_EarningsPerShareDiluted_1">Earnings Per Share, Diluted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarningsPerShareDiluted" xlink:to="label_EarningsPerShareDiluted_1" xlink:title="Label : EarningsPerShareDiluted to label_EarningsPerShareDiluted_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:label="WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:title="WeightedAverageNumberOfSharesOutstandingBasicAbstract" />
    <link:label xlink:type="resource" xlink:label="label_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xml:lang="en-US" id="label_WeightedAverageNumberOfSharesOutstandingBasicAbstract">Weighted Average Number of Common Shares Outstanding(1)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:to="label_WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:title="Label : WeightedAverageNumberOfSharesOutstandingBasicAbstract to label_WeightedAverageNumberOfSharesOutstandingBasicAbstract" />
    <link:label xlink:type="resource" xlink:label="label_WeightedAverageNumberOfSharesOutstandingBasicAbstract_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_WeightedAverageNumberOfSharesOutstandingBasicAbstract_1" xml:lang="en-US" id="label_WeightedAverageNumberOfSharesOutstandingBasicAbstract_1">Weighted Average Number of Shares Outstanding, Basic [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WeightedAverageNumberOfSharesOutstandingBasicAbstract" xlink:to="label_WeightedAverageNumberOfSharesOutstandingBasicAbstract_1" xlink:title="Label : WeightedAverageNumberOfSharesOutstandingBasicAbstract to label_WeightedAverageNumberOfSharesOutstandingBasicAbstract_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="WeightedAverageNumberOfSharesOutstandingBasic" xlink:title="WeightedAverageNumberOfSharesOutstandingBasic" />
    <link:label xlink:type="resource" xlink:label="label_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_WeightedAverageNumberOfSharesOutstandingBasic" xml:lang="en-US" id="label_WeightedAverageNumberOfSharesOutstandingBasic">Basic (in Shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="label_WeightedAverageNumberOfSharesOutstandingBasic" xlink:title="Label : WeightedAverageNumberOfSharesOutstandingBasic to label_WeightedAverageNumberOfSharesOutstandingBasic" />
    <link:label xlink:type="resource" xlink:label="label_WeightedAverageNumberOfSharesOutstandingBasic_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_WeightedAverageNumberOfSharesOutstandingBasic_1" xml:lang="en-US" id="label_WeightedAverageNumberOfSharesOutstandingBasic_1">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="label_WeightedAverageNumberOfSharesOutstandingBasic_1" xlink:title="Label : WeightedAverageNumberOfSharesOutstandingBasic to label_WeightedAverageNumberOfSharesOutstandingBasic_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="WeightedAverageNumberOfDilutedSharesOutstanding" xlink:title="WeightedAverageNumberOfDilutedSharesOutstanding" />
    <link:label xlink:type="resource" xlink:label="label_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_WeightedAverageNumberOfDilutedSharesOutstanding" xml:lang="en-US" id="label_WeightedAverageNumberOfDilutedSharesOutstanding">Diluted (in Shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="label_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:title="Label : WeightedAverageNumberOfDilutedSharesOutstanding to label_WeightedAverageNumberOfDilutedSharesOutstanding" />
    <link:label xlink:type="resource" xlink:label="label_WeightedAverageNumberOfDilutedSharesOutstanding_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_WeightedAverageNumberOfDilutedSharesOutstanding_1" xml:lang="en-US" id="label_WeightedAverageNumberOfDilutedSharesOutstanding_1">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="label_WeightedAverageNumberOfDilutedSharesOutstanding_1" xlink:title="Label : WeightedAverageNumberOfDilutedSharesOutstanding to label_WeightedAverageNumberOfDilutedSharesOutstanding_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="StatementOfStockholdersEquityAbstract" xlink:title="StatementOfStockholdersEquityAbstract" />
    <link:label xlink:type="resource" xlink:label="label_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StatementOfStockholdersEquityAbstract" xml:lang="en-US" id="label_StatementOfStockholdersEquityAbstract">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementOfStockholdersEquityAbstract" xlink:to="label_StatementOfStockholdersEquityAbstract" xlink:title="Label : StatementOfStockholdersEquityAbstract to label_StatementOfStockholdersEquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="StatementEquityComponentsAxis" xlink:title="StatementEquityComponentsAxis" />
    <link:label xlink:type="resource" xlink:label="label_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StatementEquityComponentsAxis" xml:lang="en-US" id="label_StatementEquityComponentsAxis">Equity Components [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementEquityComponentsAxis" xlink:to="label_StatementEquityComponentsAxis" xlink:title="Label : StatementEquityComponentsAxis to label_StatementEquityComponentsAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockMember" xlink:label="PreferredStockMember" xlink:title="PreferredStockMember" />
    <link:label xlink:type="resource" xlink:label="label_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_PreferredStockMember" xml:lang="en-US" id="label_PreferredStockMember">Preferred Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockMember" xlink:to="label_PreferredStockMember" xlink:title="Label : PreferredStockMember to label_PreferredStockMember" />
    <link:label xlink:type="resource" xlink:label="label_PreferredStockMember_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_PreferredStockMember_1" xml:lang="en-US" id="label_PreferredStockMember_1">Preferred Stock [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockMember" xlink:to="label_PreferredStockMember_1" xlink:title="Label : PreferredStockMember to label_PreferredStockMember_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="AdditionalPaidInCapitalMember" xlink:title="AdditionalPaidInCapitalMember" />
    <link:label xlink:type="resource" xlink:label="label_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_AdditionalPaidInCapitalMember" xml:lang="en-US" id="label_AdditionalPaidInCapitalMember">Additional Paid-In Capital</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdditionalPaidInCapitalMember" xlink:to="label_AdditionalPaidInCapitalMember" xlink:title="Label : AdditionalPaidInCapitalMember to label_AdditionalPaidInCapitalMember" />
    <link:label xlink:type="resource" xlink:label="label_AdditionalPaidInCapitalMember_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AdditionalPaidInCapitalMember_1" xml:lang="en-US" id="label_AdditionalPaidInCapitalMember_1">Additional Paid-in Capital [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdditionalPaidInCapitalMember" xlink:to="label_AdditionalPaidInCapitalMember_1" xlink:title="Label : AdditionalPaidInCapitalMember to label_AdditionalPaidInCapitalMember_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsUnappropriatedMember" xlink:label="RetainedEarningsUnappropriatedMember" xlink:title="RetainedEarningsUnappropriatedMember" />
    <link:label xlink:type="resource" xlink:label="label_RetainedEarningsUnappropriatedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_RetainedEarningsUnappropriatedMember" xml:lang="en-US" id="label_RetainedEarningsUnappropriatedMember">Accumulated Deficit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RetainedEarningsUnappropriatedMember" xlink:to="label_RetainedEarningsUnappropriatedMember" xlink:title="Label : RetainedEarningsUnappropriatedMember to label_RetainedEarningsUnappropriatedMember" />
    <link:label xlink:type="resource" xlink:label="label_RetainedEarningsUnappropriatedMember_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_RetainedEarningsUnappropriatedMember_1" xml:lang="en-US" id="label_RetainedEarningsUnappropriatedMember_1">Retained Earnings, Unappropriated [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RetainedEarningsUnappropriatedMember" xlink:to="label_RetainedEarningsUnappropriatedMember_1" xlink:title="Label : RetainedEarningsUnappropriatedMember to label_RetainedEarningsUnappropriatedMember_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="AccumulatedOtherComprehensiveIncomeMember" xlink:title="AccumulatedOtherComprehensiveIncomeMember" />
    <link:label xlink:type="resource" xlink:label="label_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_AccumulatedOtherComprehensiveIncomeMember" xml:lang="en-US" id="label_AccumulatedOtherComprehensiveIncomeMember">Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccumulatedOtherComprehensiveIncomeMember" xlink:to="label_AccumulatedOtherComprehensiveIncomeMember" xlink:title="Label : AccumulatedOtherComprehensiveIncomeMember to label_AccumulatedOtherComprehensiveIncomeMember" />
    <link:label xlink:type="resource" xlink:label="label_AccumulatedOtherComprehensiveIncomeMember_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AccumulatedOtherComprehensiveIncomeMember_1" xml:lang="en-US" id="label_AccumulatedOtherComprehensiveIncomeMember_1">AOCI Attributable to Parent [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccumulatedOtherComprehensiveIncomeMember" xlink:to="label_AccumulatedOtherComprehensiveIncomeMember_1" xlink:title="Label : AccumulatedOtherComprehensiveIncomeMember to label_AccumulatedOtherComprehensiveIncomeMember_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ParentMember" xlink:label="ParentMember" xlink:title="ParentMember" />
    <link:label xlink:type="resource" xlink:label="label_ParentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ParentMember" xml:lang="en-US" id="label_ParentMember">Total Shareholders&#x2019; Equity Attributable to 60P</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ParentMember" xlink:to="label_ParentMember" xlink:title="Label : ParentMember to label_ParentMember" />
    <link:label xlink:type="resource" xlink:label="label_ParentMember_1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_ParentMember_1" xml:lang="en-US" id="label_ParentMember_1">Total Shareholders&#x2019; Equity (Deficit) Attributable to 60P</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ParentMember" xlink:to="label_ParentMember_1" xlink:title="Label : ParentMember to label_ParentMember_1" />
    <link:label xlink:type="resource" xlink:label="label_ParentMember_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ParentMember_2" xml:lang="en-US" id="label_ParentMember_2">Parent [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ParentMember" xlink:to="label_ParentMember_2" xlink:title="Label : ParentMember to label_ParentMember_2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="NoncontrollingInterestMember" xlink:title="NoncontrollingInterestMember" />
    <link:label xlink:type="resource" xlink:label="label_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_NoncontrollingInterestMember" xml:lang="en-US" id="label_NoncontrollingInterestMember">Noncontrolling Interest on Shareholders</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NoncontrollingInterestMember" xlink:to="label_NoncontrollingInterestMember" xlink:title="Label : NoncontrollingInterestMember to label_NoncontrollingInterestMember" />
    <link:label xlink:type="resource" xlink:label="label_NoncontrollingInterestMember_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_NoncontrollingInterestMember_1" xml:lang="en-US" id="label_NoncontrollingInterestMember_1">Noncontrolling Interest [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NoncontrollingInterestMember" xlink:to="label_NoncontrollingInterestMember_1" xlink:title="Label : NoncontrollingInterestMember to label_NoncontrollingInterestMember_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain" xlink:title="EquityComponentDomain" />
    <link:label xlink:type="resource" xlink:label="label_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_EquityComponentDomain" xml:lang="en-US" id="label_EquityComponentDomain">Equity Component [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquityComponentDomain" xlink:to="label_EquityComponentDomain" xlink:title="Label : EquityComponentDomain to label_EquityComponentDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesOutstanding" xlink:label="SharesOutstanding" xlink:title="SharesOutstanding" />
    <link:label xlink:type="resource" xlink:label="label_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="label_SharesOutstanding" xml:lang="en-US" id="label_SharesOutstanding">Balance (in Shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharesOutstanding" xlink:to="label_SharesOutstanding" xlink:title="Label : SharesOutstanding to label_SharesOutstanding" />
    <link:label xlink:type="resource" xlink:label="label_SharesOutstanding_1" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="label_SharesOutstanding_1" xml:lang="en-US" id="label_SharesOutstanding_1">Balance (in Shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharesOutstanding" xlink:to="label_SharesOutstanding_1" xlink:title="Label : SharesOutstanding to label_SharesOutstanding_1" />
    <link:label xlink:type="resource" xlink:label="label_SharesOutstanding_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_SharesOutstanding_2" xml:lang="en-US" id="label_SharesOutstanding_2">Shares, Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharesOutstanding" xlink:to="label_SharesOutstanding_2" xlink:title="Label : SharesOutstanding to label_SharesOutstanding_2" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPursuantToJanuary2025OfferingNetOfOfferingCosts" xlink:label="StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPursuantToJanuary2025OfferingNetOfOfferingCosts" xlink:title="StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPursuantToJanuary2025OfferingNetOfOfferingCosts" />
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPursuantToJanuary2025OfferingNetOfOfferingCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPursuantToJanuary2025OfferingNetOfOfferingCosts" xml:lang="en-US" id="label_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPursuantToJanuary2025OfferingNetOfOfferingCosts">Issuance of common stock and warrants pursuant to January 2025 Offering, net of offering costs paid at closing and deferred offering costs (Note 6)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPursuantToJanuary2025OfferingNetOfOfferingCosts" xlink:to="label_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPursuantToJanuary2025OfferingNetOfOfferingCosts" xlink:title="Label : StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPursuantToJanuary2025OfferingNetOfOfferingCosts to label_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPursuantToJanuary2025OfferingNetOfOfferingCosts" />
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPursuantToJanuary2025OfferingNetOfOfferingCosts_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPursuantToJanuary2025OfferingNetOfOfferingCosts_1" xml:lang="en-US" id="label_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPursuantToJanuary2025OfferingNetOfOfferingCosts_1">The amount of issuance of common stock and warrants pursuant to January 2025 Offering, net of offering costs ...</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPursuantToJanuary2025OfferingNetOfOfferingCosts" xlink:to="label_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPursuantToJanuary2025OfferingNetOfOfferingCosts_1" xlink:title="Label : StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPursuantToJanuary2025OfferingNetOfOfferingCosts to label_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPursuantToJanuary2025OfferingNetOfOfferingCosts_1" />
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPursuantToJanuary2025OfferingNetOfOfferingCosts_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPursuantToJanuary2025OfferingNetOfOfferingCosts_2" xml:lang="en-US" id="label_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPursuantToJanuary2025OfferingNetOfOfferingCosts_2">Stock Issued During Period Value Issuance Of Common Stock And Warrants Pursuant To January2025 Offering Net Of Offering Costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPursuantToJanuary2025OfferingNetOfOfferingCosts" xlink:to="label_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPursuantToJanuary2025OfferingNetOfOfferingCosts_2" xlink:title="Label : StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPursuantToJanuary2025OfferingNetOfOfferingCosts to label_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPursuantToJanuary2025OfferingNetOfOfferingCosts_2" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_StockIssuedDuringPeriodIssuanceOfCommonStockAndWarrantsPursuantToJanuary2025OfferingNetOfOfferingCosts" xlink:label="StockIssuedDuringPeriodIssuanceOfCommonStockAndWarrantsPursuantToJanuary2025OfferingNetOfOfferingCosts" xlink:title="StockIssuedDuringPeriodIssuanceOfCommonStockAndWarrantsPursuantToJanuary2025OfferingNetOfOfferingCosts" />
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodIssuanceOfCommonStockAndWarrantsPursuantToJanuary2025OfferingNetOfOfferingCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_StockIssuedDuringPeriodIssuanceOfCommonStockAndWarrantsPursuantToJanuary2025OfferingNetOfOfferingCosts" xml:lang="en-US" id="label_StockIssuedDuringPeriodIssuanceOfCommonStockAndWarrantsPursuantToJanuary2025OfferingNetOfOfferingCosts">Issuance of common stock and warrants pursuant to January 2025 Offering, net of offering costs paid at closing and deferred offering costs (Note 6) (in Shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodIssuanceOfCommonStockAndWarrantsPursuantToJanuary2025OfferingNetOfOfferingCosts" xlink:to="label_StockIssuedDuringPeriodIssuanceOfCommonStockAndWarrantsPursuantToJanuary2025OfferingNetOfOfferingCosts" xlink:title="Label : StockIssuedDuringPeriodIssuanceOfCommonStockAndWarrantsPursuantToJanuary2025OfferingNetOfOfferingCosts to label_StockIssuedDuringPeriodIssuanceOfCommonStockAndWarrantsPursuantToJanuary2025OfferingNetOfOfferingCosts" />
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodIssuanceOfCommonStockAndWarrantsPursuantToJanuary2025OfferingNetOfOfferingCosts_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_StockIssuedDuringPeriodIssuanceOfCommonStockAndWarrantsPursuantToJanuary2025OfferingNetOfOfferingCosts_1" xml:lang="en-US" id="label_StockIssuedDuringPeriodIssuanceOfCommonStockAndWarrantsPursuantToJanuary2025OfferingNetOfOfferingCosts_1">Issuance of common stock and warrants pursuant to January 2025 Offering, net of offering costs .</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodIssuanceOfCommonStockAndWarrantsPursuantToJanuary2025OfferingNetOfOfferingCosts" xlink:to="label_StockIssuedDuringPeriodIssuanceOfCommonStockAndWarrantsPursuantToJanuary2025OfferingNetOfOfferingCosts_1" xlink:title="Label : StockIssuedDuringPeriodIssuanceOfCommonStockAndWarrantsPursuantToJanuary2025OfferingNetOfOfferingCosts to label_StockIssuedDuringPeriodIssuanceOfCommonStockAndWarrantsPursuantToJanuary2025OfferingNetOfOfferingCosts_1" />
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodIssuanceOfCommonStockAndWarrantsPursuantToJanuary2025OfferingNetOfOfferingCosts_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StockIssuedDuringPeriodIssuanceOfCommonStockAndWarrantsPursuantToJanuary2025OfferingNetOfOfferingCosts_2" xml:lang="en-US" id="label_StockIssuedDuringPeriodIssuanceOfCommonStockAndWarrantsPursuantToJanuary2025OfferingNetOfOfferingCosts_2">Stock Issued During Period Issuance Of Common Stock And Warrants Pursuant To January2025 Offering Net Of Offering Costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodIssuanceOfCommonStockAndWarrantsPursuantToJanuary2025OfferingNetOfOfferingCosts" xlink:to="label_StockIssuedDuringPeriodIssuanceOfCommonStockAndWarrantsPursuantToJanuary2025OfferingNetOfOfferingCosts_2" xlink:title="Label : StockIssuedDuringPeriodIssuanceOfCommonStockAndWarrantsPursuantToJanuary2025OfferingNetOfOfferingCosts to label_StockIssuedDuringPeriodIssuanceOfCommonStockAndWarrantsPursuantToJanuary2025OfferingNetOfOfferingCosts_2" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPursuantToFebruary2025OfferingNetOfOfferingCosts" xlink:label="StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPursuantToFebruary2025OfferingNetOfOfferingCosts" xlink:title="StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPursuantToFebruary2025OfferingNetOfOfferingCosts" />
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPursuantToFebruary2025OfferingNetOfOfferingCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPursuantToFebruary2025OfferingNetOfOfferingCosts" xml:lang="en-US" id="label_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPursuantToFebruary2025OfferingNetOfOfferingCosts">Issuance of common stock and warrants pursuant to February 2025 Offering, net of offering costs paid at closing and deferred offering costs (Note 6)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPursuantToFebruary2025OfferingNetOfOfferingCosts" xlink:to="label_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPursuantToFebruary2025OfferingNetOfOfferingCosts" xlink:title="Label : StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPursuantToFebruary2025OfferingNetOfOfferingCosts to label_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPursuantToFebruary2025OfferingNetOfOfferingCosts" />
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPursuantToFebruary2025OfferingNetOfOfferingCosts_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPursuantToFebruary2025OfferingNetOfOfferingCosts_1" xml:lang="en-US" id="label_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPursuantToFebruary2025OfferingNetOfOfferingCosts_1">The amount of Issuance of common stock and warrants pursuant to February 2025 Offering, net of offering costs ...</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPursuantToFebruary2025OfferingNetOfOfferingCosts" xlink:to="label_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPursuantToFebruary2025OfferingNetOfOfferingCosts_1" xlink:title="Label : StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPursuantToFebruary2025OfferingNetOfOfferingCosts to label_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPursuantToFebruary2025OfferingNetOfOfferingCosts_1" />
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPursuantToFebruary2025OfferingNetOfOfferingCosts_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPursuantToFebruary2025OfferingNetOfOfferingCosts_2" xml:lang="en-US" id="label_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPursuantToFebruary2025OfferingNetOfOfferingCosts_2">Stock Issued During Period Value Issuance Of Common Stock And Warrants Pursuant To February2025 Offering Net Of Offering Costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPursuantToFebruary2025OfferingNetOfOfferingCosts" xlink:to="label_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPursuantToFebruary2025OfferingNetOfOfferingCosts_2" xlink:title="Label : StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPursuantToFebruary2025OfferingNetOfOfferingCosts to label_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPursuantToFebruary2025OfferingNetOfOfferingCosts_2" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_StockIssuedDuringPeriodIssuanceOfCommonStockAndWarrantsPursuantToFebruary2025OfferingNetOfOfferingCosts" xlink:label="StockIssuedDuringPeriodIssuanceOfCommonStockAndWarrantsPursuantToFebruary2025OfferingNetOfOfferingCosts" xlink:title="StockIssuedDuringPeriodIssuanceOfCommonStockAndWarrantsPursuantToFebruary2025OfferingNetOfOfferingCosts" />
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodIssuanceOfCommonStockAndWarrantsPursuantToFebruary2025OfferingNetOfOfferingCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_StockIssuedDuringPeriodIssuanceOfCommonStockAndWarrantsPursuantToFebruary2025OfferingNetOfOfferingCosts" xml:lang="en-US" id="label_StockIssuedDuringPeriodIssuanceOfCommonStockAndWarrantsPursuantToFebruary2025OfferingNetOfOfferingCosts">Issuance of common stock and warrants pursuant to February 2025 Offering, net of offering costs paid at closing and deferred offering costs (Note 6) (in Shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodIssuanceOfCommonStockAndWarrantsPursuantToFebruary2025OfferingNetOfOfferingCosts" xlink:to="label_StockIssuedDuringPeriodIssuanceOfCommonStockAndWarrantsPursuantToFebruary2025OfferingNetOfOfferingCosts" xlink:title="Label : StockIssuedDuringPeriodIssuanceOfCommonStockAndWarrantsPursuantToFebruary2025OfferingNetOfOfferingCosts to label_StockIssuedDuringPeriodIssuanceOfCommonStockAndWarrantsPursuantToFebruary2025OfferingNetOfOfferingCosts" />
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodIssuanceOfCommonStockAndWarrantsPursuantToFebruary2025OfferingNetOfOfferingCosts_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_StockIssuedDuringPeriodIssuanceOfCommonStockAndWarrantsPursuantToFebruary2025OfferingNetOfOfferingCosts_1" xml:lang="en-US" id="label_StockIssuedDuringPeriodIssuanceOfCommonStockAndWarrantsPursuantToFebruary2025OfferingNetOfOfferingCosts_1">Issuance of common stock and warrants pursuant to February 2025 Offering, net of offering costs .</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodIssuanceOfCommonStockAndWarrantsPursuantToFebruary2025OfferingNetOfOfferingCosts" xlink:to="label_StockIssuedDuringPeriodIssuanceOfCommonStockAndWarrantsPursuantToFebruary2025OfferingNetOfOfferingCosts_1" xlink:title="Label : StockIssuedDuringPeriodIssuanceOfCommonStockAndWarrantsPursuantToFebruary2025OfferingNetOfOfferingCosts to label_StockIssuedDuringPeriodIssuanceOfCommonStockAndWarrantsPursuantToFebruary2025OfferingNetOfOfferingCosts_1" />
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodIssuanceOfCommonStockAndWarrantsPursuantToFebruary2025OfferingNetOfOfferingCosts_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StockIssuedDuringPeriodIssuanceOfCommonStockAndWarrantsPursuantToFebruary2025OfferingNetOfOfferingCosts_2" xml:lang="en-US" id="label_StockIssuedDuringPeriodIssuanceOfCommonStockAndWarrantsPursuantToFebruary2025OfferingNetOfOfferingCosts_2">Stock Issued During Period Issuance Of Common Stock And Warrants Pursuant To February2025 Offering Net Of Offering Costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodIssuanceOfCommonStockAndWarrantsPursuantToFebruary2025OfferingNetOfOfferingCosts" xlink:to="label_StockIssuedDuringPeriodIssuanceOfCommonStockAndWarrantsPursuantToFebruary2025OfferingNetOfOfferingCosts_2" xlink:title="Label : StockIssuedDuringPeriodIssuanceOfCommonStockAndWarrantsPursuantToFebruary2025OfferingNetOfOfferingCosts to label_StockIssuedDuringPeriodIssuanceOfCommonStockAndWarrantsPursuantToFebruary2025OfferingNetOfOfferingCosts_2" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_IssuanceOfCommonStockAndWarrantsOfUnderwritingDiscountsAndOfferingCostsPaidAtClosingAndDeferredOfferingCosts" xlink:label="IssuanceOfCommonStockAndWarrantsOfUnderwritingDiscountsAndOfferingCostsPaidAtClosingAndDeferredOfferingCosts" xlink:title="IssuanceOfCommonStockAndWarrantsOfUnderwritingDiscountsAndOfferingCostsPaidAtClosingAndDeferredOfferingCosts" />
    <link:label xlink:type="resource" xlink:label="label_IssuanceOfCommonStockAndWarrantsOfUnderwritingDiscountsAndOfferingCostsPaidAtClosingAndDeferredOfferingCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_IssuanceOfCommonStockAndWarrantsOfUnderwritingDiscountsAndOfferingCostsPaidAtClosingAndDeferredOfferingCosts" xml:lang="en-US" id="label_IssuanceOfCommonStockAndWarrantsOfUnderwritingDiscountsAndOfferingCostsPaidAtClosingAndDeferredOfferingCosts">Issuance of common stock and warrants, net of underwriting discounts and offering costs paid at closing and deferred offering costs (Note 6)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IssuanceOfCommonStockAndWarrantsOfUnderwritingDiscountsAndOfferingCostsPaidAtClosingAndDeferredOfferingCosts" xlink:to="label_IssuanceOfCommonStockAndWarrantsOfUnderwritingDiscountsAndOfferingCostsPaidAtClosingAndDeferredOfferingCosts" xlink:title="Label : IssuanceOfCommonStockAndWarrantsOfUnderwritingDiscountsAndOfferingCostsPaidAtClosingAndDeferredOfferingCosts to label_IssuanceOfCommonStockAndWarrantsOfUnderwritingDiscountsAndOfferingCostsPaidAtClosingAndDeferredOfferingCosts" />
    <link:label xlink:type="resource" xlink:label="label_IssuanceOfCommonStockAndWarrantsOfUnderwritingDiscountsAndOfferingCostsPaidAtClosingAndDeferredOfferingCosts_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_IssuanceOfCommonStockAndWarrantsOfUnderwritingDiscountsAndOfferingCostsPaidAtClosingAndDeferredOfferingCosts_1" xml:lang="en-US" id="label_IssuanceOfCommonStockAndWarrantsOfUnderwritingDiscountsAndOfferingCostsPaidAtClosingAndDeferredOfferingCosts_1">Represent the amount of issuance of common stock and warrants, net of underwriting discounts and offering costs paid at closing and deferred offering costs.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IssuanceOfCommonStockAndWarrantsOfUnderwritingDiscountsAndOfferingCostsPaidAtClosingAndDeferredOfferingCosts" xlink:to="label_IssuanceOfCommonStockAndWarrantsOfUnderwritingDiscountsAndOfferingCostsPaidAtClosingAndDeferredOfferingCosts_1" xlink:title="Label : IssuanceOfCommonStockAndWarrantsOfUnderwritingDiscountsAndOfferingCostsPaidAtClosingAndDeferredOfferingCosts to label_IssuanceOfCommonStockAndWarrantsOfUnderwritingDiscountsAndOfferingCostsPaidAtClosingAndDeferredOfferingCosts_1" />
    <link:label xlink:type="resource" xlink:label="label_IssuanceOfCommonStockAndWarrantsOfUnderwritingDiscountsAndOfferingCostsPaidAtClosingAndDeferredOfferingCosts_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_IssuanceOfCommonStockAndWarrantsOfUnderwritingDiscountsAndOfferingCostsPaidAtClosingAndDeferredOfferingCosts_2" xml:lang="en-US" id="label_IssuanceOfCommonStockAndWarrantsOfUnderwritingDiscountsAndOfferingCostsPaidAtClosingAndDeferredOfferingCosts_2">Issuance Of Common Stock And Warrants Of Underwriting Discounts And Offering Costs Paid At Closing And Deferred Offering Costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IssuanceOfCommonStockAndWarrantsOfUnderwritingDiscountsAndOfferingCostsPaidAtClosingAndDeferredOfferingCosts" xlink:to="label_IssuanceOfCommonStockAndWarrantsOfUnderwritingDiscountsAndOfferingCostsPaidAtClosingAndDeferredOfferingCosts_2" xlink:title="Label : IssuanceOfCommonStockAndWarrantsOfUnderwritingDiscountsAndOfferingCostsPaidAtClosingAndDeferredOfferingCosts to label_IssuanceOfCommonStockAndWarrantsOfUnderwritingDiscountsAndOfferingCostsPaidAtClosingAndDeferredOfferingCosts_2" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_StockIssuedDuringPeriodSharesOfCommonStockAndWarrantsOfUnderwritingDiscountsAndOfferingCostsPaidAtClosingAndDeferredOfferingCosts" xlink:label="StockIssuedDuringPeriodSharesOfCommonStockAndWarrantsOfUnderwritingDiscountsAndOfferingCostsPaidAtClosingAndDeferredOfferingCosts" xlink:title="StockIssuedDuringPeriodSharesOfCommonStockAndWarrantsOfUnderwritingDiscountsAndOfferingCostsPaidAtClosingAndDeferredOfferingCosts" />
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodSharesOfCommonStockAndWarrantsOfUnderwritingDiscountsAndOfferingCostsPaidAtClosingAndDeferredOfferingCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_StockIssuedDuringPeriodSharesOfCommonStockAndWarrantsOfUnderwritingDiscountsAndOfferingCostsPaidAtClosingAndDeferredOfferingCosts" xml:lang="en-US" id="label_StockIssuedDuringPeriodSharesOfCommonStockAndWarrantsOfUnderwritingDiscountsAndOfferingCostsPaidAtClosingAndDeferredOfferingCosts">Issuance of common stock and warrants, net of underwriting discounts and offering costs paid at closing and deferred offering costs (Note 6) (in Shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesOfCommonStockAndWarrantsOfUnderwritingDiscountsAndOfferingCostsPaidAtClosingAndDeferredOfferingCosts" xlink:to="label_StockIssuedDuringPeriodSharesOfCommonStockAndWarrantsOfUnderwritingDiscountsAndOfferingCostsPaidAtClosingAndDeferredOfferingCosts" xlink:title="Label : StockIssuedDuringPeriodSharesOfCommonStockAndWarrantsOfUnderwritingDiscountsAndOfferingCostsPaidAtClosingAndDeferredOfferingCosts to label_StockIssuedDuringPeriodSharesOfCommonStockAndWarrantsOfUnderwritingDiscountsAndOfferingCostsPaidAtClosingAndDeferredOfferingCosts" />
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodSharesOfCommonStockAndWarrantsOfUnderwritingDiscountsAndOfferingCostsPaidAtClosingAndDeferredOfferingCosts_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_StockIssuedDuringPeriodSharesOfCommonStockAndWarrantsOfUnderwritingDiscountsAndOfferingCostsPaidAtClosingAndDeferredOfferingCosts_1" xml:lang="en-US" id="label_StockIssuedDuringPeriodSharesOfCommonStockAndWarrantsOfUnderwritingDiscountsAndOfferingCostsPaidAtClosingAndDeferredOfferingCosts_1">Represent the shares issuance of common stock and warrants, net of underwriting discounts and offering costs paid at closing and deferred offering costs.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesOfCommonStockAndWarrantsOfUnderwritingDiscountsAndOfferingCostsPaidAtClosingAndDeferredOfferingCosts" xlink:to="label_StockIssuedDuringPeriodSharesOfCommonStockAndWarrantsOfUnderwritingDiscountsAndOfferingCostsPaidAtClosingAndDeferredOfferingCosts_1" xlink:title="Label : StockIssuedDuringPeriodSharesOfCommonStockAndWarrantsOfUnderwritingDiscountsAndOfferingCostsPaidAtClosingAndDeferredOfferingCosts to label_StockIssuedDuringPeriodSharesOfCommonStockAndWarrantsOfUnderwritingDiscountsAndOfferingCostsPaidAtClosingAndDeferredOfferingCosts_1" />
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodSharesOfCommonStockAndWarrantsOfUnderwritingDiscountsAndOfferingCostsPaidAtClosingAndDeferredOfferingCosts_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StockIssuedDuringPeriodSharesOfCommonStockAndWarrantsOfUnderwritingDiscountsAndOfferingCostsPaidAtClosingAndDeferredOfferingCosts_2" xml:lang="en-US" id="label_StockIssuedDuringPeriodSharesOfCommonStockAndWarrantsOfUnderwritingDiscountsAndOfferingCostsPaidAtClosingAndDeferredOfferingCosts_2">Stock Issued During Period Shares Of Common Stock And Warrants Of Underwriting Discounts And Offering Costs Paid At Closing And Deferred Offering Costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesOfCommonStockAndWarrantsOfUnderwritingDiscountsAndOfferingCostsPaidAtClosingAndDeferredOfferingCosts" xlink:to="label_StockIssuedDuringPeriodSharesOfCommonStockAndWarrantsOfUnderwritingDiscountsAndOfferingCostsPaidAtClosingAndDeferredOfferingCosts_2" xlink:title="Label : StockIssuedDuringPeriodSharesOfCommonStockAndWarrantsOfUnderwritingDiscountsAndOfferingCostsPaidAtClosingAndDeferredOfferingCosts to label_StockIssuedDuringPeriodSharesOfCommonStockAndWarrantsOfUnderwritingDiscountsAndOfferingCostsPaidAtClosingAndDeferredOfferingCosts_2" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_StockIssuedDuringPeriodValueStockIssuanceOfCommonStockUponExerciseOfPreFundedWarrants" xlink:label="StockIssuedDuringPeriodValueStockIssuanceOfCommonStockUponExerciseOfPreFundedWarrants" xlink:title="StockIssuedDuringPeriodValueStockIssuanceOfCommonStockUponExerciseOfPreFundedWarrants" />
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodValueStockIssuanceOfCommonStockUponExerciseOfPreFundedWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_StockIssuedDuringPeriodValueStockIssuanceOfCommonStockUponExerciseOfPreFundedWarrants" xml:lang="en-US" id="label_StockIssuedDuringPeriodValueStockIssuanceOfCommonStockUponExerciseOfPreFundedWarrants">Issuance of common stock upon exercise of Pre-Funded Warrants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueStockIssuanceOfCommonStockUponExerciseOfPreFundedWarrants" xlink:to="label_StockIssuedDuringPeriodValueStockIssuanceOfCommonStockUponExerciseOfPreFundedWarrants" xlink:title="Label : StockIssuedDuringPeriodValueStockIssuanceOfCommonStockUponExerciseOfPreFundedWarrants to label_StockIssuedDuringPeriodValueStockIssuanceOfCommonStockUponExerciseOfPreFundedWarrants" />
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodValueStockIssuanceOfCommonStockUponExerciseOfPreFundedWarrants_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_StockIssuedDuringPeriodValueStockIssuanceOfCommonStockUponExerciseOfPreFundedWarrants_1" xml:lang="en-US" id="label_StockIssuedDuringPeriodValueStockIssuanceOfCommonStockUponExerciseOfPreFundedWarrants_1">Issuance of common stock upon exercise of pre-funded warrants.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueStockIssuanceOfCommonStockUponExerciseOfPreFundedWarrants" xlink:to="label_StockIssuedDuringPeriodValueStockIssuanceOfCommonStockUponExerciseOfPreFundedWarrants_1" xlink:title="Label : StockIssuedDuringPeriodValueStockIssuanceOfCommonStockUponExerciseOfPreFundedWarrants to label_StockIssuedDuringPeriodValueStockIssuanceOfCommonStockUponExerciseOfPreFundedWarrants_1" />
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodValueStockIssuanceOfCommonStockUponExerciseOfPreFundedWarrants_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StockIssuedDuringPeriodValueStockIssuanceOfCommonStockUponExerciseOfPreFundedWarrants_2" xml:lang="en-US" id="label_StockIssuedDuringPeriodValueStockIssuanceOfCommonStockUponExerciseOfPreFundedWarrants_2">Stock Issued During Period Value Stock Issuance Of Common Stock Upon Exercise Of Pre Funded Warrants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueStockIssuanceOfCommonStockUponExerciseOfPreFundedWarrants" xlink:to="label_StockIssuedDuringPeriodValueStockIssuanceOfCommonStockUponExerciseOfPreFundedWarrants_2" xlink:title="Label : StockIssuedDuringPeriodValueStockIssuanceOfCommonStockUponExerciseOfPreFundedWarrants to label_StockIssuedDuringPeriodValueStockIssuanceOfCommonStockUponExerciseOfPreFundedWarrants_2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:title="StockIssuedDuringPeriodValueRestrictedStockAwardGross" />
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xml:lang="en-US" id="label_StockIssuedDuringPeriodValueRestrictedStockAwardGross">Issuance of shares for RSUs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="label_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:title="Label : StockIssuedDuringPeriodValueRestrictedStockAwardGross to label_StockIssuedDuringPeriodValueRestrictedStockAwardGross" />
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodValueRestrictedStockAwardGross_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StockIssuedDuringPeriodValueRestrictedStockAwardGross_1" xml:lang="en-US" id="label_StockIssuedDuringPeriodValueRestrictedStockAwardGross_1">Stock Issued During Period, Value, Restricted Stock Award, Gross</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="label_StockIssuedDuringPeriodValueRestrictedStockAwardGross_1" xlink:title="Label : StockIssuedDuringPeriodValueRestrictedStockAwardGross to label_StockIssuedDuringPeriodValueRestrictedStockAwardGross_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:label="StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:title="StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" />
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xml:lang="en-US" id="label_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited">Issuance of shares for RSUs (in Shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:to="label_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:title="Label : StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited to label_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" />
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_1" xml:lang="en-US" id="label_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_1">Stock Issued During Period, Shares, Restricted Stock Award, Forfeited</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:to="label_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_1" xlink:title="Label : StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited to label_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_1" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_StockIssuedDuringPeriodValueIssuanceOfSharesForAnnualPerformanceBonusesNetOfSharesWithheldForTaxes" xlink:label="StockIssuedDuringPeriodValueIssuanceOfSharesForAnnualPerformanceBonusesNetOfSharesWithheldForTaxes" xlink:title="StockIssuedDuringPeriodValueIssuanceOfSharesForAnnualPerformanceBonusesNetOfSharesWithheldForTaxes" />
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodValueIssuanceOfSharesForAnnualPerformanceBonusesNetOfSharesWithheldForTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_StockIssuedDuringPeriodValueIssuanceOfSharesForAnnualPerformanceBonusesNetOfSharesWithheldForTaxes" xml:lang="en-US" id="label_StockIssuedDuringPeriodValueIssuanceOfSharesForAnnualPerformanceBonusesNetOfSharesWithheldForTaxes">Issuance of shares for annual performance bonuses, net of shares withheld for taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueIssuanceOfSharesForAnnualPerformanceBonusesNetOfSharesWithheldForTaxes" xlink:to="label_StockIssuedDuringPeriodValueIssuanceOfSharesForAnnualPerformanceBonusesNetOfSharesWithheldForTaxes" xlink:title="Label : StockIssuedDuringPeriodValueIssuanceOfSharesForAnnualPerformanceBonusesNetOfSharesWithheldForTaxes to label_StockIssuedDuringPeriodValueIssuanceOfSharesForAnnualPerformanceBonusesNetOfSharesWithheldForTaxes" />
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodValueIssuanceOfSharesForAnnualPerformanceBonusesNetOfSharesWithheldForTaxes_1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_StockIssuedDuringPeriodValueIssuanceOfSharesForAnnualPerformanceBonusesNetOfSharesWithheldForTaxes_1" xml:lang="en-US" id="label_StockIssuedDuringPeriodValueIssuanceOfSharesForAnnualPerformanceBonusesNetOfSharesWithheldForTaxes_1">Shares of common stock to the executives in settlement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueIssuanceOfSharesForAnnualPerformanceBonusesNetOfSharesWithheldForTaxes" xlink:to="label_StockIssuedDuringPeriodValueIssuanceOfSharesForAnnualPerformanceBonusesNetOfSharesWithheldForTaxes_1" xlink:title="Label : StockIssuedDuringPeriodValueIssuanceOfSharesForAnnualPerformanceBonusesNetOfSharesWithheldForTaxes to label_StockIssuedDuringPeriodValueIssuanceOfSharesForAnnualPerformanceBonusesNetOfSharesWithheldForTaxes_1" />
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodValueIssuanceOfSharesForAnnualPerformanceBonusesNetOfSharesWithheldForTaxes_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_StockIssuedDuringPeriodValueIssuanceOfSharesForAnnualPerformanceBonusesNetOfSharesWithheldForTaxes_2" xml:lang="en-US" id="label_StockIssuedDuringPeriodValueIssuanceOfSharesForAnnualPerformanceBonusesNetOfSharesWithheldForTaxes_2">The amount of issuance of shares for annual performance bonuses, net of shares withheld for taxes.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueIssuanceOfSharesForAnnualPerformanceBonusesNetOfSharesWithheldForTaxes" xlink:to="label_StockIssuedDuringPeriodValueIssuanceOfSharesForAnnualPerformanceBonusesNetOfSharesWithheldForTaxes_2" xlink:title="Label : StockIssuedDuringPeriodValueIssuanceOfSharesForAnnualPerformanceBonusesNetOfSharesWithheldForTaxes to label_StockIssuedDuringPeriodValueIssuanceOfSharesForAnnualPerformanceBonusesNetOfSharesWithheldForTaxes_2" />
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodValueIssuanceOfSharesForAnnualPerformanceBonusesNetOfSharesWithheldForTaxes_3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StockIssuedDuringPeriodValueIssuanceOfSharesForAnnualPerformanceBonusesNetOfSharesWithheldForTaxes_3" xml:lang="en-US" id="label_StockIssuedDuringPeriodValueIssuanceOfSharesForAnnualPerformanceBonusesNetOfSharesWithheldForTaxes_3">Stock Issued During Period Value Issuance Of Shares For Annual Performance Bonuses Net Of Shares Withheld For Taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueIssuanceOfSharesForAnnualPerformanceBonusesNetOfSharesWithheldForTaxes" xlink:to="label_StockIssuedDuringPeriodValueIssuanceOfSharesForAnnualPerformanceBonusesNetOfSharesWithheldForTaxes_3" xlink:title="Label : StockIssuedDuringPeriodValueIssuanceOfSharesForAnnualPerformanceBonusesNetOfSharesWithheldForTaxes to label_StockIssuedDuringPeriodValueIssuanceOfSharesForAnnualPerformanceBonusesNetOfSharesWithheldForTaxes_3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:title="AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" />
    <link:label xlink:type="resource" xlink:label="label_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xml:lang="en-US" id="label_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition">Share-based compensation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:to="label_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:title="Label : AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition to label_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" />
    <link:label xlink:type="resource" xlink:label="label_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_1" xml:lang="en-US" id="label_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_1">Stock option award</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:to="label_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_1" xlink:title="Label : AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition to label_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_1" />
    <link:label xlink:type="resource" xlink:label="label_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_2" xml:lang="en-US" id="label_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_2">APIC, Share-Based Payment Arrangement, Option, Increase for Cost Recognition</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:to="label_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_2" xlink:title="Label : AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition to label_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="StatementOfCashFlowsAbstract" xlink:title="StatementOfCashFlowsAbstract" />
    <link:label xlink:type="resource" xlink:label="label_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StatementOfCashFlowsAbstract" xml:lang="en-US" id="label_StatementOfCashFlowsAbstract">Statement of Cash Flows [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementOfCashFlowsAbstract" xlink:to="label_StatementOfCashFlowsAbstract" xlink:title="Label : StatementOfCashFlowsAbstract to label_StatementOfCashFlowsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:label xlink:type="resource" xlink:label="label_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_NetCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US" id="label_NetCashProvidedByUsedInOperatingActivitiesAbstract">CASH FLOWS FROM OPERATING ACTIVITIES</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="label_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="Label : NetCashProvidedByUsedInOperatingActivitiesAbstract to label_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:label xlink:type="resource" xlink:label="label_NetCashProvidedByUsedInOperatingActivitiesAbstract_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_NetCashProvidedByUsedInOperatingActivitiesAbstract_1" xml:lang="en-US" id="label_NetCashProvidedByUsedInOperatingActivitiesAbstract_1">Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="label_NetCashProvidedByUsedInOperatingActivitiesAbstract_1" xlink:title="Label : NetCashProvidedByUsedInOperatingActivitiesAbstract to label_NetCashProvidedByUsedInOperatingActivitiesAbstract_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation" xlink:label="Depreciation" xlink:title="Depreciation" />
    <link:label xlink:type="resource" xlink:label="label_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_Depreciation" xml:lang="en-US" id="label_Depreciation">Depreciation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Depreciation" xlink:to="label_Depreciation" xlink:title="Label : Depreciation to label_Depreciation" />
    <link:label xlink:type="resource" xlink:label="label_Depreciation_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_Depreciation_1" xml:lang="en-US" id="label_Depreciation_1">Depreciation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Depreciation" xlink:to="label_Depreciation_1" xlink:title="Label : Depreciation to label_Depreciation_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentForAmortization" xlink:label="AdjustmentForAmortization" xlink:title="AdjustmentForAmortization" />
    <link:label xlink:type="resource" xlink:label="label_AdjustmentForAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_AdjustmentForAmortization" xml:lang="en-US" id="label_AdjustmentForAmortization">Amortization</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentForAmortization" xlink:to="label_AdjustmentForAmortization" xlink:title="Label : AdjustmentForAmortization to label_AdjustmentForAmortization" />
    <link:label xlink:type="resource" xlink:label="label_AdjustmentForAmortization_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AdjustmentForAmortization_1" xml:lang="en-US" id="label_AdjustmentForAmortization_1">Amortization</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentForAmortization" xlink:to="label_AdjustmentForAmortization_1" xlink:title="Label : AdjustmentForAmortization to label_AdjustmentForAmortization_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:title="OperatingLeaseRightOfUseAssetAmortizationExpense" />
    <link:label xlink:type="resource" xlink:label="label_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_OperatingLeaseRightOfUseAssetAmortizationExpense" xml:lang="en-US" id="label_OperatingLeaseRightOfUseAssetAmortizationExpense">Amortization of ROU Asset</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="label_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:title="Label : OperatingLeaseRightOfUseAssetAmortizationExpense to label_OperatingLeaseRightOfUseAssetAmortizationExpense" />
    <link:label xlink:type="resource" xlink:label="label_OperatingLeaseRightOfUseAssetAmortizationExpense_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_OperatingLeaseRightOfUseAssetAmortizationExpense_1" xml:lang="en-US" id="label_OperatingLeaseRightOfUseAssetAmortizationExpense_1">Operating Lease, Right-of-Use Asset, Periodic Reduction</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="label_OperatingLeaseRightOfUseAssetAmortizationExpense_1" xlink:title="Label : OperatingLeaseRightOfUseAssetAmortizationExpense to label_OperatingLeaseRightOfUseAssetAmortizationExpense_1" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_AmortizationOfCapitalizedShareBasedPayments" xlink:label="AmortizationOfCapitalizedShareBasedPayments" xlink:title="AmortizationOfCapitalizedShareBasedPayments" />
    <link:label xlink:type="resource" xlink:label="label_AmortizationOfCapitalizedShareBasedPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_AmortizationOfCapitalizedShareBasedPayments" xml:lang="en-US" id="label_AmortizationOfCapitalizedShareBasedPayments">Amortization of Capitalized Share-Based Payments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmortizationOfCapitalizedShareBasedPayments" xlink:to="label_AmortizationOfCapitalizedShareBasedPayments" xlink:title="Label : AmortizationOfCapitalizedShareBasedPayments to label_AmortizationOfCapitalizedShareBasedPayments" />
    <link:label xlink:type="resource" xlink:label="label_AmortizationOfCapitalizedShareBasedPayments_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_AmortizationOfCapitalizedShareBasedPayments_1" xml:lang="en-US" id="label_AmortizationOfCapitalizedShareBasedPayments_1">Amount of amortization of capitalized share-based payments.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmortizationOfCapitalizedShareBasedPayments" xlink:to="label_AmortizationOfCapitalizedShareBasedPayments_1" xlink:title="Label : AmortizationOfCapitalizedShareBasedPayments to label_AmortizationOfCapitalizedShareBasedPayments_1" />
    <link:label xlink:type="resource" xlink:label="label_AmortizationOfCapitalizedShareBasedPayments_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AmortizationOfCapitalizedShareBasedPayments_2" xml:lang="en-US" id="label_AmortizationOfCapitalizedShareBasedPayments_2">Amortization Of Capitalized Share Based Payments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmortizationOfCapitalizedShareBasedPayments" xlink:to="label_AmortizationOfCapitalizedShareBasedPayments_2" xlink:title="Label : AmortizationOfCapitalizedShareBasedPayments to label_AmortizationOfCapitalizedShareBasedPayments_2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:label="EmployeeBenefitsAndShareBasedCompensation" xlink:title="EmployeeBenefitsAndShareBasedCompensation" />
    <link:label xlink:type="resource" xlink:label="label_EmployeeBenefitsAndShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_EmployeeBenefitsAndShareBasedCompensation" xml:lang="en-US" id="label_EmployeeBenefitsAndShareBasedCompensation">Share-Based Compensation under Equity Incentive Plan</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeBenefitsAndShareBasedCompensation" xlink:to="label_EmployeeBenefitsAndShareBasedCompensation" xlink:title="Label : EmployeeBenefitsAndShareBasedCompensation to label_EmployeeBenefitsAndShareBasedCompensation" />
    <link:label xlink:type="resource" xlink:label="label_EmployeeBenefitsAndShareBasedCompensation_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_EmployeeBenefitsAndShareBasedCompensation_1" xml:lang="en-US" id="label_EmployeeBenefitsAndShareBasedCompensation_1">Employee Benefits and Share-Based Compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeBenefitsAndShareBasedCompensation" xlink:to="label_EmployeeBenefitsAndShareBasedCompensation_1" xlink:title="Label : EmployeeBenefitsAndShareBasedCompensation to label_EmployeeBenefitsAndShareBasedCompensation_1" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_WriteoffsOfCapitalizedPatents" xlink:label="WriteoffsOfCapitalizedPatents" xlink:title="WriteoffsOfCapitalizedPatents" />
    <link:label xlink:type="resource" xlink:label="label_WriteoffsOfCapitalizedPatents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_WriteoffsOfCapitalizedPatents" xml:lang="en-US" id="label_WriteoffsOfCapitalizedPatents">Write-offs of Capitalized Patents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WriteoffsOfCapitalizedPatents" xlink:to="label_WriteoffsOfCapitalizedPatents" xlink:title="Label : WriteoffsOfCapitalizedPatents to label_WriteoffsOfCapitalizedPatents" />
    <link:label xlink:type="resource" xlink:label="label_WriteoffsOfCapitalizedPatents_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_WriteoffsOfCapitalizedPatents_1" xml:lang="en-US" id="label_WriteoffsOfCapitalizedPatents_1">The amount of write-offs of capitalized patents.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WriteoffsOfCapitalizedPatents" xlink:to="label_WriteoffsOfCapitalizedPatents_1" xlink:title="Label : WriteoffsOfCapitalizedPatents to label_WriteoffsOfCapitalizedPatents_1" />
    <link:label xlink:type="resource" xlink:label="label_WriteoffsOfCapitalizedPatents_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_WriteoffsOfCapitalizedPatents_2" xml:lang="en-US" id="label_WriteoffsOfCapitalizedPatents_2">Writeoffs Of Capitalized Patents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WriteoffsOfCapitalizedPatents" xlink:to="label_WriteoffsOfCapitalizedPatents_2" xlink:title="Label : WriteoffsOfCapitalizedPatents to label_WriteoffsOfCapitalizedPatents_2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="IncreaseDecreaseInOperatingCapitalAbstract" xlink:title="IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:label xlink:type="resource" xlink:label="label_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_IncreaseDecreaseInOperatingCapitalAbstract" xml:lang="en-US" id="label_IncreaseDecreaseInOperatingCapitalAbstract">Changes in Operating Assets and Liabilities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="label_IncreaseDecreaseInOperatingCapitalAbstract" xlink:title="Label : IncreaseDecreaseInOperatingCapitalAbstract to label_IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:label xlink:type="resource" xlink:label="label_IncreaseDecreaseInOperatingCapitalAbstract_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_IncreaseDecreaseInOperatingCapitalAbstract_1" xml:lang="en-US" id="label_IncreaseDecreaseInOperatingCapitalAbstract_1">Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="label_IncreaseDecreaseInOperatingCapitalAbstract_1" xlink:title="Label : IncreaseDecreaseInOperatingCapitalAbstract to label_IncreaseDecreaseInOperatingCapitalAbstract_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="IncreaseDecreaseInAccountsReceivable" xlink:title="IncreaseDecreaseInAccountsReceivable" />
    <link:label xlink:type="resource" xlink:label="label_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_IncreaseDecreaseInAccountsReceivable" xml:lang="en-US" id="label_IncreaseDecreaseInAccountsReceivable">Accounts Receivable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInAccountsReceivable" xlink:to="label_IncreaseDecreaseInAccountsReceivable" xlink:title="Label : IncreaseDecreaseInAccountsReceivable to label_IncreaseDecreaseInAccountsReceivable" />
    <link:label xlink:type="resource" xlink:label="label_IncreaseDecreaseInAccountsReceivable_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_IncreaseDecreaseInAccountsReceivable_1" xml:lang="en-US" id="label_IncreaseDecreaseInAccountsReceivable_1">Increase (Decrease) in Accounts Receivable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInAccountsReceivable" xlink:to="label_IncreaseDecreaseInAccountsReceivable_1" xlink:title="Label : IncreaseDecreaseInAccountsReceivable to label_IncreaseDecreaseInAccountsReceivable_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:title="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:label xlink:type="resource" xlink:label="label_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xml:lang="en-US" id="label_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">Prepaid and Other Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="label_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:title="Label : IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets to label_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:label xlink:type="resource" xlink:label="label_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_1" xml:lang="en-US" id="label_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_1">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="label_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_1" xlink:title="Label : IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets to label_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="IncreaseDecreaseInInventories" xlink:title="IncreaseDecreaseInInventories" />
    <link:label xlink:type="resource" xlink:label="label_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_IncreaseDecreaseInInventories" xml:lang="en-US" id="label_IncreaseDecreaseInInventories">Inventory</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInInventories" xlink:to="label_IncreaseDecreaseInInventories" xlink:title="Label : IncreaseDecreaseInInventories to label_IncreaseDecreaseInInventories" />
    <link:label xlink:type="resource" xlink:label="label_IncreaseDecreaseInInventories_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_IncreaseDecreaseInInventories_1" xml:lang="en-US" id="label_IncreaseDecreaseInInventories_1">Increase (Decrease) in Inventories</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInInventories" xlink:to="label_IncreaseDecreaseInInventories_1" xlink:title="Label : IncreaseDecreaseInInventories to label_IncreaseDecreaseInInventories_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:title="IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
    <link:label xlink:type="resource" xlink:label="label_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xml:lang="en-US" id="label_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">Accounts Payable and Accrued Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="label_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:title="Label : IncreaseDecreaseInAccountsPayableAndAccruedLiabilities to label_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
    <link:label xlink:type="resource" xlink:label="label_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_1" xml:lang="en-US" id="label_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_1">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="label_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_1" xlink:title="Label : IncreaseDecreaseInAccountsPayableAndAccruedLiabilities to label_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:label="IncreaseDecreaseInAccruedInterestReceivableNet" xlink:title="IncreaseDecreaseInAccruedInterestReceivableNet" />
    <link:label xlink:type="resource" xlink:label="label_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_IncreaseDecreaseInAccruedInterestReceivableNet" xml:lang="en-US" id="label_IncreaseDecreaseInAccruedInterestReceivableNet">Accrued Interest, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInAccruedInterestReceivableNet" xlink:to="label_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:title="Label : IncreaseDecreaseInAccruedInterestReceivableNet to label_IncreaseDecreaseInAccruedInterestReceivableNet" />
    <link:label xlink:type="resource" xlink:label="label_IncreaseDecreaseInAccruedInterestReceivableNet_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_IncreaseDecreaseInAccruedInterestReceivableNet_1" xml:lang="en-US" id="label_IncreaseDecreaseInAccruedInterestReceivableNet_1">Increase (Decrease) in Accrued Interest Receivable, Net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInAccruedInterestReceivableNet" xlink:to="label_IncreaseDecreaseInAccruedInterestReceivableNet_1" xlink:title="Label : IncreaseDecreaseInAccruedInterestReceivableNet to label_IncreaseDecreaseInAccruedInterestReceivableNet_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="IncreaseDecreaseInOperatingLeaseLiability" xlink:title="IncreaseDecreaseInOperatingLeaseLiability" />
    <link:label xlink:type="resource" xlink:label="label_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_IncreaseDecreaseInOperatingLeaseLiability" xml:lang="en-US" id="label_IncreaseDecreaseInOperatingLeaseLiability">Reduction of Lease Liability</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInOperatingLeaseLiability" xlink:to="label_IncreaseDecreaseInOperatingLeaseLiability" xlink:title="Label : IncreaseDecreaseInOperatingLeaseLiability to label_IncreaseDecreaseInOperatingLeaseLiability" />
    <link:label xlink:type="resource" xlink:label="label_IncreaseDecreaseInOperatingLeaseLiability_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_IncreaseDecreaseInOperatingLeaseLiability_1" xml:lang="en-US" id="label_IncreaseDecreaseInOperatingLeaseLiability_1">Increase (Decrease) in Operating Lease Liability</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInOperatingLeaseLiability" xlink:to="label_IncreaseDecreaseInOperatingLeaseLiability_1" xlink:title="Label : IncreaseDecreaseInOperatingLeaseLiability to label_IncreaseDecreaseInOperatingLeaseLiability_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="NetCashProvidedByUsedInOperatingActivities" xlink:title="NetCashProvidedByUsedInOperatingActivities" />
    <link:label xlink:type="resource" xlink:label="label_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US" id="label_NetCashProvidedByUsedInOperatingActivities">Net Cash Used in Operating Activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="label_NetCashProvidedByUsedInOperatingActivities" xlink:title="Label : NetCashProvidedByUsedInOperatingActivities to label_NetCashProvidedByUsedInOperatingActivities" />
    <link:label xlink:type="resource" xlink:label="label_NetCashProvidedByUsedInOperatingActivities_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_NetCashProvidedByUsedInOperatingActivities_1" xml:lang="en-US" id="label_NetCashProvidedByUsedInOperatingActivities_1">Net cash used in operating activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="label_NetCashProvidedByUsedInOperatingActivities_1" xlink:title="Label : NetCashProvidedByUsedInOperatingActivities to label_NetCashProvidedByUsedInOperatingActivities_1" />
    <link:label xlink:type="resource" xlink:label="label_NetCashProvidedByUsedInOperatingActivities_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_NetCashProvidedByUsedInOperatingActivities_2" xml:lang="en-US" id="label_NetCashProvidedByUsedInOperatingActivities_2">Cash Provided by (Used in) Operating Activity, Including Discontinued Operation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="label_NetCashProvidedByUsedInOperatingActivities_2" xlink:title="Label : NetCashProvidedByUsedInOperatingActivities to label_NetCashProvidedByUsedInOperatingActivities_2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:title="NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:label xlink:type="resource" xlink:label="label_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_NetCashProvidedByUsedInInvestingActivitiesAbstract" xml:lang="en-US" id="label_NetCashProvidedByUsedInInvestingActivitiesAbstract">CASH FLOWS FROM INVESTING ACTIVITIES</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="label_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:title="Label : NetCashProvidedByUsedInInvestingActivitiesAbstract to label_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:label xlink:type="resource" xlink:label="label_NetCashProvidedByUsedInInvestingActivitiesAbstract_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_NetCashProvidedByUsedInInvestingActivitiesAbstract_1" xml:lang="en-US" id="label_NetCashProvidedByUsedInInvestingActivitiesAbstract_1">Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="label_NetCashProvidedByUsedInInvestingActivitiesAbstract_1" xlink:title="Label : NetCashProvidedByUsedInInvestingActivitiesAbstract to label_NetCashProvidedByUsedInInvestingActivitiesAbstract_1" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_PaymentOfCapitalizationOfPatents" xlink:label="PaymentOfCapitalizationOfPatents" xlink:title="PaymentOfCapitalizationOfPatents" />
    <link:label xlink:type="resource" xlink:label="label_PaymentOfCapitalizationOfPatents" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_PaymentOfCapitalizationOfPatents" xml:lang="en-US" id="label_PaymentOfCapitalizationOfPatents">Capitalization of Patents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentOfCapitalizationOfPatents" xlink:to="label_PaymentOfCapitalizationOfPatents" xlink:title="Label : PaymentOfCapitalizationOfPatents to label_PaymentOfCapitalizationOfPatents" />
    <link:label xlink:type="resource" xlink:label="label_PaymentOfCapitalizationOfPatents_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_PaymentOfCapitalizationOfPatents_1" xml:lang="en-US" id="label_PaymentOfCapitalizationOfPatents_1">The cash outflow to acquire an asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentOfCapitalizationOfPatents" xlink:to="label_PaymentOfCapitalizationOfPatents_1" xlink:title="Label : PaymentOfCapitalizationOfPatents to label_PaymentOfCapitalizationOfPatents_1" />
    <link:label xlink:type="resource" xlink:label="label_PaymentOfCapitalizationOfPatents_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_PaymentOfCapitalizationOfPatents_2" xml:lang="en-US" id="label_PaymentOfCapitalizationOfPatents_2">Payment Of Capitalization Of Patents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentOfCapitalizationOfPatents" xlink:to="label_PaymentOfCapitalizationOfPatents_2" xlink:title="Label : PaymentOfCapitalizationOfPatents to label_PaymentOfCapitalizationOfPatents_2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="PaymentsToAcquirePropertyPlantAndEquipment" xlink:title="PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:label xlink:type="resource" xlink:label="label_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_PaymentsToAcquirePropertyPlantAndEquipment" xml:lang="en-US" id="label_PaymentsToAcquirePropertyPlantAndEquipment">Purchases of Fixed Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="label_PaymentsToAcquirePropertyPlantAndEquipment" xlink:title="Label : PaymentsToAcquirePropertyPlantAndEquipment to label_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:label xlink:type="resource" xlink:label="label_PaymentsToAcquirePropertyPlantAndEquipment_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_PaymentsToAcquirePropertyPlantAndEquipment_1" xml:lang="en-US" id="label_PaymentsToAcquirePropertyPlantAndEquipment_1">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="label_PaymentsToAcquirePropertyPlantAndEquipment_1" xlink:title="Label : PaymentsToAcquirePropertyPlantAndEquipment to label_PaymentsToAcquirePropertyPlantAndEquipment_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="PaymentsToAcquireIntangibleAssets" xlink:title="PaymentsToAcquireIntangibleAssets" />
    <link:label xlink:type="resource" xlink:label="label_PaymentsToAcquireIntangibleAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_PaymentsToAcquireIntangibleAssets" xml:lang="en-US" id="label_PaymentsToAcquireIntangibleAssets">Acquisition of Intangibles</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsToAcquireIntangibleAssets" xlink:to="label_PaymentsToAcquireIntangibleAssets" xlink:title="Label : PaymentsToAcquireIntangibleAssets to label_PaymentsToAcquireIntangibleAssets" />
    <link:label xlink:type="resource" xlink:label="label_PaymentsToAcquireIntangibleAssets_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_PaymentsToAcquireIntangibleAssets_1" xml:lang="en-US" id="label_PaymentsToAcquireIntangibleAssets_1">Payments to Acquire Intangible Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsToAcquireIntangibleAssets" xlink:to="label_PaymentsToAcquireIntangibleAssets_1" xlink:title="Label : PaymentsToAcquireIntangibleAssets to label_PaymentsToAcquireIntangibleAssets_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" xlink:label="ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" xlink:title="ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" />
    <link:label xlink:type="resource" xlink:label="label_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" xml:lang="en-US" id="label_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments">Maturities of Short-Term Investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" xlink:to="label_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" xlink:title="Label : ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments to label_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" />
    <link:label xlink:type="resource" xlink:label="label_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments_1" xml:lang="en-US" id="label_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments_1">Proceeds from Maturities, Prepayments and Calls of Short-Term Investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" xlink:to="label_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments_1" xlink:title="Label : ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments to label_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="NetCashProvidedByUsedInInvestingActivities" xlink:title="NetCashProvidedByUsedInInvestingActivities" />
    <link:label xlink:type="resource" xlink:label="label_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_NetCashProvidedByUsedInInvestingActivities" xml:lang="en-US" id="label_NetCashProvidedByUsedInInvestingActivities">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInInvestingActivities" xlink:to="label_NetCashProvidedByUsedInInvestingActivities" xlink:title="Label : NetCashProvidedByUsedInInvestingActivities to label_NetCashProvidedByUsedInInvestingActivities" />
    <link:label xlink:type="resource" xlink:label="label_NetCashProvidedByUsedInInvestingActivities_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_NetCashProvidedByUsedInInvestingActivities_1" xml:lang="en-US" id="label_NetCashProvidedByUsedInInvestingActivities_1">Cash Provided by (Used in) Investing Activity, Including Discontinued Operation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInInvestingActivities" xlink:to="label_NetCashProvidedByUsedInInvestingActivities_1" xlink:title="Label : NetCashProvidedByUsedInInvestingActivities to label_NetCashProvidedByUsedInInvestingActivities_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:title="NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:label xlink:type="resource" xlink:label="label_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_NetCashProvidedByUsedInFinancingActivitiesAbstract" xml:lang="en-US" id="label_NetCashProvidedByUsedInFinancingActivitiesAbstract">CASH FLOWS FROM FINANCING ACTIVITIES</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="label_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:title="Label : NetCashProvidedByUsedInFinancingActivitiesAbstract to label_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:label xlink:type="resource" xlink:label="label_NetCashProvidedByUsedInFinancingActivitiesAbstract_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_NetCashProvidedByUsedInFinancingActivitiesAbstract_1" xml:lang="en-US" id="label_NetCashProvidedByUsedInFinancingActivitiesAbstract_1">Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="label_NetCashProvidedByUsedInFinancingActivitiesAbstract_1" xlink:title="Label : NetCashProvidedByUsedInFinancingActivitiesAbstract to label_NetCashProvidedByUsedInFinancingActivitiesAbstract_1" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_NetProceedsFromSharesAndWarrantsOffering" xlink:label="NetProceedsFromSharesAndWarrantsOffering" xlink:title="NetProceedsFromSharesAndWarrantsOffering" />
    <link:label xlink:type="resource" xlink:label="label_NetProceedsFromSharesAndWarrantsOffering" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_NetProceedsFromSharesAndWarrantsOffering" xml:lang="en-US" id="label_NetProceedsFromSharesAndWarrantsOffering">Net Proceeds from January 2024 Offering</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetProceedsFromSharesAndWarrantsOffering" xlink:to="label_NetProceedsFromSharesAndWarrantsOffering" xlink:title="Label : NetProceedsFromSharesAndWarrantsOffering to label_NetProceedsFromSharesAndWarrantsOffering" />
    <link:label xlink:type="resource" xlink:label="label_NetProceedsFromSharesAndWarrantsOffering_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_NetProceedsFromSharesAndWarrantsOffering_1" xml:lang="en-US" id="label_NetProceedsFromSharesAndWarrantsOffering_1">Net proceed from shares offering.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetProceedsFromSharesAndWarrantsOffering" xlink:to="label_NetProceedsFromSharesAndWarrantsOffering_1" xlink:title="Label : NetProceedsFromSharesAndWarrantsOffering to label_NetProceedsFromSharesAndWarrantsOffering_1" />
    <link:label xlink:type="resource" xlink:label="label_NetProceedsFromSharesAndWarrantsOffering_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_NetProceedsFromSharesAndWarrantsOffering_2" xml:lang="en-US" id="label_NetProceedsFromSharesAndWarrantsOffering_2">Net Proceeds From Shares And Warrants Offering</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetProceedsFromSharesAndWarrantsOffering" xlink:to="label_NetProceedsFromSharesAndWarrantsOffering_2" xlink:title="Label : NetProceedsFromSharesAndWarrantsOffering to label_NetProceedsFromSharesAndWarrantsOffering_2" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_NetProceedsFromJanuary2025Offering" xlink:label="NetProceedsFromJanuary2025Offering" xlink:title="NetProceedsFromJanuary2025Offering" />
    <link:label xlink:type="resource" xlink:label="label_NetProceedsFromJanuary2025Offering" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_NetProceedsFromJanuary2025Offering" xml:lang="en-US" id="label_NetProceedsFromJanuary2025Offering">Net Proceeds from January 2025 Offering</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetProceedsFromJanuary2025Offering" xlink:to="label_NetProceedsFromJanuary2025Offering" xlink:title="Label : NetProceedsFromJanuary2025Offering to label_NetProceedsFromJanuary2025Offering" />
    <link:label xlink:type="resource" xlink:label="label_NetProceedsFromJanuary2025Offering_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_NetProceedsFromJanuary2025Offering_1" xml:lang="en-US" id="label_NetProceedsFromJanuary2025Offering_1">The amount of net proceeds from january 2025 offering.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetProceedsFromJanuary2025Offering" xlink:to="label_NetProceedsFromJanuary2025Offering_1" xlink:title="Label : NetProceedsFromJanuary2025Offering to label_NetProceedsFromJanuary2025Offering_1" />
    <link:label xlink:type="resource" xlink:label="label_NetProceedsFromJanuary2025Offering_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_NetProceedsFromJanuary2025Offering_2" xml:lang="en-US" id="label_NetProceedsFromJanuary2025Offering_2">Net Proceeds From January2025 Offering</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetProceedsFromJanuary2025Offering" xlink:to="label_NetProceedsFromJanuary2025Offering_2" xlink:title="Label : NetProceedsFromJanuary2025Offering to label_NetProceedsFromJanuary2025Offering_2" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_NetProceedsFromFebruary2025Offering" xlink:label="NetProceedsFromFebruary2025Offering" xlink:title="NetProceedsFromFebruary2025Offering" />
    <link:label xlink:type="resource" xlink:label="label_NetProceedsFromFebruary2025Offering" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_NetProceedsFromFebruary2025Offering" xml:lang="en-US" id="label_NetProceedsFromFebruary2025Offering">Net Proceeds from February 2025 Offering</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetProceedsFromFebruary2025Offering" xlink:to="label_NetProceedsFromFebruary2025Offering" xlink:title="Label : NetProceedsFromFebruary2025Offering to label_NetProceedsFromFebruary2025Offering" />
    <link:label xlink:type="resource" xlink:label="label_NetProceedsFromFebruary2025Offering_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_NetProceedsFromFebruary2025Offering_1" xml:lang="en-US" id="label_NetProceedsFromFebruary2025Offering_1">The amount of net proceeds from february 2025 offering.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetProceedsFromFebruary2025Offering" xlink:to="label_NetProceedsFromFebruary2025Offering_1" xlink:title="Label : NetProceedsFromFebruary2025Offering to label_NetProceedsFromFebruary2025Offering_1" />
    <link:label xlink:type="resource" xlink:label="label_NetProceedsFromFebruary2025Offering_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_NetProceedsFromFebruary2025Offering_2" xml:lang="en-US" id="label_NetProceedsFromFebruary2025Offering_2">Net Proceeds From February2025 Offering</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetProceedsFromFebruary2025Offering" xlink:to="label_NetProceedsFromFebruary2025Offering_2" xlink:title="Label : NetProceedsFromFebruary2025Offering to label_NetProceedsFromFebruary2025Offering_2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:title="PaymentsRelatedToTaxWithholdingForShareBasedCompensation" />
    <link:label xlink:type="resource" xlink:label="label_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xml:lang="en-US" id="label_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">Shares Withheld for Net Share Settlement of Performance Bonuses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="label_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:title="Label : PaymentsRelatedToTaxWithholdingForShareBasedCompensation to label_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" />
    <link:label xlink:type="resource" xlink:label="label_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_1" xml:lang="en-US" id="label_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_1">Payment, Tax Withholding, Share-Based Payment Arrangement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="label_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_1" xlink:title="Label : PaymentsRelatedToTaxWithholdingForShareBasedCompensation to label_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_1" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_ProceedsFromExerciseOfPreFundedWarrants" xlink:label="ProceedsFromExerciseOfPreFundedWarrants" xlink:title="ProceedsFromExerciseOfPreFundedWarrants" />
    <link:label xlink:type="resource" xlink:label="label_ProceedsFromExerciseOfPreFundedWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ProceedsFromExerciseOfPreFundedWarrants" xml:lang="en-US" id="label_ProceedsFromExerciseOfPreFundedWarrants">Proceeds from Exercise of Pre-Funded Warrants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromExerciseOfPreFundedWarrants" xlink:to="label_ProceedsFromExerciseOfPreFundedWarrants" xlink:title="Label : ProceedsFromExerciseOfPreFundedWarrants to label_ProceedsFromExerciseOfPreFundedWarrants" />
    <link:label xlink:type="resource" xlink:label="label_ProceedsFromExerciseOfPreFundedWarrants_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_ProceedsFromExerciseOfPreFundedWarrants_1" xml:lang="en-US" id="label_ProceedsFromExerciseOfPreFundedWarrants_1">Proceeds from exercise of pre-funded warrants.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromExerciseOfPreFundedWarrants" xlink:to="label_ProceedsFromExerciseOfPreFundedWarrants_1" xlink:title="Label : ProceedsFromExerciseOfPreFundedWarrants to label_ProceedsFromExerciseOfPreFundedWarrants_1" />
    <link:label xlink:type="resource" xlink:label="label_ProceedsFromExerciseOfPreFundedWarrants_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ProceedsFromExerciseOfPreFundedWarrants_2" xml:lang="en-US" id="label_ProceedsFromExerciseOfPreFundedWarrants_2">Proceeds From Exercise Of Pre Funded Warrants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromExerciseOfPreFundedWarrants" xlink:to="label_ProceedsFromExerciseOfPreFundedWarrants_2" xlink:title="Label : ProceedsFromExerciseOfPreFundedWarrants to label_ProceedsFromExerciseOfPreFundedWarrants_2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="NetCashProvidedByUsedInFinancingActivities" xlink:title="NetCashProvidedByUsedInFinancingActivities" />
    <link:label xlink:type="resource" xlink:label="label_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_NetCashProvidedByUsedInFinancingActivities" xml:lang="en-US" id="label_NetCashProvidedByUsedInFinancingActivities">Net Cash Provided by Financing Activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInFinancingActivities" xlink:to="label_NetCashProvidedByUsedInFinancingActivities" xlink:title="Label : NetCashProvidedByUsedInFinancingActivities to label_NetCashProvidedByUsedInFinancingActivities" />
    <link:label xlink:type="resource" xlink:label="label_NetCashProvidedByUsedInFinancingActivities_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_NetCashProvidedByUsedInFinancingActivities_1" xml:lang="en-US" id="label_NetCashProvidedByUsedInFinancingActivities_1">Cash Provided by (Used in) Financing Activity, Including Discontinued Operation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInFinancingActivities" xlink:to="label_NetCashProvidedByUsedInFinancingActivities_1" xlink:title="Label : NetCashProvidedByUsedInFinancingActivities to label_NetCashProvidedByUsedInFinancingActivities_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:title="EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:label xlink:type="resource" xlink:label="label_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xml:lang="en-US" id="label_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">Effect of Exchange Rate Changes on Cash</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="label_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:title="Label : EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents to label_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:label xlink:type="resource" xlink:label="label_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1" xml:lang="en-US" id="label_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1">Effect of Exchange Rate on Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="label_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1" xlink:title="Label : EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents to label_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:title="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:label xlink:type="resource" xlink:label="label_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xml:lang="en-US" id="label_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">Change in Cash and Cash Equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="label_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:title="Label : CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect to label_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:label xlink:type="resource" xlink:label="label_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_1" xml:lang="en-US" id="label_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_1">Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="label_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_1" xlink:title="Label : CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect to label_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:title="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:label xlink:type="resource" xlink:label="label_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="label_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xml:lang="en-US" id="label_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">Cash and Cash Equivalents&#x2014;Beginning of Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="label_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:title="Label : CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents to label_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:label xlink:type="resource" xlink:label="label_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="label_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1" xml:lang="en-US" id="label_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1">Cash and Cash Equivalents&#x2014;End of Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="label_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1" xlink:title="Label : CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents to label_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1" />
    <link:label xlink:type="resource" xlink:label="label_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2" xml:lang="en-US" id="label_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2">Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="label_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2" xlink:title="Label : CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents to label_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:title="CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
    <link:label xlink:type="resource" xlink:label="label_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xml:lang="en-US" id="label_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">NONCASH INVESTING/FINANCING ACTIVITIES</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="label_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:title="Label : CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract to label_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
    <link:label xlink:type="resource" xlink:label="label_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_1" xml:lang="en-US" id="label_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_1">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="label_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_1" xlink:title="Label : CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract to label_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_1" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_FairValueOfWarrantsIssuedToUnderwriters" xlink:label="FairValueOfWarrantsIssuedToUnderwriters" xlink:title="FairValueOfWarrantsIssuedToUnderwriters" />
    <link:label xlink:type="resource" xlink:label="label_FairValueOfWarrantsIssuedToUnderwriters" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_FairValueOfWarrantsIssuedToUnderwriters" xml:lang="en-US" id="label_FairValueOfWarrantsIssuedToUnderwriters">Fair Value of Warrants Issued to Underwriters</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueOfWarrantsIssuedToUnderwriters" xlink:to="label_FairValueOfWarrantsIssuedToUnderwriters" xlink:title="Label : FairValueOfWarrantsIssuedToUnderwriters to label_FairValueOfWarrantsIssuedToUnderwriters" />
    <link:label xlink:type="resource" xlink:label="label_FairValueOfWarrantsIssuedToUnderwriters_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_FairValueOfWarrantsIssuedToUnderwriters_1" xml:lang="en-US" id="label_FairValueOfWarrantsIssuedToUnderwriters_1">Represent the amount of fair value of warrants issued to underwriters.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueOfWarrantsIssuedToUnderwriters" xlink:to="label_FairValueOfWarrantsIssuedToUnderwriters_1" xlink:title="Label : FairValueOfWarrantsIssuedToUnderwriters to label_FairValueOfWarrantsIssuedToUnderwriters_1" />
    <link:label xlink:type="resource" xlink:label="label_FairValueOfWarrantsIssuedToUnderwriters_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FairValueOfWarrantsIssuedToUnderwriters_2" xml:lang="en-US" id="label_FairValueOfWarrantsIssuedToUnderwriters_2">Fair Value Of Warrants Issued To Underwriters</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueOfWarrantsIssuedToUnderwriters" xlink:to="label_FairValueOfWarrantsIssuedToUnderwriters_2" xlink:title="Label : FairValueOfWarrantsIssuedToUnderwriters to label_FairValueOfWarrantsIssuedToUnderwriters_2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1" xlink:label="NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1" xlink:title="NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1" />
    <link:label xlink:type="resource" xlink:label="label_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1" xml:lang="en-US" id="label_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1">Purchases of Fixed Assets included in Accounts Payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1" xlink:to="label_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1" xlink:title="Label : NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1 to label_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1" />
    <link:label xlink:type="resource" xlink:label="label_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1_1" xml:lang="en-US" id="label_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1_1">Noncash or Part Noncash Acquisition, Fixed Assets Acquired</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1" xlink:to="label_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1_1" xlink:title="Label : NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1 to label_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1_1" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_GrossSharesIssuedForAnnualPerformanceBonuses" xlink:label="GrossSharesIssuedForAnnualPerformanceBonuses" xlink:title="GrossSharesIssuedForAnnualPerformanceBonuses" />
    <link:label xlink:type="resource" xlink:label="label_GrossSharesIssuedForAnnualPerformanceBonuses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_GrossSharesIssuedForAnnualPerformanceBonuses" xml:lang="en-US" id="label_GrossSharesIssuedForAnnualPerformanceBonuses">Gross Shares Issued for Annual Performance Bonuses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GrossSharesIssuedForAnnualPerformanceBonuses" xlink:to="label_GrossSharesIssuedForAnnualPerformanceBonuses" xlink:title="Label : GrossSharesIssuedForAnnualPerformanceBonuses to label_GrossSharesIssuedForAnnualPerformanceBonuses" />
    <link:label xlink:type="resource" xlink:label="label_GrossSharesIssuedForAnnualPerformanceBonuses_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_GrossSharesIssuedForAnnualPerformanceBonuses_1" xml:lang="en-US" id="label_GrossSharesIssuedForAnnualPerformanceBonuses_1">Represent the amount of gross shares issued for annual performance bonuses.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GrossSharesIssuedForAnnualPerformanceBonuses" xlink:to="label_GrossSharesIssuedForAnnualPerformanceBonuses_1" xlink:title="Label : GrossSharesIssuedForAnnualPerformanceBonuses to label_GrossSharesIssuedForAnnualPerformanceBonuses_1" />
    <link:label xlink:type="resource" xlink:label="label_GrossSharesIssuedForAnnualPerformanceBonuses_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_GrossSharesIssuedForAnnualPerformanceBonuses_2" xml:lang="en-US" id="label_GrossSharesIssuedForAnnualPerformanceBonuses_2">Gross Shares Issued For Annual Performance Bonuses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GrossSharesIssuedForAnnualPerformanceBonuses" xlink:to="label_GrossSharesIssuedForAnnualPerformanceBonuses_2" xlink:title="Label : GrossSharesIssuedForAnnualPerformanceBonuses to label_GrossSharesIssuedForAnnualPerformanceBonuses_2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NatureOfOperations" xlink:label="NatureOfOperations" xlink:title="NatureOfOperations" />
    <link:label xlink:type="resource" xlink:label="label_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_NatureOfOperations" xml:lang="en-US" id="label_NatureOfOperations">NATURE OF OPERATIONS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NatureOfOperations" xlink:to="label_NatureOfOperations" xlink:title="Label : NatureOfOperations to label_NatureOfOperations" />
    <link:label xlink:type="resource" xlink:label="label_NatureOfOperations_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_NatureOfOperations_1" xml:lang="en-US" id="label_NatureOfOperations_1">Nature of Operations [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NatureOfOperations" xlink:to="label_NatureOfOperations_1" xlink:title="Label : NatureOfOperations to label_NatureOfOperations_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="SignificantAccountingPoliciesTextBlock" xlink:title="SignificantAccountingPoliciesTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_SignificantAccountingPoliciesTextBlock" xml:lang="en-US" id="label_SignificantAccountingPoliciesTextBlock">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SignificantAccountingPoliciesTextBlock" xlink:to="label_SignificantAccountingPoliciesTextBlock" xlink:title="Label : SignificantAccountingPoliciesTextBlock to label_SignificantAccountingPoliciesTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_SignificantAccountingPoliciesTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_SignificantAccountingPoliciesTextBlock_1" xml:lang="en-US" id="label_SignificantAccountingPoliciesTextBlock_1">Significant Accounting Policies [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SignificantAccountingPoliciesTextBlock" xlink:to="label_SignificantAccountingPoliciesTextBlock_1" xlink:title="Label : SignificantAccountingPoliciesTextBlock to label_SignificantAccountingPoliciesTextBlock_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="InventoryDisclosureTextBlock" xlink:title="InventoryDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_InventoryDisclosureTextBlock" xml:lang="en-US" id="label_InventoryDisclosureTextBlock">INVENTORY</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InventoryDisclosureTextBlock" xlink:to="label_InventoryDisclosureTextBlock" xlink:title="Label : InventoryDisclosureTextBlock to label_InventoryDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_InventoryDisclosureTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_InventoryDisclosureTextBlock_1" xml:lang="en-US" id="label_InventoryDisclosureTextBlock_1">Inventory Disclosure [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InventoryDisclosureTextBlock" xlink:to="label_InventoryDisclosureTextBlock_1" xlink:title="Label : InventoryDisclosureTextBlock to label_InventoryDisclosureTextBlock_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="PropertyPlantAndEquipmentDisclosureTextBlock" xlink:title="PropertyPlantAndEquipmentDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_PropertyPlantAndEquipmentDisclosureTextBlock" xml:lang="en-US" id="label_PropertyPlantAndEquipmentDisclosureTextBlock">PROPERTY AND EQUIPMENT</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="label_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:title="Label : PropertyPlantAndEquipmentDisclosureTextBlock to label_PropertyPlantAndEquipmentDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_PropertyPlantAndEquipmentDisclosureTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_PropertyPlantAndEquipmentDisclosureTextBlock_1" xml:lang="en-US" id="label_PropertyPlantAndEquipmentDisclosureTextBlock_1">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="label_PropertyPlantAndEquipmentDisclosureTextBlock_1" xlink:title="Label : PropertyPlantAndEquipmentDisclosureTextBlock to label_PropertyPlantAndEquipmentDisclosureTextBlock_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="IntangibleAssetsDisclosureTextBlock" xlink:title="IntangibleAssetsDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_IntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_IntangibleAssetsDisclosureTextBlock" xml:lang="en-US" id="label_IntangibleAssetsDisclosureTextBlock">INTANGIBLE ASSETS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IntangibleAssetsDisclosureTextBlock" xlink:to="label_IntangibleAssetsDisclosureTextBlock" xlink:title="Label : IntangibleAssetsDisclosureTextBlock to label_IntangibleAssetsDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_IntangibleAssetsDisclosureTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_IntangibleAssetsDisclosureTextBlock_1" xml:lang="en-US" id="label_IntangibleAssetsDisclosureTextBlock_1">Intangible Assets Disclosure [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IntangibleAssetsDisclosureTextBlock" xlink:to="label_IntangibleAssetsDisclosureTextBlock_1" xlink:title="Label : IntangibleAssetsDisclosureTextBlock to label_IntangibleAssetsDisclosureTextBlock_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="StockholdersEquityNoteDisclosureTextBlock" xlink:title="StockholdersEquityNoteDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_StockholdersEquityNoteDisclosureTextBlock" xml:lang="en-US" id="label_StockholdersEquityNoteDisclosureTextBlock">STOCKHOLDERS&#x2019; EQUITY</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquityNoteDisclosureTextBlock" xlink:to="label_StockholdersEquityNoteDisclosureTextBlock" xlink:title="Label : StockholdersEquityNoteDisclosureTextBlock to label_StockholdersEquityNoteDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_StockholdersEquityNoteDisclosureTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StockholdersEquityNoteDisclosureTextBlock_1" xml:lang="en-US" id="label_StockholdersEquityNoteDisclosureTextBlock_1">Equity [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquityNoteDisclosureTextBlock" xlink:to="label_StockholdersEquityNoteDisclosureTextBlock_1" xlink:title="Label : StockholdersEquityNoteDisclosureTextBlock to label_StockholdersEquityNoteDisclosureTextBlock_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="DebtDisclosureTextBlock" xlink:title="DebtDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_DebtDisclosureTextBlock" xml:lang="en-US" id="label_DebtDisclosureTextBlock">DEBT</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtDisclosureTextBlock" xlink:to="label_DebtDisclosureTextBlock" xlink:title="Label : DebtDisclosureTextBlock to label_DebtDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_DebtDisclosureTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DebtDisclosureTextBlock_1" xml:lang="en-US" id="label_DebtDisclosureTextBlock_1">Debt Disclosure [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtDisclosureTextBlock" xlink:to="label_DebtDisclosureTextBlock_1" xlink:title="Label : DebtDisclosureTextBlock to label_DebtDisclosureTextBlock_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:label="DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:title="DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xml:lang="en-US" id="label_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock">DERIVATIVE LIABILITIES</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:to="label_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:title="Label : DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock to label_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_1" xml:lang="en-US" id="label_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_1">Derivative Instruments and Hedging Activities Disclosure [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:to="label_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_1" xlink:title="Label : DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock to label_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="IncomeTaxDisclosureTextBlock" xlink:title="IncomeTaxDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_IncomeTaxDisclosureTextBlock" xml:lang="en-US" id="label_IncomeTaxDisclosureTextBlock">INCOME TAXES</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxDisclosureTextBlock" xlink:to="label_IncomeTaxDisclosureTextBlock" xlink:title="Label : IncomeTaxDisclosureTextBlock to label_IncomeTaxDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_IncomeTaxDisclosureTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_IncomeTaxDisclosureTextBlock_1" xml:lang="en-US" id="label_IncomeTaxDisclosureTextBlock_1">Income Tax Disclosure [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxDisclosureTextBlock" xlink:to="label_IncomeTaxDisclosureTextBlock_1" xlink:title="Label : IncomeTaxDisclosureTextBlock to label_IncomeTaxDisclosureTextBlock_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:title="DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xml:lang="en-US" id="label_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">SHARE-BASED COMPENSATION</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="label_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:title="Label : DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock to label_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_1" xml:lang="en-US" id="label_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_1">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="label_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_1" xlink:title="Label : DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock to label_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="CommitmentsAndContingenciesDisclosureTextBlock" xlink:title="CommitmentsAndContingenciesDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_CommitmentsAndContingenciesDisclosureTextBlock" xml:lang="en-US" id="label_CommitmentsAndContingenciesDisclosureTextBlock">COMMITMENTS AND CONTINGENCIES</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="label_CommitmentsAndContingenciesDisclosureTextBlock" xlink:title="Label : CommitmentsAndContingenciesDisclosureTextBlock to label_CommitmentsAndContingenciesDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_CommitmentsAndContingenciesDisclosureTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_CommitmentsAndContingenciesDisclosureTextBlock_1" xml:lang="en-US" id="label_CommitmentsAndContingenciesDisclosureTextBlock_1">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="label_CommitmentsAndContingenciesDisclosureTextBlock_1" xlink:title="Label : CommitmentsAndContingenciesDisclosureTextBlock to label_CommitmentsAndContingenciesDisclosureTextBlock_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="SubsequentEventsTextBlock" xlink:title="SubsequentEventsTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_SubsequentEventsTextBlock" xml:lang="en-US" id="label_SubsequentEventsTextBlock">SUBSEQUENT EVENTS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsequentEventsTextBlock" xlink:to="label_SubsequentEventsTextBlock" xlink:title="Label : SubsequentEventsTextBlock to label_SubsequentEventsTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_SubsequentEventsTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_SubsequentEventsTextBlock_1" xml:lang="en-US" id="label_SubsequentEventsTextBlock_1">Subsequent Events [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsequentEventsTextBlock" xlink:to="label_SubsequentEventsTextBlock_1" xlink:title="Label : SubsequentEventsTextBlock to label_SubsequentEventsTextBlock_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="BasisOfAccountingPolicyPolicyTextBlock" xlink:title="BasisOfAccountingPolicyPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_BasisOfAccountingPolicyPolicyTextBlock" xml:lang="en-US" id="label_BasisOfAccountingPolicyPolicyTextBlock">Basis of Presentation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BasisOfAccountingPolicyPolicyTextBlock" xlink:to="label_BasisOfAccountingPolicyPolicyTextBlock" xlink:title="Label : BasisOfAccountingPolicyPolicyTextBlock to label_BasisOfAccountingPolicyPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_BasisOfAccountingPolicyPolicyTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_BasisOfAccountingPolicyPolicyTextBlock_1" xml:lang="en-US" id="label_BasisOfAccountingPolicyPolicyTextBlock_1">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BasisOfAccountingPolicyPolicyTextBlock" xlink:to="label_BasisOfAccountingPolicyPolicyTextBlock_1" xlink:title="Label : BasisOfAccountingPolicyPolicyTextBlock to label_BasisOfAccountingPolicyPolicyTextBlock_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UseOfEstimates" xlink:label="UseOfEstimates" xlink:title="UseOfEstimates" />
    <link:label xlink:type="resource" xlink:label="label_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_UseOfEstimates" xml:lang="en-US" id="label_UseOfEstimates">Use of Estimates</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UseOfEstimates" xlink:to="label_UseOfEstimates" xlink:title="Label : UseOfEstimates to label_UseOfEstimates" />
    <link:label xlink:type="resource" xlink:label="label_UseOfEstimates_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_UseOfEstimates_1" xml:lang="en-US" id="label_UseOfEstimates_1">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UseOfEstimates" xlink:to="label_UseOfEstimates_1" xlink:title="Label : UseOfEstimates to label_UseOfEstimates_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityPolicyTextBlock" xlink:label="StockholdersEquityPolicyTextBlock" xlink:title="StockholdersEquityPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_StockholdersEquityPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_StockholdersEquityPolicyTextBlock" xml:lang="en-US" id="label_StockholdersEquityPolicyTextBlock">Reverse Stock Splits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquityPolicyTextBlock" xlink:to="label_StockholdersEquityPolicyTextBlock" xlink:title="Label : StockholdersEquityPolicyTextBlock to label_StockholdersEquityPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_StockholdersEquityPolicyTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StockholdersEquityPolicyTextBlock_1" xml:lang="en-US" id="label_StockholdersEquityPolicyTextBlock_1">Stockholders' Equity, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquityPolicyTextBlock" xlink:to="label_StockholdersEquityPolicyTextBlock_1" xlink:title="Label : StockholdersEquityPolicyTextBlock to label_StockholdersEquityPolicyTextBlock_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="ConcentrationRiskCreditRisk" xlink:title="ConcentrationRiskCreditRisk" />
    <link:label xlink:type="resource" xlink:label="label_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ConcentrationRiskCreditRisk" xml:lang="en-US" id="label_ConcentrationRiskCreditRisk">Concentrations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConcentrationRiskCreditRisk" xlink:to="label_ConcentrationRiskCreditRisk" xlink:title="Label : ConcentrationRiskCreditRisk to label_ConcentrationRiskCreditRisk" />
    <link:label xlink:type="resource" xlink:label="label_ConcentrationRiskCreditRisk_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ConcentrationRiskCreditRisk_1" xml:lang="en-US" id="label_ConcentrationRiskCreditRisk_1">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConcentrationRiskCreditRisk" xlink:to="label_ConcentrationRiskCreditRisk_1" xlink:title="Label : ConcentrationRiskCreditRisk to label_ConcentrationRiskCreditRisk_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="SegmentReportingPolicyPolicyTextBlock" xlink:title="SegmentReportingPolicyPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_SegmentReportingPolicyPolicyTextBlock" xml:lang="en-US" id="label_SegmentReportingPolicyPolicyTextBlock">Segment Information</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SegmentReportingPolicyPolicyTextBlock" xlink:to="label_SegmentReportingPolicyPolicyTextBlock" xlink:title="Label : SegmentReportingPolicyPolicyTextBlock to label_SegmentReportingPolicyPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_SegmentReportingPolicyPolicyTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_SegmentReportingPolicyPolicyTextBlock_1" xml:lang="en-US" id="label_SegmentReportingPolicyPolicyTextBlock_1">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SegmentReportingPolicyPolicyTextBlock" xlink:to="label_SegmentReportingPolicyPolicyTextBlock_1" xlink:title="Label : SegmentReportingPolicyPolicyTextBlock to label_SegmentReportingPolicyPolicyTextBlock_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="DerivativesPolicyTextBlock" xlink:title="DerivativesPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_DerivativesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_DerivativesPolicyTextBlock" xml:lang="en-US" id="label_DerivativesPolicyTextBlock">Derivative Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DerivativesPolicyTextBlock" xlink:to="label_DerivativesPolicyTextBlock" xlink:title="Label : DerivativesPolicyTextBlock to label_DerivativesPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_DerivativesPolicyTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DerivativesPolicyTextBlock_1" xml:lang="en-US" id="label_DerivativesPolicyTextBlock_1">Derivatives, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DerivativesPolicyTextBlock" xlink:to="label_DerivativesPolicyTextBlock_1" xlink:title="Label : DerivativesPolicyTextBlock to label_DerivativesPolicyTextBlock_1" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_EquityClassifiedWarrantsPolicyTextBlock" xlink:label="EquityClassifiedWarrantsPolicyTextBlock" xlink:title="EquityClassifiedWarrantsPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_EquityClassifiedWarrantsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_EquityClassifiedWarrantsPolicyTextBlock" xml:lang="en-US" id="label_EquityClassifiedWarrantsPolicyTextBlock">Equity-Classified Warrants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquityClassifiedWarrantsPolicyTextBlock" xlink:to="label_EquityClassifiedWarrantsPolicyTextBlock" xlink:title="Label : EquityClassifiedWarrantsPolicyTextBlock to label_EquityClassifiedWarrantsPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_EquityClassifiedWarrantsPolicyTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_EquityClassifiedWarrantsPolicyTextBlock_1" xml:lang="en-US" id="label_EquityClassifiedWarrantsPolicyTextBlock_1">Disclosure of accounting policy for equity-classified warrants.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquityClassifiedWarrantsPolicyTextBlock" xlink:to="label_EquityClassifiedWarrantsPolicyTextBlock_1" xlink:title="Label : EquityClassifiedWarrantsPolicyTextBlock to label_EquityClassifiedWarrantsPolicyTextBlock_1" />
    <link:label xlink:type="resource" xlink:label="label_EquityClassifiedWarrantsPolicyTextBlock_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_EquityClassifiedWarrantsPolicyTextBlock_2" xml:lang="en-US" id="label_EquityClassifiedWarrantsPolicyTextBlock_2">Equity Classified Warrants Policy Text Block</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquityClassifiedWarrantsPolicyTextBlock" xlink:to="label_EquityClassifiedWarrantsPolicyTextBlock_2" xlink:title="Label : EquityClassifiedWarrantsPolicyTextBlock to label_EquityClassifiedWarrantsPolicyTextBlock_2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="RevenueFromContractWithCustomerPolicyTextBlock" xlink:title="RevenueFromContractWithCustomerPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_RevenueFromContractWithCustomerPolicyTextBlock" xml:lang="en-US" id="label_RevenueFromContractWithCustomerPolicyTextBlock">Revenue Recognition</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="label_RevenueFromContractWithCustomerPolicyTextBlock" xlink:title="Label : RevenueFromContractWithCustomerPolicyTextBlock to label_RevenueFromContractWithCustomerPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_RevenueFromContractWithCustomerPolicyTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_RevenueFromContractWithCustomerPolicyTextBlock_1" xml:lang="en-US" id="label_RevenueFromContractWithCustomerPolicyTextBlock_1">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="label_RevenueFromContractWithCustomerPolicyTextBlock_1" xlink:title="Label : RevenueFromContractWithCustomerPolicyTextBlock to label_RevenueFromContractWithCustomerPolicyTextBlock_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="ResearchAndDevelopmentExpensePolicy" xlink:title="ResearchAndDevelopmentExpensePolicy" />
    <link:label xlink:type="resource" xlink:label="label_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ResearchAndDevelopmentExpensePolicy" xml:lang="en-US" id="label_ResearchAndDevelopmentExpensePolicy">Research and Development Costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchAndDevelopmentExpensePolicy" xlink:to="label_ResearchAndDevelopmentExpensePolicy" xlink:title="Label : ResearchAndDevelopmentExpensePolicy to label_ResearchAndDevelopmentExpensePolicy" />
    <link:label xlink:type="resource" xlink:label="label_ResearchAndDevelopmentExpensePolicy_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ResearchAndDevelopmentExpensePolicy_1" xml:lang="en-US" id="label_ResearchAndDevelopmentExpensePolicy_1">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchAndDevelopmentExpensePolicy" xlink:to="label_ResearchAndDevelopmentExpensePolicy_1" xlink:title="Label : ResearchAndDevelopmentExpensePolicy to label_ResearchAndDevelopmentExpensePolicy_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="FairValueOfFinancialInstrumentsPolicy" xlink:title="FairValueOfFinancialInstrumentsPolicy" />
    <link:label xlink:type="resource" xlink:label="label_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_FairValueOfFinancialInstrumentsPolicy" xml:lang="en-US" id="label_FairValueOfFinancialInstrumentsPolicy">Fair Value of Financial Instruments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueOfFinancialInstrumentsPolicy" xlink:to="label_FairValueOfFinancialInstrumentsPolicy" xlink:title="Label : FairValueOfFinancialInstrumentsPolicy to label_FairValueOfFinancialInstrumentsPolicy" />
    <link:label xlink:type="resource" xlink:label="label_FairValueOfFinancialInstrumentsPolicy_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FairValueOfFinancialInstrumentsPolicy_1" xml:lang="en-US" id="label_FairValueOfFinancialInstrumentsPolicy_1">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueOfFinancialInstrumentsPolicy" xlink:to="label_FairValueOfFinancialInstrumentsPolicy_1" xlink:title="Label : FairValueOfFinancialInstrumentsPolicy to label_FairValueOfFinancialInstrumentsPolicy_1" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_AssetsAndLiabilitiesNotMeasuredAtFairValueOnARecurringBasisPolicyTextBlock" xlink:label="AssetsAndLiabilitiesNotMeasuredAtFairValueOnARecurringBasisPolicyTextBlock" xlink:title="AssetsAndLiabilitiesNotMeasuredAtFairValueOnARecurringBasisPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_AssetsAndLiabilitiesNotMeasuredAtFairValueOnARecurringBasisPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_AssetsAndLiabilitiesNotMeasuredAtFairValueOnARecurringBasisPolicyTextBlock" xml:lang="en-US" id="label_AssetsAndLiabilitiesNotMeasuredAtFairValueOnARecurringBasisPolicyTextBlock">Assets and Liabilities Not Measured at Fair Value on a Recurring Basis</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsAndLiabilitiesNotMeasuredAtFairValueOnARecurringBasisPolicyTextBlock" xlink:to="label_AssetsAndLiabilitiesNotMeasuredAtFairValueOnARecurringBasisPolicyTextBlock" xlink:title="Label : AssetsAndLiabilitiesNotMeasuredAtFairValueOnARecurringBasisPolicyTextBlock to label_AssetsAndLiabilitiesNotMeasuredAtFairValueOnARecurringBasisPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_AssetsAndLiabilitiesNotMeasuredAtFairValueOnARecurringBasisPolicyTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_AssetsAndLiabilitiesNotMeasuredAtFairValueOnARecurringBasisPolicyTextBlock_1" xml:lang="en-US" id="label_AssetsAndLiabilitiesNotMeasuredAtFairValueOnARecurringBasisPolicyTextBlock_1">Disclosure of accounting policy for assets and liabilities not measured at fair value on a recurring basis.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsAndLiabilitiesNotMeasuredAtFairValueOnARecurringBasisPolicyTextBlock" xlink:to="label_AssetsAndLiabilitiesNotMeasuredAtFairValueOnARecurringBasisPolicyTextBlock_1" xlink:title="Label : AssetsAndLiabilitiesNotMeasuredAtFairValueOnARecurringBasisPolicyTextBlock to label_AssetsAndLiabilitiesNotMeasuredAtFairValueOnARecurringBasisPolicyTextBlock_1" />
    <link:label xlink:type="resource" xlink:label="label_AssetsAndLiabilitiesNotMeasuredAtFairValueOnARecurringBasisPolicyTextBlock_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AssetsAndLiabilitiesNotMeasuredAtFairValueOnARecurringBasisPolicyTextBlock_2" xml:lang="en-US" id="label_AssetsAndLiabilitiesNotMeasuredAtFairValueOnARecurringBasisPolicyTextBlock_2">Assets And Liabilities Not Measured At Fair Value On ARecurring Basis Policy Text Block</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsAndLiabilitiesNotMeasuredAtFairValueOnARecurringBasisPolicyTextBlock" xlink:to="label_AssetsAndLiabilitiesNotMeasuredAtFairValueOnARecurringBasisPolicyTextBlock_2" xlink:title="Label : AssetsAndLiabilitiesNotMeasuredAtFairValueOnARecurringBasisPolicyTextBlock to label_AssetsAndLiabilitiesNotMeasuredAtFairValueOnARecurringBasisPolicyTextBlock_2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:title="ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xml:lang="en-US" id="label_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">Foreign Currency Transactions and Translation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="label_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:title="Label : ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock to label_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_1" xml:lang="en-US" id="label_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_1">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="label_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_1" xlink:title="Label : ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock to label_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:label="PriorPeriodReclassificationAdjustmentDescription" xlink:title="PriorPeriodReclassificationAdjustmentDescription" />
    <link:label xlink:type="resource" xlink:label="label_PriorPeriodReclassificationAdjustmentDescription" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_PriorPeriodReclassificationAdjustmentDescription" xml:lang="en-US" id="label_PriorPeriodReclassificationAdjustmentDescription">Reclassifications</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PriorPeriodReclassificationAdjustmentDescription" xlink:to="label_PriorPeriodReclassificationAdjustmentDescription" xlink:title="Label : PriorPeriodReclassificationAdjustmentDescription to label_PriorPeriodReclassificationAdjustmentDescription" />
    <link:label xlink:type="resource" xlink:label="label_PriorPeriodReclassificationAdjustmentDescription_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_PriorPeriodReclassificationAdjustmentDescription_1" xml:lang="en-US" id="label_PriorPeriodReclassificationAdjustmentDescription_1">Reclassification, Comparability Adjustment [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PriorPeriodReclassificationAdjustmentDescription" xlink:to="label_PriorPeriodReclassificationAdjustmentDescription_1" xlink:title="Label : PriorPeriodReclassificationAdjustmentDescription to label_PriorPeriodReclassificationAdjustmentDescription_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:title="ShareBasedCompensationOptionAndIncentivePlansPolicy" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ShareBasedCompensationOptionAndIncentivePlansPolicy" xml:lang="en-US" id="label_ShareBasedCompensationOptionAndIncentivePlansPolicy">Share-Based Payments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="label_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:title="Label : ShareBasedCompensationOptionAndIncentivePlansPolicy to label_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationOptionAndIncentivePlansPolicy_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ShareBasedCompensationOptionAndIncentivePlansPolicy_1" xml:lang="en-US" id="label_ShareBasedCompensationOptionAndIncentivePlansPolicy_1">Share-Based Payment Arrangement [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="label_ShareBasedCompensationOptionAndIncentivePlansPolicy_1" xlink:title="Label : ShareBasedCompensationOptionAndIncentivePlansPolicy to label_ShareBasedCompensationOptionAndIncentivePlansPolicy_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="CompensationRelatedCostsPolicyTextBlock" xlink:title="CompensationRelatedCostsPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_CompensationRelatedCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_CompensationRelatedCostsPolicyTextBlock" xml:lang="en-US" id="label_CompensationRelatedCostsPolicyTextBlock">Related Parties</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CompensationRelatedCostsPolicyTextBlock" xlink:to="label_CompensationRelatedCostsPolicyTextBlock" xlink:title="Label : CompensationRelatedCostsPolicyTextBlock to label_CompensationRelatedCostsPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_CompensationRelatedCostsPolicyTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_CompensationRelatedCostsPolicyTextBlock_1" xml:lang="en-US" id="label_CompensationRelatedCostsPolicyTextBlock_1">Compensation Related Costs, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CompensationRelatedCostsPolicyTextBlock" xlink:to="label_CompensationRelatedCostsPolicyTextBlock_1" xlink:title="Label : CompensationRelatedCostsPolicyTextBlock to label_CompensationRelatedCostsPolicyTextBlock_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsPolicyPolicyTextBlock" xlink:label="SubsequentEventsPolicyPolicyTextBlock" xlink:title="SubsequentEventsPolicyPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_SubsequentEventsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_SubsequentEventsPolicyPolicyTextBlock" xml:lang="en-US" id="label_SubsequentEventsPolicyPolicyTextBlock">Subsequent Events</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsequentEventsPolicyPolicyTextBlock" xlink:to="label_SubsequentEventsPolicyPolicyTextBlock" xlink:title="Label : SubsequentEventsPolicyPolicyTextBlock to label_SubsequentEventsPolicyPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_SubsequentEventsPolicyPolicyTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_SubsequentEventsPolicyPolicyTextBlock_1" xml:lang="en-US" id="label_SubsequentEventsPolicyPolicyTextBlock_1">Subsequent Events, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsequentEventsPolicyPolicyTextBlock" xlink:to="label_SubsequentEventsPolicyPolicyTextBlock_1" xlink:title="Label : SubsequentEventsPolicyPolicyTextBlock to label_SubsequentEventsPolicyPolicyTextBlock_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:title="NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_NewAccountingPronouncementsPolicyPolicyTextBlock" xml:lang="en-US" id="label_NewAccountingPronouncementsPolicyPolicyTextBlock">Recently Adopted and Issued Accounting Pronouncements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="label_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:title="Label : NewAccountingPronouncementsPolicyPolicyTextBlock to label_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_NewAccountingPronouncementsPolicyPolicyTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_NewAccountingPronouncementsPolicyPolicyTextBlock_1" xml:lang="en-US" id="label_NewAccountingPronouncementsPolicyPolicyTextBlock_1">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="label_NewAccountingPronouncementsPolicyPolicyTextBlock_1" xlink:title="Label : NewAccountingPronouncementsPolicyPolicyTextBlock to label_NewAccountingPronouncementsPolicyPolicyTextBlock_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:label="FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:title="FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xml:lang="en-US" id="label_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock">Schedule of Liabilities Measured at Fair Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:to="label_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:title="Label : FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock to label_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_1" xml:lang="en-US" id="label_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_1">Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:to="label_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_1" xlink:title="Label : FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock to label_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock" xlink:label="ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock" xlink:title="ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock" xml:lang="en-US" id="label_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock">Schedule of Exchange Rates along with Historical Rates</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock" xlink:to="label_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock" xlink:title="Label : ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock to label_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock_1" xml:lang="en-US" id="label_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock_1">Schedule of Foreign Exchange Contracts, Statement of Financial Position [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock" xlink:to="label_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock_1" xlink:title="Label : ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock to label_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="ScheduleOfInventoryCurrentTableTextBlock" xlink:title="ScheduleOfInventoryCurrentTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ScheduleOfInventoryCurrentTableTextBlock" xml:lang="en-US" id="label_ScheduleOfInventoryCurrentTableTextBlock">Schedule of Inventory</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfInventoryCurrentTableTextBlock" xlink:to="label_ScheduleOfInventoryCurrentTableTextBlock" xlink:title="Label : ScheduleOfInventoryCurrentTableTextBlock to label_ScheduleOfInventoryCurrentTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_ScheduleOfInventoryCurrentTableTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ScheduleOfInventoryCurrentTableTextBlock_1" xml:lang="en-US" id="label_ScheduleOfInventoryCurrentTableTextBlock_1">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfInventoryCurrentTableTextBlock" xlink:to="label_ScheduleOfInventoryCurrentTableTextBlock_1" xlink:title="Label : ScheduleOfInventoryCurrentTableTextBlock to label_ScheduleOfInventoryCurrentTableTextBlock_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="PropertyPlantAndEquipmentTextBlock" xlink:title="PropertyPlantAndEquipmentTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_PropertyPlantAndEquipmentTextBlock" xml:lang="en-US" id="label_PropertyPlantAndEquipmentTextBlock">Schedule of Property and Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentTextBlock" xlink:to="label_PropertyPlantAndEquipmentTextBlock" xlink:title="Label : PropertyPlantAndEquipmentTextBlock to label_PropertyPlantAndEquipmentTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_PropertyPlantAndEquipmentTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_PropertyPlantAndEquipmentTextBlock_1" xml:lang="en-US" id="label_PropertyPlantAndEquipmentTextBlock_1">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentTextBlock" xlink:to="label_PropertyPlantAndEquipmentTextBlock_1" xlink:title="Label : PropertyPlantAndEquipmentTextBlock to label_PropertyPlantAndEquipmentTextBlock_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:title="ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xml:lang="en-US" id="label_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">Schedule of Intangible Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="label_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:title="Label : ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock to label_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_1" xml:lang="en-US" id="label_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_1">Schedule of Finite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="label_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_1" xlink:title="Label : ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock to label_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:title="ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xml:lang="en-US" id="label_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">Schedule of Estimated Future Amortization Expense for Our Patents and Website Development Costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="label_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:title="Label : ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock to label_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_1" xml:lang="en-US" id="label_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_1">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="label_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_1" xlink:title="Label : ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock to label_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:title="ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xml:lang="en-US" id="label_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">Schedule of Equity-Classified Warrants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="label_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:title="Label : ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock to label_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_1" xml:lang="en-US" id="label_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_1">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="label_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_1" xlink:title="Label : ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock to label_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:title="ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xml:lang="en-US" id="label_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">Schedule of the Current Future Payment Obligations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="label_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:title="Label : ScheduleOfMaturitiesOfLongTermDebtTableTextBlock to label_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_1" xml:lang="en-US" id="label_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_1">Schedule of Maturities of Long-Term Debt [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="label_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_1" xlink:title="Label : ScheduleOfMaturitiesOfLongTermDebtTableTextBlock to label_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:label="ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:title="ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xml:lang="en-US" id="label_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock">Schedule of Derivative Liabilities Measured at Fair Value on a Recurring Basis</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:to="label_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:title="Label : ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock to label_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_1" xml:lang="en-US" id="label_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_1">Schedule of Derivative Liabilities at Fair Value [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:to="label_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_1" xlink:title="Label : ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock to label_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:title="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xml:lang="en-US" id="label_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">Schedule of Share-Based Compensation Expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="label_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:title="Label : ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock to label_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_1" xml:lang="en-US" id="label_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_1">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="label_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_1" xlink:title="Label : ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock to label_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock">Schedule of Fair Value of Options Granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock" xlink:title="Label : ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock to label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock_1" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock_1">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock_1" xlink:title="Label : ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock to label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock_1" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_NatureofOperationsDetailsTable" xlink:label="NatureofOperationsDetailsTable" xlink:title="NatureofOperationsDetailsTable" />
    <link:label xlink:type="resource" xlink:label="label_NatureofOperationsDetailsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_NatureofOperationsDetailsTable" xml:lang="en-US" id="label_NatureofOperationsDetailsTable">Nature of Operations (Details) [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NatureofOperationsDetailsTable" xlink:to="label_NatureofOperationsDetailsTable" xlink:title="Label : NatureofOperationsDetailsTable to label_NatureofOperationsDetailsTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="SubsidiarySaleOfStockAxis" xlink:title="SubsidiarySaleOfStockAxis" />
    <link:label xlink:type="resource" xlink:label="label_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_SubsidiarySaleOfStockAxis" xml:lang="en-US" id="label_SubsidiarySaleOfStockAxis">Sale of Stock [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsidiarySaleOfStockAxis" xlink:to="label_SubsidiarySaleOfStockAxis" xlink:title="Label : SubsidiarySaleOfStockAxis to label_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="SaleOfStockNameOfTransactionDomain" xlink:title="SaleOfStockNameOfTransactionDomain" />
    <link:label xlink:type="resource" xlink:label="label_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_SaleOfStockNameOfTransactionDomain" xml:lang="en-US" id="label_SaleOfStockNameOfTransactionDomain">Sale of Stock [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SaleOfStockNameOfTransactionDomain" xlink:to="label_SaleOfStockNameOfTransactionDomain" xlink:title="Label : SaleOfStockNameOfTransactionDomain to label_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IPOMember" xlink:label="IPOMember" xlink:title="IPOMember" />
    <link:label xlink:type="resource" xlink:label="label_IPOMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_IPOMember" xml:lang="en-US" id="label_IPOMember">Initial Public Offering [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IPOMember" xlink:to="label_IPOMember" xlink:title="Label : IPOMember to label_IPOMember" />
    <link:label xlink:type="resource" xlink:label="label_IPOMember_1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_IPOMember_1" xml:lang="en-US" id="label_IPOMember_1">IPO [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IPOMember" xlink:to="label_IPOMember_1" xlink:title="Label : IPOMember to label_IPOMember_1" />
    <link:label xlink:type="resource" xlink:label="label_IPOMember_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_IPOMember_2" xml:lang="en-US" id="label_IPOMember_2">IPO [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IPOMember" xlink:to="label_IPOMember_2" xlink:title="Label : IPOMember to label_IPOMember_2" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_TradeableWarrantsMember" xlink:label="TradeableWarrantsMember" xlink:title="TradeableWarrantsMember" />
    <link:label xlink:type="resource" xlink:label="label_TradeableWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_TradeableWarrantsMember" xml:lang="en-US" id="label_TradeableWarrantsMember">Tradeable Warrants [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TradeableWarrantsMember" xlink:to="label_TradeableWarrantsMember" xlink:title="Label : TradeableWarrantsMember to label_TradeableWarrantsMember" />
    <link:label xlink:type="resource" xlink:label="label_TradeableWarrantsMember_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_TradeableWarrantsMember_1" xml:lang="en-US" id="label_TradeableWarrantsMember_1">Tradeable Warrants Member</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TradeableWarrantsMember" xlink:to="label_TradeableWarrantsMember_1" xlink:title="Label : TradeableWarrantsMember to label_TradeableWarrantsMember_1" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_NontradeableWarrantsMember" xlink:label="NontradeableWarrantsMember" xlink:title="NontradeableWarrantsMember" />
    <link:label xlink:type="resource" xlink:label="label_NontradeableWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_NontradeableWarrantsMember" xml:lang="en-US" id="label_NontradeableWarrantsMember">Non-Tradeable Warrants [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NontradeableWarrantsMember" xlink:to="label_NontradeableWarrantsMember" xlink:title="Label : NontradeableWarrantsMember to label_NontradeableWarrantsMember" />
    <link:label xlink:type="resource" xlink:label="label_NontradeableWarrantsMember_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_NontradeableWarrantsMember_1" xml:lang="en-US" id="label_NontradeableWarrantsMember_1">Nontradeable Warrants Member</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NontradeableWarrantsMember" xlink:to="label_NontradeableWarrantsMember_1" xlink:title="Label : NontradeableWarrantsMember to label_NontradeableWarrantsMember_1" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_TradeableAndNonTradeableWarrantsMember" xlink:label="TradeableAndNonTradeableWarrantsMember" xlink:title="TradeableAndNonTradeableWarrantsMember" />
    <link:label xlink:type="resource" xlink:label="label_TradeableAndNonTradeableWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_TradeableAndNonTradeableWarrantsMember" xml:lang="en-US" id="label_TradeableAndNonTradeableWarrantsMember">Tradeable and Non-Tradeable Warrants [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TradeableAndNonTradeableWarrantsMember" xlink:to="label_TradeableAndNonTradeableWarrantsMember" xlink:title="Label : TradeableAndNonTradeableWarrantsMember to label_TradeableAndNonTradeableWarrantsMember" />
    <link:label xlink:type="resource" xlink:label="label_TradeableAndNonTradeableWarrantsMember_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_TradeableAndNonTradeableWarrantsMember_1" xml:lang="en-US" id="label_TradeableAndNonTradeableWarrantsMember_1">Tradeable And Non Tradeable Warrants Member</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TradeableAndNonTradeableWarrantsMember" xlink:to="label_TradeableAndNonTradeableWarrantsMember_1" xlink:title="Label : TradeableAndNonTradeableWarrantsMember to label_TradeableAndNonTradeableWarrantsMember_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:title="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:label xlink:type="resource" xlink:label="label_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xml:lang="en-US" id="label_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">Nature of Operations [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="label_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:title="Label : CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems to label_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="StockIssuedDuringPeriodSharesNewIssues" xlink:title="StockIssuedDuringPeriodSharesNewIssues" />
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US" id="label_StockIssuedDuringPeriodSharesNewIssues">Number of shares issued (in Shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesNewIssues" xlink:to="label_StockIssuedDuringPeriodSharesNewIssues" xlink:title="Label : StockIssuedDuringPeriodSharesNewIssues to label_StockIssuedDuringPeriodSharesNewIssues" />
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodSharesNewIssues_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StockIssuedDuringPeriodSharesNewIssues_1" xml:lang="en-US" id="label_StockIssuedDuringPeriodSharesNewIssues_1">Stock Issued During Period, Shares, New Issues</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesNewIssues" xlink:to="label_StockIssuedDuringPeriodSharesNewIssues_1" xlink:title="Label : StockIssuedDuringPeriodSharesNewIssues to label_StockIssuedDuringPeriodSharesNewIssues_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="SharesIssuedPricePerShare" xlink:title="SharesIssuedPricePerShare" />
    <link:label xlink:type="resource" xlink:label="label_SharesIssuedPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_SharesIssuedPricePerShare" xml:lang="en-US" id="label_SharesIssuedPricePerShare">Price per unit (in Dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharesIssuedPricePerShare" xlink:to="label_SharesIssuedPricePerShare" xlink:title="Label : SharesIssuedPricePerShare to label_SharesIssuedPricePerShare" />
    <link:label xlink:type="resource" xlink:label="label_SharesIssuedPricePerShare_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_SharesIssuedPricePerShare_1" xml:lang="en-US" id="label_SharesIssuedPricePerShare_1">Shares Issued, Price Per Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharesIssuedPricePerShare" xlink:to="label_SharesIssuedPricePerShare_1" xlink:title="Label : SharesIssuedPricePerShare to label_SharesIssuedPricePerShare_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="ProceedsFromIssuanceInitialPublicOffering" xlink:title="ProceedsFromIssuanceInitialPublicOffering" />
    <link:label xlink:type="resource" xlink:label="label_ProceedsFromIssuanceInitialPublicOffering" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ProceedsFromIssuanceInitialPublicOffering" xml:lang="en-US" id="label_ProceedsFromIssuanceInitialPublicOffering">Net proceeds</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromIssuanceInitialPublicOffering" xlink:to="label_ProceedsFromIssuanceInitialPublicOffering" xlink:title="Label : ProceedsFromIssuanceInitialPublicOffering to label_ProceedsFromIssuanceInitialPublicOffering" />
    <link:label xlink:type="resource" xlink:label="label_ProceedsFromIssuanceInitialPublicOffering_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ProceedsFromIssuanceInitialPublicOffering_1" xml:lang="en-US" id="label_ProceedsFromIssuanceInitialPublicOffering_1">Proceeds from Issuance Initial Public Offering</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromIssuanceInitialPublicOffering" xlink:to="label_ProceedsFromIssuanceInitialPublicOffering_1" xlink:title="Label : ProceedsFromIssuanceInitialPublicOffering to label_ProceedsFromIssuanceInitialPublicOffering_1" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:label="SummaryofSignificantAccountingPoliciesDetailsTable" xlink:title="SummaryofSignificantAccountingPoliciesDetailsTable" />
    <link:label xlink:type="resource" xlink:label="label_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_SummaryofSignificantAccountingPoliciesDetailsTable" xml:lang="en-US" id="label_SummaryofSignificantAccountingPoliciesDetailsTable">Summary of Significant Accounting Policies (Details) [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="label_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:title="Label : SummaryofSignificantAccountingPoliciesDetailsTable to label_SummaryofSignificantAccountingPoliciesDetailsTable" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_ReverseStockSplitsMember" xlink:label="ReverseStockSplitsMember" xlink:title="ReverseStockSplitsMember" />
    <link:label xlink:type="resource" xlink:label="label_ReverseStockSplitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ReverseStockSplitsMember" xml:lang="en-US" id="label_ReverseStockSplitsMember">Reverse Stock Splits [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ReverseStockSplitsMember" xlink:to="label_ReverseStockSplitsMember" xlink:title="Label : ReverseStockSplitsMember to label_ReverseStockSplitsMember" />
    <link:label xlink:type="resource" xlink:label="label_ReverseStockSplitsMember_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ReverseStockSplitsMember_1" xml:lang="en-US" id="label_ReverseStockSplitsMember_1">Reverse Stock Splits Member</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ReverseStockSplitsMember" xlink:to="label_ReverseStockSplitsMember_1" xlink:title="Label : ReverseStockSplitsMember to label_ReverseStockSplitsMember_1" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_NetLossPerCommonShareMember" xlink:label="NetLossPerCommonShareMember" xlink:title="NetLossPerCommonShareMember" />
    <link:label xlink:type="resource" xlink:label="label_NetLossPerCommonShareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_NetLossPerCommonShareMember" xml:lang="en-US" id="label_NetLossPerCommonShareMember">Net Loss Per Common Share [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetLossPerCommonShareMember" xlink:to="label_NetLossPerCommonShareMember" xlink:title="Label : NetLossPerCommonShareMember to label_NetLossPerCommonShareMember" />
    <link:label xlink:type="resource" xlink:label="label_NetLossPerCommonShareMember_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_NetLossPerCommonShareMember_1" xml:lang="en-US" id="label_NetLossPerCommonShareMember_1">Net Loss Per Common Share Member</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetLossPerCommonShareMember" xlink:to="label_NetLossPerCommonShareMember_1" xlink:title="Label : NetLossPerCommonShareMember to label_NetLossPerCommonShareMember_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="ConcentrationRiskByTypeAxis" xlink:title="ConcentrationRiskByTypeAxis" />
    <link:label xlink:type="resource" xlink:label="label_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ConcentrationRiskByTypeAxis" xml:lang="en-US" id="label_ConcentrationRiskByTypeAxis">Concentration Risk Type [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConcentrationRiskByTypeAxis" xlink:to="label_ConcentrationRiskByTypeAxis" xlink:title="Label : ConcentrationRiskByTypeAxis to label_ConcentrationRiskByTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="ConcentrationRiskTypeDomain" xlink:title="ConcentrationRiskTypeDomain" />
    <link:label xlink:type="resource" xlink:label="label_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ConcentrationRiskTypeDomain" xml:lang="en-US" id="label_ConcentrationRiskTypeDomain">Concentration Risk Type [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConcentrationRiskTypeDomain" xlink:to="label_ConcentrationRiskTypeDomain" xlink:title="Label : ConcentrationRiskTypeDomain to label_ConcentrationRiskTypeDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="CustomerConcentrationRiskMember" xlink:title="CustomerConcentrationRiskMember" />
    <link:label xlink:type="resource" xlink:label="label_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_CustomerConcentrationRiskMember" xml:lang="en-US" id="label_CustomerConcentrationRiskMember">Customer Concentration Risk [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CustomerConcentrationRiskMember" xlink:to="label_CustomerConcentrationRiskMember" xlink:title="Label : CustomerConcentrationRiskMember to label_CustomerConcentrationRiskMember" />
    <link:label xlink:type="resource" xlink:label="label_CustomerConcentrationRiskMember_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_CustomerConcentrationRiskMember_1" xml:lang="en-US" id="label_CustomerConcentrationRiskMember_1">Customer Concentration Risk [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CustomerConcentrationRiskMember" xlink:to="label_CustomerConcentrationRiskMember_1" xlink:title="Label : CustomerConcentrationRiskMember to label_CustomerConcentrationRiskMember_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MajorCustomersAxis" xlink:label="MajorCustomersAxis" xlink:title="MajorCustomersAxis" />
    <link:label xlink:type="resource" xlink:label="label_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_MajorCustomersAxis" xml:lang="en-US" id="label_MajorCustomersAxis">Customer [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MajorCustomersAxis" xlink:to="label_MajorCustomersAxis" xlink:title="Label : MajorCustomersAxis to label_MajorCustomersAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_NameOfMajorCustomerDomain" xlink:label="NameOfMajorCustomerDomain" xlink:title="NameOfMajorCustomerDomain" />
    <link:label xlink:type="resource" xlink:label="label_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_NameOfMajorCustomerDomain" xml:lang="en-US" id="label_NameOfMajorCustomerDomain">Customer [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NameOfMajorCustomerDomain" xlink:to="label_NameOfMajorCustomerDomain" xlink:title="Label : NameOfMajorCustomerDomain to label_NameOfMajorCustomerDomain" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_SignificantCustomersMember" xlink:label="SignificantCustomersMember" xlink:title="SignificantCustomersMember" />
    <link:label xlink:type="resource" xlink:label="label_SignificantCustomersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_SignificantCustomersMember" xml:lang="en-US" id="label_SignificantCustomersMember">Customer One [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SignificantCustomersMember" xlink:to="label_SignificantCustomersMember" xlink:title="Label : SignificantCustomersMember to label_SignificantCustomersMember" />
    <link:label xlink:type="resource" xlink:label="label_SignificantCustomersMember_1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_SignificantCustomersMember_1" xml:lang="en-US" id="label_SignificantCustomersMember_1">Significant Customers [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SignificantCustomersMember" xlink:to="label_SignificantCustomersMember_1" xlink:title="Label : SignificantCustomersMember to label_SignificantCustomersMember_1" />
    <link:label xlink:type="resource" xlink:label="label_SignificantCustomersMember_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_SignificantCustomersMember_2" xml:lang="en-US" id="label_SignificantCustomersMember_2">Significant Customers Member</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SignificantCustomersMember" xlink:to="label_SignificantCustomersMember_2" xlink:title="Label : SignificantCustomersMember to label_SignificantCustomersMember_2" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_CustomerTwoMember" xlink:label="CustomerTwoMember" xlink:title="CustomerTwoMember" />
    <link:label xlink:type="resource" xlink:label="label_CustomerTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_CustomerTwoMember" xml:lang="en-US" id="label_CustomerTwoMember">Customer Two [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CustomerTwoMember" xlink:to="label_CustomerTwoMember" xlink:title="Label : CustomerTwoMember to label_CustomerTwoMember" />
    <link:label xlink:type="resource" xlink:label="label_CustomerTwoMember_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_CustomerTwoMember_1" xml:lang="en-US" id="label_CustomerTwoMember_1">Customer Two Member</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CustomerTwoMember" xlink:to="label_CustomerTwoMember_1" xlink:title="Label : CustomerTwoMember to label_CustomerTwoMember_1" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_CustomerThreeMember" xlink:label="CustomerThreeMember" xlink:title="CustomerThreeMember" />
    <link:label xlink:type="resource" xlink:label="label_CustomerThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_CustomerThreeMember" xml:lang="en-US" id="label_CustomerThreeMember">Customer Three [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CustomerThreeMember" xlink:to="label_CustomerThreeMember" xlink:title="Label : CustomerThreeMember to label_CustomerThreeMember" />
    <link:label xlink:type="resource" xlink:label="label_CustomerThreeMember_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_CustomerThreeMember_1" xml:lang="en-US" id="label_CustomerThreeMember_1">Customer Three Member</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CustomerThreeMember" xlink:to="label_CustomerThreeMember_1" xlink:title="Label : CustomerThreeMember to label_CustomerThreeMember_1" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_SignificantCustomerOneMember" xlink:label="SignificantCustomerOneMember" xlink:title="SignificantCustomerOneMember" />
    <link:label xlink:type="resource" xlink:label="label_SignificantCustomerOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_SignificantCustomerOneMember" xml:lang="en-US" id="label_SignificantCustomerOneMember">Significant Customer One [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SignificantCustomerOneMember" xlink:to="label_SignificantCustomerOneMember" xlink:title="Label : SignificantCustomerOneMember to label_SignificantCustomerOneMember" />
    <link:label xlink:type="resource" xlink:label="label_SignificantCustomerOneMember_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_SignificantCustomerOneMember_1" xml:lang="en-US" id="label_SignificantCustomerOneMember_1">Significant Customer One Member</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SignificantCustomerOneMember" xlink:to="label_SignificantCustomerOneMember_1" xlink:title="Label : SignificantCustomerOneMember to label_SignificantCustomerOneMember_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="ConcentrationRiskByBenchmarkAxis" xlink:title="ConcentrationRiskByBenchmarkAxis" />
    <link:label xlink:type="resource" xlink:label="label_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ConcentrationRiskByBenchmarkAxis" xml:lang="en-US" id="label_ConcentrationRiskByBenchmarkAxis">Concentration Risk Benchmark [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConcentrationRiskByBenchmarkAxis" xlink:to="label_ConcentrationRiskByBenchmarkAxis" xlink:title="Label : ConcentrationRiskByBenchmarkAxis to label_ConcentrationRiskByBenchmarkAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="ConcentrationRiskBenchmarkDomain" xlink:title="ConcentrationRiskBenchmarkDomain" />
    <link:label xlink:type="resource" xlink:label="label_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ConcentrationRiskBenchmarkDomain" xml:lang="en-US" id="label_ConcentrationRiskBenchmarkDomain">Concentration Risk Benchmark [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConcentrationRiskBenchmarkDomain" xlink:to="label_ConcentrationRiskBenchmarkDomain" xlink:title="Label : ConcentrationRiskBenchmarkDomain to label_ConcentrationRiskBenchmarkDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableMember" xlink:label="AccountsReceivableMember" xlink:title="AccountsReceivableMember" />
    <link:label xlink:type="resource" xlink:label="label_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_AccountsReceivableMember" xml:lang="en-US" id="label_AccountsReceivableMember">Accounts Receivable [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccountsReceivableMember" xlink:to="label_AccountsReceivableMember" xlink:title="Label : AccountsReceivableMember to label_AccountsReceivableMember" />
    <link:label xlink:type="resource" xlink:label="label_AccountsReceivableMember_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AccountsReceivableMember_1" xml:lang="en-US" id="label_AccountsReceivableMember_1">Accounts Receivable [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccountsReceivableMember" xlink:to="label_AccountsReceivableMember_1" xlink:title="Label : AccountsReceivableMember to label_AccountsReceivableMember_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SalesRevenueNetMember" xlink:label="SalesRevenueNetMember" xlink:title="SalesRevenueNetMember" />
    <link:label xlink:type="resource" xlink:label="label_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_SalesRevenueNetMember" xml:lang="en-US" id="label_SalesRevenueNetMember">Revenue Benchmark [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SalesRevenueNetMember" xlink:to="label_SalesRevenueNetMember" xlink:title="Label : SalesRevenueNetMember to label_SalesRevenueNetMember" />
    <link:label xlink:type="resource" xlink:label="label_SalesRevenueNetMember_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_SalesRevenueNetMember_1" xml:lang="en-US" id="label_SalesRevenueNetMember_1">Revenue Benchmark [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SalesRevenueNetMember" xlink:to="label_SalesRevenueNetMember_1" xlink:title="Label : SalesRevenueNetMember to label_SalesRevenueNetMember_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ChangeInAccountingEstimateLineItems" xlink:label="ChangeInAccountingEstimateLineItems" xlink:title="ChangeInAccountingEstimateLineItems" />
    <link:label xlink:type="resource" xlink:label="label_ChangeInAccountingEstimateLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ChangeInAccountingEstimateLineItems" xml:lang="en-US" id="label_ChangeInAccountingEstimateLineItems">Summary of Significant Accounting Policies [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ChangeInAccountingEstimateLineItems" xlink:to="label_ChangeInAccountingEstimateLineItems" xlink:title="Label : ChangeInAccountingEstimateLineItems to label_ChangeInAccountingEstimateLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="StockholdersEquityReverseStockSplit" xlink:title="StockholdersEquityReverseStockSplit" />
    <link:label xlink:type="resource" xlink:label="label_StockholdersEquityReverseStockSplit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_StockholdersEquityReverseStockSplit" xml:lang="en-US" id="label_StockholdersEquityReverseStockSplit">Reverse stock split</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquityReverseStockSplit" xlink:to="label_StockholdersEquityReverseStockSplit" xlink:title="Label : StockholdersEquityReverseStockSplit to label_StockholdersEquityReverseStockSplit" />
    <link:label xlink:type="resource" xlink:label="label_StockholdersEquityReverseStockSplit_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StockholdersEquityReverseStockSplit_1" xml:lang="en-US" id="label_StockholdersEquityReverseStockSplit_1">Stockholders' Equity, Reverse Stock Split</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquityReverseStockSplit" xlink:to="label_StockholdersEquityReverseStockSplit_1" xlink:title="Label : StockholdersEquityReverseStockSplit to label_StockholdersEquityReverseStockSplit_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="ConcentrationRiskPercentage1" xlink:title="ConcentrationRiskPercentage1" />
    <link:label xlink:type="resource" xlink:label="label_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ConcentrationRiskPercentage1" xml:lang="en-US" id="label_ConcentrationRiskPercentage1">Concentration percentage</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConcentrationRiskPercentage1" xlink:to="label_ConcentrationRiskPercentage1" xlink:title="Label : ConcentrationRiskPercentage1 to label_ConcentrationRiskPercentage1" />
    <link:label xlink:type="resource" xlink:label="label_ConcentrationRiskPercentage1_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ConcentrationRiskPercentage1_1" xml:lang="en-US" id="label_ConcentrationRiskPercentage1_1">Concentration Risk, Percentage</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConcentrationRiskPercentage1" xlink:to="label_ConcentrationRiskPercentage1_1" xlink:title="Label : ConcentrationRiskPercentage1 to label_ConcentrationRiskPercentage1_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="CashCashEquivalentsAndShortTermInvestments" xlink:title="CashCashEquivalentsAndShortTermInvestments" />
    <link:label xlink:type="resource" xlink:label="label_CashCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_CashCashEquivalentsAndShortTermInvestments" xml:lang="en-US" id="label_CashCashEquivalentsAndShortTermInvestments">Cash equivalents and short-term (in Dollars)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashCashEquivalentsAndShortTermInvestments" xlink:to="label_CashCashEquivalentsAndShortTermInvestments" xlink:title="Label : CashCashEquivalentsAndShortTermInvestments to label_CashCashEquivalentsAndShortTermInvestments" />
    <link:label xlink:type="resource" xlink:label="label_CashCashEquivalentsAndShortTermInvestments_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_CashCashEquivalentsAndShortTermInvestments_1" xml:lang="en-US" id="label_CashCashEquivalentsAndShortTermInvestments_1">Cash, Cash Equivalents, and Short-Term Investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashCashEquivalentsAndShortTermInvestments" xlink:to="label_CashCashEquivalentsAndShortTermInvestments_1" xlink:title="Label : CashCashEquivalentsAndShortTermInvestments to label_CashCashEquivalentsAndShortTermInvestments_1" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_ScheduleOfLiabilitiesMeasuredAtFairValueAbstract" xlink:label="ScheduleOfLiabilitiesMeasuredAtFairValueAbstract" xlink:title="ScheduleOfLiabilitiesMeasuredAtFairValueAbstract" />
    <link:label xlink:type="resource" xlink:label="label_ScheduleOfLiabilitiesMeasuredAtFairValueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ScheduleOfLiabilitiesMeasuredAtFairValueAbstract" xml:lang="en-US" id="label_ScheduleOfLiabilitiesMeasuredAtFairValueAbstract">Schedule Of Liabilities Measured At Fair Value Abstract</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfLiabilitiesMeasuredAtFairValueAbstract" xlink:to="label_ScheduleOfLiabilitiesMeasuredAtFairValueAbstract" xlink:title="Label : ScheduleOfLiabilitiesMeasuredAtFairValueAbstract to label_ScheduleOfLiabilitiesMeasuredAtFairValueAbstract" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_SummaryofSignificantAccountingPoliciesScheduleofLiabilitiesMeasuredatFairValueDetailsTable" xlink:label="SummaryofSignificantAccountingPoliciesScheduleofLiabilitiesMeasuredatFairValueDetailsTable" xlink:title="SummaryofSignificantAccountingPoliciesScheduleofLiabilitiesMeasuredatFairValueDetailsTable" />
    <link:label xlink:type="resource" xlink:label="label_SummaryofSignificantAccountingPoliciesScheduleofLiabilitiesMeasuredatFairValueDetailsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_SummaryofSignificantAccountingPoliciesScheduleofLiabilitiesMeasuredatFairValueDetailsTable" xml:lang="en-US" id="label_SummaryofSignificantAccountingPoliciesScheduleofLiabilitiesMeasuredatFairValueDetailsTable">Summary of Significant Accounting Policies - Schedule of Liabilities Measured at Fair Value (Details) [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SummaryofSignificantAccountingPoliciesScheduleofLiabilitiesMeasuredatFairValueDetailsTable" xlink:to="label_SummaryofSignificantAccountingPoliciesScheduleofLiabilitiesMeasuredatFairValueDetailsTable" xlink:title="Label : SummaryofSignificantAccountingPoliciesScheduleofLiabilitiesMeasuredatFairValueDetailsTable to label_SummaryofSignificantAccountingPoliciesScheduleofLiabilitiesMeasuredatFairValueDetailsTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="FinancialInstrumentAxis" xlink:title="FinancialInstrumentAxis" />
    <link:label xlink:type="resource" xlink:label="label_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FinancialInstrumentAxis" xml:lang="en-US" id="label_FinancialInstrumentAxis">Financial Instrument [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FinancialInstrumentAxis" xlink:to="label_FinancialInstrumentAxis" xlink:title="Label : FinancialInstrumentAxis to label_FinancialInstrumentAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:title="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <link:label xlink:type="resource" xlink:label="label_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xml:lang="en-US" id="label_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain">Financial Instruments [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="label_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:title="Label : TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain to label_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeMember" xlink:label="DerivativeMember" xlink:title="DerivativeMember" />
    <link:label xlink:type="resource" xlink:label="label_DerivativeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_DerivativeMember" xml:lang="en-US" id="label_DerivativeMember">Derivative Liabilities [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DerivativeMember" xlink:to="label_DerivativeMember" xlink:title="Label : DerivativeMember to label_DerivativeMember" />
    <link:label xlink:type="resource" xlink:label="label_DerivativeMember_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DerivativeMember_1" xml:lang="en-US" id="label_DerivativeMember_1">Derivative [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DerivativeMember" xlink:to="label_DerivativeMember_1" xlink:title="Label : DerivativeMember to label_DerivativeMember_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="FairValueByFairValueHierarchyLevelAxis" xlink:title="FairValueByFairValueHierarchyLevelAxis" />
    <link:label xlink:type="resource" xlink:label="label_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FairValueByFairValueHierarchyLevelAxis" xml:lang="en-US" id="label_FairValueByFairValueHierarchyLevelAxis">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueByFairValueHierarchyLevelAxis" xlink:to="label_FairValueByFairValueHierarchyLevelAxis" xlink:title="Label : FairValueByFairValueHierarchyLevelAxis to label_FairValueByFairValueHierarchyLevelAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="FairValueMeasurementsFairValueHierarchyDomain" xlink:title="FairValueMeasurementsFairValueHierarchyDomain" />
    <link:label xlink:type="resource" xlink:label="label_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FairValueMeasurementsFairValueHierarchyDomain" xml:lang="en-US" id="label_FairValueMeasurementsFairValueHierarchyDomain">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueMeasurementsFairValueHierarchyDomain" xlink:to="label_FairValueMeasurementsFairValueHierarchyDomain" xlink:title="Label : FairValueMeasurementsFairValueHierarchyDomain to label_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="FairValueInputsLevel1Member" xlink:title="FairValueInputsLevel1Member" />
    <link:label xlink:type="resource" xlink:label="label_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_FairValueInputsLevel1Member" xml:lang="en-US" id="label_FairValueInputsLevel1Member">Level 1 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueInputsLevel1Member" xlink:to="label_FairValueInputsLevel1Member" xlink:title="Label : FairValueInputsLevel1Member to label_FairValueInputsLevel1Member" />
    <link:label xlink:type="resource" xlink:label="label_FairValueInputsLevel1Member_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FairValueInputsLevel1Member_1" xml:lang="en-US" id="label_FairValueInputsLevel1Member_1">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueInputsLevel1Member" xlink:to="label_FairValueInputsLevel1Member_1" xlink:title="Label : FairValueInputsLevel1Member to label_FairValueInputsLevel1Member_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="FairValueInputsLevel2Member" xlink:title="FairValueInputsLevel2Member" />
    <link:label xlink:type="resource" xlink:label="label_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_FairValueInputsLevel2Member" xml:lang="en-US" id="label_FairValueInputsLevel2Member">Level 2 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueInputsLevel2Member" xlink:to="label_FairValueInputsLevel2Member" xlink:title="Label : FairValueInputsLevel2Member to label_FairValueInputsLevel2Member" />
    <link:label xlink:type="resource" xlink:label="label_FairValueInputsLevel2Member_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FairValueInputsLevel2Member_1" xml:lang="en-US" id="label_FairValueInputsLevel2Member_1">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueInputsLevel2Member" xlink:to="label_FairValueInputsLevel2Member_1" xlink:title="Label : FairValueInputsLevel2Member to label_FairValueInputsLevel2Member_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="FairValueInputsLevel3Member" xlink:title="FairValueInputsLevel3Member" />
    <link:label xlink:type="resource" xlink:label="label_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_FairValueInputsLevel3Member" xml:lang="en-US" id="label_FairValueInputsLevel3Member">Level 3 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueInputsLevel3Member" xlink:to="label_FairValueInputsLevel3Member" xlink:title="Label : FairValueInputsLevel3Member to label_FairValueInputsLevel3Member" />
    <link:label xlink:type="resource" xlink:label="label_FairValueInputsLevel3Member_1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_FairValueInputsLevel3Member_1" xml:lang="en-US" id="label_FairValueInputsLevel3Member_1">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueInputsLevel3Member" xlink:to="label_FairValueInputsLevel3Member_1" xlink:title="Label : FairValueInputsLevel3Member to label_FairValueInputsLevel3Member_1" />
    <link:label xlink:type="resource" xlink:label="label_FairValueInputsLevel3Member_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FairValueInputsLevel3Member_2" xml:lang="en-US" id="label_FairValueInputsLevel3Member_2">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueInputsLevel3Member" xlink:to="label_FairValueInputsLevel3Member_2" xlink:title="Label : FairValueInputsLevel3Member to label_FairValueInputsLevel3Member_2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:title="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:label xlink:type="resource" xlink:label="label_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xml:lang="en-US" id="label_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">Schedule of Liabilities Measured at Fair Value [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="label_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:title="Label : FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems to label_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_ScheduleOfExchangeRatesAlongWithHistoricalRatesAbstract" xlink:label="ScheduleOfExchangeRatesAlongWithHistoricalRatesAbstract" xlink:title="ScheduleOfExchangeRatesAlongWithHistoricalRatesAbstract" />
    <link:label xlink:type="resource" xlink:label="label_ScheduleOfExchangeRatesAlongWithHistoricalRatesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ScheduleOfExchangeRatesAlongWithHistoricalRatesAbstract" xml:lang="en-US" id="label_ScheduleOfExchangeRatesAlongWithHistoricalRatesAbstract">Schedule Of Exchange Rates Along With Historical Rates Abstract</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfExchangeRatesAlongWithHistoricalRatesAbstract" xlink:to="label_ScheduleOfExchangeRatesAlongWithHistoricalRatesAbstract" xlink:title="Label : ScheduleOfExchangeRatesAlongWithHistoricalRatesAbstract to label_ScheduleOfExchangeRatesAlongWithHistoricalRatesAbstract" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_SummaryofSignificantAccountingPoliciesScheduleofExchangeRatesalongwithHistoricalRatesDetailsTable" xlink:label="SummaryofSignificantAccountingPoliciesScheduleofExchangeRatesalongwithHistoricalRatesDetailsTable" xlink:title="SummaryofSignificantAccountingPoliciesScheduleofExchangeRatesalongwithHistoricalRatesDetailsTable" />
    <link:label xlink:type="resource" xlink:label="label_SummaryofSignificantAccountingPoliciesScheduleofExchangeRatesalongwithHistoricalRatesDetailsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_SummaryofSignificantAccountingPoliciesScheduleofExchangeRatesalongwithHistoricalRatesDetailsTable" xml:lang="en-US" id="label_SummaryofSignificantAccountingPoliciesScheduleofExchangeRatesalongwithHistoricalRatesDetailsTable">Summary of Significant Accounting Policies - Schedule of Exchange Rates along with Historical Rates (Details) [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SummaryofSignificantAccountingPoliciesScheduleofExchangeRatesalongwithHistoricalRatesDetailsTable" xlink:to="label_SummaryofSignificantAccountingPoliciesScheduleofExchangeRatesalongwithHistoricalRatesDetailsTable" xlink:title="Label : SummaryofSignificantAccountingPoliciesScheduleofExchangeRatesalongwithHistoricalRatesDetailsTable to label_SummaryofSignificantAccountingPoliciesScheduleofExchangeRatesalongwithHistoricalRatesDetailsTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CurrencyAxis" xlink:label="CurrencyAxis" xlink:title="CurrencyAxis" />
    <link:label xlink:type="resource" xlink:label="label_CurrencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_CurrencyAxis" xml:lang="en-US" id="label_CurrencyAxis">Currency [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CurrencyAxis" xlink:to="label_CurrencyAxis" xlink:title="Label : CurrencyAxis to label_CurrencyAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2025/currency-2025.xsd#currency_USD" xlink:label="USD" xlink:title="USD" />
    <link:label xlink:type="resource" xlink:label="label_USD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_USD" xml:lang="en-US" id="label_USD">United States of America, Dollars</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="USD" xlink:to="label_USD" xlink:title="Label : USD to label_USD" />
    <link:label xlink:type="resource" xlink:label="label_USD_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_USD_1" xml:lang="en-US" id="label_USD_1">United States of America, Dollars</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="USD" xlink:to="label_USD_1" xlink:title="Label : USD to label_USD_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntercompanyForeignCurrencyBalanceLineItems" xlink:label="IntercompanyForeignCurrencyBalanceLineItems" xlink:title="IntercompanyForeignCurrencyBalanceLineItems" />
    <link:label xlink:type="resource" xlink:label="label_IntercompanyForeignCurrencyBalanceLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_IntercompanyForeignCurrencyBalanceLineItems" xml:lang="en-US" id="label_IntercompanyForeignCurrencyBalanceLineItems">Schedule of Exchange Rates along with Historical Rates [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IntercompanyForeignCurrencyBalanceLineItems" xlink:to="label_IntercompanyForeignCurrencyBalanceLineItems" xlink:title="Label : IntercompanyForeignCurrencyBalanceLineItems to label_IntercompanyForeignCurrencyBalanceLineItems" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_AverageExchangeRate" xlink:label="AverageExchangeRate" xlink:title="AverageExchangeRate" />
    <link:label xlink:type="resource" xlink:label="label_AverageExchangeRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_AverageExchangeRate" xml:lang="en-US" id="label_AverageExchangeRate">Average Exchange Rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AverageExchangeRate" xlink:to="label_AverageExchangeRate" xlink:title="Label : AverageExchangeRate to label_AverageExchangeRate" />
    <link:label xlink:type="resource" xlink:label="label_AverageExchangeRate_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_AverageExchangeRate_1" xml:lang="en-US" id="label_AverageExchangeRate_1">Average Exchange Rate.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AverageExchangeRate" xlink:to="label_AverageExchangeRate_1" xlink:title="Label : AverageExchangeRate to label_AverageExchangeRate_1" />
    <link:label xlink:type="resource" xlink:label="label_AverageExchangeRate_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AverageExchangeRate_2" xml:lang="en-US" id="label_AverageExchangeRate_2">Average Exchange Rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AverageExchangeRate" xlink:to="label_AverageExchangeRate_2" xlink:title="Label : AverageExchangeRate to label_AverageExchangeRate_2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCurrencyExchangeRateTranslation1" xlink:label="ForeignCurrencyExchangeRateTranslation1" xlink:title="ForeignCurrencyExchangeRateTranslation1" />
    <link:label xlink:type="resource" xlink:label="label_ForeignCurrencyExchangeRateTranslation1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ForeignCurrencyExchangeRateTranslation1" xml:lang="en-US" id="label_ForeignCurrencyExchangeRateTranslation1">Exchange Rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ForeignCurrencyExchangeRateTranslation1" xlink:to="label_ForeignCurrencyExchangeRateTranslation1" xlink:title="Label : ForeignCurrencyExchangeRateTranslation1 to label_ForeignCurrencyExchangeRateTranslation1" />
    <link:label xlink:type="resource" xlink:label="label_ForeignCurrencyExchangeRateTranslation1_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ForeignCurrencyExchangeRateTranslation1_1" xml:lang="en-US" id="label_ForeignCurrencyExchangeRateTranslation1_1">Foreign Currency Exchange Rate, Translation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ForeignCurrencyExchangeRateTranslation1" xlink:to="label_ForeignCurrencyExchangeRateTranslation1_1" xlink:title="Label : ForeignCurrencyExchangeRateTranslation1 to label_ForeignCurrencyExchangeRateTranslation1_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2025/currency-2025.xsd#currency_AllCurrenciesDomain" xlink:label="AllCurrenciesDomain" xlink:title="AllCurrenciesDomain" />
    <link:label xlink:type="resource" xlink:label="label_AllCurrenciesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AllCurrenciesDomain" xml:lang="en-US" id="label_AllCurrenciesDomain">All Currencies [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AllCurrenciesDomain" xlink:to="label_AllCurrenciesDomain" xlink:title="Label : AllCurrenciesDomain to label_AllCurrenciesDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryNetAbstract" xlink:label="InventoryNetAbstract" xlink:title="InventoryNetAbstract" />
    <link:label xlink:type="resource" xlink:label="label_InventoryNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_InventoryNetAbstract" xml:lang="en-US" id="label_InventoryNetAbstract">Schedule of Inventory [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InventoryNetAbstract" xlink:to="label_InventoryNetAbstract" xlink:title="Label : InventoryNetAbstract to label_InventoryNetAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryRawMaterials" xlink:label="InventoryRawMaterials" xlink:title="InventoryRawMaterials" />
    <link:label xlink:type="resource" xlink:label="label_InventoryRawMaterials" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_InventoryRawMaterials" xml:lang="en-US" id="label_InventoryRawMaterials">Raw Material (API)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InventoryRawMaterials" xlink:to="label_InventoryRawMaterials" xlink:title="Label : InventoryRawMaterials to label_InventoryRawMaterials" />
    <link:label xlink:type="resource" xlink:label="label_InventoryRawMaterials_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_InventoryRawMaterials_1" xml:lang="en-US" id="label_InventoryRawMaterials_1">Inventory, Raw Materials, Gross</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InventoryRawMaterials" xlink:to="label_InventoryRawMaterials_1" xlink:title="Label : InventoryRawMaterials to label_InventoryRawMaterials_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryWorkInProcess" xlink:label="InventoryWorkInProcess" xlink:title="InventoryWorkInProcess" />
    <link:label xlink:type="resource" xlink:label="label_InventoryWorkInProcess" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_InventoryWorkInProcess" xml:lang="en-US" id="label_InventoryWorkInProcess">Work in Process</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InventoryWorkInProcess" xlink:to="label_InventoryWorkInProcess" xlink:title="Label : InventoryWorkInProcess to label_InventoryWorkInProcess" />
    <link:label xlink:type="resource" xlink:label="label_InventoryWorkInProcess_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_InventoryWorkInProcess_1" xml:lang="en-US" id="label_InventoryWorkInProcess_1">Inventory, Work in Process, Gross</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InventoryWorkInProcess" xlink:to="label_InventoryWorkInProcess_1" xlink:title="Label : InventoryWorkInProcess to label_InventoryWorkInProcess_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryFinishedGoods" xlink:label="InventoryFinishedGoods" xlink:title="InventoryFinishedGoods" />
    <link:label xlink:type="resource" xlink:label="label_InventoryFinishedGoods" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_InventoryFinishedGoods" xml:lang="en-US" id="label_InventoryFinishedGoods">Finished Goods</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InventoryFinishedGoods" xlink:to="label_InventoryFinishedGoods" xlink:title="Label : InventoryFinishedGoods to label_InventoryFinishedGoods" />
    <link:label xlink:type="resource" xlink:label="label_InventoryFinishedGoods_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_InventoryFinishedGoods_1" xml:lang="en-US" id="label_InventoryFinishedGoods_1">Inventory, Finished Goods, Gross</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InventoryFinishedGoods" xlink:to="label_InventoryFinishedGoods_1" xlink:title="Label : InventoryFinishedGoods to label_InventoryFinishedGoods_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="DepreciationDepletionAndAmortization" xlink:title="DepreciationDepletionAndAmortization" />
    <link:label xlink:type="resource" xlink:label="label_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_DepreciationDepletionAndAmortization" xml:lang="en-US" id="label_DepreciationDepletionAndAmortization">Depreciation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DepreciationDepletionAndAmortization" xlink:to="label_DepreciationDepletionAndAmortization" xlink:title="Label : DepreciationDepletionAndAmortization to label_DepreciationDepletionAndAmortization" />
    <link:label xlink:type="resource" xlink:label="label_DepreciationDepletionAndAmortization_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DepreciationDepletionAndAmortization_1" xml:lang="en-US" id="label_DepreciationDepletionAndAmortization_1">Depreciation, Depletion and Amortization</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DepreciationDepletionAndAmortization" xlink:to="label_DepreciationDepletionAndAmortization_1" xlink:title="Label : DepreciationDepletionAndAmortization to label_DepreciationDepletionAndAmortization_1" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_ScheduleOfPropertyAndEquipmentAbstract" xlink:label="ScheduleOfPropertyAndEquipmentAbstract" xlink:title="ScheduleOfPropertyAndEquipmentAbstract" />
    <link:label xlink:type="resource" xlink:label="label_ScheduleOfPropertyAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ScheduleOfPropertyAndEquipmentAbstract" xml:lang="en-US" id="label_ScheduleOfPropertyAndEquipmentAbstract">Schedule Of Property And Equipment Abstract</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfPropertyAndEquipmentAbstract" xlink:to="label_ScheduleOfPropertyAndEquipmentAbstract" xlink:title="Label : ScheduleOfPropertyAndEquipmentAbstract to label_ScheduleOfPropertyAndEquipmentAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="ScheduleOfPropertyPlantAndEquipmentTable" xlink:title="ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:label xlink:type="resource" xlink:label="label_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ScheduleOfPropertyPlantAndEquipmentTable" xml:lang="en-US" id="label_ScheduleOfPropertyPlantAndEquipmentTable">Property, Plant and Equipment [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="label_ScheduleOfPropertyPlantAndEquipmentTable" xlink:title="Label : ScheduleOfPropertyPlantAndEquipmentTable to label_ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="PropertyPlantAndEquipmentByTypeAxis" xlink:title="PropertyPlantAndEquipmentByTypeAxis" />
    <link:label xlink:type="resource" xlink:label="label_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_PropertyPlantAndEquipmentByTypeAxis" xml:lang="en-US" id="label_PropertyPlantAndEquipmentByTypeAxis">Long-Lived Tangible Asset [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentByTypeAxis" xlink:to="label_PropertyPlantAndEquipmentByTypeAxis" xlink:title="Label : PropertyPlantAndEquipmentByTypeAxis to label_PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="PropertyPlantAndEquipmentTypeDomain" xlink:title="PropertyPlantAndEquipmentTypeDomain" />
    <link:label xlink:type="resource" xlink:label="label_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_PropertyPlantAndEquipmentTypeDomain" xml:lang="en-US" id="label_PropertyPlantAndEquipmentTypeDomain">Long-Lived Tangible Asset [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="label_PropertyPlantAndEquipmentTypeDomain" xlink:title="Label : PropertyPlantAndEquipmentTypeDomain to label_PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_LabEquipmentMember" xlink:label="LabEquipmentMember" xlink:title="LabEquipmentMember" />
    <link:label xlink:type="resource" xlink:label="label_LabEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_LabEquipmentMember" xml:lang="en-US" id="label_LabEquipmentMember">Lab Equipment [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LabEquipmentMember" xlink:to="label_LabEquipmentMember" xlink:title="Label : LabEquipmentMember to label_LabEquipmentMember" />
    <link:label xlink:type="resource" xlink:label="label_LabEquipmentMember_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_LabEquipmentMember_1" xml:lang="en-US" id="label_LabEquipmentMember_1">Lab Equipment Member</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LabEquipmentMember" xlink:to="label_LabEquipmentMember_1" xlink:title="Label : LabEquipmentMember to label_LabEquipmentMember_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="MachineryAndEquipmentMember" xlink:title="MachineryAndEquipmentMember" />
    <link:label xlink:type="resource" xlink:label="label_MachineryAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_MachineryAndEquipmentMember" xml:lang="en-US" id="label_MachineryAndEquipmentMember">Machinery [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MachineryAndEquipmentMember" xlink:to="label_MachineryAndEquipmentMember" xlink:title="Label : MachineryAndEquipmentMember to label_MachineryAndEquipmentMember" />
    <link:label xlink:type="resource" xlink:label="label_MachineryAndEquipmentMember_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_MachineryAndEquipmentMember_1" xml:lang="en-US" id="label_MachineryAndEquipmentMember_1">Machinery and Equipment [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MachineryAndEquipmentMember" xlink:to="label_MachineryAndEquipmentMember_1" xlink:title="Label : MachineryAndEquipmentMember to label_MachineryAndEquipmentMember_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComputerEquipmentMember" xlink:label="ComputerEquipmentMember" xlink:title="ComputerEquipmentMember" />
    <link:label xlink:type="resource" xlink:label="label_ComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ComputerEquipmentMember" xml:lang="en-US" id="label_ComputerEquipmentMember">Computer Equipment [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ComputerEquipmentMember" xlink:to="label_ComputerEquipmentMember" xlink:title="Label : ComputerEquipmentMember to label_ComputerEquipmentMember" />
    <link:label xlink:type="resource" xlink:label="label_ComputerEquipmentMember_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ComputerEquipmentMember_1" xml:lang="en-US" id="label_ComputerEquipmentMember_1">Computer Equipment [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ComputerEquipmentMember" xlink:to="label_ComputerEquipmentMember_1" xlink:title="Label : ComputerEquipmentMember to label_ComputerEquipmentMember_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="FurnitureAndFixturesMember" xlink:title="FurnitureAndFixturesMember" />
    <link:label xlink:type="resource" xlink:label="label_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_FurnitureAndFixturesMember" xml:lang="en-US" id="label_FurnitureAndFixturesMember">Furniture [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FurnitureAndFixturesMember" xlink:to="label_FurnitureAndFixturesMember" xlink:title="Label : FurnitureAndFixturesMember to label_FurnitureAndFixturesMember" />
    <link:label xlink:type="resource" xlink:label="label_FurnitureAndFixturesMember_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FurnitureAndFixturesMember_1" xml:lang="en-US" id="label_FurnitureAndFixturesMember_1">Furniture and Fixtures [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FurnitureAndFixturesMember" xlink:to="label_FurnitureAndFixturesMember_1" xlink:title="Label : FurnitureAndFixturesMember to label_FurnitureAndFixturesMember_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="PropertyPlantAndEquipmentLineItems" xlink:title="PropertyPlantAndEquipmentLineItems" />
    <link:label xlink:type="resource" xlink:label="label_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_PropertyPlantAndEquipmentLineItems" xml:lang="en-US" id="label_PropertyPlantAndEquipmentLineItems">Schedule of Property and Equipment [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentLineItems" xlink:to="label_PropertyPlantAndEquipmentLineItems" xlink:title="Label : PropertyPlantAndEquipmentLineItems to label_PropertyPlantAndEquipmentLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="PropertyPlantAndEquipmentGross" xlink:title="PropertyPlantAndEquipmentGross" />
    <link:label xlink:type="resource" xlink:label="label_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_PropertyPlantAndEquipmentGross" xml:lang="en-US" id="label_PropertyPlantAndEquipmentGross">Property and Equipment, at cost</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentGross" xlink:to="label_PropertyPlantAndEquipmentGross" xlink:title="Label : PropertyPlantAndEquipmentGross to label_PropertyPlantAndEquipmentGross" />
    <link:label xlink:type="resource" xlink:label="label_PropertyPlantAndEquipmentGross_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_PropertyPlantAndEquipmentGross_1" xml:lang="en-US" id="label_PropertyPlantAndEquipmentGross_1">Property, Plant and Equipment, Gross</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentGross" xlink:to="label_PropertyPlantAndEquipmentGross_1" xlink:title="Label : PropertyPlantAndEquipmentGross to label_PropertyPlantAndEquipmentGross_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:title="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:label xlink:type="resource" xlink:label="label_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xml:lang="en-US" id="label_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">Accumulated Depreciation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="label_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:title="Label : AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment to label_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:label xlink:type="resource" xlink:label="label_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1" xml:lang="en-US" id="label_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="label_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1" xlink:title="Label : AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment to label_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_CapitalizedWebsiteDevelopmentrelatedCosts" xlink:label="CapitalizedWebsiteDevelopmentrelatedCosts" xlink:title="CapitalizedWebsiteDevelopmentrelatedCosts" />
    <link:label xlink:type="resource" xlink:label="label_CapitalizedWebsiteDevelopmentrelatedCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_CapitalizedWebsiteDevelopmentrelatedCosts" xml:lang="en-US" id="label_CapitalizedWebsiteDevelopmentrelatedCosts">Capitalized website development-related costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CapitalizedWebsiteDevelopmentrelatedCosts" xlink:to="label_CapitalizedWebsiteDevelopmentrelatedCosts" xlink:title="Label : CapitalizedWebsiteDevelopmentrelatedCosts to label_CapitalizedWebsiteDevelopmentrelatedCosts" />
    <link:label xlink:type="resource" xlink:label="label_CapitalizedWebsiteDevelopmentrelatedCosts_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_CapitalizedWebsiteDevelopmentrelatedCosts_1" xml:lang="en-US" id="label_CapitalizedWebsiteDevelopmentrelatedCosts_1">Amount of capitalized website development-related costs.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CapitalizedWebsiteDevelopmentrelatedCosts" xlink:to="label_CapitalizedWebsiteDevelopmentrelatedCosts_1" xlink:title="Label : CapitalizedWebsiteDevelopmentrelatedCosts to label_CapitalizedWebsiteDevelopmentrelatedCosts_1" />
    <link:label xlink:type="resource" xlink:label="label_CapitalizedWebsiteDevelopmentrelatedCosts_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_CapitalizedWebsiteDevelopmentrelatedCosts_2" xml:lang="en-US" id="label_CapitalizedWebsiteDevelopmentrelatedCosts_2">Capitalized Website Developmentrelated Costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CapitalizedWebsiteDevelopmentrelatedCosts" xlink:to="label_CapitalizedWebsiteDevelopmentrelatedCosts_2" xlink:title="Label : CapitalizedWebsiteDevelopmentrelatedCosts to label_CapitalizedWebsiteDevelopmentrelatedCosts_2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="AmortizationOfIntangibleAssets" xlink:title="AmortizationOfIntangibleAssets" />
    <link:label xlink:type="resource" xlink:label="label_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_AmortizationOfIntangibleAssets" xml:lang="en-US" id="label_AmortizationOfIntangibleAssets">Amortization expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmortizationOfIntangibleAssets" xlink:to="label_AmortizationOfIntangibleAssets" xlink:title="Label : AmortizationOfIntangibleAssets to label_AmortizationOfIntangibleAssets" />
    <link:label xlink:type="resource" xlink:label="label_AmortizationOfIntangibleAssets_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AmortizationOfIntangibleAssets_1" xml:lang="en-US" id="label_AmortizationOfIntangibleAssets_1">Amortization of Intangible Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmortizationOfIntangibleAssets" xlink:to="label_AmortizationOfIntangibleAssets_1" xlink:title="Label : AmortizationOfIntangibleAssets to label_AmortizationOfIntangibleAssets_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:title="ImpairmentOfIntangibleAssetsExcludingGoodwill" />
    <link:label xlink:type="resource" xlink:label="label_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ImpairmentOfIntangibleAssetsExcludingGoodwill" xml:lang="en-US" id="label_ImpairmentOfIntangibleAssetsExcludingGoodwill">Write-downs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:to="label_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:title="Label : ImpairmentOfIntangibleAssetsExcludingGoodwill to label_ImpairmentOfIntangibleAssetsExcludingGoodwill" />
    <link:label xlink:type="resource" xlink:label="label_ImpairmentOfIntangibleAssetsExcludingGoodwill_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ImpairmentOfIntangibleAssetsExcludingGoodwill_1" xml:lang="en-US" id="label_ImpairmentOfIntangibleAssetsExcludingGoodwill_1">Impairment of Intangible Assets (Excluding Goodwill)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:to="label_ImpairmentOfIntangibleAssetsExcludingGoodwill_1" xlink:title="Label : ImpairmentOfIntangibleAssetsExcludingGoodwill to label_ImpairmentOfIntangibleAssetsExcludingGoodwill_1" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_CapitalizedPatentExpenses" xlink:label="CapitalizedPatentExpenses" xlink:title="CapitalizedPatentExpenses" />
    <link:label xlink:type="resource" xlink:label="label_CapitalizedPatentExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_CapitalizedPatentExpenses" xml:lang="en-US" id="label_CapitalizedPatentExpenses">Capitalized patent expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CapitalizedPatentExpenses" xlink:to="label_CapitalizedPatentExpenses" xlink:title="Label : CapitalizedPatentExpenses to label_CapitalizedPatentExpenses" />
    <link:label xlink:type="resource" xlink:label="label_CapitalizedPatentExpenses_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_CapitalizedPatentExpenses_1" xml:lang="en-US" id="label_CapitalizedPatentExpenses_1">Amount of capitalized patent expenses.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CapitalizedPatentExpenses" xlink:to="label_CapitalizedPatentExpenses_1" xlink:title="Label : CapitalizedPatentExpenses to label_CapitalizedPatentExpenses_1" />
    <link:label xlink:type="resource" xlink:label="label_CapitalizedPatentExpenses_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_CapitalizedPatentExpenses_2" xml:lang="en-US" id="label_CapitalizedPatentExpenses_2">Capitalized Patent Expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CapitalizedPatentExpenses" xlink:to="label_CapitalizedPatentExpenses_2" xlink:title="Label : CapitalizedPatentExpenses to label_CapitalizedPatentExpenses_2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:label="IntangibleAssetsNetExcludingGoodwillAbstract" xlink:title="IntangibleAssetsNetExcludingGoodwillAbstract" />
    <link:label xlink:type="resource" xlink:label="label_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_IntangibleAssetsNetExcludingGoodwillAbstract" xml:lang="en-US" id="label_IntangibleAssetsNetExcludingGoodwillAbstract">Schedule of Intangible Assets [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IntangibleAssetsNetExcludingGoodwillAbstract" xlink:to="label_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:title="Label : IntangibleAssetsNetExcludingGoodwillAbstract to label_IntangibleAssetsNetExcludingGoodwillAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedPatentsGross" xlink:label="FiniteLivedPatentsGross" xlink:title="FiniteLivedPatentsGross" />
    <link:label xlink:type="resource" xlink:label="label_FiniteLivedPatentsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_FiniteLivedPatentsGross" xml:lang="en-US" id="label_FiniteLivedPatentsGross">Patents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedPatentsGross" xlink:to="label_FiniteLivedPatentsGross" xlink:title="Label : FiniteLivedPatentsGross to label_FiniteLivedPatentsGross" />
    <link:label xlink:type="resource" xlink:label="label_FiniteLivedPatentsGross_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FiniteLivedPatentsGross_1" xml:lang="en-US" id="label_FiniteLivedPatentsGross_1">Finite-Lived Patents, Gross</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedPatentsGross" xlink:to="label_FiniteLivedPatentsGross_1" xlink:title="Label : FiniteLivedPatentsGross to label_FiniteLivedPatentsGross_1" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_FiniteLivedWebsiteDevelopmentCostsGross" xlink:label="FiniteLivedWebsiteDevelopmentCostsGross" xlink:title="FiniteLivedWebsiteDevelopmentCostsGross" />
    <link:label xlink:type="resource" xlink:label="label_FiniteLivedWebsiteDevelopmentCostsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_FiniteLivedWebsiteDevelopmentCostsGross" xml:lang="en-US" id="label_FiniteLivedWebsiteDevelopmentCostsGross">Website Development Costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedWebsiteDevelopmentCostsGross" xlink:to="label_FiniteLivedWebsiteDevelopmentCostsGross" xlink:title="Label : FiniteLivedWebsiteDevelopmentCostsGross to label_FiniteLivedWebsiteDevelopmentCostsGross" />
    <link:label xlink:type="resource" xlink:label="label_FiniteLivedWebsiteDevelopmentCostsGross_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_FiniteLivedWebsiteDevelopmentCostsGross_1" xml:lang="en-US" id="label_FiniteLivedWebsiteDevelopmentCostsGross_1">Gross carrying amount before accumulated amortization as of the balance sheet date of the costs.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedWebsiteDevelopmentCostsGross" xlink:to="label_FiniteLivedWebsiteDevelopmentCostsGross_1" xlink:title="Label : FiniteLivedWebsiteDevelopmentCostsGross to label_FiniteLivedWebsiteDevelopmentCostsGross_1" />
    <link:label xlink:type="resource" xlink:label="label_FiniteLivedWebsiteDevelopmentCostsGross_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FiniteLivedWebsiteDevelopmentCostsGross_2" xml:lang="en-US" id="label_FiniteLivedWebsiteDevelopmentCostsGross_2">Finite Lived Website Development Costs Gross</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedWebsiteDevelopmentCostsGross" xlink:to="label_FiniteLivedWebsiteDevelopmentCostsGross_2" xlink:title="Label : FiniteLivedWebsiteDevelopmentCostsGross to label_FiniteLivedWebsiteDevelopmentCostsGross_2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="FiniteLivedIntangibleAssetsGross" xlink:title="FiniteLivedIntangibleAssetsGross" />
    <link:label xlink:type="resource" xlink:label="label_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_FiniteLivedIntangibleAssetsGross" xml:lang="en-US" id="label_FiniteLivedIntangibleAssetsGross">Intangible Assets, at cost</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetsGross" xlink:to="label_FiniteLivedIntangibleAssetsGross" xlink:title="Label : FiniteLivedIntangibleAssetsGross to label_FiniteLivedIntangibleAssetsGross" />
    <link:label xlink:type="resource" xlink:label="label_FiniteLivedIntangibleAssetsGross_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FiniteLivedIntangibleAssetsGross_1" xml:lang="en-US" id="label_FiniteLivedIntangibleAssetsGross_1">Finite-Lived Intangible Assets, Gross</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetsGross" xlink:to="label_FiniteLivedIntangibleAssetsGross_1" xlink:title="Label : FiniteLivedIntangibleAssetsGross to label_FiniteLivedIntangibleAssetsGross_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:title="FiniteLivedIntangibleAssetsAccumulatedAmortization" />
    <link:label xlink:type="resource" xlink:label="label_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_FiniteLivedIntangibleAssetsAccumulatedAmortization" xml:lang="en-US" id="label_FiniteLivedIntangibleAssetsAccumulatedAmortization">Accumulated Amortization</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="label_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:title="Label : FiniteLivedIntangibleAssetsAccumulatedAmortization to label_FiniteLivedIntangibleAssetsAccumulatedAmortization" />
    <link:label xlink:type="resource" xlink:label="label_FiniteLivedIntangibleAssetsAccumulatedAmortization_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FiniteLivedIntangibleAssetsAccumulatedAmortization_1" xml:lang="en-US" id="label_FiniteLivedIntangibleAssetsAccumulatedAmortization_1">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="label_FiniteLivedIntangibleAssetsAccumulatedAmortization_1" xlink:title="Label : FiniteLivedIntangibleAssetsAccumulatedAmortization to label_FiniteLivedIntangibleAssetsAccumulatedAmortization_1" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_ScheduleOfEstimatedFutureAmortizationExpenseForOurPatentsAndWebsiteDevelopmentCostsAbstract" xlink:label="ScheduleOfEstimatedFutureAmortizationExpenseForOurPatentsAndWebsiteDevelopmentCostsAbstract" xlink:title="ScheduleOfEstimatedFutureAmortizationExpenseForOurPatentsAndWebsiteDevelopmentCostsAbstract" />
    <link:label xlink:type="resource" xlink:label="label_ScheduleOfEstimatedFutureAmortizationExpenseForOurPatentsAndWebsiteDevelopmentCostsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ScheduleOfEstimatedFutureAmortizationExpenseForOurPatentsAndWebsiteDevelopmentCostsAbstract" xml:lang="en-US" id="label_ScheduleOfEstimatedFutureAmortizationExpenseForOurPatentsAndWebsiteDevelopmentCostsAbstract">Schedule Of Estimated Future Amortization Expense For Our Patents And Website Development Costs Abstract</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfEstimatedFutureAmortizationExpenseForOurPatentsAndWebsiteDevelopmentCostsAbstract" xlink:to="label_ScheduleOfEstimatedFutureAmortizationExpenseForOurPatentsAndWebsiteDevelopmentCostsAbstract" xlink:title="Label : ScheduleOfEstimatedFutureAmortizationExpenseForOurPatentsAndWebsiteDevelopmentCostsAbstract to label_ScheduleOfEstimatedFutureAmortizationExpenseForOurPatentsAndWebsiteDevelopmentCostsAbstract" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_IntangibleAssetsScheduleofEstimatedFutureAmortizationExpenseforOurPatentsandWebsiteDevelopmentCostsDetailsTable" xlink:label="IntangibleAssetsScheduleofEstimatedFutureAmortizationExpenseforOurPatentsandWebsiteDevelopmentCostsDetailsTable" xlink:title="IntangibleAssetsScheduleofEstimatedFutureAmortizationExpenseforOurPatentsandWebsiteDevelopmentCostsDetailsTable" />
    <link:label xlink:type="resource" xlink:label="label_IntangibleAssetsScheduleofEstimatedFutureAmortizationExpenseforOurPatentsandWebsiteDevelopmentCostsDetailsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_IntangibleAssetsScheduleofEstimatedFutureAmortizationExpenseforOurPatentsandWebsiteDevelopmentCostsDetailsTable" xml:lang="en-US" id="label_IntangibleAssetsScheduleofEstimatedFutureAmortizationExpenseforOurPatentsandWebsiteDevelopmentCostsDetailsTable">Intangible Assets - Schedule of Estimated Future Amortization Expense for Our Patents and Website Development Costs (Details) [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IntangibleAssetsScheduleofEstimatedFutureAmortizationExpenseforOurPatentsandWebsiteDevelopmentCostsDetailsTable" xlink:to="label_IntangibleAssetsScheduleofEstimatedFutureAmortizationExpenseforOurPatentsandWebsiteDevelopmentCostsDetailsTable" xlink:title="Label : IntangibleAssetsScheduleofEstimatedFutureAmortizationExpenseforOurPatentsandWebsiteDevelopmentCostsDetailsTable to label_IntangibleAssetsScheduleofEstimatedFutureAmortizationExpenseforOurPatentsandWebsiteDevelopmentCostsDetailsTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:title="FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:label xlink:type="resource" xlink:label="label_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FiniteLivedIntangibleAssetsByMajorClassAxis" xml:lang="en-US" id="label_FiniteLivedIntangibleAssetsByMajorClassAxis">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="label_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:title="Label : FiniteLivedIntangibleAssetsByMajorClassAxis to label_FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PatentsMember" xlink:label="PatentsMember" xlink:title="PatentsMember" />
    <link:label xlink:type="resource" xlink:label="label_PatentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_PatentsMember" xml:lang="en-US" id="label_PatentsMember">Patents [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PatentsMember" xlink:to="label_PatentsMember" xlink:title="Label : PatentsMember to label_PatentsMember" />
    <link:label xlink:type="resource" xlink:label="label_PatentsMember_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_PatentsMember_1" xml:lang="en-US" id="label_PatentsMember_1">Patents [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PatentsMember" xlink:to="label_PatentsMember_1" xlink:title="Label : PatentsMember to label_PatentsMember_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:label="SoftwareAndSoftwareDevelopmentCostsMember" xlink:title="SoftwareAndSoftwareDevelopmentCostsMember" />
    <link:label xlink:type="resource" xlink:label="label_SoftwareAndSoftwareDevelopmentCostsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_SoftwareAndSoftwareDevelopmentCostsMember" xml:lang="en-US" id="label_SoftwareAndSoftwareDevelopmentCostsMember">Website Development Costs [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SoftwareAndSoftwareDevelopmentCostsMember" xlink:to="label_SoftwareAndSoftwareDevelopmentCostsMember" xlink:title="Label : SoftwareAndSoftwareDevelopmentCostsMember to label_SoftwareAndSoftwareDevelopmentCostsMember" />
    <link:label xlink:type="resource" xlink:label="label_SoftwareAndSoftwareDevelopmentCostsMember_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_SoftwareAndSoftwareDevelopmentCostsMember_1" xml:lang="en-US" id="label_SoftwareAndSoftwareDevelopmentCostsMember_1">Software and Software Development Costs [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SoftwareAndSoftwareDevelopmentCostsMember" xlink:to="label_SoftwareAndSoftwareDevelopmentCostsMember_1" xlink:title="Label : SoftwareAndSoftwareDevelopmentCostsMember to label_SoftwareAndSoftwareDevelopmentCostsMember_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="FiniteLivedIntangibleAssetsLineItems" xlink:title="FiniteLivedIntangibleAssetsLineItems" />
    <link:label xlink:type="resource" xlink:label="label_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FiniteLivedIntangibleAssetsLineItems" xml:lang="en-US" id="label_FiniteLivedIntangibleAssetsLineItems">Schedule of Estimated Future Amortization Expense for Our Patents and Website Development Costs [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetsLineItems" xlink:to="label_FiniteLivedIntangibleAssetsLineItems" xlink:title="Label : FiniteLivedIntangibleAssetsLineItems to label_FiniteLivedIntangibleAssetsLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:label="FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:title="FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" />
    <link:label xlink:type="resource" xlink:label="label_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xml:lang="en-US" id="label_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear">2025 (remaining nine months)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:to="label_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:title="Label : FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear to label_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" />
    <link:label xlink:type="resource" xlink:label="label_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_1" xml:lang="en-US" id="label_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_1">Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:to="label_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_1" xlink:title="Label : FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear to label_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:title="FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />
    <link:label xlink:type="resource" xlink:label="label_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xml:lang="en-US" id="label_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">2026</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="label_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:title="Label : FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths to label_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />
    <link:label xlink:type="resource" xlink:label="label_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_1" xml:lang="en-US" id="label_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_1">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="label_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_1" xlink:title="Label : FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths to label_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:title="FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
    <link:label xlink:type="resource" xlink:label="label_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xml:lang="en-US" id="label_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">2027</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="label_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:title="Label : FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo to label_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
    <link:label xlink:type="resource" xlink:label="label_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_1" xml:lang="en-US" id="label_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_1">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="label_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_1" xlink:title="Label : FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo to label_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:title="FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />
    <link:label xlink:type="resource" xlink:label="label_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xml:lang="en-US" id="label_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">2028</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="label_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:title="Label : FiniteLivedIntangibleAssetsAmortizationExpenseYearThree to label_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />
    <link:label xlink:type="resource" xlink:label="label_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_1" xml:lang="en-US" id="label_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_1">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="label_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_1" xlink:title="Label : FiniteLivedIntangibleAssetsAmortizationExpenseYearThree to label_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:title="FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" />
    <link:label xlink:type="resource" xlink:label="label_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xml:lang="en-US" id="label_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">2029</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="label_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:title="Label : FiniteLivedIntangibleAssetsAmortizationExpenseYearFour to label_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" />
    <link:label xlink:type="resource" xlink:label="label_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_1" xml:lang="en-US" id="label_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_1">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="label_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_1" xlink:title="Label : FiniteLivedIntangibleAssetsAmortizationExpenseYearFour to label_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:label="FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:title="FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" />
    <link:label xlink:type="resource" xlink:label="label_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xml:lang="en-US" id="label_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive">Thereafter</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:to="label_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:title="Label : FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive to label_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" />
    <link:label xlink:type="resource" xlink:label="label_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_1" xml:lang="en-US" id="label_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_1">Finite-Lived Intangible Asset, Expected Amortization, after Year Five</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:to="label_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_1" xlink:title="Label : FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive to label_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="FiniteLivedIntangibleAssetsNet" xlink:title="FiniteLivedIntangibleAssetsNet" />
    <link:label xlink:type="resource" xlink:label="label_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_FiniteLivedIntangibleAssetsNet" xml:lang="en-US" id="label_FiniteLivedIntangibleAssetsNet">Total</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetsNet" xlink:to="label_FiniteLivedIntangibleAssetsNet" xlink:title="Label : FiniteLivedIntangibleAssetsNet to label_FiniteLivedIntangibleAssetsNet" />
    <link:label xlink:type="resource" xlink:label="label_FiniteLivedIntangibleAssetsNet_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FiniteLivedIntangibleAssetsNet_1" xml:lang="en-US" id="label_FiniteLivedIntangibleAssetsNet_1">Finite-Lived Intangible Assets, Net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetsNet" xlink:to="label_FiniteLivedIntangibleAssetsNet_1" xlink:title="Label : FiniteLivedIntangibleAssetsNet to label_FiniteLivedIntangibleAssetsNet_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:title="FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:label xlink:type="resource" xlink:label="label_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FiniteLivedIntangibleAssetsMajorClassNameDomain" xml:lang="en-US" id="label_FiniteLivedIntangibleAssetsMajorClassNameDomain">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="label_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:title="Label : FiniteLivedIntangibleAssetsMajorClassNameDomain to label_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_StockholdersEquityDetailsTable" xlink:label="StockholdersEquityDetailsTable" xlink:title="StockholdersEquityDetailsTable" />
    <link:label xlink:type="resource" xlink:label="label_StockholdersEquityDetailsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StockholdersEquityDetailsTable" xml:lang="en-US" id="label_StockholdersEquityDetailsTable">Stockholders' Equity (Details) [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquityDetailsTable" xlink:to="label_StockholdersEquityDetailsTable" xlink:title="Label : StockholdersEquityDetailsTable to label_StockholdersEquityDetailsTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="OverAllotmentOptionMember" xlink:title="OverAllotmentOptionMember" />
    <link:label xlink:type="resource" xlink:label="label_OverAllotmentOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_OverAllotmentOptionMember" xml:lang="en-US" id="label_OverAllotmentOptionMember">Over-Allotment Option [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OverAllotmentOptionMember" xlink:to="label_OverAllotmentOptionMember" xlink:title="Label : OverAllotmentOptionMember to label_OverAllotmentOptionMember" />
    <link:label xlink:type="resource" xlink:label="label_OverAllotmentOptionMember_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_OverAllotmentOptionMember_1" xml:lang="en-US" id="label_OverAllotmentOptionMember_1">Over-Allotment Option [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OverAllotmentOptionMember" xlink:to="label_OverAllotmentOptionMember_1" xlink:title="Label : OverAllotmentOptionMember to label_OverAllotmentOptionMember_1" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_SeriesANonVotingConvertiblePreferredStockMember" xlink:label="SeriesANonVotingConvertiblePreferredStockMember" xlink:title="SeriesANonVotingConvertiblePreferredStockMember" />
    <link:label xlink:type="resource" xlink:label="label_SeriesANonVotingConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_SeriesANonVotingConvertiblePreferredStockMember" xml:lang="en-US" id="label_SeriesANonVotingConvertiblePreferredStockMember">Series A Non-Voting Convertible Preferred Stock [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeriesANonVotingConvertiblePreferredStockMember" xlink:to="label_SeriesANonVotingConvertiblePreferredStockMember" xlink:title="Label : SeriesANonVotingConvertiblePreferredStockMember to label_SeriesANonVotingConvertiblePreferredStockMember" />
    <link:label xlink:type="resource" xlink:label="label_SeriesANonVotingConvertiblePreferredStockMember_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_SeriesANonVotingConvertiblePreferredStockMember_1" xml:lang="en-US" id="label_SeriesANonVotingConvertiblePreferredStockMember_1">Series ANon Voting Convertible Preferred Stock Member</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeriesANonVotingConvertiblePreferredStockMember" xlink:to="label_SeriesANonVotingConvertiblePreferredStockMember_1" xlink:title="Label : SeriesANonVotingConvertiblePreferredStockMember to label_SeriesANonVotingConvertiblePreferredStockMember_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="RelatedPartyTransactionAxis" xlink:title="RelatedPartyTransactionAxis" />
    <link:label xlink:type="resource" xlink:label="label_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_RelatedPartyTransactionAxis" xml:lang="en-US" id="label_RelatedPartyTransactionAxis">Related Party Transaction [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RelatedPartyTransactionAxis" xlink:to="label_RelatedPartyTransactionAxis" xlink:title="Label : RelatedPartyTransactionAxis to label_RelatedPartyTransactionAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="RelatedPartyTransactionDomain" xlink:title="RelatedPartyTransactionDomain" />
    <link:label xlink:type="resource" xlink:label="label_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_RelatedPartyTransactionDomain" xml:lang="en-US" id="label_RelatedPartyTransactionDomain">Related Party Transaction [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RelatedPartyTransactionDomain" xlink:to="label_RelatedPartyTransactionDomain" xlink:title="Label : RelatedPartyTransactionDomain to label_RelatedPartyTransactionDomain" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_WallachBethCapitalLLCMember" xlink:label="WallachBethCapitalLLCMember" xlink:title="WallachBethCapitalLLCMember" />
    <link:label xlink:type="resource" xlink:label="label_WallachBethCapitalLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_WallachBethCapitalLLCMember" xml:lang="en-US" id="label_WallachBethCapitalLLCMember">WallachBeth Capital LLC [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WallachBethCapitalLLCMember" xlink:to="label_WallachBethCapitalLLCMember" xlink:title="Label : WallachBethCapitalLLCMember to label_WallachBethCapitalLLCMember" />
    <link:label xlink:type="resource" xlink:label="label_WallachBethCapitalLLCMember_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_WallachBethCapitalLLCMember_1" xml:lang="en-US" id="label_WallachBethCapitalLLCMember_1">Wallach Beth Capital LLCMember</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WallachBethCapitalLLCMember" xlink:to="label_WallachBethCapitalLLCMember_1" xlink:title="Label : WallachBethCapitalLLCMember to label_WallachBethCapitalLLCMember_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:label xlink:type="resource" xlink:label="label_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_RelatedPartyTransactionsByRelatedPartyAxis" xml:lang="en-US" id="label_RelatedPartyTransactionsByRelatedPartyAxis">Related and Nonrelated Parties [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="label_RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="Label : RelatedPartyTransactionsByRelatedPartyAxis to label_RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="RelatedPartyDomain" xlink:title="RelatedPartyDomain" />
    <link:label xlink:type="resource" xlink:label="label_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_RelatedPartyDomain" xml:lang="en-US" id="label_RelatedPartyDomain">Related and Nonrelated Parties [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RelatedPartyDomain" xlink:to="label_RelatedPartyDomain" xlink:title="Label : RelatedPartyDomain to label_RelatedPartyDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardDateAxis" xlink:label="AwardDateAxis" xlink:title="AwardDateAxis" />
    <link:label xlink:type="resource" xlink:label="label_AwardDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AwardDateAxis" xml:lang="en-US" id="label_AwardDateAxis">Award Date [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AwardDateAxis" xlink:to="label_AwardDateAxis" xlink:title="Label : AwardDateAxis to label_AwardDateAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardDateDomain" xlink:label="AwardDateDomain" xlink:title="AwardDateDomain" />
    <link:label xlink:type="resource" xlink:label="label_AwardDateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AwardDateDomain" xml:lang="en-US" id="label_AwardDateDomain">Award Date [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AwardDateDomain" xlink:to="label_AwardDateDomain" xlink:title="Label : AwardDateDomain to label_AwardDateDomain" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_January2024OfferingMember" xlink:label="January2024OfferingMember" xlink:title="January2024OfferingMember" />
    <link:label xlink:type="resource" xlink:label="label_January2024OfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_January2024OfferingMember" xml:lang="en-US" id="label_January2024OfferingMember">January 2024 Offering [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="January2024OfferingMember" xlink:to="label_January2024OfferingMember" xlink:title="Label : January2024OfferingMember to label_January2024OfferingMember" />
    <link:label xlink:type="resource" xlink:label="label_January2024OfferingMember_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_January2024OfferingMember_1" xml:lang="en-US" id="label_January2024OfferingMember_1">January2024 Offering Member</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="January2024OfferingMember" xlink:to="label_January2024OfferingMember_1" xlink:title="Label : January2024OfferingMember to label_January2024OfferingMember_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="ClassOfWarrantOrRightAxis" xlink:title="ClassOfWarrantOrRightAxis" />
    <link:label xlink:type="resource" xlink:label="label_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ClassOfWarrantOrRightAxis" xml:lang="en-US" id="label_ClassOfWarrantOrRightAxis">Class of Warrant or Right [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightAxis" xlink:to="label_ClassOfWarrantOrRightAxis" xlink:title="Label : ClassOfWarrantOrRightAxis to label_ClassOfWarrantOrRightAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="ClassOfWarrantOrRightDomain" xlink:title="ClassOfWarrantOrRightDomain" />
    <link:label xlink:type="resource" xlink:label="label_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ClassOfWarrantOrRightDomain" xml:lang="en-US" id="label_ClassOfWarrantOrRightDomain">Class of Warrant or Right [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightDomain" xlink:to="label_ClassOfWarrantOrRightDomain" xlink:title="Label : ClassOfWarrantOrRightDomain to label_ClassOfWarrantOrRightDomain" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_PlacementAgentWarrantsMember" xlink:label="PlacementAgentWarrantsMember" xlink:title="PlacementAgentWarrantsMember" />
    <link:label xlink:type="resource" xlink:label="label_PlacementAgentWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_PlacementAgentWarrantsMember" xml:lang="en-US" id="label_PlacementAgentWarrantsMember">Placement Agent Warrants [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PlacementAgentWarrantsMember" xlink:to="label_PlacementAgentWarrantsMember" xlink:title="Label : PlacementAgentWarrantsMember to label_PlacementAgentWarrantsMember" />
    <link:label xlink:type="resource" xlink:label="label_PlacementAgentWarrantsMember_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_PlacementAgentWarrantsMember_1" xml:lang="en-US" id="label_PlacementAgentWarrantsMember_1">Placement Agent Warrants Member</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PlacementAgentWarrantsMember" xlink:to="label_PlacementAgentWarrantsMember_1" xlink:title="Label : PlacementAgentWarrantsMember to label_PlacementAgentWarrantsMember_1" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_PreFundedWarrantMember" xlink:label="PreFundedWarrantMember" xlink:title="PreFundedWarrantMember" />
    <link:label xlink:type="resource" xlink:label="label_PreFundedWarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_PreFundedWarrantMember" xml:lang="en-US" id="label_PreFundedWarrantMember">Pre-Funded Warrant [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreFundedWarrantMember" xlink:to="label_PreFundedWarrantMember" xlink:title="Label : PreFundedWarrantMember to label_PreFundedWarrantMember" />
    <link:label xlink:type="resource" xlink:label="label_PreFundedWarrantMember_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_PreFundedWarrantMember_1" xml:lang="en-US" id="label_PreFundedWarrantMember_1">Pre Funded Warrant Member</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreFundedWarrantMember" xlink:to="label_PreFundedWarrantMember_1" xlink:title="Label : PreFundedWarrantMember to label_PreFundedWarrantMember_1" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_JanuaryTwoThousandTwentyFourPreFundedWarrantsMember" xlink:label="JanuaryTwoThousandTwentyFourPreFundedWarrantsMember" xlink:title="JanuaryTwoThousandTwentyFourPreFundedWarrantsMember" />
    <link:label xlink:type="resource" xlink:label="label_JanuaryTwoThousandTwentyFourPreFundedWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_JanuaryTwoThousandTwentyFourPreFundedWarrantsMember" xml:lang="en-US" id="label_JanuaryTwoThousandTwentyFourPreFundedWarrantsMember">January 2024 Pre-Funded Warrants [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JanuaryTwoThousandTwentyFourPreFundedWarrantsMember" xlink:to="label_JanuaryTwoThousandTwentyFourPreFundedWarrantsMember" xlink:title="Label : JanuaryTwoThousandTwentyFourPreFundedWarrantsMember to label_JanuaryTwoThousandTwentyFourPreFundedWarrantsMember" />
    <link:label xlink:type="resource" xlink:label="label_JanuaryTwoThousandTwentyFourPreFundedWarrantsMember_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_JanuaryTwoThousandTwentyFourPreFundedWarrantsMember_1" xml:lang="en-US" id="label_JanuaryTwoThousandTwentyFourPreFundedWarrantsMember_1">January Two Thousand Twenty Four Pre Funded Warrants Member</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JanuaryTwoThousandTwentyFourPreFundedWarrantsMember" xlink:to="label_JanuaryTwoThousandTwentyFourPreFundedWarrantsMember_1" xlink:title="Label : JanuaryTwoThousandTwentyFourPreFundedWarrantsMember to label_JanuaryTwoThousandTwentyFourPreFundedWarrantsMember_1" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_JanuaryTwoThousandTwentyFourWarrantMember" xlink:label="JanuaryTwoThousandTwentyFourWarrantMember" xlink:title="JanuaryTwoThousandTwentyFourWarrantMember" />
    <link:label xlink:type="resource" xlink:label="label_JanuaryTwoThousandTwentyFourWarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_JanuaryTwoThousandTwentyFourWarrantMember" xml:lang="en-US" id="label_JanuaryTwoThousandTwentyFourWarrantMember">January 2024 Warrants [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JanuaryTwoThousandTwentyFourWarrantMember" xlink:to="label_JanuaryTwoThousandTwentyFourWarrantMember" xlink:title="Label : JanuaryTwoThousandTwentyFourWarrantMember to label_JanuaryTwoThousandTwentyFourWarrantMember" />
    <link:label xlink:type="resource" xlink:label="label_JanuaryTwoThousandTwentyFourWarrantMember_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_JanuaryTwoThousandTwentyFourWarrantMember_1" xml:lang="en-US" id="label_JanuaryTwoThousandTwentyFourWarrantMember_1">January Two Thousand Twenty Four Warrant Member</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JanuaryTwoThousandTwentyFourWarrantMember" xlink:to="label_JanuaryTwoThousandTwentyFourWarrantMember_1" xlink:title="Label : JanuaryTwoThousandTwentyFourWarrantMember to label_JanuaryTwoThousandTwentyFourWarrantMember_1" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_JanuaryRepresentativeWarrantsMember" xlink:label="JanuaryRepresentativeWarrantsMember" xlink:title="JanuaryRepresentativeWarrantsMember" />
    <link:label xlink:type="resource" xlink:label="label_JanuaryRepresentativeWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_JanuaryRepresentativeWarrantsMember" xml:lang="en-US" id="label_JanuaryRepresentativeWarrantsMember">January 2024 Representative Warrants [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JanuaryRepresentativeWarrantsMember" xlink:to="label_JanuaryRepresentativeWarrantsMember" xlink:title="Label : JanuaryRepresentativeWarrantsMember to label_JanuaryRepresentativeWarrantsMember" />
    <link:label xlink:type="resource" xlink:label="label_JanuaryRepresentativeWarrantsMember_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_JanuaryRepresentativeWarrantsMember_1" xml:lang="en-US" id="label_JanuaryRepresentativeWarrantsMember_1">January Representative Warrants Member</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JanuaryRepresentativeWarrantsMember" xlink:to="label_JanuaryRepresentativeWarrantsMember_1" xlink:title="Label : JanuaryRepresentativeWarrantsMember to label_JanuaryRepresentativeWarrantsMember_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems" xlink:label="ClassOfStockLineItems" xlink:title="ClassOfStockLineItems" />
    <link:label xlink:type="resource" xlink:label="label_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ClassOfStockLineItems" xml:lang="en-US" id="label_ClassOfStockLineItems">Stockholders&#x2019; Equity [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfStockLineItems" xlink:to="label_ClassOfStockLineItems" xlink:title="Label : ClassOfStockLineItems to label_ClassOfStockLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ExcessStockSharesAuthorized" xlink:label="ExcessStockSharesAuthorized" xlink:title="ExcessStockSharesAuthorized" />
    <link:label xlink:type="resource" xlink:label="label_ExcessStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ExcessStockSharesAuthorized" xml:lang="en-US" id="label_ExcessStockSharesAuthorized">Designated shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ExcessStockSharesAuthorized" xlink:to="label_ExcessStockSharesAuthorized" xlink:title="Label : ExcessStockSharesAuthorized to label_ExcessStockSharesAuthorized" />
    <link:label xlink:type="resource" xlink:label="label_ExcessStockSharesAuthorized_1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_ExcessStockSharesAuthorized_1" xml:lang="en-US" id="label_ExcessStockSharesAuthorized_1">Designated shares (in Shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ExcessStockSharesAuthorized" xlink:to="label_ExcessStockSharesAuthorized_1" xlink:title="Label : ExcessStockSharesAuthorized to label_ExcessStockSharesAuthorized_1" />
    <link:label xlink:type="resource" xlink:label="label_ExcessStockSharesAuthorized_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ExcessStockSharesAuthorized_2" xml:lang="en-US" id="label_ExcessStockSharesAuthorized_2">Excess Stock, Shares Authorized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ExcessStockSharesAuthorized" xlink:to="label_ExcessStockSharesAuthorized_2" xlink:title="Label : ExcessStockSharesAuthorized to label_ExcessStockSharesAuthorized_2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">Additional common share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:title="Label : ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized to label_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_1" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_1">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_1" xlink:title="Label : ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized to label_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:title="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:label xlink:type="resource" xlink:label="label_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xml:lang="en-US" id="label_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">Exercise of warrants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="label_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:title="Label : ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights to label_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:label xlink:type="resource" xlink:label="label_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_1" xml:lang="en-US" id="label_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_1">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="label_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_1" xlink:title="Label : ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights to label_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="SaleOfStockNumberOfSharesIssuedInTransaction" xlink:title="SaleOfStockNumberOfSharesIssuedInTransaction" />
    <link:label xlink:type="resource" xlink:label="label_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_SaleOfStockNumberOfSharesIssuedInTransaction" xml:lang="en-US" id="label_SaleOfStockNumberOfSharesIssuedInTransaction">Aggregate shares of common stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="label_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:title="Label : SaleOfStockNumberOfSharesIssuedInTransaction to label_SaleOfStockNumberOfSharesIssuedInTransaction" />
    <link:label xlink:type="resource" xlink:label="label_SaleOfStockNumberOfSharesIssuedInTransaction_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_SaleOfStockNumberOfSharesIssuedInTransaction_1" xml:lang="en-US" id="label_SaleOfStockNumberOfSharesIssuedInTransaction_1">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="label_SaleOfStockNumberOfSharesIssuedInTransaction_1" xlink:title="Label : SaleOfStockNumberOfSharesIssuedInTransaction to label_SaleOfStockNumberOfSharesIssuedInTransaction_1" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_UnitsIssuedDuringPeriodSharesNewIssues" xlink:label="UnitsIssuedDuringPeriodSharesNewIssues" xlink:title="UnitsIssuedDuringPeriodSharesNewIssues" />
    <link:label xlink:type="resource" xlink:label="label_UnitsIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_UnitsIssuedDuringPeriodSharesNewIssues" xml:lang="en-US" id="label_UnitsIssuedDuringPeriodSharesNewIssues">Units issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UnitsIssuedDuringPeriodSharesNewIssues" xlink:to="label_UnitsIssuedDuringPeriodSharesNewIssues" xlink:title="Label : UnitsIssuedDuringPeriodSharesNewIssues to label_UnitsIssuedDuringPeriodSharesNewIssues" />
    <link:label xlink:type="resource" xlink:label="label_UnitsIssuedDuringPeriodSharesNewIssues_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_UnitsIssuedDuringPeriodSharesNewIssues_1" xml:lang="en-US" id="label_UnitsIssuedDuringPeriodSharesNewIssues_1">Number of units issued during the period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UnitsIssuedDuringPeriodSharesNewIssues" xlink:to="label_UnitsIssuedDuringPeriodSharesNewIssues_1" xlink:title="Label : UnitsIssuedDuringPeriodSharesNewIssues to label_UnitsIssuedDuringPeriodSharesNewIssues_1" />
    <link:label xlink:type="resource" xlink:label="label_UnitsIssuedDuringPeriodSharesNewIssues_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_UnitsIssuedDuringPeriodSharesNewIssues_2" xml:lang="en-US" id="label_UnitsIssuedDuringPeriodSharesNewIssues_2">Units Issued During Period Shares New Issues</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UnitsIssuedDuringPeriodSharesNewIssues" xlink:to="label_UnitsIssuedDuringPeriodSharesNewIssues_2" xlink:title="Label : UnitsIssuedDuringPeriodSharesNewIssues to label_UnitsIssuedDuringPeriodSharesNewIssues_2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="ClassOfWarrantOrRightOutstanding" xlink:title="ClassOfWarrantOrRightOutstanding" />
    <link:label xlink:type="resource" xlink:label="label_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ClassOfWarrantOrRightOutstanding" xml:lang="en-US" id="label_ClassOfWarrantOrRightOutstanding">Warrant shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightOutstanding" xlink:to="label_ClassOfWarrantOrRightOutstanding" xlink:title="Label : ClassOfWarrantOrRightOutstanding to label_ClassOfWarrantOrRightOutstanding" />
    <link:label xlink:type="resource" xlink:label="label_ClassOfWarrantOrRightOutstanding_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ClassOfWarrantOrRightOutstanding_1" xml:lang="en-US" id="label_ClassOfWarrantOrRightOutstanding_1">Class of Warrant or Right, Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightOutstanding" xlink:to="label_ClassOfWarrantOrRightOutstanding_1" xlink:title="Label : ClassOfWarrantOrRightOutstanding to label_ClassOfWarrantOrRightOutstanding_1" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_SharesOfWarrants" xlink:label="SharesOfWarrants" xlink:title="SharesOfWarrants" />
    <link:label xlink:type="resource" xlink:label="label_SharesOfWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_SharesOfWarrants" xml:lang="en-US" id="label_SharesOfWarrants">Shares warrants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharesOfWarrants" xlink:to="label_SharesOfWarrants" xlink:title="Label : SharesOfWarrants to label_SharesOfWarrants" />
    <link:label xlink:type="resource" xlink:label="label_SharesOfWarrants_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_SharesOfWarrants_1" xml:lang="en-US" id="label_SharesOfWarrants_1">Number of shares warrants.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharesOfWarrants" xlink:to="label_SharesOfWarrants_1" xlink:title="Label : SharesOfWarrants to label_SharesOfWarrants_1" />
    <link:label xlink:type="resource" xlink:label="label_SharesOfWarrants_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_SharesOfWarrants_2" xml:lang="en-US" id="label_SharesOfWarrants_2">Shares Of Warrants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharesOfWarrants" xlink:to="label_SharesOfWarrants_2" xlink:title="Label : SharesOfWarrants to label_SharesOfWarrants_2" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_NumberofWarrantExercisable" xlink:label="NumberofWarrantExercisable" xlink:title="NumberofWarrantExercisable" />
    <link:label xlink:type="resource" xlink:label="label_NumberofWarrantExercisable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_NumberofWarrantExercisable" xml:lang="en-US" id="label_NumberofWarrantExercisable">Number of warrant exercisable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberofWarrantExercisable" xlink:to="label_NumberofWarrantExercisable" xlink:title="Label : NumberofWarrantExercisable to label_NumberofWarrantExercisable" />
    <link:label xlink:type="resource" xlink:label="label_NumberofWarrantExercisable_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_NumberofWarrantExercisable_1" xml:lang="en-US" id="label_NumberofWarrantExercisable_1">Number of warrants exercisable.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberofWarrantExercisable" xlink:to="label_NumberofWarrantExercisable_1" xlink:title="Label : NumberofWarrantExercisable to label_NumberofWarrantExercisable_1" />
    <link:label xlink:type="resource" xlink:label="label_NumberofWarrantExercisable_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_NumberofWarrantExercisable_2" xml:lang="en-US" id="label_NumberofWarrantExercisable_2">Numberof Warrant Exercisable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberofWarrantExercisable" xlink:to="label_NumberofWarrantExercisable_2" xlink:title="Label : NumberofWarrantExercisable to label_NumberofWarrantExercisable_2" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_NumberOfShares" xlink:label="NumberOfShares" xlink:title="NumberOfShares" />
    <link:label xlink:type="resource" xlink:label="label_NumberOfShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_NumberOfShares" xml:lang="en-US" id="label_NumberOfShares">Number of shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfShares" xlink:to="label_NumberOfShares" xlink:title="Label : NumberOfShares to label_NumberOfShares" />
    <link:label xlink:type="resource" xlink:label="label_NumberOfShares_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_NumberOfShares_1" xml:lang="en-US" id="label_NumberOfShares_1">Number of shares purchased or issued.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfShares" xlink:to="label_NumberOfShares_1" xlink:title="Label : NumberOfShares to label_NumberOfShares_1" />
    <link:label xlink:type="resource" xlink:label="label_NumberOfShares_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_NumberOfShares_2" xml:lang="en-US" id="label_NumberOfShares_2">Number Of Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfShares" xlink:to="label_NumberOfShares_2" xlink:title="Label : NumberOfShares to label_NumberOfShares_2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested" xlink:label="ProceedsFromDivestitureOfBusinessesNetOfCashDivested" xlink:title="ProceedsFromDivestitureOfBusinessesNetOfCashDivested" />
    <link:label xlink:type="resource" xlink:label="label_ProceedsFromDivestitureOfBusinessesNetOfCashDivested" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ProceedsFromDivestitureOfBusinessesNetOfCashDivested" xml:lang="en-US" id="label_ProceedsFromDivestitureOfBusinessesNetOfCashDivested">Cash proceeds (in Dollars)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromDivestitureOfBusinessesNetOfCashDivested" xlink:to="label_ProceedsFromDivestitureOfBusinessesNetOfCashDivested" xlink:title="Label : ProceedsFromDivestitureOfBusinessesNetOfCashDivested to label_ProceedsFromDivestitureOfBusinessesNetOfCashDivested" />
    <link:label xlink:type="resource" xlink:label="label_ProceedsFromDivestitureOfBusinessesNetOfCashDivested_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ProceedsFromDivestitureOfBusinessesNetOfCashDivested_1" xml:lang="en-US" id="label_ProceedsFromDivestitureOfBusinessesNetOfCashDivested_1">Proceeds from Divestiture of Businesses, Net of Cash Divested</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromDivestitureOfBusinessesNetOfCashDivested" xlink:to="label_ProceedsFromDivestitureOfBusinessesNetOfCashDivested_1" xlink:title="Label : ProceedsFromDivestitureOfBusinessesNetOfCashDivested to label_ProceedsFromDivestitureOfBusinessesNetOfCashDivested_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="PreferredStockDividendRatePercentage" xlink:title="PreferredStockDividendRatePercentage" />
    <link:label xlink:type="resource" xlink:label="label_PreferredStockDividendRatePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_PreferredStockDividendRatePercentage" xml:lang="en-US" id="label_PreferredStockDividendRatePercentage">Dividends percentage</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockDividendRatePercentage" xlink:to="label_PreferredStockDividendRatePercentage" xlink:title="Label : PreferredStockDividendRatePercentage to label_PreferredStockDividendRatePercentage" />
    <link:label xlink:type="resource" xlink:label="label_PreferredStockDividendRatePercentage_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_PreferredStockDividendRatePercentage_1" xml:lang="en-US" id="label_PreferredStockDividendRatePercentage_1">Preferred Stock, Dividend Rate, Percentage</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockDividendRatePercentage" xlink:to="label_PreferredStockDividendRatePercentage_1" xlink:title="Label : PreferredStockDividendRatePercentage to label_PreferredStockDividendRatePercentage_1" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_ScheduleOfEquityClassifiedWarrantsAbstract" xlink:label="ScheduleOfEquityClassifiedWarrantsAbstract" xlink:title="ScheduleOfEquityClassifiedWarrantsAbstract" />
    <link:label xlink:type="resource" xlink:label="label_ScheduleOfEquityClassifiedWarrantsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ScheduleOfEquityClassifiedWarrantsAbstract" xml:lang="en-US" id="label_ScheduleOfEquityClassifiedWarrantsAbstract">Schedule Of Equity Classified Warrants Abstract</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfEquityClassifiedWarrantsAbstract" xlink:to="label_ScheduleOfEquityClassifiedWarrantsAbstract" xlink:title="Label : ScheduleOfEquityClassifiedWarrantsAbstract to label_ScheduleOfEquityClassifiedWarrantsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="ClassOfWarrantOrRightTable" xlink:title="ClassOfWarrantOrRightTable" />
    <link:label xlink:type="resource" xlink:label="label_ClassOfWarrantOrRightTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ClassOfWarrantOrRightTable" xml:lang="en-US" id="label_ClassOfWarrantOrRightTable">Class of Warrant or Right [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightTable" xlink:to="label_ClassOfWarrantOrRightTable" xlink:title="Label : ClassOfWarrantOrRightTable to label_ClassOfWarrantOrRightTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="ClassOfWarrantOrRightLineItems" xlink:title="ClassOfWarrantOrRightLineItems" />
    <link:label xlink:type="resource" xlink:label="label_ClassOfWarrantOrRightLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ClassOfWarrantOrRightLineItems" xml:lang="en-US" id="label_ClassOfWarrantOrRightLineItems">Schedule of Equity-Classified Warrants [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightLineItems" xlink:to="label_ClassOfWarrantOrRightLineItems" xlink:title="Label : ClassOfWarrantOrRightLineItems to label_ClassOfWarrantOrRightLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">Number of Warrants, Total outstanding, Beginning</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:title="Label : ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber to label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1">Number of Warrants, Total outstanding, Ending</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1" xlink:title="Label : ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber to label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2" xlink:title="Label : ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber to label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">Weighted Average Exercise Price, Total outstanding, Beginning</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:title="Label : ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue to label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_1" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_1" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_1">Weighted Average Exercise Price, Total outstanding, Ending</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_1" xlink:title="Label : ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue to label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_1" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2" xlink:title="Label : ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue to label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">Weighted Average Remaining Contractual Life (Years), Total outstanding, Beginning</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:title="Label : ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms to label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_1" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_1">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_1" xlink:title="Label : ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms to label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">Weighted Average Exercise Price, Granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:title="Label : ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue to label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1" xlink:title="Label : ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue to label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsGranted" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsGranted" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsGranted" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsGranted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsGranted" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsGranted">Weighted Average Remaining Contractual Life (Years), Granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsGranted" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsGranted" xlink:title="Label : ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsGranted to label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsGranted" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsGranted_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsGranted_1" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsGranted_1">Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsGranted" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsGranted_1" xlink:title="Label : ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsGranted to label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsGranted_1" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsGranted_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsGranted_2" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsGranted_2">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Weighted Average Remaining Contractual Life Years Granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsGranted" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsGranted_2" xlink:title="Label : ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsGranted to label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsGranted_2" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfWarrantsExercised" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfWarrantsExercised" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfWarrantsExercised" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfWarrantsExercised" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfWarrantsExercised">Number of Warrants, Exercised</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfWarrantsExercised" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfWarrantsExercised" xlink:title="Label : ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfWarrantsExercised to label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfWarrantsExercised" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfWarrantsExercised_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfWarrantsExercised_1" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfWarrantsExercised_1">The number of number of warrants, exercised.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfWarrantsExercised" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfWarrantsExercised_1" xlink:title="Label : ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfWarrantsExercised to label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfWarrantsExercised_1" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfWarrantsExercised_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfWarrantsExercised_2" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfWarrantsExercised_2">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Number Of Warrants Exercised</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfWarrantsExercised" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfWarrantsExercised_2" xlink:title="Label : ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfWarrantsExercised to label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfWarrantsExercised_2" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsExercised" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsExercised" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsExercised" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsExercised" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsExercised">Weighted Average Remaining Contractual Life (Years), Exercised</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsExercised" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsExercised" xlink:title="Label : ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsExercised to label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsExercised" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsExercised_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsExercised_1" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsExercised_1">Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsExercised" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsExercised_1" xlink:title="Label : ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsExercised to label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsExercised_1" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsExercised_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsExercised_2" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsExercised_2">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Weighted Average Remaining Contractual Life Years Exercised</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsExercised" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsExercised_2" xlink:title="Label : ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsExercised to label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsExercised_2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">Number of Warrants, Forfeited</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:title="Label : ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod to label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_1" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_1">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_1" xlink:title="Label : ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod to label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">Weighted Average Exercise Price, Forfeited</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:title="Label : ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue to label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_1" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_1">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_1" xlink:title="Label : ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue to label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_1" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsForfeited" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsForfeited" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsForfeited" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsForfeited" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsForfeited" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsForfeited">Weighted Average Remaining Contractual Life (Years), Forfeited</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsForfeited" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsForfeited" xlink:title="Label : ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsForfeited to label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsForfeited" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsForfeited_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsForfeited_1" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsForfeited_1">Weighted average remaining contractual life (years), forfeited.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsForfeited" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsForfeited_1" xlink:title="Label : ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsForfeited to label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsForfeited_1" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsForfeited_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsForfeited_2" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsForfeited_2">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Weighted Average Remaining Contractual Life Years Forfeited</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsForfeited" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsForfeited_2" xlink:title="Label : ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsForfeited to label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsForfeited_2" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfWarrantsExpired" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfWarrantsExpired" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfWarrantsExpired" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfWarrantsExpired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfWarrantsExpired" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfWarrantsExpired">Number of Warrants, Expired</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfWarrantsExpired" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfWarrantsExpired" xlink:title="Label : ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfWarrantsExpired to label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfWarrantsExpired" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfWarrantsExpired_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfWarrantsExpired_1" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfWarrantsExpired_1">Number of number of warrants, expired.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfWarrantsExpired" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfWarrantsExpired_1" xlink:title="Label : ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfWarrantsExpired to label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfWarrantsExpired_1" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfWarrantsExpired_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfWarrantsExpired_2" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfWarrantsExpired_2">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Number Of Warrants Expired</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfWarrantsExpired" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfWarrantsExpired_2" xlink:title="Label : ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfWarrantsExpired to label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfWarrantsExpired_2" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExpired" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExpired" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExpired" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExpired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExpired" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExpired">Weighted Average Exercise Price, Expired</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExpired" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExpired" xlink:title="Label : ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExpired to label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExpired" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExpired_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExpired_1" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExpired_1">Weighted average exercise price, expired.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExpired" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExpired_1" xlink:title="Label : ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExpired to label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExpired_1" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExpired_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExpired_2" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExpired_2">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Weighted Average Exercise Price Expired</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExpired" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExpired_2" xlink:title="Label : ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExpired to label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExpired_2" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsExpired" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsExpired" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsExpired" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsExpired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsExpired" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsExpired">Weighted Average Remaining Contractual Life (Years), Expired</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsExpired" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsExpired" xlink:title="Label : ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsExpired to label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsExpired" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsExpired_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsExpired_1" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsExpired_1">Weighted average remaining contractual life (years), expired.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsExpired" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsExpired_1" xlink:title="Label : ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsExpired to label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsExpired_1" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsExpired_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsExpired_2" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsExpired_2">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Weighted Average Remaining Contractual Life Years Expired</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsExpired" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsExpired_2" xlink:title="Label : ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsExpired to label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsExpired_2" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms1" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms1" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms1" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms1" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms1">Weighted Average Remaining Contractual Life (Years), Total outstanding, Ending</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms1" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms1" xlink:title="Label : ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms1 to label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms1" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms1_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms1_1" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms1_1">Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms1" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms1_1" xlink:title="Label : ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms1 to label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms1_1" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms1_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms1_2" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms1_2">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms1</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms1" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms1_2" xlink:title="Label : ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms1 to label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms1_2" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableOutstandingWeightedAverageRemainingContractualTerms" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableOutstandingWeightedAverageRemainingContractualTerms" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableOutstandingWeightedAverageRemainingContractualTerms" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableOutstandingWeightedAverageRemainingContractualTerms" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableOutstandingWeightedAverageRemainingContractualTerms" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableOutstandingWeightedAverageRemainingContractualTerms">Weighted Average Remaining Contractual Life (Years),Total exercisable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableOutstandingWeightedAverageRemainingContractualTerms" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableOutstandingWeightedAverageRemainingContractualTerms" xlink:title="Label : ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableOutstandingWeightedAverageRemainingContractualTerms to label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableOutstandingWeightedAverageRemainingContractualTerms" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableOutstandingWeightedAverageRemainingContractualTerms_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableOutstandingWeightedAverageRemainingContractualTerms_1" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableOutstandingWeightedAverageRemainingContractualTerms_1">Weighted average remaining contractual term exercisable for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableOutstandingWeightedAverageRemainingContractualTerms" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableOutstandingWeightedAverageRemainingContractualTerms_1" xlink:title="Label : ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableOutstandingWeightedAverageRemainingContractualTerms to label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableOutstandingWeightedAverageRemainingContractualTerms_1" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableOutstandingWeightedAverageRemainingContractualTerms_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableOutstandingWeightedAverageRemainingContractualTerms_2" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableOutstandingWeightedAverageRemainingContractualTerms_2">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercisable Outstanding Weighted Average Remaining Contractual Terms</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableOutstandingWeightedAverageRemainingContractualTerms" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableOutstandingWeightedAverageRemainingContractualTerms_2" xlink:title="Label : ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableOutstandingWeightedAverageRemainingContractualTerms to label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableOutstandingWeightedAverageRemainingContractualTerms_2" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_DebtDetailsTable" xlink:label="DebtDetailsTable" xlink:title="DebtDetailsTable" />
    <link:label xlink:type="resource" xlink:label="label_DebtDetailsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DebtDetailsTable" xml:lang="en-US" id="label_DebtDetailsTable">Debt (Details) [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtDetailsTable" xlink:to="label_DebtDetailsTable" xlink:title="Label : DebtDetailsTable to label_DebtDetailsTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis" xlink:label="DebtInstrumentAxis" xlink:title="DebtInstrumentAxis" />
    <link:label xlink:type="resource" xlink:label="label_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DebtInstrumentAxis" xml:lang="en-US" id="label_DebtInstrumentAxis">Debt Instrument [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentAxis" xlink:to="label_DebtInstrumentAxis" xlink:title="Label : DebtInstrumentAxis to label_DebtInstrumentAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="DebtInstrumentNameDomain" xlink:title="DebtInstrumentNameDomain" />
    <link:label xlink:type="resource" xlink:label="label_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DebtInstrumentNameDomain" xml:lang="en-US" id="label_DebtInstrumentNameDomain">Debt Instrument, Name [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentNameDomain" xlink:to="label_DebtInstrumentNameDomain" xlink:title="Label : DebtInstrumentNameDomain to label_DebtInstrumentNameDomain" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_SmallBusinessAdministrationMember" xlink:label="SmallBusinessAdministrationMember" xlink:title="SmallBusinessAdministrationMember" />
    <link:label xlink:type="resource" xlink:label="label_SmallBusinessAdministrationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_SmallBusinessAdministrationMember" xml:lang="en-US" id="label_SmallBusinessAdministrationMember">Small Business Administration [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SmallBusinessAdministrationMember" xlink:to="label_SmallBusinessAdministrationMember" xlink:title="Label : SmallBusinessAdministrationMember to label_SmallBusinessAdministrationMember" />
    <link:label xlink:type="resource" xlink:label="label_SmallBusinessAdministrationMember_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_SmallBusinessAdministrationMember_1" xml:lang="en-US" id="label_SmallBusinessAdministrationMember_1">Small Business Administration Member</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SmallBusinessAdministrationMember" xlink:to="label_SmallBusinessAdministrationMember_1" xlink:title="Label : SmallBusinessAdministrationMember to label_SmallBusinessAdministrationMember_1" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_BalloonPaymentMember" xlink:label="BalloonPaymentMember" xlink:title="BalloonPaymentMember" />
    <link:label xlink:type="resource" xlink:label="label_BalloonPaymentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_BalloonPaymentMember" xml:lang="en-US" id="label_BalloonPaymentMember">Balloon Payment [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BalloonPaymentMember" xlink:to="label_BalloonPaymentMember" xlink:title="Label : BalloonPaymentMember to label_BalloonPaymentMember" />
    <link:label xlink:type="resource" xlink:label="label_BalloonPaymentMember_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_BalloonPaymentMember_1" xml:lang="en-US" id="label_BalloonPaymentMember_1">Balloon Payment Member</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BalloonPaymentMember" xlink:to="label_BalloonPaymentMember_1" xlink:title="Label : BalloonPaymentMember to label_BalloonPaymentMember_1" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_SBAMember" xlink:label="SBAMember" xlink:title="SBAMember" />
    <link:label xlink:type="resource" xlink:label="label_SBAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_SBAMember" xml:lang="en-US" id="label_SBAMember">SBA [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBAMember" xlink:to="label_SBAMember" xlink:title="Label : SBAMember to label_SBAMember" />
    <link:label xlink:type="resource" xlink:label="label_SBAMember_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_SBAMember_1" xml:lang="en-US" id="label_SBAMember_1">SBAMember</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SBAMember" xlink:to="label_SBAMember_1" xlink:title="Label : SBAMember to label_SBAMember_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="DebtInstrumentLineItems" xlink:title="DebtInstrumentLineItems" />
    <link:label xlink:type="resource" xlink:label="label_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DebtInstrumentLineItems" xml:lang="en-US" id="label_DebtInstrumentLineItems">Debt [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentLineItems" xlink:to="label_DebtInstrumentLineItems" xlink:title="Label : DebtInstrumentLineItems to label_DebtInstrumentLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="DebtInstrumentFaceAmount" xlink:title="DebtInstrumentFaceAmount" />
    <link:label xlink:type="resource" xlink:label="label_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_DebtInstrumentFaceAmount" xml:lang="en-US" id="label_DebtInstrumentFaceAmount">Principal amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentFaceAmount" xlink:to="label_DebtInstrumentFaceAmount" xlink:title="Label : DebtInstrumentFaceAmount to label_DebtInstrumentFaceAmount" />
    <link:label xlink:type="resource" xlink:label="label_DebtInstrumentFaceAmount_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DebtInstrumentFaceAmount_1" xml:lang="en-US" id="label_DebtInstrumentFaceAmount_1">Debt Instrument, Face Amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentFaceAmount" xlink:to="label_DebtInstrumentFaceAmount_1" xlink:title="Label : DebtInstrumentFaceAmount to label_DebtInstrumentFaceAmount_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="DebtInstrumentInterestRateEffectivePercentage" xlink:title="DebtInstrumentInterestRateEffectivePercentage" />
    <link:label xlink:type="resource" xlink:label="label_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_DebtInstrumentInterestRateEffectivePercentage" xml:lang="en-US" id="label_DebtInstrumentInterestRateEffectivePercentage">Annual interest rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentInterestRateEffectivePercentage" xlink:to="label_DebtInstrumentInterestRateEffectivePercentage" xlink:title="Label : DebtInstrumentInterestRateEffectivePercentage to label_DebtInstrumentInterestRateEffectivePercentage" />
    <link:label xlink:type="resource" xlink:label="label_DebtInstrumentInterestRateEffectivePercentage_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DebtInstrumentInterestRateEffectivePercentage_1" xml:lang="en-US" id="label_DebtInstrumentInterestRateEffectivePercentage_1">Debt Instrument, Interest Rate, Effective Percentage</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentInterestRateEffectivePercentage" xlink:to="label_DebtInstrumentInterestRateEffectivePercentage_1" xlink:title="Label : DebtInstrumentInterestRateEffectivePercentage to label_DebtInstrumentInterestRateEffectivePercentage_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" xlink:label="DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" xlink:title="DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" />
    <link:label xlink:type="resource" xlink:label="label_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" xml:lang="en-US" id="label_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid">Balloon payment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" xlink:to="label_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" xlink:title="Label : DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid to label_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" />
    <link:label xlink:type="resource" xlink:label="label_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_1" xml:lang="en-US" id="label_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_1">Debt Instrument, Periodic Payment Terms, Balloon Payment to be Paid</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" xlink:to="label_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_1" xlink:title="Label : DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid to label_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="DebtInstrumentMaturityDate" xlink:title="DebtInstrumentMaturityDate" />
    <link:label xlink:type="resource" xlink:label="label_DebtInstrumentMaturityDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_DebtInstrumentMaturityDate" xml:lang="en-US" id="label_DebtInstrumentMaturityDate">Maturity date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentMaturityDate" xlink:to="label_DebtInstrumentMaturityDate" xlink:title="Label : DebtInstrumentMaturityDate to label_DebtInstrumentMaturityDate" />
    <link:label xlink:type="resource" xlink:label="label_DebtInstrumentMaturityDate_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DebtInstrumentMaturityDate_1" xml:lang="en-US" id="label_DebtInstrumentMaturityDate_1">Debt Instrument, Maturity Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentMaturityDate" xlink:to="label_DebtInstrumentMaturityDate_1" xlink:title="Label : DebtInstrumentMaturityDate to label_DebtInstrumentMaturityDate_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:label="AmortizationOfFinancingCostsAndDiscounts" xlink:title="AmortizationOfFinancingCostsAndDiscounts" />
    <link:label xlink:type="resource" xlink:label="label_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_AmortizationOfFinancingCostsAndDiscounts" xml:lang="en-US" id="label_AmortizationOfFinancingCostsAndDiscounts">Amortization discount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmortizationOfFinancingCostsAndDiscounts" xlink:to="label_AmortizationOfFinancingCostsAndDiscounts" xlink:title="Label : AmortizationOfFinancingCostsAndDiscounts to label_AmortizationOfFinancingCostsAndDiscounts" />
    <link:label xlink:type="resource" xlink:label="label_AmortizationOfFinancingCostsAndDiscounts_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AmortizationOfFinancingCostsAndDiscounts_1" xml:lang="en-US" id="label_AmortizationOfFinancingCostsAndDiscounts_1">Amortization of Debt Issuance Costs and Discounts</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmortizationOfFinancingCostsAndDiscounts" xlink:to="label_AmortizationOfFinancingCostsAndDiscounts_1" xlink:title="Label : AmortizationOfFinancingCostsAndDiscounts to label_AmortizationOfFinancingCostsAndDiscounts_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtCurrent" xlink:label="LongTermDebtCurrent" xlink:title="LongTermDebtCurrent" />
    <link:label xlink:type="resource" xlink:label="label_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_LongTermDebtCurrent" xml:lang="en-US" id="label_LongTermDebtCurrent">Current maturity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongTermDebtCurrent" xlink:to="label_LongTermDebtCurrent" xlink:title="Label : LongTermDebtCurrent to label_LongTermDebtCurrent" />
    <link:label xlink:type="resource" xlink:label="label_LongTermDebtCurrent_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_LongTermDebtCurrent_1" xml:lang="en-US" id="label_LongTermDebtCurrent_1">Long-Term Debt, Current Maturities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongTermDebtCurrent" xlink:to="label_LongTermDebtCurrent_1" xlink:title="Label : LongTermDebtCurrent to label_LongTermDebtCurrent_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtByMaturityAbstract" xlink:label="LongTermDebtByMaturityAbstract" xlink:title="LongTermDebtByMaturityAbstract" />
    <link:label xlink:type="resource" xlink:label="label_LongTermDebtByMaturityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_LongTermDebtByMaturityAbstract" xml:lang="en-US" id="label_LongTermDebtByMaturityAbstract">Schedule of the Current Future Payment Obligations [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongTermDebtByMaturityAbstract" xlink:to="label_LongTermDebtByMaturityAbstract" xlink:title="Label : LongTermDebtByMaturityAbstract to label_LongTermDebtByMaturityAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:title="LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" />
    <link:label xlink:type="resource" xlink:label="label_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xml:lang="en-US" id="label_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">2026</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="label_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:title="Label : LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths to label_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" />
    <link:label xlink:type="resource" xlink:label="label_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_1" xml:lang="en-US" id="label_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_1">Long-Term Debt, Maturity, Year One</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="label_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_1" xlink:title="Label : LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths to label_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:title="LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" />
    <link:label xlink:type="resource" xlink:label="label_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xml:lang="en-US" id="label_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">2027</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="label_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:title="Label : LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo to label_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" />
    <link:label xlink:type="resource" xlink:label="label_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_1" xml:lang="en-US" id="label_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_1">Long-Term Debt, Maturity, Year Two</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="label_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_1" xlink:title="Label : LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo to label_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:title="LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" />
    <link:label xlink:type="resource" xlink:label="label_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xml:lang="en-US" id="label_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">2028</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="label_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:title="Label : LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree to label_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" />
    <link:label xlink:type="resource" xlink:label="label_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_1" xml:lang="en-US" id="label_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_1">Long-Term Debt, Maturity, Year Three</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="label_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_1" xlink:title="Label : LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree to label_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:label="LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:title="LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" />
    <link:label xlink:type="resource" xlink:label="label_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xml:lang="en-US" id="label_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour">2029</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:to="label_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:title="Label : LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour to label_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" />
    <link:label xlink:type="resource" xlink:label="label_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_1" xml:lang="en-US" id="label_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_1">Long-Term Debt, Maturity, Year Four</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:to="label_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_1" xlink:title="Label : LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour to label_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:label="LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:title="LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" />
    <link:label xlink:type="resource" xlink:label="label_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xml:lang="en-US" id="label_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive">Thereafter</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:to="label_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:title="Label : LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive to label_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" />
    <link:label xlink:type="resource" xlink:label="label_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_1" xml:lang="en-US" id="label_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_1">Long-Term Debt, Maturity, after Year Five</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:to="label_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_1" xlink:title="Label : LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive to label_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebt" xlink:label="LongTermDebt" xlink:title="LongTermDebt" />
    <link:label xlink:type="resource" xlink:label="label_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_LongTermDebt" xml:lang="en-US" id="label_LongTermDebt">Total</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongTermDebt" xlink:to="label_LongTermDebt" xlink:title="Label : LongTermDebt to label_LongTermDebt" />
    <link:label xlink:type="resource" xlink:label="label_LongTermDebt_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_LongTermDebt_1" xml:lang="en-US" id="label_LongTermDebt_1">Long-Term Debt</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongTermDebt" xlink:to="label_LongTermDebt_1" xlink:title="Label : LongTermDebt to label_LongTermDebt_1" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_DerivativeLiabilitiesDetailsTable" xlink:label="DerivativeLiabilitiesDetailsTable" xlink:title="DerivativeLiabilitiesDetailsTable" />
    <link:label xlink:type="resource" xlink:label="label_DerivativeLiabilitiesDetailsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DerivativeLiabilitiesDetailsTable" xml:lang="en-US" id="label_DerivativeLiabilitiesDetailsTable">Derivative Liabilities (Details) [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DerivativeLiabilitiesDetailsTable" xlink:to="label_DerivativeLiabilitiesDetailsTable" xlink:title="Label : DerivativeLiabilitiesDetailsTable to label_DerivativeLiabilitiesDetailsTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems" xlink:label="DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems" xlink:title="DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems" />
    <link:label xlink:type="resource" xlink:label="label_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems" xml:lang="en-US" id="label_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems">Derivative Liabilities [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems" xlink:to="label_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems" xlink:title="Label : DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems to label_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_MilestonePayment" xlink:label="MilestonePayment" xlink:title="MilestonePayment" />
    <link:label xlink:type="resource" xlink:label="label_MilestonePayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_MilestonePayment" xml:lang="en-US" id="label_MilestonePayment">Milestone Payment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MilestonePayment" xlink:to="label_MilestonePayment" xlink:title="Label : MilestonePayment to label_MilestonePayment" />
    <link:label xlink:type="resource" xlink:label="label_MilestonePayment_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_MilestonePayment_1" xml:lang="en-US" id="label_MilestonePayment_1">The amount of milestone payment.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MilestonePayment" xlink:to="label_MilestonePayment_1" xlink:title="Label : MilestonePayment to label_MilestonePayment_1" />
    <link:label xlink:type="resource" xlink:label="label_MilestonePayment_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_MilestonePayment_2" xml:lang="en-US" id="label_MilestonePayment_2">Milestone Payment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MilestonePayment" xlink:to="label_MilestonePayment_2" xlink:title="Label : MilestonePayment to label_MilestonePayment_2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockRedemptionTerms" xlink:label="PreferredStockRedemptionTerms" xlink:title="PreferredStockRedemptionTerms" />
    <link:label xlink:type="resource" xlink:label="label_PreferredStockRedemptionTerms" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_PreferredStockRedemptionTerms" xml:lang="en-US" id="label_PreferredStockRedemptionTerms">Redemption term.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockRedemptionTerms" xlink:to="label_PreferredStockRedemptionTerms" xlink:title="Label : PreferredStockRedemptionTerms to label_PreferredStockRedemptionTerms" />
    <link:label xlink:type="resource" xlink:label="label_PreferredStockRedemptionTerms_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_PreferredStockRedemptionTerms_1" xml:lang="en-US" id="label_PreferredStockRedemptionTerms_1">Preferred Stock, Redemption Terms</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockRedemptionTerms" xlink:to="label_PreferredStockRedemptionTerms_1" xlink:title="Label : PreferredStockRedemptionTerms to label_PreferredStockRedemptionTerms_1" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_RoyaltyPercentage" xlink:label="RoyaltyPercentage" xlink:title="RoyaltyPercentage" />
    <link:label xlink:type="resource" xlink:label="label_RoyaltyPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_RoyaltyPercentage" xml:lang="en-US" id="label_RoyaltyPercentage">Royalty percentage</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RoyaltyPercentage" xlink:to="label_RoyaltyPercentage" xlink:title="Label : RoyaltyPercentage to label_RoyaltyPercentage" />
    <link:label xlink:type="resource" xlink:label="label_RoyaltyPercentage_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_RoyaltyPercentage_1" xml:lang="en-US" id="label_RoyaltyPercentage_1">The percentage of royalty.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RoyaltyPercentage" xlink:to="label_RoyaltyPercentage_1" xlink:title="Label : RoyaltyPercentage to label_RoyaltyPercentage_1" />
    <link:label xlink:type="resource" xlink:label="label_RoyaltyPercentage_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_RoyaltyPercentage_2" xml:lang="en-US" id="label_RoyaltyPercentage_2">Royalty Percentage</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RoyaltyPercentage" xlink:to="label_RoyaltyPercentage_2" xlink:title="Label : RoyaltyPercentage to label_RoyaltyPercentage_2" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_ScheduleOfDerivativeLiabilitiesMeasuredAtFairValueOnARecurringBasisAbstract" xlink:label="ScheduleOfDerivativeLiabilitiesMeasuredAtFairValueOnARecurringBasisAbstract" xlink:title="ScheduleOfDerivativeLiabilitiesMeasuredAtFairValueOnARecurringBasisAbstract" />
    <link:label xlink:type="resource" xlink:label="label_ScheduleOfDerivativeLiabilitiesMeasuredAtFairValueOnARecurringBasisAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ScheduleOfDerivativeLiabilitiesMeasuredAtFairValueOnARecurringBasisAbstract" xml:lang="en-US" id="label_ScheduleOfDerivativeLiabilitiesMeasuredAtFairValueOnARecurringBasisAbstract">Schedule Of Derivative Liabilities Measured At Fair Value On ARecurring Basis Abstract</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfDerivativeLiabilitiesMeasuredAtFairValueOnARecurringBasisAbstract" xlink:to="label_ScheduleOfDerivativeLiabilitiesMeasuredAtFairValueOnARecurringBasisAbstract" xlink:title="Label : ScheduleOfDerivativeLiabilitiesMeasuredAtFairValueOnARecurringBasisAbstract to label_ScheduleOfDerivativeLiabilitiesMeasuredAtFairValueOnARecurringBasisAbstract" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_DerivativeLiabilitiesScheduleofDerivativeLiabilitiesMeasuredatFairValueonaRecurringBasisDetailsTable" xlink:label="DerivativeLiabilitiesScheduleofDerivativeLiabilitiesMeasuredatFairValueonaRecurringBasisDetailsTable" xlink:title="DerivativeLiabilitiesScheduleofDerivativeLiabilitiesMeasuredatFairValueonaRecurringBasisDetailsTable" />
    <link:label xlink:type="resource" xlink:label="label_DerivativeLiabilitiesScheduleofDerivativeLiabilitiesMeasuredatFairValueonaRecurringBasisDetailsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DerivativeLiabilitiesScheduleofDerivativeLiabilitiesMeasuredatFairValueonaRecurringBasisDetailsTable" xml:lang="en-US" id="label_DerivativeLiabilitiesScheduleofDerivativeLiabilitiesMeasuredatFairValueonaRecurringBasisDetailsTable">Derivative Liabilities - Schedule of Derivative Liabilities Measured at Fair Value on a Recurring Basis (Details) [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DerivativeLiabilitiesScheduleofDerivativeLiabilitiesMeasuredatFairValueonaRecurringBasisDetailsTable" xlink:to="label_DerivativeLiabilitiesScheduleofDerivativeLiabilitiesMeasuredatFairValueonaRecurringBasisDetailsTable" xlink:title="Label : DerivativeLiabilitiesScheduleofDerivativeLiabilitiesMeasuredatFairValueonaRecurringBasisDetailsTable to label_DerivativeLiabilitiesScheduleofDerivativeLiabilitiesMeasuredatFairValueonaRecurringBasisDetailsTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="FairValueByMeasurementFrequencyAxis" xlink:title="FairValueByMeasurementFrequencyAxis" />
    <link:label xlink:type="resource" xlink:label="label_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FairValueByMeasurementFrequencyAxis" xml:lang="en-US" id="label_FairValueByMeasurementFrequencyAxis">Measurement Frequency [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueByMeasurementFrequencyAxis" xlink:to="label_FairValueByMeasurementFrequencyAxis" xlink:title="Label : FairValueByMeasurementFrequencyAxis to label_FairValueByMeasurementFrequencyAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="FairValueMeasurementsRecurringMember" xlink:title="FairValueMeasurementsRecurringMember" />
    <link:label xlink:type="resource" xlink:label="label_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_FairValueMeasurementsRecurringMember" xml:lang="en-US" id="label_FairValueMeasurementsRecurringMember">Fair Value, Recurring [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueMeasurementsRecurringMember" xlink:to="label_FairValueMeasurementsRecurringMember" xlink:title="Label : FairValueMeasurementsRecurringMember to label_FairValueMeasurementsRecurringMember" />
    <link:label xlink:type="resource" xlink:label="label_FairValueMeasurementsRecurringMember_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FairValueMeasurementsRecurringMember_1" xml:lang="en-US" id="label_FairValueMeasurementsRecurringMember_1">Fair Value, Recurring [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueMeasurementsRecurringMember" xlink:to="label_FairValueMeasurementsRecurringMember_1" xlink:title="Label : FairValueMeasurementsRecurringMember to label_FairValueMeasurementsRecurringMember_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="DerivativeInstrumentRiskAxis" xlink:title="DerivativeInstrumentRiskAxis" />
    <link:label xlink:type="resource" xlink:label="label_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DerivativeInstrumentRiskAxis" xml:lang="en-US" id="label_DerivativeInstrumentRiskAxis">Derivative Instrument [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DerivativeInstrumentRiskAxis" xlink:to="label_DerivativeInstrumentRiskAxis" xlink:title="Label : DerivativeInstrumentRiskAxis to label_DerivativeInstrumentRiskAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="DerivativeContractTypeDomain" xlink:title="DerivativeContractTypeDomain" />
    <link:label xlink:type="resource" xlink:label="label_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DerivativeContractTypeDomain" xml:lang="en-US" id="label_DerivativeContractTypeDomain">Derivative Contract [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DerivativeContractTypeDomain" xlink:to="label_DerivativeContractTypeDomain" xlink:title="Label : DerivativeContractTypeDomain to label_DerivativeContractTypeDomain" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_ContingentMilestonePaymentMember" xlink:label="ContingentMilestonePaymentMember" xlink:title="ContingentMilestonePaymentMember" />
    <link:label xlink:type="resource" xlink:label="label_ContingentMilestonePaymentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ContingentMilestonePaymentMember" xml:lang="en-US" id="label_ContingentMilestonePaymentMember">Contingent Milestone Payment [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ContingentMilestonePaymentMember" xlink:to="label_ContingentMilestonePaymentMember" xlink:title="Label : ContingentMilestonePaymentMember to label_ContingentMilestonePaymentMember" />
    <link:label xlink:type="resource" xlink:label="label_ContingentMilestonePaymentMember_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_ContingentMilestonePaymentMember_1" xml:lang="en-US" id="label_ContingentMilestonePaymentMember_1">Contingent Milestone Payment [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ContingentMilestonePaymentMember" xlink:to="label_ContingentMilestonePaymentMember_1" xlink:title="Label : ContingentMilestonePaymentMember to label_ContingentMilestonePaymentMember_1" />
    <link:label xlink:type="resource" xlink:label="label_ContingentMilestonePaymentMember_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ContingentMilestonePaymentMember_2" xml:lang="en-US" id="label_ContingentMilestonePaymentMember_2">Contingent Milestone Payment Member</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ContingentMilestonePaymentMember" xlink:to="label_ContingentMilestonePaymentMember_2" xlink:title="Label : ContingentMilestonePaymentMember to label_ContingentMilestonePaymentMember_2" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_BridgeSharesMember" xlink:label="BridgeSharesMember" xlink:title="BridgeSharesMember" />
    <link:label xlink:type="resource" xlink:label="label_BridgeSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_BridgeSharesMember" xml:lang="en-US" id="label_BridgeSharesMember">Bridge Shares [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BridgeSharesMember" xlink:to="label_BridgeSharesMember" xlink:title="Label : BridgeSharesMember to label_BridgeSharesMember" />
    <link:label xlink:type="resource" xlink:label="label_BridgeSharesMember_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_BridgeSharesMember_1" xml:lang="en-US" id="label_BridgeSharesMember_1">Bridge Shares Member</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BridgeSharesMember" xlink:to="label_BridgeSharesMember_1" xlink:title="Label : BridgeSharesMember to label_BridgeSharesMember_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:title="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" />
    <link:label xlink:type="resource" xlink:label="label_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xml:lang="en-US" id="label_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems">Schedule of Derivative Liabilities Measured at Fair Value on a Recurring Basis [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="label_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:title="Label : FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems to label_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisMarkToMarketAdjustment" xlink:label="FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisMarkToMarketAdjustment" xlink:title="FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisMarkToMarketAdjustment" />
    <link:label xlink:type="resource" xlink:label="label_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisMarkToMarketAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisMarkToMarketAdjustment" xml:lang="en-US" id="label_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisMarkToMarketAdjustment">Change in fair value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisMarkToMarketAdjustment" xlink:to="label_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisMarkToMarketAdjustment" xlink:title="Label : FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisMarkToMarketAdjustment to label_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisMarkToMarketAdjustment" />
    <link:label xlink:type="resource" xlink:label="label_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisMarkToMarketAdjustment_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisMarkToMarketAdjustment_1" xml:lang="en-US" id="label_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisMarkToMarketAdjustment_1">Fair value, measurement with unobservable inputs reconciliation, recurring Basis, fair value - mark to market adjustment.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisMarkToMarketAdjustment" xlink:to="label_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisMarkToMarketAdjustment_1" xlink:title="Label : FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisMarkToMarketAdjustment to label_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisMarkToMarketAdjustment_1" />
    <link:label xlink:type="resource" xlink:label="label_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisMarkToMarketAdjustment_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisMarkToMarketAdjustment_2" xml:lang="en-US" id="label_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisMarkToMarketAdjustment_2">Fair Value Measurementwith Unobservable Inputs Reconciliation Recurring Basis Mark To Market Adjustment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisMarkToMarketAdjustment" xlink:to="label_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisMarkToMarketAdjustment_2" xlink:title="Label : FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisMarkToMarketAdjustment to label_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisMarkToMarketAdjustment_2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="FairValueMeasurementFrequencyDomain" xlink:title="FairValueMeasurementFrequencyDomain" />
    <link:label xlink:type="resource" xlink:label="label_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FairValueMeasurementFrequencyDomain" xml:lang="en-US" id="label_FairValueMeasurementFrequencyDomain">Measurement Frequency [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueMeasurementFrequencyDomain" xlink:to="label_FairValueMeasurementFrequencyDomain" xlink:title="Label : FairValueMeasurementFrequencyDomain to label_FairValueMeasurementFrequencyDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:title="DeferredTaxAssetsOperatingLossCarryforwardsDomestic" />
    <link:label xlink:type="resource" xlink:label="label_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xml:lang="en-US" id="label_DeferredTaxAssetsOperatingLossCarryforwardsDomestic">U.S. federal net operating loss carryforwards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:to="label_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:title="Label : DeferredTaxAssetsOperatingLossCarryforwardsDomestic to label_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" />
    <link:label xlink:type="resource" xlink:label="label_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_1" xml:lang="en-US" id="label_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_1">Deferred Tax Assets, Operating Loss Carryforwards, Domestic</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:to="label_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_1" xlink:title="Label : DeferredTaxAssetsOperatingLossCarryforwardsDomestic to label_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther" xlink:label="DeferredTaxAssetsTaxCreditCarryforwardsOther" xlink:title="DeferredTaxAssetsTaxCreditCarryforwardsOther" />
    <link:label xlink:type="resource" xlink:label="label_DeferredTaxAssetsTaxCreditCarryforwardsOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_DeferredTaxAssetsTaxCreditCarryforwardsOther" xml:lang="en-US" id="label_DeferredTaxAssetsTaxCreditCarryforwardsOther">U.S. federal tax</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsTaxCreditCarryforwardsOther" xlink:to="label_DeferredTaxAssetsTaxCreditCarryforwardsOther" xlink:title="Label : DeferredTaxAssetsTaxCreditCarryforwardsOther to label_DeferredTaxAssetsTaxCreditCarryforwardsOther" />
    <link:label xlink:type="resource" xlink:label="label_DeferredTaxAssetsTaxCreditCarryforwardsOther_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DeferredTaxAssetsTaxCreditCarryforwardsOther_1" xml:lang="en-US" id="label_DeferredTaxAssetsTaxCreditCarryforwardsOther_1">Deferred Tax Assets, Tax Credit Carryforwards, Other</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsTaxCreditCarryforwardsOther" xlink:to="label_DeferredTaxAssetsTaxCreditCarryforwardsOther_1" xlink:title="Label : DeferredTaxAssetsTaxCreditCarryforwardsOther to label_DeferredTaxAssetsTaxCreditCarryforwardsOther_1" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_ShareBasedCompensationDetailsTable" xlink:label="ShareBasedCompensationDetailsTable" xlink:title="ShareBasedCompensationDetailsTable" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationDetailsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ShareBasedCompensationDetailsTable" xml:lang="en-US" id="label_ShareBasedCompensationDetailsTable">Share-Based Compensation (Details) [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationDetailsTable" xlink:to="label_ShareBasedCompensationDetailsTable" xlink:title="Label : ShareBasedCompensationDetailsTable to label_ShareBasedCompensationDetailsTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="PlanNameAxis" xlink:title="PlanNameAxis" />
    <link:label xlink:type="resource" xlink:label="label_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_PlanNameAxis" xml:lang="en-US" id="label_PlanNameAxis">Plan Name [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PlanNameAxis" xlink:to="label_PlanNameAxis" xlink:title="Label : PlanNameAxis to label_PlanNameAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="PlanNameDomain" xlink:title="PlanNameDomain" />
    <link:label xlink:type="resource" xlink:label="label_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_PlanNameDomain" xml:lang="en-US" id="label_PlanNameDomain">Plan Name [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PlanNameDomain" xlink:to="label_PlanNameDomain" xlink:title="Label : PlanNameDomain to label_PlanNameDomain" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_TwoThousandTwentyTwoEquityIncentivePlanMember" xlink:label="TwoThousandTwentyTwoEquityIncentivePlanMember" xlink:title="TwoThousandTwentyTwoEquityIncentivePlanMember" />
    <link:label xlink:type="resource" xlink:label="label_TwoThousandTwentyTwoEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_TwoThousandTwentyTwoEquityIncentivePlanMember" xml:lang="en-US" id="label_TwoThousandTwentyTwoEquityIncentivePlanMember">Two Thousand Twenty Two Equity Incentive Plan [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TwoThousandTwentyTwoEquityIncentivePlanMember" xlink:to="label_TwoThousandTwentyTwoEquityIncentivePlanMember" xlink:title="Label : TwoThousandTwentyTwoEquityIncentivePlanMember to label_TwoThousandTwentyTwoEquityIncentivePlanMember" />
    <link:label xlink:type="resource" xlink:label="label_TwoThousandTwentyTwoEquityIncentivePlanMember_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_TwoThousandTwentyTwoEquityIncentivePlanMember_1" xml:lang="en-US" id="label_TwoThousandTwentyTwoEquityIncentivePlanMember_1">Two Thousand Twenty Two Equity Incentive Plan Member</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TwoThousandTwentyTwoEquityIncentivePlanMember" xlink:to="label_TwoThousandTwentyTwoEquityIncentivePlanMember_1" xlink:title="Label : TwoThousandTwentyTwoEquityIncentivePlanMember to label_TwoThousandTwentyTwoEquityIncentivePlanMember_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VestingAxis" xlink:label="VestingAxis" xlink:title="VestingAxis" />
    <link:label xlink:type="resource" xlink:label="label_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_VestingAxis" xml:lang="en-US" id="label_VestingAxis">Vesting [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="VestingAxis" xlink:to="label_VestingAxis" xlink:title="Label : VestingAxis to label_VestingAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VestingDomain" xlink:label="VestingDomain" xlink:title="VestingDomain" />
    <link:label xlink:type="resource" xlink:label="label_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_VestingDomain" xml:lang="en-US" id="label_VestingDomain">Vesting [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="VestingDomain" xlink:to="label_VestingDomain" xlink:title="Label : VestingDomain to label_VestingDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="ShareBasedCompensationAwardTrancheOneMember" xlink:title="ShareBasedCompensationAwardTrancheOneMember" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ShareBasedCompensationAwardTrancheOneMember" xml:lang="en-US" id="label_ShareBasedCompensationAwardTrancheOneMember">First Tranche [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationAwardTrancheOneMember" xlink:to="label_ShareBasedCompensationAwardTrancheOneMember" xlink:title="Label : ShareBasedCompensationAwardTrancheOneMember to label_ShareBasedCompensationAwardTrancheOneMember" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationAwardTrancheOneMember_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ShareBasedCompensationAwardTrancheOneMember_1" xml:lang="en-US" id="label_ShareBasedCompensationAwardTrancheOneMember_1">Share-Based Payment Arrangement, Tranche One [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationAwardTrancheOneMember" xlink:to="label_ShareBasedCompensationAwardTrancheOneMember_1" xlink:title="Label : ShareBasedCompensationAwardTrancheOneMember to label_ShareBasedCompensationAwardTrancheOneMember_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xml:lang="en-US" id="label_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain">Award Type [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="label_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="Label : ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to label_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_StockOptionsMember" xlink:label="StockOptionsMember" xlink:title="StockOptionsMember" />
    <link:label xlink:type="resource" xlink:label="label_StockOptionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_StockOptionsMember" xml:lang="en-US" id="label_StockOptionsMember">Stock Options [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockOptionsMember" xlink:to="label_StockOptionsMember" xlink:title="Label : StockOptionsMember to label_StockOptionsMember" />
    <link:label xlink:type="resource" xlink:label="label_StockOptionsMember_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StockOptionsMember_1" xml:lang="en-US" id="label_StockOptionsMember_1">Stock Options Member</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockOptionsMember" xlink:to="label_StockOptionsMember_1" xlink:title="Label : StockOptionsMember to label_StockOptionsMember_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="RestrictedStockUnitsRSUMember" xlink:title="RestrictedStockUnitsRSUMember" />
    <link:label xlink:type="resource" xlink:label="label_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_RestrictedStockUnitsRSUMember" xml:lang="en-US" id="label_RestrictedStockUnitsRSUMember">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RestrictedStockUnitsRSUMember" xlink:to="label_RestrictedStockUnitsRSUMember" xlink:title="Label : RestrictedStockUnitsRSUMember to label_RestrictedStockUnitsRSUMember" />
    <link:label xlink:type="resource" xlink:label="label_RestrictedStockUnitsRSUMember_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_RestrictedStockUnitsRSUMember_1" xml:lang="en-US" id="label_RestrictedStockUnitsRSUMember_1">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RestrictedStockUnitsRSUMember" xlink:to="label_RestrictedStockUnitsRSUMember_1" xlink:title="Label : RestrictedStockUnitsRSUMember to label_RestrictedStockUnitsRSUMember_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:title="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <link:label xlink:type="resource" xlink:label="label_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xml:lang="en-US" id="label_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">Schedule of Share-Based Compensation Expenses [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="label_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:title="Label : EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems to label_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <link:label xlink:type="resource" xlink:label="label_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1" xml:lang="en-US" id="label_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1">Share-Based Compensation [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="label_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1" xlink:title="Label : EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems to label_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
    <link:label xlink:type="resource" xlink:label="label_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xml:lang="en-US" id="label_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">Options Vesting percentage</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="label_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:title="Label : SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage to label_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
    <link:label xlink:type="resource" xlink:label="label_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_1" xml:lang="en-US" id="label_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_1">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="label_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_1" xlink:title="Label : SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage to label_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" />
    <link:label xlink:type="resource" xlink:label="label_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xml:lang="en-US" id="label_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue">Weighted average grant date fair value of options granted (in Dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:to="label_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:title="Label : SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue to label_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" />
    <link:label xlink:type="resource" xlink:label="label_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_1" xml:lang="en-US" id="label_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_1">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:to="label_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_1" xlink:title="Label : SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue to label_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" />
    <link:label xlink:type="resource" xlink:label="label_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xml:lang="en-US" id="label_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">Vested shares (in Shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="label_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:title="Label : SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares to label_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" />
    <link:label xlink:type="resource" xlink:label="label_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_1" xml:lang="en-US" id="label_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_1">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="label_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_1" xlink:title="Label : SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares to label_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="AllocatedShareBasedCompensationExpense" xlink:title="AllocatedShareBasedCompensationExpense" />
    <link:label xlink:type="resource" xlink:label="label_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_AllocatedShareBasedCompensationExpense" xml:lang="en-US" id="label_AllocatedShareBasedCompensationExpense">Total Share-Based Compensation Expense Included in Operating Expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AllocatedShareBasedCompensationExpense" xlink:to="label_AllocatedShareBasedCompensationExpense" xlink:title="Label : AllocatedShareBasedCompensationExpense to label_AllocatedShareBasedCompensationExpense" />
    <link:label xlink:type="resource" xlink:label="label_AllocatedShareBasedCompensationExpense_1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_AllocatedShareBasedCompensationExpense_1" xml:lang="en-US" id="label_AllocatedShareBasedCompensationExpense_1">Compensation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AllocatedShareBasedCompensationExpense" xlink:to="label_AllocatedShareBasedCompensationExpense_1" xlink:title="Label : AllocatedShareBasedCompensationExpense to label_AllocatedShareBasedCompensationExpense_1" />
    <link:label xlink:type="resource" xlink:label="label_AllocatedShareBasedCompensationExpense_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AllocatedShareBasedCompensationExpense_2" xml:lang="en-US" id="label_AllocatedShareBasedCompensationExpense_2">Share-Based Payment Arrangement, Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AllocatedShareBasedCompensationExpense" xlink:to="label_AllocatedShareBasedCompensationExpense_2" xlink:title="Label : AllocatedShareBasedCompensationExpense to label_AllocatedShareBasedCompensationExpense_2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Cash" xlink:label="Cash" xlink:title="Cash" />
    <link:label xlink:type="resource" xlink:label="label_Cash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_Cash" xml:lang="en-US" id="label_Cash">Cash</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Cash" xlink:to="label_Cash" xlink:title="Label : Cash to label_Cash" />
    <link:label xlink:type="resource" xlink:label="label_Cash_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_Cash_1" xml:lang="en-US" id="label_Cash_1">Cash</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Cash" xlink:to="label_Cash_1" xlink:title="Label : Cash to label_Cash_1" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_SharesIssuedPayrollTaxesWithholdings" xlink:label="SharesIssuedPayrollTaxesWithholdings" xlink:title="SharesIssuedPayrollTaxesWithholdings" />
    <link:label xlink:type="resource" xlink:label="label_SharesIssuedPayrollTaxesWithholdings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_SharesIssuedPayrollTaxesWithholdings" xml:lang="en-US" id="label_SharesIssuedPayrollTaxesWithholdings">Shares payroll tax withholdings (in Shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharesIssuedPayrollTaxesWithholdings" xlink:to="label_SharesIssuedPayrollTaxesWithholdings" xlink:title="Label : SharesIssuedPayrollTaxesWithholdings to label_SharesIssuedPayrollTaxesWithholdings" />
    <link:label xlink:type="resource" xlink:label="label_SharesIssuedPayrollTaxesWithholdings_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_SharesIssuedPayrollTaxesWithholdings_1" xml:lang="en-US" id="label_SharesIssuedPayrollTaxesWithholdings_1">The shares issued payroll taxes withholdings.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharesIssuedPayrollTaxesWithholdings" xlink:to="label_SharesIssuedPayrollTaxesWithholdings_1" xlink:title="Label : SharesIssuedPayrollTaxesWithholdings to label_SharesIssuedPayrollTaxesWithholdings_1" />
    <link:label xlink:type="resource" xlink:label="label_SharesIssuedPayrollTaxesWithholdings_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_SharesIssuedPayrollTaxesWithholdings_2" xml:lang="en-US" id="label_SharesIssuedPayrollTaxesWithholdings_2">Shares Issued Payroll Taxes Withholdings</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharesIssuedPayrollTaxesWithholdings" xlink:to="label_SharesIssuedPayrollTaxesWithholdings_2" xlink:title="Label : SharesIssuedPayrollTaxesWithholdings to label_SharesIssuedPayrollTaxesWithholdings_2" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_UnamortizedBalance" xlink:label="UnamortizedBalance" xlink:title="UnamortizedBalance" />
    <link:label xlink:type="resource" xlink:label="label_UnamortizedBalance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_UnamortizedBalance" xml:lang="en-US" id="label_UnamortizedBalance">Unamortized balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UnamortizedBalance" xlink:to="label_UnamortizedBalance" xlink:title="Label : UnamortizedBalance to label_UnamortizedBalance" />
    <link:label xlink:type="resource" xlink:label="label_UnamortizedBalance_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_UnamortizedBalance_1" xml:lang="en-US" id="label_UnamortizedBalance_1">The amount of unamortized balance.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UnamortizedBalance" xlink:to="label_UnamortizedBalance_1" xlink:title="Label : UnamortizedBalance to label_UnamortizedBalance_1" />
    <link:label xlink:type="resource" xlink:label="label_UnamortizedBalance_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_UnamortizedBalance_2" xml:lang="en-US" id="label_UnamortizedBalance_2">Unamortized Balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UnamortizedBalance" xlink:to="label_UnamortizedBalance_2" xlink:title="Label : UnamortizedBalance to label_UnamortizedBalance_2" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_ScheduleOfShareBasedCompensationExpensesAbstract" xlink:label="ScheduleOfShareBasedCompensationExpensesAbstract" xlink:title="ScheduleOfShareBasedCompensationExpensesAbstract" />
    <link:label xlink:type="resource" xlink:label="label_ScheduleOfShareBasedCompensationExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ScheduleOfShareBasedCompensationExpensesAbstract" xml:lang="en-US" id="label_ScheduleOfShareBasedCompensationExpensesAbstract">Schedule Of Share Based Compensation Expenses Abstract</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfShareBasedCompensationExpensesAbstract" xlink:to="label_ScheduleOfShareBasedCompensationExpensesAbstract" xlink:title="Label : ScheduleOfShareBasedCompensationExpensesAbstract to label_ScheduleOfShareBasedCompensationExpensesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:title="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <link:label xlink:type="resource" xlink:label="label_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xml:lang="en-US" id="label_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="label_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:title="Label : ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable to label_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="IncomeStatementLocationAxis" xlink:title="IncomeStatementLocationAxis" />
    <link:label xlink:type="resource" xlink:label="label_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_IncomeStatementLocationAxis" xml:lang="en-US" id="label_IncomeStatementLocationAxis">Statement of Income Location, Balance [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeStatementLocationAxis" xlink:to="label_IncomeStatementLocationAxis" xlink:title="Label : IncomeStatementLocationAxis to label_IncomeStatementLocationAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="IncomeStatementLocationDomain" xlink:title="IncomeStatementLocationDomain" />
    <link:label xlink:type="resource" xlink:label="label_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_IncomeStatementLocationDomain" xml:lang="en-US" id="label_IncomeStatementLocationDomain">Statement of Income Location, Balance [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeStatementLocationDomain" xlink:to="label_IncomeStatementLocationDomain" xlink:title="Label : IncomeStatementLocationDomain to label_IncomeStatementLocationDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="GeneralAndAdministrativeExpenseMember" xlink:title="GeneralAndAdministrativeExpenseMember" />
    <link:label xlink:type="resource" xlink:label="label_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_GeneralAndAdministrativeExpenseMember" xml:lang="en-US" id="label_GeneralAndAdministrativeExpenseMember">General and Administrative Expenses [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GeneralAndAdministrativeExpenseMember" xlink:to="label_GeneralAndAdministrativeExpenseMember" xlink:title="Label : GeneralAndAdministrativeExpenseMember to label_GeneralAndAdministrativeExpenseMember" />
    <link:label xlink:type="resource" xlink:label="label_GeneralAndAdministrativeExpenseMember_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_GeneralAndAdministrativeExpenseMember_1" xml:lang="en-US" id="label_GeneralAndAdministrativeExpenseMember_1">General and Administrative Expense [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GeneralAndAdministrativeExpenseMember" xlink:to="label_GeneralAndAdministrativeExpenseMember_1" xlink:title="Label : GeneralAndAdministrativeExpenseMember to label_GeneralAndAdministrativeExpenseMember_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract">Fair Value Measurement Inputs and Valuation Techniques [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:title="Label : ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract to label_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">Weighted-average grant date fair value (in Dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:title="Label : ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue to label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1" xlink:title="Label : ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue to label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">Risk-free interest rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:title="Label : ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate to label_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_1" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_1">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_1" xlink:title="Label : ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate to label_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">Expected volatility</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:title="Label : ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate to label_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1" xlink:title="Label : ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate to label_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:label xlink:type="resource" xlink:label="label_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xml:lang="en-US" id="label_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">Expected term (years)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="label_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:title="Label : SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 to label_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:label xlink:type="resource" xlink:label="label_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1" xml:lang="en-US" id="label_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="label_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1" xlink:title="Label : SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 to label_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">Expected dividend yield</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:title="Label : ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate to label_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1" xlink:title="Label : ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate to label_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_CommitmentsandContingenciesDetailsTable" xlink:label="CommitmentsandContingenciesDetailsTable" xlink:title="CommitmentsandContingenciesDetailsTable" />
    <link:label xlink:type="resource" xlink:label="label_CommitmentsandContingenciesDetailsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_CommitmentsandContingenciesDetailsTable" xml:lang="en-US" id="label_CommitmentsandContingenciesDetailsTable">Commitments and Contingencies (Details) [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommitmentsandContingenciesDetailsTable" xlink:to="label_CommitmentsandContingenciesDetailsTable" xlink:title="Label : CommitmentsandContingenciesDetailsTable to label_CommitmentsandContingenciesDetailsTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:label xlink:type="resource" xlink:label="label_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_RangeAxis" xml:lang="en-US" id="label_RangeAxis">Statistical Measurement [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RangeAxis" xlink:to="label_RangeAxis" xlink:title="Label : RangeAxis to label_RangeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:label xlink:type="resource" xlink:label="label_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_RangeMember" xml:lang="en-US" id="label_RangeMember">Statistical Measurement [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RangeMember" xlink:to="label_RangeMember" xlink:title="Label : RangeMember to label_RangeMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="MinimumMember" xlink:title="MinimumMember" />
    <link:label xlink:type="resource" xlink:label="label_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_MinimumMember" xml:lang="en-US" id="label_MinimumMember">Minimum [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MinimumMember" xlink:to="label_MinimumMember" xlink:title="Label : MinimumMember to label_MinimumMember" />
    <link:label xlink:type="resource" xlink:label="label_MinimumMember_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_MinimumMember_1" xml:lang="en-US" id="label_MinimumMember_1">Minimum [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MinimumMember" xlink:to="label_MinimumMember_1" xlink:title="Label : MinimumMember to label_MinimumMember_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember" />
    <link:label xlink:type="resource" xlink:label="label_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_MaximumMember" xml:lang="en-US" id="label_MaximumMember">Maximum [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MaximumMember" xlink:to="label_MaximumMember" xlink:title="Label : MaximumMember to label_MaximumMember" />
    <link:label xlink:type="resource" xlink:label="label_MaximumMember_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_MaximumMember_1" xml:lang="en-US" id="label_MaximumMember_1">Maximum [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MaximumMember" xlink:to="label_MaximumMember_1" xlink:title="Label : MaximumMember to label_MaximumMember_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis" xlink:label="TitleOfIndividualAxis" xlink:title="TitleOfIndividualAxis" />
    <link:label xlink:type="resource" xlink:label="label_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_TitleOfIndividualAxis" xml:lang="en-US" id="label_TitleOfIndividualAxis">Title and Position [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TitleOfIndividualAxis" xlink:to="label_TitleOfIndividualAxis" xlink:title="Label : TitleOfIndividualAxis to label_TitleOfIndividualAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:label xlink:type="resource" xlink:label="label_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_TitleOfIndividualWithRelationshipToEntityDomain" xml:lang="en-US" id="label_TitleOfIndividualWithRelationshipToEntityDomain">Title and Position [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="label_TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="Label : TitleOfIndividualWithRelationshipToEntityDomain to label_TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_BoardOfDirectorsChairmanMember" xlink:label="BoardOfDirectorsChairmanMember" xlink:title="BoardOfDirectorsChairmanMember" />
    <link:label xlink:type="resource" xlink:label="label_BoardOfDirectorsChairmanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_BoardOfDirectorsChairmanMember" xml:lang="en-US" id="label_BoardOfDirectorsChairmanMember">Board of Directors [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BoardOfDirectorsChairmanMember" xlink:to="label_BoardOfDirectorsChairmanMember" xlink:title="Label : BoardOfDirectorsChairmanMember to label_BoardOfDirectorsChairmanMember" />
    <link:label xlink:type="resource" xlink:label="label_BoardOfDirectorsChairmanMember_1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_BoardOfDirectorsChairmanMember_1" xml:lang="en-US" id="label_BoardOfDirectorsChairmanMember_1">Board of Directors Chairman [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BoardOfDirectorsChairmanMember" xlink:to="label_BoardOfDirectorsChairmanMember_1" xlink:title="Label : BoardOfDirectorsChairmanMember to label_BoardOfDirectorsChairmanMember_1" />
    <link:label xlink:type="resource" xlink:label="label_BoardOfDirectorsChairmanMember_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_BoardOfDirectorsChairmanMember_2" xml:lang="en-US" id="label_BoardOfDirectorsChairmanMember_2">Board of Directors Chairman [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BoardOfDirectorsChairmanMember" xlink:to="label_BoardOfDirectorsChairmanMember_2" xlink:title="Label : BoardOfDirectorsChairmanMember to label_BoardOfDirectorsChairmanMember_2" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_CherylXuMember" xlink:label="CherylXuMember" xlink:title="CherylXuMember" />
    <link:label xlink:type="resource" xlink:label="label_CherylXuMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_CherylXuMember" xml:lang="en-US" id="label_CherylXuMember">Cheryl Xu [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CherylXuMember" xlink:to="label_CherylXuMember" xlink:title="Label : CherylXuMember to label_CherylXuMember" />
    <link:label xlink:type="resource" xlink:label="label_CherylXuMember_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_CherylXuMember_1" xml:lang="en-US" id="label_CherylXuMember_1">Cheryl Xu Member</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CherylXuMember" xlink:to="label_CherylXuMember_1" xlink:title="Label : CherylXuMember to label_CherylXuMember_1" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_PaulFieldMember" xlink:label="PaulFieldMember" xlink:title="PaulFieldMember" />
    <link:label xlink:type="resource" xlink:label="label_PaulFieldMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_PaulFieldMember" xml:lang="en-US" id="label_PaulFieldMember">Paul Field [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaulFieldMember" xlink:to="label_PaulFieldMember" xlink:title="Label : PaulFieldMember to label_PaulFieldMember" />
    <link:label xlink:type="resource" xlink:label="label_PaulFieldMember_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_PaulFieldMember_1" xml:lang="en-US" id="label_PaulFieldMember_1">Paul Field Member</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaulFieldMember" xlink:to="label_PaulFieldMember_1" xlink:title="Label : PaulFieldMember to label_PaulFieldMember_1" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_CharlesAllenMember" xlink:label="CharlesAllenMember" xlink:title="CharlesAllenMember" />
    <link:label xlink:type="resource" xlink:label="label_CharlesAllenMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_CharlesAllenMember" xml:lang="en-US" id="label_CharlesAllenMember">Charles Allen [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CharlesAllenMember" xlink:to="label_CharlesAllenMember" xlink:title="Label : CharlesAllenMember to label_CharlesAllenMember" />
    <link:label xlink:type="resource" xlink:label="label_CharlesAllenMember_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_CharlesAllenMember_1" xml:lang="en-US" id="label_CharlesAllenMember_1">Charles Allen Member</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CharlesAllenMember" xlink:to="label_CharlesAllenMember_1" xlink:title="Label : CharlesAllenMember to label_CharlesAllenMember_1" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_StephenTooveyMember" xlink:label="StephenTooveyMember" xlink:title="StephenTooveyMember" />
    <link:label xlink:type="resource" xlink:label="label_StephenTooveyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_StephenTooveyMember" xml:lang="en-US" id="label_StephenTooveyMember">Stephen Toovey [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StephenTooveyMember" xlink:to="label_StephenTooveyMember" xlink:title="Label : StephenTooveyMember to label_StephenTooveyMember" />
    <link:label xlink:type="resource" xlink:label="label_StephenTooveyMember_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StephenTooveyMember_1" xml:lang="en-US" id="label_StephenTooveyMember_1">Stephen Toovey Member</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StephenTooveyMember" xlink:to="label_StephenTooveyMember_1" xlink:title="Label : StephenTooveyMember to label_StephenTooveyMember_1" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_USGovernmentSalesMember" xlink:label="USGovernmentSalesMember" xlink:title="USGovernmentSalesMember" />
    <link:label xlink:type="resource" xlink:label="label_USGovernmentSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_USGovernmentSalesMember" xml:lang="en-US" id="label_USGovernmentSalesMember">US Government Sales [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="USGovernmentSalesMember" xlink:to="label_USGovernmentSalesMember" xlink:title="Label : USGovernmentSalesMember to label_USGovernmentSalesMember" />
    <link:label xlink:type="resource" xlink:label="label_USGovernmentSalesMember_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_USGovernmentSalesMember_1" xml:lang="en-US" id="label_USGovernmentSalesMember_1">USGovernment Sales Member</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="USGovernmentSalesMember" xlink:to="label_USGovernmentSalesMember_1" xlink:title="Label : USGovernmentSalesMember to label_USGovernmentSalesMember_1" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_USArmyAgreementMember" xlink:label="USArmyAgreementMember" xlink:title="USArmyAgreementMember" />
    <link:label xlink:type="resource" xlink:label="label_USArmyAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_USArmyAgreementMember" xml:lang="en-US" id="label_USArmyAgreementMember">U.S. Army Agreement [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="USArmyAgreementMember" xlink:to="label_USArmyAgreementMember" xlink:title="Label : USArmyAgreementMember to label_USArmyAgreementMember" />
    <link:label xlink:type="resource" xlink:label="label_USArmyAgreementMember_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_USArmyAgreementMember_1" xml:lang="en-US" id="label_USArmyAgreementMember_1">USArmy Agreement Member</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="USArmyAgreementMember" xlink:to="label_USArmyAgreementMember_1" xlink:title="Label : USArmyAgreementMember to label_USArmyAgreementMember_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCommitmentsLineItems" xlink:label="OtherCommitmentsLineItems" xlink:title="OtherCommitmentsLineItems" />
    <link:label xlink:type="resource" xlink:label="label_OtherCommitmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_OtherCommitmentsLineItems" xml:lang="en-US" id="label_OtherCommitmentsLineItems">Commitments and Contingencies [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherCommitmentsLineItems" xlink:to="label_OtherCommitmentsLineItems" xlink:title="Label : OtherCommitmentsLineItems to label_OtherCommitmentsLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseCost" xlink:label="OperatingLeaseCost" xlink:title="OperatingLeaseCost" />
    <link:label xlink:type="resource" xlink:label="label_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_OperatingLeaseCost" xml:lang="en-US" id="label_OperatingLeaseCost">Operating lease costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseCost" xlink:to="label_OperatingLeaseCost" xlink:title="Label : OperatingLeaseCost to label_OperatingLeaseCost" />
    <link:label xlink:type="resource" xlink:label="label_OperatingLeaseCost_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_OperatingLeaseCost_1" xml:lang="en-US" id="label_OperatingLeaseCost_1">Operating Lease, Cost</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseCost" xlink:to="label_OperatingLeaseCost_1" xlink:title="Label : OperatingLeaseCost to label_OperatingLeaseCost_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CompensationAndBenefitsTrust" xlink:label="CompensationAndBenefitsTrust" xlink:title="CompensationAndBenefitsTrust" />
    <link:label xlink:type="resource" xlink:label="label_CompensationAndBenefitsTrust" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_CompensationAndBenefitsTrust" xml:lang="en-US" id="label_CompensationAndBenefitsTrust">Cash compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CompensationAndBenefitsTrust" xlink:to="label_CompensationAndBenefitsTrust" xlink:title="Label : CompensationAndBenefitsTrust to label_CompensationAndBenefitsTrust" />
    <link:label xlink:type="resource" xlink:label="label_CompensationAndBenefitsTrust_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_CompensationAndBenefitsTrust_1" xml:lang="en-US" id="label_CompensationAndBenefitsTrust_1">Compensation and Benefits Trust</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CompensationAndBenefitsTrust" xlink:to="label_CompensationAndBenefitsTrust_1" xlink:title="Label : CompensationAndBenefitsTrust to label_CompensationAndBenefitsTrust_1" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_NumberOfNonAuditCommitteeChairs" xlink:label="NumberOfNonAuditCommitteeChairs" xlink:title="NumberOfNonAuditCommitteeChairs" />
    <link:label xlink:type="resource" xlink:label="label_NumberOfNonAuditCommitteeChairs" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_NumberOfNonAuditCommitteeChairs" xml:lang="en-US" id="label_NumberOfNonAuditCommitteeChairs">Number of non audit committee chairs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfNonAuditCommitteeChairs" xlink:to="label_NumberOfNonAuditCommitteeChairs" xlink:title="Label : NumberOfNonAuditCommitteeChairs to label_NumberOfNonAuditCommitteeChairs" />
    <link:label xlink:type="resource" xlink:label="label_NumberOfNonAuditCommitteeChairs_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_NumberOfNonAuditCommitteeChairs_1" xml:lang="en-US" id="label_NumberOfNonAuditCommitteeChairs_1">Number of non-audit committee chairs.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfNonAuditCommitteeChairs" xlink:to="label_NumberOfNonAuditCommitteeChairs_1" xlink:title="Label : NumberOfNonAuditCommitteeChairs to label_NumberOfNonAuditCommitteeChairs_1" />
    <link:label xlink:type="resource" xlink:label="label_NumberOfNonAuditCommitteeChairs_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_NumberOfNonAuditCommitteeChairs_2" xml:lang="en-US" id="label_NumberOfNonAuditCommitteeChairs_2">Number Of Non Audit Committee Chairs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfNonAuditCommitteeChairs" xlink:to="label_NumberOfNonAuditCommitteeChairs_2" xlink:title="Label : NumberOfNonAuditCommitteeChairs to label_NumberOfNonAuditCommitteeChairs_2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="BusinessCombinationContingentConsiderationLiability" xlink:title="BusinessCombinationContingentConsiderationLiability" />
    <link:label xlink:type="resource" xlink:label="label_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_BusinessCombinationContingentConsiderationLiability" xml:lang="en-US" id="label_BusinessCombinationContingentConsiderationLiability">Payment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessCombinationContingentConsiderationLiability" xlink:to="label_BusinessCombinationContingentConsiderationLiability" xlink:title="Label : BusinessCombinationContingentConsiderationLiability to label_BusinessCombinationContingentConsiderationLiability" />
    <link:label xlink:type="resource" xlink:label="label_BusinessCombinationContingentConsiderationLiability_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_BusinessCombinationContingentConsiderationLiability_1" xml:lang="en-US" id="label_BusinessCombinationContingentConsiderationLiability_1">Business Combination, Contingent Consideration, Liability</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BusinessCombinationContingentConsiderationLiability" xlink:to="label_BusinessCombinationContingentConsiderationLiability_1" xlink:title="Label : BusinessCombinationContingentConsiderationLiability to label_BusinessCombinationContingentConsiderationLiability_1" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_LicensedTechnologyTerm" xlink:label="LicensedTechnologyTerm" xlink:title="LicensedTechnologyTerm" />
    <link:label xlink:type="resource" xlink:label="label_LicensedTechnologyTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_LicensedTechnologyTerm" xml:lang="en-US" id="label_LicensedTechnologyTerm">Licensed technology term.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LicensedTechnologyTerm" xlink:to="label_LicensedTechnologyTerm" xlink:title="Label : LicensedTechnologyTerm to label_LicensedTechnologyTerm" />
    <link:label xlink:type="resource" xlink:label="label_LicensedTechnologyTerm_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_LicensedTechnologyTerm_1" xml:lang="en-US" id="label_LicensedTechnologyTerm_1">Licensed technology term.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LicensedTechnologyTerm" xlink:to="label_LicensedTechnologyTerm_1" xlink:title="Label : LicensedTechnologyTerm to label_LicensedTechnologyTerm_1" />
    <link:label xlink:type="resource" xlink:label="label_LicensedTechnologyTerm_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_LicensedTechnologyTerm_2" xml:lang="en-US" id="label_LicensedTechnologyTerm_2">Licensed Technology Term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LicensedTechnologyTerm" xlink:to="label_LicensedTechnologyTerm_2" xlink:title="Label : LicensedTechnologyTerm to label_LicensedTechnologyTerm_2" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_AnnualRoyaltyPaymentPercentage" xlink:label="AnnualRoyaltyPaymentPercentage" xlink:title="AnnualRoyaltyPaymentPercentage" />
    <link:label xlink:type="resource" xlink:label="label_AnnualRoyaltyPaymentPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_AnnualRoyaltyPaymentPercentage" xml:lang="en-US" id="label_AnnualRoyaltyPaymentPercentage">Annual royalty payment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AnnualRoyaltyPaymentPercentage" xlink:to="label_AnnualRoyaltyPaymentPercentage" xlink:title="Label : AnnualRoyaltyPaymentPercentage to label_AnnualRoyaltyPaymentPercentage" />
    <link:label xlink:type="resource" xlink:label="label_AnnualRoyaltyPaymentPercentage_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_AnnualRoyaltyPaymentPercentage_1" xml:lang="en-US" id="label_AnnualRoyaltyPaymentPercentage_1">Percentage of annual royalty payment.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AnnualRoyaltyPaymentPercentage" xlink:to="label_AnnualRoyaltyPaymentPercentage_1" xlink:title="Label : AnnualRoyaltyPaymentPercentage to label_AnnualRoyaltyPaymentPercentage_1" />
    <link:label xlink:type="resource" xlink:label="label_AnnualRoyaltyPaymentPercentage_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AnnualRoyaltyPaymentPercentage_2" xml:lang="en-US" id="label_AnnualRoyaltyPaymentPercentage_2">Annual Royalty Payment Percentage</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AnnualRoyaltyPaymentPercentage" xlink:to="label_AnnualRoyaltyPaymentPercentage_2" xlink:title="Label : AnnualRoyaltyPaymentPercentage to label_AnnualRoyaltyPaymentPercentage_2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RoyaltyExpense" xlink:label="RoyaltyExpense" xlink:title="RoyaltyExpense" />
    <link:label xlink:type="resource" xlink:label="label_RoyaltyExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_RoyaltyExpense" xml:lang="en-US" id="label_RoyaltyExpense">Royalty expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RoyaltyExpense" xlink:to="label_RoyaltyExpense" xlink:title="Label : RoyaltyExpense to label_RoyaltyExpense" />
    <link:label xlink:type="resource" xlink:label="label_RoyaltyExpense_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_RoyaltyExpense_1" xml:lang="en-US" id="label_RoyaltyExpense_1">Royalty Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RoyaltyExpense" xlink:to="label_RoyaltyExpense_1" xlink:title="Label : RoyaltyExpense to label_RoyaltyExpense_1" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_PercentageOfRoyaltyPaymentsOfNetSales" xlink:label="PercentageOfRoyaltyPaymentsOfNetSales" xlink:title="PercentageOfRoyaltyPaymentsOfNetSales" />
    <link:label xlink:type="resource" xlink:label="label_PercentageOfRoyaltyPaymentsOfNetSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_PercentageOfRoyaltyPaymentsOfNetSales" xml:lang="en-US" id="label_PercentageOfRoyaltyPaymentsOfNetSales">Percentage of royalty payments of net sales</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageOfRoyaltyPaymentsOfNetSales" xlink:to="label_PercentageOfRoyaltyPaymentsOfNetSales" xlink:title="Label : PercentageOfRoyaltyPaymentsOfNetSales to label_PercentageOfRoyaltyPaymentsOfNetSales" />
    <link:label xlink:type="resource" xlink:label="label_PercentageOfRoyaltyPaymentsOfNetSales_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_PercentageOfRoyaltyPaymentsOfNetSales_1" xml:lang="en-US" id="label_PercentageOfRoyaltyPaymentsOfNetSales_1">Percentage of royalty payments of net sales.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageOfRoyaltyPaymentsOfNetSales" xlink:to="label_PercentageOfRoyaltyPaymentsOfNetSales_1" xlink:title="Label : PercentageOfRoyaltyPaymentsOfNetSales to label_PercentageOfRoyaltyPaymentsOfNetSales_1" />
    <link:label xlink:type="resource" xlink:label="label_PercentageOfRoyaltyPaymentsOfNetSales_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_PercentageOfRoyaltyPaymentsOfNetSales_2" xml:lang="en-US" id="label_PercentageOfRoyaltyPaymentsOfNetSales_2">Percentage Of Royalty Payments Of Net Sales</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageOfRoyaltyPaymentsOfNetSales" xlink:to="label_PercentageOfRoyaltyPaymentsOfNetSales_2" xlink:title="Label : PercentageOfRoyaltyPaymentsOfNetSales to label_PercentageOfRoyaltyPaymentsOfNetSales_2" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_PercentageOfTreatmentOfBabesiosis" xlink:label="PercentageOfTreatmentOfBabesiosis" xlink:title="PercentageOfTreatmentOfBabesiosis" />
    <link:label xlink:type="resource" xlink:label="label_PercentageOfTreatmentOfBabesiosis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_PercentageOfTreatmentOfBabesiosis" xml:lang="en-US" id="label_PercentageOfTreatmentOfBabesiosis">Percentage of treatment of babesiosis</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageOfTreatmentOfBabesiosis" xlink:to="label_PercentageOfTreatmentOfBabesiosis" xlink:title="Label : PercentageOfTreatmentOfBabesiosis to label_PercentageOfTreatmentOfBabesiosis" />
    <link:label xlink:type="resource" xlink:label="label_PercentageOfTreatmentOfBabesiosis_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_PercentageOfTreatmentOfBabesiosis_1" xml:lang="en-US" id="label_PercentageOfTreatmentOfBabesiosis_1">Percentage of treatment of babesiosis.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageOfTreatmentOfBabesiosis" xlink:to="label_PercentageOfTreatmentOfBabesiosis_1" xlink:title="Label : PercentageOfTreatmentOfBabesiosis to label_PercentageOfTreatmentOfBabesiosis_1" />
    <link:label xlink:type="resource" xlink:label="label_PercentageOfTreatmentOfBabesiosis_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_PercentageOfTreatmentOfBabesiosis_2" xml:lang="en-US" id="label_PercentageOfTreatmentOfBabesiosis_2">Percentage Of Treatment Of Babesiosis</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageOfTreatmentOfBabesiosis" xlink:to="label_PercentageOfTreatmentOfBabesiosis_2" xlink:title="Label : PercentageOfTreatmentOfBabesiosis to label_PercentageOfTreatmentOfBabesiosis_2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueRemainingPerformanceObligationPercentage" xlink:label="RevenueRemainingPerformanceObligationPercentage" xlink:title="RevenueRemainingPerformanceObligationPercentage" />
    <link:label xlink:type="resource" xlink:label="label_RevenueRemainingPerformanceObligationPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_RevenueRemainingPerformanceObligationPercentage" xml:lang="en-US" id="label_RevenueRemainingPerformanceObligationPercentage">Percentage of revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RevenueRemainingPerformanceObligationPercentage" xlink:to="label_RevenueRemainingPerformanceObligationPercentage" xlink:title="Label : RevenueRemainingPerformanceObligationPercentage to label_RevenueRemainingPerformanceObligationPercentage" />
    <link:label xlink:type="resource" xlink:label="label_RevenueRemainingPerformanceObligationPercentage_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_RevenueRemainingPerformanceObligationPercentage_1" xml:lang="en-US" id="label_RevenueRemainingPerformanceObligationPercentage_1">Revenue, Remaining Performance Obligation, Percentage</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RevenueRemainingPerformanceObligationPercentage" xlink:to="label_RevenueRemainingPerformanceObligationPercentage_1" xlink:title="Label : RevenueRemainingPerformanceObligationPercentage to label_RevenueRemainingPerformanceObligationPercentage_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="ResearchAndDevelopmentExpenseMember" xlink:title="ResearchAndDevelopmentExpenseMember" />
    <link:label xlink:type="resource" xlink:label="label_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ResearchAndDevelopmentExpenseMember" xml:lang="en-US" id="label_ResearchAndDevelopmentExpenseMember">Research and Development Expense [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchAndDevelopmentExpenseMember" xlink:to="label_ResearchAndDevelopmentExpenseMember" xlink:title="Label : ResearchAndDevelopmentExpenseMember to label_ResearchAndDevelopmentExpenseMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" xlink:title="CoverAbstract" />
    <link:label xlink:type="resource" xlink:label="label_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_CoverAbstract" xml:lang="en-US" id="label_CoverAbstract">Cover [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CoverAbstract" xlink:to="label_CoverAbstract" xlink:title="Label : CoverAbstract to label_CoverAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentInformationLineItems" xlink:label="DocumentInformationLineItems" xlink:title="DocumentInformationLineItems" />
    <link:label xlink:type="resource" xlink:label="label_DocumentInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DocumentInformationLineItems" xml:lang="en-US" id="label_DocumentInformationLineItems">Document Information [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentInformationLineItems" xlink:to="label_DocumentInformationLineItems" xlink:title="Label : DocumentInformationLineItems to label_DocumentInformationLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="DocumentType" xlink:title="DocumentType" />
    <link:label xlink:type="resource" xlink:label="label_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DocumentType" xml:lang="en-US" id="label_DocumentType">Document Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentType" xlink:to="label_DocumentType" xlink:title="Label : DocumentType to label_DocumentType" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="AmendmentFlag" xlink:title="AmendmentFlag" />
    <link:label xlink:type="resource" xlink:label="label_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AmendmentFlag" xml:lang="en-US" id="label_AmendmentFlag">Amendment Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmendmentFlag" xlink:to="label_AmendmentFlag" xlink:title="Label : AmendmentFlag to label_AmendmentFlag" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="DocumentPeriodEndDate" xlink:title="DocumentPeriodEndDate" />
    <link:label xlink:type="resource" xlink:label="label_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DocumentPeriodEndDate" xml:lang="en-US" id="label_DocumentPeriodEndDate">Document Period End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentPeriodEndDate" xlink:to="label_DocumentPeriodEndDate" xlink:title="Label : DocumentPeriodEndDate to label_DocumentPeriodEndDate" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="DocumentFiscalYearFocus" xlink:title="DocumentFiscalYearFocus" />
    <link:label xlink:type="resource" xlink:label="label_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DocumentFiscalYearFocus" xml:lang="en-US" id="label_DocumentFiscalYearFocus">Document Fiscal Year Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentFiscalYearFocus" xlink:to="label_DocumentFiscalYearFocus" xlink:title="Label : DocumentFiscalYearFocus to label_DocumentFiscalYearFocus" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="DocumentFiscalPeriodFocus" xlink:title="DocumentFiscalPeriodFocus" />
    <link:label xlink:type="resource" xlink:label="label_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DocumentFiscalPeriodFocus" xml:lang="en-US" id="label_DocumentFiscalPeriodFocus">Document Fiscal Period Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentFiscalPeriodFocus" xlink:to="label_DocumentFiscalPeriodFocus" xlink:title="Label : DocumentFiscalPeriodFocus to label_DocumentFiscalPeriodFocus" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="EntityRegistrantName" xlink:title="EntityRegistrantName" />
    <link:label xlink:type="resource" xlink:label="label_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_EntityRegistrantName" xml:lang="en-US" id="label_EntityRegistrantName">Entity Registrant Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityRegistrantName" xlink:to="label_EntityRegistrantName" xlink:title="Label : EntityRegistrantName to label_EntityRegistrantName" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="EntityCentralIndexKey" xlink:title="EntityCentralIndexKey" />
    <link:label xlink:type="resource" xlink:label="label_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_EntityCentralIndexKey" xml:lang="en-US" id="label_EntityCentralIndexKey">Entity Central Index Key</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityCentralIndexKey" xlink:to="label_EntityCentralIndexKey" xlink:title="Label : EntityCentralIndexKey to label_EntityCentralIndexKey" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="CurrentFiscalYearEndDate" xlink:title="CurrentFiscalYearEndDate" />
    <link:label xlink:type="resource" xlink:label="label_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_CurrentFiscalYearEndDate" xml:lang="en-US" id="label_CurrentFiscalYearEndDate">Current Fiscal Year End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CurrentFiscalYearEndDate" xlink:to="label_CurrentFiscalYearEndDate" xlink:title="Label : CurrentFiscalYearEndDate to label_CurrentFiscalYearEndDate" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="EntityFilerCategory" xlink:title="EntityFilerCategory" />
    <link:label xlink:type="resource" xlink:label="label_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_EntityFilerCategory" xml:lang="en-US" id="label_EntityFilerCategory">Entity Filer Category</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityFilerCategory" xlink:to="label_EntityFilerCategory" xlink:title="Label : EntityFilerCategory to label_EntityFilerCategory" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="EntityEmergingGrowthCompany" xlink:title="EntityEmergingGrowthCompany" />
    <link:label xlink:type="resource" xlink:label="label_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_EntityEmergingGrowthCompany" xml:lang="en-US" id="label_EntityEmergingGrowthCompany">Entity Emerging Growth Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityEmergingGrowthCompany" xlink:to="label_EntityEmergingGrowthCompany" xlink:title="Label : EntityEmergingGrowthCompany to label_EntityEmergingGrowthCompany" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="EntitySmallBusiness" xlink:title="EntitySmallBusiness" />
    <link:label xlink:type="resource" xlink:label="label_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_EntitySmallBusiness" xml:lang="en-US" id="label_EntitySmallBusiness">Entity Small Business</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntitySmallBusiness" xlink:to="label_EntitySmallBusiness" xlink:title="Label : EntitySmallBusiness to label_EntitySmallBusiness" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="EntityFileNumber" xlink:title="EntityFileNumber" />
    <link:label xlink:type="resource" xlink:label="label_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_EntityFileNumber" xml:lang="en-US" id="label_EntityFileNumber">Entity File Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityFileNumber" xlink:to="label_EntityFileNumber" xlink:title="Label : EntityFileNumber to label_EntityFileNumber" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="EntityTaxIdentificationNumber" xlink:title="EntityTaxIdentificationNumber" />
    <link:label xlink:type="resource" xlink:label="label_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_EntityTaxIdentificationNumber" xml:lang="en-US" id="label_EntityTaxIdentificationNumber">Entity Tax Identification Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityTaxIdentificationNumber" xlink:to="label_EntityTaxIdentificationNumber" xlink:title="Label : EntityTaxIdentificationNumber to label_EntityTaxIdentificationNumber" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="EntityInteractiveDataCurrent" xlink:title="EntityInteractiveDataCurrent" />
    <link:label xlink:type="resource" xlink:label="label_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_EntityInteractiveDataCurrent" xml:lang="en-US" id="label_EntityInteractiveDataCurrent">Entity Interactive Data Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityInteractiveDataCurrent" xlink:to="label_EntityInteractiveDataCurrent" xlink:title="Label : EntityInteractiveDataCurrent to label_EntityInteractiveDataCurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="EntityShellCompany" xlink:title="EntityShellCompany" />
    <link:label xlink:type="resource" xlink:label="label_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_EntityShellCompany" xml:lang="en-US" id="label_EntityShellCompany">Entity Shell Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityShellCompany" xlink:to="label_EntityShellCompany" xlink:title="Label : EntityShellCompany to label_EntityShellCompany" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport" xlink:label="DocumentQuarterlyReport" xlink:title="DocumentQuarterlyReport" />
    <link:label xlink:type="resource" xlink:label="label_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DocumentQuarterlyReport" xml:lang="en-US" id="label_DocumentQuarterlyReport">Document Quarterly Report</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentQuarterlyReport" xlink:to="label_DocumentQuarterlyReport" xlink:title="Label : DocumentQuarterlyReport to label_DocumentQuarterlyReport" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="DocumentTransitionReport" xlink:title="DocumentTransitionReport" />
    <link:label xlink:type="resource" xlink:label="label_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DocumentTransitionReport" xml:lang="en-US" id="label_DocumentTransitionReport">Document Transition Report</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentTransitionReport" xlink:to="label_DocumentTransitionReport" xlink:title="Label : DocumentTransitionReport to label_DocumentTransitionReport" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="EntityExTransitionPeriod" xlink:title="EntityExTransitionPeriod" />
    <link:label xlink:type="resource" xlink:label="label_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_EntityExTransitionPeriod" xml:lang="en-US" id="label_EntityExTransitionPeriod">Entity Ex Transition Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityExTransitionPeriod" xlink:to="label_EntityExTransitionPeriod" xlink:title="Label : EntityExTransitionPeriod to label_EntityExTransitionPeriod" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="EntityIncorporationStateCountryCode" xlink:title="EntityIncorporationStateCountryCode" />
    <link:label xlink:type="resource" xlink:label="label_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_EntityIncorporationStateCountryCode" xml:lang="en-US" id="label_EntityIncorporationStateCountryCode">Entity Incorporation, State or Country Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityIncorporationStateCountryCode" xlink:to="label_EntityIncorporationStateCountryCode" xlink:title="Label : EntityIncorporationStateCountryCode to label_EntityIncorporationStateCountryCode" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="EntityAddressAddressLine1" xlink:title="EntityAddressAddressLine1" />
    <link:label xlink:type="resource" xlink:label="label_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_EntityAddressAddressLine1" xml:lang="en-US" id="label_EntityAddressAddressLine1">Entity Address, Address Line One</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressAddressLine1" xlink:to="label_EntityAddressAddressLine1" xlink:title="Label : EntityAddressAddressLine1 to label_EntityAddressAddressLine1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="EntityAddressAddressLine2" xlink:title="EntityAddressAddressLine2" />
    <link:label xlink:type="resource" xlink:label="label_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_EntityAddressAddressLine2" xml:lang="en-US" id="label_EntityAddressAddressLine2">Entity Address, Address Line Two</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressAddressLine2" xlink:to="label_EntityAddressAddressLine2" xlink:title="Label : EntityAddressAddressLine2 to label_EntityAddressAddressLine2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="EntityAddressCityOrTown" xlink:title="EntityAddressCityOrTown" />
    <link:label xlink:type="resource" xlink:label="label_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_EntityAddressCityOrTown" xml:lang="en-US" id="label_EntityAddressCityOrTown">Entity Address, City or Town</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressCityOrTown" xlink:to="label_EntityAddressCityOrTown" xlink:title="Label : EntityAddressCityOrTown to label_EntityAddressCityOrTown" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="EntityAddressStateOrProvince" xlink:title="EntityAddressStateOrProvince" />
    <link:label xlink:type="resource" xlink:label="label_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_EntityAddressStateOrProvince" xml:lang="en-US" id="label_EntityAddressStateOrProvince">Entity Address, State or Province</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressStateOrProvince" xlink:to="label_EntityAddressStateOrProvince" xlink:title="Label : EntityAddressStateOrProvince to label_EntityAddressStateOrProvince" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="EntityAddressPostalZipCode" xlink:title="EntityAddressPostalZipCode" />
    <link:label xlink:type="resource" xlink:label="label_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_EntityAddressPostalZipCode" xml:lang="en-US" id="label_EntityAddressPostalZipCode">Entity Address, Postal Zip Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressPostalZipCode" xlink:to="label_EntityAddressPostalZipCode" xlink:title="Label : EntityAddressPostalZipCode to label_EntityAddressPostalZipCode" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="CityAreaCode" xlink:title="CityAreaCode" />
    <link:label xlink:type="resource" xlink:label="label_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_CityAreaCode" xml:lang="en-US" id="label_CityAreaCode">City Area Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CityAreaCode" xlink:to="label_CityAreaCode" xlink:title="Label : CityAreaCode to label_CityAreaCode" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="LocalPhoneNumber" xlink:title="LocalPhoneNumber" />
    <link:label xlink:type="resource" xlink:label="label_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_LocalPhoneNumber" xml:lang="en-US" id="label_LocalPhoneNumber">Local Phone Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LocalPhoneNumber" xlink:to="label_LocalPhoneNumber" xlink:title="Label : LocalPhoneNumber to label_LocalPhoneNumber" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="Security12bTitle" xlink:title="Security12bTitle" />
    <link:label xlink:type="resource" xlink:label="label_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_Security12bTitle" xml:lang="en-US" id="label_Security12bTitle">Title of 12(b) Security</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Security12bTitle" xlink:to="label_Security12bTitle" xlink:title="Label : Security12bTitle to label_Security12bTitle" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="SecurityExchangeName" xlink:title="SecurityExchangeName" />
    <link:label xlink:type="resource" xlink:label="label_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_SecurityExchangeName" xml:lang="en-US" id="label_SecurityExchangeName">Security Exchange Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SecurityExchangeName" xlink:to="label_SecurityExchangeName" xlink:title="Label : SecurityExchangeName to label_SecurityExchangeName" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="TradingSymbol" xlink:title="TradingSymbol" />
    <link:label xlink:type="resource" xlink:label="label_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_TradingSymbol" xml:lang="en-US" id="label_TradingSymbol">Trading Symbol</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TradingSymbol" xlink:to="label_TradingSymbol" xlink:title="Label : TradingSymbol to label_TradingSymbol" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="EntityCommonStockSharesOutstanding" xlink:title="EntityCommonStockSharesOutstanding" />
    <link:label xlink:type="resource" xlink:label="label_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_EntityCommonStockSharesOutstanding" xml:lang="en-US" id="label_EntityCommonStockSharesOutstanding">Entity Common Stock, Shares Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityCommonStockSharesOutstanding" xlink:to="label_EntityCommonStockSharesOutstanding" xlink:title="Label : EntityCommonStockSharesOutstanding to label_EntityCommonStockSharesOutstanding" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="EntityCurrentReportingStatus" xlink:title="EntityCurrentReportingStatus" />
    <link:label xlink:type="resource" xlink:label="label_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_EntityCurrentReportingStatus" xml:lang="en-US" id="label_EntityCurrentReportingStatus">Entity Current Reporting Status</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityCurrentReportingStatus" xlink:to="label_EntityCurrentReportingStatus" xlink:title="Label : EntityCurrentReportingStatus to label_EntityCurrentReportingStatus" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="CommonStockMember" xlink:title="CommonStockMember" />
    <link:label xlink:type="resource" xlink:label="label_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_CommonStockMember" xml:lang="en-US" id="label_CommonStockMember">Common Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockMember" xlink:to="label_CommonStockMember" xlink:title="Label : CommonStockMember to label_CommonStockMember" />
    <link:label xlink:type="resource" xlink:label="label_CommonStockMember_1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_CommonStockMember_1" xml:lang="en-US" id="label_CommonStockMember_1">Common Stock, par value $0.0001 per share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockMember" xlink:to="label_CommonStockMember_1" xlink:title="Label : CommonStockMember to label_CommonStockMember_1" />
    <link:label xlink:type="resource" xlink:label="label_CommonStockMember_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_CommonStockMember_2" xml:lang="en-US" id="label_CommonStockMember_2">Common Stock [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockMember" xlink:to="label_CommonStockMember_2" xlink:title="Label : CommonStockMember to label_CommonStockMember_2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantMember" xlink:label="WarrantMember" xlink:title="WarrantMember" />
    <link:label xlink:type="resource" xlink:label="label_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_WarrantMember" xml:lang="en-US" id="label_WarrantMember">Warrants [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantMember" xlink:to="label_WarrantMember" xlink:title="Label : WarrantMember to label_WarrantMember" />
    <link:label xlink:type="resource" xlink:label="label_WarrantMember_1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_WarrantMember_1" xml:lang="en-US" id="label_WarrantMember_1">Warrants, each warrant to purchase one share of Common Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantMember" xlink:to="label_WarrantMember_1" xlink:title="Label : WarrantMember to label_WarrantMember_1" />
    <link:label xlink:type="resource" xlink:label="label_WarrantMember_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_WarrantMember_2" xml:lang="en-US" id="label_WarrantMember_2">Warrant [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantMember" xlink:to="label_WarrantMember_2" xlink:title="Label : WarrantMember to label_WarrantMember_2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="StockIssuedDuringPeriodValueIssuedForServices" xlink:title="StockIssuedDuringPeriodValueIssuedForServices" />
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodValueIssuedForServices" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StockIssuedDuringPeriodValueIssuedForServices" xml:lang="en-US" id="label_StockIssuedDuringPeriodValueIssuedForServices">Stock Issued During Period, Value, Issued for Services</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueIssuedForServices" xlink:to="label_StockIssuedDuringPeriodValueIssuedForServices" xlink:title="Label : StockIssuedDuringPeriodValueIssuedForServices to label_StockIssuedDuringPeriodValueIssuedForServices" />
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodValueIssuedForServices_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_StockIssuedDuringPeriodValueIssuedForServices_1" xml:lang="en-US" id="label_StockIssuedDuringPeriodValueIssuedForServices_1">Voluntary return of shares issued to vendor for services</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueIssuedForServices" xlink:to="label_StockIssuedDuringPeriodValueIssuedForServices_1" xlink:title="Label : StockIssuedDuringPeriodValueIssuedForServices to label_StockIssuedDuringPeriodValueIssuedForServices_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="AdditionalPaidInCapital" xlink:title="AdditionalPaidInCapital" />
    <link:label xlink:type="resource" xlink:label="label_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_AdditionalPaidInCapital" xml:lang="en-US" id="label_AdditionalPaidInCapital">Additional Paid-in Capital(1)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdditionalPaidInCapital" xlink:to="label_AdditionalPaidInCapital" xlink:title="Label : AdditionalPaidInCapital to label_AdditionalPaidInCapital" />
    <link:label xlink:type="resource" xlink:label="label_AdditionalPaidInCapital_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AdditionalPaidInCapital_1" xml:lang="en-US" id="label_AdditionalPaidInCapital_1">Additional Paid in Capital</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdditionalPaidInCapital" xlink:to="label_AdditionalPaidInCapital_1" xlink:title="Label : AdditionalPaidInCapital to label_AdditionalPaidInCapital_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="AwardTypeAxis" xlink:title="AwardTypeAxis" />
    <link:label xlink:type="resource" xlink:label="label_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AwardTypeAxis" xml:lang="en-US" id="label_AwardTypeAxis">Award Type Axis</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AwardTypeAxis" xlink:to="label_AwardTypeAxis" xlink:title="Label : AwardTypeAxis to label_AwardTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitiesTable" xlink:label="EntitiesTable" xlink:title="EntitiesTable" />
    <link:label xlink:type="resource" xlink:label="label_EntitiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_EntitiesTable" xml:lang="en-US" id="label_EntitiesTable">Entities [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntitiesTable" xlink:to="label_EntitiesTable" xlink:title="Label : EntitiesTable to label_EntitiesTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:title="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <link:label xlink:type="resource" xlink:label="label_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xml:lang="en-US" id="label_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">Loss from Operations before Provision for Income Taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="label_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:title="Label : IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest to label_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <link:label xlink:type="resource" xlink:label="label_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1" xml:lang="en-US" id="label_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="label_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1" xlink:title="Label : IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest to label_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:label xlink:type="resource" xlink:label="label_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_NetIncomeLoss" xml:lang="en-US" id="label_NetIncomeLoss">Net Loss &#x2013; attributed to 60 Degrees Pharmaceuticals, Inc.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetIncomeLoss" xlink:to="label_NetIncomeLoss" xlink:title="Label : NetIncomeLoss to label_NetIncomeLoss" />
    <link:label xlink:type="resource" xlink:label="label_NetIncomeLoss_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_NetIncomeLoss_1" xml:lang="en-US" id="label_NetIncomeLoss_1">Net Income (Loss)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetIncomeLoss" xlink:to="label_NetIncomeLoss_1" xlink:title="Label : NetIncomeLoss to label_NetIncomeLoss_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:title="OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" />
    <link:label xlink:type="resource" xlink:label="label_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xml:lang="en-US" id="label_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">Comprehensive Loss:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="label_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:title="Label : OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract to label_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" />
    <link:label xlink:type="resource" xlink:label="label_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_1" xml:lang="en-US" id="label_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_1">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="label_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_1" xlink:title="Label : OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract to label_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:title="ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" />
    <link:label xlink:type="resource" xlink:label="label_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xml:lang="en-US" id="label_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">Total Comprehensive Loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="label_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:title="Label : ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest to label_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" />
    <link:label xlink:type="resource" xlink:label="label_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_1" xml:lang="en-US" id="label_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_1">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="label_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_1" xlink:title="Label : ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest to label_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="ComprehensiveIncomeNetOfTax" xlink:title="ComprehensiveIncomeNetOfTax" />
    <link:label xlink:type="resource" xlink:label="label_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_ComprehensiveIncomeNetOfTax" xml:lang="en-US" id="label_ComprehensiveIncomeNetOfTax">Comprehensive Loss &#x2013; attributed to 60 Degrees Pharmaceuticals, Inc.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ComprehensiveIncomeNetOfTax" xlink:to="label_ComprehensiveIncomeNetOfTax" xlink:title="Label : ComprehensiveIncomeNetOfTax to label_ComprehensiveIncomeNetOfTax" />
    <link:label xlink:type="resource" xlink:label="label_ComprehensiveIncomeNetOfTax_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ComprehensiveIncomeNetOfTax_1" xml:lang="en-US" id="label_ComprehensiveIncomeNetOfTax_1">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ComprehensiveIncomeNetOfTax" xlink:to="label_ComprehensiveIncomeNetOfTax_1" xlink:title="Label : ComprehensiveIncomeNetOfTax to label_ComprehensiveIncomeNetOfTax_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="NetIncomeLossAvailableToCommonStockholdersBasic" xlink:title="NetIncomeLossAvailableToCommonStockholdersBasic" />
    <link:label xlink:type="resource" xlink:label="label_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_NetIncomeLossAvailableToCommonStockholdersBasic" xml:lang="en-US" id="label_NetIncomeLossAvailableToCommonStockholdersBasic">Net Loss - attributed to common stockholders</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="label_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:title="Label : NetIncomeLossAvailableToCommonStockholdersBasic to label_NetIncomeLossAvailableToCommonStockholdersBasic" />
    <link:label xlink:type="resource" xlink:label="label_NetIncomeLossAvailableToCommonStockholdersBasic_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_NetIncomeLossAvailableToCommonStockholdersBasic_1" xml:lang="en-US" id="label_NetIncomeLossAvailableToCommonStockholdersBasic_1">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="label_NetIncomeLossAvailableToCommonStockholdersBasic_1" xlink:title="Label : NetIncomeLossAvailableToCommonStockholdersBasic to label_NetIncomeLossAvailableToCommonStockholdersBasic_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="EarningsPerShareAbstract" xlink:title="EarningsPerShareAbstract" />
    <link:label xlink:type="resource" xlink:label="label_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_EarningsPerShareAbstract" xml:lang="en-US" id="label_EarningsPerShareAbstract">Net Loss per Common Share:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarningsPerShareAbstract" xlink:to="label_EarningsPerShareAbstract" xlink:title="Label : EarningsPerShareAbstract to label_EarningsPerShareAbstract" />
    <link:label xlink:type="resource" xlink:label="label_EarningsPerShareAbstract_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_EarningsPerShareAbstract_1" xml:lang="en-US" id="label_EarningsPerShareAbstract_1">Earnings Per Share [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarningsPerShareAbstract" xlink:to="label_EarningsPerShareAbstract_1" xlink:title="Label : EarningsPerShareAbstract to label_EarningsPerShareAbstract_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss" xlink:label="ProfitLoss" xlink:title="ProfitLoss" />
    <link:label xlink:type="resource" xlink:label="label_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_ProfitLoss" xml:lang="en-US" id="label_ProfitLoss">Net Loss including Noncontrolling Interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProfitLoss" xlink:to="label_ProfitLoss" xlink:title="Label : ProfitLoss to label_ProfitLoss" />
    <link:label xlink:type="resource" xlink:label="label_ProfitLoss_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ProfitLoss_1" xml:lang="en-US" id="label_ProfitLoss_1">Net Loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProfitLoss" xlink:to="label_ProfitLoss_1" xlink:title="Label : ProfitLoss to label_ProfitLoss_1" />
    <link:label xlink:type="resource" xlink:label="label_ProfitLoss_2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_ProfitLoss_2" xml:lang="en-US" id="label_ProfitLoss_2">Net income (loss)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProfitLoss" xlink:to="label_ProfitLoss_2" xlink:title="Label : ProfitLoss to label_ProfitLoss_2" />
    <link:label xlink:type="resource" xlink:label="label_ProfitLoss_3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ProfitLoss_3" xml:lang="en-US" id="label_ProfitLoss_3">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProfitLoss" xlink:to="label_ProfitLoss_3" xlink:title="Label : ProfitLoss to label_ProfitLoss_3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:label xlink:type="resource" xlink:label="label_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US" id="label_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">Adjustments to Reconcile Net Loss to Net Cash Used in Operating Activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="label_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="Label : AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to label_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:label xlink:type="resource" xlink:label="label_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1" xml:lang="en-US" id="label_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1">Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Noncash Item [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="label_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1" xlink:title="Label : AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to label_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="LesseeOperatingLeaseRenewalTerm" xlink:title="LesseeOperatingLeaseRenewalTerm" />
    <link:label xlink:type="resource" xlink:label="label_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_LesseeOperatingLeaseRenewalTerm" xml:lang="en-US" id="label_LesseeOperatingLeaseRenewalTerm">Lessee, Operating Lease, Renewal Term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseRenewalTerm" xlink:to="label_LesseeOperatingLeaseRenewalTerm" xlink:title="Label : LesseeOperatingLeaseRenewalTerm to label_LesseeOperatingLeaseRenewalTerm" />
    <link:label xlink:type="resource" xlink:label="label_LesseeOperatingLeaseRenewalTerm_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_LesseeOperatingLeaseRenewalTerm_1" xml:lang="en-US" id="label_LesseeOperatingLeaseRenewalTerm_1">Office space lease renewed term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseRenewalTerm" xlink:to="label_LesseeOperatingLeaseRenewalTerm_1" xlink:title="Label : LesseeOperatingLeaseRenewalTerm to label_LesseeOperatingLeaseRenewalTerm_1" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_NumberOfExecutives" xlink:label="NumberOfExecutives" xlink:title="NumberOfExecutives" />
    <link:label xlink:type="resource" xlink:label="label_NumberOfExecutives" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_NumberOfExecutives" xml:lang="en-US" id="label_NumberOfExecutives">Stock option granted to number of executives</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfExecutives" xlink:to="label_NumberOfExecutives" xlink:title="Label : NumberOfExecutives to label_NumberOfExecutives" />
    <link:label xlink:type="resource" xlink:label="label_NumberOfExecutives_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_NumberOfExecutives_1" xml:lang="en-US" id="label_NumberOfExecutives_1">Number of executives.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfExecutives" xlink:to="label_NumberOfExecutives_1" xlink:title="Label : NumberOfExecutives to label_NumberOfExecutives_1" />
    <link:label xlink:type="resource" xlink:label="label_NumberOfExecutives_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_NumberOfExecutives_2" xml:lang="en-US" id="label_NumberOfExecutives_2">Number Of Executives</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfExecutives" xlink:to="label_NumberOfExecutives_2" xlink:title="Label : NumberOfExecutives to label_NumberOfExecutives_2" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_SignificantCustomerTwoMember" xlink:label="SignificantCustomerTwoMember" xlink:title="SignificantCustomerTwoMember" />
    <link:label xlink:type="resource" xlink:label="label_SignificantCustomerTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_SignificantCustomerTwoMember" xml:lang="en-US" id="label_SignificantCustomerTwoMember">Significant Customer Two [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SignificantCustomerTwoMember" xlink:to="label_SignificantCustomerTwoMember" xlink:title="Label : SignificantCustomerTwoMember to label_SignificantCustomerTwoMember" />
    <link:label xlink:type="resource" xlink:label="label_SignificantCustomerTwoMember_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_SignificantCustomerTwoMember_1" xml:lang="en-US" id="label_SignificantCustomerTwoMember_1">This member stands for the information pertaining to "Significant Customer Two".</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SignificantCustomerTwoMember" xlink:to="label_SignificantCustomerTwoMember_1" xlink:title="Label : SignificantCustomerTwoMember to label_SignificantCustomerTwoMember_1" />
    <link:label xlink:type="resource" xlink:label="label_SignificantCustomerTwoMember_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_SignificantCustomerTwoMember_2" xml:lang="en-US" id="label_SignificantCustomerTwoMember_2">Significant Customer Two [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SignificantCustomerTwoMember" xlink:to="label_SignificantCustomerTwoMember_2" xlink:title="Label : SignificantCustomerTwoMember to label_SignificantCustomerTwoMember_2" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_SignificantCustomerThreeMember" xlink:label="SignificantCustomerThreeMember" xlink:title="SignificantCustomerThreeMember" />
    <link:label xlink:type="resource" xlink:label="label_SignificantCustomerThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_SignificantCustomerThreeMember" xml:lang="en-US" id="label_SignificantCustomerThreeMember">Significant Customer Three [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SignificantCustomerThreeMember" xlink:to="label_SignificantCustomerThreeMember" xlink:title="Label : SignificantCustomerThreeMember to label_SignificantCustomerThreeMember" />
    <link:label xlink:type="resource" xlink:label="label_SignificantCustomerThreeMember_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_SignificantCustomerThreeMember_1" xml:lang="en-US" id="label_SignificantCustomerThreeMember_1">Significant Customer Three [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SignificantCustomerThreeMember" xlink:to="label_SignificantCustomerThreeMember_1" xlink:title="Label : SignificantCustomerThreeMember to label_SignificantCustomerThreeMember_1" />
    <link:label xlink:type="resource" xlink:label="label_SignificantCustomerThreeMember_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_SignificantCustomerThreeMember_2" xml:lang="en-US" id="label_SignificantCustomerThreeMember_2">This member stands for the information pertaining to "Significant Customer Three".</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SignificantCustomerThreeMember" xlink:to="label_SignificantCustomerThreeMember_2" xlink:title="Label : SignificantCustomerThreeMember to label_SignificantCustomerThreeMember_2" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_TrevallyLLCMember" xlink:label="TrevallyLLCMember" xlink:title="TrevallyLLCMember" />
    <link:label xlink:type="resource" xlink:label="label_TrevallyLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_TrevallyLLCMember" xml:lang="en-US" id="label_TrevallyLLCMember">Trevally, LLC [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TrevallyLLCMember" xlink:to="label_TrevallyLLCMember" xlink:title="Label : TrevallyLLCMember to label_TrevallyLLCMember" />
    <link:label xlink:type="resource" xlink:label="label_TrevallyLLCMember_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_TrevallyLLCMember_1" xml:lang="en-US" id="label_TrevallyLLCMember_1">Trevally, LLC [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TrevallyLLCMember" xlink:to="label_TrevallyLLCMember_1" xlink:title="Label : TrevallyLLCMember to label_TrevallyLLCMember_1" />
    <link:label xlink:type="resource" xlink:label="label_TrevallyLLCMember_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_TrevallyLLCMember_2" xml:lang="en-US" id="label_TrevallyLLCMember_2">This member stands for the information pertaining to "Trevally, LLC".</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TrevallyLLCMember" xlink:to="label_TrevallyLLCMember_2" xlink:title="Label : TrevallyLLCMember to label_TrevallyLLCMember_2" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_AgreedToReturnShares" xlink:label="AgreedToReturnShares" xlink:title="AgreedToReturnShares" />
    <link:label xlink:type="resource" xlink:label="label_AgreedToReturnShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AgreedToReturnShares" xml:lang="en-US" id="label_AgreedToReturnShares">Agreed to return shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AgreedToReturnShares" xlink:to="label_AgreedToReturnShares" xlink:title="Label : AgreedToReturnShares to label_AgreedToReturnShares" />
    <link:label xlink:type="resource" xlink:label="label_AgreedToReturnShares_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_AgreedToReturnShares_1" xml:lang="en-US" id="label_AgreedToReturnShares_1">Agreed to return shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AgreedToReturnShares" xlink:to="label_AgreedToReturnShares_1" xlink:title="Label : AgreedToReturnShares to label_AgreedToReturnShares_1" />
    <link:label xlink:type="resource" xlink:label="label_AgreedToReturnShares_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_AgreedToReturnShares_2" xml:lang="en-US" id="label_AgreedToReturnShares_2">Number of agreed to return shares.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AgreedToReturnShares" xlink:to="label_AgreedToReturnShares_2" xlink:title="Label : AgreedToReturnShares to label_AgreedToReturnShares_2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="Label : ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross to label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1">Stock option granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1" xlink:title="Label : ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross to label_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTable" xlink:label="SubsequentEventTable" xlink:title="SubsequentEventTable" />
    <link:label xlink:type="resource" xlink:label="label_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_SubsequentEventTable" xml:lang="en-US" id="label_SubsequentEventTable">Subsequent Event [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsequentEventTable" xlink:to="label_SubsequentEventTable" xlink:title="Label : SubsequentEventTable to label_SubsequentEventTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="SubsequentEventTypeAxis" xlink:title="SubsequentEventTypeAxis" />
    <link:label xlink:type="resource" xlink:label="label_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_SubsequentEventTypeAxis" xml:lang="en-US" id="label_SubsequentEventTypeAxis">Subsequent Event Type [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsequentEventTypeAxis" xlink:to="label_SubsequentEventTypeAxis" xlink:title="Label : SubsequentEventTypeAxis to label_SubsequentEventTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="SubsequentEventTypeDomain" xlink:title="SubsequentEventTypeDomain" />
    <link:label xlink:type="resource" xlink:label="label_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_SubsequentEventTypeDomain" xml:lang="en-US" id="label_SubsequentEventTypeDomain">Subsequent Event Type [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsequentEventTypeDomain" xlink:to="label_SubsequentEventTypeDomain" xlink:title="Label : SubsequentEventTypeDomain to label_SubsequentEventTypeDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember" xlink:label="SubsequentEventMember" xlink:title="SubsequentEventMember" />
    <link:label xlink:type="resource" xlink:label="label_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_SubsequentEventMember" xml:lang="en-US" id="label_SubsequentEventMember">Subsequent Event [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsequentEventMember" xlink:to="label_SubsequentEventMember" xlink:title="Label : SubsequentEventMember to label_SubsequentEventMember" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_JulyTwoThousandTwentyFivePreFundedWarrantsMember" xlink:label="JulyTwoThousandTwentyFivePreFundedWarrantsMember" xlink:title="JulyTwoThousandTwentyFivePreFundedWarrantsMember" />
    <link:label xlink:type="resource" xlink:label="label_JulyTwoThousandTwentyFivePreFundedWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_JulyTwoThousandTwentyFivePreFundedWarrantsMember" xml:lang="en-US" id="label_JulyTwoThousandTwentyFivePreFundedWarrantsMember">July Two Thousand Twenty Five Pre Funded Warrants [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JulyTwoThousandTwentyFivePreFundedWarrantsMember" xlink:to="label_JulyTwoThousandTwentyFivePreFundedWarrantsMember" xlink:title="Label : JulyTwoThousandTwentyFivePreFundedWarrantsMember to label_JulyTwoThousandTwentyFivePreFundedWarrantsMember" />
    <link:label xlink:type="resource" xlink:label="label_JulyTwoThousandTwentyFivePreFundedWarrantsMember_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_JulyTwoThousandTwentyFivePreFundedWarrantsMember_1" xml:lang="en-US" id="label_JulyTwoThousandTwentyFivePreFundedWarrantsMember_1">This member stands for the information pertaining to "July 2025 Pre-Funded Warrants".</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JulyTwoThousandTwentyFivePreFundedWarrantsMember" xlink:to="label_JulyTwoThousandTwentyFivePreFundedWarrantsMember_1" xlink:title="Label : JulyTwoThousandTwentyFivePreFundedWarrantsMember to label_JulyTwoThousandTwentyFivePreFundedWarrantsMember_1" />
    <link:label xlink:type="resource" xlink:label="label_JulyTwoThousandTwentyFivePreFundedWarrantsMember_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_JulyTwoThousandTwentyFivePreFundedWarrantsMember_2" xml:lang="en-US" id="label_JulyTwoThousandTwentyFivePreFundedWarrantsMember_2">July 2025 Pre-Funded Warrants [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JulyTwoThousandTwentyFivePreFundedWarrantsMember" xlink:to="label_JulyTwoThousandTwentyFivePreFundedWarrantsMember_2" xlink:title="Label : JulyTwoThousandTwentyFivePreFundedWarrantsMember to label_JulyTwoThousandTwentyFivePreFundedWarrantsMember_2" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_JulyTwoThousandTwentyFiveAOneWarrantsMember" xlink:label="JulyTwoThousandTwentyFiveAOneWarrantsMember" xlink:title="JulyTwoThousandTwentyFiveAOneWarrantsMember" />
    <link:label xlink:type="resource" xlink:label="label_JulyTwoThousandTwentyFiveAOneWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_JulyTwoThousandTwentyFiveAOneWarrantsMember" xml:lang="en-US" id="label_JulyTwoThousandTwentyFiveAOneWarrantsMember">July Two Thousand Twenty Five A One Warrants [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JulyTwoThousandTwentyFiveAOneWarrantsMember" xlink:to="label_JulyTwoThousandTwentyFiveAOneWarrantsMember" xlink:title="Label : JulyTwoThousandTwentyFiveAOneWarrantsMember to label_JulyTwoThousandTwentyFiveAOneWarrantsMember" />
    <link:label xlink:type="resource" xlink:label="label_JulyTwoThousandTwentyFiveAOneWarrantsMember_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_JulyTwoThousandTwentyFiveAOneWarrantsMember_1" xml:lang="en-US" id="label_JulyTwoThousandTwentyFiveAOneWarrantsMember_1">This member stands for the information pertaining to "July 2025 A-1 Warrants".</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JulyTwoThousandTwentyFiveAOneWarrantsMember" xlink:to="label_JulyTwoThousandTwentyFiveAOneWarrantsMember_1" xlink:title="Label : JulyTwoThousandTwentyFiveAOneWarrantsMember to label_JulyTwoThousandTwentyFiveAOneWarrantsMember_1" />
    <link:label xlink:type="resource" xlink:label="label_JulyTwoThousandTwentyFiveAOneWarrantsMember_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_JulyTwoThousandTwentyFiveAOneWarrantsMember_2" xml:lang="en-US" id="label_JulyTwoThousandTwentyFiveAOneWarrantsMember_2">July 2025 A-1 Warrants [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JulyTwoThousandTwentyFiveAOneWarrantsMember" xlink:to="label_JulyTwoThousandTwentyFiveAOneWarrantsMember_2" xlink:title="Label : JulyTwoThousandTwentyFiveAOneWarrantsMember to label_JulyTwoThousandTwentyFiveAOneWarrantsMember_2" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_JulyTwoThousandTwentyFiveATwoWarrantsMember" xlink:label="JulyTwoThousandTwentyFiveATwoWarrantsMember" xlink:title="JulyTwoThousandTwentyFiveATwoWarrantsMember" />
    <link:label xlink:type="resource" xlink:label="label_JulyTwoThousandTwentyFiveATwoWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_JulyTwoThousandTwentyFiveATwoWarrantsMember" xml:lang="en-US" id="label_JulyTwoThousandTwentyFiveATwoWarrantsMember">July Two Thousand Twenty Five A Two Warrants [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JulyTwoThousandTwentyFiveATwoWarrantsMember" xlink:to="label_JulyTwoThousandTwentyFiveATwoWarrantsMember" xlink:title="Label : JulyTwoThousandTwentyFiveATwoWarrantsMember to label_JulyTwoThousandTwentyFiveATwoWarrantsMember" />
    <link:label xlink:type="resource" xlink:label="label_JulyTwoThousandTwentyFiveATwoWarrantsMember_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_JulyTwoThousandTwentyFiveATwoWarrantsMember_1" xml:lang="en-US" id="label_JulyTwoThousandTwentyFiveATwoWarrantsMember_1">This member stands for the information pertaining to "July 2025 A-2 Warrants".</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JulyTwoThousandTwentyFiveATwoWarrantsMember" xlink:to="label_JulyTwoThousandTwentyFiveATwoWarrantsMember_1" xlink:title="Label : JulyTwoThousandTwentyFiveATwoWarrantsMember to label_JulyTwoThousandTwentyFiveATwoWarrantsMember_1" />
    <link:label xlink:type="resource" xlink:label="label_JulyTwoThousandTwentyFiveATwoWarrantsMember_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_JulyTwoThousandTwentyFiveATwoWarrantsMember_2" xml:lang="en-US" id="label_JulyTwoThousandTwentyFiveATwoWarrantsMember_2">July 2025 A-2 Warrants [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JulyTwoThousandTwentyFiveATwoWarrantsMember" xlink:to="label_JulyTwoThousandTwentyFiveATwoWarrantsMember_2" xlink:title="Label : JulyTwoThousandTwentyFiveATwoWarrantsMember to label_JulyTwoThousandTwentyFiveATwoWarrantsMember_2" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_JulyTwoThousandTwentyFivePlacementAgentWarrantsMember" xlink:label="JulyTwoThousandTwentyFivePlacementAgentWarrantsMember" xlink:title="JulyTwoThousandTwentyFivePlacementAgentWarrantsMember" />
    <link:label xlink:type="resource" xlink:label="label_JulyTwoThousandTwentyFivePlacementAgentWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_JulyTwoThousandTwentyFivePlacementAgentWarrantsMember" xml:lang="en-US" id="label_JulyTwoThousandTwentyFivePlacementAgentWarrantsMember">July Two Thousand Twenty Five Placement Agent Warrants [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JulyTwoThousandTwentyFivePlacementAgentWarrantsMember" xlink:to="label_JulyTwoThousandTwentyFivePlacementAgentWarrantsMember" xlink:title="Label : JulyTwoThousandTwentyFivePlacementAgentWarrantsMember to label_JulyTwoThousandTwentyFivePlacementAgentWarrantsMember" />
    <link:label xlink:type="resource" xlink:label="label_JulyTwoThousandTwentyFivePlacementAgentWarrantsMember_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_JulyTwoThousandTwentyFivePlacementAgentWarrantsMember_1" xml:lang="en-US" id="label_JulyTwoThousandTwentyFivePlacementAgentWarrantsMember_1">This member stands for the information pertaining to "July 2025 Placement Agent Warrants".</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JulyTwoThousandTwentyFivePlacementAgentWarrantsMember" xlink:to="label_JulyTwoThousandTwentyFivePlacementAgentWarrantsMember_1" xlink:title="Label : JulyTwoThousandTwentyFivePlacementAgentWarrantsMember to label_JulyTwoThousandTwentyFivePlacementAgentWarrantsMember_1" />
    <link:label xlink:type="resource" xlink:label="label_JulyTwoThousandTwentyFivePlacementAgentWarrantsMember_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_JulyTwoThousandTwentyFivePlacementAgentWarrantsMember_2" xml:lang="en-US" id="label_JulyTwoThousandTwentyFivePlacementAgentWarrantsMember_2">July 2025 Placement Agent Warrants [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="JulyTwoThousandTwentyFivePlacementAgentWarrantsMember" xlink:to="label_JulyTwoThousandTwentyFivePlacementAgentWarrantsMember_2" xlink:title="Label : JulyTwoThousandTwentyFivePlacementAgentWarrantsMember to label_JulyTwoThousandTwentyFivePlacementAgentWarrantsMember_2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventLineItems" xlink:label="SubsequentEventLineItems" xlink:title="SubsequentEventLineItems" />
    <link:label xlink:type="resource" xlink:label="label_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_SubsequentEventLineItems" xml:lang="en-US" id="label_SubsequentEventLineItems">Subsequent Event [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsequentEventLineItems" xlink:to="label_SubsequentEventLineItems" xlink:title="Label : SubsequentEventLineItems to label_SubsequentEventLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:label="ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:title="ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" />
    <link:label xlink:type="resource" xlink:label="label_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xml:lang="en-US" id="label_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable">Class of Warrant or Right, Date from which Warrants or Rights Exercisable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:to="label_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:title="Label : ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable to label_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" />
    <link:label xlink:type="resource" xlink:label="label_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_1" xml:lang="en-US" id="label_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_1">Date from which warrants exercisable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:to="label_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_1" xlink:title="Label : ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable to label_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="WarrantsAndRightsOutstandingMaturityDate" xlink:title="WarrantsAndRightsOutstandingMaturityDate" />
    <link:label xlink:type="resource" xlink:label="label_WarrantsAndRightsOutstandingMaturityDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_WarrantsAndRightsOutstandingMaturityDate" xml:lang="en-US" id="label_WarrantsAndRightsOutstandingMaturityDate">Warrants and Rights Outstanding, Maturity Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantsAndRightsOutstandingMaturityDate" xlink:to="label_WarrantsAndRightsOutstandingMaturityDate" xlink:title="Label : WarrantsAndRightsOutstandingMaturityDate to label_WarrantsAndRightsOutstandingMaturityDate" />
    <link:label xlink:type="resource" xlink:label="label_WarrantsAndRightsOutstandingMaturityDate_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_WarrantsAndRightsOutstandingMaturityDate_1" xml:lang="en-US" id="label_WarrantsAndRightsOutstandingMaturityDate_1">Date of warrants exercisable expiry</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantsAndRightsOutstandingMaturityDate" xlink:to="label_WarrantsAndRightsOutstandingMaturityDate_1" xlink:title="Label : WarrantsAndRightsOutstandingMaturityDate to label_WarrantsAndRightsOutstandingMaturityDate_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="WarrantsAndRightsOutstandingTerm" xlink:title="WarrantsAndRightsOutstandingTerm" />
    <link:label xlink:type="resource" xlink:label="label_WarrantsAndRightsOutstandingTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_WarrantsAndRightsOutstandingTerm" xml:lang="en-US" id="label_WarrantsAndRightsOutstandingTerm">Representative warrants exercisable term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantsAndRightsOutstandingTerm" xlink:to="label_WarrantsAndRightsOutstandingTerm" xlink:title="Label : WarrantsAndRightsOutstandingTerm to label_WarrantsAndRightsOutstandingTerm" />
    <link:label xlink:type="resource" xlink:label="label_WarrantsAndRightsOutstandingTerm_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_WarrantsAndRightsOutstandingTerm_1" xml:lang="en-US" id="label_WarrantsAndRightsOutstandingTerm_1">Warrants and Rights Outstanding, Term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantsAndRightsOutstandingTerm" xlink:to="label_WarrantsAndRightsOutstandingTerm_1" xlink:title="Label : WarrantsAndRightsOutstandingTerm to label_WarrantsAndRightsOutstandingTerm_1" />
    <link:label xlink:type="resource" xlink:label="label_WarrantsAndRightsOutstandingTerm_2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_WarrantsAndRightsOutstandingTerm_2" xml:lang="en-US" id="label_WarrantsAndRightsOutstandingTerm_2">Warrants exercisable expiry term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantsAndRightsOutstandingTerm" xlink:to="label_WarrantsAndRightsOutstandingTerm_2" xlink:title="Label : WarrantsAndRightsOutstandingTerm to label_WarrantsAndRightsOutstandingTerm_2" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_July2025OfferingMember" xlink:label="July2025OfferingMember" xlink:title="July2025OfferingMember" />
    <link:label xlink:type="resource" xlink:label="label_July2025OfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_July2025OfferingMember" xml:lang="en-US" id="label_July2025OfferingMember">July 2025 Offering [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="July2025OfferingMember" xlink:to="label_July2025OfferingMember" xlink:title="Label : July2025OfferingMember to label_July2025OfferingMember" />
    <link:label xlink:type="resource" xlink:label="label_July2025OfferingMember_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_July2025OfferingMember_1" xml:lang="en-US" id="label_July2025OfferingMember_1">July 2025 Offering [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="July2025OfferingMember" xlink:to="label_July2025OfferingMember_1" xlink:title="Label : July2025OfferingMember to label_July2025OfferingMember_1" />
    <link:label xlink:type="resource" xlink:label="label_July2025OfferingMember_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_July2025OfferingMember_2" xml:lang="en-US" id="label_July2025OfferingMember_2">This member stands for the information pertaining to "July 2025 Offering".</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="July2025OfferingMember" xlink:to="label_July2025OfferingMember_2" xlink:title="Label : July2025OfferingMember to label_July2025OfferingMember_2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="EarningsPerSharePolicyTextBlock" xlink:title="EarningsPerSharePolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_EarningsPerSharePolicyTextBlock" xml:lang="en-US" id="label_EarningsPerSharePolicyTextBlock">Net Loss per Common Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarningsPerSharePolicyTextBlock" xlink:to="label_EarningsPerSharePolicyTextBlock" xlink:title="Label : EarningsPerSharePolicyTextBlock to label_EarningsPerSharePolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="label_EarningsPerSharePolicyTextBlock_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_EarningsPerSharePolicyTextBlock_1" xml:lang="en-US" id="label_EarningsPerSharePolicyTextBlock_1">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarningsPerSharePolicyTextBlock" xlink:to="label_EarningsPerSharePolicyTextBlock_1" xlink:title="Label : EarningsPerSharePolicyTextBlock to label_EarningsPerSharePolicyTextBlock_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues" xlink:label="Revenues" xlink:title="Revenues" />
    <link:label xlink:type="resource" xlink:label="label_Revenues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_Revenues" xml:lang="en-US" id="label_Revenues">Product Revenues &#x2013; net of Discounts and Rebates</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Revenues" xlink:to="label_Revenues" xlink:title="Label : Revenues to label_Revenues" />
    <link:label xlink:type="resource" xlink:label="label_Revenues_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_Revenues_1" xml:lang="en-US" id="label_Revenues_1">Revenues</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Revenues" xlink:to="label_Revenues_1" xlink:title="Label : Revenues to label_Revenues_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="StockholdersEquityAbstract" xlink:title="StockholdersEquityAbstract" />
    <link:label xlink:type="resource" xlink:label="label_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_StockholdersEquityAbstract" xml:lang="en-US" id="label_StockholdersEquityAbstract">SHAREHOLDERS' EQUITY:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquityAbstract" xlink:to="label_StockholdersEquityAbstract" xlink:title="Label : StockholdersEquityAbstract to label_StockholdersEquityAbstract" />
    <link:label xlink:type="resource" xlink:label="label_StockholdersEquityAbstract_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StockholdersEquityAbstract_1" xml:lang="en-US" id="label_StockholdersEquityAbstract_1">Equity, Attributable to Parent [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquityAbstract" xlink:to="label_StockholdersEquityAbstract_1" xlink:title="Label : StockholdersEquityAbstract to label_StockholdersEquityAbstract_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:title="StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
    <link:label xlink:type="resource" xlink:label="label_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xml:lang="en-US" id="label_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">Total Shareholders' Equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="label_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:title="Label : StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest to label_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
    <link:label xlink:type="resource" xlink:label="label_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_1" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="label_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_1" xml:lang="en-US" id="label_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_1">Balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="label_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_1" xlink:title="Label : StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest to label_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_1" />
    <link:label xlink:type="resource" xlink:label="label_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="label_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2" xml:lang="en-US" id="label_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2">Balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="label_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2" xlink:title="Label : StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest to label_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2" />
    <link:label xlink:type="resource" xlink:label="label_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3" xml:lang="en-US" id="label_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3">Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="label_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3" xlink:title="Label : StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest to label_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="LiabilitiesAndStockholdersEquity" xlink:title="LiabilitiesAndStockholdersEquity" />
    <link:label xlink:type="resource" xlink:label="label_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_LiabilitiesAndStockholdersEquity" xml:lang="en-US" id="label_LiabilitiesAndStockholdersEquity">Total Liabilities and Shareholders' Equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="label_LiabilitiesAndStockholdersEquity" xlink:title="Label : LiabilitiesAndStockholdersEquity to label_LiabilitiesAndStockholdersEquity" />
    <link:label xlink:type="resource" xlink:label="label_LiabilitiesAndStockholdersEquity_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_LiabilitiesAndStockholdersEquity_1" xml:lang="en-US" id="label_LiabilitiesAndStockholdersEquity_1">Liabilities and Equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="label_LiabilitiesAndStockholdersEquity_1" xlink:title="Label : LiabilitiesAndStockholdersEquity to label_LiabilitiesAndStockholdersEquity_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:title="OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" />
    <link:label xlink:type="resource" xlink:label="label_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xml:lang="en-US" id="label_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">Net foreign translation gain (loss)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="label_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:title="Label : OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax to label_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" />
    <link:label xlink:type="resource" xlink:label="label_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_1" xml:lang="en-US" id="label_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_1">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="label_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_1" xlink:title="Label : OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax to label_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="DerivativeGainLossOnDerivativeNet" xlink:title="DerivativeGainLossOnDerivativeNet" />
    <link:label xlink:type="resource" xlink:label="label_DerivativeGainLossOnDerivativeNet" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_DerivativeGainLossOnDerivativeNet" xml:lang="en-US" id="label_DerivativeGainLossOnDerivativeNet">Change in Fair Value of Derivative Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DerivativeGainLossOnDerivativeNet" xlink:to="label_DerivativeGainLossOnDerivativeNet" xlink:title="Label : DerivativeGainLossOnDerivativeNet to label_DerivativeGainLossOnDerivativeNet" />
    <link:label xlink:type="resource" xlink:label="label_DerivativeGainLossOnDerivativeNet_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_DerivativeGainLossOnDerivativeNet_1" xml:lang="en-US" id="label_DerivativeGainLossOnDerivativeNet_1">(Gain) loss on change in fair value of derivative liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DerivativeGainLossOnDerivativeNet" xlink:to="label_DerivativeGainLossOnDerivativeNet_1" xlink:title="Label : DerivativeGainLossOnDerivativeNet to label_DerivativeGainLossOnDerivativeNet_1" />
    <link:label xlink:type="resource" xlink:label="label_DerivativeGainLossOnDerivativeNet_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DerivativeGainLossOnDerivativeNet_2" xml:lang="en-US" id="label_DerivativeGainLossOnDerivativeNet_2">Derivative, Gain (Loss) on Derivative, Net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DerivativeGainLossOnDerivativeNet" xlink:to="label_DerivativeGainLossOnDerivativeNet_2" xlink:title="Label : DerivativeGainLossOnDerivativeNet to label_DerivativeGainLossOnDerivativeNet_2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="NetIncomeLossAttributableToNoncontrollingInterest" xlink:title="NetIncomeLossAttributableToNoncontrollingInterest" />
    <link:label xlink:type="resource" xlink:label="label_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_NetIncomeLossAttributableToNoncontrollingInterest" xml:lang="en-US" id="label_NetIncomeLossAttributableToNoncontrollingInterest">Net Loss &#x2013; Noncontrolling Interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="label_NetIncomeLossAttributableToNoncontrollingInterest" xlink:title="Label : NetIncomeLossAttributableToNoncontrollingInterest to label_NetIncomeLossAttributableToNoncontrollingInterest" />
    <link:label xlink:type="resource" xlink:label="label_NetIncomeLossAttributableToNoncontrollingInterest_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_NetIncomeLossAttributableToNoncontrollingInterest_1" xml:lang="en-US" id="label_NetIncomeLossAttributableToNoncontrollingInterest_1">Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="label_NetIncomeLossAttributableToNoncontrollingInterest_1" xlink:title="Label : NetIncomeLossAttributableToNoncontrollingInterest to label_NetIncomeLossAttributableToNoncontrollingInterest_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryWriteDown" xlink:label="InventoryWriteDown" xlink:title="InventoryWriteDown" />
    <link:label xlink:type="resource" xlink:label="label_InventoryWriteDown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_InventoryWriteDown" xml:lang="en-US" id="label_InventoryWriteDown">Inventory Write-down</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InventoryWriteDown" xlink:to="label_InventoryWriteDown" xlink:title="Label : InventoryWriteDown to label_InventoryWriteDown" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:title="Label : ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 to label_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_1" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_1">Option granted to purchase common stock period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_1" xlink:title="Label : ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 to label_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract" xlink:label="AssetsAbstract" xlink:title="AssetsAbstract" />
    <link:label xlink:type="resource" xlink:label="label_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AssetsAbstract" xml:lang="en-US" id="label_AssetsAbstract">Assets [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsAbstract" xlink:to="label_AssetsAbstract" xlink:title="Label : AssetsAbstract to label_AssetsAbstract" />
    <link:label xlink:type="resource" xlink:label="label_AssetsAbstract_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_AssetsAbstract_1" xml:lang="en-US" id="label_AssetsAbstract_1">ASSETS:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsAbstract" xlink:to="label_AssetsAbstract_1" xlink:title="Label : AssetsAbstract to label_AssetsAbstract_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingArrLineItems" xlink:label="InsiderTradingArrLineItems" xlink:title="InsiderTradingArrLineItems" />
    <link:label xlink:type="resource" xlink:label="label_InsiderTradingArrLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_InsiderTradingArrLineItems" xml:lang="en-US" id="label_InsiderTradingArrLineItems">Insider Trading Arrangements [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InsiderTradingArrLineItems" xlink:to="label_InsiderTradingArrLineItems" xlink:title="Label : InsiderTradingArrLineItems to label_InsiderTradingArrLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrAdoptedFlag" xlink:label="Rule10b51ArrAdoptedFlag" xlink:title="Rule10b51ArrAdoptedFlag" />
    <link:label xlink:type="resource" xlink:label="label_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_Rule10b51ArrAdoptedFlag" xml:lang="en-US" id="label_Rule10b51ArrAdoptedFlag">Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Rule10b51ArrAdoptedFlag" xlink:to="label_Rule10b51ArrAdoptedFlag" xlink:title="Label : Rule10b51ArrAdoptedFlag to label_Rule10b51ArrAdoptedFlag" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrAdoptedFlag" xlink:label="NonRule10b51ArrAdoptedFlag" xlink:title="NonRule10b51ArrAdoptedFlag" />
    <link:label xlink:type="resource" xlink:label="label_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_NonRule10b51ArrAdoptedFlag" xml:lang="en-US" id="label_NonRule10b51ArrAdoptedFlag">Non-Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NonRule10b51ArrAdoptedFlag" xlink:to="label_NonRule10b51ArrAdoptedFlag" xlink:title="Label : NonRule10b51ArrAdoptedFlag to label_NonRule10b51ArrAdoptedFlag" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrTrmntdFlag" xlink:label="Rule10b51ArrTrmntdFlag" xlink:title="Rule10b51ArrTrmntdFlag" />
    <link:label xlink:type="resource" xlink:label="label_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_Rule10b51ArrTrmntdFlag" xml:lang="en-US" id="label_Rule10b51ArrTrmntdFlag">Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Rule10b51ArrTrmntdFlag" xlink:to="label_Rule10b51ArrTrmntdFlag" xlink:title="Label : Rule10b51ArrTrmntdFlag to label_Rule10b51ArrTrmntdFlag" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrTrmntdFlag" xlink:label="NonRule10b51ArrTrmntdFlag" xlink:title="NonRule10b51ArrTrmntdFlag" />
    <link:label xlink:type="resource" xlink:label="label_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_NonRule10b51ArrTrmntdFlag" xml:lang="en-US" id="label_NonRule10b51ArrTrmntdFlag">Non-Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NonRule10b51ArrTrmntdFlag" xlink:to="label_NonRule10b51ArrTrmntdFlag" xlink:title="Label : NonRule10b51ArrTrmntdFlag to label_NonRule10b51ArrTrmntdFlag" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:title="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:label xlink:type="resource" xlink:label="label_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xml:lang="en-US" id="label_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">NATURE OF OPERATIONS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="label_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:title="Label : OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to label_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" xlink:title="AccountingPoliciesAbstract" />
    <link:label xlink:type="resource" xlink:label="label_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AccountingPoliciesAbstract" xml:lang="en-US" id="label_AccountingPoliciesAbstract">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccountingPoliciesAbstract" xlink:to="label_AccountingPoliciesAbstract" xlink:title="Label : AccountingPoliciesAbstract to label_AccountingPoliciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="InventoryDisclosureAbstract" xlink:title="InventoryDisclosureAbstract" />
    <link:label xlink:type="resource" xlink:label="label_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_InventoryDisclosureAbstract" xml:lang="en-US" id="label_InventoryDisclosureAbstract">INVENTORY</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InventoryDisclosureAbstract" xlink:to="label_InventoryDisclosureAbstract" xlink:title="Label : InventoryDisclosureAbstract to label_InventoryDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="PropertyPlantAndEquipmentAbstract" xlink:title="PropertyPlantAndEquipmentAbstract" />
    <link:label xlink:type="resource" xlink:label="label_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_PropertyPlantAndEquipmentAbstract" xml:lang="en-US" id="label_PropertyPlantAndEquipmentAbstract">PROPERTY AND EQUIPMENT</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentAbstract" xlink:to="label_PropertyPlantAndEquipmentAbstract" xlink:title="Label : PropertyPlantAndEquipmentAbstract to label_PropertyPlantAndEquipmentAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:label="FiniteLivedIntangibleAssetsNetAbstract" xlink:title="FiniteLivedIntangibleAssetsNetAbstract" />
    <link:label xlink:type="resource" xlink:label="label_FiniteLivedIntangibleAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FiniteLivedIntangibleAssetsNetAbstract" xml:lang="en-US" id="label_FiniteLivedIntangibleAssetsNetAbstract">INTANGIBLE ASSETS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetsNetAbstract" xlink:to="label_FiniteLivedIntangibleAssetsNetAbstract" xlink:title="Label : FiniteLivedIntangibleAssetsNetAbstract to label_FiniteLivedIntangibleAssetsNetAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract" xlink:label="EquityAbstract" xlink:title="EquityAbstract" />
    <link:label xlink:type="resource" xlink:label="label_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_EquityAbstract" xml:lang="en-US" id="label_EquityAbstract">STOCKHOLDERS&#x2019; EQUITY</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquityAbstract" xlink:to="label_EquityAbstract" xlink:title="Label : EquityAbstract to label_EquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="DebtDisclosureAbstract" xlink:title="DebtDisclosureAbstract" />
    <link:label xlink:type="resource" xlink:label="label_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DebtDisclosureAbstract" xml:lang="en-US" id="label_DebtDisclosureAbstract">DEBT</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtDisclosureAbstract" xlink:to="label_DebtDisclosureAbstract" xlink:title="Label : DebtDisclosureAbstract to label_DebtDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:title="DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" />
    <link:label xlink:type="resource" xlink:label="label_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xml:lang="en-US" id="label_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">DERIVATIVE LIABILITIES</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="label_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:title="Label : DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract to label_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" xlink:title="IncomeTaxDisclosureAbstract" />
    <link:label xlink:type="resource" xlink:label="label_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_IncomeTaxDisclosureAbstract" xml:lang="en-US" id="label_IncomeTaxDisclosureAbstract">INCOME TAXES</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="label_IncomeTaxDisclosureAbstract" xlink:title="Label : IncomeTaxDisclosureAbstract to label_IncomeTaxDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:title="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:label xlink:type="resource" xlink:label="label_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xml:lang="en-US" id="label_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">SHARE-BASED COMPENSATION</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="label_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:title="Label : DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract to label_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="CommitmentsAndContingenciesDisclosureAbstract" xlink:title="CommitmentsAndContingenciesDisclosureAbstract" />
    <link:label xlink:type="resource" xlink:label="label_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_CommitmentsAndContingenciesDisclosureAbstract" xml:lang="en-US" id="label_CommitmentsAndContingenciesDisclosureAbstract">COMMITMENTS AND CONTINGENCIES</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="label_CommitmentsAndContingenciesDisclosureAbstract" xlink:title="Label : CommitmentsAndContingenciesDisclosureAbstract to label_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="SubsequentEventsAbstract" xlink:title="SubsequentEventsAbstract" />
    <link:label xlink:type="resource" xlink:label="label_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_SubsequentEventsAbstract" xml:lang="en-US" id="label_SubsequentEventsAbstract">SUBSEQUENT EVENTS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsequentEventsAbstract" xlink:to="label_SubsequentEventsAbstract" xlink:title="Label : SubsequentEventsAbstract to label_SubsequentEventsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FederalStateAndLocalIncomeTaxExpenseBenefitContinuingOperations" xlink:label="FederalStateAndLocalIncomeTaxExpenseBenefitContinuingOperations" xlink:title="FederalStateAndLocalIncomeTaxExpenseBenefitContinuingOperations" />
    <link:label xlink:type="resource" xlink:label="label_FederalStateAndLocalIncomeTaxExpenseBenefitContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_FederalStateAndLocalIncomeTaxExpenseBenefitContinuingOperations" xml:lang="en-US" id="label_FederalStateAndLocalIncomeTaxExpenseBenefitContinuingOperations">Federal, District of Columbia Income Tax Provision or Benefit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FederalStateAndLocalIncomeTaxExpenseBenefitContinuingOperations" xlink:to="label_FederalStateAndLocalIncomeTaxExpenseBenefitContinuingOperations" xlink:title="Label : FederalStateAndLocalIncomeTaxExpenseBenefitContinuingOperations to label_FederalStateAndLocalIncomeTaxExpenseBenefitContinuingOperations" />
    <link:label xlink:type="resource" xlink:label="label_FederalStateAndLocalIncomeTaxExpenseBenefitContinuingOperations_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_FederalStateAndLocalIncomeTaxExpenseBenefitContinuingOperations_1" xml:lang="en-US" id="label_FederalStateAndLocalIncomeTaxExpenseBenefitContinuingOperations_1">Federal, State, and Local, Income Tax Expense (Benefit), Continuing Operations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FederalStateAndLocalIncomeTaxExpenseBenefitContinuingOperations" xlink:to="label_FederalStateAndLocalIncomeTaxExpenseBenefitContinuingOperations_1" xlink:title="Label : FederalStateAndLocalIncomeTaxExpenseBenefitContinuingOperations to label_FederalStateAndLocalIncomeTaxExpenseBenefitContinuingOperations_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:label="PaymentsToAcquireShortTermInvestments" xlink:title="PaymentsToAcquireShortTermInvestments" />
    <link:label xlink:type="resource" xlink:label="label_PaymentsToAcquireShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_PaymentsToAcquireShortTermInvestments" xml:lang="en-US" id="label_PaymentsToAcquireShortTermInvestments">Payments to Acquire Short-Term Investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsToAcquireShortTermInvestments" xlink:to="label_PaymentsToAcquireShortTermInvestments" xlink:title="Label : PaymentsToAcquireShortTermInvestments to label_PaymentsToAcquireShortTermInvestments" />
    <link:label xlink:type="resource" xlink:label="label_PaymentsToAcquireShortTermInvestments_1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_PaymentsToAcquireShortTermInvestments_1" xml:lang="en-US" id="label_PaymentsToAcquireShortTermInvestments_1">Purchase of Short-Term Investments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsToAcquireShortTermInvestments" xlink:to="label_PaymentsToAcquireShortTermInvestments_1" xlink:title="Label : PaymentsToAcquireShortTermInvestments to label_PaymentsToAcquireShortTermInvestments_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="IncomeTaxExpenseBenefit" xlink:title="IncomeTaxExpenseBenefit" />
    <link:label xlink:type="resource" xlink:label="label_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_IncomeTaxExpenseBenefit" xml:lang="en-US" id="label_IncomeTaxExpenseBenefit">Provision for Income Taxes (Note 9)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxExpenseBenefit" xlink:to="label_IncomeTaxExpenseBenefit" xlink:title="Label : IncomeTaxExpenseBenefit to label_IncomeTaxExpenseBenefit" />
    <link:label xlink:type="resource" xlink:label="label_IncomeTaxExpenseBenefit_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_IncomeTaxExpenseBenefit_1" xml:lang="en-US" id="label_IncomeTaxExpenseBenefit_1">Income Tax Expense (Benefit)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxExpenseBenefit" xlink:to="label_IncomeTaxExpenseBenefit_1" xlink:title="Label : IncomeTaxExpenseBenefit to label_IncomeTaxExpenseBenefit_1" />
    <link:label xlink:type="resource" xlink:label="label_IncomeTaxExpenseBenefit_2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_IncomeTaxExpenseBenefit_2" xml:lang="en-US" id="label_IncomeTaxExpenseBenefit_2">Provision for income taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxExpenseBenefit" xlink:to="label_IncomeTaxExpenseBenefit_2" xlink:title="Label : IncomeTaxExpenseBenefit to label_IncomeTaxExpenseBenefit_2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="StockIssuedDuringPeriodSharesOther" xlink:title="StockIssuedDuringPeriodSharesOther" />
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodSharesOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_StockIssuedDuringPeriodSharesOther" xml:lang="en-US" id="label_StockIssuedDuringPeriodSharesOther">Purchase of common stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesOther" xlink:to="label_StockIssuedDuringPeriodSharesOther" xlink:title="Label : StockIssuedDuringPeriodSharesOther to label_StockIssuedDuringPeriodSharesOther" />
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodSharesOther_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StockIssuedDuringPeriodSharesOther_1" xml:lang="en-US" id="label_StockIssuedDuringPeriodSharesOther_1">Stock Issued During Period, Shares, Other</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesOther" xlink:to="label_StockIssuedDuringPeriodSharesOther_1" xlink:title="Label : StockIssuedDuringPeriodSharesOther to label_StockIssuedDuringPeriodSharesOther_1" />
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodSharesOther_2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_StockIssuedDuringPeriodSharesOther_2" xml:lang="en-US" id="label_StockIssuedDuringPeriodSharesOther_2">Voluntary conversion of Series A Preferred Stock into common stock (in Shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesOther" xlink:to="label_StockIssuedDuringPeriodSharesOther_2" xlink:title="Label : StockIssuedDuringPeriodSharesOther to label_StockIssuedDuringPeriodSharesOther_2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="ConversionOfStockAmountConverted1" xlink:title="ConversionOfStockAmountConverted1" />
    <link:label xlink:type="resource" xlink:label="label_ConversionOfStockAmountConverted1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ConversionOfStockAmountConverted1" xml:lang="en-US" id="label_ConversionOfStockAmountConverted1">Conversion of Stock, Amount Converted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConversionOfStockAmountConverted1" xlink:to="label_ConversionOfStockAmountConverted1" xlink:title="Label : ConversionOfStockAmountConverted1 to label_ConversionOfStockAmountConverted1" />
    <link:label xlink:type="resource" xlink:label="label_ConversionOfStockAmountConverted1_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ConversionOfStockAmountConverted1_1" xml:lang="en-US" id="label_ConversionOfStockAmountConverted1_1">Voluntary conversion of Series A Preferred Stock into common stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConversionOfStockAmountConverted1" xlink:to="label_ConversionOfStockAmountConverted1_1" xlink:title="Label : ConversionOfStockAmountConverted1 to label_ConversionOfStockAmountConverted1_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="StockIssuedDuringPeriodValueNewIssues" xlink:title="StockIssuedDuringPeriodValueNewIssues" />
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StockIssuedDuringPeriodValueNewIssues" xml:lang="en-US" id="label_StockIssuedDuringPeriodValueNewIssues">Stock Issued During Period, Value, New Issues</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueNewIssues" xlink:to="label_StockIssuedDuringPeriodValueNewIssues" xlink:title="Label : StockIssuedDuringPeriodValueNewIssues to label_StockIssuedDuringPeriodValueNewIssues" />
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodValueNewIssues_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_StockIssuedDuringPeriodValueNewIssues_1" xml:lang="en-US" id="label_StockIssuedDuringPeriodValueNewIssues_1">Issuance of warrants in Private Placement, net of offering costs paid at closing and deferred offering costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueNewIssues" xlink:to="label_StockIssuedDuringPeriodValueNewIssues_1" xlink:title="Label : StockIssuedDuringPeriodValueNewIssues to label_StockIssuedDuringPeriodValueNewIssues_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:label="LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:title="LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" />
    <link:label xlink:type="resource" xlink:label="label_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xml:lang="en-US" id="label_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear">2025 (remaining three months)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:to="label_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:title="Label : LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear to label_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" />
    <link:label xlink:type="resource" xlink:label="label_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_1" xml:lang="en-US" id="label_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_1">Long-Term Debt, Maturity, Remainder of Fiscal Year</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:to="label_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_1" xlink:title="Label : LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear to label_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="ProceedsFromWarrantExercises" xlink:title="ProceedsFromWarrantExercises" />
    <link:label xlink:type="resource" xlink:label="label_ProceedsFromWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ProceedsFromWarrantExercises" xml:lang="en-US" id="label_ProceedsFromWarrantExercises">Proceeds from Warrant Exercises</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromWarrantExercises" xlink:to="label_ProceedsFromWarrantExercises" xlink:title="Label : ProceedsFromWarrantExercises to label_ProceedsFromWarrantExercises" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_StockIssuedDuringPeriodIssuanceOfSharesForAnnualPerformanceBonusesNetOfSharesWithheldForTaxesinShares" xlink:label="StockIssuedDuringPeriodIssuanceOfSharesForAnnualPerformanceBonusesNetOfSharesWithheldForTaxesinShares" xlink:title="StockIssuedDuringPeriodIssuanceOfSharesForAnnualPerformanceBonusesNetOfSharesWithheldForTaxesinShares" />
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodIssuanceOfSharesForAnnualPerformanceBonusesNetOfSharesWithheldForTaxesinShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_StockIssuedDuringPeriodIssuanceOfSharesForAnnualPerformanceBonusesNetOfSharesWithheldForTaxesinShares" xml:lang="en-US" id="label_StockIssuedDuringPeriodIssuanceOfSharesForAnnualPerformanceBonusesNetOfSharesWithheldForTaxesinShares">Issuance of shares for annual performance bonuses, net of shares withheld for taxes (in Shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodIssuanceOfSharesForAnnualPerformanceBonusesNetOfSharesWithheldForTaxesinShares" xlink:to="label_StockIssuedDuringPeriodIssuanceOfSharesForAnnualPerformanceBonusesNetOfSharesWithheldForTaxesinShares" xlink:title="Label : StockIssuedDuringPeriodIssuanceOfSharesForAnnualPerformanceBonusesNetOfSharesWithheldForTaxesinShares to label_StockIssuedDuringPeriodIssuanceOfSharesForAnnualPerformanceBonusesNetOfSharesWithheldForTaxesinShares" />
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodIssuanceOfSharesForAnnualPerformanceBonusesNetOfSharesWithheldForTaxesinShares_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_StockIssuedDuringPeriodIssuanceOfSharesForAnnualPerformanceBonusesNetOfSharesWithheldForTaxesinShares_1" xml:lang="en-US" id="label_StockIssuedDuringPeriodIssuanceOfSharesForAnnualPerformanceBonusesNetOfSharesWithheldForTaxesinShares_1">Issuance of shares for annual performance bonuses, net of shares withheld for taxes (in Shares).</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodIssuanceOfSharesForAnnualPerformanceBonusesNetOfSharesWithheldForTaxesinShares" xlink:to="label_StockIssuedDuringPeriodIssuanceOfSharesForAnnualPerformanceBonusesNetOfSharesWithheldForTaxesinShares_1" xlink:title="Label : StockIssuedDuringPeriodIssuanceOfSharesForAnnualPerformanceBonusesNetOfSharesWithheldForTaxesinShares to label_StockIssuedDuringPeriodIssuanceOfSharesForAnnualPerformanceBonusesNetOfSharesWithheldForTaxesinShares_1" />
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodIssuanceOfSharesForAnnualPerformanceBonusesNetOfSharesWithheldForTaxesinShares_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StockIssuedDuringPeriodIssuanceOfSharesForAnnualPerformanceBonusesNetOfSharesWithheldForTaxesinShares_2" xml:lang="en-US" id="label_StockIssuedDuringPeriodIssuanceOfSharesForAnnualPerformanceBonusesNetOfSharesWithheldForTaxesinShares_2">Stock Issued During Period Issuance Of Shares For Annual Performance Bonuses Net Of Shares Withheld For Taxesin Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodIssuanceOfSharesForAnnualPerformanceBonusesNetOfSharesWithheldForTaxesinShares" xlink:to="label_StockIssuedDuringPeriodIssuanceOfSharesForAnnualPerformanceBonusesNetOfSharesWithheldForTaxesinShares_2" xlink:title="Label : StockIssuedDuringPeriodIssuanceOfSharesForAnnualPerformanceBonusesNetOfSharesWithheldForTaxesinShares to label_StockIssuedDuringPeriodIssuanceOfSharesForAnnualPerformanceBonusesNetOfSharesWithheldForTaxesinShares_2" />
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodIssuanceOfSharesForAnnualPerformanceBonusesNetOfSharesWithheldForTaxesinShares_3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_StockIssuedDuringPeriodIssuanceOfSharesForAnnualPerformanceBonusesNetOfSharesWithheldForTaxesinShares_3" xml:lang="en-US" id="label_StockIssuedDuringPeriodIssuanceOfSharesForAnnualPerformanceBonusesNetOfSharesWithheldForTaxesinShares_3">Shares of common stock to the executives in settlement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodIssuanceOfSharesForAnnualPerformanceBonusesNetOfSharesWithheldForTaxesinShares" xlink:to="label_StockIssuedDuringPeriodIssuanceOfSharesForAnnualPerformanceBonusesNetOfSharesWithheldForTaxesinShares_3" xlink:title="Label : StockIssuedDuringPeriodIssuanceOfSharesForAnnualPerformanceBonusesNetOfSharesWithheldForTaxesinShares to label_StockIssuedDuringPeriodIssuanceOfSharesForAnnualPerformanceBonusesNetOfSharesWithheldForTaxesinShares_3" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_ATMOfferingNetOfOfferingCostsPaid" xlink:label="ATMOfferingNetOfOfferingCostsPaid" xlink:title="ATMOfferingNetOfOfferingCostsPaid" />
    <link:label xlink:type="resource" xlink:label="label_ATMOfferingNetOfOfferingCostsPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ATMOfferingNetOfOfferingCostsPaid" xml:lang="en-US" id="label_ATMOfferingNetOfOfferingCostsPaid">ATM Offering Net of Offering Costs Paid</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ATMOfferingNetOfOfferingCostsPaid" xlink:to="label_ATMOfferingNetOfOfferingCostsPaid" xlink:title="Label : ATMOfferingNetOfOfferingCostsPaid to label_ATMOfferingNetOfOfferingCostsPaid" />
    <link:label xlink:type="resource" xlink:label="label_ATMOfferingNetOfOfferingCostsPaid_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ATMOfferingNetOfOfferingCostsPaid_1" xml:lang="en-US" id="label_ATMOfferingNetOfOfferingCostsPaid_1">ATM Offering, net of offering costs paid</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ATMOfferingNetOfOfferingCostsPaid" xlink:to="label_ATMOfferingNetOfOfferingCostsPaid_1" xlink:title="Label : ATMOfferingNetOfOfferingCostsPaid to label_ATMOfferingNetOfOfferingCostsPaid_1" />
    <link:label xlink:type="resource" xlink:label="label_ATMOfferingNetOfOfferingCostsPaid_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_ATMOfferingNetOfOfferingCostsPaid_2" xml:lang="en-US" id="label_ATMOfferingNetOfOfferingCostsPaid_2">ATM Offering, net of offering costs paid.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ATMOfferingNetOfOfferingCostsPaid" xlink:to="label_ATMOfferingNetOfOfferingCostsPaid_2" xlink:title="Label : ATMOfferingNetOfOfferingCostsPaid to label_ATMOfferingNetOfOfferingCostsPaid_2" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsNetOfOfferingCostsPaidAtClosingAndDeferredOfferingCosts" xlink:label="StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsNetOfOfferingCostsPaidAtClosingAndDeferredOfferingCosts" xlink:title="StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsNetOfOfferingCostsPaidAtClosingAndDeferredOfferingCosts" />
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsNetOfOfferingCostsPaidAtClosingAndDeferredOfferingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsNetOfOfferingCostsPaidAtClosingAndDeferredOfferingCosts" xml:lang="en-US" id="label_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsNetOfOfferingCostsPaidAtClosingAndDeferredOfferingCosts">Stock Issued During Period Shares Issuance Of Common Stock And Warrants Net Of Offering Costs Paid At Closing And Deferred Offering Costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsNetOfOfferingCostsPaidAtClosingAndDeferredOfferingCosts" xlink:to="label_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsNetOfOfferingCostsPaidAtClosingAndDeferredOfferingCosts" xlink:title="Label : StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsNetOfOfferingCostsPaidAtClosingAndDeferredOfferingCosts to label_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsNetOfOfferingCostsPaidAtClosingAndDeferredOfferingCosts" />
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsNetOfOfferingCostsPaidAtClosingAndDeferredOfferingCosts_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsNetOfOfferingCostsPaidAtClosingAndDeferredOfferingCosts_1" xml:lang="en-US" id="label_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsNetOfOfferingCostsPaidAtClosingAndDeferredOfferingCosts_1">Issuance of common stock and warrants, net of offering costs paid at closing and deferred offering costs (Note 6) (in Shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsNetOfOfferingCostsPaidAtClosingAndDeferredOfferingCosts" xlink:to="label_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsNetOfOfferingCostsPaidAtClosingAndDeferredOfferingCosts_1" xlink:title="Label : StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsNetOfOfferingCostsPaidAtClosingAndDeferredOfferingCosts to label_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsNetOfOfferingCostsPaidAtClosingAndDeferredOfferingCosts_1" />
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsNetOfOfferingCostsPaidAtClosingAndDeferredOfferingCosts_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsNetOfOfferingCostsPaidAtClosingAndDeferredOfferingCosts_2" xml:lang="en-US" id="label_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsNetOfOfferingCostsPaidAtClosingAndDeferredOfferingCosts_2">Represent the shares issuance of common stock and warrants, net of offering costs paid at closing and deferred offering costs.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsNetOfOfferingCostsPaidAtClosingAndDeferredOfferingCosts" xlink:to="label_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsNetOfOfferingCostsPaidAtClosingAndDeferredOfferingCosts_2" xlink:title="Label : StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsNetOfOfferingCostsPaidAtClosingAndDeferredOfferingCosts to label_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsNetOfOfferingCostsPaidAtClosingAndDeferredOfferingCosts_2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryLIFOReservePeriodCharge" xlink:label="InventoryLIFOReservePeriodCharge" xlink:title="InventoryLIFOReservePeriodCharge" />
    <link:label xlink:type="resource" xlink:label="label_InventoryLIFOReservePeriodCharge" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_InventoryLIFOReservePeriodCharge" xml:lang="en-US" id="label_InventoryLIFOReservePeriodCharge">Inventory, LIFO Reserve, Period Charge</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InventoryLIFOReservePeriodCharge" xlink:to="label_InventoryLIFOReservePeriodCharge" xlink:title="Label : InventoryLIFOReservePeriodCharge to label_InventoryLIFOReservePeriodCharge" />
    <link:label xlink:type="resource" xlink:label="label_InventoryLIFOReservePeriodCharge_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_InventoryLIFOReservePeriodCharge_1" xml:lang="en-US" id="label_InventoryLIFOReservePeriodCharge_1">Change in Inventory Reserve</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InventoryLIFOReservePeriodCharge" xlink:to="label_InventoryLIFOReservePeriodCharge_1" xlink:title="Label : InventoryLIFOReservePeriodCharge to label_InventoryLIFOReservePeriodCharge_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryGross" xlink:label="InventoryGross" xlink:title="InventoryGross" />
    <link:label xlink:type="resource" xlink:label="label_InventoryGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_InventoryGross" xml:lang="en-US" id="label_InventoryGross">Inventory, Gross</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InventoryGross" xlink:to="label_InventoryGross" xlink:title="Label : InventoryGross to label_InventoryGross" />
    <link:label xlink:type="resource" xlink:label="label_InventoryGross_1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_InventoryGross_1" xml:lang="en-US" id="label_InventoryGross_1">Total Inventory</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InventoryGross" xlink:to="label_InventoryGross_1" xlink:title="Label : InventoryGross to label_InventoryGross_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryAdjustments" xlink:label="InventoryAdjustments" xlink:title="InventoryAdjustments" />
    <link:label xlink:type="resource" xlink:label="label_InventoryAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_InventoryAdjustments" xml:lang="en-US" id="label_InventoryAdjustments">Inventory Adjustments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InventoryAdjustments" xlink:to="label_InventoryAdjustments" xlink:title="Label : InventoryAdjustments to label_InventoryAdjustments" />
    <link:label xlink:type="resource" xlink:label="label_InventoryAdjustments_1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_InventoryAdjustments_1" xml:lang="en-US" id="label_InventoryAdjustments_1">Reserve for Expiring Inventory</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InventoryAdjustments" xlink:to="label_InventoryAdjustments_1" xlink:title="Label : InventoryAdjustments to label_InventoryAdjustments_1" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_ProceedsFromIssuanceATMOfferingCosts" xlink:label="ProceedsFromIssuanceATMOfferingCosts" xlink:title="ProceedsFromIssuanceATMOfferingCosts" />
    <link:label xlink:type="resource" xlink:label="label_ProceedsFromIssuanceATMOfferingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ProceedsFromIssuanceATMOfferingCosts" xml:lang="en-US" id="label_ProceedsFromIssuanceATMOfferingCosts">Proceeds from Issuance A T M Offering Costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromIssuanceATMOfferingCosts" xlink:to="label_ProceedsFromIssuanceATMOfferingCosts" xlink:title="Label : ProceedsFromIssuanceATMOfferingCosts to label_ProceedsFromIssuanceATMOfferingCosts" />
    <link:label xlink:type="resource" xlink:label="label_ProceedsFromIssuanceATMOfferingCosts_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ProceedsFromIssuanceATMOfferingCosts_1" xml:lang="en-US" id="label_ProceedsFromIssuanceATMOfferingCosts_1">Net proceeds from ATM Offering</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromIssuanceATMOfferingCosts" xlink:to="label_ProceedsFromIssuanceATMOfferingCosts_1" xlink:title="Label : ProceedsFromIssuanceATMOfferingCosts to label_ProceedsFromIssuanceATMOfferingCosts_1" />
    <link:label xlink:type="resource" xlink:label="label_ProceedsFromIssuanceATMOfferingCosts_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_ProceedsFromIssuanceATMOfferingCosts_2" xml:lang="en-US" id="label_ProceedsFromIssuanceATMOfferingCosts_2">Proceeds from ATM offering, net of offering cost.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromIssuanceATMOfferingCosts" xlink:to="label_ProceedsFromIssuanceATMOfferingCosts_2" xlink:title="Label : ProceedsFromIssuanceATMOfferingCosts to label_ProceedsFromIssuanceATMOfferingCosts_2" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_SeriesAWarrantsMember" xlink:label="SeriesAWarrantsMember" xlink:title="SeriesAWarrantsMember" />
    <link:label xlink:type="resource" xlink:label="label_SeriesAWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_SeriesAWarrantsMember" xml:lang="en-US" id="label_SeriesAWarrantsMember">Series A Warrants [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeriesAWarrantsMember" xlink:to="label_SeriesAWarrantsMember" xlink:title="Label : SeriesAWarrantsMember to label_SeriesAWarrantsMember" />
    <link:label xlink:type="resource" xlink:label="label_SeriesAWarrantsMember_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_SeriesAWarrantsMember_1" xml:lang="en-US" id="label_SeriesAWarrantsMember_1">Series A Warrants [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeriesAWarrantsMember" xlink:to="label_SeriesAWarrantsMember_1" xlink:title="Label : SeriesAWarrantsMember to label_SeriesAWarrantsMember_1" />
    <link:label xlink:type="resource" xlink:label="label_SeriesAWarrantsMember_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_SeriesAWarrantsMember_2" xml:lang="en-US" id="label_SeriesAWarrantsMember_2">This member stands for the information pertaining to "Series A Warrants".</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeriesAWarrantsMember" xlink:to="label_SeriesAWarrantsMember_2" xlink:title="Label : SeriesAWarrantsMember to label_SeriesAWarrantsMember_2" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_SeriesBWarrantsMember" xlink:label="SeriesBWarrantsMember" xlink:title="SeriesBWarrantsMember" />
    <link:label xlink:type="resource" xlink:label="label_SeriesBWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_SeriesBWarrantsMember" xml:lang="en-US" id="label_SeriesBWarrantsMember">Series B Warrants [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeriesBWarrantsMember" xlink:to="label_SeriesBWarrantsMember" xlink:title="Label : SeriesBWarrantsMember to label_SeriesBWarrantsMember" />
    <link:label xlink:type="resource" xlink:label="label_SeriesBWarrantsMember_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_SeriesBWarrantsMember_1" xml:lang="en-US" id="label_SeriesBWarrantsMember_1">Series B Warrants [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeriesBWarrantsMember" xlink:to="label_SeriesBWarrantsMember_1" xlink:title="Label : SeriesBWarrantsMember to label_SeriesBWarrantsMember_1" />
    <link:label xlink:type="resource" xlink:label="label_SeriesBWarrantsMember_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_SeriesBWarrantsMember_2" xml:lang="en-US" id="label_SeriesBWarrantsMember_2">This member stands for the information pertaining to "Series B Warrants".</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeriesBWarrantsMember" xlink:to="label_SeriesBWarrantsMember_2" xlink:title="Label : SeriesBWarrantsMember to label_SeriesBWarrantsMember_2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="ConvertiblePreferredStockSharesIssuedUponConversion" xlink:title="ConvertiblePreferredStockSharesIssuedUponConversion" />
    <link:label xlink:type="resource" xlink:label="label_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ConvertiblePreferredStockSharesIssuedUponConversion" xml:lang="en-US" id="label_ConvertiblePreferredStockSharesIssuedUponConversion">Convertible Preferred Stock, Shares Issued upon Conversion</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConvertiblePreferredStockSharesIssuedUponConversion" xlink:to="label_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:title="Label : ConvertiblePreferredStockSharesIssuedUponConversion to label_ConvertiblePreferredStockSharesIssuedUponConversion" />
    <link:label xlink:type="resource" xlink:label="label_ConvertiblePreferredStockSharesIssuedUponConversion_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ConvertiblePreferredStockSharesIssuedUponConversion_1" xml:lang="en-US" id="label_ConvertiblePreferredStockSharesIssuedUponConversion_1">Converted shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConvertiblePreferredStockSharesIssuedUponConversion" xlink:to="label_ConvertiblePreferredStockSharesIssuedUponConversion_1" xlink:title="Label : ConvertiblePreferredStockSharesIssuedUponConversion to label_ConvertiblePreferredStockSharesIssuedUponConversion_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="ConversionOfStockSharesConverted1" xlink:title="ConversionOfStockSharesConverted1" />
    <link:label xlink:type="resource" xlink:label="label_ConversionOfStockSharesConverted1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ConversionOfStockSharesConverted1" xml:lang="en-US" id="label_ConversionOfStockSharesConverted1">Conversion of Stock, Shares Converted (in Shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConversionOfStockSharesConverted1" xlink:to="label_ConversionOfStockSharesConverted1" xlink:title="Label : ConversionOfStockSharesConverted1 to label_ConversionOfStockSharesConverted1" />
    <link:label xlink:type="resource" xlink:label="label_ConversionOfStockSharesConverted1_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ConversionOfStockSharesConverted1_1" xml:lang="en-US" id="label_ConversionOfStockSharesConverted1_1">Conversion of Stock, Shares Converted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConversionOfStockSharesConverted1" xlink:to="label_ConversionOfStockSharesConverted1_1" xlink:title="Label : ConversionOfStockSharesConverted1 to label_ConversionOfStockSharesConverted1_1" />
    <link:label xlink:type="resource" xlink:label="label_ConversionOfStockSharesConverted1_2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_ConversionOfStockSharesConverted1_2" xml:lang="en-US" id="label_ConversionOfStockSharesConverted1_2">Shares converted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConversionOfStockSharesConverted1" xlink:to="label_ConversionOfStockSharesConverted1_2" xlink:title="Label : ConversionOfStockSharesConverted1 to label_ConversionOfStockSharesConverted1_2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantExercisePriceDecrease" xlink:label="WarrantExercisePriceDecrease" xlink:title="WarrantExercisePriceDecrease" />
    <link:label xlink:type="resource" xlink:label="label_WarrantExercisePriceDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_WarrantExercisePriceDecrease" xml:lang="en-US" id="label_WarrantExercisePriceDecrease">Warrant, Exercise Price, Decrease</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantExercisePriceDecrease" xlink:to="label_WarrantExercisePriceDecrease" xlink:title="Label : WarrantExercisePriceDecrease to label_WarrantExercisePriceDecrease" />
    <link:label xlink:type="resource" xlink:label="label_WarrantExercisePriceDecrease_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_WarrantExercisePriceDecrease_1" xml:lang="en-US" id="label_WarrantExercisePriceDecrease_1">Exercise price (in Dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantExercisePriceDecrease" xlink:to="label_WarrantExercisePriceDecrease_1" xlink:title="Label : WarrantExercisePriceDecrease to label_WarrantExercisePriceDecrease_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="WarrantsAndRightsOutstanding" xlink:title="WarrantsAndRightsOutstanding" />
    <link:label xlink:type="resource" xlink:label="label_WarrantsAndRightsOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_WarrantsAndRightsOutstanding" xml:lang="en-US" id="label_WarrantsAndRightsOutstanding">Warrants and Rights Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantsAndRightsOutstanding" xlink:to="label_WarrantsAndRightsOutstanding" xlink:title="Label : WarrantsAndRightsOutstanding to label_WarrantsAndRightsOutstanding" />
    <link:label xlink:type="resource" xlink:label="label_WarrantsAndRightsOutstanding_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_WarrantsAndRightsOutstanding_1" xml:lang="en-US" id="label_WarrantsAndRightsOutstanding_1">Warrants and rights outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantsAndRightsOutstanding" xlink:to="label_WarrantsAndRightsOutstanding_1" xlink:title="Label : WarrantsAndRightsOutstanding to label_WarrantsAndRightsOutstanding_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockConvertibleSharesIssuable" xlink:label="PreferredStockConvertibleSharesIssuable" xlink:title="PreferredStockConvertibleSharesIssuable" />
    <link:label xlink:type="resource" xlink:label="label_PreferredStockConvertibleSharesIssuable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_PreferredStockConvertibleSharesIssuable" xml:lang="en-US" id="label_PreferredStockConvertibleSharesIssuable">Preferred Stock, Convertible, Shares Issuable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockConvertibleSharesIssuable" xlink:to="label_PreferredStockConvertibleSharesIssuable" xlink:title="Label : PreferredStockConvertibleSharesIssuable to label_PreferredStockConvertibleSharesIssuable" />
    <link:label xlink:type="resource" xlink:label="label_PreferredStockConvertibleSharesIssuable_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_PreferredStockConvertibleSharesIssuable_1" xml:lang="en-US" id="label_PreferredStockConvertibleSharesIssuable_1">Preferred stock, convertible, shares issuable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockConvertibleSharesIssuable" xlink:to="label_PreferredStockConvertibleSharesIssuable_1" xlink:title="Label : PreferredStockConvertibleSharesIssuable to label_PreferredStockConvertibleSharesIssuable_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConvertibleCommonStockMember" xlink:label="ConvertibleCommonStockMember" xlink:title="ConvertibleCommonStockMember" />
    <link:label xlink:type="resource" xlink:label="label_ConvertibleCommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ConvertibleCommonStockMember" xml:lang="en-US" id="label_ConvertibleCommonStockMember">Convertible Common Stock [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConvertibleCommonStockMember" xlink:to="label_ConvertibleCommonStockMember" xlink:title="Label : ConvertibleCommonStockMember to label_ConvertibleCommonStockMember" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_HCWainwrightAndCoLLCMember" xlink:label="HCWainwrightAndCoLLCMember" xlink:title="HCWainwrightAndCoLLCMember" />
    <link:label xlink:type="resource" xlink:label="label_HCWainwrightAndCoLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_HCWainwrightAndCoLLCMember" xml:lang="en-US" id="label_HCWainwrightAndCoLLCMember">H C Wainwright And Co LLC [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HCWainwrightAndCoLLCMember" xlink:to="label_HCWainwrightAndCoLLCMember" xlink:title="Label : HCWainwrightAndCoLLCMember to label_HCWainwrightAndCoLLCMember" />
    <link:label xlink:type="resource" xlink:label="label_HCWainwrightAndCoLLCMember_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_HCWainwrightAndCoLLCMember_1" xml:lang="en-US" id="label_HCWainwrightAndCoLLCMember_1">H.C. Wainwright &amp; Co., LLC [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HCWainwrightAndCoLLCMember" xlink:to="label_HCWainwrightAndCoLLCMember_1" xlink:title="Label : HCWainwrightAndCoLLCMember to label_HCWainwrightAndCoLLCMember_1" />
    <link:label xlink:type="resource" xlink:label="label_HCWainwrightAndCoLLCMember_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_HCWainwrightAndCoLLCMember_2" xml:lang="en-US" id="label_HCWainwrightAndCoLLCMember_2">This member stands for the information pertaining to "H.C. Wainwright &amp; Co., LLC ".</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HCWainwrightAndCoLLCMember" xlink:to="label_HCWainwrightAndCoLLCMember_2" xlink:title="Label : HCWainwrightAndCoLLCMember to label_HCWainwrightAndCoLLCMember_2" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_SeptemberTwoThousandTwentyFourAgentWarrantsMember" xlink:label="SeptemberTwoThousandTwentyFourAgentWarrantsMember" xlink:title="SeptemberTwoThousandTwentyFourAgentWarrantsMember" />
    <link:label xlink:type="resource" xlink:label="label_SeptemberTwoThousandTwentyFourAgentWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_SeptemberTwoThousandTwentyFourAgentWarrantsMember" xml:lang="en-US" id="label_SeptemberTwoThousandTwentyFourAgentWarrantsMember">September Two Thousand Twenty Four Agent Warrants [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeptemberTwoThousandTwentyFourAgentWarrantsMember" xlink:to="label_SeptemberTwoThousandTwentyFourAgentWarrantsMember" xlink:title="Label : SeptemberTwoThousandTwentyFourAgentWarrantsMember to label_SeptemberTwoThousandTwentyFourAgentWarrantsMember" />
    <link:label xlink:type="resource" xlink:label="label_SeptemberTwoThousandTwentyFourAgentWarrantsMember_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_SeptemberTwoThousandTwentyFourAgentWarrantsMember_1" xml:lang="en-US" id="label_SeptemberTwoThousandTwentyFourAgentWarrantsMember_1">September 2024 Agent Warrants [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeptemberTwoThousandTwentyFourAgentWarrantsMember" xlink:to="label_SeptemberTwoThousandTwentyFourAgentWarrantsMember_1" xlink:title="Label : SeptemberTwoThousandTwentyFourAgentWarrantsMember to label_SeptemberTwoThousandTwentyFourAgentWarrantsMember_1" />
    <link:label xlink:type="resource" xlink:label="label_SeptemberTwoThousandTwentyFourAgentWarrantsMember_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_SeptemberTwoThousandTwentyFourAgentWarrantsMember_2" xml:lang="en-US" id="label_SeptemberTwoThousandTwentyFourAgentWarrantsMember_2">This member stands for the information pertaining to "September 2024 Agent Warrants".</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeptemberTwoThousandTwentyFourAgentWarrantsMember" xlink:to="label_SeptemberTwoThousandTwentyFourAgentWarrantsMember_2" xlink:title="Label : SeptemberTwoThousandTwentyFourAgentWarrantsMember to label_SeptemberTwoThousandTwentyFourAgentWarrantsMember_2" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_SeriesAAndSeriesBWarrantsMember" xlink:label="SeriesAAndSeriesBWarrantsMember" xlink:title="SeriesAAndSeriesBWarrantsMember" />
    <link:label xlink:type="resource" xlink:label="label_SeriesAAndSeriesBWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_SeriesAAndSeriesBWarrantsMember" xml:lang="en-US" id="label_SeriesAAndSeriesBWarrantsMember">Series A And Series B Warrants [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeriesAAndSeriesBWarrantsMember" xlink:to="label_SeriesAAndSeriesBWarrantsMember" xlink:title="Label : SeriesAAndSeriesBWarrantsMember to label_SeriesAAndSeriesBWarrantsMember" />
    <link:label xlink:type="resource" xlink:label="label_SeriesAAndSeriesBWarrantsMember_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_SeriesAAndSeriesBWarrantsMember_1" xml:lang="en-US" id="label_SeriesAAndSeriesBWarrantsMember_1">Series A And Series B Warrants [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeriesAAndSeriesBWarrantsMember" xlink:to="label_SeriesAAndSeriesBWarrantsMember_1" xlink:title="Label : SeriesAAndSeriesBWarrantsMember to label_SeriesAAndSeriesBWarrantsMember_1" />
    <link:label xlink:type="resource" xlink:label="label_SeriesAAndSeriesBWarrantsMember_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_SeriesAAndSeriesBWarrantsMember_2" xml:lang="en-US" id="label_SeriesAAndSeriesBWarrantsMember_2">This member stands for the information pertaining to "Series B And Series B Warrants".</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeriesAAndSeriesBWarrantsMember" xlink:to="label_SeriesAAndSeriesBWarrantsMember_2" xlink:title="Label : SeriesAAndSeriesBWarrantsMember to label_SeriesAAndSeriesBWarrantsMember_2" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_ATMOfferingShares" xlink:label="ATMOfferingShares" xlink:title="ATMOfferingShares" />
    <link:label xlink:type="resource" xlink:label="label_ATMOfferingShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ATMOfferingShares" xml:lang="en-US" id="label_ATMOfferingShares">ATM Offering Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ATMOfferingShares" xlink:to="label_ATMOfferingShares" xlink:title="Label : ATMOfferingShares to label_ATMOfferingShares" />
    <link:label xlink:type="resource" xlink:label="label_ATMOfferingShares_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ATMOfferingShares_1" xml:lang="en-US" id="label_ATMOfferingShares_1">ATM Offering</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ATMOfferingShares" xlink:to="label_ATMOfferingShares_1" xlink:title="Label : ATMOfferingShares to label_ATMOfferingShares_1" />
    <link:label xlink:type="resource" xlink:label="label_ATMOfferingShares_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_ATMOfferingShares_2" xml:lang="en-US" id="label_ATMOfferingShares_2">ATM Offering.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ATMOfferingShares" xlink:to="label_ATMOfferingShares_2" xlink:title="Label : ATMOfferingShares to label_ATMOfferingShares_2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GrossProfit" xlink:label="GrossProfit" xlink:title="GrossProfit" />
    <link:label xlink:type="resource" xlink:label="label_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_GrossProfit" xml:lang="en-US" id="label_GrossProfit">Gross (Loss) Profit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GrossProfit" xlink:to="label_GrossProfit" xlink:title="Label : GrossProfit to label_GrossProfit" />
    <link:label xlink:type="resource" xlink:label="label_GrossProfit_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_GrossProfit_1" xml:lang="en-US" id="label_GrossProfit_1">Gross Profit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GrossProfit" xlink:to="label_GrossProfit_1" xlink:title="Label : GrossProfit to label_GrossProfit_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="InterestIncomeExpenseNonoperatingNet" xlink:title="InterestIncomeExpenseNonoperatingNet" />
    <link:label xlink:type="resource" xlink:label="label_InterestIncomeExpenseNonoperatingNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_InterestIncomeExpenseNonoperatingNet" xml:lang="en-US" id="label_InterestIncomeExpenseNonoperatingNet">Total Interest and Other Income (Expense), net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InterestIncomeExpenseNonoperatingNet" xlink:to="label_InterestIncomeExpenseNonoperatingNet" xlink:title="Label : InterestIncomeExpenseNonoperatingNet to label_InterestIncomeExpenseNonoperatingNet" />
    <link:label xlink:type="resource" xlink:label="label_InterestIncomeExpenseNonoperatingNet_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_InterestIncomeExpenseNonoperatingNet_1" xml:lang="en-US" id="label_InterestIncomeExpenseNonoperatingNet_1">Interest Income (Expense), Nonoperating</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InterestIncomeExpenseNonoperatingNet" xlink:to="label_InterestIncomeExpenseNonoperatingNet_1" xlink:title="Label : InterestIncomeExpenseNonoperatingNet to label_InterestIncomeExpenseNonoperatingNet_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealizedAfterTax" xlink:label="ForeignCurrencyTransactionGainLossUnrealizedAfterTax" xlink:title="ForeignCurrencyTransactionGainLossUnrealizedAfterTax" />
    <link:label xlink:type="resource" xlink:label="label_ForeignCurrencyTransactionGainLossUnrealizedAfterTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ForeignCurrencyTransactionGainLossUnrealizedAfterTax" xml:lang="en-US" id="label_ForeignCurrencyTransactionGainLossUnrealizedAfterTax">Unrealized Foreign Currency Translation Gain</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ForeignCurrencyTransactionGainLossUnrealizedAfterTax" xlink:to="label_ForeignCurrencyTransactionGainLossUnrealizedAfterTax" xlink:title="Label : ForeignCurrencyTransactionGainLossUnrealizedAfterTax to label_ForeignCurrencyTransactionGainLossUnrealizedAfterTax" />
    <link:label xlink:type="resource" xlink:label="label_ForeignCurrencyTransactionGainLossUnrealizedAfterTax_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ForeignCurrencyTransactionGainLossUnrealizedAfterTax_1" xml:lang="en-US" id="label_ForeignCurrencyTransactionGainLossUnrealizedAfterTax_1">Unrealized Gain (Loss), Foreign Currency Transaction, after Tax</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ForeignCurrencyTransactionGainLossUnrealizedAfterTax" xlink:to="label_ForeignCurrencyTransactionGainLossUnrealizedAfterTax_1" xlink:title="Label : ForeignCurrencyTransactionGainLossUnrealizedAfterTax to label_ForeignCurrencyTransactionGainLossUnrealizedAfterTax_1" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsPursuantToJuly2025OfferingNetOfOfferingCosts" xlink:label="StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsPursuantToJuly2025OfferingNetOfOfferingCosts" xlink:title="StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsPursuantToJuly2025OfferingNetOfOfferingCosts" />
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsPursuantToJuly2025OfferingNetOfOfferingCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsPursuantToJuly2025OfferingNetOfOfferingCosts" xml:lang="en-US" id="label_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsPursuantToJuly2025OfferingNetOfOfferingCosts">Issuance of common stock and warrants pursuant to July 2025 Offering, net of offering costs paid at closing and deferred offering costs (Note 6) (in Shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsPursuantToJuly2025OfferingNetOfOfferingCosts" xlink:to="label_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsPursuantToJuly2025OfferingNetOfOfferingCosts" xlink:title="Label : StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsPursuantToJuly2025OfferingNetOfOfferingCosts to label_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsPursuantToJuly2025OfferingNetOfOfferingCosts" />
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsPursuantToJuly2025OfferingNetOfOfferingCosts_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsPursuantToJuly2025OfferingNetOfOfferingCosts_1" xml:lang="en-US" id="label_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsPursuantToJuly2025OfferingNetOfOfferingCosts_1">Stock Issued During Period Shares Issuance Of Common Stock And Warrants Pursuant To July 2025 Offering Net Of Offering Costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsPursuantToJuly2025OfferingNetOfOfferingCosts" xlink:to="label_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsPursuantToJuly2025OfferingNetOfOfferingCosts_1" xlink:title="Label : StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsPursuantToJuly2025OfferingNetOfOfferingCosts to label_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsPursuantToJuly2025OfferingNetOfOfferingCosts_1" />
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsPursuantToJuly2025OfferingNetOfOfferingCosts_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsPursuantToJuly2025OfferingNetOfOfferingCosts_2" xml:lang="en-US" id="label_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsPursuantToJuly2025OfferingNetOfOfferingCosts_2">Issuance of common stock and warrants pursuant to july 2025 offering, net of offering costs.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsPursuantToJuly2025OfferingNetOfOfferingCosts" xlink:to="label_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsPursuantToJuly2025OfferingNetOfOfferingCosts_2" xlink:title="Label : StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsPursuantToJuly2025OfferingNetOfOfferingCosts to label_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsPursuantToJuly2025OfferingNetOfOfferingCosts_2" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPursuantToJuly2025OfferingNetOfOfferingCosts" xlink:label="StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPursuantToJuly2025OfferingNetOfOfferingCosts" xlink:title="StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPursuantToJuly2025OfferingNetOfOfferingCosts" />
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPursuantToJuly2025OfferingNetOfOfferingCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPursuantToJuly2025OfferingNetOfOfferingCosts" xml:lang="en-US" id="label_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPursuantToJuly2025OfferingNetOfOfferingCosts">Issuance of common stock and warrants pursuant to July 2025 Offering, net of offering costs paid at closing and deferred offering costs (Note 6)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPursuantToJuly2025OfferingNetOfOfferingCosts" xlink:to="label_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPursuantToJuly2025OfferingNetOfOfferingCosts" xlink:title="Label : StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPursuantToJuly2025OfferingNetOfOfferingCosts to label_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPursuantToJuly2025OfferingNetOfOfferingCosts" />
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPursuantToJuly2025OfferingNetOfOfferingCosts_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPursuantToJuly2025OfferingNetOfOfferingCosts_1" xml:lang="en-US" id="label_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPursuantToJuly2025OfferingNetOfOfferingCosts_1">Stock Issued During Period Value Issuance Of Common Stock And Warrants Pursuant To July 2025 Offering Net Of Offering Costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPursuantToJuly2025OfferingNetOfOfferingCosts" xlink:to="label_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPursuantToJuly2025OfferingNetOfOfferingCosts_1" xlink:title="Label : StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPursuantToJuly2025OfferingNetOfOfferingCosts to label_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPursuantToJuly2025OfferingNetOfOfferingCosts_1" />
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPursuantToJuly2025OfferingNetOfOfferingCosts_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPursuantToJuly2025OfferingNetOfOfferingCosts_2" xml:lang="en-US" id="label_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPursuantToJuly2025OfferingNetOfOfferingCosts_2">The amount of Issuance of common stock and warrants pursuant to july 2025 offering, net of offering costs.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPursuantToJuly2025OfferingNetOfOfferingCosts" xlink:to="label_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPursuantToJuly2025OfferingNetOfOfferingCosts_2" xlink:title="Label : StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPursuantToJuly2025OfferingNetOfOfferingCosts to label_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPursuantToJuly2025OfferingNetOfOfferingCosts_2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="PropertyPlantAndEquipmentNet" xlink:title="PropertyPlantAndEquipmentNet" />
    <link:label xlink:type="resource" xlink:label="label_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_PropertyPlantAndEquipmentNet" xml:lang="en-US" id="label_PropertyPlantAndEquipmentNet">Property and Equipment, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentNet" xlink:to="label_PropertyPlantAndEquipmentNet" xlink:title="Label : PropertyPlantAndEquipmentNet to label_PropertyPlantAndEquipmentNet" />
    <link:label xlink:type="resource" xlink:label="label_PropertyPlantAndEquipmentNet_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_PropertyPlantAndEquipmentNet_1" xml:lang="en-US" id="label_PropertyPlantAndEquipmentNet_1">Property and Equipment, net (Note 4)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentNet" xlink:to="label_PropertyPlantAndEquipmentNet_1" xlink:title="Label : PropertyPlantAndEquipmentNet to label_PropertyPlantAndEquipmentNet_1" />
    <link:label xlink:type="resource" xlink:label="label_PropertyPlantAndEquipmentNet_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_PropertyPlantAndEquipmentNet_2" xml:lang="en-US" id="label_PropertyPlantAndEquipmentNet_2">Property, Plant and Equipment, Net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentNet" xlink:to="label_PropertyPlantAndEquipmentNet_2" xlink:title="Label : PropertyPlantAndEquipmentNet to label_PropertyPlantAndEquipmentNet_2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction" xlink:label="SaleOfStockPercentageOfOwnershipAfterTransaction" xlink:title="SaleOfStockPercentageOfOwnershipAfterTransaction" />
    <link:label xlink:type="resource" xlink:label="label_SaleOfStockPercentageOfOwnershipAfterTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_SaleOfStockPercentageOfOwnershipAfterTransaction" xml:lang="en-US" id="label_SaleOfStockPercentageOfOwnershipAfterTransaction">Sale of stock, percentage of ownership</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SaleOfStockPercentageOfOwnershipAfterTransaction" xlink:to="label_SaleOfStockPercentageOfOwnershipAfterTransaction" xlink:title="Label : SaleOfStockPercentageOfOwnershipAfterTransaction to label_SaleOfStockPercentageOfOwnershipAfterTransaction" />
    <link:label xlink:type="resource" xlink:label="label_SaleOfStockPercentageOfOwnershipAfterTransaction_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_SaleOfStockPercentageOfOwnershipAfterTransaction_1" xml:lang="en-US" id="label_SaleOfStockPercentageOfOwnershipAfterTransaction_1">Sale of Stock, Percentage of Ownership after Transaction</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SaleOfStockPercentageOfOwnershipAfterTransaction" xlink:to="label_SaleOfStockPercentageOfOwnershipAfterTransaction_1" xlink:title="Label : SaleOfStockPercentageOfOwnershipAfterTransaction to label_SaleOfStockPercentageOfOwnershipAfterTransaction_1" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_TuftsMedicalCenterAgreementMember" xlink:label="TuftsMedicalCenterAgreementMember" xlink:title="TuftsMedicalCenterAgreementMember" />
    <link:label xlink:type="resource" xlink:label="label_TuftsMedicalCenterAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_TuftsMedicalCenterAgreementMember" xml:lang="en-US" id="label_TuftsMedicalCenterAgreementMember">Tufts Medical Center Agreement [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TuftsMedicalCenterAgreementMember" xlink:to="label_TuftsMedicalCenterAgreementMember" xlink:title="Label : TuftsMedicalCenterAgreementMember to label_TuftsMedicalCenterAgreementMember" />
    <link:label xlink:type="resource" xlink:label="label_TuftsMedicalCenterAgreementMember_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_TuftsMedicalCenterAgreementMember_1" xml:lang="en-US" id="label_TuftsMedicalCenterAgreementMember_1">Tufts MC Agreement [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TuftsMedicalCenterAgreementMember" xlink:to="label_TuftsMedicalCenterAgreementMember_1" xlink:title="Label : TuftsMedicalCenterAgreementMember to label_TuftsMedicalCenterAgreementMember_1" />
    <link:label xlink:type="resource" xlink:label="label_TuftsMedicalCenterAgreementMember_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_TuftsMedicalCenterAgreementMember_2" xml:lang="en-US" id="label_TuftsMedicalCenterAgreementMember_2">This member stands for the information pertaining to "Tufts MC Agreement".</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TuftsMedicalCenterAgreementMember" xlink:to="label_TuftsMedicalCenterAgreementMember_2" xlink:title="Label : TuftsMedicalCenterAgreementMember to label_TuftsMedicalCenterAgreementMember_2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_DirectorMember" xlink:label="DirectorMember" xlink:title="DirectorMember" />
    <link:label xlink:type="resource" xlink:label="label_DirectorMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DirectorMember" xml:lang="en-US" id="label_DirectorMember">Director [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DirectorMember" xlink:to="label_DirectorMember" xlink:title="Label : DirectorMember to label_DirectorMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward">Share-Based Compensation Arrangement by Share-Based Payment Award, Terms of Award</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" xlink:title="Label : ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward to label_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_1" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_1">Stock option granted term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_1" xlink:title="Label : ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward to label_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_1" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_2" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_2">Equity-based compensation awards term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_2" xlink:title="Label : ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward to label_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingencyPendingClaimsNumber" xlink:label="LossContingencyPendingClaimsNumber" xlink:title="LossContingencyPendingClaimsNumber" />
    <link:label xlink:type="resource" xlink:label="label_LossContingencyPendingClaimsNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_LossContingencyPendingClaimsNumber" xml:lang="en-US" id="label_LossContingencyPendingClaimsNumber">Loss Contingency, Pending Claims, Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LossContingencyPendingClaimsNumber" xlink:to="label_LossContingencyPendingClaimsNumber" xlink:title="Label : LossContingencyPendingClaimsNumber to label_LossContingencyPendingClaimsNumber" />
    <link:label xlink:type="resource" xlink:label="label_LossContingencyPendingClaimsNumber_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_LossContingencyPendingClaimsNumber_1" xml:lang="en-US" id="label_LossContingencyPendingClaimsNumber_1">Number of pending or threatened lawsuits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LossContingencyPendingClaimsNumber" xlink:to="label_LossContingencyPendingClaimsNumber_1" xlink:title="Label : LossContingencyPendingClaimsNumber to label_LossContingencyPendingClaimsNumber_1" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1Minimum" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1Minimum" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1Minimum" />
    <link:label xlink:type="resource" xlink:label="label_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1Minimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1Minimum" xml:lang="en-US" id="label_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1Minimum">Share-based Compensation Arrangement By Share-based Payment Award Fair Value Assumptions Expected Term 1 Minimum</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1Minimum" xlink:to="label_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1Minimum" xlink:title="Label : SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1Minimum to label_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1Minimum" />
    <link:label xlink:type="resource" xlink:label="label_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1Minimum_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1Minimum_1" xml:lang="en-US" id="label_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1Minimum_1">Expected term, minimum (years)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1Minimum" xlink:to="label_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1Minimum_1" xlink:title="Label : SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1Minimum to label_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1Minimum_1" />
    <link:label xlink:type="resource" xlink:label="label_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1Minimum_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1Minimum_2" xml:lang="en-US" id="label_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1Minimum_2">Expected minimum term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1Minimum" xlink:to="label_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1Minimum_2" xlink:title="Label : SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1Minimum to label_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1Minimum_2" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1Maximum" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1Maximum" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1Maximum" />
    <link:label xlink:type="resource" xlink:label="label_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1Maximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1Maximum" xml:lang="en-US" id="label_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1Maximum">Share-based Compensation Arrangement By Share-based Payment Award Fair Value Assumptions Expected Term 1 Maximum</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1Maximum" xlink:to="label_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1Maximum" xlink:title="Label : SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1Maximum to label_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1Maximum" />
    <link:label xlink:type="resource" xlink:label="label_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1Maximum_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1Maximum_1" xml:lang="en-US" id="label_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1Maximum_1">Expected term, maximum (years)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1Maximum" xlink:to="label_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1Maximum_1" xlink:title="Label : SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1Maximum to label_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1Maximum_1" />
    <link:label xlink:type="resource" xlink:label="label_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1Maximum_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1Maximum_2" xml:lang="en-US" id="label_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1Maximum_2">Expected maximum term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1Maximum" xlink:to="label_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1Maximum_2" xlink:title="Label : SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1Maximum to label_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1Maximum_2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:title="Label : ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum to label_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_1" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_1">Risk-free interest rate, minimum</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_1" xlink:title="Label : ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum to label_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:title="Label : ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum to label_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_1" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_1">Risk-free interest rate, maximum</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_1" xlink:title="Label : ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum to label_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:title="Label : ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum to label_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_1" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_1">Expected volatility, minimum</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_1" xlink:title="Label : ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum to label_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:title="Label : ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum to label_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_1" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_1">Expected volatility, maximum</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_1" xlink:title="Label : ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum to label_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_1" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_NetProceedsFromJuly2025Offering" xlink:label="NetProceedsFromJuly2025Offering" xlink:title="NetProceedsFromJuly2025Offering" />
    <link:label xlink:type="resource" xlink:label="label_NetProceedsFromJuly2025Offering" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_NetProceedsFromJuly2025Offering" xml:lang="en-US" id="label_NetProceedsFromJuly2025Offering">Net Proceeds From July 2025 Offering</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetProceedsFromJuly2025Offering" xlink:to="label_NetProceedsFromJuly2025Offering" xlink:title="Label : NetProceedsFromJuly2025Offering to label_NetProceedsFromJuly2025Offering" />
    <link:label xlink:type="resource" xlink:label="label_NetProceedsFromJuly2025Offering_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_NetProceedsFromJuly2025Offering_1" xml:lang="en-US" id="label_NetProceedsFromJuly2025Offering_1">Net Proceeds from July 2025 Offering</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetProceedsFromJuly2025Offering" xlink:to="label_NetProceedsFromJuly2025Offering_1" xlink:title="Label : NetProceedsFromJuly2025Offering to label_NetProceedsFromJuly2025Offering_1" />
    <link:label xlink:type="resource" xlink:label="label_NetProceedsFromJuly2025Offering_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_NetProceedsFromJuly2025Offering_2" xml:lang="en-US" id="label_NetProceedsFromJuly2025Offering_2">The amount of net proceeds from july 2025 offering.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetProceedsFromJuly2025Offering" xlink:to="label_NetProceedsFromJuly2025Offering_2" xlink:title="Label : NetProceedsFromJuly2025Offering to label_NetProceedsFromJuly2025Offering_2" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_ConversionOfSeriesAPreferredStockIntoCommonStock" xlink:label="ConversionOfSeriesAPreferredStockIntoCommonStock" xlink:title="ConversionOfSeriesAPreferredStockIntoCommonStock" />
    <link:label xlink:type="resource" xlink:label="label_ConversionOfSeriesAPreferredStockIntoCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ConversionOfSeriesAPreferredStockIntoCommonStock" xml:lang="en-US" id="label_ConversionOfSeriesAPreferredStockIntoCommonStock">Conversion Of Series A Preferred Stock Into Common Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConversionOfSeriesAPreferredStockIntoCommonStock" xlink:to="label_ConversionOfSeriesAPreferredStockIntoCommonStock" xlink:title="Label : ConversionOfSeriesAPreferredStockIntoCommonStock to label_ConversionOfSeriesAPreferredStockIntoCommonStock" />
    <link:label xlink:type="resource" xlink:label="label_ConversionOfSeriesAPreferredStockIntoCommonStock_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ConversionOfSeriesAPreferredStockIntoCommonStock_1" xml:lang="en-US" id="label_ConversionOfSeriesAPreferredStockIntoCommonStock_1">Conversion of Series A Preferred Stock into Common Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConversionOfSeriesAPreferredStockIntoCommonStock" xlink:to="label_ConversionOfSeriesAPreferredStockIntoCommonStock_1" xlink:title="Label : ConversionOfSeriesAPreferredStockIntoCommonStock to label_ConversionOfSeriesAPreferredStockIntoCommonStock_1" />
    <link:label xlink:type="resource" xlink:label="label_ConversionOfSeriesAPreferredStockIntoCommonStock_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_ConversionOfSeriesAPreferredStockIntoCommonStock_2" xml:lang="en-US" id="label_ConversionOfSeriesAPreferredStockIntoCommonStock_2">The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConversionOfSeriesAPreferredStockIntoCommonStock" xlink:to="label_ConversionOfSeriesAPreferredStockIntoCommonStock_2" xlink:title="Label : ConversionOfSeriesAPreferredStockIntoCommonStock to label_ConversionOfSeriesAPreferredStockIntoCommonStock_2" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_AtTheMarket2025AgreementMember" xlink:label="AtTheMarket2025AgreementMember" xlink:title="AtTheMarket2025AgreementMember" />
    <link:label xlink:type="resource" xlink:label="label_AtTheMarket2025AgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_AtTheMarket2025AgreementMember" xml:lang="en-US" id="label_AtTheMarket2025AgreementMember">2025 ATM Agreement [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AtTheMarket2025AgreementMember" xlink:to="label_AtTheMarket2025AgreementMember" xlink:title="Label : AtTheMarket2025AgreementMember to label_AtTheMarket2025AgreementMember" />
    <link:label xlink:type="resource" xlink:label="label_AtTheMarket2025AgreementMember_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AtTheMarket2025AgreementMember_1" xml:lang="en-US" id="label_AtTheMarket2025AgreementMember_1">At-the-Market 2025 Agreement [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AtTheMarket2025AgreementMember" xlink:to="label_AtTheMarket2025AgreementMember_1" xlink:title="Label : AtTheMarket2025AgreementMember to label_AtTheMarket2025AgreementMember_1" />
    <link:label xlink:type="resource" xlink:label="label_AtTheMarket2025AgreementMember_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_AtTheMarket2025AgreementMember_2" xml:lang="en-US" id="label_AtTheMarket2025AgreementMember_2">This member stands for the information pertaining to "2025 ATM Agreement".</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AtTheMarket2025AgreementMember" xlink:to="label_AtTheMarket2025AgreementMember_2" xlink:title="Label : AtTheMarket2025AgreementMember to label_AtTheMarket2025AgreementMember_2" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_SalesAgentCommissionPercentage" xlink:label="SalesAgentCommissionPercentage" xlink:title="SalesAgentCommissionPercentage" />
    <link:label xlink:type="resource" xlink:label="label_SalesAgentCommissionPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_SalesAgentCommissionPercentage" xml:lang="en-US" id="label_SalesAgentCommissionPercentage">Sales agent commission percentage</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SalesAgentCommissionPercentage" xlink:to="label_SalesAgentCommissionPercentage" xlink:title="Label : SalesAgentCommissionPercentage to label_SalesAgentCommissionPercentage" />
    <link:label xlink:type="resource" xlink:label="label_SalesAgentCommissionPercentage_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_SalesAgentCommissionPercentage_1" xml:lang="en-US" id="label_SalesAgentCommissionPercentage_1">Sales Agent Commission Percentage</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SalesAgentCommissionPercentage" xlink:to="label_SalesAgentCommissionPercentage_1" xlink:title="Label : SalesAgentCommissionPercentage to label_SalesAgentCommissionPercentage_1" />
    <link:label xlink:type="resource" xlink:label="label_SalesAgentCommissionPercentage_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_SalesAgentCommissionPercentage_2" xml:lang="en-US" id="label_SalesAgentCommissionPercentage_2">Percentage of sales agent commission.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SalesAgentCommissionPercentage" xlink:to="label_SalesAgentCommissionPercentage_2" xlink:title="Label : SalesAgentCommissionPercentage to label_SalesAgentCommissionPercentage_2" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_NumberOfDirectors" xlink:label="NumberOfDirectors" xlink:title="NumberOfDirectors" />
    <link:label xlink:type="resource" xlink:label="label_NumberOfDirectors" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_NumberOfDirectors" xml:lang="en-US" id="label_NumberOfDirectors">Number of Directors</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfDirectors" xlink:to="label_NumberOfDirectors" xlink:title="Label : NumberOfDirectors to label_NumberOfDirectors" />
    <link:label xlink:type="resource" xlink:label="label_NumberOfDirectors_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_NumberOfDirectors_1" xml:lang="en-US" id="label_NumberOfDirectors_1">Number of directors.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfDirectors" xlink:to="label_NumberOfDirectors_1" xlink:title="Label : NumberOfDirectors to label_NumberOfDirectors_1" />
    <link:label xlink:type="resource" xlink:label="label_NumberOfDirectors_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_NumberOfDirectors_2" xml:lang="en-US" id="label_NumberOfDirectors_2">Number of directors</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfDirectors" xlink:to="label_NumberOfDirectors_2" xlink:title="Label : NumberOfDirectors to label_NumberOfDirectors_2" />
    <link:label xlink:type="resource" xlink:label="label_NumberOfDirectors_3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_NumberOfDirectors_3" xml:lang="en-US" id="label_NumberOfDirectors_3">Number of director nominees</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfDirectors" xlink:to="label_NumberOfDirectors_3" xlink:title="Label : NumberOfDirectors to label_NumberOfDirectors_3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xml:lang="en-US" id="label_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">Per share exercise price (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="label_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:title="Label : ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice to label_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1" xml:lang="en-US" id="label_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="label_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1" xlink:title="Label : ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice to label_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:label xlink:type="resource" xlink:label="label_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xml:lang="en-US" id="label_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="label_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:title="Label : SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 to label_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:label xlink:type="resource" xlink:label="label_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_1" xml:lang="en-US" id="label_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_1">Stock option term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="label_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_1" xlink:title="Label : SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 to label_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_1" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_CommonStockSalesAgreementWeightedAveragePricePerShare" xlink:label="CommonStockSalesAgreementWeightedAveragePricePerShare" xlink:title="CommonStockSalesAgreementWeightedAveragePricePerShare" />
    <link:label xlink:type="resource" xlink:label="label_CommonStockSalesAgreementWeightedAveragePricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_CommonStockSalesAgreementWeightedAveragePricePerShare" xml:lang="en-US" id="label_CommonStockSalesAgreementWeightedAveragePricePerShare">Common Stock Sales Agreement Weighted Average Price Per Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockSalesAgreementWeightedAveragePricePerShare" xlink:to="label_CommonStockSalesAgreementWeightedAveragePricePerShare" xlink:title="Label : CommonStockSalesAgreementWeightedAveragePricePerShare to label_CommonStockSalesAgreementWeightedAveragePricePerShare" />
    <link:label xlink:type="resource" xlink:label="label_CommonStockSalesAgreementWeightedAveragePricePerShare_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_CommonStockSalesAgreementWeightedAveragePricePerShare_1" xml:lang="en-US" id="label_CommonStockSalesAgreementWeightedAveragePricePerShare_1">Per share weighted-average price of common stock under sales agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockSalesAgreementWeightedAveragePricePerShare" xlink:to="label_CommonStockSalesAgreementWeightedAveragePricePerShare_1" xlink:title="Label : CommonStockSalesAgreementWeightedAveragePricePerShare to label_CommonStockSalesAgreementWeightedAveragePricePerShare_1" />
    <link:label xlink:type="resource" xlink:label="label_CommonStockSalesAgreementWeightedAveragePricePerShare_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_CommonStockSalesAgreementWeightedAveragePricePerShare_2" xml:lang="en-US" id="label_CommonStockSalesAgreementWeightedAveragePricePerShare_2">Common stock sales agreement weighted average price per share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockSalesAgreementWeightedAveragePricePerShare" xlink:to="label_CommonStockSalesAgreementWeightedAveragePricePerShare_2" xlink:title="Label : CommonStockSalesAgreementWeightedAveragePricePerShare to label_CommonStockSalesAgreementWeightedAveragePricePerShare_2" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_DirectorOneMember" xlink:label="DirectorOneMember" xlink:title="DirectorOneMember" />
    <link:label xlink:type="resource" xlink:label="label_DirectorOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DirectorOneMember" xml:lang="en-US" id="label_DirectorOneMember">Director One [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DirectorOneMember" xlink:to="label_DirectorOneMember" xlink:title="Label : DirectorOneMember to label_DirectorOneMember" />
    <link:label xlink:type="resource" xlink:label="label_DirectorOneMember_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_DirectorOneMember_1" xml:lang="en-US" id="label_DirectorOneMember_1">This member stands for the information pertaining to "Director One".</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DirectorOneMember" xlink:to="label_DirectorOneMember_1" xlink:title="Label : DirectorOneMember to label_DirectorOneMember_1" />
    <link:label xlink:type="resource" xlink:label="label_DirectorOneMember_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_DirectorOneMember_2" xml:lang="en-US" id="label_DirectorOneMember_2">Director One [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DirectorOneMember" xlink:to="label_DirectorOneMember_2" xlink:title="Label : DirectorOneMember to label_DirectorOneMember_2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">Number of shares available for grant (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:title="Label : ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant to label_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_1" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_1">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_1" xlink:title="Label : ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant to label_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_1" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_2" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_2">Number of shares available for issuance (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_2" xlink:title="Label : ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant to label_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1" xlink:label="NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1" xlink:title="NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1" />
    <link:label xlink:type="resource" xlink:label="label_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1" xml:lang="en-US" id="label_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1">Noncash or Part Noncash Acquisition, Intangible Assets Acquired</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1" xlink:to="label_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1" xlink:title="Label : NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1 to label_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1" />
    <link:label xlink:type="resource" xlink:label="label_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1_1" xml:lang="en-US" id="label_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1_1">Capitalized Patent Costs included in Accounts Payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1" xlink:to="label_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1_1" xlink:title="Label : NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1 to label_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="CommonStockParOrStatedValuePerShare" xlink:title="CommonStockParOrStatedValuePerShare" />
    <link:label xlink:type="resource" xlink:label="label_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_CommonStockParOrStatedValuePerShare" xml:lang="en-US" id="label_CommonStockParOrStatedValuePerShare">Common stock, par value (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockParOrStatedValuePerShare" xlink:to="label_CommonStockParOrStatedValuePerShare" xlink:title="Label : CommonStockParOrStatedValuePerShare to label_CommonStockParOrStatedValuePerShare" />
    <link:label xlink:type="resource" xlink:label="label_CommonStockParOrStatedValuePerShare_1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_CommonStockParOrStatedValuePerShare_1" xml:lang="en-US" id="label_CommonStockParOrStatedValuePerShare_1">Common stock par value (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockParOrStatedValuePerShare" xlink:to="label_CommonStockParOrStatedValuePerShare_1" xlink:title="Label : CommonStockParOrStatedValuePerShare to label_CommonStockParOrStatedValuePerShare_1" />
    <link:label xlink:type="resource" xlink:label="label_CommonStockParOrStatedValuePerShare_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_CommonStockParOrStatedValuePerShare_2" xml:lang="en-US" id="label_CommonStockParOrStatedValuePerShare_2">Common Stock, Par or Stated Value Per Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockParOrStatedValuePerShare" xlink:to="label_CommonStockParOrStatedValuePerShare_2" xlink:title="Label : CommonStockParOrStatedValuePerShare to label_CommonStockParOrStatedValuePerShare_2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="PreferredStockParOrStatedValuePerShare" xlink:title="PreferredStockParOrStatedValuePerShare" />
    <link:label xlink:type="resource" xlink:label="label_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_PreferredStockParOrStatedValuePerShare" xml:lang="en-US" id="label_PreferredStockParOrStatedValuePerShare">Preferred stock, par value (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockParOrStatedValuePerShare" xlink:to="label_PreferredStockParOrStatedValuePerShare" xlink:title="Label : PreferredStockParOrStatedValuePerShare to label_PreferredStockParOrStatedValuePerShare" />
    <link:label xlink:type="resource" xlink:label="label_PreferredStockParOrStatedValuePerShare_1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_PreferredStockParOrStatedValuePerShare_1" xml:lang="en-US" id="label_PreferredStockParOrStatedValuePerShare_1">Preferred stock shares, par value (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockParOrStatedValuePerShare" xlink:to="label_PreferredStockParOrStatedValuePerShare_1" xlink:title="Label : PreferredStockParOrStatedValuePerShare to label_PreferredStockParOrStatedValuePerShare_1" />
    <link:label xlink:type="resource" xlink:label="label_PreferredStockParOrStatedValuePerShare_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_PreferredStockParOrStatedValuePerShare_2" xml:lang="en-US" id="label_PreferredStockParOrStatedValuePerShare_2">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockParOrStatedValuePerShare" xlink:to="label_PreferredStockParOrStatedValuePerShare_2" xlink:title="Label : PreferredStockParOrStatedValuePerShare to label_PreferredStockParOrStatedValuePerShare_2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="SaleOfStockPricePerShare" xlink:title="SaleOfStockPricePerShare" />
    <link:label xlink:type="resource" xlink:label="label_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_SaleOfStockPricePerShare" xml:lang="en-US" id="label_SaleOfStockPricePerShare">Sale of stock price per share (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SaleOfStockPricePerShare" xlink:to="label_SaleOfStockPricePerShare" xlink:title="Label : SaleOfStockPricePerShare to label_SaleOfStockPricePerShare" />
    <link:label xlink:type="resource" xlink:label="label_SaleOfStockPricePerShare_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_SaleOfStockPricePerShare_1" xml:lang="en-US" id="label_SaleOfStockPricePerShare_1">Sale of Stock, Price Per Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SaleOfStockPricePerShare" xlink:to="label_SaleOfStockPricePerShare_1" xlink:title="Label : SaleOfStockPricePerShare to label_SaleOfStockPricePerShare_1" />
    <link:label xlink:type="resource" xlink:label="label_SaleOfStockPricePerShare_2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_SaleOfStockPricePerShare_2" xml:lang="en-US" id="label_SaleOfStockPricePerShare_2">Sale of stock price per unit (in dollars per unit)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SaleOfStockPricePerShare" xlink:to="label_SaleOfStockPricePerShare_2" xlink:title="Label : SaleOfStockPricePerShare to label_SaleOfStockPricePerShare_2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:title="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:label xlink:type="resource" xlink:label="label_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xml:lang="en-US" id="label_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">Exercise price per share (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="label_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:title="Label : ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 to label_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:label xlink:type="resource" xlink:label="label_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1" xml:lang="en-US" id="label_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1">Exercise price of warrants (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="label_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1" xlink:title="Label : ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 to label_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1" />
    <link:label xlink:type="resource" xlink:label="label_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2" xml:lang="en-US" id="label_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="label_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2" xlink:title="Label : ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 to label_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="ProceedsFromIssuanceOfPrivatePlacement" xlink:title="ProceedsFromIssuanceOfPrivatePlacement" />
    <link:label xlink:type="resource" xlink:label="label_ProceedsFromIssuanceOfPrivatePlacement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ProceedsFromIssuanceOfPrivatePlacement" xml:lang="en-US" id="label_ProceedsFromIssuanceOfPrivatePlacement">Deducting placement agent fees</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromIssuanceOfPrivatePlacement" xlink:to="label_ProceedsFromIssuanceOfPrivatePlacement" xlink:title="Label : ProceedsFromIssuanceOfPrivatePlacement to label_ProceedsFromIssuanceOfPrivatePlacement" />
    <link:label xlink:type="resource" xlink:label="label_ProceedsFromIssuanceOfPrivatePlacement_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ProceedsFromIssuanceOfPrivatePlacement_1" xml:lang="en-US" id="label_ProceedsFromIssuanceOfPrivatePlacement_1">Proceeds from Issuance of Private Placement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromIssuanceOfPrivatePlacement" xlink:to="label_ProceedsFromIssuanceOfPrivatePlacement_1" xlink:title="Label : ProceedsFromIssuanceOfPrivatePlacement to label_ProceedsFromIssuanceOfPrivatePlacement_1" />
    <link:label xlink:type="resource" xlink:label="label_ProceedsFromIssuanceOfPrivatePlacement_2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_ProceedsFromIssuanceOfPrivatePlacement_2" xml:lang="en-US" id="label_ProceedsFromIssuanceOfPrivatePlacement_2">Net proceeds from Private Placement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromIssuanceOfPrivatePlacement" xlink:to="label_ProceedsFromIssuanceOfPrivatePlacement_2" xlink:title="Label : ProceedsFromIssuanceOfPrivatePlacement to label_ProceedsFromIssuanceOfPrivatePlacement_2" />
    <link:label xlink:type="resource" xlink:label="label_ProceedsFromIssuanceOfPrivatePlacement_3" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:title="label_ProceedsFromIssuanceOfPrivatePlacement_3" xml:lang="en-US" id="label_ProceedsFromIssuanceOfPrivatePlacement_3">Net Proceeds from offering</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromIssuanceOfPrivatePlacement" xlink:to="label_ProceedsFromIssuanceOfPrivatePlacement_3" xlink:title="Label : ProceedsFromIssuanceOfPrivatePlacement to label_ProceedsFromIssuanceOfPrivatePlacement_3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:label="ProceedsFromDebtNetOfIssuanceCosts" xlink:title="ProceedsFromDebtNetOfIssuanceCosts" />
    <link:label xlink:type="resource" xlink:label="label_ProceedsFromDebtNetOfIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ProceedsFromDebtNetOfIssuanceCosts" xml:lang="en-US" id="label_ProceedsFromDebtNetOfIssuanceCosts">Net proceeds</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromDebtNetOfIssuanceCosts" xlink:to="label_ProceedsFromDebtNetOfIssuanceCosts" xlink:title="Label : ProceedsFromDebtNetOfIssuanceCosts to label_ProceedsFromDebtNetOfIssuanceCosts" />
    <link:label xlink:type="resource" xlink:label="label_ProceedsFromDebtNetOfIssuanceCosts_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ProceedsFromDebtNetOfIssuanceCosts_1" xml:lang="en-US" id="label_ProceedsFromDebtNetOfIssuanceCosts_1">Proceeds from Debt, Net of Issuance Costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromDebtNetOfIssuanceCosts" xlink:to="label_ProceedsFromDebtNetOfIssuanceCosts_1" xlink:title="Label : ProceedsFromDebtNetOfIssuanceCosts to label_ProceedsFromDebtNetOfIssuanceCosts_1" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_OtherOfferingExpensesPaid" xlink:label="OtherOfferingExpensesPaid" xlink:title="OtherOfferingExpensesPaid" />
    <link:label xlink:type="resource" xlink:label="label_OtherOfferingExpensesPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_OtherOfferingExpensesPaid" xml:lang="en-US" id="label_OtherOfferingExpensesPaid">Other offering expenses paid</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherOfferingExpensesPaid" xlink:to="label_OtherOfferingExpensesPaid" xlink:title="Label : OtherOfferingExpensesPaid to label_OtherOfferingExpensesPaid" />
    <link:label xlink:type="resource" xlink:label="label_OtherOfferingExpensesPaid_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_OtherOfferingExpensesPaid_1" xml:lang="en-US" id="label_OtherOfferingExpensesPaid_1">Cash outflow for other offering expenses.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherOfferingExpensesPaid" xlink:to="label_OtherOfferingExpensesPaid_1" xlink:title="Label : OtherOfferingExpensesPaid to label_OtherOfferingExpensesPaid_1" />
    <link:label xlink:type="resource" xlink:label="label_OtherOfferingExpensesPaid_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_OtherOfferingExpensesPaid_2" xml:lang="en-US" id="label_OtherOfferingExpensesPaid_2">Other Offering Expenses Paid</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherOfferingExpensesPaid" xlink:to="label_OtherOfferingExpensesPaid_2" xlink:title="Label : OtherOfferingExpensesPaid to label_OtherOfferingExpensesPaid_2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WarrantExercisePriceIncrease" xlink:label="WarrantExercisePriceIncrease" xlink:title="WarrantExercisePriceIncrease" />
    <link:label xlink:type="resource" xlink:label="label_WarrantExercisePriceIncrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_WarrantExercisePriceIncrease" xml:lang="en-US" id="label_WarrantExercisePriceIncrease">Exercise price (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantExercisePriceIncrease" xlink:to="label_WarrantExercisePriceIncrease" xlink:title="Label : WarrantExercisePriceIncrease to label_WarrantExercisePriceIncrease" />
    <link:label xlink:type="resource" xlink:label="label_WarrantExercisePriceIncrease_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_WarrantExercisePriceIncrease_1" xml:lang="en-US" id="label_WarrantExercisePriceIncrease_1">Warrant, Exercise Price, Increase</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantExercisePriceIncrease" xlink:to="label_WarrantExercisePriceIncrease_1" xlink:title="Label : WarrantExercisePriceIncrease to label_WarrantExercisePriceIncrease_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:label="OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:title="OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" />
    <link:label xlink:type="resource" xlink:label="label_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xml:lang="en-US" id="label_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax">Cash proceeds</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:to="label_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:title="Label : OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax to label_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" />
    <link:label xlink:type="resource" xlink:label="label_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_1" xml:lang="en-US" id="label_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_1">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:to="label_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_1" xlink:title="Label : OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax to label_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DividendsPreferredStock" xlink:label="DividendsPreferredStock" xlink:title="DividendsPreferredStock" />
    <link:label xlink:type="resource" xlink:label="label_DividendsPreferredStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_DividendsPreferredStock" xml:lang="en-US" id="label_DividendsPreferredStock">Dividends preferred stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DividendsPreferredStock" xlink:to="label_DividendsPreferredStock" xlink:title="Label : DividendsPreferredStock to label_DividendsPreferredStock" />
    <link:label xlink:type="resource" xlink:label="label_DividendsPreferredStock_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_DividendsPreferredStock_1" xml:lang="en-US" id="label_DividendsPreferredStock_1">Dividends, Preferred Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DividendsPreferredStock" xlink:to="label_DividendsPreferredStock_1" xlink:title="Label : DividendsPreferredStock to label_DividendsPreferredStock_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockConvertibleConversionPriceIncrease" xlink:label="CommonStockConvertibleConversionPriceIncrease" xlink:title="CommonStockConvertibleConversionPriceIncrease" />
    <link:label xlink:type="resource" xlink:label="label_CommonStockConvertibleConversionPriceIncrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_CommonStockConvertibleConversionPriceIncrease" xml:lang="en-US" id="label_CommonStockConvertibleConversionPriceIncrease">Common stock conversion price per share (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockConvertibleConversionPriceIncrease" xlink:to="label_CommonStockConvertibleConversionPriceIncrease" xlink:title="Label : CommonStockConvertibleConversionPriceIncrease to label_CommonStockConvertibleConversionPriceIncrease" />
    <link:label xlink:type="resource" xlink:label="label_CommonStockConvertibleConversionPriceIncrease_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_CommonStockConvertibleConversionPriceIncrease_1" xml:lang="en-US" id="label_CommonStockConvertibleConversionPriceIncrease_1">Common Stock, Convertible, Conversion Price, Increase</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockConvertibleConversionPriceIncrease" xlink:to="label_CommonStockConvertibleConversionPriceIncrease_1" xlink:title="Label : CommonStockConvertibleConversionPriceIncrease to label_CommonStockConvertibleConversionPriceIncrease_1" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_CommonStockAggregateOfferingPrice" xlink:label="CommonStockAggregateOfferingPrice" xlink:title="CommonStockAggregateOfferingPrice" />
    <link:label xlink:type="resource" xlink:label="label_CommonStockAggregateOfferingPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_CommonStockAggregateOfferingPrice" xml:lang="en-US" id="label_CommonStockAggregateOfferingPrice">Common Stock Aggregate Offering Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockAggregateOfferingPrice" xlink:to="label_CommonStockAggregateOfferingPrice" xlink:title="Label : CommonStockAggregateOfferingPrice to label_CommonStockAggregateOfferingPrice" />
    <link:label xlink:type="resource" xlink:label="label_CommonStockAggregateOfferingPrice_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_CommonStockAggregateOfferingPrice_1" xml:lang="en-US" id="label_CommonStockAggregateOfferingPrice_1">Common stock aggregate offering price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockAggregateOfferingPrice" xlink:to="label_CommonStockAggregateOfferingPrice_1" xlink:title="Label : CommonStockAggregateOfferingPrice to label_CommonStockAggregateOfferingPrice_1" />
    <link:label xlink:type="resource" xlink:label="label_CommonStockAggregateOfferingPrice_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_CommonStockAggregateOfferingPrice_2" xml:lang="en-US" id="label_CommonStockAggregateOfferingPrice_2">Common stock having an aggregate offering price.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockAggregateOfferingPrice" xlink:to="label_CommonStockAggregateOfferingPrice_2" xlink:title="Label : CommonStockAggregateOfferingPrice to label_CommonStockAggregateOfferingPrice_2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromOtherEquity" xlink:label="ProceedsFromOtherEquity" xlink:title="ProceedsFromOtherEquity" />
    <link:label xlink:type="resource" xlink:label="label_ProceedsFromOtherEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ProceedsFromOtherEquity" xml:lang="en-US" id="label_ProceedsFromOtherEquity">Proceeds from Other Equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromOtherEquity" xlink:to="label_ProceedsFromOtherEquity" xlink:title="Label : ProceedsFromOtherEquity to label_ProceedsFromOtherEquity" />
    <link:label xlink:type="resource" xlink:label="label_ProceedsFromOtherEquity_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ProceedsFromOtherEquity_1" xml:lang="en-US" id="label_ProceedsFromOtherEquity_1">Gross proceeds</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromOtherEquity" xlink:to="label_ProceedsFromOtherEquity_1" xlink:title="Label : ProceedsFromOtherEquity to label_ProceedsFromOtherEquity_1" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageGrantDateFairValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageGrantDateFairValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageGrantDateFairValue" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageGrantDateFairValue" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageGrantDateFairValue">Weighted Average Exercise Price,Total exercisable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageGrantDateFairValue" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageGrantDateFairValue" xlink:title="Label : ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageGrantDateFairValue to label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageGrantDateFairValue" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageGrantDateFairValue_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageGrantDateFairValue_1" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageGrantDateFairValue_1">Weighted average fair value as of the exercisable date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageGrantDateFairValue" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageGrantDateFairValue_1" xlink:title="Label : ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageGrantDateFairValue to label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageGrantDateFairValue_1" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageGrantDateFairValue_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageGrantDateFairValue_2" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageGrantDateFairValue_2">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercisable Weighted Average Grant Date Fair Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageGrantDateFairValue" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageGrantDateFairValue_2" xlink:title="Label : ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageGrantDateFairValue to label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageGrantDateFairValue_2" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable">Number of Warrants, Total exercisable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable" xlink:title="Label : ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable to label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable_1" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable_1">The number of equity-based payment instruments, excluding stock (or unit) options, that were exercisable, during the reporting period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable_1" xlink:title="Label : ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable to label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable_1" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable_2" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable_2">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercisable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable_2" xlink:title="Label : ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable to label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable_2" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable_3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable_3" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable_3">Number of warrants exercisable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable_3" xlink:title="Label : ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable to label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable_3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">Number of Warrants, Granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:title="Label : ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod to label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1" xlink:title="Label : ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod to label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_2" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_2">Number of warrants granted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_2" xlink:title="Label : ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod to label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_2" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_StockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfPreFundedWarrantsinShares" xlink:label="StockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfPreFundedWarrantsinShares" xlink:title="StockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfPreFundedWarrantsinShares" />
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfPreFundedWarrantsinShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_StockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfPreFundedWarrantsinShares" xml:lang="en-US" id="label_StockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfPreFundedWarrantsinShares">Issuance of common stock upon exercise of Pre-Funded Warrants (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfPreFundedWarrantsinShares" xlink:to="label_StockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfPreFundedWarrantsinShares" xlink:title="Label : StockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfPreFundedWarrantsinShares to label_StockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfPreFundedWarrantsinShares" />
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfPreFundedWarrantsinShares_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_StockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfPreFundedWarrantsinShares_1" xml:lang="en-US" id="label_StockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfPreFundedWarrantsinShares_1">Issuance of common stock upon exercise of Pre-Funded Warrants (in Shares).</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfPreFundedWarrantsinShares" xlink:to="label_StockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfPreFundedWarrantsinShares_1" xlink:title="Label : StockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfPreFundedWarrantsinShares to label_StockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfPreFundedWarrantsinShares_1" />
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfPreFundedWarrantsinShares_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfPreFundedWarrantsinShares_2" xml:lang="en-US" id="label_StockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfPreFundedWarrantsinShares_2">Stock Issued During Period Issuance Of Common Stock Upon Exercise Of Pre Funded Warrantsin Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfPreFundedWarrantsinShares" xlink:to="label_StockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfPreFundedWarrantsinShares_2" xlink:title="Label : StockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfPreFundedWarrantsinShares to label_StockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfPreFundedWarrantsinShares_2" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExercised" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExercised" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExercised" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExercised" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExercised">Weighted Average Exercise Price, Exercised</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExercised" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExercised" xlink:title="Label : ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExercised to label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExercised" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExercised_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExercised_1" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExercised_1">Weighted average exercise price, exercised.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExercised" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExercised_1" xlink:title="Label : ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExercised to label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExercised_1" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExercised_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExercised_2" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExercised_2">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Weighted Average Exercise Price Exercised</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExercised" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExercised_2" xlink:title="Label : ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExercised to label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExercised_2" />
    <link:label xlink:type="resource" xlink:label="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExercised_3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExercised_3" xml:lang="en-US" id="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExercised_3">Weighted average exercise price (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExercised" xlink:to="label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExercised_3" xlink:title="Label : ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExercised to label_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExercised_3" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_CommonStockAggregateGrossSalesProceedAuthorized" xlink:label="CommonStockAggregateGrossSalesProceedAuthorized" xlink:title="CommonStockAggregateGrossSalesProceedAuthorized" />
    <link:label xlink:type="resource" xlink:label="label_CommonStockAggregateGrossSalesProceedAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_CommonStockAggregateGrossSalesProceedAuthorized" xml:lang="en-US" id="label_CommonStockAggregateGrossSalesProceedAuthorized">Common stock aggregate gross sales proceeds authorized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockAggregateGrossSalesProceedAuthorized" xlink:to="label_CommonStockAggregateGrossSalesProceedAuthorized" xlink:title="Label : CommonStockAggregateGrossSalesProceedAuthorized to label_CommonStockAggregateGrossSalesProceedAuthorized" />
    <link:label xlink:type="resource" xlink:label="label_CommonStockAggregateGrossSalesProceedAuthorized_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_CommonStockAggregateGrossSalesProceedAuthorized_1" xml:lang="en-US" id="label_CommonStockAggregateGrossSalesProceedAuthorized_1">Common Stock Aggregate Gross Sales Proceed Authorized</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockAggregateGrossSalesProceedAuthorized" xlink:to="label_CommonStockAggregateGrossSalesProceedAuthorized_1" xlink:title="Label : CommonStockAggregateGrossSalesProceedAuthorized to label_CommonStockAggregateGrossSalesProceedAuthorized_1" />
    <link:label xlink:type="resource" xlink:label="label_CommonStockAggregateGrossSalesProceedAuthorized_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_CommonStockAggregateGrossSalesProceedAuthorized_2" xml:lang="en-US" id="label_CommonStockAggregateGrossSalesProceedAuthorized_2">Authorized aggregate gross sales proceeds of common stock.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockAggregateGrossSalesProceedAuthorized" xlink:to="label_CommonStockAggregateGrossSalesProceedAuthorized_2" xlink:title="Label : CommonStockAggregateGrossSalesProceedAuthorized to label_CommonStockAggregateGrossSalesProceedAuthorized_2" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsNetOfOfferingCostsPaidAtClosingAndDeferredOfferingCosts" xlink:label="StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsNetOfOfferingCostsPaidAtClosingAndDeferredOfferingCosts" xlink:title="StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsNetOfOfferingCostsPaidAtClosingAndDeferredOfferingCosts" />
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsNetOfOfferingCostsPaidAtClosingAndDeferredOfferingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsNetOfOfferingCostsPaidAtClosingAndDeferredOfferingCosts" xml:lang="en-US" id="label_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsNetOfOfferingCostsPaidAtClosingAndDeferredOfferingCosts">Stock Issued During Period Value Issuance Of Common Stock And Warrants Net Of Offering Costs Paid At Closing And Deferred Offering Costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsNetOfOfferingCostsPaidAtClosingAndDeferredOfferingCosts" xlink:to="label_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsNetOfOfferingCostsPaidAtClosingAndDeferredOfferingCosts" xlink:title="Label : StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsNetOfOfferingCostsPaidAtClosingAndDeferredOfferingCosts to label_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsNetOfOfferingCostsPaidAtClosingAndDeferredOfferingCosts" />
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsNetOfOfferingCostsPaidAtClosingAndDeferredOfferingCosts_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsNetOfOfferingCostsPaidAtClosingAndDeferredOfferingCosts_1" xml:lang="en-US" id="label_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsNetOfOfferingCostsPaidAtClosingAndDeferredOfferingCosts_1">Issuance of common stock and warrants, net of offering costs paid at closing and deferred offering costs (Note 6)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsNetOfOfferingCostsPaidAtClosingAndDeferredOfferingCosts" xlink:to="label_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsNetOfOfferingCostsPaidAtClosingAndDeferredOfferingCosts_1" xlink:title="Label : StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsNetOfOfferingCostsPaidAtClosingAndDeferredOfferingCosts to label_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsNetOfOfferingCostsPaidAtClosingAndDeferredOfferingCosts_1" />
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsNetOfOfferingCostsPaidAtClosingAndDeferredOfferingCosts_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsNetOfOfferingCostsPaidAtClosingAndDeferredOfferingCosts_2" xml:lang="en-US" id="label_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsNetOfOfferingCostsPaidAtClosingAndDeferredOfferingCosts_2">Represent the amount of issuance of common stock and warrants, net of offering costs paid at closing and deferred offering costs.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsNetOfOfferingCostsPaidAtClosingAndDeferredOfferingCosts" xlink:to="label_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsNetOfOfferingCostsPaidAtClosingAndDeferredOfferingCosts_2" xlink:title="Label : StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsNetOfOfferingCostsPaidAtClosingAndDeferredOfferingCosts to label_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsNetOfOfferingCostsPaidAtClosingAndDeferredOfferingCosts_2" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_ProceedsFromCommonStockSalesAgreementNet" xlink:label="ProceedsFromCommonStockSalesAgreementNet" xlink:title="ProceedsFromCommonStockSalesAgreementNet" />
    <link:label xlink:type="resource" xlink:label="label_ProceedsFromCommonStockSalesAgreementNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ProceedsFromCommonStockSalesAgreementNet" xml:lang="en-US" id="label_ProceedsFromCommonStockSalesAgreementNet">Proceeds From Common Stock Sales Agreement Net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromCommonStockSalesAgreementNet" xlink:to="label_ProceedsFromCommonStockSalesAgreementNet" xlink:title="Label : ProceedsFromCommonStockSalesAgreementNet to label_ProceedsFromCommonStockSalesAgreementNet" />
    <link:label xlink:type="resource" xlink:label="label_ProceedsFromCommonStockSalesAgreementNet_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_ProceedsFromCommonStockSalesAgreementNet_1" xml:lang="en-US" id="label_ProceedsFromCommonStockSalesAgreementNet_1">The cash inflow associated with common stock sales agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromCommonStockSalesAgreementNet" xlink:to="label_ProceedsFromCommonStockSalesAgreementNet_1" xlink:title="Label : ProceedsFromCommonStockSalesAgreementNet to label_ProceedsFromCommonStockSalesAgreementNet_1" />
    <link:label xlink:type="resource" xlink:label="label_ProceedsFromCommonStockSalesAgreementNet_2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_ProceedsFromCommonStockSalesAgreementNet_2" xml:lang="en-US" id="label_ProceedsFromCommonStockSalesAgreementNet_2">Proceeds from common stock sales agreement net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromCommonStockSalesAgreementNet" xlink:to="label_ProceedsFromCommonStockSalesAgreementNet_2" xlink:title="Label : ProceedsFromCommonStockSalesAgreementNet to label_ProceedsFromCommonStockSalesAgreementNet_2" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_AccountsReceivableOrSalesRevenueNetMember" xlink:label="AccountsReceivableOrSalesRevenueNetMember" xlink:title="AccountsReceivableOrSalesRevenueNetMember" />
    <link:label xlink:type="resource" xlink:label="label_AccountsReceivableOrSalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_AccountsReceivableOrSalesRevenueNetMember" xml:lang="en-US" id="label_AccountsReceivableOrSalesRevenueNetMember">Accounts Receivable Or Revenue Benchmark [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccountsReceivableOrSalesRevenueNetMember" xlink:to="label_AccountsReceivableOrSalesRevenueNetMember" xlink:title="Label : AccountsReceivableOrSalesRevenueNetMember to label_AccountsReceivableOrSalesRevenueNetMember" />
    <link:label xlink:type="resource" xlink:label="label_AccountsReceivableOrSalesRevenueNetMember_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_AccountsReceivableOrSalesRevenueNetMember_1" xml:lang="en-US" id="label_AccountsReceivableOrSalesRevenueNetMember_1">Accounts Receivable Or Sales Revenue Net [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccountsReceivableOrSalesRevenueNetMember" xlink:to="label_AccountsReceivableOrSalesRevenueNetMember_1" xlink:title="Label : AccountsReceivableOrSalesRevenueNetMember to label_AccountsReceivableOrSalesRevenueNetMember_1" />
    <link:label xlink:type="resource" xlink:label="label_AccountsReceivableOrSalesRevenueNetMember_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_AccountsReceivableOrSalesRevenueNetMember_2" xml:lang="en-US" id="label_AccountsReceivableOrSalesRevenueNetMember_2">This member stands for the information pertaining to "Accounts Receivable Or Revenue Benchmark</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccountsReceivableOrSalesRevenueNetMember" xlink:to="label_AccountsReceivableOrSalesRevenueNetMember_2" xlink:title="Label : AccountsReceivableOrSalesRevenueNetMember to label_AccountsReceivableOrSalesRevenueNetMember_2" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_NetRevenueLoss" xlink:label="NetRevenueLoss" xlink:title="NetRevenueLoss" />
    <link:label xlink:type="resource" xlink:label="label_NetRevenueLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="label_NetRevenueLoss" xml:lang="en-US" id="label_NetRevenueLoss">Net (Loss) Revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetRevenueLoss" xlink:to="label_NetRevenueLoss" xlink:title="Label : NetRevenueLoss to label_NetRevenueLoss" />
    <link:label xlink:type="resource" xlink:label="label_NetRevenueLoss_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_NetRevenueLoss_1" xml:lang="en-US" id="label_NetRevenueLoss_1">The amount of net revenue loss.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetRevenueLoss" xlink:to="label_NetRevenueLoss_1" xlink:title="Label : NetRevenueLoss to label_NetRevenueLoss_1" />
    <link:label xlink:type="resource" xlink:label="label_NetRevenueLoss_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_NetRevenueLoss_2" xml:lang="en-US" id="label_NetRevenueLoss_2">Net Revenue Loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetRevenueLoss" xlink:to="label_NetRevenueLoss_2" xlink:title="Label : NetRevenueLoss to label_NetRevenueLoss_2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="StockIssuedDuringPeriodSharesIssuedForServices" xlink:title="StockIssuedDuringPeriodSharesIssuedForServices" />
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodSharesIssuedForServices" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StockIssuedDuringPeriodSharesIssuedForServices" xml:lang="en-US" id="label_StockIssuedDuringPeriodSharesIssuedForServices">Stock Issued During Period, Shares, Issued for Services</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="label_StockIssuedDuringPeriodSharesIssuedForServices" xlink:title="Label : StockIssuedDuringPeriodSharesIssuedForServices to label_StockIssuedDuringPeriodSharesIssuedForServices" />
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodSharesIssuedForServices_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_StockIssuedDuringPeriodSharesIssuedForServices_1" xml:lang="en-US" id="label_StockIssuedDuringPeriodSharesIssuedForServices_1">Voluntary return of shares issued to vendor for services (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="label_StockIssuedDuringPeriodSharesIssuedForServices_1" xlink:title="Label : StockIssuedDuringPeriodSharesIssuedForServices to label_StockIssuedDuringPeriodSharesIssuedForServices_1" />
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodSharesIssuedForServices_2" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="label_StockIssuedDuringPeriodSharesIssuedForServices_2" xml:lang="en-US" id="label_StockIssuedDuringPeriodSharesIssuedForServices_2">Voluntary return of shares issued to vendor for services (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="label_StockIssuedDuringPeriodSharesIssuedForServices_2" xlink:title="Label : StockIssuedDuringPeriodSharesIssuedForServices to label_StockIssuedDuringPeriodSharesIssuedForServices_2" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_ShareRoundingAdjustmentForReverseStockSplit" xlink:label="ShareRoundingAdjustmentForReverseStockSplit" xlink:title="ShareRoundingAdjustmentForReverseStockSplit" />
    <link:label xlink:type="resource" xlink:label="label_ShareRoundingAdjustmentForReverseStockSplit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_ShareRoundingAdjustmentForReverseStockSplit" xml:lang="en-US" id="label_ShareRoundingAdjustmentForReverseStockSplit">Share Rounding Adjustment For Reverse Stock Split</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareRoundingAdjustmentForReverseStockSplit" xlink:to="label_ShareRoundingAdjustmentForReverseStockSplit" xlink:title="Label : ShareRoundingAdjustmentForReverseStockSplit to label_ShareRoundingAdjustmentForReverseStockSplit" />
    <link:label xlink:type="resource" xlink:label="label_ShareRoundingAdjustmentForReverseStockSplit_1" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:title="label_ShareRoundingAdjustmentForReverseStockSplit_1" xml:lang="en-US" id="label_ShareRoundingAdjustmentForReverseStockSplit_1">Share rounding adjustment for reverse stock split (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareRoundingAdjustmentForReverseStockSplit" xlink:to="label_ShareRoundingAdjustmentForReverseStockSplit_1" xlink:title="Label : ShareRoundingAdjustmentForReverseStockSplit to label_ShareRoundingAdjustmentForReverseStockSplit_1" />
    <link:label xlink:type="resource" xlink:label="label_ShareRoundingAdjustmentForReverseStockSplit_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_ShareRoundingAdjustmentForReverseStockSplit_2" xml:lang="en-US" id="label_ShareRoundingAdjustmentForReverseStockSplit_2">Number of shares adjustment for share rounding in reverse stock split.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareRoundingAdjustmentForReverseStockSplit" xlink:to="label_ShareRoundingAdjustmentForReverseStockSplit_2" xlink:title="Label : ShareRoundingAdjustmentForReverseStockSplit to label_ShareRoundingAdjustmentForReverseStockSplit_2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="LiabilitiesAndStockholdersEquityAbstract" xlink:title="LiabilitiesAndStockholdersEquityAbstract" />
    <link:label xlink:type="resource" xlink:label="label_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US" id="label_LiabilitiesAndStockholdersEquityAbstract">LIABILITIES AND SHAREHOLDERS' EQUITY:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="label_LiabilitiesAndStockholdersEquityAbstract" xlink:title="Label : LiabilitiesAndStockholdersEquityAbstract to label_LiabilitiesAndStockholdersEquityAbstract" />
    <link:label xlink:type="resource" xlink:label="label_LiabilitiesAndStockholdersEquityAbstract_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_LiabilitiesAndStockholdersEquityAbstract_1" xml:lang="en-US" id="label_LiabilitiesAndStockholdersEquityAbstract_1">Liabilities and Equity [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="label_LiabilitiesAndStockholdersEquityAbstract_1" xlink:title="Label : LiabilitiesAndStockholdersEquityAbstract to label_LiabilitiesAndStockholdersEquityAbstract_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue" xlink:label="PreferredStockValue" xlink:title="PreferredStockValue" />
    <link:label xlink:type="resource" xlink:label="label_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_PreferredStockValue" xml:lang="en-US" id="label_PreferredStockValue">Series A Preferred Stock, $0.0001 par value, 1,000,000 shares authorized&#x37E; 76,480 and 76,480 shares issued and outstanding as of September 30, 2025 and December 31, 2024, respectively (Note 6)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockValue" xlink:to="label_PreferredStockValue" xlink:title="Label : PreferredStockValue to label_PreferredStockValue" />
    <link:label xlink:type="resource" xlink:label="label_PreferredStockValue_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_PreferredStockValue_1" xml:lang="en-US" id="label_PreferredStockValue_1">Preferred Stock, Value, Issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockValue" xlink:to="label_PreferredStockValue_1" xlink:title="Label : PreferredStockValue to label_PreferredStockValue_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue" xlink:label="CommonStockValue" xlink:title="CommonStockValue" />
    <link:label xlink:type="resource" xlink:label="label_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_CommonStockValue" xml:lang="en-US" id="label_CommonStockValue">Common Stock, $0.0001 par value, 150,000,000 shares authorized&#x37E; 4,104,469 and 566,908 shares issued and outstanding as of September 30, 2025 and December 31, 2024, respectively (Note 6)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockValue" xlink:to="label_CommonStockValue" xlink:title="Label : CommonStockValue to label_CommonStockValue" />
    <link:label xlink:type="resource" xlink:label="label_CommonStockValue_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_CommonStockValue_1" xml:lang="en-US" id="label_CommonStockValue_1">Common Stock, Value, Issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockValue" xlink:to="label_CommonStockValue_1" xlink:title="Label : CommonStockValue to label_CommonStockValue_1" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_StockIssuedDuringPeriodValueIssuanceOfCommonStockPursuantToATMOfferingNetOfOfferingCosts" xlink:label="StockIssuedDuringPeriodValueIssuanceOfCommonStockPursuantToATMOfferingNetOfOfferingCosts" xlink:title="StockIssuedDuringPeriodValueIssuanceOfCommonStockPursuantToATMOfferingNetOfOfferingCosts" />
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodValueIssuanceOfCommonStockPursuantToATMOfferingNetOfOfferingCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_StockIssuedDuringPeriodValueIssuanceOfCommonStockPursuantToATMOfferingNetOfOfferingCosts" xml:lang="en-US" id="label_StockIssuedDuringPeriodValueIssuanceOfCommonStockPursuantToATMOfferingNetOfOfferingCosts">Issuance of common stock pursuant to ATM Offering, net of offering costs paid at closing and deferred offering costs (Note 6)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueIssuanceOfCommonStockPursuantToATMOfferingNetOfOfferingCosts" xlink:to="label_StockIssuedDuringPeriodValueIssuanceOfCommonStockPursuantToATMOfferingNetOfOfferingCosts" xlink:title="Label : StockIssuedDuringPeriodValueIssuanceOfCommonStockPursuantToATMOfferingNetOfOfferingCosts to label_StockIssuedDuringPeriodValueIssuanceOfCommonStockPursuantToATMOfferingNetOfOfferingCosts" />
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodValueIssuanceOfCommonStockPursuantToATMOfferingNetOfOfferingCosts_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_StockIssuedDuringPeriodValueIssuanceOfCommonStockPursuantToATMOfferingNetOfOfferingCosts_1" xml:lang="en-US" id="label_StockIssuedDuringPeriodValueIssuanceOfCommonStockPursuantToATMOfferingNetOfOfferingCosts_1">Issuance of common stock pursuant to ATM offering.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueIssuanceOfCommonStockPursuantToATMOfferingNetOfOfferingCosts" xlink:to="label_StockIssuedDuringPeriodValueIssuanceOfCommonStockPursuantToATMOfferingNetOfOfferingCosts_1" xlink:title="Label : StockIssuedDuringPeriodValueIssuanceOfCommonStockPursuantToATMOfferingNetOfOfferingCosts to label_StockIssuedDuringPeriodValueIssuanceOfCommonStockPursuantToATMOfferingNetOfOfferingCosts_1" />
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodValueIssuanceOfCommonStockPursuantToATMOfferingNetOfOfferingCosts_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StockIssuedDuringPeriodValueIssuanceOfCommonStockPursuantToATMOfferingNetOfOfferingCosts_2" xml:lang="en-US" id="label_StockIssuedDuringPeriodValueIssuanceOfCommonStockPursuantToATMOfferingNetOfOfferingCosts_2">Stock Issued During Period Value Issuance Of Common Stock Pursuant To ATMOffering Net Of Offering Costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueIssuanceOfCommonStockPursuantToATMOfferingNetOfOfferingCosts" xlink:to="label_StockIssuedDuringPeriodValueIssuanceOfCommonStockPursuantToATMOfferingNetOfOfferingCosts_2" xlink:title="Label : StockIssuedDuringPeriodValueIssuanceOfCommonStockPursuantToATMOfferingNetOfOfferingCosts to label_StockIssuedDuringPeriodValueIssuanceOfCommonStockPursuantToATMOfferingNetOfOfferingCosts_2" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_IssuanceOfCommonStockPursuantToATMOfferingNetOfOfferingCostsPaid" xlink:label="IssuanceOfCommonStockPursuantToATMOfferingNetOfOfferingCostsPaid" xlink:title="IssuanceOfCommonStockPursuantToATMOfferingNetOfOfferingCostsPaid" />
    <link:label xlink:type="resource" xlink:label="label_IssuanceOfCommonStockPursuantToATMOfferingNetOfOfferingCostsPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_IssuanceOfCommonStockPursuantToATMOfferingNetOfOfferingCostsPaid" xml:lang="en-US" id="label_IssuanceOfCommonStockPursuantToATMOfferingNetOfOfferingCostsPaid">Issuance of common stock pursuant to ATM Offering, net of offering costs paid at closing and deferred offering costs (Note 6) (in Shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IssuanceOfCommonStockPursuantToATMOfferingNetOfOfferingCostsPaid" xlink:to="label_IssuanceOfCommonStockPursuantToATMOfferingNetOfOfferingCostsPaid" xlink:title="Label : IssuanceOfCommonStockPursuantToATMOfferingNetOfOfferingCostsPaid to label_IssuanceOfCommonStockPursuantToATMOfferingNetOfOfferingCostsPaid" />
    <link:label xlink:type="resource" xlink:label="label_IssuanceOfCommonStockPursuantToATMOfferingNetOfOfferingCostsPaid_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_IssuanceOfCommonStockPursuantToATMOfferingNetOfOfferingCostsPaid_1" xml:lang="en-US" id="label_IssuanceOfCommonStockPursuantToATMOfferingNetOfOfferingCostsPaid_1">Issuance Of Common Stock Pursuant To ATMOffering Net Of Offering Costs Paid</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IssuanceOfCommonStockPursuantToATMOfferingNetOfOfferingCostsPaid" xlink:to="label_IssuanceOfCommonStockPursuantToATMOfferingNetOfOfferingCostsPaid_1" xlink:title="Label : IssuanceOfCommonStockPursuantToATMOfferingNetOfOfferingCostsPaid to label_IssuanceOfCommonStockPursuantToATMOfferingNetOfOfferingCostsPaid_1" />
    <link:label xlink:type="resource" xlink:label="label_IssuanceOfCommonStockPursuantToATMOfferingNetOfOfferingCostsPaid_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_IssuanceOfCommonStockPursuantToATMOfferingNetOfOfferingCostsPaid_2" xml:lang="en-US" id="label_IssuanceOfCommonStockPursuantToATMOfferingNetOfOfferingCostsPaid_2">Issuance of common stock pursuant to ATM offering.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IssuanceOfCommonStockPursuantToATMOfferingNetOfOfferingCostsPaid" xlink:to="label_IssuanceOfCommonStockPursuantToATMOfferingNetOfOfferingCostsPaid_2" xlink:title="Label : IssuanceOfCommonStockPursuantToATMOfferingNetOfOfferingCostsPaid to label_IssuanceOfCommonStockPursuantToATMOfferingNetOfOfferingCostsPaid_2" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_StockIssuedDuringPeriodValueIssuanceOfCommonStockForFractionalSharesPursuantToReverseStockSplitRoundingAdjustment" xlink:label="StockIssuedDuringPeriodValueIssuanceOfCommonStockForFractionalSharesPursuantToReverseStockSplitRoundingAdjustment" xlink:title="StockIssuedDuringPeriodValueIssuanceOfCommonStockForFractionalSharesPursuantToReverseStockSplitRoundingAdjustment" />
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodValueIssuanceOfCommonStockForFractionalSharesPursuantToReverseStockSplitRoundingAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_StockIssuedDuringPeriodValueIssuanceOfCommonStockForFractionalSharesPursuantToReverseStockSplitRoundingAdjustment" xml:lang="en-US" id="label_StockIssuedDuringPeriodValueIssuanceOfCommonStockForFractionalSharesPursuantToReverseStockSplitRoundingAdjustment">Issuance of common stock for fractional shares pursuant to Reverse Stock Split rounding adjustment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueIssuanceOfCommonStockForFractionalSharesPursuantToReverseStockSplitRoundingAdjustment" xlink:to="label_StockIssuedDuringPeriodValueIssuanceOfCommonStockForFractionalSharesPursuantToReverseStockSplitRoundingAdjustment" xlink:title="Label : StockIssuedDuringPeriodValueIssuanceOfCommonStockForFractionalSharesPursuantToReverseStockSplitRoundingAdjustment to label_StockIssuedDuringPeriodValueIssuanceOfCommonStockForFractionalSharesPursuantToReverseStockSplitRoundingAdjustment" />
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodValueIssuanceOfCommonStockForFractionalSharesPursuantToReverseStockSplitRoundingAdjustment_1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_StockIssuedDuringPeriodValueIssuanceOfCommonStockForFractionalSharesPursuantToReverseStockSplitRoundingAdjustment_1" xml:lang="en-US" id="label_StockIssuedDuringPeriodValueIssuanceOfCommonStockForFractionalSharesPursuantToReverseStockSplitRoundingAdjustment_1">Value of issuance of common stock for fractional shares pursuant to Reverse Stock split rounding adjustment.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueIssuanceOfCommonStockForFractionalSharesPursuantToReverseStockSplitRoundingAdjustment" xlink:to="label_StockIssuedDuringPeriodValueIssuanceOfCommonStockForFractionalSharesPursuantToReverseStockSplitRoundingAdjustment_1" xlink:title="Label : StockIssuedDuringPeriodValueIssuanceOfCommonStockForFractionalSharesPursuantToReverseStockSplitRoundingAdjustment to label_StockIssuedDuringPeriodValueIssuanceOfCommonStockForFractionalSharesPursuantToReverseStockSplitRoundingAdjustment_1" />
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodValueIssuanceOfCommonStockForFractionalSharesPursuantToReverseStockSplitRoundingAdjustment_2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StockIssuedDuringPeriodValueIssuanceOfCommonStockForFractionalSharesPursuantToReverseStockSplitRoundingAdjustment_2" xml:lang="en-US" id="label_StockIssuedDuringPeriodValueIssuanceOfCommonStockForFractionalSharesPursuantToReverseStockSplitRoundingAdjustment_2">Stock Issued During Period Value Issuance Of Common Stock For Fractional Shares Pursuant To Reverse Stock Split Rounding Adjustment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueIssuanceOfCommonStockForFractionalSharesPursuantToReverseStockSplitRoundingAdjustment" xlink:to="label_StockIssuedDuringPeriodValueIssuanceOfCommonStockForFractionalSharesPursuantToReverseStockSplitRoundingAdjustment_2" xlink:title="Label : StockIssuedDuringPeriodValueIssuanceOfCommonStockForFractionalSharesPursuantToReverseStockSplitRoundingAdjustment to label_StockIssuedDuringPeriodValueIssuanceOfCommonStockForFractionalSharesPursuantToReverseStockSplitRoundingAdjustment_2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:label="StockIssuedDuringPeriodSharesReverseStockSplits" xlink:title="StockIssuedDuringPeriodSharesReverseStockSplits" />
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_StockIssuedDuringPeriodSharesReverseStockSplits" xml:lang="en-US" id="label_StockIssuedDuringPeriodSharesReverseStockSplits">Stock Issued During Period, Shares, Reverse Stock Splits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesReverseStockSplits" xlink:to="label_StockIssuedDuringPeriodSharesReverseStockSplits" xlink:title="Label : StockIssuedDuringPeriodSharesReverseStockSplits to label_StockIssuedDuringPeriodSharesReverseStockSplits" />
    <link:label xlink:type="resource" xlink:label="label_StockIssuedDuringPeriodSharesReverseStockSplits_1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_StockIssuedDuringPeriodSharesReverseStockSplits_1" xml:lang="en-US" id="label_StockIssuedDuringPeriodSharesReverseStockSplits_1">Issuance of common stock for fractional shares pursuant to Reverse Stock Split rounding adjustment (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesReverseStockSplits" xlink:to="label_StockIssuedDuringPeriodSharesReverseStockSplits_1" xlink:title="Label : StockIssuedDuringPeriodSharesReverseStockSplits to label_StockIssuedDuringPeriodSharesReverseStockSplits_1" />
    <link:loc xlink:type="locator" xlink:href="sxtp-20250930.xsd#sxtp_SalesAgreementTerminationDate" xlink:label="SalesAgreementTerminationDate" xlink:title="SalesAgreementTerminationDate" />
    <link:label xlink:type="resource" xlink:label="label_SalesAgreementTerminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="label_SalesAgreementTerminationDate" xml:lang="en-US" id="label_SalesAgreementTerminationDate">Sales agreement termination date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SalesAgreementTerminationDate" xlink:to="label_SalesAgreementTerminationDate" xlink:title="Label : SalesAgreementTerminationDate to label_SalesAgreementTerminationDate" />
    <link:label xlink:type="resource" xlink:label="label_SalesAgreementTerminationDate_1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="label_SalesAgreementTerminationDate_1" xml:lang="en-US" id="label_SalesAgreementTerminationDate_1">Sales Agreement Termination Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SalesAgreementTerminationDate" xlink:to="label_SalesAgreementTerminationDate_1" xlink:title="Label : SalesAgreementTerminationDate to label_SalesAgreementTerminationDate_1" />
    <link:label xlink:type="resource" xlink:label="label_SalesAgreementTerminationDate_2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="label_SalesAgreementTerminationDate_2" xml:lang="en-US" id="label_SalesAgreementTerminationDate_2">Termination date of sales agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SalesAgreementTerminationDate" xlink:to="label_SalesAgreementTerminationDate_2" xlink:title="Label : SalesAgreementTerminationDate to label_SalesAgreementTerminationDate_2" />
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>sxtp-20250930.xsd
<DESCRIPTION>SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!--Created by IRIS Business Services_Direct, Powered by IRIS Carbon, Unique Code 691618107ea6641f94c6a05b, Generated At Thu, 13 Nov 2025 17:41:17 GMT-->
<xsd:schema xmlns:srt="http://fasb.org/srt/2025" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2024-01-31" xmlns:us-roles="http://fasb.org/us-roles/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:us-types="http://fasb.org/us-types/2025" xmlns:ecd="http://xbrl.sec.gov/ecd/2025" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:currency="http://xbrl.sec.gov/currency/2025" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:sxtp="http://60degreespharma.com/20250930" elementFormDefault="qualified" attributeFormDefault="unqualified" targetNamespace="http://60degreespharma.com/20250930">
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="sxtp-20250930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="sxtp-20250930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="sxtp-20250930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="sxtp-20250930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:roleType roleURI="http://60degreespharma.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://60degreespharma.com/role/sxtp_r_ConsolidatedBalanceSheet" id="sxtp_r_ConsolidatedBalanceSheet">
        <link:definition>00100 - Statement - Consolidated Condensed Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://60degreespharma.com/role/sxtp_r_ConsolidatedBalanceSheet_Parentheticals" id="sxtp_r_ConsolidatedBalanceSheet_Parentheticals">
        <link:definition>00150 - Statement - Consolidated Condensed Balance Sheets (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://60degreespharma.com/role/sxtp_r_ConsolidatedIncomeStatement" id="sxtp_r_ConsolidatedIncomeStatement">
        <link:definition>00200 - Statement - Consolidated Condensed Statements of Operations and Comprehensive (Loss) Income (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://60degreespharma.com/role/ConsolidatedCondensedStatementsofOperationsandComprehensiveLossIncomeUnauditedCalc2" id="ConsolidatedCondensedStatementsofOperationsandComprehensiveLossIncomeUnauditedCalc2">
        <link:definition>00250 - Statement - Consolidated Condensed Statements of Operations and Comprehensive (Loss) Income (Unaudited) (Calc 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://60degreespharma.com/role/ConsolidatedCondensedStatementsofShareholdersEquityUnaudited" id="ConsolidatedCondensedStatementsofShareholdersEquityUnaudited">
        <link:definition>00300 - Statement - Consolidated Condensed Statements of Shareholders' Equity (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://60degreespharma.com/role/ConsolidatedCondensedStatementsofShareholdersEquityDeficitUnauditedParentheticals" id="ConsolidatedCondensedStatementsofShareholdersEquityDeficitUnauditedParentheticals">
        <link:definition>00301 - Statement - Consolidated Condensed Statements of Shareholders' Equity (Deficit) (Unaudited) (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://60degreespharma.com/role/sxtp_r_ConsolidatedCashFlow" id="sxtp_r_ConsolidatedCashFlow">
        <link:definition>00400 - Statement - Consolidated Condensed Statements of Cash Flows (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://60degreespharma.com/role/ConsolidatedCondensedStatementsofCashFlowsUnauditedParentheticals" id="ConsolidatedCondensedStatementsofCashFlowsUnauditedParentheticals">
        <link:definition>00410 - Statement - Consolidated Condensed Statements of Cash Flows (Unaudited) (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://60degreespharma.com/role/NATUREOFOPERATIONS" id="NATUREOFOPERATIONS">
        <link:definition>10001 - Disclosure - NATURE OF OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://60degreespharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES">
        <link:definition>10002 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://60degreespharma.com/role/INVENTORY" id="INVENTORY">
        <link:definition>10003 - Disclosure - INVENTORY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://60degreespharma.com/role/PROPERTYANDEQUIPMENT" id="PROPERTYANDEQUIPMENT">
        <link:definition>10004 - Disclosure - PROPERTY AND EQUIPMENT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://60degreespharma.com/role/INTANGIBLEASSETS" id="INTANGIBLEASSETS">
        <link:definition>10005 - Disclosure - INTANGIBLE ASSETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://60degreespharma.com/role/STOCKHOLDERSEQUITY" id="STOCKHOLDERSEQUITY">
        <link:definition>10006 - Disclosure - STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://60degreespharma.com/role/DEBT" id="DEBT">
        <link:definition>10007 - Disclosure - DEBT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://60degreespharma.com/role/DERIVATIVELIABILITIES" id="DERIVATIVELIABILITIES">
        <link:definition>10008 - Disclosure - DERIVATIVE LIABILITIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://60degreespharma.com/role/INCOMETAXES" id="INCOMETAXES">
        <link:definition>10009 - Disclosure - INCOME TAXES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://60degreespharma.com/role/SHAREBASEDCOMPENSATION" id="SHAREBASEDCOMPENSATION">
        <link:definition>10010 - Disclosure - SHARE-BASED COMPENSATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://60degreespharma.com/role/COMMITMENTSANDCONTINGENCIES" id="COMMITMENTSANDCONTINGENCIES">
        <link:definition>10011 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://60degreespharma.com/role/SUBSEQUENTEVENTS" id="SUBSEQUENTEVENTS">
        <link:definition>10012 - Disclosure - SUBSEQUENT EVENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://60degreespharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies">
        <link:definition>996000 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://60degreespharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables" id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables">
        <link:definition>996001 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://60degreespharma.com/role/INVENTORYTables" id="INVENTORYTables">
        <link:definition>996002 - Disclosure - INVENTORY (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://60degreespharma.com/role/PROPERTYANDEQUIPMENTTables" id="PROPERTYANDEQUIPMENTTables">
        <link:definition>996003 - Disclosure - PROPERTY AND EQUIPMENT (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://60degreespharma.com/role/INTANGIBLEASSETSTables" id="INTANGIBLEASSETSTables">
        <link:definition>996004 - Disclosure - INTANGIBLE ASSETS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://60degreespharma.com/role/STOCKHOLDERSEQUITYTables" id="STOCKHOLDERSEQUITYTables">
        <link:definition>996005 - Disclosure - STOCKHOLDERS' EQUITY (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://60degreespharma.com/role/DEBTTables" id="DEBTTables">
        <link:definition>996006 - Disclosure - DEBT (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://60degreespharma.com/role/DERIVATIVELIABILITIESTables" id="DERIVATIVELIABILITIESTables">
        <link:definition>996007 - Disclosure - DERIVATIVE LIABILITIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://60degreespharma.com/role/SHAREBASEDCOMPENSATIONTables" id="SHAREBASEDCOMPENSATIONTables">
        <link:definition>996008 - Disclosure - SHARE-BASED COMPENSATION (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://60degreespharma.com/role/NATUREOFOPERATIONSDetails" id="NATUREOFOPERATIONSDetails">
        <link:definition>996009 - Disclosure - NATURE OF OPERATIONS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://60degreespharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails" id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails">
        <link:definition>996010 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://60degreespharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofLiabilitiesMeasuredatFairValueDetails" id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofLiabilitiesMeasuredatFairValueDetails">
        <link:definition>996011 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Liabilities Measured at Fair Value (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://60degreespharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofExchangeRatesalongwithHistoricalRatesDetails" id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofExchangeRatesalongwithHistoricalRatesDetails">
        <link:definition>996012 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Exchange Rates along with Historical Rates (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://60degreespharma.com/role/INVENTORYScheduleofInventoryDetails" id="INVENTORYScheduleofInventoryDetails">
        <link:definition>996013 - Disclosure - INVENTORY - Schedule of Inventory (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://60degreespharma.com/role/INVENTORYDetails" id="INVENTORYDetails">
        <link:definition>9960131 - Disclosure - INVENTORY (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://60degreespharma.com/role/PROPERTYANDEQUIPMENTDetails" id="PROPERTYANDEQUIPMENTDetails">
        <link:definition>996014 - Disclosure - PROPERTY AND EQUIPMENT (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://60degreespharma.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails" id="PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails">
        <link:definition>996015 - Disclosure - PROPERTY AND EQUIPMENT - Schedule of Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://60degreespharma.com/role/INTANGIBLEASSETSDetails" id="INTANGIBLEASSETSDetails">
        <link:definition>996016 - Disclosure - INTANGIBLE ASSETS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://60degreespharma.com/role/INTANGIBLEASSETSScheduleofIntangibleAssetsDetails" id="INTANGIBLEASSETSScheduleofIntangibleAssetsDetails">
        <link:definition>996017 - Disclosure - INTANGIBLE ASSETS - Schedule of Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://60degreespharma.com/role/INTANGIBLEASSETSScheduleofEstimatedFutureAmortizationExpenseforOurPatentsandWebsiteDevelopmentCostsDetails" id="INTANGIBLEASSETSScheduleofEstimatedFutureAmortizationExpenseforOurPatentsandWebsiteDevelopmentCostsDetails">
        <link:definition>996018 - Disclosure - INTANGIBLE ASSETS - Schedule of Estimated Future Amortization Expense for Our Patents and Website Development Costs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://60degreespharma.com/role/STOCKHOLDERSEQUITYDetails" id="STOCKHOLDERSEQUITYDetails">
        <link:definition>996019 - Disclosure - STOCKHOLDERS' EQUITY (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://60degreespharma.com/role/STOCKHOLDERSEQUITYScheduleofEquityClassifiedWarrantsDetails" id="STOCKHOLDERSEQUITYScheduleofEquityClassifiedWarrantsDetails">
        <link:definition>996020 - Disclosure - STOCKHOLDERS' EQUITY - Schedule of Equity-Classified Warrants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://60degreespharma.com/role/DEBTDetails" id="DEBTDetails">
        <link:definition>996021 - Disclosure - DEBT (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://60degreespharma.com/role/DEBTScheduleoftheCurrentFuturePaymentObligationsDetails" id="DEBTScheduleoftheCurrentFuturePaymentObligationsDetails">
        <link:definition>996022 - Disclosure - DEBT - Schedule of the Current Future Payment Obligations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://60degreespharma.com/role/DERIVATIVELIABILITIESDetails" id="DERIVATIVELIABILITIESDetails">
        <link:definition>996023 - Disclosure - DERIVATIVE LIABILITIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://60degreespharma.com/role/DERIVATIVELIABILITIESScheduleofDerivativeLiabilitiesMeasuredatFairValueonaRecurringBasisDetails" id="DERIVATIVELIABILITIESScheduleofDerivativeLiabilitiesMeasuredatFairValueonaRecurringBasisDetails">
        <link:definition>996024 - Disclosure - DERIVATIVE LIABILITIES - Schedule of Derivative Liabilities Measured at Fair Value on a Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://60degreespharma.com/role/INCOMETAXESDetails" id="INCOMETAXESDetails">
        <link:definition>996025 - Disclosure - INCOME TAXES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://60degreespharma.com/role/SHAREBASEDCOMPENSATIONDetails" id="SHAREBASEDCOMPENSATIONDetails">
        <link:definition>996026 - Disclosure - SHARE-BASED COMPENSATION (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://60degreespharma.com/role/SHAREBASEDCOMPENSATIONScheduleofShareBasedCompensationExpensesDetails" id="SHAREBASEDCOMPENSATIONScheduleofShareBasedCompensationExpensesDetails">
        <link:definition>996027 - Disclosure - SHARE-BASED COMPENSATION - Schedule of Share-Based Compensation Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://60degreespharma.com/role/SHAREBASEDCOMPENSATIONScheduleofFairValueofOptionsGrantedDetails" id="SHAREBASEDCOMPENSATIONScheduleofFairValueofOptionsGrantedDetails">
        <link:definition>996028 - Disclosure - SHARE-BASED COMPENSATION - Schedule of Fair Value of Options Granted (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://60degreespharma.com/role/COMMITMENTSANDCONTINGENCIESDetails" id="COMMITMENTSANDCONTINGENCIESDetails">
        <link:definition>996029 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://60degreespharma.com/role/SUBSEQUENTEVENTSDetails" id="SUBSEQUENTEVENTSDetails">
        <link:definition>996030 - Disclosure - SUBSEQUENT EVENTS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="http://fasb.org/srt/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/2024-01-31" schemaLocation="https://www.xbrl.org/dtr/type/2024-01-31/types.xsd" />
  <xsd:import namespace="http://fasb.org/us-roles/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd" />
  <xsd:import namespace="http://fasb.org/us-gaap/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd" />
  <xsd:import namespace="http://fasb.org/us-types/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/ecd/2025" schemaLocation="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/currency/2025" schemaLocation="https://xbrl.sec.gov/currency/2025/currency-2025.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/XLink" schemaLocation="http://www.xbrl.org/2003/xl-2003-12-31.xsd" />
  <xsd:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2006/ref" schemaLocation="http://www.xbrl.org/2006/ref-2006-02-27.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:element name="SBAEIDLincludingAccruedInterestCurrent" id="sxtp_SBAEIDLincludingAccruedInterestCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="SBAEIDLincludingAccruedInterestNonCurrent" id="sxtp_SBAEIDLincludingAccruedInterestNonCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element name="NetRevenueLoss" id="sxtp_NetRevenueLoss" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPursuantToJanuary2025OfferingNetOfOfferingCosts" id="sxtp_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPursuantToJanuary2025OfferingNetOfOfferingCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="StockIssuedDuringPeriodIssuanceOfCommonStockAndWarrantsPursuantToJanuary2025OfferingNetOfOfferingCosts" id="sxtp_StockIssuedDuringPeriodIssuanceOfCommonStockAndWarrantsPursuantToJanuary2025OfferingNetOfOfferingCosts" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xsd:element name="StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPursuantToFebruary2025OfferingNetOfOfferingCosts" id="sxtp_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPursuantToFebruary2025OfferingNetOfOfferingCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="StockIssuedDuringPeriodIssuanceOfCommonStockAndWarrantsPursuantToFebruary2025OfferingNetOfOfferingCosts" id="sxtp_StockIssuedDuringPeriodIssuanceOfCommonStockAndWarrantsPursuantToFebruary2025OfferingNetOfOfferingCosts" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xsd:element name="IssuanceOfCommonStockAndWarrantsOfUnderwritingDiscountsAndOfferingCostsPaidAtClosingAndDeferredOfferingCosts" id="sxtp_IssuanceOfCommonStockAndWarrantsOfUnderwritingDiscountsAndOfferingCostsPaidAtClosingAndDeferredOfferingCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="StockIssuedDuringPeriodSharesOfCommonStockAndWarrantsOfUnderwritingDiscountsAndOfferingCostsPaidAtClosingAndDeferredOfferingCosts" id="sxtp_StockIssuedDuringPeriodSharesOfCommonStockAndWarrantsOfUnderwritingDiscountsAndOfferingCostsPaidAtClosingAndDeferredOfferingCosts" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xsd:element name="StockIssuedDuringPeriodValueStockIssuanceOfCommonStockUponExerciseOfPreFundedWarrants" id="sxtp_StockIssuedDuringPeriodValueStockIssuanceOfCommonStockUponExerciseOfPreFundedWarrants" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="StockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfPreFundedWarrantsinShares" id="sxtp_StockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfPreFundedWarrantsinShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xsd:element name="StockIssuedDuringPeriodValueIssuanceOfSharesForAnnualPerformanceBonusesNetOfSharesWithheldForTaxes" id="sxtp_StockIssuedDuringPeriodValueIssuanceOfSharesForAnnualPerformanceBonusesNetOfSharesWithheldForTaxes" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="StockIssuedDuringPeriodIssuanceOfSharesForAnnualPerformanceBonusesNetOfSharesWithheldForTaxesinShares" id="sxtp_StockIssuedDuringPeriodIssuanceOfSharesForAnnualPerformanceBonusesNetOfSharesWithheldForTaxesinShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xsd:element name="StockIssuedDuringPeriodValueIssuanceOfCommonStockForFractionalSharesPursuantToReverseStockSplitRoundingAdjustment" id="sxtp_StockIssuedDuringPeriodValueIssuanceOfCommonStockForFractionalSharesPursuantToReverseStockSplitRoundingAdjustment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="AmortizationOfCapitalizedShareBasedPayments" id="sxtp_AmortizationOfCapitalizedShareBasedPayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="WriteoffsOfCapitalizedPatents" id="sxtp_WriteoffsOfCapitalizedPatents" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="PaymentOfCapitalizationOfPatents" id="sxtp_PaymentOfCapitalizationOfPatents" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="NetProceedsFromSharesAndWarrantsOffering" id="sxtp_NetProceedsFromSharesAndWarrantsOffering" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="NetProceedsFromJanuary2025Offering" id="sxtp_NetProceedsFromJanuary2025Offering" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="NetProceedsFromFebruary2025Offering" id="sxtp_NetProceedsFromFebruary2025Offering" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="ProceedsFromExerciseOfPreFundedWarrants" id="sxtp_ProceedsFromExerciseOfPreFundedWarrants" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="FairValueOfWarrantsIssuedToUnderwriters" id="sxtp_FairValueOfWarrantsIssuedToUnderwriters" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="GrossSharesIssuedForAnnualPerformanceBonuses" id="sxtp_GrossSharesIssuedForAnnualPerformanceBonuses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="EquityClassifiedWarrantsPolicyTextBlock" id="sxtp_EquityClassifiedWarrantsPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xsd:element name="AssetsAndLiabilitiesNotMeasuredAtFairValueOnARecurringBasisPolicyTextBlock" id="sxtp_AssetsAndLiabilitiesNotMeasuredAtFairValueOnARecurringBasisPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xsd:element name="NatureofOperationsDetailsTable" id="sxtp_NatureofOperationsDetailsTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="TradeableWarrantsMember" id="sxtp_TradeableWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="NontradeableWarrantsMember" id="sxtp_NontradeableWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="TradeableAndNonTradeableWarrantsMember" id="sxtp_TradeableAndNonTradeableWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="SummaryofSignificantAccountingPoliciesDetailsTable" id="sxtp_SummaryofSignificantAccountingPoliciesDetailsTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="ReverseStockSplitsMember" id="sxtp_ReverseStockSplitsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="NetLossPerCommonShareMember" id="sxtp_NetLossPerCommonShareMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="SignificantCustomersMember" id="sxtp_SignificantCustomersMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="CustomerTwoMember" id="sxtp_CustomerTwoMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="CustomerThreeMember" id="sxtp_CustomerThreeMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="SignificantCustomerOneMember" id="sxtp_SignificantCustomerOneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="ScheduleOfLiabilitiesMeasuredAtFairValueAbstract" id="sxtp_ScheduleOfLiabilitiesMeasuredAtFairValueAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="SummaryofSignificantAccountingPoliciesScheduleofLiabilitiesMeasuredatFairValueDetailsTable" id="sxtp_SummaryofSignificantAccountingPoliciesScheduleofLiabilitiesMeasuredatFairValueDetailsTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="ScheduleOfExchangeRatesAlongWithHistoricalRatesAbstract" id="sxtp_ScheduleOfExchangeRatesAlongWithHistoricalRatesAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="SummaryofSignificantAccountingPoliciesScheduleofExchangeRatesalongwithHistoricalRatesDetailsTable" id="sxtp_SummaryofSignificantAccountingPoliciesScheduleofExchangeRatesalongwithHistoricalRatesDetailsTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="AverageExchangeRate" id="sxtp_AverageExchangeRate" type="xbrli:pureItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xsd:element name="ScheduleOfPropertyAndEquipmentAbstract" id="sxtp_ScheduleOfPropertyAndEquipmentAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="LabEquipmentMember" id="sxtp_LabEquipmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="CapitalizedWebsiteDevelopmentrelatedCosts" id="sxtp_CapitalizedWebsiteDevelopmentrelatedCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="CapitalizedPatentExpenses" id="sxtp_CapitalizedPatentExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="FiniteLivedWebsiteDevelopmentCostsGross" id="sxtp_FiniteLivedWebsiteDevelopmentCostsGross" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element name="ScheduleOfEstimatedFutureAmortizationExpenseForOurPatentsAndWebsiteDevelopmentCostsAbstract" id="sxtp_ScheduleOfEstimatedFutureAmortizationExpenseForOurPatentsAndWebsiteDevelopmentCostsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="IntangibleAssetsScheduleofEstimatedFutureAmortizationExpenseforOurPatentsandWebsiteDevelopmentCostsDetailsTable" id="sxtp_IntangibleAssetsScheduleofEstimatedFutureAmortizationExpenseforOurPatentsandWebsiteDevelopmentCostsDetailsTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="StockholdersEquityDetailsTable" id="sxtp_StockholdersEquityDetailsTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="SeriesANonVotingConvertiblePreferredStockMember" id="sxtp_SeriesANonVotingConvertiblePreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="WallachBethCapitalLLCMember" id="sxtp_WallachBethCapitalLLCMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="January2024OfferingMember" id="sxtp_January2024OfferingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="PlacementAgentWarrantsMember" id="sxtp_PlacementAgentWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="PreFundedWarrantMember" id="sxtp_PreFundedWarrantMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="JanuaryTwoThousandTwentyFourPreFundedWarrantsMember" id="sxtp_JanuaryTwoThousandTwentyFourPreFundedWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="JanuaryTwoThousandTwentyFourWarrantMember" id="sxtp_JanuaryTwoThousandTwentyFourWarrantMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="JanuaryRepresentativeWarrantsMember" id="sxtp_JanuaryRepresentativeWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="UnitsIssuedDuringPeriodSharesNewIssues" id="sxtp_UnitsIssuedDuringPeriodSharesNewIssues" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xsd:element name="OtherOfferingExpensesPaid" id="sxtp_OtherOfferingExpensesPaid" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="SharesOfWarrants" id="sxtp_SharesOfWarrants" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xsd:element name="NumberofWarrantExercisable" id="sxtp_NumberofWarrantExercisable" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xsd:element name="NumberOfShares" id="sxtp_NumberOfShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xsd:element name="ScheduleOfEquityClassifiedWarrantsAbstract" id="sxtp_ScheduleOfEquityClassifiedWarrantsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsGranted" id="sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsGranted" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfWarrantsExercised" id="sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfWarrantsExercised" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExercised" id="sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExercised" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsExercised" id="sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsExercised" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsForfeited" id="sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsForfeited" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfWarrantsExpired" id="sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfWarrantsExpired" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExpired" id="sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExpired" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsExpired" id="sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsExpired" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms1" id="sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms1" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable" id="sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageGrantDateFairValue" id="sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageGrantDateFairValue" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableOutstandingWeightedAverageRemainingContractualTerms" id="sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableOutstandingWeightedAverageRemainingContractualTerms" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xsd:element name="DebtDetailsTable" id="sxtp_DebtDetailsTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="SmallBusinessAdministrationMember" id="sxtp_SmallBusinessAdministrationMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="BalloonPaymentMember" id="sxtp_BalloonPaymentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="SBAMember" id="sxtp_SBAMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="DerivativeLiabilitiesDetailsTable" id="sxtp_DerivativeLiabilitiesDetailsTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="MilestonePayment" id="sxtp_MilestonePayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="RoyaltyPercentage" id="sxtp_RoyaltyPercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xsd:element name="ScheduleOfDerivativeLiabilitiesMeasuredAtFairValueOnARecurringBasisAbstract" id="sxtp_ScheduleOfDerivativeLiabilitiesMeasuredAtFairValueOnARecurringBasisAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="DerivativeLiabilitiesScheduleofDerivativeLiabilitiesMeasuredatFairValueonaRecurringBasisDetailsTable" id="sxtp_DerivativeLiabilitiesScheduleofDerivativeLiabilitiesMeasuredatFairValueonaRecurringBasisDetailsTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="ContingentMilestonePaymentMember" id="sxtp_ContingentMilestonePaymentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="BridgeSharesMember" id="sxtp_BridgeSharesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisMarkToMarketAdjustment" id="sxtp_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisMarkToMarketAdjustment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="ShareBasedCompensationDetailsTable" id="sxtp_ShareBasedCompensationDetailsTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="TwoThousandTwentyTwoEquityIncentivePlanMember" id="sxtp_TwoThousandTwentyTwoEquityIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="StockOptionsMember" id="sxtp_StockOptionsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="SharesIssuedPayrollTaxesWithholdings" id="sxtp_SharesIssuedPayrollTaxesWithholdings" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xsd:element name="UnamortizedBalance" id="sxtp_UnamortizedBalance" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="ScheduleOfShareBasedCompensationExpensesAbstract" id="sxtp_ScheduleOfShareBasedCompensationExpensesAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="CommitmentsandContingenciesDetailsTable" id="sxtp_CommitmentsandContingenciesDetailsTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="CherylXuMember" id="sxtp_CherylXuMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="PaulFieldMember" id="sxtp_PaulFieldMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="CharlesAllenMember" id="sxtp_CharlesAllenMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="StephenTooveyMember" id="sxtp_StephenTooveyMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="USGovernmentSalesMember" id="sxtp_USGovernmentSalesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="USArmyAgreementMember" id="sxtp_USArmyAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="NumberOfNonAuditCommitteeChairs" id="sxtp_NumberOfNonAuditCommitteeChairs" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" />
  <xsd:element name="LicensedTechnologyTerm" id="sxtp_LicensedTechnologyTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xsd:element name="AnnualRoyaltyPaymentPercentage" id="sxtp_AnnualRoyaltyPaymentPercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xsd:element name="PercentageOfRoyaltyPaymentsOfNetSales" id="sxtp_PercentageOfRoyaltyPaymentsOfNetSales" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xsd:element name="PercentageOfTreatmentOfBabesiosis" id="sxtp_PercentageOfTreatmentOfBabesiosis" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xsd:element name="NumberOfExecutives" id="sxtp_NumberOfExecutives" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" />
  <xsd:element name="SignificantCustomerTwoMember" id="sxtp_SignificantCustomerTwoMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="SignificantCustomerThreeMember" id="sxtp_SignificantCustomerThreeMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="TrevallyLLCMember" id="sxtp_TrevallyLLCMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="AgreedToReturnShares" id="sxtp_AgreedToReturnShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xsd:element name="July2025OfferingMember" id="sxtp_July2025OfferingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="JulyTwoThousandTwentyFivePreFundedWarrantsMember" id="sxtp_JulyTwoThousandTwentyFivePreFundedWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="JulyTwoThousandTwentyFiveAOneWarrantsMember" id="sxtp_JulyTwoThousandTwentyFiveAOneWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="JulyTwoThousandTwentyFiveATwoWarrantsMember" id="sxtp_JulyTwoThousandTwentyFiveATwoWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="JulyTwoThousandTwentyFivePlacementAgentWarrantsMember" id="sxtp_JulyTwoThousandTwentyFivePlacementAgentWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="ProceedsFromIssuanceATMOfferingCosts" id="sxtp_ProceedsFromIssuanceATMOfferingCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="ATMOfferingNetOfOfferingCostsPaid" id="sxtp_ATMOfferingNetOfOfferingCostsPaid" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="IssuanceOfCommonStockPursuantToATMOfferingNetOfOfferingCostsPaid" id="sxtp_IssuanceOfCommonStockPursuantToATMOfferingNetOfOfferingCostsPaid" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xsd:element name="StockIssuedDuringPeriodValueIssuanceOfCommonStockPursuantToATMOfferingNetOfOfferingCosts" id="sxtp_StockIssuedDuringPeriodValueIssuanceOfCommonStockPursuantToATMOfferingNetOfOfferingCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsNetOfOfferingCostsPaidAtClosingAndDeferredOfferingCosts" id="sxtp_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsNetOfOfferingCostsPaidAtClosingAndDeferredOfferingCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsNetOfOfferingCostsPaidAtClosingAndDeferredOfferingCosts" id="sxtp_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsNetOfOfferingCostsPaidAtClosingAndDeferredOfferingCosts" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xsd:element name="StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPursuantToJuly2025OfferingNetOfOfferingCosts" id="sxtp_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPursuantToJuly2025OfferingNetOfOfferingCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsPursuantToJuly2025OfferingNetOfOfferingCosts" id="sxtp_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsPursuantToJuly2025OfferingNetOfOfferingCosts" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xsd:element name="NetProceedsFromJuly2025Offering" id="sxtp_NetProceedsFromJuly2025Offering" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="ConversionOfSeriesAPreferredStockIntoCommonStock" id="sxtp_ConversionOfSeriesAPreferredStockIntoCommonStock" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="SeriesAWarrantsMember" id="sxtp_SeriesAWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="SeriesBWarrantsMember" id="sxtp_SeriesBWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="SeptemberTwoThousandTwentyFourAgentWarrantsMember" id="sxtp_SeptemberTwoThousandTwentyFourAgentWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="CommonStockAggregateOfferingPrice" id="sxtp_CommonStockAggregateOfferingPrice" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="ATMOfferingShares" id="sxtp_ATMOfferingShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xsd:element name="NumberOfDirectors" id="sxtp_NumberOfDirectors" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" />
  <xsd:element name="HCWainwrightAndCoLLCMember" id="sxtp_HCWainwrightAndCoLLCMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="SeriesAAndSeriesBWarrantsMember" id="sxtp_SeriesAAndSeriesBWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="TuftsMedicalCenterAgreementMember" id="sxtp_TuftsMedicalCenterAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1Minimum" id="sxtp_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1Minimum" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xsd:element name="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1Maximum" id="sxtp_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1Maximum" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xsd:element name="AtTheMarket2025AgreementMember" id="sxtp_AtTheMarket2025AgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="SalesAgreementTerminationDate" id="sxtp_SalesAgreementTerminationDate" type="xbrli:dateItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xsd:element name="CommonStockAggregateGrossSalesProceedAuthorized" id="sxtp_CommonStockAggregateGrossSalesProceedAuthorized" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element name="SalesAgentCommissionPercentage" id="sxtp_SalesAgentCommissionPercentage" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" />
  <xsd:element name="CommonStockSalesAgreementWeightedAveragePricePerShare" id="sxtp_CommonStockSalesAgreementWeightedAveragePricePerShare" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xsd:element name="ProceedsFromCommonStockSalesAgreementNet" id="sxtp_ProceedsFromCommonStockSalesAgreementNet" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="DirectorOneMember" id="sxtp_DirectorOneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="AccountsReceivableOrSalesRevenueNetMember" id="sxtp_AccountsReceivableOrSalesRevenueNetMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="ShareRoundingAdjustmentForReverseStockSplit" id="sxtp_ShareRoundingAdjustmentForReverseStockSplit" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>7
<FILENAME>ex311_1.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<html><head><title></title><meta content="text/html"></meta></head><body><div class="content_container" style="font-family:'Times New Roman' !important; font-size:12pt"><div class="Section_1"><p style="margin-top:0pt; margin-bottom:0pt; text-indent:18pt; text-align:right; font-size:10pt"><font id="EXH_68a5582bc0bf431834c5ad90"></font><font style="font-weight:bold">Exhibit 31.1</font></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><font>&#160;</font></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><font style="font-weight:bold">CERTIFICATION OF PRINCIPAL EXECTUIVE OFFICER</font></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><font style="font-weight:bold">PURSUANT TO RULE 13a-14(a)/15d-14(a), AS ADOPTED</font></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><font style="font-weight:bold">PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><font>&#160;</font></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><font>I, Geoffrey Dow, certify that:</font></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><font>&#160;</font></p><table cellspacing="0" cellpadding="0" style="width:98%"><tr><td style="width:3.3%; vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><font>1.</font></p></td><td style="width:96.7%; vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><font>I have reviewed this Quarterly Report on Form 10-Q of 60 Degrees Pharmaceuticals, Inc.;</font></p></td></tr></table><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><font>&#160;</font></p><table cellspacing="0" cellpadding="0" style="width:100%"><tr><td style="width:3.3%; vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><font>2.</font></p></td><td style="width:96.7%; vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><font>Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></p></td></tr></table><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><font>&#160;</font></p><table cellspacing="0" cellpadding="0" style="width:100%"><tr><td style="width:3.3%; vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><font>3.</font></p></td><td style="width:96.7%; vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><font>Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></p></td></tr></table><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><font>&#160;</font></p><table cellspacing="0" cellpadding="0" style="width:100%"><tr><td style="width:3.3%; vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><font>4.</font></p></td><td style="width:96.7%; vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><font>The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></p></td></tr></table><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><font>&#160;</font></p><table cellspacing="0" cellpadding="0" style="width:100%"><tr><td style="width:7.2pt; vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><font>&#160;</font></p></td><td style="width:18pt; vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><font>(a)</font></p></td><td style="vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><font>Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></p></td></tr><tr><td style="vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><font>&#160;</font></p></td><td style="vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><font>&#160;</font></p></td><td style="vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><font>&#160;</font></p></td></tr><tr><td style="vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><font>&#160;</font></p></td><td style="vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><font>(b)</font></p></td><td style="vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><font>Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></p></td></tr><tr><td style="vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><font>&#160;</font></p></td><td style="vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><font>&#160;</font></p></td><td style="vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><font>&#160;</font></p></td></tr><tr><td style="vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><font>&#160;</font></p></td><td style="vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><font>(c)</font></p></td><td style="vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><font>Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></p></td></tr><tr><td style="vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><font>&#160;</font></p></td><td style="vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><font>&#160;</font></p></td><td style="vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><font>&#160;</font></p></td></tr><tr><td style="vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><font>&#160;</font></p></td><td style="vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><font>(d)</font></p></td><td style="vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><font>Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></p></td></tr></table><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><font>&#160;</font></p><table cellspacing="0" cellpadding="0" style="width:100%"><tr><td style="width:3.3%; vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><font>5.</font></p></td><td style="width:96.7%; vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><font>The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></p></td></tr></table><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><font>&#160;</font></p><table cellspacing="0" cellpadding="0" style="width:100%"><tr><td style="width:7.2pt; vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><font>&#160;</font></p></td><td style="width:18pt; vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><font>(a)</font></p></td><td style="vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><font>All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></p></td></tr><tr><td style="vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><font>&#160;</font></p></td><td style="vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><font>&#160;</font></p></td><td style="vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><font>&#160;</font></p></td></tr><tr><td style="vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><font>&#160;</font></p></td><td style="vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><font>(b)</font></p></td><td style="vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><font>Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></p></td></tr></table><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><font>&#160;</font></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><font>Date: </font><font style="-aw-sdt-tag:'c149816d74a4b8c4e292'; -aw-sdt-title:'Signature_Date_P3'"><font>November 13, 2025</font></font></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><font>&#160;</font></p><table cellspacing="0" cellpadding="0" style="width:100%; border-collapse:collapse"><tr><td style="vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><font>&#160;</font></p></td><td colspan="2" style="border-bottom:1.5pt solid #000000; vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><font style="font-style:italic">/s/ Geoffrey Dow</font></p></td></tr><tr><td style="width:60%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><font>&#160;</font></p></td><td style="width:5%; vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><font>Name: </font></p></td><td style="width:35%; vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><font>Geoffrey Dow</font></p></td></tr><tr><td style="vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><font>&#160;</font></p></td><td style="vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><font>Title:</font></p></td><td style="vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><font>Chief Executive Officer and President</font></p></td></tr><tr><td style="vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><font>&#160;</font></p></td><td style="vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><font>&#160;</font></p></td><td style="vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><font>(Principal Executive Officer)</font></p></td></tr></table><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><font>&#160;</font></p><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><font>&#160;</font></p><p style="margin-top:0pt; margin-bottom:0pt"><font style="-aw-import:ignore">&#160;</font></p></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>8
<FILENAME>ex312_2.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<html><head><title></title><meta content="text/html"></meta></head><body><div class="content_container" style="font-family:'Times New Roman' !important; font-size:12pt"><div class="Section_1"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><font id="EXH_68a5582bc0bf431834c5ad91"></font><font style="font-weight:bold">Exhibit 31.2</font></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><font>&#160;</font></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><font style="font-weight:bold">CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER</font></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><font style="font-weight:bold">PURSUANT TO RULE 13a-14(a)/15d-14(a), AS ADOPTED</font></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><font style="font-weight:bold">PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><font>&#160;</font></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><font>I, Tyrone Miller, certify that:</font></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><font>&#160;</font></p><table cellspacing="0" cellpadding="0" style="width:99.54%"><tr><td style="width:3.34%; vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><font>1.</font></p></td><td style="width:96.66%; vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><font>I have reviewed this Quarterly Report on Form 10-Q of 60 Degrees Pharmaceuticals, Inc.;</font></p></td></tr></table><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><font>&#160;</font></p><table cellspacing="0" cellpadding="0" style="width:99.54%"><tr><td style="width:3.34%; vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><font>2.</font></p></td><td style="width:96.66%; vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><font>Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></p></td></tr></table><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><font>&#160;</font></p><table cellspacing="0" cellpadding="0" style="width:99.54%"><tr><td style="width:3.34%; vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><font>3.</font></p></td><td style="width:96.66%; vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><font>Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></p></td></tr></table><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><font>&#160;</font></p><table cellspacing="0" cellpadding="0" style="width:99.54%"><tr><td style="width:3.34%; vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><font>4.</font></p></td><td style="width:96.66%; vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><font>The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></p></td></tr></table><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><font>&#160;</font></p><table cellspacing="0" cellpadding="0" style="width:100%"><tr><td style="width:7.2pt; vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><font>&#160;</font></p></td><td style="width:18pt; vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><font>(a)</font></p></td><td style="vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><font>Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></p></td></tr><tr><td style="vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><font>&#160;</font></p></td><td style="vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><font>&#160;</font></p></td><td style="vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><font>&#160;</font></p></td></tr><tr><td style="vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><font>&#160;</font></p></td><td style="vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><font>(b)</font></p></td><td style="vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><font>Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></p></td></tr><tr><td style="vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><font>&#160;</font></p></td><td style="vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><font>&#160;</font></p></td><td style="vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><font>&#160;</font></p></td></tr><tr><td style="vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><font>&#160;</font></p></td><td style="vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><font>(c)</font></p></td><td style="vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><font>Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></p></td></tr><tr><td style="vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><font>&#160;</font></p></td><td style="vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><font>&#160;</font></p></td><td style="vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><font>&#160;</font></p></td></tr><tr><td style="vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><font>&#160;</font></p></td><td style="vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><font>(d)</font></p></td><td style="vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><font>Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></p></td></tr></table><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><font>&#160;</font></p><table cellspacing="0" cellpadding="0" style="width:99.54%"><tr><td style="width:3.34%; vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><font>5.</font></p></td><td style="width:96.66%; vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><font>The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)</font></p></td></tr></table><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><font>&#160;</font></p><table cellspacing="0" cellpadding="0" style="width:100%"><tr><td style="width:7.2pt; vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><font>&#160;</font></p></td><td style="width:18pt; vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><font>(a)</font></p></td><td style="vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><font>All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></p></td></tr><tr><td style="vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><font>&#160;</font></p></td><td style="vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><font>&#160;</font></p></td><td style="vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><font>&#160;</font></p></td></tr><tr><td style="vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><font>&#160;</font></p></td><td style="vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><font>(b)</font></p></td><td style="vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><font>Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></p></td></tr></table><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><font>&#160;</font></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><font>Date: </font><font style="-aw-sdt-tag:'cda33a991f2f5edbbcb7'; -aw-sdt-title:'Signature_Date_P4'"><font>November 13, 2025</font></font></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><font>&#160;</font></p><table cellspacing="0" cellpadding="0" style="width:100%; border-collapse:collapse"><tr><td style="vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><font>&#160;</font></p></td><td colspan="2" style="border-bottom:1.5pt solid #000000; vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><font style="font-style:italic">/s/ Tyrone Miller</font></p></td></tr><tr><td style="width:60%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><font>&#160;</font></p></td><td style="width:5%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><font>Name: </font></p></td><td style="width:35%; vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><font>Tyrone Miller</font></p></td></tr><tr><td style="vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><font style="-aw-import:ignore">&#160;</font></p></td><td style="vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><font>Title:</font></p></td><td style="vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><font>Chief Financial Officer</font></p></td></tr><tr><td style="vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><font style="-aw-import:ignore">&#160;</font></p></td><td style="vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><font>&#160;</font></p></td><td style="vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><font>(Principal Financial and Accounting Officer)</font></p></td></tr></table><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><font style="-aw-import:ignore">&#160;</font></p></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>9
<FILENAME>ex321_3.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<html><head><title></title><meta content="text/html"></meta></head><body><div class="content_container" style="font-family:'Times New Roman' !important; font-size:12pt"><div class="Section_1"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><font id="EXH_68a5582bc0bf431834c5ad92"></font><font style="font-weight:bold">Exhibit 32.1</font></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><font>&#160;</font></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><font style="font-weight:bold">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER</font></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><font style="font-weight:bold">PURSUANT TO 18 U.S.C. SECTION 1350,</font></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><font style="font-weight:bold">AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><font>&#160;</font></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><font>Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, I, Geoffrey Dow, the Chief Executive Officer and President of 60 Degrees Pharmaceuticals, Inc. (the &#8220;Company&#8221;), hereby certify, that, to my knowledge:</font></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><font>&#160;</font></p><table cellspacing="0" cellpadding="0" style="width:100%"><tr><td style="vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><font>&#160;</font></p></td><td style="width:18pt; vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><font>1.</font></p></td><td style="vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><font>The Quarterly Report on Form 10-Q for the period ended </font><font style="-aw-sdt-tag:'ed1-748-23e-d53-340a'; -aw-sdt-title:'Current_Period_P41'"><font>September 30, 2025</font></font><font> (the &#8220;Report&#8221;) of the Company fully complies with the requirements of Section 13(a) and 15(d) of the Securities Exchange Act of 1934; and</font></p></td></tr></table><p style="margin-top:0pt; margin-bottom:0pt; text-indent:36pt; text-align:justify; font-size:10pt"><font>&#160;</font></p><table cellspacing="0" cellpadding="0" style="width:100%"><tr><td style="vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><font>&#160;</font></p></td><td style="width:18pt; vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><font>2.</font></p></td><td style="vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><font>The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></p></td></tr></table><p style="margin-top:0pt; margin-bottom:0pt; text-indent:36pt; text-align:justify; font-size:10pt"><font>&#160;</font></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><font>Dated: </font><font style="-aw-sdt-tag:'c74ed140b0c4fbfb84ab'; -aw-sdt-title:'Signature_Date_P5'"><font>November 13, 2025</font></font></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><font>&#160;</font></p><table cellspacing="0" cellpadding="0" style="width:100%; border-collapse:collapse"><tr><td style="vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><font>&#160;</font></p></td><td colspan="2" style="border-bottom:1.5pt solid #000000; vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><font style="font-style:italic">/s/ Geoffrey Dow</font></p></td></tr><tr><td style="width:60%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><font>&#160;</font></p></td><td style="width:5%; vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><font>Name: </font></p></td><td style="width:35%; vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><font>Geoffrey Dow</font></p></td></tr><tr><td style="vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><font>&#160;</font></p></td><td style="vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><font>Title:</font></p></td><td style="vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><font>Chief Executive Officer and President</font></p></td></tr><tr><td style="vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><font>&#160;</font></p></td><td style="vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><font>&#160;</font></p></td><td style="vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><font>(Principal Executive Officer)</font></p></td></tr></table><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><font>&#160;</font></p><p style="margin-top:0pt; margin-bottom:0pt"><font id="ex322_4"></font></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><font style="-aw-import:ignore">&#160;</font></p></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>10
<FILENAME>ex322_4.htm
<DESCRIPTION>EXHIBIT 32.2
<TEXT>
<html><head><title></title><meta content="text/html"></meta></head><body><div class="content_container" style="font-family:'Times New Roman' !important; font-size:12pt"><div class="Section_1"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><font id="EXH_68a5582bc0bf431834c5ad93"></font><font style="font-weight:bold">Exhibit 32.2</font></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><font>&#160;</font></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><font style="font-weight:bold">CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER</font></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><font style="font-weight:bold">PURSUANT TO 18 U.S.C. SECTION 1350,</font></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><font style="font-weight:bold">AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><font>&#160;</font></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><font>Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, I, Tyrone Miller, the Chief Financial Officer of 60 Degrees Pharmaceuticals, Inc. (the &#8220;Company&#8221;), hereby certify, that, to my knowledge:</font></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><font>&#160;</font></p><table cellspacing="0" cellpadding="0" style="width:100%"><tr><td style="vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><font>&#160;</font></p></td><td style="width:18pt; vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><font>1.</font></p></td><td style="vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><font>The Quarterly Report on Form 10-Q for the period ended </font><font style="-aw-sdt-tag:'253-8d2-adb-daf-ab4c'; -aw-sdt-title:'Current_Period_P42'"><font>September 30, 2025</font></font><font> (the &#8220;Report&#8221;) of the Company fully complies with the requirements of Section 13(a)/15(d) of the Securities Exchange Act of 1934; and</font></p></td></tr></table><p style="margin-top:0pt; margin-bottom:0pt; text-indent:36pt; text-align:justify; font-size:10pt"><font>&#160;</font></p><table cellspacing="0" cellpadding="0" style="width:100%"><tr><td style="vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><font>&#160;</font></p></td><td style="width:18pt; vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><font>2.</font></p></td><td style="vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><font>The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></p></td></tr></table><p style="margin-top:0pt; margin-bottom:0pt; text-indent:36pt; text-align:justify; font-size:10pt"><font>&#160;</font></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><font>Dated: </font><font style="-aw-sdt-tag:'c12da831a12443014e39'; -aw-sdt-title:'Signature_Date_P6'"><font>November 13, 2025</font></font></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><font>&#160;</font></p><table cellspacing="0" cellpadding="0" style="width:100%; border-collapse:collapse"><tr><td style="vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><font>&#160;</font></p></td><td colspan="2" style="border-bottom:1.5pt solid #000000; vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><font style="font-style:italic">/s/ Tyrone Miller</font></p></td></tr><tr><td style="width:60%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><font>&#160;</font></p></td><td style="width:5%; vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><font>Name: </font></p></td><td style="width:35%; vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><font>Tyrone Miller</font></p></td></tr><tr><td style="vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><font>&#160;</font></p></td><td style="vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><font>Title:</font></p></td><td style="vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><font>Chief Financial Officer</font></p></td></tr><tr><td style="vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><font>&#160;</font></p></td><td style="vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><font>&#160;</font></p></td><td style="vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><font>(Principal Financial and Accounting Officer)</font></p></td></tr></table><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><font>&#160;</font></p></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document And Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Nov. 13, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">60 DEGREES PHARMACEUTICALS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001946563<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-41719<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">45-2406880<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1025 Connecticut Avenue<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">NW Suite 1000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Washington<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">DC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">20036<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">202<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">327-5422<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,230,448<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock, par value $0.0001 per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.0001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">SXTP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_WarrantMember', window );">Warrants, each warrant to purchase one share of Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Warrants, each warrant to purchase one share of Common Stock<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">SXTPW<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Consolidated Condensed Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current Assets:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 4,115,779<span></span>
</td>
<td class="nump">$ 1,659,353<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts Receivable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">674,036<span></span>
</td>
<td class="nump">486,748<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid and Other Assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">992,390<span></span>
</td>
<td class="nump">1,068,940<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-Term Investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,728,472<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory (Note 3)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">527,004<span></span>
</td>
<td class="nump">442,764<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total Current Assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6,309,209<span></span>
</td>
<td class="nump">5,386,277<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and Equipment, net (Note 4)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">227,752<span></span>
</td>
<td class="nump">149,808<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsAbstract', window );"><strong>Other Assets:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseNoncurrent', window );">Long-Term Prepaid Expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">66,176<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible Assets, net (Note 5)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">152,383<span></span>
</td>
<td class="nump">157,084<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Total Other Assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">152,383<span></span>
</td>
<td class="nump">223,260<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6,689,344<span></span>
</td>
<td class="nump">5,759,345<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current Liabilities:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts Payable and Accrued Expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,391,347<span></span>
</td>
<td class="nump">1,007,618<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sxtp_SBAEIDLincludingAccruedInterestCurrent', window );">SBA EIDL (including accrued interest) (Note 7)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">8,772<span></span>
</td>
<td class="nump">8,772<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Derivative Liabilities (Note 8)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">797,275<span></span>
</td>
<td class="nump">640,830<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total Current Liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,197,394<span></span>
</td>
<td class="nump">1,657,220<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Long-Term Liabilities:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sxtp_SBAEIDLincludingAccruedInterestNonCurrent', window );">SBA EIDL (including accrued interest) (Note 7)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">144,992<span></span>
</td>
<td class="nump">147,119<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total Long-Term Liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">144,992<span></span>
</td>
<td class="nump">147,119<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total Liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,342,386<span></span>
</td>
<td class="nump">1,804,339<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>SHAREHOLDERS' EQUITY:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Series A Preferred Stock, $0.0001 par value, 1,000,000 shares authorized&#894; 76,480 and 76,480 shares issued and outstanding as of September 30, 2025 and December 31, 2024, respectively (Note 6)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">9,567,439<span></span>
</td>
<td class="nump">9,567,439<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common Stock, $0.0001 par value, 150,000,000 shares authorized&#894; 4,104,469 and 566,908 shares issued and outstanding as of September 30, 2025 and December 31, 2024, respectively (Note 6)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">410<span></span>
</td>
<td class="nump">57<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional Paid-in Capital(1)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">41,172,888<span></span>
</td>
<td class="nump">34,860,590<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated Other Comprehensive Income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">144,039<span></span>
</td>
<td class="nump">135,471<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated Deficit</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(46,454,556)<span></span>
</td>
<td class="num">(40,527,957)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">60P Shareholders&#8217; Equity:</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,430,220<span></span>
</td>
<td class="nump">4,035,600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling Interest</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(83,262)<span></span>
</td>
<td class="num">(80,594)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total Shareholders' Equity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,346,958<span></span>
</td>
<td class="nump">3,955,006<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total Liabilities and Shareholders' Equity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 6,689,344<span></span>
</td>
<td class="nump">$ 5,759,345<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><div style="-aw-sdt-tag:'c13961dbf06a06abf874'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">Prior periods presented have been adjusted to reflect the 1:5 reverse stock split on February 24, 2025.</span></p></div></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sxtp_SBAEIDLincludingAccruedInterestCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of SBA EIDL including accrued interest payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sxtp_SBAEIDLincludingAccruedInterestCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sxtp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sxtp_SBAEIDLincludingAccruedInterestNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of SBA EIDL including accrued interest long-term debt payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sxtp_SBAEIDLincludingAccruedInterestNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sxtp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480870/815-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 19: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 31: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of amounts paid in advance for expenses which will be charged against earnings in periods after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-24<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-23<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-5<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 42: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-3<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 47: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 51: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 52: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 53: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-15<br><br>Reference 54: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-16<br><br>Reference 55: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4I<br><br>Reference 56: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1<br><br>Reference 57: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Consolidated Condensed Balance Sheets (Parentheticals) - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">150,000,000<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">4,104,469<span></span>
</td>
<td class="nump">566,908<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">4,104,469<span></span>
</td>
<td class="nump">566,908<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">76,480<span></span>
</td>
<td class="nump">76,480<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">76,480<span></span>
</td>
<td class="nump">76,480<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><div style="-aw-sdt-tag:'c13961dbf06a06abf874'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">Prior periods presented have been adjusted to reflect the 1:5 reverse stock split on February 24, 2025.</span></p></div></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Consolidated Condensed Statements of Operations and Comprehensive (Loss) Income (Unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product Revenues &#8211; net of Discounts and Rebates</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 437,602<span></span>
</td>
<td class="nump">$ 135,293<span></span>
</td>
<td class="nump">$ 702,086<span></span>
</td>
<td class="nump">$ 365,939<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">537,690<span></span>
</td>
<td class="nump">111,687<span></span>
</td>
<td class="nump">661,013<span></span>
</td>
<td class="nump">266,688<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross (Loss) Profit</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(100,088)<span></span>
</td>
<td class="nump">23,606<span></span>
</td>
<td class="nump">41,073<span></span>
</td>
<td class="nump">99,251<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueNotFromContractWithCustomerOther', window );">Research Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">90,960<span></span>
</td>
<td class="nump">12,818<span></span>
</td>
<td class="nump">390,630<span></span>
</td>
<td class="nump">43,177<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sxtp_NetRevenueLoss', window );">Net (Loss) Revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(9,128)<span></span>
</td>
<td class="nump">36,424<span></span>
</td>
<td class="nump">431,703<span></span>
</td>
<td class="nump">142,428<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating Expenses:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and Development</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">809,777<span></span>
</td>
<td class="nump">940,063<span></span>
</td>
<td class="nump">1,467,283<span></span>
</td>
<td class="nump">4,372,571<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and Administrative Expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,506,620<span></span>
</td>
<td class="nump">1,215,053<span></span>
</td>
<td class="nump">4,805,648<span></span>
</td>
<td class="nump">3,419,747<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total Operating Expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,316,397<span></span>
</td>
<td class="nump">2,155,116<span></span>
</td>
<td class="nump">6,272,931<span></span>
</td>
<td class="nump">7,792,318<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from Operations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(2,325,525)<span></span>
</td>
<td class="num">(2,118,692)<span></span>
</td>
<td class="num">(5,841,228)<span></span>
</td>
<td class="num">(7,649,890)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseNonoperating', window );">Interest Expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1,708)<span></span>
</td>
<td class="num">(1,467)<span></span>
</td>
<td class="num">(4,719)<span></span>
</td>
<td class="num">(6,490)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in Fair Value of Derivative Liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(21,103)<span></span>
</td>
<td class="num">(56,712)<span></span>
</td>
<td class="num">(156,445)<span></span>
</td>
<td class="nump">1,683,034<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other Income, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">31,550<span></span>
</td>
<td class="nump">16,623<span></span>
</td>
<td class="nump">74,938<span></span>
</td>
<td class="nump">67,358<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Total Interest and Other Income (Expense), net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">8,739<span></span>
</td>
<td class="num">(41,556)<span></span>
</td>
<td class="num">(86,226)<span></span>
</td>
<td class="nump">1,743,902<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss from Operations before Provision for Income Taxes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(2,316,786)<span></span>
</td>
<td class="num">(2,160,248)<span></span>
</td>
<td class="num">(5,927,454)<span></span>
</td>
<td class="num">(5,905,988)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for Income Taxes (Note 9)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">250<span></span>
</td>
<td class="nump">250<span></span>
</td>
<td class="nump">1,813<span></span>
</td>
<td class="nump">751<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net Loss including Noncontrolling Interest</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(2,317,036)<span></span>
</td>
<td class="num">(2,160,498)<span></span>
</td>
<td class="num">(5,929,267)<span></span>
</td>
<td class="num">(5,906,739)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net Loss &#8211; Noncontrolling Interest</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(712)<span></span>
</td>
<td class="num">(713)<span></span>
</td>
<td class="num">(2,668)<span></span>
</td>
<td class="num">(4,669)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss &#8211; attributed to 60 Degrees Pharmaceuticals, Inc.</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(2,316,324)<span></span>
</td>
<td class="num">(2,159,785)<span></span>
</td>
<td class="num">(5,926,599)<span></span>
</td>
<td class="num">(5,902,070)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Comprehensive Loss:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net Loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(2,317,036)<span></span>
</td>
<td class="num">(2,160,498)<span></span>
</td>
<td class="num">(5,929,267)<span></span>
</td>
<td class="num">(5,906,739)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealizedAfterTax', window );">Unrealized Foreign Currency Translation Gain</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,230<span></span>
</td>
<td class="nump">4,403<span></span>
</td>
<td class="nump">8,568<span></span>
</td>
<td class="nump">3,646<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Total Comprehensive Loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(2,315,806)<span></span>
</td>
<td class="num">(2,156,095)<span></span>
</td>
<td class="num">(5,920,699)<span></span>
</td>
<td class="num">(5,903,093)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest', window );">Net Loss &#8211; Noncontrolling Interest</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(712)<span></span>
</td>
<td class="num">(713)<span></span>
</td>
<td class="num">(2,668)<span></span>
</td>
<td class="num">(4,669)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive Loss &#8211; attributed to 60 Degrees Pharmaceuticals, Inc.</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(2,315,094)<span></span>
</td>
<td class="num">(2,155,382)<span></span>
</td>
<td class="num">(5,918,031)<span></span>
</td>
<td class="num">(5,898,424)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockDividendsAndOtherAdjustments', window );">Cumulative Dividends on Series A Preferred Stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(128,097)<span></span>
</td>
<td class="num">(116,571)<span></span>
</td>
<td class="num">(372,960)<span></span>
</td>
<td class="num">(352,333)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net Loss - attributed to common stockholders</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (2,443,191)<span></span>
</td>
<td class="num">$ (2,271,953)<span></span>
</td>
<td class="num">$ (6,290,991)<span></span>
</td>
<td class="num">$ (6,250,757)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net Loss per Common Share:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (0.66)<span></span>
</td>
<td class="num">$ (4.65)<span></span>
</td>
<td class="num">$ (2.92)<span></span>
</td>
<td class="num">$ (21.74)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (in Dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (0.66)<span></span>
</td>
<td class="num">$ (2.92)<span></span>
</td>
<td class="num">$ (4.65)<span></span>
</td>
<td class="num">$ (21.74)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract', window );"><strong>Weighted Average Number of Common Shares Outstanding(1)</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (in Shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">3,675,407<span></span>
</td>
<td class="nump">488,654<span></span>
</td>
<td class="nump">2,152,682<span></span>
</td>
<td class="nump">287,529<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (in Shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">3,675,407<span></span>
</td>
<td class="nump">2,152,682<span></span>
</td>
<td class="nump">488,654<span></span>
</td>
<td class="nump">287,529<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><div style="-aw-sdt-tag:'c734aea3392f6a6b2ec2'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">Prior periods presented have been adjusted to reflect the 1:5 reverse stock split on February 24, 2025.</span></p></div></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sxtp_NetRevenueLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net revenue loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sxtp_NetRevenueLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sxtp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-21<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealizedAfterTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of unrealized gain (loss) from foreign currency transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 38<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477346/946-830-45-38<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossUnrealizedAfterTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as nonoperating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNonoperatingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest income (expense) classified as nonoperating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNonoperatingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-11<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendsAndOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate value of preferred stock dividends and other adjustments necessary to derive net income apportioned to common stockholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-11<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendsAndOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 37: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 38: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueNotFromContractWithCustomerOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue that is not accounted for under Topic 606, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1)(e))<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueNotFromContractWithCustomerOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Condensed Statements of Shareholders' Equity (Unaudited) - USD ($)<br></strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th">
<div>Preferred Stock </div>
<div>Series A</div>
</th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss)</div></th>
<th class="th"><div>Total Shareholders&#8217; Equity (Deficit) Attributable to 60P</div></th>
<th class="th"><div>Noncontrolling Interest on Shareholders</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Dec. 31, 2023</a></td>
<td class="nump">$ 4,798,096<span></span>
</td>
<td class="nump">$ 9,858,040<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">$ 27,457,373<span></span>
</td>
<td class="num">$ (32,580,850)<span></span>
</td>
<td class="nump">$ 135,561<span></span>
</td>
<td class="nump">$ 4,870,134<span></span>
</td>
<td class="num">$ (72,038)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78,803<span></span>
</td>
<td class="nump">96,847<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sxtp_IssuanceOfCommonStockAndWarrantsOfUnderwritingDiscountsAndOfferingCostsPaidAtClosingAndDeferredOfferingCosts', window );">Issuance of common stock and warrants, net of underwriting discounts and offering costs paid at closing and deferred offering costs (Note 6)</a></td>
<td class="nump">1,898,296<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">1,898,287<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,898,296<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sxtp_StockIssuedDuringPeriodSharesOfCommonStockAndWarrantsOfUnderwritingDiscountsAndOfferingCostsPaidAtClosingAndDeferredOfferingCosts', window );">Issuance of common stock and warrants, net of underwriting discounts and offering costs paid at closing and deferred offering costs (Note 6) (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87,683<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sxtp_StockIssuedDuringPeriodValueStockIssuanceOfCommonStockUponExerciseOfPreFundedWarrants', window );">Issuance of common stock upon exercise of Pre-Funded Warrants</a></td>
<td class="nump">4,995<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">4,994<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,995<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sxtp_StockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfPreFundedWarrantsinShares', window );">Issuance of common stock upon exercise of Pre-Funded Warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,326<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited', window );">Issuance of shares for RSUs (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,201<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Net foreign translation gain (loss)</a></td>
<td class="num">(3,894)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,894)<span></span>
</td>
<td class="num">(3,894)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="nump">427,985<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">430,470<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">430,470<span></span>
</td>
<td class="num">(2,485)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Mar. 31, 2024</a></td>
<td class="nump">7,125,478<span></span>
</td>
<td class="nump">$ 9,858,040<span></span>
</td>
<td class="nump">$ 20<span></span>
</td>
<td class="nump">29,360,654<span></span>
</td>
<td class="num">(32,150,380)<span></span>
</td>
<td class="nump">131,667<span></span>
</td>
<td class="nump">7,200,001<span></span>
</td>
<td class="num">(74,523)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Mar. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78,803<span></span>
</td>
<td class="nump">196,057<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Dec. 31, 2023</a></td>
<td class="nump">4,798,096<span></span>
</td>
<td class="nump">$ 9,858,040<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">27,457,373<span></span>
</td>
<td class="num">(32,580,850)<span></span>
</td>
<td class="nump">135,561<span></span>
</td>
<td class="nump">4,870,134<span></span>
</td>
<td class="num">(72,038)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78,803<span></span>
</td>
<td class="nump">96,847<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Share-based compensation expense</a></td>
<td class="nump">15,246<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="num">(5,906,739)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Sep. 30, 2024</a></td>
<td class="nump">5,962,847<span></span>
</td>
<td class="nump">$ 9,567,439<span></span>
</td>
<td class="nump">$ 38<span></span>
</td>
<td class="nump">34,815,790<span></span>
</td>
<td class="num">(38,482,920)<span></span>
</td>
<td class="nump">139,207<span></span>
</td>
<td class="nump">6,039,554<span></span>
</td>
<td class="num">(76,707)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Sep. 30, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76,480<span></span>
</td>
<td class="nump">372,397<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Mar. 31, 2024</a></td>
<td class="nump">7,125,478<span></span>
</td>
<td class="nump">$ 9,858,040<span></span>
</td>
<td class="nump">$ 20<span></span>
</td>
<td class="nump">29,360,654<span></span>
</td>
<td class="num">(32,150,380)<span></span>
</td>
<td class="nump">131,667<span></span>
</td>
<td class="nump">7,200,001<span></span>
</td>
<td class="num">(74,523)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Mar. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78,803<span></span>
</td>
<td class="nump">196,057<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sxtp_StockIssuedDuringPeriodValueStockIssuanceOfCommonStockUponExerciseOfPreFundedWarrants', window );">Issuance of common stock upon exercise of Pre-Funded Warrants</a></td>
<td class="nump">4,995<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">4,994<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,995<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sxtp_StockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfPreFundedWarrantsinShares', window );">Issuance of common stock upon exercise of Pre-Funded Warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,326<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited', window );">Issuance of shares for RSUs (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,069<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Voluntary return of shares issued to vendor for services (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Net foreign translation gain (loss)</a></td>
<td class="nump">3,137<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,137<span></span>
</td>
<td class="nump">3,137<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="num">(4,174,226)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,172,755)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,172,755)<span></span>
</td>
<td class="num">(1,471)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Jun. 30, 2024</a></td>
<td class="nump">2,959,384<span></span>
</td>
<td class="nump">$ 9,858,040<span></span>
</td>
<td class="nump">$ 21<span></span>
</td>
<td class="nump">29,365,648<span></span>
</td>
<td class="num">(36,323,135)<span></span>
</td>
<td class="nump">134,804<span></span>
</td>
<td class="nump">3,035,378<span></span>
</td>
<td class="num">(75,994)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Jun. 30, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78,803<span></span>
</td>
<td class="nump">203,452<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountConverted1', window );">Voluntary conversion of Series A Preferred Stock into common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (290,601)<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">290,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Voluntary conversion of Series A Preferred Stock into common stock (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,323)<span></span>
</td>
<td class="nump">14,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sxtp_StockIssuedDuringPeriodValueIssuanceOfCommonStockPursuantToATMOfferingNetOfOfferingCosts', window );">Issuance of common stock pursuant to ATM Offering, net of offering costs paid at closing and deferred offering costs (Note 6)</a></td>
<td class="nump">1,729,810<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14<span></span>
</td>
<td class="nump">1,729,796<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,729,810<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sxtp_IssuanceOfCommonStockPursuantToATMOfferingNetOfOfferingCostsPaid', window );">Issuance of common stock pursuant to ATM Offering, net of offering costs paid at closing and deferred offering costs (Note 6) (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">135,568<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of warrants in Private Placement, net of offering costs paid at closing and deferred offering costs</a></td>
<td class="nump">3,414,502<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,414,502<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,414,502<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Share-based compensation expense</a></td>
<td class="nump">15,246<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,246<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,246<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Net foreign translation gain (loss)</a></td>
<td class="nump">4,403<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,403<span></span>
</td>
<td class="nump">4,403<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="num">(2,160,498)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,159,785)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,159,785)<span></span>
</td>
<td class="num">(713)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sxtp_StockIssuedDuringPeriodValueIssuanceOfCommonStockForFractionalSharesPursuantToReverseStockSplitRoundingAdjustment', window );">Issuance of common stock for fractional shares pursuant to Reverse Stock Split rounding adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="num">(2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits', window );">Issuance of common stock for fractional shares pursuant to Reverse Stock Split rounding adjustment (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,710<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Sep. 30, 2024</a></td>
<td class="nump">5,962,847<span></span>
</td>
<td class="nump">$ 9,567,439<span></span>
</td>
<td class="nump">$ 38<span></span>
</td>
<td class="nump">34,815,790<span></span>
</td>
<td class="num">(38,482,920)<span></span>
</td>
<td class="nump">139,207<span></span>
</td>
<td class="nump">6,039,554<span></span>
</td>
<td class="num">(76,707)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Sep. 30, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76,480<span></span>
</td>
<td class="nump">372,397<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Dec. 31, 2024</a></td>
<td class="nump">3,955,006<span></span>
</td>
<td class="nump">$ 9,567,439<span></span>
</td>
<td class="nump">$ 57<span></span>
</td>
<td class="nump">34,860,590<span></span>
</td>
<td class="num">(40,527,957)<span></span>
</td>
<td class="nump">135,471<span></span>
</td>
<td class="nump">4,035,600<span></span>
</td>
<td class="num">(80,594)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76,480<span></span>
</td>
<td class="nump">566,908<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sxtp_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPursuantToJanuary2025OfferingNetOfOfferingCosts', window );">Issuance of common stock and warrants pursuant to January 2025 Offering, net of offering costs paid at closing and deferred offering costs (Note 6)</a></td>
<td class="nump">804,346<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20<span></span>
</td>
<td class="nump">804,326<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">804,346<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sxtp_StockIssuedDuringPeriodIssuanceOfCommonStockAndWarrantsPursuantToJanuary2025OfferingNetOfOfferingCosts', window );">Issuance of common stock and warrants pursuant to January 2025 Offering, net of offering costs paid at closing and deferred offering costs (Note 6) (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">204,312<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sxtp_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPursuantToFebruary2025OfferingNetOfOfferingCosts', window );">Issuance of common stock and warrants pursuant to February 2025 Offering, net of offering costs paid at closing and deferred offering costs (Note 6)</a></td>
<td class="nump">908,627<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30<span></span>
</td>
<td class="nump">908,597<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">908,627<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sxtp_StockIssuedDuringPeriodIssuanceOfCommonStockAndWarrantsPursuantToFebruary2025OfferingNetOfOfferingCosts', window );">Issuance of common stock and warrants pursuant to February 2025 Offering, net of offering costs paid at closing and deferred offering costs (Note 6) (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sxtp_StockIssuedDuringPeriodValueStockIssuanceOfCommonStockUponExerciseOfPreFundedWarrants', window );">Issuance of common stock upon exercise of Pre-Funded Warrants</a></td>
<td class="nump">1,926<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 38<span></span>
</td>
<td class="nump">1,888<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,926<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sxtp_StockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfPreFundedWarrantsinShares', window );">Issuance of common stock upon exercise of Pre-Funded Warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">385,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sxtp_StockIssuedDuringPeriodValueIssuanceOfSharesForAnnualPerformanceBonusesNetOfSharesWithheldForTaxes', window );">Issuance of shares for annual performance bonuses, net of shares withheld for taxes</a></td>
<td class="nump">103,544<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">103,542<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">103,544<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sxtp_StockIssuedDuringPeriodIssuanceOfSharesForAnnualPerformanceBonusesNetOfSharesWithheldForTaxesinShares', window );">Issuance of shares for annual performance bonuses, net of shares withheld for taxes (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,809<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Share-based compensation expense</a></td>
<td class="nump">142,645<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">142,645<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">142,645<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Net foreign translation gain (loss)</a></td>
<td class="num">(9,904)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9,904)<span></span>
</td>
<td class="num">(9,904)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="num">(1,877,301)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,876,549)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,876,549)<span></span>
</td>
<td class="num">(752)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits', window );">Issuance of common stock for fractional shares pursuant to Reverse Stock Split rounding adjustment (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Mar. 31, 2025</a></td>
<td class="nump">4,028,889<span></span>
</td>
<td class="nump">$ 9,567,439<span></span>
</td>
<td class="nump">$ 147<span></span>
</td>
<td class="nump">36,821,588<span></span>
</td>
<td class="num">(42,404,506)<span></span>
</td>
<td class="nump">125,567<span></span>
</td>
<td class="nump">4,110,235<span></span>
</td>
<td class="num">(81,346)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Mar. 31, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76,480<span></span>
</td>
<td class="nump">1,472,891<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Dec. 31, 2024</a></td>
<td class="nump">3,955,006<span></span>
</td>
<td class="nump">$ 9,567,439<span></span>
</td>
<td class="nump">$ 57<span></span>
</td>
<td class="nump">34,860,590<span></span>
</td>
<td class="num">(40,527,957)<span></span>
</td>
<td class="nump">135,471<span></span>
</td>
<td class="nump">4,035,600<span></span>
</td>
<td class="num">(80,594)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76,480<span></span>
</td>
<td class="nump">566,908<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Share-based compensation expense</a></td>
<td class="nump">212,030<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="num">(5,929,267)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Sep. 30, 2025</a></td>
<td class="nump">4,346,958<span></span>
</td>
<td class="nump">$ 9,567,439<span></span>
</td>
<td class="nump">$ 410<span></span>
</td>
<td class="nump">41,172,888<span></span>
</td>
<td class="num">(46,454,556)<span></span>
</td>
<td class="nump">144,039<span></span>
</td>
<td class="nump">4,430,220<span></span>
</td>
<td class="num">(83,262)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Sep. 30, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76,480<span></span>
</td>
<td class="nump">4,104,469<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Mar. 31, 2025</a></td>
<td class="nump">4,028,889<span></span>
</td>
<td class="nump">$ 9,567,439<span></span>
</td>
<td class="nump">$ 147<span></span>
</td>
<td class="nump">36,821,588<span></span>
</td>
<td class="num">(42,404,506)<span></span>
</td>
<td class="nump">125,567<span></span>
</td>
<td class="nump">4,110,235<span></span>
</td>
<td class="num">(81,346)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Mar. 31, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76,480<span></span>
</td>
<td class="nump">1,472,891<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Share-based compensation expense</a></td>
<td class="nump">34,503<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,503<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,503<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Net foreign translation gain (loss)</a></td>
<td class="nump">17,242<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,242<span></span>
</td>
<td class="nump">17,242<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="num">(1,734,930)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,733,726)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,733,726)<span></span>
</td>
<td class="num">(1,204)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Jun. 30, 2025</a></td>
<td class="nump">2,345,704<span></span>
</td>
<td class="nump">$ 9,567,439<span></span>
</td>
<td class="nump">$ 147<span></span>
</td>
<td class="nump">36,856,091<span></span>
</td>
<td class="num">(44,138,232)<span></span>
</td>
<td class="nump">142,809<span></span>
</td>
<td class="nump">2,428,254<span></span>
</td>
<td class="num">(82,550)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Jun. 30, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76,480<span></span>
</td>
<td class="nump">1,472,891<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sxtp_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPursuantToJuly2025OfferingNetOfOfferingCosts', window );">Issuance of common stock and warrants pursuant to July 2025 Offering, net of offering costs paid at closing and deferred offering costs (Note 6)</a></td>
<td class="nump">4,281,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 175<span></span>
</td>
<td class="nump">4,281,125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,281,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sxtp_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsPursuantToJuly2025OfferingNetOfOfferingCosts', window );">Issuance of common stock and warrants pursuant to July 2025 Offering, net of offering costs paid at closing and deferred offering costs (Note 6) (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,753,314<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sxtp_StockIssuedDuringPeriodValueStockIssuanceOfCommonStockUponExerciseOfPreFundedWarrants', window );">Issuance of common stock upon exercise of Pre-Funded Warrants</a></td>
<td class="nump">878<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 88<span></span>
</td>
<td class="nump">790<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">878<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sxtp_StockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfPreFundedWarrantsinShares', window );">Issuance of common stock upon exercise of Pre-Funded Warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">878,264<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Share-based compensation expense</a></td>
<td class="nump">34,882<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,882<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,882<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Net foreign translation gain (loss)</a></td>
<td class="nump">1,230<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,230<span></span>
</td>
<td class="nump">1,230<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="num">(2,317,036)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,316,324)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,316,324)<span></span>
</td>
<td class="num">(712)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Sep. 30, 2025</a></td>
<td class="nump">$ 4,346,958<span></span>
</td>
<td class="nump">$ 9,567,439<span></span>
</td>
<td class="nump">$ 410<span></span>
</td>
<td class="nump">$ 41,172,888<span></span>
</td>
<td class="num">$ (46,454,556)<span></span>
</td>
<td class="nump">$ 144,039<span></span>
</td>
<td class="nump">$ 4,430,220<span></span>
</td>
<td class="num">$ (83,262)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Sep. 30, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76,480<span></span>
</td>
<td class="nump">4,104,469<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sxtp_IssuanceOfCommonStockAndWarrantsOfUnderwritingDiscountsAndOfferingCostsPaidAtClosingAndDeferredOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represent the amount of issuance of common stock and warrants, net of underwriting discounts and offering costs paid at closing and deferred offering costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sxtp_IssuanceOfCommonStockAndWarrantsOfUnderwritingDiscountsAndOfferingCostsPaidAtClosingAndDeferredOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sxtp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sxtp_IssuanceOfCommonStockPursuantToATMOfferingNetOfOfferingCostsPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock pursuant to ATM offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sxtp_IssuanceOfCommonStockPursuantToATMOfferingNetOfOfferingCostsPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sxtp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sxtp_StockIssuedDuringPeriodIssuanceOfCommonStockAndWarrantsPursuantToFebruary2025OfferingNetOfOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock and warrants pursuant to February 2025 Offering, net of offering costs .</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sxtp_StockIssuedDuringPeriodIssuanceOfCommonStockAndWarrantsPursuantToFebruary2025OfferingNetOfOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sxtp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sxtp_StockIssuedDuringPeriodIssuanceOfCommonStockAndWarrantsPursuantToJanuary2025OfferingNetOfOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock and warrants pursuant to January 2025 Offering, net of offering costs .</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sxtp_StockIssuedDuringPeriodIssuanceOfCommonStockAndWarrantsPursuantToJanuary2025OfferingNetOfOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sxtp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sxtp_StockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfPreFundedWarrantsinShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock upon exercise of Pre-Funded Warrants (in Shares).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sxtp_StockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfPreFundedWarrantsinShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sxtp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sxtp_StockIssuedDuringPeriodIssuanceOfSharesForAnnualPerformanceBonusesNetOfSharesWithheldForTaxesinShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of shares for annual performance bonuses, net of shares withheld for taxes (in Shares).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sxtp_StockIssuedDuringPeriodIssuanceOfSharesForAnnualPerformanceBonusesNetOfSharesWithheldForTaxesinShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sxtp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sxtp_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsPursuantToJuly2025OfferingNetOfOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock and warrants pursuant to july 2025 offering, net of offering costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sxtp_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsPursuantToJuly2025OfferingNetOfOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sxtp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sxtp_StockIssuedDuringPeriodSharesOfCommonStockAndWarrantsOfUnderwritingDiscountsAndOfferingCostsPaidAtClosingAndDeferredOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represent the shares issuance of common stock and warrants, net of underwriting discounts and offering costs paid at closing and deferred offering costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sxtp_StockIssuedDuringPeriodSharesOfCommonStockAndWarrantsOfUnderwritingDiscountsAndOfferingCostsPaidAtClosingAndDeferredOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sxtp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sxtp_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPursuantToFebruary2025OfferingNetOfOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of Issuance of common stock and warrants pursuant to February 2025 Offering, net of offering costs ...</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sxtp_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPursuantToFebruary2025OfferingNetOfOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sxtp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sxtp_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPursuantToJanuary2025OfferingNetOfOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of issuance of common stock and warrants pursuant to January 2025 Offering, net of offering costs ...</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sxtp_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPursuantToJanuary2025OfferingNetOfOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sxtp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sxtp_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPursuantToJuly2025OfferingNetOfOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of Issuance of common stock and warrants pursuant to july 2025 offering, net of offering costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sxtp_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPursuantToJuly2025OfferingNetOfOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sxtp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sxtp_StockIssuedDuringPeriodValueIssuanceOfCommonStockForFractionalSharesPursuantToReverseStockSplitRoundingAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of issuance of common stock for fractional shares pursuant to Reverse Stock split rounding adjustment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sxtp_StockIssuedDuringPeriodValueIssuanceOfCommonStockForFractionalSharesPursuantToReverseStockSplitRoundingAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sxtp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sxtp_StockIssuedDuringPeriodValueIssuanceOfCommonStockPursuantToATMOfferingNetOfOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock pursuant to ATM offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sxtp_StockIssuedDuringPeriodValueIssuanceOfCommonStockPursuantToATMOfferingNetOfOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sxtp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sxtp_StockIssuedDuringPeriodValueIssuanceOfSharesForAnnualPerformanceBonusesNetOfSharesWithheldForTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of issuance of shares for annual performance bonuses, net of shares withheld for taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sxtp_StockIssuedDuringPeriodValueIssuanceOfSharesForAnnualPerformanceBonusesNetOfSharesWithheldForTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sxtp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sxtp_StockIssuedDuringPeriodValueStockIssuanceOfCommonStockUponExerciseOfPreFundedWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock upon exercise of pre-funded warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sxtp_StockIssuedDuringPeriodValueStockIssuanceOfCommonStockUponExerciseOfPreFundedWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sxtp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockAmountConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockAmountConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 37: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 38: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares related to Restricted Stock Award forfeited during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reduction in the number of shares during the period as a result of a reverse stock split.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-24<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-23<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-5<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 42: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-3<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 47: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 51: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 52: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 53: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-15<br><br>Reference 54: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-16<br><br>Reference 55: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4I<br><br>Reference 56: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1<br><br>Reference 57: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Condensed Statements of Cash Flows (Unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net Loss</a></td>
<td class="num">$ (5,929,267)<span></span>
</td>
<td class="num">$ (5,906,739)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to Reconcile Net Loss to Net Cash Used in Operating Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">28,155<span></span>
</td>
<td class="nump">6,277<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentForAmortization', window );">Amortization</a></td>
<td class="nump">31,150<span></span>
</td>
<td class="nump">28,004<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Amortization of ROU Asset</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">13,517<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sxtp_AmortizationOfCapitalizedShareBasedPayments', window );">Amortization of Capitalized Share-Based Payments</a></td>
<td class="nump">132,353<span></span>
</td>
<td class="nump">3,531,763<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeBenefitsAndShareBasedCompensation', window );">Share-Based Compensation under Equity Incentive Plan</a></td>
<td class="nump">212,030<span></span>
</td>
<td class="nump">15,246<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Change in Fair Value of Derivative Liabilities</a></td>
<td class="nump">156,445<span></span>
</td>
<td class="num">(1,683,034)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sxtp_WriteoffsOfCapitalizedPatents', window );">Write-offs of Capitalized Patents</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">11,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryLIFOReservePeriodCharge', window );">Change in Inventory Reserve</a></td>
<td class="nump">244,682<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in Operating Assets and Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts Receivable</a></td>
<td class="num">(187,288)<span></span>
</td>
<td class="num">(92,490)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid and Other Assets</a></td>
<td class="nump">10,373<span></span>
</td>
<td class="num">(99,756)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="num">(328,922)<span></span>
</td>
<td class="nump">14,133<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts Payable and Accrued Liabilities</a></td>
<td class="nump">455,378<span></span>
</td>
<td class="nump">171,411<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet', window );">Accrued Interest, net</a></td>
<td class="nump">18,345<span></span>
</td>
<td class="num">(5,853)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Reduction of Lease Liability</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(13,650)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net Cash Used in Operating Activities</a></td>
<td class="num">(5,156,566)<span></span>
</td>
<td class="num">(4,009,871)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sxtp_PaymentOfCapitalizationOfPatents', window );">Capitalization of Patents</a></td>
<td class="num">(20,868)<span></span>
</td>
<td class="num">(49,869)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of Fixed Assets</a></td>
<td class="num">(60,000)<span></span>
</td>
<td class="num">(103,773)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Acquisition of Intangibles</a></td>
<td class="num">(1,785)<span></span>
</td>
<td class="num">(25,374)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireShortTermInvestments', window );">Purchase of Short-Term Investments</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(1,708,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments', window );">Maturities of Short-Term Investments</a></td>
<td class="nump">1,708,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net Cash Provided by (Used in) Investing Activities</a></td>
<td class="nump">1,625,347<span></span>
</td>
<td class="num">(1,887,016)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sxtp_NetProceedsFromSharesAndWarrantsOffering', window );">Net Proceeds from January 2024 Offering</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,898,296<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sxtp_NetProceedsFromJanuary2025Offering', window );">Net Proceeds from January 2025 Offering</a></td>
<td class="nump">804,346<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sxtp_NetProceedsFromFebruary2025Offering', window );">Net Proceeds from February 2025 Offering</a></td>
<td class="nump">908,627<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sxtp_NetProceedsFromJuly2025Offering', window );">Net Proceeds from July 2025 Offering</a></td>
<td class="nump">4,281,300<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Shares Withheld for Net Share Settlement of Performance Bonuses</a></td>
<td class="num">(18,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sxtp_ProceedsFromIssuanceATMOfferingCosts', window );">Net proceeds from ATM Offering</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,729,810<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Net proceeds from Private Placement</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">3,414,502<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sxtp_ProceedsFromExerciseOfPreFundedWarrants', window );">Proceeds from Exercise of Pre-Funded Warrants</a></td>
<td class="nump">2,804<span></span>
</td>
<td class="nump">9,990<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net Cash Provided by Financing Activities</a></td>
<td class="nump">5,979,077<span></span>
</td>
<td class="nump">7,052,598<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of Exchange Rate Changes on Cash</a></td>
<td class="nump">8,568<span></span>
</td>
<td class="nump">2,492<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Change in Cash and Cash Equivalents</a></td>
<td class="nump">2,456,426<span></span>
</td>
<td class="nump">1,158,203<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and Cash Equivalents&#8212;Beginning of Period</a></td>
<td class="nump">1,659,353<span></span>
</td>
<td class="nump">2,142,485<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and Cash Equivalents&#8212;End of Period</a></td>
<td class="nump">4,115,779<span></span>
</td>
<td class="nump">3,300,688<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>NONCASH INVESTING/FINANCING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sxtp_FairValueOfWarrantsIssuedToUnderwriters', window );">Fair Value of Warrants Issued to Underwriters</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">71,364<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1', window );">Purchases of Fixed Assets included in Accounts Payable</a></td>
<td class="nump">46,099<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sxtp_ConversionOfSeriesAPreferredStockIntoCommonStock', window );">Conversion Of Series A Preferred Stock Into Common Stock</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">290,601<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1', window );">Capitalized Patent Costs included in Accounts Payable</a></td>
<td class="nump">3,796<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sxtp_GrossSharesIssuedForAnnualPerformanceBonuses', window );">Gross Shares Issued for Annual Performance Bonuses</a></td>
<td class="nump">$ 121,544<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sxtp_AmortizationOfCapitalizedShareBasedPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization of capitalized share-based payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sxtp_AmortizationOfCapitalizedShareBasedPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sxtp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sxtp_ConversionOfSeriesAPreferredStockIntoCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sxtp_ConversionOfSeriesAPreferredStockIntoCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sxtp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sxtp_FairValueOfWarrantsIssuedToUnderwriters">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represent the amount of fair value of warrants issued to underwriters.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sxtp_FairValueOfWarrantsIssuedToUnderwriters</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sxtp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sxtp_GrossSharesIssuedForAnnualPerformanceBonuses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represent the amount of gross shares issued for annual performance bonuses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sxtp_GrossSharesIssuedForAnnualPerformanceBonuses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sxtp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sxtp_NetProceedsFromFebruary2025Offering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net proceeds from february 2025 offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sxtp_NetProceedsFromFebruary2025Offering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sxtp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sxtp_NetProceedsFromJanuary2025Offering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net proceeds from january 2025 offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sxtp_NetProceedsFromJanuary2025Offering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sxtp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sxtp_NetProceedsFromJuly2025Offering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net proceeds from july 2025 offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sxtp_NetProceedsFromJuly2025Offering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sxtp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sxtp_NetProceedsFromSharesAndWarrantsOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net proceed from shares offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sxtp_NetProceedsFromSharesAndWarrantsOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sxtp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sxtp_PaymentOfCapitalizationOfPatents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire an asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sxtp_PaymentOfCapitalizationOfPatents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sxtp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sxtp_ProceedsFromExerciseOfPreFundedWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from exercise of pre-funded warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sxtp_ProceedsFromExerciseOfPreFundedWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sxtp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sxtp_ProceedsFromIssuanceATMOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from ATM offering, net of offering cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sxtp_ProceedsFromIssuanceATMOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sxtp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sxtp_WriteoffsOfCapitalizedPatents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of write-offs of capitalized patents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sxtp_WriteoffsOfCapitalizedPatents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sxtp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentForAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentForAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including effect from exchange rate change and including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-12<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossOnDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482881/825-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainLossOnDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate change on cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; held in foreign currency; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 230<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeBenefitsAndShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for employee benefit and equity-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeBenefitsAndShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount due from borrowers for interest payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryLIFOReservePeriodCharge">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The change in the inventory reserve representing the cumulative difference in cost between the first in, first out and the last in, first out inventory valuation methods, which change has been reflected in the statement of income during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480581/330-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryLIFOReservePeriodCharge</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of fixed assets that an Entity acquires in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of intangibles that an Entity acquires in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from maturities, prepayments, calls and collections of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 37: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 38: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NATURE OF OPERATIONS<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>NATURE OF OPERATIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">NATURE OF OPERATIONS</a></td>
<td class="text"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">1. NATURE OF OPERATIONS</span></p><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">60 Degrees Pharmaceuticals, Inc. was incorporated in Delaware on June 1, </span><span style="-aw-sdt-tag:'c270bf7cd5ba984b5e1c'; font-family: 'Times New Roman'"><span>2022</span></span><span style="font-family: 'Times New Roman';"> and merged on the same day with </span><span style="-aw-sdt-tag:'c657950d5b1564663aa5'; font-family: 'Times New Roman'"><span>60</span></span><span style="font-family: 'Times New Roman';"> Degrees Pharmaceuticals, LLC, a District of Columbia limited liability company organized on September </span><span style="-aw-sdt-tag:'c1c7e4992ee8ee67833d'; font-family: 'Times New Roman'"><span>9</span></span><span style="font-family: 'Times New Roman';">, </span><span style="-aw-sdt-tag:'ca396d6e4d1f987f4646'; font-family: 'Times New Roman'"><span>2010</span></span><span style="font-family: 'Times New Roman';"> (&#8220;</span><span style="-aw-sdt-tag:'ccbaaf62d4129f0282b6'; font-family: 'Times New Roman'"><span>60</span></span><span style="font-family: 'Times New Roman';">P LLC&#8221;). </span><span style="-aw-sdt-tag:'cba51fa10334af688698'; font-family: 'Times New Roman'"><span>60</span></span><span style="font-family: 'Times New Roman';"> Degrees Pharmaceuticals, Inc. and its subsidiary (referred to collectively as the &#8220;Company&#8221;, &#8220;</span><span style="-aw-sdt-tag:'c5523ac12e81e3a392be'; font-family: 'Times New Roman'"><span>60</span></span><span style="font-family: 'Times New Roman';">P&#8221;, or &#8220;</span><span style="-aw-sdt-tag:'c784671fbd07bf0d40cf'; font-family: 'Times New Roman'"><span>60</span></span><span style="font-family: 'Times New Roman';"> Degrees Pharmaceuticals&#8221;) is a specialty pharmaceutical company that specializes in the development and marketing of new medicines for the treatment and prevention of infectious diseases. </span><span style="-aw-sdt-tag:'c834b08102bb9356bc64'; font-family: 'Times New Roman'"><span>60</span></span><span style="font-family: 'Times New Roman';">P achieved FDA approval of its lead product, ARAKODA&#174; (tafenoquine), for malaria prevention, in </span><span style="-aw-sdt-tag:'ce4eef3e3aca50301650'; font-family: 'Times New Roman'"><span>2018</span></span><span style="font-family: 'Times New Roman';">. Currently, </span><span style="-aw-sdt-tag:'c93fc95f7e4cdd4f571a'; font-family: 'Times New Roman'"><span>60</span></span><span style="font-family: 'Times New Roman';">P&#8217;s pipeline under development covers development programs for tick-borne fungal and other viral diseases utilizing three of the Company&#8217;s future products: (i) new products that contain the Arakoda regimen of tafenoquine; (ii) new products that contain tafenoquine; and (iii) celgosivir and/or botanical extracts from Australian Chestnut Trees. The Company&#8217;s headquarters are located in Washington, D.C., with a majority-owned subsidiary in Australia.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; text-decoration:underline; font-family: 'Times New Roman'">Risks and Uncertainties</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">The Company is subject to risks common to companies in the biopharmaceutical industry including, but not limited to, the risks associated with developing product candidates and successfully launching and commercializing its drug/device combination products, the Company&#8217;s ability to obtain regulatory approval of such products in the United States and other geography markets, the uncertainty of the broad adoption of its approved products by physicians and consumers, and significant competition.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">In addition, higher rates of inflation have resulted in the U.S. Federal Reserve raising interest rates. Increases in interest rates, especially if coupled with reduced government spending and volatility in financial markets, may further increase economic uncertainty and heighten these risks. Furthermore, if additional banks and financial institutions enter receivership or become insolvent in the future in response to financial conditions affecting the banking system and financial markets, the Company or its partners&#8217; ability to access existing cash, cash equivalents and investments may be threatened and could have a material adverse effect on the Company&#8217;s business and financial condition, including the Company&#8217;s ability to access additional capital on favorable terms, or at all, which could in the future negatively affect the Company&#8217;s ability to pursue its business strategy.</span><span style="font-weight:bold; font-family: 'Times New Roman'">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; text-decoration:underline; font-family: 'Times New Roman'">Going Concern</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">The Company&#8217;s future results are subject to substantial risks and uncertainties. Since its inception, the Company has not demonstrated the ability to generate enough revenues to date to cover operating expenses and has accumulated losses to date. At </span><span style="-aw-sdt-tag:'c6621e838f6e2797b148'; -aw-sdt-title:'Current_Period_P26'; font-family: 'Times New Roman'"><span>September 30, 2025</span></span><span style="font-family: 'Times New Roman';">, the Company had cash and cash equivalents totaling $</span><span style="-aw-sdt-tag:'ccf01eed229ee36500f5'; -aw-sdt-title:'cash and cash equivalents_CP'; font-family: 'Times New Roman'"><span>4,115,779</span></span><span style="font-family: 'Times New Roman';">, as compared to cash and cash equivalents totaling $</span><span style="-aw-sdt-tag:'c9861c7425fd7e3efbf3'; -aw-sdt-title:'cash and cash equivalents_PY'; font-family: 'Times New Roman'"><span>1,659,353</span></span><span style="font-family: 'Times New Roman';"> at </span><span style="-aw-sdt-tag:'c3b49d62cc46a9e3bf26'; -aw-sdt-title:'Previous_Year_End_P19'; font-family: 'Times New Roman'"><span>December 31, 2024</span></span><span style="font-family: 'Times New Roman';">. During the </span><span style="-aw-sdt-tag:'c1d42859dfcea9ae8a6a'; -aw-sdt-title:'Current_YTD_P3'; font-family: 'Times New Roman'"><span>nine months ended September 30, 2025</span></span><span style="font-family: 'Times New Roman';"> the Company used cash of $</span><span style="-aw-sdt-tag:'c1c30bf00acb9628ea81'; -aw-sdt-title:'Operating activities_CYTD'; font-family: 'Times New Roman'"><span>5,156,566</span></span><span style="font-family: 'Times New Roman';"> in its operating activities. The Company&#8217;s capital commitments over the next twelve months include interest payments on the Company&#8217;s debt arrangement of $</span><span style="-aw-sdt-tag:'c7df475d3e16907ec478'; -aw-sdt-title:'Next 12M Debt Payments'; font-family: 'Times New Roman'"><span>8,772</span></span><span style="font-family: 'Times New Roman';"> and $</span><span style="-aw-sdt-tag:'bbd-7d3-a59-176-8056'; -aw-sdt-title:'Next 12M AP and Accruals'; font-family: 'Times New Roman'"><span>1,391,347</span></span><span style="font-family: 'Times New Roman';"> to satisfy accounts payable and accrued expenses.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">To date, the Company has funded its operations primarily with proceeds from sales of common stock and warrants for the purchase of common stock, sales of preferred stock, proceeds from the issuance of convertible debt and borrowings under loan and security agreements.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">Continuation as a going concern is dependent upon the Company&#8217;s ability to meet its financial requirements, raise additional capital, and achieve gross profitability from the Company&#8217;s single marketed product. To achieve profitability, the Company expects it will need to raise additional capital to fund its activities relating to commercial support for its existing product and any future clinical research trials and operating activities. However, there can be no assurance that it will ever achieve or maintain profitability. These conditions, among others, raise substantial doubt about the ability of the Company to continue as a going concern for one year from the date these consolidated condensed financial statements are issued.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><div style="-aw-sdt-tag:'PG_c12ebe76f85b70d02c5e'"></div><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">Management plans to fund operations of the Company through third party and related party debt/advances, private placement of restricted securities and the issuance of stock in a subsequent offering until such a time as the business achieves profitability or a business combination may be achieved. However, there can be no assurance that the Company will be successful in raising additional capital or that such capital, if available, will be on terms that are favorable to the Company. Debt financing and equity financing, if available, may involve agreements that include covenants limiting or restricting the Company&#8217;s ability to take specific actions, such as incurring additional debt, making capital expenditures, or declaring dividends. If the Company raises funds through collaborations, or other similar arrangements with third parties, it may have to relinquish valuable rights to its technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to the Company and/or may reduce the value of its common stock. If the Company is unable to raise additional funds through equity or debt financings when needed, it may be required to delay, limit, reduce or terminate its product development or future commercialization efforts or grant rights to develop and market its product candidates even if the Company would otherwise prefer to develop and market such product candidates itself.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">As such, management concluded that such plans do not alleviate the substantial doubt about the ability of the Company to continue as a going concern for one year from the date these consolidated condensed financial statements are issued.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">The consolidated condensed financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of obligations in the normal course of business, and do not include any adjustments to the amount and classification of assets and liabilities that may be necessary should the Company be unable to continue as a going concern.</span><span style="font-family: 'Times New Roman';">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </span><span style="font-family: 'Times New Roman';">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482836/275-10-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482836/275-10-55-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-import:spaces; font-family: 'Times New Roman'">&#160;</span></p><div style="-aw-sdt-tag:'cdb505dc74cc1259e26b'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; text-decoration:underline; font-family: 'Times New Roman'">Basis of Presentation</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">The financial statements of </span><span style="-aw-sdt-tag:'ce903abe84353d2391d6'; font-family: 'Times New Roman'"><span>60</span></span><span style="font-family: 'Times New Roman';">P are prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;). The Company has prepared the accompanying consolidated condensed financial statements pursuant to the instructions to Form </span><span style="-aw-sdt-tag:'c90d6f77918f6efd358d'; font-family: 'Times New Roman'"><span>10</span></span><span style="font-family: 'Times New Roman';">-Q and Article </span><span style="-aw-sdt-tag:'c8389d80e96daea9720b'; font-family: 'Times New Roman'"><span>8</span></span><span style="font-family: 'Times New Roman';"> of Regulation S-X of the Securities and Exchange Commission (&#8220;SEC&#8221;). These financial statements are unaudited and, in the opinion of management, all adjustments considered necessary for a fair presentation of the Company&#8217;s financial position, results of operations, and cash flows have been included and are of a normal and recurring nature. Operating results for the periods presented are not necessarily indicative of the results that may be expected for the year ending </span><span style="-aw-sdt-tag:'c0c7176b5bdb194bfddc'; -aw-sdt-title:'Current_Year_End_P1'; font-family: 'Times New Roman'"><span>December 31, 2025</span></span><span style="font-family: 'Times New Roman';"> due to various factors. These consolidated condensed financial statements should be read in conjunction with the audited consolidated financial statements and related notes thereto as of and for the years ended </span><span style="-aw-sdt-tag:'c18cdcd3e90810c9b66a'; -aw-sdt-title:'Previous_Year_End_P6'; font-family: 'Times New Roman'"><span>December 31, 2024</span></span><span style="font-family: 'Times New Roman';"> and </span><span style="-aw-sdt-tag:'c81138fdfee9b110fdf9'; font-family: 'Times New Roman'"><span>2023</span></span><span style="font-family: 'Times New Roman';">, included in the Company&#8217;s annual report on Form </span><span style="-aw-sdt-tag:'c4c00800b9e2d5f1439e'; font-family: 'Times New Roman'"><span>10</span></span><span style="font-family: 'Times New Roman';">-K, as filed with the SEC on March </span><span style="-aw-sdt-tag:'c48ed363e59cdbbb1e8b'; font-family: 'Times New Roman'"><span>27</span></span><span style="font-family: 'Times New Roman';">, </span><span style="-aw-sdt-tag:'c7da1b0fe69d8d60fb79'; font-family: 'Times New Roman'"><span>2025</span></span><span style="font-family: 'Times New Roman';"> (the &#8220;Annual Report&#8221;). Certain information, footnote disclosures, and significant accounting policies that would substantially duplicate the disclosures contained in the Annual Report have been omitted.</span></p></div><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p><div style="-aw-sdt-tag:'d24-ead-d5b-0d7-fd95'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; text-decoration:underline; font-family: 'Times New Roman'">Use of Estimates</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates, and those estimates may be material. Significant estimates include the reserve for inventory, the fair value of derivative liabilities, and stock-based compensation.</span></p></div><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p><div style="-aw-sdt-tag:'PG_c5050bfc508bd0645091'"></div><div style="-aw-sdt-tag:'c6fb7024e47107499fcb'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; text-decoration:underline; font-family: 'Times New Roman'">Reverse Stock Splits</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-sdt-tag:'dac-e32-fd4-981-41a6'; font-family: 'Times New Roman'"><span>Following stockholder approval in July 2024, the Company effected a reverse stock split at a ratio of 1:12, which was effective as of August 12, 2024 (the &#8220;1:12 Reverse Stock Split&#8221;).</span></span><span style="font-family: 'Times New Roman';"> </span><span style="-aw-sdt-tag:'731-9b8-7ee-b5e-cc0f'; font-family: 'Times New Roman'"><span>On November 6, 2024, a majority of the Company&#8217;s stockholders approved an additional reverse stock split at a split ratio ranging between 1:3 and 1:5, as determined by the Board of Directors in its sole discretion.</span></span><span style="font-family: 'Times New Roman';"> </span><span style="-aw-sdt-tag:'013-0eb-6cc-bc0-02a0'; font-family: 'Times New Roman'"><span>On February 10, 2025, the Board of Directors approved a 1:5 reverse split ratio. On February 24, 2025, the Company effected the 1:5 reverse stock split (the &#8220;1:5 Reverse Stock Split&#8221;, and together with the 1:12 Reverse Stock Split, the &#8220;Reverse Stock Splits&#8221;).</span></span><span style="font-family: 'Times New Roman';"> Beginning February </span><span style="-aw-sdt-tag:'c26c29b86737c43d1066'; font-family: 'Times New Roman'"><span>24</span></span><span style="font-family: 'Times New Roman';">, </span><span style="-aw-sdt-tag:'c7cca48741fbb787a7db'; font-family: 'Times New Roman'"><span>2025</span></span><span style="font-family: 'Times New Roman';">, the common stock traded on The Nasdaq Capital Market on a split adjusted basis.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">Proportional adjustments were made to the number of shares of common stock issuable upon exercise or conversion of the Company&#8217;s equity awards, warrants, and other equity instruments convertible into common stock, as well as the respective exercise prices, if applicable, in accordance with the terms of the instruments. Unless otherwise noted, all references to numbers of shares of the Company&#8217;s common stock and per share information presented in these consolidated condensed financial statements have been retroactively adjusted, as appropriate, to reflect the Reverse Stock Splits, including reclassifying an amount equal to the reduction in par value of common stock to additional paid-in capital.</span></p></div><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><div style="-aw-sdt-tag:'ce4d5252ffc132995fd3'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; text-decoration:underline; font-family: 'Times New Roman'">Concentrations</span></p><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents, short-term investments, accounts receivable, inventory purchases, and borrowings.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">Significant customers represent any customer whose business makes up </span><span style="-aw-sdt-tag:'c38d441a704cc0769f2e'; font-family: 'Times New Roman'"><span>10</span></span><span style="font-family: 'Times New Roman';">% of receivables or revenues. At </span><span style="-aw-sdt-tag:'c8aefa95b7837b6c59db'; -aw-sdt-title:'Current_Period_P1'; font-family: 'Times New Roman'"><span>September 30, 2025</span></span><span style="font-family: 'Times New Roman';">, significant customers represented </span><span style="-aw-sdt-tag:'c7d0ee37bbed719c14fb'; -aw-sdt-title:'Current_Sig. Cust AR Percent'; font-family: 'Times New Roman'"><span>89</span></span><span style="font-family: 'Times New Roman';">% of receivables (consisting of </span><span style="-aw-sdt-tag:'efa-f25-b7a-0c0-3393'; -aw-sdt-title:'Current_Total Customers in AR'; font-family: 'Times New Roman'"><span>six</span></span><span style="font-family: 'Times New Roman';"> total customers and </span><span style="-aw-sdt-tag:'6bd-f9c-095-2b1-0b97'; -aw-sdt-title:'Current_Sigificant Customers in AR'; font-family: 'Times New Roman'"><span>two</span></span><span style="font-family: 'Times New Roman';"> significant customers at </span><span style="-aw-sdt-tag:'757-b3e-309-2f1-7957'; -aw-sdt-title:'AR Sig Customer 1 _Current'; font-family: 'Times New Roman'"><span>75</span></span><span style="font-family: 'Times New Roman';">% and </span><span style="-aw-sdt-tag:'053-64b-d59-480-934c'; font-family: 'Times New Roman'"><span>13</span></span><span style="font-family: 'Times New Roman';">%, respectively), and </span><span style="-aw-sdt-tag:'c8865edd41199200cda9'; -aw-sdt-title:'Prior_Sig. Cust AR Percent'; font-family: 'Times New Roman'"><span>95</span></span><span style="font-family: 'Times New Roman';">% of receivables at </span><span style="-aw-sdt-tag:'c612e322ca6f5a44144a'; -aw-sdt-title:'Previous_Year_End_P7'; font-family: 'Times New Roman'"><span>December 31, 2024</span></span><span style="font-family: 'Times New Roman';"> (consisting of </span><span style="-aw-sdt-tag:'58c-1fd-4c8-cbc-24e3'; -aw-sdt-title:'Prior_Total Customers in AR'; font-family: 'Times New Roman'"><span>three</span></span><span style="font-family: 'Times New Roman';"> total customers and </span><span style="-aw-sdt-tag:'0cd-eb1-27d-ce1-d261'; -aw-sdt-title:'Prior_Sigificant Customers in AR'; font-family: 'Times New Roman'"><span>one</span></span><span style="font-family: 'Times New Roman';"> significant customer). For the </span><span style="-aw-sdt-tag:'ca0e62e990a606583b94'; -aw-sdt-title:'Current_Quarter_P14'; font-family: 'Times New Roman'"><span>three months ended September 30, 2025</span></span><span style="font-family: 'Times New Roman';">, significant customers comprised </span><span style="-aw-sdt-tag:'c610c2cb61e4f95ffd6c'; -aw-sdt-title:'CQTD_Sig.Cust Percent Net Revenue'; font-family: 'Times New Roman'"><span>80</span></span><span style="font-family: 'Times New Roman';">% of total net product revenues (consisting of </span><span style="-aw-sdt-tag:'7ac-793-8fb-7b6-6b7e'; -aw-sdt-title:'CQTD_Total Customers'; font-family: 'Times New Roman'"><span>four</span></span><span style="font-family: 'Times New Roman';"> total customers and </span><span style="-aw-sdt-tag:'935-1d8-24e-b55-3697'; -aw-sdt-title:'CWTD_Significant Customers'; font-family: 'Times New Roman'"><span>one</span></span><span style="font-family: 'Times New Roman';"> significant customer at </span><span style="-aw-sdt-tag:'fd4-598-fc6-c55-b5b3'; -aw-sdt-title:'CQTD_Sig Customer 1 Percent'; font-family: 'Times New Roman'"><span>80</span></span><span style="font-family: 'Times New Roman';">%). For the </span><span style="-aw-sdt-tag:'c89b221bf86e60e80aee'; -aw-sdt-title:'Previous_Quarter_P5'; font-family: 'Times New Roman'"><span>three months ended September 30, 2024</span></span><span style="font-family: 'Times New Roman';">, </span><span style="-aw-sdt-tag:'c4871e9ed0486ef91d28'; -aw-sdt-title:'PQTD_Sig.Cust Percent Net Revenue'; font-family: 'Times New Roman'"><span>92</span></span><span style="font-family: 'Times New Roman';">% of total net product revenues (consisting of </span><span style="-aw-sdt-tag:'92a-ab1-dc7-7a9-7dd3'; -aw-sdt-title:'PQTD_Total Customers'; font-family: 'Times New Roman'"><span>two</span></span><span style="font-family: 'Times New Roman';"> total customers and </span><span style="-aw-sdt-tag:'813-a74-d78-4e2-d0ec'; -aw-sdt-title:'PQTD_Significant Customers'; font-family: 'Times New Roman'"><span>one</span></span><span style="font-family: 'Times New Roman';"> significant customer) were generated from significant customers. For the </span><span style="-aw-sdt-tag:'c71fb825a8fc9183fba4'; -aw-sdt-title:'Current_YTD_P9'; font-family: 'Times New Roman'"><span>nine months ended September 30, 2025</span></span><span style="font-family: 'Times New Roman';">,</span><span style="font-family: 'Times New Roman';">&#160;</span><span style="-aw-sdt-tag:'cd703ca85832d9e6ccd9'; -aw-sdt-title:'CYTD_Sig.Cust Percent Net Revenue'; font-family: 'Times New Roman'"><span>91</span></span><span style="font-family: 'Times New Roman';">% of total net product revenues (consisting of </span><span style="-aw-sdt-tag:'d25-e87-6c3-44b-77b8'; -aw-sdt-title:'CYTD_Total Customers'; font-family: 'Times New Roman'"><span>four</span></span><span style="font-family: 'Times New Roman';"> total customers and </span><span style="-aw-sdt-tag:'623-163-567-ed7-13d7'; -aw-sdt-title:'CYTD_Significant Customers'; font-family: 'Times New Roman'"><span>two</span></span><span style="font-family: 'Times New Roman';"> significant customers at </span><span style="-aw-sdt-tag:'fd4-589-ac0-f12-5f6a'; font-family: 'Times New Roman'"><span>73</span></span><span style="font-family: 'Times New Roman';">% and </span><span style="-aw-sdt-tag:'aa0-f10-986-33c-5f25'; -aw-sdt-title:'CYTD_Sig Customer 2 Percent'; font-family: 'Times New Roman'"><span>18</span></span><span style="font-family: 'Times New Roman';">%, respectively) were generated from significant customers. For the </span><span style="-aw-sdt-tag:'cd6d62b9c3ce9b21e230'; -aw-sdt-title:'Previous_YTD_P4'; font-family: 'Times New Roman'"><span>nine months ended September 30, 2024</span></span><span style="font-family: 'Times New Roman';">,</span><span style="font-family: 'Times New Roman';">&#160;</span><span style="-aw-sdt-tag:'c34cf87b1815b4a11766'; -aw-sdt-title:'PYTD_Sig.Cust Percent Net Revenue'; font-family: 'Times New Roman'"><span>94</span></span><span style="font-family: 'Times New Roman';">% of total net product revenues (consisting of </span><span style="-aw-sdt-tag:'f2f-f63-4d3-652-810a'; -aw-sdt-title:'PYTD_Total Customers'; font-family: 'Times New Roman'"><span>three</span></span><span style="font-family: 'Times New Roman';"> total customers and </span><span style="-aw-sdt-tag:'20a-b2d-e5b-ae2-0417'; -aw-sdt-title:'PYTD_Significant Customers'; font-family: 'Times New Roman'"><span>one</span></span><span style="font-family: 'Times New Roman';"> significant customer) were generated from significant customers.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">Currently, the Company has exclusive relationships with distributors in Australia and Europe. A failure to perform by any of our current distributors would create disruption for patients in those markets.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">Since the Company first started working on tafenoquine, all inventory has been acquired in a collaborative relationship from a sole vendor. Should the vendor cease to supply tafenoquine, it would take significant costs and efforts to rebuild the supply chain with a new sole vendor sourcing the active pharmaceutical ingredient (&#8220;API&#8221;).</span></p></div><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><div style="-aw-sdt-tag:'cb21377b78bedc008a21'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; text-decoration:underline; font-family: 'Times New Roman'">Segment Information</span></p><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">Since its inception, the Company operates and manages its business as a single identifiable segment, focused on the development and marketing of new medicines for the treatment and prevention of infectious diseases. The determination of a single business segment is consistent with the consolidated financial information regularly provided to the Company&#8217;s chief operating decision maker (&#8220;CODM&#8221;).</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:10pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">The Company&#8217;s CODM is its Chief Executive Officer, who reviews and evaluates consolidated net income or loss for purposes of evaluating performance, making operating decisions, allocating resources, and planning and forecasting for future periods. The significant components of consolidated net income or loss regularly provided to the CODM include net product revenues and the significant expense categories presented in the accompanying </span><span style="-aw-sdt-tag:'40d-f92-19d-c95-c73e'; -aw-sdt-title:'PandL_title_P2'; font-family: 'Times New Roman'"><span>consolidated condensed statements of operations and comprehensive loss</span></span><span style="font-family: 'Times New Roman';"> (cost of revenues, research and development, and general and administrative expenses). These are presented at the consolidated level and used by the CODM to monitor budgeted versus actual results to make key operating decisions. The information and operating expense categories presented in the accompanying </span><span style="-aw-sdt-tag:'253-c33-1cd-8c6-3ae5'; -aw-sdt-title:'PandL_title_P3'; font-family: 'Times New Roman'"><span>consolidated condensed statements of operations and comprehensive loss</span></span><span style="font-family: 'Times New Roman';"> are fully reflective of the significant expense categories and amounts that are regularly provided to the CODM.</span></p><div style="-aw-sdt-tag:'PG_c24bb3258a68b0280db8'"></div></div><div style="-aw-sdt-tag:'cb21377b78bedc008a21'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">The measure of segment assets that is regularly reported to the CODM includes cash and cash equivalents and short-term investments, each as reported on the </span><span style="-aw-sdt-tag:'139-b42-89d-4af-5020'; -aw-sdt-title:'Balance_Sheet_Title_P1'; font-family: 'Times New Roman'"><span>consolidated condensed balance sheets</span></span><span style="font-family: 'Times New Roman';">. Total consolidated cash and cash equivalents and short-term investments were $</span><span style="-aw-sdt-tag:'c26449208c3edf5c7aa8'; font-family: 'Times New Roman'"><span>4,115,779</span></span><span style="font-family: 'Times New Roman';"> and $</span><span style="-aw-sdt-tag:'cdccccade90e66a13fb9'; font-family: 'Times New Roman'"><span>3,387,825</span></span><span style="font-family: 'Times New Roman';"> as of </span><span style="-aw-sdt-tag:'c7407e74fc85ec3ccdfe'; -aw-sdt-title:'Current_Period_P2'; font-family: 'Times New Roman'"><span>September 30, 2025</span></span><span style="font-family: 'Times New Roman';"> and </span><span style="-aw-sdt-tag:'c00bf74fe48b3c64541d'; -aw-sdt-title:'Previous_Year_End_P12'; font-family: 'Times New Roman'"><span>December 31, 2024</span></span><span style="font-family: 'Times New Roman';">, respectively.</span></p></div><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p><div style="-aw-sdt-tag:'aed-ca6-c7c-350-2bc6'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; text-decoration:underline; font-family: 'Times New Roman'">Derivative Liabilities</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">The Company analyzes all financial instruments with features of both liabilities and equity under FASB ASC Topic No. </span><span style="-aw-sdt-tag:'c4a98c0f9c305eb9ad0a'; font-family: 'Times New Roman'"><span>480</span></span><span style="font-family: 'Times New Roman';">, </span><span style="font-style:italic; font-family: 'Times New Roman'">Distinguishing Liabilities from Equity</span><span style="font-family: 'Times New Roman';"> (&#8220;ASC </span><span style="-aw-sdt-tag:'ce2b75a3274a6a43e17f'; font-family: 'Times New Roman'"><span>480</span></span><span style="font-family: 'Times New Roman';">&#8221;), and FASB ASC Topic No. </span><span style="-aw-sdt-tag:'ced90c7d41ecdbd49877'; font-family: 'Times New Roman'"><span>815</span></span><span style="font-family: 'Times New Roman';">, </span><span style="font-style:italic; font-family: 'Times New Roman'">Derivatives and Hedging</span><span style="font-family: 'Times New Roman';"> (&#8220;ASC </span><span style="-aw-sdt-tag:'ccd1349dccf1b3e1afae'; font-family: 'Times New Roman'"><span>815</span></span><span style="font-family: 'Times New Roman';">&#8221;). The classification of derivative financial instruments is reassessed each reporting period. Derivative liabilities are adjusted to reflect fair value at each reporting period, with any increase or decrease in the fair value recorded in the results of operations, as a component of other income or expense as change in fair value of derivative liabilities. As of </span><span style="-aw-sdt-tag:'c1af92d97c032e45d07a'; -aw-sdt-title:'Current_Period_P14'; font-family: 'Times New Roman'"><span>September 30, 2025</span></span><span style="font-family: 'Times New Roman';">, derivative liabilities consist of contingent payment arrangements. The Company uses a probability-weighted expected return method to determine the fair value of these instruments.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">Upon conversion or repayment of a debt or equity instrument in exchange for equity shares, where the embedded conversion option has been bifurcated and accounted for as a derivative liability (generally convertible debt and warrants), the Company records the equity shares at fair value on the date of conversion, relieves all related debt, derivative liabilities, and unamortized debt discounts, and recognizes a net gain or loss on debt extinguishment, if any.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">Equity or liability instruments that become subject to reclassification under ASC Topic </span><span style="-aw-sdt-tag:'ce08ae8c5268be0628c7'; font-family: 'Times New Roman'"><span>815</span></span><span style="font-family: 'Times New Roman';"> are reclassified at the fair value of the instrument on the reclassification date.</span></p></div><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p><div style="-aw-sdt-tag:'c263c163ec50c04829df'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; text-decoration:underline; font-family: 'Times New Roman'">Equity-Classified Warrants</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">As of </span><span style="-aw-sdt-tag:'c7bcd8e778eedd1caaab'; -aw-sdt-title:'Current_Period_P11'; font-family: 'Times New Roman'"><span>September 30, 2025</span></span><span style="font-family: 'Times New Roman';">, the Company accounts for all outstanding warrants to purchase common stock as equity-classified instruments based on an assessment of the warrants&#8217; specific terms and applicable authoritative guidance in ASC </span><span style="-aw-sdt-tag:'cdb856b4f4bde6d47eab'; font-family: 'Times New Roman'"><span>480</span></span><span style="font-family: 'Times New Roman';"> and ASC </span><span style="-aw-sdt-tag:'cd5e76a6a6ce96ef7c87'; font-family: 'Times New Roman'"><span>815</span></span><span style="font-family: 'Times New Roman';">. This assessment considers whether the warrants are freestanding financial instruments pursuant to ASC </span><span style="-aw-sdt-tag:'cd481df4cd7bb454097c'; font-family: 'Times New Roman'"><span>480</span></span><span style="font-family: 'Times New Roman';">, meet the definition of a liability pursuant to ASC </span><span style="-aw-sdt-tag:'c75d25a4963187f34a5b'; font-family: 'Times New Roman'"><span>480</span></span><span style="font-family: 'Times New Roman';">, whether the warrants meet all of the requirements for equity classification under ASC </span><span style="-aw-sdt-tag:'c8f59ed9b1458f19f86f'; font-family: 'Times New Roman'"><span>815</span></span><span style="font-family: 'Times New Roman';">, including whether the warrants are indexed to the Company&#8217;s own common stock and whether the warrant holders could potentially require &#8220;net cash settlement&#8221; in a circumstance outside of the Company&#8217;s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the respective issuance dates and as of each subsequent reporting period while the warrants are outstanding.</span></p></div><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><div style="-aw-sdt-tag:'cd350ef809c535d516f7'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; text-decoration:underline; font-family: 'Times New Roman'">Revenue Recognition</span></p><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">The Company recognizes revenue in accordance with FASB ASC Topic No. </span><span style="-aw-sdt-tag:'c1024005423a4297ddef'; font-family: 'Times New Roman'"><span>606</span></span><span style="font-family: 'Times New Roman';">, </span><span style="font-style:italic; font-family: 'Times New Roman'">Revenue from Contracts with Customers</span><span style="font-family: 'Times New Roman';"> (&#8220;ASC </span><span style="-aw-sdt-tag:'c01990ecd114b774522a'; font-family: 'Times New Roman'"><span>606</span></span><span style="font-family: 'Times New Roman';">&#8221;). Revenues are recognized when control is transferred to customers in amounts that reflect the consideration the Company expects to be entitled to receive in exchange for those goods. Revenue recognition is evaluated through the following five steps: (i) identification of the contract, or contracts, with a customer; (ii) identification of the performance obligations in the contract; (iii) determination of the transaction price; (iv) allocation of the transaction price to the performance obligations in the contract; and (v) recognition of revenue when or as a performance obligation is satisfied. As part of the accounting for these arrangements, the Company may be required to make significant judgments, including identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each performance obligation.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">Revenues from product sales are recorded at the net sales price, or &#8220;transaction price,&#8221; which may include estimates of variable consideration that result from product returns. The Company determines the amount of variable consideration by using either the expected value method or the most-likely-amount method. The Company includes the unconstrained amount of estimated variable consideration in the transaction price, which reflects the amount for which it is probable that a significant reversal of cumulative revenue recognized will not occur. At the end of each subsequent reporting period, the Company re-evaluates the estimated variable consideration included in the transaction price and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis in the period of adjustment. Reserves are established for the estimates of variable consideration based on the amounts the Company expects to be earned or to be claimed on the related sales.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p><div style="-aw-sdt-tag:'PG_c6053e6c5f792d82acc2'"></div></div><div style="-aw-sdt-tag:'cd350ef809c535d516f7'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">The Company receives the majority of its revenues from sales of its Arakoda product to resellers in the US and abroad. The Company records US commercial revenues as a receivable when our American distributor transfers shipped product to their title model for </span><span style="-aw-sdt-tag:'cfae9bd6533b6134b81a'; font-family: 'Times New Roman'"><span>60</span></span><span style="font-family: 'Times New Roman';">P. Foreign sales to both Australia and Europe are recognized as a receivable at the point product is shipped to distributor. The shipments to Australia and Europe are further subject to profit sharing agreements for boxes sold to customers.</span></p></div><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span><span style="font-family: 'Times New Roman';">&#160;</span></p><div style="-aw-sdt-tag:'c84f7303a81bfc500dea'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; text-decoration:underline; font-family: 'Times New Roman'">Research and Development Costs </span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">The Company accounts for research and development costs in accordance with FASB ASC Subtopic No. </span><span style="-aw-sdt-tag:'cbc781f7013a6eaa59f8'; font-family: 'Times New Roman'"><span>730</span></span><span style="font-family: 'Times New Roman';">-</span><span style="-aw-sdt-tag:'c82ed5ff78a1295bb276'; font-family: 'Times New Roman'"><span>10</span></span><span style="font-family: 'Times New Roman';">, Research and Development (&#8220;ASC </span><span style="-aw-sdt-tag:'c8d16d1806c924bd6931'; font-family: 'Times New Roman'"><span>730</span></span><span style="font-family: 'Times New Roman';">-</span><span style="-aw-sdt-tag:'ca09ffaa8d3135cb1e6b'; font-family: 'Times New Roman'"><span>10</span></span><span style="font-family: 'Times New Roman';">&#8221;). Under ASC </span><span style="-aw-sdt-tag:'c9a334fab141f1bfcaaa'; font-family: 'Times New Roman'"><span>730</span></span><span style="font-family: 'Times New Roman';">-</span><span style="-aw-sdt-tag:'cd9c059505344e7aa50b'; font-family: 'Times New Roman'"><span>10</span></span><span style="font-family: 'Times New Roman';">, research and development costs are expensed as incurred. Accordingly, internal research and development costs are expensed as incurred. Prepayments for research and development services are deferred and amortized over the service period as the services are provided. Advance payments for specific materials, equipment, or facilities determined to have no alternative future use are initially deferred and recognized as research and development expense when the related goods are delivered.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">The Company recorded $</span><span style="-aw-sdt-tag:'c0cae7d3178274b183f7'; -aw-sdt-title:'CQTD_RandD Expense'; font-family: 'Times New Roman'"><span>809,777</span></span><span style="font-family: 'Times New Roman';">&#160;</span><span style="font-family: 'Times New Roman';">and $</span><span style="-aw-sdt-tag:'c819708eba76301c2ea4'; -aw-sdt-title:'PQTD_RandD Expense'; font-family: 'Times New Roman'"><span>940,063</span></span><span style="font-family: 'Times New Roman';">&#160;</span><span style="font-family: 'Times New Roman';">in research and development expense during the </span><span style="-aw-sdt-tag:'cc1e5d1af75cc719a927'; -aw-sdt-title:'Current_Quarter_P15'; font-family: 'Times New Roman'"><span>three months ended September 30, 2025</span></span><span style="font-family: 'Times New Roman';"> and </span><span style="-aw-sdt-tag:'cc35a31294de2fb9966a'; -aw-sdt-title:'Previous_Year_P29'; font-family: 'Times New Roman'"><span>2024</span></span><span style="font-family: 'Times New Roman';">, respectively, ($</span><span style="-aw-sdt-tag:'c0a12c3296b44a12831e'; -aw-sdt-title:'CYTD_RandD Expense'; font-family: 'Times New Roman'"><span>1,467,283</span></span><span style="font-family: 'Times New Roman';"> and $</span><span style="-aw-sdt-tag:'c0c5d0d81b151b0a0872'; -aw-sdt-title:'PYTD_RandD Expense'; font-family: 'Times New Roman'"><span>4,372,571</span></span><span style="font-family: 'Times New Roman';"> for the </span><span style="-aw-sdt-tag:'c14bc5f963419ab2aed9'; -aw-sdt-title:'Current_YTD_P12'; font-family: 'Times New Roman'"><span>nine months ended September 30, 2025</span></span><span style="font-family: 'Times New Roman';"> and </span><span style="-aw-sdt-tag:'c141bbe47f263859b34f'; -aw-sdt-title:'Previous_Year_P30'; font-family: 'Times New Roman'"><span>2024</span></span><span style="font-family: 'Times New Roman';">, respectively). The Company has also issued shares of common stock to nonemployees in exchange for research and development services. The Company recognizes prepaid research and development costs on the grant date, as defined in FASB ASC Subtopic No. </span><span style="-aw-sdt-tag:'c5f925ba06665ac933a5'; font-family: 'Times New Roman'"><span>718</span></span><span style="font-family: 'Times New Roman';">, </span><span style="font-style:italic; font-family: 'Times New Roman'">Compensation - Stock Compensation</span><span style="font-family: 'Times New Roman';">. See Note </span><span style="-aw-sdt-tag:'cd731d5a4723c771d07e'; font-family: 'Times New Roman'"><span>10</span></span><span style="font-family: 'Times New Roman';"> for further details.</span></p></div><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><div style="-aw-sdt-tag:'c8e2e451fcc7fadfeb42'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; text-decoration:underline; font-family: 'Times New Roman'">Fair Value of Financial Instruments</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">The carrying value of the Company&#8217;s financial instruments included in current assets and current liabilities (such as cash and cash equivalents, accounts receivable, accounts payable, and accrued expenses) approximate their fair value due to the short-term nature of such instruments.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">The inputs used to measure fair value are based on a hierarchy that prioritizes observable and unobservable inputs used in valuation techniques. These levels, in order of highest to lowest priority, are described below:</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td style="width:36pt; vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">Level </span><span style="-aw-sdt-tag:'c10a34efbf72f35b33de'; font-family: 'Times New Roman'"><span style="font-weight:bold">1</span></span></p></td><td style="width:18pt; vertical-align:top"><div style="-aw-sdt-tag:'c574d522f70efd479dc3'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">Quoted prices (unadjusted) in active markets that are accessible at the measurement date for identical assets or liabilities.</span></p></td></tr><tr><td style="vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p></td><td style="vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p></td><td style="vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p></td></tr><tr><td style="vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">Level </span><span style="-aw-sdt-tag:'c152bc38d599e5fa0056'; font-family: 'Times New Roman'"><span style="font-weight:bold">2</span></span></p></td><td style="vertical-align:top"><div style="-aw-sdt-tag:'c41453b900cbc0348861'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">Observable prices that are based on inputs not quoted on active markets but corroborated by market data.</span></p></td></tr><tr><td style="vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p></td><td style="vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p></td><td style="vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p></td></tr><tr><td style="vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">Level </span><span style="-aw-sdt-tag:'cae8e9dbfa205b2e8396'; font-family: 'Times New Roman'"><span style="font-weight:bold">3</span></span></p></td><td style="vertical-align:top"><div style="-aw-sdt-tag:'c38191d9430425b3ee7b'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">Unobservable inputs reflecting the Company&#8217;s assumptions, consistent with reasonably available assumptions made by other market participants. These valuations require significant judgment.</span></p></td></tr></tbody></table><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">The Company&#8217;s financial instruments recorded at fair value on a recurring basis at </span><span style="-aw-sdt-tag:'ccb07ec5194190047e9d'; -aw-sdt-title:'Current_Period_P12'; font-family: 'Times New Roman'"><span>September 30, 2025</span></span><span style="font-family: 'Times New Roman';">, and </span><span style="-aw-sdt-tag:'c12a3919fe92233b9c27'; -aw-sdt-title:'Previous_Year_End_P13'; font-family: 'Times New Roman'"><span>December 31, 2024</span></span><span style="font-family: 'Times New Roman';"> include the derivative liability associated with the contingent milestone payment due to Knight upon a future sale of Arakoda or a Change of Control, which is carried at fair value based on Level </span><span style="-aw-sdt-tag:'cf44dbdc1b5a3adb8e5d'; font-family: 'Times New Roman'"><span>3</span></span><span style="font-family: 'Times New Roman';"> inputs. The Company uses a probability-weighted expected return method to determine the fair value of the contingent milestone payment using significant inputs such as the timing and probability of discrete potential exit scenarios, forward interest rate curves, and discount rates based on implied and market yields. See Note </span><span style="-aw-sdt-tag:'c607a69561493866770f'; font-family: 'Times New Roman'"><span>8</span></span><span style="font-family: 'Times New Roman';"> for more information on Derivative Liabilities.</span><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p><div style="-aw-sdt-tag:'PG_c0c20bca974f854c1494'"></div></div><div style="-aw-sdt-tag:'c8e2e451fcc7fadfeb42'"><div style="-aw-sdt-tag:'ce01f1bed3993d32f2f9'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Liabilities measured at fair value at </span><span style="-aw-sdt-tag:'c0bf68fbeefde243c15a'; -aw-sdt-title:'Current_Period_P15'; font-family: 'Times New Roman'"><span>September 30, 2025</span></span><span style="font-family: 'Times New Roman';"> and </span><span style="-aw-sdt-tag:'c732f17c4f405be7abd5'; -aw-sdt-title:'Previous_Year_End_P15'; font-family: 'Times New Roman'"><span>December 31, 2024</span></span><span style="font-family: 'Times New Roman';"> are as follows:</span></p><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p><div style="-aw-sdt-tag:'cf921e92f02c49f734d5'; -aw-sdt-title:'SIGNIFICANT ACCOUNTING POLICIES T1'"><table cellpadding="0" cellspacing="0" style="width:100%; border-collapse:collapse"><tbody><tr style="height:11.5pt"><td style="width:53%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:spaces; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="11" style="border-bottom:1.5pt solid #000000; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_1f865470141349c9b37ae84a55aacecc'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">September 30, 2025</span></p></div></td></tr><tr style="height:11.5pt"><td style="width:53%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="2" style="border-top:1.5pt solid #000000; border-bottom:1pt solid #000000; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_a9a7008663a046198bc1b79f62990348'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; -aw-import:spaces; font-family: 'Times New Roman'">&#160;</span><span style="font-weight:bold; font-family: 'Times New Roman'">Level 1</span></p></div></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="2" style="border-top:1.5pt solid #000000; border-bottom:1pt solid #000000; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_81f8a817fe384b62ae7dcf394585ad13'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; -aw-import:spaces; font-family: 'Times New Roman'">&#160;</span><span style="font-weight:bold; font-family: 'Times New Roman'">Level 2</span></p></div></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="2" style="border-top:1.5pt solid #000000; border-bottom:1pt solid #000000; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_0f2ddb2f4dea4255b9372b845c3d8cf9'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; -aw-import:spaces; font-family: 'Times New Roman'">&#160;</span><span style="font-weight:bold; font-family: 'Times New Roman'">Level 3</span></p></div></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="2" style="border-top:1.5pt solid #000000; border-bottom:1pt solid #000000; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_5169a80e4244429fb7957e47ebcd8580'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; -aw-import:spaces; font-family: 'Times New Roman'">&#160;</span><span style="font-weight:bold; font-family: 'Times New Roman'">Total</span></p></div></td></tr><tr style="height:11.5pt"><td style="width:53%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_c3fe79fa6419450bb2de75dc0fbcb8e0'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:spaces; font-family: 'Times New Roman'">&#160;</span><span style="font-family: 'Times New Roman';">Liabilities:</span></p></div></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td></tr><tr style="height:11.5pt"><td style="width:53%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_37594b78a4ff46fda8c7c6c31dda2819'"><p style="margin-top:0pt; margin-left:5.4pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:spaces; font-family: 'Times New Roman'">&#160;</span><span style="font-family: 'Times New Roman';">Derivative Liabilities</span></p></div></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_7f6e995134194c1f85dce5bf4027caab'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-tag:'C_1ebf3664e1d74ad8aa7a5f6f86bcafc6'"><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_2f314ddebd474b209bfcbd65835b25ed'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-tag:'C_ab7845e24d35492db1dd11a0aaa21e2e'"><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_e71039cd49df4ed0a91d801f3eecd241'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_c478d60eaf6f4ba79d74d84f29ff1501'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">797,275</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_d7e156ea5a164ce28ac588dac4d1a77f'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_706a282cea3b4dce906d3c671c501ff6'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">797,275</span></p></div></td></tr><tr style="height:11.5pt"><td style="width:53%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_e3a4e18287cc4026a749060e1e8fb5a9'"><p style="margin-top:0pt; margin-left:5.4pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:spaces; font-family: 'Times New Roman'">&#160;</span><span style="font-family: 'Times New Roman';">Total</span></p></div></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_105c7afdf9de422991cf5a00287ac307'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-tag:'C_7d18406ed78f4c4f8c3bb851f3c5e787'"><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_49026756b4a640278f43ece44be0ab14'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-tag:'C_a3c7a3645b97455cade875ff7e738781'"><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_8bbc20c75ef0447fa466d4bfaafb8f5f'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_62a7e9f4e692400483031bb740e41569'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">797,275</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_07827564eb61499086af507f234ed67f'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_1600b9fa42ba44889bf927265c22067e'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">797,275</span></p></div></td></tr></tbody></table></div><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p><div style="-aw-sdt-tag:'cb468fdcd6e0460b0777'; -aw-sdt-title:'SIGNIFICANT ACCOUNTING POLICIES T2'"><table cellpadding="0" cellspacing="0" style="width:100%; border-collapse:collapse"><tbody><tr style="height:11.5pt"><td style="width:53%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:spaces; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="11" style="border-bottom:1pt solid #000000; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_4b44e1528e8c4f3cbca59f75d6bdc366'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">December 31, 2024</span></p></div></td></tr><tr style="height:11.5pt"><td style="width:53%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="2" style="border-top:1.5pt solid #000000; border-bottom:1pt solid #000000; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_63bb47cb4152462c97cb5bc1a070ad98'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; -aw-import:spaces; font-family: 'Times New Roman'">&#160;</span><span style="font-weight:bold; font-family: 'Times New Roman'">Level 1</span></p></div></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="2" style="border-top:1.5pt solid #000000; border-bottom:1pt solid #000000; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_b9e93ac9d9e9420ea54dc08f973671b4'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; -aw-import:spaces; font-family: 'Times New Roman'">&#160;</span><span style="font-weight:bold; font-family: 'Times New Roman'">Level 2</span></p></div></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="2" style="border-top:1.5pt solid #000000; border-bottom:1pt solid #000000; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_6cfd423b093941b7a426daca9a7c4fd9'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; -aw-import:spaces; font-family: 'Times New Roman'">&#160;</span><span style="font-weight:bold; font-family: 'Times New Roman'">Level 3</span></p></div></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="2" style="border-top:1.5pt solid #000000; border-bottom:1pt solid #000000; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_ba6b2c8ff28f4584a84bb8a1cf763836'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; -aw-import:spaces; font-family: 'Times New Roman'">&#160;</span><span style="font-weight:bold; font-family: 'Times New Roman'">Total</span></p></div></td></tr><tr style="height:11.5pt"><td style="width:53%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_a6ef2c6558264f7ca0c50be6c5f2e477'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:spaces; font-family: 'Times New Roman'">&#160;</span><span style="font-family: 'Times New Roman';">Liabilities:</span></p></div></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td></tr><tr style="height:11.5pt"><td style="width:53%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_1ad21d4a0f664c76a8a1de7dc61969e3'"><p style="margin-top:0pt; margin-left:5.4pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:spaces; font-family: 'Times New Roman'">&#160;</span><span style="font-family: 'Times New Roman';">Derivative Liabilities</span></p></div></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_0c00d5728d434da99efe8bee0a732f0f'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-tag:'C_38b73fa55f154f55af3cfbeff629bf16'"><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_e025b21daccb422bbc8f2753e7ae30b9'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-tag:'C_333fc1e0c3f6433084115dd2779c80c0'"><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_ccf3e162c56f48aabe5b242a8d57684f'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_fda27296d6fe4023a90164878a00a1d8'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">640,830</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_121a4a1679bd49579650a47153a7674a'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_8c697e7693374899bebfc6db6f39b905'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">640,830</span></p></div></td></tr><tr style="height:11.5pt"><td style="width:53%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_cb56be67da024df7ab547d83c57f3594'"><p style="margin-top:0pt; margin-left:5.4pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:spaces; font-family: 'Times New Roman'">&#160;</span><span style="font-family: 'Times New Roman';">Total</span></p></div></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_1d0941b2301d4640a725a3c444db0b29'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-tag:'C_34e9411fc246454890a3839765ba75c7'"><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_5c011b0873844cb68a8ad4cfa194d590'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-tag:'C_59708d0fdeda4619aa91fe10eff71319'"><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_fcc1b7589a9c4ce3859c970a7eb6b9c6'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_712785fcd2f54bfb89d8883eed8aebd5'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">640,830</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_e0ed0ee91ac4479e99c9a1322299ae2a'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_a4fc6be6554e49b0832d0ac5c0e1c4d7'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">640,830</span></p></div></td></tr></tbody></table></div></div><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">There were no transfers of financial instruments between Level </span><span style="-aw-sdt-tag:'c512200b7f4efb193a74'; font-family: 'Times New Roman'"><span>1</span></span><span style="font-family: 'Times New Roman';">, Level </span><span style="-aw-sdt-tag:'cc88af1c10b9095520b3'; font-family: 'Times New Roman'"><span>2</span></span><span style="font-family: 'Times New Roman';">, and Level </span><span style="-aw-sdt-tag:'c28cda9bda6d116b1482'; font-family: 'Times New Roman'"><span>3</span></span><span style="font-family: 'Times New Roman';"> during the periods presented.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">A rollforward of liabilities measured at fair value using Level </span><span style="-aw-sdt-tag:'c3417e051371b629cb2b'; font-family: 'Times New Roman'"><span>3</span></span><span style="font-family: 'Times New Roman';"> inputs for the </span><span style="-aw-sdt-tag:'c07ff2f3886b9784d3b4'; -aw-sdt-title:'Current_Quarter_and_YTD_P9'; font-family: 'Times New Roman'"><span>three and nine months ended September 30, 2025</span></span><span style="font-family: 'Times New Roman';"> and </span><span style="-aw-sdt-tag:'ce922678da5c46f0ab60'; font-family: 'Times New Roman'"><span>2024</span></span><span style="font-family: 'Times New Roman';"> is presented in Note </span><span style="-aw-sdt-tag:'cb6b017f206e8e342188'; font-family: 'Times New Roman'"><span>8</span></span><span style="font-family: 'Times New Roman';"> &#8211; Derivative Liabilities.</span><span style="font-family: 'Times New Roman';">&#160;</span></p></div><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><div style="-aw-sdt-tag:'ce957af50e61212b40ab'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; text-decoration:underline; font-family: 'Times New Roman'">Assets and Liabilities Not Measured at Fair Value on a Recurring Basis</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">In addition to assets and liabilities that are measured at fair value on a recurring basis, the Company also measures certain assets and liabilities at fair value on a nonrecurring basis. The Company&#8217;s non-financial assets, including Intangible Assets and Property and Equipment, are measured at fair value when there is an indication of impairment and the carrying amount exceeds the asset&#8217;s projected undiscounted cash flows. These assets are recorded at fair value only when an impairment charge is recognized.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">Certificates of deposit, classified as cash equivalents or short-term investments depending on the instrument&#8217;s original time to maturity, are measured at amortized cost, which approximates fair value as of </span><span style="-aw-sdt-tag:'cbcda125eaa60887c6fa'; -aw-sdt-title:'Current_Period_P21'; font-family: 'Times New Roman'"><span>September 30, 2025</span></span><span style="font-family: 'Times New Roman';"> and </span><span style="-aw-sdt-tag:'c1cb724ff032da6352c4'; -aw-sdt-title:'Previous_Year_End_P18'; font-family: 'Times New Roman'"><span>December 31, 2024</span></span><span style="font-family: 'Times New Roman';">.</span></p></div><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><div style="-aw-sdt-tag:'856-502-b92-78d-804f'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; text-decoration:underline; font-family: 'Times New Roman'">Foreign Currency Transactions and Translation</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">The individual financial statements of each group entity are measured and presented in the currency of the primary economic environment in which the entity operates (its functional currency). The consolidated condensed financial statements of the Company are presented in United States dollars, which is the functional currency of the Company and the presentation currency for the consolidated condensed financial statements.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">For the purpose of presenting consolidated condensed financial statements, the assets and liabilities of the Company&#8217;s foreign operations are mostly translated at exchange rates prevailing on the reporting date. Income and expense items are translated at the average exchange rates for the period, unless exchange rates fluctuate significantly during that period, in which case the exchange rates at the dates of the transactions are used. Exchange differences arising, if any, are recognized as a component of other comprehensive income (loss) as unrealized foreign currency translation gain (loss).</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p><div style="-aw-sdt-tag:'PG_c0a5df5ef4dd14c932ff'"></div></div><div style="-aw-sdt-tag:'856-502-b92-78d-804f'"><div style="-aw-sdt-tag:'c777f028f5d92d4cc514'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">Exchange rates along with historical rates used in these financial statements are as follows:</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p><div style="-aw-sdt-tag:'549-6dd-c75-531-a655'; -aw-sdt-title:'SIGNIFICANT ACCOUNTING POLICIES T3'"><table cellpadding="0" cellspacing="0" style="width:100%; border-collapse:collapse"><tbody><tr style="height:11.5pt"><td style="width:34%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="17" style="border-bottom:1.5pt solid #000000; padding:0.75pt; vertical-align:bottom; -aw-padding-bottom:0.75pt"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_9482da9e9ef24112bed6d94f9f662d7c'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">Average Exchange Rate</span></p></div></td></tr><tr style="height:11.5pt"><td style="width:34%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="5" style="border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; padding:0.75pt; vertical-align:bottom; -aw-padding-bottom:0.75pt; -aw-padding-top:0.75pt"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_659f3565fccf471d885d5bbcc6f23513'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">Three Months Ended September 30,</span></p></div></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="5" style="border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_af26db9d568a41c18f4404ac7ead58b6'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">Nine Months Ended September 30,</span></p></div></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="5" style="border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_cf885fb35a704f019f0cad0d5795b8d8'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">As of</span></p></div></td></tr><tr style="height:11.5pt"><td style="width:34%; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_973ee19447724c17b71b4faa457b2249'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">Currency</span></p></div></td><td style="width:1%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="2" style="border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; padding:0.75pt; vertical-align:bottom; -aw-padding-bottom:0.75pt; -aw-padding-top:0.75pt"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_e3e1c97c5b854e929dfeef87960bfbc4'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">2025</span></p></div></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="2" style="border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_91424ca5026c4cce945405cc6ea74a81'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">2024</span></p></div></td><td style="width:1%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="2" style="border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_791c5860584c493ba5598384cfdde256'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">2025</span></p></div></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="2" style="border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_fd4986cad1d4488da73173ef15330bc0'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">2024</span></p></div></td><td style="width:1%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="2" style="border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_63ce180cbb5d445f83c9530d4f721062'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">September 30, 2025</span></p></div></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="2" style="border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_d9d1430a9c7a400390a13074b0c685af'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">December 31, 2024</span></p></div></td></tr><tr style="height:11.5pt"><td style="width:34%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_dde09534ca0e4664b9e7a6dbce09d46b'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">1 AUD =</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:6%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_7254928b2f564e559f8c533598d728fb'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">0.65</span></p></div></td><td style="width:4%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_01fc1cc76a7d496482338117b041e5d7'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">USD</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:6%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_0dd2b89b644c47918dd20e0ae4036641'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">0.67</span></p></div></td><td style="width:4%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_60bc7b550ded4fd0b8454a10aff9f2b9'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">USD</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:6%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_39890b79d6d94e83bbb6512adb82089c'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">0.64</span></p></div></td><td style="width:4%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_bcf46b0b9cd64fa28023abd0bd2f9eeb'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">USD</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:4%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_ffd190f4cb644fdc858572d0e04df5bc'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">0.66</span></p></div></td><td style="width:4%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_2ed4c46e122f4c9388749a2785a69bc5'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">USD</span></p></div></td><td style="width:1%; vertical-align:bottom; background-color:#ccecff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:6%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_deaa0fa001c447fa9db5c11c7e69f76e'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">0.66</span></p></div></td><td style="width:4%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_4ed3d209ddad4027b90139f12205d725'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">USD</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:6%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_f1dbbad2340443dba35674893ccabab6'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">0.62</span></p></div></td><td style="width:4%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'0b4-c37-b49-3e0-c6cf'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">USD</span></p></div></td></tr></tbody></table></div></div></div><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p><div style="-aw-sdt-tag:'cfbab6fdada9c08626e2'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; text-decoration:underline; font-family: 'Times New Roman'">Reclassifications</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">Certain prior period interim amounts have been reclassified for consistency with the current period presentation. These reclassifications had no material effect on the consolidated condensed results of operations and comprehensive loss, shareholders&#8217; equity, or cash flows.</span></p></div><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><div style="-aw-sdt-tag:'c5ae9390f02706bea469'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; text-decoration:underline; font-family: 'Times New Roman'">Share-Based Payments</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">On November </span><span style="-aw-sdt-tag:'cb8e4cad4e4d214394a1'; font-family: 'Times New Roman'"><span>22</span></span><span style="font-family: 'Times New Roman';">, </span><span style="-aw-sdt-tag:'c07fc0c7362febea5ed1'; font-family: 'Times New Roman'"><span>2022</span></span><span style="font-family: 'Times New Roman';">, the Company adopted the </span><span style="-aw-sdt-tag:'c82523a8da0311b6da03'; font-family: 'Times New Roman'"><span>2022</span></span><span style="font-family: 'Times New Roman';"> Equity Incentive Plan also referred to as (&#8220;</span><span style="-aw-sdt-tag:'c84ff39eab4b2b69d4e5'; font-family: 'Times New Roman'"><span>2022</span></span><span style="font-family: 'Times New Roman';"> Plan&#8221;). The </span><span style="-aw-sdt-tag:'c77a8fd767458ed89fe9'; font-family: 'Times New Roman'"><span>2022</span></span><span style="font-family: 'Times New Roman';"> Plan and related share-based awards are discussed more fully in Note </span><span style="-aw-sdt-tag:'c89592db43d1d0460416'; font-family: 'Times New Roman'"><span>10</span></span><span style="font-family: 'Times New Roman';">.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">The Company accounts for share-based payments in accordance with ASC Subtopic </span><span style="-aw-sdt-tag:'cfb759d6c4e98b9f102c'; font-family: 'Times New Roman'"><span>718</span></span><span style="font-family: 'Times New Roman';">, </span><span style="font-style:italic; font-family: 'Times New Roman'">Compensation - Stock Compensation </span><span style="font-family: 'Times New Roman';">(&#8220;ASC </span><span style="-aw-sdt-tag:'c28e007bf795e0cf0e4d'; font-family: 'Times New Roman'"><span>718</span></span><span style="font-family: 'Times New Roman';">&#8221;). The Company measures compensation for all share-based payment awards granted to employees, directors, and nonemployees, based on the estimated fair value of the awards on the date of grant. For awards that vest based on continued service, the service-based compensation cost is recognized on a straight-line basis over the requisite service period, which is generally the vesting period of the awards. For service vesting awards with compensation expense recognized on a straight-line basis, at no point in time does the cumulative grant date value of vested awards exceed the cumulative amount of compensation expense recognized. The grant date is determined based on the date when a mutual understanding of the key terms of the share-based awards is established. The Company accounts for forfeitures as they occur.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">The Company estimates the fair value of all stock option awards as of the grant date by applying the Black-Scholes option pricing model. The application of this valuation model involves assumptions, including the fair value of the common stock, expected volatility, risk-free interest rate, expected dividends and the expected term of the option. Due to the lack of a public market for the Company&#8217;s common stock prior to the IPO and lack of company-specific historical implied volatility data, the Company has based its computations of expected volatility on the historical volatility of a representative group of public companies with similar characteristics of the Company, including stage of development and industry focus. The historical volatility is calculated based on a period of time commensurate with the expected term assumption. The Company generally uses the simplified method as prescribed by the SEC Staff Accounting Bulletin Topic </span><span style="-aw-sdt-tag:'cdc65a3ad6830dc2131f'; font-family: 'Times New Roman'"><span>14</span></span><span style="font-family: 'Times New Roman';">, </span><span style="font-style:italic; font-family: 'Times New Roman'">Share-Based Payment</span><span style="font-family: 'Times New Roman';">, to estimate the expected term for stock options, whereby, the expected term equals the midpoint of the weighted average remaining time to vest, vesting period and the contractual term of the options due to its lack of historical exercise data. For certain options granted out-of-the-money, the Company&#8217;s best estimate of the expected term is the contractual term of the award. The risk-free interest rate is based on U.S. Treasury securities with a maturity date commensurate with the expected term of the associated award. The expected dividend yield is assumed to be zero as the Company has never paid dividends and has no current plans to pay any dividends on its common stock. The assumptions used in calculating the fair value of share-based awards represent management&#8217;s best estimates and involve inherent uncertainties and the application of significant judgment.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">Compensation expense for restricted stock units (&#8220;RSUs&#8221;) with only service-based vesting conditions is recognized on a straight-line basis over the vesting period. Compensation cost for service-based RSUs is based on the grant date fair value of the award, which is the closing market price of the Company&#8217;s common stock on the grant date multiplied by the number of shares awarded.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">For awards that vest upon a liquidity event or a change in control, the performance condition is not probable of being achieved until the event occurs. As a result, no compensation expense is recognized until the performance-based vesting condition is achieved, at which time the cumulative compensation expense is recognized. Compensation cost related to any remaining time-based service for share-based awards after the liquidity-based event is recognized on a straight-line basis over the remaining service period.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">For fully vested, nonforfeitable equity instruments that are granted at the date the Company and a nonemployee enter into an agreement for goods or services, the Company recognizes the fair value of the equity instruments on the grant date. The corresponding cost is recognized as an immediate expense or a prepaid asset and expensed over the service period depending on the specific facts and circumstances of the agreement with the nonemployee. See Note </span><span style="-aw-sdt-tag:'c7c93237c1946f635b03'; font-family: 'Times New Roman'"><span>10</span></span><span style="font-family: 'Times New Roman';"> for further details.</span></p></div><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p><div style="-aw-sdt-tag:'PG_c8b1ac81b7bf3b856ef3'"></div><div style="-aw-sdt-tag:'c37c1b3b29bcf7d9b9ab'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; text-decoration:underline; font-family: 'Times New Roman'">Net Loss per Common Share</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-sdt-tag:'a31-2b2-f34-82d-cfe6'; -aw-sdt-title:'Net_(Loss)_Income_Title_P2'; font-family: 'Times New Roman'"><span>Net Loss</span></span><span style="font-family: 'Times New Roman';"> per Common Share is computed by dividing </span><span style="-aw-sdt-tag:'a78-fb5-6f5-642-14ce'; -aw-sdt-title:'Net_(Loss)_Income_Title___Lower_P1'; font-family: 'Times New Roman'"><span>net loss</span></span><span style="font-family: 'Times New Roman';"> attributable to common shareholders by the weighted average number of common shares outstanding during each period. The Company includes pre-funded warrants, which carry a nominal exercise price per share, in its computation of basic and diluted net loss per share beginning on the date of issuance. The cumulative dividends accrued on the Series A Preferred Stock during the period are reflected as an increase to net loss or a reduction of net income in determining basic and diluted </span><span style="-aw-sdt-tag:'31c-481-9ce-577-2088'; -aw-sdt-title:'Net_(Loss)_Income_Title___Lower_P2'; font-family: 'Times New Roman'"><span>net loss</span></span><span style="font-family: 'Times New Roman';"> attributable to common stockholders.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">As the Company reported a net loss for all periods presented, the calculation of diluted net loss per common share is the same as basic net loss per common share. </span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">As a result of the </span><span style="-aw-sdt-tag:'5f0-31e-83e-591-f354'; font-family: 'Times New Roman'"><span>1:5</span></span><span style="font-family: 'Times New Roman';"> Reverse Stock Split, which was effective as of February 24, 2025, all shares of outstanding common stock and net loss per common share calculations have been retroactively adjusted for all periods presented.</span></p></div><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p><div style="-aw-sdt-tag:'c5700c4a179318bf9512'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; text-decoration:underline; font-family: 'Times New Roman'">Related Parties</span></p><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">Parties are considered to be related to the Company if the parties, directly or indirectly, through one or more intermediaries, control, are controlled by, or are under common control with the Company. Related parties also include principal owners of the Company, its management, members of the immediate families of principal owners of the Company and its management and other parties with which the Company may deal with if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.</span></p></div><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span><span style="font-family: 'Times New Roman';">&#160;</span></p><div style="-aw-sdt-tag:'c49a2178ae9eff53812a'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; text-decoration:underline; font-family: 'Times New Roman'">Subsequent Events</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">The Company considers events or transactions that occur after the balance sheet date, but prior to the issuance of the financial statements to provide additional evidence relative to certain estimates or to identify matters that require additional disclosure. Subsequent events have been evaluated through </span><span style="-aw-sdt-tag:'cb270f797852c1e1f2a5'; -aw-sdt-title:'Current_Period_Date_FS_Issued_P1'; font-family: 'Times New Roman'"><span>November 13, 2025</span></span><span style="font-family: 'Times New Roman';">, which is the date the financial statements were issued. See Note </span><span style="-aw-sdt-tag:'c8dbf1260408b95c5a15'; font-family: 'Times New Roman'"><span>12</span></span><span style="font-family: 'Times New Roman';">.</span></p></div><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><div style="-aw-sdt-tag:'b58-716-f7b-33e-6c0c'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; text-decoration:underline; font-family: 'Times New Roman'">Recently Adopted and Issued Accounting Pronouncements</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">From time to time, the FASB issues Accounting Standards Updates (&#8220;ASU&#8221;) to amend the authoritative literature in the ASC. The Company regularly evaluates new ASUs to determine the impact that these pronouncements may have on the consolidated condensed financial statements. Other than the pronouncements listed below, the Company believes that those issued to date either (i) provide supplemental guidance, (ii) are technical corrections, or (iii) are not applicable to the Company&#8217;s consolidated condensed financial statements or related disclosures.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">In November </span><span style="-aw-sdt-tag:'c40fc8bff493befc18d6'; font-family: 'Times New Roman'"><span>2023</span></span><span style="font-family: 'Times New Roman';">, the FASB issued ASU </span><span style="-aw-sdt-tag:'c0a6b49074383096c882'; font-family: 'Times New Roman'"><span>2023</span></span><span style="font-family: 'Times New Roman';">-</span><span style="-aw-sdt-tag:'cd25ae9feb1743719bb1'; font-family: 'Times New Roman'"><span>07</span></span><span style="font-family: 'Times New Roman';">, </span><span style="font-style:italic; font-family: 'Times New Roman'">Segment Reporting (Topic </span><span style="-aw-sdt-tag:'c48474e3644a54930dfc'; font-family: 'Times New Roman'"><span style="font-style:italic">280</span></span><span style="font-style:italic; font-family: 'Times New Roman'">): Improvements to Reportable Segment Disclosures</span><span style="font-family: 'Times New Roman';"> (&#8220;ASU </span><span style="-aw-sdt-tag:'c731ea50ea67c7e4b420'; font-family: 'Times New Roman'"><span>2023</span></span><span style="font-family: 'Times New Roman';">-</span><span style="-aw-sdt-tag:'cce9c44e2351f5ac2796'; font-family: 'Times New Roman'"><span>07</span></span><span style="font-family: 'Times New Roman';">&#8221;) which expands annual and interim disclosure requirements for reportable segments, primarily through enhanced disclosures about significant segment expenses and segment profit or loss. ASU </span><span style="-aw-sdt-tag:'c7a9ce0a0ac8993d0acf'; font-family: 'Times New Roman'"><span>2023</span></span><span style="font-family: 'Times New Roman';">-</span><span style="-aw-sdt-tag:'cdd16562ce807243ed58'; font-family: 'Times New Roman'"><span>07</span></span><span style="font-family: 'Times New Roman';"> also requires entities with a single reportable segment to provide all segment disclosures under ASC </span><span style="-aw-sdt-tag:'cf6e9777e809f25e1b07'; font-family: 'Times New Roman'"><span>280</span></span><span style="font-family: 'Times New Roman';">, including the new required disclosures under the ASU. The Company adopted ASU </span><span style="-aw-sdt-tag:'cc9be51d0fa22b72f687'; font-family: 'Times New Roman'"><span>2023</span></span><span style="font-family: 'Times New Roman';">-</span><span style="-aw-sdt-tag:'cc2f4662055f1cf358a4'; font-family: 'Times New Roman'"><span>07</span></span><span style="font-family: 'Times New Roman';"> on a retrospective basis for the </span><span style="-aw-sdt-tag:'c304e39ce5549b67326b'; font-family: 'Times New Roman'"><span>2024</span></span><span style="font-family: 'Times New Roman';"> annual period, and for interim periods beginning in </span><span style="-aw-sdt-tag:'c50e039416b6752cbc9e'; font-family: 'Times New Roman'"><span>2025</span></span><span style="font-family: 'Times New Roman';">. The impact is limited to the Company&#8217;s financial statement disclosures, which are presented in the Segment Information section above.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">In December </span><span style="-aw-sdt-tag:'cf066c3ed14287513469'; font-family: 'Times New Roman'"><span>2023</span></span><span style="font-family: 'Times New Roman';">, the FASB issued ASU </span><span style="-aw-sdt-tag:'c0565bc7ca2af95b4c7c'; font-family: 'Times New Roman'"><span>2023</span></span><span style="font-family: 'Times New Roman';">-</span><span style="-aw-sdt-tag:'ceb96c9259852308d896'; font-family: 'Times New Roman'"><span>09</span></span><span style="font-family: 'Times New Roman';">, </span><span style="font-style:italic; font-family: 'Times New Roman'">Income Taxes (ASC </span><span style="-aw-sdt-tag:'c0282851b575f38250ce'; font-family: 'Times New Roman'"><span style="font-style:italic">740</span></span><span style="font-style:italic; font-family: 'Times New Roman'">): Improvements to Income Tax Disclosures</span><span style="font-family: 'Times New Roman';"> (&#8220;ASU </span><span style="-aw-sdt-tag:'c397c2576fab14a6843a'; font-family: 'Times New Roman'"><span>2023</span></span><span style="font-family: 'Times New Roman';">-</span><span style="-aw-sdt-tag:'c43ea664edca3b7d1221'; font-family: 'Times New Roman'"><span>09</span></span><span style="font-family: 'Times New Roman';">&#8221;) which requires disaggregated information about a reporting entity&#8217;s effective tax rate reconciliation as well as information on income taxes paid. ASU </span><span style="-aw-sdt-tag:'ced6791b435360aa514d'; font-family: 'Times New Roman'"><span>2023</span></span><span style="font-family: 'Times New Roman';">-</span><span style="-aw-sdt-tag:'c152d39afa37813cff35'; font-family: 'Times New Roman'"><span>09</span></span><span style="font-family: 'Times New Roman';"> is effective for annual periods beginning after December </span><span style="-aw-sdt-tag:'c65d60af908ae022a7fb'; font-family: 'Times New Roman'"><span>15</span></span><span style="font-family: 'Times New Roman';">, </span><span style="-aw-sdt-tag:'c9d2f568ca33a0e3ddc2'; font-family: 'Times New Roman'"><span>2024</span></span><span style="font-family: 'Times New Roman';">. The Company will adopt this standard for the annual period ending December 31, 2025. The impact of ASU 2023-09 will be limited to the Company&#8217;s financial statement disclosures.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">In November </span><span style="-aw-sdt-tag:'cb06da4c60c3ed718870'; font-family: 'Times New Roman'"><span>2024</span></span><span style="font-family: 'Times New Roman';">, the FASB issued ASU </span><span style="-aw-sdt-tag:'c5896724f85326b5cf6c'; font-family: 'Times New Roman'"><span>2024</span></span><span style="font-family: 'Times New Roman';">-</span><span style="-aw-sdt-tag:'c5ee0130675746e94982'; font-family: 'Times New Roman'"><span>03</span></span><span style="font-family: 'Times New Roman';">, </span><span style="font-style:italic; font-family: 'Times New Roman'">Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic </span><span style="-aw-sdt-tag:'c686357b9151070c0b80'; font-family: 'Times New Roman'"><span style="font-style:italic">220</span></span><span style="font-style:italic; font-family: 'Times New Roman'">-</span><span style="-aw-sdt-tag:'ccb37deca24433c43642'; font-family: 'Times New Roman'"><span style="font-style:italic">40</span></span><span style="font-style:italic; font-family: 'Times New Roman'">): Disaggregation of Income Statement Expenses </span><span style="font-family: 'Times New Roman';">(&#8220;ASU </span><span style="-aw-sdt-tag:'c82c510f162b91f255e5'; font-family: 'Times New Roman'"><span>2024</span></span><span style="font-family: 'Times New Roman';">-</span><span style="-aw-sdt-tag:'c9b3edff03a8224442ee'; font-family: 'Times New Roman'"><span>03</span></span><span style="font-family: 'Times New Roman';">&#8221;), which applies to all public business entities that file financial statements with the SEC. The amendments in this ASU require public business entities to disclose on an annual and interim basis, disaggregated information about certain income statement expense line items. The new standard is effective for fiscal years beginning after December </span><span style="-aw-sdt-tag:'c4227d4f684c80f6fc7b'; font-family: 'Times New Roman'"><span>15</span></span><span style="font-family: 'Times New Roman';">, </span><span style="-aw-sdt-tag:'cdb1897f2589fc5290f5'; font-family: 'Times New Roman'"><span>2026</span></span><span style="font-family: 'Times New Roman';">, with early adoption permitted. The Company is currently evaluating the impact that ASU </span><span style="-aw-sdt-tag:'cd9fcbee88c447594d3d'; font-family: 'Times New Roman'"><span>2024</span></span><span style="font-family: 'Times New Roman';">-</span><span style="-aw-sdt-tag:'cea1fdf602d68e8ea393'; font-family: 'Times New Roman'"><span>03</span></span><span style="font-family: 'Times New Roman';"> will have on its financial statement disclosures.</span><span style="font-family: 'Times New Roman';">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </span></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORY<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>INVENTORY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">INVENTORY</a></td>
<td class="text"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">3. INVENTORY</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><div style="-aw-sdt-tag:'c4b64ef482d85585ddef'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">Inventory consists of the following major classes:</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><div style="-aw-sdt-tag:'c3ad763587e21d5ec175'; -aw-sdt-title:'INVENTORY T1'"><table cellpadding="0" cellspacing="0" style="width:100%; margin-right:auto; margin-left:auto; border-collapse:collapse"><tbody><tr style="height:11.5pt"><td style="width:77%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="2" style="border-bottom:1.5pt solid #000000; padding-right:5.75pt; padding-left:5.75pt; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_8c78ee49c91e44ce918f2ebd1b7927a2'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">September 30, 2025</span></p></div></td><td style="width:1%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="2" style="border-bottom:1.5pt solid #000000; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_eb198c15a0e04e4e8352b8854a5daadc'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">December 31, 2024</span></p></div></td></tr><tr style="height:11.5pt"><td style="width:77%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_9f6e148ddfbd43bd85c0bd773b3ebd5b'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Raw Material (API)</span></p></div></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_00a19566ed1c43f99c98897b148d8d2a'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_f16c7a3406eb4165a5632f4b2432cc52'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">345,195</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_97a890fb4676459799df39011e8dd53c'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-tag:'C_ab71897d07ac40d28dfd83405a9dfafe'"><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td></tr><tr style="height:11.5pt"><td style="width:77%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_aeef74c84e0f4d1f96536ddc357d7064'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Work in Process</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-tag:'C_6a3655bdab5d48dd86ca61227681b415'"><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_ef00ca8ecef947d48a2392dce651f727'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">284,883</span></p></div></td></tr><tr style="height:11.5pt"><td style="width:77%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_d5d56b1ac61047c8bb2cd738f043bffa'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Finished Goods</span></p></div></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_5b0903d97dea4325b613f810a8c5eaf2'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">426,491</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_36ca9b2fc2674b1b9e7c5ee6ac7b2cc2'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">157,881</span></p></div></td></tr><tr style="height:11.5pt"><td style="width:77%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_be61fc4bb0cc4c4ba6288d79409b3e45'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Total Inventory</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_83e5c4c46f15469f98bfb74b9c0152cc'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">771,686</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_a90105c86d004c7988263596647fb77a'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">442,764</span></p></div></td></tr><tr style="height:11.5pt"><td style="width:77%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_4beb2619f3b64a17be38dcd2cbe156d3'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Reserve for Expiring Inventory</span></p></div></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_93d116c0bb494287916a99a01a7fd59c'; font-family: 'Times New Roman'"><span>244,682</span></span><span style="font-family: 'Times New Roman';">)</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-tag:'C_dee47b6fa0dc487eba64f4acdf903ada'"><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td></tr><tr style="height:11.5pt"><td style="width:77%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_73dc86a2354c42c5af659415f686502c'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">Inventory</span></p></div></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_18ec2a0d235e48ca8dccc53077caf073'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">$</span></p></div></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_352a37dac1dc493db25e225319ba1514'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">527,004</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_14f157594d2f42b2a8d7ac54924f20bb'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">$</span></p></div></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'d7b-8b1-5fc-6b2-f7e6'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">442,764</span></p></div></td></tr></tbody></table></div></div><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">The Company regularly monitors its inventory levels to identify inventory that may expire or has a cost basis in excess of its estimated net realizable value, and records write-downs for inventory that has expired, inventory that has a cost basis in excess of its expected net realizable value, and inventory in excess of expected sales requirements. Any write-downs of inventories are charged to cost of revenues in the </span><span style="-aw-sdt-tag:'ffb-eda-e3e-f96-f173'; -aw-sdt-title:'PandL_title_P4'; font-family: 'Times New Roman'"><span>consolidated condensed statements of operations and comprehensive loss</span></span><span style="font-family: 'Times New Roman';">. During the </span><span style="-aw-sdt-tag:'b1e-16f-504-955-dd45'; -aw-sdt-title:'Current_Quarter_P48'; font-family: 'Times New Roman'"><span>three months ended September 30, 2025</span></span><span style="font-family: 'Times New Roman';"> and </span><span style="-aw-sdt-tag:'19f-9c4-d3b-e65-dd8f'; -aw-sdt-title:'Previous_Year_P54'; font-family: 'Times New Roman'"><span>2024</span></span><span style="font-family: 'Times New Roman';">, write downs for expired inventory were $</span><span style="-aw-sdt-tag:'8c7-42a-927-d0d-4aae'; -aw-sdt-title:'Inventory Write-downs CQ'; font-family: 'Times New Roman'"><span>436,561</span></span><span style="font-family: 'Times New Roman';"> and $</span><span style="-aw-sdt-tag:'dc4-345-946-2cb-8a9f'; -aw-sdt-title:'Inventory Write-downs PQ'; font-family: 'Times New Roman'"><span>1,165</span></span><span style="font-family: 'Times New Roman';">, respectively ($</span><span style="-aw-sdt-tag:'1ec-156-b10-d9c-e801'; -aw-sdt-title:'Inventory Write-downs CYTD'; font-family: 'Times New Roman'"><span>436,596</span></span><span style="font-family: 'Times New Roman';"> and $</span><span style="-aw-sdt-tag:'acd-db4-0d0-210-5cfb'; -aw-sdt-title:'Inventory Write-downs PYTD'; font-family: 'Times New Roman'"><span>18,490</span></span><span style="font-family: 'Times New Roman';"> for the </span><span style="-aw-sdt-tag:'497-514-bce-6c1-7d4b'; -aw-sdt-title:'Current_YTD_P56'; font-family: 'Times New Roman'"><span>nine months ended September 30, 2025</span></span><span style="font-family: 'Times New Roman';"> and </span><span style="-aw-sdt-tag:'860-e12-55e-aec-5da2'; -aw-sdt-title:'Previous_Year_P55'; font-family: 'Times New Roman'"><span>2024</span></span><span style="font-family: 'Times New Roman';">, respectively).</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/330/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>PROPERTY AND EQUIPMENT</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">PROPERTY AND EQUIPMENT</a></td>
<td class="text"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-sdt-tag:'362-52b-f94-e85-08c1'; font-family: 'Times New Roman'"><span style="font-weight:bold">4</span></span><span style="font-weight:bold; font-family: 'Times New Roman'">. PROPERTY AND EQUIPMENT</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><div style="-aw-sdt-tag:'c3328980f611b2c2c18e'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">Property and Equipment, net consists of:</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><div style="-aw-sdt-tag:'c585e2b6503490e35b6e'; -aw-sdt-title:'PROPERTY AND EQUIPMENT T1'"><table cellpadding="0" cellspacing="0" style="width:100%; border-collapse:collapse"><tbody><tr style="height:11.5pt"><td style="width:77%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="2" style="border-bottom:1.5pt solid #000000; padding-right:5.75pt; padding-left:5.75pt; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_d243be9044f94e5789d1c03995fef724'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">September 30, 2025</span></p></div></td><td style="width:1%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="2" style="border-bottom:1.5pt solid #000000; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_cdf2c2bb81134c98a67579ef3ca9e8ac'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">December 31, 2024</span></p></div></td></tr><tr style="height:11.5pt"><td style="width:77%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_210216e127fe482781b410d7ec74a0b8'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Lab Equipment</span></p></div></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_53af035c51d0478aa394754c413e6ffb'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_9328eadfcc594ac596b0acc136f7b8f0'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">333,010</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_e940a18328bb4ad9bea7def38d0d559f'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_2329b86c972f422ba404be9dd3277495'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">233,411</span></p></div></td></tr><tr style="height:11.5pt"><td style="width:77%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_0319c462920c42afa0d3176c000bd9f7'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Machinery</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_ef8d24443e6e4e8cb5980f37db5e774c'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">55,800</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_c8ff641cd4744c44a8ca4ea45f4e85c8'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">55,800</span></p></div></td></tr><tr style="height:11.5pt"><td style="width:77%; vertical-align:middle; background-color:#ccecff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_6249934fa3de4adaa792e486a851badc'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Computer Equipment</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ccecff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:middle; background-color:#ccecff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_aca3f556efe04148b984c56098021a99'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">11,597</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ccecff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#ccecff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:middle; background-color:#ccecff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_a531e0c254db4110ad34d073164553f9'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">7,000</span></p></div></td></tr><tr style="height:11.5pt"><td style="width:77%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_aebc173cb2c8413fa5fcf35341f8657a'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Furniture</span></p></div></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_b504fb680d844731bb0cd3fabd739eac'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">3,030</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_6e01e63464c941e29d2034653b8107e5'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">3,030</span></p></div></td></tr><tr style="height:11.5pt"><td style="width:77%; vertical-align:middle; background-color:#ccecff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_8a33d8c7b8f447cf9991bc44f6e506d2'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Property and Equipment, at cost</span></p></div></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ccecff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ccecff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_7e9128e9f9104afc873f970c6a9135ce'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">403,437</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ccecff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ccecff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ccecff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_0083050d4387424b9262c3e3b6a9fee5'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">299,241</span></p></div></td></tr><tr style="height:11.5pt"><td style="width:77%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_b6b62697f29548dbaf51d4cf72f0c5f7'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Accumulated Depreciation</span></p></div></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_d1d3c66b3b5440948d85580b0ecb68ec'; font-family: 'Times New Roman'"><span>175,685</span></span><span style="font-family: 'Times New Roman';">)</span></p></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_6e53c81a6ded46cca2cd24a44cf411d0'; font-family: 'Times New Roman'"><span>149,433</span></span><span style="font-family: 'Times New Roman';">)</span></p></td></tr><tr style="height:11.5pt"><td style="width:77%; vertical-align:middle; background-color:#ccecff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_11c099461546454a8d4b17afa85db567'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">Property and Equipment, net</span></p></div></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ccecff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_e7ec042f6b194d6a858be22c9a1b091a'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">$</span></p></div></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ccecff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_2faa5c0453e4450596c4956cffc1df1e'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">227,752</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ccecff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ccecff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_05cfb6f1de00493d99ff10680b286a1a'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">$</span></p></div></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ccecff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_519d7c2bff0c454799f8e791a58c7103'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">149,808</span></p></div></td></tr></tbody></table></div></div><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">Depreciation expense for the </span><span style="-aw-sdt-tag:'3df-38b-a90-624-8e5d'; -aw-sdt-title:'Current_Quarter_P44'; font-family: 'Times New Roman'"><span>three months ended September 30, 2025</span></span><span style="font-family: 'Times New Roman';"> and </span><span style="-aw-sdt-tag:'382-eed-505-ecf-e5da'; -aw-sdt-title:'Previous_Year_P47'; font-family: 'Times New Roman'"><span>2024</span></span><span style="font-family: 'Times New Roman';"> was in the amount of $</span><span style="-aw-sdt-tag:'c6f-708-7ed-a12-e87f'; -aw-sdt-title:'Depreciation expense_CQTD'; font-family: 'Times New Roman'"><span>12,225</span></span><span style="font-family: 'Times New Roman';"> and $</span><span style="-aw-sdt-tag:'05d-cb7-531-47b-40f1'; -aw-sdt-title:'Depreciation expense_PYQTD'; font-family: 'Times New Roman'"><span>4,334</span></span><span style="font-family: 'Times New Roman';">, respectively ($</span><span style="-aw-sdt-tag:'cd782fa2db2ddfc0ea5e'; -aw-sdt-title:'Depreciation expense_CYTD'; font-family: 'Times New Roman'"><span>28,155</span></span><span style="font-family: 'Times New Roman';"> and $</span><span style="-aw-sdt-tag:'c3e71056f41b8e6237d0'; -aw-sdt-title:'Depreciation expense_PYTD'; font-family: 'Times New Roman'"><span>6,277</span></span><span style="font-family: 'Times New Roman';"> for the </span><span style="-aw-sdt-tag:'cecb412e14ad226c62ea'; -aw-sdt-title:'Current_YTD_P4'; font-family: 'Times New Roman'"><span>nine months ended September 30, 2025</span></span><span style="font-family: 'Times New Roman';"> and </span><span style="-aw-sdt-tag:'cd2da8121dd3f61410cb'; -aw-sdt-title:'Previous_Year_P6'; font-family: 'Times New Roman'"><span>2024</span></span><span style="font-family: 'Times New Roman';">, respectively).</span><span style="font-family: 'Times New Roman';">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLE ASSETS<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>INTANGIBLE ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">INTANGIBLE ASSETS</a></td>
<td class="text"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">5. INTANGIBLE ASSETS</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><div style="-aw-sdt-tag:'ce139b5a70e6301672f2'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">Intangible Assets, net consists of:</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><div style="-aw-sdt-tag:'c07707b83cb3f173b9aa'; -aw-sdt-title:'INTANGIBLE ASSETS T1'"><table cellpadding="0" cellspacing="0" style="width:100%; border-collapse:collapse"><tbody><tr style="height:11.5pt"><td style="width:76%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="2" style="border-bottom:1.5pt solid #000000; padding-right:5.75pt; padding-left:5.75pt; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_e87ec5587e3840c4a97f2064f2104ed4'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">September 30, 2025</span></p></div></td><td style="width:1%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="2" style="border-bottom:1.5pt solid #000000; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_6084f1e1489b48879fcbbe5600141f97'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">December 31, 2024</span></p></div></td></tr><tr style="height:11.5pt"><td style="width:76%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_a974f35cc65443269ff066743129189d'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Patents</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_d202bcb88b044d028a4bbb28f6a6e8b0'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_11b78614bac54ef0a49e4b893a15b1d0'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">152,267</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_51a78629619a4b75ba95f8f8f4f7ec7b'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_860e11faa60f4e3cb17c35e447e6d321'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">127,603</span></p></div></td></tr><tr style="height:11.5pt"><td style="width:76%; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_f612ea6912ea4de8936ab11fa94001b2'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Website Development Costs</span></p></div></td><td style="width:1%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_bd5beeeb98654d3cb378b1f150cf237e'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">106,407</span></p></div></td><td style="width:1%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_0297394f2e174985a9011e14c17a1c32'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">104,622</span></p></div></td></tr><tr style="height:11.5pt"><td style="width:76%; vertical-align:middle; background-color:#ccecff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_69283753d7194d8481cb58344618da62'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Intangible Assets, at cost</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ccecff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ccecff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ccecff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_67428270244741e190f4ba5b6f6c89a4'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">258,674</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ccecff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ccecff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ccecff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_ce68356243274a62b8341406f23e7284'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">232,225</span></p></div></td></tr><tr style="height:11.5pt"><td style="width:76%; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_5ec84ad9cbbb4a728206c96fd6d9a6ac'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Accumulated Amortization</span></p></div></td><td style="width:1%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_a4c0c57793a24539a911c71110c0a6db'; font-family: 'Times New Roman'"><span>106,291</span></span><span style="font-family: 'Times New Roman';">)</span></p></td><td style="width:1%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_ba8b1931203d40b8b853f7cd33fb68a0'; font-family: 'Times New Roman'"><span>75,141</span></span><span style="font-family: 'Times New Roman';">)</span></p></td></tr><tr style="height:11.5pt"><td style="width:76%; vertical-align:middle; background-color:#ccecff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_609bae755e8b4231bb1d4b943acee2ff'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">Intangible Assets, net</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ccecff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ccecff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_bbacba70555c4d44a3ed2b95ac3cb5f3'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">$</span></p></div></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ccecff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_2fda802cc17945c78daa21dc34cb0e8e'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">152,383</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ccecff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ccecff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_0f46f04104944ac794c1fcc3501b0184'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">$</span></p></div></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ccecff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_01b52cfeb567443aae2cc897f6e6903c'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">157,084</span></p></div></td></tr></tbody></table></div></div><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">During the </span><span style="-aw-sdt-tag:'cfddb1f69b08f6739761'; -aw-sdt-title:'Current_Quarter_P8'; font-family: 'Times New Roman'"><span>three months ended September 30, 2025</span></span><span style="font-family: 'Times New Roman';"> and </span><span style="-aw-sdt-tag:'c29e36ff587f2ca8119a'; -aw-sdt-title:'Previous_Year_P7'; font-family: 'Times New Roman'"><span>2024</span></span><span style="font-family: 'Times New Roman';">, the Company capitalized website development related costs of $</span><span style="-aw-sdt-tag:'c2a1e8afbb1fb6a25958'; -aw-sdt-title:'Capitalized website cost_CQ'; font-family: 'Times New Roman'"><span>1,785</span></span><span style="font-family: 'Times New Roman';"> and $</span><span style="-aw-sdt-tag:'cda0d70b09d724d001f4'; -aw-sdt-title:'Capitalized website cost_PQ'; font-family: 'Times New Roman'"><span>3,299</span></span><span style="font-family: 'Times New Roman';">, respectively, in connection with the upgrade and enhancement of functionality of the corporate website at www.60degreespharma.com</span><span style="-aw-import:spaces; font-family: 'Times New Roman'">&#160; </span><span style="font-family: 'Times New Roman';">($</span><span style="-aw-sdt-tag:'c3dc95a82a1b1e546d01'; -aw-sdt-title:'Capitalized website cost_CYTD'; font-family: 'Times New Roman'"><span>1,785</span></span><span style="font-family: 'Times New Roman';">&#160;</span><span style="font-family: 'Times New Roman';">and $</span><span style="-aw-sdt-tag:'cf4550241ecb006a41f6'; -aw-sdt-title:'Capitalized website cost_PYTD'; font-family: 'Times New Roman'"><span>25,374</span></span><span style="font-family: 'Times New Roman';">&#160;</span><span style="font-family: 'Times New Roman';">for the </span><span style="-aw-sdt-tag:'c33b8fe0f39e14089973'; -aw-sdt-title:'Current_YTD_P5'; font-family: 'Times New Roman'"><span>nine months ended September 30, 2025</span></span><span style="font-family: 'Times New Roman';"> and </span><span style="-aw-sdt-tag:'ce5f4b2075d79cc2478c'; -aw-sdt-title:'Previous_Year_P8'; font-family: 'Times New Roman'"><span>2024</span></span><span style="font-family: 'Times New Roman';">, respectively). Amortization expense for the </span><span style="-aw-sdt-tag:'c44e3479c6cf2fd17b26'; -aw-sdt-title:'Current_Quarter_P9'; font-family: 'Times New Roman'"><span>three months ended September 30, 2025</span></span><span style="font-family: 'Times New Roman';"> and </span><span style="-aw-sdt-tag:'c17bd43eeffe59b5f10e'; -aw-sdt-title:'Previous_Year_P9'; font-family: 'Times New Roman'"><span>2024</span></span><span style="font-family: 'Times New Roman';">, was in the amount of $</span><span style="-aw-sdt-tag:'cdf9166bedebda2ed9aa'; -aw-sdt-title:'Amortization expense_CQ'; font-family: 'Times New Roman'"><span>10,605</span></span><span style="font-family: 'Times New Roman';"> and $</span><span style="-aw-sdt-tag:'ca20761b02425983f940'; -aw-sdt-title:'Amortization expense_PQ'; font-family: 'Times New Roman'"><span>10,325</span></span><span style="font-family: 'Times New Roman';">, respectively ($</span><span style="-aw-sdt-tag:'c8ce6837087c033d4286'; -aw-sdt-title:'Amortization expense_CYTD'; font-family: 'Times New Roman'"><span>31,150</span></span><span style="font-family: 'Times New Roman';">&#160;</span><span style="font-family: 'Times New Roman';">and $</span><span style="-aw-sdt-tag:'cc44d6d5241d199376d1'; -aw-sdt-title:'Amortization expense_PYTD'; font-family: 'Times New Roman'"><span>28,004</span></span><span style="font-family: 'Times New Roman';">&#160;</span><span style="font-family: 'Times New Roman';">for the </span><span style="-aw-sdt-tag:'ce158ad54306c4664c5b'; -aw-sdt-title:'Current_YTD_P6'; font-family: 'Times New Roman'"><span>nine months ended September 30, 2025</span></span><span style="font-family: 'Times New Roman';"> and </span><span style="-aw-sdt-tag:'c4c2c545f5f21414391e'; -aw-sdt-title:'Previous_Year_P10'; font-family: 'Times New Roman'"><span>2024</span></span><span style="font-family: 'Times New Roman';">, respectively). During the </span><span style="-aw-sdt-tag:'c457dc719db4eca31b2a'; -aw-sdt-title:'Current_Quarter_P10'; font-family: 'Times New Roman'"><span>three months ended September 30, 2025</span></span><span style="font-family: 'Times New Roman';"> and </span><span style="-aw-sdt-tag:'cdc79815474d680ddd9e'; -aw-sdt-title:'Previous_Year_P45'; font-family: 'Times New Roman'"><span>2024</span></span><span style="font-family: 'Times New Roman';"> write-downs for expired or obsolete patents totaled $</span><span style="-aw-sdt-tag:'7d9-88c-e97-7af-e31e'; -aw-sdt-title:'Write-downs CQ'; font-family: 'Times New Roman'"><span>0</span></span><span style="font-family: 'Times New Roman';"> and $</span><span style="-aw-sdt-tag:'283-f1b-606-cfc-9b44'; -aw-sdt-title:'Write-downs PQ'; font-family: 'Times New Roman'"><span>2,922</span></span><span style="font-family: 'Times New Roman';">, respectively ($</span><span style="-aw-sdt-tag:'e6c-293-14b-bb4-26d0'; -aw-sdt-title:'Write downs_CYTD'; font-family: 'Times New Roman'"><span>0</span></span><span style="font-family: 'Times New Roman';"> and</span><span style="font-family: 'Times New Roman';">&#160;</span><span style="font-family: 'Times New Roman';">$</span><span style="-aw-sdt-tag:'cac27d69e412e4ba21e5'; -aw-sdt-title:'Write-downs_PYTD'; font-family: 'Times New Roman'"><span>11,300</span></span><span style="font-family: 'Times New Roman';">&#160;</span><span style="font-family: 'Times New Roman';">for the </span><span style="-aw-sdt-tag:'c72938f4a0ec43514747'; -aw-sdt-title:'Current_YTD_P7'; font-family: 'Times New Roman'"><span>nine months ended September 30, 2025</span></span><span style="font-family: 'Times New Roman';"> and </span><span style="-aw-sdt-tag:'cbbf9cb9616e40a9b45a'; -aw-sdt-title:'Previous_Year_P11'; font-family: 'Times New Roman'"><span>2024</span></span><span style="font-family: 'Times New Roman';">, respectively).</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><div style="-aw-sdt-tag:'c3bc236d7ffc1c5b8cde'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">The following table summarizes the estimated future amortization expense for our patents and website development costs as of </span><span style="-aw-sdt-tag:'ce96f421a46d06d458b3'; -aw-sdt-title:'Current_Period_P7'; font-family: 'Times New Roman'"><span>September 30, 2025</span></span><span style="font-family: 'Times New Roman';">:</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><div style="-aw-sdt-tag:'c0f2fdd191b23a42f69c'; -aw-sdt-title:'INTANGIBLE ASSETS T2'"><table cellpadding="0" cellspacing="0" style="width:100%; border-collapse:collapse"><tbody><tr style="height:11.5pt"><td style="width:76%; border-bottom:1.5pt solid #000000; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_174dcc19aadc45dcbec245e8e5590546'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">Period</span></p></div></td><td style="width:1%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="2" style="border-bottom:1.5pt solid #000000; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_2b4fd151a35e427f81944ed4aef3cd03'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">Patents</span></p></div></td><td style="width:1%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="2" style="border-bottom:1.5pt solid #000000; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_eac02702a1b6481292e04477eabff1f5'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">Website Development Costs</span></p></div></td></tr><tr style="height:11.5pt"><td style="width:76%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_bed21abb624848b39d25a0e5198a3eea'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">2025 (remaining three months)</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_0628bafa871b46b6b23c7839bac84a2b'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; border-top:1.5pt solid #000000; padding-right:0.7pt; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_9ed72b1fc9a841678c6414ffa9250716'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">1,816</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_9971da9e37cf45c6965a560295ce2ee3'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_b86b8d6612d346b299a1f4e8b716937d'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">5,754</span></p></div></td></tr><tr style="height:11.5pt"><td style="width:76%; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_98ee970e69c748c69cc8bbd0ed8e7995'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">2026</span></p></div></td><td style="width:1%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; padding-right:0.7pt; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_29d81502a5fc40d6b3b22b749ae8c2cc'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">7,264</span></p></div></td><td style="width:1%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_d2022197ea7e432dad2b843e2cba5634'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">13,027</span></p></div></td></tr><tr style="height:11.5pt"><td style="width:76%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_4130c067c39a40829ddaa2a81e97ae4b'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">2027</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; padding-right:0.7pt; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_4d3a475d713840deb210ba44e18e1f33'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">7,264</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_5fd36d2d7338473a98e0eaca4c3bb72e'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">3,689</span></p></div></td></tr><tr style="height:11.5pt"><td style="width:76%; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_313ade7de15848e1805861fa9d495eb2'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">2028</span></p></div></td><td style="width:1%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; padding-right:0.7pt; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_9a518cad7b5f4600b17899e4df170f7e'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">7,264</span></p></div></td><td style="width:1%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_ba37da8a5d21434286c58831bdac112f'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">397</span></p></div></td></tr><tr style="height:11.5pt"><td style="width:76%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_faf1ce39ee004fdbacf45816b0cd8e1b'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">2029</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; padding-right:0.7pt; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_1dbfcb6bede14893b1d590e5550007a7'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">7,264</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-tag:'C_4124ac0cb341498b8445cea7bd35d757'"><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td></tr><tr style="height:11.5pt"><td style="width:76%; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_a93ca8f84d704c2685aef38dd6e616fb'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Thereafter</span></p></div></td><td style="width:1%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-bottom:1.5pt solid #000000; padding-right:0.7pt; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_6321783027ee42c18b71f36dd0941a2f'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">38,435</span></p></div></td><td style="width:1%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle"><div style="-aw-sdt-tag:'C_257cb67d346b4113ac890add634412f6'"><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td></tr><tr style="height:11.5pt"><td style="width:76%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_d7c76dd6b9cc422d8a6b884dacaa3365'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">Total</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_75767eb28a1d449ab596ff84732f7256'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">$</span></p></div></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; padding-right:0.7pt; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_2ee72c55a7204d64a57ac09c73611a03'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">69,307</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_6779a62c90a14cb8b35f588ce92d9296'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">$</span></p></div></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'e65-d56-30f-2c3-e9f3'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">22,867</span></p></div></td></tr></tbody></table></div></div><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">The Company has recorded $</span><span style="-aw-sdt-tag:'cbd86a35bd29e0f037ae'; -aw-sdt-title:'capitalized patent expenses'; font-family: 'Times New Roman'"><span>60,209</span></span><span style="font-family: 'Times New Roman';"> in capitalized patent expenses that will become amortizable as the patents they are associated with are awarded.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/985-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>STOCKHOLDERS&#8217; EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">STOCKHOLDERS&#8217; EQUITY</a></td>
<td class="text"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">6. STOCKHOLDERS&#8217; EQUITY</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">Pursuant to the Certificate of Incorporation of </span><span style="-aw-sdt-tag:'c00395ab615233e65b60'; font-family: 'Times New Roman'"><span>60</span></span><span style="font-family: 'Times New Roman';"> Degrees Pharmaceuticals, Inc., the Company&#8217;s authorized shares consist of (a) </span><span style="-aw-sdt-tag:'c8256dca101917b93f72'; font-family: 'Times New Roman'"><span>150,000,000</span></span><span style="font-family: 'Times New Roman';"> shares of common stock, par value $</span><span style="-aw-sdt-tag:'c3bf7f20ec7068739bfa'; font-family: 'Times New Roman'"><span>0.0001</span></span><span style="font-family: 'Times New Roman';"> per share and (b) </span><span style="-aw-sdt-tag:'c047a66335e6c7190382'; font-family: 'Times New Roman'"><span>1,000,000</span></span><span style="font-family: 'Times New Roman';"> shares of preferred stock, par value $</span><span style="-aw-sdt-tag:'c911e740c0eb8459e49a'; font-family: 'Times New Roman'"><span>0.0001</span></span><span style="font-family: 'Times New Roman';"> per share, of which </span><span style="-aw-sdt-tag:'c8d91dff0ef3b8a20008'; -aw-sdt-title:'Series A Designated Shares'; font-family: 'Times New Roman'"><span>80,965</span></span><span style="font-family: 'Times New Roman';"> have been designated as Series A Non-Voting Convertible Preferred Stock (&#8220;Series A Preferred Stock&#8221;). As of </span><span style="-aw-sdt-tag:'c34ccecbf9d8ef0f5dec'; -aw-sdt-title:'Current_Period_P29'; font-family: 'Times New Roman'"><span>September 30, 2025</span></span><span style="font-family: 'Times New Roman';">, </span><span style="-aw-sdt-tag:'cf2aa1a6a0c77e7c2fd3'; -aw-sdt-title:'Current Common Shares Outstanding'; font-family: 'Times New Roman'"><span>4,104,469</span></span><span style="font-family: 'Times New Roman';"> shares of Common Stock and </span><span style="-aw-sdt-tag:'ca0007fd29b564fc54fa'; -aw-sdt-title:'Current Series A Shares Outstanding'; font-family: 'Times New Roman'"><span>76,480</span></span><span style="font-family: 'Times New Roman';"> shares of Series A Preferred Stock are issued and outstanding.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">Following stockholder approval in November </span><span style="-aw-sdt-tag:'ce5446ee6a7ba063dc41'; font-family: 'Times New Roman'"><span>2024</span></span><span style="font-family: 'Times New Roman';">, on February </span><span style="-aw-sdt-tag:'c208cdf92af8907a4aa6'; font-family: 'Times New Roman'"><span>18</span></span><span style="font-family: 'Times New Roman';">, </span><span style="-aw-sdt-tag:'c37dc585619006d80d82'; font-family: 'Times New Roman'"><span>2025</span></span><span style="font-family: 'Times New Roman';">, the Company filed an additional Amendment to the Certificate of Incorporation with the Secretary of State of Delaware to effect the </span><span style="-aw-sdt-tag:'c81652786d96c9a5557d'; font-family: 'Times New Roman'"><span>1:5</span></span><span style="font-family: 'Times New Roman';"> Reverse Stock Split of the issued and outstanding shares of the Company&#8217;s common stock, which was effective as of February </span><span style="-aw-sdt-tag:'cb3826fdc552899bbbcd'; font-family: 'Times New Roman'"><span>24</span></span><span style="font-family: 'Times New Roman';">, </span><span style="-aw-sdt-tag:'cbb3cb20b9a2ea915ff9'; font-family: 'Times New Roman'"><span>2025</span></span><span style="font-family: 'Times New Roman';">. As of the effective time of the </span><span style="-aw-sdt-tag:'c0fc832f2594da84f996'; font-family: 'Times New Roman'"><span>1:5</span></span><span style="font-family: 'Times New Roman';"> Reverse Stock Split, every five (</span><span style="-aw-sdt-tag:'c5da0431da494b8ec1a4'; font-family: 'Times New Roman'"><span>5</span></span><span style="font-family: 'Times New Roman';">) issued and outstanding shares of the Company&#8217;s common stock were automatically combined and converted into one (</span><span style="-aw-sdt-tag:'c6f015b36370d0756173'; font-family: 'Times New Roman'"><span>1</span></span><span style="font-family: 'Times New Roman';">) issued and outstanding share of the Company&#8217;s common stock. </span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">No fractional shares of common stock were issued in connection with the Reverse Stock Splits. All fractional shares were rounded up to the nearest whole share with respect to outstanding shares of common stock. The Reverse Stock Splits did not change the authorized number of shares of common stock or preferred stock, the par value of the common stock, or the number of issued and outstanding shares of Series A Preferred Stock. All references to numbers of shares of the Company&#8217;s common stock and per share information in these consolidated condensed financial statements have been retroactively adjusted, as appropriate, to reflect the Reverse Stock Splits, including reclassifying an amount equal to the reduction in par value of common stock to additional paid-in capital.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; text-decoration:underline; font-family: 'Times New Roman'">Common Stock</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-style:italic; font-family: 'Times New Roman'">January </span><span style="-aw-sdt-tag:'c766051bc4fd2494d06a'; font-family: 'Times New Roman'"><span style="font-style:italic">2025</span></span><span style="font-style:italic; font-family: 'Times New Roman'"> Offering</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-style:italic; font-family: 'Times New Roman'">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">On January </span><span style="-aw-sdt-tag:'c4b9a9512956ad47ecaf'; font-family: 'Times New Roman'"><span>28</span></span><span style="font-family: 'Times New Roman';">, </span><span style="-aw-sdt-tag:'c6f16f1df2bab72eed3c'; font-family: 'Times New Roman'"><span>2025</span></span><span style="font-family: 'Times New Roman';">, the Company entered into a securities purchase agreement with certain institutional investors pursuant to which the Company sold, in a registered direct offering priced at-the-market under the rules of Nasdaq, an aggregate of </span><span style="-aw-sdt-tag:'34f-dfe-350-c12-0797'; -aw-sdt-title:'January 2025_Shares Sold'; font-family: 'Times New Roman'"><span>204,312</span></span><span style="font-family: 'Times New Roman';"> shares of common stock at a purchase price of $</span><span style="-aw-sdt-tag:'c1872eac4741b1175066'; font-family: 'Times New Roman'"><span>5.105</span></span><span style="font-family: 'Times New Roman';"> per share. The shares were offered pursuant to a &#8220;shelf&#8221; registration statement on Form S-</span><span style="-aw-sdt-tag:'cac83fd442a049f28577'; font-family: 'Times New Roman'"><span>3</span></span><span style="font-family: 'Times New Roman';"> (Registration No. </span><span style="-aw-sdt-tag:'c202eae5d68d3a899c77'; font-family: 'Times New Roman'"><span>333</span></span><span style="font-family: 'Times New Roman';">-</span><span style="-aw-sdt-tag:'c9a4b74ad6cb16c00e24'; font-family: 'Times New Roman'"><span>280796</span></span><span style="font-family: 'Times New Roman';">). In a concurrent private placement, the Company also issued to the investors unregistered warrants (the &#8220;January </span><span style="-aw-sdt-tag:'c0d7448c7d769ad24bc4'; font-family: 'Times New Roman'"><span>2025</span></span><span style="font-family: 'Times New Roman';"> Warrants&#8221;) to purchase up to an aggregate of </span><span style="-aw-sdt-tag:'c906142c107a5541bca4'; -aw-sdt-title:'January 2025 Common Warrants'; font-family: 'Times New Roman'"><span>408,621</span></span><span style="font-family: 'Times New Roman';"> shares of common stock at an exercise price of $</span><span style="-aw-sdt-tag:'c3c56402ae377ab0a7f9'; -aw-sdt-title:'January 2025 Common Warrants_Ex.Price'; font-family: 'Times New Roman'"><span>3.855</span></span><span style="font-family: 'Times New Roman';"> per share. The January </span><span style="-aw-sdt-tag:'cfa07e0e67817e897454'; font-family: 'Times New Roman'"><span>2025</span></span><span style="font-family: 'Times New Roman';"> Warrants are exercisable upon issuance, or January </span><span style="-aw-sdt-tag:'c7e84c25b2f65bdff56b'; font-family: 'Times New Roman'"><span>30</span></span><span style="font-family: 'Times New Roman';">, </span><span style="-aw-sdt-tag:'cce83998a76b653b7691'; font-family: 'Times New Roman'"><span>2025</span></span><span style="font-family: 'Times New Roman';">, and expire twenty-four months from the date of issuance, or January </span><span style="-aw-sdt-tag:'c57fd77fa1237d600805'; font-family: 'Times New Roman'"><span>30</span></span><span style="font-family: 'Times New Roman';">, </span><span style="-aw-sdt-tag:'c7aaa60fc0eec6a0fd8c'; font-family: 'Times New Roman'"><span>2027</span></span><span style="font-family: 'Times New Roman';">. The registered direct offering and concurrent private placement (together, the &#8220;January </span><span style="-aw-sdt-tag:'cd52d29afd3f5d2eccf7'; font-family: 'Times New Roman'"><span>2025</span></span><span style="font-family: 'Times New Roman';"> Offering&#8221;) closed on January </span><span style="-aw-sdt-tag:'c494798979cbe56b695a'; font-family: 'Times New Roman'"><span>30</span></span><span style="font-family: 'Times New Roman';">, </span><span style="-aw-sdt-tag:'c4016c0efa1198b21f27'; font-family: 'Times New Roman'"><span>2025</span></span><span style="font-family: 'Times New Roman';">, resulting in net proceeds to the Company of approximately $</span><span style="-aw-sdt-tag:'c580de3ddd57ac018e42'; font-family: 'Times New Roman'"><span>804,346</span></span><span style="font-family: 'Times New Roman';">, after deducting the placement agent fees and other offering expenses paid by the Company.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">As compensation for acting as the placement agent for the January </span><span style="-aw-sdt-tag:'cee7ccbe0d04fba82a6c'; font-family: 'Times New Roman'"><span>2025</span></span><span style="font-family: 'Times New Roman';"> Offering, in addition to certain cash fees, the Company issued H.C. Wainwright &amp; Co., LLC (the &#8220;Placement Agent&#8221;) warrants to purchase up to </span><span style="-aw-sdt-tag:'c0f8089b6089330b6b04'; -aw-sdt-title:'January 2025 Agent Warrants'; font-family: 'Times New Roman'"><span>15,325</span></span><span style="font-family: 'Times New Roman';"> shares of common stock at an exercise price of $</span><span style="-aw-sdt-tag:'c37edb8ca4f2c575ae63'; -aw-sdt-title:'January 2025 Agent Warrants_Ex.Price'; font-family: 'Times New Roman'"><span>6.382</span></span><span style="font-family: 'Times New Roman';"> (the &#8220;January </span><span style="-aw-sdt-tag:'cf18e7f7a6818d437bb7'; font-family: 'Times New Roman'"><span>2025</span></span><span style="font-family: 'Times New Roman';"> Agent Warrants&#8221;). The January </span><span style="-aw-sdt-tag:'c31825f688b0d9e23238'; font-family: 'Times New Roman'"><span>2025</span></span><span style="font-family: 'Times New Roman';"> Agent Warrants were exercisable upon issuance and expire twenty-four months from the date of issuance.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-style:italic; font-family: 'Times New Roman'">February </span><span style="-aw-sdt-tag:'c5b0aa4c07ace5151d7d'; font-family: 'Times New Roman'"><span style="font-style:italic">2025</span></span><span style="font-style:italic; font-family: 'Times New Roman'"> Offering</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-style:italic; font-family: 'Times New Roman'">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">On February </span><span style="-aw-sdt-tag:'c72b369793d8cb0663de'; font-family: 'Times New Roman'"><span>5</span></span><span style="font-family: 'Times New Roman';">, </span><span style="-aw-sdt-tag:'ccfae45335d3132329d8'; font-family: 'Times New Roman'"><span>2025</span></span><span style="font-family: 'Times New Roman';">, the Company entered into a securities purchase agreement with certain institutional investors pursuant to which the Company sold, in a registered direct offering priced at-the-market under the rules of Nasdaq, an aggregate of </span><span style="-aw-sdt-tag:'c7a47a1b4a61568a79ee'; font-family: 'Times New Roman'"><span>300,700</span></span><span style="font-family: 'Times New Roman';"> shares of the Company&#8217;s common stock at a purchase price of $</span><span style="-aw-sdt-tag:'cd40fa8984cf91955d65'; -aw-sdt-title:'February 2025_Purchase Price'; font-family: 'Times New Roman'"><span>3.575</span></span><span style="font-family: 'Times New Roman';"> per share. In a concurrent private placement, the Company separately issued to the investors unregistered warrants to purchase up to an aggregate of </span><span style="-aw-sdt-tag:'c70410176c474a809bb6'; -aw-sdt-title:'February 2025 Warrants'; font-family: 'Times New Roman'"><span>300,700</span></span><span style="font-family: 'Times New Roman';"> shares of common stock at an exercise price of $</span><span style="-aw-sdt-tag:'c9ab699f16e4535f6559'; -aw-sdt-title:'February 2025 Warrants_Ex.Price'; font-family: 'Times New Roman'"><span>2.95</span></span><span style="font-family: 'Times New Roman';"> per share (the &#8220;February </span><span style="-aw-sdt-tag:'ce612c83cf1f52410608'; font-family: 'Times New Roman'"><span>2025</span></span><span style="font-family: 'Times New Roman';"> Warrants&#8221;). The February </span><span style="-aw-sdt-tag:'c94c89dae7699225143d'; font-family: 'Times New Roman'"><span>2025</span></span><span style="font-family: 'Times New Roman';"> Warrants were immediately exercisable upon issuance and expire twenty-four months from the date of issuance. The registered direct offering and concurrent private placement (together, the &#8220;February </span><span style="-aw-sdt-tag:'cb9faf62303c5603f05f'; font-family: 'Times New Roman'"><span>2025</span></span><span style="font-family: 'Times New Roman';"> Offering&#8221;) closed on February </span><span style="-aw-sdt-tag:'cab9c9f59f2aa9bdd2ea'; font-family: 'Times New Roman'"><span>6</span></span><span style="font-family: 'Times New Roman';">, </span><span style="-aw-sdt-tag:'c02d9a9c7a98c7cb6b11'; font-family: 'Times New Roman'"><span>2025</span></span><span style="font-family: 'Times New Roman';">, resulting in net proceeds to the Company of approximately $</span><span style="-aw-sdt-tag:'cae17f4b26b5215dec57'; font-family: 'Times New Roman'"><span>908,627</span></span><span style="font-family: 'Times New Roman';">, after deducting the placement agent fees and other offering expenses paid by the Company.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">As compensation for acting as the placement agent for the February </span><span style="-aw-sdt-tag:'ca49d3c0f55aa58250b8'; font-family: 'Times New Roman'"><span>2025</span></span><span style="font-family: 'Times New Roman';"> Offering, in addition to certain cash fees, the Company issued the Placement Agent warrants to purchase up to </span><span style="-aw-sdt-tag:'cdaf4a5d62e024e6958a'; -aw-sdt-title:'February 2025 Agent Warrants'; font-family: 'Times New Roman'"><span>22,554</span></span><span style="font-family: 'Times New Roman';"> shares of common stock at an exercise price of $</span><span style="-aw-sdt-tag:'ca55514cbc775909ead5'; -aw-sdt-title:'February 2025 Agent Warrants_Ex.Price'; font-family: 'Times New Roman'"><span>4.469</span></span><span style="font-family: 'Times New Roman';"> (the &#8220;February </span><span style="-aw-sdt-tag:'c33357b171c6a2bbe58b'; font-family: 'Times New Roman'"><span>2025</span></span><span style="font-family: 'Times New Roman';"> Agent Warrants&#8221;). The February </span><span style="-aw-sdt-tag:'cb0e922589e5ea34bfd9'; font-family: 'Times New Roman'"><span>2025</span></span><span style="font-family: 'Times New Roman';"> Agent Warrants were exercisable upon issuance and expire twenty-four months from the date of issuance.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-style:italic; font-family: 'Times New Roman'">July 2025 Offering</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">On July 15, 2025, the Company entered into a securities purchase agreement with certain institutional investors pursuant to which the Company sold, in a registered direct offering (the &#8220;July 2025 Offering&#8221;), </span><span style="-aw-sdt-tag:'963-08e-7a4-81c-04b1'; -aw-sdt-title:'July 2025_Common Units'; font-family: 'Times New Roman'"><span>1,753,314</span></span><span style="font-family: 'Times New Roman';"> units at an offering price of $</span><span style="-aw-sdt-tag:'35d-504-224-bc2-70b0'; -aw-sdt-title:'July 2025_Common Units Price'; font-family: 'Times New Roman'"><span>1.90</span></span><span style="font-family: 'Times New Roman';"> per unit and </span><span style="-aw-sdt-tag:'0de-3a9-e49-e5f-bc0e'; -aw-sdt-title:'July 2025_Pre Funded Units'; font-family: 'Times New Roman'"><span>878,264</span></span><span style="font-family: 'Times New Roman';"> pre-funded units at an offering price of $</span><span style="-aw-sdt-tag:'31f-af2-e74-9f4-4be5'; -aw-sdt-title:'July 2025_Pre Funded Units Price'; font-family: 'Times New Roman'"><span>1.899</span></span><span style="font-family: 'Times New Roman';"> per pre-funded unit. Each unit consisted of (i) one share of common stock, (ii) one series A-1 warrant exercisable for one share of common stock (the &#8220;July 2025 A-1 Warrants&#8221;), and (iii) one series A-2 warrant exercisable for one share of common stock (the &#8220;July 2025 A-2 Warrants&#8221; and together with the July 2025 A-1 Warrants, the &#8220;July 2025 Warrants&#8221;). Each pre-funded unit consists of one pre-funded warrant exercisable for one share of common stock (the &#8220;July 2025 Pre-Funded Warrants&#8221;) and warrants identical to the July 2025 Warrants included in the units. The July 2025 Pre-Funded Warrants have an exercise price of $</span><span style="-aw-sdt-tag:'2e3-1e4-caf-c40-41a1'; -aw-sdt-title:'July 2025_Pre Funded Units Exercise Price'; font-family: 'Times New Roman'"><span>0.001</span></span><span style="font-family: 'Times New Roman';"> per share, and were immediately exercisable beginning on </span><span style="-aw-sdt-tag:'270-92e-ea6-8c6-95e7'; -aw-sdt-title:'July 2025_Pre Funded Units Issue Date'; font-family: 'Times New Roman'"><span>July 16, 2025</span></span><span style="font-family: 'Times New Roman';"> until exercised in full. The July 2025 A-1 Warrants have an exercise price of $</span><span style="-aw-sdt-tag:'85a-9a8-4d9-ee9-1793'; -aw-sdt-title:'July 2025_A-1 Exercise Price'; font-family: 'Times New Roman'"><span>1.90</span></span><span style="font-family: 'Times New Roman';"> per share and are exercisable beginning on </span><span style="-aw-sdt-tag:'745-2b8-404-908-2d8c'; -aw-sdt-title:'July 2025_A-1 Issue Date'; font-family: 'Times New Roman'"><span>July 16, 2025</span></span><span style="font-family: 'Times New Roman';"> until </span><span style="-aw-sdt-tag:'303-107-340-789-0138'; -aw-sdt-title:'July 2025_A-1 Expiry Date'; font-family: 'Times New Roman'"><span>July 15, 2030</span></span><span style="font-family: 'Times New Roman';">. The July 2025 A-2 Warrants have an exercise price of $</span><span style="-aw-sdt-tag:'7d7-395-569-007-7e21'; -aw-sdt-title:'July 2025_A-2 Exercise Price'; font-family: 'Times New Roman'"><span>1.90</span></span><span style="font-family: 'Times New Roman';"> per share and are exercisable beginning on </span><span style="-aw-sdt-tag:'926-d02-8ee-91c-294d'; -aw-sdt-title:'July 2025_A-2 Issue Date'; font-family: 'Times New Roman'"><span>July 16, 2025</span></span><span style="font-family: 'Times New Roman';"> until </span><span style="-aw-sdt-tag:'73a-95e-768-9a2-c4cc'; -aw-sdt-title:'July 2025_A-2 Expiry Date'; font-family: 'Times New Roman'"><span>January 15, 2027</span></span><span style="font-family: 'Times New Roman';">.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">As compensation for acting as the placement agent for the July 2025 Offering, the Company also issued to H.C. Wainwright &amp; Co., LLC warrants (the &#8220;July 2025 Placement Agent Warrants&#8221;) to purchase up to </span><span style="-aw-sdt-tag:'0b5-721-1f3-439-eaf1'; -aw-sdt-title:'July 2025 Placement Agent Warrants'; font-family: 'Times New Roman'"><span>197,368</span></span><span style="font-family: 'Times New Roman';"> shares of common stock. The July 2025 Placement Agent Warrants have an exercise price equal to $</span><span style="-aw-sdt-tag:'8d1-309-84e-2ab-e8ac'; -aw-sdt-title:'July 2025_Agent Warrants Exercise Price'; font-family: 'Times New Roman'"><span>2.375</span></span><span style="font-family: 'Times New Roman';"> per share and are exercisable upon issuance, or </span><span style="-aw-sdt-tag:'960-754-5c2-f81-ad5e'; -aw-sdt-title:'July 2025_Agent Warrants Issue Date'; font-family: 'Times New Roman'"><span>July 16, 2025</span></span><span style="font-family: 'Times New Roman';">, and expire </span><span style="-aw-sdt-tag:'295-24e-c09-37d-52db'; font-family: 'Times New Roman'"><span>five years</span></span><span style="font-family: 'Times New Roman';"> from the date of issuance, or </span><span style="-aw-sdt-tag:'663-3e7-37e-91f-6134'; -aw-sdt-title:'July 2025_Agent Warrants Expiry Date'; font-family: 'Times New Roman'"><span>July 15, 2030</span></span><span style="font-family: 'Times New Roman';">.</span><span style="-aw-import:spaces; font-family: 'Times New Roman'">&#160; </span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p><div style="-aw-sdt-tag:'PG_6327b60d7f0da94a'"></div><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">The July 2025 Offering was made pursuant to the Company&#8217;s registration statement on Form S-1 (File No. 333-288550), which was declared effective by the Securities and Exchange Commission (the &#8220;SEC&#8221;) on July 15, 2025, and the final prospectus, which was filed with the SEC on July 16, 2025. The Offering closed on July 16, 2025, resulting in net proceeds to the Company of approximately $</span><span style="-aw-sdt-tag:'1ea-cd6-103-d88-c43a'; -aw-sdt-title:'July 2025_Net Proceeds'; font-family: 'Times New Roman'"><span>4,281,300</span></span><span style="font-family: 'Times New Roman';">, after deducting placement agent fees and other offering expenses paid by the Company. </span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-style:italic; font-family: 'Times New Roman'">2025 ATM Agreement</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-import:spaces; font-family: 'Times New Roman'">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">On September 5, 2025, the Company entered into an At-The-Market Sales Agreement (the &#8220;2025 ATM Agreement&#8221;) with H.C. Wainwright &amp; Co., LLC (&#8220;Wainwright&#8221;) pursuant to which the Company may, from time to time, offer and sell shares of its common stock, having aggregate gross sales proceeds of up to $</span><span style="-aw-sdt-tag:'5e1-86e-ff2-592-8db0'; font-family: 'Times New Roman'"><span>1,397,532</span></span><span style="font-family: 'Times New Roman';"> (the &#8220;2025 ATM Offering&#8221;). As compensation for acting as the sales agent for the 2025 ATM Offering, Wainwright will be entitled to a commission of </span><span style="-aw-sdt-tag:'ec6-04e-04d-299-5b8e'; font-family: 'Times New Roman'"><span>3.0</span></span><span style="font-family: 'Times New Roman';">% of the gross proceeds from sales of shares in the 2025 ATM Offering. </span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">The common stock to be sold under the 2025 ATM Agreement, if any, will be issued and sold pursuant to the Company&#8217;s shelf registration statement on Form S-3 and accompanying base prospectus (Registration Statement No. 333-280796), which was declared effective by the SEC on July 18, 2024, and a prospectus supplement dated September 5, 2025 relating to the offer and sale of the shares pursuant to the 2025 ATM Agreement. As of </span><span style="-aw-sdt-tag:'1dd-95e-3f2-a00-31c0'; -aw-sdt-title:'Current_Period_P44'; font-family: 'Times New Roman'"><span>September 30, 2025</span></span><span style="font-family: 'Times New Roman';">, </span><span style="-aw-sdt-tag:'d31-fbf-141-727-882c'; font-family: 'Times New Roman'"><span>no</span></span><span style="font-family: 'Times New Roman';"> shares had been sold pursuant to the 2025 ATM Agreement. See Note 12 &#8211; Subsequent Events. </span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-style:italic; font-family: 'Times New Roman'">2024 ATM Offering</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-style:italic; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">On July 12, 2024, the Company entered into an At-the-Market Issuance Sales Agreement (the &#8220;2024 ATM Agreement&#8221;) with WallachBeth Capital LLC as sales agent, to sell shares of common stock having an aggregate offering price of up to $</span><span style="-aw-sdt-tag:'f78-d1a-df1-988-f9d9'; font-family: 'Times New Roman'"><span>1,253,603</span></span><span style="font-family: 'Times New Roman';"> from time to time, through an &#8220;at the market offering&#8221; program (the &#8220;2024 ATM Offering&#8221;). The offer and sale of shares of common stock from the ATM Offering were made pursuant to the Company&#8217;s shelf registration statement on Form S-3 and accompanying base prospectus (Registration Statement No. 333-280796) contained therein which became effective on July 18, 2024. The prospectus supplement was subsequently amended four times to increase the maximum aggregate offering price under the ATM Agreement. From July 19, 2024 to August 1, 2024, the Company sold a total of </span><span style="-aw-sdt-tag:'215-287-a05-1c1-a884'; font-family: 'Times New Roman'"><span>135,568</span></span><span style="font-family: 'Times New Roman';"> shares in the ATM Offering for gross proceeds of $</span><span style="-aw-sdt-tag:'596-827-921-65f-fb9d'; font-family: 'Times New Roman'"><span>1,994,583</span></span><span style="font-family: 'Times New Roman';">. </span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">On September 3, 2025, the Company and Wallachbeth Capital LLC entered into a Waiver and Termination Agreement, agreeing to terminate the 2024 ATM Agreement effective as of </span><span style="-aw-sdt-tag:'613-61b-e90-595-df3c'; font-family: 'Times New Roman'"><span>September 3, 2025</span></span><span style="font-family: 'Times New Roman';">.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-style:italic; font-family: 'Times New Roman'">Preferred Stock Conversions</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-style:italic; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">On July 22, 2024 and July 26, 2024, the Company converted </span><span style="-aw-sdt-tag:'ce3-ac4-d73-7d2-12d8'; font-family: 'Times New Roman'"><span>1,291</span></span><span style="font-family: 'Times New Roman';"> and </span><span style="-aw-sdt-tag:'9a0-00a-e5a-a76-32bc'; font-family: 'Times New Roman'"><span>1,032</span></span><span style="font-family: 'Times New Roman';"> shares of Series A Preferred Stock, respectively, held by Knight Therapeutics Inc. into </span><span style="-aw-sdt-tag:'93a-f5c-959-7bf-1e56'; font-family: 'Times New Roman'"><span>8,000</span></span><span style="font-family: 'Times New Roman';"> shares and </span><span style="-aw-sdt-tag:'562-eef-59d-7f7-d8f5'; font-family: 'Times New Roman'"><span>6,667</span></span><span style="font-family: 'Times New Roman';"> shares of common stock, respectively.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-style:italic; font-family: 'Times New Roman'">Warrant Exercises</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-style:italic; font-family: 'Times New Roman'">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">During the </span><span style="-aw-sdt-tag:'841-1ba-bd6-f3b-ce0b'; -aw-sdt-title:'Current_Quarter_P47'; font-family: 'Times New Roman'"><span>three months ended September 30, 2025</span></span><span style="font-family: 'Times New Roman';"> and </span><span style="-aw-sdt-tag:'91c-dae-554-39a-2bb2'; -aw-sdt-title:'Previous_Year_P51'; font-family: 'Times New Roman'"><span>2024</span></span><span style="font-family: 'Times New Roman';"> the Company issued </span><span style="-aw-sdt-tag:'645-280-92b-f86-2352'; -aw-sdt-title:'CQTD_Shares Issued for Warrant Exercises'; font-family: 'Times New Roman'"><span>878,264</span></span><span style="font-family: 'Times New Roman';"> and </span><span style="-aw-sdt-tag:'d79-532-1f1-c9c-9b2d'; font-family: 'Times New Roman'"><span>0</span></span><span style="font-family: 'Times New Roman';"> shares of common stock upon the exercise of </span><span style="-aw-sdt-tag:'7c5-227-e1d-0f7-eb4e'; -aw-sdt-title:'CQTD_Warrants Exercised'; font-family: 'Times New Roman'"><span>878,264</span></span><span style="font-family: 'Times New Roman';"> and </span><span style="-aw-sdt-tag:'67f-ac0-19d-0e1-1c4f'; font-family: 'Times New Roman'"><span>0</span></span><span style="font-family: 'Times New Roman';"> pre-funded warrants, respectively, resulting in proceeds to the Company of $</span><span style="-aw-sdt-tag:'2bc-7cc-b50-b2e-86ef'; -aw-sdt-title:'CQTD_Warrant Exercise Proceeds'; font-family: 'Times New Roman'"><span>878</span></span><span style="font-family: 'Times New Roman';"> and $</span><span style="-aw-sdt-tag:'adb-c80-e7b-bbe-6898'; font-family: 'Times New Roman'"><span>0</span></span><span style="font-family: 'Times New Roman';">, respectively. During the </span><span style="-aw-sdt-tag:'7e7-2e9-110-4e9-daa7'; -aw-sdt-title:'Current_YTD_P55'; font-family: 'Times New Roman'"><span>nine months ended September 30, 2025</span></span><span style="font-family: 'Times New Roman';"> and </span><span style="-aw-sdt-tag:'12b-9be-73b-065-6355'; -aw-sdt-title:'Previous_Year_P52'; font-family: 'Times New Roman'"><span>2024</span></span><span style="font-family: 'Times New Roman';"> the Company issued </span><span style="-aw-sdt-tag:'bd7-fd5-83b-da2-1fa0'; font-family: 'Times New Roman'"><span>1,263,464</span></span><span style="font-family: 'Times New Roman';"> and </span><span style="-aw-sdt-tag:'cf9c544cf94ba4b58a99'; -aw-sdt-title:'PYTD_CS issued for warrants'; font-family: 'Times New Roman'"><span>16,652</span></span><span style="font-family: 'Times New Roman';"> shares of common stock upon the exercise of </span><span style="-aw-sdt-tag:'0ba-275-7d5-d83-6d9c'; font-family: 'Times New Roman'"><span>1,263,464</span></span><span style="font-family: 'Times New Roman';"> and </span><span style="-aw-sdt-tag:'c38e9982b4c14bef4cf7'; -aw-sdt-title:'PYTD_PFW Exercises'; font-family: 'Times New Roman'"><span>16,652</span></span><span style="font-family: 'Times New Roman';"> pre-funded warrants, respectively, resulting in proceeds to the Company of $</span><span style="-aw-sdt-tag:'687-1b4-df6-4c3-39b0'; -aw-sdt-title:'CYTD_Warrant exercise proceeds'; font-family: 'Times New Roman'"><span>2,804</span></span><span style="font-family: 'Times New Roman';"> and $</span><span style="-aw-sdt-tag:'cb9d9b63f679ae3cb8e1'; -aw-sdt-title:'PYTD_Warrant exercise proceeds'; font-family: 'Times New Roman'"><span>9,990</span></span><span style="font-family: 'Times New Roman';">, respectively.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; text-decoration:underline; font-family: 'Times New Roman'">Common Stock Warrants</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">As of </span><span style="-aw-sdt-tag:'c97818c1951368fe0e26'; -aw-sdt-title:'Current_Period_P19'; font-family: 'Times New Roman'"><span>September 30, 2025</span></span><span style="font-family: 'Times New Roman';">, the Company accounts for all issued and outstanding warrants to purchase common stock as equity-classified instruments based on the guidance in ASC </span><span style="-aw-sdt-tag:'c0eabc92e2fa2c832655'; font-family: 'Times New Roman'"><span>480</span></span><span style="font-family: 'Times New Roman';"> and ASC </span><span style="-aw-sdt-tag:'c064d77ec2d1f973d46b'; font-family: 'Times New Roman'"><span>815</span></span><span style="font-family: 'Times New Roman';">.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">As compensation for acting as the placement agent for the Private Placement, the Company issued to H.C. Wainwright &amp; Co., LLC warrants to purchase up to </span><span style="-aw-sdt-tag:'cdf-796-b0c-6e9-ff08'; font-family: 'Times New Roman'"><span>43,479</span></span><span style="font-family: 'Times New Roman';"> shares of stock (the &#8220;September 2024 Agent Warrants&#8221;). The September 2024 Agent Warrants have substantially the same terms as the Series A Warrants, except that the September 2024 Agent Warrants have an exercise price equal to $</span><span style="-aw-sdt-tag:'398-324-697-f50-ef44'; font-family: 'Times New Roman'"><span>8.63</span></span><span style="font-family: 'Times New Roman';"> per share.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p><div style="-aw-sdt-tag:'PG_79108baa3f2dac7d'"></div><div style="-aw-sdt-tag:'0b9-32d-758-bbb-7d61'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">The following table presents a summary of the activity for the Company&#8217;s equity-classified warrants during the </span><span style="-aw-sdt-tag:'c564d7f6835302971ae2'; -aw-sdt-title:'Current_Quarter_and_YTD_P11'; font-family: 'Times New Roman'"><span>three and nine months ended September 30, 2025</span></span><span style="font-family: 'Times New Roman';">:</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><div style="-aw-sdt-tag:'c03fb2d1c9552e699f9f'; -aw-sdt-title:'STOCKHOLDERS EQUITY T1'"><table cellpadding="0" cellspacing="0" style="width:100%; border-collapse:collapse"><tbody><tr style="height:51pt"><td style="width:65.32%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1.02%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10.2%; border-bottom:1.5pt solid #000000; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_255042d0e6a541a388b409c03b69aa6a'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">Number of Warrants</span></p></div></td><td style="width:1.02%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="2" style="border-bottom:1.5pt solid #000000; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_1d3baab02d8c401b900003c44b2c7c3f'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">Weighted Average Exercise Price</span></p></div></td><td style="width:1.02%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10.2%; border-bottom:1.5pt solid #000000; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_d9d36dc13cae43cf8b651c83ff0751cb'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">Weighted Average Remaining Contractual Life (Years)</span></p></div></td></tr><tr style="height:12.75pt"><td style="width:65.32%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_0df67d8471e9467a89ff88e0439581e5'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Total outstanding, December 31, 2024</span><span style="font-size:6.67pt; vertical-align:super; font-family: 'Times New Roman'">(1)</span></p></div></td><td style="width:1.02%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10.2%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_cfd86fffd9a24a8681860699bbc5835a'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">1,765,070</span></p></div></td><td style="width:1.02%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1.02%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_018f691c6c554fcd9f2ea902cef36ea6'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10.2%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_401143ee48e043d3b3536cd6cdf9c432'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">17.59</span></p></div></td><td style="width:1.02%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10.2%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_b26821ca78ac44ef92c209c2bc9c966d'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">3.26</span></p></div></td></tr><tr style="height:12.75pt"><td style="width:65.32%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_56484066bcc74bf8b3793fd9b87e4059'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Granted</span></p></div></td><td style="width:1.02%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10.2%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_1e370c5c9b7142789405b4714e344dcf'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">747,200</span></p></div></td><td style="width:1.02%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1.02%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10.2%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_49bb5b90dc4242be96236f035345724d'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">3.56</span></p></div></td><td style="width:1.02%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10.2%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_a636cf72eae548238b35fe47161c70e0'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">2.00</span></p></div></td></tr><tr style="height:12.75pt"><td style="width:65.32%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_092740af605f4bc4a7ada8bdf5055958'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Exercised</span></p></div></td><td style="width:1.02%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10.2%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_be464264c8194207a861f4cab206040c'; font-family: 'Times New Roman'"><span>385,200</span></span><span style="font-family: 'Times New Roman';">)</span></p></td><td style="width:1.02%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1.02%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10.2%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_9014c8bd62e048859509a2426149ef61'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">0.01</span></p></div></td><td style="width:1.02%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10.2%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_99814e762c194b82bf77fe18e9120666'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:spaces; font-family: 'Times New Roman'">&#160;</span><span style="font-family: 'Times New Roman';">Indefinite </span></p></div></td></tr><tr style="height:12.75pt"><td style="width:65.32%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_96b027d191d3489eb4634d84c32b33bb'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Forfeited</span></p></div></td><td style="width:1.02%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10.2%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-tag:'C_ebc58888ed7e443eb0bed3fbb4e296cd'"><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:1.02%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1.02%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10.2%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-tag:'C_1cbf9c8fae99456bb1db09f419f10e3b'"><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:1.02%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10.2%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-tag:'C_023e956011684a2e8efc0a2c95e7aafa'"><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td></tr><tr style="height:12.75pt"><td style="width:65.32%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_3a9cd327c03648eabee6def9efeb8a16'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Expired</span></p></div></td><td style="width:1.02%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10.2%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-tag:'C_1b9506549baa4d28b730114acf607f9d'"><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:1.02%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1.02%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10.2%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-tag:'C_ceb7f15a6ff64d289ae12ddbd0b82690'"><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:1.02%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10.2%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-tag:'C_28fd827460b74eed914d939d69a18b99'"><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td></tr><tr style="height:8.4pt"><td style="width:65.32%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_940a2249f6b3409bbd4cf1fd3bfef304'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Total outstanding, March 31, 2025</span></p></div></td><td style="width:1.02%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10.2%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_dc623020fea849eba11ebc4bfb2db46b'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">2,127,070</span></p></div></td><td style="width:1.02%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1.02%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_4a782ea234b64abda040b2705b8054db'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10.2%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_6c6bbe87d4d04a50ba3802b29e13ca71'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">15.85</span></p></div></td><td style="width:1.02%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10.2%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_13fb13eaf08b49a2b57074280816ad0b'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">2.60</span></p></div></td></tr><tr style="height:12.75pt"><td style="width:65.32%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_ea5e3e245b884185986e713469cfdfa7'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Granted</span></p></div></td><td style="width:1.02%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10.2%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-tag:'C_57e1c8a9723f46f5b83a7dc55783fee9'"><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:1.02%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1.02%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10.2%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-tag:'C_243d18f890714f9fa13c4b72d28af692'"><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:1.02%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10.2%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-tag:'C_f31c5abd07e34d559789feb6be7b30a9'"><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td></tr><tr style="height:12.75pt"><td style="width:65.32%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_5f1d9b909eb24eac860bae5956db20ff'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Exercised</span></p></div></td><td style="width:1.02%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10.2%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-tag:'C_c4963ba6c9714c2b848973d90745bbe7'"><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:1.02%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1.02%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10.2%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-tag:'C_00ce71b2c5d1489abe5ef8882e6eb43b'"><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:1.02%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10.2%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-tag:'C_87370543a6f5422cb31f728fb2213f65'"><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td></tr><tr style="height:12.75pt"><td style="width:65.32%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_de6f15e3ec76429fb39fe3cc06dcd0b4'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Forfeited</span></p></div></td><td style="width:1.02%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10.2%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-tag:'C_1226676f1bf44f8197d4965d8019abfa'"><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:1.02%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1.02%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10.2%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-tag:'C_38dc8b6b23e14f2fb10ac0aab43b0957'"><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:1.02%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10.2%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-tag:'C_71849749deae49b1affc3ffaa76a7bf6'"><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td></tr><tr style="height:12.75pt"><td style="width:65.32%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_8cdb6926b5124838a53f846006ffe4d5'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Expired</span></p></div></td><td style="width:1.02%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10.2%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-tag:'C_85eba8ce16524c9c992ae58a76b43a52'"><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:1.02%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1.02%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10.2%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-tag:'C_3fa373d813a84ebaac3667eead34d3c5'"><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:1.02%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10.2%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-tag:'C_b9f06ff4ca7a45779ddab62a866d8364'"><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td></tr><tr style="height:13.5pt"><td style="width:65.32%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_c764316e0a5941d382adb9acefbbf02d'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Total outstanding, June 30, 2025</span></p></div></td><td style="width:1.02%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10.2%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_bd4af9854bee45f4a6e8551c9ffeab14'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">2,127,070</span></p></div></td><td style="width:1.02%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1.02%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_06b30492d24443dea9f922ac7c5991eb'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10.2%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_dd5b51e6504c4fe485896034c4ab5aaf'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">15.85</span></p></div></td><td style="width:1.02%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10.2%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_8c4c3f1235014bbd826251d11d481ada'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">2.10</span></p></div></td></tr><tr style="height:1.3pt"><td style="width:65.32%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_c64851bf815b4da8863747dd5755f707'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Granted</span><span style="font-size:6.67pt; vertical-align:super; font-family: 'Times New Roman'">(2)</span></p></div></td><td style="width:1.02%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10.2%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_807950b3ae924a2f975de95c2d052326'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">6,338,788</span></p></div></td><td style="width:1.02%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1.02%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10.2%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_4fd32df330bb4ce6a8e82401cf8bfee9'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">1.65</span></p></div></td><td style="width:1.02%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10.2%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_ed4130eba4504c2992f76b5ad495c647'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">3.31</span></p></div></td></tr><tr style="height:13.5pt"><td style="width:65.32%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_d9b5d3e46cf0480dbe71aa1b85fd2730'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Exercised</span></p></div></td><td style="width:1.02%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10.2%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_453fa426afc145e39bde490d351be1d5'; font-family: 'Times New Roman'"><span>878,264</span></span><span style="font-family: 'Times New Roman';">)</span></p></td><td style="width:1.02%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1.02%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10.2%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_b3cd337ad3c643b98646dee9eafdf4db'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">0.001</span></p></div></td><td style="width:1.02%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10.2%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_ebf6d0f4a79044b1a96cec392910afa3'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:spaces; font-family: 'Times New Roman'">&#160;</span><span style="font-family: 'Times New Roman';">Indefinite </span></p></div></td></tr><tr style="height:13.5pt"><td style="width:65.32%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_9941868f9f2b4eeb9ad1e9a0ec7731e5'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Forfeited</span></p></div></td><td style="width:1.02%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10.2%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-tag:'C_f6c86e35bf8044009a4b4a9ffa2be0b9'"><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:1.02%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1.02%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10.2%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-tag:'C_5120de4eb07c46d1a887d6f33993bd48'"><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:1.02%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10.2%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-tag:'C_d16cd40451854e3c9422892d316527ed'"><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td></tr><tr style="height:13.5pt"><td style="width:65.32%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_d493e9ce3b6e44bcb5f236c8e5cf90bc'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Expired</span></p></div></td><td style="width:1.02%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10.2%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-tag:'C_5eee2f2968084f68bd96a105a2a456ba'"><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:1.02%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1.02%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10.2%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-tag:'C_351547f4bdc341548bd95be3a56c990b'"><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:1.02%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10.2%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-tag:'C_e5c3e7a2d1ea48788874fe6f1aaa160e'"><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td></tr><tr style="height:13.5pt"><td style="width:65.32%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_a711a12f9677437590c66b5950b17bd5'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Total outstanding, September 30, 2025</span></p></div></td><td style="width:1.02%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10.2%; border-top:0.75pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#ffffff; -aw-border-top:0.5pt single"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_8ea7f7a4e1d24d429c6f06db22b55e6d'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">7,587,594</span></p></div></td><td style="width:1.02%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1.02%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_2d3b290467d343018ea51921f595758a'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10.2%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_7047b295f89941d1bdfff27a2c97d2f6'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">5.82</span></p></div></td><td style="width:1.02%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10.2%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_01e4caaff41844e1ae7feb1c2ae66d69'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">2.82</span></p></div></td></tr><tr style="height:13.5pt"><td style="width:65.32%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_d51b62342edd4404956c0bf1cb0b2079'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Total exercisable, September 30, 2025</span></p></div></td><td style="width:1.02%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10.2%; border-top:4.5pt double #000000; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_7b1ea82a944942ceb4546250d540a297'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">7,587,594</span></p></div></td><td style="width:1.02%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1.02%; border-top:4.5pt double #000000; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_f78db16daa4a48f09d41316116f43005'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10.2%; border-top:4.5pt double #000000; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_f6c5be1b8d51432b8279c89401af163b'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">5.82</span></p></div></td><td style="width:1.02%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10.2%; border-top:4.5pt double #000000; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_28a537d0722b41f7ba4474c4041f1592'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">2.82</span></p></div></td></tr></tbody></table></div><p style="margin-top:0pt; margin-bottom:0pt"><span style="-aw-import:ignore; font-family: 'Times New Roman';  font-size: 12pt;">&#160;</span></p><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td style="width:3.3%; vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; font-size:12.5pt"><span style="font-size:8.33pt; vertical-align:super; font-family: 'Times New Roman'">(1)</span></p></td><td style="width:96.7%; vertical-align:top"><div style="-aw-sdt-tag:'cc60b45585da36d079a6'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">Weighted average remaining contractual life at </span><span style="-aw-sdt-tag:'cb7acd8bf727a3348920'; -aw-sdt-title:'Previous_Year_End_P16'; font-family: 'Times New Roman'"><span>December 31, 2024</span></span><span style="font-family: 'Times New Roman';"> excludes </span><span style="-aw-sdt-tag:'c9eaac2b3a02e0ecbfed'; font-family: 'Times New Roman'"><span>385,200</span></span><span style="font-family: 'Times New Roman';"> Pre-Funded Warrants issued September </span><span style="-aw-sdt-tag:'c084844e24a211ebd242'; font-family: 'Times New Roman'"><span>2024</span></span><span style="font-family: 'Times New Roman';"> that do not have a contractual expiration date, for which </span><span style="-aw-sdt-tag:'c6c65c3f0bb7343724f4'; font-family: 'Times New Roman'"><span>0</span></span><span style="font-family: 'Times New Roman';"> warrants remain outstanding and exercisable at March 31, 2025, June 30, 2025 and </span><span style="-aw-sdt-tag:'c3f8bf32fba6f0a28902'; -aw-sdt-title:'Current_Period_P16'; font-family: 'Times New Roman'"><span>September 30, 2025</span></span><span style="font-family: 'Times New Roman';">.</span></p></div></td></tr></tbody></table><table cellpadding="0" cellspacing="0" style="width:100%; border-collapse:collapse"><tbody><tr><td style="width:3.3%; vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:12.5pt"><span style="font-size:8.33pt; vertical-align:super; font-family: 'Times New Roman'">(2)</span></p></td><td style="width:96.7%; vertical-align:top"><div style="-aw-sdt-tag:'4e2-557-131-530-ea28'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">Weighted average remaining contractual life excludes </span><span style="-aw-sdt-tag:'155-a3e-4e3-421-5e47'; font-family: 'Times New Roman'"><span>878,264</span></span><span style="font-family: 'Times New Roman';"> Pre-Funded Warrants issued July 2025 that do not have a contractual expiration date, for which </span><span style="-aw-sdt-tag:'cfe-9a0-ea6-43f-4379'; font-family: 'Times New Roman'"><span>0</span></span><span style="font-family: 'Times New Roman';"> warrants remain outstanding and exercisable at </span><span style="-aw-sdt-tag:'b56-24f-fd5-c1f-b53f'; -aw-sdt-title:'Current_Period_P43'; font-family: 'Times New Roman'"><span>September 30, 2025</span></span><span style="font-family: 'Times New Roman';">.</span></p></div></td></tr><tr><td style="width:3.3%; vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:5pt"><span style="font-size:3.33pt; vertical-align:super; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:96.7%; vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:5pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td></tr></tbody></table><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-import:spaces; font-family: 'Times New Roman'">&#160;</span></p><div style="-aw-sdt-tag:'PG_2924caba445ee74c'"></div></div><div style="-aw-sdt-tag:'0b9-32d-758-bbb-7d61'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">The following table presents a summary of the activity for the Company&#8217;s equity-classified warrants during the </span><span style="-aw-sdt-tag:'cb837e6a667bb2d8e81a'; -aw-sdt-title:'Previous_Quarter_and_YTD_P4'; font-family: 'Times New Roman'"><span>three and nine months ended September 30, 2024</span></span><span style="font-family: 'Times New Roman';">:</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p><div style="-aw-sdt-tag:'5ef-bd1-660-949-dac4'; -aw-sdt-title:'PYTD Warrant Activity Table'"><table cellpadding="0" cellspacing="0" style="width:100%; border-collapse:collapse"><tbody><tr style="height:66pt"><td style="width:66%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_2fe24833a44b41479778dfa15ea39d75'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">Number of Warrants</span></p></div></td><td style="width:1%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="2" style="border-bottom:1.5pt solid #000000; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_f18fecd537364a0f93431550cd6beb89'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">Weighted Average Exercise Price</span></p></div></td><td style="width:1%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_46e2237dbc934f6b9426112c9d46cff7'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">Weighted Average Remaining Contractual Life (Years)</span></p></div></td></tr><tr style="height:13.2pt"><td style="width:66%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_e3159a48c35a441588285bc5f08adbb5'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Total outstanding, December 31, 2023</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_26c6e8ba5c4f437b898bce96847ea990'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">52,737</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_7932e86b6155416a856e4b9e3135e6a0'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_1e1cfe2fee02428fb18bed385db26f5b'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">369.98</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_0fdf3faee9384a09b6fb1053d73cd117'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">4.47</span></p></div></td></tr><tr style="height:13.2pt"><td style="width:66%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_d2f19f5220f34a67a6cf0ad536ecceaf'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Granted</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_ca72a78fc17a4df2b8b050de41cb1fb2'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">140,884</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_03da05c614d4494ab5a425272003c87d'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">22.48</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_1e23442a8f184d09a6640f316b286c13'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">5.00</span></p></div></td></tr><tr style="height:13.2pt"><td style="width:66%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_5bc3ca100224454db31571d2f7b1902d'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Exercised</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_947713b195ad4820bbb30058fc78b8f8'; font-family: 'Times New Roman'"><span>8,326</span></span><span style="font-family: 'Times New Roman';">)</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_6653a7d365a745d882b7652b6ee003cf'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">0.60</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_d11cc3479bef4b49bb34a26fb81a3dab'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:spaces; font-family: 'Times New Roman'">&#160;</span><span style="font-family: 'Times New Roman';">Indefinite </span></p></div></td></tr><tr style="height:13.2pt"><td style="width:66%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_036865088ae34687ad76ec0118f6c13a'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Forfeited</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-tag:'C_0b98733a323540198451b82d59cb06fc'"><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-tag:'C_b095fd6b9be94bbc8c5bffe34783b7e9'"><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-tag:'C_62e43591234846379c4d980c1b569ce5'"><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td></tr><tr style="height:13.2pt"><td style="width:66%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_ed4f3a89e25f4188a6c83db8976197d5'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Expired</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-tag:'C_e3ce5466c2be49d1857c06466db44631'"><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-tag:'C_dfdbdd8338f8414d8f83aae99237906a'"><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-tag:'C_fe44fba7b4ea4e7aa0021a9bccd19da2'"><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td></tr><tr style="height:13.8pt"><td style="width:66%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_3d817872bae142abb1bdde9aec1609a3'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Total outstanding, March 31, 2024</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_c163a2b7f7f04b69b4d13a118cc458f9'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">185,295</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_2b8349367e4e49bd8341592d5d525a88'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_f13c7faf7831462aab2cb911bc2f0dd6'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">122.36</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_0005a1e335884fc7ac7b8d95109bce26'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">4.67</span></p></div></td></tr><tr style="height:13.8pt"><td style="width:66%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_dcc561ad8f5141e9ad4b5045a2890934'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Granted</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-tag:'C_88de1f197d034065b9cd32ef1dcd9706'"><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-tag:'C_f73d194d7c854624909dcf76b8ba5ce8'"><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-tag:'C_fb1a4c504f914dc289bb53a1b30080ae'"><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td></tr><tr style="height:13.2pt"><td style="width:66%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_a977d41b2c174189a08b961656853a60'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Exercised</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_79bdaacfa9994fb2b69b6344f572705f'; font-family: 'Times New Roman'"><span>8,326</span></span><span style="font-family: 'Times New Roman';">)</span></p></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_31638e6c276c4f2fa99250fcb9843150'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">0.60</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_f5cdcd321c28407aa89715dc54333513'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:spaces; font-family: 'Times New Roman'">&#160;</span><span style="font-family: 'Times New Roman';">Indefinite </span></p></div></td></tr><tr style="height:13.2pt"><td style="width:66%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_fa7dd320f8ff4aac96b933a7fbc11384'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Forfeited</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-tag:'C_110cf5dfc8bd4bc080a6b64cb16f3187'"><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-tag:'C_4a2d3439c11443f6b2da01418ec74397'"><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-tag:'C_0da9202225b040e19c3d69fa37a95f80'"><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td></tr><tr style="height:13.2pt"><td style="width:66%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_59813ff6f1844a788243218269af1e79'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Expired</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-tag:'C_9b5fd3e6aa1b4e4cb21d298ea65de0ea'"><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-tag:'C_f2ddee167a494c22b7bd797d8ae1c6c2'"><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-tag:'C_7a4c7af18d3f4f77813081f40c1d117a'"><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td></tr><tr style="height:13.8pt"><td style="width:66%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_a82321d8724e48d9a9d4e5fea605470a'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Total outstanding, June 30, 2024</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_2a6ee883b436439caf9659428ef1344a'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">176,969</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_aa95f7f315f940a2a5739ae21aafd495'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_dedfd6de48f64fde8de26755f4cdd4e4'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">128.09</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_79c28b5186b7430280974bffea1c6e69'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">4.41</span></p></div></td></tr><tr style="height:4.05pt"><td style="width:66%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_1e54e27571a64e8887f09b7346aff7c4'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Granted</span><span style="font-size:6.67pt; vertical-align:super; font-family: 'Times New Roman'">(1)</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_adfe2fb2d65545cba64b8094d9c2cc08'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">1,782,612</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_b0770c488b2d44c0b74d38914ce1a1f4'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">4.70</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-tag:'C_8a1c8815f35841ef9b2cf22465a70cbd'"><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td></tr><tr style="height:4.05pt"><td style="width:66%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_e4111cde5ebf4e2db2c6ef266cda76df'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Exercised</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-tag:'C_667abf06483d4e4aab4ecd254ca4fb4d'"><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-tag:'C_1b9a47ca596e4271804077a0fce457bd'"><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-tag:'C_c7fead391f1c4bedaf8cbd7c73bfcbf9'"><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td></tr><tr style="height:4.05pt"><td style="width:66%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_19cb9448efb54e7e898444eb0f2563a8'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Forfeited</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-tag:'C_60dcc17070434c6ab1cafb9462e1e3d6'"><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-tag:'C_ba07f171b24f486fa792b6c7c3444cc7'"><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-tag:'C_1e57ce7e25864bb89046552a08c0e3fc'"><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td></tr><tr style="height:4.05pt"><td style="width:66%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_350af71c0b4948a6a77dfcd4075ad433'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Expired</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-tag:'C_aedbe4e189824914abc8f3a4b2bda114'"><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-tag:'C_9d6d068f7ee644de9a393925a4cbfc15'"><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-tag:'C_bfabe0e863a542ac80153555a0367873'"><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td></tr><tr style="height:4.05pt"><td style="width:66%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_1de26c9af20040a29472d2ca9138d19f'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Total outstanding, September 30, 2024</span><span style="font-size:6.67pt; vertical-align:super; font-family: 'Times New Roman'">(1)</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_f4d9856e21884f16b54c37b835a9f33a'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">1,959,581</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_f8d0824dee194343b9daffd0ef500eda'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_2419a538771d4014a0aa04299e82b736'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">15.84</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_7ddd3f67b2d74622afae5bc4f4059994'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">4.16</span></p></div></td></tr><tr style="height:4.05pt"><td style="width:66%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_db4c1fd8ae924d69b46bdc6baf2841b1'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Total exercisable, September 30, 2024</span><span style="font-size:6.67pt; vertical-align:super; font-family: 'Times New Roman'">(2)</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:4.5pt double #000000; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_8f538a18dc5c4b0789915e07028c8a3b'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">756,680</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:4.5pt double #000000; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_b445e814ada34f288326ca954e930c27'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; border-top:4.5pt double #000000; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_e1118852385841f19496c5a949e0e0bb'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">29.96</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:4.5pt double #000000; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'a4f-f6d-3a4-587-6f95'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">4.16</span></p></div></td></tr></tbody></table></div><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p><table cellpadding="0" cellspacing="0" style="width:100%; border-collapse:collapse"><tbody><tr style="height:11.5pt"><td style="width:3.3%; vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; font-size:12.5pt"><span style="font-size:8.33pt; vertical-align:super; font-family: 'Times New Roman'">(1)</span></p></td><td style="width:96.7%; vertical-align:top"><div style="-aw-sdt-tag:'54e-de6-a74-b52-df70'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">Weighted average remaining contractual life calculations exclude (i) </span><span style="-aw-sdt-tag:'732-da0-de5-bf5-8dbb'; font-family: 'Times New Roman'"><span>579,711</span></span><span style="font-family: 'Times New Roman';"> Pre-Funded Warrants issued September 2024 that do not have a contractual expiration date, (ii) </span><span style="-aw-sdt-tag:'f2c-5f7-8bf-af8-594f'; font-family: 'Times New Roman'"><span>43,479</span></span><span style="font-family: 'Times New Roman';"> September 2024 Agent Warrants and </span><span style="-aw-sdt-tag:'e8a-7d2-dd0-c63-800f'; font-family: 'Times New Roman'"><span>579,711</span></span><span style="font-family: 'Times New Roman';"> Series A Warrants issued September 2024 that expire </span><span style="-aw-sdt-tag:'316-f81-d28-80c-a600'; font-family: 'Times New Roman'"><span>five years</span></span><span style="font-family: 'Times New Roman';"> from the Stockholder Approval Date, defined above, and (iii) </span><span style="-aw-sdt-tag:'051-85c-a14-d67-3f56'; font-family: 'Times New Roman'"><span>579,711</span></span><span style="font-family: 'Times New Roman';"> Series B Warrants issued September 2024 that expire </span><span style="-aw-sdt-tag:'5a3-db5-072-293-bc68'; font-family: 'Times New Roman'"><span>eighteen months</span></span><span style="font-family: 'Times New Roman';"> from the Stockholder Approval Date, which had not yet occurred as of September 30, 2024.</span></p></div></td></tr><tr style="height:11.5pt"><td style="width:3.3%; vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; font-size:12.5pt"><span style="font-size:8.33pt; vertical-align:super; font-family: 'Times New Roman'">(2)</span></p></td><td style="width:96.7%; vertical-align:top"><div style="-aw-sdt-tag:'f6b-c28-fc7-73a-bf3d'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">Weighted average remaining contractual life calculation excludes </span><span style="-aw-sdt-tag:'789-7d3-dde-216-e566'; font-family: 'Times New Roman'"><span>579,711</span></span><span style="font-family: 'Times New Roman';"> exercisable Pre-Funded Warrants issued September 2024 that do not have a contractual expiration date.</span></p></div></td></tr></tbody></table></div><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p><div style="-aw-sdt-tag:'PG_c093876e3a43e140a243'"></div><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; text-decoration:underline; font-family: 'Times New Roman'">Series A Preferred Stock</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">During the </span><span style="-aw-sdt-tag:'5c9-2a4-edd-9b2-9f2b'; -aw-sdt-title:'Current_Quarter_and_YTD_P14'; font-family: 'Times New Roman'"><span>three and nine months ended September 30, 2025</span></span><span style="font-family: 'Times New Roman';"> and </span><span style="-aw-sdt-tag:'30c-b61-ed7-5bc-836f'; -aw-sdt-title:'Previous_Year_P53'; font-family: 'Times New Roman'"><span>2024</span></span><span style="font-family: 'Times New Roman';">, the Company converted </span><span style="-aw-sdt-tag:'26e-8f7-c03-a34-5fdd'; font-family: 'Times New Roman'"><span>0</span></span><span style="font-family: 'Times New Roman';"> and </span><span style="-aw-sdt-tag:'c8c-9b4-436-87f-0fad'; -aw-sdt-title:'PY_Preferred Shares Converted'; font-family: 'Times New Roman'"><span>2,323</span></span><span style="font-family: 'Times New Roman';"> shares of Series A Preferred Stock, respectively, held by Knight Therapeutics Inc. into </span><span style="-aw-sdt-tag:'46f-111-ec1-a22-3bfa'; font-family: 'Times New Roman'"><span>0</span></span><span style="font-family: 'Times New Roman';"> shares and </span><span style="-aw-sdt-tag:'5d3-ac8-a1a-288-a527'; -aw-sdt-title:'PY_CS Issued for Preferred'; font-family: 'Times New Roman'"><span>14,667</span></span><span style="font-family: 'Times New Roman';"> shares of common stock, respectively.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">The holders of shares of Series A Preferred Stock have the rights, preferences, powers, restrictions, and limitations as set forth below.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-style:italic; font-family: 'Times New Roman'">Voting Rights</span><span style="font-family: 'Times New Roman';"> - The holders of shares of Series A Preferred Stock are not entitled to any voting rights.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-style:italic; font-family: 'Times New Roman'">Dividends</span><span style="font-family: 'Times New Roman';"> - From and after the date of issuance of any share of Series A Preferred Stock, cumulative dividends shall accrue, whether or not declared by the Board and whether or not there are funds legally available for the payment of dividends, on a daily basis in arrears at the rate of </span><span style="-aw-sdt-tag:'c892c80e3878c0cecf8e'; font-family: 'Times New Roman'"><span>6.0</span></span><span style="font-family: 'Times New Roman';">% per annum on the sum of the Liquidation Value (as defined below). Accrued dividends shall be paid in cash only when, as and if declared by the Board out of funds legally available therefor or upon a liquidation or redemption of the Series A Preferred Stock. On March 31 of each calendar year, any accrued and unpaid dividends shall accumulate and compound on such date, and are cumulative until paid or converted. Holders of shares of Series A Preferred Stock are entitled to receive accrued and accumulated dividends prior to and in preference to any dividend, distribution, or redemption on shares of Common Stock or any other class of securities that is designated as junior to the Series A Preferred Stock. During the </span><span style="-aw-sdt-tag:'cc911d4ba3e887d4a594'; -aw-sdt-title:'Current_Quarter_and_YTD_P12'; font-family: 'Times New Roman'"><span>three and nine months ended September 30, 2025</span></span><span style="font-family: 'Times New Roman';">, dividends in the amount of $</span><span style="-aw-sdt-tag:'c5d01b9ca1ecc7a2ced3'; -aw-sdt-title:'CQTD_Preferred Dividends Accrued'; font-family: 'Times New Roman'"><span>128,097</span></span><span style="font-family: 'Times New Roman';"> and $</span><span style="-aw-sdt-tag:'c4dc3d0e64763e414812'; -aw-sdt-title:'CYTD_Preferred Dividends Accrued'; font-family: 'Times New Roman'"><span>372,960</span></span><span style="font-family: 'Times New Roman';"> accrued on outstanding shares of Series A Preferred Stock ($</span><span style="-aw-sdt-tag:'cea75396bb906943a436'; -aw-sdt-title:'PQTD_Preferred Dividends Accrued'; font-family: 'Times New Roman'"><span>116,571</span></span><span style="font-family: 'Times New Roman';"> and $</span><span style="-aw-sdt-tag:'ca40e5f7b0254ff2f7e6'; -aw-sdt-title:'PYTD_Preferred Dividends Accrued'; font-family: 'Times New Roman'"><span>352,333</span></span><span style="font-family: 'Times New Roman';"> during the </span><span style="-aw-sdt-tag:'c3c0fdc97672faa58e7e'; -aw-sdt-title:'Previous_Quarter_and_YTD_P5'; font-family: 'Times New Roman'"><span>three and nine months ended September 30, 2024</span></span><span style="font-family: 'Times New Roman';">). As of </span><span style="-aw-sdt-tag:'c2299401c4c85264b52f'; -aw-sdt-title:'Current_Period_P18'; font-family: 'Times New Roman'"><span>September 30, 2025</span></span><span style="font-family: 'Times New Roman';">, cumulative dividends on outstanding shares of Series A Preferred Stock amount to $</span><span style="-aw-sdt-tag:'c813e72b0da56ce25468'; -aw-sdt-title:'Cumulative Preferred Dividends'; font-family: 'Times New Roman'"><span>1,076,975</span></span><span style="font-family: 'Times New Roman';">. To date, the Company has not declared or paid any dividends.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-style:italic; font-family: 'Times New Roman'">Liquidation Rights - </span><span style="font-family: 'Times New Roman';">In the event of any voluntary or involuntary liquidation, dissolution or winding up of the Company, the holders of shares of Series A Preferred Stock then outstanding will share ratably in any distribution of the remaining assets and funds of the Company with all other stockholders as if each share of Series A Preferred Stock had been converted by the Company to Common Stock as described below.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-style:italic; font-family: 'Times New Roman'">Conversion Rights </span><span style="font-family: 'Times New Roman';">- The Company has the right, in its sole discretion, to convert all or any portion of the outstanding shares of Series A Preferred Stock (including any fraction of a share), plus the aggregate accrued or accumulated and unpaid dividends thereon into a number of shares of Common Stock determined by (i) multiplying the number of shares to be converted by $</span><span style="-aw-sdt-tag:'c6021622cfc46b68553d'; font-family: 'Times New Roman'"><span>100</span></span><span style="font-family: 'Times New Roman';"> per share, as adjusted for any stock splits, stock dividends, recapitalizations or similar transactions with respect to the Series A Preferred Stock (but unchanged as a result of the Reverse Stock Splits impacting the common stock on August </span><span style="-aw-sdt-tag:'cf52d7caefe8194001c1'; font-family: 'Times New Roman'"><span>12</span></span><span style="font-family: 'Times New Roman';">, </span><span style="-aw-sdt-tag:'c75ba405cdf0dec60ee5'; font-family: 'Times New Roman'"><span>2024</span></span><span style="font-family: 'Times New Roman';"> and February </span><span style="-aw-sdt-tag:'cc9a608cfc1faa48bbb2'; font-family: 'Times New Roman'"><span>24</span></span><span style="font-family: 'Times New Roman';">, </span><span style="-aw-sdt-tag:'cad67accf5f2bbc138d0'; font-family: 'Times New Roman'"><span>2025</span></span><span style="font-family: 'Times New Roman';">) (the &#8220;Liquidation Value&#8221;), (ii) plus all accrued and accumulated and unpaid dividends on such shares to be converted, and then (ii) dividing the result by the then-effective Conversion Price in effect, provided that such conversion would not result in the holders of shares of Series A Preferred Stock owning more than </span><span style="-aw-sdt-tag:'c6205514cffce1e92bc3'; font-family: 'Times New Roman'"><span>19.9</span></span><span style="font-family: 'Times New Roman';">% of the outstanding shares of common stock on an as-converted basis. The &#8220;Conversion Price&#8221; is equal to the lesser of (a) the Liquidation Value, (b) the offering price per share of Common Stock in the Company&#8217;s IPO, </span><span style="-aw-sdt-tag:'fc2-007-c74-683-0eb3'; font-family: 'Times New Roman'"><span>as adjusted for the 1:12 Reverse Stock Split after August 12, 2024 and the 1:5 Reverse Stock Split after February 24, 2025</span></span><span style="font-family: 'Times New Roman';">, or $</span><span style="-aw-sdt-tag:'c941adacc45bab52df52'; font-family: 'Times New Roman'"><span>300</span></span><span style="font-family: 'Times New Roman';"> per share, or (c) the </span><span style="-aw-sdt-tag:'c0d54e0a97864e25394d'; font-family: 'Times New Roman'"><span>10</span></span><span style="font-family: 'Times New Roman';">-day volume weighted average price per share of Common Stock, as reasonably determined by the Company.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEBT<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>DEBT</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">DEBT</a></td>
<td class="text"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">7. DEBT</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">On May 14, 2020, the Company received COVID-19 EIDL lending from the U.S. Small Business Administration (SBA) in the amount of $</span><span style="-aw-sdt-tag:'c48cb4c9162d422015d4'; font-family: 'Times New Roman'"><span>150,000</span></span><span style="font-family: 'Times New Roman';">. The loan bears interest at an annual rate of </span><span style="-aw-sdt-tag:'c6f785f17e52ccfa7dc3'; font-family: 'Times New Roman'"><span>3.75</span></span><span style="font-family: 'Times New Roman';">% calculated on a monthly basis. Monthly payments of $</span><span style="-aw-sdt-tag:'ce8d5e1c3a4b0eab7645'; font-family: 'Times New Roman'"><span>731</span></span><span style="font-family: 'Times New Roman';"> were required beginning in November 2022, with a final balloon payment equal to the remaining principal due at the maturity date of </span><span style="-aw-sdt-tag:'cc3ad40f0dbc4577a481'; font-family: 'Times New Roman'"><span>October 12, 2050</span></span><span style="font-family: 'Times New Roman';">. The balance as of </span><span style="-aw-sdt-tag:'cd38c0f163fbd87499cc'; -aw-sdt-title:'Current_Period_P8'; font-family: 'Times New Roman'"><span>September 30, 2025</span></span><span style="font-family: 'Times New Roman';"> and </span><span style="-aw-sdt-tag:'c5acf3df8535129173ae'; -aw-sdt-title:'Previous_Year_End_P10'; font-family: 'Times New Roman'"><span>December 31, 2024</span></span><span style="font-family: 'Times New Roman';"> was $</span><span style="-aw-sdt-tag:'c87f7d68622df072b284'; -aw-sdt-title:'Total Maturity_CP'; font-family: 'Times New Roman'"><span>153,764</span></span><span style="font-family: 'Times New Roman';"> and $</span><span style="-aw-sdt-tag:'cc7ee715ff42ce67d2e4'; -aw-sdt-title:'Total Maturity_PY'; font-family: 'Times New Roman'"><span>155,891</span></span><span style="font-family: 'Times New Roman';">, respectively. The current maturity at </span><span style="-aw-sdt-tag:'c5a0ccdcf213162f587b'; -aw-sdt-title:'Current_Period_P9'; font-family: 'Times New Roman'"><span>September 30, 2025</span></span><span style="font-family: 'Times New Roman';"> is $</span><span style="-aw-sdt-tag:'ce635aff7ad263800b94'; -aw-sdt-title:'Current maturity of SBA loan_CP'; font-family: 'Times New Roman'"><span>8,772</span></span><span style="font-family: 'Times New Roman';"> and the long-term liability is $</span><span style="-aw-sdt-tag:'cfdb6cde5a192d0a563f'; -aw-sdt-title:'Long-term maturity of SBA loan_CP'; font-family: 'Times New Roman'"><span>144,992</span></span><span style="font-family: 'Times New Roman';"> ($</span><span style="-aw-sdt-tag:'ce15e0c8eedcfdb512e2'; -aw-sdt-title:'Current maturity of SBA loan_PY'; font-family: 'Times New Roman'"><span>8,772</span></span><span style="font-family: 'Times New Roman';"> and $</span><span style="-aw-sdt-tag:'c6ea72e7c7e452607500'; -aw-sdt-title:'Long-term maturity of SBA loan_PY'; font-family: 'Times New Roman'"><span>147,119</span></span><span style="font-family: 'Times New Roman';"> at </span><span style="-aw-sdt-tag:'ce2f78b521ed062187e6'; -aw-sdt-title:'Previous_Year_End_P11'; font-family: 'Times New Roman'"><span>December 31, 2024</span></span><span style="font-family: 'Times New Roman';">, respectively). The loan is collateralized by all tangible and intangible personal property of the Company. The Company is prohibited from accepting future advances under any superior liens on the collateral without the prior consent of SBA.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p><div style="-aw-sdt-tag:'PG_c57a1a7c3051a319b430'"></div><div style="-aw-sdt-tag:'cd9aa1ed7e4867c19560'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">The current future payment obligations of the principal are as follows:</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><div style="-aw-sdt-tag:'c317e04dae973ecfbe43'; -aw-sdt-title:'DEBT T1'"><table cellpadding="0" cellspacing="0" style="width:100%; border-collapse:collapse"><tbody><tr style="height:11.5pt"><td style="width:88%; border-bottom:1.5pt solid #000000; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_5c968b0016b149cfb1f12fa47b1bca41'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">Period</span></p></div></td><td style="width:1%; padding-bottom:1.75pt; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="2" style="border-bottom:1.5pt solid #000000; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_5c764bbf41d64098a324b0fa0eee9c97'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">Principal Payments</span></p></div></td></tr><tr style="height:11.5pt"><td style="width:88%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_0bb61a42b37543a7b09da928c987f7ac'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">2025 (remaining three months)</span></p></div></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_ed70aeb871a64cbcae4e1e638cd44d8c'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-tag:'C_9cc5803ea7e44342b95a83be6a937207'"><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td></tr><tr style="height:11.5pt"><td style="width:88%; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_897e8cb5c5764f54bf36adbea961583d'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">2026</span></p></div></td><td style="width:1%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p></td><td style="width:1%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p></td><td style="width:10%; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_11851a9e806d4f58b44ce574ad2a99ae'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">465</span></p></div></td></tr><tr style="height:11.5pt"><td style="width:88%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_bd218f23a8534654beb35d354f005013'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">2027</span></p></div></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p></td><td style="width:10%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_9e76a127fe434806b75dd7251717545a'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">3,220</span></p></div></td></tr><tr style="height:11.5pt"><td style="width:88%; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_5f57e987c26c48cb8368c698d86412c7'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">2028</span></p></div></td><td style="width:1%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p></td><td style="width:1%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p></td><td style="width:10%; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_a641af32d4f142d4896d4e72026bfbf6'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">3,333</span></p></div></td></tr><tr style="height:11.5pt"><td style="width:88%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_39e1010cfe6e4fc0b5e28f5cfced0432'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">2029</span></p></div></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p></td><td style="width:10%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_b3e786a7693a420dbcb23ba7b9111b35'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">3,470</span></p></div></td></tr><tr style="height:11.5pt"><td style="width:88%; padding-bottom:1.75pt; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_61dc3ec600314411bf83aaf42b0afb2c'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Thereafter</span></p></div></td><td style="width:1%; padding-bottom:1.75pt; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_d9ea3ec1cd2f4f809bcc21cdbccf2901'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">139,512</span></p></div></td></tr><tr style="height:11.5pt"><td style="width:88%; padding-bottom:4.25pt; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_5b82b081b0cd4cd7810fcd446de801b1'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">Total</span></p></div></td><td style="width:1%; padding-bottom:4.25pt; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_0749ec546c48465eb63ec47c309b1dfa'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">$</span></p></div></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_cfd83dce046d4d62badcc6025377dc63'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">150,000</span></p></div></td></tr></tbody></table></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/470/tableOfContent<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DERIVATIVE LIABILITIES<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>DERIVATIVE LIABILITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock', window );">DERIVATIVE LIABILITIES</a></td>
<td class="text"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">8. DERIVATIVE LIABILITIES</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">In accordance with the provisions of ASC 815, derivative liabilities are initially measured at fair value at the commitment date and subsequently remeasured at each reporting period, with any increase or decrease in the fair value recorded in the results of operations within other income/expense as the change in fair value of derivative liabilities.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">As of </span><span style="-aw-sdt-tag:'c5350c81469bdad05f66'; -aw-sdt-title:'Current_Period_P3'; font-family: 'Times New Roman'"><span>September 30, 2025</span></span><span style="font-family: 'Times New Roman';"> and </span><span style="-aw-sdt-tag:'cc24fc16174c59980f1b'; -aw-sdt-title:'Previous_Year_End_P5'; font-family: 'Times New Roman'"><span>December 31, 2024</span></span><span style="font-family: 'Times New Roman';">, derivative liabilities consist of the contingent milestone payment due to Knight Therapeutics, Inc. (&#8220;Knight&#8221;), a former lender of the Company, as required by the Debt Conversion Agreement executed between the Company and Knight on January 9, 2023, as subsequently amended (the &#8220;Knight Debt Conversion Agreement&#8221;). Key points of this agreement were as follows:</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td style="width:18pt; vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:18pt; vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">&#9679;</span></p></td><td style="vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">The Parties agreed to fix Knight&#8217;s cumulative debt to the value as it stood on March 31, 2022, which consisted of</span><span style="font-family: 'Times New Roman';">&#160;</span><span style="font-family: 'Times New Roman';">principal and accumulated interest. As a result of the completion of the IPO, the cumulative outstanding principal as of March 31, 2022 converted to </span><span style="-aw-sdt-tag:'fae-f38-9d2-e8b-9372'; font-family: 'Times New Roman'"><span>18,473</span></span><span style="font-family: 'Times New Roman';"> shares of common stock (representing </span><span style="-aw-sdt-tag:'c9be0aef95d1594431cf'; font-family: 'Times New Roman'"><span>19.9</span></span><span style="font-family: 'Times New Roman';">% ownership of the Company&#8217;s common stock after giving effect to the IPO), and the entirety of the accumulated interest as of March 31, 2022 converted into </span><span style="-aw-sdt-tag:'b9a-c0f-a3d-679-5200'; font-family: 'Times New Roman'"><span>80,965</span></span><span style="font-family: 'Times New Roman';"> shares of Series A Preferred Stock, in full satisfaction of the Company&#8217;s obligations with respect to the outstanding principal and accumulated interest.</span></p></td></tr></tbody></table><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span><span style="font-family: 'Times New Roman';">&#160;</span></p><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td style="width:18pt; vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:18pt; vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">&#9679;</span></p></td><td style="vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">The Parties agreed that the Company will make a milestone payment of $</span><span style="-aw-sdt-tag:'327-c72-933-ea9-2221'; font-family: 'Times New Roman'"><span>10</span></span><span style="font-family: 'Times New Roman';"> million to Knight if, after the IPO, the Company sells Arakoda&#8482; or if a Change of Control (as per the definition included in the original loan agreement dated on December 10, 2015) occurs, provided that the purchaser of Arakoda&#8482; or individual or entity gaining control of the Borrower is not the Lender or an affiliate of the Lender.</span></p></td></tr></tbody></table><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td style="width:18pt; vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:18pt; vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">&#9679;</span></p></td><td style="vertical-align:top"><div style="-aw-sdt-tag:'675-b6d-46f-99f-ad14'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">For the period ending upon the earlier of (i) </span><span style="-aw-sdt-tag:'550-977-3ca-73c-4910'; font-family: 'Times New Roman'"><span>10 years</span></span><span style="font-family: 'Times New Roman';"> after the closing of the IPO, or (ii) the conversion or redemption in full of the Series A Preferred Stock, the Company will pay to Knight a royalty equal to </span><span style="-aw-sdt-tag:'c0b4d8ca01f4210c3db8'; font-family: 'Times New Roman'"><span>3.5</span></span><span style="font-family: 'Times New Roman';">% of the Company&#8217;s net sales (the &#8220;Royalty&#8221;) on a quarterly basis, where &#8220;Net Sales&#8221; has the same meaning as in the Company&#8217;s license agreement with the U.S. Army for tafenoquine.</span></p></div></td></tr></tbody></table><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">Upon consummation of the IPO, the Company concluded that the contingent milestone payment is a freestanding financial instrument that meets the definition of a derivative under ASC 815, and accordingly, the fair value of the derivative liability is marked to market each reporting period until settled. The Royalty due to Knight was determined to be an embedded component of the Series A Preferred Stock, however, is exempt from derivative accounting under the ASC 815 scope exception for specified volumes of sales or service revenues. Therefore, the Company accrues a royalty expense as sales are made.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">The valuation of the contingent milestone payment includes significant unobservable inputs such as the timing and probability of discrete potential exit scenarios, forward interest rate curves, and discount rates based on implied and market yields.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><div style="-aw-sdt-tag:'c06f707a4f647dbf011d'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">A reconciliation of the beginning and ending balances for the derivative liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) is as follows for the </span><span style="-aw-sdt-tag:'ca75fd2c5ebfac9ccdc1'; -aw-sdt-title:'Current_Quarter_and_YTD_P7'; font-family: 'Times New Roman'"><span>three and nine months ended September 30, 2025</span></span><span style="font-family: 'Times New Roman';">:</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p><div style="-aw-sdt-tag:'c6639d815e653fadd5ae'; -aw-sdt-title:'DERIVATIVE LIABILITIES T1'"><table cellpadding="0" cellspacing="0" style="width:100%; border-collapse:collapse"><tbody><tr style="height:11.5pt"><td style="width:88%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1.14%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="2" style="border-bottom:1.5pt solid #000000; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_fd577863c4914b8ea632e84e6f1d9eec'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">Contingent Milestone Payment</span></p></div></td></tr><tr style="height:11.5pt"><td style="width:88%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_ff0051b243e64116bbf90efbe05a88e3'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Derivative</span><span style="font-family: 'Times New Roman';">&#160;</span><span style="font-family: 'Times New Roman';">liabilities - December 31, 2024</span></p></div></td><td style="width:1.14%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_ef378dbe0e17475fa21c77879bdff28f'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_c7aae7bfd1584e14a5a3a5d58fab1fd6'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">640,830</span></p></div></td></tr><tr style="height:11.5pt"><td style="width:88%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_4377246d44bb4cfc863de19c989a5202'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Change in fair value</span></p></div></td><td style="width:1.14%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_c327358aecad485cba82f75897b00fec'; font-family: 'Times New Roman'"><span>5,105</span></span><span style="font-family: 'Times New Roman';">)</span></p></td></tr><tr style="height:11.5pt"><td style="width:88%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_5a97f90a3edd45afa8a36844a79b2ea4'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Derivative</span><span style="font-family: 'Times New Roman';">&#160;</span><span style="font-family: 'Times New Roman';">liabilities - March 31, 2025</span></p></div></td><td style="width:1.14%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_9f633fdc6b9242d381ac51540e4153ee'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">635,725</span></p></div></td></tr><tr style="height:11.5pt"><td style="width:88%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_078e4af6f8af42d295052694ed2c2427'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Change in fair value</span></p></div></td><td style="width:1.14%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_23198fd411e74a64b8eeef85300e3dcf'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">140,447</span></p></div></td></tr><tr style="height:11.5pt"><td style="width:88%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_9462c6e0577448ed88294c1d0aae294c'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Derivative</span><span style="font-family: 'Times New Roman';">&#160;</span><span style="font-family: 'Times New Roman';">liabilities - June 30, 2025</span></p></div></td><td style="width:1.14%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_a0832472ffb74935b23fb706f1e8f50b'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">776,172</span></p></div></td></tr><tr style="height:11.5pt"><td style="width:88%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_2150e1d56b154f04bf9d302078fa6006'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Change in fair value</span></p></div></td><td style="width:1.14%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_ae80a322a7494033b888a0b4927f3dcd'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">21,103</span></p></div></td></tr><tr style="height:11.5pt"><td style="width:88%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_adfe59ed6a5b4ce1ad247b7d83b2b16e'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Derivative</span><span style="font-family: 'Times New Roman';">&#160;</span><span style="font-family: 'Times New Roman';">liabilities - September 30, 2025</span></p></div></td><td style="width:1.14%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_fc90d64ea50e4c308d229a9c947721a7'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_8c7042f142d54906ae51e9d2fb2300b4'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">797,275</span></p></div></td></tr></tbody></table></div><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p><div style="-aw-sdt-tag:'PG_c50ece2c23a2dc4329b4'"></div></div><div style="-aw-sdt-tag:'c06f707a4f647dbf011d'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">A reconciliation of the beginning and ending balances for the derivative liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) is as follows for the </span><span style="-aw-sdt-tag:'cd848d58778f479d6fa9'; -aw-sdt-title:'Previous_Quarter_and_YTD_P3'; font-family: 'Times New Roman'"><span>three and nine months ended September 30, 2024</span></span><span style="font-family: 'Times New Roman';">:</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><table cellpadding="0" cellspacing="0" style="width:100%; border-collapse:collapse"><tbody><tr style="height:11.5pt"><td style="width:88%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1.14%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="2" style="border-bottom:1.5pt solid #000000; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_9b7bbdd2b0ad450593bb39fcb5204a2d'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">Contingent Milestone Payment</span></p></div></td></tr><tr style="height:11.5pt"><td style="width:88%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_349fc0c506ae466a8afcdbfdf7eb138c'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Derivative</span><span style="font-family: 'Times New Roman';">&#160;</span><span style="font-family: 'Times New Roman';">liabilities - December 31, 2023</span></p></div></td><td style="width:1.14%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_e6028efd12ee4fa482ca3e0bf101af8e'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_7ab6157566fd406ba29b6922a10b9ec9'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">2,306,796</span></p></div></td></tr><tr style="height:11.5pt"><td style="width:88%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_c6bf1ed06ead4adf9f2296394e5d94fe'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Change in fair value</span></p></div></td><td style="width:1.14%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_fd1f212ea84445ea8753de1b222fe7fa'; font-family: 'Times New Roman'"><span>1,740,847</span></span><span style="font-family: 'Times New Roman';">)</span></p></td></tr><tr style="height:11.5pt"><td style="width:88%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_ebba7a73ac5447149cff86376061747e'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Derivative</span><span style="font-family: 'Times New Roman';">&#160;</span><span style="font-family: 'Times New Roman';">liabilities - March 31, 2024</span></p></div></td><td style="width:1.14%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_6c58f57330b54183b08d956ee1ecbd60'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">565,949</span></p></div></td></tr><tr style="height:11.5pt"><td style="width:88%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_a251d932ed0f4f349433c36d59e8d1c5'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Change in fair value</span></p></div></td><td style="width:1.14%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_f59f8bc8d656446584c1334e2dc483b9'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">1,101</span></p></div></td></tr><tr style="height:11.5pt"><td style="width:88%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_a2f0ff1379314111b76e648c5de945d5'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Derivative</span><span style="font-family: 'Times New Roman';">&#160;</span><span style="font-family: 'Times New Roman';">liabilities - June 30, 2024</span></p></div></td><td style="width:1.14%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_2dbbcbe08cd646c49d4ad4090192625e'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">567,050</span></p></div></td></tr><tr style="height:11.5pt"><td style="width:88%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_97ca7a3e4491452f85dadb11644bd7ed'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Change in fair value</span></p></div></td><td style="width:1.14%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_b81e163c70f24c44b27596e3b6f00f4d'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">56,712</span></p></div></td></tr><tr style="height:11.5pt"><td style="width:88%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_2d719b55a9614add8a41b0e7dc9bd875'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Derivative</span><span style="font-family: 'Times New Roman';">&#160;</span><span style="font-family: 'Times New Roman';">liabilities - September 30, 2024</span></p></div></td><td style="width:1.14%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_28189adff441454eb8ae6052808da967'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_1e958d79d6f442799205fed39a546989'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">623,762</span></p></div></td></tr></tbody></table></div><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">Changes in the fair value of derivative liabilities are included in </span><span style="-aw-sdt-tag:'336-1f6-b4d-7ae-89fc'; -aw-sdt-title:'Other_income_(expense)_P1'; font-family: 'Times New Roman'"><span>other income (expense)</span></span><span style="font-family: 'Times New Roman';"> in the accompanying consolidated condensed statements of operations and comprehensive loss. During the </span><span style="-aw-sdt-tag:'c7a870c15245e746541a'; -aw-sdt-title:'Current_YTD_P10'; font-family: 'Times New Roman'"><span>nine months ended September 30, 2025</span></span><span style="font-family: 'Times New Roman';"> and </span><span style="-aw-sdt-tag:'c515be331bb8d4793eb8'; -aw-sdt-title:'Previous_Year_P12'; font-family: 'Times New Roman'"><span>2024</span></span><span style="font-family: 'Times New Roman';">, the Company recorded a net (loss) gain on the change in the fair value of derivative liabilities of ($</span><span style="-aw-sdt-tag:'c77e4e2e8d34f16dd511'; -aw-sdt-title:'CYTD_Change in FV Derivatives'; font-family: 'Times New Roman'"><span>156,445</span></span><span style="font-family: 'Times New Roman';">) and $</span><span style="-aw-sdt-tag:'c93e5c070ddcafae864d'; -aw-sdt-title:'PYTD_Change in FV Derivatives'; font-family: 'Times New Roman'"><span>1,683,034</span></span><span style="font-family: 'Times New Roman';">, respectively.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 182<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480401/815-10-55-182<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 185<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480401/815-10-55-185<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 184<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480401/815-10-55-184<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 181<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480401/815-10-55-181<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4K<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4K<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4K<br> -Subparagraph (a)(5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4K<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4K<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4K<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4K<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4K<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4K<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4K<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4H<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4H<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4H<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4H<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 15<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480960/815-15-50-3<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 183<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480401/815-10-55-183<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4K<br> -Subparagraph (a)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4K<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4K<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4K<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4K<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4K<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4I<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4I<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4F<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4F<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/815/tableOfContent<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-5<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-5C<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>INCOME TAXES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES</a></td>
<td class="text"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">9. INCOME TAXES</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">The Company did not record a federal income tax provision or benefit for the </span><span style="-aw-sdt-tag:'cd80ebf44dd4a49459a3'; -aw-sdt-title:'Current_Quarter_and_YTD_P8'; font-family: 'Times New Roman'"><span>three and nine months ended September 30, 2025</span></span><span style="font-family: 'Times New Roman';"> and </span><span style="-aw-sdt-tag:'ca9a1d3291cee7dfe7d3'; -aw-sdt-title:'Previous_Year_P22'; font-family: 'Times New Roman'"><span>2024</span></span><span style="font-family: 'Times New Roman';"> due to taxable losses. The Company recorded a provision for income taxes for the District of Columbia of $</span><span style="-aw-sdt-tag:'908-1ae-370-c57-56fb'; font-family: 'Times New Roman'"><span>250</span></span><span style="font-family: 'Times New Roman';">&#160;</span><span style="font-family: 'Times New Roman';">and $</span><span style="-aw-sdt-tag:'6f4-8fe-bb5-dd0-f075'; font-family: 'Times New Roman'"><span>250</span></span><span style="font-family: 'Times New Roman';">&#160;</span><span style="font-family: 'Times New Roman';">for the </span><span style="-aw-sdt-tag:'24f-910-caa-173-01a4'; -aw-sdt-title:'Current_Quarter_P45'; font-family: 'Times New Roman'"><span>three months ended September 30, 2025</span></span><span style="font-family: 'Times New Roman';"> and </span><span style="-aw-sdt-tag:'1e7-2ec-a39-80f-df36'; -aw-sdt-title:'Previous_Year_P48'; font-family: 'Times New Roman'"><span>2024</span></span><span style="font-family: 'Times New Roman';">, respectively, thereby reflecting the minimum statutory tax due ($</span><span style="-aw-sdt-tag:'02d-fa8-465-f09-3ba2'; -aw-sdt-title:'DC_Taxes_CY_YTD'; font-family: 'Times New Roman'"><span>1,813</span></span><span style="font-family: 'Times New Roman';">&#160;</span><span style="font-family: 'Times New Roman';">and $</span><span style="-aw-sdt-tag:'d32-f75-fc1-36a-e6f0'; font-family: 'Times New Roman'"><span>751</span></span><span style="font-family: 'Times New Roman';">&#160;</span><span style="font-family: 'Times New Roman';">for the </span><span style="-aw-sdt-tag:'65b-b80-259-dec-ff1c'; -aw-sdt-title:'Current_YTD_P54'; font-family: 'Times New Roman'"><span>nine months ended September 30, 2025</span></span><span style="font-family: 'Times New Roman';"> and </span><span style="-aw-sdt-tag:'679-3d3-4cd-809-ad81'; -aw-sdt-title:'Previous_Year_P49'; font-family: 'Times New Roman'"><span>2024</span></span><span style="font-family: 'Times New Roman';">, respectively). </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 740<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477617/942-740-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 740<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478822/944-740-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE-BASED COMPENSATION<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>SHARE-BASED COMPENSATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">SHARE-BASED COMPENSATION</a></td>
<td class="text"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">10. SHARE-BASED COMPENSATION</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><div style="-aw-sdt-tag:'c037fface987eb1f9566'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">The following is a summary of share-based compensation expenses reported in the </span><span style="-aw-sdt-tag:'928-fd0-43f-33f-a583'; -aw-sdt-title:'PandL_title_P1'; font-family: 'Times New Roman'"><span>consolidated condensed statements of operations and comprehensive loss</span></span><span style="font-family: 'Times New Roman';"> for the </span><span style="-aw-sdt-tag:'ce72a01889339805360e'; -aw-sdt-title:'Current_Quarter_and_YTD_P1'; font-family: 'Times New Roman'"><span>three and nine months ended September 30, 2025</span></span><span style="font-family: 'Times New Roman';"> and </span><span style="-aw-sdt-tag:'cb6dccf48217e97e781f'; -aw-sdt-title:'Previous_Year_P14'; font-family: 'Times New Roman'"><span>2024</span></span><span style="font-family: 'Times New Roman';">:</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><div style="-aw-sdt-tag:'c13275b5451f7f9fa78e'; -aw-sdt-title:'SHARE-BASED COMPENSATION T1'"><table cellpadding="0" cellspacing="0" style="width:100%; border-collapse:collapse"><tbody><tr style="height:11.5pt"><td style="width:52%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="5" style="border-bottom:1.5pt solid #000000; padding-right:3.6pt; padding-left:3.6pt; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_b793b7deaa5f4e1d950f54932847ec4e'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">For the Three Months Ended September 30,</span></p></div></td><td style="width:1%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="5" style="border-bottom:1.5pt solid #000000; padding-left:11.5pt; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_537410e7812d486a9a1750abab377793'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">For the Nine Months Ended September 30,</span></p></div></td></tr><tr style="height:11.5pt"><td style="width:52%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="2" style="border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_1c65bd1b721f4fdbb0598ff8d89de949'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">2025</span></p></div></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="2" style="border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_e80ebe59c55b4da093ced29e2c908199'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">2024</span></p></div></td><td style="width:1%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="2" style="border-bottom:1.5pt solid #000000; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_91ed7e22685d417984396bafa04be366'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">2025</span></p></div></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="2" style="border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_df669bbe060d4fb4868590c39a9103dd'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">2024</span></p></div></td></tr><tr style="height:11.5pt"><td style="width:52%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_1f65a7c0fbbf45a68b9646858ce371ce'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Research and Development</span></p></div></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_23d3849a725541999e62bbfea44aac84'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-tag:'C_11384fc8b65f4d7db353787823d55423'"><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_025187fdcd654094abb16118f061da90'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_2b22ee8f24c54fa896add2668695efcb'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">600,000</span></p></div></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_b4c10c58c0314c169080c9c8b8fcbf8e'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-tag:'C_a08e3c8a4c6f4085aa8a9d31befcd057'"><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_78842318fd574561a2884382a7738a2b'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_35eff82596e143da87976fe2e081d8ab'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">3,227,300</span></p></div></td></tr><tr style="height:11.5pt"><td style="width:52%; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_61c64308dfc6458ea1fbb4a8c7b703f2'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">General and Administrative Expenses</span></p></div></td><td style="width:1%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_ddd5fe7024e34d6d8b4886992b4b418e'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">79,000</span></p></div></td><td style="width:1%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_b1923603f0314dcc9f9dff054d6a03da'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">68,974</span></p></div></td><td style="width:1%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_be2f81c4d0954142a92c2d69272f7316'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">344,383</span></p></div></td><td style="width:1%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_62aa8b68d8d0491db7039e6b80dd5e0e'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">319,709</span></p></div></td></tr><tr style="height:11.5pt"><td style="width:52%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_bfa6fe246dec48e885d05f0057213748'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Total Share-Based Compensation Expense Included in Operating Expenses</span></p></div></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_f745775470c94315af299adf55367ded'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_74b13f97c0cf48dab5e62d86746dd071'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">79,000</span></p></div></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_f2f730e985d34774bbed0f63d2691b9d'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_40018e5c15e74eda9b9f7804866b0d19'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">668,974</span></p></div></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_6d7a61fde61344dc8721193a9a15d53c'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_04eded1abc4d4ad9aef27f111b48a590'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">344,383</span></p></div></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_9c2d8eda549747ef9ba345afb4170af9'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'761-c75-0e8-f8a-eee2'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">3,547,009</span></p></div></td></tr></tbody></table></div></div><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; text-decoration:underline; font-family: 'Times New Roman'">Share-Based Compensation under </span><span style="-aw-sdt-tag:'c2cce9b34b4cce207dc3'; font-family: 'Times New Roman'"><span style="font-weight:bold; text-decoration:underline">2022</span></span><span style="font-weight:bold; text-decoration:underline; font-family: 'Times New Roman'"> Equity Incentive Plan</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">On November </span><span style="-aw-sdt-tag:'ce33ff49852d9b6cc9af'; font-family: 'Times New Roman'"><span>22</span></span><span style="font-family: 'Times New Roman';">, </span><span style="-aw-sdt-tag:'cd04e73f864219172e17'; font-family: 'Times New Roman'"><span>2022</span></span><span style="font-family: 'Times New Roman';">, the Company adopted the </span><span style="-aw-sdt-tag:'cc81a70adfa65fd8fe85'; font-family: 'Times New Roman'"><span>2022</span></span><span style="font-family: 'Times New Roman';"> Equity Incentive Plan (the &#8220;</span><span style="-aw-sdt-tag:'c84237e68151d396e260'; font-family: 'Times New Roman'"><span>2022</span></span><span style="font-family: 'Times New Roman';"> Plan&#8221;), which provides for the grant of stock options, stock appreciation rights, restricted stock, restricted stock units and performance awards to eligible employees, directors and consultants, to be granted from time to time by the Board of Directors of the Company. To date, the Company has granted shares of common stock, restricted stock units, stock options to employees, non-employees, and directors under the </span><span style="-aw-sdt-tag:'c6469f80875469d8dcaa'; font-family: 'Times New Roman'"><span>2022</span></span><span style="font-family: 'Times New Roman';"> Plan. As of </span><span style="-aw-sdt-tag:'c119f5f4ee3e094a8aad'; -aw-sdt-title:'Current_Period_P17'; font-family: 'Times New Roman'"><span>September 30, 2025</span></span><span style="font-family: 'Times New Roman';">, the number of remaining shares available for issuance under the 2022 Plan is equal to </span><span style="-aw-sdt-tag:'c0d4a4d9d67084ea6d66'; -aw-sdt-title:'2022 Plan _Shares Available for Issuance'; font-family: 'Times New Roman'"><span>57,068</span></span><span style="font-family: 'Times New Roman';">.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-style:italic; font-family: 'Times New Roman'">Stock Options</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-style:italic; font-family: 'Times New Roman'">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">The Company grants stock options to employees, non-employees, and directors with exercise prices equal to the closing price of the underlying shares of the Company&#8217;s common stock on the Nasdaq Capital Market on the date that the options are granted. Options granted generally have a </span><span style="-aw-sdt-tag:'e63-273-caa-f00-1383'; font-family: 'Times New Roman'"><span>term of five to ten years</span></span><span style="font-family: 'Times New Roman';"> from the grant date and are subject to vesting as determined in the individual award agreement. The Company estimates the fair value of stock options on the grant date by applying the Black-Scholes option pricing valuation model.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><div style="-aw-sdt-tag:'PG_ccc01229426adb7fbfee'"></div><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">There were </span><span style="-aw-sdt-tag:'5f1-2bf-683-a23-2ca7'; font-family: 'Times New Roman'"><span>no</span></span><span style="font-family: 'Times New Roman';"> stock options granted during the </span><span style="-aw-sdt-tag:'9f5-d6b-c4e-520-d6a5'; -aw-sdt-title:'Current_Quarter_P46'; font-family: 'Times New Roman'"><span>three months ended September 30, 2025</span></span><span style="font-family: 'Times New Roman';">. During the </span><span style="-aw-sdt-tag:'918-ef8-5a7-218-1704'; -aw-sdt-title:'Current_YTD_P53'; font-family: 'Times New Roman'"><span>nine months ended September 30, 2025</span></span><span style="font-family: 'Times New Roman';">, the Company granted a total of </span><span style="-aw-sdt-tag:'cc4f82113885d00917ff'; -aw-sdt-title:'CYTD_Stock Options Granted'; font-family: 'Times New Roman'"><span>120,000</span></span><span style="font-family: 'Times New Roman';"> stock options to </span><span style="-aw-sdt-tag:'2e4-092-32a-f6f-c96e'; font-family: 'Times New Roman'"><span>two</span></span><span style="font-family: 'Times New Roman';"> executives at a per share exercise price of $</span><span style="-aw-sdt-tag:'c8fe171f9f46a4304c75'; -aw-sdt-title:'CYTD_Stock Options Ex.Price'; font-family: 'Times New Roman'"><span>6.55</span></span><span style="font-family: 'Times New Roman';">. These options are subject to vesting annually in five equal tranches, with the first </span><span style="-aw-sdt-tag:'cbd22998573814036f2e'; font-family: 'Times New Roman'"><span>20</span></span><span style="font-family: 'Times New Roman';">% tranche fully vested on the date of grant and thereafter, vest on the last date of each fiscal year beginning December 31, 2025. The weighted average grant date fair value of options granted during the </span><span style="-aw-sdt-tag:'c6aa6012cf7103ba2a01'; -aw-sdt-title:'Current_YTD_P2'; font-family: 'Times New Roman'"><span>nine months ended September 30, 2025</span></span><span style="font-family: 'Times New Roman';"> was $</span><span style="-aw-sdt-tag:'c2ff4eac22c6343b6acb'; -aw-sdt-title:'CYTD_Stock Options WA Grant Date FV'; font-family: 'Times New Roman'"><span>4.55</span></span><span style="font-family: 'Times New Roman';">. </span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">During the </span><span style="-aw-sdt-tag:'0e2-2b6-e25-ec0-511e'; -aw-sdt-title:'Previous_Quarter_and_YTD_P6'; font-family: 'Times New Roman'"><span>three and nine months ended September 30, 2024</span></span><span style="font-family: 'Times New Roman';">, Company granted a total of </span><span style="-aw-sdt-tag:'844-d69-61d-665-d9fe'; -aw-sdt-title:'PYTD_Stock Options Granted'; font-family: 'Times New Roman'"><span>17,005</span></span><span style="font-family: 'Times New Roman';"> stock options at a weighted average per share exercise price of $</span><span style="-aw-sdt-tag:'266-3e1-8af-307-25b7'; -aw-sdt-title:'PYTD_Stock Options_Avg Ex Price'; font-family: 'Times New Roman'"><span>54.62</span></span><span style="font-family: 'Times New Roman';">. The weighted average grant date fair value of options granted during the </span><span style="-aw-sdt-tag:'27d-ea8-614-ca9-2785'; -aw-sdt-title:'Previous_Quarter_and_YTD_P9'; font-family: 'Times New Roman'"><span>three and nine months ended September 30, 2024</span></span><span style="font-family: 'Times New Roman';"> was $</span><span style="-aw-sdt-tag:'4bf-904-a4c-ccb-354e'; -aw-sdt-title:'PYTD_Options Granted_Avg. Grant Date Fair Value'; font-family: 'Times New Roman'"><span>8.78</span></span><span style="font-family: 'Times New Roman';">.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><div style="-aw-sdt-tag:'2b8-829-358-045-27fb'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">The following table summarizes the significant assumptions used in determining the fair value of options granted during the </span><span style="-aw-sdt-tag:'cb926b1bec8a5c9d7e88'; -aw-sdt-title:'Current_Quarter_and_YTD_P3'; font-family: 'Times New Roman'"><span>three and nine months ended September 30, 2025</span></span><span style="font-family: 'Times New Roman';"> and </span><span style="-aw-sdt-tag:'c208469c38a8aafffc4c'; -aw-sdt-title:'Previous_Year_P15'; font-family: 'Times New Roman'"><span>2024</span></span><span style="font-family: 'Times New Roman';">:</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p><div style="-aw-sdt-tag:'c6b82afc388c401d9e30'; -aw-sdt-title:'SBC Table FMV Assumptions'"><table cellpadding="0" cellspacing="0" style="width:100%; border-collapse:collapse"><tbody><tr style="height:11.5pt"><td style="width:53%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="5" style="border-bottom:1.5pt solid #000000; padding-right:3.6pt; padding-left:3.6pt; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_371d5f2bfb054b0e8460d09bb59858a9'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">For the Three Months Ended September 30,</span></p></div></td><td style="width:0.86%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="5" style="border-bottom:1.5pt solid #000000; padding-left:18.7pt; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_e2d4b0f5404c484680abbbec2fbb1cd5'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">For the Nine Months Ended September 30,</span></p></div></td></tr><tr style="height:11.5pt"><td style="width:53%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="2" style="border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_58cd0c9841254a3dac116deef4bcbc41'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">2025</span></p></div></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="2" style="border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_78c64d6266234af3b75e0972a6752883'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">2024</span></p></div></td><td style="width:0.86%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="2" style="border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_4b5707f7e1f340fabeba896192704cbf'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">2025</span></p></div></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="2" style="border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_c0b54a2289c946b5b7a0a1ca7a79bae1'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">2024</span></p></div></td></tr><tr style="height:11.5pt"><td style="width:53%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_bdbe21d861f54e598b6c2ebeaf8c95fe'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Weighted-average grant date fair value</span></p></div></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_7890dccaab874e7d92cb7b0e72fc317f'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_22b11df71f0d47098e6e2bded099c637'"><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:spaces; font-family: 'Times New Roman'">&#160;</span><span style="font-family: 'Times New Roman';">N/A </span></p></div></td><td style="width:1%; padding-right:1.45pt; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_0a2dcde2664d42579b74f707d6505d93'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_37a0df27750945fc9b6899c1a6a047ca'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">8.78</span></p></div></td><td style="width:0.86%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_f54f277a21d94c4cacdd010927e3433e'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_61461e1150e24180814adbbea8f0035f'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">4.55</span></p></div></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_7ea73308c7384caa83280f67a66a433e'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_2e5e3ada99254986ae82736208308e85'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">8.78</span></p></div></td></tr><tr style="height:11.5pt"><td style="width:53%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_a86fcbd02d504a77b42500289cd5f9c5'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Risk-free interest rate</span></p></div></td><td style="width:1%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_422b919e53604b4d9b01e6a4ff8ae470'"><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:spaces; font-family: 'Times New Roman'">&#160;</span><span style="font-family: 'Times New Roman';">N/A </span></p></div></td><td style="width:1%; padding-right:1.45pt; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-sdt-tag:'5c3-4af-63f-0a8-8170'; font-family: 'Times New Roman'"><span>3.62</span></span><span style="font-family: 'Times New Roman';">% - </span><span style="-aw-sdt-tag:'f97-3e4-a51-d60-5557'; font-family: 'Times New Roman'"><span>4.17</span></span><span style="font-family: 'Times New Roman';">%</span></p></td><td style="width:0.86%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-sdt-tag:'C_a0a8c0c2864a4afbb105903f2b68b28b'; font-family: 'Times New Roman'"><span>4.36</span></span><span style="font-family: 'Times New Roman';">%</span></p></td><td style="width:1%; padding-right:1.45pt; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-sdt-tag:'30e-490-8f8-814-d30e'; font-family: 'Times New Roman'"><span>3.62</span></span><span style="font-family: 'Times New Roman';">% - </span><span style="-aw-sdt-tag:'ee3-181-3dc-e8f-312d'; font-family: 'Times New Roman'"><span>4.17</span></span><span style="font-family: 'Times New Roman';">%</span></p></td></tr><tr style="height:11.5pt"><td style="width:53%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_5fe58341b1494de19749b138fb5378ee'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Expected volatility</span></p></div></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_0c331ee129f64ed1b9fa50dc73136fcd'"><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:spaces; font-family: 'Times New Roman'">&#160;</span><span style="font-family: 'Times New Roman';">N/A </span></p></div></td><td style="width:1%; padding-right:1.45pt; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-sdt-tag:'bda-6e1-a52-5f0-7b06'; font-family: 'Times New Roman'"><span>86.00</span></span><span style="font-family: 'Times New Roman';">% - </span><span style="-aw-sdt-tag:'07d-67f-348-6f7-ba1e'; font-family: 'Times New Roman'"><span>87.00</span></span><span style="font-family: 'Times New Roman';">%</span></p></td><td style="width:0.86%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-sdt-tag:'C_3c6e0737f3d74b34934c2901d877dee2'; font-family: 'Times New Roman'"><span>90.00</span></span><span style="font-family: 'Times New Roman';">%</span></p></td><td style="width:1%; padding-right:1.45pt; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-sdt-tag:'64f-7fb-a1f-61b-8c23'; font-family: 'Times New Roman'"><span>86.00</span></span><span style="font-family: 'Times New Roman';">% - </span><span style="-aw-sdt-tag:'163-d0d-e3e-4ea-7923'; font-family: 'Times New Roman'"><span>87.00</span></span><span style="font-family: 'Times New Roman';">%</span></p></td></tr><tr style="height:11.5pt"><td style="width:53%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_f98e805c00b14edb84da40ce6346c721'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Expected term (years)</span></p></div></td><td style="width:1%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_e4b5461f1a1746da98b836b10b7a794a'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:spaces; font-family: 'Times New Roman'">&#160;</span><span style="font-family: 'Times New Roman';">N/A </span></p></div></td><td style="width:1%; padding-right:1.45pt; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-sdt-tag:'9fd-a7d-dce-aee-b8d3'; font-family: 'Times New Roman'"><span>6.41</span></span><span style="font-family: 'Times New Roman';"> - </span><span style="-aw-sdt-tag:'922-43a-fd5-af0-7c6d'; font-family: 'Times New Roman'"><span>10.00</span></span></p></td><td style="width:0.86%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_67fa179582ea40ab85e70f2d97a7168b'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">4.50</span></p></div></td><td style="width:1%; padding-right:1.45pt; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-sdt-tag:'39b-8fc-eba-917-6b4f'; font-family: 'Times New Roman'"><span>6.41</span></span><span style="font-family: 'Times New Roman';"> - </span><span style="-aw-sdt-tag:'c62-ee5-3a2-e98-0fdf'; font-family: 'Times New Roman'"><span>10.00</span></span></p></td></tr><tr style="height:11.5pt"><td style="width:53%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_04267cb0abf54990bdf4b71fb0d4b3f1'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Expected dividend yield</span></p></div></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_3310313796d64fcca52c3a9e78c2bec2'"><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:spaces; font-family: 'Times New Roman'">&#160;</span><span style="font-family: 'Times New Roman';">N/A </span></p></div></td><td style="width:1%; padding-right:1.45pt; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-sdt-tag:'C_d9ef82eb21d54263b8ca618d8d975456'; font-family: 'Times New Roman'"><span>0.00</span></span><span style="font-family: 'Times New Roman';">%</span></p></td><td style="width:0.86%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-sdt-tag:'C_555c1c1a0720497ba6cdc1357d20b8ce'; font-family: 'Times New Roman'"><span>0.00</span></span><span style="font-family: 'Times New Roman';">%</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-sdt-tag:'bd0-9dc-c14-a77-e224'; font-family: 'Times New Roman'"><span>0.00</span></span><span style="font-family: 'Times New Roman';">%</span></p></td></tr></tbody></table></div></div><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">For the </span><span style="-aw-sdt-tag:'e0c-27a-82f-8b3-9fea'; -aw-sdt-title:'Current_Quarter_P50'; font-family: 'Times New Roman'"><span>three months ended September 30, 2025</span></span><span style="font-family: 'Times New Roman';"> and </span><span style="-aw-sdt-tag:'88b-dd6-6a9-1fd-8fb5'; -aw-sdt-title:'Previous_Year_P56'; font-family: 'Times New Roman'"><span>2024</span></span><span style="font-family: 'Times New Roman';">, the Company recognized $</span><span style="-aw-sdt-tag:'cfbc46a1a35c78396973'; -aw-sdt-title:'Option Expense CQ'; font-family: 'Times New Roman'"><span>34,882</span></span><span style="font-family: 'Times New Roman';"> and $</span><span style="-aw-sdt-tag:'49b-c31-e1c-ca4-3665'; -aw-sdt-title:'Option Expense PQ'; font-family: 'Times New Roman'"><span>15,246</span></span><span style="font-family: 'Times New Roman';"> of compensation expense related to stock option awards, respectively ($</span><span style="-aw-sdt-tag:'04d-477-46c-4d6-fb29'; -aw-sdt-title:'Option Expenses CYTD'; font-family: 'Times New Roman'"><span>212,030</span></span><span style="font-family: 'Times New Roman';"> and $</span><span style="-aw-sdt-tag:'b15-7a6-d2f-027-2572'; -aw-sdt-title:'Option Expense PYTD'; font-family: 'Times New Roman'"><span>15,246</span></span><span style="font-family: 'Times New Roman';"> for the </span><span style="-aw-sdt-tag:'d56-222-98b-71d-4fce'; -aw-sdt-title:'Current_YTD_P58'; font-family: 'Times New Roman'"><span>nine months ended September 30, 2025</span></span><span style="font-family: 'Times New Roman';"> and </span><span style="-aw-sdt-tag:'147-551-d96-263-b55d'; -aw-sdt-title:'Previous_Year_P57'; font-family: 'Times New Roman'"><span>2024</span></span><span style="font-family: 'Times New Roman';">, respectively). </span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-style:italic; font-family: 'Times New Roman'">Restricted Stock Units</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-style:italic; font-family: 'Times New Roman'">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">Compensation cost for service-based RSUs is based on the grant date fair value of the award, which is the closing market price of the Company&#8217;s common stock on the grant date multiplied by the number of shares awarded.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">During the </span><span style="-aw-sdt-tag:'c8156768d3ede0db34bd'; -aw-sdt-title:'Current_Quarter_and_YTD_P5'; font-family: 'Times New Roman'"><span>three and nine months ended September 30, 2025</span></span><span style="font-family: 'Times New Roman';"> and </span><span style="-aw-sdt-tag:'cf953a8ed1d8c57cfe06'; -aw-sdt-title:'Previous_Year_P16'; font-family: 'Times New Roman'"><span>2024</span></span><span style="font-family: 'Times New Roman';">, </span><span style="-aw-sdt-tag:'c2d498a80f581c1e21a0'; font-family: 'Times New Roman'"><span>0</span></span><span style="font-family: 'Times New Roman';"> shares of common stock underlying RSUs vested and </span><span style="-aw-sdt-tag:'f83-1f3-cda-5bd-ab74'; font-family: 'Times New Roman'"><span>no</span></span><span style="font-family: 'Times New Roman';"> RSUs were granted. The Company recognized $</span><span style="-aw-sdt-tag:'cd379d5b42a143859706'; font-family: 'Times New Roman'"><span>0</span></span><span style="font-family: 'Times New Roman';"> of compensation expense related to vested RSUs for the </span><span style="-aw-sdt-tag:'c9e6e47e8d91295983e5'; -aw-sdt-title:'Current_Quarter_and_YTD_P6'; font-family: 'Times New Roman'"><span>three and nine months ended September 30, 2025</span></span><span style="font-family: 'Times New Roman';"> and </span><span style="-aw-sdt-tag:'c4363c78014d853fb341'; -aw-sdt-title:'Previous_Year_P17'; font-family: 'Times New Roman'"><span>2024</span></span><span style="font-family: 'Times New Roman';">.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; text-decoration:underline; font-family: 'Times New Roman'">Annual Performance Bonus</span></p><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span><span style="width:360pt; display:inline-block; -aw-tabstop-align:left; -aw-tabstop-pos:362.5pt; font-family: 'Times New Roman'">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">In December </span><span style="-aw-sdt-tag:'ca6d224b0a30d2bead97'; font-family: 'Times New Roman'"><span>2024</span></span><span style="font-family: 'Times New Roman';">, the Board approved the payment of </span><span style="-aw-sdt-tag:'cf9ad02c046ec83aca33'; font-family: 'Times New Roman'"><span>2024</span></span><span style="font-family: 'Times New Roman';"> performance bonuses to executives of the Company. Each executive was provided the option of receiving up to $</span><span style="-aw-sdt-tag:'c4ee71f3aad053507c7f'; font-family: 'Times New Roman'"><span>20,000</span></span><span style="font-family: 'Times New Roman';"> in cash, with the remainder paid in shares of common stock determined based on the closing market price on January </span><span style="-aw-sdt-tag:'ce3e6a83235437c0275c'; font-family: 'Times New Roman'"><span>2</span></span><span style="font-family: 'Times New Roman';">, </span><span style="-aw-sdt-tag:'c1824d9e08acec6d5251'; font-family: 'Times New Roman'"><span>2025</span></span><span style="font-family: 'Times New Roman';">. On January </span><span style="-aw-sdt-tag:'c8530f88525131331e3a'; font-family: 'Times New Roman'"><span>20</span></span><span style="font-family: 'Times New Roman';">, </span><span style="-aw-sdt-tag:'c599c9f4b2e63ebb486c'; font-family: 'Times New Roman'"><span>2025</span></span><span style="font-family: 'Times New Roman';">, the Company issued a total of </span><span style="-aw-sdt-tag:'cfc988ccd41d40490852'; font-family: 'Times New Roman'"><span>15,809</span></span><span style="font-family: 'Times New Roman';"> shares of common stock to the executives in settlement of the share-based portion of the </span><span style="-aw-sdt-tag:'cfa3618d6dccb054d4d7'; font-family: 'Times New Roman'"><span>2024</span></span><span style="font-family: 'Times New Roman';"> performance bonuses. Approximately </span><span style="-aw-sdt-tag:'c85caee2925573fd285e'; font-family: 'Times New Roman'"><span>2,748</span></span><span style="font-family: 'Times New Roman';"> shares were withheld to cover payroll tax withholdings.</span><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; text-decoration:underline; font-family: 'Times New Roman'">Share-Based Payments to Vendors for Services</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">In </span><span style="-aw-sdt-tag:'c70630d4e04440e9a333'; font-family: 'Times New Roman'"><span>2023</span></span><span style="font-family: 'Times New Roman';">, the Company issued shares of common stock as share-based payments to certain vendors in exchange for services to be rendered to the Company in the future. For fully vested, nonforfeitable equity instruments that are granted at the date the Company and a nonemployee enter into an agreement for goods or services, the Company recognizes the fair value of the equity instruments as a prepaid asset on the grant date, as defined in ASC </span><span style="-aw-sdt-tag:'c7013a8e8550887fe160'; font-family: 'Times New Roman'"><span>718</span></span><span style="font-family: 'Times New Roman';">. The corresponding cost is expensed over the service period depending on the specific facts and circumstances of the agreement with the nonemployee. As of </span><span style="-aw-sdt-tag:'c237df05d38456da6ce7'; -aw-sdt-title:'Current_Period_P6'; font-family: 'Times New Roman'"><span>September 30, 2025</span></span><span style="font-family: 'Times New Roman';">, the remaining unamortized balance of prepaid assets related to these share-based payments for which the grant date criteria has been met and the services are expected to be rendered within one year is $</span><span style="-aw-sdt-tag:'c3aab794da6a33ebaf3d'; -aw-sdt-title:'Current Unamortized Vendor SBC'; font-family: 'Times New Roman'"><span>240,004</span></span><span style="font-family: 'Times New Roman';"> ($</span><span style="-aw-sdt-tag:'cf8ef19d090c64e5bbab'; -aw-sdt-title:'Prior Period Unamortized Vendor SBC'; font-family: 'Times New Roman'"><span>306,181</span></span><span style="font-family: 'Times New Roman';"> at </span><span style="-aw-sdt-tag:'c26c82bd0ee1b08b856a'; -aw-sdt-title:'Previous_Year_End_P8'; font-family: 'Times New Roman'"><span>December 31, 2024</span></span><span style="font-family: 'Times New Roman';">), which is presented as a component of prepaid and other assets on the accompanying </span><span style="-aw-sdt-tag:'be6-d2e-cb9-321-e328'; -aw-sdt-title:'Balance_Sheet_Title_P2'; font-family: 'Times New Roman'"><span>consolidated condensed balance sheets</span></span><span style="font-family: 'Times New Roman';">. The unamortized balance of noncurrent prepaid assets related to these share-based payments for which the services are expected to be rendered beyond one year is $</span><span style="-aw-sdt-tag:'c4028fc370a9695f41ea'; font-family: 'Times New Roman'"><span>0</span></span><span style="font-family: 'Times New Roman';"> ($</span><span style="-aw-sdt-tag:'c8c2a095517ee623341c'; -aw-sdt-title:'Prior Period Long Term Unamortized Vendor SBC'; font-family: 'Times New Roman'"><span>66,176</span></span><span style="font-family: 'Times New Roman';"> at </span><span style="-aw-sdt-tag:'c43649c75076a44f9e67'; -aw-sdt-title:'Previous_Year_End_P9'; font-family: 'Times New Roman'"><span>December 31, 2024</span></span><span style="font-family: 'Times New Roman';">), reported in long-term prepaid expense on the accompanying </span><span style="-aw-sdt-tag:'8d3-6a2-4c1-ed7-7507'; -aw-sdt-title:'Balance_Sheet_Title_P3'; font-family: 'Times New Roman'"><span>consolidated condensed balance sheets</span></span><span style="font-family: 'Times New Roman';">.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">The agreements with the nonemployees do not include any provisions to claw back the share-based payments in the event of nonperformance by the nonemployees. Subject to applicable federal and state securities laws, the nonemployees can sell the received equity instruments.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>COMMITMENTS AND CONTINGENCIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-sdt-tag:'c7916e61a7bda9b51eb5'; font-family: 'Times New Roman'"><span style="font-weight:bold">11</span></span><span style="font-weight:bold; font-family: 'Times New Roman'">. COMMITMENTS AND CONTINGENCIES</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; text-decoration:underline; font-family: 'Times New Roman'">Leases</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">The Company is a party to a single lease for its office space located in Washington, DC, which was most recently renewed for an additional </span><span style="-sec-ix-hidden:Tag1013;-aw-sdt-tag:'471-47d-78e-0c2-c68d'; font-family: 'Times New Roman';"><span>one-year</span></span><span style="font-family: 'Times New Roman';"> term that expires March </span><span style="-aw-sdt-tag:'c8d35c399c9a3442b96c'; font-family: 'Times New Roman'"><span>31</span></span><span style="font-family: 'Times New Roman';">, </span><span style="-aw-sdt-tag:'ceb220ef0c9941bd9af2'; font-family: 'Times New Roman'"><span>2026</span></span><span style="font-family: 'Times New Roman';">. As the term of the office lease is </span><span style="-aw-sdt-tag:'cd0fb876e27f05507c99'; font-family: 'Times New Roman'"><span>12</span></span><span style="font-family: 'Times New Roman';"> months, the lease is not recorded on the balance sheet. The Company recognizes lease expense on this lease as short-term lease costs. Operating lease costs, including short-term leases, were in the amount of $</span><span style="-aw-sdt-tag:'cd5c94b9c313d289b382'; -aw-sdt-title:'Operating lease costs_CQ'; font-family: 'Times New Roman'"><span>5,573</span></span><span style="font-family: 'Times New Roman';">&#160;</span><span style="font-family: 'Times New Roman';">and $</span><span style="-aw-sdt-tag:'c0db659496b5badf8a70'; -aw-sdt-title:'Operating lease costs_PQ'; font-family: 'Times New Roman'"><span>4,938</span></span><span style="font-family: 'Times New Roman';">&#160;</span><span style="font-family: 'Times New Roman';">for the </span><span style="-aw-sdt-tag:'c00f68e43fb81f0a3a6f'; -aw-sdt-title:'Current_Quarter_P18'; font-family: 'Times New Roman'"><span>three months ended September 30, 2025</span></span><span style="font-family: 'Times New Roman';"> and </span><span style="-aw-sdt-tag:'c0544c7e1d672dd6a524'; -aw-sdt-title:'Previous_Year_P39'; font-family: 'Times New Roman'"><span>2024</span></span><span style="font-family: 'Times New Roman';">, respectively ($</span><span style="-aw-sdt-tag:'c19f05d774f689867aee'; -aw-sdt-title:'Operating lease costs_CYTD'; font-family: 'Times New Roman'"><span>15,340</span></span><span style="font-family: 'Times New Roman';">&#160;</span><span style="font-family: 'Times New Roman';">and $</span><span style="-aw-sdt-tag:'c323f9f24f97d741bebf'; -aw-sdt-title:'Operating lease costs_PYTD'; font-family: 'Times New Roman'"><span>24,067</span></span><span style="font-family: 'Times New Roman';">&#160;</span><span style="font-family: 'Times New Roman';">for the </span><span style="-aw-sdt-tag:'c3eaf105153db479206c'; -aw-sdt-title:'Current_YTD_P17'; font-family: 'Times New Roman'"><span>nine months ended September 30, 2025</span></span><span style="font-family: 'Times New Roman';"> and </span><span style="-aw-sdt-tag:'ccde6b94d63a3ed0d73b'; -aw-sdt-title:'Previous_Year_P40'; font-family: 'Times New Roman'"><span>2024</span></span><span style="font-family: 'Times New Roman';">, respectively).</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; text-decoration:underline; font-family: 'Times New Roman'">Board of Directors</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">In November and December </span><span style="-aw-sdt-tag:'ceded28c546cdff3103d'; font-family: 'Times New Roman'"><span>2022</span></span><span style="font-family: 'Times New Roman';">, the Company signed agreements with </span><span style="-aw-sdt-tag:'047-f50-789-ede-ed65'; font-family: 'Times New Roman'"><span>four</span></span><span style="font-family: 'Times New Roman';"> director nominees (Cheryl Xu, Paul Field, Charles Allen, and Stephen Toovey) which came into effect on July </span><span style="-aw-sdt-tag:'c5ebe60d064ae023bc98'; font-family: 'Times New Roman'"><span>11</span></span><span style="font-family: 'Times New Roman';">, </span><span style="-aw-sdt-tag:'c0db6f79eaa785e55516'; font-family: 'Times New Roman'"><span>2023</span></span><span style="font-family: 'Times New Roman';">, the date the Company&#8217;s Registration Statement was declared effective. Each director is entitled to receive cash compensation of $</span><span style="-aw-sdt-tag:'cead4e48e0e3dfb38324'; font-family: 'Times New Roman'"><span>11,250</span></span><span style="font-family: 'Times New Roman';"> quarterly. In addition, the </span><span style="-aw-sdt-tag:'c2b8816960a856041d4d'; font-family: 'Times New Roman'"><span>two</span></span><span style="font-family: 'Times New Roman';"> non-audit committee chairs (Toovey, Field) will receive $</span><span style="-aw-sdt-tag:'cf60737ac055ebc86af7'; font-family: 'Times New Roman'"><span>1,250</span></span><span style="font-family: 'Times New Roman';"> per quarter and the audit committee chair (Allen) will receive an additional $</span><span style="-aw-sdt-tag:'c678970b8b9f3d32b9e0'; font-family: 'Times New Roman'"><span>2,000</span></span><span style="font-family: 'Times New Roman';"> per quarter. In addition, each director is entitled to receive </span><span style="-aw-sdt-tag:'c45-3ff-244-abc-9e9e'; font-family: 'Times New Roman'"><span>annual</span></span><span style="font-family: 'Times New Roman';"> equity-based compensation awards, with the amounts and terms to be determined by the Compensation Committee.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; text-decoration:underline; font-family: 'Times New Roman'">Contingencies</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">The Company&#8217;s operations are subject to a variety of local and state regulations. Failure to comply with one or more of those regulations could result in fines, restrictions on its operations, or losses of permits that could result in the Company ceasing operations.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; text-decoration:underline; font-family: 'Times New Roman'">Contingent Compensation </span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">Following the Company&#8217;s IPO and the conversion of the outstanding debt pursuant to the Knight Debt Conversion Agreement as discussed in Note </span><span style="-aw-sdt-tag:'cb6de7e290230b8a811a'; font-family: 'Times New Roman'"><span>8</span></span><span style="font-family: 'Times New Roman';">, the Company is obligated to pay Knight a contingent milestone payment of $</span><span style="-aw-sdt-tag:'c55651d68ed1749336c5'; font-family: 'Times New Roman'"><span>10</span></span><span style="font-family: 'Times New Roman';"> million if the Company sells Arakoda or if a Change of Control occurs. The Company accounts for the contingent milestone payment as a derivative liability (See Note </span><span style="-aw-sdt-tag:'cb46d3d5eed43a8991ab'; font-family: 'Times New Roman'"><span>8</span></span><span style="font-family: 'Times New Roman';">).</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">On July </span><span style="-aw-sdt-tag:'c9ddb49ff306b2e819bc'; font-family: 'Times New Roman'"><span>15</span></span><span style="font-family: 'Times New Roman';">, </span><span style="-aw-sdt-tag:'c62eea5dde02cf11a936'; font-family: 'Times New Roman'"><span>2015</span></span><span style="font-family: 'Times New Roman';">, the Company entered into the Exclusive License Agreement with the U.S. Army Medical Materiel Development Activity (the &#8220;U.S. Army&#8221;), which was subsequently amended (the &#8220;U.S. Army Agreement&#8221;), in which the Company obtained a license to develop and commercialize the licensed technology with respect to all therapeutic applications and uses excluding radical cure of symptomatic vivax malaria. The term of the U.S. Army Agreement will continue until the expiration of the last to expire of the patent application or valid claim of the licensed technology, or </span><span style="-aw-sdt-tag:'cbf97d3e60b36d2a50b8'; font-family: 'Times New Roman'"><span>20</span></span><span style="font-family: 'Times New Roman';"> years from the start date of the U.S. Army Agreement, unless terminated earlier by the parties. The Company must make a minimum annual royalty payment of </span><span style="-aw-sdt-tag:'c0743d438ddf722d27fc'; font-family: 'Times New Roman'"><span>3</span></span><span style="font-family: 'Times New Roman';">% of Net Sales (as defined in the U.S. Army Agreement) for Net Sales less than $</span><span style="-aw-sdt-tag:'cf2e115de1723a0ed45f'; font-family: 'Times New Roman'"><span>35</span></span><span style="font-family: 'Times New Roman';"> million, and </span><span style="-aw-sdt-tag:'c4481b3b4d4093d568f0'; font-family: 'Times New Roman'"><span>5</span></span><span style="font-family: 'Times New Roman';">% of Net Sales greater than $</span><span style="-aw-sdt-tag:'cc31fd6e0a8dcfc322fa'; font-family: 'Times New Roman'"><span>35</span></span><span style="font-family: 'Times New Roman';"> million, with US government sales excluded from the definition of Net Sales. In addition, the Company must pay fees upon the achievement of certain milestones. The Company accrues the minimum annual royalty when the related sales occur. The achievement of the remaining milestones under the U.S. Army Agreement are not considered probable and thus no accruals for the related milestone payments have been made.</span></p><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">On December </span><span style="-aw-sdt-tag:'cbb240240b052d6f8172'; font-family: 'Times New Roman'"><span>20</span></span><span style="font-family: 'Times New Roman';">, </span><span style="-aw-sdt-tag:'c027369bd0398d6eba8f'; font-family: 'Times New Roman'"><span>2024</span></span><span style="font-family: 'Times New Roman';">, the Company entered into a Patent License Agreement with Tufts Medical Center (&#8220;Tufts MC&#8221;), in which the Company obtained a license to research and commercialize the licensed technology with respect to the use of tafenoquine for treatment and/or prevention of babesiosis (the &#8220;Tufts MC Agreement&#8221;). The term of the Tufts MC Agreement will continue until the expiration or final abandonment of the last patent application or issued patent for the use of tafenoquine for treatment and/or prevention of babesiosis, unless terminated earlier by the parties. On the earlier of (x) the date of patent issuance or (y) the date of regulatory approval for the use of tafenoquine product in treatment of babesiosis, the Company must make royalty payments equal to </span><span style="-aw-sdt-tag:'c54edac88924604315c8'; font-family: 'Times New Roman'"><span>4</span></span><span style="font-family: 'Times New Roman';">% of Net Sales (as defined in the Tufts MC Agreement) for tafenoquine sold in a format labeled for use in the treatment of babesiosis or </span><span style="-aw-sdt-tag:'cf88cbfc1ea21062cba6'; font-family: 'Times New Roman'"><span>2</span></span><span style="font-family: 'Times New Roman';">% of Net Sales for </span><span style="-aw-sdt-tag:'c074caac69bf4612113a'; font-family: 'Times New Roman'"><span>60</span></span><span style="font-family: 'Times New Roman';">P products that are not sold in a format labeled for use in the treatment of babesiosis. In addition, for all sublicense revenue received by </span><span style="-aw-sdt-tag:'c86ede9c1c4a486b5149'; font-family: 'Times New Roman'"><span>60</span></span><span style="font-family: 'Times New Roman';">P from sales of sublicensed products, the Company must make royalty payments equal to </span><span style="-aw-sdt-tag:'c636764bc4488d0fba9e'; font-family: 'Times New Roman'"><span>20</span></span><span style="font-family: 'Times New Roman';">% of the revenue received by the Company for sales of tafenoquine sold in a format labeled for use in the treatment of babesiosis or </span><span style="-aw-sdt-tag:'cb710989fdd28cf064c7'; font-family: 'Times New Roman'"><span>10</span></span><span style="font-family: 'Times New Roman';">% for sales of tafenoquine that are not sold in a format labeled for use in the treatment of babesiosis. As of </span><span style="-aw-sdt-tag:'cce588c7b78411dd262d'; -aw-sdt-title:'Current_Period_P24'; font-family: 'Times New Roman'"><span>September 30, 2025</span></span><span style="font-family: 'Times New Roman';">, the royalty period has not commenced, thus </span><span style="-aw-sdt-tag:'1dc-6d9-7b7-ffb-8c04'; font-family: 'Times New Roman'"><span>no</span></span><span style="font-family: 'Times New Roman';"> accruals have been made.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; text-decoration:underline; font-family: 'Times New Roman'">Litigation, Claims and Assessments</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">From time to time, the Company may be involved in litigation relating to claims arising out of operations in the normal course of business. As of </span><span style="-aw-sdt-tag:'c68a81d7a6d5e41ec529'; -aw-sdt-title:'Current_Period_P23'; font-family: 'Times New Roman'"><span>September 30, 2025</span></span><span style="font-family: 'Times New Roman';">, there were </span><span style="-aw-sdt-tag:'493-5d4-85c-584-67d2'; font-family: 'Times New Roman'"><span>no</span></span><span style="font-family: 'Times New Roman';"> pending or threatened lawsuits that could reasonably be expected to have a material effect on the results of the Company&#8217;s operations.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>SUBSEQUENT EVENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">12. SUBSEQUENT EVENTS</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span><span style="width:104.75pt; display:inline-block; -aw-tabstop-align:left; -aw-tabstop-pos:107.25pt; font-family: 'Times New Roman'">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">The Company has evaluated subsequent events through </span><span style="-aw-sdt-tag:'e16-1c0-097-c46-bd43'; -aw-sdt-title:'Current_Period_Date_FS_Issued_P2'; font-family: 'Times New Roman'"><span>November 13, 2025</span></span><span style="font-family: 'Times New Roman';">, which is the date the financial statements were issued. </span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-style:italic; font-family: 'Times New Roman'">2025 Annual Meeting of Stockholders</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">On October 8, 2025, the Company conducted its virtual 2025 Annual Meeting of Stockholders (the &#8220;2025 Annual Meeting&#8221;). The Company&#8217;s stockholders of record at the close of business on August 29, 2025, the record date for the determination of stockholders entitled to vote at the 2025 Annual Meeting, approved the proposals to (1) elect </span><span style="-aw-sdt-tag:'454-79f-b5b-ad3-7921'; font-family: 'Times New Roman'"><span>five</span></span><span style="font-family: 'Times New Roman';"> directors to serve until the 2026 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified&#894; (2) approve an amendment to the 2022 Plan to increase the number of shares of common stock available for issuance by </span><span style="-aw-sdt-tag:'ad1-9b9-eb6-e8c-4870'; font-family: 'Times New Roman'"><span>250,000</span></span><span style="font-family: 'Times New Roman';"> shares&#894; (3) approve an amendment to the Company&#8217;s Certificate of Incorporation, to effect a reverse stock split of the common stock at a reverse stock split ratio ranging from </span><span style="-aw-sdt-tag:'6e9-6db-b5f-c60-506b'; font-family: 'Times New Roman'"><span>1:3 to 1:10</span></span><span style="font-family: 'Times New Roman';"> inclusive, as may be determined at the appropriate time by the Board of Directors, in its sole discretion&#894; and (4) ratify the selection of RBSM LLP by the Board of Directors as the Company&#8217;s independent registered public accounting firm for the fiscal year ending December 31, 2025.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-style:italic; font-family: 'Times New Roman'">Option Grant</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">On October 21, 2025, the Company&#8217;s Board of Directors approved the grant of </span><span style="-aw-sdt-tag:'df3-cbb-b07-8bb-c693'; font-family: 'Times New Roman'"><span>32,000</span></span><span style="font-family: 'Times New Roman';"> stock options to each of the </span><span style="-aw-sdt-tag:'705-e1a-464-35f-5940'; font-family: 'Times New Roman'"><span>four</span></span><span style="font-family: 'Times New Roman';"> directors (</span><span style="-aw-sdt-tag:'50a-16a-20d-537-e8de'; font-family: 'Times New Roman'"><span>8,000</span></span><span style="font-family: 'Times New Roman';"> per director) at a per share exercise price of $</span><span style="-aw-sdt-tag:'1ec-25c-5ee-eca-013d'; font-family: 'Times New Roman'"><span>1.46</span></span><span style="font-family: 'Times New Roman';">. These stock options were fully vested on the date of grant and have a term of </span><span style="-aw-sdt-tag:'71a-74e-77b-7dc-6383'; font-family: 'Times New Roman'"><span>seven years</span></span><span style="font-family: 'Times New Roman';">. </span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-style:italic; font-family: 'Times New Roman'">2025 ATM Agreement</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">Pursuant to the 2025 ATM Agreement described in Note 6, between </span><span style="-aw-sdt-tag:'075-02e-67e-8cb-173b'; -aw-sdt-title:'ATM_Sales_Start Date'; font-family: 'Times New Roman'"><span>October 16, 2025</span></span><span style="font-family: 'Times New Roman';"> and </span><span style="-aw-sdt-tag:'9c6-a68-8ff-273-4e9d'; -aw-sdt-title:'Signature_Date_P8'; font-family: 'Times New Roman'"><span>November 13, 2025</span></span><span style="font-family: 'Times New Roman';">, the Company sold an aggregate of </span><span style="-aw-sdt-tag:'3bd-c63-bbc-85b-e9a5'; -aw-sdt-title:'ATM_Shares_Sold'; font-family: 'Times New Roman'"><span>125,979</span></span><span style="font-family: 'Times New Roman';"> shares at a weighted average price per share of $</span><span style="-aw-sdt-tag:'88e-ea0-f71-977-3a31'; -aw-sdt-title:'ATM_Sales_WeightedAvgPrice'; font-family: 'Times New Roman'"><span>1.62</span></span><span style="font-family: 'Times New Roman';">, generating net proceeds to the Company of $</span><span style="-aw-sdt-tag:'63a-f84-1ca-24b-ad31'; -aw-sdt-title:'ATM_Sales_NetProceeds'; font-family: 'Times New Roman'"><span>196,356</span></span><span style="font-family: 'Times New Roman';">, after deducting commissions and certain other offering expenses. </span><span style="-aw-import:spaces; font-family: 'Times New Roman'">&#160; </span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">There have been no other events or transactions during this time which would have a material effect on these consolidated condensed financial statements.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTradingArrLineItems', window );"><strong>Insider Trading Arrangements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTradingArrLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTradingArrLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; text-decoration:underline; font-family: 'Times New Roman'">Basis of Presentation</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">The financial statements of </span><span style="-aw-sdt-tag:'ce903abe84353d2391d6'; font-family: 'Times New Roman'"><span>60</span></span><span style="font-family: 'Times New Roman';">P are prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;). The Company has prepared the accompanying consolidated condensed financial statements pursuant to the instructions to Form </span><span style="-aw-sdt-tag:'c90d6f77918f6efd358d'; font-family: 'Times New Roman'"><span>10</span></span><span style="font-family: 'Times New Roman';">-Q and Article </span><span style="-aw-sdt-tag:'c8389d80e96daea9720b'; font-family: 'Times New Roman'"><span>8</span></span><span style="font-family: 'Times New Roman';"> of Regulation S-X of the Securities and Exchange Commission (&#8220;SEC&#8221;). These financial statements are unaudited and, in the opinion of management, all adjustments considered necessary for a fair presentation of the Company&#8217;s financial position, results of operations, and cash flows have been included and are of a normal and recurring nature. Operating results for the periods presented are not necessarily indicative of the results that may be expected for the year ending </span><span style="-aw-sdt-tag:'c0c7176b5bdb194bfddc'; -aw-sdt-title:'Current_Year_End_P1'; font-family: 'Times New Roman'"><span>December 31, 2025</span></span><span style="font-family: 'Times New Roman';"> due to various factors. These consolidated condensed financial statements should be read in conjunction with the audited consolidated financial statements and related notes thereto as of and for the years ended </span><span style="-aw-sdt-tag:'c18cdcd3e90810c9b66a'; -aw-sdt-title:'Previous_Year_End_P6'; font-family: 'Times New Roman'"><span>December 31, 2024</span></span><span style="font-family: 'Times New Roman';"> and </span><span style="-aw-sdt-tag:'c81138fdfee9b110fdf9'; font-family: 'Times New Roman'"><span>2023</span></span><span style="font-family: 'Times New Roman';">, included in the Company&#8217;s annual report on Form </span><span style="-aw-sdt-tag:'c4c00800b9e2d5f1439e'; font-family: 'Times New Roman'"><span>10</span></span><span style="font-family: 'Times New Roman';">-K, as filed with the SEC on March </span><span style="-aw-sdt-tag:'c48ed363e59cdbbb1e8b'; font-family: 'Times New Roman'"><span>27</span></span><span style="font-family: 'Times New Roman';">, </span><span style="-aw-sdt-tag:'c7da1b0fe69d8d60fb79'; font-family: 'Times New Roman'"><span>2025</span></span><span style="font-family: 'Times New Roman';"> (the &#8220;Annual Report&#8221;). Certain information, footnote disclosures, and significant accounting policies that would substantially duplicate the disclosures contained in the Annual Report have been omitted.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; text-decoration:underline; font-family: 'Times New Roman'">Use of Estimates</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates, and those estimates may be material. Significant estimates include the reserve for inventory, the fair value of derivative liabilities, and stock-based compensation.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityPolicyTextBlock', window );">Reverse Stock Splits</a></td>
<td class="text"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; text-decoration:underline; font-family: 'Times New Roman'">Reverse Stock Splits</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-sdt-tag:'dac-e32-fd4-981-41a6'; font-family: 'Times New Roman'"><span>Following stockholder approval in July 2024, the Company effected a reverse stock split at a ratio of 1:12, which was effective as of August 12, 2024 (the &#8220;1:12 Reverse Stock Split&#8221;).</span></span><span style="font-family: 'Times New Roman';"> </span><span style="-aw-sdt-tag:'731-9b8-7ee-b5e-cc0f'; font-family: 'Times New Roman'"><span>On November 6, 2024, a majority of the Company&#8217;s stockholders approved an additional reverse stock split at a split ratio ranging between 1:3 and 1:5, as determined by the Board of Directors in its sole discretion.</span></span><span style="font-family: 'Times New Roman';"> </span><span style="-aw-sdt-tag:'013-0eb-6cc-bc0-02a0'; font-family: 'Times New Roman'"><span>On February 10, 2025, the Board of Directors approved a 1:5 reverse split ratio. On February 24, 2025, the Company effected the 1:5 reverse stock split (the &#8220;1:5 Reverse Stock Split&#8221;, and together with the 1:12 Reverse Stock Split, the &#8220;Reverse Stock Splits&#8221;).</span></span><span style="font-family: 'Times New Roman';"> Beginning February </span><span style="-aw-sdt-tag:'c26c29b86737c43d1066'; font-family: 'Times New Roman'"><span>24</span></span><span style="font-family: 'Times New Roman';">, </span><span style="-aw-sdt-tag:'c7cca48741fbb787a7db'; font-family: 'Times New Roman'"><span>2025</span></span><span style="font-family: 'Times New Roman';">, the common stock traded on The Nasdaq Capital Market on a split adjusted basis.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">Proportional adjustments were made to the number of shares of common stock issuable upon exercise or conversion of the Company&#8217;s equity awards, warrants, and other equity instruments convertible into common stock, as well as the respective exercise prices, if applicable, in accordance with the terms of the instruments. Unless otherwise noted, all references to numbers of shares of the Company&#8217;s common stock and per share information presented in these consolidated condensed financial statements have been retroactively adjusted, as appropriate, to reflect the Reverse Stock Splits, including reclassifying an amount equal to the reduction in par value of common stock to additional paid-in capital.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations</a></td>
<td class="text"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; text-decoration:underline; font-family: 'Times New Roman'">Concentrations</span></p><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents, short-term investments, accounts receivable, inventory purchases, and borrowings.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">Significant customers represent any customer whose business makes up </span><span style="-aw-sdt-tag:'c38d441a704cc0769f2e'; font-family: 'Times New Roman'"><span>10</span></span><span style="font-family: 'Times New Roman';">% of receivables or revenues. At </span><span style="-aw-sdt-tag:'c8aefa95b7837b6c59db'; -aw-sdt-title:'Current_Period_P1'; font-family: 'Times New Roman'"><span>September 30, 2025</span></span><span style="font-family: 'Times New Roman';">, significant customers represented </span><span style="-aw-sdt-tag:'c7d0ee37bbed719c14fb'; -aw-sdt-title:'Current_Sig. Cust AR Percent'; font-family: 'Times New Roman'"><span>89</span></span><span style="font-family: 'Times New Roman';">% of receivables (consisting of </span><span style="-aw-sdt-tag:'efa-f25-b7a-0c0-3393'; -aw-sdt-title:'Current_Total Customers in AR'; font-family: 'Times New Roman'"><span>six</span></span><span style="font-family: 'Times New Roman';"> total customers and </span><span style="-aw-sdt-tag:'6bd-f9c-095-2b1-0b97'; -aw-sdt-title:'Current_Sigificant Customers in AR'; font-family: 'Times New Roman'"><span>two</span></span><span style="font-family: 'Times New Roman';"> significant customers at </span><span style="-aw-sdt-tag:'757-b3e-309-2f1-7957'; -aw-sdt-title:'AR Sig Customer 1 _Current'; font-family: 'Times New Roman'"><span>75</span></span><span style="font-family: 'Times New Roman';">% and </span><span style="-aw-sdt-tag:'053-64b-d59-480-934c'; font-family: 'Times New Roman'"><span>13</span></span><span style="font-family: 'Times New Roman';">%, respectively), and </span><span style="-aw-sdt-tag:'c8865edd41199200cda9'; -aw-sdt-title:'Prior_Sig. Cust AR Percent'; font-family: 'Times New Roman'"><span>95</span></span><span style="font-family: 'Times New Roman';">% of receivables at </span><span style="-aw-sdt-tag:'c612e322ca6f5a44144a'; -aw-sdt-title:'Previous_Year_End_P7'; font-family: 'Times New Roman'"><span>December 31, 2024</span></span><span style="font-family: 'Times New Roman';"> (consisting of </span><span style="-aw-sdt-tag:'58c-1fd-4c8-cbc-24e3'; -aw-sdt-title:'Prior_Total Customers in AR'; font-family: 'Times New Roman'"><span>three</span></span><span style="font-family: 'Times New Roman';"> total customers and </span><span style="-aw-sdt-tag:'0cd-eb1-27d-ce1-d261'; -aw-sdt-title:'Prior_Sigificant Customers in AR'; font-family: 'Times New Roman'"><span>one</span></span><span style="font-family: 'Times New Roman';"> significant customer). For the </span><span style="-aw-sdt-tag:'ca0e62e990a606583b94'; -aw-sdt-title:'Current_Quarter_P14'; font-family: 'Times New Roman'"><span>three months ended September 30, 2025</span></span><span style="font-family: 'Times New Roman';">, significant customers comprised </span><span style="-aw-sdt-tag:'c610c2cb61e4f95ffd6c'; -aw-sdt-title:'CQTD_Sig.Cust Percent Net Revenue'; font-family: 'Times New Roman'"><span>80</span></span><span style="font-family: 'Times New Roman';">% of total net product revenues (consisting of </span><span style="-aw-sdt-tag:'7ac-793-8fb-7b6-6b7e'; -aw-sdt-title:'CQTD_Total Customers'; font-family: 'Times New Roman'"><span>four</span></span><span style="font-family: 'Times New Roman';"> total customers and </span><span style="-aw-sdt-tag:'935-1d8-24e-b55-3697'; -aw-sdt-title:'CWTD_Significant Customers'; font-family: 'Times New Roman'"><span>one</span></span><span style="font-family: 'Times New Roman';"> significant customer at </span><span style="-aw-sdt-tag:'fd4-598-fc6-c55-b5b3'; -aw-sdt-title:'CQTD_Sig Customer 1 Percent'; font-family: 'Times New Roman'"><span>80</span></span><span style="font-family: 'Times New Roman';">%). For the </span><span style="-aw-sdt-tag:'c89b221bf86e60e80aee'; -aw-sdt-title:'Previous_Quarter_P5'; font-family: 'Times New Roman'"><span>three months ended September 30, 2024</span></span><span style="font-family: 'Times New Roman';">, </span><span style="-aw-sdt-tag:'c4871e9ed0486ef91d28'; -aw-sdt-title:'PQTD_Sig.Cust Percent Net Revenue'; font-family: 'Times New Roman'"><span>92</span></span><span style="font-family: 'Times New Roman';">% of total net product revenues (consisting of </span><span style="-aw-sdt-tag:'92a-ab1-dc7-7a9-7dd3'; -aw-sdt-title:'PQTD_Total Customers'; font-family: 'Times New Roman'"><span>two</span></span><span style="font-family: 'Times New Roman';"> total customers and </span><span style="-aw-sdt-tag:'813-a74-d78-4e2-d0ec'; -aw-sdt-title:'PQTD_Significant Customers'; font-family: 'Times New Roman'"><span>one</span></span><span style="font-family: 'Times New Roman';"> significant customer) were generated from significant customers. For the </span><span style="-aw-sdt-tag:'c71fb825a8fc9183fba4'; -aw-sdt-title:'Current_YTD_P9'; font-family: 'Times New Roman'"><span>nine months ended September 30, 2025</span></span><span style="font-family: 'Times New Roman';">,</span><span style="font-family: 'Times New Roman';">&#160;</span><span style="-aw-sdt-tag:'cd703ca85832d9e6ccd9'; -aw-sdt-title:'CYTD_Sig.Cust Percent Net Revenue'; font-family: 'Times New Roman'"><span>91</span></span><span style="font-family: 'Times New Roman';">% of total net product revenues (consisting of </span><span style="-aw-sdt-tag:'d25-e87-6c3-44b-77b8'; -aw-sdt-title:'CYTD_Total Customers'; font-family: 'Times New Roman'"><span>four</span></span><span style="font-family: 'Times New Roman';"> total customers and </span><span style="-aw-sdt-tag:'623-163-567-ed7-13d7'; -aw-sdt-title:'CYTD_Significant Customers'; font-family: 'Times New Roman'"><span>two</span></span><span style="font-family: 'Times New Roman';"> significant customers at </span><span style="-aw-sdt-tag:'fd4-589-ac0-f12-5f6a'; font-family: 'Times New Roman'"><span>73</span></span><span style="font-family: 'Times New Roman';">% and </span><span style="-aw-sdt-tag:'aa0-f10-986-33c-5f25'; -aw-sdt-title:'CYTD_Sig Customer 2 Percent'; font-family: 'Times New Roman'"><span>18</span></span><span style="font-family: 'Times New Roman';">%, respectively) were generated from significant customers. For the </span><span style="-aw-sdt-tag:'cd6d62b9c3ce9b21e230'; -aw-sdt-title:'Previous_YTD_P4'; font-family: 'Times New Roman'"><span>nine months ended September 30, 2024</span></span><span style="font-family: 'Times New Roman';">,</span><span style="font-family: 'Times New Roman';">&#160;</span><span style="-aw-sdt-tag:'c34cf87b1815b4a11766'; -aw-sdt-title:'PYTD_Sig.Cust Percent Net Revenue'; font-family: 'Times New Roman'"><span>94</span></span><span style="font-family: 'Times New Roman';">% of total net product revenues (consisting of </span><span style="-aw-sdt-tag:'f2f-f63-4d3-652-810a'; -aw-sdt-title:'PYTD_Total Customers'; font-family: 'Times New Roman'"><span>three</span></span><span style="font-family: 'Times New Roman';"> total customers and </span><span style="-aw-sdt-tag:'20a-b2d-e5b-ae2-0417'; -aw-sdt-title:'PYTD_Significant Customers'; font-family: 'Times New Roman'"><span>one</span></span><span style="font-family: 'Times New Roman';"> significant customer) were generated from significant customers.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">Currently, the Company has exclusive relationships with distributors in Australia and Europe. A failure to perform by any of our current distributors would create disruption for patients in those markets.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">Since the Company first started working on tafenoquine, all inventory has been acquired in a collaborative relationship from a sole vendor. Should the vendor cease to supply tafenoquine, it would take significant costs and efforts to rebuild the supply chain with a new sole vendor sourcing the active pharmaceutical ingredient (&#8220;API&#8221;).</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Information</a></td>
<td class="text"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; text-decoration:underline; font-family: 'Times New Roman'">Segment Information</span></p><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">Since its inception, the Company operates and manages its business as a single identifiable segment, focused on the development and marketing of new medicines for the treatment and prevention of infectious diseases. The determination of a single business segment is consistent with the consolidated financial information regularly provided to the Company&#8217;s chief operating decision maker (&#8220;CODM&#8221;).</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:10pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">The Company&#8217;s CODM is its Chief Executive Officer, who reviews and evaluates consolidated net income or loss for purposes of evaluating performance, making operating decisions, allocating resources, and planning and forecasting for future periods. The significant components of consolidated net income or loss regularly provided to the CODM include net product revenues and the significant expense categories presented in the accompanying </span><span style="-aw-sdt-tag:'40d-f92-19d-c95-c73e'; -aw-sdt-title:'PandL_title_P2'; font-family: 'Times New Roman'"><span>consolidated condensed statements of operations and comprehensive loss</span></span><span style="font-family: 'Times New Roman';"> (cost of revenues, research and development, and general and administrative expenses). These are presented at the consolidated level and used by the CODM to monitor budgeted versus actual results to make key operating decisions. The information and operating expense categories presented in the accompanying </span><span style="-aw-sdt-tag:'253-c33-1cd-8c6-3ae5'; -aw-sdt-title:'PandL_title_P3'; font-family: 'Times New Roman'"><span>consolidated condensed statements of operations and comprehensive loss</span></span><span style="font-family: 'Times New Roman';"> are fully reflective of the significant expense categories and amounts that are regularly provided to the CODM.</span></p><div style="-aw-sdt-tag:'PG_c24bb3258a68b0280db8'"></div><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">The measure of segment assets that is regularly reported to the CODM includes cash and cash equivalents and short-term investments, each as reported on the </span><span style="-aw-sdt-tag:'139-b42-89d-4af-5020'; -aw-sdt-title:'Balance_Sheet_Title_P1'; font-family: 'Times New Roman'"><span>consolidated condensed balance sheets</span></span><span style="font-family: 'Times New Roman';">. Total consolidated cash and cash equivalents and short-term investments were $</span><span style="-aw-sdt-tag:'c26449208c3edf5c7aa8'; font-family: 'Times New Roman'"><span>4,115,779</span></span><span style="font-family: 'Times New Roman';"> and $</span><span style="-aw-sdt-tag:'cdccccade90e66a13fb9'; font-family: 'Times New Roman'"><span>3,387,825</span></span><span style="font-family: 'Times New Roman';"> as of </span><span style="-aw-sdt-tag:'c7407e74fc85ec3ccdfe'; -aw-sdt-title:'Current_Period_P2'; font-family: 'Times New Roman'"><span>September 30, 2025</span></span><span style="font-family: 'Times New Roman';"> and </span><span style="-aw-sdt-tag:'c00bf74fe48b3c64541d'; -aw-sdt-title:'Previous_Year_End_P12'; font-family: 'Times New Roman'"><span>December 31, 2024</span></span><span style="font-family: 'Times New Roman';">, respectively.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Derivative Liabilities</a></td>
<td class="text"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; text-decoration:underline; font-family: 'Times New Roman'">Derivative Liabilities</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">The Company analyzes all financial instruments with features of both liabilities and equity under FASB ASC Topic No. </span><span style="-aw-sdt-tag:'c4a98c0f9c305eb9ad0a'; font-family: 'Times New Roman'"><span>480</span></span><span style="font-family: 'Times New Roman';">, </span><span style="font-style:italic; font-family: 'Times New Roman'">Distinguishing Liabilities from Equity</span><span style="font-family: 'Times New Roman';"> (&#8220;ASC </span><span style="-aw-sdt-tag:'ce2b75a3274a6a43e17f'; font-family: 'Times New Roman'"><span>480</span></span><span style="font-family: 'Times New Roman';">&#8221;), and FASB ASC Topic No. </span><span style="-aw-sdt-tag:'ced90c7d41ecdbd49877'; font-family: 'Times New Roman'"><span>815</span></span><span style="font-family: 'Times New Roman';">, </span><span style="font-style:italic; font-family: 'Times New Roman'">Derivatives and Hedging</span><span style="font-family: 'Times New Roman';"> (&#8220;ASC </span><span style="-aw-sdt-tag:'ccd1349dccf1b3e1afae'; font-family: 'Times New Roman'"><span>815</span></span><span style="font-family: 'Times New Roman';">&#8221;). The classification of derivative financial instruments is reassessed each reporting period. Derivative liabilities are adjusted to reflect fair value at each reporting period, with any increase or decrease in the fair value recorded in the results of operations, as a component of other income or expense as change in fair value of derivative liabilities. As of </span><span style="-aw-sdt-tag:'c1af92d97c032e45d07a'; -aw-sdt-title:'Current_Period_P14'; font-family: 'Times New Roman'"><span>September 30, 2025</span></span><span style="font-family: 'Times New Roman';">, derivative liabilities consist of contingent payment arrangements. The Company uses a probability-weighted expected return method to determine the fair value of these instruments.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">Upon conversion or repayment of a debt or equity instrument in exchange for equity shares, where the embedded conversion option has been bifurcated and accounted for as a derivative liability (generally convertible debt and warrants), the Company records the equity shares at fair value on the date of conversion, relieves all related debt, derivative liabilities, and unamortized debt discounts, and recognizes a net gain or loss on debt extinguishment, if any.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">Equity or liability instruments that become subject to reclassification under ASC Topic </span><span style="-aw-sdt-tag:'ce08ae8c5268be0628c7'; font-family: 'Times New Roman'"><span>815</span></span><span style="font-family: 'Times New Roman';"> are reclassified at the fair value of the instrument on the reclassification date.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sxtp_EquityClassifiedWarrantsPolicyTextBlock', window );">Equity-Classified Warrants</a></td>
<td class="text"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; text-decoration:underline; font-family: 'Times New Roman'">Equity-Classified Warrants</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">As of </span><span style="-aw-sdt-tag:'c7bcd8e778eedd1caaab'; -aw-sdt-title:'Current_Period_P11'; font-family: 'Times New Roman'"><span>September 30, 2025</span></span><span style="font-family: 'Times New Roman';">, the Company accounts for all outstanding warrants to purchase common stock as equity-classified instruments based on an assessment of the warrants&#8217; specific terms and applicable authoritative guidance in ASC </span><span style="-aw-sdt-tag:'cdb856b4f4bde6d47eab'; font-family: 'Times New Roman'"><span>480</span></span><span style="font-family: 'Times New Roman';"> and ASC </span><span style="-aw-sdt-tag:'cd5e76a6a6ce96ef7c87'; font-family: 'Times New Roman'"><span>815</span></span><span style="font-family: 'Times New Roman';">. This assessment considers whether the warrants are freestanding financial instruments pursuant to ASC </span><span style="-aw-sdt-tag:'cd481df4cd7bb454097c'; font-family: 'Times New Roman'"><span>480</span></span><span style="font-family: 'Times New Roman';">, meet the definition of a liability pursuant to ASC </span><span style="-aw-sdt-tag:'c75d25a4963187f34a5b'; font-family: 'Times New Roman'"><span>480</span></span><span style="font-family: 'Times New Roman';">, whether the warrants meet all of the requirements for equity classification under ASC </span><span style="-aw-sdt-tag:'c8f59ed9b1458f19f86f'; font-family: 'Times New Roman'"><span>815</span></span><span style="font-family: 'Times New Roman';">, including whether the warrants are indexed to the Company&#8217;s own common stock and whether the warrant holders could potentially require &#8220;net cash settlement&#8221; in a circumstance outside of the Company&#8217;s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the respective issuance dates and as of each subsequent reporting period while the warrants are outstanding.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; text-decoration:underline; font-family: 'Times New Roman'">Revenue Recognition</span></p><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">The Company recognizes revenue in accordance with FASB ASC Topic No. </span><span style="-aw-sdt-tag:'c1024005423a4297ddef'; font-family: 'Times New Roman'"><span>606</span></span><span style="font-family: 'Times New Roman';">, </span><span style="font-style:italic; font-family: 'Times New Roman'">Revenue from Contracts with Customers</span><span style="font-family: 'Times New Roman';"> (&#8220;ASC </span><span style="-aw-sdt-tag:'c01990ecd114b774522a'; font-family: 'Times New Roman'"><span>606</span></span><span style="font-family: 'Times New Roman';">&#8221;). Revenues are recognized when control is transferred to customers in amounts that reflect the consideration the Company expects to be entitled to receive in exchange for those goods. Revenue recognition is evaluated through the following five steps: (i) identification of the contract, or contracts, with a customer; (ii) identification of the performance obligations in the contract; (iii) determination of the transaction price; (iv) allocation of the transaction price to the performance obligations in the contract; and (v) recognition of revenue when or as a performance obligation is satisfied. As part of the accounting for these arrangements, the Company may be required to make significant judgments, including identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each performance obligation.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">Revenues from product sales are recorded at the net sales price, or &#8220;transaction price,&#8221; which may include estimates of variable consideration that result from product returns. The Company determines the amount of variable consideration by using either the expected value method or the most-likely-amount method. The Company includes the unconstrained amount of estimated variable consideration in the transaction price, which reflects the amount for which it is probable that a significant reversal of cumulative revenue recognized will not occur. At the end of each subsequent reporting period, the Company re-evaluates the estimated variable consideration included in the transaction price and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis in the period of adjustment. Reserves are established for the estimates of variable consideration based on the amounts the Company expects to be earned or to be claimed on the related sales.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p><div style="-aw-sdt-tag:'PG_c6053e6c5f792d82acc2'"></div><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">The Company receives the majority of its revenues from sales of its Arakoda product to resellers in the US and abroad. The Company records US commercial revenues as a receivable when our American distributor transfers shipped product to their title model for </span><span style="-aw-sdt-tag:'cfae9bd6533b6134b81a'; font-family: 'Times New Roman'"><span>60</span></span><span style="font-family: 'Times New Roman';">P. Foreign sales to both Australia and Europe are recognized as a receivable at the point product is shipped to distributor. The shipments to Australia and Europe are further subject to profit sharing agreements for boxes sold to customers.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
<td class="text"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; text-decoration:underline; font-family: 'Times New Roman'">Research and Development Costs </span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">The Company accounts for research and development costs in accordance with FASB ASC Subtopic No. </span><span style="-aw-sdt-tag:'cbc781f7013a6eaa59f8'; font-family: 'Times New Roman'"><span>730</span></span><span style="font-family: 'Times New Roman';">-</span><span style="-aw-sdt-tag:'c82ed5ff78a1295bb276'; font-family: 'Times New Roman'"><span>10</span></span><span style="font-family: 'Times New Roman';">, Research and Development (&#8220;ASC </span><span style="-aw-sdt-tag:'c8d16d1806c924bd6931'; font-family: 'Times New Roman'"><span>730</span></span><span style="font-family: 'Times New Roman';">-</span><span style="-aw-sdt-tag:'ca09ffaa8d3135cb1e6b'; font-family: 'Times New Roman'"><span>10</span></span><span style="font-family: 'Times New Roman';">&#8221;). Under ASC </span><span style="-aw-sdt-tag:'c9a334fab141f1bfcaaa'; font-family: 'Times New Roman'"><span>730</span></span><span style="font-family: 'Times New Roman';">-</span><span style="-aw-sdt-tag:'cd9c059505344e7aa50b'; font-family: 'Times New Roman'"><span>10</span></span><span style="font-family: 'Times New Roman';">, research and development costs are expensed as incurred. Accordingly, internal research and development costs are expensed as incurred. Prepayments for research and development services are deferred and amortized over the service period as the services are provided. Advance payments for specific materials, equipment, or facilities determined to have no alternative future use are initially deferred and recognized as research and development expense when the related goods are delivered.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">The Company recorded $</span><span style="-aw-sdt-tag:'c0cae7d3178274b183f7'; -aw-sdt-title:'CQTD_RandD Expense'; font-family: 'Times New Roman'"><span>809,777</span></span><span style="font-family: 'Times New Roman';">&#160;</span><span style="font-family: 'Times New Roman';">and $</span><span style="-aw-sdt-tag:'c819708eba76301c2ea4'; -aw-sdt-title:'PQTD_RandD Expense'; font-family: 'Times New Roman'"><span>940,063</span></span><span style="font-family: 'Times New Roman';">&#160;</span><span style="font-family: 'Times New Roman';">in research and development expense during the </span><span style="-aw-sdt-tag:'cc1e5d1af75cc719a927'; -aw-sdt-title:'Current_Quarter_P15'; font-family: 'Times New Roman'"><span>three months ended September 30, 2025</span></span><span style="font-family: 'Times New Roman';"> and </span><span style="-aw-sdt-tag:'cc35a31294de2fb9966a'; -aw-sdt-title:'Previous_Year_P29'; font-family: 'Times New Roman'"><span>2024</span></span><span style="font-family: 'Times New Roman';">, respectively, ($</span><span style="-aw-sdt-tag:'c0a12c3296b44a12831e'; -aw-sdt-title:'CYTD_RandD Expense'; font-family: 'Times New Roman'"><span>1,467,283</span></span><span style="font-family: 'Times New Roman';"> and $</span><span style="-aw-sdt-tag:'c0c5d0d81b151b0a0872'; -aw-sdt-title:'PYTD_RandD Expense'; font-family: 'Times New Roman'"><span>4,372,571</span></span><span style="font-family: 'Times New Roman';"> for the </span><span style="-aw-sdt-tag:'c14bc5f963419ab2aed9'; -aw-sdt-title:'Current_YTD_P12'; font-family: 'Times New Roman'"><span>nine months ended September 30, 2025</span></span><span style="font-family: 'Times New Roman';"> and </span><span style="-aw-sdt-tag:'c141bbe47f263859b34f'; -aw-sdt-title:'Previous_Year_P30'; font-family: 'Times New Roman'"><span>2024</span></span><span style="font-family: 'Times New Roman';">, respectively). The Company has also issued shares of common stock to nonemployees in exchange for research and development services. The Company recognizes prepaid research and development costs on the grant date, as defined in FASB ASC Subtopic No. </span><span style="-aw-sdt-tag:'c5f925ba06665ac933a5'; font-family: 'Times New Roman'"><span>718</span></span><span style="font-family: 'Times New Roman';">, </span><span style="font-style:italic; font-family: 'Times New Roman'">Compensation - Stock Compensation</span><span style="font-family: 'Times New Roman';">. See Note </span><span style="-aw-sdt-tag:'cd731d5a4723c771d07e'; font-family: 'Times New Roman'"><span>10</span></span><span style="font-family: 'Times New Roman';"> for further details.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; text-decoration:underline; font-family: 'Times New Roman'">Fair Value of Financial Instruments</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">The carrying value of the Company&#8217;s financial instruments included in current assets and current liabilities (such as cash and cash equivalents, accounts receivable, accounts payable, and accrued expenses) approximate their fair value due to the short-term nature of such instruments.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">The inputs used to measure fair value are based on a hierarchy that prioritizes observable and unobservable inputs used in valuation techniques. These levels, in order of highest to lowest priority, are described below:</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td style="width:36pt; vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">Level </span><span style="-aw-sdt-tag:'c10a34efbf72f35b33de'; font-family: 'Times New Roman'"><span style="font-weight:bold">1</span></span></p></td><td style="width:18pt; vertical-align:top"><div style="-aw-sdt-tag:'c574d522f70efd479dc3'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">Quoted prices (unadjusted) in active markets that are accessible at the measurement date for identical assets or liabilities.</span></p></td></tr><tr><td style="vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p></td><td style="vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p></td><td style="vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p></td></tr><tr><td style="vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">Level </span><span style="-aw-sdt-tag:'c152bc38d599e5fa0056'; font-family: 'Times New Roman'"><span style="font-weight:bold">2</span></span></p></td><td style="vertical-align:top"><div style="-aw-sdt-tag:'c41453b900cbc0348861'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">Observable prices that are based on inputs not quoted on active markets but corroborated by market data.</span></p></td></tr><tr><td style="vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p></td><td style="vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p></td><td style="vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p></td></tr><tr><td style="vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">Level </span><span style="-aw-sdt-tag:'cae8e9dbfa205b2e8396'; font-family: 'Times New Roman'"><span style="font-weight:bold">3</span></span></p></td><td style="vertical-align:top"><div style="-aw-sdt-tag:'c38191d9430425b3ee7b'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">Unobservable inputs reflecting the Company&#8217;s assumptions, consistent with reasonably available assumptions made by other market participants. These valuations require significant judgment.</span></p></td></tr></tbody></table><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">The Company&#8217;s financial instruments recorded at fair value on a recurring basis at </span><span style="-aw-sdt-tag:'ccb07ec5194190047e9d'; -aw-sdt-title:'Current_Period_P12'; font-family: 'Times New Roman'"><span>September 30, 2025</span></span><span style="font-family: 'Times New Roman';">, and </span><span style="-aw-sdt-tag:'c12a3919fe92233b9c27'; -aw-sdt-title:'Previous_Year_End_P13'; font-family: 'Times New Roman'"><span>December 31, 2024</span></span><span style="font-family: 'Times New Roman';"> include the derivative liability associated with the contingent milestone payment due to Knight upon a future sale of Arakoda or a Change of Control, which is carried at fair value based on Level </span><span style="-aw-sdt-tag:'cf44dbdc1b5a3adb8e5d'; font-family: 'Times New Roman'"><span>3</span></span><span style="font-family: 'Times New Roman';"> inputs. The Company uses a probability-weighted expected return method to determine the fair value of the contingent milestone payment using significant inputs such as the timing and probability of discrete potential exit scenarios, forward interest rate curves, and discount rates based on implied and market yields. See Note </span><span style="-aw-sdt-tag:'c607a69561493866770f'; font-family: 'Times New Roman'"><span>8</span></span><span style="font-family: 'Times New Roman';"> for more information on Derivative Liabilities.</span><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p><div style="-aw-sdt-tag:'PG_c0c20bca974f854c1494'"></div><div style="-aw-sdt-tag:'ce01f1bed3993d32f2f9'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Liabilities measured at fair value at </span><span style="-aw-sdt-tag:'c0bf68fbeefde243c15a'; -aw-sdt-title:'Current_Period_P15'; font-family: 'Times New Roman'"><span>September 30, 2025</span></span><span style="font-family: 'Times New Roman';"> and </span><span style="-aw-sdt-tag:'c732f17c4f405be7abd5'; -aw-sdt-title:'Previous_Year_End_P15'; font-family: 'Times New Roman'"><span>December 31, 2024</span></span><span style="font-family: 'Times New Roman';"> are as follows:</span></p><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p><div style="-aw-sdt-tag:'cf921e92f02c49f734d5'; -aw-sdt-title:'SIGNIFICANT ACCOUNTING POLICIES T1'"><table cellpadding="0" cellspacing="0" style="width:100%; border-collapse:collapse"><tbody><tr style="height:11.5pt"><td style="width:53%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:spaces; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="11" style="border-bottom:1.5pt solid #000000; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_1f865470141349c9b37ae84a55aacecc'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">September 30, 2025</span></p></div></td></tr><tr style="height:11.5pt"><td style="width:53%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="2" style="border-top:1.5pt solid #000000; border-bottom:1pt solid #000000; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_a9a7008663a046198bc1b79f62990348'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; -aw-import:spaces; font-family: 'Times New Roman'">&#160;</span><span style="font-weight:bold; font-family: 'Times New Roman'">Level 1</span></p></div></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="2" style="border-top:1.5pt solid #000000; border-bottom:1pt solid #000000; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_81f8a817fe384b62ae7dcf394585ad13'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; -aw-import:spaces; font-family: 'Times New Roman'">&#160;</span><span style="font-weight:bold; font-family: 'Times New Roman'">Level 2</span></p></div></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="2" style="border-top:1.5pt solid #000000; border-bottom:1pt solid #000000; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_0f2ddb2f4dea4255b9372b845c3d8cf9'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; -aw-import:spaces; font-family: 'Times New Roman'">&#160;</span><span style="font-weight:bold; font-family: 'Times New Roman'">Level 3</span></p></div></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="2" style="border-top:1.5pt solid #000000; border-bottom:1pt solid #000000; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_5169a80e4244429fb7957e47ebcd8580'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; -aw-import:spaces; font-family: 'Times New Roman'">&#160;</span><span style="font-weight:bold; font-family: 'Times New Roman'">Total</span></p></div></td></tr><tr style="height:11.5pt"><td style="width:53%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_c3fe79fa6419450bb2de75dc0fbcb8e0'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:spaces; font-family: 'Times New Roman'">&#160;</span><span style="font-family: 'Times New Roman';">Liabilities:</span></p></div></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td></tr><tr style="height:11.5pt"><td style="width:53%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_37594b78a4ff46fda8c7c6c31dda2819'"><p style="margin-top:0pt; margin-left:5.4pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:spaces; font-family: 'Times New Roman'">&#160;</span><span style="font-family: 'Times New Roman';">Derivative Liabilities</span></p></div></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_7f6e995134194c1f85dce5bf4027caab'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-tag:'C_1ebf3664e1d74ad8aa7a5f6f86bcafc6'"><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_2f314ddebd474b209bfcbd65835b25ed'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-tag:'C_ab7845e24d35492db1dd11a0aaa21e2e'"><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_e71039cd49df4ed0a91d801f3eecd241'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_c478d60eaf6f4ba79d74d84f29ff1501'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">797,275</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_d7e156ea5a164ce28ac588dac4d1a77f'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_706a282cea3b4dce906d3c671c501ff6'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">797,275</span></p></div></td></tr><tr style="height:11.5pt"><td style="width:53%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_e3a4e18287cc4026a749060e1e8fb5a9'"><p style="margin-top:0pt; margin-left:5.4pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:spaces; font-family: 'Times New Roman'">&#160;</span><span style="font-family: 'Times New Roman';">Total</span></p></div></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_105c7afdf9de422991cf5a00287ac307'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-tag:'C_7d18406ed78f4c4f8c3bb851f3c5e787'"><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_49026756b4a640278f43ece44be0ab14'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-tag:'C_a3c7a3645b97455cade875ff7e738781'"><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_8bbc20c75ef0447fa466d4bfaafb8f5f'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_62a7e9f4e692400483031bb740e41569'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">797,275</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_07827564eb61499086af507f234ed67f'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_1600b9fa42ba44889bf927265c22067e'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">797,275</span></p></div></td></tr></tbody></table></div><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p><div style="-aw-sdt-tag:'cb468fdcd6e0460b0777'; -aw-sdt-title:'SIGNIFICANT ACCOUNTING POLICIES T2'"><table cellpadding="0" cellspacing="0" style="width:100%; border-collapse:collapse"><tbody><tr style="height:11.5pt"><td style="width:53%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:spaces; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="11" style="border-bottom:1pt solid #000000; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_4b44e1528e8c4f3cbca59f75d6bdc366'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">December 31, 2024</span></p></div></td></tr><tr style="height:11.5pt"><td style="width:53%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="2" style="border-top:1.5pt solid #000000; border-bottom:1pt solid #000000; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_63bb47cb4152462c97cb5bc1a070ad98'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; -aw-import:spaces; font-family: 'Times New Roman'">&#160;</span><span style="font-weight:bold; font-family: 'Times New Roman'">Level 1</span></p></div></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="2" style="border-top:1.5pt solid #000000; border-bottom:1pt solid #000000; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_b9e93ac9d9e9420ea54dc08f973671b4'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; -aw-import:spaces; font-family: 'Times New Roman'">&#160;</span><span style="font-weight:bold; font-family: 'Times New Roman'">Level 2</span></p></div></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="2" style="border-top:1.5pt solid #000000; border-bottom:1pt solid #000000; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_6cfd423b093941b7a426daca9a7c4fd9'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; -aw-import:spaces; font-family: 'Times New Roman'">&#160;</span><span style="font-weight:bold; font-family: 'Times New Roman'">Level 3</span></p></div></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="2" style="border-top:1.5pt solid #000000; border-bottom:1pt solid #000000; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_ba6b2c8ff28f4584a84bb8a1cf763836'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; -aw-import:spaces; font-family: 'Times New Roman'">&#160;</span><span style="font-weight:bold; font-family: 'Times New Roman'">Total</span></p></div></td></tr><tr style="height:11.5pt"><td style="width:53%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_a6ef2c6558264f7ca0c50be6c5f2e477'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:spaces; font-family: 'Times New Roman'">&#160;</span><span style="font-family: 'Times New Roman';">Liabilities:</span></p></div></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td></tr><tr style="height:11.5pt"><td style="width:53%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_1ad21d4a0f664c76a8a1de7dc61969e3'"><p style="margin-top:0pt; margin-left:5.4pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:spaces; font-family: 'Times New Roman'">&#160;</span><span style="font-family: 'Times New Roman';">Derivative Liabilities</span></p></div></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_0c00d5728d434da99efe8bee0a732f0f'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-tag:'C_38b73fa55f154f55af3cfbeff629bf16'"><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_e025b21daccb422bbc8f2753e7ae30b9'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-tag:'C_333fc1e0c3f6433084115dd2779c80c0'"><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_ccf3e162c56f48aabe5b242a8d57684f'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_fda27296d6fe4023a90164878a00a1d8'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">640,830</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_121a4a1679bd49579650a47153a7674a'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_8c697e7693374899bebfc6db6f39b905'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">640,830</span></p></div></td></tr><tr style="height:11.5pt"><td style="width:53%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_cb56be67da024df7ab547d83c57f3594'"><p style="margin-top:0pt; margin-left:5.4pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:spaces; font-family: 'Times New Roman'">&#160;</span><span style="font-family: 'Times New Roman';">Total</span></p></div></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_1d0941b2301d4640a725a3c444db0b29'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-tag:'C_34e9411fc246454890a3839765ba75c7'"><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_5c011b0873844cb68a8ad4cfa194d590'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-tag:'C_59708d0fdeda4619aa91fe10eff71319'"><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_fcc1b7589a9c4ce3859c970a7eb6b9c6'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_712785fcd2f54bfb89d8883eed8aebd5'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">640,830</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_e0ed0ee91ac4479e99c9a1322299ae2a'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_a4fc6be6554e49b0832d0ac5c0e1c4d7'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">640,830</span></p></div></td></tr></tbody></table></div></div><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">There were no transfers of financial instruments between Level </span><span style="-aw-sdt-tag:'c512200b7f4efb193a74'; font-family: 'Times New Roman'"><span>1</span></span><span style="font-family: 'Times New Roman';">, Level </span><span style="-aw-sdt-tag:'cc88af1c10b9095520b3'; font-family: 'Times New Roman'"><span>2</span></span><span style="font-family: 'Times New Roman';">, and Level </span><span style="-aw-sdt-tag:'c28cda9bda6d116b1482'; font-family: 'Times New Roman'"><span>3</span></span><span style="font-family: 'Times New Roman';"> during the periods presented.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">A rollforward of liabilities measured at fair value using Level </span><span style="-aw-sdt-tag:'c3417e051371b629cb2b'; font-family: 'Times New Roman'"><span>3</span></span><span style="font-family: 'Times New Roman';"> inputs for the </span><span style="-aw-sdt-tag:'c07ff2f3886b9784d3b4'; -aw-sdt-title:'Current_Quarter_and_YTD_P9'; font-family: 'Times New Roman'"><span>three and nine months ended September 30, 2025</span></span><span style="font-family: 'Times New Roman';"> and </span><span style="-aw-sdt-tag:'ce922678da5c46f0ab60'; font-family: 'Times New Roman'"><span>2024</span></span><span style="font-family: 'Times New Roman';"> is presented in Note </span><span style="-aw-sdt-tag:'cb6b017f206e8e342188'; font-family: 'Times New Roman'"><span>8</span></span><span style="font-family: 'Times New Roman';"> &#8211; Derivative Liabilities.</span><span style="font-family: 'Times New Roman';">&#160;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sxtp_AssetsAndLiabilitiesNotMeasuredAtFairValueOnARecurringBasisPolicyTextBlock', window );">Assets and Liabilities Not Measured at Fair Value on a Recurring Basis</a></td>
<td class="text"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; text-decoration:underline; font-family: 'Times New Roman'">Assets and Liabilities Not Measured at Fair Value on a Recurring Basis</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">In addition to assets and liabilities that are measured at fair value on a recurring basis, the Company also measures certain assets and liabilities at fair value on a nonrecurring basis. The Company&#8217;s non-financial assets, including Intangible Assets and Property and Equipment, are measured at fair value when there is an indication of impairment and the carrying amount exceeds the asset&#8217;s projected undiscounted cash flows. These assets are recorded at fair value only when an impairment charge is recognized.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">Certificates of deposit, classified as cash equivalents or short-term investments depending on the instrument&#8217;s original time to maturity, are measured at amortized cost, which approximates fair value as of </span><span style="-aw-sdt-tag:'cbcda125eaa60887c6fa'; -aw-sdt-title:'Current_Period_P21'; font-family: 'Times New Roman'"><span>September 30, 2025</span></span><span style="font-family: 'Times New Roman';"> and </span><span style="-aw-sdt-tag:'c1cb724ff032da6352c4'; -aw-sdt-title:'Previous_Year_End_P18'; font-family: 'Times New Roman'"><span>December 31, 2024</span></span><span style="font-family: 'Times New Roman';">.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency Transactions and Translation</a></td>
<td class="text"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; text-decoration:underline; font-family: 'Times New Roman'">Foreign Currency Transactions and Translation</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">The individual financial statements of each group entity are measured and presented in the currency of the primary economic environment in which the entity operates (its functional currency). The consolidated condensed financial statements of the Company are presented in United States dollars, which is the functional currency of the Company and the presentation currency for the consolidated condensed financial statements.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">For the purpose of presenting consolidated condensed financial statements, the assets and liabilities of the Company&#8217;s foreign operations are mostly translated at exchange rates prevailing on the reporting date. Income and expense items are translated at the average exchange rates for the period, unless exchange rates fluctuate significantly during that period, in which case the exchange rates at the dates of the transactions are used. Exchange differences arising, if any, are recognized as a component of other comprehensive income (loss) as unrealized foreign currency translation gain (loss).</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p><div style="-aw-sdt-tag:'PG_c0a5df5ef4dd14c932ff'"></div><div style="-aw-sdt-tag:'c777f028f5d92d4cc514'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">Exchange rates along with historical rates used in these financial statements are as follows:</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p><div style="-aw-sdt-tag:'549-6dd-c75-531-a655'; -aw-sdt-title:'SIGNIFICANT ACCOUNTING POLICIES T3'"><table cellpadding="0" cellspacing="0" style="width:100%; border-collapse:collapse"><tbody><tr style="height:11.5pt"><td style="width:34%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="17" style="border-bottom:1.5pt solid #000000; padding:0.75pt; vertical-align:bottom; -aw-padding-bottom:0.75pt"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_9482da9e9ef24112bed6d94f9f662d7c'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">Average Exchange Rate</span></p></div></td></tr><tr style="height:11.5pt"><td style="width:34%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="5" style="border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; padding:0.75pt; vertical-align:bottom; -aw-padding-bottom:0.75pt; -aw-padding-top:0.75pt"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_659f3565fccf471d885d5bbcc6f23513'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">Three Months Ended September 30,</span></p></div></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="5" style="border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_af26db9d568a41c18f4404ac7ead58b6'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">Nine Months Ended September 30,</span></p></div></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="5" style="border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_cf885fb35a704f019f0cad0d5795b8d8'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">As of</span></p></div></td></tr><tr style="height:11.5pt"><td style="width:34%; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_973ee19447724c17b71b4faa457b2249'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">Currency</span></p></div></td><td style="width:1%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="2" style="border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; padding:0.75pt; vertical-align:bottom; -aw-padding-bottom:0.75pt; -aw-padding-top:0.75pt"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_e3e1c97c5b854e929dfeef87960bfbc4'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">2025</span></p></div></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="2" style="border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_91424ca5026c4cce945405cc6ea74a81'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">2024</span></p></div></td><td style="width:1%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="2" style="border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_791c5860584c493ba5598384cfdde256'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">2025</span></p></div></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="2" style="border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_fd4986cad1d4488da73173ef15330bc0'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">2024</span></p></div></td><td style="width:1%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="2" style="border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_63ce180cbb5d445f83c9530d4f721062'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">September 30, 2025</span></p></div></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="2" style="border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_d9d1430a9c7a400390a13074b0c685af'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">December 31, 2024</span></p></div></td></tr><tr style="height:11.5pt"><td style="width:34%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_dde09534ca0e4664b9e7a6dbce09d46b'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">1 AUD =</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:6%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_7254928b2f564e559f8c533598d728fb'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">0.65</span></p></div></td><td style="width:4%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_01fc1cc76a7d496482338117b041e5d7'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">USD</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:6%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_0dd2b89b644c47918dd20e0ae4036641'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">0.67</span></p></div></td><td style="width:4%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_60bc7b550ded4fd0b8454a10aff9f2b9'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">USD</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:6%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_39890b79d6d94e83bbb6512adb82089c'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">0.64</span></p></div></td><td style="width:4%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_bcf46b0b9cd64fa28023abd0bd2f9eeb'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">USD</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:4%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_ffd190f4cb644fdc858572d0e04df5bc'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">0.66</span></p></div></td><td style="width:4%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_2ed4c46e122f4c9388749a2785a69bc5'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">USD</span></p></div></td><td style="width:1%; vertical-align:bottom; background-color:#ccecff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:6%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_deaa0fa001c447fa9db5c11c7e69f76e'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">0.66</span></p></div></td><td style="width:4%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_4ed3d209ddad4027b90139f12205d725'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">USD</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:6%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_f1dbbad2340443dba35674893ccabab6'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">0.62</span></p></div></td><td style="width:4%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'0b4-c37-b49-3e0-c6cf'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">USD</span></p></div></td></tr></tbody></table></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription', window );">Reclassifications</a></td>
<td class="text"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; text-decoration:underline; font-family: 'Times New Roman'">Reclassifications</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">Certain prior period interim amounts have been reclassified for consistency with the current period presentation. These reclassifications had no material effect on the consolidated condensed results of operations and comprehensive loss, shareholders&#8217; equity, or cash flows.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-Based Payments</a></td>
<td class="text"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; text-decoration:underline; font-family: 'Times New Roman'">Share-Based Payments</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">On November </span><span style="-aw-sdt-tag:'cb8e4cad4e4d214394a1'; font-family: 'Times New Roman'"><span>22</span></span><span style="font-family: 'Times New Roman';">, </span><span style="-aw-sdt-tag:'c07fc0c7362febea5ed1'; font-family: 'Times New Roman'"><span>2022</span></span><span style="font-family: 'Times New Roman';">, the Company adopted the </span><span style="-aw-sdt-tag:'c82523a8da0311b6da03'; font-family: 'Times New Roman'"><span>2022</span></span><span style="font-family: 'Times New Roman';"> Equity Incentive Plan also referred to as (&#8220;</span><span style="-aw-sdt-tag:'c84ff39eab4b2b69d4e5'; font-family: 'Times New Roman'"><span>2022</span></span><span style="font-family: 'Times New Roman';"> Plan&#8221;). The </span><span style="-aw-sdt-tag:'c77a8fd767458ed89fe9'; font-family: 'Times New Roman'"><span>2022</span></span><span style="font-family: 'Times New Roman';"> Plan and related share-based awards are discussed more fully in Note </span><span style="-aw-sdt-tag:'c89592db43d1d0460416'; font-family: 'Times New Roman'"><span>10</span></span><span style="font-family: 'Times New Roman';">.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">The Company accounts for share-based payments in accordance with ASC Subtopic </span><span style="-aw-sdt-tag:'cfb759d6c4e98b9f102c'; font-family: 'Times New Roman'"><span>718</span></span><span style="font-family: 'Times New Roman';">, </span><span style="font-style:italic; font-family: 'Times New Roman'">Compensation - Stock Compensation </span><span style="font-family: 'Times New Roman';">(&#8220;ASC </span><span style="-aw-sdt-tag:'c28e007bf795e0cf0e4d'; font-family: 'Times New Roman'"><span>718</span></span><span style="font-family: 'Times New Roman';">&#8221;). The Company measures compensation for all share-based payment awards granted to employees, directors, and nonemployees, based on the estimated fair value of the awards on the date of grant. For awards that vest based on continued service, the service-based compensation cost is recognized on a straight-line basis over the requisite service period, which is generally the vesting period of the awards. For service vesting awards with compensation expense recognized on a straight-line basis, at no point in time does the cumulative grant date value of vested awards exceed the cumulative amount of compensation expense recognized. The grant date is determined based on the date when a mutual understanding of the key terms of the share-based awards is established. The Company accounts for forfeitures as they occur.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">The Company estimates the fair value of all stock option awards as of the grant date by applying the Black-Scholes option pricing model. The application of this valuation model involves assumptions, including the fair value of the common stock, expected volatility, risk-free interest rate, expected dividends and the expected term of the option. Due to the lack of a public market for the Company&#8217;s common stock prior to the IPO and lack of company-specific historical implied volatility data, the Company has based its computations of expected volatility on the historical volatility of a representative group of public companies with similar characteristics of the Company, including stage of development and industry focus. The historical volatility is calculated based on a period of time commensurate with the expected term assumption. The Company generally uses the simplified method as prescribed by the SEC Staff Accounting Bulletin Topic </span><span style="-aw-sdt-tag:'cdc65a3ad6830dc2131f'; font-family: 'Times New Roman'"><span>14</span></span><span style="font-family: 'Times New Roman';">, </span><span style="font-style:italic; font-family: 'Times New Roman'">Share-Based Payment</span><span style="font-family: 'Times New Roman';">, to estimate the expected term for stock options, whereby, the expected term equals the midpoint of the weighted average remaining time to vest, vesting period and the contractual term of the options due to its lack of historical exercise data. For certain options granted out-of-the-money, the Company&#8217;s best estimate of the expected term is the contractual term of the award. The risk-free interest rate is based on U.S. Treasury securities with a maturity date commensurate with the expected term of the associated award. The expected dividend yield is assumed to be zero as the Company has never paid dividends and has no current plans to pay any dividends on its common stock. The assumptions used in calculating the fair value of share-based awards represent management&#8217;s best estimates and involve inherent uncertainties and the application of significant judgment.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">Compensation expense for restricted stock units (&#8220;RSUs&#8221;) with only service-based vesting conditions is recognized on a straight-line basis over the vesting period. Compensation cost for service-based RSUs is based on the grant date fair value of the award, which is the closing market price of the Company&#8217;s common stock on the grant date multiplied by the number of shares awarded.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">For awards that vest upon a liquidity event or a change in control, the performance condition is not probable of being achieved until the event occurs. As a result, no compensation expense is recognized until the performance-based vesting condition is achieved, at which time the cumulative compensation expense is recognized. Compensation cost related to any remaining time-based service for share-based awards after the liquidity-based event is recognized on a straight-line basis over the remaining service period.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">For fully vested, nonforfeitable equity instruments that are granted at the date the Company and a nonemployee enter into an agreement for goods or services, the Company recognizes the fair value of the equity instruments on the grant date. The corresponding cost is recognized as an immediate expense or a prepaid asset and expensed over the service period depending on the specific facts and circumstances of the agreement with the nonemployee. See Note </span><span style="-aw-sdt-tag:'c7c93237c1946f635b03'; font-family: 'Times New Roman'"><span>10</span></span><span style="font-family: 'Times New Roman';"> for further details.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss per Common Share</a></td>
<td class="text"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; text-decoration:underline; font-family: 'Times New Roman'">Net Loss per Common Share</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-sdt-tag:'a31-2b2-f34-82d-cfe6'; -aw-sdt-title:'Net_(Loss)_Income_Title_P2'; font-family: 'Times New Roman'"><span>Net Loss</span></span><span style="font-family: 'Times New Roman';"> per Common Share is computed by dividing </span><span style="-aw-sdt-tag:'a78-fb5-6f5-642-14ce'; -aw-sdt-title:'Net_(Loss)_Income_Title___Lower_P1'; font-family: 'Times New Roman'"><span>net loss</span></span><span style="font-family: 'Times New Roman';"> attributable to common shareholders by the weighted average number of common shares outstanding during each period. The Company includes pre-funded warrants, which carry a nominal exercise price per share, in its computation of basic and diluted net loss per share beginning on the date of issuance. The cumulative dividends accrued on the Series A Preferred Stock during the period are reflected as an increase to net loss or a reduction of net income in determining basic and diluted </span><span style="-aw-sdt-tag:'31c-481-9ce-577-2088'; -aw-sdt-title:'Net_(Loss)_Income_Title___Lower_P2'; font-family: 'Times New Roman'"><span>net loss</span></span><span style="font-family: 'Times New Roman';"> attributable to common stockholders.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">As the Company reported a net loss for all periods presented, the calculation of diluted net loss per common share is the same as basic net loss per common share. </span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">As a result of the </span><span style="-aw-sdt-tag:'5f0-31e-83e-591-f354'; font-family: 'Times New Roman'"><span>1:5</span></span><span style="font-family: 'Times New Roman';"> Reverse Stock Split, which was effective as of February 24, 2025, all shares of outstanding common stock and net loss per common share calculations have been retroactively adjusted for all periods presented.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsPolicyTextBlock', window );">Related Parties</a></td>
<td class="text"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; text-decoration:underline; font-family: 'Times New Roman'">Related Parties</span></p><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">Parties are considered to be related to the Company if the parties, directly or indirectly, through one or more intermediaries, control, are controlled by, or are under common control with the Company. Related parties also include principal owners of the Company, its management, members of the immediate families of principal owners of the Company and its management and other parties with which the Company may deal with if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsPolicyPolicyTextBlock', window );">Subsequent Events</a></td>
<td class="text"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; text-decoration:underline; font-family: 'Times New Roman'">Subsequent Events</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">The Company considers events or transactions that occur after the balance sheet date, but prior to the issuance of the financial statements to provide additional evidence relative to certain estimates or to identify matters that require additional disclosure. Subsequent events have been evaluated through </span><span style="-aw-sdt-tag:'cb270f797852c1e1f2a5'; -aw-sdt-title:'Current_Period_Date_FS_Issued_P1'; font-family: 'Times New Roman'"><span>November 13, 2025</span></span><span style="font-family: 'Times New Roman';">, which is the date the financial statements were issued. See Note </span><span style="-aw-sdt-tag:'c8dbf1260408b95c5a15'; font-family: 'Times New Roman'"><span>12</span></span><span style="font-family: 'Times New Roman';">.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted and Issued Accounting Pronouncements</a></td>
<td class="text"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; text-decoration:underline; font-family: 'Times New Roman'">Recently Adopted and Issued Accounting Pronouncements</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">From time to time, the FASB issues Accounting Standards Updates (&#8220;ASU&#8221;) to amend the authoritative literature in the ASC. The Company regularly evaluates new ASUs to determine the impact that these pronouncements may have on the consolidated condensed financial statements. Other than the pronouncements listed below, the Company believes that those issued to date either (i) provide supplemental guidance, (ii) are technical corrections, or (iii) are not applicable to the Company&#8217;s consolidated condensed financial statements or related disclosures.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">In November </span><span style="-aw-sdt-tag:'c40fc8bff493befc18d6'; font-family: 'Times New Roman'"><span>2023</span></span><span style="font-family: 'Times New Roman';">, the FASB issued ASU </span><span style="-aw-sdt-tag:'c0a6b49074383096c882'; font-family: 'Times New Roman'"><span>2023</span></span><span style="font-family: 'Times New Roman';">-</span><span style="-aw-sdt-tag:'cd25ae9feb1743719bb1'; font-family: 'Times New Roman'"><span>07</span></span><span style="font-family: 'Times New Roman';">, </span><span style="font-style:italic; font-family: 'Times New Roman'">Segment Reporting (Topic </span><span style="-aw-sdt-tag:'c48474e3644a54930dfc'; font-family: 'Times New Roman'"><span style="font-style:italic">280</span></span><span style="font-style:italic; font-family: 'Times New Roman'">): Improvements to Reportable Segment Disclosures</span><span style="font-family: 'Times New Roman';"> (&#8220;ASU </span><span style="-aw-sdt-tag:'c731ea50ea67c7e4b420'; font-family: 'Times New Roman'"><span>2023</span></span><span style="font-family: 'Times New Roman';">-</span><span style="-aw-sdt-tag:'cce9c44e2351f5ac2796'; font-family: 'Times New Roman'"><span>07</span></span><span style="font-family: 'Times New Roman';">&#8221;) which expands annual and interim disclosure requirements for reportable segments, primarily through enhanced disclosures about significant segment expenses and segment profit or loss. ASU </span><span style="-aw-sdt-tag:'c7a9ce0a0ac8993d0acf'; font-family: 'Times New Roman'"><span>2023</span></span><span style="font-family: 'Times New Roman';">-</span><span style="-aw-sdt-tag:'cdd16562ce807243ed58'; font-family: 'Times New Roman'"><span>07</span></span><span style="font-family: 'Times New Roman';"> also requires entities with a single reportable segment to provide all segment disclosures under ASC </span><span style="-aw-sdt-tag:'cf6e9777e809f25e1b07'; font-family: 'Times New Roman'"><span>280</span></span><span style="font-family: 'Times New Roman';">, including the new required disclosures under the ASU. The Company adopted ASU </span><span style="-aw-sdt-tag:'cc9be51d0fa22b72f687'; font-family: 'Times New Roman'"><span>2023</span></span><span style="font-family: 'Times New Roman';">-</span><span style="-aw-sdt-tag:'cc2f4662055f1cf358a4'; font-family: 'Times New Roman'"><span>07</span></span><span style="font-family: 'Times New Roman';"> on a retrospective basis for the </span><span style="-aw-sdt-tag:'c304e39ce5549b67326b'; font-family: 'Times New Roman'"><span>2024</span></span><span style="font-family: 'Times New Roman';"> annual period, and for interim periods beginning in </span><span style="-aw-sdt-tag:'c50e039416b6752cbc9e'; font-family: 'Times New Roman'"><span>2025</span></span><span style="font-family: 'Times New Roman';">. The impact is limited to the Company&#8217;s financial statement disclosures, which are presented in the Segment Information section above.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">In December </span><span style="-aw-sdt-tag:'cf066c3ed14287513469'; font-family: 'Times New Roman'"><span>2023</span></span><span style="font-family: 'Times New Roman';">, the FASB issued ASU </span><span style="-aw-sdt-tag:'c0565bc7ca2af95b4c7c'; font-family: 'Times New Roman'"><span>2023</span></span><span style="font-family: 'Times New Roman';">-</span><span style="-aw-sdt-tag:'ceb96c9259852308d896'; font-family: 'Times New Roman'"><span>09</span></span><span style="font-family: 'Times New Roman';">, </span><span style="font-style:italic; font-family: 'Times New Roman'">Income Taxes (ASC </span><span style="-aw-sdt-tag:'c0282851b575f38250ce'; font-family: 'Times New Roman'"><span style="font-style:italic">740</span></span><span style="font-style:italic; font-family: 'Times New Roman'">): Improvements to Income Tax Disclosures</span><span style="font-family: 'Times New Roman';"> (&#8220;ASU </span><span style="-aw-sdt-tag:'c397c2576fab14a6843a'; font-family: 'Times New Roman'"><span>2023</span></span><span style="font-family: 'Times New Roman';">-</span><span style="-aw-sdt-tag:'c43ea664edca3b7d1221'; font-family: 'Times New Roman'"><span>09</span></span><span style="font-family: 'Times New Roman';">&#8221;) which requires disaggregated information about a reporting entity&#8217;s effective tax rate reconciliation as well as information on income taxes paid. ASU </span><span style="-aw-sdt-tag:'ced6791b435360aa514d'; font-family: 'Times New Roman'"><span>2023</span></span><span style="font-family: 'Times New Roman';">-</span><span style="-aw-sdt-tag:'c152d39afa37813cff35'; font-family: 'Times New Roman'"><span>09</span></span><span style="font-family: 'Times New Roman';"> is effective for annual periods beginning after December </span><span style="-aw-sdt-tag:'c65d60af908ae022a7fb'; font-family: 'Times New Roman'"><span>15</span></span><span style="font-family: 'Times New Roman';">, </span><span style="-aw-sdt-tag:'c9d2f568ca33a0e3ddc2'; font-family: 'Times New Roman'"><span>2024</span></span><span style="font-family: 'Times New Roman';">. The Company will adopt this standard for the annual period ending December 31, 2025. The impact of ASU 2023-09 will be limited to the Company&#8217;s financial statement disclosures.</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">In November </span><span style="-aw-sdt-tag:'cb06da4c60c3ed718870'; font-family: 'Times New Roman'"><span>2024</span></span><span style="font-family: 'Times New Roman';">, the FASB issued ASU </span><span style="-aw-sdt-tag:'c5896724f85326b5cf6c'; font-family: 'Times New Roman'"><span>2024</span></span><span style="font-family: 'Times New Roman';">-</span><span style="-aw-sdt-tag:'c5ee0130675746e94982'; font-family: 'Times New Roman'"><span>03</span></span><span style="font-family: 'Times New Roman';">, </span><span style="font-style:italic; font-family: 'Times New Roman'">Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic </span><span style="-aw-sdt-tag:'c686357b9151070c0b80'; font-family: 'Times New Roman'"><span style="font-style:italic">220</span></span><span style="font-style:italic; font-family: 'Times New Roman'">-</span><span style="-aw-sdt-tag:'ccb37deca24433c43642'; font-family: 'Times New Roman'"><span style="font-style:italic">40</span></span><span style="font-style:italic; font-family: 'Times New Roman'">): Disaggregation of Income Statement Expenses </span><span style="font-family: 'Times New Roman';">(&#8220;ASU </span><span style="-aw-sdt-tag:'c82c510f162b91f255e5'; font-family: 'Times New Roman'"><span>2024</span></span><span style="font-family: 'Times New Roman';">-</span><span style="-aw-sdt-tag:'c9b3edff03a8224442ee'; font-family: 'Times New Roman'"><span>03</span></span><span style="font-family: 'Times New Roman';">&#8221;), which applies to all public business entities that file financial statements with the SEC. The amendments in this ASU require public business entities to disclose on an annual and interim basis, disaggregated information about certain income statement expense line items. The new standard is effective for fiscal years beginning after December </span><span style="-aw-sdt-tag:'c4227d4f684c80f6fc7b'; font-family: 'Times New Roman'"><span>15</span></span><span style="font-family: 'Times New Roman';">, </span><span style="-aw-sdt-tag:'cdb1897f2589fc5290f5'; font-family: 'Times New Roman'"><span>2026</span></span><span style="font-family: 'Times New Roman';">, with early adoption permitted. The Company is currently evaluating the impact that ASU </span><span style="-aw-sdt-tag:'cd9fcbee88c447594d3d'; font-family: 'Times New Roman'"><span>2024</span></span><span style="font-family: 'Times New Roman';">-</span><span style="-aw-sdt-tag:'cea1fdf602d68e8ea393'; font-family: 'Times New Roman'"><span>03</span></span><span style="font-family: 'Times New Roman';"> will have on its financial statement disclosures.</span><span style="font-family: 'Times New Roman';">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sxtp_AssetsAndLiabilitiesNotMeasuredAtFairValueOnARecurringBasisPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for assets and liabilities not measured at fair value on a recurring basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sxtp_AssetsAndLiabilitiesNotMeasuredAtFairValueOnARecurringBasisPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sxtp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sxtp_EquityClassifiedWarrantsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for equity-classified warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sxtp_EquityClassifiedWarrantsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sxtp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk. Includes, but is not limited to, policy for entering into master netting arrangement or similar agreement to mitigate credit risk of financial instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479693/815-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-7<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4F<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/815/tableOfContent<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(n))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/830/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 205<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483504/205-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PriorPeriodReclassificationAdjustmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-18<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org/606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 36<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-36<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-4<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its capital stock transactions, including dividends and accumulated other comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reporting subsequent events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482836/275-10-55-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock', window );">Schedule of Liabilities Measured at Fair Value</a></td>
<td class="text"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Liabilities measured at fair value at </span><span style="-aw-sdt-tag:'c0bf68fbeefde243c15a'; -aw-sdt-title:'Current_Period_P15'; font-family: 'Times New Roman'"><span>September 30, 2025</span></span><span style="font-family: 'Times New Roman';"> and </span><span style="-aw-sdt-tag:'c732f17c4f405be7abd5'; -aw-sdt-title:'Previous_Year_End_P15'; font-family: 'Times New Roman'"><span>December 31, 2024</span></span><span style="font-family: 'Times New Roman';"> are as follows:</span></p><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p><div style="-aw-sdt-tag:'cf921e92f02c49f734d5'; -aw-sdt-title:'SIGNIFICANT ACCOUNTING POLICIES T1'"><table cellpadding="0" cellspacing="0" style="width:100%; border-collapse:collapse"><tbody><tr style="height:11.5pt"><td style="width:53%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:spaces; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="11" style="border-bottom:1.5pt solid #000000; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_1f865470141349c9b37ae84a55aacecc'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">September 30, 2025</span></p></div></td></tr><tr style="height:11.5pt"><td style="width:53%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="2" style="border-top:1.5pt solid #000000; border-bottom:1pt solid #000000; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_a9a7008663a046198bc1b79f62990348'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; -aw-import:spaces; font-family: 'Times New Roman'">&#160;</span><span style="font-weight:bold; font-family: 'Times New Roman'">Level 1</span></p></div></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="2" style="border-top:1.5pt solid #000000; border-bottom:1pt solid #000000; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_81f8a817fe384b62ae7dcf394585ad13'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; -aw-import:spaces; font-family: 'Times New Roman'">&#160;</span><span style="font-weight:bold; font-family: 'Times New Roman'">Level 2</span></p></div></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="2" style="border-top:1.5pt solid #000000; border-bottom:1pt solid #000000; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_0f2ddb2f4dea4255b9372b845c3d8cf9'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; -aw-import:spaces; font-family: 'Times New Roman'">&#160;</span><span style="font-weight:bold; font-family: 'Times New Roman'">Level 3</span></p></div></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="2" style="border-top:1.5pt solid #000000; border-bottom:1pt solid #000000; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_5169a80e4244429fb7957e47ebcd8580'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; -aw-import:spaces; font-family: 'Times New Roman'">&#160;</span><span style="font-weight:bold; font-family: 'Times New Roman'">Total</span></p></div></td></tr><tr style="height:11.5pt"><td style="width:53%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_c3fe79fa6419450bb2de75dc0fbcb8e0'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:spaces; font-family: 'Times New Roman'">&#160;</span><span style="font-family: 'Times New Roman';">Liabilities:</span></p></div></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td></tr><tr style="height:11.5pt"><td style="width:53%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_37594b78a4ff46fda8c7c6c31dda2819'"><p style="margin-top:0pt; margin-left:5.4pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:spaces; font-family: 'Times New Roman'">&#160;</span><span style="font-family: 'Times New Roman';">Derivative Liabilities</span></p></div></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_7f6e995134194c1f85dce5bf4027caab'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-tag:'C_1ebf3664e1d74ad8aa7a5f6f86bcafc6'"><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_2f314ddebd474b209bfcbd65835b25ed'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-tag:'C_ab7845e24d35492db1dd11a0aaa21e2e'"><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_e71039cd49df4ed0a91d801f3eecd241'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_c478d60eaf6f4ba79d74d84f29ff1501'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">797,275</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_d7e156ea5a164ce28ac588dac4d1a77f'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_706a282cea3b4dce906d3c671c501ff6'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">797,275</span></p></div></td></tr><tr style="height:11.5pt"><td style="width:53%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_e3a4e18287cc4026a749060e1e8fb5a9'"><p style="margin-top:0pt; margin-left:5.4pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:spaces; font-family: 'Times New Roman'">&#160;</span><span style="font-family: 'Times New Roman';">Total</span></p></div></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_105c7afdf9de422991cf5a00287ac307'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-tag:'C_7d18406ed78f4c4f8c3bb851f3c5e787'"><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_49026756b4a640278f43ece44be0ab14'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-tag:'C_a3c7a3645b97455cade875ff7e738781'"><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_8bbc20c75ef0447fa466d4bfaafb8f5f'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_62a7e9f4e692400483031bb740e41569'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">797,275</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_07827564eb61499086af507f234ed67f'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_1600b9fa42ba44889bf927265c22067e'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">797,275</span></p></div></td></tr></tbody></table></div><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p><div style="-aw-sdt-tag:'cb468fdcd6e0460b0777'; -aw-sdt-title:'SIGNIFICANT ACCOUNTING POLICIES T2'"><table cellpadding="0" cellspacing="0" style="width:100%; border-collapse:collapse"><tbody><tr style="height:11.5pt"><td style="width:53%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:spaces; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="11" style="border-bottom:1pt solid #000000; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_4b44e1528e8c4f3cbca59f75d6bdc366'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">December 31, 2024</span></p></div></td></tr><tr style="height:11.5pt"><td style="width:53%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="2" style="border-top:1.5pt solid #000000; border-bottom:1pt solid #000000; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_63bb47cb4152462c97cb5bc1a070ad98'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; -aw-import:spaces; font-family: 'Times New Roman'">&#160;</span><span style="font-weight:bold; font-family: 'Times New Roman'">Level 1</span></p></div></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="2" style="border-top:1.5pt solid #000000; border-bottom:1pt solid #000000; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_b9e93ac9d9e9420ea54dc08f973671b4'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; -aw-import:spaces; font-family: 'Times New Roman'">&#160;</span><span style="font-weight:bold; font-family: 'Times New Roman'">Level 2</span></p></div></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="2" style="border-top:1.5pt solid #000000; border-bottom:1pt solid #000000; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_6cfd423b093941b7a426daca9a7c4fd9'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; -aw-import:spaces; font-family: 'Times New Roman'">&#160;</span><span style="font-weight:bold; font-family: 'Times New Roman'">Level 3</span></p></div></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="2" style="border-top:1.5pt solid #000000; border-bottom:1pt solid #000000; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_ba6b2c8ff28f4584a84bb8a1cf763836'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; -aw-import:spaces; font-family: 'Times New Roman'">&#160;</span><span style="font-weight:bold; font-family: 'Times New Roman'">Total</span></p></div></td></tr><tr style="height:11.5pt"><td style="width:53%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_a6ef2c6558264f7ca0c50be6c5f2e477'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:spaces; font-family: 'Times New Roman'">&#160;</span><span style="font-family: 'Times New Roman';">Liabilities:</span></p></div></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td></tr><tr style="height:11.5pt"><td style="width:53%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_1ad21d4a0f664c76a8a1de7dc61969e3'"><p style="margin-top:0pt; margin-left:5.4pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:spaces; font-family: 'Times New Roman'">&#160;</span><span style="font-family: 'Times New Roman';">Derivative Liabilities</span></p></div></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_0c00d5728d434da99efe8bee0a732f0f'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-tag:'C_38b73fa55f154f55af3cfbeff629bf16'"><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_e025b21daccb422bbc8f2753e7ae30b9'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-tag:'C_333fc1e0c3f6433084115dd2779c80c0'"><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_ccf3e162c56f48aabe5b242a8d57684f'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_fda27296d6fe4023a90164878a00a1d8'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">640,830</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_121a4a1679bd49579650a47153a7674a'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_8c697e7693374899bebfc6db6f39b905'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">640,830</span></p></div></td></tr><tr style="height:11.5pt"><td style="width:53%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_cb56be67da024df7ab547d83c57f3594'"><p style="margin-top:0pt; margin-left:5.4pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:spaces; font-family: 'Times New Roman'">&#160;</span><span style="font-family: 'Times New Roman';">Total</span></p></div></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_1d0941b2301d4640a725a3c444db0b29'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-tag:'C_34e9411fc246454890a3839765ba75c7'"><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_5c011b0873844cb68a8ad4cfa194d590'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-tag:'C_59708d0fdeda4619aa91fe10eff71319'"><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_fcc1b7589a9c4ce3859c970a7eb6b9c6'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_712785fcd2f54bfb89d8883eed8aebd5'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">640,830</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_e0ed0ee91ac4479e99c9a1322299ae2a'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_a4fc6be6554e49b0832d0ac5c0e1c4d7'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">640,830</span></p></div></td></tr></tbody></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock', window );">Schedule of Exchange Rates along with Historical Rates</a></td>
<td class="text"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">Exchange rates along with historical rates used in these financial statements are as follows:</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p><div style="-aw-sdt-tag:'549-6dd-c75-531-a655'; -aw-sdt-title:'SIGNIFICANT ACCOUNTING POLICIES T3'"><table cellpadding="0" cellspacing="0" style="width:100%; border-collapse:collapse"><tbody><tr style="height:11.5pt"><td style="width:34%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="17" style="border-bottom:1.5pt solid #000000; padding:0.75pt; vertical-align:bottom; -aw-padding-bottom:0.75pt"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_9482da9e9ef24112bed6d94f9f662d7c'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">Average Exchange Rate</span></p></div></td></tr><tr style="height:11.5pt"><td style="width:34%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="5" style="border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; padding:0.75pt; vertical-align:bottom; -aw-padding-bottom:0.75pt; -aw-padding-top:0.75pt"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_659f3565fccf471d885d5bbcc6f23513'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">Three Months Ended September 30,</span></p></div></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="5" style="border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_af26db9d568a41c18f4404ac7ead58b6'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">Nine Months Ended September 30,</span></p></div></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="5" style="border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_cf885fb35a704f019f0cad0d5795b8d8'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">As of</span></p></div></td></tr><tr style="height:11.5pt"><td style="width:34%; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_973ee19447724c17b71b4faa457b2249'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">Currency</span></p></div></td><td style="width:1%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="2" style="border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; padding:0.75pt; vertical-align:bottom; -aw-padding-bottom:0.75pt; -aw-padding-top:0.75pt"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_e3e1c97c5b854e929dfeef87960bfbc4'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">2025</span></p></div></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="2" style="border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_91424ca5026c4cce945405cc6ea74a81'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">2024</span></p></div></td><td style="width:1%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="2" style="border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_791c5860584c493ba5598384cfdde256'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">2025</span></p></div></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="2" style="border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_fd4986cad1d4488da73173ef15330bc0'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">2024</span></p></div></td><td style="width:1%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="2" style="border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_63ce180cbb5d445f83c9530d4f721062'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">September 30, 2025</span></p></div></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="2" style="border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_d9d1430a9c7a400390a13074b0c685af'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">December 31, 2024</span></p></div></td></tr><tr style="height:11.5pt"><td style="width:34%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_dde09534ca0e4664b9e7a6dbce09d46b'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">1 AUD =</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:6%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_7254928b2f564e559f8c533598d728fb'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">0.65</span></p></div></td><td style="width:4%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_01fc1cc76a7d496482338117b041e5d7'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">USD</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:6%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_0dd2b89b644c47918dd20e0ae4036641'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">0.67</span></p></div></td><td style="width:4%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_60bc7b550ded4fd0b8454a10aff9f2b9'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">USD</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:6%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_39890b79d6d94e83bbb6512adb82089c'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">0.64</span></p></div></td><td style="width:4%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_bcf46b0b9cd64fa28023abd0bd2f9eeb'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">USD</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:4%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_ffd190f4cb644fdc858572d0e04df5bc'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">0.66</span></p></div></td><td style="width:4%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_2ed4c46e122f4c9388749a2785a69bc5'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">USD</span></p></div></td><td style="width:1%; vertical-align:bottom; background-color:#ccecff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:6%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_deaa0fa001c447fa9db5c11c7e69f76e'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">0.66</span></p></div></td><td style="width:4%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_4ed3d209ddad4027b90139f12205d725'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">USD</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:6%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_f1dbbad2340443dba35674893ccabab6'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">0.62</span></p></div></td><td style="width:4%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'0b4-c37-b49-3e0-c6cf'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">USD</span></p></div></td></tr></tbody></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the presentation of foreign exchange contracts on the statement of financial position, including the fair value amounts and location of such amounts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4E<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORY (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>INVENTORY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventory</a></td>
<td class="text"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">Inventory consists of the following major classes:</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><div style="-aw-sdt-tag:'c3ad763587e21d5ec175'; -aw-sdt-title:'INVENTORY T1'"><table cellpadding="0" cellspacing="0" style="width:100%; margin-right:auto; margin-left:auto; border-collapse:collapse"><tbody><tr style="height:11.5pt"><td style="width:77%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="2" style="border-bottom:1.5pt solid #000000; padding-right:5.75pt; padding-left:5.75pt; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_8c78ee49c91e44ce918f2ebd1b7927a2'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">September 30, 2025</span></p></div></td><td style="width:1%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="2" style="border-bottom:1.5pt solid #000000; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_eb198c15a0e04e4e8352b8854a5daadc'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">December 31, 2024</span></p></div></td></tr><tr style="height:11.5pt"><td style="width:77%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_9f6e148ddfbd43bd85c0bd773b3ebd5b'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Raw Material (API)</span></p></div></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_00a19566ed1c43f99c98897b148d8d2a'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_f16c7a3406eb4165a5632f4b2432cc52'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">345,195</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_97a890fb4676459799df39011e8dd53c'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-tag:'C_ab71897d07ac40d28dfd83405a9dfafe'"><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td></tr><tr style="height:11.5pt"><td style="width:77%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_aeef74c84e0f4d1f96536ddc357d7064'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Work in Process</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-tag:'C_6a3655bdab5d48dd86ca61227681b415'"><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_ef00ca8ecef947d48a2392dce651f727'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">284,883</span></p></div></td></tr><tr style="height:11.5pt"><td style="width:77%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_d5d56b1ac61047c8bb2cd738f043bffa'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Finished Goods</span></p></div></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_5b0903d97dea4325b613f810a8c5eaf2'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">426,491</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_36ca9b2fc2674b1b9e7c5ee6ac7b2cc2'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">157,881</span></p></div></td></tr><tr style="height:11.5pt"><td style="width:77%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_be61fc4bb0cc4c4ba6288d79409b3e45'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Total Inventory</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_83e5c4c46f15469f98bfb74b9c0152cc'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">771,686</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_a90105c86d004c7988263596647fb77a'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">442,764</span></p></div></td></tr><tr style="height:11.5pt"><td style="width:77%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_4beb2619f3b64a17be38dcd2cbe156d3'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Reserve for Expiring Inventory</span></p></div></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_93d116c0bb494287916a99a01a7fd59c'; font-family: 'Times New Roman'"><span>244,682</span></span><span style="font-family: 'Times New Roman';">)</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-tag:'C_dee47b6fa0dc487eba64f4acdf903ada'"><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td></tr><tr style="height:11.5pt"><td style="width:77%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_73dc86a2354c42c5af659415f686502c'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">Inventory</span></p></div></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_18ec2a0d235e48ca8dccc53077caf073'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">$</span></p></div></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_352a37dac1dc493db25e225319ba1514'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">527,004</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_14f157594d2f42b2a8d7ac54924f20bb'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">$</span></p></div></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'d7b-8b1-5fc-6b2-f7e6'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">442,764</span></p></div></td></tr></tbody></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483489/210-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>PROPERTY AND EQUIPMENT</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment</a></td>
<td class="text"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">Property and Equipment, net consists of:</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><div style="-aw-sdt-tag:'c585e2b6503490e35b6e'; -aw-sdt-title:'PROPERTY AND EQUIPMENT T1'"><table cellpadding="0" cellspacing="0" style="width:100%; border-collapse:collapse"><tbody><tr style="height:11.5pt"><td style="width:77%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="2" style="border-bottom:1.5pt solid #000000; padding-right:5.75pt; padding-left:5.75pt; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_d243be9044f94e5789d1c03995fef724'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">September 30, 2025</span></p></div></td><td style="width:1%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="2" style="border-bottom:1.5pt solid #000000; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_cdf2c2bb81134c98a67579ef3ca9e8ac'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">December 31, 2024</span></p></div></td></tr><tr style="height:11.5pt"><td style="width:77%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_210216e127fe482781b410d7ec74a0b8'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Lab Equipment</span></p></div></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_53af035c51d0478aa394754c413e6ffb'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_9328eadfcc594ac596b0acc136f7b8f0'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">333,010</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_e940a18328bb4ad9bea7def38d0d559f'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_2329b86c972f422ba404be9dd3277495'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">233,411</span></p></div></td></tr><tr style="height:11.5pt"><td style="width:77%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_0319c462920c42afa0d3176c000bd9f7'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Machinery</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_ef8d24443e6e4e8cb5980f37db5e774c'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">55,800</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_c8ff641cd4744c44a8ca4ea45f4e85c8'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">55,800</span></p></div></td></tr><tr style="height:11.5pt"><td style="width:77%; vertical-align:middle; background-color:#ccecff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_6249934fa3de4adaa792e486a851badc'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Computer Equipment</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ccecff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:middle; background-color:#ccecff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_aca3f556efe04148b984c56098021a99'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">11,597</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ccecff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#ccecff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:middle; background-color:#ccecff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_a531e0c254db4110ad34d073164553f9'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">7,000</span></p></div></td></tr><tr style="height:11.5pt"><td style="width:77%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_aebc173cb2c8413fa5fcf35341f8657a'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Furniture</span></p></div></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_b504fb680d844731bb0cd3fabd739eac'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">3,030</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_6e01e63464c941e29d2034653b8107e5'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">3,030</span></p></div></td></tr><tr style="height:11.5pt"><td style="width:77%; vertical-align:middle; background-color:#ccecff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_8a33d8c7b8f447cf9991bc44f6e506d2'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Property and Equipment, at cost</span></p></div></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ccecff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ccecff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_7e9128e9f9104afc873f970c6a9135ce'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">403,437</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ccecff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ccecff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ccecff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_0083050d4387424b9262c3e3b6a9fee5'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">299,241</span></p></div></td></tr><tr style="height:11.5pt"><td style="width:77%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_b6b62697f29548dbaf51d4cf72f0c5f7'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Accumulated Depreciation</span></p></div></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_d1d3c66b3b5440948d85580b0ecb68ec'; font-family: 'Times New Roman'"><span>175,685</span></span><span style="font-family: 'Times New Roman';">)</span></p></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_6e53c81a6ded46cca2cd24a44cf411d0'; font-family: 'Times New Roman'"><span>149,433</span></span><span style="font-family: 'Times New Roman';">)</span></p></td></tr><tr style="height:11.5pt"><td style="width:77%; vertical-align:middle; background-color:#ccecff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_11c099461546454a8d4b17afa85db567'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">Property and Equipment, net</span></p></div></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ccecff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_e7ec042f6b194d6a858be22c9a1b091a'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">$</span></p></div></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ccecff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_2faa5c0453e4450596c4956cffc1df1e'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">227,752</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ccecff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ccecff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_05cfb6f1de00493d99ff10680b286a1a'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">$</span></p></div></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ccecff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_519d7c2bff0c454799f8e791a58c7103'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">149,808</span></p></div></td></tr></tbody></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLE ASSETS (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>INTANGIBLE ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Intangible Assets</a></td>
<td class="text"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">Intangible Assets, net consists of:</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><div style="-aw-sdt-tag:'c07707b83cb3f173b9aa'; -aw-sdt-title:'INTANGIBLE ASSETS T1'"><table cellpadding="0" cellspacing="0" style="width:100%; border-collapse:collapse"><tbody><tr style="height:11.5pt"><td style="width:76%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="2" style="border-bottom:1.5pt solid #000000; padding-right:5.75pt; padding-left:5.75pt; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_e87ec5587e3840c4a97f2064f2104ed4'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">September 30, 2025</span></p></div></td><td style="width:1%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="2" style="border-bottom:1.5pt solid #000000; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_6084f1e1489b48879fcbbe5600141f97'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">December 31, 2024</span></p></div></td></tr><tr style="height:11.5pt"><td style="width:76%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_a974f35cc65443269ff066743129189d'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Patents</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_d202bcb88b044d028a4bbb28f6a6e8b0'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_11b78614bac54ef0a49e4b893a15b1d0'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">152,267</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_51a78629619a4b75ba95f8f8f4f7ec7b'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_860e11faa60f4e3cb17c35e447e6d321'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">127,603</span></p></div></td></tr><tr style="height:11.5pt"><td style="width:76%; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_f612ea6912ea4de8936ab11fa94001b2'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Website Development Costs</span></p></div></td><td style="width:1%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_bd5beeeb98654d3cb378b1f150cf237e'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">106,407</span></p></div></td><td style="width:1%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_0297394f2e174985a9011e14c17a1c32'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">104,622</span></p></div></td></tr><tr style="height:11.5pt"><td style="width:76%; vertical-align:middle; background-color:#ccecff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_69283753d7194d8481cb58344618da62'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Intangible Assets, at cost</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ccecff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ccecff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ccecff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_67428270244741e190f4ba5b6f6c89a4'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">258,674</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ccecff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ccecff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ccecff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_ce68356243274a62b8341406f23e7284'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">232,225</span></p></div></td></tr><tr style="height:11.5pt"><td style="width:76%; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_5ec84ad9cbbb4a728206c96fd6d9a6ac'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Accumulated Amortization</span></p></div></td><td style="width:1%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_a4c0c57793a24539a911c71110c0a6db'; font-family: 'Times New Roman'"><span>106,291</span></span><span style="font-family: 'Times New Roman';">)</span></p></td><td style="width:1%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_ba8b1931203d40b8b853f7cd33fb68a0'; font-family: 'Times New Roman'"><span>75,141</span></span><span style="font-family: 'Times New Roman';">)</span></p></td></tr><tr style="height:11.5pt"><td style="width:76%; vertical-align:middle; background-color:#ccecff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_609bae755e8b4231bb1d4b943acee2ff'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">Intangible Assets, net</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ccecff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ccecff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_bbacba70555c4d44a3ed2b95ac3cb5f3'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">$</span></p></div></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ccecff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_2fda802cc17945c78daa21dc34cb0e8e'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">152,383</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ccecff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ccecff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_0f46f04104944ac794c1fcc3501b0184'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">$</span></p></div></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ccecff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_01b52cfeb567443aae2cc897f6e6903c'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">157,084</span></p></div></td></tr></tbody></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of Estimated Future Amortization Expense for Our Patents and Website Development Costs</a></td>
<td class="text"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">The following table summarizes the estimated future amortization expense for our patents and website development costs as of </span><span style="-aw-sdt-tag:'ce96f421a46d06d458b3'; -aw-sdt-title:'Current_Period_P7'; font-family: 'Times New Roman'"><span>September 30, 2025</span></span><span style="font-family: 'Times New Roman';">:</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><div style="-aw-sdt-tag:'c0f2fdd191b23a42f69c'; -aw-sdt-title:'INTANGIBLE ASSETS T2'"><table cellpadding="0" cellspacing="0" style="width:100%; border-collapse:collapse"><tbody><tr style="height:11.5pt"><td style="width:76%; border-bottom:1.5pt solid #000000; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_174dcc19aadc45dcbec245e8e5590546'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">Period</span></p></div></td><td style="width:1%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="2" style="border-bottom:1.5pt solid #000000; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_2b4fd151a35e427f81944ed4aef3cd03'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">Patents</span></p></div></td><td style="width:1%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="2" style="border-bottom:1.5pt solid #000000; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_eac02702a1b6481292e04477eabff1f5'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">Website Development Costs</span></p></div></td></tr><tr style="height:11.5pt"><td style="width:76%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_bed21abb624848b39d25a0e5198a3eea'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">2025 (remaining three months)</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_0628bafa871b46b6b23c7839bac84a2b'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; border-top:1.5pt solid #000000; padding-right:0.7pt; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_9ed72b1fc9a841678c6414ffa9250716'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">1,816</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_9971da9e37cf45c6965a560295ce2ee3'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_b86b8d6612d346b299a1f4e8b716937d'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">5,754</span></p></div></td></tr><tr style="height:11.5pt"><td style="width:76%; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_98ee970e69c748c69cc8bbd0ed8e7995'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">2026</span></p></div></td><td style="width:1%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; padding-right:0.7pt; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_29d81502a5fc40d6b3b22b749ae8c2cc'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">7,264</span></p></div></td><td style="width:1%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_d2022197ea7e432dad2b843e2cba5634'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">13,027</span></p></div></td></tr><tr style="height:11.5pt"><td style="width:76%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_4130c067c39a40829ddaa2a81e97ae4b'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">2027</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; padding-right:0.7pt; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_4d3a475d713840deb210ba44e18e1f33'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">7,264</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_5fd36d2d7338473a98e0eaca4c3bb72e'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">3,689</span></p></div></td></tr><tr style="height:11.5pt"><td style="width:76%; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_313ade7de15848e1805861fa9d495eb2'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">2028</span></p></div></td><td style="width:1%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; padding-right:0.7pt; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_9a518cad7b5f4600b17899e4df170f7e'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">7,264</span></p></div></td><td style="width:1%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_ba37da8a5d21434286c58831bdac112f'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">397</span></p></div></td></tr><tr style="height:11.5pt"><td style="width:76%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_faf1ce39ee004fdbacf45816b0cd8e1b'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">2029</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; padding-right:0.7pt; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_1dbfcb6bede14893b1d590e5550007a7'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">7,264</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-tag:'C_4124ac0cb341498b8445cea7bd35d757'"><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td></tr><tr style="height:11.5pt"><td style="width:76%; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_a93ca8f84d704c2685aef38dd6e616fb'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Thereafter</span></p></div></td><td style="width:1%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-bottom:1.5pt solid #000000; padding-right:0.7pt; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_6321783027ee42c18b71f36dd0941a2f'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">38,435</span></p></div></td><td style="width:1%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle"><div style="-aw-sdt-tag:'C_257cb67d346b4113ac890add634412f6'"><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td></tr><tr style="height:11.5pt"><td style="width:76%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_d7c76dd6b9cc422d8a6b884dacaa3365'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">Total</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_75767eb28a1d449ab596ff84732f7256'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">$</span></p></div></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; padding-right:0.7pt; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_2ee72c55a7204d64a57ac09c73611a03'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">69,307</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_6779a62c90a14cb8b35f588ce92d9296'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">$</span></p></div></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'e65-d56-30f-2c3-e9f3'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">22,867</span></p></div></td></tr></tbody></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>STOCKHOLDERS&#8217; EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of Equity-Classified Warrants</a></td>
<td class="text"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">The following table presents a summary of the activity for the Company&#8217;s equity-classified warrants during the </span><span style="-aw-sdt-tag:'c564d7f6835302971ae2'; -aw-sdt-title:'Current_Quarter_and_YTD_P11'; font-family: 'Times New Roman'"><span>three and nine months ended September 30, 2025</span></span><span style="font-family: 'Times New Roman';">:</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><div style="-aw-sdt-tag:'c03fb2d1c9552e699f9f'; -aw-sdt-title:'STOCKHOLDERS EQUITY T1'"><table cellpadding="0" cellspacing="0" style="width:100%; border-collapse:collapse"><tbody><tr style="height:51pt"><td style="width:65.32%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1.02%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10.2%; border-bottom:1.5pt solid #000000; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_255042d0e6a541a388b409c03b69aa6a'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">Number of Warrants</span></p></div></td><td style="width:1.02%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="2" style="border-bottom:1.5pt solid #000000; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_1d3baab02d8c401b900003c44b2c7c3f'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">Weighted Average Exercise Price</span></p></div></td><td style="width:1.02%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10.2%; border-bottom:1.5pt solid #000000; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_d9d36dc13cae43cf8b651c83ff0751cb'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">Weighted Average Remaining Contractual Life (Years)</span></p></div></td></tr><tr style="height:12.75pt"><td style="width:65.32%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_0df67d8471e9467a89ff88e0439581e5'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Total outstanding, December 31, 2024</span><span style="font-size:6.67pt; vertical-align:super; font-family: 'Times New Roman'">(1)</span></p></div></td><td style="width:1.02%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10.2%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_cfd86fffd9a24a8681860699bbc5835a'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">1,765,070</span></p></div></td><td style="width:1.02%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1.02%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_018f691c6c554fcd9f2ea902cef36ea6'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10.2%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_401143ee48e043d3b3536cd6cdf9c432'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">17.59</span></p></div></td><td style="width:1.02%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10.2%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_b26821ca78ac44ef92c209c2bc9c966d'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">3.26</span></p></div></td></tr><tr style="height:12.75pt"><td style="width:65.32%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_56484066bcc74bf8b3793fd9b87e4059'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Granted</span></p></div></td><td style="width:1.02%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10.2%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_1e370c5c9b7142789405b4714e344dcf'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">747,200</span></p></div></td><td style="width:1.02%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1.02%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10.2%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_49bb5b90dc4242be96236f035345724d'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">3.56</span></p></div></td><td style="width:1.02%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10.2%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_a636cf72eae548238b35fe47161c70e0'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">2.00</span></p></div></td></tr><tr style="height:12.75pt"><td style="width:65.32%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_092740af605f4bc4a7ada8bdf5055958'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Exercised</span></p></div></td><td style="width:1.02%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10.2%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_be464264c8194207a861f4cab206040c'; font-family: 'Times New Roman'"><span>385,200</span></span><span style="font-family: 'Times New Roman';">)</span></p></td><td style="width:1.02%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1.02%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10.2%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_9014c8bd62e048859509a2426149ef61'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">0.01</span></p></div></td><td style="width:1.02%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10.2%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_99814e762c194b82bf77fe18e9120666'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:spaces; font-family: 'Times New Roman'">&#160;</span><span style="font-family: 'Times New Roman';">Indefinite </span></p></div></td></tr><tr style="height:12.75pt"><td style="width:65.32%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_96b027d191d3489eb4634d84c32b33bb'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Forfeited</span></p></div></td><td style="width:1.02%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10.2%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-tag:'C_ebc58888ed7e443eb0bed3fbb4e296cd'"><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:1.02%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1.02%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10.2%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-tag:'C_1cbf9c8fae99456bb1db09f419f10e3b'"><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:1.02%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10.2%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-tag:'C_023e956011684a2e8efc0a2c95e7aafa'"><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td></tr><tr style="height:12.75pt"><td style="width:65.32%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_3a9cd327c03648eabee6def9efeb8a16'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Expired</span></p></div></td><td style="width:1.02%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10.2%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-tag:'C_1b9506549baa4d28b730114acf607f9d'"><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:1.02%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1.02%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10.2%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-tag:'C_ceb7f15a6ff64d289ae12ddbd0b82690'"><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:1.02%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10.2%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-tag:'C_28fd827460b74eed914d939d69a18b99'"><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td></tr><tr style="height:8.4pt"><td style="width:65.32%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_940a2249f6b3409bbd4cf1fd3bfef304'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Total outstanding, March 31, 2025</span></p></div></td><td style="width:1.02%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10.2%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_dc623020fea849eba11ebc4bfb2db46b'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">2,127,070</span></p></div></td><td style="width:1.02%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1.02%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_4a782ea234b64abda040b2705b8054db'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10.2%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_6c6bbe87d4d04a50ba3802b29e13ca71'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">15.85</span></p></div></td><td style="width:1.02%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10.2%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_13fb13eaf08b49a2b57074280816ad0b'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">2.60</span></p></div></td></tr><tr style="height:12.75pt"><td style="width:65.32%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_ea5e3e245b884185986e713469cfdfa7'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Granted</span></p></div></td><td style="width:1.02%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10.2%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-tag:'C_57e1c8a9723f46f5b83a7dc55783fee9'"><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:1.02%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1.02%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10.2%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-tag:'C_243d18f890714f9fa13c4b72d28af692'"><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:1.02%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10.2%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-tag:'C_f31c5abd07e34d559789feb6be7b30a9'"><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td></tr><tr style="height:12.75pt"><td style="width:65.32%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_5f1d9b909eb24eac860bae5956db20ff'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Exercised</span></p></div></td><td style="width:1.02%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10.2%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-tag:'C_c4963ba6c9714c2b848973d90745bbe7'"><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:1.02%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1.02%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10.2%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-tag:'C_00ce71b2c5d1489abe5ef8882e6eb43b'"><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:1.02%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10.2%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-tag:'C_87370543a6f5422cb31f728fb2213f65'"><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td></tr><tr style="height:12.75pt"><td style="width:65.32%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_de6f15e3ec76429fb39fe3cc06dcd0b4'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Forfeited</span></p></div></td><td style="width:1.02%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10.2%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-tag:'C_1226676f1bf44f8197d4965d8019abfa'"><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:1.02%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1.02%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10.2%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-tag:'C_38dc8b6b23e14f2fb10ac0aab43b0957'"><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:1.02%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10.2%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-tag:'C_71849749deae49b1affc3ffaa76a7bf6'"><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td></tr><tr style="height:12.75pt"><td style="width:65.32%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_8cdb6926b5124838a53f846006ffe4d5'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Expired</span></p></div></td><td style="width:1.02%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10.2%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-tag:'C_85eba8ce16524c9c992ae58a76b43a52'"><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:1.02%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1.02%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10.2%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-tag:'C_3fa373d813a84ebaac3667eead34d3c5'"><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:1.02%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10.2%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-tag:'C_b9f06ff4ca7a45779ddab62a866d8364'"><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td></tr><tr style="height:13.5pt"><td style="width:65.32%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_c764316e0a5941d382adb9acefbbf02d'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Total outstanding, June 30, 2025</span></p></div></td><td style="width:1.02%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10.2%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_bd4af9854bee45f4a6e8551c9ffeab14'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">2,127,070</span></p></div></td><td style="width:1.02%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1.02%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_06b30492d24443dea9f922ac7c5991eb'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10.2%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_dd5b51e6504c4fe485896034c4ab5aaf'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">15.85</span></p></div></td><td style="width:1.02%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10.2%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_8c4c3f1235014bbd826251d11d481ada'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">2.10</span></p></div></td></tr><tr style="height:1.3pt"><td style="width:65.32%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_c64851bf815b4da8863747dd5755f707'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Granted</span><span style="font-size:6.67pt; vertical-align:super; font-family: 'Times New Roman'">(2)</span></p></div></td><td style="width:1.02%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10.2%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_807950b3ae924a2f975de95c2d052326'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">6,338,788</span></p></div></td><td style="width:1.02%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1.02%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10.2%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_4fd32df330bb4ce6a8e82401cf8bfee9'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">1.65</span></p></div></td><td style="width:1.02%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10.2%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_ed4130eba4504c2992f76b5ad495c647'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">3.31</span></p></div></td></tr><tr style="height:13.5pt"><td style="width:65.32%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_d9b5d3e46cf0480dbe71aa1b85fd2730'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Exercised</span></p></div></td><td style="width:1.02%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10.2%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_453fa426afc145e39bde490d351be1d5'; font-family: 'Times New Roman'"><span>878,264</span></span><span style="font-family: 'Times New Roman';">)</span></p></td><td style="width:1.02%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1.02%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10.2%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_b3cd337ad3c643b98646dee9eafdf4db'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">0.001</span></p></div></td><td style="width:1.02%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10.2%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_ebf6d0f4a79044b1a96cec392910afa3'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:spaces; font-family: 'Times New Roman'">&#160;</span><span style="font-family: 'Times New Roman';">Indefinite </span></p></div></td></tr><tr style="height:13.5pt"><td style="width:65.32%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_9941868f9f2b4eeb9ad1e9a0ec7731e5'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Forfeited</span></p></div></td><td style="width:1.02%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10.2%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-tag:'C_f6c86e35bf8044009a4b4a9ffa2be0b9'"><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:1.02%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1.02%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10.2%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-tag:'C_5120de4eb07c46d1a887d6f33993bd48'"><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:1.02%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10.2%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-tag:'C_d16cd40451854e3c9422892d316527ed'"><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td></tr><tr style="height:13.5pt"><td style="width:65.32%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_d493e9ce3b6e44bcb5f236c8e5cf90bc'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Expired</span></p></div></td><td style="width:1.02%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10.2%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-tag:'C_5eee2f2968084f68bd96a105a2a456ba'"><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:1.02%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1.02%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10.2%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-tag:'C_351547f4bdc341548bd95be3a56c990b'"><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:1.02%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10.2%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-tag:'C_e5c3e7a2d1ea48788874fe6f1aaa160e'"><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td></tr><tr style="height:13.5pt"><td style="width:65.32%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_a711a12f9677437590c66b5950b17bd5'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Total outstanding, September 30, 2025</span></p></div></td><td style="width:1.02%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10.2%; border-top:0.75pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#ffffff; -aw-border-top:0.5pt single"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_8ea7f7a4e1d24d429c6f06db22b55e6d'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">7,587,594</span></p></div></td><td style="width:1.02%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1.02%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_2d3b290467d343018ea51921f595758a'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10.2%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_7047b295f89941d1bdfff27a2c97d2f6'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">5.82</span></p></div></td><td style="width:1.02%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10.2%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_01e4caaff41844e1ae7feb1c2ae66d69'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">2.82</span></p></div></td></tr><tr style="height:13.5pt"><td style="width:65.32%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_d51b62342edd4404956c0bf1cb0b2079'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Total exercisable, September 30, 2025</span></p></div></td><td style="width:1.02%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10.2%; border-top:4.5pt double #000000; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_7b1ea82a944942ceb4546250d540a297'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">7,587,594</span></p></div></td><td style="width:1.02%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1.02%; border-top:4.5pt double #000000; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_f78db16daa4a48f09d41316116f43005'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10.2%; border-top:4.5pt double #000000; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_f6c5be1b8d51432b8279c89401af163b'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">5.82</span></p></div></td><td style="width:1.02%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10.2%; border-top:4.5pt double #000000; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_28a537d0722b41f7ba4474c4041f1592'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">2.82</span></p></div></td></tr></tbody></table></div><p style="margin-top:0pt; margin-bottom:0pt"><span style="-aw-import:ignore; font-family: 'Times New Roman';  font-size: 12pt;">&#160;</span></p><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td style="width:3.3%; vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; font-size:12.5pt"><span style="font-size:8.33pt; vertical-align:super; font-family: 'Times New Roman'">(1)</span></p></td><td style="width:96.7%; vertical-align:top"><div style="-aw-sdt-tag:'cc60b45585da36d079a6'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">Weighted average remaining contractual life at </span><span style="-aw-sdt-tag:'cb7acd8bf727a3348920'; -aw-sdt-title:'Previous_Year_End_P16'; font-family: 'Times New Roman'"><span>December 31, 2024</span></span><span style="font-family: 'Times New Roman';"> excludes </span><span style="-aw-sdt-tag:'c9eaac2b3a02e0ecbfed'; font-family: 'Times New Roman'"><span>385,200</span></span><span style="font-family: 'Times New Roman';"> Pre-Funded Warrants issued September </span><span style="-aw-sdt-tag:'c084844e24a211ebd242'; font-family: 'Times New Roman'"><span>2024</span></span><span style="font-family: 'Times New Roman';"> that do not have a contractual expiration date, for which </span><span style="-aw-sdt-tag:'c6c65c3f0bb7343724f4'; font-family: 'Times New Roman'"><span>0</span></span><span style="font-family: 'Times New Roman';"> warrants remain outstanding and exercisable at March 31, 2025, June 30, 2025 and </span><span style="-aw-sdt-tag:'c3f8bf32fba6f0a28902'; -aw-sdt-title:'Current_Period_P16'; font-family: 'Times New Roman'"><span>September 30, 2025</span></span><span style="font-family: 'Times New Roman';">.</span></p></div></td></tr></tbody></table><table cellpadding="0" cellspacing="0" style="width:100%; border-collapse:collapse"><tbody><tr><td style="width:3.3%; vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:12.5pt"><span style="font-size:8.33pt; vertical-align:super; font-family: 'Times New Roman'">(2)</span></p></td><td style="width:96.7%; vertical-align:top"><div style="-aw-sdt-tag:'4e2-557-131-530-ea28'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">Weighted average remaining contractual life excludes </span><span style="-aw-sdt-tag:'155-a3e-4e3-421-5e47'; font-family: 'Times New Roman'"><span>878,264</span></span><span style="font-family: 'Times New Roman';"> Pre-Funded Warrants issued July 2025 that do not have a contractual expiration date, for which </span><span style="-aw-sdt-tag:'cfe-9a0-ea6-43f-4379'; font-family: 'Times New Roman'"><span>0</span></span><span style="font-family: 'Times New Roman';"> warrants remain outstanding and exercisable at </span><span style="-aw-sdt-tag:'b56-24f-fd5-c1f-b53f'; -aw-sdt-title:'Current_Period_P43'; font-family: 'Times New Roman'"><span>September 30, 2025</span></span><span style="font-family: 'Times New Roman';">.</span></p></div></td></tr><tr><td style="width:3.3%; vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:5pt"><span style="font-size:3.33pt; vertical-align:super; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:96.7%; vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:5pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td></tr></tbody></table><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-import:spaces; font-family: 'Times New Roman'">&#160;</span></p><div style="-aw-sdt-tag:'PG_2924caba445ee74c'"></div><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">The following table presents a summary of the activity for the Company&#8217;s equity-classified warrants during the </span><span style="-aw-sdt-tag:'cb837e6a667bb2d8e81a'; -aw-sdt-title:'Previous_Quarter_and_YTD_P4'; font-family: 'Times New Roman'"><span>three and nine months ended September 30, 2024</span></span><span style="font-family: 'Times New Roman';">:</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p><div style="-aw-sdt-tag:'5ef-bd1-660-949-dac4'; -aw-sdt-title:'PYTD Warrant Activity Table'"><table cellpadding="0" cellspacing="0" style="width:100%; border-collapse:collapse"><tbody><tr style="height:66pt"><td style="width:66%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_2fe24833a44b41479778dfa15ea39d75'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">Number of Warrants</span></p></div></td><td style="width:1%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="2" style="border-bottom:1.5pt solid #000000; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_f18fecd537364a0f93431550cd6beb89'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">Weighted Average Exercise Price</span></p></div></td><td style="width:1%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_46e2237dbc934f6b9426112c9d46cff7'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">Weighted Average Remaining Contractual Life (Years)</span></p></div></td></tr><tr style="height:13.2pt"><td style="width:66%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_e3159a48c35a441588285bc5f08adbb5'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Total outstanding, December 31, 2023</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_26c6e8ba5c4f437b898bce96847ea990'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">52,737</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_7932e86b6155416a856e4b9e3135e6a0'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_1e1cfe2fee02428fb18bed385db26f5b'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">369.98</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_0fdf3faee9384a09b6fb1053d73cd117'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">4.47</span></p></div></td></tr><tr style="height:13.2pt"><td style="width:66%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_d2f19f5220f34a67a6cf0ad536ecceaf'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Granted</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_ca72a78fc17a4df2b8b050de41cb1fb2'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">140,884</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_03da05c614d4494ab5a425272003c87d'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">22.48</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_1e23442a8f184d09a6640f316b286c13'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">5.00</span></p></div></td></tr><tr style="height:13.2pt"><td style="width:66%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_5bc3ca100224454db31571d2f7b1902d'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Exercised</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_947713b195ad4820bbb30058fc78b8f8'; font-family: 'Times New Roman'"><span>8,326</span></span><span style="font-family: 'Times New Roman';">)</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_6653a7d365a745d882b7652b6ee003cf'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">0.60</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_d11cc3479bef4b49bb34a26fb81a3dab'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:spaces; font-family: 'Times New Roman'">&#160;</span><span style="font-family: 'Times New Roman';">Indefinite </span></p></div></td></tr><tr style="height:13.2pt"><td style="width:66%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_036865088ae34687ad76ec0118f6c13a'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Forfeited</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-tag:'C_0b98733a323540198451b82d59cb06fc'"><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-tag:'C_b095fd6b9be94bbc8c5bffe34783b7e9'"><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-tag:'C_62e43591234846379c4d980c1b569ce5'"><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td></tr><tr style="height:13.2pt"><td style="width:66%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_ed4f3a89e25f4188a6c83db8976197d5'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Expired</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-tag:'C_e3ce5466c2be49d1857c06466db44631'"><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-tag:'C_dfdbdd8338f8414d8f83aae99237906a'"><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-tag:'C_fe44fba7b4ea4e7aa0021a9bccd19da2'"><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td></tr><tr style="height:13.8pt"><td style="width:66%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_3d817872bae142abb1bdde9aec1609a3'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Total outstanding, March 31, 2024</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_c163a2b7f7f04b69b4d13a118cc458f9'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">185,295</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_2b8349367e4e49bd8341592d5d525a88'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_f13c7faf7831462aab2cb911bc2f0dd6'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">122.36</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_0005a1e335884fc7ac7b8d95109bce26'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">4.67</span></p></div></td></tr><tr style="height:13.8pt"><td style="width:66%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_dcc561ad8f5141e9ad4b5045a2890934'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Granted</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-tag:'C_88de1f197d034065b9cd32ef1dcd9706'"><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-tag:'C_f73d194d7c854624909dcf76b8ba5ce8'"><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-tag:'C_fb1a4c504f914dc289bb53a1b30080ae'"><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td></tr><tr style="height:13.2pt"><td style="width:66%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_a977d41b2c174189a08b961656853a60'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Exercised</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_79bdaacfa9994fb2b69b6344f572705f'; font-family: 'Times New Roman'"><span>8,326</span></span><span style="font-family: 'Times New Roman';">)</span></p></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_31638e6c276c4f2fa99250fcb9843150'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">0.60</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_f5cdcd321c28407aa89715dc54333513'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:spaces; font-family: 'Times New Roman'">&#160;</span><span style="font-family: 'Times New Roman';">Indefinite </span></p></div></td></tr><tr style="height:13.2pt"><td style="width:66%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_fa7dd320f8ff4aac96b933a7fbc11384'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Forfeited</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-tag:'C_110cf5dfc8bd4bc080a6b64cb16f3187'"><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-tag:'C_4a2d3439c11443f6b2da01418ec74397'"><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-tag:'C_0da9202225b040e19c3d69fa37a95f80'"><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td></tr><tr style="height:13.2pt"><td style="width:66%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_59813ff6f1844a788243218269af1e79'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Expired</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-tag:'C_9b5fd3e6aa1b4e4cb21d298ea65de0ea'"><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-tag:'C_f2ddee167a494c22b7bd797d8ae1c6c2'"><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-tag:'C_7a4c7af18d3f4f77813081f40c1d117a'"><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td></tr><tr style="height:13.8pt"><td style="width:66%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_a82321d8724e48d9a9d4e5fea605470a'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Total outstanding, June 30, 2024</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_2a6ee883b436439caf9659428ef1344a'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">176,969</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_aa95f7f315f940a2a5739ae21aafd495'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_dedfd6de48f64fde8de26755f4cdd4e4'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">128.09</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_79c28b5186b7430280974bffea1c6e69'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">4.41</span></p></div></td></tr><tr style="height:4.05pt"><td style="width:66%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_1e54e27571a64e8887f09b7346aff7c4'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Granted</span><span style="font-size:6.67pt; vertical-align:super; font-family: 'Times New Roman'">(1)</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_adfe2fb2d65545cba64b8094d9c2cc08'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">1,782,612</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_b0770c488b2d44c0b74d38914ce1a1f4'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">4.70</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-tag:'C_8a1c8815f35841ef9b2cf22465a70cbd'"><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td></tr><tr style="height:4.05pt"><td style="width:66%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_e4111cde5ebf4e2db2c6ef266cda76df'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Exercised</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-tag:'C_667abf06483d4e4aab4ecd254ca4fb4d'"><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-tag:'C_1b9a47ca596e4271804077a0fce457bd'"><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-tag:'C_c7fead391f1c4bedaf8cbd7c73bfcbf9'"><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td></tr><tr style="height:4.05pt"><td style="width:66%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_19cb9448efb54e7e898444eb0f2563a8'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Forfeited</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-tag:'C_60dcc17070434c6ab1cafb9462e1e3d6'"><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-tag:'C_ba07f171b24f486fa792b6c7c3444cc7'"><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-tag:'C_1e57ce7e25864bb89046552a08c0e3fc'"><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td></tr><tr style="height:4.05pt"><td style="width:66%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_350af71c0b4948a6a77dfcd4075ad433'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Expired</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-tag:'C_aedbe4e189824914abc8f3a4b2bda114'"><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-tag:'C_9d6d068f7ee644de9a393925a4cbfc15'"><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-tag:'C_bfabe0e863a542ac80153555a0367873'"><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td></tr><tr style="height:4.05pt"><td style="width:66%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_1de26c9af20040a29472d2ca9138d19f'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Total outstanding, September 30, 2024</span><span style="font-size:6.67pt; vertical-align:super; font-family: 'Times New Roman'">(1)</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_f4d9856e21884f16b54c37b835a9f33a'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">1,959,581</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_f8d0824dee194343b9daffd0ef500eda'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_2419a538771d4014a0aa04299e82b736'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">15.84</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_7ddd3f67b2d74622afae5bc4f4059994'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">4.16</span></p></div></td></tr><tr style="height:4.05pt"><td style="width:66%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_db4c1fd8ae924d69b46bdc6baf2841b1'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Total exercisable, September 30, 2024</span><span style="font-size:6.67pt; vertical-align:super; font-family: 'Times New Roman'">(2)</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:4.5pt double #000000; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_8f538a18dc5c4b0789915e07028c8a3b'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">756,680</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:4.5pt double #000000; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_b445e814ada34f288326ca954e930c27'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; border-top:4.5pt double #000000; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_e1118852385841f19496c5a949e0e0bb'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">29.96</span></p></div></td><td style="width:1%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:4.5pt double #000000; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'a4f-f6d-3a4-587-6f95'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">4.16</span></p></div></td></tr></tbody></table></div><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p><table cellpadding="0" cellspacing="0" style="width:100%; border-collapse:collapse"><tbody><tr style="height:11.5pt"><td style="width:3.3%; vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; font-size:12.5pt"><span style="font-size:8.33pt; vertical-align:super; font-family: 'Times New Roman'">(1)</span></p></td><td style="width:96.7%; vertical-align:top"><div style="-aw-sdt-tag:'54e-de6-a74-b52-df70'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">Weighted average remaining contractual life calculations exclude (i) </span><span style="-aw-sdt-tag:'732-da0-de5-bf5-8dbb'; font-family: 'Times New Roman'"><span>579,711</span></span><span style="font-family: 'Times New Roman';"> Pre-Funded Warrants issued September 2024 that do not have a contractual expiration date, (ii) </span><span style="-aw-sdt-tag:'f2c-5f7-8bf-af8-594f'; font-family: 'Times New Roman'"><span>43,479</span></span><span style="font-family: 'Times New Roman';"> September 2024 Agent Warrants and </span><span style="-aw-sdt-tag:'e8a-7d2-dd0-c63-800f'; font-family: 'Times New Roman'"><span>579,711</span></span><span style="font-family: 'Times New Roman';"> Series A Warrants issued September 2024 that expire </span><span style="-aw-sdt-tag:'316-f81-d28-80c-a600'; font-family: 'Times New Roman'"><span>five years</span></span><span style="font-family: 'Times New Roman';"> from the Stockholder Approval Date, defined above, and (iii) </span><span style="-aw-sdt-tag:'051-85c-a14-d67-3f56'; font-family: 'Times New Roman'"><span>579,711</span></span><span style="font-family: 'Times New Roman';"> Series B Warrants issued September 2024 that expire </span><span style="-aw-sdt-tag:'5a3-db5-072-293-bc68'; font-family: 'Times New Roman'"><span>eighteen months</span></span><span style="font-family: 'Times New Roman';"> from the Stockholder Approval Date, which had not yet occurred as of September 30, 2024.</span></p></div></td></tr><tr style="height:11.5pt"><td style="width:3.3%; vertical-align:top"><p style="margin-top:0pt; margin-bottom:0pt; font-size:12.5pt"><span style="font-size:8.33pt; vertical-align:super; font-family: 'Times New Roman'">(2)</span></p></td><td style="width:96.7%; vertical-align:top"><div style="-aw-sdt-tag:'f6b-c28-fc7-73a-bf3d'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">Weighted average remaining contractual life calculation excludes </span><span style="-aw-sdt-tag:'789-7d3-dde-216-e566'; font-family: 'Times New Roman'"><span>579,711</span></span><span style="font-family: 'Times New Roman';"> exercisable Pre-Funded Warrants issued September 2024 that do not have a contractual expiration date.</span></p></div></td></tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEBT (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>DEBT</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Schedule of the Current Future Payment Obligations</a></td>
<td class="text"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">The current future payment obligations of the principal are as follows:</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><div style="-aw-sdt-tag:'c317e04dae973ecfbe43'; -aw-sdt-title:'DEBT T1'"><table cellpadding="0" cellspacing="0" style="width:100%; border-collapse:collapse"><tbody><tr style="height:11.5pt"><td style="width:88%; border-bottom:1.5pt solid #000000; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_5c968b0016b149cfb1f12fa47b1bca41'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">Period</span></p></div></td><td style="width:1%; padding-bottom:1.75pt; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="2" style="border-bottom:1.5pt solid #000000; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_5c764bbf41d64098a324b0fa0eee9c97'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">Principal Payments</span></p></div></td></tr><tr style="height:11.5pt"><td style="width:88%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_0bb61a42b37543a7b09da928c987f7ac'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">2025 (remaining three months)</span></p></div></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_ed70aeb871a64cbcae4e1e638cd44d8c'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-tag:'C_9cc5803ea7e44342b95a83be6a937207'"><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td></tr><tr style="height:11.5pt"><td style="width:88%; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_897e8cb5c5764f54bf36adbea961583d'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">2026</span></p></div></td><td style="width:1%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p></td><td style="width:1%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p></td><td style="width:10%; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_11851a9e806d4f58b44ce574ad2a99ae'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">465</span></p></div></td></tr><tr style="height:11.5pt"><td style="width:88%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_bd218f23a8534654beb35d354f005013'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">2027</span></p></div></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p></td><td style="width:10%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_9e76a127fe434806b75dd7251717545a'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">3,220</span></p></div></td></tr><tr style="height:11.5pt"><td style="width:88%; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_5f57e987c26c48cb8368c698d86412c7'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">2028</span></p></div></td><td style="width:1%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p></td><td style="width:1%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p></td><td style="width:10%; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_a641af32d4f142d4896d4e72026bfbf6'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">3,333</span></p></div></td></tr><tr style="height:11.5pt"><td style="width:88%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_39e1010cfe6e4fc0b5e28f5cfced0432'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">2029</span></p></div></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p></td><td style="width:10%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_b3e786a7693a420dbcb23ba7b9111b35'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">3,470</span></p></div></td></tr><tr style="height:11.5pt"><td style="width:88%; padding-bottom:1.75pt; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_61dc3ec600314411bf83aaf42b0afb2c'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Thereafter</span></p></div></td><td style="width:1%; padding-bottom:1.75pt; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_d9ea3ec1cd2f4f809bcc21cdbccf2901'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">139,512</span></p></div></td></tr><tr style="height:11.5pt"><td style="width:88%; padding-bottom:4.25pt; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_5b82b081b0cd4cd7810fcd446de801b1'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">Total</span></p></div></td><td style="width:1%; padding-bottom:4.25pt; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_0749ec546c48465eb63ec47c309b1dfa'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">$</span></p></div></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_cfd83dce046d4d62badcc6025377dc63'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">150,000</span></p></div></td></tr></tbody></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity and sinking fund requirement for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DERIVATIVE LIABILITIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>DERIVATIVE LIABILITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock', window );">Schedule of Derivative Liabilities Measured at Fair Value on a Recurring Basis</a></td>
<td class="text"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">A reconciliation of the beginning and ending balances for the derivative liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) is as follows for the </span><span style="-aw-sdt-tag:'ca75fd2c5ebfac9ccdc1'; -aw-sdt-title:'Current_Quarter_and_YTD_P7'; font-family: 'Times New Roman'"><span>three and nine months ended September 30, 2025</span></span><span style="font-family: 'Times New Roman';">:</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p><div style="-aw-sdt-tag:'c6639d815e653fadd5ae'; -aw-sdt-title:'DERIVATIVE LIABILITIES T1'"><table cellpadding="0" cellspacing="0" style="width:100%; border-collapse:collapse"><tbody><tr style="height:11.5pt"><td style="width:88%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1.14%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="2" style="border-bottom:1.5pt solid #000000; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_fd577863c4914b8ea632e84e6f1d9eec'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">Contingent Milestone Payment</span></p></div></td></tr><tr style="height:11.5pt"><td style="width:88%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_ff0051b243e64116bbf90efbe05a88e3'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Derivative</span><span style="font-family: 'Times New Roman';">&#160;</span><span style="font-family: 'Times New Roman';">liabilities - December 31, 2024</span></p></div></td><td style="width:1.14%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_ef378dbe0e17475fa21c77879bdff28f'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_c7aae7bfd1584e14a5a3a5d58fab1fd6'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">640,830</span></p></div></td></tr><tr style="height:11.5pt"><td style="width:88%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_4377246d44bb4cfc863de19c989a5202'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Change in fair value</span></p></div></td><td style="width:1.14%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_c327358aecad485cba82f75897b00fec'; font-family: 'Times New Roman'"><span>5,105</span></span><span style="font-family: 'Times New Roman';">)</span></p></td></tr><tr style="height:11.5pt"><td style="width:88%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_5a97f90a3edd45afa8a36844a79b2ea4'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Derivative</span><span style="font-family: 'Times New Roman';">&#160;</span><span style="font-family: 'Times New Roman';">liabilities - March 31, 2025</span></p></div></td><td style="width:1.14%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_9f633fdc6b9242d381ac51540e4153ee'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">635,725</span></p></div></td></tr><tr style="height:11.5pt"><td style="width:88%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_078e4af6f8af42d295052694ed2c2427'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Change in fair value</span></p></div></td><td style="width:1.14%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_23198fd411e74a64b8eeef85300e3dcf'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">140,447</span></p></div></td></tr><tr style="height:11.5pt"><td style="width:88%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_9462c6e0577448ed88294c1d0aae294c'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Derivative</span><span style="font-family: 'Times New Roman';">&#160;</span><span style="font-family: 'Times New Roman';">liabilities - June 30, 2025</span></p></div></td><td style="width:1.14%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_a0832472ffb74935b23fb706f1e8f50b'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">776,172</span></p></div></td></tr><tr style="height:11.5pt"><td style="width:88%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_2150e1d56b154f04bf9d302078fa6006'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Change in fair value</span></p></div></td><td style="width:1.14%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_ae80a322a7494033b888a0b4927f3dcd'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">21,103</span></p></div></td></tr><tr style="height:11.5pt"><td style="width:88%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_adfe59ed6a5b4ce1ad247b7d83b2b16e'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Derivative</span><span style="font-family: 'Times New Roman';">&#160;</span><span style="font-family: 'Times New Roman';">liabilities - September 30, 2025</span></p></div></td><td style="width:1.14%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_fc90d64ea50e4c308d229a9c947721a7'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_8c7042f142d54906ae51e9d2fb2300b4'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">797,275</span></p></div></td></tr></tbody></table></div><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p><div style="-aw-sdt-tag:'PG_c50ece2c23a2dc4329b4'"></div><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">A reconciliation of the beginning and ending balances for the derivative liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) is as follows for the </span><span style="-aw-sdt-tag:'cd848d58778f479d6fa9'; -aw-sdt-title:'Previous_Quarter_and_YTD_P3'; font-family: 'Times New Roman'"><span>three and nine months ended September 30, 2024</span></span><span style="font-family: 'Times New Roman';">:</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><table cellpadding="0" cellspacing="0" style="width:100%; border-collapse:collapse"><tbody><tr style="height:11.5pt"><td style="width:88%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1.14%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="2" style="border-bottom:1.5pt solid #000000; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_9b7bbdd2b0ad450593bb39fcb5204a2d'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">Contingent Milestone Payment</span></p></div></td></tr><tr style="height:11.5pt"><td style="width:88%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_349fc0c506ae466a8afcdbfdf7eb138c'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Derivative</span><span style="font-family: 'Times New Roman';">&#160;</span><span style="font-family: 'Times New Roman';">liabilities - December 31, 2023</span></p></div></td><td style="width:1.14%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_e6028efd12ee4fa482ca3e0bf101af8e'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_7ab6157566fd406ba29b6922a10b9ec9'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">2,306,796</span></p></div></td></tr><tr style="height:11.5pt"><td style="width:88%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_c6bf1ed06ead4adf9f2296394e5d94fe'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Change in fair value</span></p></div></td><td style="width:1.14%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">(</span><span style="-aw-sdt-tag:'C_fd1f212ea84445ea8753de1b222fe7fa'; font-family: 'Times New Roman'"><span>1,740,847</span></span><span style="font-family: 'Times New Roman';">)</span></p></td></tr><tr style="height:11.5pt"><td style="width:88%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_ebba7a73ac5447149cff86376061747e'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Derivative</span><span style="font-family: 'Times New Roman';">&#160;</span><span style="font-family: 'Times New Roman';">liabilities - March 31, 2024</span></p></div></td><td style="width:1.14%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_6c58f57330b54183b08d956ee1ecbd60'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">565,949</span></p></div></td></tr><tr style="height:11.5pt"><td style="width:88%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_a251d932ed0f4f349433c36d59e8d1c5'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Change in fair value</span></p></div></td><td style="width:1.14%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_f59f8bc8d656446584c1334e2dc483b9'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">1,101</span></p></div></td></tr><tr style="height:11.5pt"><td style="width:88%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_a2f0ff1379314111b76e648c5de945d5'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Derivative</span><span style="font-family: 'Times New Roman';">&#160;</span><span style="font-family: 'Times New Roman';">liabilities - June 30, 2024</span></p></div></td><td style="width:1.14%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_2dbbcbe08cd646c49d4ad4090192625e'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">567,050</span></p></div></td></tr><tr style="height:11.5pt"><td style="width:88%; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_97ca7a3e4491452f85dadb11644bd7ed'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Change in fair value</span></p></div></td><td style="width:1.14%; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_b81e163c70f24c44b27596e3b6f00f4d'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">56,712</span></p></div></td></tr><tr style="height:11.5pt"><td style="width:88%; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_2d719b55a9614add8a41b0e7dc9bd875'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Derivative</span><span style="font-family: 'Times New Roman';">&#160;</span><span style="font-family: 'Times New Roman';">liabilities - September 30, 2024</span></p></div></td><td style="width:1.14%; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_28189adff441454eb8ae6052808da967'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_1e958d79d6f442799205fed39a546989'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">623,762</span></p></div></td></tr></tbody></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of derivative liabilities at fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4E<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE-BASED COMPENSATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>SHARE-BASED COMPENSATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Share-Based Compensation Expenses</a></td>
<td class="text"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">The following is a summary of share-based compensation expenses reported in the </span><span style="-aw-sdt-tag:'928-fd0-43f-33f-a583'; -aw-sdt-title:'PandL_title_P1'; font-family: 'Times New Roman'"><span>consolidated condensed statements of operations and comprehensive loss</span></span><span style="font-family: 'Times New Roman';"> for the </span><span style="-aw-sdt-tag:'ce72a01889339805360e'; -aw-sdt-title:'Current_Quarter_and_YTD_P1'; font-family: 'Times New Roman'"><span>three and nine months ended September 30, 2025</span></span><span style="font-family: 'Times New Roman';"> and </span><span style="-aw-sdt-tag:'cb6dccf48217e97e781f'; -aw-sdt-title:'Previous_Year_P14'; font-family: 'Times New Roman'"><span>2024</span></span><span style="font-family: 'Times New Roman';">:</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">&#160;</span></p><div style="-aw-sdt-tag:'c13275b5451f7f9fa78e'; -aw-sdt-title:'SHARE-BASED COMPENSATION T1'"><table cellpadding="0" cellspacing="0" style="width:100%; border-collapse:collapse"><tbody><tr style="height:11.5pt"><td style="width:52%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="5" style="border-bottom:1.5pt solid #000000; padding-right:3.6pt; padding-left:3.6pt; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_b793b7deaa5f4e1d950f54932847ec4e'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">For the Three Months Ended September 30,</span></p></div></td><td style="width:1%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="5" style="border-bottom:1.5pt solid #000000; padding-left:11.5pt; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_537410e7812d486a9a1750abab377793'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">For the Nine Months Ended September 30,</span></p></div></td></tr><tr style="height:11.5pt"><td style="width:52%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="2" style="border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_1c65bd1b721f4fdbb0598ff8d89de949'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">2025</span></p></div></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="2" style="border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_e80ebe59c55b4da093ced29e2c908199'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">2024</span></p></div></td><td style="width:1%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="2" style="border-bottom:1.5pt solid #000000; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_91ed7e22685d417984396bafa04be366'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">2025</span></p></div></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="2" style="border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_df669bbe060d4fb4868590c39a9103dd'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">2024</span></p></div></td></tr><tr style="height:11.5pt"><td style="width:52%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_1f65a7c0fbbf45a68b9646858ce371ce'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Research and Development</span></p></div></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_23d3849a725541999e62bbfea44aac84'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-tag:'C_11384fc8b65f4d7db353787823d55423'"><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_025187fdcd654094abb16118f061da90'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_2b22ee8f24c54fa896add2668695efcb'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">600,000</span></p></div></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_b4c10c58c0314c169080c9c8b8fcbf8e'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-tag:'C_a08e3c8a4c6f4085aa8a9d31befcd057'"><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">-</span></p></div></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_78842318fd574561a2884382a7738a2b'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_35eff82596e143da87976fe2e081d8ab'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">3,227,300</span></p></div></td></tr><tr style="height:11.5pt"><td style="width:52%; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_61c64308dfc6458ea1fbb4a8c7b703f2'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">General and Administrative Expenses</span></p></div></td><td style="width:1%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_ddd5fe7024e34d6d8b4886992b4b418e'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">79,000</span></p></div></td><td style="width:1%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_b1923603f0314dcc9f9dff054d6a03da'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">68,974</span></p></div></td><td style="width:1%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_be2f81c4d0954142a92c2d69272f7316'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">344,383</span></p></div></td><td style="width:1%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:bottom"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_62aa8b68d8d0491db7039e6b80dd5e0e'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">319,709</span></p></div></td></tr><tr style="height:11.5pt"><td style="width:52%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_bfa6fe246dec48e885d05f0057213748'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Total Share-Based Compensation Expense Included in Operating Expenses</span></p></div></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_f745775470c94315af299adf55367ded'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_74b13f97c0cf48dab5e62d86746dd071'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">79,000</span></p></div></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_f2f730e985d34774bbed0f63d2691b9d'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_40018e5c15e74eda9b9f7804866b0d19'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">668,974</span></p></div></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_6d7a61fde61344dc8721193a9a15d53c'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_04eded1abc4d4ad9aef27f111b48a590'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">344,383</span></p></div></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_9c2d8eda549747ef9ba345afb4170af9'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'761-c75-0e8-f8a-eee2'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">3,547,009</span></p></div></td></tr></tbody></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock', window );">Schedule of Fair Value of Options Granted</a></td>
<td class="text"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">The following table summarizes the significant assumptions used in determining the fair value of options granted during the </span><span style="-aw-sdt-tag:'cb926b1bec8a5c9d7e88'; -aw-sdt-title:'Current_Quarter_and_YTD_P3'; font-family: 'Times New Roman'"><span>three and nine months ended September 30, 2025</span></span><span style="font-family: 'Times New Roman';"> and </span><span style="-aw-sdt-tag:'c208469c38a8aafffc4c'; -aw-sdt-title:'Previous_Year_P15'; font-family: 'Times New Roman'"><span>2024</span></span><span style="font-family: 'Times New Roman';">:</span></p><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p><div style="-aw-sdt-tag:'c6b82afc388c401d9e30'; -aw-sdt-title:'SBC Table FMV Assumptions'"><table cellpadding="0" cellspacing="0" style="width:100%; border-collapse:collapse"><tbody><tr style="height:11.5pt"><td style="width:53%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="5" style="border-bottom:1.5pt solid #000000; padding-right:3.6pt; padding-left:3.6pt; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_371d5f2bfb054b0e8460d09bb59858a9'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">For the Three Months Ended September 30,</span></p></div></td><td style="width:0.86%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="5" style="border-bottom:1.5pt solid #000000; padding-left:18.7pt; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_e2d4b0f5404c484680abbbec2fbb1cd5'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">For the Nine Months Ended September 30,</span></p></div></td></tr><tr style="height:11.5pt"><td style="width:53%; vertical-align:bottom"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="2" style="border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_58cd0c9841254a3dac116deef4bcbc41'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">2025</span></p></div></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="2" style="border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_78c64d6266234af3b75e0972a6752883'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">2024</span></p></div></td><td style="width:0.86%; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="2" style="border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_4b5707f7e1f340fabeba896192704cbf'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">2025</span></p></div></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td colspan="2" style="border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_c0b54a2289c946b5b7a0a1ca7a79bae1'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"><span style="font-weight:bold; font-family: 'Times New Roman'">2024</span></p></div></td></tr><tr style="height:11.5pt"><td style="width:53%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_bdbe21d861f54e598b6c2ebeaf8c95fe'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Weighted-average grant date fair value</span></p></div></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_7890dccaab874e7d92cb7b0e72fc317f'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_22b11df71f0d47098e6e2bded099c637'"><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:spaces; font-family: 'Times New Roman'">&#160;</span><span style="font-family: 'Times New Roman';">N/A </span></p></div></td><td style="width:1%; padding-right:1.45pt; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_0a2dcde2664d42579b74f707d6505d93'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_37a0df27750945fc9b6899c1a6a047ca'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">8.78</span></p></div></td><td style="width:0.86%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_f54f277a21d94c4cacdd010927e3433e'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_61461e1150e24180814adbbea8f0035f'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">4.55</span></p></div></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_7ea73308c7384caa83280f67a66a433e'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">$</span></p></div></td><td style="width:10%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_2e5e3ada99254986ae82736208308e85'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">8.78</span></p></div></td></tr><tr style="height:11.5pt"><td style="width:53%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_a86fcbd02d504a77b42500289cd5f9c5'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Risk-free interest rate</span></p></div></td><td style="width:1%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_422b919e53604b4d9b01e6a4ff8ae470'"><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:spaces; font-family: 'Times New Roman'">&#160;</span><span style="font-family: 'Times New Roman';">N/A </span></p></div></td><td style="width:1%; padding-right:1.45pt; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-sdt-tag:'5c3-4af-63f-0a8-8170'; font-family: 'Times New Roman'"><span>3.62</span></span><span style="font-family: 'Times New Roman';">% - </span><span style="-aw-sdt-tag:'f97-3e4-a51-d60-5557'; font-family: 'Times New Roman'"><span>4.17</span></span><span style="font-family: 'Times New Roman';">%</span></p></td><td style="width:0.86%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-sdt-tag:'C_a0a8c0c2864a4afbb105903f2b68b28b'; font-family: 'Times New Roman'"><span>4.36</span></span><span style="font-family: 'Times New Roman';">%</span></p></td><td style="width:1%; padding-right:1.45pt; vertical-align:middle; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-sdt-tag:'30e-490-8f8-814-d30e'; font-family: 'Times New Roman'"><span>3.62</span></span><span style="font-family: 'Times New Roman';">% - </span><span style="-aw-sdt-tag:'ee3-181-3dc-e8f-312d'; font-family: 'Times New Roman'"><span>4.17</span></span><span style="font-family: 'Times New Roman';">%</span></p></td></tr><tr style="height:11.5pt"><td style="width:53%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_5fe58341b1494de19749b138fb5378ee'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Expected volatility</span></p></div></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_0c331ee129f64ed1b9fa50dc73136fcd'"><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:spaces; font-family: 'Times New Roman'">&#160;</span><span style="font-family: 'Times New Roman';">N/A </span></p></div></td><td style="width:1%; padding-right:1.45pt; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-sdt-tag:'bda-6e1-a52-5f0-7b06'; font-family: 'Times New Roman'"><span>86.00</span></span><span style="font-family: 'Times New Roman';">% - </span><span style="-aw-sdt-tag:'07d-67f-348-6f7-ba1e'; font-family: 'Times New Roman'"><span>87.00</span></span><span style="font-family: 'Times New Roman';">%</span></p></td><td style="width:0.86%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-sdt-tag:'C_3c6e0737f3d74b34934c2901d877dee2'; font-family: 'Times New Roman'"><span>90.00</span></span><span style="font-family: 'Times New Roman';">%</span></p></td><td style="width:1%; padding-right:1.45pt; vertical-align:middle; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-sdt-tag:'64f-7fb-a1f-61b-8c23'; font-family: 'Times New Roman'"><span>86.00</span></span><span style="font-family: 'Times New Roman';">% - </span><span style="-aw-sdt-tag:'163-d0d-e3e-4ea-7923'; font-family: 'Times New Roman'"><span>87.00</span></span><span style="font-family: 'Times New Roman';">%</span></p></td></tr><tr style="height:11.5pt"><td style="width:53%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_f98e805c00b14edb84da40ce6346c721'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Expected term (years)</span></p></div></td><td style="width:1%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_e4b5461f1a1746da98b836b10b7a794a'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:spaces; font-family: 'Times New Roman'">&#160;</span><span style="font-family: 'Times New Roman';">N/A </span></p></div></td><td style="width:1%; padding-right:1.45pt; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-sdt-tag:'9fd-a7d-dce-aee-b8d3'; font-family: 'Times New Roman'"><span>6.41</span></span><span style="font-family: 'Times New Roman';"> - </span><span style="-aw-sdt-tag:'922-43a-fd5-af0-7c6d'; font-family: 'Times New Roman'"><span>10.00</span></span></p></td><td style="width:0.86%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:bottom; background-color:#ffffff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_67fa179582ea40ab85e70f2d97a7168b'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="font-family: 'Times New Roman';">4.50</span></p></div></td><td style="width:1%; padding-right:1.45pt; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:bottom; background-color:#ffffff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-sdt-tag:'39b-8fc-eba-917-6b4f'; font-family: 'Times New Roman'"><span>6.41</span></span><span style="font-family: 'Times New Roman';"> - </span><span style="-aw-sdt-tag:'c62-ee5-3a2-e98-0fdf'; font-family: 'Times New Roman'"><span>10.00</span></span></p></td></tr><tr style="height:11.5pt"><td style="width:53%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_04267cb0abf54990bdf4b71fb0d4b3f1'"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="font-family: 'Times New Roman';">Expected dividend yield</span></p></div></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:bottom; background-color:#cceeff"><div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_3310313796d64fcca52c3a9e78c2bec2'"><span title="&amp;#13;nil='true'"></span><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-import:spaces; font-family: 'Times New Roman'">&#160;</span><span style="font-family: 'Times New Roman';">N/A </span></p></div></td><td style="width:1%; padding-right:1.45pt; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-sdt-tag:'C_d9ef82eb21d54263b8ca618d8d975456'; font-family: 'Times New Roman'"><span>0.00</span></span><span style="font-family: 'Times New Roman';">%</span></p></td><td style="width:0.86%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-sdt-tag:'C_555c1c1a0720497ba6cdc1357d20b8ce'; font-family: 'Times New Roman'"><span>0.00</span></span><span style="font-family: 'Times New Roman';">%</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:1%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"><span style="-aw-import:ignore; font-family: 'Times New Roman'">&#160;</span></p></td><td style="width:10%; vertical-align:bottom; background-color:#cceeff"><p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"><span style="-aw-sdt-tag:'bd0-9dc-c14-a77-e224'; font-family: 'Times New Roman'"><span>0.00</span></span><span style="font-family: 'Times New Roman';">%</span></p></td></tr></tbody></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the weighted-average grant-date fair value of equity options or other equity instruments granted during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NATURE OF OPERATIONS (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Nature of Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 4,115,779<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,659,353<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(5,156,566)<span></span>
</td>
<td class="num">$ (4,009,871)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sxtp_SBAEIDLincludingAccruedInterestCurrent', window );">Company&#8217;s debt</a></td>
<td class="nump">8,772<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,772<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">$ 1,391,347<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,007,618<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sxtp_SBAEIDLincludingAccruedInterestCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of SBA EIDL including accrued interest payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sxtp_SBAEIDLincludingAccruedInterestCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sxtp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Feb. 24, 2025</div></th>
<th class="th"><div>Feb. 18, 2025</div></th>
<th class="th"><div>Feb. 10, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Nov. 06, 2024</div></th>
<th class="th"><div>Jul. 31, 2024</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInAccountingEstimateLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Reverse stock split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1:5<span></span>
</td>
<td class="text">1:5<span></span>
</td>
<td class="text">On February 10, 2025, the Board of Directors approved a 1:5 reverse split ratio. On February 24, 2025, the Company effected the 1:5 reverse stock split (the &#8220;1:5 Reverse Stock Split&#8221;, and together with the 1:12 Reverse Stock Split, the &#8220;Reverse Stock Splits&#8221;).<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">On November 6, 2024, a majority of the Company&#8217;s stockholders approved an additional reverse stock split at a split ratio ranging between 1:3 and 1:5, as determined by the Board of Directors in its sole discretion.<span></span>
</td>
<td class="text">Following stockholder approval in July 2024, the Company effected a reverse stock split at a ratio of 1:12, which was effective as of August 12, 2024 (the &#8220;1:12 Reverse Stock Split&#8221;).<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1:5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash equivalents and short-term (in Dollars)</a></td>
<td class="nump">$ 4,115,779<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,387,825<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,115,779<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,115,779<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 809,777<span></span>
</td>
<td class="nump">$ 940,063<span></span>
</td>
<td class="nump">$ 1,467,283<span></span>
</td>
<td class="nump">$ 4,372,571<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk [Member] | Significant Customers [Member] | Accounts Receivable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInAccountingEstimateLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration percentage</a></td>
<td class="nump">89.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk [Member] | Significant Customers [Member] | Revenue Benchmark [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInAccountingEstimateLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
<td class="nump">92.00%<span></span>
</td>
<td class="nump">91.00%<span></span>
</td>
<td class="nump">94.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk [Member] | Significant Customers [Member] | Accounts Receivable Or Revenue Benchmark [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInAccountingEstimateLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk [Member] | Significant Customer One [Member] | Accounts Receivable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInAccountingEstimateLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration percentage</a></td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk [Member] | Significant Customer One [Member] | Revenue Benchmark [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInAccountingEstimateLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">73.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk [Member] | Significant Customer Two [Member] | Accounts Receivable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInAccountingEstimateLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration percentage</a></td>
<td class="nump">13.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk [Member] | Significant Customer Two [Member] | Revenue Benchmark [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInAccountingEstimateLineItems', window );"><strong>Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingEstimateLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingEstimateLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=sxtp_SignificantCustomersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=sxtp_SignificantCustomersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=sxtp_AccountsReceivableOrSalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=sxtp_AccountsReceivableOrSalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=sxtp_SignificantCustomerOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=sxtp_SignificantCustomerOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=sxtp_SignificantCustomerTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=sxtp_SignificantCustomerTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Liabilities Measured at Fair Value (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Schedule of Liabilities Measured at Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Total derivative liabilities</a></td>
<td class="nump">$ 797,275<span></span>
</td>
<td class="nump">$ 640,830<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Schedule of Liabilities Measured at Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Total derivative liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Schedule of Liabilities Measured at Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Total derivative liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Schedule of Liabilities Measured at Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Total derivative liabilities</a></td>
<td class="nump">797,275<span></span>
</td>
<td class="nump">640,830<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_DerivativeMember', window );">Derivative Liabilities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Schedule of Liabilities Measured at Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Total derivative liabilities</a></td>
<td class="nump">797,275<span></span>
</td>
<td class="nump">640,830<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_DerivativeMember', window );">Derivative Liabilities [Member] | Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Schedule of Liabilities Measured at Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Total derivative liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_DerivativeMember', window );">Derivative Liabilities [Member] | Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Schedule of Liabilities Measured at Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Total derivative liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_DerivativeMember', window );">Derivative Liabilities [Member] | Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Schedule of Liabilities Measured at Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Total derivative liabilities</a></td>
<td class="nump">$ 797,275<span></span>
</td>
<td class="nump">$ 640,830<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_DerivativeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_DerivativeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Exchange Rates along with Historical Rates (Details) - United States of America, Dollars<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntercompanyForeignCurrencyBalanceLineItems', window );"><strong>Schedule of Exchange Rates along with Historical Rates [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sxtp_AverageExchangeRate', window );">Average Exchange Rate</a></td>
<td class="nump">0.65<span></span>
</td>
<td class="nump">0.67<span></span>
</td>
<td class="nump">0.64<span></span>
</td>
<td class="nump">0.66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyExchangeRateTranslation1', window );">Exchange Rate</a></td>
<td class="nump">0.66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.62<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sxtp_AverageExchangeRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Average Exchange Rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sxtp_AverageExchangeRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sxtp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyExchangeRateTranslation1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Foreign exchange rate used to translate amounts denominated in functional currency to reporting currency.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479424/830-30-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyExchangeRateTranslation1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntercompanyForeignCurrencyBalanceLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntercompanyForeignCurrencyBalanceLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_USD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_USD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INVENTORY - Schedule of Inventory (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNetAbstract', window );"><strong>Schedule of Inventory [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryRawMaterials', window );">Raw Material (API)</a></td>
<td class="nump">$ 345,195<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcess', window );">Work in Process</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">284,883<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished Goods</a></td>
<td class="nump">426,491<span></span>
</td>
<td class="nump">157,881<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryGross', window );">Total Inventory</a></td>
<td class="nump">771,686<span></span>
</td>
<td class="nump">442,764<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryAdjustments', window );">Reserve for Expiring Inventory</a></td>
<td class="num">(244,682)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">$ 527,004<span></span>
</td>
<td class="nump">$ 442,764<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of inventory reserves for last-in first-out (LIFO) and other inventory valuation methods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483080/330-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORY (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>INVENTORY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Inventory Write-down</a></td>
<td class="nump">$ 436,561<span></span>
</td>
<td class="nump">$ 1,165<span></span>
</td>
<td class="nump">$ 436,596<span></span>
</td>
<td class="nump">$ 18,490<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483080/330-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>PROPERTY AND EQUIPMENT</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation</a></td>
<td class="nump">$ 12,225<span></span>
</td>
<td class="nump">$ 4,334<span></span>
</td>
<td class="nump">$ 28,155<span></span>
</td>
<td class="nump">$ 6,277<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT - Schedule of Property and Equipment (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Property and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and Equipment, at cost</a></td>
<td class="nump">$ 403,437<span></span>
</td>
<td class="nump">$ 299,241<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated Depreciation</a></td>
<td class="num">(175,685)<span></span>
</td>
<td class="num">(149,433)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and Equipment, net</a></td>
<td class="nump">227,752<span></span>
</td>
<td class="nump">149,808<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=sxtp_LabEquipmentMember', window );">Lab Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Property and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and Equipment, at cost</a></td>
<td class="nump">333,010<span></span>
</td>
<td class="nump">233,411<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Machinery [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Property and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and Equipment, at cost</a></td>
<td class="nump">55,800<span></span>
</td>
<td class="nump">55,800<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Property and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and Equipment, at cost</a></td>
<td class="nump">11,597<span></span>
</td>
<td class="nump">7,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Schedule of Property and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and Equipment, at cost</a></td>
<td class="nump">$ 3,030<span></span>
</td>
<td class="nump">$ 3,030<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=sxtp_LabEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=sxtp_LabEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLE ASSETS (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>INTANGIBLE ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sxtp_CapitalizedWebsiteDevelopmentrelatedCosts', window );">Capitalized website development-related costs</a></td>
<td class="nump">$ 1,785<span></span>
</td>
<td class="nump">$ 3,299<span></span>
</td>
<td class="nump">$ 1,785<span></span>
</td>
<td class="nump">$ 25,374<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense</a></td>
<td class="nump">10,605<span></span>
</td>
<td class="nump">10,325<span></span>
</td>
<td class="nump">31,150<span></span>
</td>
<td class="nump">28,004<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Write-downs</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 2,922<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 11,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sxtp_CapitalizedPatentExpenses', window );">Capitalized patent expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,209<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sxtp_CapitalizedPatentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of capitalized patent expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sxtp_CapitalizedPatentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sxtp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sxtp_CapitalizedWebsiteDevelopmentrelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of capitalized website development-related costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sxtp_CapitalizedWebsiteDevelopmentrelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sxtp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-12<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-21<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INTANGIBLE ASSETS - Schedule of Intangible Assets (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Schedule of Intangible Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedPatentsGross', window );">Patents</a></td>
<td class="nump">$ 152,267<span></span>
</td>
<td class="nump">$ 127,603<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sxtp_FiniteLivedWebsiteDevelopmentCostsGross', window );">Website Development Costs</a></td>
<td class="nump">106,407<span></span>
</td>
<td class="nump">104,622<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Intangible Assets, at cost</a></td>
<td class="nump">258,674<span></span>
</td>
<td class="nump">232,225<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(106,291)<span></span>
</td>
<td class="num">(75,141)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible Assets, net</a></td>
<td class="nump">$ 152,383<span></span>
</td>
<td class="nump">$ 157,084<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sxtp_FiniteLivedWebsiteDevelopmentCostsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross carrying amount before accumulated amortization as of the balance sheet date of the costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sxtp_FiniteLivedWebsiteDevelopmentCostsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sxtp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 928<br> -SubTopic 340<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478859/928-340-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedPatentsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross carrying amount before accumulated amortization as of the balance sheet date of the costs pertaining to the exclusive legal rights granted to the owner of the patent to exploit an invention or a process for a period of time specified by law. Such costs may have been expended to directly apply and receive patent rights, or to acquire such rights.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedPatentsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INTANGIBLE ASSETS - Schedule of Estimated Future Amortization Expense for Our Patents and Website Development Costs (Details)<br></strong></div></th>
<th class="th">
<div>Sep. 30, 2025 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember', window );">Patents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Schedule of Estimated Future Amortization Expense for Our Patents and Website Development Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear', window );">2025 (remaining nine months)</a></td>
<td class="nump">$ 1,816<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2026</a></td>
<td class="nump">7,264<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2027</a></td>
<td class="nump">7,264<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2028</a></td>
<td class="nump">7,264<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2029</a></td>
<td class="nump">7,264<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive', window );">Thereafter</a></td>
<td class="nump">38,435<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">69,307<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember', window );">Website Development Costs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Schedule of Estimated Future Amortization Expense for Our Patents and Website Development Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear', window );">2025 (remaining nine months)</a></td>
<td class="nump">5,754<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2026</a></td>
<td class="nump">13,027<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2027</a></td>
<td class="nump">3,689<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2028</a></td>
<td class="nump">397<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2029</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive', window );">Thereafter</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">$ 22,867<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 31<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-31<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-20<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-20<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 38<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-38<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 31<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-31<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 38<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-38<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 38<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-38<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 38<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-38<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 38<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-38<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 38<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-38<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 31<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-31<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 31<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-31<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 31<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-31<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 31<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-31<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 31<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-31<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 31<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-31<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 31<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-31<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-31<br><br>Reference 19: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-29<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-29<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-20<br><br>Reference 22: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-20<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-14<br><br>Reference 24: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-14<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-14<br><br>Reference 26: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-14<br><br>Reference 27: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-14<br><br>Reference 28: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 03, 2025</div></th>
<th class="th"><div>Jul. 16, 2025</div></th>
<th class="th"><div>Jul. 15, 2025</div></th>
<th class="th"><div>Feb. 24, 2025</div></th>
<th class="th"><div>Feb. 18, 2025</div></th>
<th class="th"><div>Feb. 10, 2025</div></th>
<th class="th"><div>Feb. 06, 2025</div></th>
<th class="th"><div>Feb. 05, 2025</div></th>
<th class="th"><div>Jan. 30, 2025</div></th>
<th class="th"><div>Jan. 28, 2025</div></th>
<th class="th"><div>Nov. 06, 2024</div></th>
<th class="th"><div>Aug. 01, 2024</div></th>
<th class="th"><div>Jul. 26, 2024</div></th>
<th class="th"><div>Jul. 22, 2024</div></th>
<th class="th"><div>Jul. 12, 2024</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Jul. 31, 2025</div></th>
<th class="th" colspan="2"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Jul. 31, 2024</div></th>
<th class="th" colspan="2"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th" colspan="2"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th" colspan="2"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Jan. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock shares authorized</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock par value (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">4,104,469<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,104,469<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,104,469<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">566,908<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock outstanding</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">4,104,469<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,104,469<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,104,469<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">566,908<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Reverse stock split</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1:5<span></span>
</td>
<td class="text">1:5<span></span>
</td>
<td class="text">On February 10, 2025, the Board of Directors approved a 1:5 reverse split ratio. On February 24, 2025, the Company effected the 1:5 reverse stock split (the &#8220;1:5 Reverse Stock Split&#8221;, and together with the 1:12 Reverse Stock Split, the &#8220;Reverse Stock Splits&#8221;).<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">On November 6, 2024, a majority of the Company&#8217;s stockholders approved an additional reverse stock split at a split ratio ranging between 1:3 and 1:5, as determined by the Board of Directors in its sole discretion.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">Following stockholder approval in July 2024, the Company effected a reverse stock split at a ratio of 1:12, which was effective as of August 12, 2024 (the &#8220;1:12 Reverse Stock Split&#8221;).<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1:5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Additional common share</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">204,312<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock price per share (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.575<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.105<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Exercise of warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">408,621<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.855<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Net proceeds from Private Placement</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 908,627<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 804,346<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 3,414,502<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Aggregate shares of common stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockDividendRatePercentage', window );">Dividends percentage</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsPreferredStock', window );">Dividends preferred stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,076,975<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Shares converted</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,473<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sxtp_ProceedsFromExerciseOfPreFundedWarrants', window );">Proceeds from Exercise of Pre-Funded Warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,804<span></span>
</td>
<td class="nump">$ 9,990<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=sxtp_PlacementAgentWarrantsMember', window );">Placement Agent Warrants [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Exercise of warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,554<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,325<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.469<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.382<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember', window );">Warrants, each warrant to purchase one share of Common Stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfWarrantsExercised', window );">Number of Warrants, Exercised</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">878,264<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="num">(385,200)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(8,326)<span></span>
</td>
<td class="num">(8,326)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of warrants granted</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,338,788<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">747,200<span></span>
</td>
<td class="nump">1,782,612<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="nump">140,884<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable', window );">Number of warrants exercisable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">7,587,594<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">756,680<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,587,594<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">756,680<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,587,594<span></span>
</td>
<td class="nump">756,680<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExercised', window );">Weighted average exercise price (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 0.6<span></span>
</td>
<td class="nump">$ 0.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=sxtp_PreFundedWarrantMember', window );">Pre-Funded Warrant [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock price per share (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.899<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sxtp_UnitsIssuedDuringPeriodSharesNewIssues', window );">Units issued</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">878,264<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrant shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfWarrantsExercised', window );">Number of Warrants, Exercised</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">878,264<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,263,464<span></span>
</td>
<td class="nump">16,652<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sxtp_ProceedsFromExerciseOfPreFundedWarrants', window );">Proceeds from Exercise of Pre-Funded Warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 878<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,804<span></span>
</td>
<td class="nump">$ 9,990<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of warrants granted</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">878,264<span></span>
</td>
<td class="nump">579,711<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable', window );">Number of warrants exercisable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">385,200<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">385,200<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">385,200<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sxtp_StockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfPreFundedWarrantsinShares', window );">Issuance of common stock upon exercise of Pre-Funded Warrants (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">878,264<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,263,464<span></span>
</td>
<td class="nump">16,652<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Class of Warrant or Right, Outstanding</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=sxtp_SeriesAWarrantsMember', window );">Series A Warrants [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of warrants granted</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">579,711<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=sxtp_SeriesBWarrantsMember', window );">Series B Warrants [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants exercisable expiry term</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">18 months<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">18 months<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">18 months<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of warrants granted</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">579,711<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=sxtp_SeptemberTwoThousandTwentyFourAgentWarrantsMember', window );">September 2024 Agent Warrants [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of warrants granted</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,479<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=sxtp_JulyTwoThousandTwentyFivePreFundedWarrantsMember', window );">July 2025 Pre-Funded Warrants [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable', window );">Date from which warrants exercisable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jul. 16,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=sxtp_JulyTwoThousandTwentyFiveAOneWarrantsMember', window );">July 2025 A-1 Warrants [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable', window );">Date from which warrants exercisable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jul. 16,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Date of warrants exercisable expiry</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jul. 15,  2030<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=sxtp_JulyTwoThousandTwentyFiveATwoWarrantsMember', window );">July Two Thousand Twenty Five A Two Warrants [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable', window );">Date from which warrants exercisable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jul. 16,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Date of warrants exercisable expiry</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jan. 15,  2027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=sxtp_JulyTwoThousandTwentyFivePlacementAgentWarrantsMember', window );">July 2025 Placement Agent Warrants [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants exercisable expiry term</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.375<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable', window );">Date from which warrants exercisable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jul. 16,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Date of warrants exercisable expiry</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jul. 15,  2030<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=sxtp_JulyTwoThousandTwentyFivePlacementAgentWarrantsMember', window );">July 2025 Placement Agent Warrants [Member] | Maximum [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Aggregate shares of common stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">197,368<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardDateAxis=sxtp_July2025OfferingMember', window );">July 2025 Offering [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock price per share (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Net proceeds from Private Placement</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,281,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sxtp_UnitsIssuedDuringPeriodSharesNewIssues', window );">Units issued</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,753,314<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock, par value $0.0001 per share</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Purchase of common stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,667<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Shares converted</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,667<span></span>
</td>
<td class="nump">8,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sxtp_StockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfPreFundedWarrantsinShares', window );">Issuance of common stock upon exercise of Pre-Funded Warrants (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">878,264<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">385,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">8,326<span></span>
</td>
<td class="nump">8,326<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=sxtp_WallachBethCapitalLLCMember', window );">WallachBeth Capital LLC [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sxtp_CommonStockAggregateOfferingPrice', window );">Common stock aggregate offering price</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,253,603<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sxtp_ATMOfferingShares', window );">ATM Offering</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">135,568<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromOtherEquity', window );">Gross proceeds</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,994,583<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sxtp_SalesAgreementTerminationDate', window );">Sales agreement termination date</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Sep.  03,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=sxtp_HCWainwrightAndCoLLCMember', window );">H C Wainwright And Co LLC [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Exercise of warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">43,479<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,479<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,479<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 8.63<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.63<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.63<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=sxtp_HCWainwrightAndCoLLCMember', window );">H C Wainwright And Co LLC [Member] | 2025 ATM Agreement [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sxtp_ATMOfferingShares', window );">ATM Offering</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sxtp_CommonStockAggregateGrossSalesProceedAuthorized', window );">Common stock aggregate gross sales proceeds authorized</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,397,532<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sxtp_SalesAgentCommissionPercentage', window );">Sales agent commission percentage</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock shares authorized</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock shares, par value (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock shares issued</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">76,480<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76,480<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76,480<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">76,480<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock shares outstanding</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">76,480<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76,480<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76,480<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">76,480<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Reverse stock split</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">as adjusted for the 1:12 Reverse Stock Split after August 12, 2024 and the 1:5 Reverse Stock Split after February 24, 2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants exercisable expiry term</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockDividendRatePercentage', window );">Dividends percentage</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsPreferredStock', window );">Dividends preferred stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 128,097<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 116,571<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 372,960<span></span>
</td>
<td class="nump">$ 352,333<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockConvertibleConversionPriceIncrease', window );">Common stock conversion price per share (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Convertible Preferred Stock, Shares Issued upon Conversion</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,032<span></span>
</td>
<td class="nump">1,291<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleSharesIssuable', window );">Preferred stock, convertible, shares issuable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,323<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,323<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,323<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=sxtp_SeriesANonVotingConvertiblePreferredStockMember', window );">Series A Non-Voting Convertible Preferred Stock [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExcessStockSharesAuthorized', window );">Designated shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">80,965<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80,965<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80,965<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80,965<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock, par value $0.0001 per share | Warrants, each warrant to purchase one share of Common Stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Aggregate shares of common stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertibleCommonStockMember', window );">Convertible Common Stock [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,667<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,667<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">14,667<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders&#8217; Equity [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock price per share (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="35"></td></tr>
<tr><td colspan="35"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><div style="-aw-sdt-tag:'c13961dbf06a06abf874'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">Prior periods presented have been adjusted to reflect the 1:5 reverse stock split on February 24, 2025.</span></p></div></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><div style="-aw-sdt-tag:'4e2-557-131-530-ea28'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">Weighted average remaining contractual life excludes </span><span style="-aw-sdt-tag:'155-a3e-4e3-421-5e47'; font-family: 'Times New Roman'"><span>878,264</span></span><span style="font-family: 'Times New Roman';"> Pre-Funded Warrants issued July 2025 that do not have a contractual expiration date, for which </span><span style="-aw-sdt-tag:'cfe-9a0-ea6-43f-4379'; font-family: 'Times New Roman'"><span>0</span></span><span style="font-family: 'Times New Roman';"> warrants remain outstanding and exercisable at </span><span style="-aw-sdt-tag:'b56-24f-fd5-c1f-b53f'; -aw-sdt-title:'Current_Period_P43'; font-family: 'Times New Roman'"><span>September 30, 2025</span></span><span style="font-family: 'Times New Roman';">.</span></p></div></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top"><div style="-aw-sdt-tag:'f6b-c28-fc7-73a-bf3d'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">Weighted average remaining contractual life calculation excludes </span><span style="-aw-sdt-tag:'789-7d3-dde-216-e566'; font-family: 'Times New Roman'"><span>579,711</span></span><span style="font-family: 'Times New Roman';"> exercisable Pre-Funded Warrants issued September 2024 that do not have a contractual expiration date.</span></p></div></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sxtp_ATMOfferingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ATM Offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sxtp_ATMOfferingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sxtp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sxtp_CommonStockAggregateGrossSalesProceedAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Authorized aggregate gross sales proceeds of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sxtp_CommonStockAggregateGrossSalesProceedAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sxtp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sxtp_CommonStockAggregateOfferingPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common stock having an aggregate offering price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sxtp_CommonStockAggregateOfferingPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sxtp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sxtp_ProceedsFromExerciseOfPreFundedWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from exercise of pre-funded warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sxtp_ProceedsFromExerciseOfPreFundedWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sxtp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sxtp_SalesAgentCommissionPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of sales agent commission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sxtp_SalesAgentCommissionPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sxtp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sxtp_SalesAgreementTerminationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Termination date of sales agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sxtp_SalesAgreementTerminationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sxtp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were exercisable, during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sxtp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of number of warrants, exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sxtp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price, exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sxtp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sxtp_StockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfPreFundedWarrantsinShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock upon exercise of Pre-Funded Warrants (in Shares).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sxtp_StockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfPreFundedWarrantsinShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sxtp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sxtp_UnitsIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of units issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sxtp_UnitsIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sxtp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date the warrants or rights are exercisable, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockConvertibleConversionPriceIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share increase in conversion price of convertible common stock. Excludes change due to standard antidilution provision.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockConvertibleConversionPriceIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid preferred stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -SubTopic 405<br> -Topic 942<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477787/942-405-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExcessStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum number of excess stock shares permitted to be issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExcessStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockConvertibleSharesIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of common shares issuable upon conversion of preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockConvertibleSharesIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendRatePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage rate used to calculate dividend payments on preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.12-12A(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendRatePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromOtherEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from the issuance of equity classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromOtherEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=sxtp_PlacementAgentWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=sxtp_PlacementAgentWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=sxtp_PreFundedWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=sxtp_PreFundedWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=sxtp_SeriesAWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=sxtp_SeriesAWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=sxtp_SeriesBWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=sxtp_SeriesBWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=sxtp_SeptemberTwoThousandTwentyFourAgentWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=sxtp_SeptemberTwoThousandTwentyFourAgentWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=sxtp_JulyTwoThousandTwentyFivePreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=sxtp_JulyTwoThousandTwentyFivePreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=sxtp_JulyTwoThousandTwentyFiveAOneWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=sxtp_JulyTwoThousandTwentyFiveAOneWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=sxtp_JulyTwoThousandTwentyFiveATwoWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=sxtp_JulyTwoThousandTwentyFiveATwoWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=sxtp_JulyTwoThousandTwentyFivePlacementAgentWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=sxtp_JulyTwoThousandTwentyFivePlacementAgentWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=sxtp_July2025OfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=sxtp_July2025OfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=sxtp_WallachBethCapitalLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=sxtp_WallachBethCapitalLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=sxtp_HCWainwrightAndCoLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=sxtp_HCWainwrightAndCoLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=sxtp_AtTheMarket2025AgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=sxtp_AtTheMarket2025AgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=sxtp_SeriesANonVotingConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=sxtp_SeriesANonVotingConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertibleCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_ConvertibleCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY - Schedule of Equity-Classified Warrants (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="9">3 Months Ended</th>
<th class="th" colspan="4">9 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th" colspan="2"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th" colspan="2"><div>Mar. 31, 2025</div></th>
<th class="th" colspan="2"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th" colspan="2"><div>Sep. 30, 2025</div></th>
<th class="th" colspan="2"><div>Sep. 30, 2024</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Schedule of Equity-Classified Warrants [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsExpired', window );">Weighted Average Remaining Contractual Life (Years), Expired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember', window );">Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Schedule of Equity-Classified Warrants [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of Warrants, Total outstanding, Beginning</a></td>
<td class="nump">2,127,070<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">2,127,070<span></span>
</td>
<td class="nump">1,765,070<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">176,969<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">185,295<span></span>
</td>
<td class="nump">52,737<span></span>
</td>
<td class="nump">1,765,070<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">52,737<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">52,737<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Exercise Price, Total outstanding, Beginning</a></td>
<td class="nump">$ 15.85<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 15.85<span></span>
</td>
<td class="nump">$ 17.59<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 128.09<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 122.36<span></span>
</td>
<td class="nump">$ 369.98<span></span>
</td>
<td class="nump">$ 17.59<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 369.98<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 369.98<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Weighted Average Remaining Contractual Life (Years), Total outstanding, Beginning</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">3 years 3 months 3 days<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">4 years 5 months 19 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of Warrants, Granted</a></td>
<td class="nump">6,338,788<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">747,200<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,782,612<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="nump">140,884<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Exercise Price, Granted</a></td>
<td class="nump">$ 1.65<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 3.56<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 4.7<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 22.48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsGranted', window );">Weighted Average Remaining Contractual Life (Years), Granted</a></td>
<td class="text">3 years 3 months 21 days<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text"> <span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfWarrantsExercised', window );">Number of Warrants, Exercised</a></td>
<td class="nump">878,264<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="num">(385,200)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(8,326)<span></span>
</td>
<td class="num">(8,326)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExercised', window );">Weighted Average Exercise Price, Exercised</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 0.6<span></span>
</td>
<td class="nump">$ 0.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsExercised', window );">Weighted Average Remaining Contractual Life (Years), Exercised</a></td>
<td class="text">&#160;Indefinite <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;Indefinite <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;Indefinite <span></span>
</td>
<td class="text">&#160;Indefinite <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Number of Warrants, Forfeited</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Weighted Average Exercise Price, Forfeited</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsForfeited', window );">Weighted Average Remaining Contractual Life (Years), Forfeited</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfWarrantsExpired', window );">Number of Warrants, Expired</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExpired', window );">Weighted Average Exercise Price, Expired</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsExpired', window );">Weighted Average Remaining Contractual Life (Years), Expired</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of Warrants, Total outstanding, Ending</a></td>
<td class="nump">7,587,594<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">2,127,070<span></span>
</td>
<td class="nump">2,127,070<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,959,581<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">176,969<span></span>
</td>
<td class="nump">185,295<span></span>
</td>
<td class="nump">7,587,594<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,959,581<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">1,765,070<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">52,737<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Exercise Price, Total outstanding, Ending</a></td>
<td class="nump">$ 5.82<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 15.85<span></span>
</td>
<td class="nump">$ 15.85<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 15.84<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">$ 128.09<span></span>
</td>
<td class="nump">$ 122.36<span></span>
</td>
<td class="nump">$ 5.82<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 15.84<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">$ 17.59<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 369.98<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms1', window );">Weighted Average Remaining Contractual Life (Years), Total outstanding, Ending</a></td>
<td class="text">2 years 9 months 25 days<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">2 years 1 month 6 days<span></span>
</td>
<td class="text">2 years 7 months 6 days<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">4 years 1 month 28 days<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="text">4 years 4 months 28 days<span></span>
</td>
<td class="text">4 years 8 months 1 day<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable', window );">Number of Warrants, Total exercisable</a></td>
<td class="nump">7,587,594<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">756,680<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,587,594<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">756,680<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageGrantDateFairValue', window );">Weighted Average Exercise Price,Total exercisable</a></td>
<td class="nump">$ 5.82<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 29.96<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.82<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 29.96<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableOutstandingWeightedAverageRemainingContractualTerms', window );">Weighted Average Remaining Contractual Life (Years),Total exercisable</a></td>
<td class="text">2 years 9 months 25 days<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">4 years 1 month 28 days<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[4]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="17"></td></tr>
<tr><td colspan="17"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><div style="-aw-sdt-tag:'cc60b45585da36d079a6'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">Weighted average remaining contractual life at </span><span style="-aw-sdt-tag:'cb7acd8bf727a3348920'; -aw-sdt-title:'Previous_Year_End_P16'; font-family: 'Times New Roman'"><span>December 31, 2024</span></span><span style="font-family: 'Times New Roman';"> excludes </span><span style="-aw-sdt-tag:'c9eaac2b3a02e0ecbfed'; font-family: 'Times New Roman'"><span>385,200</span></span><span style="font-family: 'Times New Roman';"> Pre-Funded Warrants issued September </span><span style="-aw-sdt-tag:'c084844e24a211ebd242'; font-family: 'Times New Roman'"><span>2024</span></span><span style="font-family: 'Times New Roman';"> that do not have a contractual expiration date, for which </span><span style="-aw-sdt-tag:'c6c65c3f0bb7343724f4'; font-family: 'Times New Roman'"><span>0</span></span><span style="font-family: 'Times New Roman';"> warrants remain outstanding and exercisable at March 31, 2025, June 30, 2025 and </span><span style="-aw-sdt-tag:'c3f8bf32fba6f0a28902'; -aw-sdt-title:'Current_Period_P16'; font-family: 'Times New Roman'"><span>September 30, 2025</span></span><span style="font-family: 'Times New Roman';">.</span></p></div></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><div style="-aw-sdt-tag:'4e2-557-131-530-ea28'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">Weighted average remaining contractual life excludes </span><span style="-aw-sdt-tag:'155-a3e-4e3-421-5e47'; font-family: 'Times New Roman'"><span>878,264</span></span><span style="font-family: 'Times New Roman';"> Pre-Funded Warrants issued July 2025 that do not have a contractual expiration date, for which </span><span style="-aw-sdt-tag:'cfe-9a0-ea6-43f-4379'; font-family: 'Times New Roman'"><span>0</span></span><span style="font-family: 'Times New Roman';"> warrants remain outstanding and exercisable at </span><span style="-aw-sdt-tag:'b56-24f-fd5-c1f-b53f'; -aw-sdt-title:'Current_Period_P43'; font-family: 'Times New Roman'"><span>September 30, 2025</span></span><span style="font-family: 'Times New Roman';">.</span></p></div></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top"><div style="-aw-sdt-tag:'54e-de6-a74-b52-df70'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">Weighted average remaining contractual life calculations exclude (i) </span><span style="-aw-sdt-tag:'732-da0-de5-bf5-8dbb'; font-family: 'Times New Roman'"><span>579,711</span></span><span style="font-family: 'Times New Roman';"> Pre-Funded Warrants issued September 2024 that do not have a contractual expiration date, (ii) </span><span style="-aw-sdt-tag:'f2c-5f7-8bf-af8-594f'; font-family: 'Times New Roman'"><span>43,479</span></span><span style="font-family: 'Times New Roman';"> September 2024 Agent Warrants and </span><span style="-aw-sdt-tag:'e8a-7d2-dd0-c63-800f'; font-family: 'Times New Roman'"><span>579,711</span></span><span style="font-family: 'Times New Roman';"> Series A Warrants issued September 2024 that expire </span><span style="-aw-sdt-tag:'316-f81-d28-80c-a600'; font-family: 'Times New Roman'"><span>five years</span></span><span style="font-family: 'Times New Roman';"> from the Stockholder Approval Date, defined above, and (iii) </span><span style="-aw-sdt-tag:'051-85c-a14-d67-3f56'; font-family: 'Times New Roman'"><span>579,711</span></span><span style="font-family: 'Times New Roman';"> Series B Warrants issued September 2024 that expire </span><span style="-aw-sdt-tag:'5a3-db5-072-293-bc68'; font-family: 'Times New Roman'"><span>eighteen months</span></span><span style="font-family: 'Times New Roman';"> from the Stockholder Approval Date, which had not yet occurred as of September 30, 2024.</span></p></div></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[4]</td>
<td style="vertical-align: top;" valign="top"><div style="-aw-sdt-tag:'f6b-c28-fc7-73a-bf3d'"><p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><span style="font-family: 'Times New Roman';">Weighted average remaining contractual life calculation excludes </span><span style="-aw-sdt-tag:'789-7d3-dde-216-e566'; font-family: 'Times New Roman'"><span>579,711</span></span><span style="font-family: 'Times New Roman';"> exercisable Pre-Funded Warrants issued September 2024 that do not have a contractual expiration date.</span></p></div></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were exercisable, during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sxtp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableOutstandingWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term exercisable for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableOutstandingWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sxtp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the exercisable date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sxtp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of number of warrants, exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sxtp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfWarrantsExpired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of number of warrants, expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfWarrantsExpired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sxtp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sxtp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price, exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sxtp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExpired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price, expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExpired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sxtp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sxtp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsExpired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual life (years), expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsExpired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sxtp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsForfeited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual life (years), forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsForfeited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sxtp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sxtp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEBT (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 14, 2020</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 153,764<span></span>
</td>
<td class="nump">$ 155,891<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current maturity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,772<span></span>
</td>
<td class="nump">8,772<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Long-Term Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 144,992<span></span>
</td>
<td class="nump">$ 147,119<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=sxtp_SmallBusinessAdministrationMember', window );">Small Business Administration [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount</a></td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Annual interest rate</a></td>
<td class="nump">3.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=sxtp_BalloonPaymentMember', window );">Balloon Payment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid', window );">Balloon payment</a></td>
<td class="nump">$ 731<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=sxtp_SBAMember', window );">SBA [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="text">Oct. 12,  2050<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 30: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 31: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of payment greater than the preceding installment payments to be paid at final maturity date of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=sxtp_SmallBusinessAdministrationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=sxtp_SmallBusinessAdministrationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=sxtp_BalloonPaymentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=sxtp_BalloonPaymentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=sxtp_SBAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=sxtp_SBAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>DEBT - Schedule of the Current Future Payment Obligations (Details)<br></strong></div></th>
<th class="th">
<div>Sep. 30, 2025 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtByMaturityAbstract', window );"><strong>Schedule of the Current Future Payment Obligations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear', window );">2025 (remaining three months)</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2026</a></td>
<td class="nump">465<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2027</a></td>
<td class="nump">3,220<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2028</a></td>
<td class="nump">3,333<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">2029</a></td>
<td class="nump">3,470<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive', window );">Thereafter</a></td>
<td class="nump">139,512<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total</a></td>
<td class="nump">$ 150,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtByMaturityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtByMaturityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DERIVATIVE LIABILITIES (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems', window );"><strong>Derivative Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Conversion of Stock, Shares Converted (in Shares)</a></td>
<td class="nump">18,473<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction', window );">Sale of stock, percentage of ownership</a></td>
<td class="nump">19.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sxtp_MilestonePayment', window );">Milestone Payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockRedemptionTerms', window );">Redemption term.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">For the period ending upon the earlier of (i) 10 years after the closing of the IPO, or (ii) the conversion or redemption in full of the Series A Preferred Stock, the Company will pay to Knight a royalty equal to 3.5% of the Company&#8217;s net sales (the &#8220;Royalty&#8221;) on a quarterly basis, where &#8220;Net Sales&#8221; has the same meaning as in the Company&#8217;s license agreement with the U.S. Army for tafenoquine.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sxtp_RoyaltyPercentage', window );">Royalty percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">(Gain) loss on change in fair value of derivative liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (156,445)<span></span>
</td>
<td class="nump">$ 1,683,034<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=sxtp_SeriesANonVotingConvertiblePreferredStockMember', window );">Series A Non-Voting Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems', window );"><strong>Derivative Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExcessStockSharesAuthorized', window );">Designated shares (in Shares)</a></td>
<td class="nump">80,965<span></span>
</td>
<td class="nump">80,965<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sxtp_MilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of milestone payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sxtp_MilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sxtp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sxtp_RoyaltyPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of royalty.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sxtp_RoyaltyPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sxtp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossOnDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482881/825-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainLossOnDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4EE<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4EE<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4EE<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4EE<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 181<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480401/815-10-55-181<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4EEE<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4EEE<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4EEE<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4EEE<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4EEE<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4EEE<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4EE<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4EE<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExcessStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum number of excess stock shares permitted to be issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExcessStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockRedemptionTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The redemption terms of preferred stock of an entity that has priority over common stock in the distribution of dividends and in the event of liquidation of the entity. The redemption features of this capital stock are solely within the control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockRedemptionTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of subsidiary's or equity investee's stock owned by parent company after stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=sxtp_SeriesANonVotingConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=sxtp_SeriesANonVotingConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DERIVATIVE LIABILITIES - Schedule of Derivative Liabilities Measured at Fair Value on a Recurring Basis (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="6">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Schedule of Derivative Liabilities Measured at Fair Value on a Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 640,830<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Ending balance</a></td>
<td class="nump">$ 797,275<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Schedule of Derivative Liabilities Measured at Fair Value on a Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">640,830<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Ending balance</a></td>
<td class="nump">797,275<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring [Member] | Contingent Milestone Payment [Member] | Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Schedule of Derivative Liabilities Measured at Fair Value on a Recurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Beginning balance</a></td>
<td class="nump">776,172<span></span>
</td>
<td class="nump">$ 635,725<span></span>
</td>
<td class="nump">640,830<span></span>
</td>
<td class="nump">$ 567,050<span></span>
</td>
<td class="nump">$ 565,949<span></span>
</td>
<td class="nump">$ 2,306,796<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sxtp_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisMarkToMarketAdjustment', window );">Change in fair value</a></td>
<td class="nump">21,103<span></span>
</td>
<td class="nump">140,447<span></span>
</td>
<td class="num">(5,105)<span></span>
</td>
<td class="nump">56,712<span></span>
</td>
<td class="nump">1,101<span></span>
</td>
<td class="num">(1,740,847)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Ending balance</a></td>
<td class="nump">$ 797,275<span></span>
</td>
<td class="nump">$ 776,172<span></span>
</td>
<td class="nump">$ 635,725<span></span>
</td>
<td class="nump">$ 623,762<span></span>
</td>
<td class="nump">$ 567,050<span></span>
</td>
<td class="nump">$ 565,949<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sxtp_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisMarkToMarketAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, measurement with unobservable inputs reconciliation, recurring Basis, fair value - mark to market adjustment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sxtp_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisMarkToMarketAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sxtp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=sxtp_ContingentMilestonePaymentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=sxtp_ContingentMilestonePaymentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>INCOME TAXES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">$ 250<span></span>
</td>
<td class="nump">$ 250<span></span>
</td>
<td class="nump">$ 1,813<span></span>
</td>
<td class="nump">$ 751<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE-BASED COMPENSATION (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jan. 20, 2025 </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2025 </div>
<div>USD ($) </div>
<div>Number </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2025 </div>
<div>USD ($) </div>
<div>Number </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Per share exercise price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 54.62<span></span>
</td>
<td class="nump">$ 6.55<span></span>
</td>
<td class="nump">$ 54.62<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value of options granted (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.78<span></span>
</td>
<td class="nump">$ 4.55<span></span>
</td>
<td class="nump">$ 8.78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock option award | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34,882<span></span>
</td>
<td class="nump">$ 34,503<span></span>
</td>
<td class="nump">$ 142,645<span></span>
</td>
<td class="nump">$ 15,246<span></span>
</td>
<td class="nump">$ 212,030<span></span>
</td>
<td class="nump">$ 15,246<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">79,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 668,974<span></span>
</td>
<td class="nump">344,383<span></span>
</td>
<td class="nump">$ 3,547,009<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sxtp_SharesIssuedPayrollTaxesWithholdings', window );">Shares payroll tax withholdings (in Shares)</a></td>
<td class="nump">2,748<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sxtp_UnamortizedBalance', window );">Unamortized balance | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">240,004<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">306,181<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseNoncurrent', window );">Long-term prepaid expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 66,176<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sxtp_NumberOfExecutives', window );">Stock option granted to number of executives | Number</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Stock option granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,005<span></span>
</td>
<td class="nump">120,000<span></span>
</td>
<td class="nump">17,005<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=sxtp_StockOptionsMember', window );">Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward', window );">Stock option granted term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">term of five to ten years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember', window );">First Tranche [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Options Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock, par value $0.0001 per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sxtp_StockIssuedDuringPeriodIssuanceOfSharesForAnnualPerformanceBonusesNetOfSharesWithheldForTaxesinShares', window );">Shares of common stock to the executives in settlement</a></td>
<td class="nump">15,809<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock, par value $0.0001 per share | Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Vested shares (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock, par value $0.0001 per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sxtp_StockIssuedDuringPeriodIssuanceOfSharesForAnnualPerformanceBonusesNetOfSharesWithheldForTaxesinShares', window );">Shares of common stock to the executives in settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,809<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock, par value $0.0001 per share | Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Stock option granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=sxtp_TwoThousandTwentyTwoEquityIncentivePlanMember', window );">Two Thousand Twenty Two Equity Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for grant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57,068<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57,068<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sxtp_NumberOfExecutives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of executives.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sxtp_NumberOfExecutives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sxtp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sxtp_SharesIssuedPayrollTaxesWithholdings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The shares issued payroll taxes withholdings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sxtp_SharesIssuedPayrollTaxesWithholdings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sxtp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sxtp_StockIssuedDuringPeriodIssuanceOfSharesForAnnualPerformanceBonusesNetOfSharesWithheldForTaxesinShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Issuance of shares for annual performance bonuses, net of shares withheld for taxes (in Shares).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sxtp_StockIssuedDuringPeriodIssuanceOfSharesForAnnualPerformanceBonusesNetOfSharesWithheldForTaxesinShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sxtp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sxtp_UnamortizedBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of unamortized balance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sxtp_UnamortizedBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sxtp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479983/718-10-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477796/946-210-45-21<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 210<br> -Topic 946<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477796/946-210-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of amounts paid in advance for expenses which will be charged against earnings in periods after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of terms of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of options vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=sxtp_StockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=sxtp_StockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=sxtp_TwoThousandTwentyTwoEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=sxtp_TwoThousandTwentyTwoEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE-BASED COMPENSATION - Schedule of Share-Based Compensation Expenses (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Schedule of Share-Based Compensation Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total Share-Based Compensation Expense Included in Operating Expenses</a></td>
<td class="nump">$ 79,000<span></span>
</td>
<td class="nump">$ 668,974<span></span>
</td>
<td class="nump">$ 344,383<span></span>
</td>
<td class="nump">$ 3,547,009<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Schedule of Share-Based Compensation Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total Share-Based Compensation Expense Included in Operating Expenses</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,227,300<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Schedule of Share-Based Compensation Expenses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total Share-Based Compensation Expense Included in Operating Expenses</a></td>
<td class="nump">$ 79,000<span></span>
</td>
<td class="nump">$ 68,974<span></span>
</td>
<td class="nump">$ 344,383<span></span>
</td>
<td class="nump">$ 319,709<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479983/718-10-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE-BASED COMPENSATION - Schedule of Fair Value of Options Granted (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value (in Dollars per share)</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 8.78<span></span>
</td>
<td class="nump">$ 4.55<span></span>
</td>
<td class="nump">$ 8.78<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.36%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.62%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.62%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.17%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.17%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility, minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected volatility, maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sxtp_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1Minimum', window );">Expected term, minimum (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 4 months 28 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 4 months 28 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sxtp_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1Maximum', window );">Expected term, maximum (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sxtp_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1Maximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected maximum term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sxtp_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1Maximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sxtp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sxtp_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1Minimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected minimum term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sxtp_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1Minimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sxtp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 20, 2024</div></th>
<th class="th">
<div>Jul. 15, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2025 </div>
<div>USD ($) </div>
<div>Director</div>
</th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2025 </div>
<div>USD ($) </div>
<div>Director</div>
</th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of pending or threatened lawsuits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Office space lease renewed term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,573<span></span>
</td>
<td class="nump">$ 4,938<span></span>
</td>
<td class="nump">$ 15,340<span></span>
</td>
<td class="nump">$ 24,067<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sxtp_NumberOfNonAuditCommitteeChairs', window );">Number of non audit committee chairs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sxtp_LicensedTechnologyTerm', window );">Licensed technology term.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sxtp_AnnualRoyaltyPaymentPercentage', window );">Annual royalty payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sxtp_PercentageOfRoyaltyPaymentsOfNetSales', window );">Percentage of royalty payments of net sales</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationPercentage', window );">Percentage of revenue</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=sxtp_CharlesAllenMember', window );">Charles Allen [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndBenefitsTrust', window );">Cash compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=sxtp_PaulFieldMember', window );">Paul Field [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndBenefitsTrust', window );">Cash compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=sxtp_USGovernmentSalesMember', window );">US Government Sales [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Royalty expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=sxtp_USArmyAgreementMember', window );">U.S. Army Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Royalty expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=sxtp_TuftsMedicalCenterAgreementMember', window );">Tufts MC Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Royalty expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_BoardOfDirectorsChairmanMember', window );">Board of Directors Chairman [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sxtp_AnnualRoyaltyPaymentPercentage', window );">Annual royalty payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_BoardOfDirectorsChairmanMember', window );">Board of Directors Chairman [Member] | Stephen Toovey [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndBenefitsTrust', window );">Cash compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_DirectorMember', window );">Director [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sxtp_NumberOfDirectors', window );">Number of director nominees | Director</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward', window );">Equity-based compensation awards term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">annual<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sxtp_PercentageOfTreatmentOfBabesiosis', window );">Percentage of treatment of babesiosis</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sxtp_PercentageOfTreatmentOfBabesiosis', window );">Percentage of treatment of babesiosis</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sxtp_AnnualRoyaltyPaymentPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of annual royalty payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sxtp_AnnualRoyaltyPaymentPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sxtp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sxtp_LicensedTechnologyTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Licensed technology term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sxtp_LicensedTechnologyTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sxtp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sxtp_NumberOfDirectors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of directors.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sxtp_NumberOfDirectors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sxtp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sxtp_NumberOfNonAuditCommitteeChairs">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-audit committee chairs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sxtp_NumberOfNonAuditCommitteeChairs</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sxtp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sxtp_PercentageOfRoyaltyPaymentsOfNetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of royalty payments of net sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sxtp_PercentageOfRoyaltyPaymentsOfNetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sxtp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sxtp_PercentageOfTreatmentOfBabesiosis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of treatment of babesiosis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sxtp_PercentageOfTreatmentOfBabesiosis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sxtp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 43<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-43<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndBenefitsTrust">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of a trust established to hold the stock of an employee compensation and benefits plan as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndBenefitsTrust</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyPendingClaimsNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of pending claims pertaining to a loss contingency.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyPendingClaimsNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of remaining performance obligation to total remaining performance obligation not recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(1)<br> -SubTopic 10<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of terms of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=sxtp_CharlesAllenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=sxtp_CharlesAllenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=sxtp_PaulFieldMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=sxtp_PaulFieldMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=sxtp_USGovernmentSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=sxtp_USGovernmentSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=sxtp_USArmyAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=sxtp_USArmyAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=sxtp_TuftsMedicalCenterAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=sxtp_TuftsMedicalCenterAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_BoardOfDirectorsChairmanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_BoardOfDirectorsChairmanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=sxtp_StephenTooveyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=sxtp_StephenTooveyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Oct. 21, 2025 </div>
<div>Number </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 08, 2025 </div>
<div>Number </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2025 </div>
<div>Director </div>
<div>shares</div>
</th>
<th class="th"><div>Feb. 24, 2025</div></th>
<th class="th"><div>Feb. 18, 2025</div></th>
<th class="th"><div>Feb. 10, 2025</div></th>
<th class="th"><div>Nov. 06, 2024</div></th>
<th class="th">
<div>Nov. 13, 2025 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th"><div>Jul. 31, 2024</div></th>
<th class="th">
<div>Sep. 30, 2025 </div>
<div>Director </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2025 </div>
<div>Director </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Reverse stock split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1:5<span></span>
</td>
<td class="text">1:5<span></span>
</td>
<td class="text">On February 10, 2025, the Board of Directors approved a 1:5 reverse split ratio. On February 24, 2025, the Company effected the 1:5 reverse stock split (the &#8220;1:5 Reverse Stock Split&#8221;, and together with the 1:12 Reverse Stock Split, the &#8220;Reverse Stock Splits&#8221;).<span></span>
</td>
<td class="text">On November 6, 2024, a majority of the Company&#8217;s stockholders approved an additional reverse stock split at a split ratio ranging between 1:3 and 1:5, as determined by the Board of Directors in its sole discretion.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Following stockholder approval in July 2024, the Company effected a reverse stock split at a ratio of 1:12, which was effective as of August 12, 2024 (the &#8220;1:12 Reverse Stock Split&#8221;).<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1:5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Stock option granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">17,005<span></span>
</td>
<td class="nump">120,000<span></span>
</td>
<td class="nump">17,005<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Per share exercise price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 54.62<span></span>
</td>
<td class="nump">$ 6.55<span></span>
</td>
<td class="nump">$ 54.62<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_DirectorMember', window );">Director [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sxtp_NumberOfDirectors', window );">Number of directors | Director</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=sxtp_HCWainwrightAndCoLLCMember', window );">H.C. Wainwright &amp; Co., LLC [Member] | 2025 ATM Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sxtp_ATMOfferingShares', window );">ATM Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sxtp_NumberOfDirectors', window );">Number of directors | Number</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Reverse stock split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1:3 to 1:10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Stock Options [Member] | Director [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sxtp_NumberOfDirectors', window );">Number of directors | Number</a></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Stock option granted</a></td>
<td class="nump">32,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Per share exercise price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 1.46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Stock option term</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Stock Options [Member] | Director One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Stock option granted</a></td>
<td class="nump">8,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | H.C. Wainwright &amp; Co., LLC [Member] | 2025 ATM Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sxtp_ATMOfferingShares', window );">ATM Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125,979<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sxtp_CommonStockSalesAgreementWeightedAveragePricePerShare', window );">Common stock sales agreement weighted average price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.62<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sxtp_ProceedsFromCommonStockSalesAgreementNet', window );">Proceeds from common stock sales agreement net | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 196,356<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sxtp_ATMOfferingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ATM Offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sxtp_ATMOfferingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sxtp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sxtp_CommonStockSalesAgreementWeightedAveragePricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share weighted-average price of common stock under sales agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sxtp_CommonStockSalesAgreementWeightedAveragePricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sxtp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sxtp_NumberOfDirectors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of directors.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sxtp_NumberOfDirectors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sxtp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sxtp_ProceedsFromCommonStockSalesAgreementNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with common stock sales agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sxtp_ProceedsFromCommonStockSalesAgreementNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sxtp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=sxtp_HCWainwrightAndCoLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=sxtp_HCWainwrightAndCoLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=sxtp_AtTheMarket2025AgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=sxtp_AtTheMarket2025AgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=sxtp_StockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=sxtp_StockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=sxtp_DirectorOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=sxtp_DirectorOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>299</ContextCount>
  <ElementCount>329</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>68</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="sxtp-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://60degreespharma.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="sxtp-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00100 - Statement - Consolidated Condensed Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://60degreespharma.com/role/sxtp_r_ConsolidatedBalanceSheet</Role>
      <ShortName>Consolidated Condensed Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="sxtp-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00150 - Statement - Consolidated Condensed Balance Sheets (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://60degreespharma.com/role/sxtp_r_ConsolidatedBalanceSheet_Parentheticals</Role>
      <ShortName>Consolidated Condensed Balance Sheets (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="sxtp-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00200 - Statement - Consolidated Condensed Statements of Operations and Comprehensive (Loss) Income (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://60degreespharma.com/role/sxtp_r_ConsolidatedIncomeStatement</Role>
      <ShortName>Consolidated Condensed Statements of Operations and Comprehensive (Loss) Income (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="sxtp-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00300 - Statement - Consolidated Condensed Statements of Shareholders' Equity (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://60degreespharma.com/role/ConsolidatedCondensedStatementsofShareholdersEquityUnaudited</Role>
      <ShortName>Consolidated Condensed Statements of Shareholders' Equity (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="sxtp-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00400 - Statement - Consolidated Condensed Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://60degreespharma.com/role/sxtp_r_ConsolidatedCashFlow</Role>
      <ShortName>Consolidated Condensed Statements of Cash Flows (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="sxtp-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>10001 - Disclosure - NATURE OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://60degreespharma.com/role/NATUREOFOPERATIONS</Role>
      <ShortName>NATURE OF OPERATIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="sxtp-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>10002 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://60degreespharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="sxtp-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>10003 - Disclosure - INVENTORY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://60degreespharma.com/role/INVENTORY</Role>
      <ShortName>INVENTORY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="sxtp-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>10004 - Disclosure - PROPERTY AND EQUIPMENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://60degreespharma.com/role/PROPERTYANDEQUIPMENT</Role>
      <ShortName>PROPERTY AND EQUIPMENT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="sxtp-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>10005 - Disclosure - INTANGIBLE ASSETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://60degreespharma.com/role/INTANGIBLEASSETS</Role>
      <ShortName>INTANGIBLE ASSETS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="sxtp-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>10006 - Disclosure - STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://60degreespharma.com/role/STOCKHOLDERSEQUITY</Role>
      <ShortName>STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="sxtp-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>10007 - Disclosure - DEBT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://60degreespharma.com/role/DEBT</Role>
      <ShortName>DEBT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="sxtp-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>10008 - Disclosure - DERIVATIVE LIABILITIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://60degreespharma.com/role/DERIVATIVELIABILITIES</Role>
      <ShortName>DERIVATIVE LIABILITIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="sxtp-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>10009 - Disclosure - INCOME TAXES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://60degreespharma.com/role/INCOMETAXES</Role>
      <ShortName>INCOME TAXES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="sxtp-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>10010 - Disclosure - SHARE-BASED COMPENSATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://60degreespharma.com/role/SHAREBASEDCOMPENSATION</Role>
      <ShortName>SHARE-BASED COMPENSATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="sxtp-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>10011 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://60degreespharma.com/role/COMMITMENTSANDCONTINGENCIES</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="sxtp-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>10012 - Disclosure - SUBSEQUENT EVENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://60degreespharma.com/role/SUBSEQUENTEVENTS</Role>
      <ShortName>SUBSEQUENT EVENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="sxtp-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="sxtp-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>996000 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://60degreespharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="sxtp-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>996001 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://60degreespharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://60degreespharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="sxtp-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>996002 - Disclosure - INVENTORY (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://60degreespharma.com/role/INVENTORYTables</Role>
      <ShortName>INVENTORY (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://60degreespharma.com/role/INVENTORY</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="sxtp-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>996003 - Disclosure - PROPERTY AND EQUIPMENT (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://60degreespharma.com/role/PROPERTYANDEQUIPMENTTables</Role>
      <ShortName>PROPERTY AND EQUIPMENT (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://60degreespharma.com/role/PROPERTYANDEQUIPMENT</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="sxtp-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>996004 - Disclosure - INTANGIBLE ASSETS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://60degreespharma.com/role/INTANGIBLEASSETSTables</Role>
      <ShortName>INTANGIBLE ASSETS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://60degreespharma.com/role/INTANGIBLEASSETS</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="sxtp-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>996005 - Disclosure - STOCKHOLDERS' EQUITY (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://60degreespharma.com/role/STOCKHOLDERSEQUITYTables</Role>
      <ShortName>STOCKHOLDERS' EQUITY (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://60degreespharma.com/role/STOCKHOLDERSEQUITY</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="sxtp-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>996006 - Disclosure - DEBT (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://60degreespharma.com/role/DEBTTables</Role>
      <ShortName>DEBT (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://60degreespharma.com/role/DEBT</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="sxtp-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>996007 - Disclosure - DERIVATIVE LIABILITIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://60degreespharma.com/role/DERIVATIVELIABILITIESTables</Role>
      <ShortName>DERIVATIVE LIABILITIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://60degreespharma.com/role/DERIVATIVELIABILITIES</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="sxtp-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>996008 - Disclosure - SHARE-BASED COMPENSATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://60degreespharma.com/role/SHAREBASEDCOMPENSATIONTables</Role>
      <ShortName>SHARE-BASED COMPENSATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://60degreespharma.com/role/SHAREBASEDCOMPENSATION</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="sxtp-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>996009 - Disclosure - NATURE OF OPERATIONS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://60degreespharma.com/role/NATUREOFOPERATIONSDetails</Role>
      <ShortName>NATURE OF OPERATIONS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://60degreespharma.com/role/NATUREOFOPERATIONS</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="sxtp-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>996010 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://60degreespharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://60degreespharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="sxtp-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>996011 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Liabilities Measured at Fair Value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://60degreespharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofLiabilitiesMeasuredatFairValueDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Liabilities Measured at Fair Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="sxtp-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>996012 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Exchange Rates along with Historical Rates (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://60degreespharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofExchangeRatesalongwithHistoricalRatesDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Exchange Rates along with Historical Rates (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="sxtp-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>996013 - Disclosure - INVENTORY - Schedule of Inventory (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://60degreespharma.com/role/INVENTORYScheduleofInventoryDetails</Role>
      <ShortName>INVENTORY - Schedule of Inventory (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="sxtp-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>9960131 - Disclosure - INVENTORY (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://60degreespharma.com/role/INVENTORYDetails</Role>
      <ShortName>INVENTORY (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://60degreespharma.com/role/INVENTORYTables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="sxtp-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>996014 - Disclosure - PROPERTY AND EQUIPMENT (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://60degreespharma.com/role/PROPERTYANDEQUIPMENTDetails</Role>
      <ShortName>PROPERTY AND EQUIPMENT (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://60degreespharma.com/role/PROPERTYANDEQUIPMENTTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="sxtp-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>996015 - Disclosure - PROPERTY AND EQUIPMENT - Schedule of Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://60degreespharma.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails</Role>
      <ShortName>PROPERTY AND EQUIPMENT - Schedule of Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="sxtp-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>996016 - Disclosure - INTANGIBLE ASSETS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://60degreespharma.com/role/INTANGIBLEASSETSDetails</Role>
      <ShortName>INTANGIBLE ASSETS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://60degreespharma.com/role/INTANGIBLEASSETSTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="sxtp-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>996017 - Disclosure - INTANGIBLE ASSETS - Schedule of Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://60degreespharma.com/role/INTANGIBLEASSETSScheduleofIntangibleAssetsDetails</Role>
      <ShortName>INTANGIBLE ASSETS - Schedule of Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="sxtp-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>996018 - Disclosure - INTANGIBLE ASSETS - Schedule of Estimated Future Amortization Expense for Our Patents and Website Development Costs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://60degreespharma.com/role/INTANGIBLEASSETSScheduleofEstimatedFutureAmortizationExpenseforOurPatentsandWebsiteDevelopmentCostsDetails</Role>
      <ShortName>INTANGIBLE ASSETS - Schedule of Estimated Future Amortization Expense for Our Patents and Website Development Costs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="sxtp-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>996019 - Disclosure - STOCKHOLDERS' EQUITY (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://60degreespharma.com/role/STOCKHOLDERSEQUITYDetails</Role>
      <ShortName>STOCKHOLDERS' EQUITY (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://60degreespharma.com/role/STOCKHOLDERSEQUITYTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="sxtp-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>996020 - Disclosure - STOCKHOLDERS' EQUITY - Schedule of Equity-Classified Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://60degreespharma.com/role/STOCKHOLDERSEQUITYScheduleofEquityClassifiedWarrantsDetails</Role>
      <ShortName>STOCKHOLDERS' EQUITY - Schedule of Equity-Classified Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="sxtp-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>996021 - Disclosure - DEBT (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://60degreespharma.com/role/DEBTDetails</Role>
      <ShortName>DEBT (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://60degreespharma.com/role/DEBTTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="sxtp-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>996022 - Disclosure - DEBT - Schedule of the Current Future Payment Obligations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://60degreespharma.com/role/DEBTScheduleoftheCurrentFuturePaymentObligationsDetails</Role>
      <ShortName>DEBT - Schedule of the Current Future Payment Obligations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="sxtp-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>996023 - Disclosure - DERIVATIVE LIABILITIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://60degreespharma.com/role/DERIVATIVELIABILITIESDetails</Role>
      <ShortName>DERIVATIVE LIABILITIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://60degreespharma.com/role/DERIVATIVELIABILITIESTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="sxtp-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>996024 - Disclosure - DERIVATIVE LIABILITIES - Schedule of Derivative Liabilities Measured at Fair Value on a Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://60degreespharma.com/role/DERIVATIVELIABILITIESScheduleofDerivativeLiabilitiesMeasuredatFairValueonaRecurringBasisDetails</Role>
      <ShortName>DERIVATIVE LIABILITIES - Schedule of Derivative Liabilities Measured at Fair Value on a Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="sxtp-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>996025 - Disclosure - INCOME TAXES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://60degreespharma.com/role/INCOMETAXESDetails</Role>
      <ShortName>INCOME TAXES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://60degreespharma.com/role/INCOMETAXES</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="sxtp-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>996026 - Disclosure - SHARE-BASED COMPENSATION (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://60degreespharma.com/role/SHAREBASEDCOMPENSATIONDetails</Role>
      <ShortName>SHARE-BASED COMPENSATION (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://60degreespharma.com/role/SHAREBASEDCOMPENSATIONTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="sxtp-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>996027 - Disclosure - SHARE-BASED COMPENSATION - Schedule of Share-Based Compensation Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://60degreespharma.com/role/SHAREBASEDCOMPENSATIONScheduleofShareBasedCompensationExpensesDetails</Role>
      <ShortName>SHARE-BASED COMPENSATION - Schedule of Share-Based Compensation Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="sxtp-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>996028 - Disclosure - SHARE-BASED COMPENSATION - Schedule of Fair Value of Options Granted (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://60degreespharma.com/role/SHAREBASEDCOMPENSATIONScheduleofFairValueofOptionsGrantedDetails</Role>
      <ShortName>SHARE-BASED COMPENSATION - Schedule of Fair Value of Options Granted (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="sxtp-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>996029 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://60degreespharma.com/role/COMMITMENTSANDCONTINGENCIESDetails</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://60degreespharma.com/role/COMMITMENTSANDCONTINGENCIES</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="sxtp-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>996030 - Disclosure - SUBSEQUENT EVENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://60degreespharma.com/role/SUBSEQUENTEVENTSDetails</Role>
      <ShortName>SUBSEQUENT EVENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://60degreespharma.com/role/SUBSEQUENTEVENTS</ParentRole>
      <Position>51</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" isDefinitelyFs="true" isUsgaap="true" original="sxtp-20250930.htm">sxtp-20250930.htm</File>
    <File>sxtp-20250930.xsd</File>
    <File>sxtp-20250930_cal.xml</File>
    <File>sxtp-20250930_def.xml</File>
    <File>sxtp-20250930_lab.xml</File>
    <File>sxtp-20250930_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="765">http://fasb.org/us-gaap/2025</BaseTaxonomy>
    <BaseTaxonomy items="34">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
    <BaseTaxonomy items="4">http://xbrl.sec.gov/ecd/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>69
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "sxtp-20250930.htm": {
   "nsprefix": "sxtp",
   "nsuri": "http://60degreespharma.com/20250930",
   "dts": {
    "inline": {
     "local": [
      "sxtp-20250930.htm"
     ]
    },
    "schema": {
     "local": [
      "sxtp-20250930.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/currency/2025/currency-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "sxtp-20250930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "sxtp-20250930_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "sxtp-20250930_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "sxtp-20250930_pre.xml"
     ]
    }
   },
   "keyStandard": 259,
   "keyCustom": 70,
   "axisStandard": 25,
   "axisCustom": 0,
   "memberStandard": 34,
   "memberCustom": 32,
   "hidden": {
    "total": 11,
    "http://xbrl.sec.gov/dei/2025": 6,
    "http://xbrl.sec.gov/ecd/2025": 4,
    "http://fasb.org/us-gaap/2025": 1
   },
   "contextCount": 299,
   "entityCount": 1,
   "segmentCount": 68,
   "elementCount": 563,
   "unitCount": 6,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2025": 765,
    "http://xbrl.sec.gov/dei/2025": 34,
    "http://xbrl.sec.gov/ecd/2025": 4
   },
   "report": {
    "R1": {
     "role": "http://60degreespharma.com/role/DocumentAndEntityInformation",
     "longName": "000 - Document - Document And Entity Information",
     "shortName": "Document And Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "D20250930_1",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sxtp-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "D20250930_1",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sxtp-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://60degreespharma.com/role/sxtp_r_ConsolidatedBalanceSheet",
     "longName": "00100 - Statement - Consolidated Condensed Balance Sheets",
     "shortName": "Consolidated Condensed Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "I20250930",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:NatureOfOperations",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sxtp-20250930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "I20250930",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "div",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sxtp-20250930.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://60degreespharma.com/role/sxtp_r_ConsolidatedBalanceSheet_Parentheticals",
     "longName": "00150 - Statement - Consolidated Condensed Balance Sheets (Parentheticals)",
     "shortName": "Consolidated Condensed Balance Sheets (Parentheticals)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "I20250930",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "USDPerShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sxtp-20250930.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R4": {
     "role": "http://60degreespharma.com/role/sxtp_r_ConsolidatedIncomeStatement",
     "longName": "00200 - Statement - Consolidated Condensed Statements of Operations and Comprehensive (Loss) Income (Unaudited)",
     "shortName": "Consolidated Condensed Statements of Operations and Comprehensive (Loss) Income (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "D20250930",
      "name": "us-gaap:Revenues",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "div",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sxtp-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "D20250930",
      "name": "us-gaap:Revenues",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "div",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sxtp-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R5": {
     "role": "http://60degreespharma.com/role/ConsolidatedCondensedStatementsofShareholdersEquityUnaudited",
     "longName": "00300 - Statement - Consolidated Condensed Statements of Shareholders' Equity (Unaudited)",
     "shortName": "Consolidated Condensed Statements of Shareholders' Equity (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "I20231231",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "div",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sxtp-20250930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "D20240331",
      "name": "sxtp:IssuanceOfCommonStockAndWarrantsOfUnderwritingDiscountsAndOfferingCostsPaidAtClosingAndDeferredOfferingCosts",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "div",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sxtp-20250930.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://60degreespharma.com/role/sxtp_r_ConsolidatedCashFlow",
     "longName": "00400 - Statement - Consolidated Condensed Statements of Cash Flows (Unaudited)",
     "shortName": "Consolidated Condensed Statements of Cash Flows (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "D20250930_1",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sxtp-20250930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "D20250930_1",
      "name": "us-gaap:Depreciation",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "div",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sxtp-20250930.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://60degreespharma.com/role/NATUREOFOPERATIONS",
     "longName": "10001 - Disclosure - NATURE OF OPERATIONS",
     "shortName": "NATURE OF OPERATIONS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "D20250930_1",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sxtp-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "D20250930_1",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sxtp-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://60degreespharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES",
     "longName": "10002 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "D20250930_1",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sxtp-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "D20250930_1",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sxtp-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://60degreespharma.com/role/INVENTORY",
     "longName": "10003 - Disclosure - INVENTORY",
     "shortName": "INVENTORY",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "D20250930_1",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sxtp-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "D20250930_1",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sxtp-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://60degreespharma.com/role/PROPERTYANDEQUIPMENT",
     "longName": "10004 - Disclosure - PROPERTY AND EQUIPMENT",
     "shortName": "PROPERTY AND EQUIPMENT",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "D20250930_1",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sxtp-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "D20250930_1",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sxtp-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://60degreespharma.com/role/INTANGIBLEASSETS",
     "longName": "10005 - Disclosure - INTANGIBLE ASSETS",
     "shortName": "INTANGIBLE ASSETS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "D20250930_1",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sxtp-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "D20250930_1",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sxtp-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://60degreespharma.com/role/STOCKHOLDERSEQUITY",
     "longName": "10006 - Disclosure - STOCKHOLDERS' EQUITY",
     "shortName": "STOCKHOLDERS' EQUITY",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "D20250930_1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sxtp-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "D20250930_1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sxtp-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://60degreespharma.com/role/DEBT",
     "longName": "10007 - Disclosure - DEBT",
     "shortName": "DEBT",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "D20250930_1",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sxtp-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "D20250930_1",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sxtp-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://60degreespharma.com/role/DERIVATIVELIABILITIES",
     "longName": "10008 - Disclosure - DERIVATIVE LIABILITIES",
     "shortName": "DERIVATIVE LIABILITIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "D20250930_1",
      "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sxtp-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "D20250930_1",
      "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sxtp-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://60degreespharma.com/role/INCOMETAXES",
     "longName": "10009 - Disclosure - INCOME TAXES",
     "shortName": "INCOME TAXES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "D20250930_1",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sxtp-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "D20250930_1",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sxtp-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://60degreespharma.com/role/SHAREBASEDCOMPENSATION",
     "longName": "10010 - Disclosure - SHARE-BASED COMPENSATION",
     "shortName": "SHARE-BASED COMPENSATION",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "D20250930_1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sxtp-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "D20250930_1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sxtp-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://60degreespharma.com/role/COMMITMENTSANDCONTINGENCIES",
     "longName": "10011 - Disclosure - COMMITMENTS AND CONTINGENCIES",
     "shortName": "COMMITMENTS AND CONTINGENCIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "D20250930_1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sxtp-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "D20250930_1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sxtp-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://60degreespharma.com/role/SUBSEQUENTEVENTS",
     "longName": "10012 - Disclosure - SUBSEQUENT EVENTS",
     "shortName": "SUBSEQUENT EVENTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "D20250930_1",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sxtp-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "D20250930_1",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sxtp-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": null,
     "uniqueAnchor": null
    },
    "R20": {
     "role": "http://60degreespharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies",
     "longName": "996000 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "20",
     "firstAnchor": {
      "contextRef": "D20250930_1",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sxtp-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "D20250930_1",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sxtp-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://60degreespharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables",
     "longName": "996001 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "21",
     "firstAnchor": {
      "contextRef": "D20250930_1",
      "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sxtp-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "D20250930_1",
      "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sxtp-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://60degreespharma.com/role/INVENTORYTables",
     "longName": "996002 - Disclosure - INVENTORY (Tables)",
     "shortName": "INVENTORY (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "22",
     "firstAnchor": {
      "contextRef": "D20250930_1",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sxtp-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "D20250930_1",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sxtp-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://60degreespharma.com/role/PROPERTYANDEQUIPMENTTables",
     "longName": "996003 - Disclosure - PROPERTY AND EQUIPMENT (Tables)",
     "shortName": "PROPERTY AND EQUIPMENT (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "23",
     "firstAnchor": {
      "contextRef": "D20250930_1",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sxtp-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "D20250930_1",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sxtp-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://60degreespharma.com/role/INTANGIBLEASSETSTables",
     "longName": "996004 - Disclosure - INTANGIBLE ASSETS (Tables)",
     "shortName": "INTANGIBLE ASSETS (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "24",
     "firstAnchor": {
      "contextRef": "D20250930_1",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sxtp-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "D20250930_1",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sxtp-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://60degreespharma.com/role/STOCKHOLDERSEQUITYTables",
     "longName": "996005 - Disclosure - STOCKHOLDERS' EQUITY (Tables)",
     "shortName": "STOCKHOLDERS' EQUITY (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "25",
     "firstAnchor": {
      "contextRef": "D20250930_1",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sxtp-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "D20250930_1",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sxtp-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://60degreespharma.com/role/DEBTTables",
     "longName": "996006 - Disclosure - DEBT (Tables)",
     "shortName": "DEBT (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "D20250930_1",
      "name": "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sxtp-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "D20250930_1",
      "name": "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sxtp-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://60degreespharma.com/role/DERIVATIVELIABILITIESTables",
     "longName": "996007 - Disclosure - DERIVATIVE LIABILITIES (Tables)",
     "shortName": "DERIVATIVE LIABILITIES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "D20250930_1",
      "name": "us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sxtp-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "D20250930_1",
      "name": "us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sxtp-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://60degreespharma.com/role/SHAREBASEDCOMPENSATIONTables",
     "longName": "996008 - Disclosure - SHARE-BASED COMPENSATION (Tables)",
     "shortName": "SHARE-BASED COMPENSATION (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "D20250930_1",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sxtp-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "D20250930_1",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sxtp-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://60degreespharma.com/role/NATUREOFOPERATIONSDetails",
     "longName": "996009 - Disclosure - NATURE OF OPERATIONS (Details)",
     "shortName": "NATURE OF OPERATIONS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "29",
     "firstAnchor": {
      "contextRef": "I20250930",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:NatureOfOperations",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sxtp-20250930.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R30": {
     "role": "http://60degreespharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails",
     "longName": "996010 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "30",
     "firstAnchor": {
      "contextRef": "D20250224",
      "name": "us-gaap:StockholdersEquityReverseStockSplit",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sxtp-20250930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "I20241231",
      "name": "us-gaap:CashCashEquivalentsAndShortTermInvestments",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sxtp-20250930.htm",
      "unique": true
     }
    },
    "R31": {
     "role": "http://60degreespharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofLiabilitiesMeasuredatFairValueDetails",
     "longName": "996011 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Liabilities Measured at Fair Value (Details)",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Liabilities Measured at Fair Value (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "31",
     "firstAnchor": {
      "contextRef": "I20250930",
      "name": "us-gaap:DerivativeLiabilitiesCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "div",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sxtp-20250930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "I20250930_FairValueInputsLevel1Member",
      "name": "us-gaap:DerivativeLiabilitiesCurrent",
      "unitRef": "USD",
      "xsiNil": "true",
      "lang": null,
      "decimals": null,
      "ancestors": [
       "div",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock",
       "div",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sxtp-20250930.htm",
      "unique": true
     }
    },
    "R32": {
     "role": "http://60degreespharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofExchangeRatesalongwithHistoricalRatesDetails",
     "longName": "996012 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Exchange Rates along with Historical Rates (Details)",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Schedule of Exchange Rates along with Historical Rates (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "32",
     "firstAnchor": {
      "contextRef": "D20250930_USD",
      "name": "sxtp:AverageExchangeRate",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "div",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "us-gaap:ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sxtp-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "D20250930_USD",
      "name": "sxtp:AverageExchangeRate",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "div",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "us-gaap:ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sxtp-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://60degreespharma.com/role/INVENTORYScheduleofInventoryDetails",
     "longName": "996013 - Disclosure - INVENTORY - Schedule of Inventory (Details)",
     "shortName": "INVENTORY - Schedule of Inventory (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "I20250930",
      "name": "us-gaap:InventoryRawMaterials",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "div",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "div",
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sxtp-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "I20250930",
      "name": "us-gaap:InventoryRawMaterials",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "div",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "div",
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sxtp-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://60degreespharma.com/role/INVENTORYDetails",
     "longName": "9960131 - Disclosure - INVENTORY (Details)",
     "shortName": "INVENTORY (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "D20250930",
      "name": "us-gaap:InventoryWriteDown",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sxtp-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "D20250930",
      "name": "us-gaap:InventoryWriteDown",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sxtp-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://60degreespharma.com/role/PROPERTYANDEQUIPMENTDetails",
     "longName": "996014 - Disclosure - PROPERTY AND EQUIPMENT (Details)",
     "shortName": "PROPERTY AND EQUIPMENT (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "D20250930",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sxtp-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "D20250930",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sxtp-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://60degreespharma.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails",
     "longName": "996015 - Disclosure - PROPERTY AND EQUIPMENT - Schedule of Property and Equipment (Details)",
     "shortName": "PROPERTY AND EQUIPMENT - Schedule of Property and Equipment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "I20250930",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "div",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sxtp-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "I20250930",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "div",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sxtp-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://60degreespharma.com/role/INTANGIBLEASSETSDetails",
     "longName": "996016 - Disclosure - INTANGIBLE ASSETS (Details)",
     "shortName": "INTANGIBLE ASSETS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "D20250930",
      "name": "sxtp:CapitalizedWebsiteDevelopmentrelatedCosts",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sxtp-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "D20250930",
      "name": "sxtp:CapitalizedWebsiteDevelopmentrelatedCosts",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sxtp-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://60degreespharma.com/role/INTANGIBLEASSETSScheduleofIntangibleAssetsDetails",
     "longName": "996017 - Disclosure - INTANGIBLE ASSETS - Schedule of Intangible Assets (Details)",
     "shortName": "INTANGIBLE ASSETS - Schedule of Intangible Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "I20250930",
      "name": "us-gaap:FiniteLivedPatentsGross",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "div",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "div",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sxtp-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "I20250930",
      "name": "us-gaap:FiniteLivedPatentsGross",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "div",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "div",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sxtp-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://60degreespharma.com/role/INTANGIBLEASSETSScheduleofEstimatedFutureAmortizationExpenseforOurPatentsandWebsiteDevelopmentCostsDetails",
     "longName": "996018 - Disclosure - INTANGIBLE ASSETS - Schedule of Estimated Future Amortization Expense for Our Patents and Website Development Costs (Details)",
     "shortName": "INTANGIBLE ASSETS - Schedule of Estimated Future Amortization Expense for Our Patents and Website Development Costs (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "I20250930_PatentsMember",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "div",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "div",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sxtp-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "I20250930_PatentsMember",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "div",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "div",
       "us-gaap:IntangibleAssetsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sxtp-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://60degreespharma.com/role/STOCKHOLDERSEQUITYDetails",
     "longName": "996019 - Disclosure - STOCKHOLDERS' EQUITY (Details)",
     "shortName": "STOCKHOLDERS' EQUITY (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "I20250930",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sxtp-20250930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "D20250128",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sxtp-20250930.htm",
      "unique": true
     }
    },
    "R41": {
     "role": "http://60degreespharma.com/role/STOCKHOLDERSEQUITYScheduleofEquityClassifiedWarrantsDetails",
     "longName": "996020 - Disclosure - STOCKHOLDERS' EQUITY - Schedule of Equity-Classified Warrants (Details)",
     "shortName": "STOCKHOLDERS' EQUITY - Schedule of Equity-Classified Warrants (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "D20250331",
      "name": "sxtp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsExpired",
      "unitRef": null,
      "xsiNil": "true",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sxtp-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "D20250331",
      "name": "sxtp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsExpired",
      "unitRef": null,
      "xsiNil": "true",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sxtp-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://60degreespharma.com/role/DEBTDetails",
     "longName": "996021 - Disclosure - DEBT (Details)",
     "shortName": "DEBT (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "D20250930_1",
      "name": "us-gaap:AmortizationOfFinancingCostsAndDiscounts",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sxtp-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "D20250930_1",
      "name": "us-gaap:AmortizationOfFinancingCostsAndDiscounts",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sxtp-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://60degreespharma.com/role/DEBTScheduleoftheCurrentFuturePaymentObligationsDetails",
     "longName": "996022 - Disclosure - DEBT - Schedule of the Current Future Payment Obligations (Details)",
     "shortName": "DEBT - Schedule of the Current Future Payment Obligations (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "I20250930",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
      "unitRef": "USD",
      "xsiNil": "true",
      "lang": null,
      "decimals": null,
      "ancestors": [
       "div",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sxtp-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "I20250930",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
      "unitRef": "USD",
      "xsiNil": "true",
      "lang": null,
      "decimals": null,
      "ancestors": [
       "div",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sxtp-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://60degreespharma.com/role/DERIVATIVELIABILITIESDetails",
     "longName": "996023 - Disclosure - DERIVATIVE LIABILITIES (Details)",
     "shortName": "DERIVATIVE LIABILITIES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "D20220331",
      "name": "us-gaap:ConversionOfStockSharesConverted1",
      "unitRef": "Shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sxtp-20250930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "D20220331",
      "name": "us-gaap:SaleOfStockPercentageOfOwnershipAfterTransaction",
      "unitRef": "Pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "span",
       "span",
       "p",
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sxtp-20250930.htm",
      "unique": true
     }
    },
    "R45": {
     "role": "http://60degreespharma.com/role/DERIVATIVELIABILITIESScheduleofDerivativeLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
     "longName": "996024 - Disclosure - DERIVATIVE LIABILITIES - Schedule of Derivative Liabilities Measured at Fair Value on a Recurring Basis (Details)",
     "shortName": "DERIVATIVE LIABILITIES - Schedule of Derivative Liabilities Measured at Fair Value on a Recurring Basis (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "I20241231",
      "name": "us-gaap:DerivativeLiabilitiesCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "div",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock",
       "div",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sxtp-20250930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "I20241231_FairValueMeasurementsRecurringMember_ContingentMilestonePaymentMember_FairValueInputsLevel3Member",
      "name": "us-gaap:DerivativeLiabilitiesCurrent",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "div",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock",
       "div",
       "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sxtp-20250930.htm",
      "unique": true
     }
    },
    "R46": {
     "role": "http://60degreespharma.com/role/INCOMETAXESDetails",
     "longName": "996025 - Disclosure - INCOME TAXES (Details)",
     "shortName": "INCOME TAXES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "D20250930",
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sxtp-20250930.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R47": {
     "role": "http://60degreespharma.com/role/SHAREBASEDCOMPENSATIONDetails",
     "longName": "996026 - Disclosure - SHARE-BASED COMPENSATION (Details)",
     "shortName": "SHARE-BASED COMPENSATION (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "D20240930",
      "name": "us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
      "unitRef": "USDPerShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sxtp-20250930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "D20240930",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue",
      "unitRef": "USDPerShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sxtp-20250930.htm",
      "unique": true
     }
    },
    "R48": {
     "role": "http://60degreespharma.com/role/SHAREBASEDCOMPENSATIONScheduleofShareBasedCompensationExpensesDetails",
     "longName": "996027 - Disclosure - SHARE-BASED COMPENSATION - Schedule of Share-Based Compensation Expenses (Details)",
     "shortName": "SHARE-BASED COMPENSATION - Schedule of Share-Based Compensation Expenses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "D20250930",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "div",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sxtp-20250930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "D20250930_ResearchAndDevelopmentExpenseMember",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "USD",
      "xsiNil": "true",
      "lang": null,
      "decimals": null,
      "ancestors": [
       "div",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sxtp-20250930.htm",
      "unique": true
     }
    },
    "R49": {
     "role": "http://60degreespharma.com/role/SHAREBASEDCOMPENSATIONScheduleofFairValueofOptionsGrantedDetails",
     "longName": "996028 - Disclosure - SHARE-BASED COMPENSATION - Schedule of Fair Value of Options Granted (Details)",
     "shortName": "SHARE-BASED COMPENSATION - Schedule of Fair Value of Options Granted (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "D20250930",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "unitRef": "USDPerShare",
      "xsiNil": "true",
      "lang": null,
      "decimals": null,
      "ancestors": [
       "div",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sxtp-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "D20250930",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "unitRef": "USDPerShare",
      "xsiNil": "true",
      "lang": null,
      "decimals": null,
      "ancestors": [
       "div",
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sxtp-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://60degreespharma.com/role/COMMITMENTSANDCONTINGENCIESDetails",
     "longName": "996029 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "I20250930",
      "name": "us-gaap:LossContingencyPendingClaimsNumber",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sxtp-20250930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "D20250930",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sxtp-20250930.htm",
      "unique": true
     }
    },
    "R51": {
     "role": "http://60degreespharma.com/role/SUBSEQUENTEVENTSDetails",
     "longName": "996030 - Disclosure - SUBSEQUENT EVENTS (Details)",
     "shortName": "SUBSEQUENT EVENTS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "D20250224",
      "name": "us-gaap:StockholdersEquityReverseStockSplit",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sxtp-20250930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "I20251008_SubsequentEventMember",
      "name": "sxtp:NumberOfDirectors",
      "unitRef": "Number",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "sxtp-20250930.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "sxtp_ATMOfferingNetOfOfferingCostsPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://60degreespharma.com/20250930",
     "localname": "ATMOfferingNetOfOfferingCostsPaid",
     "crdr": "debit",
     "presentation": [
      "http://60degreespharma.com/role/ConsolidatedCondensedStatementsofCashFlowsUnauditedParentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ATM Offering Net of Offering Costs Paid",
        "terseLabel": "ATM Offering, net of offering costs paid",
        "documentation": "ATM Offering, net of offering costs paid."
       }
      }
     },
     "auth_ref": []
    },
    "sxtp_ATMOfferingShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://60degreespharma.com/20250930",
     "localname": "ATMOfferingShares",
     "presentation": [
      "http://60degreespharma.com/role/STOCKHOLDERSEQUITYDetails",
      "http://60degreespharma.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ATM Offering Shares",
        "terseLabel": "ATM Offering",
        "documentation": "ATM Offering."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://60degreespharma.com/role/NATUREOFOPERATIONSDetails",
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts Payable and Accrued Expenses",
        "verboseLabel": "Accounts payable and accrued expenses",
        "label": "Accounts Payable and Accrued Liabilities, Current",
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r43"
     ]
    },
    "us-gaap_AccountsReceivableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsReceivableMember",
     "presentation": [
      "http://60degreespharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts Receivable [Member]",
        "label": "Accounts Receivable [Member]",
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold."
       }
      }
     },
     "auth_ref": [
      "r802",
      "r988"
     ]
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsReceivableNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts Receivable",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r997"
     ]
    },
    "sxtp_AccountsReceivableOrSalesRevenueNetMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://60degreespharma.com/20250930",
     "localname": "AccountsReceivableOrSalesRevenueNetMember",
     "presentation": [
      "http://60degreespharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts Receivable Or Revenue Benchmark [Member]",
        "label": "Accounts Receivable Or Sales Revenue Net [Member]",
        "documentation": "This member stands for the information pertaining to \"Accounts Receivable Or Revenue Benchmark"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://60degreespharma.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://60degreespharma.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accumulated Depreciation",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r124",
      "r669"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Other Comprehensive Income",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r17",
      "r61",
      "r133",
      "r664",
      "r690",
      "r691",
      "r1070"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://60degreespharma.com/role/ConsolidatedCondensedStatementsofShareholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Other Comprehensive Income (Loss)",
        "label": "AOCI Attributable to Parent [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r12",
      "r17",
      "r550",
      "r553",
      "r606",
      "r686",
      "r687",
      "r964",
      "r965",
      "r966",
      "r980",
      "r981",
      "r982",
      "r983"
     ]
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional Paid-in Capital(1)",
        "label": "Additional Paid in Capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r905",
      "r1141"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://60degreespharma.com/role/ConsolidatedCondensedStatementsofShareholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional Paid-In Capital",
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r706",
      "r980",
      "r981",
      "r982",
      "r983",
      "r1071",
      "r1145"
     ]
    },
    "us-gaap_AdjustmentForAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentForAmortization",
     "crdr": "debit",
     "calculation": {
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization",
        "label": "Amortization",
        "documentation": "The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments to Reconcile Net Loss to Net Cash Used in Operating Activities:",
        "label": "Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Noncash Item [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition",
     "crdr": "credit",
     "presentation": [
      "http://60degreespharma.com/role/ConsolidatedCondensedStatementsofShareholdersEquityUnaudited",
      "http://60degreespharma.com/role/SHAREBASEDCOMPENSATIONDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based compensation expense",
        "verboseLabel": "Stock option award",
        "label": "APIC, Share-Based Payment Arrangement, Option, Increase for Cost Recognition",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1027",
      "r1029"
     ]
    },
    "sxtp_AgreedToReturnShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://60degreespharma.com/20250930",
     "localname": "AgreedToReturnShares",
     "presentation": [
      "http://60degreespharma.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Agreed to return shares",
        "terseLabel": "Agreed to return shares",
        "documentation": "Number of agreed to return shares."
       }
      }
     },
     "auth_ref": []
    },
    "currency_AllCurrenciesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/currency/2025",
     "localname": "AllCurrenciesDomain",
     "presentation": [
      "http://60degreespharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofExchangeRatesalongwithHistoricalRatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Currencies [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://60degreespharma.com/role/SHAREBASEDCOMPENSATIONDetails",
      "http://60degreespharma.com/role/SHAREBASEDCOMPENSATIONScheduleofShareBasedCompensationExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Share-Based Compensation Expense Included in Operating Expenses",
        "verboseLabel": "Compensation expense",
        "label": "Share-Based Payment Arrangement, Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r434",
      "r439",
      "r448"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://60degreespharma.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "sxtp_AmortizationOfCapitalizedShareBasedPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://60degreespharma.com/20250930",
     "localname": "AmortizationOfCapitalizedShareBasedPayments",
     "crdr": "debit",
     "calculation": {
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of Capitalized Share-Based Payments",
        "documentation": "Amount of amortization of capitalized share-based payments.",
        "label": "Amortization Of Capitalized Share Based Payments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "crdr": "debit",
     "presentation": [
      "http://60degreespharma.com/role/DEBTDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization discount",
        "label": "Amortization of Debt Issuance Costs and Discounts",
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r342",
      "r839",
      "r840",
      "r971",
      "r1094"
     ]
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AmortizationOfIntangibleAssets",
     "crdr": "debit",
     "presentation": [
      "http://60degreespharma.com/role/INTANGIBLEASSETSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization expense",
        "label": "Amortization of Intangible Assets",
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r155",
      "r280",
      "r286",
      "r810",
      "r816",
      "r817",
      "r819",
      "r821"
     ]
    },
    "sxtp_AnnualRoyaltyPaymentPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://60degreespharma.com/20250930",
     "localname": "AnnualRoyaltyPaymentPercentage",
     "presentation": [
      "http://60degreespharma.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Annual royalty payment",
        "documentation": "Percentage of annual royalty payment.",
        "label": "Annual Royalty Payment Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedBalanceSheet": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Assets",
        "label": "Assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r102",
      "r127",
      "r164",
      "r167",
      "r168",
      "r203",
      "r213",
      "r227",
      "r228",
      "r264",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r478",
      "r482",
      "r585",
      "r651",
      "r652",
      "r658",
      "r744",
      "r831",
      "r832",
      "r841",
      "r905",
      "r910",
      "r911",
      "r922",
      "r1022",
      "r1023",
      "r1099"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS:"
       }
      }
     },
     "auth_ref": []
    },
    "sxtp_AssetsAndLiabilitiesNotMeasuredAtFairValueOnARecurringBasisPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://60degreespharma.com/20250930",
     "localname": "AssetsAndLiabilitiesNotMeasuredAtFairValueOnARecurringBasisPolicyTextBlock",
     "presentation": [
      "http://60degreespharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets and Liabilities Not Measured at Fair Value on a Recurring Basis",
        "documentation": "Disclosure of accounting policy for assets and liabilities not measured at fair value on a recurring basis.",
        "label": "Assets And Liabilities Not Measured At Fair Value On ARecurring Basis Policy Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Current Assets",
        "label": "Assets, Current",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r120",
      "r135",
      "r164",
      "r167",
      "r168",
      "r264",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r478",
      "r482",
      "r585",
      "r905",
      "r1022",
      "r1023",
      "r1099"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Assets:",
        "label": "Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sxtp_AtTheMarket2025AgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://60degreespharma.com/20250930",
     "localname": "AtTheMarket2025AgreementMember",
     "presentation": [
      "http://60degreespharma.com/role/STOCKHOLDERSEQUITYDetails",
      "http://60degreespharma.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025 ATM Agreement [Member]",
        "label": "At-the-Market 2025 Agreement [Member]",
        "documentation": "This member stands for the information pertaining to \"2025 ATM Agreement\"."
       }
      }
     },
     "auth_ref": []
    },
    "sxtp_AverageExchangeRate": {
     "xbrltype": "pureItemType",
     "nsuri": "http://60degreespharma.com/20250930",
     "localname": "AverageExchangeRate",
     "presentation": [
      "http://60degreespharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofExchangeRatesalongwithHistoricalRatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Average Exchange Rate",
        "documentation": "Average Exchange Rate.",
        "label": "Average Exchange Rate"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AwardDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AwardDateAxis",
     "presentation": [
      "http://60degreespharma.com/role/STOCKHOLDERSEQUITYDetails",
      "http://60degreespharma.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Date [Axis]",
        "documentation": "Information by date or year award under share-based payment arrangement is granted."
       }
      }
     },
     "auth_ref": [
      "r1030",
      "r1031",
      "r1032",
      "r1033",
      "r1034",
      "r1035",
      "r1036",
      "r1037",
      "r1038",
      "r1039",
      "r1040",
      "r1041",
      "r1042",
      "r1043",
      "r1044",
      "r1045",
      "r1046",
      "r1047",
      "r1048",
      "r1049",
      "r1050",
      "r1051",
      "r1052",
      "r1053",
      "r1054",
      "r1055"
     ]
    },
    "us-gaap_AwardDateDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AwardDateDomain",
     "presentation": [
      "http://60degreespharma.com/role/STOCKHOLDERSEQUITYDetails",
      "http://60degreespharma.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Date [Domain]",
        "documentation": "Date or year award under share-based payment arrangement is granted."
       }
      }
     },
     "auth_ref": [
      "r1030",
      "r1031",
      "r1032",
      "r1033",
      "r1034",
      "r1035",
      "r1036",
      "r1037",
      "r1038",
      "r1039",
      "r1040",
      "r1041",
      "r1042",
      "r1043",
      "r1044",
      "r1045",
      "r1046",
      "r1047",
      "r1048",
      "r1049",
      "r1050",
      "r1051",
      "r1052",
      "r1053",
      "r1054",
      "r1055"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://60degreespharma.com/role/SHAREBASEDCOMPENSATIONDetails",
      "http://60degreespharma.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type Axis",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r405",
      "r406",
      "r407",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433"
     ]
    },
    "sxtp_BalloonPaymentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://60degreespharma.com/20250930",
     "localname": "BalloonPaymentMember",
     "presentation": [
      "http://60degreespharma.com/role/DEBTDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Balloon Payment [Member]",
        "label": "Balloon Payment Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://60degreespharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis of Presentation",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": [
      "r972"
     ]
    },
    "srt_BoardOfDirectorsChairmanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "BoardOfDirectorsChairmanMember",
     "presentation": [
      "http://60degreespharma.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Board of Directors [Member]",
        "verboseLabel": "Board of Directors Chairman [Member]",
        "label": "Board of Directors Chairman [Member]"
       }
      }
     },
     "auth_ref": [
      "r996"
     ]
    },
    "sxtp_BridgeSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://60degreespharma.com/20250930",
     "localname": "BridgeSharesMember",
     "presentation": [
      "http://60degreespharma.com/role/DERIVATIVELIABILITIESScheduleofDerivativeLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Bridge Shares [Member]",
        "label": "Bridge Shares Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "crdr": "credit",
     "presentation": [
      "http://60degreespharma.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payment",
        "label": "Business Combination, Contingent Consideration, Liability",
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination."
       }
      }
     },
     "auth_ref": [
      "r472",
      "r473",
      "r567",
      "r568",
      "r569",
      "r853",
      "r855"
     ]
    },
    "sxtp_CapitalizedPatentExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://60degreespharma.com/20250930",
     "localname": "CapitalizedPatentExpenses",
     "crdr": "debit",
     "presentation": [
      "http://60degreespharma.com/role/INTANGIBLEASSETSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capitalized patent expenses",
        "documentation": "Amount of capitalized patent expenses.",
        "label": "Capitalized Patent Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "sxtp_CapitalizedWebsiteDevelopmentrelatedCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://60degreespharma.com/20250930",
     "localname": "CapitalizedWebsiteDevelopmentrelatedCosts",
     "crdr": "debit",
     "presentation": [
      "http://60degreespharma.com/role/INTANGIBLEASSETSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capitalized website development-related costs",
        "documentation": "Amount of capitalized website development-related costs.",
        "label": "Capitalized Website Developmentrelated Costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Cash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Cash",
     "crdr": "debit",
     "presentation": [
      "http://60degreespharma.com/role/SHAREBASEDCOMPENSATIONDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash",
        "label": "Cash",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r661",
      "r718",
      "r739",
      "r905",
      "r910",
      "r911",
      "r922",
      "r944"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://60degreespharma.com/role/NATUREOFOPERATIONSDetails",
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Cash Equivalents",
        "verboseLabel": "Cash and cash equivalents",
        "label": "Cash and Cash Equivalent",
        "documentation": "Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r122",
      "r811"
     ]
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsAndShortTermInvestments",
     "crdr": "debit",
     "presentation": [
      "http://60degreespharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash equivalents and short-term (in Dollars)",
        "label": "Cash, Cash Equivalents, and Short-Term Investments",
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable."
       }
      }
     },
     "auth_ref": [
      "r954"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash and Cash Equivalents\u2014Beginning of Period",
        "periodEndLabel": "Cash and Cash Equivalents\u2014End of Period",
        "label": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation",
        "documentation": "Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r71",
      "r161"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedCashFlow": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Change in Cash and Cash Equivalents",
        "label": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation",
        "documentation": "Amount of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including effect from exchange rate change and including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r71"
     ]
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "presentation": [
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "NONCASH INVESTING/FINANCING ACTIVITIES",
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ChangeInAccountingEstimateLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ChangeInAccountingEstimateLineItems",
     "presentation": [
      "http://60degreespharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r185",
      "r651",
      "r653"
     ]
    },
    "sxtp_CharlesAllenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://60degreespharma.com/20250930",
     "localname": "CharlesAllenMember",
     "presentation": [
      "http://60degreespharma.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Charles Allen [Member]",
        "label": "Charles Allen Member"
       }
      }
     },
     "auth_ref": []
    },
    "sxtp_CherylXuMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://60degreespharma.com/20250930",
     "localname": "CherylXuMember",
     "presentation": [
      "http://60degreespharma.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cheryl Xu [Member]",
        "label": "Cheryl Xu Member"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://60degreespharma.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://60degreespharma.com/role/ConsolidatedCondensedStatementsofShareholdersEquityUnaudited",
      "http://60degreespharma.com/role/DERIVATIVELIABILITIESDetails",
      "http://60degreespharma.com/role/DocumentAndEntityInformation",
      "http://60degreespharma.com/role/SHAREBASEDCOMPENSATIONDetails",
      "http://60degreespharma.com/role/STOCKHOLDERSEQUITYDetails",
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedBalanceSheet_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Domain]",
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r114",
      "r130",
      "r131",
      "r132",
      "r164",
      "r168",
      "r194",
      "r195",
      "r198",
      "r200",
      "r205",
      "r206",
      "r264",
      "r311",
      "r313",
      "r314",
      "r315",
      "r318",
      "r319",
      "r351",
      "r352",
      "r354",
      "r355",
      "r357",
      "r360",
      "r363",
      "r364",
      "r368",
      "r371",
      "r379",
      "r585",
      "r698",
      "r699",
      "r700",
      "r701",
      "r706",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r719",
      "r731",
      "r752",
      "r770",
      "r790",
      "r791",
      "r792",
      "r793",
      "r794",
      "r933",
      "r975",
      "r977",
      "r984"
     ]
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://60degreespharma.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders\u2019 Equity [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r130",
      "r131",
      "r132",
      "r205",
      "r354",
      "r363",
      "r364",
      "r366",
      "r368",
      "r371",
      "r377",
      "r379",
      "r545",
      "r698",
      "r699",
      "r700",
      "r701",
      "r842",
      "r933",
      "r973",
      "r975"
     ]
    },
    "us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable",
     "presentation": [
      "http://60degreespharma.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right, Date from which Warrants or Rights Exercisable",
        "terseLabel": "Date from which warrants exercisable",
        "documentation": "Date the warrants or rights are exercisable, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r380"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightAxis",
     "presentation": [
      "http://60degreespharma.com/role/STOCKHOLDERSEQUITYDetails",
      "http://60degreespharma.com/role/STOCKHOLDERSEQUITYScheduleofEquityClassifiedWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Axis]",
        "documentation": "Information by type of warrant or right issued."
       }
      }
     },
     "auth_ref": [
      "r1028"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightDomain",
     "presentation": [
      "http://60degreespharma.com/role/STOCKHOLDERSEQUITYDetails",
      "http://60degreespharma.com/role/STOCKHOLDERSEQUITYScheduleofEquityClassifiedWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Domain]",
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://60degreespharma.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise price per share (in dollars per share)",
        "verboseLabel": "Exercise price of warrants (in dollars per share)",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r164",
      "r170",
      "r380"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightLineItems",
     "presentation": [
      "http://60degreespharma.com/role/STOCKHOLDERSEQUITYScheduleofEquityClassifiedWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Equity-Classified Warrants [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://60degreespharma.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise of warrants",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r380"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightOutstanding",
     "presentation": [
      "http://60degreespharma.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrant shares",
        "label": "Class of Warrant or Right, Outstanding",
        "documentation": "Number of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightTable",
     "presentation": [
      "http://60degreespharma.com/role/STOCKHOLDERSEQUITYScheduleofEquityClassifiedWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Table]",
        "documentation": "Disclosure of information about warrant or right issued that give holder right to purchase security from issuer at specific price within certain time frame."
       }
      }
     },
     "auth_ref": [
      "r1028"
     ]
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "presentation": [
      "http://60degreespharma.com/role/NATUREOFOPERATIONSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nature of Operations [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r476"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies (Note 11)",
        "label": "Commitments and Contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r92",
      "r660",
      "r730"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "COMMITMENTS AND CONTINGENCIES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://60degreespharma.com/role/COMMITMENTSANDCONTINGENCIES"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "COMMITMENTS AND CONTINGENCIES",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r303",
      "r304",
      "r803",
      "r1014",
      "r1019"
     ]
    },
    "sxtp_CommitmentsandContingenciesDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://60degreespharma.com/20250930",
     "localname": "CommitmentsandContingenciesDetailsTable",
     "presentation": [
      "http://60degreespharma.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "sxtp_CommonStockAggregateGrossSalesProceedAuthorized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://60degreespharma.com/20250930",
     "localname": "CommonStockAggregateGrossSalesProceedAuthorized",
     "crdr": "debit",
     "presentation": [
      "http://60degreespharma.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock aggregate gross sales proceeds authorized",
        "label": "Common Stock Aggregate Gross Sales Proceed Authorized",
        "documentation": "Authorized aggregate gross sales proceeds of common stock."
       }
      }
     },
     "auth_ref": []
    },
    "sxtp_CommonStockAggregateOfferingPrice": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://60degreespharma.com/20250930",
     "localname": "CommonStockAggregateOfferingPrice",
     "crdr": "debit",
     "presentation": [
      "http://60degreespharma.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock Aggregate Offering Price",
        "terseLabel": "Common stock aggregate offering price",
        "documentation": "Common stock having an aggregate offering price."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockConvertibleConversionPriceIncrease": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockConvertibleConversionPriceIncrease",
     "presentation": [
      "http://60degreespharma.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock conversion price per share (in dollars per share)",
        "label": "Common Stock, Convertible, Conversion Price, Increase",
        "documentation": "Per share increase in conversion price of convertible common stock. Excludes change due to standard antidilution provision."
       }
      }
     },
     "auth_ref": [
      "r380"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockMember",
     "presentation": [
      "http://60degreespharma.com/role/ConsolidatedCondensedStatementsofShareholdersEquityUnaudited",
      "http://60degreespharma.com/role/DocumentAndEntityInformation",
      "http://60degreespharma.com/role/SHAREBASEDCOMPENSATIONDetails",
      "http://60degreespharma.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock",
        "verboseLabel": "Common Stock, par value $0.0001 per share",
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r912",
      "r913",
      "r914",
      "r916",
      "r917",
      "r918",
      "r919",
      "r980",
      "r981",
      "r983",
      "r1071",
      "r1139",
      "r1145"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://60degreespharma.com/role/STOCKHOLDERSEQUITYDetails",
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedBalanceSheet_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, par value (in dollars per share)",
        "verboseLabel": "Common stock par value (in dollars per share)",
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r51"
     ]
    },
    "sxtp_CommonStockSalesAgreementWeightedAveragePricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://60degreespharma.com/20250930",
     "localname": "CommonStockSalesAgreementWeightedAveragePricePerShare",
     "presentation": [
      "http://60degreespharma.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock Sales Agreement Weighted Average Price Per Share",
        "documentation": "Per share weighted-average price of common stock under sales agreement.",
        "terseLabel": "Common stock sales agreement weighted average price per share"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://60degreespharma.com/role/STOCKHOLDERSEQUITYDetails",
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedBalanceSheet_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares authorized",
        "verboseLabel": "Common stock shares authorized",
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r731"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://60degreespharma.com/role/STOCKHOLDERSEQUITYDetails",
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedBalanceSheet_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares issued",
        "label": "Common Stock, Shares, Issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r51"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://60degreespharma.com/role/STOCKHOLDERSEQUITYDetails",
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedBalanceSheet_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares outstanding",
        "verboseLabel": "Common stock outstanding",
        "label": "Common Stock, Shares, Outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r51",
      "r731",
      "r750",
      "r1145",
      "r1146"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock, $0.0001 par value, 150,000,000 shares authorized\u037e 4,104,469 and 566,908 shares issued and outstanding as of September 30, 2025 and December 31, 2024, respectively (Note 6)",
        "label": "Common Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r352",
      "r359",
      "r663",
      "r905"
     ]
    },
    "us-gaap_CompensationAndBenefitsTrust": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CompensationAndBenefitsTrust",
     "crdr": "credit",
     "presentation": [
      "http://60degreespharma.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash compensation",
        "label": "Compensation and Benefits Trust",
        "documentation": "The value of a trust established to hold the stock of an employee compensation and benefits plan as of the balance sheet date."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CompensationRelatedCostsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CompensationRelatedCostsPolicyTextBlock",
     "presentation": [
      "http://60degreespharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Parties",
        "label": "Compensation Related Costs, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r85"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://60degreespharma.com/role/ConsolidatedCondensedStatementsofOperationsandComprehensiveLossIncomeUnauditedCalc2": {
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Comprehensive Loss \u2013 attributed to 60 Degrees Pharmaceuticals, Inc.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r140",
      "r142",
      "r149",
      "r649",
      "r677",
      "r679"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest",
     "crdr": "debit",
     "calculation": {
      "http://60degreespharma.com/role/ConsolidatedCondensedStatementsofOperationsandComprehensiveLossIncomeUnauditedCalc2": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Loss \u2013 Noncontrolling Interest",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r38",
      "r41",
      "r140",
      "r142",
      "r148",
      "r648",
      "r677",
      "r678"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://60degreespharma.com/role/ConsolidatedCondensedStatementsofOperationsandComprehensiveLossIncomeUnauditedCalc2": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Comprehensive Loss",
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r87",
      "r140",
      "r142",
      "r147",
      "r647",
      "r677"
     ]
    },
    "us-gaap_ComputerEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ComputerEquipmentMember",
     "presentation": [
      "http://60degreespharma.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Computer Equipment [Member]",
        "label": "Computer Equipment [Member]",
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConcentrationRiskBenchmarkDomain",
     "presentation": [
      "http://60degreespharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Benchmark [Domain]",
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage."
       }
      }
     },
     "auth_ref": [
      "r209",
      "r232",
      "r695",
      "r696",
      "r802",
      "r987",
      "r988",
      "r989",
      "r990",
      "r991"
     ]
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "presentation": [
      "http://60degreespharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Benchmark [Axis]",
        "documentation": "Information by benchmark of concentration risk."
       }
      }
     },
     "auth_ref": [
      "r209",
      "r232",
      "r695",
      "r696",
      "r802",
      "r987",
      "r988",
      "r989",
      "r990",
      "r991"
     ]
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConcentrationRiskByTypeAxis",
     "presentation": [
      "http://60degreespharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Type [Axis]",
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender."
       }
      }
     },
     "auth_ref": [
      "r209",
      "r232",
      "r695",
      "r696",
      "r802",
      "r987",
      "r988",
      "r989",
      "r990",
      "r991"
     ]
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://60degreespharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentrations",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for credit risk. Includes, but is not limited to, policy for entering into master netting arrangement or similar agreement to mitigate credit risk of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r582",
      "r583"
     ]
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConcentrationRiskPercentage1",
     "presentation": [
      "http://60degreespharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration percentage",
        "label": "Concentration Risk, Percentage",
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division."
       }
      }
     },
     "auth_ref": [
      "r209",
      "r232",
      "r987",
      "r988",
      "r989",
      "r990",
      "r991"
     ]
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConcentrationRiskTypeDomain",
     "presentation": [
      "http://60degreespharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Type [Domain]",
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration."
       }
      }
     },
     "auth_ref": [
      "r209",
      "r232",
      "r695",
      "r696",
      "r802",
      "r987",
      "r988",
      "r989",
      "r990",
      "r991"
     ]
    },
    "sxtp_ContingentMilestonePaymentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://60degreespharma.com/20250930",
     "localname": "ContingentMilestonePaymentMember",
     "presentation": [
      "http://60degreespharma.com/role/DERIVATIVELIABILITIESScheduleofDerivativeLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent Milestone Payment [Member]",
        "documentation": "Contingent Milestone Payment [Member]",
        "label": "Contingent Milestone Payment Member"
       }
      }
     },
     "auth_ref": []
    },
    "sxtp_ConversionOfSeriesAPreferredStockIntoCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://60degreespharma.com/20250930",
     "localname": "ConversionOfSeriesAPreferredStockIntoCommonStock",
     "crdr": "debit",
     "presentation": [
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion Of Series A Preferred Stock Into Common Stock",
        "terseLabel": "Conversion of Series A Preferred Stock into Common Stock",
        "documentation": "The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConversionOfStockAmountConverted1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConversionOfStockAmountConverted1",
     "crdr": "debit",
     "presentation": [
      "http://60degreespharma.com/role/ConsolidatedCondensedStatementsofShareholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion of Stock, Amount Converted",
        "terseLabel": "Voluntary conversion of Series A Preferred Stock into common stock",
        "documentation": "The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r23",
      "r24"
     ]
    },
    "us-gaap_ConversionOfStockSharesConverted1": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConversionOfStockSharesConverted1",
     "presentation": [
      "http://60degreespharma.com/role/DERIVATIVELIABILITIESDetails",
      "http://60degreespharma.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion of Stock, Shares Converted (in Shares)",
        "label": "Conversion of Stock, Shares Converted",
        "verboseLabel": "Shares converted",
        "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r23",
      "r24"
     ]
    },
    "us-gaap_ConvertibleCommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConvertibleCommonStockMember",
     "presentation": [
      "http://60degreespharma.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Common Stock [Member]",
        "documentation": "Common stock securities that may be converted to another form of security."
       }
      }
     },
     "auth_ref": [
      "r51"
     ]
    },
    "us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConvertiblePreferredStockSharesIssuedUponConversion",
     "presentation": [
      "http://60degreespharma.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Preferred Stock, Shares Issued upon Conversion",
        "terseLabel": "Converted shares",
        "documentation": "Number of shares issued for each share of convertible preferred stock that is converted."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r32",
      "r50",
      "r81",
      "r374"
     ]
    },
    "us-gaap_CostOfRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CostOfRevenue",
     "crdr": "debit",
     "calculation": {
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost of Revenues",
        "label": "Cost of Revenue",
        "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r164",
      "r167",
      "r168",
      "r264",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r585",
      "r831",
      "r1022"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "srt_CurrencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "CurrencyAxis",
     "presentation": [
      "http://60degreespharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofExchangeRatesalongwithHistoricalRatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Currency [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1092"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://60degreespharma.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CustomerConcentrationRiskMember",
     "presentation": [
      "http://60degreespharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer Concentration Risk [Member]",
        "label": "Customer Concentration Risk [Member]",
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer."
       }
      }
     },
     "auth_ref": [
      "r232",
      "r988"
     ]
    },
    "sxtp_CustomerThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://60degreespharma.com/20250930",
     "localname": "CustomerThreeMember",
     "presentation": [
      "http://60degreespharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer Three [Member]",
        "label": "Customer Three Member"
       }
      }
     },
     "auth_ref": []
    },
    "sxtp_CustomerTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://60degreespharma.com/20250930",
     "localname": "CustomerTwoMember",
     "presentation": [
      "http://60degreespharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer Two [Member]",
        "label": "Customer Two Member"
       }
      }
     },
     "auth_ref": []
    },
    "sxtp_DebtDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://60degreespharma.com/20250930",
     "localname": "DebtDetailsTable",
     "presentation": [
      "http://60degreespharma.com/role/DEBTDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "DEBT"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtDisclosureTextBlock",
     "presentation": [
      "http://60degreespharma.com/role/DEBT"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "DEBT",
        "label": "Debt Disclosure [Text Block]",
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r164",
      "r166",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r309",
      "r310",
      "r320",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r336",
      "r343",
      "r344",
      "r346",
      "r545",
      "r599"
     ]
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://60degreespharma.com/role/DEBTDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Axis]",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r42",
      "r43",
      "r90",
      "r91",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r327",
      "r332",
      "r333",
      "r334",
      "r335",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r836",
      "r837",
      "r838",
      "r839",
      "r840",
      "r903",
      "r973",
      "r974",
      "r976",
      "r979",
      "r1015",
      "r1016",
      "r1017",
      "r1093",
      "r1095",
      "r1108"
     ]
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentFaceAmount",
     "crdr": "credit",
     "presentation": [
      "http://60degreespharma.com/role/DEBTDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Principal amount",
        "label": "Debt Instrument, Face Amount",
        "documentation": "Face (par) amount of debt instrument at time of issuance."
       }
      }
     },
     "auth_ref": [
      "r321",
      "r599",
      "r600",
      "r837",
      "r838",
      "r903"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "presentation": [
      "http://60degreespharma.com/role/DEBTDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Annual interest rate",
        "label": "Debt Instrument, Interest Rate, Effective Percentage",
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r348",
      "r599",
      "r600",
      "r903"
     ]
    },
    "us-gaap_DebtInstrumentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentLineItems",
     "presentation": [
      "http://60degreespharma.com/role/DEBTDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r327",
      "r332",
      "r333",
      "r334",
      "r335",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r345",
      "r545",
      "r654",
      "r836",
      "r837",
      "r838",
      "r839",
      "r840",
      "r903",
      "r973",
      "r974",
      "r976",
      "r979",
      "r1093",
      "r1095"
     ]
    },
    "us-gaap_DebtInstrumentMaturityDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentMaturityDate",
     "presentation": [
      "http://60degreespharma.com/role/DEBTDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maturity date",
        "label": "Debt Instrument, Maturity Date",
        "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r129",
      "r836",
      "r1076",
      "r1077"
     ]
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://60degreespharma.com/role/DEBTDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Name [Domain]",
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r327",
      "r332",
      "r333",
      "r334",
      "r335",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r836",
      "r837",
      "r838",
      "r839",
      "r840",
      "r903",
      "r973",
      "r974",
      "r976",
      "r979",
      "r1015",
      "r1016",
      "r1017",
      "r1093",
      "r1095",
      "r1108"
     ]
    },
    "us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid",
     "crdr": "credit",
     "presentation": [
      "http://60degreespharma.com/role/DEBTDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Balloon payment",
        "label": "Debt Instrument, Periodic Payment Terms, Balloon Payment to be Paid",
        "documentation": "Amount of payment greater than the preceding installment payments to be paid at final maturity date of debt."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsDomestic",
     "crdr": "debit",
     "presentation": [
      "http://60degreespharma.com/role/INCOMETAXESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. federal net operating loss carryforwards",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, Domestic",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1058"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsOther",
     "crdr": "debit",
     "presentation": [
      "http://60degreespharma.com/role/INCOMETAXESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. federal tax",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Other",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible tax credit carryforwards, classified as other."
       }
      }
     },
     "auth_ref": [
      "r1058"
     ]
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Depreciation",
     "crdr": "debit",
     "calculation": {
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation",
        "label": "Depreciation",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r29",
      "r154",
      "r816",
      "r817",
      "r819",
      "r821"
     ]
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DepreciationDepletionAndAmortization",
     "crdr": "debit",
     "presentation": [
      "http://60degreespharma.com/role/PROPERTYANDEQUIPMENTDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation",
        "label": "Depreciation, Depletion and Amortization",
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r156",
      "r203",
      "r217",
      "r228",
      "r816",
      "r831",
      "r832"
     ]
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DerivativeContractTypeDomain",
     "presentation": [
      "http://60degreespharma.com/role/DERIVATIVELIABILITIESScheduleofDerivativeLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Contract [Domain]",
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset."
       }
      }
     },
     "auth_ref": [
      "r153",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r720",
      "r722",
      "r736",
      "r737",
      "r738",
      "r740",
      "r741",
      "r742",
      "r743",
      "r745",
      "r746",
      "r747",
      "r748",
      "r758",
      "r759",
      "r760",
      "r761",
      "r764",
      "r765",
      "r766",
      "r767",
      "r784",
      "r785",
      "r786",
      "r787",
      "r813",
      "r814",
      "r815",
      "r887",
      "r888",
      "r912",
      "r914",
      "r955",
      "r956",
      "r957",
      "r958",
      "r959",
      "r960",
      "r961",
      "r962",
      "r963",
      "r1066",
      "r1067",
      "r1068",
      "r1069",
      "r1078",
      "r1079",
      "r1080",
      "r1081",
      "r1082",
      "r1083",
      "r1085",
      "r1086"
     ]
    },
    "us-gaap_DerivativeGainLossOnDerivativeNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DerivativeGainLossOnDerivativeNet",
     "crdr": "credit",
     "calculation": {
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://60degreespharma.com/role/DERIVATIVELIABILITIESDetails",
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Change in Fair Value of Derivative Liabilities",
        "terseLabel": "(Gain) loss on change in fair value of derivative liabilities",
        "label": "Derivative, Gain (Loss) on Derivative, Net",
        "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement."
       }
      }
     },
     "auth_ref": [
      "r809",
      "r1063"
     ]
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DerivativeInstrumentRiskAxis",
     "presentation": [
      "http://60degreespharma.com/role/DERIVATIVELIABILITIESScheduleofDerivativeLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Instrument [Axis]",
        "documentation": "Information by type of derivative contract."
       }
      }
     },
     "auth_ref": [
      "r153",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r720",
      "r722",
      "r736",
      "r737",
      "r738",
      "r740",
      "r741",
      "r742",
      "r743",
      "r745",
      "r746",
      "r747",
      "r748",
      "r758",
      "r759",
      "r760",
      "r761",
      "r764",
      "r765",
      "r766",
      "r767",
      "r784",
      "r785",
      "r786",
      "r787",
      "r813",
      "r814",
      "r815",
      "r887",
      "r888",
      "r912",
      "r914",
      "r955",
      "r956",
      "r957",
      "r958",
      "r959",
      "r960",
      "r961",
      "r962",
      "r963",
      "r1066",
      "r1067",
      "r1068",
      "r1069",
      "r1078",
      "r1079",
      "r1080",
      "r1081",
      "r1082",
      "r1083",
      "r1085",
      "r1086"
     ]
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "DERIVATIVE LIABILITIES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
     "presentation": [
      "http://60degreespharma.com/role/DERIVATIVELIABILITIES"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "DERIVATIVE LIABILITIES",
        "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]",
        "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts."
       }
      }
     },
     "auth_ref": [
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r548",
      "r559",
      "r887",
      "r888",
      "r889",
      "r890",
      "r891"
     ]
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems",
     "presentation": [
      "http://60degreespharma.com/role/DERIVATIVELIABILITIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Liabilities [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r887"
     ]
    },
    "us-gaap_DerivativeLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DerivativeLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://60degreespharma.com/role/DERIVATIVELIABILITIESScheduleofDerivativeLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://60degreespharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofLiabilitiesMeasuredatFairValueDetails",
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "terseLabel": "Derivative Liabilities (Note 8)",
        "verboseLabel": "Total derivative liabilities",
        "label": "Derivative Liability, Current",
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset."
       }
      }
     },
     "auth_ref": [
      "r136"
     ]
    },
    "sxtp_DerivativeLiabilitiesDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://60degreespharma.com/20250930",
     "localname": "DerivativeLiabilitiesDetailsTable",
     "presentation": [
      "http://60degreespharma.com/role/DERIVATIVELIABILITIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Liabilities (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "sxtp_DerivativeLiabilitiesScheduleofDerivativeLiabilitiesMeasuredatFairValueonaRecurringBasisDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://60degreespharma.com/20250930",
     "localname": "DerivativeLiabilitiesScheduleofDerivativeLiabilitiesMeasuredatFairValueonaRecurringBasisDetailsTable",
     "presentation": [
      "http://60degreespharma.com/role/DERIVATIVELIABILITIESScheduleofDerivativeLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Liabilities - Schedule of Derivative Liabilities Measured at Fair Value on a Recurring Basis (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DerivativeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DerivativeMember",
     "presentation": [
      "http://60degreespharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofLiabilitiesMeasuredatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative Liabilities [Member]",
        "label": "Derivative [Member]",
        "documentation": "This element represents types of derivative financial instruments which are financial instruments or other contractual arrangements with all three of the following characteristics: (a) it has (1) one or more underlyings and (2) one or more notional amounts or payment provisions or both. Those terms determine the amount of the settlement or settlements, and, in some cases, whether or not a settlement is required; (b) it requires no initial net investment or an initial net investment that is smaller than would be required for other types of contracts that would be expected to have a similar response to changes in market factors; and (c) its terms require or permit net settlement, it can readily be settled net by a means outside the contract, or it provides for delivery of an asset that puts the recipient in a position not substantially different from net settlement. Notwithstanding the above characteristics, loan commitments that relate to the origination of mortgage loans that will be held for sale are accounted for as derivative instruments by the issuer of the loan commitment (that is, the potential lender)."
       }
      }
     },
     "auth_ref": [
      "r893"
     ]
    },
    "us-gaap_DerivativesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DerivativesPolicyTextBlock",
     "presentation": [
      "http://60degreespharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative Liabilities",
        "label": "Derivatives, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities."
       }
      }
     },
     "auth_ref": [
      "r164",
      "r173",
      "r190",
      "r484",
      "r526",
      "r541",
      "r542",
      "r543",
      "r544",
      "r546",
      "r547"
     ]
    },
    "srt_DirectorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "DirectorMember",
     "presentation": [
      "http://60degreespharma.com/role/COMMITMENTSANDCONTINGENCIESDetails",
      "http://60degreespharma.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Director [Member]"
       }
      }
     },
     "auth_ref": [
      "r996",
      "r1140"
     ]
    },
    "sxtp_DirectorOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://60degreespharma.com/20250930",
     "localname": "DirectorOneMember",
     "presentation": [
      "http://60degreespharma.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Director One [Member]",
        "documentation": "This member stands for the information pertaining to \"Director One\".",
        "terseLabel": "Director One [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://60degreespharma.com/role/SHAREBASEDCOMPENSATION"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SHARE-BASED COMPENSATION",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r403",
      "r404",
      "r435",
      "r436",
      "r437",
      "r851"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "SHARE-BASED COMPENSATION"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DividendsPreferredStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DividendsPreferredStock",
     "crdr": "debit",
     "presentation": [
      "http://60degreespharma.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividends preferred stock",
        "label": "Dividends, Preferred Stock",
        "documentation": "Amount of paid and unpaid preferred stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK)."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r82"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://60degreespharma.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://60degreespharma.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentInformationLineItems",
     "presentation": [
      "http://60degreespharma.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://60degreespharma.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://60degreespharma.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r926"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://60degreespharma.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r927"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://60degreespharma.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareAbstract",
     "presentation": [
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Loss per Common Share:",
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic (in Dollars per share)",
        "label": "Earnings Per Share, Basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r118",
      "r150",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r191",
      "r194",
      "r198",
      "r199",
      "r200",
      "r202",
      "r350",
      "r438",
      "r470",
      "r475",
      "r562",
      "r563",
      "r650",
      "r680",
      "r823"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Diluted (in Dollars per share)",
        "label": "Earnings Per Share, Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r118",
      "r150",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r194",
      "r198",
      "r199",
      "r200",
      "r202",
      "r350",
      "r438",
      "r470",
      "r475",
      "r562",
      "r563",
      "r650",
      "r680",
      "r823"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://60degreespharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Loss per Common Share",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r27",
      "r201"
     ]
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedCashFlow": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effect of Exchange Rate Changes on Cash",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation",
        "documentation": "Amount of increase (decrease) from effect of exchange rate change on cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; held in foreign currency; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r590"
     ]
    },
    "us-gaap_EmployeeBenefitsAndShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeBenefitsAndShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-Based Compensation under Equity Incentive Plan",
        "label": "Employee Benefits and Share-Based Compensation",
        "documentation": "Amount of expense for employee benefit and equity-based compensation."
       }
      }
     },
     "auth_ref": [
      "r967"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "presentation": [
      "http://60degreespharma.com/role/SHAREBASEDCOMPENSATIONDetails",
      "http://60degreespharma.com/role/SHAREBASEDCOMPENSATIONScheduleofShareBasedCompensationExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Compensation Expenses [Line Items]",
        "terseLabel": "Share-Based Compensation [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r1056"
     ]
    },
    "dei_EntitiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntitiesTable",
     "presentation": [
      "http://60degreespharma.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entities [Table]",
        "documentation": "Container to assemble all relevant information about each entity associated with the document instance"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://60degreespharma.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://60degreespharma.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://60degreespharma.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://60degreespharma.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://60degreespharma.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://60degreespharma.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r924"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://60degreespharma.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://60degreespharma.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://60degreespharma.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r924"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://60degreespharma.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r931"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://60degreespharma.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://60degreespharma.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r924"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://60degreespharma.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://60degreespharma.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r930"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://60degreespharma.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r924"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://60degreespharma.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r924"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://60degreespharma.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r924"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://60degreespharma.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r924"
     ]
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "auth_ref": []
    },
    "sxtp_EquityClassifiedWarrantsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://60degreespharma.com/20250930",
     "localname": "EquityClassifiedWarrantsPolicyTextBlock",
     "presentation": [
      "http://60degreespharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity-Classified Warrants",
        "documentation": "Disclosure of accounting policy for equity-classified warrants.",
        "label": "Equity Classified Warrants Policy Text Block"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://60degreespharma.com/role/ConsolidatedCondensedStatementsofShareholdersEquityUnaudited",
      "http://60degreespharma.com/role/SHAREBASEDCOMPENSATIONDetails",
      "http://60degreespharma.com/role/STOCKHOLDERSEQUITYDetails",
      "http://60degreespharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r115",
      "r117",
      "r118",
      "r143",
      "r144",
      "r145",
      "r175",
      "r176",
      "r177",
      "r179",
      "r186",
      "r188",
      "r190",
      "r204",
      "r265",
      "r266",
      "r294",
      "r349",
      "r381",
      "r438",
      "r460",
      "r461",
      "r467",
      "r468",
      "r469",
      "r471",
      "r474",
      "r475",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r561",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r601",
      "r603",
      "r606",
      "r675",
      "r686",
      "r687",
      "r688",
      "r706",
      "r770"
     ]
    },
    "us-gaap_ExcessStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ExcessStockSharesAuthorized",
     "presentation": [
      "http://60degreespharma.com/role/DERIVATIVELIABILITIESDetails",
      "http://60degreespharma.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Designated shares",
        "verboseLabel": "Designated shares (in Shares)",
        "label": "Excess Stock, Shares Authorized",
        "documentation": "Maximum number of excess stock shares permitted to be issued."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAdjustmentOfWarrants",
     "crdr": "debit",
     "calculation": {
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_InterestIncomeExpenseNonoperatingNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Change in Fair Value of Derivative Liabilities",
        "label": "Fair Value Adjustment of Warrants",
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://60degreespharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofLiabilitiesMeasuredatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Liabilities Measured at Fair Value [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r565",
      "r566",
      "r577",
      "r892"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://60degreespharma.com/role/DERIVATIVELIABILITIESScheduleofDerivativeLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://60degreespharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofLiabilitiesMeasuredatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r334",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r398",
      "r399",
      "r564",
      "r566",
      "r567",
      "r568",
      "r569",
      "r576",
      "r577",
      "r579",
      "r581",
      "r615",
      "r616",
      "r617",
      "r809",
      "r837",
      "r838",
      "r845",
      "r846",
      "r847",
      "r848",
      "r849",
      "r892",
      "r895",
      "r902"
     ]
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://60degreespharma.com/role/DERIVATIVELIABILITIESScheduleofDerivativeLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Axis]",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r565",
      "r566",
      "r567",
      "r569",
      "r892",
      "r1076",
      "r1087"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://60degreespharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofLiabilitiesMeasuredatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 1 [Member]",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r334",
      "r391",
      "r396",
      "r398",
      "r566",
      "r577",
      "r581",
      "r615",
      "r809",
      "r845",
      "r846",
      "r847",
      "r848",
      "r849",
      "r892",
      "r902"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://60degreespharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofLiabilitiesMeasuredatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 2 [Member]",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r334",
      "r391",
      "r396",
      "r398",
      "r400",
      "r566",
      "r567",
      "r577",
      "r581",
      "r616",
      "r809",
      "r837",
      "r838",
      "r845",
      "r846",
      "r847",
      "r848",
      "r849",
      "r892",
      "r902"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://60degreespharma.com/role/DERIVATIVELIABILITIESScheduleofDerivativeLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://60degreespharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofLiabilitiesMeasuredatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 3 [Member]",
        "verboseLabel": "Fair Value, Inputs, Level 3 [Member]",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r334",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r398",
      "r399",
      "r566",
      "r567",
      "r568",
      "r569",
      "r577",
      "r581",
      "r617",
      "r809",
      "r837",
      "r838",
      "r845",
      "r846",
      "r847",
      "r848",
      "r849",
      "r892",
      "r895",
      "r902"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock",
     "presentation": [
      "http://60degreespharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Liabilities Measured at Fair Value",
        "label": "Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]",
        "documentation": "Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset."
       }
      }
     },
     "auth_ref": [
      "r1073",
      "r1074"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems",
     "presentation": [
      "http://60degreespharma.com/role/DERIVATIVELIABILITIESScheduleofDerivativeLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Derivative Liabilities Measured at Fair Value on a Recurring Basis [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575"
     ]
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementFrequencyDomain",
     "presentation": [
      "http://60degreespharma.com/role/DERIVATIVELIABILITIESScheduleofDerivativeLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Domain]",
        "documentation": "Measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r565",
      "r566",
      "r567",
      "r569",
      "r892",
      "r1076",
      "r1087"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://60degreespharma.com/role/DERIVATIVELIABILITIESScheduleofDerivativeLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://60degreespharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofLiabilitiesMeasuredatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r334",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r398",
      "r399",
      "r564",
      "r566",
      "r567",
      "r568",
      "r569",
      "r576",
      "r577",
      "r579",
      "r581",
      "r615",
      "r616",
      "r617",
      "r809",
      "r837",
      "r838",
      "r845",
      "r846",
      "r847",
      "r848",
      "r849",
      "r892",
      "r895",
      "r902"
     ]
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementsRecurringMember",
     "presentation": [
      "http://60degreespharma.com/role/DERIVATIVELIABILITIESScheduleofDerivativeLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Recurring [Member]",
        "label": "Fair Value, Recurring [Member]",
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r892",
      "r1073",
      "r1074",
      "r1075",
      "r1076",
      "r1077",
      "r1087"
     ]
    },
    "sxtp_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisMarkToMarketAdjustment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://60degreespharma.com/20250930",
     "localname": "FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisMarkToMarketAdjustment",
     "crdr": "credit",
     "presentation": [
      "http://60degreespharma.com/role/DERIVATIVELIABILITIESScheduleofDerivativeLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in fair value",
        "documentation": "Fair value, measurement with unobservable inputs reconciliation, recurring Basis, fair value - mark to market adjustment.",
        "label": "Fair Value Measurementwith Unobservable Inputs Reconciliation Recurring Basis Mark To Market Adjustment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "presentation": [
      "http://60degreespharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value of Financial Instruments",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r1088"
     ]
    },
    "sxtp_FairValueOfWarrantsIssuedToUnderwriters": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://60degreespharma.com/20250930",
     "localname": "FairValueOfWarrantsIssuedToUnderwriters",
     "crdr": "credit",
     "presentation": [
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value of Warrants Issued to Underwriters",
        "documentation": "Represent the amount of fair value of warrants issued to underwriters.",
        "label": "Fair Value Of Warrants Issued To Underwriters"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FederalStateAndLocalIncomeTaxExpenseBenefitContinuingOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FederalStateAndLocalIncomeTaxExpenseBenefitContinuingOperations",
     "crdr": "debit",
     "presentation": [
      "http://60degreespharma.com/role/INCOMETAXESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal, District of Columbia Income Tax Provision or Benefit",
        "label": "Federal, State, and Local, Income Tax Expense (Benefit), Continuing Operations",
        "documentation": "Amount of current and deferred federal, state, and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current and deferred national, regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r1059"
     ]
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://60degreespharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofLiabilitiesMeasuredatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r345",
      "r377",
      "r545",
      "r559",
      "r580",
      "r584",
      "r587",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r657",
      "r676",
      "r835",
      "r892",
      "r893",
      "r895",
      "r896",
      "r897",
      "r898",
      "r899",
      "r900",
      "r901",
      "r906",
      "r936",
      "r937",
      "r938",
      "r939",
      "r940",
      "r941",
      "r942",
      "r998",
      "r999",
      "r1000",
      "r1001",
      "r1072",
      "r1075",
      "r1076",
      "r1077",
      "r1084",
      "r1087",
      "r1089",
      "r1090"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "crdr": "credit",
     "calculation": {
      "http://60degreespharma.com/role/INTANGIBLEASSETSScheduleofIntangibleAssetsDetails": {
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://60degreespharma.com/role/INTANGIBLEASSETSScheduleofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accumulated Amortization",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r125",
      "r277",
      "r285",
      "r810"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive",
     "crdr": "debit",
     "calculation": {
      "http://60degreespharma.com/role/INTANGIBLEASSETSScheduleofEstimatedFutureAmortizationExpenseforOurPatentsandWebsiteDevelopmentCostsDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://60degreespharma.com/role/INTANGIBLEASSETSScheduleofEstimatedFutureAmortizationExpenseforOurPatentsandWebsiteDevelopmentCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Thereafter",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, after Year Five",
        "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r1010",
      "r1147"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "crdr": "debit",
     "calculation": {
      "http://60degreespharma.com/role/INTANGIBLEASSETSScheduleofEstimatedFutureAmortizationExpenseforOurPatentsandWebsiteDevelopmentCostsDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://60degreespharma.com/role/INTANGIBLEASSETSScheduleofEstimatedFutureAmortizationExpenseforOurPatentsandWebsiteDevelopmentCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r287",
      "r807",
      "r810"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
     "crdr": "debit",
     "calculation": {
      "http://60degreespharma.com/role/INTANGIBLEASSETSScheduleofEstimatedFutureAmortizationExpenseforOurPatentsandWebsiteDevelopmentCostsDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://60degreespharma.com/role/INTANGIBLEASSETSScheduleofEstimatedFutureAmortizationExpenseforOurPatentsandWebsiteDevelopmentCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025 (remaining nine months)",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year."
       }
      }
     },
     "auth_ref": [
      "r1147"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "crdr": "debit",
     "calculation": {
      "http://60degreespharma.com/role/INTANGIBLEASSETSScheduleofEstimatedFutureAmortizationExpenseforOurPatentsandWebsiteDevelopmentCostsDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://60degreespharma.com/role/INTANGIBLEASSETSScheduleofEstimatedFutureAmortizationExpenseforOurPatentsandWebsiteDevelopmentCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2029",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r287",
      "r807",
      "r810"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "crdr": "debit",
     "calculation": {
      "http://60degreespharma.com/role/INTANGIBLEASSETSScheduleofEstimatedFutureAmortizationExpenseforOurPatentsandWebsiteDevelopmentCostsDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://60degreespharma.com/role/INTANGIBLEASSETSScheduleofEstimatedFutureAmortizationExpenseforOurPatentsandWebsiteDevelopmentCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r287",
      "r807",
      "r810"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "crdr": "debit",
     "calculation": {
      "http://60degreespharma.com/role/INTANGIBLEASSETSScheduleofEstimatedFutureAmortizationExpenseforOurPatentsandWebsiteDevelopmentCostsDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://60degreespharma.com/role/INTANGIBLEASSETSScheduleofEstimatedFutureAmortizationExpenseforOurPatentsandWebsiteDevelopmentCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r287",
      "r807",
      "r810"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "presentation": [
      "http://60degreespharma.com/role/INTANGIBLEASSETSScheduleofEstimatedFutureAmortizationExpenseforOurPatentsandWebsiteDevelopmentCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "documentation": "Information by major type or class of finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r279",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r288",
      "r289",
      "r645",
      "r646",
      "r694",
      "r807",
      "r810",
      "r857",
      "r858",
      "r859",
      "r860",
      "r861",
      "r862",
      "r863",
      "r864",
      "r865",
      "r866",
      "r867",
      "r868",
      "r869",
      "r870",
      "r871",
      "r872",
      "r873",
      "r874",
      "r875",
      "r876",
      "r877",
      "r878",
      "r879",
      "r880",
      "r881",
      "r882",
      "r883"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://60degreespharma.com/role/INTANGIBLEASSETSScheduleofIntangibleAssetsDetails": {
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://60degreespharma.com/role/INTANGIBLEASSETSScheduleofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Intangible Assets, at cost",
        "label": "Finite-Lived Intangible Assets, Gross",
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r277",
      "r285",
      "r646",
      "r810"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "presentation": [
      "http://60degreespharma.com/role/INTANGIBLEASSETSScheduleofEstimatedFutureAmortizationExpenseforOurPatentsandWebsiteDevelopmentCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Estimated Future Amortization Expense for Our Patents and Website Development Costs [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r279",
      "r285",
      "r288",
      "r289",
      "r292",
      "r645",
      "r807",
      "r810",
      "r857",
      "r858",
      "r859",
      "r860",
      "r861",
      "r862",
      "r863",
      "r864",
      "r865",
      "r866",
      "r867",
      "r868",
      "r869",
      "r870",
      "r871",
      "r872",
      "r873",
      "r874",
      "r875",
      "r876",
      "r877",
      "r878",
      "r879",
      "r880",
      "r881",
      "r882",
      "r883"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "presentation": [
      "http://60degreespharma.com/role/INTANGIBLEASSETSScheduleofEstimatedFutureAmortizationExpenseforOurPatentsandWebsiteDevelopmentCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company."
       }
      }
     },
     "auth_ref": [
      "r279",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r288",
      "r289",
      "r694",
      "r807",
      "r810",
      "r857",
      "r858",
      "r859",
      "r860",
      "r861",
      "r862",
      "r863",
      "r864",
      "r865",
      "r866",
      "r867",
      "r868",
      "r869",
      "r870",
      "r871",
      "r872",
      "r873",
      "r874",
      "r875",
      "r876",
      "r877",
      "r878",
      "r879",
      "r880",
      "r881",
      "r882",
      "r883"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://60degreespharma.com/role/INTANGIBLEASSETSScheduleofEstimatedFutureAmortizationExpenseforOurPatentsandWebsiteDevelopmentCostsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://60degreespharma.com/role/INTANGIBLEASSETSScheduleofEstimatedFutureAmortizationExpenseforOurPatentsandWebsiteDevelopmentCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Finite-Lived Intangible Assets, Net",
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r645",
      "r1009"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsNetAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "INTANGIBLE ASSETS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedPatentsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedPatentsGross",
     "crdr": "debit",
     "calculation": {
      "http://60degreespharma.com/role/INTANGIBLEASSETSScheduleofIntangibleAssetsDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsGross",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://60degreespharma.com/role/INTANGIBLEASSETSScheduleofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Patents",
        "label": "Finite-Lived Patents, Gross",
        "documentation": "Gross carrying amount before accumulated amortization as of the balance sheet date of the costs pertaining to the exclusive legal rights granted to the owner of the patent to exploit an invention or a process for a period of time specified by law. Such costs may have been expended to directly apply and receive patent rights, or to acquire such rights."
       }
      }
     },
     "auth_ref": [
      "r945",
      "r1009"
     ]
    },
    "sxtp_FiniteLivedWebsiteDevelopmentCostsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://60degreespharma.com/20250930",
     "localname": "FiniteLivedWebsiteDevelopmentCostsGross",
     "crdr": "debit",
     "calculation": {
      "http://60degreespharma.com/role/INTANGIBLEASSETSScheduleofIntangibleAssetsDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://60degreespharma.com/role/INTANGIBLEASSETSScheduleofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Website Development Costs",
        "documentation": "Gross carrying amount before accumulated amortization as of the balance sheet date of the costs.",
        "label": "Finite Lived Website Development Costs Gross"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ForeignCurrencyExchangeRateTranslation1": {
     "xbrltype": "pureItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ForeignCurrencyExchangeRateTranslation1",
     "presentation": [
      "http://60degreespharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofExchangeRatesalongwithHistoricalRatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exchange Rate",
        "label": "Foreign Currency Exchange Rate, Translation",
        "documentation": "Foreign exchange rate used to translate amounts denominated in functional currency to reporting currency."
       }
      }
     },
     "auth_ref": [
      "r597",
      "r598"
     ]
    },
    "us-gaap_ForeignCurrencyTransactionGainLossUnrealizedAfterTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ForeignCurrencyTransactionGainLossUnrealizedAfterTax",
     "crdr": "credit",
     "calculation": {
      "http://60degreespharma.com/role/ConsolidatedCondensedStatementsofOperationsandComprehensiveLossIncomeUnauditedCalc2": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized Foreign Currency Translation Gain",
        "label": "Unrealized Gain (Loss), Foreign Currency Transaction, after Tax",
        "documentation": "Amount, after tax, of unrealized gain (loss) from foreign currency transaction."
       }
      }
     },
     "auth_ref": [
      "r705",
      "r797",
      "r921",
      "r1143",
      "r1144"
     ]
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "presentation": [
      "http://60degreespharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign Currency Transactions and Translation",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy."
       }
      }
     },
     "auth_ref": [
      "r589"
     ]
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FurnitureAndFixturesMember",
     "presentation": [
      "http://60degreespharma.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Furniture [Member]",
        "label": "Furniture and Fixtures [Member]",
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and Administrative Expenses",
        "label": "General and Administrative Expense",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r754"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://60degreespharma.com/role/SHAREBASEDCOMPENSATIONScheduleofShareBasedCompensationExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and Administrative Expenses [Member]",
        "label": "General and Administrative Expense [Member]",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r67"
     ]
    },
    "us-gaap_GrossProfit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GrossProfit",
     "crdr": "credit",
     "calculation": {
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedIncomeStatement": {
       "parentTag": "sxtp_NetRevenueLoss",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Gross (Loss) Profit",
        "label": "Gross Profit",
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r64",
      "r101",
      "r164",
      "r167",
      "r168",
      "r264",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r585",
      "r828",
      "r831",
      "r986",
      "r992",
      "r993",
      "r994",
      "r995",
      "r1022"
     ]
    },
    "sxtp_GrossSharesIssuedForAnnualPerformanceBonuses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://60degreespharma.com/20250930",
     "localname": "GrossSharesIssuedForAnnualPerformanceBonuses",
     "crdr": "credit",
     "presentation": [
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross Shares Issued for Annual Performance Bonuses",
        "documentation": "Represent the amount of gross shares issued for annual performance bonuses.",
        "label": "Gross Shares Issued For Annual Performance Bonuses"
       }
      }
     },
     "auth_ref": []
    },
    "sxtp_HCWainwrightAndCoLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://60degreespharma.com/20250930",
     "localname": "HCWainwrightAndCoLLCMember",
     "presentation": [
      "http://60degreespharma.com/role/STOCKHOLDERSEQUITYDetails",
      "http://60degreespharma.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "H C Wainwright And Co LLC [Member]",
        "terseLabel": "H.C. Wainwright &amp; Co., LLC [Member]",
        "documentation": "This member stands for the information pertaining to \"H.C. Wainwright &amp; Co., LLC \"."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IPOMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IPOMember",
     "presentation": [
      "http://60degreespharma.com/role/COMMITMENTSANDCONTINGENCIESDetails",
      "http://60degreespharma.com/role/NATUREOFOPERATIONSDetails",
      "http://60degreespharma.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Initial Public Offering [Member]",
        "verboseLabel": "IPO [Member]",
        "label": "IPO [Member]",
        "documentation": "First sale of stock by a private company to the public."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ImpairmentOfIntangibleAssetsExcludingGoodwill",
     "crdr": "debit",
     "presentation": [
      "http://60degreespharma.com/role/INTANGIBLEASSETSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Write-downs",
        "label": "Impairment of Intangible Assets (Excluding Goodwill)",
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r152",
      "r280",
      "r291"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss from Operations before Provision for Income Taxes",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r97",
      "r101",
      "r651",
      "r653",
      "r671",
      "r818",
      "r820",
      "r822",
      "r828",
      "r831",
      "r986",
      "r992",
      "r993",
      "r994",
      "r995"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://60degreespharma.com/role/SHAREBASEDCOMPENSATIONScheduleofShareBasedCompensationExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Axis]",
        "documentation": "Information by location in statement of income where disaggregated amount is reported."
       }
      }
     },
     "auth_ref": [
      "r295",
      "r301",
      "r302",
      "r496",
      "r502",
      "r519",
      "r527",
      "r571",
      "r575",
      "r578",
      "r586",
      "r587",
      "r588",
      "r683",
      "r685",
      "r755",
      "r807",
      "r809",
      "r853",
      "r854",
      "r888",
      "r890",
      "r894",
      "r902",
      "r1060",
      "r1061",
      "r1111"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://60degreespharma.com/role/SHAREBASEDCOMPENSATIONScheduleofShareBasedCompensationExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Domain]",
        "documentation": "Location in statement of income where disaggregated amount is reported."
       }
      }
     },
     "auth_ref": [
      "r301",
      "r302",
      "r496",
      "r502",
      "r519",
      "r527",
      "r571",
      "r575",
      "r578",
      "r586",
      "r587",
      "r588",
      "r683",
      "r685",
      "r755",
      "r807",
      "r809",
      "r853",
      "r854",
      "r888",
      "r890",
      "r894",
      "r902",
      "r1060",
      "r1061",
      "r1111"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "INCOME TAXES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://60degreespharma.com/role/INCOMETAXES"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "INCOME TAXES",
        "label": "Income Tax Disclosure [Text Block]",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r164",
      "r169",
      "r452",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r462",
      "r464",
      "r465",
      "r466",
      "r656",
      "r693",
      "r703",
      "r852"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://60degreespharma.com/role/INCOMETAXESDetails",
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Provision for Income Taxes (Note 9)",
        "label": "Income Tax Expense (Benefit)",
        "verboseLabel": "Provision for income taxes",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r103",
      "r111",
      "r164",
      "r189",
      "r190",
      "r203",
      "r218",
      "r228",
      "r453",
      "r454",
      "r463",
      "r681",
      "r818",
      "r820",
      "r822",
      "r852"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts Payable and Accrued Liabilities",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accounts Receivable",
        "label": "Increase (Decrease) in Accounts Receivable",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInAccruedInterestReceivableNet",
     "crdr": "credit",
     "calculation": {
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accrued Interest, net",
        "label": "Increase (Decrease) in Accrued Interest Receivable, Net",
        "documentation": "The increase (decrease) during the reporting period in the amount due from borrowers for interest payments."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInInventories",
     "crdr": "credit",
     "calculation": {
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Inventory",
        "label": "Increase (Decrease) in Inventories",
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in Operating Assets and Liabilities:",
        "label": "Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reduction of Lease Liability",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r935",
      "r970"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid and Other Assets",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r928"
     ]
    },
    "us-gaap_IntangibleAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IntangibleAssetsDisclosureTextBlock",
     "presentation": [
      "http://60degreespharma.com/role/INTANGIBLEASSETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "INTANGIBLE ASSETS",
        "label": "Intangible Assets Disclosure [Text Block]",
        "documentation": "The entire disclosure for all or part of the information related to intangible assets."
       }
      }
     },
     "auth_ref": [
      "r278",
      "r290",
      "r293",
      "r806",
      "r807"
     ]
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_OtherAssetsNoncurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://60degreespharma.com/role/INTANGIBLEASSETSScheduleofIntangibleAssetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://60degreespharma.com/role/INTANGIBLEASSETSScheduleofIntangibleAssetsDetails",
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Intangible Assets, net",
        "terseLabel": "Intangible Assets, net (Note 5)",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges."
       }
      }
     },
     "auth_ref": [
      "r279",
      "r1009",
      "r1011"
     ]
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IntangibleAssetsNetExcludingGoodwillAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Intangible Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sxtp_IntangibleAssetsScheduleofEstimatedFutureAmortizationExpenseforOurPatentsandWebsiteDevelopmentCostsDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://60degreespharma.com/20250930",
     "localname": "IntangibleAssetsScheduleofEstimatedFutureAmortizationExpenseforOurPatentsandWebsiteDevelopmentCostsDetailsTable",
     "presentation": [
      "http://60degreespharma.com/role/INTANGIBLEASSETSScheduleofEstimatedFutureAmortizationExpenseforOurPatentsandWebsiteDevelopmentCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Assets - Schedule of Estimated Future Amortization Expense for Our Patents and Website Development Costs (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IntercompanyForeignCurrencyBalanceLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IntercompanyForeignCurrencyBalanceLineItems",
     "presentation": [
      "http://60degreespharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofExchangeRatesalongwithHistoricalRatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Exchange Rates along with Historical Rates [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestExpenseNonoperating": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestExpenseNonoperating",
     "crdr": "debit",
     "calculation": {
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_InterestIncomeExpenseNonoperatingNet",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Interest Expense",
        "label": "Interest Expense, Nonoperating",
        "documentation": "Amount of interest expense classified as nonoperating."
       }
      }
     },
     "auth_ref": [
      "r216",
      "r818",
      "r822",
      "r968"
     ]
    },
    "us-gaap_InterestIncomeExpenseNonoperatingNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestIncomeExpenseNonoperatingNet",
     "crdr": "credit",
     "calculation": {
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Interest and Other Income (Expense), net",
        "label": "Interest Income (Expense), Nonoperating",
        "documentation": "Amount of interest income (expense) classified as nonoperating."
       }
      }
     },
     "auth_ref": [
      "r831",
      "r886",
      "r968",
      "r992"
     ]
    },
    "us-gaap_InventoryAdjustments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InventoryAdjustments",
     "crdr": "credit",
     "calculation": {
      "http://60degreespharma.com/role/INVENTORYScheduleofInventoryDetails": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://60degreespharma.com/role/INVENTORYScheduleofInventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Adjustments",
        "negatedLabel": "Reserve for Expiring Inventory",
        "documentation": "Amount of inventory reserves for last-in first-out (LIFO) and other inventory valuation methods."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r952"
     ]
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InventoryDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "INVENTORY"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InventoryDisclosureTextBlock",
     "presentation": [
      "http://60degreespharma.com/role/INVENTORY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "INVENTORY",
        "label": "Inventory Disclosure [Text Block]",
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory."
       }
      }
     },
     "auth_ref": [
      "r275"
     ]
    },
    "us-gaap_InventoryFinishedGoods": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InventoryFinishedGoods",
     "crdr": "debit",
     "calculation": {
      "http://60degreespharma.com/role/INVENTORYScheduleofInventoryDetails": {
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://60degreespharma.com/role/INVENTORYScheduleofInventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finished Goods",
        "label": "Inventory, Finished Goods, Gross",
        "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r949"
     ]
    },
    "us-gaap_InventoryGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InventoryGross",
     "crdr": "debit",
     "calculation": {
      "http://60degreespharma.com/role/INVENTORYScheduleofInventoryDetails": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://60degreespharma.com/role/INVENTORYScheduleofInventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Gross",
        "totalLabel": "Total Inventory",
        "documentation": "Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process."
       }
      }
     },
     "auth_ref": [
      "r952"
     ]
    },
    "us-gaap_InventoryLIFOReservePeriodCharge": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InventoryLIFOReservePeriodCharge",
     "crdr": "debit",
     "calculation": {
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, LIFO Reserve, Period Charge",
        "terseLabel": "Change in Inventory Reserve",
        "documentation": "The change in the inventory reserve representing the cumulative difference in cost between the first in, first out and the last in, first out inventory valuation methods, which change has been reflected in the statement of income during the period."
       }
      }
     },
     "auth_ref": [
      "r75"
     ]
    },
    "us-gaap_InventoryNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InventoryNet",
     "crdr": "debit",
     "calculation": {
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      },
      "http://60degreespharma.com/role/INVENTORYScheduleofInventoryDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://60degreespharma.com/role/INVENTORYScheduleofInventoryDetails",
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Inventory",
        "terseLabel": "Inventory (Note 3)",
        "label": "Inventory, Net",
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r134",
      "r812",
      "r905"
     ]
    },
    "us-gaap_InventoryNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InventoryNetAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Inventory [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryRawMaterials": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InventoryRawMaterials",
     "crdr": "debit",
     "calculation": {
      "http://60degreespharma.com/role/INVENTORYScheduleofInventoryDetails": {
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://60degreespharma.com/role/INVENTORYScheduleofInventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Raw Material (API)",
        "label": "Inventory, Raw Materials, Gross",
        "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r951"
     ]
    },
    "us-gaap_InventoryWorkInProcess": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InventoryWorkInProcess",
     "crdr": "debit",
     "calculation": {
      "http://60degreespharma.com/role/INVENTORYScheduleofInventoryDetails": {
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://60degreespharma.com/role/INVENTORYScheduleofInventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Work in Process",
        "label": "Inventory, Work in Process, Gross",
        "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r950"
     ]
    },
    "us-gaap_InventoryWriteDown": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InventoryWriteDown",
     "crdr": "debit",
     "presentation": [
      "http://60degreespharma.com/role/INVENTORYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Write-down",
        "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels."
       }
      }
     },
     "auth_ref": [
      "r276"
     ]
    },
    "sxtp_IssuanceOfCommonStockAndWarrantsOfUnderwritingDiscountsAndOfferingCostsPaidAtClosingAndDeferredOfferingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://60degreespharma.com/20250930",
     "localname": "IssuanceOfCommonStockAndWarrantsOfUnderwritingDiscountsAndOfferingCostsPaidAtClosingAndDeferredOfferingCosts",
     "crdr": "credit",
     "presentation": [
      "http://60degreespharma.com/role/ConsolidatedCondensedStatementsofShareholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock and warrants, net of underwriting discounts and offering costs paid at closing and deferred offering costs (Note 6)",
        "documentation": "Represent the amount of issuance of common stock and warrants, net of underwriting discounts and offering costs paid at closing and deferred offering costs.",
        "label": "Issuance Of Common Stock And Warrants Of Underwriting Discounts And Offering Costs Paid At Closing And Deferred Offering Costs"
       }
      }
     },
     "auth_ref": []
    },
    "sxtp_IssuanceOfCommonStockPursuantToATMOfferingNetOfOfferingCostsPaid": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://60degreespharma.com/20250930",
     "localname": "IssuanceOfCommonStockPursuantToATMOfferingNetOfOfferingCostsPaid",
     "presentation": [
      "http://60degreespharma.com/role/ConsolidatedCondensedStatementsofShareholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock pursuant to ATM Offering, net of offering costs paid at closing and deferred offering costs (Note 6) (in Shares)",
        "label": "Issuance Of Common Stock Pursuant To ATMOffering Net Of Offering Costs Paid",
        "documentation": "Issuance of common stock pursuant to ATM offering."
       }
      }
     },
     "auth_ref": []
    },
    "sxtp_January2024OfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://60degreespharma.com/20250930",
     "localname": "January2024OfferingMember",
     "presentation": [
      "http://60degreespharma.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "January 2024 Offering [Member]",
        "label": "January2024 Offering Member"
       }
      }
     },
     "auth_ref": []
    },
    "sxtp_JanuaryRepresentativeWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://60degreespharma.com/20250930",
     "localname": "JanuaryRepresentativeWarrantsMember",
     "presentation": [
      "http://60degreespharma.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "January 2024 Representative Warrants [Member]",
        "label": "January Representative Warrants Member"
       }
      }
     },
     "auth_ref": []
    },
    "sxtp_JanuaryTwoThousandTwentyFourPreFundedWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://60degreespharma.com/20250930",
     "localname": "JanuaryTwoThousandTwentyFourPreFundedWarrantsMember",
     "presentation": [
      "http://60degreespharma.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "January 2024 Pre-Funded Warrants [Member]",
        "label": "January Two Thousand Twenty Four Pre Funded Warrants Member"
       }
      }
     },
     "auth_ref": []
    },
    "sxtp_JanuaryTwoThousandTwentyFourWarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://60degreespharma.com/20250930",
     "localname": "JanuaryTwoThousandTwentyFourWarrantMember",
     "presentation": [
      "http://60degreespharma.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "January 2024 Warrants [Member]",
        "label": "January Two Thousand Twenty Four Warrant Member"
       }
      }
     },
     "auth_ref": []
    },
    "sxtp_July2025OfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://60degreespharma.com/20250930",
     "localname": "July2025OfferingMember",
     "presentation": [
      "http://60degreespharma.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "July 2025 Offering [Member]",
        "terseLabel": "July 2025 Offering [Member]",
        "documentation": "This member stands for the information pertaining to \"July 2025 Offering\"."
       }
      }
     },
     "auth_ref": []
    },
    "sxtp_JulyTwoThousandTwentyFiveAOneWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://60degreespharma.com/20250930",
     "localname": "JulyTwoThousandTwentyFiveAOneWarrantsMember",
     "presentation": [
      "http://60degreespharma.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "July Two Thousand Twenty Five A One Warrants [Member]",
        "documentation": "This member stands for the information pertaining to \"July 2025 A-1 Warrants\".",
        "terseLabel": "July 2025 A-1 Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sxtp_JulyTwoThousandTwentyFiveATwoWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://60degreespharma.com/20250930",
     "localname": "JulyTwoThousandTwentyFiveATwoWarrantsMember",
     "presentation": [
      "http://60degreespharma.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "July Two Thousand Twenty Five A Two Warrants [Member]",
        "documentation": "This member stands for the information pertaining to \"July 2025 A-2 Warrants\".",
        "terseLabel": "July 2025 A-2 Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sxtp_JulyTwoThousandTwentyFivePlacementAgentWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://60degreespharma.com/20250930",
     "localname": "JulyTwoThousandTwentyFivePlacementAgentWarrantsMember",
     "presentation": [
      "http://60degreespharma.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "July Two Thousand Twenty Five Placement Agent Warrants [Member]",
        "documentation": "This member stands for the information pertaining to \"July 2025 Placement Agent Warrants\".",
        "terseLabel": "July 2025 Placement Agent Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sxtp_JulyTwoThousandTwentyFivePreFundedWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://60degreespharma.com/20250930",
     "localname": "JulyTwoThousandTwentyFivePreFundedWarrantsMember",
     "presentation": [
      "http://60degreespharma.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "July Two Thousand Twenty Five Pre Funded Warrants [Member]",
        "documentation": "This member stands for the information pertaining to \"July 2025 Pre-Funded Warrants\".",
        "terseLabel": "July 2025 Pre-Funded Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sxtp_LabEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://60degreespharma.com/20250930",
     "localname": "LabEquipmentMember",
     "presentation": [
      "http://60degreespharma.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lab Equipment [Member]",
        "label": "Lab Equipment Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "presentation": [
      "http://60degreespharma.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Office space lease renewed term",
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1096"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Liabilities",
        "label": "Liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r42",
      "r43",
      "r44",
      "r46",
      "r47",
      "r48",
      "r49",
      "r164",
      "r167",
      "r168",
      "r264",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r479",
      "r482",
      "r483",
      "r585",
      "r729",
      "r827",
      "r841",
      "r922",
      "r1022",
      "r1099",
      "r1100"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedBalanceSheet": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Liabilities and Shareholders' Equity",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r94",
      "r667",
      "r905",
      "r910",
      "r911",
      "r973",
      "r978",
      "r1002",
      "r1091"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "LIABILITIES AND SHAREHOLDERS' EQUITY:",
        "label": "Liabilities and Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Current Liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r121",
      "r164",
      "r167",
      "r168",
      "r264",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r479",
      "r482",
      "r483",
      "r585",
      "r905",
      "r1022",
      "r1099",
      "r1100"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Liabilities:",
        "label": "Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://60degreespharma.com/role/DEBTDetails",
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Long-Term Liabilities",
        "terseLabel": "Long-Term Liabilities",
        "label": "Liabilities, Noncurrent",
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r46",
      "r47",
      "r48",
      "r49",
      "r164",
      "r167",
      "r168",
      "r264",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r479",
      "r482",
      "r483",
      "r585",
      "r1022",
      "r1099",
      "r1100"
     ]
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesNoncurrentAbstract",
     "presentation": [
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Term Liabilities:",
        "label": "Liabilities, Noncurrent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sxtp_LicensedTechnologyTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://60degreespharma.com/20250930",
     "localname": "LicensedTechnologyTerm",
     "presentation": [
      "http://60degreespharma.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Licensed technology term.",
        "documentation": "Licensed technology term.",
        "label": "Licensed Technology Term"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://60degreespharma.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongTermDebt",
     "crdr": "credit",
     "calculation": {
      "http://60degreespharma.com/role/DEBTScheduleoftheCurrentFuturePaymentObligationsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://60degreespharma.com/role/DEBTScheduleoftheCurrentFuturePaymentObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Long-Term Debt",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r91",
      "r165",
      "r174",
      "r333",
      "r347",
      "r654",
      "r837",
      "r838",
      "r903",
      "r1109"
     ]
    },
    "us-gaap_LongTermDebtByMaturityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongTermDebtByMaturityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of the Current Future Payment Obligations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebtCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongTermDebtCurrent",
     "crdr": "credit",
     "presentation": [
      "http://60degreespharma.com/role/DEBTDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current maturity",
        "label": "Long-Term Debt, Current Maturities",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r128"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive",
     "crdr": "credit",
     "calculation": {
      "http://60degreespharma.com/role/DEBTScheduleoftheCurrentFuturePaymentObligationsDetails": {
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://60degreespharma.com/role/DEBTScheduleoftheCurrentFuturePaymentObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Thereafter",
        "label": "Long-Term Debt, Maturity, after Year Five",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r974",
      "r979",
      "r1025",
      "r1108"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://60degreespharma.com/role/DEBTScheduleoftheCurrentFuturePaymentObligationsDetails": {
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://60degreespharma.com/role/DEBTScheduleoftheCurrentFuturePaymentObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Long-Term Debt, Maturity, Year One",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r165",
      "r174",
      "r338",
      "r654"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour",
     "crdr": "credit",
     "calculation": {
      "http://60degreespharma.com/role/DEBTScheduleoftheCurrentFuturePaymentObligationsDetails": {
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://60degreespharma.com/role/DEBTScheduleoftheCurrentFuturePaymentObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2029",
        "label": "Long-Term Debt, Maturity, Year Four",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r165",
      "r174",
      "r338",
      "r654"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
     "crdr": "credit",
     "calculation": {
      "http://60degreespharma.com/role/DEBTScheduleoftheCurrentFuturePaymentObligationsDetails": {
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://60degreespharma.com/role/DEBTScheduleoftheCurrentFuturePaymentObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028",
        "label": "Long-Term Debt, Maturity, Year Three",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r165",
      "r174",
      "r338",
      "r654"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://60degreespharma.com/role/DEBTScheduleoftheCurrentFuturePaymentObligationsDetails": {
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://60degreespharma.com/role/DEBTScheduleoftheCurrentFuturePaymentObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Long-Term Debt, Maturity, Year Two",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r165",
      "r174",
      "r338",
      "r654"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
     "crdr": "credit",
     "calculation": {
      "http://60degreespharma.com/role/DEBTScheduleoftheCurrentFuturePaymentObligationsDetails": {
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://60degreespharma.com/role/DEBTScheduleoftheCurrentFuturePaymentObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025 (remaining three months)",
        "label": "Long-Term Debt, Maturity, Remainder of Fiscal Year",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year."
       }
      }
     },
     "auth_ref": [
      "r974",
      "r979"
     ]
    },
    "us-gaap_LossContingencyPendingClaimsNumber": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LossContingencyPendingClaimsNumber",
     "presentation": [
      "http://60degreespharma.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss Contingency, Pending Claims, Number",
        "terseLabel": "Number of pending or threatened lawsuits",
        "documentation": "Number of pending claims pertaining to a loss contingency."
       }
      }
     },
     "auth_ref": [
      "r1020",
      "r1021"
     ]
    },
    "us-gaap_MachineryAndEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MachineryAndEquipmentMember",
     "presentation": [
      "http://60degreespharma.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Machinery [Member]",
        "label": "Machinery and Equipment [Member]",
        "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment."
       }
      }
     },
     "auth_ref": []
    },
    "srt_MajorCustomersAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MajorCustomersAxis",
     "presentation": [
      "http://60degreespharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]"
       }
      }
     },
     "auth_ref": [
      "r232",
      "r843",
      "r844",
      "r907",
      "r909",
      "r1110",
      "r1112",
      "r1113",
      "r1114",
      "r1115",
      "r1116",
      "r1117",
      "r1118",
      "r1119",
      "r1120",
      "r1121",
      "r1122",
      "r1123",
      "r1124",
      "r1125",
      "r1126",
      "r1127",
      "r1128",
      "r1129",
      "r1130",
      "r1131",
      "r1132",
      "r1133",
      "r1134",
      "r1135",
      "r1136",
      "r1137",
      "r1138"
     ]
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MaximumMember",
     "presentation": [
      "http://60degreespharma.com/role/COMMITMENTSANDCONTINGENCIESDetails",
      "http://60degreespharma.com/role/STOCKHOLDERSEQUITYDetails",
      "http://60degreespharma.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum [Member]",
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r212",
      "r305",
      "r306",
      "r307",
      "r308",
      "r402",
      "r430",
      "r431",
      "r432",
      "r449",
      "r569",
      "r643",
      "r682",
      "r684",
      "r692",
      "r721",
      "r722",
      "r777",
      "r779",
      "r782",
      "r783",
      "r788",
      "r798",
      "r799",
      "r800",
      "r801",
      "r804",
      "r805",
      "r834",
      "r842",
      "r850",
      "r853",
      "r855",
      "r856",
      "r895",
      "r896",
      "r900",
      "r901",
      "r908",
      "r1024",
      "r1101",
      "r1102",
      "r1103",
      "r1104",
      "r1105",
      "r1106"
     ]
    },
    "sxtp_MilestonePayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://60degreespharma.com/20250930",
     "localname": "MilestonePayment",
     "crdr": "credit",
     "presentation": [
      "http://60degreespharma.com/role/DERIVATIVELIABILITIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestone Payment",
        "documentation": "The amount of milestone payment.",
        "label": "Milestone Payment"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MinimumMember",
     "presentation": [
      "http://60degreespharma.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum [Member]",
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r212",
      "r305",
      "r306",
      "r307",
      "r308",
      "r402",
      "r430",
      "r431",
      "r432",
      "r449",
      "r569",
      "r643",
      "r682",
      "r684",
      "r692",
      "r721",
      "r722",
      "r777",
      "r779",
      "r782",
      "r783",
      "r788",
      "r798",
      "r799",
      "r800",
      "r801",
      "r804",
      "r805",
      "r834",
      "r842",
      "r850",
      "r853",
      "r855",
      "r856",
      "r895",
      "r896",
      "r900",
      "r908",
      "r1024",
      "r1101",
      "r1102",
      "r1103",
      "r1104",
      "r1105",
      "r1106"
     ]
    },
    "us-gaap_MinorityInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MinorityInterest",
     "crdr": "credit",
     "calculation": {
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Noncontrolling Interest",
        "label": "Equity, Attributable to Noncontrolling Interest",
        "documentation": "Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r93",
      "r164",
      "r167",
      "r168",
      "r264",
      "r311",
      "r313",
      "r314",
      "r315",
      "r318",
      "r319",
      "r666",
      "r733",
      "r1091"
     ]
    },
    "srt_NameOfMajorCustomerDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "NameOfMajorCustomerDomain",
     "presentation": [
      "http://60degreespharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]"
       }
      }
     },
     "auth_ref": [
      "r232",
      "r843",
      "r844",
      "r907",
      "r909",
      "r1110",
      "r1112",
      "r1113",
      "r1114",
      "r1115",
      "r1116",
      "r1117",
      "r1118",
      "r1119",
      "r1120",
      "r1121",
      "r1122",
      "r1123",
      "r1124",
      "r1125",
      "r1126",
      "r1127",
      "r1128",
      "r1129",
      "r1130",
      "r1131",
      "r1132",
      "r1133",
      "r1134",
      "r1135",
      "r1136",
      "r1137",
      "r1138"
     ]
    },
    "us-gaap_NatureOfOperations": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NatureOfOperations",
     "presentation": [
      "http://60degreespharma.com/role/NATUREOFOPERATIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "NATURE OF OPERATIONS",
        "label": "Nature of Operations [Text Block]",
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward."
       }
      }
     },
     "auth_ref": [
      "r105",
      "r208",
      "r824",
      "r825"
     ]
    },
    "sxtp_NatureofOperationsDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://60degreespharma.com/20250930",
     "localname": "NatureofOperationsDetailsTable",
     "presentation": [
      "http://60degreespharma.com/role/NATUREOFOPERATIONSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nature of Operations (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedCashFlow": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net Cash Provided by Financing Activities",
        "label": "Cash Provided by (Used in) Financing Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r160"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CASH FLOWS FROM FINANCING ACTIVITIES",
        "label": "Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedCashFlow": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net Cash Provided by (Used in) Investing Activities",
        "label": "Cash Provided by (Used in) Investing Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r160"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CASH FLOWS FROM INVESTING ACTIVITIES",
        "label": "Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedCashFlow": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://60degreespharma.com/role/NATUREOFOPERATIONSDetails",
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net Cash Used in Operating Activities",
        "terseLabel": "Net cash used in operating activities",
        "label": "Cash Provided by (Used in) Operating Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r72",
      "r73"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CASH FLOWS FROM OPERATING ACTIVITIES",
        "label": "Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedIncomeStatement": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net Loss \u2013 attributed to 60 Degrees Pharmaceuticals, Inc.",
        "label": "Net Income (Loss)",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r73",
      "r98",
      "r118",
      "r119",
      "r139",
      "r141",
      "r145",
      "r164",
      "r167",
      "r168",
      "r172",
      "r178",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r189",
      "r190",
      "r196",
      "r264",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r350",
      "r353",
      "r356",
      "r361",
      "r438",
      "r470",
      "r475",
      "r563",
      "r585",
      "r674",
      "r751",
      "r768",
      "r769",
      "r818",
      "r820",
      "r822",
      "r920",
      "r1022"
     ]
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "crdr": "debit",
     "calculation": {
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Loss \u2013 Noncontrolling Interest",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r88",
      "r139",
      "r141",
      "r186",
      "r189",
      "r190",
      "r673",
      "r966"
     ]
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "crdr": "credit",
     "calculation": {
      "http://60degreespharma.com/role/ConsolidatedCondensedStatementsofOperationsandComprehensiveLossIncomeUnauditedCalc2": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net Loss - attributed to common stockholders",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders."
       }
      }
     },
     "auth_ref": [
      "r118",
      "r151",
      "r182",
      "r183",
      "r184",
      "r185",
      "r191",
      "r192",
      "r197",
      "r200",
      "r353",
      "r356",
      "r361",
      "r475"
     ]
    },
    "sxtp_NetLossPerCommonShareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://60degreespharma.com/20250930",
     "localname": "NetLossPerCommonShareMember",
     "presentation": [
      "http://60degreespharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Loss Per Common Share [Member]",
        "label": "Net Loss Per Common Share Member"
       }
      }
     },
     "auth_ref": []
    },
    "sxtp_NetProceedsFromFebruary2025Offering": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://60degreespharma.com/20250930",
     "localname": "NetProceedsFromFebruary2025Offering",
     "crdr": "debit",
     "calculation": {
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Proceeds from February 2025 Offering",
        "documentation": "The amount of net proceeds from february 2025 offering.",
        "label": "Net Proceeds From February2025 Offering"
       }
      }
     },
     "auth_ref": []
    },
    "sxtp_NetProceedsFromJanuary2025Offering": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://60degreespharma.com/20250930",
     "localname": "NetProceedsFromJanuary2025Offering",
     "crdr": "debit",
     "calculation": {
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Proceeds from January 2025 Offering",
        "documentation": "The amount of net proceeds from january 2025 offering.",
        "label": "Net Proceeds From January2025 Offering"
       }
      }
     },
     "auth_ref": []
    },
    "sxtp_NetProceedsFromJuly2025Offering": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://60degreespharma.com/20250930",
     "localname": "NetProceedsFromJuly2025Offering",
     "crdr": "debit",
     "calculation": {
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Proceeds From July 2025 Offering",
        "terseLabel": "Net Proceeds from July 2025 Offering",
        "documentation": "The amount of net proceeds from july 2025 offering."
       }
      }
     },
     "auth_ref": []
    },
    "sxtp_NetProceedsFromSharesAndWarrantsOffering": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://60degreespharma.com/20250930",
     "localname": "NetProceedsFromSharesAndWarrantsOffering",
     "crdr": "debit",
     "calculation": {
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Proceeds from January 2024 Offering",
        "documentation": "Net proceed from shares offering.",
        "label": "Net Proceeds From Shares And Warrants Offering"
       }
      }
     },
     "auth_ref": []
    },
    "sxtp_NetRevenueLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://60degreespharma.com/20250930",
     "localname": "NetRevenueLoss",
     "crdr": "credit",
     "calculation": {
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net (Loss) Revenue",
        "documentation": "The amount of net revenue loss.",
        "label": "Net Revenue Loss"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://60degreespharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recently Adopted and Issued Accounting Pronouncements",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r929"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r929"
     ]
    },
    "us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1",
     "crdr": "debit",
     "presentation": [
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchases of Fixed Assets included in Accounts Payable",
        "label": "Noncash or Part Noncash Acquisition, Fixed Assets Acquired",
        "documentation": "The amount of fixed assets that an Entity acquires in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r23",
      "r24"
     ]
    },
    "us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1",
     "crdr": "debit",
     "presentation": [
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncash or Part Noncash Acquisition, Intangible Assets Acquired",
        "terseLabel": "Capitalized Patent Costs included in Accounts Payable",
        "documentation": "The amount of intangibles that an Entity acquires in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r23",
      "r24"
     ]
    },
    "us-gaap_NoncontrollingInterestMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NoncontrollingInterestMember",
     "presentation": [
      "http://60degreespharma.com/role/ConsolidatedCondensedStatementsofShareholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Noncontrolling Interest on Shareholders",
        "label": "Noncontrolling Interest [Member]",
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r381",
      "r980",
      "r981",
      "r982",
      "r983",
      "r1145"
     ]
    },
    "sxtp_NontradeableWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://60degreespharma.com/20250930",
     "localname": "NontradeableWarrantsMember",
     "presentation": [
      "http://60degreespharma.com/role/NATUREOFOPERATIONSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Tradeable Warrants [Member]",
        "label": "Nontradeable Warrants Member"
       }
      }
     },
     "auth_ref": []
    },
    "sxtp_NumberOfDirectors": {
     "xbrltype": "integerItemType",
     "nsuri": "http://60degreespharma.com/20250930",
     "localname": "NumberOfDirectors",
     "presentation": [
      "http://60degreespharma.com/role/COMMITMENTSANDCONTINGENCIESDetails",
      "http://60degreespharma.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Directors",
        "documentation": "Number of directors.",
        "terseLabel": "Number of directors",
        "verboseLabel": "Number of director nominees"
       }
      }
     },
     "auth_ref": []
    },
    "sxtp_NumberOfExecutives": {
     "xbrltype": "integerItemType",
     "nsuri": "http://60degreespharma.com/20250930",
     "localname": "NumberOfExecutives",
     "presentation": [
      "http://60degreespharma.com/role/SHAREBASEDCOMPENSATIONDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock option granted to number of executives",
        "documentation": "Number of executives.",
        "label": "Number Of Executives"
       }
      }
     },
     "auth_ref": []
    },
    "sxtp_NumberOfNonAuditCommitteeChairs": {
     "xbrltype": "integerItemType",
     "nsuri": "http://60degreespharma.com/20250930",
     "localname": "NumberOfNonAuditCommitteeChairs",
     "presentation": [
      "http://60degreespharma.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of non audit committee chairs",
        "documentation": "Number of non-audit committee chairs.",
        "label": "Number Of Non Audit Committee Chairs"
       }
      }
     },
     "auth_ref": []
    },
    "sxtp_NumberOfShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://60degreespharma.com/20250930",
     "localname": "NumberOfShares",
     "presentation": [
      "http://60degreespharma.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares",
        "documentation": "Number of shares purchased or issued.",
        "label": "Number Of Shares"
       }
      }
     },
     "auth_ref": []
    },
    "sxtp_NumberofWarrantExercisable": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://60degreespharma.com/20250930",
     "localname": "NumberofWarrantExercisable",
     "presentation": [
      "http://60degreespharma.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of warrant exercisable",
        "documentation": "Number of warrants exercisable.",
        "label": "Numberof Warrant Exercisable"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Operating Expenses",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r822"
     ]
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Expenses:",
        "label": "Operating Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss from Operations",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r101",
      "r818",
      "r822",
      "r828",
      "r986",
      "r992",
      "r993",
      "r994",
      "r995"
     ]
    },
    "us-gaap_OperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://60degreespharma.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease costs",
        "label": "Operating Lease, Cost",
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability."
       }
      }
     },
     "auth_ref": [
      "r604",
      "r904"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "crdr": "debit",
     "calculation": {
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of ROU Asset",
        "label": "Operating Lease, Right-of-Use Asset, Periodic Reduction",
        "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease."
       }
      }
     },
     "auth_ref": [
      "r971"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "NATURE OF OPERATIONS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherAssetsAbstract",
     "presentation": [
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Assets:",
        "label": "Other Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Other Assets",
        "label": "Other Assets, Noncurrent",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r126"
     ]
    },
    "us-gaap_OtherCommitmentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherCommitmentsLineItems",
     "presentation": [
      "http://60degreespharma.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax",
     "crdr": "credit",
     "presentation": [
      "http://60degreespharma.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash proceeds",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax",
        "documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness."
       }
      }
     },
     "auth_ref": [
      "r137",
      "r138",
      "r675"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "crdr": "credit",
     "presentation": [
      "http://60degreespharma.com/role/ConsolidatedCondensedStatementsofShareholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net foreign translation gain (loss)",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r675"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "presentation": [
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Comprehensive Loss:",
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_InterestIncomeExpenseNonoperatingNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Income, net",
        "label": "Other Nonoperating Income (Expense)",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r886"
     ]
    },
    "sxtp_OtherOfferingExpensesPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://60degreespharma.com/20250930",
     "localname": "OtherOfferingExpensesPaid",
     "crdr": "credit",
     "presentation": [
      "http://60degreespharma.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other offering expenses paid",
        "documentation": "Cash outflow for other offering expenses.",
        "label": "Other Offering Expenses Paid"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OverAllotmentOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OverAllotmentOptionMember",
     "presentation": [
      "http://60degreespharma.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Over-Allotment Option [Member]",
        "label": "Over-Allotment Option [Member]",
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ParentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ParentMember",
     "presentation": [
      "http://60degreespharma.com/role/ConsolidatedCondensedStatementsofShareholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholders\u2019 Equity Attributable to 60P",
        "verboseLabel": "Total Shareholders\u2019 Equity (Deficit) Attributable to 60P",
        "label": "Parent [Member]",
        "documentation": "Portion of equity, or net assets, in the consolidated entity attributable, directly or indirectly, to the parent. Excludes noncontrolling interests."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PatentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PatentsMember",
     "presentation": [
      "http://60degreespharma.com/role/INTANGIBLEASSETSScheduleofEstimatedFutureAmortizationExpenseforOurPatentsandWebsiteDevelopmentCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Patents [Member]",
        "label": "Patents [Member]",
        "documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law."
       }
      }
     },
     "auth_ref": [
      "r1003",
      "r1004",
      "r1005",
      "r1006",
      "r1007",
      "r1009",
      "r1012",
      "r1013"
     ]
    },
    "sxtp_PaulFieldMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://60degreespharma.com/20250930",
     "localname": "PaulFieldMember",
     "presentation": [
      "http://60degreespharma.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Paul Field [Member]",
        "label": "Paul Field Member"
       }
      }
     },
     "auth_ref": []
    },
    "sxtp_PaymentOfCapitalizationOfPatents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://60degreespharma.com/20250930",
     "localname": "PaymentOfCapitalizationOfPatents",
     "crdr": "credit",
     "calculation": {
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Capitalization of Patents",
        "documentation": "The cash outflow to acquire an asset without physical form usually arising from contractual or other legal rights, excluding goodwill.",
        "label": "Payment Of Capitalization Of Patents"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "crdr": "credit",
     "calculation": {
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Shares Withheld for Net Share Settlement of Performance Bonuses",
        "label": "Payment, Tax Withholding, Share-Based Payment Arrangement",
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r158"
     ]
    },
    "us-gaap_PaymentsToAcquireIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsToAcquireIntangibleAssets",
     "crdr": "credit",
     "calculation": {
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Acquisition of Intangibles",
        "label": "Payments to Acquire Intangible Assets",
        "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill."
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of Fixed Assets",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "us-gaap_PaymentsToAcquireShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsToAcquireShortTermInvestments",
     "crdr": "credit",
     "calculation": {
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments to Acquire Short-Term Investments",
        "negatedLabel": "Purchase of Short-Term Investments",
        "documentation": "The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term."
       }
      }
     },
     "auth_ref": [
      "r69"
     ]
    },
    "sxtp_PercentageOfRoyaltyPaymentsOfNetSales": {
     "xbrltype": "percentItemType",
     "nsuri": "http://60degreespharma.com/20250930",
     "localname": "PercentageOfRoyaltyPaymentsOfNetSales",
     "presentation": [
      "http://60degreespharma.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of royalty payments of net sales",
        "documentation": "Percentage of royalty payments of net sales.",
        "label": "Percentage Of Royalty Payments Of Net Sales"
       }
      }
     },
     "auth_ref": []
    },
    "sxtp_PercentageOfTreatmentOfBabesiosis": {
     "xbrltype": "percentItemType",
     "nsuri": "http://60degreespharma.com/20250930",
     "localname": "PercentageOfTreatmentOfBabesiosis",
     "presentation": [
      "http://60degreespharma.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of treatment of babesiosis",
        "documentation": "Percentage of treatment of babesiosis.",
        "label": "Percentage Of Treatment Of Babesiosis"
       }
      }
     },
     "auth_ref": []
    },
    "sxtp_PlacementAgentWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://60degreespharma.com/20250930",
     "localname": "PlacementAgentWarrantsMember",
     "presentation": [
      "http://60degreespharma.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Placement Agent Warrants [Member]",
        "label": "Placement Agent Warrants Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://60degreespharma.com/role/SHAREBASEDCOMPENSATIONDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1030",
      "r1031",
      "r1032",
      "r1033",
      "r1034",
      "r1035",
      "r1036",
      "r1037",
      "r1038",
      "r1039",
      "r1040",
      "r1041",
      "r1042",
      "r1043",
      "r1044",
      "r1045",
      "r1046",
      "r1047",
      "r1048",
      "r1049",
      "r1050",
      "r1051",
      "r1052",
      "r1053",
      "r1054",
      "r1055"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://60degreespharma.com/role/SHAREBASEDCOMPENSATIONDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1030",
      "r1031",
      "r1032",
      "r1033",
      "r1034",
      "r1035",
      "r1036",
      "r1037",
      "r1038",
      "r1039",
      "r1040",
      "r1041",
      "r1042",
      "r1043",
      "r1044",
      "r1045",
      "r1046",
      "r1047",
      "r1048",
      "r1049",
      "r1050",
      "r1051",
      "r1052",
      "r1053",
      "r1054",
      "r1055"
     ]
    },
    "sxtp_PreFundedWarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://60degreespharma.com/20250930",
     "localname": "PreFundedWarrantMember",
     "presentation": [
      "http://60degreespharma.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-Funded Warrant [Member]",
        "label": "Pre Funded Warrant Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockConvertibleSharesIssuable": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockConvertibleSharesIssuable",
     "presentation": [
      "http://60degreespharma.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Convertible, Shares Issuable",
        "terseLabel": "Preferred stock, convertible, shares issuable",
        "documentation": "Number of common shares issuable upon conversion of preferred stock."
       }
      }
     },
     "auth_ref": [
      "r365"
     ]
    },
    "us-gaap_PreferredStockDividendRatePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockDividendRatePercentage",
     "presentation": [
      "http://60degreespharma.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividends percentage",
        "label": "Preferred Stock, Dividend Rate, Percentage",
        "documentation": "The percentage rate used to calculate dividend payments on preferred stock."
       }
      }
     },
     "auth_ref": [
      "r364",
      "r778",
      "r780",
      "r781",
      "r789"
     ]
    },
    "us-gaap_PreferredStockDividendsAndOtherAdjustments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockDividendsAndOtherAdjustments",
     "crdr": "debit",
     "calculation": {
      "http://60degreespharma.com/role/ConsolidatedCondensedStatementsofOperationsandComprehensiveLossIncomeUnauditedCalc2": {
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Cumulative Dividends on Series A Preferred Stock",
        "label": "Preferred Stock Dividends and Other Adjustments",
        "documentation": "The aggregate value of preferred stock dividends and other adjustments necessary to derive net income apportioned to common stockholders."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r932",
      "r985"
     ]
    },
    "us-gaap_PreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockMember",
     "presentation": [
      "http://60degreespharma.com/role/ConsolidatedCondensedStatementsofShareholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred Stock",
        "label": "Preferred Stock [Member]",
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company."
       }
      }
     },
     "auth_ref": [
      "r912",
      "r913",
      "r916",
      "r917",
      "r918",
      "r919",
      "r1139",
      "r1145"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://60degreespharma.com/role/STOCKHOLDERSEQUITYDetails",
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedBalanceSheet_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, par value (in dollars per share)",
        "verboseLabel": "Preferred stock shares, par value (in dollars per share)",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r363"
     ]
    },
    "us-gaap_PreferredStockRedemptionTerms": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockRedemptionTerms",
     "presentation": [
      "http://60degreespharma.com/role/DERIVATIVELIABILITIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Redemption term.",
        "label": "Preferred Stock, Redemption Terms",
        "documentation": "The redemption terms of preferred stock of an entity that has priority over common stock in the distribution of dividends and in the event of liquidation of the entity. The redemption features of this capital stock are solely within the control of the issuer."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r32"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://60degreespharma.com/role/STOCKHOLDERSEQUITYDetails",
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedBalanceSheet_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares authorized",
        "verboseLabel": "Preferred stock shares authorized",
        "label": "Preferred Stock, Shares Authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r731"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://60degreespharma.com/role/STOCKHOLDERSEQUITYDetails",
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedBalanceSheet_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares issued",
        "verboseLabel": "Preferred stock shares issued",
        "label": "Preferred Stock, Shares Issued",
        "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r363"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://60degreespharma.com/role/STOCKHOLDERSEQUITYDetails",
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedBalanceSheet_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares outstanding",
        "verboseLabel": "Preferred stock shares outstanding",
        "label": "Preferred Stock, Shares Outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r731",
      "r750",
      "r1145",
      "r1146"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series A Preferred Stock, $0.0001 par value, 1,000,000 shares authorized\u037e 76,480 and 76,480 shares issued and outstanding as of September 30, 2025 and December 31, 2024, respectively (Note 6)",
        "label": "Preferred Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r352",
      "r358",
      "r662",
      "r905"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid and Other Assets",
        "label": "Prepaid Expense and Other Assets, Current",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r954"
     ]
    },
    "us-gaap_PrepaidExpenseNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PrepaidExpenseNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_OtherAssetsNoncurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://60degreespharma.com/role/SHAREBASEDCOMPENSATIONDetails",
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Term Prepaid Expense",
        "verboseLabel": "Long-term prepaid expense",
        "label": "Prepaid Expense, Noncurrent",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of amounts paid in advance for expenses which will be charged against earnings in periods after one year or beyond the operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r946"
     ]
    },
    "us-gaap_PriorPeriodReclassificationAdjustmentDescription": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PriorPeriodReclassificationAdjustmentDescription",
     "presentation": [
      "http://60degreespharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reclassifications",
        "label": "Reclassification, Comparability Adjustment [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error."
       }
      }
     },
     "auth_ref": [
      "r943"
     ]
    },
    "sxtp_ProceedsFromCommonStockSalesAgreementNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://60degreespharma.com/20250930",
     "localname": "ProceedsFromCommonStockSalesAgreementNet",
     "crdr": "debit",
     "presentation": [
      "http://60degreespharma.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds From Common Stock Sales Agreement Net",
        "documentation": "The cash inflow associated with common stock sales agreement.",
        "terseLabel": "Proceeds from common stock sales agreement net"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromDebtNetOfIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromDebtNetOfIssuanceCosts",
     "crdr": "debit",
     "presentation": [
      "http://60degreespharma.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net proceeds",
        "label": "Proceeds from Debt, Net of Issuance Costs",
        "documentation": "The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination."
       }
      }
     },
     "auth_ref": [
      "r157"
     ]
    },
    "us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromDivestitureOfBusinessesNetOfCashDivested",
     "crdr": "debit",
     "presentation": [
      "http://60degreespharma.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash proceeds (in Dollars)",
        "label": "Proceeds from Divestiture of Businesses, Net of Cash Divested",
        "documentation": "This element represents the cash inflow during the period from the sale of a component of the entity."
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "sxtp_ProceedsFromExerciseOfPreFundedWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://60degreespharma.com/20250930",
     "localname": "ProceedsFromExerciseOfPreFundedWarrants",
     "crdr": "debit",
     "calculation": {
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://60degreespharma.com/role/STOCKHOLDERSEQUITYDetails",
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from Exercise of Pre-Funded Warrants",
        "documentation": "Proceeds from exercise of pre-funded warrants.",
        "label": "Proceeds From Exercise Of Pre Funded Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "sxtp_ProceedsFromIssuanceATMOfferingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://60degreespharma.com/20250930",
     "localname": "ProceedsFromIssuanceATMOfferingCosts",
     "crdr": "debit",
     "calculation": {
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance A T M Offering Costs",
        "terseLabel": "Net proceeds from ATM Offering",
        "documentation": "Proceeds from ATM offering, net of offering cost."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "crdr": "debit",
     "presentation": [
      "http://60degreespharma.com/role/NATUREOFOPERATIONSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net proceeds",
        "label": "Proceeds from Issuance Initial Public Offering",
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceOfPrivatePlacement",
     "crdr": "debit",
     "calculation": {
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://60degreespharma.com/role/STOCKHOLDERSEQUITYDetails",
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deducting placement agent fees",
        "label": "Proceeds from Issuance of Private Placement",
        "verboseLabel": "Net proceeds from Private Placement",
        "positiveLabel": "Net Proceeds from offering",
        "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments",
     "crdr": "debit",
     "calculation": {
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maturities of Short-Term Investments",
        "label": "Proceeds from Maturities, Prepayments and Calls of Short-Term Investments",
        "documentation": "The cash inflow from maturities, prepayments, calls and collections of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r69"
     ]
    },
    "us-gaap_ProceedsFromOtherEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromOtherEquity",
     "crdr": "debit",
     "presentation": [
      "http://60degreespharma.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Other Equity",
        "terseLabel": "Gross proceeds",
        "documentation": "Amount of cash inflow from the issuance of equity classified as other."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromWarrantExercises",
     "crdr": "debit",
     "presentation": [
      "http://60degreespharma.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Warrant Exercises",
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants."
       }
      }
     },
     "auth_ref": [
      "r969"
     ]
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 0.0
      },
      "http://60degreespharma.com/role/ConsolidatedCondensedStatementsofOperationsandComprehensiveLossIncomeUnauditedCalc2": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 0.0
      },
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://60degreespharma.com/role/ConsolidatedCondensedStatementsofShareholdersEquityUnaudited",
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedCashFlow",
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net Loss including Noncontrolling Interest",
        "terseLabel": "Net Loss",
        "verboseLabel": "Net income (loss)",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r118",
      "r119",
      "r139",
      "r141",
      "r159",
      "r164",
      "r167",
      "r168",
      "r172",
      "r178",
      "r186",
      "r189",
      "r190",
      "r264",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r350",
      "r438",
      "r470",
      "r475",
      "r477",
      "r480",
      "r481",
      "r563",
      "r585",
      "r651",
      "r653",
      "r672",
      "r705",
      "r751",
      "r768",
      "r769",
      "r884",
      "r885",
      "r921",
      "r966",
      "r1022"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "PROPERTY AND EQUIPMENT"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://60degreespharma.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r605"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://60degreespharma.com/role/PROPERTYANDEQUIPMENT"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PROPERTY AND EQUIPMENT",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r108",
      "r109",
      "r110"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://60degreespharma.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://60degreespharma.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and Equipment, at cost",
        "label": "Property, Plant and Equipment, Gross",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r123",
      "r670"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://60degreespharma.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Property and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r605"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      },
      "http://60degreespharma.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://60degreespharma.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails",
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Property and Equipment, net",
        "terseLabel": "Property and Equipment, net (Note 4)",
        "label": "Property, Plant and Equipment, Net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r605",
      "r655",
      "r670",
      "r905"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://60degreespharma.com/role/PROPERTYANDEQUIPMENTTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Property and Equipment",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://60degreespharma.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r605"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RangeAxis",
     "presentation": [
      "http://60degreespharma.com/role/COMMITMENTSANDCONTINGENCIESDetails",
      "http://60degreespharma.com/role/STOCKHOLDERSEQUITYDetails",
      "http://60degreespharma.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r212",
      "r305",
      "r306",
      "r307",
      "r308",
      "r390",
      "r402",
      "r430",
      "r431",
      "r432",
      "r437",
      "r449",
      "r569",
      "r618",
      "r627",
      "r643",
      "r682",
      "r684",
      "r692",
      "r721",
      "r722",
      "r777",
      "r779",
      "r782",
      "r783",
      "r788",
      "r798",
      "r799",
      "r800",
      "r801",
      "r804",
      "r805",
      "r834",
      "r842",
      "r850",
      "r853",
      "r855",
      "r856",
      "r895",
      "r896",
      "r900",
      "r901",
      "r908",
      "r914",
      "r1018",
      "r1024",
      "r1076",
      "r1102",
      "r1103",
      "r1104",
      "r1105",
      "r1106"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RangeMember",
     "presentation": [
      "http://60degreespharma.com/role/COMMITMENTSANDCONTINGENCIESDetails",
      "http://60degreespharma.com/role/STOCKHOLDERSEQUITYDetails",
      "http://60degreespharma.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r212",
      "r305",
      "r306",
      "r307",
      "r308",
      "r390",
      "r402",
      "r430",
      "r431",
      "r432",
      "r437",
      "r449",
      "r569",
      "r618",
      "r627",
      "r643",
      "r682",
      "r684",
      "r692",
      "r721",
      "r722",
      "r777",
      "r779",
      "r782",
      "r783",
      "r788",
      "r798",
      "r799",
      "r800",
      "r801",
      "r804",
      "r805",
      "r834",
      "r842",
      "r850",
      "r853",
      "r855",
      "r856",
      "r895",
      "r896",
      "r900",
      "r901",
      "r908",
      "r914",
      "r1018",
      "r1024",
      "r1076",
      "r1102",
      "r1103",
      "r1104",
      "r1105",
      "r1106"
     ]
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://60degreespharma.com/role/COMMITMENTSANDCONTINGENCIESDetails",
      "http://60degreespharma.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related and Nonrelated Parties [Domain]",
        "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r164",
      "r171",
      "r172",
      "r233",
      "r397",
      "r401",
      "r607",
      "r608",
      "r659",
      "r668",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r749",
      "r776",
      "r1142"
     ]
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionAxis",
     "presentation": [
      "http://60degreespharma.com/role/COMMITMENTSANDCONTINGENCIESDetails",
      "http://60degreespharma.com/role/STOCKHOLDERSEQUITYDetails",
      "http://60degreespharma.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Axis]",
        "documentation": "Information by type of related party transaction."
       }
      }
     },
     "auth_ref": [
      "r164",
      "r171",
      "r172",
      "r607",
      "r608",
      "r1098"
     ]
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionDomain",
     "presentation": [
      "http://60degreespharma.com/role/COMMITMENTSANDCONTINGENCIESDetails",
      "http://60degreespharma.com/role/STOCKHOLDERSEQUITYDetails",
      "http://60degreespharma.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Domain]",
        "documentation": "Transaction between related party."
       }
      }
     },
     "auth_ref": [
      "r164",
      "r171",
      "r172",
      "r1098"
     ]
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://60degreespharma.com/role/COMMITMENTSANDCONTINGENCIESDetails",
      "http://60degreespharma.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related and Nonrelated Parties [Axis]",
        "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r164",
      "r171",
      "r172",
      "r233",
      "r397",
      "r401",
      "r607",
      "r608",
      "r659",
      "r668",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r749",
      "r776",
      "r1098",
      "r1142"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://60degreespharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails",
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development",
        "verboseLabel": "Research and development (in Dollars)",
        "label": "Research and Development Expense",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r451",
      "r807",
      "r818",
      "r819",
      "r831",
      "r1107"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://60degreespharma.com/role/SHAREBASEDCOMPENSATIONScheduleofShareBasedCompensationExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://60degreespharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development Costs",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r450"
     ]
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://60degreespharma.com/role/SHAREBASEDCOMPENSATIONDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted Stock Units (RSUs) [Member]",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": [
      "r1030",
      "r1031",
      "r1032",
      "r1033",
      "r1034",
      "r1035",
      "r1036",
      "r1037",
      "r1038",
      "r1039",
      "r1040",
      "r1041",
      "r1042",
      "r1043",
      "r1044",
      "r1045",
      "r1046",
      "r1047",
      "r1048",
      "r1049",
      "r1050",
      "r1051",
      "r1052",
      "r1053",
      "r1054",
      "r1055"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Deficit",
        "label": "Retained Earnings (Accumulated Deficit)",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r82",
      "r665",
      "r689",
      "r691",
      "r702",
      "r732",
      "r905"
     ]
    },
    "us-gaap_RetainedEarningsUnappropriatedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RetainedEarningsUnappropriatedMember",
     "presentation": [
      "http://60degreespharma.com/role/ConsolidatedCondensedStatementsofShareholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Deficit",
        "label": "Retained Earnings, Unappropriated [Member]",
        "documentation": "Accumulated undistributed earnings (deficit) available for dividend distribution. Includes, but is not limited to, retained earnings not appropriated for specific business purpose."
       }
      }
     },
     "auth_ref": [
      "r53"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "presentation": [
      "http://60degreespharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue Recognition",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for revenue from contract with customer."
       }
      }
     },
     "auth_ref": [
      "r113",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r808"
     ]
    },
    "us-gaap_RevenueNotFromContractWithCustomerOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueNotFromContractWithCustomerOther",
     "crdr": "credit",
     "calculation": {
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedIncomeStatement": {
       "parentTag": "sxtp_NetRevenueLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research Revenues",
        "label": "Revenue Not from Contract with Customer, Other",
        "documentation": "Amount of revenue that is not accounted for under Topic 606, classified as other."
       }
      }
     },
     "auth_ref": [
      "r112"
     ]
    },
    "us-gaap_RevenueRemainingPerformanceObligationPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueRemainingPerformanceObligationPercentage",
     "presentation": [
      "http://60degreespharma.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of revenue",
        "label": "Revenue, Remaining Performance Obligation, Percentage",
        "documentation": "Percentage of remaining performance obligation to total remaining performance obligation not recognized as revenue."
       }
      }
     },
     "auth_ref": [
      "r934"
     ]
    },
    "us-gaap_Revenues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Revenues",
     "crdr": "credit",
     "calculation": {
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedIncomeStatement": {
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product Revenues \u2013 net of Discounts and Rebates",
        "label": "Revenues",
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)."
       }
      }
     },
     "auth_ref": [
      "r99",
      "r100",
      "r146",
      "r164",
      "r167",
      "r168",
      "r203",
      "r214",
      "r215",
      "r226",
      "r228",
      "r230",
      "r231",
      "r232",
      "r264",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r585",
      "r651",
      "r653",
      "r831",
      "r886",
      "r910",
      "r911",
      "r1022"
     ]
    },
    "sxtp_ReverseStockSplitsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://60degreespharma.com/20250930",
     "localname": "ReverseStockSplitsMember",
     "presentation": [
      "http://60degreespharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reverse Stock Splits [Member]",
        "label": "Reverse Stock Splits Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RoyaltyExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RoyaltyExpense",
     "crdr": "debit",
     "presentation": [
      "http://60degreespharma.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalty expense",
        "label": "Royalty Expense",
        "documentation": "Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property."
       }
      }
     },
     "auth_ref": [
      "r66"
     ]
    },
    "sxtp_RoyaltyPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://60degreespharma.com/20250930",
     "localname": "RoyaltyPercentage",
     "presentation": [
      "http://60degreespharma.com/role/DERIVATIVELIABILITIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalty percentage",
        "documentation": "The percentage of royalty.",
        "label": "Royalty Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r929"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r929"
     ]
    },
    "sxtp_SBAEIDLincludingAccruedInterestCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://60degreespharma.com/20250930",
     "localname": "SBAEIDLincludingAccruedInterestCurrent",
     "crdr": "credit",
     "calculation": {
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://60degreespharma.com/role/NATUREOFOPERATIONSDetails",
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SBA EIDL (including accrued interest) (Note 7)",
        "verboseLabel": "Company\u2019s debt",
        "documentation": "Represents the amount of SBA EIDL including accrued interest payable.",
        "label": "SBAEIDLincluding Accrued Interest Current"
       }
      }
     },
     "auth_ref": []
    },
    "sxtp_SBAEIDLincludingAccruedInterestNonCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://60degreespharma.com/20250930",
     "localname": "SBAEIDLincludingAccruedInterestNonCurrent",
     "crdr": "credit",
     "calculation": {
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SBA EIDL (including accrued interest) (Note 7)",
        "documentation": "Represents the amount of SBA EIDL including accrued interest long-term debt payable.",
        "label": "SBAEIDLincluding Accrued Interest Non Current"
       }
      }
     },
     "auth_ref": []
    },
    "sxtp_SBAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://60degreespharma.com/20250930",
     "localname": "SBAMember",
     "presentation": [
      "http://60degreespharma.com/role/DEBTDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SBA [Member]",
        "label": "SBAMember"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://60degreespharma.com/role/COMMITMENTSANDCONTINGENCIESDetails",
      "http://60degreespharma.com/role/NATUREOFOPERATIONSDetails",
      "http://60degreespharma.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "presentation": [
      "http://60degreespharma.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate shares of common stock",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockPercentageOfOwnershipAfterTransaction",
     "presentation": [
      "http://60degreespharma.com/role/DERIVATIVELIABILITIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of stock, percentage of ownership",
        "label": "Sale of Stock, Percentage of Ownership after Transaction",
        "documentation": "Percentage of subsidiary's or equity investee's stock owned by parent company after stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockPricePerShare",
     "presentation": [
      "http://60degreespharma.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of stock price per share (in dollars per share)",
        "label": "Sale of Stock, Price Per Share",
        "verboseLabel": "Sale of stock price per unit (in dollars per unit)",
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "sxtp_SalesAgentCommissionPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://60degreespharma.com/20250930",
     "localname": "SalesAgentCommissionPercentage",
     "presentation": [
      "http://60degreespharma.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sales agent commission percentage",
        "label": "Sales Agent Commission Percentage",
        "documentation": "Percentage of sales agent commission."
       }
      }
     },
     "auth_ref": []
    },
    "sxtp_SalesAgreementTerminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://60degreespharma.com/20250930",
     "localname": "SalesAgreementTerminationDate",
     "presentation": [
      "http://60degreespharma.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sales agreement termination date",
        "label": "Sales Agreement Termination Date",
        "documentation": "Termination date of sales agreement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SalesRevenueNetMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SalesRevenueNetMember",
     "presentation": [
      "http://60degreespharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue Benchmark [Member]",
        "label": "Revenue Benchmark [Member]",
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation."
       }
      }
     },
     "auth_ref": [
      "r232",
      "r988",
      "r989"
     ]
    },
    "us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock",
     "presentation": [
      "http://60degreespharma.com/role/DERIVATIVELIABILITIESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Derivative Liabilities Measured at Fair Value on a Recurring Basis",
        "label": "Schedule of Derivative Liabilities at Fair Value [Table Text Block]",
        "documentation": "Tabular disclosure of derivative liabilities at fair value."
       }
      }
     },
     "auth_ref": [
      "r1062",
      "r1064",
      "r1065"
     ]
    },
    "sxtp_ScheduleOfDerivativeLiabilitiesMeasuredAtFairValueOnARecurringBasisAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://60degreespharma.com/20250930",
     "localname": "ScheduleOfDerivativeLiabilitiesMeasuredAtFairValueOnARecurringBasisAbstract",
     "presentation": [
      "http://60degreespharma.com/role/DERIVATIVELIABILITIESScheduleofDerivativeLiabilitiesMeasuredatFairValueonaRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Derivative Liabilities Measured At Fair Value On ARecurring Basis Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "presentation": [
      "http://60degreespharma.com/role/SHAREBASEDCOMPENSATIONScheduleofShareBasedCompensationExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://60degreespharma.com/role/SHAREBASEDCOMPENSATIONTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Share-Based Compensation Expenses",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "sxtp_ScheduleOfEquityClassifiedWarrantsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://60degreespharma.com/20250930",
     "localname": "ScheduleOfEquityClassifiedWarrantsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Equity Classified Warrants Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "sxtp_ScheduleOfEstimatedFutureAmortizationExpenseForOurPatentsAndWebsiteDevelopmentCostsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://60degreespharma.com/20250930",
     "localname": "ScheduleOfEstimatedFutureAmortizationExpenseForOurPatentsAndWebsiteDevelopmentCostsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Estimated Future Amortization Expense For Our Patents And Website Development Costs Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "sxtp_ScheduleOfExchangeRatesAlongWithHistoricalRatesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://60degreespharma.com/20250930",
     "localname": "ScheduleOfExchangeRatesAlongWithHistoricalRatesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Exchange Rates Along With Historical Rates Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "presentation": [
      "http://60degreespharma.com/role/INTANGIBLEASSETSTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Intangible Assets",
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment."
       }
      }
     },
     "auth_ref": [
      "r810",
      "r1008"
     ]
    },
    "us-gaap_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock",
     "presentation": [
      "http://60degreespharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Exchange Rates along with Historical Rates",
        "label": "Schedule of Foreign Exchange Contracts, Statement of Financial Position [Table Text Block]",
        "documentation": "Tabular disclosure of the presentation of foreign exchange contracts on the statement of financial position, including the fair value amounts and location of such amounts."
       }
      }
     },
     "auth_ref": [
      "r1062",
      "r1064",
      "r1065"
     ]
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "presentation": [
      "http://60degreespharma.com/role/INVENTORYTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Inventory",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r58",
      "r59",
      "r60"
     ]
    },
    "sxtp_ScheduleOfLiabilitiesMeasuredAtFairValueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://60degreespharma.com/20250930",
     "localname": "ScheduleOfLiabilitiesMeasuredAtFairValueAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Liabilities Measured At Fair Value Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "presentation": [
      "http://60degreespharma.com/role/DEBTTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of the Current Future Payment Obligations",
        "label": "Schedule of Maturities of Long-Term Debt [Table Text Block]",
        "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "sxtp_ScheduleOfPropertyAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://60degreespharma.com/20250930",
     "localname": "ScheduleOfPropertyAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Property And Equipment Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://60degreespharma.com/role/PROPERTYANDEQUIPMENTScheduleofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r605"
     ]
    },
    "sxtp_ScheduleOfShareBasedCompensationExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://60degreespharma.com/20250930",
     "localname": "ScheduleOfShareBasedCompensationExpensesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Share Based Compensation Expenses Abstract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "presentation": [
      "http://60degreespharma.com/role/STOCKHOLDERSEQUITYTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Equity-Classified Warrants",
        "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]",
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable."
       }
      }
     },
     "auth_ref": [
      "r1028"
     ]
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "presentation": [
      "http://60degreespharma.com/role/INTANGIBLEASSETSTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Estimated Future Amortization Expense for Our Patents and Website Development Costs",
        "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]",
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r810",
      "r1010"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://60degreespharma.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r923"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://60degreespharma.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r925"
     ]
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://60degreespharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Information",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r229",
      "r231",
      "r829",
      "r830",
      "r833"
     ]
    },
    "sxtp_SeptemberTwoThousandTwentyFourAgentWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://60degreespharma.com/20250930",
     "localname": "SeptemberTwoThousandTwentyFourAgentWarrantsMember",
     "presentation": [
      "http://60degreespharma.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "September Two Thousand Twenty Four Agent Warrants [Member]",
        "terseLabel": "September 2024 Agent Warrants [Member]",
        "documentation": "This member stands for the information pertaining to \"September 2024 Agent Warrants\"."
       }
      }
     },
     "auth_ref": []
    },
    "sxtp_SeriesAAndSeriesBWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://60degreespharma.com/20250930",
     "localname": "SeriesAAndSeriesBWarrantsMember",
     "presentation": [
      "http://60degreespharma.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series A And Series B Warrants [Member]",
        "terseLabel": "Series A And Series B Warrants [Member]",
        "documentation": "This member stands for the information pertaining to \"Series B And Series B Warrants\"."
       }
      }
     },
     "auth_ref": []
    },
    "sxtp_SeriesANonVotingConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://60degreespharma.com/20250930",
     "localname": "SeriesANonVotingConvertiblePreferredStockMember",
     "presentation": [
      "http://60degreespharma.com/role/DERIVATIVELIABILITIESDetails",
      "http://60degreespharma.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series A Non-Voting Convertible Preferred Stock [Member]",
        "label": "Series ANon Voting Convertible Preferred Stock Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SeriesAPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SeriesAPreferredStockMember",
     "presentation": [
      "http://60degreespharma.com/role/ConsolidatedCondensedStatementsofShareholdersEquityUnaudited",
      "http://60degreespharma.com/role/STOCKHOLDERSEQUITYDetails",
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedBalanceSheet_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series A Preferred Stock",
        "verboseLabel": "Series A",
        "netLabel": "Series A Preferred Stock [Member]",
        "label": "Series A Preferred Stock [Member]",
        "documentation": "Series A preferred stock."
       }
      }
     },
     "auth_ref": [
      "r947",
      "r948",
      "r1026",
      "r1027"
     ]
    },
    "sxtp_SeriesAWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://60degreespharma.com/20250930",
     "localname": "SeriesAWarrantsMember",
     "presentation": [
      "http://60degreespharma.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series A Warrants [Member]",
        "terseLabel": "Series A Warrants [Member]",
        "documentation": "This member stands for the information pertaining to \"Series A Warrants\"."
       }
      }
     },
     "auth_ref": []
    },
    "sxtp_SeriesBWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://60degreespharma.com/20250930",
     "localname": "SeriesBWarrantsMember",
     "presentation": [
      "http://60degreespharma.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series B Warrants [Member]",
        "terseLabel": "Series B Warrants [Member]",
        "documentation": "This member stands for the information pertaining to \"Series B Warrants\"."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://60degreespharma.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "terseLabel": "Option granted to purchase common stock period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r851"
     ]
    },
    "sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://60degreespharma.com/20250930",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable",
     "presentation": [
      "http://60degreespharma.com/role/STOCKHOLDERSEQUITYDetails",
      "http://60degreespharma.com/role/STOCKHOLDERSEQUITYScheduleofEquityClassifiedWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Warrants, Total exercisable",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were exercisable, during the reporting period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercisable",
        "verboseLabel": "Number of warrants exercisable"
       }
      }
     },
     "auth_ref": []
    },
    "sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableOutstandingWeightedAverageRemainingContractualTerms": {
     "xbrltype": "durationItemType",
     "nsuri": "http://60degreespharma.com/20250930",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableOutstandingWeightedAverageRemainingContractualTerms",
     "presentation": [
      "http://60degreespharma.com/role/STOCKHOLDERSEQUITYScheduleofEquityClassifiedWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Remaining Contractual Life (Years),Total exercisable",
        "documentation": "Weighted average remaining contractual term exercisable for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercisable Outstanding Weighted Average Remaining Contractual Terms"
       }
      }
     },
     "auth_ref": []
    },
    "sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://60degreespharma.com/20250930",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://60degreespharma.com/role/STOCKHOLDERSEQUITYScheduleofEquityClassifiedWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price,Total exercisable",
        "documentation": "Weighted average fair value as of the exercisable date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Exercisable Weighted Average Grant Date Fair Value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://60degreespharma.com/role/STOCKHOLDERSEQUITYScheduleofEquityClassifiedWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Warrants, Forfeited",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r422"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://60degreespharma.com/role/STOCKHOLDERSEQUITYScheduleofEquityClassifiedWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price, Forfeited",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r422"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://60degreespharma.com/role/STOCKHOLDERSEQUITYDetails",
      "http://60degreespharma.com/role/STOCKHOLDERSEQUITYScheduleofEquityClassifiedWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Warrants, Granted",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "verboseLabel": "Number of warrants granted",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r420"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://60degreespharma.com/role/STOCKHOLDERSEQUITYScheduleofEquityClassifiedWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price, Granted",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r420"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://60degreespharma.com/role/STOCKHOLDERSEQUITYScheduleofEquityClassifiedWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Number of Warrants, Total outstanding, Beginning",
        "periodEndLabel": "Number of Warrants, Total outstanding, Ending",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r417",
      "r418"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://60degreespharma.com/role/STOCKHOLDERSEQUITYScheduleofEquityClassifiedWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Weighted Average Exercise Price, Total outstanding, Beginning",
        "periodEndLabel": "Weighted Average Exercise Price, Total outstanding, Ending",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r417",
      "r418"
     ]
    },
    "sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfWarrantsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://60degreespharma.com/20250930",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfWarrantsExercised",
     "presentation": [
      "http://60degreespharma.com/role/STOCKHOLDERSEQUITYDetails",
      "http://60degreespharma.com/role/STOCKHOLDERSEQUITYScheduleofEquityClassifiedWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Warrants, Exercised",
        "documentation": "The number of number of warrants, exercised.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Number Of Warrants Exercised"
       }
      }
     },
     "auth_ref": []
    },
    "sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfWarrantsExpired": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://60degreespharma.com/20250930",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfWarrantsExpired",
     "presentation": [
      "http://60degreespharma.com/role/STOCKHOLDERSEQUITYScheduleofEquityClassifiedWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Warrants, Expired",
        "documentation": "Number of number of warrants, expired.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Number Of Warrants Expired"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms",
     "presentation": [
      "http://60degreespharma.com/role/STOCKHOLDERSEQUITYScheduleofEquityClassifiedWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Remaining Contractual Life (Years), Total outstanding, Beginning",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms",
        "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r86"
     ]
    },
    "sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://60degreespharma.com/20250930",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms1",
     "presentation": [
      "http://60degreespharma.com/role/STOCKHOLDERSEQUITYScheduleofEquityClassifiedWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Remaining Contractual Life (Years), Total outstanding, Ending",
        "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms1"
       }
      }
     },
     "auth_ref": []
    },
    "sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExercised": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://60degreespharma.com/20250930",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExercised",
     "presentation": [
      "http://60degreespharma.com/role/STOCKHOLDERSEQUITYDetails",
      "http://60degreespharma.com/role/STOCKHOLDERSEQUITYScheduleofEquityClassifiedWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price, Exercised",
        "documentation": "Weighted average exercise price, exercised.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Weighted Average Exercise Price Exercised",
        "verboseLabel": "Weighted average exercise price (in dollars per share)"
       }
      }
     },
     "auth_ref": []
    },
    "sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExpired": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://60degreespharma.com/20250930",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExpired",
     "presentation": [
      "http://60degreespharma.com/role/STOCKHOLDERSEQUITYScheduleofEquityClassifiedWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price, Expired",
        "documentation": "Weighted average exercise price, expired.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Weighted Average Exercise Price Expired"
       }
      }
     },
     "auth_ref": []
    },
    "sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsExercised": {
     "xbrltype": "stringItemType",
     "nsuri": "http://60degreespharma.com/20250930",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsExercised",
     "presentation": [
      "http://60degreespharma.com/role/STOCKHOLDERSEQUITYScheduleofEquityClassifiedWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Remaining Contractual Life (Years), Exercised",
        "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Weighted Average Remaining Contractual Life Years Exercised"
       }
      }
     },
     "auth_ref": []
    },
    "sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsExpired": {
     "xbrltype": "durationItemType",
     "nsuri": "http://60degreespharma.com/20250930",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsExpired",
     "presentation": [
      "http://60degreespharma.com/role/STOCKHOLDERSEQUITYScheduleofEquityClassifiedWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Remaining Contractual Life (Years), Expired",
        "documentation": "Weighted average remaining contractual life (years), expired.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Weighted Average Remaining Contractual Life Years Expired"
       }
      }
     },
     "auth_ref": []
    },
    "sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsForfeited": {
     "xbrltype": "durationItemType",
     "nsuri": "http://60degreespharma.com/20250930",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsForfeited",
     "presentation": [
      "http://60degreespharma.com/role/STOCKHOLDERSEQUITYScheduleofEquityClassifiedWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Remaining Contractual Life (Years), Forfeited",
        "documentation": "Weighted average remaining contractual life (years), forfeited.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Weighted Average Remaining Contractual Life Years Forfeited"
       }
      }
     },
     "auth_ref": []
    },
    "sxtp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsGranted": {
     "xbrltype": "durationItemType",
     "nsuri": "http://60degreespharma.com/20250930",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsGranted",
     "presentation": [
      "http://60degreespharma.com/role/STOCKHOLDERSEQUITYScheduleofEquityClassifiedWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Remaining Contractual Life (Years), Granted",
        "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Weighted Average Remaining Contractual Life Years Granted"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://60degreespharma.com/role/SHAREBASEDCOMPENSATIONScheduleofFairValueofOptionsGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected dividend yield",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r431"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://60degreespharma.com/role/SHAREBASEDCOMPENSATIONScheduleofFairValueofOptionsGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected volatility",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r430"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "presentation": [
      "http://60degreespharma.com/role/SHAREBASEDCOMPENSATIONScheduleofFairValueofOptionsGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum",
        "terseLabel": "Expected volatility, maximum",
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r430"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "presentation": [
      "http://60degreespharma.com/role/SHAREBASEDCOMPENSATIONScheduleofFairValueofOptionsGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum",
        "terseLabel": "Expected volatility, minimum",
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r430"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://60degreespharma.com/role/SHAREBASEDCOMPENSATIONScheduleofFairValueofOptionsGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free interest rate",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r432"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "presentation": [
      "http://60degreespharma.com/role/SHAREBASEDCOMPENSATIONScheduleofFairValueofOptionsGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum",
        "terseLabel": "Risk-free interest rate, maximum",
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r432"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "presentation": [
      "http://60degreespharma.com/role/SHAREBASEDCOMPENSATIONScheduleofFairValueofOptionsGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum",
        "terseLabel": "Risk-free interest rate, minimum",
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r432"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "presentation": [
      "http://60degreespharma.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional common share",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized",
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1057"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://60degreespharma.com/role/SHAREBASEDCOMPENSATIONDetails",
      "http://60degreespharma.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares available for grant (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "verboseLabel": "Number of shares available for issuance (in shares)",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://60degreespharma.com/role/SHAREBASEDCOMPENSATIONDetails",
      "http://60degreespharma.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Stock option granted",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r413"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://60degreespharma.com/role/SHAREBASEDCOMPENSATIONScheduleofFairValueofOptionsGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average grant date fair value (in Dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r423"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock",
     "presentation": [
      "http://60degreespharma.com/role/SHAREBASEDCOMPENSATIONTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Fair Value of Options Granted",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value [Table Text Block]",
        "documentation": "Tabular disclosure of the weighted-average grant-date fair value of equity options or other equity instruments granted during the year."
       }
      }
     },
     "auth_ref": [
      "r34"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward",
     "presentation": [
      "http://60degreespharma.com/role/COMMITMENTSANDCONTINGENCIESDetails",
      "http://60degreespharma.com/role/SHAREBASEDCOMPENSATIONDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Terms of Award",
        "terseLabel": "Stock option granted term",
        "verboseLabel": "Equity-based compensation awards term",
        "documentation": "Description of terms of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r404"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://60degreespharma.com/role/SHAREBASEDCOMPENSATIONDetails",
      "http://60degreespharma.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Domain]",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r405",
      "r406",
      "r407",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://60degreespharma.com/role/SHAREBASEDCOMPENSATIONDetails",
      "http://60degreespharma.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Per share exercise price (in dollars per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r413"
     ]
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "presentation": [
      "http://60degreespharma.com/role/SHAREBASEDCOMPENSATIONDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "First Tranche [Member]",
        "label": "Share-Based Payment Arrangement, Tranche One [Member]",
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period."
       }
      }
     },
     "auth_ref": [
      "r1030",
      "r1031",
      "r1032",
      "r1033",
      "r1034",
      "r1035",
      "r1036",
      "r1037",
      "r1038",
      "r1039",
      "r1040",
      "r1041",
      "r1042",
      "r1043",
      "r1044",
      "r1045",
      "r1046",
      "r1047",
      "r1048",
      "r1049",
      "r1050",
      "r1051",
      "r1052",
      "r1053",
      "r1054",
      "r1055"
     ]
    },
    "sxtp_ShareBasedCompensationDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://60degreespharma.com/20250930",
     "localname": "ShareBasedCompensationDetailsTable",
     "presentation": [
      "http://60degreespharma.com/role/SHAREBASEDCOMPENSATIONDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://60degreespharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-Based Payments",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r403",
      "r408",
      "r427",
      "r428",
      "r429",
      "r430",
      "r433",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "presentation": [
      "http://60degreespharma.com/role/SHAREBASEDCOMPENSATIONDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options Vesting percentage",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage",
        "documentation": "Percentage of vesting of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1030"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://60degreespharma.com/role/SHAREBASEDCOMPENSATIONScheduleofFairValueofOptionsGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected term (years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r429"
     ]
    },
    "sxtp_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1Maximum": {
     "xbrltype": "durationItemType",
     "nsuri": "http://60degreespharma.com/20250930",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1Maximum",
     "presentation": [
      "http://60degreespharma.com/role/SHAREBASEDCOMPENSATIONScheduleofFairValueofOptionsGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement By Share-based Payment Award Fair Value Assumptions Expected Term 1 Maximum",
        "terseLabel": "Expected term, maximum (years)",
        "documentation": "Expected maximum term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "sxtp_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1Minimum": {
     "xbrltype": "durationItemType",
     "nsuri": "http://60degreespharma.com/20250930",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1Minimum",
     "presentation": [
      "http://60degreespharma.com/role/SHAREBASEDCOMPENSATIONScheduleofFairValueofOptionsGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement By Share-based Payment Award Fair Value Assumptions Expected Term 1 Minimum",
        "terseLabel": "Expected term, minimum (years)",
        "documentation": "Expected minimum term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://60degreespharma.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Stock option term",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r86"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares",
     "presentation": [
      "http://60degreespharma.com/role/SHAREBASEDCOMPENSATIONDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested shares (in Shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares",
        "documentation": "Number of options vested."
       }
      }
     },
     "auth_ref": [
      "r1057"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://60degreespharma.com/role/SHAREBASEDCOMPENSATIONDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average grant date fair value of options granted (in Dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value",
        "documentation": "Weighted average grant-date fair value of options vested."
       }
      }
     },
     "auth_ref": [
      "r1057"
     ]
    },
    "sxtp_SharesIssuedPayrollTaxesWithholdings": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://60degreespharma.com/20250930",
     "localname": "SharesIssuedPayrollTaxesWithholdings",
     "presentation": [
      "http://60degreespharma.com/role/SHAREBASEDCOMPENSATIONDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares payroll tax withholdings (in Shares)",
        "documentation": "The shares issued payroll taxes withholdings.",
        "label": "Shares Issued Payroll Taxes Withholdings"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharesIssuedPricePerShare",
     "presentation": [
      "http://60degreespharma.com/role/NATUREOFOPERATIONSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Price per unit (in Dollars per share)",
        "label": "Shares Issued, Price Per Share",
        "documentation": "Per share or per unit amount of equity securities issued."
       }
      }
     },
     "auth_ref": []
    },
    "sxtp_SharesOfWarrants": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://60degreespharma.com/20250930",
     "localname": "SharesOfWarrants",
     "presentation": [
      "http://60degreespharma.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares warrants",
        "documentation": "Number of shares warrants.",
        "label": "Shares Of Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://60degreespharma.com/role/ConsolidatedCondensedStatementsofShareholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance (in Shares)",
        "periodEndLabel": "Balance (in Shares)",
        "label": "Shares, Outstanding",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShortTermInvestments",
     "crdr": "debit",
     "calculation": {
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-Term Investments",
        "label": "Short-Term Investments",
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r96",
      "r953"
     ]
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://60degreespharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
        "label": "Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r162",
      "r163"
     ]
    },
    "sxtp_SignificantCustomerOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://60degreespharma.com/20250930",
     "localname": "SignificantCustomerOneMember",
     "presentation": [
      "http://60degreespharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Significant Customer One [Member]",
        "label": "Significant Customer One Member"
       }
      }
     },
     "auth_ref": []
    },
    "sxtp_SignificantCustomerThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://60degreespharma.com/20250930",
     "localname": "SignificantCustomerThreeMember",
     "presentation": [
      "http://60degreespharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Customer Three [Member]",
        "terseLabel": "Significant Customer Three [Member]",
        "documentation": "This member stands for the information pertaining to \"Significant Customer Three\"."
       }
      }
     },
     "auth_ref": []
    },
    "sxtp_SignificantCustomerTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://60degreespharma.com/20250930",
     "localname": "SignificantCustomerTwoMember",
     "presentation": [
      "http://60degreespharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Customer Two [Member]",
        "documentation": "This member stands for the information pertaining to \"Significant Customer Two\".",
        "terseLabel": "Significant Customer Two [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "sxtp_SignificantCustomersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://60degreespharma.com/20250930",
     "localname": "SignificantCustomersMember",
     "presentation": [
      "http://60degreespharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer One [Member]",
        "verboseLabel": "Significant Customers [Member]",
        "label": "Significant Customers Member"
       }
      }
     },
     "auth_ref": []
    },
    "sxtp_SmallBusinessAdministrationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://60degreespharma.com/20250930",
     "localname": "SmallBusinessAdministrationMember",
     "presentation": [
      "http://60degreespharma.com/role/DEBTDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Small Business Administration [Member]",
        "label": "Small Business Administration Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SoftwareAndSoftwareDevelopmentCostsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SoftwareAndSoftwareDevelopmentCostsMember",
     "presentation": [
      "http://60degreespharma.com/role/INTANGIBLEASSETSScheduleofEstimatedFutureAmortizationExpenseforOurPatentsandWebsiteDevelopmentCostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Website Development Costs [Member]",
        "label": "Software and Software Development Costs [Member]",
        "documentation": "Purchased software applications and internally developed software for sale, licensing or long-term internal use."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://60degreespharma.com/role/ConsolidatedCondensedStatementsofShareholdersEquityUnaudited",
      "http://60degreespharma.com/role/DERIVATIVELIABILITIESDetails",
      "http://60degreespharma.com/role/DocumentAndEntityInformation",
      "http://60degreespharma.com/role/SHAREBASEDCOMPENSATIONDetails",
      "http://60degreespharma.com/role/STOCKHOLDERSEQUITYDetails",
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedBalanceSheet_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r114",
      "r130",
      "r131",
      "r132",
      "r164",
      "r168",
      "r194",
      "r195",
      "r198",
      "r200",
      "r205",
      "r206",
      "r264",
      "r311",
      "r313",
      "r314",
      "r315",
      "r318",
      "r319",
      "r351",
      "r352",
      "r354",
      "r355",
      "r357",
      "r360",
      "r363",
      "r364",
      "r368",
      "r371",
      "r379",
      "r585",
      "r698",
      "r699",
      "r700",
      "r701",
      "r706",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r719",
      "r731",
      "r752",
      "r770",
      "r790",
      "r791",
      "r792",
      "r793",
      "r794",
      "r933",
      "r975",
      "r977",
      "r984"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://60degreespharma.com/role/ConsolidatedCondensedStatementsofShareholdersEquityUnaudited",
      "http://60degreespharma.com/role/SHAREBASEDCOMPENSATIONDetails",
      "http://60degreespharma.com/role/STOCKHOLDERSEQUITYDetails",
      "http://60degreespharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r51",
      "r55",
      "r56",
      "r115",
      "r117",
      "r118",
      "r143",
      "r144",
      "r145",
      "r175",
      "r176",
      "r177",
      "r179",
      "r186",
      "r188",
      "r190",
      "r204",
      "r265",
      "r266",
      "r294",
      "r349",
      "r381",
      "r438",
      "r460",
      "r461",
      "r467",
      "r468",
      "r469",
      "r471",
      "r474",
      "r475",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r561",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r601",
      "r603",
      "r606",
      "r675",
      "r686",
      "r687",
      "r688",
      "r706",
      "r770"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementLineItems",
     "presentation": [
      "http://60degreespharma.com/role/ConsolidatedCondensedStatementsofShareholdersEquityDeficitUnauditedParentheticals",
      "http://60degreespharma.com/role/ConsolidatedCondensedStatementsofShareholdersEquityUnaudited",
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedBalanceSheet_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r175",
      "r176",
      "r177",
      "r204",
      "r351",
      "r352",
      "r354",
      "r357",
      "r603",
      "r644",
      "r697",
      "r707",
      "r719",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r731",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r740",
      "r741",
      "r742",
      "r743",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r753",
      "r754",
      "r756",
      "r757",
      "r758",
      "r759",
      "r760",
      "r761",
      "r762",
      "r763",
      "r764",
      "r765",
      "r766",
      "r767",
      "r770",
      "r820",
      "r822",
      "r915",
      "r1142"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementTable",
     "presentation": [
      "http://60degreespharma.com/role/ConsolidatedCondensedStatementsofShareholdersEquityUnaudited",
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedBalanceSheet_Parentheticals"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Presentation of information about comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r175",
      "r176",
      "r177",
      "r204",
      "r233",
      "r351",
      "r352",
      "r354",
      "r357",
      "r603",
      "r644",
      "r697",
      "r707",
      "r719",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r731",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r740",
      "r741",
      "r742",
      "r743",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r753",
      "r754",
      "r756",
      "r757",
      "r758",
      "r759",
      "r760",
      "r761",
      "r762",
      "r763",
      "r764",
      "r765",
      "r766",
      "r767",
      "r770",
      "r820",
      "r822",
      "r915",
      "r1142"
     ]
    },
    "sxtp_StephenTooveyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://60degreespharma.com/20250930",
     "localname": "StephenTooveyMember",
     "presentation": [
      "http://60degreespharma.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stephen Toovey [Member]",
        "label": "Stephen Toovey Member"
       }
      }
     },
     "auth_ref": []
    },
    "sxtp_StockIssuedDuringPeriodIssuanceOfCommonStockAndWarrantsPursuantToFebruary2025OfferingNetOfOfferingCosts": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://60degreespharma.com/20250930",
     "localname": "StockIssuedDuringPeriodIssuanceOfCommonStockAndWarrantsPursuantToFebruary2025OfferingNetOfOfferingCosts",
     "presentation": [
      "http://60degreespharma.com/role/ConsolidatedCondensedStatementsofShareholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock and warrants pursuant to February 2025 Offering, net of offering costs paid at closing and deferred offering costs (Note 6) (in Shares)",
        "documentation": "Issuance of common stock and warrants pursuant to February 2025 Offering, net of offering costs .",
        "label": "Stock Issued During Period Issuance Of Common Stock And Warrants Pursuant To February2025 Offering Net Of Offering Costs"
       }
      }
     },
     "auth_ref": []
    },
    "sxtp_StockIssuedDuringPeriodIssuanceOfCommonStockAndWarrantsPursuantToJanuary2025OfferingNetOfOfferingCosts": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://60degreespharma.com/20250930",
     "localname": "StockIssuedDuringPeriodIssuanceOfCommonStockAndWarrantsPursuantToJanuary2025OfferingNetOfOfferingCosts",
     "presentation": [
      "http://60degreespharma.com/role/ConsolidatedCondensedStatementsofShareholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock and warrants pursuant to January 2025 Offering, net of offering costs paid at closing and deferred offering costs (Note 6) (in Shares)",
        "documentation": "Issuance of common stock and warrants pursuant to January 2025 Offering, net of offering costs .",
        "label": "Stock Issued During Period Issuance Of Common Stock And Warrants Pursuant To January2025 Offering Net Of Offering Costs"
       }
      }
     },
     "auth_ref": []
    },
    "sxtp_StockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfPreFundedWarrantsinShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://60degreespharma.com/20250930",
     "localname": "StockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfPreFundedWarrantsinShares",
     "presentation": [
      "http://60degreespharma.com/role/ConsolidatedCondensedStatementsofShareholdersEquityUnaudited",
      "http://60degreespharma.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock upon exercise of Pre-Funded Warrants (in shares)",
        "documentation": "Issuance of common stock upon exercise of Pre-Funded Warrants (in Shares).",
        "label": "Stock Issued During Period Issuance Of Common Stock Upon Exercise Of Pre Funded Warrantsin Shares"
       }
      }
     },
     "auth_ref": []
    },
    "sxtp_StockIssuedDuringPeriodIssuanceOfSharesForAnnualPerformanceBonusesNetOfSharesWithheldForTaxesinShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://60degreespharma.com/20250930",
     "localname": "StockIssuedDuringPeriodIssuanceOfSharesForAnnualPerformanceBonusesNetOfSharesWithheldForTaxesinShares",
     "presentation": [
      "http://60degreespharma.com/role/ConsolidatedCondensedStatementsofShareholdersEquityUnaudited",
      "http://60degreespharma.com/role/SHAREBASEDCOMPENSATIONDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of shares for annual performance bonuses, net of shares withheld for taxes (in Shares)",
        "documentation": "Issuance of shares for annual performance bonuses, net of shares withheld for taxes (in Shares).",
        "label": "Stock Issued During Period Issuance Of Shares For Annual Performance Bonuses Net Of Shares Withheld For Taxesin Shares",
        "verboseLabel": "Shares of common stock to the executives in settlement"
       }
      }
     },
     "auth_ref": []
    },
    "sxtp_StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsPursuantToJuly2025OfferingNetOfOfferingCosts": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://60degreespharma.com/20250930",
     "localname": "StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsPursuantToJuly2025OfferingNetOfOfferingCosts",
     "presentation": [
      "http://60degreespharma.com/role/ConsolidatedCondensedStatementsofShareholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock and warrants pursuant to July 2025 Offering, net of offering costs paid at closing and deferred offering costs (Note 6) (in Shares)",
        "label": "Stock Issued During Period Shares Issuance Of Common Stock And Warrants Pursuant To July 2025 Offering Net Of Offering Costs",
        "documentation": "Issuance of common stock and warrants pursuant to july 2025 offering, net of offering costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesIssuedForServices",
     "presentation": [
      "http://60degreespharma.com/role/ConsolidatedCondensedStatementsofShareholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, Issued for Services",
        "terseLabel": "Voluntary return of shares issued to vendor for services (in shares)",
        "negatedLabel": "Voluntary return of shares issued to vendor for services (in shares)",
        "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://60degreespharma.com/role/NATUREOFOPERATIONSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares issued (in Shares)",
        "label": "Stock Issued During Period, Shares, New Issues",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r50",
      "r51",
      "r82",
      "r698",
      "r770",
      "r791"
     ]
    },
    "sxtp_StockIssuedDuringPeriodSharesOfCommonStockAndWarrantsOfUnderwritingDiscountsAndOfferingCostsPaidAtClosingAndDeferredOfferingCosts": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://60degreespharma.com/20250930",
     "localname": "StockIssuedDuringPeriodSharesOfCommonStockAndWarrantsOfUnderwritingDiscountsAndOfferingCostsPaidAtClosingAndDeferredOfferingCosts",
     "presentation": [
      "http://60degreespharma.com/role/ConsolidatedCondensedStatementsofShareholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock and warrants, net of underwriting discounts and offering costs paid at closing and deferred offering costs (Note 6) (in Shares)",
        "documentation": "Represent the shares issuance of common stock and warrants, net of underwriting discounts and offering costs paid at closing and deferred offering costs.",
        "label": "Stock Issued During Period Shares Of Common Stock And Warrants Of Underwriting Discounts And Offering Costs Paid At Closing And Deferred Offering Costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesOther": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesOther",
     "presentation": [
      "http://60degreespharma.com/role/ConsolidatedCondensedStatementsofShareholdersEquityUnaudited",
      "http://60degreespharma.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase of common stock",
        "label": "Stock Issued During Period, Shares, Other",
        "verboseLabel": "Voluntary conversion of Series A Preferred Stock into common stock (in Shares)",
        "documentation": "Number of shares of stock issued attributable to transactions classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited",
     "presentation": [
      "http://60degreespharma.com/role/ConsolidatedCondensedStatementsofShareholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of shares for RSUs (in Shares)",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Forfeited",
        "documentation": "Number of shares related to Restricted Stock Award forfeited during the period."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r50",
      "r51",
      "r82"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesReverseStockSplits",
     "presentation": [
      "http://60degreespharma.com/role/ConsolidatedCondensedStatementsofShareholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, Reverse Stock Splits",
        "terseLabel": "Issuance of common stock for fractional shares pursuant to Reverse Stock Split rounding adjustment (in shares)",
        "documentation": "Reduction in the number of shares during the period as a result of a reverse stock split."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "sxtp_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPursuantToFebruary2025OfferingNetOfOfferingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://60degreespharma.com/20250930",
     "localname": "StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPursuantToFebruary2025OfferingNetOfOfferingCosts",
     "crdr": "credit",
     "presentation": [
      "http://60degreespharma.com/role/ConsolidatedCondensedStatementsofShareholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock and warrants pursuant to February 2025 Offering, net of offering costs paid at closing and deferred offering costs (Note 6)",
        "documentation": "The amount of Issuance of common stock and warrants pursuant to February 2025 Offering, net of offering costs ...",
        "label": "Stock Issued During Period Value Issuance Of Common Stock And Warrants Pursuant To February2025 Offering Net Of Offering Costs"
       }
      }
     },
     "auth_ref": []
    },
    "sxtp_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPursuantToJanuary2025OfferingNetOfOfferingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://60degreespharma.com/20250930",
     "localname": "StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPursuantToJanuary2025OfferingNetOfOfferingCosts",
     "crdr": "credit",
     "presentation": [
      "http://60degreespharma.com/role/ConsolidatedCondensedStatementsofShareholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock and warrants pursuant to January 2025 Offering, net of offering costs paid at closing and deferred offering costs (Note 6)",
        "documentation": "The amount of issuance of common stock and warrants pursuant to January 2025 Offering, net of offering costs ...",
        "label": "Stock Issued During Period Value Issuance Of Common Stock And Warrants Pursuant To January2025 Offering Net Of Offering Costs"
       }
      }
     },
     "auth_ref": []
    },
    "sxtp_StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPursuantToJuly2025OfferingNetOfOfferingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://60degreespharma.com/20250930",
     "localname": "StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPursuantToJuly2025OfferingNetOfOfferingCosts",
     "crdr": "credit",
     "presentation": [
      "http://60degreespharma.com/role/ConsolidatedCondensedStatementsofShareholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock and warrants pursuant to July 2025 Offering, net of offering costs paid at closing and deferred offering costs (Note 6)",
        "label": "Stock Issued During Period Value Issuance Of Common Stock And Warrants Pursuant To July 2025 Offering Net Of Offering Costs",
        "documentation": "The amount of Issuance of common stock and warrants pursuant to july 2025 offering, net of offering costs."
       }
      }
     },
     "auth_ref": []
    },
    "sxtp_StockIssuedDuringPeriodValueIssuanceOfCommonStockForFractionalSharesPursuantToReverseStockSplitRoundingAdjustment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://60degreespharma.com/20250930",
     "localname": "StockIssuedDuringPeriodValueIssuanceOfCommonStockForFractionalSharesPursuantToReverseStockSplitRoundingAdjustment",
     "crdr": "credit",
     "presentation": [
      "http://60degreespharma.com/role/ConsolidatedCondensedStatementsofShareholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock for fractional shares pursuant to Reverse Stock Split rounding adjustment",
        "documentation": "Value of issuance of common stock for fractional shares pursuant to Reverse Stock split rounding adjustment.",
        "label": "Stock Issued During Period Value Issuance Of Common Stock For Fractional Shares Pursuant To Reverse Stock Split Rounding Adjustment"
       }
      }
     },
     "auth_ref": []
    },
    "sxtp_StockIssuedDuringPeriodValueIssuanceOfCommonStockPursuantToATMOfferingNetOfOfferingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://60degreespharma.com/20250930",
     "localname": "StockIssuedDuringPeriodValueIssuanceOfCommonStockPursuantToATMOfferingNetOfOfferingCosts",
     "crdr": "debit",
     "presentation": [
      "http://60degreespharma.com/role/ConsolidatedCondensedStatementsofShareholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock pursuant to ATM Offering, net of offering costs paid at closing and deferred offering costs (Note 6)",
        "documentation": "Issuance of common stock pursuant to ATM offering.",
        "label": "Stock Issued During Period Value Issuance Of Common Stock Pursuant To ATMOffering Net Of Offering Costs"
       }
      }
     },
     "auth_ref": []
    },
    "sxtp_StockIssuedDuringPeriodValueIssuanceOfSharesForAnnualPerformanceBonusesNetOfSharesWithheldForTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://60degreespharma.com/20250930",
     "localname": "StockIssuedDuringPeriodValueIssuanceOfSharesForAnnualPerformanceBonusesNetOfSharesWithheldForTaxes",
     "crdr": "credit",
     "presentation": [
      "http://60degreespharma.com/role/ConsolidatedCondensedStatementsofShareholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of shares for annual performance bonuses, net of shares withheld for taxes",
        "verboseLabel": "Shares of common stock to the executives in settlement",
        "documentation": "The amount of issuance of shares for annual performance bonuses, net of shares withheld for taxes.",
        "label": "Stock Issued During Period Value Issuance Of Shares For Annual Performance Bonuses Net Of Shares Withheld For Taxes"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueIssuedForServices",
     "crdr": "credit",
     "presentation": [
      "http://60degreespharma.com/role/ConsolidatedCondensedStatementsofShareholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, Issued for Services",
        "terseLabel": "Voluntary return of shares issued to vendor for services",
        "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://60degreespharma.com/role/ConsolidatedCondensedStatementsofShareholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of warrants in Private Placement, net of offering costs paid at closing and deferred offering costs",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r50",
      "r51",
      "r82",
      "r706",
      "r770",
      "r791",
      "r921"
     ]
    },
    "sxtp_StockIssuedDuringPeriodValueStockIssuanceOfCommonStockUponExerciseOfPreFundedWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://60degreespharma.com/20250930",
     "localname": "StockIssuedDuringPeriodValueStockIssuanceOfCommonStockUponExerciseOfPreFundedWarrants",
     "crdr": "credit",
     "presentation": [
      "http://60degreespharma.com/role/ConsolidatedCondensedStatementsofShareholdersEquityUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock upon exercise of Pre-Funded Warrants",
        "documentation": "Issuance of common stock upon exercise of pre-funded warrants.",
        "label": "Stock Issued During Period Value Stock Issuance Of Common Stock Upon Exercise Of Pre Funded Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "sxtp_StockOptionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://60degreespharma.com/20250930",
     "localname": "StockOptionsMember",
     "presentation": [
      "http://60degreespharma.com/role/SHAREBASEDCOMPENSATIONDetails",
      "http://60degreespharma.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Options [Member]",
        "label": "Stock Options Member"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "60P Shareholders\u2019 Equity:",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r55",
      "r56",
      "r74",
      "r733",
      "r750",
      "r771",
      "r772",
      "r905",
      "r922",
      "r973",
      "r977",
      "r978",
      "r1002",
      "r1091",
      "r1145"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SHAREHOLDERS' EQUITY:",
        "label": "Equity, Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sxtp_StockholdersEquityDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://60degreespharma.com/20250930",
     "localname": "StockholdersEquityDetailsTable",
     "presentation": [
      "http://60degreespharma.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedBalanceSheet": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://60degreespharma.com/role/ConsolidatedCondensedStatementsofShareholdersEquityUnaudited",
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedBalanceSheet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Shareholders' Equity",
        "periodStartLabel": "Balance",
        "periodEndLabel": "Balance",
        "label": "Equity, Including Portion Attributable to Noncontrolling Interest",
        "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r37",
      "r39",
      "r115",
      "r116",
      "r117",
      "r118",
      "r144",
      "r175",
      "r176",
      "r177",
      "r179",
      "r186",
      "r188",
      "r265",
      "r266",
      "r294",
      "r349",
      "r381",
      "r438",
      "r460",
      "r461",
      "r467",
      "r468",
      "r469",
      "r471",
      "r474",
      "r475",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r561",
      "r591",
      "r592",
      "r596",
      "r602",
      "r606",
      "r687",
      "r688",
      "r704",
      "r733",
      "r750",
      "r771",
      "r772",
      "r795",
      "r910",
      "r911",
      "r921",
      "r973",
      "r977",
      "r978",
      "r1002",
      "r1091",
      "r1145"
     ]
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://60degreespharma.com/role/STOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "STOCKHOLDERS\u2019 EQUITY",
        "label": "Equity [Text Block]",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r362",
      "r364",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r375",
      "r376",
      "r378",
      "r381",
      "r545",
      "r560",
      "r773",
      "r775",
      "r796"
     ]
    },
    "us-gaap_StockholdersEquityPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityPolicyTextBlock",
     "presentation": [
      "http://60degreespharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reverse Stock Splits",
        "label": "Stockholders' Equity, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for its capital stock transactions, including dividends and accumulated other comprehensive income."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r774"
     ]
    },
    "us-gaap_StockholdersEquityReverseStockSplit": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityReverseStockSplit",
     "presentation": [
      "http://60degreespharma.com/role/STOCKHOLDERSEQUITYDetails",
      "http://60degreespharma.com/role/SUBSEQUENTEVENTSDetails",
      "http://60degreespharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reverse stock split",
        "label": "Stockholders' Equity, Reverse Stock Split",
        "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements."
       }
      }
     },
     "auth_ref": [
      "r83"
     ]
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://60degreespharma.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Line Items]",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r597",
      "r610"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://60degreespharma.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r597",
      "r610"
     ]
    },
    "us-gaap_SubsequentEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventTable",
     "presentation": [
      "http://60degreespharma.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Table]",
        "documentation": "Disclosure of information about significant event or transaction occurring between statement of financial position date and date when financial statements were issued."
       }
      }
     },
     "auth_ref": [
      "r597",
      "r610"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://60degreespharma.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r597",
      "r610"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://60degreespharma.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r597",
      "r610"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "SUBSEQUENT EVENTS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventsPolicyPolicyTextBlock",
     "presentation": [
      "http://60degreespharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Events",
        "label": "Subsequent Events, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for reporting subsequent events."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://60degreespharma.com/role/SUBSEQUENTEVENTS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SUBSEQUENT EVENTS",
        "label": "Subsequent Events [Text Block]",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r609",
      "r611"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://60degreespharma.com/role/COMMITMENTSANDCONTINGENCIESDetails",
      "http://60degreespharma.com/role/NATUREOFOPERATIONSDetails",
      "http://60degreespharma.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "sxtp_SummaryofSignificantAccountingPoliciesDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://60degreespharma.com/20250930",
     "localname": "SummaryofSignificantAccountingPoliciesDetailsTable",
     "presentation": [
      "http://60degreespharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "sxtp_SummaryofSignificantAccountingPoliciesScheduleofExchangeRatesalongwithHistoricalRatesDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://60degreespharma.com/20250930",
     "localname": "SummaryofSignificantAccountingPoliciesScheduleofExchangeRatesalongwithHistoricalRatesDetailsTable",
     "presentation": [
      "http://60degreespharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofExchangeRatesalongwithHistoricalRatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies - Schedule of Exchange Rates along with Historical Rates (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "sxtp_SummaryofSignificantAccountingPoliciesScheduleofLiabilitiesMeasuredatFairValueDetailsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://60degreespharma.com/20250930",
     "localname": "SummaryofSignificantAccountingPoliciesScheduleofLiabilitiesMeasuredatFairValueDetailsTable",
     "presentation": [
      "http://60degreespharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofLiabilitiesMeasuredatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies - Schedule of Liabilities Measured at Fair Value (Details) [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://60degreespharma.com/role/COMMITMENTSANDCONTINGENCIESDetails",
      "http://60degreespharma.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title and Position [Axis]"
       }
      }
     },
     "auth_ref": [
      "r996",
      "r1097"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://60degreespharma.com/role/COMMITMENTSANDCONTINGENCIESDetails",
      "http://60degreespharma.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title and Position [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "sxtp_TradeableAndNonTradeableWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://60degreespharma.com/20250930",
     "localname": "TradeableAndNonTradeableWarrantsMember",
     "presentation": [
      "http://60degreespharma.com/role/NATUREOFOPERATIONSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tradeable and Non-Tradeable Warrants [Member]",
        "label": "Tradeable And Non Tradeable Warrants Member"
       }
      }
     },
     "auth_ref": []
    },
    "sxtp_TradeableWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://60degreespharma.com/20250930",
     "localname": "TradeableWarrantsMember",
     "presentation": [
      "http://60degreespharma.com/role/NATUREOFOPERATIONSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tradeable Warrants [Member]",
        "label": "Tradeable Warrants Member"
       }
      }
     },
     "auth_ref": []
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://60degreespharma.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://60degreespharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofLiabilitiesMeasuredatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments [Domain]",
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r345",
      "r377",
      "r545",
      "r559",
      "r580",
      "r584",
      "r587",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r657",
      "r676",
      "r892",
      "r893",
      "r895",
      "r896",
      "r897",
      "r898",
      "r899",
      "r900",
      "r901",
      "r906",
      "r936",
      "r937",
      "r938",
      "r939",
      "r940",
      "r941",
      "r942",
      "r998",
      "r999",
      "r1000",
      "r1001",
      "r1072",
      "r1075",
      "r1076",
      "r1077",
      "r1084",
      "r1087",
      "r1089",
      "r1090"
     ]
    },
    "sxtp_TrevallyLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://60degreespharma.com/20250930",
     "localname": "TrevallyLLCMember",
     "presentation": [
      "http://60degreespharma.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trevally, LLC [Member]",
        "terseLabel": "Trevally, LLC [Member]",
        "documentation": "This member stands for the information pertaining to \"Trevally, LLC\"."
       }
      }
     },
     "auth_ref": []
    },
    "sxtp_TuftsMedicalCenterAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://60degreespharma.com/20250930",
     "localname": "TuftsMedicalCenterAgreementMember",
     "presentation": [
      "http://60degreespharma.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tufts Medical Center Agreement [Member]",
        "terseLabel": "Tufts MC Agreement [Member]",
        "documentation": "This member stands for the information pertaining to \"Tufts MC Agreement\"."
       }
      }
     },
     "auth_ref": []
    },
    "sxtp_TwoThousandTwentyTwoEquityIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://60degreespharma.com/20250930",
     "localname": "TwoThousandTwentyTwoEquityIncentivePlanMember",
     "presentation": [
      "http://60degreespharma.com/role/SHAREBASEDCOMPENSATIONDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Two Thousand Twenty Two Equity Incentive Plan [Member]",
        "label": "Two Thousand Twenty Two Equity Incentive Plan Member"
       }
      }
     },
     "auth_ref": []
    },
    "sxtp_USArmyAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://60degreespharma.com/20250930",
     "localname": "USArmyAgreementMember",
     "presentation": [
      "http://60degreespharma.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. Army Agreement [Member]",
        "label": "USArmy Agreement Member"
       }
      }
     },
     "auth_ref": []
    },
    "currency_USD": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/currency/2025",
     "localname": "USD",
     "presentation": [
      "http://60degreespharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESScheduleofExchangeRatesalongwithHistoricalRatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "United States of America, Dollars",
        "label": "United States of America, Dollars"
       }
      }
     },
     "auth_ref": []
    },
    "sxtp_USGovernmentSalesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://60degreespharma.com/20250930",
     "localname": "USGovernmentSalesMember",
     "presentation": [
      "http://60degreespharma.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "US Government Sales [Member]",
        "label": "USGovernment Sales Member"
       }
      }
     },
     "auth_ref": []
    },
    "sxtp_UnamortizedBalance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://60degreespharma.com/20250930",
     "localname": "UnamortizedBalance",
     "crdr": "debit",
     "presentation": [
      "http://60degreespharma.com/role/SHAREBASEDCOMPENSATIONDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unamortized balance",
        "documentation": "The amount of unamortized balance.",
        "label": "Unamortized Balance"
       }
      }
     },
     "auth_ref": []
    },
    "sxtp_UnitsIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://60degreespharma.com/20250930",
     "localname": "UnitsIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://60degreespharma.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Units issued",
        "documentation": "Number of units issued during the period.",
        "label": "Units Issued During Period Shares New Issues"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://60degreespharma.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Use of Estimates",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r106",
      "r107",
      "r207",
      "r210",
      "r211",
      "r212",
      "r651",
      "r653",
      "r826"
     ]
    },
    "us-gaap_VestingAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "VestingAxis",
     "presentation": [
      "http://60degreespharma.com/role/SHAREBASEDCOMPENSATIONDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting [Axis]",
        "documentation": "Information by vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1030",
      "r1031",
      "r1032",
      "r1033",
      "r1034",
      "r1035",
      "r1036",
      "r1037",
      "r1038",
      "r1039",
      "r1040",
      "r1041",
      "r1042",
      "r1043",
      "r1044",
      "r1045",
      "r1046",
      "r1047",
      "r1048",
      "r1049",
      "r1050",
      "r1051",
      "r1052",
      "r1053",
      "r1054",
      "r1055"
     ]
    },
    "us-gaap_VestingDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "VestingDomain",
     "presentation": [
      "http://60degreespharma.com/role/SHAREBASEDCOMPENSATIONDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting [Domain]",
        "documentation": "Vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1030",
      "r1031",
      "r1032",
      "r1033",
      "r1034",
      "r1035",
      "r1036",
      "r1037",
      "r1038",
      "r1039",
      "r1040",
      "r1041",
      "r1042",
      "r1043",
      "r1044",
      "r1045",
      "r1046",
      "r1047",
      "r1048",
      "r1049",
      "r1050",
      "r1051",
      "r1052",
      "r1053",
      "r1054",
      "r1055"
     ]
    },
    "sxtp_WallachBethCapitalLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://60degreespharma.com/20250930",
     "localname": "WallachBethCapitalLLCMember",
     "presentation": [
      "http://60degreespharma.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "WallachBeth Capital LLC [Member]",
        "label": "Wallach Beth Capital LLCMember"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantExercisePriceDecrease": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WarrantExercisePriceDecrease",
     "presentation": [
      "http://60degreespharma.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant, Exercise Price, Decrease",
        "terseLabel": "Exercise price (in Dollars per share)",
        "documentation": "Per share decrease in exercise price of warrant. Excludes change due to standard antidilution provision."
       }
      }
     },
     "auth_ref": [
      "r380"
     ]
    },
    "us-gaap_WarrantExercisePriceIncrease": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WarrantExercisePriceIncrease",
     "presentation": [
      "http://60degreespharma.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise price (in dollars per share)",
        "label": "Warrant, Exercise Price, Increase",
        "documentation": "Per share increase in exercise price of warrant. Excludes change due to standard antidilution provision."
       }
      }
     },
     "auth_ref": [
      "r380"
     ]
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WarrantMember",
     "presentation": [
      "http://60degreespharma.com/role/DERIVATIVELIABILITIESScheduleofDerivativeLiabilitiesMeasuredatFairValueonaRecurringBasisDetails",
      "http://60degreespharma.com/role/DocumentAndEntityInformation",
      "http://60degreespharma.com/role/STOCKHOLDERSEQUITYDetails",
      "http://60degreespharma.com/role/STOCKHOLDERSEQUITYScheduleofEquityClassifiedWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants [Member]",
        "verboseLabel": "Warrants, each warrant to purchase one share of Common Stock",
        "label": "Warrant [Member]",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r912",
      "r913",
      "r916",
      "r917",
      "r918",
      "r919"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstanding": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WarrantsAndRightsOutstanding",
     "crdr": "credit",
     "presentation": [
      "http://60degreespharma.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants and Rights Outstanding",
        "terseLabel": "Warrants and rights outstanding",
        "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price."
       }
      }
     },
     "auth_ref": [
      "r1075",
      "r1076",
      "r1077"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstandingMaturityDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WarrantsAndRightsOutstandingMaturityDate",
     "presentation": [
      "http://60degreespharma.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants and Rights Outstanding, Maturity Date",
        "terseLabel": "Date of warrants exercisable expiry",
        "documentation": "Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r1075",
      "r1076",
      "r1077"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WarrantsAndRightsOutstandingTerm",
     "presentation": [
      "http://60degreespharma.com/role/NATUREOFOPERATIONSDetails",
      "http://60degreespharma.com/role/STOCKHOLDERSEQUITYDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Representative warrants exercisable term",
        "label": "Warrants and Rights Outstanding, Term",
        "verboseLabel": "Warrants exercisable expiry term",
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1075",
      "r1076",
      "r1077"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Diluted (in Shares)",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r193",
      "r200"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic (in Shares)",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r191",
      "r200"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasicAbstract",
     "presentation": [
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedIncomeStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Number of Common Shares Outstanding(1)",
        "label": "Weighted Average Number of Shares Outstanding, Basic [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "sxtp_WriteoffsOfCapitalizedPatents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://60degreespharma.com/20250930",
     "localname": "WriteoffsOfCapitalizedPatents",
     "crdr": "debit",
     "calculation": {
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedCashFlow": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://60degreespharma.com/role/sxtp_r_ConsolidatedCashFlow"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Write-offs of Capitalized Patents",
        "documentation": "The amount of write-offs of capitalized patents.",
        "label": "Writeoffs Of Capitalized Patents"
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "SubTopic": "405",
   "Topic": "942",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477787/942-405-45-2"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-20"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "470",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-1"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-1"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-11"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "330",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-1"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-11"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-15"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-16"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-21"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4I"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480581/330-10-S99-1"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/360/tableOfContent"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/470/tableOfContent"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SAB Topic 4.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-4"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "210",
   "Topic": "946",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-20"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-7"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1)(e))",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/606/tableOfContent"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-10"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 6.B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-5"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-4"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(n))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-11"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-2"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-6"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "36",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/330/tableOfContent"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-2"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480265/350-10-S45-1"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-30/tableOfContent"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-2"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-4"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-1"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-2"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-3"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-1"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-2"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-3"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3A",
   "Subparagraph": "(24)(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-3A"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-17"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-19"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "17",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480336/718-10-65-17"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479983/718-10-S45-1"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-2"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-3"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-4"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-5"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-2"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/815/tableOfContent"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1A"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1A"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1A"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1A"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1B"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-2"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-2"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-2"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-2"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-2"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4CC",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4CC"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4CCC",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4CCC"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4CCC",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4CCC"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4CCC",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4CCC"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4EE",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4EE"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4EE",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4EE"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4EE",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4EE"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4EEE",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4EEE"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4EEE",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4EEE"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4EEE",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4EEE"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4F"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4F"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4F",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4F"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4H",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4H"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4H",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4H"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4I"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4K",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4K"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4K",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4K"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4K",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4K"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4K",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4K"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4K",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4K"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4K",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4K"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4K",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4K"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4K",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4K"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-5C"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-7"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8A"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8C"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479693/815-10-S50-1"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "15",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480960/815-15-50-3"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-30"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-32"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482804/825-20-50-1"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/830/tableOfContent"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "230",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479424/830-30-S99-1"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/855/tableOfContent"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483154/926-20-50-5"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "928",
   "SubTopic": "340",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478859/928-340-50-1"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478671/942-235-S50-1"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-2"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "740",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477617/942-740-50-1"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "740",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478822/944-740-50-1"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "805",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478072/944-805-50-1"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-6"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-21"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5B",
   "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5C",
   "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-3"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "38",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477346/946-830-45-38"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478322/948-310-S50-2"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478785/954-310-50-2"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/985-20/tableOfContent"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-10"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "40",
   "SubTopic": "30",
   "Topic": "350",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482640/350-30-55-40"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-15"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-12"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-11"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-14"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-18"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-21"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-24"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-4"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-2"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-4"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-6"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r830": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r831": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r832": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r833": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r834": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r835": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8"
  },
  "r836": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r837": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r838": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r839": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E"
  },
  "r840": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F"
  },
  "r841": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "64",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481620/480-10-55-64"
  },
  "r842": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r843": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r844": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r845": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r846": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r847": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r848": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r849": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r850": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r851": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r852": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r853": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-8"
  },
  "r854": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-41"
  },
  "r855": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "43",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-43"
  },
  "r856": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-47"
  },
  "r857": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14"
  },
  "r858": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14"
  },
  "r859": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14"
  },
  "r860": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14"
  },
  "r861": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14"
  },
  "r862": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-20"
  },
  "r863": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-20"
  },
  "r864": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-20"
  },
  "r865": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-20"
  },
  "r866": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-29"
  },
  "r867": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-29"
  },
  "r868": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r869": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r870": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r871": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r872": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r873": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r874": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r875": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r876": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r877": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r878": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38"
  },
  "r879": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38"
  },
  "r880": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38"
  },
  "r881": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38"
  },
  "r882": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38"
  },
  "r883": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38"
  },
  "r884": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J"
  },
  "r885": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K"
  },
  "r886": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r887": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "181",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-181"
  },
  "r888": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "182",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-182"
  },
  "r889": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "183",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-183"
  },
  "r890": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "184",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-184"
  },
  "r891": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "185",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-185"
  },
  "r892": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r893": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "101",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101"
  },
  "r894": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r895": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r896": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r897": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r898": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r899": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r900": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r901": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r902": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-12"
  },
  "r903": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8"
  },
  "r904": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r905": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r906": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4"
  },
  "r907": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r908": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r909": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r910": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-11"
  },
  "r911": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-14"
  },
  "r912": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r913": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r914": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r915": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r916": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r917": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r918": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r919": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r920": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r921": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r922": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r923": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r924": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r925": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r926": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r927": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r928": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r929": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r930": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r931": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r932": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 6.B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-5"
  },
  "r933": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r934": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)(1)",
   "SubTopic": "10",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13"
  },
  "r935": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r936": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r937": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r938": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r939": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r940": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r941": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r942": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r943": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "205",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483504/205-10-50-1"
  },
  "r944": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r945": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r946": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r947": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r948": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r949": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r950": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r951": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r952": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r953": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r954": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r955": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r956": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r957": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r958": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r959": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r960": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r961": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r962": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-10"
  },
  "r963": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-12"
  },
  "r964": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r965": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r966": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r967": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r968": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r969": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r970": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r971": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r972": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r973": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r974": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-4"
  },
  "r975": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r976": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r977": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r978": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r979": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r980": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r981": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r982": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r983": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r984": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55"
  },
  "r985": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r986": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r987": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r988": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r989": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r990": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r991": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r992": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r993": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r994": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r995": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r996": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r997": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2"
  },
  "r998": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r999": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1000": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1001": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1002": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r1003": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
  },
  "r1004": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r1005": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r1006": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r1007": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r1008": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1009": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1010": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1011": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1012": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1013": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1014": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r1015": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1016": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1017": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1018": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r1019": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r1020": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r1021": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r1022": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1023": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1024": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r1025": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r1026": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-1"
  },
  "r1027": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r1028": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r1029": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r1030": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1031": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1032": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1033": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1034": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1035": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1036": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1037": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1038": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1039": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1040": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1041": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1042": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1043": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1044": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1045": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1046": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1047": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1048": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1049": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1050": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1051": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1052": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1053": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1054": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1055": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1056": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1057": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-4"
  },
  "r1058": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6"
  },
  "r1059": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r1060": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r1061": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3"
  },
  "r1062": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r1063": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r1064": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r1065": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4E"
  },
  "r1066": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-7A"
  },
  "r1067": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r1068": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r1069": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r1070": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r1071": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r1072": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r1073": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1074": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1075": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1076": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1077": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1078": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1079": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1080": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1081": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1082": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1083": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1084": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r1085": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r1086": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r1087": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r1088": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-1"
  },
  "r1089": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10"
  },
  "r1090": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r1091": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r1092": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479424/830-30-S99-1"
  },
  "r1093": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r1094": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-3"
  },
  "r1095": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r1096": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r1097": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r1098": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r1099": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1100": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1101": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1102": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1103": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1104": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1105": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1106": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1107": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r1108": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-2"
  },
  "r1109": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1110": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r1111": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r1112": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1113": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1114": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r1115": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r1116": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1117": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1118": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1119": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1120": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1121": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1122": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1123": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1124": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1125": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1126": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1127": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1128": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1129": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1130": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1131": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1132": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1133": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1134": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1135": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1136": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1137": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1138": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1139": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r1140": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1141": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1142": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r1143": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-6"
  },
  "r1144": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1145": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1146": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1147": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>70
<FILENAME>0001554855-25-002032-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001554855-25-002032-xbrl.zip
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M'1P?U0[%AP-^$!R%!U _KN^<L)D,O;7<VKG% ;G+#-R1VKN;QLYTF"M<W#C
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MC#@#PJV96N7KDOZ=,4DCP)'J/?>5X1Q?5.WZ.=FK@J5,,J6W]^^"%19+6E0
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M/-LOA-WNO[<_5.8_8G;^!5!+ P04    " #;:VU;(X DA2_* @" T!\ $0
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MTDB(,4>LB:V 4DA-+46T<21TKKX=CDX F(*,9E6%'(*M'4*[B  F!)B1.HH
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MKWJW@Z30!O=L$%BC+$X*]YRZP;#WQ+E8O<:8LHUKYP)49Y51, A>G$'6J#,
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M.:,,$*6Q0,XY@L)D(&)BL819K+.,R_N8*)WTDCQQ;0W^)A<O-]7%K$D)8Z,
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M--P*SG"LY\Y#;*A,JBKT)+=VL)='M / S$-MZCR[5'F+C!@9 ZP$":D&9[7
MB$M -<$:U\(DFY@J4AQ*GF:B+<U"(\4M-AUZ>EO#[#R@C6#>VA#6&H+"61K/
M\(PJY9Q"0*W;9O[W6?=]?KFZYHU7D"M(_;XK+HB7L)(KQI"4CNC8B/G[(]=G
M,L]NWZXR2<>W=EB'">E-N1><W\TXTE1O,V[-'&6XQ<2;)=(90PS# ED82R*
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MI4'=RL3O@S(Q<#&TFDE+5$A5:8P9"J=?*4?"(EY+RGQ.)E9@(%\EUO;<<EH
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M:':AB=(QLQ)(1C@BW$BI!6=,6V\4<"CX2@;!K<LJJ$06A G>N /YS&6FM:Y
MT9Q 2Z#0DEDB3:QL+"'6"'CJP "O^*C:D<O']2<C3-<F+KU^8=H6H-0[_EY)
M 0K %$EI"54.$.?"Z"8OJ"$&VF@HL%VP &7P+;_>]EPVXJ[ :BLH0/&NE.Q
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M\Y%L%3*MGCJWGWELP[YDZ86Z]V<W^@8 RG H)1(D3R (B(TV%0 ,F!W:XP*
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MV.8VFAA!DT9=OV:5 H5*'7)7UV5=$9EN409.3J&BS* #6[?-B=*2=%:0A;-
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M^P2IW":,U6>+O4Y0[M@D>[ GI\[[*2D<Y;[/-EE\LM9S4-Y[$,71@[$9*)M
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MI/'$1^#:E=_8I1B;3$[ MFF! =KU@DG1>VM1Q!G$(YT7V/EY[_9^_@CEN'M
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M?<=4N^MX 2G 8C3E-D?.6$TQL1:M8M:IZ(-7"(_,]%@%><\V*J;@R,1$KG@
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MZ*&O$"QJ\ED,!$,XJ'ORDWFHBE/ &"#&R%!]4[0JL0LVM_8ARO>90QH;0.L
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MX,FI]6E;[(H'@6"=CJ"3PLA0LV?D[+20VYLGXJ%!N%/R.SM14($'5?-C,!Q
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M/,V+'/W QZK(=PUFM^"7DC*6I,G4Q#"@8<XV*'").25M^^ 1GU3Y(:KRGK7
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M=?SHA&^3(H]5D;OWR0B&?4C>-N('[6K.YK(PJ]AF/"OVGE1Y4N53J';NH,I
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M69PDI^]._^_;EZ> .B3_:_+]0GDWJ_ZYA-WYX21LSZ6:JAJDQ6I33G"C;]\
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M]XX.VR]DRBZ#8O )=@B3@E';J>IFX%<:S7%:W2/8@%3@B/"%?RQG47UJ;7'
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MT\/*K1(_8@:\ZFBP#RRW5Y@ZSU(S=!-@-!-Z*5UW!A%--LWR<MZJ.L'_NDH
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M >[<BBZB/^#IH3(?3/[M!DWAM;C#QR.^CEF<]F:>$;G/Q"@G@0/*G$FNL=/
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M(N>JN I.1#0.'>^%W0Y/S$1M_A-- 0MU<B9$7Y/]X(J#$NQG^V![U5BO4Y)
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M0I)F&L,^YRNHK+?8@,TI)'U0&B,.%AP+(7D2K5C Q;-8&9JC,]Q!&1H@.%0
M>;Y[GXHG40?/(X(G(1-0IZ-D7)7)KWKJT 5M:&0+Q,F9[#.UXA!_FQVH[=41
M&3M$>)&"#8Q)+UE<X.SN44S6=^C=8)CT@06+AH>&P).D0(E?P*+YP)_7I]%L
MBV!RHR^IH&93?_;N(?*=L?:N$?\F'&M,\@)EN2# "_"\D )@'9/>CU<W]NKW
M <87+\?C>#-N@IRQG.?UA,&X..W]^//[ES__\.-?__:Z]_+=N]?OWW4G$MF
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M,#IS5CB9I-<8[7;3<"X(RQX>#+>*9#0Y.6-"]W'U#K1#XZC8SURQ?92:"\F
M,P7H]QSZ0 I$8HP2%=//3K$;0D.YE)*O*2WN7.)%1*_SP!SO\N <W%U&I#<R
M!1F,E9O3/#;'SC%??GD,\8XAWJ:/^!2=_18\\4(IPRT#P8TUE'I%*26>6!E<
M0Q7+*TS<G 8MKU]N#LWP*BW#S JNHBV*67>@!#D013BJ^H&KNK/:4<,I(SP
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M] .*STTO_O,6[V0B/[A.MW[Z$/<VY=ZSX[OG<.RU'83BKJY@?V'BWFW'AH?
MY0.%7.Q2"L:+K*VC2W0KZ^]S/JFR7TNWT3'V4YCB\N\OR@H6O_X._]M>U439
M2DHBJ/.0 D,4$XBL?5"Q]/Y.:B'<S9ZH]P:!;IZNW>5E[YJ/?G/5JR\)@+&,
M$909(6T %;U-]2.:UI,:,E'\?TC,V4QK%P/W3Y34*(N<IJC8]L;1WX[0*>"'
MKF]'B!#0&]E<XE#F.$H8XA%&VT'V+KBK-[<3!S) >(V.951^;E;?487.\]=#
M9QJR2\-KC>+O@W%U]3 891\XG&@% HR!S]@ U^LB%BA=_Q=O>J7IK5S<[67E
MX7^VXV#_V2]=X>]XF[]/,BEK=X!#*D**!1>D\)051)D%\V&GXI:7_'R2NGZ'
M#]!0SKK\QK_B$H>\.@@L2A?S<C3*N"PO^%\_W[WEK?V<7WJ9:_)^+M'.F_1R
MYL!7G\)5H2EENI$#:R&S280^I\V.Y%X&..T-"LM,&DO1R.^I<6Y--2J7]:"
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M?KH>Y./:C^C+/A<I#ZNO)JCVTFCXH?1@86+#M]P!H5)0*EG*N J2$$U$AW9
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M(((5.I0UR3N7LL[16[R<WNP/^5[+C9E8Z&5S9";#TPD__Z]7=ZN,\<>K(6[
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M,5$7EW.5@%:$9B7&6=]G!+2@SA8NR")Q5_A(W/(#NU]N+:KQZ/PMU">"O[G
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M!S1HPZUN/<+IC$X1JI,TU$LO!"0?3&+1&L)\3%Q&*_=K]_^MKLQTS#(A3*;
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MY]1^?;AG+>T204P[\56D7ENC&$\@$TH$MRIX(93F*4;SA!44ZYN@)2?;'K&
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M%L 3_JO, 4>T>X S_/""#5 UX<S^H,A:P71"%ABW%BF(PM-4.,'3>J !O/M
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MY[/YP>)<R/15M\YH.+Y.^UN'$C_@YP?C(SJ*\/#6Y3L^!A(M\8)SQIT%.K.
M8,P#JCF'-NZ=\U2TB?4%YGHG1I)*1M*95.1,8'+*FSZ (HL_!0Q8)"5R3"E
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M*B]Z_O<DI.:# DGK7&4%UA<#*!?#8!#\QU'?_?T>[_\WT*:&H3<[?_7L1>P
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MR^0"2M>87$D&F#+]G&XI7_#]NH@;7V4'(S"XGZPL?:[;+8QS@W'VFX?DJRM
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M7%T5@>RXND(\MQ5\"=?2[_<F?^J_#!_ ]EUUBXOO;HW'",@%VG)ZP;>4!CL
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MHV19.1F"Q!QL%^*"D)Z$]>?_X6^/?OZW\_D?>OIY^ \_4[I=(72K7"ZCF*L
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M,1A9'9Q^2B8Z;5Y%=8\%OM9\W]I$)YR"L7=&D3B36AR$-WG;<(<3P)7!(Q%
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ME6WS\:@_N,FR,F%J S,+$0]K4"58V\!KNJ36D"7C=5]]_I0 ]O.KOR5A^"B
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M8(072_JDSQ[^^6.UGHN%];RMU]-2X^H5O4T'@S1\**6VO[RYTPKW(O'TNWR
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M+;]\561&+W[Y[8_B8L8!AS-IF1Y=QZ[]CBJ^ZGC?#0^O=:02>QZ)C19Q9E$
MYD0>:6NY5ER9 YQ7V/*H8G2NQ%T:FQ[KT0VDVV):,6AK.Z"P0#P05N0,,<>
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M.!!L6NVL^I!TH5KY^@/@._AWF7??Q_S6X2I]ZU6&A(SROV4J^#P#__S7#/T
M5=6K<]K9Y+D;*V@88=4HYV+G1\ ?<@0+*NH6AY"GK1W (3R(#EH[!'P8A_ @
M2FCC")3@SUXL,S0?\(<M4+L6[Y6;8J8CC$%"#+HW2:!E;>5K/LQF&!\5+7&D
MI?.FY-:7QLI'CX4L'8'QET%_V!I?L V((N=C F%\ZP_\,/3FV4+L+"EM]T=
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MH](I7\LM9-8X[@_'_?$-M['9T%VO\:ZW=?>S*SE;HYRXR-D1APL;#A9%4?'
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M=W#B.R^VVS2#D,#J/*>8YF&+ACLC%1"GD]4^27KP84",=R5I$P@MLQP#LRA
MBYA*DXRV$#SR"/.)JB2CYIR3;8K7=E/>@;Z@:K/4+;,< [,()H.*P",7&@@/
M3B5!F$'E L08>_ !X\9TF:#'FR*S:*<:DIC0(4!4R@0KN(O2)2/3H]=GSJ"5
MVAQ9&W': 76#LD%X0I.A%'B(-B;+T/M*CDLJV,%S9(9TC6Q39"V1;T/DPG.(
MH#5':@?AHC$@A0Q<>L(\@X,/EJ2LJ^E]4=66R$]MAP?*D%$=I74:G%*0;3N4
MX5;EX:DI..\//GB>HRB7O!7E+95O98W'W.I"<CFZ!HT&N!<IHCB/)@G*8.TT
MSNX[.[I4W5?L<-0),DB< G5Y9+ #IK2.@C%BF*,L2F/6KJ7<[AQ_B9,F/59[
M.FTX9=V)2FW$Y;@.YQ!9-I((<TQZ(T%""-$E:L#$Y)DERBBQ<I;-="EK<VPM
MZYX/ZVYJ@01N(_?<IZB T:B]-%%+[S.B1SC\8&(NN[ ]:L?)DU7+<N?#<C18
M[KU5-D4*Q$6KDV34$4A,N00'3XX#IUU%VH1?RW/GPW/&$.;!H=DH''#KC7*,
M@4@@K5 FK=T9MO.8*3#4<WLO13T1ZCK]Y1\<]>D8ZP'VRV,M/;;TV-+C*5Q8
M2X\M/1[3A;7T>-KT>-2)J"1-<#11=#<"Z.0M"5'0J*,1WA-J'C<1=7=&Y=;H
MW"?ORY[MQC8#C3H)EG\ZEWBV&VNI\PPN\6PWUE+G&5SBV6[LC*GS"'IDC!"@
M@E1,:P)!)Y.2LC'0X$#*2!\9DWJ5 >OG77IZRLN_EU,W)T_'%*%!!.N3 A&8
MMM$+120XPT5:WZ/<=2Y+$]-5]U:-GML%G_CR]T"?FHK$C974HOB42*<D2JNC
M4-0D3YP]-'T:(%TBGQ"XU2DO?P_T*2%PEP>>*0K@.$<%#P8BYRPCQ+N#@Z_1
M+DC59;JET)-8_AXHU 2NK!>",Z+!T5S<+'P$DX0*VHB#=_A!ERO618%^BITA
M&B*#X#6+7@& LE)IFR+:]DX'OCZ"P'9'^8\XB"-[68S[Y^&J/^B/)Z-JQ'T3
MH6\#]&VAW=$4TDD.FD1+.,._<4V-9-(&,$YIH8D_>+TX[0HBNY)MW9EY\I33
M<LWQ<$W0%'5XBIIZ!T1P1X3FV@K+F#7\&$Q.1D47%]9R3<LU1\,U-*8(DM*(
MCP9-@P9*K*#"^22"5(>?>]?51'0E;(UU<?*4TW+-\7 -"51)"!"C=0#46E":
MF8P0XY@,Y/#(&5V@IJM@[[ "6P@>&A20H&@2#B@3VGETNXF.U#,1S2/7;'T8
M3M!!O%NY]73"0VUUYD[)FQ.MP <5B!<@ -4K498PYECTP,G!?3C6Y51VN7E"
M*:26PG<;XD<3$;6?45H >%2 .=HGH^$L(NGK@[?[L2X5HDOIUA#4)T("+87O
M'#DJD)2\$PG_A_:4,\9SY@7GW,< _N!% +++%.L:?E^*H*7PD]K> 2@\,>X,
M\51+RL%ET 0C#:.<,(H.C3HX-IKJ*I,ME</.#SH%XFDW=FH;.^/ZTJ=SB6>[
ML98ZS^ 2SW9C+76>P26>[<;.F#J/('&@.>3,BTL@%5CK=504)$N:1^T97[OT
M>3L/)0,.=])H>-4D#X:#)Y0T..7E?ZNF]-@Q>G6*$DPT7 $')J/6 320@#Y\
M+G=A*V/THG/-1%<P<2"<WA.AE1-?_BF3.G#CDS>>)<Y **TY"X9$020ER4F]
M!JE3JKO2L);4SWCYITSJE#KE#1/!4@Z61NNIIXP*RR%*"6YE4A==#;3+#H:^
M?B*T<N++/V52YS(:)/ H!;/ F#1)H/EB(I',.!_ERJ2NNF@(=;4ANR7U-K%P
M]E[ZV6[LC,,/3^<2SW9C+76>P26>[<9:ZCR#2SS;C9TQ=1Y!8L&FQ"U($0UP
M4%)H&9Q&'SP*;H5;?V;,=E[4:USP*(XG32M"FU0XA>6?LD^N$V7&,L>#H>"\
M=\1ZKW4B3'BB@UK9)\^CC=K0TSDO_Y3)W"4+,8+GD SXI&UB1%BA@#*E)4MK
MD#E(U9+Y&2__E,F<:L--8LRK$"!H:<'( %2)Z"GEB:],YM!5U+1D?L;+/V4R
M-S: 8"G:/'B.FF18U"*19 254IBX,IG++IQF$F%3_#.?F-<D0G0*-"BT^937
MWJ'%1S2:@(_K[;SX; >?8J<_Z/QD^Z/.?]O+:>P,4^=E'/6_5%!=/_>MZU_V
M)_T6K>M\-W9T$8[=9#M9M#0DQJ/UD)2W&K05,@IF>" NK%[#0KMT86KLXRKC
MDR>NL]W8>7*-M$0H[XWS)*&C1EV*4=!@%+/!"4U6+X>1:,(>JNSKY(GK;#=V
MGEQCK4R>2D6YC, D-XJH*#7Z?@P(5:O72U)D&X!#%0:?/'6=[<8V8YL-O13&
MDS/&$"N"A2"]E5$*3IBB/B"!^D,WJ-.NU+Q+.!POT%:PQ/' F:6,@(C:H&#0
M*8C(#;?!KHU$M-V!O9U\CJ/.ZX$?7L5N9Q"?T(B530'L3F2'VV#T;4[=DEK)
M3$S&"P%.($6S$),2RB:I+%L[:;MS)#[:%6)KH.03(8&6R/=#Y!%]'Z<B!^83
M&&\M+E9Z#8(DGX0Y.$@KS6C@3VB41DOD>R!RL-+XE!@3#DT]*YR.QGK"@V36
MZW!P4T]!U_"M88A/A 1:(M^3N>(]>C',<V51?".-!\5=X)(I92F:,(<F<JFZ
M7!P6;6M3\4&$BTF(9 ,%[J3V !$XH)M#+5-K0S)O=XX5GO"LAB]/GEGT?#K/
MZJJ^[W?B YU\3&'.B_<BW[78YX]].)N&; *:J4IQ%@D%T-1%0K1FC"7"/#W\
M' [=5=RT'-=RW/%QW+'G%@)E6FE(*9$$P),1TE"J;>(.D,=7+[:!'!61;6JA
MY=V6=Q\K+VA$)(IIXU$M$^Y<"DE8JJB2RD!8G7>U[#+6\F[+N^?#NYN64%(O
M@XJ2H)D+5$N=%(24'7O-DE=P:$N7=A7PKB'L>).3WK&0F+5>48ZG:+6G,022
MN(3 "$V'!_/KN)B0RCOO1L,O_3'^!-\Q<^,_V#_:&4';,^>)G, ^Y=,)6!#$
M*..L#5&@\1\L6A"6&H$^?A(0O+7K@ Y2V57Z4$;$B9#;\5!;RW"':<CE@OO(
MD,.D1:=;:6*=D#8:T(JO53;>Q?/N,FB;<EN&:QGN?H:+0O&$YBB7+(%T0@L9
ME>$LR4"=3ZO7SHJN8:H+ EJ&:QFN9;C[NS=%<$Y;X_,P77#,Y#IUL)JYH"0U
MZR">&H+_KW>LX8XZX^VHI<1K[K4DH!EQWJN8)#!(U 2_=L',=M>]/__XY.-:
M;<SO?&)^EN 3I%81(@4+*+!RU0GAVJO$'3GXQ#RV?;'QR=-4RV_GPV\.9& *
MT!!G$BAX9[DAFDKD/,Z%/O@,UI;?6GX[)W[CUC.94B#4 RCF#&&*&TVB2<1+
MN?9TI=WGM#3=NM/@Y*FJY;CSX;A$1:!*6Z&#!B>=4\$8EB@-)!GJ#M_W(.Z;
M+WX$^6,T!')', BA"5C'36!XDHX:#8RAS'I<'_B7..F4'')_X"^GH3_XU/EE
M.,C[& TO+_,_FXKP-F?\5*)WIQJ:4XR:Y*.EPB&/6:L3,>C[!NU#ML17QP_,
MV5[5);S-]K:L<IZLPE*RP!)H8B4D:BV+.@9&O'+"A;ANGA9=VY956E8Y2U;Q
M&6;9*9)RHB*B5QD)DTI*%A58)58?7)HSK*;+6@#FEE7.E%6"MAD +ZD4!&@1
MK!",A A!*<+!KUZPGW.C\D;3V_GG1I5EQ$27$B@/5EHG$N7.2R&]D48<RB_\
M]W_3C-*_[LLK//G8S18]^2>_]VT "4ZZ,\FPY&6@T8!$02>M,9;P2!PXI9*-
MJ\\=:4$^6\9K&6]UQA/4,,D]\02-<4*98=X(P:F6'(T.@#48K\6D;AFO9;R5
M9[/$Z$ ZJ[TV8%*P*CGCT/VUP1'&_!H!(RD/%2PZ>?([!NIK6>^Q U"&)^("
MB98D(%IH[5.4AGO'%$-O>XVQ2%(>JT>]N=\<0D!/.09@3D(*T3!!J2)!,!>!
MQ+7+&W?L-]O)9-1WTTD,G<FP(TGG9?PTBOBU=Y_MZ JW-2V',>[F N2+-LFZ
MO-X!RD?"<.HNX]Z0[J@!:ZRB!+P#Q9,QW"+O&9TRUIURCTM)?UJ5%M:O'EGO
M-(]=/DHODN/<N) 2"$VTT11E@ 2*UPAQ]:ACU>3+6=L"=9+,*ZT)^='> )'1
M>B^82HF'X$6$M3'<6N9]%.9-PBA.J;!1 1C-'$1C@D75&:Q3?/5V*M:EPG25
M/M3TCY9YMV!>+J+Q5 O%J(*,S98(=5KZJ(D4QNB6>8^2>=%_$M(Y;C)NK<[)
M/\*CI[G97[.,)K1.:EQV\:9;YCT]YJ6<"X<.%Z"F!1*,#BXE20U+1A#I2,N\
M1\F\#*UDQ:3407N0@CBK*3#&F7<N<+5Z#BLGZUF7J'V,HOW+Q W#U_RGQ4-O
M+G3#H_W?Z7C23U_7Y=]E_+F7%?SXX7/$WUQ>#G_/*?:RY<XX3L:Y/WGRN3.<
MCCJC.)Y>XD^&J3.< WY9_%\'_^F15^VG,H9V%+_$P33^L/]5WSV=)8*D$)UG
M(:A(T4M3/*#59S-<VH(\Z4\NXP__\?K#JS<=UNWP@D$.'S^4$$YU&CY>7N)[
M/)[/W[XCWY5_7]L0FG_?8O$%'O=XKO9Z'']H_I*?61'7&O$K>J'U:2L1<O'-
M(-QQ[@#O+/_P;]_![(I7" 77A-$K(O4'?B'SHIL?7L8T^]F.%2*3B5.BM!8Z
M@.-@J 1-O0"IB!'K(P0NL&)F\/S&A]7#[Q4I.USBPR?_TW#4F:#P^?!Y%&/G
M#7[Z\[CS:A!BZ+R/UY-XY>*HPTEW5=UZ(> Q:.SN1O?)-TIND8$X4]8J7"0N
ME-@#&PF>'0KOE7 !M+.6@G7) O*0 Z/7#L<^'AO]TA^T7+11?JC6KP<8Y>0B
MYS1$=%PB&)!.>2JBT<PDP#_V,(ME+<IZ@59>WK_->:3W$_SC"G=4S, %W->7
M=F)_6)&Z'LL.>$P9;2Z47MNK>PSJ<LI8"SQ%ZCQ0&AT0*-A'3GAO^!&*,D:8
M>$)RZMO:_AP;$8Z65[1Q/&E'(C,&N!%6<)V2"89ZKW521\DK]PU3;GGE_'CE
M$7E!N9P5<RQ0G4M_DE.!LF@EM9'[J+893-7JC987SDIO$"(D<]HY0 M><NFT
M44X(@<K#><6W@;EK>>7PON!ZO+2/!CVJO1*1>",< V6-D]SX))2W29OD'[E!
M[]UH&*9^TOFUBO//"PX'<9+=PI?]L<?=HX^8H^B_1H<^XZJXIM_R#4^]CGA%
M^?5X5.4<5Y(Z(8V%:)AVTKJD/$0FJ$^'G\A#R 59&3!PJ9C"Y>X%A<HQ$AT3
M-G<;>PJ66A3_VBIAP(CUXX/;G=.?5^:MS2V$EO=VW'*ME8FY@ 62!A70R60"
M_TI0I#MEV<%QS'; >_L[/$V "YD\)QZ ,J9M,%H'S1F75M-'+OMHV>_TV$]:
MAFXLE3Q1"[GT/EHBC)$!'\SX^FCP3XK]2!)<)*91=AG@@6L+B5)4>TEJKL4C
M#X]OV>_TV ]\2"PY)Q15(&E /2B#L"%XPY0EA\?-/6;VDX(2C<X@X2Z BD);
MABJ0.<6-4HD^\B2+^]AO0Y=[QY&9W$'E->%(6PZ 6^><<HXP-!J28G'MB/YV
M9_5B."X.<N,X'UF^] RCV$0G&I*BW'$*)!&'WAJE+AI)!6&2'ES0,':AU9%%
MXMI*IM,D=B1JB\0N# T"6+2:,*VLS?J")1T/;M1J=B&.+>K<TOIITGJ0$$U(
M- EK0$?KHA<$?X:TCO2_?L_EKFG=P 5M:;VE]9VT*)*4J# QD*3!,6L8$&TC
MDX0#@?5;%'<^\P!M&'VVM+Y+1V8OOK3PWLIHB P&F/?X'R6L=!Q$Q@EDC^OB
M_&.4$4B>91R2[SOO1L/47Q6GL\W\G2& $ \1_2[#" %TOU/2*2B>*""1&N>#
M7+W'_H:?M)\6W4WC."= @&WP\WB"GX8F*Z4C7%/4WHE:KV62C'GCD4>(/+0Z
MI^H"=F&ZGCK=M#QS/#RC0%IB%;<![9M C"&")$^8L2H0T <O51$7NF69EF6.
MBF6,XMI9+H$[,(0[KQ)3GL?@(PUB[2*)G<^"51<+".1/AV>.(S$62?#),&H\
M4P#4:A2DS+#@A )N^"-[C;_&<;0C_[G-C#U> #6FH(4*/@_2I)$:(R QXBP5
M&H0]_&AVU"7F;(-*;0#U,6G=)VJ"EIQ'ARY6)"99QW3&:=0&U>+!5:&Y@#8'
MW)+Z3G+ E*$*3RX ) A&6\JM,3*7YY'<TGIH4A?B0AY;QVI+ZZ=)ZUH2#1XI
M7D4&"24\8> ]&"1Y&SP<W(1!FU[OHHCP.,G@V/-B*B;EI522 @,(43L=)=H!
M/BDE>7AD5.8,SE]GQ6H?ITV+[;NA]Z0S9U;0$!6(Z'D"HYBE7B8O4;!QCE*/
MKIXYNR#[QK8]H^C,AA'-@Y/H$^3@34O"59 2&.6)4@C$NL2,I81GV& ;TL&=
M028OS%.,B[:<=^Z<%Y#3HG21>E1L&6$_QR"#"$Y;8I0_N&\JZ07L(N1XZJ35
M<MZY<1X5R1@=B.)$@,Y0@(;3Q)1S+,EP^#88KI^FSMMQ+O (=WCN&;N]XFRM
MR69['/]Q<M&I%AVMI<M3N+66+ENZ/,9;:^FRI<MCN+5CSS)I'Y@E3J<("O!9
M3D0/C)D08B3!/3(63@W(/_C4>?7'=1R,XW@7F/RGYE7=P^E'E2,Z#(^?^DW6
M6NDL]]92Z;G<9$NE+94>_TVV5-I2Z?'=Y'%TQW!.) ,?K+8 B6C#6<PC0]&X
MMX2(1X;8FW7'9#CUE_%+O!Q>YQE<3ZU)9M>7'%*"!$1ZSD$K8SQ5C'(9HW4@
MUT<1WGGYJ!87Y,EA")WP#O9#I@0(B21$B$F#8<H0R3W7-$;E?.+QT&0J#5QH
MWI+IR>Q@3V3JB9,H3%G6G$PK[1A+'#@*5)FGIAZ:3!G1%^;)-12>\ [V0Z;
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M:HKG@7(3HC=:*&#2:1^4\2ZJ) ($:E:F>(T2WNB6WEMZ/VIZ%SH2;9QBFG.
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MD@A"(7H/7O&GHW<'7$-)1:"<)31>H"77W)&H'=7 J+6LL^UZ:+WCA W1)CQ
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MJ'($')6H]"%8QY1L?^& T8M#-TGM.%^]FX\+G" L<F6==!BB"N,9 6I5S@.
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M;W5*)R)8M$:EF# @B@YD8"Q?ZM!H^?P!\L9.3?F;,!>#NY:Q55WBS"]R;)O
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MK<SNFKQ2ME L%C1!@5I6..')#O%ZTVOPIM$BO!CN7F4%MK"<%,9"857(*]T
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M0N0ZY)G<),ZB"U19:4!X+N\ALZP=4G?6];Y1S5-*DQJK7)NEK>_+B8^CF!.
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MB.1'Q7ZL&^5O:T3+,#1145@'%0L0$%U(UH0T<0VWNK\#H0*S[GT-%HG>B4C
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M2 'ELYC1Q=:I\'Y\5%L\_G;)[U"H:HY;']#)!D92',K1#A,;EY3WO"@"+XK
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M[4E2/U)^+-(HYHGCQXI[7N:G0<" @<JU.>7C4[ ; P6[+Q3\[% K5)%D(@U
M;W9X NB4")$Y0:  N=+,%3M'+>8>.?%6\6K9;*>3/],H\5SE1JZB]BXLR91D
M@1\$D0P2X4>[!LZ=U:)OS"BH-S1FJOY\>T0T1"3+0/OIMS]3!BI? ,!-,D_Y
MRN/R09K(ZIV%[RQXX'.[?_M_+LL^CEEZ!)=&H@Y1S^-7^Y'>.'RQ5%>6\\M/
M;YJ[ZOP7(96.157]^T_G*L5@^)]>].CBD_[>CJ9'9PGUMLTGUGU-IPYU@C!Z
ME6BDZ,P HF@ (1I 6#>B6F6F;>QE212K-).QQWP6QT,#ZU=Z(TT*M=:?(7M7
M[Z)U)F^&GN])UP\C-PB\+/.! ]XS)Y8[3S@G%JYCS7'#4>IPX;)4N ZP;Y$(
M9^! JUW-I\VNYJZ>-FL-G_>]5$0N\Y- LD0E,AA LKGAH<$3#B/^."MI_OC]
M5)4;;ZZTKLL<J!@V4P^7OQ<,2:1LARD[3)@=9+$=P!87P?";F,ACZ_3[M9I4
MZL\O@*UR;4A<@JA6Y>"E7:@)'&M,KF<AK_))7DU+/7U>Z7=6EIBN@)X\2VPO
M]>P(!_5RQQ9>DMYWFHUF"?-1Y/BC@#]T(K;D@HM0^;Y(O-"1'.<"W,,?V)/Q
MAU7&(CLAMYU$V7[FVYD;VH'#!AA"'^(;#:OU1IS%H[!3;;\9Q,'L\STL#Q4"
M_@U]*0<P9([LMS+!?G@6,O%D896JFHTIT4^3C56)L:K@0TF*>44<8(($7UP5
ME/.7%E5O5#< I)A-@2^DEPT1T>(RK])9A=Q"),4W-:+OF+? :Y4H4QT$DNJ;
M&A?7-,]7KY[1HB5H:8FJ\J+**VM:YDBXJQ"GPT([<0);Q ZP'-].).>+H/]U
M?FUZ]694RD8,1(4;#L\X7AUG(C?V(NEG(@M 8BA/JH&-]ZET*V/K-Z92X6:V
MX_DV#Y2=\,1VPB&^N 3T&Y%KQ(.1YP[5LJX#>.5$@L72CQ+I.BS-E'O_@._H
M"0>7;U^OWL7 Z 'SIIG8D=R:.1[YY+5U7Y>@@S=VKCM@R1M@K&_P!$Z:"B7#
MQ&5)RE46N ,,9N6W;LHLY]O9;$:SGI,)F2@A8Q:EL?0B9V"4=Y]9>KLS>18T
M[,%K!#F\PBT"=PIDEC+IN$(X"0^]!]WB1GSWKI8L:RFF21#C&63(>!J*0, E
MW<=YXR>TCMZO+D-"$?LQ"[/($2+*'!:Q^_"1/R$^WBC0NE(%M@YI<ZE2<D5\
M8T%HAXYOJS0&P9[9$FY]Z([,FAFHBLBQK3_$=%,.$3H16-_.,&[A^E=B.BL;
MFDE!5Q5 4]5E4<*&5'EE,!UU2K1;Z8D\RU,QU=^0ZAKTC^DJ.DW(A>W[TL[B
MT,ZD:PL_&E0.AHZ_$6DM.?;JOB#7CP68>$F0.FZ89#P2]Y&4MQ5GT!)EQOH"
MQZA9DP8:<$D+6.44E,'Q+=Q/5@'W GZ5BFN2N?]"I!73UD)8#7$YMUVI;"^0
M=API._55/  )O>[)YNJ_ZXRB8-A"1_LFR[^C$53AF:YG8/6(:F56[W);R-!V
ML\R.@/08\X?8XZ=3ZU.]\&9'")SE]+8RXF5! @S<#3RP8 +N9-$0+^]S0'^O
MS!<>1K;TI)VZ@#!@OLA,#!GM7839B,)Y# @S;"PBPJS DWRPLY+0YL";W-2S
MF>LE]^'%9F+>\49A^&#SR@TX"\,H<8 796[*W'M](=Y6W$^#'&F$[HAKC.)\
M4^-;X$_'4N;HZT!F1(*SRX;&J@)U6R4@/=02U\6*#J) NBI*TBP5,O!9YL4#
M8J5/+5MQ"P]3RTJ>%C B[)1YMN#29GYL^RF/!LX@KJU_JN2=^O80)@M*0;0Y
M8:?*CC(.=)+8D0CL*(Z'C(7.-<.&'T+A:.&$@]C60Z;5L27-A,!)&4[B"T>*
M-.1#!-\GH:WXAH:%.HJW(LV!,TKK)I]>PK<OQ2156@$#^P=/F<TFJ::K?(I2
MGGQ\:5%>%R5\L2:J']/9<5_SK&<-B&%'1M8<>7U'AA>"C$Z8D)'/8U#K CE
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MZ7S8X\6MB,L$\ 6M1=0&BWZ%>;)V3M$;=9V5>8#$-E;OM$MKEQ=&YU!XD#Y
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M"HILP9K%E7ICF-9K*N=N=+H^6Y6#9R/E##Y=(4D\E,))8B>-O<"/?4>$0]U
M3*)[G2/NK=_49-4:G^'SZ%!R-9U+I6T"(9T,*G(>H<M(&)V6/%5VXSUI['2=
MA5&[DC <V4O%6)!>=*T-YAT.8W_[]5I':S#+@N@.K=(:M.2)E"HATV)!?B^D
M)YHGM"UF/%U:],/=2ZFS'YH779M4_TIG^B=Y-BM3[5C!G GMOC-I!A1?'L".
M6^M5ZRK4BT]S5()HTYU2V^IUHZ.4LJN.U(9CC_+G(E[MKK'ST!AM$JNI-D&G
M#[QL&?+J -QL(JZ0A_S+/$T9XI0$H3]O=2=!24H7Y%HK+3"624NB[\"=&D:/
MT!]AZ@CPH /"12VJZ-S-_2ZHL8E"]MB-_P/P^K)C7IR"K*D3%LR#K0J\J*=V
M$+Q)/)E[ :FJ!P/WM92[CUEF_RK&Y$<XOU2 J\<=_GLP,'G[3M=-4.TW4JCI
M90!,(9?D,R$';9/9A0+\,K\V>I_.IL.I5,0?BO)" ''7(:&RH\Y@?C#P+_KN
MR"1Q5>@EF*6H.4KS*"D89)3@=V;E-95E8,9XK@Q=W%#Q1ELY-92I57\3*VE$
MB@2F'<$%7&IB+K6B2^T*57RW5DTZSGG@MQ-XJ+C1Y'J5XT'-^@<D']>BC7]\
M_/4<:VJZL:?3L78)' Q$WIY-K./K,A\#23!7.Q>;@V,S*#7!""1HWL898C$G
M?)6\KMEK\ZSI(E-[)R9U)BX@'>[N F.>-R;I NBL3L?%9+<I)L0+^0T$NXEB
MZGC-5!=24OZ;]B(: [_I6$/]2?2VPE?B]2OW]:M?FZV=MV$BW&!6Z&"N#K,3
M84_4C=:0ON7D!VSOF7(B=!;)E\L9B75KR4GH"!*XAG9B"VE4H4Z%]]#"C?\4
M*;C]K:9[HL\;#-%17H!.B],=6YI0,2G'Q"#4V 2V"DM\$[!H,2LK14'_.BM
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MAM!%"[<F1[WM&"HPK?WG72"'CJ*E:CR&WV$OBW__R?F)?KX64M8_]P(5&*>
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MYO.Z KXYM_N@<\LXL_W8MT,5PY^AK3Q/W7]N]VG/K8MXL%3:X.WU6.C&!*#
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MNC]PC<Z?2E5AWV'=6_;D,E<9H#W0#)6E?-2E2?APX%CO- U;GRY%>07*WHP
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M9=?!4Q3\8MT'\*\06%WD >OB\NSB[.]GIQ^ <W'Q[FQV^<Z]<$[?3W^QOH
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MVA8D\AW>D8($TY":OM/AOQ$?7R*&YX7IFO#X#HU%;/&RKU05HDV]*R])V_Y
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MJ)!Q\,HBW02;'7$:TN>JODS0*)1H6"!A":?!I*YS%V"I</-JE4I#A8L<I3"
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MTRPKE-!4+P! TJF +RAB*F@(08VZO8H38.DS+_+R71BR(%> $*,4 $>U4KZ
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MJV"D2I8:^OB<&"8BVB90V+3N0@6@FS98A'4[$$5$=9"%^?!HJG$X;1H;@3*
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MF4852C;0!BII=ST ZUG<17L5X+5SAJKP\PJ 'U&"TB F>E7OU#TB" 25RC9
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M!)!^[%SDB_%0%5IN>-<4)*Q7IZ1GC<9DY9@&FWQ-N$GR3\J+<+'.*C) JFI
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MXN[2J!VVZ35\4-N"2L>O4UF$98X%HH;JJ+/.;@*W#H5=!$8=+HZ(+LU@>->
MSTZ*3J=RVTDC03K 4U*)RJZ WP"%-83IU7\'B#J5TZ),ND1GC13M:*K"1S1-
M-GB/Z /E1#L4W2?C(DU1LGE>IP&9638E#)*P_"TN)YKS%%4ZBL0OY$"Y7V8-
MR/?%S,6A8:5A-890SW))AYK)<_7.0VV1XFV47_./-=H$#4A7"5R$(5<!#>@P
MZI)V]W#'POP :P+SJ_2 ZZ.C7HGQI#E[T^QP8KYZB*-\B8LDI"$E+Z W<@?
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M#Z+@T[B=-B#3ZWC2@$"TY)0!+L=H\13ZM7SB&?/R)B-:7WAXL@"/MG.N@!8
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MJ267*7F.UWC]\>6GPM%/DXLGG$;T>(CE*H^?"R?&(L>Q%U!]01L!3DYF;S%
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M>1Q!V/69UA5\K6\:6[A<E7?I%C##\7-TNQDZGPF+,'WQ6("#@=@J*19_*(-
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MPBTJ.IA2>;P^+A5^+Q&D]/^0L#WQ+2HJS9#05MRBTG#NT2TJ$[N$:0=O(J>
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MA9"WH4]CRL7=$7E\PDG&=B-<X4U$SZ<E65[NN?H897A]&;VP7"$<_<!(JP=
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M!Y?%?(%?IZXV"_Q]9T(B,_73-M^F>/E([VW^)]L)49V,KY4B(44/<B>,:)#
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M'7;H$149&'Y""(UPZ#&I-!CB)Z#%;1]QLGIXC%+>Q3RZY.)E;@-RZ+5N7&O
M%[P-M1BM>NLS\U;Y-!1!3,!IM[EL$9P,)4V70\$F70XGQY4G7ZIMTEL8)R 7
M^M*0'-B7^-9 ^])(BXDO#9@5OA3$%*!VJTN\28H3L3?UV63>I$#6+-Y4[1;,
MKO *Q\]TAR"W^Z\BJ[Z*F,S):U3: ;K\$A5B5Q$R+>HGJ'T42"]?V9)$]ZL/
M/$%$WGK S.B ZM%+Y9N#@_;D]QD>PNZ[/4"\'0\6;7!&-Q8F6WR.<WYA1$;3
MN3>00^-\5:!0+T0-1"!??BO@F&-1_=+M(@2!='G#$:WOS+GR;T3;O^5O%AB
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M U0P,5'GCN?#NA>"REZ(,-(&UBV9!INBRLMDV/14E>F8-QQY*GH^4O)QET=
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M%R21TG=(+;U:;A#=;H;@4!-6;R0C= *FV@* 9"-5(D:KA*T3GJJXA'#[V"^
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M_GT*&B] :N7ZP5+%6@U.>8LE?\S7%BY)D?+5SSE,O_0J(U9?6$"NE+9%L!T
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M&"MDPP!YR-P,9;%-"^;J#6*O$'\W#SBKM#< M%[-(J0%ZB&H37@(#NO*JLS
MEM!)H=VC P2W1#XDO/OL;0'>;36 >.VV9P=RF285,%<K70[T#KT*ZCI\! #[
M648[_/P%WZ5L+2,K/R</(MIT)/6OE9-XH5LGU0_8"LYJ3$L;+*NGJ'V,V/.X
M0-:JBMA\6@&^,M(6N59J#P;:4VHS>;(]SS;XV__%8I$G+4T/M@,: -PJY$(
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M(NM[O-WJYI0R@GY<W2. "*LE$D&BZCY?8U#=)=_'U.SAG":'4O6($;5:A4)
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MYYXOV@=^S"O1?S/.B#%D52?V+%'+,_+$=C(#(U.#>% 3(ZS8;G&-%^U$X,K
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M+!*H&G07"ZPQ$\ &ONRV^,<?;O[U1RIXM2&/-*3[N$WN!! :J)JB3BHJO]I
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M18]C7X/@@ LR1F^#2Q+,3;N7)LP"@U!.U5J6'P3Y3<H-_(:@ZU(?*_HTEW1
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MGO/_,?*<'PY'FCK+ODCRC@JUS)TB.?7<TRAC)(Q.6A@M$*<0T?3Y>)R1,I(
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MB),6Q&S,R6L0U_OL7#GS&7XF K2^NEM 2,-43;.4!9T9[2@:!M"]RZ#J8$J
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M +6NS3GH=631&1?H.GZBV6#UI.);)(M :LR-G@9E=C-A:>17*\Q;P)RMZ0N
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M -783V3I%[Z?<[),/%6!XEW>8Q,UX-@D"@QV0AN-X-64#(#1Q]!@U$Z @05
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MW (5 I#[LQ_3V\,-8=(-*T7*;W%QJE,^.M<IGZ6C>IURP S8OO3J)-FF]$"
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M"4&+>C:$X^!$9D[GB#XJBBR^WQ?T:<TE5IHU:,MI8$]#3D@0-763/I(U-$,
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M9 #6SQV>HC@YC"OC<R6=+4Z(>?E%E,<K#J@UI0@/EP!20H*WF8ML'2P!]$*
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M/MJS0=5)I9(A;Z?;G2VGB7S"RRN:4N#=CRW%^;I,IPO >A# ;9REET*;@)V
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M4$<B7=-#E+*H$0>*JNS-2E=@]I!@JND4?=#"%0XQF^@:'\KZ4D>)2[,)*!O
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M3(J\01:\8UHJO-X#X(" SWF*+AQ0,O2IW)_A:I/"+Z247 4 'HT4EKUCTC1
MUJ#Q$U;\0G<B$U6@U"YQUY \Q-NP3$^T5C^0.-9>,@%"V;5'J9<6!E.>#^R/
MJ-=**9DAE;[3/KP^S(^G*9D-[\N#KEFQ1=ER&Z7';>I;G#Y57I6VG46AJ]]6
M;H6Z?C^[G/R<Q<'74>G!_#.6?AK>Q3CU6)X&WQ515K@^F^W6B8U]W?(TG!9&
MNHKB[-<HV6LG<O38M/XC"J!I[\'&QC<-(0X!;.IBSC+T$*5^RFX]4;3+-O86
MM+3:^!Z]K'YEC\.8EG'OB>LJ+JZG&/8>I-CJ>XL_3?7OH07Z;3R.&LUVO\EL
M>4O>\V\)IMD^1R'E?3'6Y]<-)BC969;UG<_/R]3IS&F 2=]UO$&_H2@[.!@U
M9S#^-K"6;^17 P.*2#ZZSTY(\M&R<.X)=+BU=KSF?TKY.EW#ZCGR2)O13WP1
M-.,]BJA^*U]CA:#]7=0@"BTBB.YE.HH.2DUR,A/A->D]:IA\0U\C"- 60#3Q
MY!J/'Q,S/Z*+6A/]6_>\1Y^.OG$@T0AJ&R Z6;CQ-91]Y"N<;5!,O.SL;(G;
M@M[V@ADM""C"N/]"'N_G,IH.B \_O\>'A@/WY!/[=\BDT[B^HPJP<>\!Q\YW
M]3\6 :V"Y/OU?7?&ZU76:ZCW=Y75:J)_JZQ*$P,*27XZ<'"KK(IMD/#4]QL*
M'APR/<:9^R.F6B-<'3 =&_$>1-2^DZ]A@MMZ2"#H.Y'7]3REL7'N("@H-,B'
M<Z7W8&'\_7P-'"!+($&D[^1?UT%$LM_M/JBH--"_A<Y[T.G@^P82A&"608)2
MF+6ZNYDA^E4KXO>/[]4BO-K4E7T?CW=N=>I%?%1.L3W<QIZDZV&'!_^.D>!-
M<QE4W@^1>ONJ(80B2T=(RFF_%J)4[RLKC0OJ'_M=6IFTL)^UE5X+ XI(7OHO
MB-65GFF0Z#3X-.+C=ABC)GC_BON)(S7%[^%!_CU\[?6U%D,Z<]]9MRX[L^HB
MQ\.6]1X.AK7 \<IOH0442XN;OO-X748<\UIW0;2U]Z@T]-IWGGLRM,C562T\
M"[F^GKQ2I?\&E?'V]N%+<EZD$A,U-GR;1!9'"_I:V18GY+/G!RU'A[%>CE+@
MJ$5."8?S^,7Y!EC'8D[4J*LX1PF)Z(&]B$*?TXO7<92]T ?R9IO2?,%;4%+Z
MYL$(G][Q V4P"&%UTYEOD@FUU8X.^%J&!KVS?;?1COQQ24;BG/1%8I_P42@X
M8Q., $;GH4\.,VS@"L&KFDRE-6@"E T,HS,R=QLE"2[HO.\PVQ,^'B6E;R!2
M0.\>B'!L874/\( H55I%I$#9$)^>FLYG0O2U?F^@K?)[H.CB66@%317A7;RV
M0+!ZC]TF_Q$'E2O=XXI9.MF3T3?'5SY]<),]H.F&DSV^EH&]458U$/+B)X.0
M_3I>C=!]5)/"IOT@'M]47E3C*6&\@5<3/K#)V1W*8I2/YJ?VEK8*!T@ 1S.D
MB3B<PTV (*QCM7B#M:*F%L1$XJU"[N<#Y%)D\%P1;]?M8,0M3G_%Q6&3EHS7
M14P"-@!?)B)J^W*J(CQ'H 6_*$%23U\70ZWKI<(8[W8XE4=$+EUSM&W3>8X]
MJ(5:,8\AM(L'C=PO&2J=!PXI.4L+72*68( &MEL3<R+Y73R?XW!NMT )F>2N
MYU%6O%06[8+%*H"C@3HA1V@+5KCY9DM6H9XN8J!_(!2N7T$\,"!ZLZJ%8$L.
M194EKD C (Q^KG<Y*X\O49)$J^T%*K;CZ#$NHN3Z>LQ?90#(JRL*(;FOP.(L
M)."FJZ&JL7X0JO'P6(&#JV6&GH@E+T(T<8FJ&&(0!88<F9E&>&$([W^#E@."
M7\9?2%._9C03;92NQUB(!CEU%18BZL#P 3;<""@B+0.=*N47+]5?U*?O @&P
M2113P$ F]W+G=#+79ZH=\/H3/-\'3_)]G]F+@,6!I879/4,K#XV]S_ =?YL^
M9L2!3X/M94<<@B*])(!3FNX/R9 0\?"R)-@\H8U-*BZPE"W!UM3%4[P.1Z"&
MD<)!2$C+O+G0HG4>[F XPFI&RS(H6+JJD./H&/*P(W:K^<$:4[[YV9JRO]V?
MK967R^BU5L$ PZ1I].@&36@#B,A$LP&C(;F+=Y$=#A"OU@F'!@X5#T+># =L
M5+!@HQ+X:U*94 GJ[. _HW0?92_DAW^=;4A#XO2!O[LG):YN[@F(_8$&9U4$
M-52&D<:"2"#6P^40#S'[A%KP5P!<A)0UK' H_0<*Q$15E'!D^I!5QL'$J%AN
MT4V4_8$*^N.(WN.FDV,^-F <58S(.+S'BI+)BIB1R=8]#W"]H\(LS""8[$KI
MV5< 6/2A38*AIIM-B 5: $.8<JU0]_=-ZI9"+IZ(."#P\V8"+4>4#'XJ$VNN
M-BG\@IIPSY-H58;FT0/YS^DQ)/Y ":&O#I-B>C\QQ1DP%4Q7P51CZ!1K\7!>
M;AS9CC8*4["9-(WHU: )!5L0$_7PQ)'LY55@7GC*T-6>UF@2@01 60M)',I0
M  ,WUR0,<>1WD1#=T<; 87=C^14OMWB?1^EZ^94XX^4*[[.F=8(!ST ,8_M)
M34Q0B#1WE %<M91WD>'3/Y:ED5&9&8K;D..GKE,ZPJAZE.W[H2XQ,A?H_+V?
M$#BJ0M@8:!2SA8A#!4>8(U"LK(M#Q8[*$!_N1<O1)B1D7%</&E$08PTPQ!&O
MNZ/6)3(NH,C@$+:1T2(,$!EB8XV1T1)_1(8O+Y^@QZ)L&',8!FZ":0NI(TI9
M2&!H,W.2$1*551]1ZLN3'H<@.TK7BI%,RL(8[?@L@>%-Q0'F(R!?T1%+GCS6
M0,_OV_V 3/Q4-D$T9323*M1D! 4_0Q>9S.J5-3.W?#W*YV%:,YJED(6E.CL(
MI"SV8>!3ZI@NH,E2RD2E)QE%?$/(OYJ@DLL.0R6#?2"HE#FF$U0RE#)1V>-%
M9N517?% WT@0;'P?3@J #6=U,M(+U3,AW/?)!CM-(,^*2HH ^=LY/8#\Y?<%
M?<F(D5_'_.T$QOIOH>3-B4S2RY%K2 3LZRKOT=C.AX/ @1W*V+\V(>$\Z+"_
M,I89T 1 54KM4W>9)]3SQ[Z)GN/=?L?]W,S?*Q^\\;O[3]YH*9:;P?OL!^+3
MAV](".'3J^>]EN'NNOG>GZ#4>HM64&V]0AO*<*%BLI44ZZ8& ,R4-U-=PNQ\
M1[=\,S$?[8LML>B?Y^<!^86&>1S\DL-M#E_FP1PDL:])2PP73W7KFC@7IML:
MAGEUNF+R/,IF67FA?UT^#3Q'6>D%.0YEG'P\\CF#Q"70$1;PR=?D99JM,4[G
MM8+SP% )8VJ@4\84#C"5S-?%I$S),*NYUZU6C)QJS$)X#B%^:KG##ER-HJCR
M3I9[V$Z>5RC/54(H@*-9%DG$$0XJX8;K0E&HP<-,7/MKG6F>[^'KG#JU;(US
MH@X'<3"#K:UM3M(]S+NUC[39OLB+*%W'Z0,4;@P6&>9J+ $#CV^Z-?355'1Q
M9=[]8,N:&0LCGIP!L%0)+^Z!S;:Y1%&(?LJG4WY"3QX"@5P $ 8:"-4<8!..
MJN%0>8O;/2;;._\+]$3G"0<W/"9QP<&E F>K0C" ,QQ\JCM"%Z,@30"<]IV+
M;(Y2VATOHARM:6%5E.9'(&3T_)-FNER\G$GFT4N9_$*K4=WNZ3'H;#-:K^.#
M1X K[!XT-GM%EQH#ZDV].5Z[%W;90L@Y07 U7>ZB!!T].L_BE6PG5D;>[#A<
M\H!0#S-9&[)<\1"\A?<Z,"M[\M3[[M!J3TR,43Z.D@2M+UY.&9)'0J7R?>I2
M(5765*2& W*[#M3>]#!M!:3+!%?+\F3F*%T?[*RL?98HVW'Z!)2-79Q+P!8.
MJA5=H M;N1H(+@,\'1,9KH%*#40.!8T](!&&PI#>J6$.%Y-GE*WB')63J=<?
M7\>(CRHS"*@LR+Q!+BL<)-MPEM4Y@EPW!/O*IW;N(_ \PRN$UOD5^9!TASY*
MJ?W$#4]1<;YLQ-V^5F%N[6+#F,-!M98[]/>T8<H@N WPJ*^RZGV=WU>.F:9I
MY7%&^58$6 1_>P(@(APD&[C&PC8&0"4$U9[4(?J<QL71B,L]?59CCDAKUP?C
M;M'7\J?6M4=USNH-72BG_XC4=X0J$)4T0?#7=X6A;J;#@#P>(!MDDAOHRDS1
M!5:GKLHKM.!."*M3G4MT7]RB8K8YS7G&..?NZL(9!7-3'F,XZ%1V@XTY*4\1
MY'9"<(=@-</C)Y031^XS,I^YV.?$47E.!P_BBW&4;P^_"U+2]$6)4 P6%2BN
M]5QE!>E@U1#L*Q_(62\X,RNV=/9]> -N\DQ/P5$^C^(F8F'$U6FI@-A_U"F9
MJS7Y% B'(,>3UQB.Z76O>V@LU/!H:C4K6S2!8$1BG!8TVC(AB/"C\H]JQB)O
M^55V#U'"(HB1E:\H8?0?=]IN,,I6E"B"(#2X&U7'#E@[+YBFJPQ%.2_E"<+"
M/K'DL(2#1P73#4\L.2H@&/3DC8/#KB?>U VJ5H.ICJ!RZNI8*J+V'TUJ!FN-
MKR+I$ QY\AI"?>><CYLF11LK9XJ@\,$QS  39XD0'/1]YF \GI5C-<UUSM"6
MK#?(4I4$3[Q#USC/Z>+U*L%??T'K!_0IBE/ZCZ,-:?("K:CKXDV\.B A72^C
M9\[XUX6*QGAI5X7_B._!M;KCL=TF0?I<<.<L]>MHE_%3O$;I>D'/[<FP0YW^
M "MD(F85WAKDL8:#?0U7V+D_R%,%P6IP9R\G8_.Z#SCPE% W$,FE#@>$,(-U
M<<>5#JF5$]PA2J5BP1BG3R@K8C+_/OPQ)Y9"UMI:,OA%)B RP@&KB7,LE*&
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M:J1&$@[8!*9IKSYJ(B&EZ,-[)^$6DWZ1%J0U1.K#-"4@1KD81!"6!JC$+.&
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M)F%X4[A7]J#K.9BDK1Z^,68\-DS3)V(<SEZNIU>S!7%_]G2\K#DF(^0#;T,
MRM88&>1L;ZJ#:'K3@W%!WF(/G^^RT%E6&=W0N$2'_Z^XZQ@O).>9Z@):'0@N
MP'E74CUCU/:.X6FABEX/]ZDZ@/5H=2A_2B('(G.]^X0_#L!9I5!FL3H'L08H
MA9"6^H<#9G@[Q-!FZ;=Z!NC-]=ZV[<2UCU'\6K3WN/E,:_S2:YGEYC0OA<I,
MF!3Z,&&#ZPP:/NRX>\!:9/6HT.,.<YKFQ=S"#B >*?QK/(-#.=\C'8.YIMCJ
MS,5CS)X&N'GT0D<WTG7)OV1[TLHXNH^3<DFC/)N!" //;\3"!@=_#1_V- <2
MMVB(AVQ,7U#+3U? SM-"_KF GA!(]Q (&6*W@/JL^^X@:(G5$S&/QXUZSLHI
M$KRH[^2P^>$;.4W^P2$?YJF.0<]MA-7S+$_"/OQRB_'%..,+<1X OKN+<*XN
MP'4TF\&DN_D':[KLR6W<^P0(@L%<*&@H<(=[JQO8"_5[F-?#R5$X9OE5CJ"/
M.8&"- 4H3S530<[C')@&0,-ZGE&['"IHR&M.@;P!P]Q]/R6K+O%H]><^SA!Q
M'AF7BI=Y$J4%67+3,B6/C,IK^@*:EYH5! 0.=6.?6<6]3FN&N:/>\@!98T?I
M0TPWG42G36 ^&>3;?$-%NL1#_0"\W8AA[KJW#+_;XJQ8HFQW\!SK]HL6KPS?
M;-ZA8AS@J7YPSFZ(U26F/UC/\ JA=7Y%OO!-5.RSTDWE.?'!*V0@&T=)DM-W
M;HA;"E@OL".U7<?%3.I0>HY5[W;3ITR;Z.&*ML<-'>.-'.,-' \Z2W<;-ZXV
M;#K:?O=SG_(J3J-T96&?$B (!G.AH*' '>ZM;F OU._A'1/./B6QKCJ&':I_
MDD'K])KT;$.:V"ZTJL5;W;>$\SH'K $ L9FGU*8L@@:][F/"&^)A12$8A/\S
M2O=1]D+I%, KX!+ ELDU0,#*O=,Y5)E-\+#8#PRD5^@^TT"IB$T 4S;; '$*
M\$_G0&6WP<,;1\!PND^48RF'111(6RP#1*?$+]V'T);^4!-@3UN9"Y30?<4E
M7D;/Y</4.*$EZ^FSARI%9TS%<?:WU<4%#GK+_K3:(<S;YF4*+2_]I-+M3Z]2
MC98WIYX_QCDG!46!KY:& N(+'-ZZ'K(?V&&-"#7/E67=;#,OZ]6@>1*MD"CA
M1(E9</(B8@X<R$:^ZB8J UO2Q<9:5X]?5FV:/*-L%>>E3>AJ3]^H.6VYR,(P
M@)47B86L@6/8P$_=QF-A.X983P7N-^/S$.-S$ ]@W]WYAZMSCXY@[?BX;T(F
M4ROBI,GS:ANE#VA!W#9+J4OH_VC2XU.4'%82Q'GQZOAJV"A=U_^A0LG!?X>:
MFM51N] 47(_JWM^&7:^3!@+ZJ/(C?JZ''B.7'"J=M>\4'E_<K#K_\$$XW==-
M(QH]N^]&!-?IG7XEPWC0=]L!H>+GT(;S+@;N+H;HMS88>S3L=C_ ?E1.F3@\
MDTLLR(KWSG.FY+[G_-Y]3+SH?P=23N?PX=GRD]-.!7U?,V;3-6,Y?1GGJP3G
M^PQ)\DAMB65T(3.Q0?8BBYZTT(W,6@/I29ZDFUQ%<?9KE.S1;'/:)J4' /1D
M]G-*6OJ55G//F+ODBJS577(PJW,H6X,F-O(:!]*FK7O=00>WRL.\5/,=](/W
M9MF<3/..?RGOZ.4QM?,J?D;KPU74X\V]]4?.D& @J;FGKB-I4+W%GD\[[#Q&
MC0PG?7:,B7.RO"RY<8=H*=31_-2LNP*O_IBF!1[CW0ZGY5]9PX6NC.JXH2YC
M4%W"AA^['DG4F\=)QO5P)&A6)C <#J3BU,8$@;A!]0++WG4_.@A:ZF'Y7,X0
M\2G#>7ZXT'28.=*GH=-T'R5SE&UPMJ,Y11<X)18Q5Q,Z_-6A08U_4!W"U']=
M#PEJ3>OG2OZ_?]?Z\M?D'\AOQU_H?^ZC'/WO_Q]02P$"% ,4    " #;:VU;
M;A%D8P\(  !5-0  "P              @ $     97@S,3%?,2YH=&U02P$"
M% ,4    " #;:VU;05I-KOT'  "J-   "P              @ $X"   97@S
M,3)?,BYH=&U02P$"% ,4    " #;:VU;Y]R6B)<$  "^%0  "P
M    @ %>$   97@S,C%?,RYH=&U02P$"% ,4    " #;:VU;HTH@/',$  #Y
M%   "P              @ $>%0  97@S,C)?-"YH=&U02P$"% ,4    " #;
M:VU;(X DA2_* @" T!\ $0              @ &Z&0  <WAT<"TR,#(U,#DS
M,"YH=&U02P$"% ,4    " #;:VU;EF (:*@5  #(!@$ $0
M@ $8Y ( <WAT<"TR,#(U,#DS,"YX<V102P$"% ,4    " #;:VU;S=B!2R48
M   ^50$ %0              @ 'O^0( <WAT<"TR,#(U,#DS,%]C86PN>&UL
M4$L! A0#%     @ VVMM6UAAL]*W30  EQD% !4              ( !1Q(#
M '-X=' M,C R-3 Y,S!?9&5F+GAM;%!+ 0(4 Q0    ( -MK;5O10WWN@N8
M )*<#@ 5              "  3%@ P!S>'1P+3(P,C4P.3,P7VQA8BYX;6Q0
M2P$"% ,4    " #;:VU;8]:!JWAM  "9I0< %0              @ 'F1@0
K<WAT<"TR,#(U,#DS,%]P<F4N>&UL4$L%!@     *  H ;@(  )&T!     $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>sxtp-20250930_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:currency="http://xbrl.sec.gov/currency/2025"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2025"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2025"
  xmlns:sxtp="http://60degreespharma.com/20250930"
  xmlns:us-gaap="http://fasb.org/us-gaap/2025"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xhtml="http://www.w3.org/1999/xhtml"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="sxtp-20250930.xsd" xlink:type="simple"/>
    <context id="D20250331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="D20240331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="D20250930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="D20240930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="D20250930_1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="D20240930_1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="I20250930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="I20241231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="I20250930_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="I20241231_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="I20250930_LabEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sxtp:LabEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="I20250930_MachineryAndEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="I20250930_ComputerEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="I20250930_FurnitureAndFixturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="I20241231_LabEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sxtp:LabEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="I20241231_MachineryAndEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="I20241231_ComputerEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="I20241231_FurnitureAndFixturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="I20240930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="I20231231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="I20250930_PatentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="I20250930_SoftwareAndSoftwareDevelopmentCostsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="D20240930_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="D20250930_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="D20250930_ResearchAndDevelopmentExpenseMember_1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="D20240930_ResearchAndDevelopmentExpenseMember_1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="D20250930_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="D20250930_GeneralAndAdministrativeExpenseMember_1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="D20240930_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="D20240930_GeneralAndAdministrativeExpenseMember_1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="I20250930_TwoThousandTwentyTwoEquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sxtp:TwoThousandTwentyTwoEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="I20250930_BoardOfDirectorsChairmanMember_StephenTooveyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sxtp:StephenTooveyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="I20250930_PaulFieldMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sxtp:PaulFieldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="I20250930_CharlesAllenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">sxtp:CharlesAllenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="I20250930_IPOMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="D20150715">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
        </entity>
        <period>
            <startDate>2015-07-15</startDate>
            <endDate>2015-07-15</endDate>
        </period>
    </context>
    <context id="D20150715_BoardOfDirectorsChairmanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-07-15</startDate>
            <endDate>2015-07-15</endDate>
        </period>
    </context>
    <context id="D20150715_USGovernmentSalesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sxtp:USGovernmentSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-07-15</startDate>
            <endDate>2015-07-15</endDate>
        </period>
    </context>
    <context id="D20150715_USArmyAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sxtp:USArmyAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-07-15</startDate>
            <endDate>2015-07-15</endDate>
        </period>
    </context>
    <context id="D20241220">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
        </entity>
        <period>
            <startDate>2024-12-20</startDate>
            <endDate>2024-12-20</endDate>
        </period>
    </context>
    <context id="D20241220_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-12-20</startDate>
            <endDate>2024-12-20</endDate>
        </period>
    </context>
    <context id="I20241220">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
        </entity>
        <period>
            <instant>2024-12-20</instant>
        </period>
    </context>
    <context id="D20241220_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-12-20</startDate>
            <endDate>2024-12-20</endDate>
        </period>
    </context>
    <context id="D20250930_ShareBasedCompensationAwardTrancheOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="D20250930_CommonStockMember_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="D20240930_CommonStockMember_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="D20250930_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="D20240930_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="D20250120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
        </entity>
        <period>
            <startDate>2025-01-20</startDate>
            <endDate>2025-01-20</endDate>
        </period>
    </context>
    <context id="D20241231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="I20200514_SmallBusinessAdministrationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sxtp:SmallBusinessAdministrationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-14</instant>
        </period>
    </context>
    <context id="I20200514_BalloonPaymentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sxtp:BalloonPaymentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-14</instant>
        </period>
    </context>
    <context id="D20200514_SBAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">sxtp:SBAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-14</startDate>
            <endDate>2020-05-14</endDate>
        </period>
    </context>
    <context id="D20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
        </entity>
        <period>
            <startDate>2022-03-31</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="I20220331_SeriesANonVotingConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sxtp:SeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="I20241231_FairValueMeasurementsRecurringMember_ContingentMilestonePaymentMember_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">sxtp:ContingentMilestonePaymentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="I20231231_FairValueMeasurementsRecurringMember_FairValueInputsLevel3Member_ContingentMilestonePaymentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">sxtp:ContingentMilestonePaymentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="D20240331_FairValueMeasurementsRecurringMember_ContingentMilestonePaymentMember_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">sxtp:ContingentMilestonePaymentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="I20240331_FairValueMeasurementsRecurringMember_ContingentMilestonePaymentMember_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">sxtp:ContingentMilestonePaymentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="I20241231_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="D20250930_FairValueMeasurementsRecurringMember_ContingentMilestonePaymentMember_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">sxtp:ContingentMilestonePaymentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="D20250331_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="I20250331_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="I20250930_FairValueMeasurementsRecurringMember_ContingentMilestonePaymentMember_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">sxtp:ContingentMilestonePaymentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="I20240930_FairValueMeasurementsRecurringMember_ContingentMilestonePaymentMember_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">sxtp:ContingentMilestonePaymentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="D20250930_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="I20250930_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="D20240930_FairValueMeasurementsRecurringMember_ContingentMilestonePaymentMember_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">sxtp:ContingentMilestonePaymentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="I20231231_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="D20240331_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="I20240331_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="D20240930_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="D20250331_FairValueMeasurementsRecurringMember_ContingentMilestonePaymentMember_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">sxtp:ContingentMilestonePaymentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="I20240930_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="I20250331_FairValueMeasurementsRecurringMember_ContingentMilestonePaymentMember_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">sxtp:ContingentMilestonePaymentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="I20250930_SeriesANonVotingConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sxtp:SeriesANonVotingConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="D20250218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
        </entity>
        <period>
            <startDate>2025-02-18</startDate>
            <endDate>2025-02-18</endDate>
        </period>
    </context>
    <context id="D20250128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
        </entity>
        <period>
            <startDate>2025-01-28</startDate>
            <endDate>2025-01-28</endDate>
        </period>
    </context>
    <context id="I20250128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
        </entity>
        <period>
            <instant>2025-01-28</instant>
        </period>
    </context>
    <context id="D20250130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
        </entity>
        <period>
            <startDate>2025-01-30</startDate>
            <endDate>2025-01-30</endDate>
        </period>
    </context>
    <context id="I20250131_PlacementAgentWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sxtp:PlacementAgentWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-31</instant>
        </period>
    </context>
    <context id="D20250205">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
        </entity>
        <period>
            <startDate>2025-02-05</startDate>
            <endDate>2025-02-05</endDate>
        </period>
    </context>
    <context id="I20250205">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
        </entity>
        <period>
            <instant>2025-02-05</instant>
        </period>
    </context>
    <context id="D20250205_CommonStockMember_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-05</startDate>
            <endDate>2025-02-05</endDate>
        </period>
    </context>
    <context id="I20250205_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-02-05</instant>
        </period>
    </context>
    <context id="D20250206">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
        </entity>
        <period>
            <startDate>2025-02-06</startDate>
            <endDate>2025-02-06</endDate>
        </period>
    </context>
    <context id="I20250205_PlacementAgentWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sxtp:PlacementAgentWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-02-05</instant>
        </period>
    </context>
    <context id="I20250930_CommonStockMember_1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="I20240930_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="D20240930_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="D20250930_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="I20250331_PreferredStockMember_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="I20241231_PreferredStockMember_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="I20250930_PreferredStockMember_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="D20250331_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="I20241231_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="I20250331_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="D20250331_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="I20250331_RetainedEarningsUnappropriatedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsUnappropriatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="D20250331_RetainedEarningsUnappropriatedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsUnappropriatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="I20250331_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="D20250331_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="I20250331_ParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="D20250331_ParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="I20250331_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="D20250331_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="I20250331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="I20241231_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="I20241231_RetainedEarningsUnappropriatedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsUnappropriatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="I20241231_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="I20241231_ParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="I20241231_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="D20250930_CommonStockMember_3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="D20250930_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="I20250930_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="D20250930_RetainedEarningsUnappropriatedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsUnappropriatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="I20250930_RetainedEarningsUnappropriatedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsUnappropriatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="D20250930_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="I20250930_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="D20250930_ParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="I20250930_ParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="D20250930_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="I20250930_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="I20240930_PreferredStockMember_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="I20240331_PreferredStockMember_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="I20240331_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="D20240331_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="I20240331_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="D20240331_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="I20240331_RetainedEarningsUnappropriatedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsUnappropriatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="D20240331_RetainedEarningsUnappropriatedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsUnappropriatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="I20240331_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="D20240331_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="I20240331_ParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="D20240331_ParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="I20240331_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="D20240331_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="I20240331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="D20240930_PreferredStockMember_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="D20240930_CommonStockMember_3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="D20240930_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="I20240930_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="D20240930_RetainedEarningsUnappropriatedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsUnappropriatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="I20240930_RetainedEarningsUnappropriatedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsUnappropriatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="D20240930_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="I20240930_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="D20240930_ParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="I20240930_ParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="D20240930_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="I20240930_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="D20241231_CustomerConcentrationRiskMember_SignificantCustomersMember_AccountsReceivableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">sxtp:SignificantCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-12-31</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="D20250930_CustomerConcentrationRiskMember_SignificantCustomersMember_SalesRevenueNetMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">sxtp:SignificantCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="D20240930_CustomerConcentrationRiskMember_SignificantCustomersMember_SalesRevenueNetMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">sxtp:SignificantCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="D20250930_CustomerConcentrationRiskMember_SignificantCustomersMember_SalesRevenueNetMember_1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">sxtp:SignificantCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="D20240930_CustomerConcentrationRiskMember_SignificantCustomersMember_SalesRevenueNetMember_1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">sxtp:SignificantCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="D20250930_USD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="D20250930_USD_1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="I20250930_USD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="D20240930_USD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="D20240930_USD_1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="I20241231_USD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="I20250930_FairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="I20250930_FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="I20250930_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="I20250930_FairValueInputsLevel1Member_DerivativeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DerivativeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="I20250930_DerivativeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DerivativeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="I20250930_FairValueInputsLevel2Member_DerivativeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DerivativeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="I20250930_FairValueInputsLevel3Member_DerivativeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DerivativeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="I20241231_DerivativeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DerivativeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="I20241231_DerivativeMember_FairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DerivativeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="I20241231_DerivativeMember_FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DerivativeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="I20241231_DerivativeMember_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DerivativeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="D20250930_RestrictedStockUnitsRSUMember_1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="I20250930_PreFundedWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sxtp:PreFundedWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="I20240930_PreFundedWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sxtp:PreFundedWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="D20250930_SeriesAPreferredStockMember_1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="D20240930_SeriesAPreferredStockMember_1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="I20231231_PreferredStockMember_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="I20231231_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="I20231231_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="I20231231_RetainedEarningsUnappropriatedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsUnappropriatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="I20231231_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="I20231231_ParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="I20231231_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="I20241231_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="I20250331_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="D20231231_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="I20241231_FairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="I20241231_FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="D20250930_CustomerConcentrationRiskMember_SignificantCustomerOneMember_SalesRevenueNetMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">sxtp:SignificantCustomerOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="D20241231_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="D20250930_CommonStockMember_5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="D20250930_WarrantMember_3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="D20241106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
        </entity>
        <period>
            <startDate>2024-11-06</startDate>
            <endDate>2024-11-06</endDate>
        </period>
    </context>
    <context id="D20250210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
        </entity>
        <period>
            <startDate>2025-02-10</startDate>
            <endDate>2025-02-10</endDate>
        </period>
    </context>
    <context id="D20250930_CustomerConcentrationRiskMember_SalesRevenueNetMember_SignificantCustomerOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">sxtp:SignificantCustomerOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="D20250930_CustomerConcentrationRiskMember_SalesRevenueNetMember_SignificantCustomerTwoMember_1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">sxtp:SignificantCustomerTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="D20250716_July2025OfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">sxtp:July2025OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-16</startDate>
            <endDate>2025-07-16</endDate>
        </period>
    </context>
    <context id="D20250930_CommonStockMember_RestrictedStockUnitsRSUMember_1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="D20240930_CommonStockMember_RestrictedStockUnitsRSUMember_1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="D20240930_RestrictedStockUnitsRSUMember_1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="D20240731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-07-31</endDate>
        </period>
    </context>
    <context id="D20240930_CommonStockMember_RestrictedStockUnitsRSUMember_3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="D20250930_CommonStockMember_RestrictedStockUnitsRSUMember_3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="D20250930_StockOptionsMember_1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sxtp:StockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="D20250930_CommonStockMember_RestrictedStockUnitsRSUMember_4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="D20240930_CommonStockMember_RestrictedStockUnitsRSUMember_4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="D20250930_CustomerConcentrationRiskMember_SignificantCustomersMember_AccountsReceivableMember_1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">sxtp:SignificantCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-09-30</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="D20250930_CustomerConcentrationRiskMember_AccountsReceivableMember_SignificantCustomerOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">sxtp:SignificantCustomerOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-09-30</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="D20250930_CustomerConcentrationRiskMember_AccountsReceivableMember_SignificantCustomerTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">sxtp:SignificantCustomerTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-09-30</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="D20250630_FairValueMeasurementsRecurringMember_ContingentMilestonePaymentMember_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">sxtp:ContingentMilestonePaymentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="I20240630_FairValueMeasurementsRecurringMember_ContingentMilestonePaymentMember_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">sxtp:ContingentMilestonePaymentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="D20240630_FairValueMeasurementsRecurringMember_ContingentMilestonePaymentMember_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">sxtp:ContingentMilestonePaymentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="I20250630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="D20250630_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="I20250630_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="D20250630_18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="D20240630_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="I20240630_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="D20240630_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="I20240630_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="D20240630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="I20240630_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="I20240630_RetainedEarningsUnappropriatedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsUnappropriatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="I20240630_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="I20240630_ParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="I20240630_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="I20240630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="D20240630_RetainedEarningsUnappropriatedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsUnappropriatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="D20240630_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="D20240630_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="D20240630_ParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="D20240630_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="D20250630_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="D20250630_RetainedEarningsUnappropriatedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsUnappropriatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="I20250630_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="I20250630_RetainedEarningsUnappropriatedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsUnappropriatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="D20250630_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="I20250630_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="D20250630_ParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="I20250630_ParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="D20250630_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="I20250630_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="I20250630_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="I20250630_PreferredStockMember_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="I20250630_FairValueMeasurementsRecurringMember_ContingentMilestonePaymentMember_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">sxtp:ContingentMilestonePaymentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="D20250715_July2025OfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">sxtp:July2025OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-15</startDate>
            <endDate>2025-07-15</endDate>
        </period>
    </context>
    <context id="I20250715_July2025OfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">sxtp:July2025OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-07-15</instant>
        </period>
    </context>
    <context id="I20250715_PreFundedWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sxtp:PreFundedWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-07-15</instant>
        </period>
    </context>
    <context id="D20250715_PreFundedWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sxtp:PreFundedWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-15</startDate>
            <endDate>2025-07-15</endDate>
        </period>
    </context>
    <context id="I20250715_JulyTwoThousandTwentyFivePreFundedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sxtp:JulyTwoThousandTwentyFivePreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-07-15</instant>
        </period>
    </context>
    <context id="I20250715_JulyTwoThousandTwentyFiveAOneWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sxtp:JulyTwoThousandTwentyFiveAOneWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-07-15</instant>
        </period>
    </context>
    <context id="I20250715_JulyTwoThousandTwentyFiveATwoWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sxtp:JulyTwoThousandTwentyFiveATwoWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-07-15</instant>
        </period>
    </context>
    <context id="D20250120_CommonStockMember_3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-20</startDate>
            <endDate>2025-01-20</endDate>
        </period>
    </context>
    <context id="I20240630_PreferredStockMember_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="I20240722_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-22</instant>
        </period>
    </context>
    <context id="I20240726_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-26</instant>
        </period>
    </context>
    <context id="D20240726_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-26</startDate>
            <endDate>2024-07-26</endDate>
        </period>
    </context>
    <context id="D20240722_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-22</startDate>
            <endDate>2024-07-22</endDate>
        </period>
    </context>
    <context id="I20240930_SeriesBWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sxtp:SeriesBWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="I20240930_SeriesAPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="I20250930_ConvertibleCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertibleCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="I20240930_ConvertibleCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertibleCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="D20251008_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-10-08</startDate>
            <endDate>2025-10-08</endDate>
        </period>
    </context>
    <context id="I20251008_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-10-08</instant>
        </period>
    </context>
    <context id="D20250715_JulyTwoThousandTwentyFivePreFundedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sxtp:JulyTwoThousandTwentyFivePreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-15</startDate>
            <endDate>2025-07-15</endDate>
        </period>
    </context>
    <context id="D20250715_JulyTwoThousandTwentyFiveAOneWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sxtp:JulyTwoThousandTwentyFiveAOneWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-15</startDate>
            <endDate>2025-07-15</endDate>
        </period>
    </context>
    <context id="D20240712_WallachBethCapitalLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sxtp:WallachBethCapitalLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-12</startDate>
            <endDate>2024-07-12</endDate>
        </period>
    </context>
    <context id="D20240801_WallachBethCapitalLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sxtp:WallachBethCapitalLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-19</startDate>
            <endDate>2024-08-01</endDate>
        </period>
    </context>
    <context id="I20250930_HCWainwrightAndCoLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sxtp:HCWainwrightAndCoLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="D20240930_PreFundedWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sxtp:PreFundedWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-09-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="D20250930_PreFundedWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sxtp:PreFundedWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="I20250930_DirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="D20250930_DirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="D20250930_TuftsMedicalCenterAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sxtp:TuftsMedicalCenterAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="D20250731_PreFundedWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sxtp:PreFundedWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-07-31</endDate>
        </period>
    </context>
    <context id="D20250930_PreFundedWarrantMember_1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sxtp:PreFundedWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="D20240930_PreFundedWarrantMember_1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sxtp:PreFundedWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="I20250903_HCWainwrightAndCoLLCMember_AtTheMarket2025AgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">sxtp:AtTheMarket2025AgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sxtp:HCWainwrightAndCoLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-03</instant>
        </period>
    </context>
    <context id="D20250930_HCWainwrightAndCoLLCMember_AtTheMarket2025AgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">sxtp:AtTheMarket2025AgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sxtp:HCWainwrightAndCoLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-09-30</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="D20251021_SubsequentEventMember_StockOptionsMember_DirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sxtp:StockOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-10-21</startDate>
            <endDate>2025-10-21</endDate>
        </period>
    </context>
    <context id="I20251021_SubsequentEventMember_StockOptionsMember_DirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sxtp:StockOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-10-21</instant>
        </period>
    </context>
    <context id="D20251021_SubsequentEventMember_StockOptionsMember_DirectorOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">sxtp:DirectorOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">sxtp:StockOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-10-21</startDate>
            <endDate>2025-10-21</endDate>
        </period>
    </context>
    <context id="D20240930_PreFundedWarrantMember_3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sxtp:PreFundedWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="D20240930_WarrantMember_1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="I20250715_JulyTwoThousandTwentyFivePlacementAgentWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sxtp:JulyTwoThousandTwentyFivePlacementAgentWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-07-15</instant>
        </period>
    </context>
    <context id="D20250715_MaximumMember_JulyTwoThousandTwentyFivePlacementAgentWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sxtp:JulyTwoThousandTwentyFivePlacementAgentWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-15</startDate>
            <endDate>2025-07-15</endDate>
        </period>
    </context>
    <context id="D20250715_JulyTwoThousandTwentyFiveATwoWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sxtp:JulyTwoThousandTwentyFiveATwoWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-15</startDate>
            <endDate>2025-07-15</endDate>
        </period>
    </context>
    <context id="D20250715_JulyTwoThousandTwentyFivePlacementAgentWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sxtp:JulyTwoThousandTwentyFivePlacementAgentWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-15</startDate>
            <endDate>2025-07-15</endDate>
        </period>
    </context>
    <context id="D20240930_SeriesAWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sxtp:SeriesAWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-09-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="D20240930_SeptemberTwoThousandTwentyFourAgentWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sxtp:SeptemberTwoThousandTwentyFourAgentWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-09-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="D20240930_SeriesBWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sxtp:SeriesBWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-09-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="I20250331_PreFundedWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sxtp:PreFundedWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="I20250630_PreFundedWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sxtp:PreFundedWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="D20250930_CustomerConcentrationRiskMember_SignificantCustomersMember_AccountsReceivableOrSalesRevenueNetMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">sxtp:SignificantCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">sxtp:AccountsReceivableOrSalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="D20250224">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
        </entity>
        <period>
            <startDate>2025-02-24</startDate>
            <endDate>2025-02-24</endDate>
        </period>
    </context>
    <context id="I20251113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
        </entity>
        <period>
            <instant>2025-11-13</instant>
        </period>
    </context>
    <context id="D20251113_SubsequentEventMember_HCWainwrightAndCoLLCMember_AtTheMarket2025AgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">sxtp:AtTheMarket2025AgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sxtp:HCWainwrightAndCoLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-10-16</startDate>
            <endDate>2025-11-13</endDate>
        </period>
    </context>
    <context id="D20250903_WallachBethCapitalLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001946563</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sxtp:WallachBethCapitalLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-09-03</startDate>
            <endDate>2025-09-03</endDate>
        </period>
    </context>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="USDPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Number">
        <measure>sxtp:Number</measure>
    </unit>
    <unit id="Director">
        <measure>sxtp:Director</measure>
    </unit>
    <dei:DocumentFiscalYearFocus contextRef="D20250930_1" id="Tag1004">2025</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="D20250930_1" id="Tag1005">Q3</dei:DocumentFiscalPeriodFocus>
    <dei:CurrentFiscalYearEndDate contextRef="D20250930_1" id="Tag1006">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:EntityCentralIndexKey contextRef="D20250930_1" id="Tag1007">0001946563</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="D20250930_1" id="Tag1008">false</dei:AmendmentFlag>
    <us-gaap:LesseeOperatingLeaseRenewalTerm contextRef="I20250930" id="Tag1013">P1Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="D20250930" id="Tag1014">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrAdoptedFlag contextRef="D20250930" id="Tag1015">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="D20250930" id="Tag1016">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrTrmntdFlag contextRef="D20250930" id="Tag1017">false</ecd:NonRule10b51ArrTrmntdFlag>
    <dei:EntityAddressStateOrProvince contextRef="D20250930_1" id="Tag1036">DC</dei:EntityAddressStateOrProvince>
    <dei:DocumentType contextRef="D20250930_1" id="Tag923">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="D20250930_1" id="Tag932">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="D20250930_1" id="Tag949">2025-09-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="D20250930_1" id="Tag933">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="D20250930_1" id="Tag924">001-41719</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="D20250930_1" id="Tag969">60 DEGREES PHARMACEUTICALS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="D20250930_1" id="Tag709">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="D20250930_1" id="Tag710">45-2406880</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="D20250930_1" id="Tag443">1025 Connecticut Avenue</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="D20250930_1" id="Tag444">NW Suite 1000</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="D20250930_1" id="Tag708">Washington</dei:EntityAddressCityOrTown>
    <dei:EntityAddressPostalZipCode contextRef="D20250930_1" id="Tag445">20036</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="D20250930_1" id="Tag446">202</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="D20250930_1" id="Tag447">327-5422</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="D20250930_CommonStockMember_5" id="Tag714">Common Stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="D20250930_CommonStockMember_5" id="Tag715">SXTP</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="D20250930_CommonStockMember_5" id="Tag484">NASDAQ</dei:SecurityExchangeName>
    <dei:Security12bTitle contextRef="D20250930_WarrantMember_3" id="Tag716">Warrants, each warrant to purchase one share of Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="D20250930_WarrantMember_3" id="Tag717">SXTPW</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="D20250930_WarrantMember_3" id="Tag485">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus contextRef="D20250930_1" id="Tag925">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="D20250930_1" id="Tag926">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="D20250930_1" id="Tag711">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="D20250930_1" id="Tag712">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="D20250930_1" id="Tag713">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="D20250930_1" id="Tag951">false</dei:EntityExTransitionPeriod>
    <dei:EntityShellCompany contextRef="D20250930_1" id="Tag927">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="I20251113"
      decimals="0"
      id="Tag962"
      unitRef="Shares">4230448</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="I20250930"
      decimals="0"
      id="Tag388"
      unitRef="USD">4115779</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="I20241231"
      decimals="0"
      id="Tag408"
      unitRef="USD">1659353</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="I20250930"
      decimals="0"
      id="Tag389"
      unitRef="USD">674036</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="I20241231"
      decimals="0"
      id="Tag409"
      unitRef="USD">486748</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="I20250930"
      decimals="0"
      id="Tag390"
      unitRef="USD">992390</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="I20241231"
      decimals="0"
      id="Tag410"
      unitRef="USD">1068940</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:ShortTermInvestments
      contextRef="I20250930"
      decimals="0"
      id="Tag525"
      unitRef="USD">0</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="I20241231"
      decimals="0"
      id="Tag411"
      unitRef="USD">1728472</us-gaap:ShortTermInvestments>
    <us-gaap:InventoryNet
      contextRef="I20250930"
      decimals="0"
      id="Tag391"
      unitRef="USD">527004</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="I20241231"
      decimals="0"
      id="Tag412"
      unitRef="USD">442764</us-gaap:InventoryNet>
    <us-gaap:AssetsCurrent
      contextRef="I20250930"
      decimals="0"
      id="Tag392"
      unitRef="USD">6309209</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="I20241231"
      decimals="0"
      id="Tag413"
      unitRef="USD">5386277</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="I20250930"
      decimals="0"
      id="Tag393"
      unitRef="USD">227752</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="I20241231"
      decimals="0"
      id="Tag414"
      unitRef="USD">149808</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PrepaidExpenseNoncurrent
      contextRef="I20250930"
      decimals="0"
      id="Tag524"
      unitRef="USD">0</us-gaap:PrepaidExpenseNoncurrent>
    <us-gaap:PrepaidExpenseNoncurrent
      contextRef="I20241231"
      decimals="0"
      id="Tag415"
      unitRef="USD">66176</us-gaap:PrepaidExpenseNoncurrent>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="I20250930"
      decimals="0"
      id="Tag394"
      unitRef="USD">152383</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="I20241231"
      decimals="0"
      id="Tag416"
      unitRef="USD">157084</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="I20250930"
      decimals="0"
      id="Tag395"
      unitRef="USD">152383</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="I20241231"
      decimals="0"
      id="Tag417"
      unitRef="USD">223260</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="I20250930"
      decimals="0"
      id="Tag396"
      unitRef="USD">6689344</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="I20241231"
      decimals="0"
      id="Tag418"
      unitRef="USD">5759345</us-gaap:Assets>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="I20250930"
      decimals="0"
      id="Tag397"
      unitRef="USD">1391347</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="I20241231"
      decimals="0"
      id="Tag419"
      unitRef="USD">1007618</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <sxtp:SBAEIDLincludingAccruedInterestCurrent
      contextRef="I20250930"
      decimals="0"
      id="Tag398"
      unitRef="USD">8772</sxtp:SBAEIDLincludingAccruedInterestCurrent>
    <sxtp:SBAEIDLincludingAccruedInterestCurrent
      contextRef="I20241231"
      decimals="0"
      id="Tag420"
      unitRef="USD">8772</sxtp:SBAEIDLincludingAccruedInterestCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="I20250930"
      decimals="0"
      id="Tag399"
      unitRef="USD">797275</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="I20241231"
      decimals="0"
      id="Tag421"
      unitRef="USD">640830</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="I20250930"
      decimals="0"
      id="Tag400"
      unitRef="USD">2197394</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="I20241231"
      decimals="0"
      id="Tag422"
      unitRef="USD">1657220</us-gaap:LiabilitiesCurrent>
    <sxtp:SBAEIDLincludingAccruedInterestNonCurrent
      contextRef="I20250930"
      decimals="0"
      id="Tag637"
      unitRef="USD">144992</sxtp:SBAEIDLincludingAccruedInterestNonCurrent>
    <sxtp:SBAEIDLincludingAccruedInterestNonCurrent
      contextRef="I20241231"
      decimals="0"
      id="Tag423"
      unitRef="USD">147119</sxtp:SBAEIDLincludingAccruedInterestNonCurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="I20250930"
      decimals="0"
      id="Tag401"
      unitRef="USD">144992</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="I20241231"
      decimals="0"
      id="Tag424"
      unitRef="USD">147119</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="I20250930"
      decimals="0"
      id="Tag402"
      unitRef="USD">2342386</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="I20241231"
      decimals="0"
      id="Tag425"
      unitRef="USD">1804339</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="I20241231_SeriesAPreferredStockMember"
      decimals="4"
      id="Tag992"
      unitRef="USDPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="I20250930_SeriesAPreferredStockMember"
      decimals="4"
      id="Tag237"
      unitRef="USDPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="I20241231_SeriesAPreferredStockMember"
      decimals="0"
      id="Tag993"
      unitRef="Shares">1000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="I20250930_SeriesAPreferredStockMember"
      decimals="0"
      id="Tag238"
      unitRef="Shares">1000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="I20250930_SeriesAPreferredStockMember"
      decimals="0"
      id="Tag994"
      unitRef="Shares">76480</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="I20250930_SeriesAPreferredStockMember"
      decimals="0"
      id="Tag239"
      unitRef="Shares">76480</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="I20241231_SeriesAPreferredStockMember"
      decimals="0"
      id="Tag995"
      unitRef="Shares">76480</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="I20241231_SeriesAPreferredStockMember"
      decimals="0"
      id="Tag240"
      unitRef="Shares">76480</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue
      contextRef="I20250930"
      decimals="0"
      id="Tag403"
      unitRef="USD">9567439</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="I20241231"
      decimals="0"
      id="Tag426"
      unitRef="USD">9567439</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="I20241231"
      decimals="4"
      id="Tag996"
      unitRef="USDPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="I20250930"
      decimals="4"
      id="Tag241"
      unitRef="USDPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="I20241231"
      decimals="0"
      id="Tag997"
      unitRef="Shares">150000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="I20250930"
      decimals="0"
      id="Tag242"
      unitRef="Shares">150000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="I20250930"
      decimals="0"
      id="Tag998"
      unitRef="Shares">4104469</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="I20250930"
      decimals="0"
      id="Tag243"
      unitRef="Shares">4104469</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="I20241231"
      decimals="0"
      id="Tag1009"
      unitRef="Shares">566908</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="I20241231"
      decimals="0"
      id="Tag244"
      unitRef="Shares">566908</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="I20250930"
      decimals="0"
      id="Tag433"
      unitRef="USD">410</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="I20241231"
      decimals="0"
      id="Tag434"
      unitRef="USD">57</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="I20250930"
      decimals="0"
      id="Tag431"
      unitRef="USD">41172888</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="I20241231"
      decimals="0"
      id="Tag432"
      unitRef="USD">34860590</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="I20250930"
      decimals="0"
      id="Tag404"
      unitRef="USD">144039</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="I20241231"
      decimals="0"
      id="Tag427"
      unitRef="USD">135471</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="I20250930"
      decimals="0"
      id="Tag247"
      unitRef="USD">-46454556</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="I20241231"
      decimals="0"
      id="Tag249"
      unitRef="USD">-40527957</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="I20250930"
      decimals="0"
      id="Tag405"
      unitRef="USD">4430220</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="I20241231"
      decimals="0"
      id="Tag428"
      unitRef="USD">4035600</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="I20250930"
      decimals="0"
      id="Tag248"
      unitRef="USD">-83262</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="I20241231"
      decimals="0"
      id="Tag250"
      unitRef="USD">-80594</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="I20250930"
      decimals="0"
      id="Tag406"
      unitRef="USD">4346958</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="I20241231"
      decimals="0"
      id="Tag429"
      unitRef="USD">3955006</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="I20250930"
      decimals="0"
      id="Tag407"
      unitRef="USD">6689344</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="I20241231"
      decimals="0"
      id="Tag430"
      unitRef="USD">5759345</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues
      contextRef="D20250930"
      decimals="0"
      id="Tag435"
      unitRef="USD">437602</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="D20240930"
      decimals="0"
      id="Tag436"
      unitRef="USD">135293</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="D20250930_1"
      decimals="0"
      id="Tag437"
      unitRef="USD">702086</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="D20240930_1"
      decimals="0"
      id="Tag438"
      unitRef="USD">365939</us-gaap:Revenues>
    <us-gaap:CostOfRevenue
      contextRef="D20250930"
      decimals="0"
      id="Tag517"
      unitRef="USD">537690</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="D20240930"
      decimals="0"
      id="Tag518"
      unitRef="USD">111687</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="D20250930_1"
      decimals="0"
      id="Tag519"
      unitRef="USD">661013</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="D20240930_1"
      decimals="0"
      id="Tag508"
      unitRef="USD">266688</us-gaap:CostOfRevenue>
    <us-gaap:GrossProfit
      contextRef="D20250930"
      decimals="0"
      id="Tag377"
      unitRef="USD">-100088</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="D20240930"
      decimals="0"
      id="Tag492"
      unitRef="USD">23606</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="D20250930_1"
      decimals="0"
      id="Tag500"
      unitRef="USD">41073</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="D20240930_1"
      decimals="0"
      id="Tag509"
      unitRef="USD">99251</us-gaap:GrossProfit>
    <us-gaap:RevenueNotFromContractWithCustomerOther
      contextRef="D20250930"
      decimals="0"
      id="Tag615"
      unitRef="USD">90960</us-gaap:RevenueNotFromContractWithCustomerOther>
    <us-gaap:RevenueNotFromContractWithCustomerOther
      contextRef="D20240930"
      decimals="0"
      id="Tag616"
      unitRef="USD">12818</us-gaap:RevenueNotFromContractWithCustomerOther>
    <us-gaap:RevenueNotFromContractWithCustomerOther
      contextRef="D20250930_1"
      decimals="0"
      id="Tag617"
      unitRef="USD">390630</us-gaap:RevenueNotFromContractWithCustomerOther>
    <us-gaap:RevenueNotFromContractWithCustomerOther
      contextRef="D20240930_1"
      decimals="0"
      id="Tag618"
      unitRef="USD">43177</us-gaap:RevenueNotFromContractWithCustomerOther>
    <sxtp:NetRevenueLoss
      contextRef="D20250930"
      decimals="0"
      id="Tag376"
      unitRef="USD">-9128</sxtp:NetRevenueLoss>
    <sxtp:NetRevenueLoss
      contextRef="D20240930"
      decimals="0"
      id="Tag493"
      unitRef="USD">36424</sxtp:NetRevenueLoss>
    <sxtp:NetRevenueLoss
      contextRef="D20250930_1"
      decimals="0"
      id="Tag501"
      unitRef="USD">431703</sxtp:NetRevenueLoss>
    <sxtp:NetRevenueLoss
      contextRef="D20240930_1"
      decimals="0"
      id="Tag510"
      unitRef="USD">142428</sxtp:NetRevenueLoss>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="D20250930"
      decimals="0"
      id="Tag486"
      unitRef="USD">809777</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="D20240930"
      decimals="0"
      id="Tag494"
      unitRef="USD">940063</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="D20250930_1"
      decimals="0"
      id="Tag502"
      unitRef="USD">1467283</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="D20240930_1"
      decimals="0"
      id="Tag511"
      unitRef="USD">4372571</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="D20250930"
      decimals="0"
      id="Tag487"
      unitRef="USD">1506620</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="D20240930"
      decimals="0"
      id="Tag495"
      unitRef="USD">1215053</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="D20250930_1"
      decimals="0"
      id="Tag503"
      unitRef="USD">4805648</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="D20240930_1"
      decimals="0"
      id="Tag512"
      unitRef="USD">3419747</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="D20250930"
      decimals="0"
      id="Tag488"
      unitRef="USD">2316397</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="D20240930"
      decimals="0"
      id="Tag496"
      unitRef="USD">2155116</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="D20250930_1"
      decimals="0"
      id="Tag504"
      unitRef="USD">6272931</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="D20240930_1"
      decimals="0"
      id="Tag513"
      unitRef="USD">7792318</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="D20250930"
      decimals="0"
      id="Tag298"
      unitRef="USD">-2325525</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="D20240930"
      decimals="0"
      id="Tag299"
      unitRef="USD">-2118692</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="D20250930_1"
      decimals="0"
      id="Tag300"
      unitRef="USD">-5841228</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="D20240930_1"
      decimals="0"
      id="Tag301"
      unitRef="USD">-7649890</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpenseNonoperating
      contextRef="D20250930"
      decimals="0"
      id="Tag302"
      unitRef="USD">1708</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating
      contextRef="D20240930"
      decimals="0"
      id="Tag303"
      unitRef="USD">1467</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating
      contextRef="D20250930_1"
      decimals="0"
      id="Tag304"
      unitRef="USD">4719</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating
      contextRef="D20240930_1"
      decimals="0"
      id="Tag305"
      unitRef="USD">6490</us-gaap:InterestExpenseNonoperating>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="D20250930"
      decimals="0"
      id="Tag378"
      unitRef="USD">21103</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="D20240930"
      decimals="0"
      id="Tag379"
      unitRef="USD">56712</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="D20250930_1"
      decimals="0"
      id="Tag380"
      unitRef="USD">156445</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="D20240930_1"
      decimals="0"
      id="Tag619"
      unitRef="USD">-1683034</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="D20250930"
      decimals="0"
      id="Tag489"
      unitRef="USD">31550</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="D20240930"
      decimals="0"
      id="Tag497"
      unitRef="USD">16623</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="D20250930_1"
      decimals="0"
      id="Tag505"
      unitRef="USD">74938</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="D20240930_1"
      decimals="0"
      id="Tag514"
      unitRef="USD">67358</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="D20250930"
      decimals="0"
      id="Tag614"
      unitRef="USD">8739</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="D20240930"
      decimals="0"
      id="Tag375"
      unitRef="USD">-41556</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="D20250930_1"
      decimals="0"
      id="Tag279"
      unitRef="USD">-86226</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="D20240930_1"
      decimals="0"
      id="Tag516"
      unitRef="USD">1743902</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="D20250930"
      decimals="0"
      id="Tag306"
      unitRef="USD">-2316786</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="D20240930"
      decimals="0"
      id="Tag307"
      unitRef="USD">-2160248</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="D20250930_1"
      decimals="0"
      id="Tag308"
      unitRef="USD">-5927454</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="D20240930_1"
      decimals="0"
      id="Tag309"
      unitRef="USD">-5905988</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="D20250930"
      decimals="0"
      id="Tag490"
      unitRef="USD">250</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="D20240930"
      decimals="0"
      id="Tag498"
      unitRef="USD">250</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="D20250930_1"
      decimals="0"
      id="Tag506"
      unitRef="USD">1813</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="D20240930_1"
      decimals="0"
      id="Tag515"
      unitRef="USD">751</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ProfitLoss
      contextRef="D20250930"
      decimals="0"
      id="Tag372"
      unitRef="USD">-2317036</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="D20240930"
      decimals="0"
      id="Tag310"
      unitRef="USD">-2160498</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="D20250930_1"
      decimals="0"
      id="Tag280"
      unitRef="USD">-5929267</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="D20240930_1"
      decimals="0"
      id="Tag311"
      unitRef="USD">-5906739</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="D20250930"
      decimals="0"
      id="Tag321"
      unitRef="USD">-712</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="D20240930"
      decimals="0"
      id="Tag322"
      unitRef="USD">-713</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="D20250930_1"
      decimals="0"
      id="Tag323"
      unitRef="USD">-2668</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="D20240930_1"
      decimals="0"
      id="Tag324"
      unitRef="USD">-4669</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="D20250930"
      decimals="0"
      id="Tag271"
      unitRef="USD">-2316324</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="D20240930"
      decimals="0"
      id="Tag312"
      unitRef="USD">-2159785</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="D20250930_1"
      decimals="0"
      id="Tag281"
      unitRef="USD">-5926599</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="D20240930_1"
      decimals="0"
      id="Tag313"
      unitRef="USD">-5902070</us-gaap:NetIncomeLoss>
    <us-gaap:ProfitLoss
      contextRef="D20250930"
      decimals="0"
      id="Tag373"
      unitRef="USD">-2317036</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="D20240930"
      decimals="0"
      id="Tag314"
      unitRef="USD">-2160498</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="D20250930_1"
      decimals="0"
      id="Tag315"
      unitRef="USD">-5929267</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="D20240930_1"
      decimals="0"
      id="Tag316"
      unitRef="USD">-5906739</us-gaap:ProfitLoss>
    <us-gaap:ForeignCurrencyTransactionGainLossUnrealizedAfterTax
      contextRef="D20250930"
      decimals="0"
      id="Tag491"
      unitRef="USD">1230</us-gaap:ForeignCurrencyTransactionGainLossUnrealizedAfterTax>
    <us-gaap:ForeignCurrencyTransactionGainLossUnrealizedAfterTax
      contextRef="D20240930"
      decimals="0"
      id="Tag499"
      unitRef="USD">4403</us-gaap:ForeignCurrencyTransactionGainLossUnrealizedAfterTax>
    <us-gaap:ForeignCurrencyTransactionGainLossUnrealizedAfterTax
      contextRef="D20250930_1"
      decimals="0"
      id="Tag507"
      unitRef="USD">8568</us-gaap:ForeignCurrencyTransactionGainLossUnrealizedAfterTax>
    <us-gaap:ForeignCurrencyTransactionGainLossUnrealizedAfterTax
      contextRef="D20240930_1"
      decimals="0"
      id="Tag613"
      unitRef="USD">3646</us-gaap:ForeignCurrencyTransactionGainLossUnrealizedAfterTax>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="D20250930"
      decimals="0"
      id="Tag272"
      unitRef="USD">-2315806</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="D20240930"
      decimals="0"
      id="Tag288"
      unitRef="USD">-2156095</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="D20250930_1"
      decimals="0"
      id="Tag282"
      unitRef="USD">-5920699</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="D20240930_1"
      decimals="0"
      id="Tag289"
      unitRef="USD">-5903093</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="D20250930"
      decimals="0"
      id="Tag273"
      unitRef="USD">-712</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="D20240930"
      decimals="0"
      id="Tag317"
      unitRef="USD">-713</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="D20250930_1"
      decimals="0"
      id="Tag283"
      unitRef="USD">-2668</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="D20240930_1"
      decimals="0"
      id="Tag318"
      unitRef="USD">-4669</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="D20250930"
      decimals="0"
      id="Tag291"
      unitRef="USD">-2315094</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="D20240930"
      decimals="0"
      id="Tag290"
      unitRef="USD">-2155382</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="D20250930_1"
      decimals="0"
      id="Tag292"
      unitRef="USD">-5918031</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="D20240930_1"
      decimals="0"
      id="Tag293"
      unitRef="USD">-5898424</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:PreferredStockDividendsAndOtherAdjustments
      contextRef="D20250930"
      decimals="0"
      id="Tag319"
      unitRef="USD">128097</us-gaap:PreferredStockDividendsAndOtherAdjustments>
    <us-gaap:PreferredStockDividendsAndOtherAdjustments
      contextRef="D20240930"
      decimals="0"
      id="Tag278"
      unitRef="USD">116571</us-gaap:PreferredStockDividendsAndOtherAdjustments>
    <us-gaap:PreferredStockDividendsAndOtherAdjustments
      contextRef="D20250930_1"
      decimals="0"
      id="Tag320"
      unitRef="USD">372960</us-gaap:PreferredStockDividendsAndOtherAdjustments>
    <us-gaap:PreferredStockDividendsAndOtherAdjustments
      contextRef="D20240930_1"
      decimals="0"
      id="Tag284"
      unitRef="USD">352333</us-gaap:PreferredStockDividendsAndOtherAdjustments>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="D20250930"
      decimals="0"
      id="Tag294"
      unitRef="USD">-2443191</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="D20240930"
      decimals="0"
      id="Tag295"
      unitRef="USD">-2271953</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="D20250930_1"
      decimals="0"
      id="Tag296"
      unitRef="USD">-6290991</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="D20240930_1"
      decimals="0"
      id="Tag297"
      unitRef="USD">-6250757</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="D20250930"
      decimals="2"
      id="Tag999"
      unitRef="USDPerShare">-0.66</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="D20250930"
      decimals="2"
      id="Tag274"
      unitRef="USDPerShare">-0.66</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="D20250930_1"
      decimals="2"
      id="Tag1011"
      unitRef="USDPerShare">-4.65</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="D20240930"
      decimals="2"
      id="Tag275"
      unitRef="USDPerShare">-4.65</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="D20240930"
      decimals="2"
      id="Tag1010"
      unitRef="USDPerShare">-2.92</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="D20250930_1"
      decimals="2"
      id="Tag276"
      unitRef="USDPerShare">-2.92</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="D20240930_1"
      decimals="2"
      id="Tag1012"
      unitRef="USDPerShare">-21.74</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="D20240930_1"
      decimals="2"
      id="Tag277"
      unitRef="USDPerShare">-21.74</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="D20250930"
      decimals="0"
      id="Tag1003"
      unitRef="Shares">3675407</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="D20250930"
      decimals="0"
      id="Tag520"
      unitRef="Shares">3675407</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="D20250930_1"
      decimals="0"
      id="Tag1001"
      unitRef="Shares">488654</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="D20240930"
      decimals="0"
      id="Tag521"
      unitRef="Shares">488654</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="D20240930"
      decimals="0"
      id="Tag1002"
      unitRef="Shares">2152682</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="D20250930_1"
      decimals="0"
      id="Tag522"
      unitRef="Shares">2152682</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="D20240930_1"
      decimals="0"
      id="Tag1000"
      unitRef="Shares">287529</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="D20240930_1"
      decimals="0"
      id="Tag523"
      unitRef="Shares">287529</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:SharesOutstanding
      contextRef="I20241231_PreferredStockMember_SeriesAPreferredStockMember"
      decimals="0"
      id="Tag460"
      unitRef="Shares">76480</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="I20241231_PreferredStockMember_SeriesAPreferredStockMember"
      decimals="0"
      id="Tag461"
      unitRef="USD">9567439</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="I20241231_CommonStockMember"
      decimals="0"
      id="Tag643"
      unitRef="Shares">566908</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="I20241231_CommonStockMember"
      decimals="0"
      id="Tag651"
      unitRef="USD">57</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="I20241231_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Tag659"
      unitRef="USD">34860590</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="I20241231_RetainedEarningsUnappropriatedMember"
      decimals="0"
      id="Tag267"
      unitRef="USD">-40527957</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="I20241231_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="Tag479"
      unitRef="USD">135471</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="I20241231_ParentMember"
      decimals="0"
      id="Tag480"
      unitRef="USD">4035600</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="I20241231_NoncontrollingInterestMember"
      decimals="0"
      id="Tag268"
      unitRef="USD">-80594</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="I20241231"
      decimals="0"
      id="Tag481"
      unitRef="USD">3955006</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <sxtp:StockIssuedDuringPeriodIssuanceOfCommonStockAndWarrantsPursuantToJanuary2025OfferingNetOfOfferingCosts
      contextRef="D20250331_CommonStockMember"
      decimals="0"
      id="Tag639"
      unitRef="Shares">204312</sxtp:StockIssuedDuringPeriodIssuanceOfCommonStockAndWarrantsPursuantToJanuary2025OfferingNetOfOfferingCosts>
    <sxtp:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPursuantToJanuary2025OfferingNetOfOfferingCosts
      contextRef="D20250331_CommonStockMember"
      decimals="0"
      id="Tag658"
      unitRef="USD">20</sxtp:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPursuantToJanuary2025OfferingNetOfOfferingCosts>
    <sxtp:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPursuantToJanuary2025OfferingNetOfOfferingCosts
      contextRef="D20250331_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Tag662"
      unitRef="USD">804326</sxtp:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPursuantToJanuary2025OfferingNetOfOfferingCosts>
    <sxtp:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPursuantToJanuary2025OfferingNetOfOfferingCosts
      contextRef="D20250331_ParentMember"
      decimals="0"
      id="Tag463"
      unitRef="USD">804346</sxtp:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPursuantToJanuary2025OfferingNetOfOfferingCosts>
    <sxtp:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPursuantToJanuary2025OfferingNetOfOfferingCosts
      contextRef="D20250331"
      decimals="0"
      id="Tag455"
      unitRef="USD">804346</sxtp:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPursuantToJanuary2025OfferingNetOfOfferingCosts>
    <sxtp:StockIssuedDuringPeriodIssuanceOfCommonStockAndWarrantsPursuantToFebruary2025OfferingNetOfOfferingCosts
      contextRef="D20250331_CommonStockMember"
      decimals="0"
      id="Tag640"
      unitRef="Shares">300700</sxtp:StockIssuedDuringPeriodIssuanceOfCommonStockAndWarrantsPursuantToFebruary2025OfferingNetOfOfferingCosts>
    <sxtp:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPursuantToFebruary2025OfferingNetOfOfferingCosts
      contextRef="D20250331_CommonStockMember"
      decimals="0"
      id="Tag649"
      unitRef="USD">30</sxtp:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPursuantToFebruary2025OfferingNetOfOfferingCosts>
    <sxtp:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPursuantToFebruary2025OfferingNetOfOfferingCosts
      contextRef="D20250331_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Tag663"
      unitRef="USD">908597</sxtp:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPursuantToFebruary2025OfferingNetOfOfferingCosts>
    <sxtp:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPursuantToFebruary2025OfferingNetOfOfferingCosts
      contextRef="D20250331_ParentMember"
      decimals="0"
      id="Tag464"
      unitRef="USD">908627</sxtp:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPursuantToFebruary2025OfferingNetOfOfferingCosts>
    <sxtp:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPursuantToFebruary2025OfferingNetOfOfferingCosts
      contextRef="D20250331"
      decimals="0"
      id="Tag454"
      unitRef="USD">908627</sxtp:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPursuantToFebruary2025OfferingNetOfOfferingCosts>
    <sxtp:StockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfPreFundedWarrantsinShares
      contextRef="D20250331_CommonStockMember"
      decimals="0"
      id="Tag641"
      unitRef="Shares">385200</sxtp:StockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfPreFundedWarrantsinShares>
    <sxtp:StockIssuedDuringPeriodValueStockIssuanceOfCommonStockUponExerciseOfPreFundedWarrants
      contextRef="D20250331_CommonStockMember"
      decimals="0"
      id="Tag652"
      unitRef="USD">38</sxtp:StockIssuedDuringPeriodValueStockIssuanceOfCommonStockUponExerciseOfPreFundedWarrants>
    <sxtp:StockIssuedDuringPeriodValueStockIssuanceOfCommonStockUponExerciseOfPreFundedWarrants
      contextRef="D20250331_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Tag664"
      unitRef="USD">1888</sxtp:StockIssuedDuringPeriodValueStockIssuanceOfCommonStockUponExerciseOfPreFundedWarrants>
    <sxtp:StockIssuedDuringPeriodValueStockIssuanceOfCommonStockUponExerciseOfPreFundedWarrants
      contextRef="D20250331_ParentMember"
      decimals="0"
      id="Tag465"
      unitRef="USD">1926</sxtp:StockIssuedDuringPeriodValueStockIssuanceOfCommonStockUponExerciseOfPreFundedWarrants>
    <sxtp:StockIssuedDuringPeriodValueStockIssuanceOfCommonStockUponExerciseOfPreFundedWarrants
      contextRef="D20250331"
      decimals="0"
      id="Tag456"
      unitRef="USD">1926</sxtp:StockIssuedDuringPeriodValueStockIssuanceOfCommonStockUponExerciseOfPreFundedWarrants>
    <sxtp:StockIssuedDuringPeriodIssuanceOfSharesForAnnualPerformanceBonusesNetOfSharesWithheldForTaxesinShares
      contextRef="D20250331_CommonStockMember"
      decimals="0"
      id="Tag642"
      unitRef="Shares">15809</sxtp:StockIssuedDuringPeriodIssuanceOfSharesForAnnualPerformanceBonusesNetOfSharesWithheldForTaxesinShares>
    <sxtp:StockIssuedDuringPeriodValueIssuanceOfSharesForAnnualPerformanceBonusesNetOfSharesWithheldForTaxes
      contextRef="D20250331_CommonStockMember"
      decimals="0"
      id="Tag653"
      unitRef="USD">2</sxtp:StockIssuedDuringPeriodValueIssuanceOfSharesForAnnualPerformanceBonusesNetOfSharesWithheldForTaxes>
    <sxtp:StockIssuedDuringPeriodValueIssuanceOfSharesForAnnualPerformanceBonusesNetOfSharesWithheldForTaxes
      contextRef="D20250331_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Tag665"
      unitRef="USD">103542</sxtp:StockIssuedDuringPeriodValueIssuanceOfSharesForAnnualPerformanceBonusesNetOfSharesWithheldForTaxes>
    <sxtp:StockIssuedDuringPeriodValueIssuanceOfSharesForAnnualPerformanceBonusesNetOfSharesWithheldForTaxes
      contextRef="D20250331_ParentMember"
      decimals="0"
      id="Tag466"
      unitRef="USD">103544</sxtp:StockIssuedDuringPeriodValueIssuanceOfSharesForAnnualPerformanceBonusesNetOfSharesWithheldForTaxes>
    <sxtp:StockIssuedDuringPeriodValueIssuanceOfSharesForAnnualPerformanceBonusesNetOfSharesWithheldForTaxes
      contextRef="D20250331"
      decimals="0"
      id="Tag457"
      unitRef="USD">103544</sxtp:StockIssuedDuringPeriodValueIssuanceOfSharesForAnnualPerformanceBonusesNetOfSharesWithheldForTaxes>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="D20250331_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Tag666"
      unitRef="USD">142645</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="D20250331_ParentMember"
      decimals="0"
      id="Tag467"
      unitRef="USD">142645</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="D20250331"
      decimals="0"
      id="Tag458"
      unitRef="USD">142645</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="D20250331_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="Tag381"
      unitRef="USD">-9904</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="D20250331_ParentMember"
      decimals="0"
      id="Tag382"
      unitRef="USD">-9904</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="D20250331"
      decimals="0"
      id="Tag383"
      unitRef="USD">-9904</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:ProfitLoss
      contextRef="D20250331_RetainedEarningsUnappropriatedMember"
      decimals="0"
      id="Tag257"
      unitRef="USD">-1876549</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="D20250331_ParentMember"
      decimals="0"
      id="Tag258"
      unitRef="USD">-1876549</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="D20250331_NoncontrollingInterestMember"
      decimals="0"
      id="Tag259"
      unitRef="USD">-752</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="D20250331"
      decimals="0"
      id="Tag260"
      unitRef="USD">-1877301</us-gaap:ProfitLoss>
    <us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits
      contextRef="D20250331_CommonStockMember"
      decimals="0"
      id="Tag385"
      unitRef="Shares">38</us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits>
    <us-gaap:SharesOutstanding
      contextRef="I20250331_PreferredStockMember_SeriesAPreferredStockMember"
      decimals="0"
      id="Tag483"
      unitRef="Shares">76480</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="I20250331_PreferredStockMember_SeriesAPreferredStockMember"
      decimals="0"
      id="Tag482"
      unitRef="USD">9567439</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="I20250331_CommonStockMember"
      decimals="0"
      id="Tag644"
      unitRef="Shares">1472891</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="I20250331_CommonStockMember"
      decimals="0"
      id="Tag650"
      unitRef="USD">147</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="I20250331_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Tag667"
      unitRef="USD">36821588</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="I20250331_RetainedEarningsUnappropriatedMember"
      decimals="0"
      id="Tag261"
      unitRef="USD">-42404506</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="I20250331_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="Tag462"
      unitRef="USD">125567</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="I20250331_ParentMember"
      decimals="0"
      id="Tag468"
      unitRef="USD">4110235</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="I20250331_NoncontrollingInterestMember"
      decimals="0"
      id="Tag262"
      unitRef="USD">-81346</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="I20250331"
      decimals="0"
      id="Tag459"
      unitRef="USD">4028889</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="D20250630_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Tag661"
      unitRef="USD">34503</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="D20250630_ParentMember"
      decimals="0"
      id="Tag553"
      unitRef="USD">34503</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="D20250630_18"
      decimals="0"
      id="Tag556"
      unitRef="USD">34503</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="D20250630_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="Tag626"
      unitRef="USD">17242</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="D20250630_ParentMember"
      decimals="0"
      id="Tag628"
      unitRef="USD">17242</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="D20250630_18"
      decimals="0"
      id="Tag627"
      unitRef="USD">17242</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:ProfitLoss
      contextRef="D20250630_RetainedEarningsUnappropriatedMember"
      decimals="0"
      id="Tag346"
      unitRef="USD">-1733726</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="D20250630_ParentMember"
      decimals="0"
      id="Tag347"
      unitRef="USD">-1733726</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="D20250630_NoncontrollingInterestMember"
      decimals="0"
      id="Tag349"
      unitRef="USD">-1204</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="D20250630_18"
      decimals="0"
      id="Tag348"
      unitRef="USD">-1734930</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding
      contextRef="I20250630_PreferredStockMember_SeriesAPreferredStockMember"
      decimals="0"
      id="Tag558"
      unitRef="Shares">76480</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="I20250630_PreferredStockMember_SeriesAPreferredStockMember"
      decimals="0"
      id="Tag557"
      unitRef="USD">9567439</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="I20250630_CommonStockMember"
      decimals="0"
      id="Tag645"
      unitRef="Shares">1472891</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="I20250630_CommonStockMember"
      decimals="0"
      id="Tag654"
      unitRef="USD">147</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="I20250630_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Tag668"
      unitRef="USD">36856091</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="I20250630_RetainedEarningsUnappropriatedMember"
      decimals="0"
      id="Tag344"
      unitRef="USD">-44138232</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="I20250630_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="Tag552"
      unitRef="USD">142809</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="I20250630_ParentMember"
      decimals="0"
      id="Tag554"
      unitRef="USD">2428254</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="I20250630_NoncontrollingInterestMember"
      decimals="0"
      id="Tag345"
      unitRef="USD">-82550</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="I20250630"
      decimals="0"
      id="Tag555"
      unitRef="USD">2345704</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <sxtp:StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsPursuantToJuly2025OfferingNetOfOfferingCosts
      contextRef="D20250930_CommonStockMember_3"
      decimals="0"
      id="Tag648"
      unitRef="Shares">1753314</sxtp:StockIssuedDuringPeriodSharesIssuanceOfCommonStockAndWarrantsPursuantToJuly2025OfferingNetOfOfferingCosts>
    <sxtp:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPursuantToJuly2025OfferingNetOfOfferingCosts
      contextRef="D20250930_CommonStockMember_3"
      decimals="0"
      id="Tag657"
      unitRef="USD">175</sxtp:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPursuantToJuly2025OfferingNetOfOfferingCosts>
    <sxtp:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPursuantToJuly2025OfferingNetOfOfferingCosts
      contextRef="D20250930_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Tag671"
      unitRef="USD">4281125</sxtp:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPursuantToJuly2025OfferingNetOfOfferingCosts>
    <sxtp:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPursuantToJuly2025OfferingNetOfOfferingCosts
      contextRef="D20250930_ParentMember"
      decimals="0"
      id="Tag622"
      unitRef="USD">4281300</sxtp:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPursuantToJuly2025OfferingNetOfOfferingCosts>
    <sxtp:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPursuantToJuly2025OfferingNetOfOfferingCosts
      contextRef="D20250930"
      decimals="0"
      id="Tag623"
      unitRef="USD">4281300</sxtp:StockIssuedDuringPeriodValueIssuanceOfCommonStockAndWarrantsPursuantToJuly2025OfferingNetOfOfferingCosts>
    <sxtp:StockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfPreFundedWarrantsinShares
      contextRef="D20250930_CommonStockMember_3"
      decimals="0"
      id="Tag647"
      unitRef="Shares">878264</sxtp:StockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfPreFundedWarrantsinShares>
    <sxtp:StockIssuedDuringPeriodValueStockIssuanceOfCommonStockUponExerciseOfPreFundedWarrants
      contextRef="D20250930_CommonStockMember_3"
      decimals="0"
      id="Tag656"
      unitRef="USD">88</sxtp:StockIssuedDuringPeriodValueStockIssuanceOfCommonStockUponExerciseOfPreFundedWarrants>
    <sxtp:StockIssuedDuringPeriodValueStockIssuanceOfCommonStockUponExerciseOfPreFundedWarrants
      contextRef="D20250930_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Tag670"
      unitRef="USD">790</sxtp:StockIssuedDuringPeriodValueStockIssuanceOfCommonStockUponExerciseOfPreFundedWarrants>
    <sxtp:StockIssuedDuringPeriodValueStockIssuanceOfCommonStockUponExerciseOfPreFundedWarrants
      contextRef="D20250930_ParentMember"
      decimals="0"
      id="Tag564"
      unitRef="USD">878</sxtp:StockIssuedDuringPeriodValueStockIssuanceOfCommonStockUponExerciseOfPreFundedWarrants>
    <sxtp:StockIssuedDuringPeriodValueStockIssuanceOfCommonStockUponExerciseOfPreFundedWarrants
      contextRef="D20250930"
      decimals="0"
      id="Tag563"
      unitRef="USD">878</sxtp:StockIssuedDuringPeriodValueStockIssuanceOfCommonStockUponExerciseOfPreFundedWarrants>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="D20250930_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Tag660"
      unitRef="USD">34882</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="D20250930_RetainedEarningsUnappropriatedMember"
      id="Tag612"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="D20250930_ParentMember"
      decimals="0"
      id="Tag562"
      unitRef="USD">34882</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="D20250930_NoncontrollingInterestMember"
      id="Tag611"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="D20250930"
      decimals="0"
      id="Tag561"
      unitRef="USD">34882</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="D20250930_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="Tag629"
      unitRef="USD">1230</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="D20250930_ParentMember"
      decimals="0"
      id="Tag630"
      unitRef="USD">1230</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="D20250930"
      decimals="0"
      id="Tag631"
      unitRef="USD">1230</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:ProfitLoss
      contextRef="D20250930_RetainedEarningsUnappropriatedMember"
      decimals="0"
      id="Tag350"
      unitRef="USD">-2316324</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="D20250930_ParentMember"
      decimals="0"
      id="Tag351"
      unitRef="USD">-2316324</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="D20250930_NoncontrollingInterestMember"
      decimals="0"
      id="Tag352"
      unitRef="USD">-712</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="D20250930"
      decimals="0"
      id="Tag371"
      unitRef="USD">-2317036</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding
      contextRef="I20250930_PreferredStockMember_SeriesAPreferredStockMember"
      decimals="0"
      id="Tag548"
      unitRef="Shares">76480</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="I20250930_PreferredStockMember_SeriesAPreferredStockMember"
      decimals="0"
      id="Tag549"
      unitRef="USD">9567439</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="I20250930_CommonStockMember_1"
      decimals="0"
      id="Tag646"
      unitRef="Shares">4104469</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="I20250930_CommonStockMember_1"
      decimals="0"
      id="Tag655"
      unitRef="USD">410</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="I20250930_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Tag669"
      unitRef="USD">41172888</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="I20250930_RetainedEarningsUnappropriatedMember"
      decimals="0"
      id="Tag343"
      unitRef="USD">-46454556</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="I20250930_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="Tag636"
      unitRef="USD">144039</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="I20250930_ParentMember"
      decimals="0"
      id="Tag550"
      unitRef="USD">4430220</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="I20250930_NoncontrollingInterestMember"
      decimals="0"
      id="Tag342"
      unitRef="USD">-83262</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="I20250930"
      decimals="0"
      id="Tag551"
      unitRef="USD">4346958</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="I20231231_PreferredStockMember_SeriesAPreferredStockMember"
      decimals="0"
      id="Tag449"
      unitRef="Shares">78803</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="I20231231_PreferredStockMember_SeriesAPreferredStockMember"
      decimals="0"
      id="Tag450"
      unitRef="USD">9858040</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="I20231231_CommonStockMember"
      decimals="0"
      id="Tag672"
      unitRef="Shares">96847</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="I20231231_CommonStockMember"
      decimals="0"
      id="Tag684"
      unitRef="USD">10</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="I20231231_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Tag694"
      unitRef="USD">27457373</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="I20231231_RetainedEarningsUnappropriatedMember"
      decimals="0"
      id="Tag269"
      unitRef="USD">-32580850</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="I20231231_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="Tag476"
      unitRef="USD">135561</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="I20231231_ParentMember"
      decimals="0"
      id="Tag477"
      unitRef="USD">4870134</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="I20231231_NoncontrollingInterestMember"
      decimals="0"
      id="Tag270"
      unitRef="USD">-72038</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="I20231231"
      decimals="0"
      id="Tag478"
      unitRef="USD">4798096</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <sxtp:StockIssuedDuringPeriodSharesOfCommonStockAndWarrantsOfUnderwritingDiscountsAndOfferingCostsPaidAtClosingAndDeferredOfferingCosts
      contextRef="D20240331_CommonStockMember"
      decimals="0"
      id="Tag673"
      unitRef="Shares">87683</sxtp:StockIssuedDuringPeriodSharesOfCommonStockAndWarrantsOfUnderwritingDiscountsAndOfferingCostsPaidAtClosingAndDeferredOfferingCosts>
    <sxtp:IssuanceOfCommonStockAndWarrantsOfUnderwritingDiscountsAndOfferingCostsPaidAtClosingAndDeferredOfferingCosts
      contextRef="D20240331_CommonStockMember"
      decimals="0"
      id="Tag685"
      unitRef="USD">9</sxtp:IssuanceOfCommonStockAndWarrantsOfUnderwritingDiscountsAndOfferingCostsPaidAtClosingAndDeferredOfferingCosts>
    <sxtp:IssuanceOfCommonStockAndWarrantsOfUnderwritingDiscountsAndOfferingCostsPaidAtClosingAndDeferredOfferingCosts
      contextRef="D20240331_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Tag695"
      unitRef="USD">1898287</sxtp:IssuanceOfCommonStockAndWarrantsOfUnderwritingDiscountsAndOfferingCostsPaidAtClosingAndDeferredOfferingCosts>
    <sxtp:IssuanceOfCommonStockAndWarrantsOfUnderwritingDiscountsAndOfferingCostsPaidAtClosingAndDeferredOfferingCosts
      contextRef="D20240331_ParentMember"
      decimals="0"
      id="Tag451"
      unitRef="USD">1898296</sxtp:IssuanceOfCommonStockAndWarrantsOfUnderwritingDiscountsAndOfferingCostsPaidAtClosingAndDeferredOfferingCosts>
    <sxtp:IssuanceOfCommonStockAndWarrantsOfUnderwritingDiscountsAndOfferingCostsPaidAtClosingAndDeferredOfferingCosts
      contextRef="D20240331"
      decimals="0"
      id="Tag469"
      unitRef="USD">1898296</sxtp:IssuanceOfCommonStockAndWarrantsOfUnderwritingDiscountsAndOfferingCostsPaidAtClosingAndDeferredOfferingCosts>
    <sxtp:StockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfPreFundedWarrantsinShares
      contextRef="D20240331_CommonStockMember"
      decimals="0"
      id="Tag681"
      unitRef="Shares">8326</sxtp:StockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfPreFundedWarrantsinShares>
    <sxtp:StockIssuedDuringPeriodValueStockIssuanceOfCommonStockUponExerciseOfPreFundedWarrants
      contextRef="D20240331_CommonStockMember"
      decimals="0"
      id="Tag686"
      unitRef="USD">1</sxtp:StockIssuedDuringPeriodValueStockIssuanceOfCommonStockUponExerciseOfPreFundedWarrants>
    <sxtp:StockIssuedDuringPeriodValueStockIssuanceOfCommonStockUponExerciseOfPreFundedWarrants
      contextRef="D20240331_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Tag696"
      unitRef="USD">4994</sxtp:StockIssuedDuringPeriodValueStockIssuanceOfCommonStockUponExerciseOfPreFundedWarrants>
    <sxtp:StockIssuedDuringPeriodValueStockIssuanceOfCommonStockUponExerciseOfPreFundedWarrants
      contextRef="D20240331_ParentMember"
      decimals="0"
      id="Tag472"
      unitRef="USD">4995</sxtp:StockIssuedDuringPeriodValueStockIssuanceOfCommonStockUponExerciseOfPreFundedWarrants>
    <sxtp:StockIssuedDuringPeriodValueStockIssuanceOfCommonStockUponExerciseOfPreFundedWarrants
      contextRef="D20240331"
      decimals="0"
      id="Tag470"
      unitRef="USD">4995</sxtp:StockIssuedDuringPeriodValueStockIssuanceOfCommonStockUponExerciseOfPreFundedWarrants>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited
      contextRef="D20240331_CommonStockMember"
      decimals="0"
      id="Tag674"
      unitRef="Shares">3201</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="D20240331_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="Tag264"
      unitRef="USD">-3894</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="D20240331_ParentMember"
      decimals="0"
      id="Tag265"
      unitRef="USD">-3894</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="D20240331"
      decimals="0"
      id="Tag263"
      unitRef="USD">-3894</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:ProfitLoss
      contextRef="D20240331_RetainedEarningsUnappropriatedMember"
      decimals="0"
      id="Tag473"
      unitRef="USD">430470</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="D20240331_ParentMember"
      decimals="0"
      id="Tag474"
      unitRef="USD">430470</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="D20240331_NoncontrollingInterestMember"
      decimals="0"
      id="Tag266"
      unitRef="USD">-2485</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="D20240331"
      decimals="0"
      id="Tag471"
      unitRef="USD">427985</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding
      contextRef="I20240331_PreferredStockMember_SeriesAPreferredStockMember"
      decimals="0"
      id="Tag475"
      unitRef="Shares">78803</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="I20240331_PreferredStockMember_SeriesAPreferredStockMember"
      decimals="0"
      id="Tag635"
      unitRef="USD">9858040</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="I20240331_CommonStockMember"
      decimals="0"
      id="Tag675"
      unitRef="Shares">196057</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="I20240331_CommonStockMember"
      decimals="0"
      id="Tag687"
      unitRef="USD">20</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="I20240331_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Tag704"
      unitRef="USD">29360654</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="I20240331_RetainedEarningsUnappropriatedMember"
      decimals="0"
      id="Tag256"
      unitRef="USD">-32150380</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="I20240331_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="Tag453"
      unitRef="USD">131667</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="I20240331_ParentMember"
      decimals="0"
      id="Tag452"
      unitRef="USD">7200001</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="I20240331_NoncontrollingInterestMember"
      decimals="0"
      id="Tag255"
      unitRef="USD">-74523</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="I20240331"
      decimals="0"
      id="Tag448"
      unitRef="USD">7125478</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <sxtp:StockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfPreFundedWarrantsinShares
      contextRef="D20240630_CommonStockMember"
      decimals="0"
      id="Tag676"
      unitRef="Shares">8326</sxtp:StockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfPreFundedWarrantsinShares>
    <sxtp:StockIssuedDuringPeriodValueStockIssuanceOfCommonStockUponExerciseOfPreFundedWarrants
      contextRef="D20240630_CommonStockMember"
      decimals="0"
      id="Tag689"
      unitRef="USD">1</sxtp:StockIssuedDuringPeriodValueStockIssuanceOfCommonStockUponExerciseOfPreFundedWarrants>
    <sxtp:StockIssuedDuringPeriodValueStockIssuanceOfCommonStockUponExerciseOfPreFundedWarrants
      contextRef="D20240630_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Tag698"
      unitRef="USD">4994</sxtp:StockIssuedDuringPeriodValueStockIssuanceOfCommonStockUponExerciseOfPreFundedWarrants>
    <sxtp:StockIssuedDuringPeriodValueStockIssuanceOfCommonStockUponExerciseOfPreFundedWarrants
      contextRef="D20240630_ParentMember"
      decimals="0"
      id="Tag530"
      unitRef="USD">4995</sxtp:StockIssuedDuringPeriodValueStockIssuanceOfCommonStockUponExerciseOfPreFundedWarrants>
    <sxtp:StockIssuedDuringPeriodValueStockIssuanceOfCommonStockUponExerciseOfPreFundedWarrants
      contextRef="D20240630"
      decimals="0"
      id="Tag533"
      unitRef="USD">4995</sxtp:StockIssuedDuringPeriodValueStockIssuanceOfCommonStockUponExerciseOfPreFundedWarrants>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited
      contextRef="D20240630_CommonStockMember"
      decimals="0"
      id="Tag677"
      unitRef="Shares">1069</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="D20240630_CommonStockMember"
      decimals="0"
      id="Tag386"
      unitRef="Shares">2000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="D20240630_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="Tag529"
      unitRef="USD">3137</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="D20240630_ParentMember"
      decimals="0"
      id="Tag531"
      unitRef="USD">3137</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="D20240630"
      decimals="0"
      id="Tag532"
      unitRef="USD">3137</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:ProfitLoss
      contextRef="D20240630_RetainedEarningsUnappropriatedMember"
      decimals="0"
      id="Tag330"
      unitRef="USD">-4172755</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="D20240630_ParentMember"
      decimals="0"
      id="Tag331"
      unitRef="USD">-4172755</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="D20240630_NoncontrollingInterestMember"
      decimals="0"
      id="Tag332"
      unitRef="USD">-1471</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="D20240630"
      decimals="0"
      id="Tag333"
      unitRef="USD">-4174226</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding
      contextRef="I20240630_PreferredStockMember_SeriesAPreferredStockMember"
      decimals="0"
      id="Tag560"
      unitRef="Shares">78803</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="I20240630_PreferredStockMember_SeriesAPreferredStockMember"
      decimals="0"
      id="Tag559"
      unitRef="USD">9858040</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="I20240630_CommonStockMember"
      decimals="0"
      id="Tag678"
      unitRef="Shares">203452</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="I20240630_CommonStockMember"
      decimals="0"
      id="Tag688"
      unitRef="USD">21</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="I20240630_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Tag697"
      unitRef="USD">29365648</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="I20240630_RetainedEarningsUnappropriatedMember"
      decimals="0"
      id="Tag328"
      unitRef="USD">-36323135</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="I20240630_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="Tag526"
      unitRef="USD">134804</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="I20240630_ParentMember"
      decimals="0"
      id="Tag527"
      unitRef="USD">3035378</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="I20240630_NoncontrollingInterestMember"
      decimals="0"
      id="Tag329"
      unitRef="USD">-75994</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="I20240630"
      decimals="0"
      id="Tag528"
      unitRef="USD">2959384</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="D20240930_PreferredStockMember_SeriesAPreferredStockMember"
      decimals="0"
      id="Tag341"
      unitRef="Shares">-2323</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:ConversionOfStockAmountConverted1
      contextRef="D20240930_PreferredStockMember_SeriesAPreferredStockMember"
      decimals="0"
      id="Tag340"
      unitRef="USD">-290601</us-gaap:ConversionOfStockAmountConverted1>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="D20240930_CommonStockMember_3"
      decimals="0"
      id="Tag679"
      unitRef="Shares">14667</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:ConversionOfStockAmountConverted1
      contextRef="D20240930_CommonStockMember_3"
      decimals="0"
      id="Tag690"
      unitRef="USD">1</us-gaap:ConversionOfStockAmountConverted1>
    <us-gaap:ConversionOfStockAmountConverted1
      contextRef="D20240930_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Tag699"
      unitRef="USD">290600</us-gaap:ConversionOfStockAmountConverted1>
    <sxtp:IssuanceOfCommonStockPursuantToATMOfferingNetOfOfferingCostsPaid
      contextRef="D20240930_CommonStockMember_3"
      decimals="0"
      id="Tag682"
      unitRef="Shares">135568</sxtp:IssuanceOfCommonStockPursuantToATMOfferingNetOfOfferingCostsPaid>
    <sxtp:StockIssuedDuringPeriodValueIssuanceOfCommonStockPursuantToATMOfferingNetOfOfferingCosts
      contextRef="D20240930_CommonStockMember_3"
      decimals="0"
      id="Tag691"
      unitRef="USD">14</sxtp:StockIssuedDuringPeriodValueIssuanceOfCommonStockPursuantToATMOfferingNetOfOfferingCosts>
    <sxtp:StockIssuedDuringPeriodValueIssuanceOfCommonStockPursuantToATMOfferingNetOfOfferingCosts
      contextRef="D20240930_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Tag700"
      unitRef="USD">1729796</sxtp:StockIssuedDuringPeriodValueIssuanceOfCommonStockPursuantToATMOfferingNetOfOfferingCosts>
    <sxtp:StockIssuedDuringPeriodValueIssuanceOfCommonStockPursuantToATMOfferingNetOfOfferingCosts
      contextRef="D20240930_ParentMember"
      decimals="0"
      id="Tag541"
      unitRef="USD">1729810</sxtp:StockIssuedDuringPeriodValueIssuanceOfCommonStockPursuantToATMOfferingNetOfOfferingCosts>
    <sxtp:StockIssuedDuringPeriodValueIssuanceOfCommonStockPursuantToATMOfferingNetOfOfferingCosts
      contextRef="D20240930"
      decimals="0"
      id="Tag534"
      unitRef="USD">1729810</sxtp:StockIssuedDuringPeriodValueIssuanceOfCommonStockPursuantToATMOfferingNetOfOfferingCosts>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="D20240930_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Tag703"
      unitRef="USD">3414502</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="D20240930_ParentMember"
      decimals="0"
      id="Tag542"
      unitRef="USD">3414502</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="D20240930"
      decimals="0"
      id="Tag535"
      unitRef="USD">3414502</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits
      contextRef="D20240930_CommonStockMember_3"
      decimals="0"
      id="Tag683"
      unitRef="Shares">18710</us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits>
    <sxtp:StockIssuedDuringPeriodValueIssuanceOfCommonStockForFractionalSharesPursuantToReverseStockSplitRoundingAdjustment
      contextRef="D20240930_CommonStockMember_3"
      decimals="0"
      id="Tag693"
      unitRef="USD">2</sxtp:StockIssuedDuringPeriodValueIssuanceOfCommonStockForFractionalSharesPursuantToReverseStockSplitRoundingAdjustment>
    <sxtp:StockIssuedDuringPeriodValueIssuanceOfCommonStockForFractionalSharesPursuantToReverseStockSplitRoundingAdjustment
      contextRef="D20240930_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Tag387"
      unitRef="USD">-2</sxtp:StockIssuedDuringPeriodValueIssuanceOfCommonStockForFractionalSharesPursuantToReverseStockSplitRoundingAdjustment>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="D20240930_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Tag702"
      unitRef="USD">15246</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="D20240930_ParentMember"
      decimals="0"
      id="Tag543"
      unitRef="USD">15246</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="D20240930"
      decimals="0"
      id="Tag536"
      unitRef="USD">15246</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="D20240930_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="Tag539"
      unitRef="USD">4403</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="D20240930_ParentMember"
      decimals="0"
      id="Tag544"
      unitRef="USD">4403</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="D20240930"
      decimals="0"
      id="Tag537"
      unitRef="USD">4403</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:ProfitLoss
      contextRef="D20240930_RetainedEarningsUnappropriatedMember"
      decimals="0"
      id="Tag335"
      unitRef="USD">-2159785</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="D20240930_ParentMember"
      decimals="0"
      id="Tag337"
      unitRef="USD">-2159785</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="D20240930_NoncontrollingInterestMember"
      decimals="0"
      id="Tag338"
      unitRef="USD">-713</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="D20240930"
      decimals="0"
      id="Tag334"
      unitRef="USD">-2160498</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding
      contextRef="I20240930_PreferredStockMember_SeriesAPreferredStockMember"
      decimals="0"
      id="Tag547"
      unitRef="Shares">76480</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="I20240930_PreferredStockMember_SeriesAPreferredStockMember"
      decimals="0"
      id="Tag546"
      unitRef="USD">9567439</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="I20240930_CommonStockMember"
      decimals="0"
      id="Tag680"
      unitRef="Shares">372397</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="I20240930_CommonStockMember"
      decimals="0"
      id="Tag692"
      unitRef="USD">38</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="I20240930_AdditionalPaidInCapitalMember"
      decimals="0"
      id="Tag701"
      unitRef="USD">34815790</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="I20240930_RetainedEarningsUnappropriatedMember"
      decimals="0"
      id="Tag336"
      unitRef="USD">-38482920</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="I20240930_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      id="Tag540"
      unitRef="USD">139207</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="I20240930_ParentMember"
      decimals="0"
      id="Tag545"
      unitRef="USD">6039554</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="I20240930_NoncontrollingInterestMember"
      decimals="0"
      id="Tag339"
      unitRef="USD">-76707</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="I20240930"
      decimals="0"
      id="Tag538"
      unitRef="USD">5962847</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="D20250930_1"
      decimals="0"
      id="Tag251"
      unitRef="USD">-5929267</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="D20240930_1"
      decimals="0"
      id="Tag356"
      unitRef="USD">-5906739</us-gaap:ProfitLoss>
    <us-gaap:Depreciation
      contextRef="D20250930_1"
      decimals="0"
      id="Tag439"
      unitRef="USD">28155</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="D20240930_1"
      decimals="0"
      id="Tag579"
      unitRef="USD">6277</us-gaap:Depreciation>
    <us-gaap:AdjustmentForAmortization
      contextRef="D20250930_1"
      decimals="0"
      id="Tag440"
      unitRef="USD">31150</us-gaap:AdjustmentForAmortization>
    <us-gaap:AdjustmentForAmortization
      contextRef="D20240930_1"
      decimals="0"
      id="Tag580"
      unitRef="USD">28004</us-gaap:AdjustmentForAmortization>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="D20250930_1"
      id="Tag602"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="D20240930_1"
      decimals="0"
      id="Tag624"
      unitRef="USD">13517</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <sxtp:AmortizationOfCapitalizedShareBasedPayments
      contextRef="D20250930_1"
      decimals="0"
      id="Tag441"
      unitRef="USD">132353</sxtp:AmortizationOfCapitalizedShareBasedPayments>
    <sxtp:AmortizationOfCapitalizedShareBasedPayments
      contextRef="D20240930_1"
      decimals="0"
      id="Tag581"
      unitRef="USD">3531763</sxtp:AmortizationOfCapitalizedShareBasedPayments>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensation
      contextRef="D20250930_1"
      decimals="0"
      id="Tag442"
      unitRef="USD">212030</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensation
      contextRef="D20240930_1"
      decimals="0"
      id="Tag625"
      unitRef="USD">15246</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="D20250930_1"
      decimals="0"
      id="Tag569"
      unitRef="USD">-156445</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="D20240930_1"
      decimals="0"
      id="Tag357"
      unitRef="USD">1683034</us-gaap:DerivativeGainLossOnDerivativeNet>
    <sxtp:WriteoffsOfCapitalizedPatents
      contextRef="D20250930_1"
      id="Tag603"
      unitRef="USD"
      xsi:nil="true"/>
    <sxtp:WriteoffsOfCapitalizedPatents
      contextRef="D20240930_1"
      decimals="0"
      id="Tag582"
      unitRef="USD">11300</sxtp:WriteoffsOfCapitalizedPatents>
    <us-gaap:InventoryLIFOReservePeriodCharge
      contextRef="D20250930_1"
      decimals="0"
      id="Tag610"
      unitRef="USD">244682</us-gaap:InventoryLIFOReservePeriodCharge>
    <us-gaap:InventoryLIFOReservePeriodCharge
      contextRef="D20240930_1"
      id="Tag609"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="D20250930_1"
      decimals="0"
      id="Tag360"
      unitRef="USD">187288</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="D20240930_1"
      decimals="0"
      id="Tag361"
      unitRef="USD">92490</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="D20250930_1"
      decimals="0"
      id="Tag567"
      unitRef="USD">-10373</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="D20240930_1"
      decimals="0"
      id="Tag362"
      unitRef="USD">99756</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="D20250930_1"
      decimals="0"
      id="Tag353"
      unitRef="USD">328922</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="D20240930_1"
      decimals="0"
      id="Tag583"
      unitRef="USD">-14133</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="D20250930_1"
      decimals="0"
      id="Tag607"
      unitRef="USD">455378</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="D20240930_1"
      decimals="0"
      id="Tag584"
      unitRef="USD">171411</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet
      contextRef="D20250930_1"
      decimals="0"
      id="Tag568"
      unitRef="USD">-18345</us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet>
    <us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet
      contextRef="D20240930_1"
      decimals="0"
      id="Tag363"
      unitRef="USD">5853</us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="D20250930_1"
      id="Tag601"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="D20240930_1"
      decimals="0"
      id="Tag374"
      unitRef="USD">-13650</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="D20250930_1"
      decimals="0"
      id="Tag369"
      unitRef="USD">-5156566</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="D20240930_1"
      decimals="0"
      id="Tag370"
      unitRef="USD">-4009871</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <sxtp:PaymentOfCapitalizationOfPatents
      contextRef="D20250930_1"
      decimals="0"
      id="Tag354"
      unitRef="USD">20868</sxtp:PaymentOfCapitalizationOfPatents>
    <sxtp:PaymentOfCapitalizationOfPatents
      contextRef="D20240930_1"
      decimals="0"
      id="Tag358"
      unitRef="USD">49869</sxtp:PaymentOfCapitalizationOfPatents>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="D20250930_1"
      decimals="0"
      id="Tag364"
      unitRef="USD">60000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="D20240930_1"
      decimals="0"
      id="Tag359"
      unitRef="USD">103773</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="D20250930_1"
      decimals="0"
      id="Tag365"
      unitRef="USD">1785</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="D20240930_1"
      decimals="0"
      id="Tag366"
      unitRef="USD">25374</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireShortTermInvestments
      contextRef="D20250930_1"
      id="Tag599"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PaymentsToAcquireShortTermInvestments
      contextRef="D20240930_1"
      decimals="0"
      id="Tag367"
      unitRef="USD">1708000</us-gaap:PaymentsToAcquireShortTermInvestments>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
      contextRef="D20250930_1"
      decimals="0"
      id="Tag565"
      unitRef="USD">1708000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
      contextRef="D20240930_1"
      id="Tag600"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="D20250930_1"
      decimals="0"
      id="Tag566"
      unitRef="USD">1625347</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="D20240930_1"
      decimals="0"
      id="Tag368"
      unitRef="USD">-1887016</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <sxtp:NetProceedsFromSharesAndWarrantsOffering
      contextRef="D20250930_1"
      id="Tag592"
      unitRef="USD"
      xsi:nil="true"/>
    <sxtp:NetProceedsFromSharesAndWarrantsOffering
      contextRef="D20240930_1"
      decimals="0"
      id="Tag604"
      unitRef="USD">1898296</sxtp:NetProceedsFromSharesAndWarrantsOffering>
    <sxtp:NetProceedsFromJanuary2025Offering
      contextRef="D20250930_1"
      decimals="0"
      id="Tag605"
      unitRef="USD">804346</sxtp:NetProceedsFromJanuary2025Offering>
    <sxtp:NetProceedsFromJanuary2025Offering
      contextRef="D20240930_1"
      id="Tag593"
      unitRef="USD"
      xsi:nil="true"/>
    <sxtp:NetProceedsFromFebruary2025Offering
      contextRef="D20250930_1"
      decimals="0"
      id="Tag606"
      unitRef="USD">908627</sxtp:NetProceedsFromFebruary2025Offering>
    <sxtp:NetProceedsFromFebruary2025Offering
      contextRef="D20240930_1"
      id="Tag634"
      unitRef="USD"
      xsi:nil="true"/>
    <sxtp:NetProceedsFromJuly2025Offering
      contextRef="D20250930_1"
      decimals="0"
      id="Tag620"
      unitRef="USD">4281300</sxtp:NetProceedsFromJuly2025Offering>
    <sxtp:NetProceedsFromJuly2025Offering
      contextRef="D20240930_1"
      id="Tag621"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="D20250930_1"
      decimals="0"
      id="Tag355"
      unitRef="USD">18000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="D20240930_1"
      id="Tag594"
      unitRef="USD"
      xsi:nil="true"/>
    <sxtp:ProceedsFromIssuanceATMOfferingCosts
      contextRef="D20250930_1"
      id="Tag595"
      unitRef="USD"
      xsi:nil="true"/>
    <sxtp:ProceedsFromIssuanceATMOfferingCosts
      contextRef="D20240930_1"
      decimals="0"
      id="Tag585"
      unitRef="USD">1729810</sxtp:ProceedsFromIssuanceATMOfferingCosts>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="D20250930_1"
      id="Tag596"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="D20240930_1"
      decimals="0"
      id="Tag586"
      unitRef="USD">3414502</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <sxtp:ProceedsFromExerciseOfPreFundedWarrants
      contextRef="D20250930_1"
      decimals="0"
      id="Tag570"
      unitRef="USD">2804</sxtp:ProceedsFromExerciseOfPreFundedWarrants>
    <sxtp:ProceedsFromExerciseOfPreFundedWarrants
      contextRef="D20240930_1"
      decimals="0"
      id="Tag587"
      unitRef="USD">9990</sxtp:ProceedsFromExerciseOfPreFundedWarrants>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="D20250930_1"
      decimals="0"
      id="Tag571"
      unitRef="USD">5979077</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="D20240930_1"
      decimals="0"
      id="Tag588"
      unitRef="USD">7052598</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="D20250930_1"
      decimals="0"
      id="Tag572"
      unitRef="USD">8568</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="D20240930_1"
      decimals="0"
      id="Tag589"
      unitRef="USD">2492</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="D20250930_1"
      decimals="0"
      id="Tag573"
      unitRef="USD">2456426</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="D20240930_1"
      decimals="0"
      id="Tag590"
      unitRef="USD">1158203</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="I20241231"
      decimals="0"
      id="Tag574"
      unitRef="USD">1659353</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="I20231231"
      decimals="0"
      id="Tag575"
      unitRef="USD">2142485</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="I20250930"
      decimals="0"
      id="Tag576"
      unitRef="USD">4115779</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="I20240930"
      decimals="0"
      id="Tag577"
      unitRef="USD">3300688</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <sxtp:FairValueOfWarrantsIssuedToUnderwriters
      contextRef="D20250930_1"
      id="Tag597"
      unitRef="USD"
      xsi:nil="true"/>
    <sxtp:FairValueOfWarrantsIssuedToUnderwriters
      contextRef="D20240930_1"
      decimals="0"
      id="Tag591"
      unitRef="USD">71364</sxtp:FairValueOfWarrantsIssuedToUnderwriters>
    <us-gaap:NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1
      contextRef="D20250930_1"
      decimals="0"
      id="Tag608"
      unitRef="USD">46099</us-gaap:NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1>
    <us-gaap:NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1
      contextRef="D20240930_1"
      id="Tag707"
      unitRef="USD"
      xsi:nil="true"/>
    <sxtp:ConversionOfSeriesAPreferredStockIntoCommonStock
      contextRef="D20250930_1"
      id="Tag706"
      unitRef="USD"
      xsi:nil="true"/>
    <sxtp:ConversionOfSeriesAPreferredStockIntoCommonStock
      contextRef="D20240930_1"
      decimals="0"
      id="Tag705"
      unitRef="USD">290601</sxtp:ConversionOfSeriesAPreferredStockIntoCommonStock>
    <us-gaap:NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1
      contextRef="D20250930_1"
      decimals="0"
      id="Tag632"
      unitRef="USD">3796</us-gaap:NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1>
    <us-gaap:NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1
      contextRef="D20240930_1"
      id="Tag633"
      unitRef="USD"
      xsi:nil="true"/>
    <sxtp:GrossSharesIssuedForAnnualPerformanceBonuses
      contextRef="D20250930_1"
      decimals="0"
      id="Tag578"
      unitRef="USD">121544</sxtp:GrossSharesIssuedForAnnualPerformanceBonuses>
    <sxtp:GrossSharesIssuedForAnnualPerformanceBonuses
      contextRef="D20240930_1"
      id="Tag598"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NatureOfOperations contextRef="D20250930_1" id="Tag981">&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;1. NATURE OF OPERATIONS&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;60 Degrees Pharmaceuticals, Inc. was incorporated in Delaware on June 1, &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c270bf7cd5ba984b5e1c'; font-family: 'Times New Roman'"&gt;&lt;span&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; and merged on the same day with &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c657950d5b1564663aa5'; font-family: 'Times New Roman'"&gt;&lt;span&gt;60&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; Degrees Pharmaceuticals, LLC, a District of Columbia limited liability company organized on September &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c1c7e4992ee8ee67833d'; font-family: 'Times New Roman'"&gt;&lt;span&gt;9&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;, &lt;/span&gt;&lt;span style="-aw-sdt-tag:'ca396d6e4d1f987f4646'; font-family: 'Times New Roman'"&gt;&lt;span&gt;2010&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; (&#x201c;&lt;/span&gt;&lt;span style="-aw-sdt-tag:'ccbaaf62d4129f0282b6'; font-family: 'Times New Roman'"&gt;&lt;span&gt;60&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;P LLC&#x201d;). &lt;/span&gt;&lt;span style="-aw-sdt-tag:'cba51fa10334af688698'; font-family: 'Times New Roman'"&gt;&lt;span&gt;60&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; Degrees Pharmaceuticals, Inc. and its subsidiary (referred to collectively as the &#x201c;Company&#x201d;, &#x201c;&lt;/span&gt;&lt;span style="-aw-sdt-tag:'c5523ac12e81e3a392be'; font-family: 'Times New Roman'"&gt;&lt;span&gt;60&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;P&#x201d;, or &#x201c;&lt;/span&gt;&lt;span style="-aw-sdt-tag:'c784671fbd07bf0d40cf'; font-family: 'Times New Roman'"&gt;&lt;span&gt;60&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; Degrees Pharmaceuticals&#x201d;) is a specialty pharmaceutical company that specializes in the development and marketing of new medicines for the treatment and prevention of infectious diseases. &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c834b08102bb9356bc64'; font-family: 'Times New Roman'"&gt;&lt;span&gt;60&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;P achieved FDA approval of its lead product, ARAKODA&#xae; (tafenoquine), for malaria prevention, in &lt;/span&gt;&lt;span style="-aw-sdt-tag:'ce4eef3e3aca50301650'; font-family: 'Times New Roman'"&gt;&lt;span&gt;2018&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;. Currently, &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c93fc95f7e4cdd4f571a'; font-family: 'Times New Roman'"&gt;&lt;span&gt;60&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;P&#x2019;s pipeline under development covers development programs for tick-borne fungal and other viral diseases utilizing three of the Company&#x2019;s future products: (i) new products that contain the Arakoda regimen of tafenoquine; (ii) new products that contain tafenoquine; and (iii) celgosivir and/or botanical extracts from Australian Chestnut Trees. The Company&#x2019;s headquarters are located in Washington, D.C., with a majority-owned subsidiary in Australia.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-weight:bold; text-decoration:underline; font-family: 'Times New Roman'"&gt;Risks and Uncertainties&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;The Company is subject to risks common to companies in the biopharmaceutical industry including, but not limited to, the risks associated with developing product candidates and successfully launching and commercializing its drug/device combination products, the Company&#x2019;s ability to obtain regulatory approval of such products in the United States and other geography markets, the uncertainty of the broad adoption of its approved products by physicians and consumers, and significant competition.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;In addition, higher rates of inflation have resulted in the U.S. Federal Reserve raising interest rates. Increases in interest rates, especially if coupled with reduced government spending and volatility in financial markets, may further increase economic uncertainty and heighten these risks. Furthermore, if additional banks and financial institutions enter receivership or become insolvent in the future in response to financial conditions affecting the banking system and financial markets, the Company or its partners&#x2019; ability to access existing cash, cash equivalents and investments may be threatened and could have a material adverse effect on the Company&#x2019;s business and financial condition, including the Company&#x2019;s ability to access additional capital on favorable terms, or at all, which could in the future negatively affect the Company&#x2019;s ability to pursue its business strategy.&lt;/span&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-weight:bold; text-decoration:underline; font-family: 'Times New Roman'"&gt;Going Concern&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;The Company&#x2019;s future results are subject to substantial risks and uncertainties. Since its inception, the Company has not demonstrated the ability to generate enough revenues to date to cover operating expenses and has accumulated losses to date. At &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c6621e838f6e2797b148'; -aw-sdt-title:'Current_Period_P26'; font-family: 'Times New Roman'"&gt;&lt;span&gt;September 30, 2025&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;, the Company had cash and cash equivalents totaling $&lt;/span&gt;&lt;span style="-aw-sdt-tag:'ccf01eed229ee36500f5'; -aw-sdt-title:'cash and cash equivalents_CP'; font-family: 'Times New Roman'"&gt;&lt;span&gt;4,115,779&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;, as compared to cash and cash equivalents totaling $&lt;/span&gt;&lt;span style="-aw-sdt-tag:'c9861c7425fd7e3efbf3'; -aw-sdt-title:'cash and cash equivalents_PY'; font-family: 'Times New Roman'"&gt;&lt;span&gt;1,659,353&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; at &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c3b49d62cc46a9e3bf26'; -aw-sdt-title:'Previous_Year_End_P19'; font-family: 'Times New Roman'"&gt;&lt;span&gt;December 31, 2024&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;. During the &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c1d42859dfcea9ae8a6a'; -aw-sdt-title:'Current_YTD_P3'; font-family: 'Times New Roman'"&gt;&lt;span&gt;nine months ended September 30, 2025&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; the Company used cash of $&lt;/span&gt;&lt;span style="-aw-sdt-tag:'c1c30bf00acb9628ea81'; -aw-sdt-title:'Operating activities_CYTD'; font-family: 'Times New Roman'"&gt;&lt;span&gt;5,156,566&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; in its operating activities. The Company&#x2019;s capital commitments over the next twelve months include interest payments on the Company&#x2019;s debt arrangement of $&lt;/span&gt;&lt;span style="-aw-sdt-tag:'c7df475d3e16907ec478'; -aw-sdt-title:'Next 12M Debt Payments'; font-family: 'Times New Roman'"&gt;&lt;span&gt;8,772&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; and $&lt;/span&gt;&lt;span style="-aw-sdt-tag:'bbd-7d3-a59-176-8056'; -aw-sdt-title:'Next 12M AP and Accruals'; font-family: 'Times New Roman'"&gt;&lt;span&gt;1,391,347&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; to satisfy accounts payable and accrued expenses.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;To date, the Company has funded its operations primarily with proceeds from sales of common stock and warrants for the purchase of common stock, sales of preferred stock, proceeds from the issuance of convertible debt and borrowings under loan and security agreements.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Continuation as a going concern is dependent upon the Company&#x2019;s ability to meet its financial requirements, raise additional capital, and achieve gross profitability from the Company&#x2019;s single marketed product. To achieve profitability, the Company expects it will need to raise additional capital to fund its activities relating to commercial support for its existing product and any future clinical research trials and operating activities. However, there can be no assurance that it will ever achieve or maintain profitability. These conditions, among others, raise substantial doubt about the ability of the Company to continue as a going concern for one year from the date these consolidated condensed financial statements are issued.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="-aw-sdt-tag:'PG_c12ebe76f85b70d02c5e'"&gt;&lt;/div&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Management plans to fund operations of the Company through third party and related party debt/advances, private placement of restricted securities and the issuance of stock in a subsequent offering until such a time as the business achieves profitability or a business combination may be achieved. However, there can be no assurance that the Company will be successful in raising additional capital or that such capital, if available, will be on terms that are favorable to the Company. Debt financing and equity financing, if available, may involve agreements that include covenants limiting or restricting the Company&#x2019;s ability to take specific actions, such as incurring additional debt, making capital expenditures, or declaring dividends. If the Company raises funds through collaborations, or other similar arrangements with third parties, it may have to relinquish valuable rights to its technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to the Company and/or may reduce the value of its common stock. If the Company is unable to raise additional funds through equity or debt financings when needed, it may be required to delay, limit, reduce or terminate its product development or future commercialization efforts or grant rights to develop and market its product candidates even if the Company would otherwise prefer to develop and market such product candidates itself.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;As such, management concluded that such plans do not alleviate the substantial doubt about the ability of the Company to continue as a going concern for one year from the date these consolidated condensed financial statements are issued.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;The consolidated condensed financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of obligations in the normal course of business, and do not include any adjustments to the amount and classification of assets and liabilities that may be necessary should the Company be unable to continue as a going concern.&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &lt;/span&gt;&lt;/p&gt;</us-gaap:NatureOfOperations>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="I20250930"
      decimals="0"
      id="Tag740"
      unitRef="USD">4115779</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="I20241231"
      decimals="0"
      id="Tag741"
      unitRef="USD">1659353</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="D20250930_1"
      decimals="0"
      id="Tag743"
      unitRef="USD">-5156566</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <sxtp:SBAEIDLincludingAccruedInterestCurrent
      contextRef="I20250930"
      decimals="0"
      id="Tag742"
      unitRef="USD">8772</sxtp:SBAEIDLincludingAccruedInterestCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="I20250930"
      decimals="0"
      id="Tag813"
      unitRef="USD">1391347</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="D20250930_1" id="Tag974">&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="-aw-import:spaces; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="-aw-sdt-tag:'cdb505dc74cc1259e26b'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-weight:bold; text-decoration:underline; font-family: 'Times New Roman'"&gt;Basis of Presentation&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;The financial statements of &lt;/span&gt;&lt;span style="-aw-sdt-tag:'ce903abe84353d2391d6'; font-family: 'Times New Roman'"&gt;&lt;span&gt;60&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;P are prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;). The Company has prepared the accompanying consolidated condensed financial statements pursuant to the instructions to Form &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c90d6f77918f6efd358d'; font-family: 'Times New Roman'"&gt;&lt;span&gt;10&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;-Q and Article &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c8389d80e96daea9720b'; font-family: 'Times New Roman'"&gt;&lt;span&gt;8&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; of Regulation S-X of the Securities and Exchange Commission (&#x201c;SEC&#x201d;). These financial statements are unaudited and, in the opinion of management, all adjustments considered necessary for a fair presentation of the Company&#x2019;s financial position, results of operations, and cash flows have been included and are of a normal and recurring nature. Operating results for the periods presented are not necessarily indicative of the results that may be expected for the year ending &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c0c7176b5bdb194bfddc'; -aw-sdt-title:'Current_Year_End_P1'; font-family: 'Times New Roman'"&gt;&lt;span&gt;December 31, 2025&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; due to various factors. These consolidated condensed financial statements should be read in conjunction with the audited consolidated financial statements and related notes thereto as of and for the years ended &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c18cdcd3e90810c9b66a'; -aw-sdt-title:'Previous_Year_End_P6'; font-family: 'Times New Roman'"&gt;&lt;span&gt;December 31, 2024&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; and &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c81138fdfee9b110fdf9'; font-family: 'Times New Roman'"&gt;&lt;span&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;, included in the Company&#x2019;s annual report on Form &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c4c00800b9e2d5f1439e'; font-family: 'Times New Roman'"&gt;&lt;span&gt;10&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;-K, as filed with the SEC on March &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c48ed363e59cdbbb1e8b'; font-family: 'Times New Roman'"&gt;&lt;span&gt;27&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;, &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c7da1b0fe69d8d60fb79'; font-family: 'Times New Roman'"&gt;&lt;span&gt;2025&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; (the &#x201c;Annual Report&#x201d;). Certain information, footnote disclosures, and significant accounting policies that would substantially duplicate the disclosures contained in the Annual Report have been omitted.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="-aw-sdt-tag:'d24-ead-d5b-0d7-fd95'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-weight:bold; text-decoration:underline; font-family: 'Times New Roman'"&gt;Use of Estimates&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates, and those estimates may be material. Significant estimates include the reserve for inventory, the fair value of derivative liabilities, and stock-based compensation.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="-aw-sdt-tag:'PG_c5050bfc508bd0645091'"&gt;&lt;/div&gt;&lt;div style="-aw-sdt-tag:'c6fb7024e47107499fcb'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-weight:bold; text-decoration:underline; font-family: 'Times New Roman'"&gt;Reverse Stock Splits&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="-aw-sdt-tag:'dac-e32-fd4-981-41a6'; font-family: 'Times New Roman'"&gt;&lt;span&gt;Following stockholder approval in July 2024, the Company effected a reverse stock split at a ratio of 1:12, which was effective as of August 12, 2024 (the &#x201c;1:12 Reverse Stock Split&#x201d;).&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;span style="-aw-sdt-tag:'731-9b8-7ee-b5e-cc0f'; font-family: 'Times New Roman'"&gt;&lt;span&gt;On November 6, 2024, a majority of the Company&#x2019;s stockholders approved an additional reverse stock split at a split ratio ranging between 1:3 and 1:5, as determined by the Board of Directors in its sole discretion.&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;span style="-aw-sdt-tag:'013-0eb-6cc-bc0-02a0'; font-family: 'Times New Roman'"&gt;&lt;span&gt;On February 10, 2025, the Board of Directors approved a 1:5 reverse split ratio. On February 24, 2025, the Company effected the 1:5 reverse stock split (the &#x201c;1:5 Reverse Stock Split&#x201d;, and together with the 1:12 Reverse Stock Split, the &#x201c;Reverse Stock Splits&#x201d;).&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; Beginning February &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c26c29b86737c43d1066'; font-family: 'Times New Roman'"&gt;&lt;span&gt;24&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;, &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c7cca48741fbb787a7db'; font-family: 'Times New Roman'"&gt;&lt;span&gt;2025&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;, the common stock traded on The Nasdaq Capital Market on a split adjusted basis.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Proportional adjustments were made to the number of shares of common stock issuable upon exercise or conversion of the Company&#x2019;s equity awards, warrants, and other equity instruments convertible into common stock, as well as the respective exercise prices, if applicable, in accordance with the terms of the instruments. Unless otherwise noted, all references to numbers of shares of the Company&#x2019;s common stock and per share information presented in these consolidated condensed financial statements have been retroactively adjusted, as appropriate, to reflect the Reverse Stock Splits, including reclassifying an amount equal to the reduction in par value of common stock to additional paid-in capital.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="-aw-sdt-tag:'ce4d5252ffc132995fd3'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-weight:bold; text-decoration:underline; font-family: 'Times New Roman'"&gt;Concentrations&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents, short-term investments, accounts receivable, inventory purchases, and borrowings.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Significant customers represent any customer whose business makes up &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c38d441a704cc0769f2e'; font-family: 'Times New Roman'"&gt;&lt;span&gt;10&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;% of receivables or revenues. At &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c8aefa95b7837b6c59db'; -aw-sdt-title:'Current_Period_P1'; font-family: 'Times New Roman'"&gt;&lt;span&gt;September 30, 2025&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;, significant customers represented &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c7d0ee37bbed719c14fb'; -aw-sdt-title:'Current_Sig. Cust AR Percent'; font-family: 'Times New Roman'"&gt;&lt;span&gt;89&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;% of receivables (consisting of &lt;/span&gt;&lt;span style="-aw-sdt-tag:'efa-f25-b7a-0c0-3393'; -aw-sdt-title:'Current_Total Customers in AR'; font-family: 'Times New Roman'"&gt;&lt;span&gt;six&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; total customers and &lt;/span&gt;&lt;span style="-aw-sdt-tag:'6bd-f9c-095-2b1-0b97'; -aw-sdt-title:'Current_Sigificant Customers in AR'; font-family: 'Times New Roman'"&gt;&lt;span&gt;two&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; significant customers at &lt;/span&gt;&lt;span style="-aw-sdt-tag:'757-b3e-309-2f1-7957'; -aw-sdt-title:'AR Sig Customer 1 _Current'; font-family: 'Times New Roman'"&gt;&lt;span&gt;75&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;% and &lt;/span&gt;&lt;span style="-aw-sdt-tag:'053-64b-d59-480-934c'; font-family: 'Times New Roman'"&gt;&lt;span&gt;13&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;%, respectively), and &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c8865edd41199200cda9'; -aw-sdt-title:'Prior_Sig. Cust AR Percent'; font-family: 'Times New Roman'"&gt;&lt;span&gt;95&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;% of receivables at &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c612e322ca6f5a44144a'; -aw-sdt-title:'Previous_Year_End_P7'; font-family: 'Times New Roman'"&gt;&lt;span&gt;December 31, 2024&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; (consisting of &lt;/span&gt;&lt;span style="-aw-sdt-tag:'58c-1fd-4c8-cbc-24e3'; -aw-sdt-title:'Prior_Total Customers in AR'; font-family: 'Times New Roman'"&gt;&lt;span&gt;three&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; total customers and &lt;/span&gt;&lt;span style="-aw-sdt-tag:'0cd-eb1-27d-ce1-d261'; -aw-sdt-title:'Prior_Sigificant Customers in AR'; font-family: 'Times New Roman'"&gt;&lt;span&gt;one&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; significant customer). For the &lt;/span&gt;&lt;span style="-aw-sdt-tag:'ca0e62e990a606583b94'; -aw-sdt-title:'Current_Quarter_P14'; font-family: 'Times New Roman'"&gt;&lt;span&gt;three months ended September 30, 2025&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;, significant customers comprised &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c610c2cb61e4f95ffd6c'; -aw-sdt-title:'CQTD_Sig.Cust Percent Net Revenue'; font-family: 'Times New Roman'"&gt;&lt;span&gt;80&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;% of total net product revenues (consisting of &lt;/span&gt;&lt;span style="-aw-sdt-tag:'7ac-793-8fb-7b6-6b7e'; -aw-sdt-title:'CQTD_Total Customers'; font-family: 'Times New Roman'"&gt;&lt;span&gt;four&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; total customers and &lt;/span&gt;&lt;span style="-aw-sdt-tag:'935-1d8-24e-b55-3697'; -aw-sdt-title:'CWTD_Significant Customers'; font-family: 'Times New Roman'"&gt;&lt;span&gt;one&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; significant customer at &lt;/span&gt;&lt;span style="-aw-sdt-tag:'fd4-598-fc6-c55-b5b3'; -aw-sdt-title:'CQTD_Sig Customer 1 Percent'; font-family: 'Times New Roman'"&gt;&lt;span&gt;80&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;%). For the &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c89b221bf86e60e80aee'; -aw-sdt-title:'Previous_Quarter_P5'; font-family: 'Times New Roman'"&gt;&lt;span&gt;three months ended September 30, 2024&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;, &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c4871e9ed0486ef91d28'; -aw-sdt-title:'PQTD_Sig.Cust Percent Net Revenue'; font-family: 'Times New Roman'"&gt;&lt;span&gt;92&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;% of total net product revenues (consisting of &lt;/span&gt;&lt;span style="-aw-sdt-tag:'92a-ab1-dc7-7a9-7dd3'; -aw-sdt-title:'PQTD_Total Customers'; font-family: 'Times New Roman'"&gt;&lt;span&gt;two&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; total customers and &lt;/span&gt;&lt;span style="-aw-sdt-tag:'813-a74-d78-4e2-d0ec'; -aw-sdt-title:'PQTD_Significant Customers'; font-family: 'Times New Roman'"&gt;&lt;span&gt;one&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; significant customer) were generated from significant customers. For the &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c71fb825a8fc9183fba4'; -aw-sdt-title:'Current_YTD_P9'; font-family: 'Times New Roman'"&gt;&lt;span&gt;nine months ended September 30, 2025&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;,&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;span style="-aw-sdt-tag:'cd703ca85832d9e6ccd9'; -aw-sdt-title:'CYTD_Sig.Cust Percent Net Revenue'; font-family: 'Times New Roman'"&gt;&lt;span&gt;91&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;% of total net product revenues (consisting of &lt;/span&gt;&lt;span style="-aw-sdt-tag:'d25-e87-6c3-44b-77b8'; -aw-sdt-title:'CYTD_Total Customers'; font-family: 'Times New Roman'"&gt;&lt;span&gt;four&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; total customers and &lt;/span&gt;&lt;span style="-aw-sdt-tag:'623-163-567-ed7-13d7'; -aw-sdt-title:'CYTD_Significant Customers'; font-family: 'Times New Roman'"&gt;&lt;span&gt;two&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; significant customers at &lt;/span&gt;&lt;span style="-aw-sdt-tag:'fd4-589-ac0-f12-5f6a'; font-family: 'Times New Roman'"&gt;&lt;span&gt;73&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;% and &lt;/span&gt;&lt;span style="-aw-sdt-tag:'aa0-f10-986-33c-5f25'; -aw-sdt-title:'CYTD_Sig Customer 2 Percent'; font-family: 'Times New Roman'"&gt;&lt;span&gt;18&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;%, respectively) were generated from significant customers. For the &lt;/span&gt;&lt;span style="-aw-sdt-tag:'cd6d62b9c3ce9b21e230'; -aw-sdt-title:'Previous_YTD_P4'; font-family: 'Times New Roman'"&gt;&lt;span&gt;nine months ended September 30, 2024&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;,&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;span style="-aw-sdt-tag:'c34cf87b1815b4a11766'; -aw-sdt-title:'PYTD_Sig.Cust Percent Net Revenue'; font-family: 'Times New Roman'"&gt;&lt;span&gt;94&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;% of total net product revenues (consisting of &lt;/span&gt;&lt;span style="-aw-sdt-tag:'f2f-f63-4d3-652-810a'; -aw-sdt-title:'PYTD_Total Customers'; font-family: 'Times New Roman'"&gt;&lt;span&gt;three&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; total customers and &lt;/span&gt;&lt;span style="-aw-sdt-tag:'20a-b2d-e5b-ae2-0417'; -aw-sdt-title:'PYTD_Significant Customers'; font-family: 'Times New Roman'"&gt;&lt;span&gt;one&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; significant customer) were generated from significant customers.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Currently, the Company has exclusive relationships with distributors in Australia and Europe. A failure to perform by any of our current distributors would create disruption for patients in those markets.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Since the Company first started working on tafenoquine, all inventory has been acquired in a collaborative relationship from a sole vendor. Should the vendor cease to supply tafenoquine, it would take significant costs and efforts to rebuild the supply chain with a new sole vendor sourcing the active pharmaceutical ingredient (&#x201c;API&#x201d;).&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="-aw-sdt-tag:'cb21377b78bedc008a21'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-weight:bold; text-decoration:underline; font-family: 'Times New Roman'"&gt;Segment Information&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Since its inception, the Company operates and manages its business as a single identifiable segment, focused on the development and marketing of new medicines for the treatment and prevention of infectious diseases. The determination of a single business segment is consistent with the consolidated financial information regularly provided to the Company&#x2019;s chief operating decision maker (&#x201c;CODM&#x201d;).&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:10pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;The Company&#x2019;s CODM is its Chief Executive Officer, who reviews and evaluates consolidated net income or loss for purposes of evaluating performance, making operating decisions, allocating resources, and planning and forecasting for future periods. The significant components of consolidated net income or loss regularly provided to the CODM include net product revenues and the significant expense categories presented in the accompanying &lt;/span&gt;&lt;span style="-aw-sdt-tag:'40d-f92-19d-c95-c73e'; -aw-sdt-title:'PandL_title_P2'; font-family: 'Times New Roman'"&gt;&lt;span&gt;consolidated condensed statements of operations and comprehensive loss&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; (cost of revenues, research and development, and general and administrative expenses). These are presented at the consolidated level and used by the CODM to monitor budgeted versus actual results to make key operating decisions. The information and operating expense categories presented in the accompanying &lt;/span&gt;&lt;span style="-aw-sdt-tag:'253-c33-1cd-8c6-3ae5'; -aw-sdt-title:'PandL_title_P3'; font-family: 'Times New Roman'"&gt;&lt;span&gt;consolidated condensed statements of operations and comprehensive loss&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; are fully reflective of the significant expense categories and amounts that are regularly provided to the CODM.&lt;/span&gt;&lt;/p&gt;&lt;div style="-aw-sdt-tag:'PG_c24bb3258a68b0280db8'"&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="-aw-sdt-tag:'cb21377b78bedc008a21'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;The measure of segment assets that is regularly reported to the CODM includes cash and cash equivalents and short-term investments, each as reported on the &lt;/span&gt;&lt;span style="-aw-sdt-tag:'139-b42-89d-4af-5020'; -aw-sdt-title:'Balance_Sheet_Title_P1'; font-family: 'Times New Roman'"&gt;&lt;span&gt;consolidated condensed balance sheets&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;. Total consolidated cash and cash equivalents and short-term investments were $&lt;/span&gt;&lt;span style="-aw-sdt-tag:'c26449208c3edf5c7aa8'; font-family: 'Times New Roman'"&gt;&lt;span&gt;4,115,779&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; and $&lt;/span&gt;&lt;span style="-aw-sdt-tag:'cdccccade90e66a13fb9'; font-family: 'Times New Roman'"&gt;&lt;span&gt;3,387,825&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; as of &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c7407e74fc85ec3ccdfe'; -aw-sdt-title:'Current_Period_P2'; font-family: 'Times New Roman'"&gt;&lt;span&gt;September 30, 2025&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; and &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c00bf74fe48b3c64541d'; -aw-sdt-title:'Previous_Year_End_P12'; font-family: 'Times New Roman'"&gt;&lt;span&gt;December 31, 2024&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;, respectively.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="-aw-sdt-tag:'aed-ca6-c7c-350-2bc6'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-weight:bold; text-decoration:underline; font-family: 'Times New Roman'"&gt;Derivative Liabilities&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;The Company analyzes all financial instruments with features of both liabilities and equity under FASB ASC Topic No. &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c4a98c0f9c305eb9ad0a'; font-family: 'Times New Roman'"&gt;&lt;span&gt;480&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;, &lt;/span&gt;&lt;span style="font-style:italic; font-family: 'Times New Roman'"&gt;Distinguishing Liabilities from Equity&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; (&#x201c;ASC &lt;/span&gt;&lt;span style="-aw-sdt-tag:'ce2b75a3274a6a43e17f'; font-family: 'Times New Roman'"&gt;&lt;span&gt;480&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#x201d;), and FASB ASC Topic No. &lt;/span&gt;&lt;span style="-aw-sdt-tag:'ced90c7d41ecdbd49877'; font-family: 'Times New Roman'"&gt;&lt;span&gt;815&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;, &lt;/span&gt;&lt;span style="font-style:italic; font-family: 'Times New Roman'"&gt;Derivatives and Hedging&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; (&#x201c;ASC &lt;/span&gt;&lt;span style="-aw-sdt-tag:'ccd1349dccf1b3e1afae'; font-family: 'Times New Roman'"&gt;&lt;span&gt;815&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#x201d;). The classification of derivative financial instruments is reassessed each reporting period. Derivative liabilities are adjusted to reflect fair value at each reporting period, with any increase or decrease in the fair value recorded in the results of operations, as a component of other income or expense as change in fair value of derivative liabilities. As of &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c1af92d97c032e45d07a'; -aw-sdt-title:'Current_Period_P14'; font-family: 'Times New Roman'"&gt;&lt;span&gt;September 30, 2025&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;, derivative liabilities consist of contingent payment arrangements. The Company uses a probability-weighted expected return method to determine the fair value of these instruments.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Upon conversion or repayment of a debt or equity instrument in exchange for equity shares, where the embedded conversion option has been bifurcated and accounted for as a derivative liability (generally convertible debt and warrants), the Company records the equity shares at fair value on the date of conversion, relieves all related debt, derivative liabilities, and unamortized debt discounts, and recognizes a net gain or loss on debt extinguishment, if any.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Equity or liability instruments that become subject to reclassification under ASC Topic &lt;/span&gt;&lt;span style="-aw-sdt-tag:'ce08ae8c5268be0628c7'; font-family: 'Times New Roman'"&gt;&lt;span&gt;815&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; are reclassified at the fair value of the instrument on the reclassification date.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="-aw-sdt-tag:'c263c163ec50c04829df'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-weight:bold; text-decoration:underline; font-family: 'Times New Roman'"&gt;Equity-Classified Warrants&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;As of &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c7bcd8e778eedd1caaab'; -aw-sdt-title:'Current_Period_P11'; font-family: 'Times New Roman'"&gt;&lt;span&gt;September 30, 2025&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;, the Company accounts for all outstanding warrants to purchase common stock as equity-classified instruments based on an assessment of the warrants&#x2019; specific terms and applicable authoritative guidance in ASC &lt;/span&gt;&lt;span style="-aw-sdt-tag:'cdb856b4f4bde6d47eab'; font-family: 'Times New Roman'"&gt;&lt;span&gt;480&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; and ASC &lt;/span&gt;&lt;span style="-aw-sdt-tag:'cd5e76a6a6ce96ef7c87'; font-family: 'Times New Roman'"&gt;&lt;span&gt;815&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;. This assessment considers whether the warrants are freestanding financial instruments pursuant to ASC &lt;/span&gt;&lt;span style="-aw-sdt-tag:'cd481df4cd7bb454097c'; font-family: 'Times New Roman'"&gt;&lt;span&gt;480&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;, meet the definition of a liability pursuant to ASC &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c75d25a4963187f34a5b'; font-family: 'Times New Roman'"&gt;&lt;span&gt;480&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;, whether the warrants meet all of the requirements for equity classification under ASC &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c8f59ed9b1458f19f86f'; font-family: 'Times New Roman'"&gt;&lt;span&gt;815&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;, including whether the warrants are indexed to the Company&#x2019;s own common stock and whether the warrant holders could potentially require &#x201c;net cash settlement&#x201d; in a circumstance outside of the Company&#x2019;s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the respective issuance dates and as of each subsequent reporting period while the warrants are outstanding.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="-aw-sdt-tag:'cd350ef809c535d516f7'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-weight:bold; text-decoration:underline; font-family: 'Times New Roman'"&gt;Revenue Recognition&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;The Company recognizes revenue in accordance with FASB ASC Topic No. &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c1024005423a4297ddef'; font-family: 'Times New Roman'"&gt;&lt;span&gt;606&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;, &lt;/span&gt;&lt;span style="font-style:italic; font-family: 'Times New Roman'"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; (&#x201c;ASC &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c01990ecd114b774522a'; font-family: 'Times New Roman'"&gt;&lt;span&gt;606&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#x201d;). Revenues are recognized when control is transferred to customers in amounts that reflect the consideration the Company expects to be entitled to receive in exchange for those goods. Revenue recognition is evaluated through the following five steps: (i) identification of the contract, or contracts, with a customer; (ii) identification of the performance obligations in the contract; (iii) determination of the transaction price; (iv) allocation of the transaction price to the performance obligations in the contract; and (v) recognition of revenue when or as a performance obligation is satisfied. As part of the accounting for these arrangements, the Company may be required to make significant judgments, including identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each performance obligation.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Revenues from product sales are recorded at the net sales price, or &#x201c;transaction price,&#x201d; which may include estimates of variable consideration that result from product returns. The Company determines the amount of variable consideration by using either the expected value method or the most-likely-amount method. The Company includes the unconstrained amount of estimated variable consideration in the transaction price, which reflects the amount for which it is probable that a significant reversal of cumulative revenue recognized will not occur. At the end of each subsequent reporting period, the Company re-evaluates the estimated variable consideration included in the transaction price and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis in the period of adjustment. Reserves are established for the estimates of variable consideration based on the amounts the Company expects to be earned or to be claimed on the related sales.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="-aw-sdt-tag:'PG_c6053e6c5f792d82acc2'"&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="-aw-sdt-tag:'cd350ef809c535d516f7'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;The Company receives the majority of its revenues from sales of its Arakoda product to resellers in the US and abroad. The Company records US commercial revenues as a receivable when our American distributor transfers shipped product to their title model for &lt;/span&gt;&lt;span style="-aw-sdt-tag:'cfae9bd6533b6134b81a'; font-family: 'Times New Roman'"&gt;&lt;span&gt;60&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;P. Foreign sales to both Australia and Europe are recognized as a receivable at the point product is shipped to distributor. The shipments to Australia and Europe are further subject to profit sharing agreements for boxes sold to customers.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="-aw-sdt-tag:'c84f7303a81bfc500dea'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-weight:bold; text-decoration:underline; font-family: 'Times New Roman'"&gt;Research and Development Costs &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;The Company accounts for research and development costs in accordance with FASB ASC Subtopic No. &lt;/span&gt;&lt;span style="-aw-sdt-tag:'cbc781f7013a6eaa59f8'; font-family: 'Times New Roman'"&gt;&lt;span&gt;730&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;-&lt;/span&gt;&lt;span style="-aw-sdt-tag:'c82ed5ff78a1295bb276'; font-family: 'Times New Roman'"&gt;&lt;span&gt;10&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;, Research and Development (&#x201c;ASC &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c8d16d1806c924bd6931'; font-family: 'Times New Roman'"&gt;&lt;span&gt;730&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;-&lt;/span&gt;&lt;span style="-aw-sdt-tag:'ca09ffaa8d3135cb1e6b'; font-family: 'Times New Roman'"&gt;&lt;span&gt;10&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#x201d;). Under ASC &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c9a334fab141f1bfcaaa'; font-family: 'Times New Roman'"&gt;&lt;span&gt;730&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;-&lt;/span&gt;&lt;span style="-aw-sdt-tag:'cd9c059505344e7aa50b'; font-family: 'Times New Roman'"&gt;&lt;span&gt;10&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;, research and development costs are expensed as incurred. Accordingly, internal research and development costs are expensed as incurred. Prepayments for research and development services are deferred and amortized over the service period as the services are provided. Advance payments for specific materials, equipment, or facilities determined to have no alternative future use are initially deferred and recognized as research and development expense when the related goods are delivered.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;The Company recorded $&lt;/span&gt;&lt;span style="-aw-sdt-tag:'c0cae7d3178274b183f7'; -aw-sdt-title:'CQTD_RandD Expense'; font-family: 'Times New Roman'"&gt;&lt;span&gt;809,777&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;and $&lt;/span&gt;&lt;span style="-aw-sdt-tag:'c819708eba76301c2ea4'; -aw-sdt-title:'PQTD_RandD Expense'; font-family: 'Times New Roman'"&gt;&lt;span&gt;940,063&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;in research and development expense during the &lt;/span&gt;&lt;span style="-aw-sdt-tag:'cc1e5d1af75cc719a927'; -aw-sdt-title:'Current_Quarter_P15'; font-family: 'Times New Roman'"&gt;&lt;span&gt;three months ended September 30, 2025&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; and &lt;/span&gt;&lt;span style="-aw-sdt-tag:'cc35a31294de2fb9966a'; -aw-sdt-title:'Previous_Year_P29'; font-family: 'Times New Roman'"&gt;&lt;span&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;, respectively, ($&lt;/span&gt;&lt;span style="-aw-sdt-tag:'c0a12c3296b44a12831e'; -aw-sdt-title:'CYTD_RandD Expense'; font-family: 'Times New Roman'"&gt;&lt;span&gt;1,467,283&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; and $&lt;/span&gt;&lt;span style="-aw-sdt-tag:'c0c5d0d81b151b0a0872'; -aw-sdt-title:'PYTD_RandD Expense'; font-family: 'Times New Roman'"&gt;&lt;span&gt;4,372,571&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; for the &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c14bc5f963419ab2aed9'; -aw-sdt-title:'Current_YTD_P12'; font-family: 'Times New Roman'"&gt;&lt;span&gt;nine months ended September 30, 2025&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; and &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c141bbe47f263859b34f'; -aw-sdt-title:'Previous_Year_P30'; font-family: 'Times New Roman'"&gt;&lt;span&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;, respectively). The Company has also issued shares of common stock to nonemployees in exchange for research and development services. The Company recognizes prepaid research and development costs on the grant date, as defined in FASB ASC Subtopic No. &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c5f925ba06665ac933a5'; font-family: 'Times New Roman'"&gt;&lt;span&gt;718&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;, &lt;/span&gt;&lt;span style="font-style:italic; font-family: 'Times New Roman'"&gt;Compensation - Stock Compensation&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;. See Note &lt;/span&gt;&lt;span style="-aw-sdt-tag:'cd731d5a4723c771d07e'; font-family: 'Times New Roman'"&gt;&lt;span&gt;10&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; for further details.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="-aw-sdt-tag:'c8e2e451fcc7fadfeb42'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-weight:bold; text-decoration:underline; font-family: 'Times New Roman'"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;The carrying value of the Company&#x2019;s financial instruments included in current assets and current liabilities (such as cash and cash equivalents, accounts receivable, accounts payable, and accrued expenses) approximate their fair value due to the short-term nature of such instruments.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;The inputs used to measure fair value are based on a hierarchy that prioritizes observable and unobservable inputs used in valuation techniques. These levels, in order of highest to lowest priority, are described below:&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="width:100%"&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td style="width:36pt; vertical-align:top"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;Level &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c10a34efbf72f35b33de'; font-family: 'Times New Roman'"&gt;&lt;span style="font-weight:bold"&gt;1&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:18pt; vertical-align:top"&gt;&lt;div style="-aw-sdt-tag:'c574d522f70efd479dc3'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Quoted prices (unadjusted) in active markets that are accessible at the measurement date for identical assets or liabilities.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;Level &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c152bc38d599e5fa0056'; font-family: 'Times New Roman'"&gt;&lt;span style="font-weight:bold"&gt;2&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="-aw-sdt-tag:'c41453b900cbc0348861'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Observable prices that are based on inputs not quoted on active markets but corroborated by market data.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;Level &lt;/span&gt;&lt;span style="-aw-sdt-tag:'cae8e9dbfa205b2e8396'; font-family: 'Times New Roman'"&gt;&lt;span style="font-weight:bold"&gt;3&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="-aw-sdt-tag:'c38191d9430425b3ee7b'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Unobservable inputs reflecting the Company&#x2019;s assumptions, consistent with reasonably available assumptions made by other market participants. These valuations require significant judgment.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;The Company&#x2019;s financial instruments recorded at fair value on a recurring basis at &lt;/span&gt;&lt;span style="-aw-sdt-tag:'ccb07ec5194190047e9d'; -aw-sdt-title:'Current_Period_P12'; font-family: 'Times New Roman'"&gt;&lt;span&gt;September 30, 2025&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;, and &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c12a3919fe92233b9c27'; -aw-sdt-title:'Previous_Year_End_P13'; font-family: 'Times New Roman'"&gt;&lt;span&gt;December 31, 2024&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; include the derivative liability associated with the contingent milestone payment due to Knight upon a future sale of Arakoda or a Change of Control, which is carried at fair value based on Level &lt;/span&gt;&lt;span style="-aw-sdt-tag:'cf44dbdc1b5a3adb8e5d'; font-family: 'Times New Roman'"&gt;&lt;span&gt;3&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; inputs. The Company uses a probability-weighted expected return method to determine the fair value of the contingent milestone payment using significant inputs such as the timing and probability of discrete potential exit scenarios, forward interest rate curves, and discount rates based on implied and market yields. See Note &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c607a69561493866770f'; font-family: 'Times New Roman'"&gt;&lt;span&gt;8&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; for more information on Derivative Liabilities.&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="-aw-sdt-tag:'PG_c0c20bca974f854c1494'"&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="-aw-sdt-tag:'c8e2e451fcc7fadfeb42'"&gt;&lt;div style="-aw-sdt-tag:'ce01f1bed3993d32f2f9'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Liabilities measured at fair value at &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c0bf68fbeefde243c15a'; -aw-sdt-title:'Current_Period_P15'; font-family: 'Times New Roman'"&gt;&lt;span&gt;September 30, 2025&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; and &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c732f17c4f405be7abd5'; -aw-sdt-title:'Previous_Year_End_P15'; font-family: 'Times New Roman'"&gt;&lt;span&gt;December 31, 2024&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; are as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="-aw-sdt-tag:'cf921e92f02c49f734d5'; -aw-sdt-title:'SIGNIFICANT ACCOUNTING POLICIES T1'"&gt;&lt;table cellpadding="0" cellspacing="0" style="width:100%; border-collapse:collapse"&gt;&lt;tbody&gt;&lt;tr style="height:11.5pt"&gt;&lt;td style="width:53%; vertical-align:middle"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:spaces; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="border-bottom:1.5pt solid #000000; vertical-align:bottom"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_1f865470141349c9b37ae84a55aacecc'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;September 30, 2025&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.5pt"&gt;&lt;td style="width:53%; vertical-align:middle"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1.5pt solid #000000; border-bottom:1pt solid #000000; vertical-align:middle"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_a9a7008663a046198bc1b79f62990348'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"&gt;&lt;span style="font-weight:bold; -aw-import:spaces; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1.5pt solid #000000; border-bottom:1pt solid #000000; vertical-align:middle"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_81f8a817fe384b62ae7dcf394585ad13'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"&gt;&lt;span style="font-weight:bold; -aw-import:spaces; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1.5pt solid #000000; border-bottom:1pt solid #000000; vertical-align:middle"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_0f2ddb2f4dea4255b9372b845c3d8cf9'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"&gt;&lt;span style="font-weight:bold; -aw-import:spaces; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1.5pt solid #000000; border-bottom:1pt solid #000000; vertical-align:middle"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_5169a80e4244429fb7957e47ebcd8580'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"&gt;&lt;span style="font-weight:bold; -aw-import:spaces; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.5pt"&gt;&lt;td style="width:53%; vertical-align:middle; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_c3fe79fa6419450bb2de75dc0fbcb8e0'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:spaces; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.5pt"&gt;&lt;td style="width:53%; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_37594b78a4ff46fda8c7c6c31dda2819'"&gt;&lt;p style="margin-top:0pt; margin-left:5.4pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:spaces; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Derivative Liabilities&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_7f6e995134194c1f85dce5bf4027caab'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-tag:'C_1ebf3664e1d74ad8aa7a5f6f86bcafc6'"&gt;&lt;span title="&amp;amp;#13;nil='true'"&gt;&lt;/span&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_2f314ddebd474b209bfcbd65835b25ed'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-tag:'C_ab7845e24d35492db1dd11a0aaa21e2e'"&gt;&lt;span title="&amp;amp;#13;nil='true'"&gt;&lt;/span&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_e71039cd49df4ed0a91d801f3eecd241'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_c478d60eaf6f4ba79d74d84f29ff1501'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;797,275&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_d7e156ea5a164ce28ac588dac4d1a77f'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_706a282cea3b4dce906d3c671c501ff6'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;797,275&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.5pt"&gt;&lt;td style="width:53%; vertical-align:middle; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_e3a4e18287cc4026a749060e1e8fb5a9'"&gt;&lt;p style="margin-top:0pt; margin-left:5.4pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:spaces; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_105c7afdf9de422991cf5a00287ac307'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-tag:'C_7d18406ed78f4c4f8c3bb851f3c5e787'"&gt;&lt;span title="&amp;amp;#13;nil='true'"&gt;&lt;/span&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_49026756b4a640278f43ece44be0ab14'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-tag:'C_a3c7a3645b97455cade875ff7e738781'"&gt;&lt;span title="&amp;amp;#13;nil='true'"&gt;&lt;/span&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_8bbc20c75ef0447fa466d4bfaafb8f5f'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_62a7e9f4e692400483031bb740e41569'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;797,275&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_07827564eb61499086af507f234ed67f'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_1600b9fa42ba44889bf927265c22067e'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;797,275&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="-aw-sdt-tag:'cb468fdcd6e0460b0777'; -aw-sdt-title:'SIGNIFICANT ACCOUNTING POLICIES T2'"&gt;&lt;table cellpadding="0" cellspacing="0" style="width:100%; border-collapse:collapse"&gt;&lt;tbody&gt;&lt;tr style="height:11.5pt"&gt;&lt;td style="width:53%; vertical-align:middle"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:spaces; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="border-bottom:1pt solid #000000; vertical-align:bottom"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_4b44e1528e8c4f3cbca59f75d6bdc366'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.5pt"&gt;&lt;td style="width:53%; vertical-align:middle"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1.5pt solid #000000; border-bottom:1pt solid #000000; vertical-align:middle"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_63bb47cb4152462c97cb5bc1a070ad98'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"&gt;&lt;span style="font-weight:bold; -aw-import:spaces; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1.5pt solid #000000; border-bottom:1pt solid #000000; vertical-align:middle"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_b9e93ac9d9e9420ea54dc08f973671b4'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"&gt;&lt;span style="font-weight:bold; -aw-import:spaces; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1.5pt solid #000000; border-bottom:1pt solid #000000; vertical-align:middle"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_6cfd423b093941b7a426daca9a7c4fd9'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"&gt;&lt;span style="font-weight:bold; -aw-import:spaces; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1.5pt solid #000000; border-bottom:1pt solid #000000; vertical-align:middle"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_ba6b2c8ff28f4584a84bb8a1cf763836'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"&gt;&lt;span style="font-weight:bold; -aw-import:spaces; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.5pt"&gt;&lt;td style="width:53%; vertical-align:middle; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_a6ef2c6558264f7ca0c50be6c5f2e477'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:spaces; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.5pt"&gt;&lt;td style="width:53%; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_1ad21d4a0f664c76a8a1de7dc61969e3'"&gt;&lt;p style="margin-top:0pt; margin-left:5.4pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:spaces; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Derivative Liabilities&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_0c00d5728d434da99efe8bee0a732f0f'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-tag:'C_38b73fa55f154f55af3cfbeff629bf16'"&gt;&lt;span title="&amp;amp;#13;nil='true'"&gt;&lt;/span&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_e025b21daccb422bbc8f2753e7ae30b9'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-tag:'C_333fc1e0c3f6433084115dd2779c80c0'"&gt;&lt;span title="&amp;amp;#13;nil='true'"&gt;&lt;/span&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_ccf3e162c56f48aabe5b242a8d57684f'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_fda27296d6fe4023a90164878a00a1d8'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;640,830&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_121a4a1679bd49579650a47153a7674a'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_8c697e7693374899bebfc6db6f39b905'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;640,830&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.5pt"&gt;&lt;td style="width:53%; vertical-align:middle; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_cb56be67da024df7ab547d83c57f3594'"&gt;&lt;p style="margin-top:0pt; margin-left:5.4pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:spaces; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_1d0941b2301d4640a725a3c444db0b29'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-tag:'C_34e9411fc246454890a3839765ba75c7'"&gt;&lt;span title="&amp;amp;#13;nil='true'"&gt;&lt;/span&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_5c011b0873844cb68a8ad4cfa194d590'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-tag:'C_59708d0fdeda4619aa91fe10eff71319'"&gt;&lt;span title="&amp;amp;#13;nil='true'"&gt;&lt;/span&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_fcc1b7589a9c4ce3859c970a7eb6b9c6'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_712785fcd2f54bfb89d8883eed8aebd5'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;640,830&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_e0ed0ee91ac4479e99c9a1322299ae2a'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_a4fc6be6554e49b0832d0ac5c0e1c4d7'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;640,830&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;There were no transfers of financial instruments between Level &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c512200b7f4efb193a74'; font-family: 'Times New Roman'"&gt;&lt;span&gt;1&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;, Level &lt;/span&gt;&lt;span style="-aw-sdt-tag:'cc88af1c10b9095520b3'; font-family: 'Times New Roman'"&gt;&lt;span&gt;2&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;, and Level &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c28cda9bda6d116b1482'; font-family: 'Times New Roman'"&gt;&lt;span&gt;3&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; during the periods presented.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;A rollforward of liabilities measured at fair value using Level &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c3417e051371b629cb2b'; font-family: 'Times New Roman'"&gt;&lt;span&gt;3&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; inputs for the &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c07ff2f3886b9784d3b4'; -aw-sdt-title:'Current_Quarter_and_YTD_P9'; font-family: 'Times New Roman'"&gt;&lt;span&gt;three and nine months ended September 30, 2025&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; and &lt;/span&gt;&lt;span style="-aw-sdt-tag:'ce922678da5c46f0ab60'; font-family: 'Times New Roman'"&gt;&lt;span&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; is presented in Note &lt;/span&gt;&lt;span style="-aw-sdt-tag:'cb6b017f206e8e342188'; font-family: 'Times New Roman'"&gt;&lt;span&gt;8&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &#x2013; Derivative Liabilities.&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="-aw-sdt-tag:'ce957af50e61212b40ab'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-weight:bold; text-decoration:underline; font-family: 'Times New Roman'"&gt;Assets and Liabilities Not Measured at Fair Value on a Recurring Basis&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;In addition to assets and liabilities that are measured at fair value on a recurring basis, the Company also measures certain assets and liabilities at fair value on a nonrecurring basis. The Company&#x2019;s non-financial assets, including Intangible Assets and Property and Equipment, are measured at fair value when there is an indication of impairment and the carrying amount exceeds the asset&#x2019;s projected undiscounted cash flows. These assets are recorded at fair value only when an impairment charge is recognized.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Certificates of deposit, classified as cash equivalents or short-term investments depending on the instrument&#x2019;s original time to maturity, are measured at amortized cost, which approximates fair value as of &lt;/span&gt;&lt;span style="-aw-sdt-tag:'cbcda125eaa60887c6fa'; -aw-sdt-title:'Current_Period_P21'; font-family: 'Times New Roman'"&gt;&lt;span&gt;September 30, 2025&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; and &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c1cb724ff032da6352c4'; -aw-sdt-title:'Previous_Year_End_P18'; font-family: 'Times New Roman'"&gt;&lt;span&gt;December 31, 2024&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="-aw-sdt-tag:'856-502-b92-78d-804f'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-weight:bold; text-decoration:underline; font-family: 'Times New Roman'"&gt;Foreign Currency Transactions and Translation&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;The individual financial statements of each group entity are measured and presented in the currency of the primary economic environment in which the entity operates (its functional currency). The consolidated condensed financial statements of the Company are presented in United States dollars, which is the functional currency of the Company and the presentation currency for the consolidated condensed financial statements.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;For the purpose of presenting consolidated condensed financial statements, the assets and liabilities of the Company&#x2019;s foreign operations are mostly translated at exchange rates prevailing on the reporting date. Income and expense items are translated at the average exchange rates for the period, unless exchange rates fluctuate significantly during that period, in which case the exchange rates at the dates of the transactions are used. Exchange differences arising, if any, are recognized as a component of other comprehensive income (loss) as unrealized foreign currency translation gain (loss).&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="-aw-sdt-tag:'PG_c0a5df5ef4dd14c932ff'"&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="-aw-sdt-tag:'856-502-b92-78d-804f'"&gt;&lt;div style="-aw-sdt-tag:'c777f028f5d92d4cc514'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Exchange rates along with historical rates used in these financial statements are as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="-aw-sdt-tag:'549-6dd-c75-531-a655'; -aw-sdt-title:'SIGNIFICANT ACCOUNTING POLICIES T3'"&gt;&lt;table cellpadding="0" cellspacing="0" style="width:100%; border-collapse:collapse"&gt;&lt;tbody&gt;&lt;tr style="height:11.5pt"&gt;&lt;td style="width:34%; vertical-align:bottom"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:bottom"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"&gt;&lt;span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="17" style="border-bottom:1.5pt solid #000000; padding:0.75pt; vertical-align:bottom; -aw-padding-bottom:0.75pt"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_9482da9e9ef24112bed6d94f9f662d7c'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;Average Exchange Rate&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.5pt"&gt;&lt;td style="width:34%; vertical-align:middle"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:bottom"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"&gt;&lt;span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; padding:0.75pt; vertical-align:bottom; -aw-padding-bottom:0.75pt; -aw-padding-top:0.75pt"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_659f3565fccf471d885d5bbcc6f23513'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; border-top:1.5pt solid #000000; vertical-align:bottom"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:bottom"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_af26db9d568a41c18f4404ac7ead58b6'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; border-top:1.5pt solid #000000; vertical-align:bottom"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:bottom"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_cf885fb35a704f019f0cad0d5795b8d8'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;As of&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.5pt"&gt;&lt;td style="width:34%; vertical-align:bottom"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_973ee19447724c17b71b4faa457b2249'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;Currency&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:bottom"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"&gt;&lt;span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; padding:0.75pt; vertical-align:bottom; -aw-padding-bottom:0.75pt; -aw-padding-top:0.75pt"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_e3e1c97c5b854e929dfeef87960bfbc4'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; border-top:1.5pt solid #000000; vertical-align:bottom"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:bottom"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_91424ca5026c4cce945405cc6ea74a81'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:bottom"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"&gt;&lt;span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:bottom"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_791c5860584c493ba5598384cfdde256'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; border-top:1.5pt solid #000000; vertical-align:bottom"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"&gt;&lt;span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:bottom"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_fd4986cad1d4488da73173ef15330bc0'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:bottom"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"&gt;&lt;span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:bottom"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_63ce180cbb5d445f83c9530d4f721062'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;September 30, 2025&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; border-top:1.5pt solid #000000; vertical-align:bottom"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"&gt;&lt;span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:bottom"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_d9d1430a9c7a400390a13074b0c685af'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.5pt"&gt;&lt;td style="width:34%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_dde09534ca0e4664b9e7a6dbce09d46b'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;1 AUD =&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:6%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_7254928b2f564e559f8c533598d728fb'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;0.65&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:4%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_01fc1cc76a7d496482338117b041e5d7'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;USD&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:6%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_0dd2b89b644c47918dd20e0ae4036641'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;0.67&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:4%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_60bc7b550ded4fd0b8454a10aff9f2b9'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;USD&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:6%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_39890b79d6d94e83bbb6512adb82089c'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;0.64&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:4%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_bcf46b0b9cd64fa28023abd0bd2f9eeb'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;USD&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:4%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_ffd190f4cb644fdc858572d0e04df5bc'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;0.66&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:4%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_2ed4c46e122f4c9388749a2785a69bc5'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;USD&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:bottom; background-color:#ccecff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:6%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_deaa0fa001c447fa9db5c11c7e69f76e'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;0.66&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:4%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_4ed3d209ddad4027b90139f12205d725'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;USD&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:6%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_f1dbbad2340443dba35674893ccabab6'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;0.62&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:4%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'0b4-c37-b49-3e0-c6cf'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;USD&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="-aw-sdt-tag:'cfbab6fdada9c08626e2'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-weight:bold; text-decoration:underline; font-family: 'Times New Roman'"&gt;Reclassifications&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Certain prior period interim amounts have been reclassified for consistency with the current period presentation. These reclassifications had no material effect on the consolidated condensed results of operations and comprehensive loss, shareholders&#x2019; equity, or cash flows.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="-aw-sdt-tag:'c5ae9390f02706bea469'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-weight:bold; text-decoration:underline; font-family: 'Times New Roman'"&gt;Share-Based Payments&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;On November &lt;/span&gt;&lt;span style="-aw-sdt-tag:'cb8e4cad4e4d214394a1'; font-family: 'Times New Roman'"&gt;&lt;span&gt;22&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;, &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c07fc0c7362febea5ed1'; font-family: 'Times New Roman'"&gt;&lt;span&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;, the Company adopted the &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c82523a8da0311b6da03'; font-family: 'Times New Roman'"&gt;&lt;span&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; Equity Incentive Plan also referred to as (&#x201c;&lt;/span&gt;&lt;span style="-aw-sdt-tag:'c84ff39eab4b2b69d4e5'; font-family: 'Times New Roman'"&gt;&lt;span&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; Plan&#x201d;). The &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c77a8fd767458ed89fe9'; font-family: 'Times New Roman'"&gt;&lt;span&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; Plan and related share-based awards are discussed more fully in Note &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c89592db43d1d0460416'; font-family: 'Times New Roman'"&gt;&lt;span&gt;10&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;The Company accounts for share-based payments in accordance with ASC Subtopic &lt;/span&gt;&lt;span style="-aw-sdt-tag:'cfb759d6c4e98b9f102c'; font-family: 'Times New Roman'"&gt;&lt;span&gt;718&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;, &lt;/span&gt;&lt;span style="font-style:italic; font-family: 'Times New Roman'"&gt;Compensation - Stock Compensation &lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;(&#x201c;ASC &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c28e007bf795e0cf0e4d'; font-family: 'Times New Roman'"&gt;&lt;span&gt;718&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#x201d;). The Company measures compensation for all share-based payment awards granted to employees, directors, and nonemployees, based on the estimated fair value of the awards on the date of grant. For awards that vest based on continued service, the service-based compensation cost is recognized on a straight-line basis over the requisite service period, which is generally the vesting period of the awards. For service vesting awards with compensation expense recognized on a straight-line basis, at no point in time does the cumulative grant date value of vested awards exceed the cumulative amount of compensation expense recognized. The grant date is determined based on the date when a mutual understanding of the key terms of the share-based awards is established. The Company accounts for forfeitures as they occur.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;The Company estimates the fair value of all stock option awards as of the grant date by applying the Black-Scholes option pricing model. The application of this valuation model involves assumptions, including the fair value of the common stock, expected volatility, risk-free interest rate, expected dividends and the expected term of the option. Due to the lack of a public market for the Company&#x2019;s common stock prior to the IPO and lack of company-specific historical implied volatility data, the Company has based its computations of expected volatility on the historical volatility of a representative group of public companies with similar characteristics of the Company, including stage of development and industry focus. The historical volatility is calculated based on a period of time commensurate with the expected term assumption. The Company generally uses the simplified method as prescribed by the SEC Staff Accounting Bulletin Topic &lt;/span&gt;&lt;span style="-aw-sdt-tag:'cdc65a3ad6830dc2131f'; font-family: 'Times New Roman'"&gt;&lt;span&gt;14&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;, &lt;/span&gt;&lt;span style="font-style:italic; font-family: 'Times New Roman'"&gt;Share-Based Payment&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;, to estimate the expected term for stock options, whereby, the expected term equals the midpoint of the weighted average remaining time to vest, vesting period and the contractual term of the options due to its lack of historical exercise data. For certain options granted out-of-the-money, the Company&#x2019;s best estimate of the expected term is the contractual term of the award. The risk-free interest rate is based on U.S. Treasury securities with a maturity date commensurate with the expected term of the associated award. The expected dividend yield is assumed to be zero as the Company has never paid dividends and has no current plans to pay any dividends on its common stock. The assumptions used in calculating the fair value of share-based awards represent management&#x2019;s best estimates and involve inherent uncertainties and the application of significant judgment.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Compensation expense for restricted stock units (&#x201c;RSUs&#x201d;) with only service-based vesting conditions is recognized on a straight-line basis over the vesting period. Compensation cost for service-based RSUs is based on the grant date fair value of the award, which is the closing market price of the Company&#x2019;s common stock on the grant date multiplied by the number of shares awarded.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;For awards that vest upon a liquidity event or a change in control, the performance condition is not probable of being achieved until the event occurs. As a result, no compensation expense is recognized until the performance-based vesting condition is achieved, at which time the cumulative compensation expense is recognized. Compensation cost related to any remaining time-based service for share-based awards after the liquidity-based event is recognized on a straight-line basis over the remaining service period.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;For fully vested, nonforfeitable equity instruments that are granted at the date the Company and a nonemployee enter into an agreement for goods or services, the Company recognizes the fair value of the equity instruments on the grant date. The corresponding cost is recognized as an immediate expense or a prepaid asset and expensed over the service period depending on the specific facts and circumstances of the agreement with the nonemployee. See Note &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c7c93237c1946f635b03'; font-family: 'Times New Roman'"&gt;&lt;span&gt;10&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; for further details.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="-aw-sdt-tag:'PG_c8b1ac81b7bf3b856ef3'"&gt;&lt;/div&gt;&lt;div style="-aw-sdt-tag:'c37c1b3b29bcf7d9b9ab'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-weight:bold; text-decoration:underline; font-family: 'Times New Roman'"&gt;Net Loss per Common Share&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="-aw-sdt-tag:'a31-2b2-f34-82d-cfe6'; -aw-sdt-title:'Net_(Loss)_Income_Title_P2'; font-family: 'Times New Roman'"&gt;&lt;span&gt;Net Loss&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; per Common Share is computed by dividing &lt;/span&gt;&lt;span style="-aw-sdt-tag:'a78-fb5-6f5-642-14ce'; -aw-sdt-title:'Net_(Loss)_Income_Title___Lower_P1'; font-family: 'Times New Roman'"&gt;&lt;span&gt;net loss&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; attributable to common shareholders by the weighted average number of common shares outstanding during each period. The Company includes pre-funded warrants, which carry a nominal exercise price per share, in its computation of basic and diluted net loss per share beginning on the date of issuance. The cumulative dividends accrued on the Series A Preferred Stock during the period are reflected as an increase to net loss or a reduction of net income in determining basic and diluted &lt;/span&gt;&lt;span style="-aw-sdt-tag:'31c-481-9ce-577-2088'; -aw-sdt-title:'Net_(Loss)_Income_Title___Lower_P2'; font-family: 'Times New Roman'"&gt;&lt;span&gt;net loss&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; attributable to common stockholders.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;As the Company reported a net loss for all periods presented, the calculation of diluted net loss per common share is the same as basic net loss per common share. &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;As a result of the &lt;/span&gt;&lt;span style="-aw-sdt-tag:'5f0-31e-83e-591-f354'; font-family: 'Times New Roman'"&gt;&lt;span&gt;1:5&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; Reverse Stock Split, which was effective as of February 24, 2025, all shares of outstanding common stock and net loss per common share calculations have been retroactively adjusted for all periods presented.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="-aw-sdt-tag:'c5700c4a179318bf9512'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-weight:bold; text-decoration:underline; font-family: 'Times New Roman'"&gt;Related Parties&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Parties are considered to be related to the Company if the parties, directly or indirectly, through one or more intermediaries, control, are controlled by, or are under common control with the Company. Related parties also include principal owners of the Company, its management, members of the immediate families of principal owners of the Company and its management and other parties with which the Company may deal with if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="-aw-sdt-tag:'c49a2178ae9eff53812a'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-weight:bold; text-decoration:underline; font-family: 'Times New Roman'"&gt;Subsequent Events&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;The Company considers events or transactions that occur after the balance sheet date, but prior to the issuance of the financial statements to provide additional evidence relative to certain estimates or to identify matters that require additional disclosure. Subsequent events have been evaluated through &lt;/span&gt;&lt;span style="-aw-sdt-tag:'cb270f797852c1e1f2a5'; -aw-sdt-title:'Current_Period_Date_FS_Issued_P1'; font-family: 'Times New Roman'"&gt;&lt;span&gt;November 13, 2025&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;, which is the date the financial statements were issued. See Note &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c8dbf1260408b95c5a15'; font-family: 'Times New Roman'"&gt;&lt;span&gt;12&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="-aw-sdt-tag:'b58-716-f7b-33e-6c0c'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-weight:bold; text-decoration:underline; font-family: 'Times New Roman'"&gt;Recently Adopted and Issued Accounting Pronouncements&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;From time to time, the FASB issues Accounting Standards Updates (&#x201c;ASU&#x201d;) to amend the authoritative literature in the ASC. The Company regularly evaluates new ASUs to determine the impact that these pronouncements may have on the consolidated condensed financial statements. Other than the pronouncements listed below, the Company believes that those issued to date either (i) provide supplemental guidance, (ii) are technical corrections, or (iii) are not applicable to the Company&#x2019;s consolidated condensed financial statements or related disclosures.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;In November &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c40fc8bff493befc18d6'; font-family: 'Times New Roman'"&gt;&lt;span&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;, the FASB issued ASU &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c0a6b49074383096c882'; font-family: 'Times New Roman'"&gt;&lt;span&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;-&lt;/span&gt;&lt;span style="-aw-sdt-tag:'cd25ae9feb1743719bb1'; font-family: 'Times New Roman'"&gt;&lt;span&gt;07&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;, &lt;/span&gt;&lt;span style="font-style:italic; font-family: 'Times New Roman'"&gt;Segment Reporting (Topic &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c48474e3644a54930dfc'; font-family: 'Times New Roman'"&gt;&lt;span style="font-style:italic"&gt;280&lt;/span&gt;&lt;/span&gt;&lt;span style="font-style:italic; font-family: 'Times New Roman'"&gt;): Improvements to Reportable Segment Disclosures&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; (&#x201c;ASU &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c731ea50ea67c7e4b420'; font-family: 'Times New Roman'"&gt;&lt;span&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;-&lt;/span&gt;&lt;span style="-aw-sdt-tag:'cce9c44e2351f5ac2796'; font-family: 'Times New Roman'"&gt;&lt;span&gt;07&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#x201d;) which expands annual and interim disclosure requirements for reportable segments, primarily through enhanced disclosures about significant segment expenses and segment profit or loss. ASU &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c7a9ce0a0ac8993d0acf'; font-family: 'Times New Roman'"&gt;&lt;span&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;-&lt;/span&gt;&lt;span style="-aw-sdt-tag:'cdd16562ce807243ed58'; font-family: 'Times New Roman'"&gt;&lt;span&gt;07&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; also requires entities with a single reportable segment to provide all segment disclosures under ASC &lt;/span&gt;&lt;span style="-aw-sdt-tag:'cf6e9777e809f25e1b07'; font-family: 'Times New Roman'"&gt;&lt;span&gt;280&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;, including the new required disclosures under the ASU. The Company adopted ASU &lt;/span&gt;&lt;span style="-aw-sdt-tag:'cc9be51d0fa22b72f687'; font-family: 'Times New Roman'"&gt;&lt;span&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;-&lt;/span&gt;&lt;span style="-aw-sdt-tag:'cc2f4662055f1cf358a4'; font-family: 'Times New Roman'"&gt;&lt;span&gt;07&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; on a retrospective basis for the &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c304e39ce5549b67326b'; font-family: 'Times New Roman'"&gt;&lt;span&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; annual period, and for interim periods beginning in &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c50e039416b6752cbc9e'; font-family: 'Times New Roman'"&gt;&lt;span&gt;2025&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;. The impact is limited to the Company&#x2019;s financial statement disclosures, which are presented in the Segment Information section above.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;In December &lt;/span&gt;&lt;span style="-aw-sdt-tag:'cf066c3ed14287513469'; font-family: 'Times New Roman'"&gt;&lt;span&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;, the FASB issued ASU &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c0565bc7ca2af95b4c7c'; font-family: 'Times New Roman'"&gt;&lt;span&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;-&lt;/span&gt;&lt;span style="-aw-sdt-tag:'ceb96c9259852308d896'; font-family: 'Times New Roman'"&gt;&lt;span&gt;09&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;, &lt;/span&gt;&lt;span style="font-style:italic; font-family: 'Times New Roman'"&gt;Income Taxes (ASC &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c0282851b575f38250ce'; font-family: 'Times New Roman'"&gt;&lt;span style="font-style:italic"&gt;740&lt;/span&gt;&lt;/span&gt;&lt;span style="font-style:italic; font-family: 'Times New Roman'"&gt;): Improvements to Income Tax Disclosures&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; (&#x201c;ASU &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c397c2576fab14a6843a'; font-family: 'Times New Roman'"&gt;&lt;span&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;-&lt;/span&gt;&lt;span style="-aw-sdt-tag:'c43ea664edca3b7d1221'; font-family: 'Times New Roman'"&gt;&lt;span&gt;09&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#x201d;) which requires disaggregated information about a reporting entity&#x2019;s effective tax rate reconciliation as well as information on income taxes paid. ASU &lt;/span&gt;&lt;span style="-aw-sdt-tag:'ced6791b435360aa514d'; font-family: 'Times New Roman'"&gt;&lt;span&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;-&lt;/span&gt;&lt;span style="-aw-sdt-tag:'c152d39afa37813cff35'; font-family: 'Times New Roman'"&gt;&lt;span&gt;09&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; is effective for annual periods beginning after December &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c65d60af908ae022a7fb'; font-family: 'Times New Roman'"&gt;&lt;span&gt;15&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;, &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c9d2f568ca33a0e3ddc2'; font-family: 'Times New Roman'"&gt;&lt;span&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;. The Company will adopt this standard for the annual period ending December 31, 2025. The impact of ASU 2023-09 will be limited to the Company&#x2019;s financial statement disclosures.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;In November &lt;/span&gt;&lt;span style="-aw-sdt-tag:'cb06da4c60c3ed718870'; font-family: 'Times New Roman'"&gt;&lt;span&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;, the FASB issued ASU &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c5896724f85326b5cf6c'; font-family: 'Times New Roman'"&gt;&lt;span&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;-&lt;/span&gt;&lt;span style="-aw-sdt-tag:'c5ee0130675746e94982'; font-family: 'Times New Roman'"&gt;&lt;span&gt;03&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;, &lt;/span&gt;&lt;span style="font-style:italic; font-family: 'Times New Roman'"&gt;Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c686357b9151070c0b80'; font-family: 'Times New Roman'"&gt;&lt;span style="font-style:italic"&gt;220&lt;/span&gt;&lt;/span&gt;&lt;span style="font-style:italic; font-family: 'Times New Roman'"&gt;-&lt;/span&gt;&lt;span style="-aw-sdt-tag:'ccb37deca24433c43642'; font-family: 'Times New Roman'"&gt;&lt;span style="font-style:italic"&gt;40&lt;/span&gt;&lt;/span&gt;&lt;span style="font-style:italic; font-family: 'Times New Roman'"&gt;): Disaggregation of Income Statement Expenses &lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;(&#x201c;ASU &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c82c510f162b91f255e5'; font-family: 'Times New Roman'"&gt;&lt;span&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;-&lt;/span&gt;&lt;span style="-aw-sdt-tag:'c9b3edff03a8224442ee'; font-family: 'Times New Roman'"&gt;&lt;span&gt;03&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#x201d;), which applies to all public business entities that file financial statements with the SEC. The amendments in this ASU require public business entities to disclose on an annual and interim basis, disaggregated information about certain income statement expense line items. The new standard is effective for fiscal years beginning after December &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c4227d4f684c80f6fc7b'; font-family: 'Times New Roman'"&gt;&lt;span&gt;15&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;, &lt;/span&gt;&lt;span style="-aw-sdt-tag:'cdb1897f2589fc5290f5'; font-family: 'Times New Roman'"&gt;&lt;span&gt;2026&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;, with early adoption permitted. The Company is currently evaluating the impact that ASU &lt;/span&gt;&lt;span style="-aw-sdt-tag:'cd9fcbee88c447594d3d'; font-family: 'Times New Roman'"&gt;&lt;span&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;-&lt;/span&gt;&lt;span style="-aw-sdt-tag:'cea1fdf602d68e8ea393'; font-family: 'Times New Roman'"&gt;&lt;span&gt;03&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; will have on its financial statement disclosures.&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="D20250930_1" id="Tag954">&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-weight:bold; text-decoration:underline; font-family: 'Times New Roman'"&gt;Basis of Presentation&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;The financial statements of &lt;/span&gt;&lt;span style="-aw-sdt-tag:'ce903abe84353d2391d6'; font-family: 'Times New Roman'"&gt;&lt;span&gt;60&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;P are prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;). The Company has prepared the accompanying consolidated condensed financial statements pursuant to the instructions to Form &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c90d6f77918f6efd358d'; font-family: 'Times New Roman'"&gt;&lt;span&gt;10&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;-Q and Article &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c8389d80e96daea9720b'; font-family: 'Times New Roman'"&gt;&lt;span&gt;8&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; of Regulation S-X of the Securities and Exchange Commission (&#x201c;SEC&#x201d;). These financial statements are unaudited and, in the opinion of management, all adjustments considered necessary for a fair presentation of the Company&#x2019;s financial position, results of operations, and cash flows have been included and are of a normal and recurring nature. Operating results for the periods presented are not necessarily indicative of the results that may be expected for the year ending &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c0c7176b5bdb194bfddc'; -aw-sdt-title:'Current_Year_End_P1'; font-family: 'Times New Roman'"&gt;&lt;span&gt;December 31, 2025&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; due to various factors. These consolidated condensed financial statements should be read in conjunction with the audited consolidated financial statements and related notes thereto as of and for the years ended &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c18cdcd3e90810c9b66a'; -aw-sdt-title:'Previous_Year_End_P6'; font-family: 'Times New Roman'"&gt;&lt;span&gt;December 31, 2024&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; and &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c81138fdfee9b110fdf9'; font-family: 'Times New Roman'"&gt;&lt;span&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;, included in the Company&#x2019;s annual report on Form &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c4c00800b9e2d5f1439e'; font-family: 'Times New Roman'"&gt;&lt;span&gt;10&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;-K, as filed with the SEC on March &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c48ed363e59cdbbb1e8b'; font-family: 'Times New Roman'"&gt;&lt;span&gt;27&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;, &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c7da1b0fe69d8d60fb79'; font-family: 'Times New Roman'"&gt;&lt;span&gt;2025&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; (the &#x201c;Annual Report&#x201d;). Certain information, footnote disclosures, and significant accounting policies that would substantially duplicate the disclosures contained in the Annual Report have been omitted.&lt;/span&gt;&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="D20250930_1" id="Tag959">&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-weight:bold; text-decoration:underline; font-family: 'Times New Roman'"&gt;Use of Estimates&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates, and those estimates may be material. Significant estimates include the reserve for inventory, the fair value of derivative liabilities, and stock-based compensation.&lt;/span&gt;&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:StockholdersEquityPolicyTextBlock contextRef="D20250930_1" id="Tag936">&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-weight:bold; text-decoration:underline; font-family: 'Times New Roman'"&gt;Reverse Stock Splits&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="-aw-sdt-tag:'dac-e32-fd4-981-41a6'; font-family: 'Times New Roman'"&gt;&lt;span&gt;Following stockholder approval in July 2024, the Company effected a reverse stock split at a ratio of 1:12, which was effective as of August 12, 2024 (the &#x201c;1:12 Reverse Stock Split&#x201d;).&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;span style="-aw-sdt-tag:'731-9b8-7ee-b5e-cc0f'; font-family: 'Times New Roman'"&gt;&lt;span&gt;On November 6, 2024, a majority of the Company&#x2019;s stockholders approved an additional reverse stock split at a split ratio ranging between 1:3 and 1:5, as determined by the Board of Directors in its sole discretion.&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;span style="-aw-sdt-tag:'013-0eb-6cc-bc0-02a0'; font-family: 'Times New Roman'"&gt;&lt;span&gt;On February 10, 2025, the Board of Directors approved a 1:5 reverse split ratio. On February 24, 2025, the Company effected the 1:5 reverse stock split (the &#x201c;1:5 Reverse Stock Split&#x201d;, and together with the 1:12 Reverse Stock Split, the &#x201c;Reverse Stock Splits&#x201d;).&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; Beginning February &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c26c29b86737c43d1066'; font-family: 'Times New Roman'"&gt;&lt;span&gt;24&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;, &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c7cca48741fbb787a7db'; font-family: 'Times New Roman'"&gt;&lt;span&gt;2025&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;, the common stock traded on The Nasdaq Capital Market on a split adjusted basis.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Proportional adjustments were made to the number of shares of common stock issuable upon exercise or conversion of the Company&#x2019;s equity awards, warrants, and other equity instruments convertible into common stock, as well as the respective exercise prices, if applicable, in accordance with the terms of the instruments. Unless otherwise noted, all references to numbers of shares of the Company&#x2019;s common stock and per share information presented in these consolidated condensed financial statements have been retroactively adjusted, as appropriate, to reflect the Reverse Stock Splits, including reclassifying an amount equal to the reduction in par value of common stock to additional paid-in capital.&lt;/span&gt;&lt;/p&gt;</us-gaap:StockholdersEquityPolicyTextBlock>
    <us-gaap:StockholdersEquityReverseStockSplit contextRef="D20240731" id="Tag739">Following stockholder approval in July 2024, the Company effected a reverse stock split at a ratio of 1:12, which was effective as of August 12, 2024 (the &#x201c;1:12 Reverse Stock Split&#x201d;).</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:StockholdersEquityReverseStockSplit contextRef="D20241106" id="Tag723">On November 6, 2024, a majority of the Company&#x2019;s stockholders approved an additional reverse stock split at a split ratio ranging between 1:3 and 1:5, as determined by the Board of Directors in its sole discretion.</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:StockholdersEquityReverseStockSplit contextRef="D20250210" id="Tag724">On February 10, 2025, the Board of Directors approved a 1:5 reverse split ratio. On February 24, 2025, the Company effected the 1:5 reverse stock split (the &#x201c;1:5 Reverse Stock Split&#x201d;, and together with the 1:12 Reverse Stock Split, the &#x201c;Reverse Stock Splits&#x201d;).</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="D20250930_1" id="Tag937">&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-weight:bold; text-decoration:underline; font-family: 'Times New Roman'"&gt;Concentrations&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents, short-term investments, accounts receivable, inventory purchases, and borrowings.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Significant customers represent any customer whose business makes up &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c38d441a704cc0769f2e'; font-family: 'Times New Roman'"&gt;&lt;span&gt;10&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;% of receivables or revenues. At &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c8aefa95b7837b6c59db'; -aw-sdt-title:'Current_Period_P1'; font-family: 'Times New Roman'"&gt;&lt;span&gt;September 30, 2025&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;, significant customers represented &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c7d0ee37bbed719c14fb'; -aw-sdt-title:'Current_Sig. Cust AR Percent'; font-family: 'Times New Roman'"&gt;&lt;span&gt;89&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;% of receivables (consisting of &lt;/span&gt;&lt;span style="-aw-sdt-tag:'efa-f25-b7a-0c0-3393'; -aw-sdt-title:'Current_Total Customers in AR'; font-family: 'Times New Roman'"&gt;&lt;span&gt;six&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; total customers and &lt;/span&gt;&lt;span style="-aw-sdt-tag:'6bd-f9c-095-2b1-0b97'; -aw-sdt-title:'Current_Sigificant Customers in AR'; font-family: 'Times New Roman'"&gt;&lt;span&gt;two&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; significant customers at &lt;/span&gt;&lt;span style="-aw-sdt-tag:'757-b3e-309-2f1-7957'; -aw-sdt-title:'AR Sig Customer 1 _Current'; font-family: 'Times New Roman'"&gt;&lt;span&gt;75&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;% and &lt;/span&gt;&lt;span style="-aw-sdt-tag:'053-64b-d59-480-934c'; font-family: 'Times New Roman'"&gt;&lt;span&gt;13&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;%, respectively), and &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c8865edd41199200cda9'; -aw-sdt-title:'Prior_Sig. Cust AR Percent'; font-family: 'Times New Roman'"&gt;&lt;span&gt;95&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;% of receivables at &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c612e322ca6f5a44144a'; -aw-sdt-title:'Previous_Year_End_P7'; font-family: 'Times New Roman'"&gt;&lt;span&gt;December 31, 2024&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; (consisting of &lt;/span&gt;&lt;span style="-aw-sdt-tag:'58c-1fd-4c8-cbc-24e3'; -aw-sdt-title:'Prior_Total Customers in AR'; font-family: 'Times New Roman'"&gt;&lt;span&gt;three&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; total customers and &lt;/span&gt;&lt;span style="-aw-sdt-tag:'0cd-eb1-27d-ce1-d261'; -aw-sdt-title:'Prior_Sigificant Customers in AR'; font-family: 'Times New Roman'"&gt;&lt;span&gt;one&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; significant customer). For the &lt;/span&gt;&lt;span style="-aw-sdt-tag:'ca0e62e990a606583b94'; -aw-sdt-title:'Current_Quarter_P14'; font-family: 'Times New Roman'"&gt;&lt;span&gt;three months ended September 30, 2025&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;, significant customers comprised &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c610c2cb61e4f95ffd6c'; -aw-sdt-title:'CQTD_Sig.Cust Percent Net Revenue'; font-family: 'Times New Roman'"&gt;&lt;span&gt;80&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;% of total net product revenues (consisting of &lt;/span&gt;&lt;span style="-aw-sdt-tag:'7ac-793-8fb-7b6-6b7e'; -aw-sdt-title:'CQTD_Total Customers'; font-family: 'Times New Roman'"&gt;&lt;span&gt;four&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; total customers and &lt;/span&gt;&lt;span style="-aw-sdt-tag:'935-1d8-24e-b55-3697'; -aw-sdt-title:'CWTD_Significant Customers'; font-family: 'Times New Roman'"&gt;&lt;span&gt;one&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; significant customer at &lt;/span&gt;&lt;span style="-aw-sdt-tag:'fd4-598-fc6-c55-b5b3'; -aw-sdt-title:'CQTD_Sig Customer 1 Percent'; font-family: 'Times New Roman'"&gt;&lt;span&gt;80&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;%). For the &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c89b221bf86e60e80aee'; -aw-sdt-title:'Previous_Quarter_P5'; font-family: 'Times New Roman'"&gt;&lt;span&gt;three months ended September 30, 2024&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;, &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c4871e9ed0486ef91d28'; -aw-sdt-title:'PQTD_Sig.Cust Percent Net Revenue'; font-family: 'Times New Roman'"&gt;&lt;span&gt;92&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;% of total net product revenues (consisting of &lt;/span&gt;&lt;span style="-aw-sdt-tag:'92a-ab1-dc7-7a9-7dd3'; -aw-sdt-title:'PQTD_Total Customers'; font-family: 'Times New Roman'"&gt;&lt;span&gt;two&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; total customers and &lt;/span&gt;&lt;span style="-aw-sdt-tag:'813-a74-d78-4e2-d0ec'; -aw-sdt-title:'PQTD_Significant Customers'; font-family: 'Times New Roman'"&gt;&lt;span&gt;one&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; significant customer) were generated from significant customers. For the &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c71fb825a8fc9183fba4'; -aw-sdt-title:'Current_YTD_P9'; font-family: 'Times New Roman'"&gt;&lt;span&gt;nine months ended September 30, 2025&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;,&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;span style="-aw-sdt-tag:'cd703ca85832d9e6ccd9'; -aw-sdt-title:'CYTD_Sig.Cust Percent Net Revenue'; font-family: 'Times New Roman'"&gt;&lt;span&gt;91&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;% of total net product revenues (consisting of &lt;/span&gt;&lt;span style="-aw-sdt-tag:'d25-e87-6c3-44b-77b8'; -aw-sdt-title:'CYTD_Total Customers'; font-family: 'Times New Roman'"&gt;&lt;span&gt;four&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; total customers and &lt;/span&gt;&lt;span style="-aw-sdt-tag:'623-163-567-ed7-13d7'; -aw-sdt-title:'CYTD_Significant Customers'; font-family: 'Times New Roman'"&gt;&lt;span&gt;two&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; significant customers at &lt;/span&gt;&lt;span style="-aw-sdt-tag:'fd4-589-ac0-f12-5f6a'; font-family: 'Times New Roman'"&gt;&lt;span&gt;73&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;% and &lt;/span&gt;&lt;span style="-aw-sdt-tag:'aa0-f10-986-33c-5f25'; -aw-sdt-title:'CYTD_Sig Customer 2 Percent'; font-family: 'Times New Roman'"&gt;&lt;span&gt;18&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;%, respectively) were generated from significant customers. For the &lt;/span&gt;&lt;span style="-aw-sdt-tag:'cd6d62b9c3ce9b21e230'; -aw-sdt-title:'Previous_YTD_P4'; font-family: 'Times New Roman'"&gt;&lt;span&gt;nine months ended September 30, 2024&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;,&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;span style="-aw-sdt-tag:'c34cf87b1815b4a11766'; -aw-sdt-title:'PYTD_Sig.Cust Percent Net Revenue'; font-family: 'Times New Roman'"&gt;&lt;span&gt;94&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;% of total net product revenues (consisting of &lt;/span&gt;&lt;span style="-aw-sdt-tag:'f2f-f63-4d3-652-810a'; -aw-sdt-title:'PYTD_Total Customers'; font-family: 'Times New Roman'"&gt;&lt;span&gt;three&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; total customers and &lt;/span&gt;&lt;span style="-aw-sdt-tag:'20a-b2d-e5b-ae2-0417'; -aw-sdt-title:'PYTD_Significant Customers'; font-family: 'Times New Roman'"&gt;&lt;span&gt;one&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; significant customer) were generated from significant customers.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Currently, the Company has exclusive relationships with distributors in Australia and Europe. A failure to perform by any of our current distributors would create disruption for patients in those markets.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Since the Company first started working on tafenoquine, all inventory has been acquired in a collaborative relationship from a sole vendor. Should the vendor cease to supply tafenoquine, it would take significant costs and efforts to rebuild the supply chain with a new sole vendor sourcing the active pharmaceutical ingredient (&#x201c;API&#x201d;).&lt;/span&gt;&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="D20250930_CustomerConcentrationRiskMember_SignificantCustomersMember_AccountsReceivableOrSalesRevenueNetMember"
      decimals="2"
      id="Tag737"
      unitRef="Pure">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="D20250930_CustomerConcentrationRiskMember_SignificantCustomersMember_AccountsReceivableMember_1"
      decimals="2"
      id="Tag734"
      unitRef="Pure">0.89</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="D20250930_CustomerConcentrationRiskMember_AccountsReceivableMember_SignificantCustomerOneMember"
      decimals="2"
      id="Tag735"
      unitRef="Pure">0.75</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="D20250930_CustomerConcentrationRiskMember_AccountsReceivableMember_SignificantCustomerTwoMember"
      decimals="2"
      id="Tag736"
      unitRef="Pure">0.13</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="D20241231_CustomerConcentrationRiskMember_SignificantCustomersMember_AccountsReceivableMember"
      decimals="2"
      id="Tag720"
      unitRef="Pure">0.95</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="D20250930_CustomerConcentrationRiskMember_SignificantCustomersMember_SalesRevenueNetMember"
      decimals="2"
      id="Tag732"
      unitRef="Pure">0.80</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="D20250930_CustomerConcentrationRiskMember_SignificantCustomerOneMember_SalesRevenueNetMember"
      decimals="2"
      id="Tag733"
      unitRef="Pure">0.80</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="D20240930_CustomerConcentrationRiskMember_SignificantCustomersMember_SalesRevenueNetMember"
      decimals="2"
      id="Tag726"
      unitRef="Pure">0.92</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="D20250930_CustomerConcentrationRiskMember_SignificantCustomersMember_SalesRevenueNetMember_1"
      decimals="2"
      id="Tag721"
      unitRef="Pure">0.91</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="D20250930_CustomerConcentrationRiskMember_SalesRevenueNetMember_SignificantCustomerOneMember"
      decimals="2"
      id="Tag725"
      unitRef="Pure">0.73</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="D20250930_CustomerConcentrationRiskMember_SalesRevenueNetMember_SignificantCustomerTwoMember_1"
      decimals="2"
      id="Tag727"
      unitRef="Pure">0.18</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="D20240930_CustomerConcentrationRiskMember_SignificantCustomersMember_SalesRevenueNetMember_1"
      decimals="2"
      id="Tag722"
      unitRef="Pure">0.94</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="D20250930_1" id="Tag938">&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-weight:bold; text-decoration:underline; font-family: 'Times New Roman'"&gt;Segment Information&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Since its inception, the Company operates and manages its business as a single identifiable segment, focused on the development and marketing of new medicines for the treatment and prevention of infectious diseases. The determination of a single business segment is consistent with the consolidated financial information regularly provided to the Company&#x2019;s chief operating decision maker (&#x201c;CODM&#x201d;).&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:10pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;The Company&#x2019;s CODM is its Chief Executive Officer, who reviews and evaluates consolidated net income or loss for purposes of evaluating performance, making operating decisions, allocating resources, and planning and forecasting for future periods. The significant components of consolidated net income or loss regularly provided to the CODM include net product revenues and the significant expense categories presented in the accompanying &lt;/span&gt;&lt;span style="-aw-sdt-tag:'40d-f92-19d-c95-c73e'; -aw-sdt-title:'PandL_title_P2'; font-family: 'Times New Roman'"&gt;&lt;span&gt;consolidated condensed statements of operations and comprehensive loss&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; (cost of revenues, research and development, and general and administrative expenses). These are presented at the consolidated level and used by the CODM to monitor budgeted versus actual results to make key operating decisions. The information and operating expense categories presented in the accompanying &lt;/span&gt;&lt;span style="-aw-sdt-tag:'253-c33-1cd-8c6-3ae5'; -aw-sdt-title:'PandL_title_P3'; font-family: 'Times New Roman'"&gt;&lt;span&gt;consolidated condensed statements of operations and comprehensive loss&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; are fully reflective of the significant expense categories and amounts that are regularly provided to the CODM.&lt;/span&gt;&lt;/p&gt;&lt;div style="-aw-sdt-tag:'PG_c24bb3258a68b0280db8'"&gt;&lt;/div&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;The measure of segment assets that is regularly reported to the CODM includes cash and cash equivalents and short-term investments, each as reported on the &lt;/span&gt;&lt;span style="-aw-sdt-tag:'139-b42-89d-4af-5020'; -aw-sdt-title:'Balance_Sheet_Title_P1'; font-family: 'Times New Roman'"&gt;&lt;span&gt;consolidated condensed balance sheets&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;. Total consolidated cash and cash equivalents and short-term investments were $&lt;/span&gt;&lt;span style="-aw-sdt-tag:'c26449208c3edf5c7aa8'; font-family: 'Times New Roman'"&gt;&lt;span&gt;4,115,779&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; and $&lt;/span&gt;&lt;span style="-aw-sdt-tag:'cdccccade90e66a13fb9'; font-family: 'Times New Roman'"&gt;&lt;span&gt;3,387,825&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; as of &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c7407e74fc85ec3ccdfe'; -aw-sdt-title:'Current_Period_P2'; font-family: 'Times New Roman'"&gt;&lt;span&gt;September 30, 2025&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; and &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c00bf74fe48b3c64541d'; -aw-sdt-title:'Previous_Year_End_P12'; font-family: 'Times New Roman'"&gt;&lt;span&gt;December 31, 2024&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;, respectively.&lt;/span&gt;&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="I20250930"
      decimals="0"
      id="Tag718"
      unitRef="USD">4115779</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="I20241231"
      decimals="0"
      id="Tag719"
      unitRef="USD">3387825</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:DerivativesPolicyTextBlock contextRef="D20250930_1" id="Tag950">&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-weight:bold; text-decoration:underline; font-family: 'Times New Roman'"&gt;Derivative Liabilities&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;The Company analyzes all financial instruments with features of both liabilities and equity under FASB ASC Topic No. &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c4a98c0f9c305eb9ad0a'; font-family: 'Times New Roman'"&gt;&lt;span&gt;480&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;, &lt;/span&gt;&lt;span style="font-style:italic; font-family: 'Times New Roman'"&gt;Distinguishing Liabilities from Equity&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; (&#x201c;ASC &lt;/span&gt;&lt;span style="-aw-sdt-tag:'ce2b75a3274a6a43e17f'; font-family: 'Times New Roman'"&gt;&lt;span&gt;480&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#x201d;), and FASB ASC Topic No. &lt;/span&gt;&lt;span style="-aw-sdt-tag:'ced90c7d41ecdbd49877'; font-family: 'Times New Roman'"&gt;&lt;span&gt;815&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;, &lt;/span&gt;&lt;span style="font-style:italic; font-family: 'Times New Roman'"&gt;Derivatives and Hedging&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; (&#x201c;ASC &lt;/span&gt;&lt;span style="-aw-sdt-tag:'ccd1349dccf1b3e1afae'; font-family: 'Times New Roman'"&gt;&lt;span&gt;815&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#x201d;). The classification of derivative financial instruments is reassessed each reporting period. Derivative liabilities are adjusted to reflect fair value at each reporting period, with any increase or decrease in the fair value recorded in the results of operations, as a component of other income or expense as change in fair value of derivative liabilities. As of &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c1af92d97c032e45d07a'; -aw-sdt-title:'Current_Period_P14'; font-family: 'Times New Roman'"&gt;&lt;span&gt;September 30, 2025&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;, derivative liabilities consist of contingent payment arrangements. The Company uses a probability-weighted expected return method to determine the fair value of these instruments.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Upon conversion or repayment of a debt or equity instrument in exchange for equity shares, where the embedded conversion option has been bifurcated and accounted for as a derivative liability (generally convertible debt and warrants), the Company records the equity shares at fair value on the date of conversion, relieves all related debt, derivative liabilities, and unamortized debt discounts, and recognizes a net gain or loss on debt extinguishment, if any.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Equity or liability instruments that become subject to reclassification under ASC Topic &lt;/span&gt;&lt;span style="-aw-sdt-tag:'ce08ae8c5268be0628c7'; font-family: 'Times New Roman'"&gt;&lt;span&gt;815&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; are reclassified at the fair value of the instrument on the reclassification date.&lt;/span&gt;&lt;/p&gt;</us-gaap:DerivativesPolicyTextBlock>
    <sxtp:EquityClassifiedWarrantsPolicyTextBlock contextRef="D20250930_1" id="Tag940">&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-weight:bold; text-decoration:underline; font-family: 'Times New Roman'"&gt;Equity-Classified Warrants&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;As of &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c7bcd8e778eedd1caaab'; -aw-sdt-title:'Current_Period_P11'; font-family: 'Times New Roman'"&gt;&lt;span&gt;September 30, 2025&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;, the Company accounts for all outstanding warrants to purchase common stock as equity-classified instruments based on an assessment of the warrants&#x2019; specific terms and applicable authoritative guidance in ASC &lt;/span&gt;&lt;span style="-aw-sdt-tag:'cdb856b4f4bde6d47eab'; font-family: 'Times New Roman'"&gt;&lt;span&gt;480&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; and ASC &lt;/span&gt;&lt;span style="-aw-sdt-tag:'cd5e76a6a6ce96ef7c87'; font-family: 'Times New Roman'"&gt;&lt;span&gt;815&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;. This assessment considers whether the warrants are freestanding financial instruments pursuant to ASC &lt;/span&gt;&lt;span style="-aw-sdt-tag:'cd481df4cd7bb454097c'; font-family: 'Times New Roman'"&gt;&lt;span&gt;480&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;, meet the definition of a liability pursuant to ASC &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c75d25a4963187f34a5b'; font-family: 'Times New Roman'"&gt;&lt;span&gt;480&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;, whether the warrants meet all of the requirements for equity classification under ASC &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c8f59ed9b1458f19f86f'; font-family: 'Times New Roman'"&gt;&lt;span&gt;815&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;, including whether the warrants are indexed to the Company&#x2019;s own common stock and whether the warrant holders could potentially require &#x201c;net cash settlement&#x201d; in a circumstance outside of the Company&#x2019;s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the respective issuance dates and as of each subsequent reporting period while the warrants are outstanding.&lt;/span&gt;&lt;/p&gt;</sxtp:EquityClassifiedWarrantsPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock contextRef="D20250930_1" id="Tag941">&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-weight:bold; text-decoration:underline; font-family: 'Times New Roman'"&gt;Revenue Recognition&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;The Company recognizes revenue in accordance with FASB ASC Topic No. &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c1024005423a4297ddef'; font-family: 'Times New Roman'"&gt;&lt;span&gt;606&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;, &lt;/span&gt;&lt;span style="font-style:italic; font-family: 'Times New Roman'"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; (&#x201c;ASC &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c01990ecd114b774522a'; font-family: 'Times New Roman'"&gt;&lt;span&gt;606&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#x201d;). Revenues are recognized when control is transferred to customers in amounts that reflect the consideration the Company expects to be entitled to receive in exchange for those goods. Revenue recognition is evaluated through the following five steps: (i) identification of the contract, or contracts, with a customer; (ii) identification of the performance obligations in the contract; (iii) determination of the transaction price; (iv) allocation of the transaction price to the performance obligations in the contract; and (v) recognition of revenue when or as a performance obligation is satisfied. As part of the accounting for these arrangements, the Company may be required to make significant judgments, including identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each performance obligation.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Revenues from product sales are recorded at the net sales price, or &#x201c;transaction price,&#x201d; which may include estimates of variable consideration that result from product returns. The Company determines the amount of variable consideration by using either the expected value method or the most-likely-amount method. The Company includes the unconstrained amount of estimated variable consideration in the transaction price, which reflects the amount for which it is probable that a significant reversal of cumulative revenue recognized will not occur. At the end of each subsequent reporting period, the Company re-evaluates the estimated variable consideration included in the transaction price and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis in the period of adjustment. Reserves are established for the estimates of variable consideration based on the amounts the Company expects to be earned or to be claimed on the related sales.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="-aw-sdt-tag:'PG_c6053e6c5f792d82acc2'"&gt;&lt;/div&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;The Company receives the majority of its revenues from sales of its Arakoda product to resellers in the US and abroad. The Company records US commercial revenues as a receivable when our American distributor transfers shipped product to their title model for &lt;/span&gt;&lt;span style="-aw-sdt-tag:'cfae9bd6533b6134b81a'; font-family: 'Times New Roman'"&gt;&lt;span&gt;60&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;P. Foreign sales to both Australia and Europe are recognized as a receivable at the point product is shipped to distributor. The shipments to Australia and Europe are further subject to profit sharing agreements for boxes sold to customers.&lt;/span&gt;&lt;/p&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="D20250930_1" id="Tag943">&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-weight:bold; text-decoration:underline; font-family: 'Times New Roman'"&gt;Research and Development Costs &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;The Company accounts for research and development costs in accordance with FASB ASC Subtopic No. &lt;/span&gt;&lt;span style="-aw-sdt-tag:'cbc781f7013a6eaa59f8'; font-family: 'Times New Roman'"&gt;&lt;span&gt;730&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;-&lt;/span&gt;&lt;span style="-aw-sdt-tag:'c82ed5ff78a1295bb276'; font-family: 'Times New Roman'"&gt;&lt;span&gt;10&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;, Research and Development (&#x201c;ASC &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c8d16d1806c924bd6931'; font-family: 'Times New Roman'"&gt;&lt;span&gt;730&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;-&lt;/span&gt;&lt;span style="-aw-sdt-tag:'ca09ffaa8d3135cb1e6b'; font-family: 'Times New Roman'"&gt;&lt;span&gt;10&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#x201d;). Under ASC &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c9a334fab141f1bfcaaa'; font-family: 'Times New Roman'"&gt;&lt;span&gt;730&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;-&lt;/span&gt;&lt;span style="-aw-sdt-tag:'cd9c059505344e7aa50b'; font-family: 'Times New Roman'"&gt;&lt;span&gt;10&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;, research and development costs are expensed as incurred. Accordingly, internal research and development costs are expensed as incurred. Prepayments for research and development services are deferred and amortized over the service period as the services are provided. Advance payments for specific materials, equipment, or facilities determined to have no alternative future use are initially deferred and recognized as research and development expense when the related goods are delivered.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;The Company recorded $&lt;/span&gt;&lt;span style="-aw-sdt-tag:'c0cae7d3178274b183f7'; -aw-sdt-title:'CQTD_RandD Expense'; font-family: 'Times New Roman'"&gt;&lt;span&gt;809,777&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;and $&lt;/span&gt;&lt;span style="-aw-sdt-tag:'c819708eba76301c2ea4'; -aw-sdt-title:'PQTD_RandD Expense'; font-family: 'Times New Roman'"&gt;&lt;span&gt;940,063&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;in research and development expense during the &lt;/span&gt;&lt;span style="-aw-sdt-tag:'cc1e5d1af75cc719a927'; -aw-sdt-title:'Current_Quarter_P15'; font-family: 'Times New Roman'"&gt;&lt;span&gt;three months ended September 30, 2025&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; and &lt;/span&gt;&lt;span style="-aw-sdt-tag:'cc35a31294de2fb9966a'; -aw-sdt-title:'Previous_Year_P29'; font-family: 'Times New Roman'"&gt;&lt;span&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;, respectively, ($&lt;/span&gt;&lt;span style="-aw-sdt-tag:'c0a12c3296b44a12831e'; -aw-sdt-title:'CYTD_RandD Expense'; font-family: 'Times New Roman'"&gt;&lt;span&gt;1,467,283&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; and $&lt;/span&gt;&lt;span style="-aw-sdt-tag:'c0c5d0d81b151b0a0872'; -aw-sdt-title:'PYTD_RandD Expense'; font-family: 'Times New Roman'"&gt;&lt;span&gt;4,372,571&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; for the &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c14bc5f963419ab2aed9'; -aw-sdt-title:'Current_YTD_P12'; font-family: 'Times New Roman'"&gt;&lt;span&gt;nine months ended September 30, 2025&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; and &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c141bbe47f263859b34f'; -aw-sdt-title:'Previous_Year_P30'; font-family: 'Times New Roman'"&gt;&lt;span&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;, respectively). The Company has also issued shares of common stock to nonemployees in exchange for research and development services. The Company recognizes prepaid research and development costs on the grant date, as defined in FASB ASC Subtopic No. &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c5f925ba06665ac933a5'; font-family: 'Times New Roman'"&gt;&lt;span&gt;718&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;, &lt;/span&gt;&lt;span style="font-style:italic; font-family: 'Times New Roman'"&gt;Compensation - Stock Compensation&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;. See Note &lt;/span&gt;&lt;span style="-aw-sdt-tag:'cd731d5a4723c771d07e'; font-family: 'Times New Roman'"&gt;&lt;span&gt;10&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; for further details.&lt;/span&gt;&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="D20250930"
      decimals="0"
      id="Tag728"
      unitRef="USD">809777</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="D20240930"
      decimals="0"
      id="Tag729"
      unitRef="USD">940063</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="D20250930_1"
      decimals="0"
      id="Tag730"
      unitRef="USD">1467283</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="D20240930_1"
      decimals="0"
      id="Tag731"
      unitRef="USD">4372571</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="D20250930_1" id="Tag944">&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-weight:bold; text-decoration:underline; font-family: 'Times New Roman'"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;The carrying value of the Company&#x2019;s financial instruments included in current assets and current liabilities (such as cash and cash equivalents, accounts receivable, accounts payable, and accrued expenses) approximate their fair value due to the short-term nature of such instruments.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;The inputs used to measure fair value are based on a hierarchy that prioritizes observable and unobservable inputs used in valuation techniques. These levels, in order of highest to lowest priority, are described below:&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="width:100%"&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td style="width:36pt; vertical-align:top"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;Level &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c10a34efbf72f35b33de'; font-family: 'Times New Roman'"&gt;&lt;span style="font-weight:bold"&gt;1&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:18pt; vertical-align:top"&gt;&lt;div style="-aw-sdt-tag:'c574d522f70efd479dc3'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Quoted prices (unadjusted) in active markets that are accessible at the measurement date for identical assets or liabilities.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;Level &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c152bc38d599e5fa0056'; font-family: 'Times New Roman'"&gt;&lt;span style="font-weight:bold"&gt;2&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="-aw-sdt-tag:'c41453b900cbc0348861'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Observable prices that are based on inputs not quoted on active markets but corroborated by market data.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;Level &lt;/span&gt;&lt;span style="-aw-sdt-tag:'cae8e9dbfa205b2e8396'; font-family: 'Times New Roman'"&gt;&lt;span style="font-weight:bold"&gt;3&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="-aw-sdt-tag:'c38191d9430425b3ee7b'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Unobservable inputs reflecting the Company&#x2019;s assumptions, consistent with reasonably available assumptions made by other market participants. These valuations require significant judgment.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;The Company&#x2019;s financial instruments recorded at fair value on a recurring basis at &lt;/span&gt;&lt;span style="-aw-sdt-tag:'ccb07ec5194190047e9d'; -aw-sdt-title:'Current_Period_P12'; font-family: 'Times New Roman'"&gt;&lt;span&gt;September 30, 2025&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;, and &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c12a3919fe92233b9c27'; -aw-sdt-title:'Previous_Year_End_P13'; font-family: 'Times New Roman'"&gt;&lt;span&gt;December 31, 2024&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; include the derivative liability associated with the contingent milestone payment due to Knight upon a future sale of Arakoda or a Change of Control, which is carried at fair value based on Level &lt;/span&gt;&lt;span style="-aw-sdt-tag:'cf44dbdc1b5a3adb8e5d'; font-family: 'Times New Roman'"&gt;&lt;span&gt;3&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; inputs. The Company uses a probability-weighted expected return method to determine the fair value of the contingent milestone payment using significant inputs such as the timing and probability of discrete potential exit scenarios, forward interest rate curves, and discount rates based on implied and market yields. See Note &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c607a69561493866770f'; font-family: 'Times New Roman'"&gt;&lt;span&gt;8&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; for more information on Derivative Liabilities.&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="-aw-sdt-tag:'PG_c0c20bca974f854c1494'"&gt;&lt;/div&gt;&lt;div style="-aw-sdt-tag:'ce01f1bed3993d32f2f9'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Liabilities measured at fair value at &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c0bf68fbeefde243c15a'; -aw-sdt-title:'Current_Period_P15'; font-family: 'Times New Roman'"&gt;&lt;span&gt;September 30, 2025&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; and &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c732f17c4f405be7abd5'; -aw-sdt-title:'Previous_Year_End_P15'; font-family: 'Times New Roman'"&gt;&lt;span&gt;December 31, 2024&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; are as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="-aw-sdt-tag:'cf921e92f02c49f734d5'; -aw-sdt-title:'SIGNIFICANT ACCOUNTING POLICIES T1'"&gt;&lt;table cellpadding="0" cellspacing="0" style="width:100%; border-collapse:collapse"&gt;&lt;tbody&gt;&lt;tr style="height:11.5pt"&gt;&lt;td style="width:53%; vertical-align:middle"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:spaces; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="border-bottom:1.5pt solid #000000; vertical-align:bottom"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_1f865470141349c9b37ae84a55aacecc'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;September 30, 2025&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.5pt"&gt;&lt;td style="width:53%; vertical-align:middle"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1.5pt solid #000000; border-bottom:1pt solid #000000; vertical-align:middle"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_a9a7008663a046198bc1b79f62990348'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"&gt;&lt;span style="font-weight:bold; -aw-import:spaces; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1.5pt solid #000000; border-bottom:1pt solid #000000; vertical-align:middle"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_81f8a817fe384b62ae7dcf394585ad13'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"&gt;&lt;span style="font-weight:bold; -aw-import:spaces; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1.5pt solid #000000; border-bottom:1pt solid #000000; vertical-align:middle"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_0f2ddb2f4dea4255b9372b845c3d8cf9'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"&gt;&lt;span style="font-weight:bold; -aw-import:spaces; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1.5pt solid #000000; border-bottom:1pt solid #000000; vertical-align:middle"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_5169a80e4244429fb7957e47ebcd8580'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"&gt;&lt;span style="font-weight:bold; -aw-import:spaces; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.5pt"&gt;&lt;td style="width:53%; vertical-align:middle; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_c3fe79fa6419450bb2de75dc0fbcb8e0'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:spaces; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.5pt"&gt;&lt;td style="width:53%; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_37594b78a4ff46fda8c7c6c31dda2819'"&gt;&lt;p style="margin-top:0pt; margin-left:5.4pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:spaces; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Derivative Liabilities&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_7f6e995134194c1f85dce5bf4027caab'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-tag:'C_1ebf3664e1d74ad8aa7a5f6f86bcafc6'"&gt;&lt;span title="&amp;amp;#13;nil='true'"&gt;&lt;/span&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_2f314ddebd474b209bfcbd65835b25ed'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-tag:'C_ab7845e24d35492db1dd11a0aaa21e2e'"&gt;&lt;span title="&amp;amp;#13;nil='true'"&gt;&lt;/span&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_e71039cd49df4ed0a91d801f3eecd241'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_c478d60eaf6f4ba79d74d84f29ff1501'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;797,275&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_d7e156ea5a164ce28ac588dac4d1a77f'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_706a282cea3b4dce906d3c671c501ff6'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;797,275&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.5pt"&gt;&lt;td style="width:53%; vertical-align:middle; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_e3a4e18287cc4026a749060e1e8fb5a9'"&gt;&lt;p style="margin-top:0pt; margin-left:5.4pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:spaces; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_105c7afdf9de422991cf5a00287ac307'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-tag:'C_7d18406ed78f4c4f8c3bb851f3c5e787'"&gt;&lt;span title="&amp;amp;#13;nil='true'"&gt;&lt;/span&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_49026756b4a640278f43ece44be0ab14'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-tag:'C_a3c7a3645b97455cade875ff7e738781'"&gt;&lt;span title="&amp;amp;#13;nil='true'"&gt;&lt;/span&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_8bbc20c75ef0447fa466d4bfaafb8f5f'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_62a7e9f4e692400483031bb740e41569'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;797,275&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_07827564eb61499086af507f234ed67f'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_1600b9fa42ba44889bf927265c22067e'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;797,275&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="-aw-sdt-tag:'cb468fdcd6e0460b0777'; -aw-sdt-title:'SIGNIFICANT ACCOUNTING POLICIES T2'"&gt;&lt;table cellpadding="0" cellspacing="0" style="width:100%; border-collapse:collapse"&gt;&lt;tbody&gt;&lt;tr style="height:11.5pt"&gt;&lt;td style="width:53%; vertical-align:middle"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:spaces; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="border-bottom:1pt solid #000000; vertical-align:bottom"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_4b44e1528e8c4f3cbca59f75d6bdc366'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.5pt"&gt;&lt;td style="width:53%; vertical-align:middle"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1.5pt solid #000000; border-bottom:1pt solid #000000; vertical-align:middle"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_63bb47cb4152462c97cb5bc1a070ad98'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"&gt;&lt;span style="font-weight:bold; -aw-import:spaces; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1.5pt solid #000000; border-bottom:1pt solid #000000; vertical-align:middle"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_b9e93ac9d9e9420ea54dc08f973671b4'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"&gt;&lt;span style="font-weight:bold; -aw-import:spaces; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1.5pt solid #000000; border-bottom:1pt solid #000000; vertical-align:middle"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_6cfd423b093941b7a426daca9a7c4fd9'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"&gt;&lt;span style="font-weight:bold; -aw-import:spaces; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1.5pt solid #000000; border-bottom:1pt solid #000000; vertical-align:middle"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_ba6b2c8ff28f4584a84bb8a1cf763836'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"&gt;&lt;span style="font-weight:bold; -aw-import:spaces; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.5pt"&gt;&lt;td style="width:53%; vertical-align:middle; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_a6ef2c6558264f7ca0c50be6c5f2e477'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:spaces; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.5pt"&gt;&lt;td style="width:53%; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_1ad21d4a0f664c76a8a1de7dc61969e3'"&gt;&lt;p style="margin-top:0pt; margin-left:5.4pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:spaces; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Derivative Liabilities&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_0c00d5728d434da99efe8bee0a732f0f'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-tag:'C_38b73fa55f154f55af3cfbeff629bf16'"&gt;&lt;span title="&amp;amp;#13;nil='true'"&gt;&lt;/span&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_e025b21daccb422bbc8f2753e7ae30b9'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-tag:'C_333fc1e0c3f6433084115dd2779c80c0'"&gt;&lt;span title="&amp;amp;#13;nil='true'"&gt;&lt;/span&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_ccf3e162c56f48aabe5b242a8d57684f'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_fda27296d6fe4023a90164878a00a1d8'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;640,830&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_121a4a1679bd49579650a47153a7674a'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_8c697e7693374899bebfc6db6f39b905'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;640,830&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.5pt"&gt;&lt;td style="width:53%; vertical-align:middle; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_cb56be67da024df7ab547d83c57f3594'"&gt;&lt;p style="margin-top:0pt; margin-left:5.4pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:spaces; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_1d0941b2301d4640a725a3c444db0b29'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-tag:'C_34e9411fc246454890a3839765ba75c7'"&gt;&lt;span title="&amp;amp;#13;nil='true'"&gt;&lt;/span&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_5c011b0873844cb68a8ad4cfa194d590'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-tag:'C_59708d0fdeda4619aa91fe10eff71319'"&gt;&lt;span title="&amp;amp;#13;nil='true'"&gt;&lt;/span&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_fcc1b7589a9c4ce3859c970a7eb6b9c6'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_712785fcd2f54bfb89d8883eed8aebd5'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;640,830&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_e0ed0ee91ac4479e99c9a1322299ae2a'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_a4fc6be6554e49b0832d0ac5c0e1c4d7'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;640,830&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;There were no transfers of financial instruments between Level &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c512200b7f4efb193a74'; font-family: 'Times New Roman'"&gt;&lt;span&gt;1&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;, Level &lt;/span&gt;&lt;span style="-aw-sdt-tag:'cc88af1c10b9095520b3'; font-family: 'Times New Roman'"&gt;&lt;span&gt;2&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;, and Level &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c28cda9bda6d116b1482'; font-family: 'Times New Roman'"&gt;&lt;span&gt;3&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; during the periods presented.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;A rollforward of liabilities measured at fair value using Level &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c3417e051371b629cb2b'; font-family: 'Times New Roman'"&gt;&lt;span&gt;3&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; inputs for the &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c07ff2f3886b9784d3b4'; -aw-sdt-title:'Current_Quarter_and_YTD_P9'; font-family: 'Times New Roman'"&gt;&lt;span&gt;three and nine months ended September 30, 2025&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; and &lt;/span&gt;&lt;span style="-aw-sdt-tag:'ce922678da5c46f0ab60'; font-family: 'Times New Roman'"&gt;&lt;span&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; is presented in Note &lt;/span&gt;&lt;span style="-aw-sdt-tag:'cb6b017f206e8e342188'; font-family: 'Times New Roman'"&gt;&lt;span&gt;8&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; &#x2013; Derivative Liabilities.&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock contextRef="D20250930_1" id="Tag810">&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Liabilities measured at fair value at &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c0bf68fbeefde243c15a'; -aw-sdt-title:'Current_Period_P15'; font-family: 'Times New Roman'"&gt;&lt;span&gt;September 30, 2025&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; and &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c732f17c4f405be7abd5'; -aw-sdt-title:'Previous_Year_End_P15'; font-family: 'Times New Roman'"&gt;&lt;span&gt;December 31, 2024&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; are as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="-aw-sdt-tag:'cf921e92f02c49f734d5'; -aw-sdt-title:'SIGNIFICANT ACCOUNTING POLICIES T1'"&gt;&lt;table cellpadding="0" cellspacing="0" style="width:100%; border-collapse:collapse"&gt;&lt;tbody&gt;&lt;tr style="height:11.5pt"&gt;&lt;td style="width:53%; vertical-align:middle"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:spaces; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="border-bottom:1.5pt solid #000000; vertical-align:bottom"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_1f865470141349c9b37ae84a55aacecc'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;September 30, 2025&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.5pt"&gt;&lt;td style="width:53%; vertical-align:middle"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1.5pt solid #000000; border-bottom:1pt solid #000000; vertical-align:middle"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_a9a7008663a046198bc1b79f62990348'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"&gt;&lt;span style="font-weight:bold; -aw-import:spaces; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1.5pt solid #000000; border-bottom:1pt solid #000000; vertical-align:middle"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_81f8a817fe384b62ae7dcf394585ad13'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"&gt;&lt;span style="font-weight:bold; -aw-import:spaces; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1.5pt solid #000000; border-bottom:1pt solid #000000; vertical-align:middle"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_0f2ddb2f4dea4255b9372b845c3d8cf9'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"&gt;&lt;span style="font-weight:bold; -aw-import:spaces; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1.5pt solid #000000; border-bottom:1pt solid #000000; vertical-align:middle"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_5169a80e4244429fb7957e47ebcd8580'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"&gt;&lt;span style="font-weight:bold; -aw-import:spaces; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.5pt"&gt;&lt;td style="width:53%; vertical-align:middle; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_c3fe79fa6419450bb2de75dc0fbcb8e0'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:spaces; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.5pt"&gt;&lt;td style="width:53%; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_37594b78a4ff46fda8c7c6c31dda2819'"&gt;&lt;p style="margin-top:0pt; margin-left:5.4pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:spaces; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Derivative Liabilities&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_7f6e995134194c1f85dce5bf4027caab'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-tag:'C_1ebf3664e1d74ad8aa7a5f6f86bcafc6'"&gt;&lt;span title="&amp;amp;#13;nil='true'"&gt;&lt;/span&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_2f314ddebd474b209bfcbd65835b25ed'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-tag:'C_ab7845e24d35492db1dd11a0aaa21e2e'"&gt;&lt;span title="&amp;amp;#13;nil='true'"&gt;&lt;/span&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_e71039cd49df4ed0a91d801f3eecd241'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_c478d60eaf6f4ba79d74d84f29ff1501'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;797,275&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_d7e156ea5a164ce28ac588dac4d1a77f'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_706a282cea3b4dce906d3c671c501ff6'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;797,275&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.5pt"&gt;&lt;td style="width:53%; vertical-align:middle; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_e3a4e18287cc4026a749060e1e8fb5a9'"&gt;&lt;p style="margin-top:0pt; margin-left:5.4pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:spaces; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_105c7afdf9de422991cf5a00287ac307'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-tag:'C_7d18406ed78f4c4f8c3bb851f3c5e787'"&gt;&lt;span title="&amp;amp;#13;nil='true'"&gt;&lt;/span&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_49026756b4a640278f43ece44be0ab14'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-tag:'C_a3c7a3645b97455cade875ff7e738781'"&gt;&lt;span title="&amp;amp;#13;nil='true'"&gt;&lt;/span&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_8bbc20c75ef0447fa466d4bfaafb8f5f'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_62a7e9f4e692400483031bb740e41569'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;797,275&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_07827564eb61499086af507f234ed67f'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_1600b9fa42ba44889bf927265c22067e'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;797,275&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="-aw-sdt-tag:'cb468fdcd6e0460b0777'; -aw-sdt-title:'SIGNIFICANT ACCOUNTING POLICIES T2'"&gt;&lt;table cellpadding="0" cellspacing="0" style="width:100%; border-collapse:collapse"&gt;&lt;tbody&gt;&lt;tr style="height:11.5pt"&gt;&lt;td style="width:53%; vertical-align:middle"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:spaces; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="border-bottom:1pt solid #000000; vertical-align:bottom"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_4b44e1528e8c4f3cbca59f75d6bdc366'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.5pt"&gt;&lt;td style="width:53%; vertical-align:middle"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1.5pt solid #000000; border-bottom:1pt solid #000000; vertical-align:middle"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_63bb47cb4152462c97cb5bc1a070ad98'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"&gt;&lt;span style="font-weight:bold; -aw-import:spaces; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1.5pt solid #000000; border-bottom:1pt solid #000000; vertical-align:middle"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_b9e93ac9d9e9420ea54dc08f973671b4'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"&gt;&lt;span style="font-weight:bold; -aw-import:spaces; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1.5pt solid #000000; border-bottom:1pt solid #000000; vertical-align:middle"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_6cfd423b093941b7a426daca9a7c4fd9'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"&gt;&lt;span style="font-weight:bold; -aw-import:spaces; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1.5pt solid #000000; border-bottom:1pt solid #000000; vertical-align:middle"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_ba6b2c8ff28f4584a84bb8a1cf763836'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"&gt;&lt;span style="font-weight:bold; -aw-import:spaces; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.5pt"&gt;&lt;td style="width:53%; vertical-align:middle; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_a6ef2c6558264f7ca0c50be6c5f2e477'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:spaces; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.5pt"&gt;&lt;td style="width:53%; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_1ad21d4a0f664c76a8a1de7dc61969e3'"&gt;&lt;p style="margin-top:0pt; margin-left:5.4pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:spaces; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Derivative Liabilities&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_0c00d5728d434da99efe8bee0a732f0f'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-tag:'C_38b73fa55f154f55af3cfbeff629bf16'"&gt;&lt;span title="&amp;amp;#13;nil='true'"&gt;&lt;/span&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_e025b21daccb422bbc8f2753e7ae30b9'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-tag:'C_333fc1e0c3f6433084115dd2779c80c0'"&gt;&lt;span title="&amp;amp;#13;nil='true'"&gt;&lt;/span&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_ccf3e162c56f48aabe5b242a8d57684f'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_fda27296d6fe4023a90164878a00a1d8'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;640,830&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_121a4a1679bd49579650a47153a7674a'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_8c697e7693374899bebfc6db6f39b905'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;640,830&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.5pt"&gt;&lt;td style="width:53%; vertical-align:middle; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_cb56be67da024df7ab547d83c57f3594'"&gt;&lt;p style="margin-top:0pt; margin-left:5.4pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:spaces; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_1d0941b2301d4640a725a3c444db0b29'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-tag:'C_34e9411fc246454890a3839765ba75c7'"&gt;&lt;span title="&amp;amp;#13;nil='true'"&gt;&lt;/span&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_5c011b0873844cb68a8ad4cfa194d590'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-tag:'C_59708d0fdeda4619aa91fe10eff71319'"&gt;&lt;span title="&amp;amp;#13;nil='true'"&gt;&lt;/span&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_fcc1b7589a9c4ce3859c970a7eb6b9c6'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_712785fcd2f54bfb89d8883eed8aebd5'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;640,830&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_e0ed0ee91ac4479e99c9a1322299ae2a'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_a4fc6be6554e49b0832d0ac5c0e1c4d7'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;640,830&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="I20250930_FairValueInputsLevel1Member_DerivativeMember"
      id="Tag29"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="I20250930_FairValueInputsLevel2Member_DerivativeMember"
      id="Tag32"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="I20250930_FairValueInputsLevel3Member_DerivativeMember"
      decimals="0"
      id="Tag7"
      unitRef="USD">797275</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="I20250930_DerivativeMember"
      decimals="0"
      id="Tag6"
      unitRef="USD">797275</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="I20250930_FairValueInputsLevel1Member"
      id="Tag31"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="I20250930_FairValueInputsLevel2Member"
      id="Tag30"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="I20250930_FairValueInputsLevel3Member"
      decimals="0"
      id="Tag8"
      unitRef="USD">797275</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent contextRef="I20250930" decimals="0" id="Tag9" unitRef="USD">797275</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="I20241231_DerivativeMember_FairValueInputsLevel1Member"
      id="Tag14"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="I20241231_DerivativeMember_FairValueInputsLevel2Member"
      id="Tag16"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="I20241231_DerivativeMember_FairValueInputsLevel3Member"
      decimals="0"
      id="Tag11"
      unitRef="USD">640830</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="I20241231_DerivativeMember"
      decimals="0"
      id="Tag10"
      unitRef="USD">640830</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="I20241231_FairValueInputsLevel1Member"
      id="Tag15"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="I20241231_FairValueInputsLevel2Member"
      id="Tag17"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="I20241231_FairValueInputsLevel3Member"
      decimals="0"
      id="Tag12"
      unitRef="USD">640830</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="I20241231"
      decimals="0"
      id="Tag13"
      unitRef="USD">640830</us-gaap:DerivativeLiabilitiesCurrent>
    <sxtp:AssetsAndLiabilitiesNotMeasuredAtFairValueOnARecurringBasisPolicyTextBlock contextRef="D20250930_1" id="Tag946">&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-weight:bold; text-decoration:underline; font-family: 'Times New Roman'"&gt;Assets and Liabilities Not Measured at Fair Value on a Recurring Basis&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;In addition to assets and liabilities that are measured at fair value on a recurring basis, the Company also measures certain assets and liabilities at fair value on a nonrecurring basis. The Company&#x2019;s non-financial assets, including Intangible Assets and Property and Equipment, are measured at fair value when there is an indication of impairment and the carrying amount exceeds the asset&#x2019;s projected undiscounted cash flows. These assets are recorded at fair value only when an impairment charge is recognized.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Certificates of deposit, classified as cash equivalents or short-term investments depending on the instrument&#x2019;s original time to maturity, are measured at amortized cost, which approximates fair value as of &lt;/span&gt;&lt;span style="-aw-sdt-tag:'cbcda125eaa60887c6fa'; -aw-sdt-title:'Current_Period_P21'; font-family: 'Times New Roman'"&gt;&lt;span&gt;September 30, 2025&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; and &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c1cb724ff032da6352c4'; -aw-sdt-title:'Previous_Year_End_P18'; font-family: 'Times New Roman'"&gt;&lt;span&gt;December 31, 2024&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;.&lt;/span&gt;&lt;/p&gt;</sxtp:AssetsAndLiabilitiesNotMeasuredAtFairValueOnARecurringBasisPolicyTextBlock>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="D20250930_1" id="Tag957">&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-weight:bold; text-decoration:underline; font-family: 'Times New Roman'"&gt;Foreign Currency Transactions and Translation&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;The individual financial statements of each group entity are measured and presented in the currency of the primary economic environment in which the entity operates (its functional currency). The consolidated condensed financial statements of the Company are presented in United States dollars, which is the functional currency of the Company and the presentation currency for the consolidated condensed financial statements.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;For the purpose of presenting consolidated condensed financial statements, the assets and liabilities of the Company&#x2019;s foreign operations are mostly translated at exchange rates prevailing on the reporting date. Income and expense items are translated at the average exchange rates for the period, unless exchange rates fluctuate significantly during that period, in which case the exchange rates at the dates of the transactions are used. Exchange differences arising, if any, are recognized as a component of other comprehensive income (loss) as unrealized foreign currency translation gain (loss).&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="-aw-sdt-tag:'PG_c0a5df5ef4dd14c932ff'"&gt;&lt;/div&gt;&lt;div style="-aw-sdt-tag:'c777f028f5d92d4cc514'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Exchange rates along with historical rates used in these financial statements are as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="-aw-sdt-tag:'549-6dd-c75-531-a655'; -aw-sdt-title:'SIGNIFICANT ACCOUNTING POLICIES T3'"&gt;&lt;table cellpadding="0" cellspacing="0" style="width:100%; border-collapse:collapse"&gt;&lt;tbody&gt;&lt;tr style="height:11.5pt"&gt;&lt;td style="width:34%; vertical-align:bottom"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:bottom"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"&gt;&lt;span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="17" style="border-bottom:1.5pt solid #000000; padding:0.75pt; vertical-align:bottom; -aw-padding-bottom:0.75pt"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_9482da9e9ef24112bed6d94f9f662d7c'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;Average Exchange Rate&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.5pt"&gt;&lt;td style="width:34%; vertical-align:middle"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:bottom"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"&gt;&lt;span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; padding:0.75pt; vertical-align:bottom; -aw-padding-bottom:0.75pt; -aw-padding-top:0.75pt"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_659f3565fccf471d885d5bbcc6f23513'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; border-top:1.5pt solid #000000; vertical-align:bottom"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:bottom"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_af26db9d568a41c18f4404ac7ead58b6'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; border-top:1.5pt solid #000000; vertical-align:bottom"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:bottom"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_cf885fb35a704f019f0cad0d5795b8d8'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;As of&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.5pt"&gt;&lt;td style="width:34%; vertical-align:bottom"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_973ee19447724c17b71b4faa457b2249'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;Currency&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:bottom"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"&gt;&lt;span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; padding:0.75pt; vertical-align:bottom; -aw-padding-bottom:0.75pt; -aw-padding-top:0.75pt"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_e3e1c97c5b854e929dfeef87960bfbc4'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; border-top:1.5pt solid #000000; vertical-align:bottom"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:bottom"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_91424ca5026c4cce945405cc6ea74a81'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:bottom"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"&gt;&lt;span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:bottom"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_791c5860584c493ba5598384cfdde256'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; border-top:1.5pt solid #000000; vertical-align:bottom"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"&gt;&lt;span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:bottom"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_fd4986cad1d4488da73173ef15330bc0'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:bottom"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"&gt;&lt;span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:bottom"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_63ce180cbb5d445f83c9530d4f721062'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;September 30, 2025&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; border-top:1.5pt solid #000000; vertical-align:bottom"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"&gt;&lt;span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:bottom"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_d9d1430a9c7a400390a13074b0c685af'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.5pt"&gt;&lt;td style="width:34%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_dde09534ca0e4664b9e7a6dbce09d46b'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;1 AUD =&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:6%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_7254928b2f564e559f8c533598d728fb'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;0.65&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:4%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_01fc1cc76a7d496482338117b041e5d7'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;USD&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:6%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_0dd2b89b644c47918dd20e0ae4036641'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;0.67&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:4%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_60bc7b550ded4fd0b8454a10aff9f2b9'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;USD&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:6%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_39890b79d6d94e83bbb6512adb82089c'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;0.64&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:4%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_bcf46b0b9cd64fa28023abd0bd2f9eeb'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;USD&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:4%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_ffd190f4cb644fdc858572d0e04df5bc'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;0.66&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:4%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_2ed4c46e122f4c9388749a2785a69bc5'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;USD&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:bottom; background-color:#ccecff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:6%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_deaa0fa001c447fa9db5c11c7e69f76e'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;0.66&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:4%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_4ed3d209ddad4027b90139f12205d725'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;USD&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:6%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_f1dbbad2340443dba35674893ccabab6'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;0.62&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:4%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'0b4-c37-b49-3e0-c6cf'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;USD&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock contextRef="D20250930_1" id="Tag904">&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Exchange rates along with historical rates used in these financial statements are as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="-aw-sdt-tag:'549-6dd-c75-531-a655'; -aw-sdt-title:'SIGNIFICANT ACCOUNTING POLICIES T3'"&gt;&lt;table cellpadding="0" cellspacing="0" style="width:100%; border-collapse:collapse"&gt;&lt;tbody&gt;&lt;tr style="height:11.5pt"&gt;&lt;td style="width:34%; vertical-align:bottom"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:bottom"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"&gt;&lt;span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="17" style="border-bottom:1.5pt solid #000000; padding:0.75pt; vertical-align:bottom; -aw-padding-bottom:0.75pt"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_9482da9e9ef24112bed6d94f9f662d7c'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;Average Exchange Rate&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.5pt"&gt;&lt;td style="width:34%; vertical-align:middle"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:bottom"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"&gt;&lt;span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; padding:0.75pt; vertical-align:bottom; -aw-padding-bottom:0.75pt; -aw-padding-top:0.75pt"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_659f3565fccf471d885d5bbcc6f23513'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; border-top:1.5pt solid #000000; vertical-align:bottom"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:bottom"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_af26db9d568a41c18f4404ac7ead58b6'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; border-top:1.5pt solid #000000; vertical-align:bottom"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:bottom"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_cf885fb35a704f019f0cad0d5795b8d8'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;As of&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.5pt"&gt;&lt;td style="width:34%; vertical-align:bottom"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_973ee19447724c17b71b4faa457b2249'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;Currency&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:bottom"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"&gt;&lt;span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; padding:0.75pt; vertical-align:bottom; -aw-padding-bottom:0.75pt; -aw-padding-top:0.75pt"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_e3e1c97c5b854e929dfeef87960bfbc4'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; border-top:1.5pt solid #000000; vertical-align:bottom"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:bottom"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_91424ca5026c4cce945405cc6ea74a81'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:bottom"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"&gt;&lt;span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:bottom"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_791c5860584c493ba5598384cfdde256'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; border-top:1.5pt solid #000000; vertical-align:bottom"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"&gt;&lt;span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:bottom"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_fd4986cad1d4488da73173ef15330bc0'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:bottom"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"&gt;&lt;span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:bottom"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_63ce180cbb5d445f83c9530d4f721062'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;September 30, 2025&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; border-top:1.5pt solid #000000; vertical-align:bottom"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"&gt;&lt;span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:bottom"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_d9d1430a9c7a400390a13074b0c685af'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.5pt"&gt;&lt;td style="width:34%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_dde09534ca0e4664b9e7a6dbce09d46b'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;1 AUD =&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:6%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_7254928b2f564e559f8c533598d728fb'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;0.65&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:4%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_01fc1cc76a7d496482338117b041e5d7'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;USD&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:6%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_0dd2b89b644c47918dd20e0ae4036641'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;0.67&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:4%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_60bc7b550ded4fd0b8454a10aff9f2b9'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;USD&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:6%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_39890b79d6d94e83bbb6512adb82089c'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;0.64&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:4%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_bcf46b0b9cd64fa28023abd0bd2f9eeb'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;USD&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:4%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_ffd190f4cb644fdc858572d0e04df5bc'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;0.66&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:4%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_2ed4c46e122f4c9388749a2785a69bc5'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;USD&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:bottom; background-color:#ccecff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:6%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_deaa0fa001c447fa9db5c11c7e69f76e'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;0.66&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:4%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_4ed3d209ddad4027b90139f12205d725'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;USD&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:6%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_f1dbbad2340443dba35674893ccabab6'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;0.62&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:4%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'0b4-c37-b49-3e0-c6cf'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;USD&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock>
    <sxtp:AverageExchangeRate
      contextRef="D20250930_USD"
      decimals="2"
      id="Tag18"
      unitRef="Pure">0.65</sxtp:AverageExchangeRate>
    <sxtp:AverageExchangeRate
      contextRef="D20240930_USD"
      decimals="2"
      id="Tag19"
      unitRef="Pure">0.67</sxtp:AverageExchangeRate>
    <sxtp:AverageExchangeRate
      contextRef="D20250930_USD_1"
      decimals="2"
      id="Tag20"
      unitRef="Pure">0.64</sxtp:AverageExchangeRate>
    <sxtp:AverageExchangeRate
      contextRef="D20240930_USD_1"
      decimals="2"
      id="Tag21"
      unitRef="Pure">0.66</sxtp:AverageExchangeRate>
    <us-gaap:ForeignCurrencyExchangeRateTranslation1
      contextRef="I20250930_USD"
      decimals="2"
      id="Tag22"
      unitRef="Pure">0.66</us-gaap:ForeignCurrencyExchangeRateTranslation1>
    <us-gaap:ForeignCurrencyExchangeRateTranslation1
      contextRef="I20241231_USD"
      decimals="2"
      id="Tag23"
      unitRef="Pure">0.62</us-gaap:ForeignCurrencyExchangeRateTranslation1>
    <us-gaap:PriorPeriodReclassificationAdjustmentDescription contextRef="D20250930_1" id="Tag947">&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-weight:bold; text-decoration:underline; font-family: 'Times New Roman'"&gt;Reclassifications&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Certain prior period interim amounts have been reclassified for consistency with the current period presentation. These reclassifications had no material effect on the consolidated condensed results of operations and comprehensive loss, shareholders&#x2019; equity, or cash flows.&lt;/span&gt;&lt;/p&gt;</us-gaap:PriorPeriodReclassificationAdjustmentDescription>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="D20250930_1" id="Tag953">&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-weight:bold; text-decoration:underline; font-family: 'Times New Roman'"&gt;Share-Based Payments&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;On November &lt;/span&gt;&lt;span style="-aw-sdt-tag:'cb8e4cad4e4d214394a1'; font-family: 'Times New Roman'"&gt;&lt;span&gt;22&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;, &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c07fc0c7362febea5ed1'; font-family: 'Times New Roman'"&gt;&lt;span&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;, the Company adopted the &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c82523a8da0311b6da03'; font-family: 'Times New Roman'"&gt;&lt;span&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; Equity Incentive Plan also referred to as (&#x201c;&lt;/span&gt;&lt;span style="-aw-sdt-tag:'c84ff39eab4b2b69d4e5'; font-family: 'Times New Roman'"&gt;&lt;span&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; Plan&#x201d;). The &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c77a8fd767458ed89fe9'; font-family: 'Times New Roman'"&gt;&lt;span&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; Plan and related share-based awards are discussed more fully in Note &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c89592db43d1d0460416'; font-family: 'Times New Roman'"&gt;&lt;span&gt;10&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;The Company accounts for share-based payments in accordance with ASC Subtopic &lt;/span&gt;&lt;span style="-aw-sdt-tag:'cfb759d6c4e98b9f102c'; font-family: 'Times New Roman'"&gt;&lt;span&gt;718&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;, &lt;/span&gt;&lt;span style="font-style:italic; font-family: 'Times New Roman'"&gt;Compensation - Stock Compensation &lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;(&#x201c;ASC &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c28e007bf795e0cf0e4d'; font-family: 'Times New Roman'"&gt;&lt;span&gt;718&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#x201d;). The Company measures compensation for all share-based payment awards granted to employees, directors, and nonemployees, based on the estimated fair value of the awards on the date of grant. For awards that vest based on continued service, the service-based compensation cost is recognized on a straight-line basis over the requisite service period, which is generally the vesting period of the awards. For service vesting awards with compensation expense recognized on a straight-line basis, at no point in time does the cumulative grant date value of vested awards exceed the cumulative amount of compensation expense recognized. The grant date is determined based on the date when a mutual understanding of the key terms of the share-based awards is established. The Company accounts for forfeitures as they occur.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;The Company estimates the fair value of all stock option awards as of the grant date by applying the Black-Scholes option pricing model. The application of this valuation model involves assumptions, including the fair value of the common stock, expected volatility, risk-free interest rate, expected dividends and the expected term of the option. Due to the lack of a public market for the Company&#x2019;s common stock prior to the IPO and lack of company-specific historical implied volatility data, the Company has based its computations of expected volatility on the historical volatility of a representative group of public companies with similar characteristics of the Company, including stage of development and industry focus. The historical volatility is calculated based on a period of time commensurate with the expected term assumption. The Company generally uses the simplified method as prescribed by the SEC Staff Accounting Bulletin Topic &lt;/span&gt;&lt;span style="-aw-sdt-tag:'cdc65a3ad6830dc2131f'; font-family: 'Times New Roman'"&gt;&lt;span&gt;14&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;, &lt;/span&gt;&lt;span style="font-style:italic; font-family: 'Times New Roman'"&gt;Share-Based Payment&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;, to estimate the expected term for stock options, whereby, the expected term equals the midpoint of the weighted average remaining time to vest, vesting period and the contractual term of the options due to its lack of historical exercise data. For certain options granted out-of-the-money, the Company&#x2019;s best estimate of the expected term is the contractual term of the award. The risk-free interest rate is based on U.S. Treasury securities with a maturity date commensurate with the expected term of the associated award. The expected dividend yield is assumed to be zero as the Company has never paid dividends and has no current plans to pay any dividends on its common stock. The assumptions used in calculating the fair value of share-based awards represent management&#x2019;s best estimates and involve inherent uncertainties and the application of significant judgment.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Compensation expense for restricted stock units (&#x201c;RSUs&#x201d;) with only service-based vesting conditions is recognized on a straight-line basis over the vesting period. Compensation cost for service-based RSUs is based on the grant date fair value of the award, which is the closing market price of the Company&#x2019;s common stock on the grant date multiplied by the number of shares awarded.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;For awards that vest upon a liquidity event or a change in control, the performance condition is not probable of being achieved until the event occurs. As a result, no compensation expense is recognized until the performance-based vesting condition is achieved, at which time the cumulative compensation expense is recognized. Compensation cost related to any remaining time-based service for share-based awards after the liquidity-based event is recognized on a straight-line basis over the remaining service period.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;For fully vested, nonforfeitable equity instruments that are granted at the date the Company and a nonemployee enter into an agreement for goods or services, the Company recognizes the fair value of the equity instruments on the grant date. The corresponding cost is recognized as an immediate expense or a prepaid asset and expensed over the service period depending on the specific facts and circumstances of the agreement with the nonemployee. See Note &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c7c93237c1946f635b03'; font-family: 'Times New Roman'"&gt;&lt;span&gt;10&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; for further details.&lt;/span&gt;&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="D20250930_1" id="Tag960">&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-weight:bold; text-decoration:underline; font-family: 'Times New Roman'"&gt;Net Loss per Common Share&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="-aw-sdt-tag:'a31-2b2-f34-82d-cfe6'; -aw-sdt-title:'Net_(Loss)_Income_Title_P2'; font-family: 'Times New Roman'"&gt;&lt;span&gt;Net Loss&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; per Common Share is computed by dividing &lt;/span&gt;&lt;span style="-aw-sdt-tag:'a78-fb5-6f5-642-14ce'; -aw-sdt-title:'Net_(Loss)_Income_Title___Lower_P1'; font-family: 'Times New Roman'"&gt;&lt;span&gt;net loss&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; attributable to common shareholders by the weighted average number of common shares outstanding during each period. The Company includes pre-funded warrants, which carry a nominal exercise price per share, in its computation of basic and diluted net loss per share beginning on the date of issuance. The cumulative dividends accrued on the Series A Preferred Stock during the period are reflected as an increase to net loss or a reduction of net income in determining basic and diluted &lt;/span&gt;&lt;span style="-aw-sdt-tag:'31c-481-9ce-577-2088'; -aw-sdt-title:'Net_(Loss)_Income_Title___Lower_P2'; font-family: 'Times New Roman'"&gt;&lt;span&gt;net loss&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; attributable to common stockholders.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;As the Company reported a net loss for all periods presented, the calculation of diluted net loss per common share is the same as basic net loss per common share. &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;As a result of the &lt;/span&gt;&lt;span style="-aw-sdt-tag:'5f0-31e-83e-591-f354'; font-family: 'Times New Roman'"&gt;&lt;span&gt;1:5&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; Reverse Stock Split, which was effective as of February 24, 2025, all shares of outstanding common stock and net loss per common share calculations have been retroactively adjusted for all periods presented.&lt;/span&gt;&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:StockholdersEquityReverseStockSplit contextRef="D20250224" id="Tag738">1:5</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:CompensationRelatedCostsPolicyTextBlock contextRef="D20250930_1" id="Tag961">&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-weight:bold; text-decoration:underline; font-family: 'Times New Roman'"&gt;Related Parties&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Parties are considered to be related to the Company if the parties, directly or indirectly, through one or more intermediaries, control, are controlled by, or are under common control with the Company. Related parties also include principal owners of the Company, its management, members of the immediate families of principal owners of the Company and its management and other parties with which the Company may deal with if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.&lt;/span&gt;&lt;/p&gt;</us-gaap:CompensationRelatedCostsPolicyTextBlock>
    <us-gaap:SubsequentEventsPolicyPolicyTextBlock contextRef="D20250930_1" id="Tag948">&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-weight:bold; text-decoration:underline; font-family: 'Times New Roman'"&gt;Subsequent Events&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;The Company considers events or transactions that occur after the balance sheet date, but prior to the issuance of the financial statements to provide additional evidence relative to certain estimates or to identify matters that require additional disclosure. Subsequent events have been evaluated through &lt;/span&gt;&lt;span style="-aw-sdt-tag:'cb270f797852c1e1f2a5'; -aw-sdt-title:'Current_Period_Date_FS_Issued_P1'; font-family: 'Times New Roman'"&gt;&lt;span&gt;November 13, 2025&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;, which is the date the financial statements were issued. See Note &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c8dbf1260408b95c5a15'; font-family: 'Times New Roman'"&gt;&lt;span&gt;12&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;.&lt;/span&gt;&lt;/p&gt;</us-gaap:SubsequentEventsPolicyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="D20250930_1" id="Tag952">&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-weight:bold; text-decoration:underline; font-family: 'Times New Roman'"&gt;Recently Adopted and Issued Accounting Pronouncements&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;From time to time, the FASB issues Accounting Standards Updates (&#x201c;ASU&#x201d;) to amend the authoritative literature in the ASC. The Company regularly evaluates new ASUs to determine the impact that these pronouncements may have on the consolidated condensed financial statements. Other than the pronouncements listed below, the Company believes that those issued to date either (i) provide supplemental guidance, (ii) are technical corrections, or (iii) are not applicable to the Company&#x2019;s consolidated condensed financial statements or related disclosures.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;In November &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c40fc8bff493befc18d6'; font-family: 'Times New Roman'"&gt;&lt;span&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;, the FASB issued ASU &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c0a6b49074383096c882'; font-family: 'Times New Roman'"&gt;&lt;span&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;-&lt;/span&gt;&lt;span style="-aw-sdt-tag:'cd25ae9feb1743719bb1'; font-family: 'Times New Roman'"&gt;&lt;span&gt;07&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;, &lt;/span&gt;&lt;span style="font-style:italic; font-family: 'Times New Roman'"&gt;Segment Reporting (Topic &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c48474e3644a54930dfc'; font-family: 'Times New Roman'"&gt;&lt;span style="font-style:italic"&gt;280&lt;/span&gt;&lt;/span&gt;&lt;span style="font-style:italic; font-family: 'Times New Roman'"&gt;): Improvements to Reportable Segment Disclosures&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; (&#x201c;ASU &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c731ea50ea67c7e4b420'; font-family: 'Times New Roman'"&gt;&lt;span&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;-&lt;/span&gt;&lt;span style="-aw-sdt-tag:'cce9c44e2351f5ac2796'; font-family: 'Times New Roman'"&gt;&lt;span&gt;07&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#x201d;) which expands annual and interim disclosure requirements for reportable segments, primarily through enhanced disclosures about significant segment expenses and segment profit or loss. ASU &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c7a9ce0a0ac8993d0acf'; font-family: 'Times New Roman'"&gt;&lt;span&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;-&lt;/span&gt;&lt;span style="-aw-sdt-tag:'cdd16562ce807243ed58'; font-family: 'Times New Roman'"&gt;&lt;span&gt;07&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; also requires entities with a single reportable segment to provide all segment disclosures under ASC &lt;/span&gt;&lt;span style="-aw-sdt-tag:'cf6e9777e809f25e1b07'; font-family: 'Times New Roman'"&gt;&lt;span&gt;280&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;, including the new required disclosures under the ASU. The Company adopted ASU &lt;/span&gt;&lt;span style="-aw-sdt-tag:'cc9be51d0fa22b72f687'; font-family: 'Times New Roman'"&gt;&lt;span&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;-&lt;/span&gt;&lt;span style="-aw-sdt-tag:'cc2f4662055f1cf358a4'; font-family: 'Times New Roman'"&gt;&lt;span&gt;07&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; on a retrospective basis for the &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c304e39ce5549b67326b'; font-family: 'Times New Roman'"&gt;&lt;span&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; annual period, and for interim periods beginning in &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c50e039416b6752cbc9e'; font-family: 'Times New Roman'"&gt;&lt;span&gt;2025&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;. The impact is limited to the Company&#x2019;s financial statement disclosures, which are presented in the Segment Information section above.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;In December &lt;/span&gt;&lt;span style="-aw-sdt-tag:'cf066c3ed14287513469'; font-family: 'Times New Roman'"&gt;&lt;span&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;, the FASB issued ASU &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c0565bc7ca2af95b4c7c'; font-family: 'Times New Roman'"&gt;&lt;span&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;-&lt;/span&gt;&lt;span style="-aw-sdt-tag:'ceb96c9259852308d896'; font-family: 'Times New Roman'"&gt;&lt;span&gt;09&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;, &lt;/span&gt;&lt;span style="font-style:italic; font-family: 'Times New Roman'"&gt;Income Taxes (ASC &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c0282851b575f38250ce'; font-family: 'Times New Roman'"&gt;&lt;span style="font-style:italic"&gt;740&lt;/span&gt;&lt;/span&gt;&lt;span style="font-style:italic; font-family: 'Times New Roman'"&gt;): Improvements to Income Tax Disclosures&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; (&#x201c;ASU &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c397c2576fab14a6843a'; font-family: 'Times New Roman'"&gt;&lt;span&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;-&lt;/span&gt;&lt;span style="-aw-sdt-tag:'c43ea664edca3b7d1221'; font-family: 'Times New Roman'"&gt;&lt;span&gt;09&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#x201d;) which requires disaggregated information about a reporting entity&#x2019;s effective tax rate reconciliation as well as information on income taxes paid. ASU &lt;/span&gt;&lt;span style="-aw-sdt-tag:'ced6791b435360aa514d'; font-family: 'Times New Roman'"&gt;&lt;span&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;-&lt;/span&gt;&lt;span style="-aw-sdt-tag:'c152d39afa37813cff35'; font-family: 'Times New Roman'"&gt;&lt;span&gt;09&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; is effective for annual periods beginning after December &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c65d60af908ae022a7fb'; font-family: 'Times New Roman'"&gt;&lt;span&gt;15&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;, &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c9d2f568ca33a0e3ddc2'; font-family: 'Times New Roman'"&gt;&lt;span&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;. The Company will adopt this standard for the annual period ending December 31, 2025. The impact of ASU 2023-09 will be limited to the Company&#x2019;s financial statement disclosures.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;In November &lt;/span&gt;&lt;span style="-aw-sdt-tag:'cb06da4c60c3ed718870'; font-family: 'Times New Roman'"&gt;&lt;span&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;, the FASB issued ASU &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c5896724f85326b5cf6c'; font-family: 'Times New Roman'"&gt;&lt;span&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;-&lt;/span&gt;&lt;span style="-aw-sdt-tag:'c5ee0130675746e94982'; font-family: 'Times New Roman'"&gt;&lt;span&gt;03&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;, &lt;/span&gt;&lt;span style="font-style:italic; font-family: 'Times New Roman'"&gt;Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c686357b9151070c0b80'; font-family: 'Times New Roman'"&gt;&lt;span style="font-style:italic"&gt;220&lt;/span&gt;&lt;/span&gt;&lt;span style="font-style:italic; font-family: 'Times New Roman'"&gt;-&lt;/span&gt;&lt;span style="-aw-sdt-tag:'ccb37deca24433c43642'; font-family: 'Times New Roman'"&gt;&lt;span style="font-style:italic"&gt;40&lt;/span&gt;&lt;/span&gt;&lt;span style="font-style:italic; font-family: 'Times New Roman'"&gt;): Disaggregation of Income Statement Expenses &lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;(&#x201c;ASU &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c82c510f162b91f255e5'; font-family: 'Times New Roman'"&gt;&lt;span&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;-&lt;/span&gt;&lt;span style="-aw-sdt-tag:'c9b3edff03a8224442ee'; font-family: 'Times New Roman'"&gt;&lt;span&gt;03&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#x201d;), which applies to all public business entities that file financial statements with the SEC. The amendments in this ASU require public business entities to disclose on an annual and interim basis, disaggregated information about certain income statement expense line items. The new standard is effective for fiscal years beginning after December &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c4227d4f684c80f6fc7b'; font-family: 'Times New Roman'"&gt;&lt;span&gt;15&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;, &lt;/span&gt;&lt;span style="-aw-sdt-tag:'cdb1897f2589fc5290f5'; font-family: 'Times New Roman'"&gt;&lt;span&gt;2026&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;, with early adoption permitted. The Company is currently evaluating the impact that ASU &lt;/span&gt;&lt;span style="-aw-sdt-tag:'cd9fcbee88c447594d3d'; font-family: 'Times New Roman'"&gt;&lt;span&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;-&lt;/span&gt;&lt;span style="-aw-sdt-tag:'cea1fdf602d68e8ea393'; font-family: 'Times New Roman'"&gt;&lt;span&gt;03&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; will have on its financial statement disclosures.&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &lt;/span&gt;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:InventoryDisclosureTextBlock contextRef="D20250930_1" id="Tag965">&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;3. INVENTORY&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="-aw-sdt-tag:'c4b64ef482d85585ddef'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Inventory consists of the following major classes:&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="-aw-sdt-tag:'c3ad763587e21d5ec175'; -aw-sdt-title:'INVENTORY T1'"&gt;&lt;table cellpadding="0" cellspacing="0" style="width:100%; margin-right:auto; margin-left:auto; border-collapse:collapse"&gt;&lt;tbody&gt;&lt;tr style="height:11.5pt"&gt;&lt;td style="width:77%; vertical-align:middle"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1.5pt solid #000000; padding-right:5.75pt; padding-left:5.75pt; vertical-align:bottom"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_8c78ee49c91e44ce918f2ebd1b7927a2'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;September 30, 2025&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1.5pt solid #000000; vertical-align:middle"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_eb198c15a0e04e4e8352b8854a5daadc'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.5pt"&gt;&lt;td style="width:77%; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_9f6e148ddfbd43bd85c0bd773b3ebd5b'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Raw Material (API)&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_00a19566ed1c43f99c98897b148d8d2a'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_f16c7a3406eb4165a5632f4b2432cc52'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;345,195&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_97a890fb4676459799df39011e8dd53c'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-tag:'C_ab71897d07ac40d28dfd83405a9dfafe'"&gt;&lt;span title="&amp;amp;#13;nil='true'"&gt;&lt;/span&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.5pt"&gt;&lt;td style="width:77%; vertical-align:middle; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_aeef74c84e0f4d1f96536ddc357d7064'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Work in Process&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; vertical-align:middle; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-tag:'C_6a3655bdab5d48dd86ca61227681b415'"&gt;&lt;span title="&amp;amp;#13;nil='true'"&gt;&lt;/span&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; vertical-align:middle; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_ef00ca8ecef947d48a2392dce651f727'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;284,883&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.5pt"&gt;&lt;td style="width:77%; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_d5d56b1ac61047c8bb2cd738f043bffa'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Finished Goods&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_5b0903d97dea4325b613f810a8c5eaf2'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;426,491&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_36ca9b2fc2674b1b9e7c5ee6ac7b2cc2'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;157,881&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.5pt"&gt;&lt;td style="width:77%; vertical-align:middle; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_be61fc4bb0cc4c4ba6288d79409b3e45'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Total Inventory&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; vertical-align:middle; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_83e5c4c46f15469f98bfb74b9c0152cc'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;771,686&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; vertical-align:middle; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_a90105c86d004c7988263596647fb77a'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;442,764&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.5pt"&gt;&lt;td style="width:77%; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_4beb2619f3b64a17be38dcd2cbe156d3'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Reserve for Expiring Inventory&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;(&lt;/span&gt;&lt;span style="-aw-sdt-tag:'C_93d116c0bb494287916a99a01a7fd59c'; font-family: 'Times New Roman'"&gt;&lt;span&gt;244,682&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-tag:'C_dee47b6fa0dc487eba64f4acdf903ada'"&gt;&lt;span title="&amp;amp;#13;nil='true'"&gt;&lt;/span&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.5pt"&gt;&lt;td style="width:77%; vertical-align:middle; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_73dc86a2354c42c5af659415f686502c'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;Inventory&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_18ec2a0d235e48ca8dccc53077caf073'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_352a37dac1dc493db25e225319ba1514'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;527,004&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_14f157594d2f42b2a8d7ac54924f20bb'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'d7b-8b1-5fc-6b2-f7e6'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;442,764&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;The Company regularly monitors its inventory levels to identify inventory that may expire or has a cost basis in excess of its estimated net realizable value, and records write-downs for inventory that has expired, inventory that has a cost basis in excess of its expected net realizable value, and inventory in excess of expected sales requirements. Any write-downs of inventories are charged to cost of revenues in the &lt;/span&gt;&lt;span style="-aw-sdt-tag:'ffb-eda-e3e-f96-f173'; -aw-sdt-title:'PandL_title_P4'; font-family: 'Times New Roman'"&gt;&lt;span&gt;consolidated condensed statements of operations and comprehensive loss&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;. During the &lt;/span&gt;&lt;span style="-aw-sdt-tag:'b1e-16f-504-955-dd45'; -aw-sdt-title:'Current_Quarter_P48'; font-family: 'Times New Roman'"&gt;&lt;span&gt;three months ended September 30, 2025&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; and &lt;/span&gt;&lt;span style="-aw-sdt-tag:'19f-9c4-d3b-e65-dd8f'; -aw-sdt-title:'Previous_Year_P54'; font-family: 'Times New Roman'"&gt;&lt;span&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;, write downs for expired inventory were $&lt;/span&gt;&lt;span style="-aw-sdt-tag:'8c7-42a-927-d0d-4aae'; -aw-sdt-title:'Inventory Write-downs CQ'; font-family: 'Times New Roman'"&gt;&lt;span&gt;436,561&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; and $&lt;/span&gt;&lt;span style="-aw-sdt-tag:'dc4-345-946-2cb-8a9f'; -aw-sdt-title:'Inventory Write-downs PQ'; font-family: 'Times New Roman'"&gt;&lt;span&gt;1,165&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;, respectively ($&lt;/span&gt;&lt;span style="-aw-sdt-tag:'1ec-156-b10-d9c-e801'; -aw-sdt-title:'Inventory Write-downs CYTD'; font-family: 'Times New Roman'"&gt;&lt;span&gt;436,596&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; and $&lt;/span&gt;&lt;span style="-aw-sdt-tag:'acd-db4-0d0-210-5cfb'; -aw-sdt-title:'Inventory Write-downs PYTD'; font-family: 'Times New Roman'"&gt;&lt;span&gt;18,490&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; for the &lt;/span&gt;&lt;span style="-aw-sdt-tag:'497-514-bce-6c1-7d4b'; -aw-sdt-title:'Current_YTD_P56'; font-family: 'Times New Roman'"&gt;&lt;span&gt;nine months ended September 30, 2025&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; and &lt;/span&gt;&lt;span style="-aw-sdt-tag:'860-e12-55e-aec-5da2'; -aw-sdt-title:'Previous_Year_P55'; font-family: 'Times New Roman'"&gt;&lt;span&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;, respectively).&lt;/span&gt;&lt;/p&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="D20250930_1" id="Tag928">&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Inventory consists of the following major classes:&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="-aw-sdt-tag:'c3ad763587e21d5ec175'; -aw-sdt-title:'INVENTORY T1'"&gt;&lt;table cellpadding="0" cellspacing="0" style="width:100%; margin-right:auto; margin-left:auto; border-collapse:collapse"&gt;&lt;tbody&gt;&lt;tr style="height:11.5pt"&gt;&lt;td style="width:77%; vertical-align:middle"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1.5pt solid #000000; padding-right:5.75pt; padding-left:5.75pt; vertical-align:bottom"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_8c78ee49c91e44ce918f2ebd1b7927a2'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;September 30, 2025&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1.5pt solid #000000; vertical-align:middle"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_eb198c15a0e04e4e8352b8854a5daadc'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.5pt"&gt;&lt;td style="width:77%; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_9f6e148ddfbd43bd85c0bd773b3ebd5b'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Raw Material (API)&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_00a19566ed1c43f99c98897b148d8d2a'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_f16c7a3406eb4165a5632f4b2432cc52'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;345,195&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_97a890fb4676459799df39011e8dd53c'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-tag:'C_ab71897d07ac40d28dfd83405a9dfafe'"&gt;&lt;span title="&amp;amp;#13;nil='true'"&gt;&lt;/span&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.5pt"&gt;&lt;td style="width:77%; vertical-align:middle; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_aeef74c84e0f4d1f96536ddc357d7064'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Work in Process&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; vertical-align:middle; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-tag:'C_6a3655bdab5d48dd86ca61227681b415'"&gt;&lt;span title="&amp;amp;#13;nil='true'"&gt;&lt;/span&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; vertical-align:middle; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_ef00ca8ecef947d48a2392dce651f727'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;284,883&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.5pt"&gt;&lt;td style="width:77%; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_d5d56b1ac61047c8bb2cd738f043bffa'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Finished Goods&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_5b0903d97dea4325b613f810a8c5eaf2'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;426,491&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_36ca9b2fc2674b1b9e7c5ee6ac7b2cc2'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;157,881&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.5pt"&gt;&lt;td style="width:77%; vertical-align:middle; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_be61fc4bb0cc4c4ba6288d79409b3e45'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Total Inventory&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; vertical-align:middle; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_83e5c4c46f15469f98bfb74b9c0152cc'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;771,686&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; vertical-align:middle; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_a90105c86d004c7988263596647fb77a'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;442,764&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.5pt"&gt;&lt;td style="width:77%; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_4beb2619f3b64a17be38dcd2cbe156d3'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Reserve for Expiring Inventory&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;(&lt;/span&gt;&lt;span style="-aw-sdt-tag:'C_93d116c0bb494287916a99a01a7fd59c'; font-family: 'Times New Roman'"&gt;&lt;span&gt;244,682&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-tag:'C_dee47b6fa0dc487eba64f4acdf903ada'"&gt;&lt;span title="&amp;amp;#13;nil='true'"&gt;&lt;/span&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.5pt"&gt;&lt;td style="width:77%; vertical-align:middle; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_73dc86a2354c42c5af659415f686502c'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;Inventory&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_18ec2a0d235e48ca8dccc53077caf073'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_352a37dac1dc493db25e225319ba1514'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;527,004&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_14f157594d2f42b2a8d7ac54924f20bb'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'d7b-8b1-5fc-6b2-f7e6'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;442,764&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterials
      contextRef="I20250930"
      decimals="0"
      id="Tag61"
      unitRef="USD">345195</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryRawMaterials
      contextRef="I20241231"
      id="Tag65"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InventoryWorkInProcess
      contextRef="I20250930"
      id="Tag190"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InventoryWorkInProcess
      contextRef="I20241231"
      decimals="0"
      id="Tag63"
      unitRef="USD">284883</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryFinishedGoods
      contextRef="I20250930"
      decimals="0"
      id="Tag62"
      unitRef="USD">426491</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryFinishedGoods
      contextRef="I20241231"
      decimals="0"
      id="Tag64"
      unitRef="USD">157881</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryGross
      contextRef="I20250930"
      decimals="0"
      id="Tag187"
      unitRef="USD">771686</us-gaap:InventoryGross>
    <us-gaap:InventoryGross
      contextRef="I20241231"
      decimals="0"
      id="Tag189"
      unitRef="USD">442764</us-gaap:InventoryGross>
    <us-gaap:InventoryAdjustments
      contextRef="I20250930"
      decimals="0"
      id="Tag27"
      unitRef="USD">244682</us-gaap:InventoryAdjustments>
    <us-gaap:InventoryAdjustments
      contextRef="I20241231"
      id="Tag191"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InventoryNet
      contextRef="I20250930"
      decimals="0"
      id="Tag188"
      unitRef="USD">527004</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="I20241231"
      decimals="0"
      id="Tag224"
      unitRef="USD">442764</us-gaap:InventoryNet>
    <us-gaap:InventoryWriteDown
      contextRef="D20250930"
      decimals="0"
      id="Tag839"
      unitRef="USD">436561</us-gaap:InventoryWriteDown>
    <us-gaap:InventoryWriteDown
      contextRef="D20240930"
      decimals="0"
      id="Tag831"
      unitRef="USD">1165</us-gaap:InventoryWriteDown>
    <us-gaap:InventoryWriteDown
      contextRef="D20250930_1"
      decimals="0"
      id="Tag832"
      unitRef="USD">436596</us-gaap:InventoryWriteDown>
    <us-gaap:InventoryWriteDown
      contextRef="D20240930_1"
      decimals="0"
      id="Tag821"
      unitRef="USD">18490</us-gaap:InventoryWriteDown>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="D20250930_1" id="Tag970">&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-sdt-tag:'362-52b-f94-e85-08c1'; font-family: 'Times New Roman'"&gt;&lt;span style="font-weight:bold"&gt;4&lt;/span&gt;&lt;/span&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;. PROPERTY AND EQUIPMENT&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="-aw-sdt-tag:'c3328980f611b2c2c18e'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Property and Equipment, net consists of:&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="-aw-sdt-tag:'c585e2b6503490e35b6e'; -aw-sdt-title:'PROPERTY AND EQUIPMENT T1'"&gt;&lt;table cellpadding="0" cellspacing="0" style="width:100%; border-collapse:collapse"&gt;&lt;tbody&gt;&lt;tr style="height:11.5pt"&gt;&lt;td style="width:77%; vertical-align:middle"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1.5pt solid #000000; padding-right:5.75pt; padding-left:5.75pt; vertical-align:bottom"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_d243be9044f94e5789d1c03995fef724'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;September 30, 2025&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1.5pt solid #000000; vertical-align:middle"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_cdf2c2bb81134c98a67579ef3ca9e8ac'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.5pt"&gt;&lt;td style="width:77%; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_210216e127fe482781b410d7ec74a0b8'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Lab Equipment&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_53af035c51d0478aa394754c413e6ffb'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_9328eadfcc594ac596b0acc136f7b8f0'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;333,010&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_e940a18328bb4ad9bea7def38d0d559f'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_2329b86c972f422ba404be9dd3277495'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;233,411&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.5pt"&gt;&lt;td style="width:77%; vertical-align:middle; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_0319c462920c42afa0d3176c000bd9f7'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Machinery&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; vertical-align:middle; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_ef8d24443e6e4e8cb5980f37db5e774c'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;55,800&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; vertical-align:middle; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_c8ff641cd4744c44a8ca4ea45f4e85c8'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;55,800&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.5pt"&gt;&lt;td style="width:77%; vertical-align:middle; background-color:#ccecff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_6249934fa3de4adaa792e486a851badc'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Computer Equipment&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#ccecff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; vertical-align:middle; background-color:#ccecff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_aca3f556efe04148b984c56098021a99'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;11,597&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#ccecff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#ccecff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; vertical-align:middle; background-color:#ccecff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_a531e0c254db4110ad34d073164553f9'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;7,000&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.5pt"&gt;&lt;td style="width:77%; vertical-align:middle; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_aebc173cb2c8413fa5fcf35341f8657a'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Furniture&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_b504fb680d844731bb0cd3fabd739eac'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;3,030&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_6e01e63464c941e29d2034653b8107e5'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;3,030&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.5pt"&gt;&lt;td style="width:77%; vertical-align:middle; background-color:#ccecff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_8a33d8c7b8f447cf9991bc44f6e506d2'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Property and Equipment, at cost&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ccecff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ccecff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_7e9128e9f9104afc873f970c6a9135ce'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;403,437&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#ccecff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ccecff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ccecff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_0083050d4387424b9262c3e3b6a9fee5'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;299,241&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.5pt"&gt;&lt;td style="width:77%; vertical-align:middle; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_b6b62697f29548dbaf51d4cf72f0c5f7'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Accumulated Depreciation&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;(&lt;/span&gt;&lt;span style="-aw-sdt-tag:'C_d1d3c66b3b5440948d85580b0ecb68ec'; font-family: 'Times New Roman'"&gt;&lt;span&gt;175,685&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;(&lt;/span&gt;&lt;span style="-aw-sdt-tag:'C_6e53c81a6ded46cca2cd24a44cf411d0'; font-family: 'Times New Roman'"&gt;&lt;span&gt;149,433&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.5pt"&gt;&lt;td style="width:77%; vertical-align:middle; background-color:#ccecff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_11c099461546454a8d4b17afa85db567'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;Property and Equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ccecff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_e7ec042f6b194d6a858be22c9a1b091a'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ccecff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_2faa5c0453e4450596c4956cffc1df1e'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;227,752&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#ccecff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ccecff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_05cfb6f1de00493d99ff10680b286a1a'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ccecff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_519d7c2bff0c454799f8e791a58c7103'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;149,808&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Depreciation expense for the &lt;/span&gt;&lt;span style="-aw-sdt-tag:'3df-38b-a90-624-8e5d'; -aw-sdt-title:'Current_Quarter_P44'; font-family: 'Times New Roman'"&gt;&lt;span&gt;three months ended September 30, 2025&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; and &lt;/span&gt;&lt;span style="-aw-sdt-tag:'382-eed-505-ecf-e5da'; -aw-sdt-title:'Previous_Year_P47'; font-family: 'Times New Roman'"&gt;&lt;span&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; was in the amount of $&lt;/span&gt;&lt;span style="-aw-sdt-tag:'c6f-708-7ed-a12-e87f'; -aw-sdt-title:'Depreciation expense_CQTD'; font-family: 'Times New Roman'"&gt;&lt;span&gt;12,225&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; and $&lt;/span&gt;&lt;span style="-aw-sdt-tag:'05d-cb7-531-47b-40f1'; -aw-sdt-title:'Depreciation expense_PYQTD'; font-family: 'Times New Roman'"&gt;&lt;span&gt;4,334&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;, respectively ($&lt;/span&gt;&lt;span style="-aw-sdt-tag:'cd782fa2db2ddfc0ea5e'; -aw-sdt-title:'Depreciation expense_CYTD'; font-family: 'Times New Roman'"&gt;&lt;span&gt;28,155&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; and $&lt;/span&gt;&lt;span style="-aw-sdt-tag:'c3e71056f41b8e6237d0'; -aw-sdt-title:'Depreciation expense_PYTD'; font-family: 'Times New Roman'"&gt;&lt;span&gt;6,277&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; for the &lt;/span&gt;&lt;span style="-aw-sdt-tag:'cecb412e14ad226c62ea'; -aw-sdt-title:'Current_YTD_P4'; font-family: 'Times New Roman'"&gt;&lt;span&gt;nine months ended September 30, 2025&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; and &lt;/span&gt;&lt;span style="-aw-sdt-tag:'cd2da8121dd3f61410cb'; -aw-sdt-title:'Previous_Year_P6'; font-family: 'Times New Roman'"&gt;&lt;span&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;, respectively).&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &lt;/span&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="D20250930_1" id="Tag929">&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Property and Equipment, net consists of:&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="-aw-sdt-tag:'c585e2b6503490e35b6e'; -aw-sdt-title:'PROPERTY AND EQUIPMENT T1'"&gt;&lt;table cellpadding="0" cellspacing="0" style="width:100%; border-collapse:collapse"&gt;&lt;tbody&gt;&lt;tr style="height:11.5pt"&gt;&lt;td style="width:77%; vertical-align:middle"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1.5pt solid #000000; padding-right:5.75pt; padding-left:5.75pt; vertical-align:bottom"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_d243be9044f94e5789d1c03995fef724'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;September 30, 2025&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1.5pt solid #000000; vertical-align:middle"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_cdf2c2bb81134c98a67579ef3ca9e8ac'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.5pt"&gt;&lt;td style="width:77%; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_210216e127fe482781b410d7ec74a0b8'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Lab Equipment&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_53af035c51d0478aa394754c413e6ffb'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_9328eadfcc594ac596b0acc136f7b8f0'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;333,010&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_e940a18328bb4ad9bea7def38d0d559f'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_2329b86c972f422ba404be9dd3277495'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;233,411&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.5pt"&gt;&lt;td style="width:77%; vertical-align:middle; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_0319c462920c42afa0d3176c000bd9f7'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Machinery&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; vertical-align:middle; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_ef8d24443e6e4e8cb5980f37db5e774c'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;55,800&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; vertical-align:middle; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_c8ff641cd4744c44a8ca4ea45f4e85c8'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;55,800&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.5pt"&gt;&lt;td style="width:77%; vertical-align:middle; background-color:#ccecff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_6249934fa3de4adaa792e486a851badc'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Computer Equipment&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#ccecff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; vertical-align:middle; background-color:#ccecff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_aca3f556efe04148b984c56098021a99'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;11,597&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#ccecff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#ccecff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; vertical-align:middle; background-color:#ccecff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_a531e0c254db4110ad34d073164553f9'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;7,000&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.5pt"&gt;&lt;td style="width:77%; vertical-align:middle; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_aebc173cb2c8413fa5fcf35341f8657a'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Furniture&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_b504fb680d844731bb0cd3fabd739eac'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;3,030&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_6e01e63464c941e29d2034653b8107e5'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;3,030&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.5pt"&gt;&lt;td style="width:77%; vertical-align:middle; background-color:#ccecff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_8a33d8c7b8f447cf9991bc44f6e506d2'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Property and Equipment, at cost&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ccecff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ccecff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_7e9128e9f9104afc873f970c6a9135ce'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;403,437&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#ccecff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ccecff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ccecff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_0083050d4387424b9262c3e3b6a9fee5'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;299,241&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.5pt"&gt;&lt;td style="width:77%; vertical-align:middle; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_b6b62697f29548dbaf51d4cf72f0c5f7'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Accumulated Depreciation&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;(&lt;/span&gt;&lt;span style="-aw-sdt-tag:'C_d1d3c66b3b5440948d85580b0ecb68ec'; font-family: 'Times New Roman'"&gt;&lt;span&gt;175,685&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;(&lt;/span&gt;&lt;span style="-aw-sdt-tag:'C_6e53c81a6ded46cca2cd24a44cf411d0'; font-family: 'Times New Roman'"&gt;&lt;span&gt;149,433&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.5pt"&gt;&lt;td style="width:77%; vertical-align:middle; background-color:#ccecff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_11c099461546454a8d4b17afa85db567'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;Property and Equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ccecff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_e7ec042f6b194d6a858be22c9a1b091a'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ccecff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_2faa5c0453e4450596c4956cffc1df1e'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;227,752&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#ccecff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ccecff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_05cfb6f1de00493d99ff10680b286a1a'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ccecff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_519d7c2bff0c454799f8e791a58c7103'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;149,808&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="I20250930_LabEquipmentMember"
      decimals="0"
      id="Tag66"
      unitRef="USD">333010</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="I20241231_LabEquipmentMember"
      decimals="0"
      id="Tag72"
      unitRef="USD">233411</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="I20250930_MachineryAndEquipmentMember"
      decimals="0"
      id="Tag67"
      unitRef="USD">55800</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="I20241231_MachineryAndEquipmentMember"
      decimals="0"
      id="Tag73"
      unitRef="USD">55800</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="I20250930_ComputerEquipmentMember"
      decimals="0"
      id="Tag68"
      unitRef="USD">11597</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="I20241231_ComputerEquipmentMember"
      decimals="0"
      id="Tag74"
      unitRef="USD">7000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="I20250930_FurnitureAndFixturesMember"
      decimals="0"
      id="Tag69"
      unitRef="USD">3030</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="I20241231_FurnitureAndFixturesMember"
      decimals="0"
      id="Tag75"
      unitRef="USD">3030</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="I20250930"
      decimals="0"
      id="Tag70"
      unitRef="USD">403437</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="I20241231"
      decimals="0"
      id="Tag76"
      unitRef="USD">299241</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="I20250930" decimals="0" id="Tag1" unitRef="USD">175685</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="I20241231" decimals="0" id="Tag2" unitRef="USD">149433</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="I20250930"
      decimals="0"
      id="Tag71"
      unitRef="USD">227752</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="I20241231"
      decimals="0"
      id="Tag77"
      unitRef="USD">149808</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="D20250930"
      decimals="0"
      id="Tag811"
      unitRef="USD">12225</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="D20240930"
      decimals="0"
      id="Tag812"
      unitRef="USD">4334</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="D20250930_1"
      decimals="0"
      id="Tag744"
      unitRef="USD">28155</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="D20240930_1"
      decimals="0"
      id="Tag745"
      unitRef="USD">6277</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:IntangibleAssetsDisclosureTextBlock contextRef="D20250930_1" id="Tag991">&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;5. INTANGIBLE ASSETS&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="-aw-sdt-tag:'ce139b5a70e6301672f2'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Intangible Assets, net consists of:&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="-aw-sdt-tag:'c07707b83cb3f173b9aa'; -aw-sdt-title:'INTANGIBLE ASSETS T1'"&gt;&lt;table cellpadding="0" cellspacing="0" style="width:100%; border-collapse:collapse"&gt;&lt;tbody&gt;&lt;tr style="height:11.5pt"&gt;&lt;td style="width:76%; vertical-align:bottom"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:bottom"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1.5pt solid #000000; padding-right:5.75pt; padding-left:5.75pt; vertical-align:bottom"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_e87ec5587e3840c4a97f2064f2104ed4'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;September 30, 2025&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:bottom"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1.5pt solid #000000; vertical-align:bottom"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_6084f1e1489b48879fcbbe5600141f97'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.5pt"&gt;&lt;td style="width:76%; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_a974f35cc65443269ff066743129189d'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Patents&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_d202bcb88b044d028a4bbb28f6a6e8b0'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_11b78614bac54ef0a49e4b893a15b1d0'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;152,267&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_51a78629619a4b75ba95f8f8f4f7ec7b'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_860e11faa60f4e3cb17c35e447e6d321'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;127,603&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.5pt"&gt;&lt;td style="width:76%; vertical-align:middle"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_f612ea6912ea4de8936ab11fa94001b2'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Website Development Costs&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_bd5beeeb98654d3cb378b1f150cf237e'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;106,407&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_0297394f2e174985a9011e14c17a1c32'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;104,622&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.5pt"&gt;&lt;td style="width:76%; vertical-align:middle; background-color:#ccecff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_69283753d7194d8481cb58344618da62'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Intangible Assets, at cost&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#ccecff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ccecff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ccecff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_67428270244741e190f4ba5b6f6c89a4'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;258,674&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#ccecff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ccecff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ccecff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_ce68356243274a62b8341406f23e7284'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;232,225&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.5pt"&gt;&lt;td style="width:76%; vertical-align:middle"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_5ec84ad9cbbb4a728206c96fd6d9a6ac'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Accumulated Amortization&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;(&lt;/span&gt;&lt;span style="-aw-sdt-tag:'C_a4c0c57793a24539a911c71110c0a6db'; font-family: 'Times New Roman'"&gt;&lt;span&gt;106,291&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;(&lt;/span&gt;&lt;span style="-aw-sdt-tag:'C_ba8b1931203d40b8b853f7cd33fb68a0'; font-family: 'Times New Roman'"&gt;&lt;span&gt;75,141&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.5pt"&gt;&lt;td style="width:76%; vertical-align:middle; background-color:#ccecff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_609bae755e8b4231bb1d4b943acee2ff'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;Intangible Assets, net&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#ccecff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ccecff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_bbacba70555c4d44a3ed2b95ac3cb5f3'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ccecff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_2fda802cc17945c78daa21dc34cb0e8e'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;152,383&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#ccecff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ccecff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_0f46f04104944ac794c1fcc3501b0184'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ccecff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_01b52cfeb567443aae2cc897f6e6903c'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;157,084&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;During the &lt;/span&gt;&lt;span style="-aw-sdt-tag:'cfddb1f69b08f6739761'; -aw-sdt-title:'Current_Quarter_P8'; font-family: 'Times New Roman'"&gt;&lt;span&gt;three months ended September 30, 2025&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; and &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c29e36ff587f2ca8119a'; -aw-sdt-title:'Previous_Year_P7'; font-family: 'Times New Roman'"&gt;&lt;span&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;, the Company capitalized website development related costs of $&lt;/span&gt;&lt;span style="-aw-sdt-tag:'c2a1e8afbb1fb6a25958'; -aw-sdt-title:'Capitalized website cost_CQ'; font-family: 'Times New Roman'"&gt;&lt;span&gt;1,785&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; and $&lt;/span&gt;&lt;span style="-aw-sdt-tag:'cda0d70b09d724d001f4'; -aw-sdt-title:'Capitalized website cost_PQ'; font-family: 'Times New Roman'"&gt;&lt;span&gt;3,299&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;, respectively, in connection with the upgrade and enhancement of functionality of the corporate website at www.60degreespharma.com&lt;/span&gt;&lt;span style="-aw-import:spaces; font-family: 'Times New Roman'"&gt;&#160; &lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;($&lt;/span&gt;&lt;span style="-aw-sdt-tag:'c3dc95a82a1b1e546d01'; -aw-sdt-title:'Capitalized website cost_CYTD'; font-family: 'Times New Roman'"&gt;&lt;span&gt;1,785&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;and $&lt;/span&gt;&lt;span style="-aw-sdt-tag:'cf4550241ecb006a41f6'; -aw-sdt-title:'Capitalized website cost_PYTD'; font-family: 'Times New Roman'"&gt;&lt;span&gt;25,374&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;for the &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c33b8fe0f39e14089973'; -aw-sdt-title:'Current_YTD_P5'; font-family: 'Times New Roman'"&gt;&lt;span&gt;nine months ended September 30, 2025&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; and &lt;/span&gt;&lt;span style="-aw-sdt-tag:'ce5f4b2075d79cc2478c'; -aw-sdt-title:'Previous_Year_P8'; font-family: 'Times New Roman'"&gt;&lt;span&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;, respectively). Amortization expense for the &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c44e3479c6cf2fd17b26'; -aw-sdt-title:'Current_Quarter_P9'; font-family: 'Times New Roman'"&gt;&lt;span&gt;three months ended September 30, 2025&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; and &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c17bd43eeffe59b5f10e'; -aw-sdt-title:'Previous_Year_P9'; font-family: 'Times New Roman'"&gt;&lt;span&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;, was in the amount of $&lt;/span&gt;&lt;span style="-aw-sdt-tag:'cdf9166bedebda2ed9aa'; -aw-sdt-title:'Amortization expense_CQ'; font-family: 'Times New Roman'"&gt;&lt;span&gt;10,605&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; and $&lt;/span&gt;&lt;span style="-aw-sdt-tag:'ca20761b02425983f940'; -aw-sdt-title:'Amortization expense_PQ'; font-family: 'Times New Roman'"&gt;&lt;span&gt;10,325&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;, respectively ($&lt;/span&gt;&lt;span style="-aw-sdt-tag:'c8ce6837087c033d4286'; -aw-sdt-title:'Amortization expense_CYTD'; font-family: 'Times New Roman'"&gt;&lt;span&gt;31,150&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;and $&lt;/span&gt;&lt;span style="-aw-sdt-tag:'cc44d6d5241d199376d1'; -aw-sdt-title:'Amortization expense_PYTD'; font-family: 'Times New Roman'"&gt;&lt;span&gt;28,004&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;for the &lt;/span&gt;&lt;span style="-aw-sdt-tag:'ce158ad54306c4664c5b'; -aw-sdt-title:'Current_YTD_P6'; font-family: 'Times New Roman'"&gt;&lt;span&gt;nine months ended September 30, 2025&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; and &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c4c2c545f5f21414391e'; -aw-sdt-title:'Previous_Year_P10'; font-family: 'Times New Roman'"&gt;&lt;span&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;, respectively). During the &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c457dc719db4eca31b2a'; -aw-sdt-title:'Current_Quarter_P10'; font-family: 'Times New Roman'"&gt;&lt;span&gt;three months ended September 30, 2025&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; and &lt;/span&gt;&lt;span style="-aw-sdt-tag:'cdc79815474d680ddd9e'; -aw-sdt-title:'Previous_Year_P45'; font-family: 'Times New Roman'"&gt;&lt;span&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; write-downs for expired or obsolete patents totaled $&lt;/span&gt;&lt;span style="-aw-sdt-tag:'7d9-88c-e97-7af-e31e'; -aw-sdt-title:'Write-downs CQ'; font-family: 'Times New Roman'"&gt;&lt;span&gt;0&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; and $&lt;/span&gt;&lt;span style="-aw-sdt-tag:'283-f1b-606-cfc-9b44'; -aw-sdt-title:'Write-downs PQ'; font-family: 'Times New Roman'"&gt;&lt;span&gt;2,922&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;, respectively ($&lt;/span&gt;&lt;span style="-aw-sdt-tag:'e6c-293-14b-bb4-26d0'; -aw-sdt-title:'Write downs_CYTD'; font-family: 'Times New Roman'"&gt;&lt;span&gt;0&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; and&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;$&lt;/span&gt;&lt;span style="-aw-sdt-tag:'cac27d69e412e4ba21e5'; -aw-sdt-title:'Write-downs_PYTD'; font-family: 'Times New Roman'"&gt;&lt;span&gt;11,300&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;for the &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c72938f4a0ec43514747'; -aw-sdt-title:'Current_YTD_P7'; font-family: 'Times New Roman'"&gt;&lt;span&gt;nine months ended September 30, 2025&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; and &lt;/span&gt;&lt;span style="-aw-sdt-tag:'cbbf9cb9616e40a9b45a'; -aw-sdt-title:'Previous_Year_P11'; font-family: 'Times New Roman'"&gt;&lt;span&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;, respectively).&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="-aw-sdt-tag:'c3bc236d7ffc1c5b8cde'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;The following table summarizes the estimated future amortization expense for our patents and website development costs as of &lt;/span&gt;&lt;span style="-aw-sdt-tag:'ce96f421a46d06d458b3'; -aw-sdt-title:'Current_Period_P7'; font-family: 'Times New Roman'"&gt;&lt;span&gt;September 30, 2025&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;:&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="-aw-sdt-tag:'c0f2fdd191b23a42f69c'; -aw-sdt-title:'INTANGIBLE ASSETS T2'"&gt;&lt;table cellpadding="0" cellspacing="0" style="width:100%; border-collapse:collapse"&gt;&lt;tbody&gt;&lt;tr style="height:11.5pt"&gt;&lt;td style="width:76%; border-bottom:1.5pt solid #000000; vertical-align:bottom"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_174dcc19aadc45dcbec245e8e5590546'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;Period&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:bottom"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1.5pt solid #000000; vertical-align:bottom"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_2b4fd151a35e427f81944ed4aef3cd03'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;Patents&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:bottom"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1.5pt solid #000000; vertical-align:bottom"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_eac02702a1b6481292e04477eabff1f5'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;Website Development Costs&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.5pt"&gt;&lt;td style="width:76%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_bed21abb624848b39d25a0e5198a3eea'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;2025 (remaining three months)&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_0628bafa871b46b6b23c7839bac84a2b'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:10%; border-top:1.5pt solid #000000; padding-right:0.7pt; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_9ed72b1fc9a841678c6414ffa9250716'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;1,816&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_9971da9e37cf45c6965a560295ce2ee3'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_b86b8d6612d346b299a1f4e8b716937d'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;5,754&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.5pt"&gt;&lt;td style="width:76%; vertical-align:middle"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_98ee970e69c748c69cc8bbd0ed8e7995'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; padding-right:0.7pt; vertical-align:middle"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_29d81502a5fc40d6b3b22b749ae8c2cc'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;7,264&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; vertical-align:middle"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_d2022197ea7e432dad2b843e2cba5634'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;13,027&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.5pt"&gt;&lt;td style="width:76%; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_4130c067c39a40829ddaa2a81e97ae4b'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;2027&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; padding-right:0.7pt; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_4d3a475d713840deb210ba44e18e1f33'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;7,264&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_5fd36d2d7338473a98e0eaca4c3bb72e'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;3,689&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.5pt"&gt;&lt;td style="width:76%; vertical-align:middle"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_313ade7de15848e1805861fa9d495eb2'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;2028&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; padding-right:0.7pt; vertical-align:middle"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_9a518cad7b5f4600b17899e4df170f7e'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;7,264&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; vertical-align:middle"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_ba37da8a5d21434286c58831bdac112f'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;397&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.5pt"&gt;&lt;td style="width:76%; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_faf1ce39ee004fdbacf45816b0cd8e1b'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;2029&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; padding-right:0.7pt; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_1dbfcb6bede14893b1d590e5550007a7'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;7,264&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-tag:'C_4124ac0cb341498b8445cea7bd35d757'"&gt;&lt;span title="&amp;amp;#13;nil='true'"&gt;&lt;/span&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.5pt"&gt;&lt;td style="width:76%; vertical-align:middle"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_a93ca8f84d704c2685aef38dd6e616fb'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Thereafter&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; border-bottom:1.5pt solid #000000; padding-right:0.7pt; vertical-align:middle"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_6321783027ee42c18b71f36dd0941a2f'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;38,435&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle"&gt;&lt;div style="-aw-sdt-tag:'C_257cb67d346b4113ac890add634412f6'"&gt;&lt;span title="&amp;amp;#13;nil='true'"&gt;&lt;/span&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.5pt"&gt;&lt;td style="width:76%; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_d7c76dd6b9cc422d8a6b884dacaa3365'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_75767eb28a1d449ab596ff84732f7256'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; padding-right:0.7pt; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_2ee72c55a7204d64a57ac09c73611a03'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;69,307&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_6779a62c90a14cb8b35f588ce92d9296'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'e65-d56-30f-2c3-e9f3'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;22,867&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;The Company has recorded $&lt;/span&gt;&lt;span style="-aw-sdt-tag:'cbd86a35bd29e0f037ae'; -aw-sdt-title:'capitalized patent expenses'; font-family: 'Times New Roman'"&gt;&lt;span&gt;60,209&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; in capitalized patent expenses that will become amortizable as the patents they are associated with are awarded.&lt;/span&gt;&lt;/p&gt;</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock contextRef="D20250930_1" id="Tag930">&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Intangible Assets, net consists of:&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="-aw-sdt-tag:'c07707b83cb3f173b9aa'; -aw-sdt-title:'INTANGIBLE ASSETS T1'"&gt;&lt;table cellpadding="0" cellspacing="0" style="width:100%; border-collapse:collapse"&gt;&lt;tbody&gt;&lt;tr style="height:11.5pt"&gt;&lt;td style="width:76%; vertical-align:bottom"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:bottom"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1.5pt solid #000000; padding-right:5.75pt; padding-left:5.75pt; vertical-align:bottom"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_e87ec5587e3840c4a97f2064f2104ed4'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;September 30, 2025&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:bottom"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1.5pt solid #000000; vertical-align:bottom"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_6084f1e1489b48879fcbbe5600141f97'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.5pt"&gt;&lt;td style="width:76%; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_a974f35cc65443269ff066743129189d'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Patents&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_d202bcb88b044d028a4bbb28f6a6e8b0'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_11b78614bac54ef0a49e4b893a15b1d0'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;152,267&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_51a78629619a4b75ba95f8f8f4f7ec7b'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_860e11faa60f4e3cb17c35e447e6d321'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;127,603&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.5pt"&gt;&lt;td style="width:76%; vertical-align:middle"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_f612ea6912ea4de8936ab11fa94001b2'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Website Development Costs&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_bd5beeeb98654d3cb378b1f150cf237e'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;106,407&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_0297394f2e174985a9011e14c17a1c32'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;104,622&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.5pt"&gt;&lt;td style="width:76%; vertical-align:middle; background-color:#ccecff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_69283753d7194d8481cb58344618da62'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Intangible Assets, at cost&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#ccecff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ccecff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ccecff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_67428270244741e190f4ba5b6f6c89a4'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;258,674&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#ccecff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ccecff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#ccecff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_ce68356243274a62b8341406f23e7284'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;232,225&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.5pt"&gt;&lt;td style="width:76%; vertical-align:middle"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_5ec84ad9cbbb4a728206c96fd6d9a6ac'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Accumulated Amortization&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;(&lt;/span&gt;&lt;span style="-aw-sdt-tag:'C_a4c0c57793a24539a911c71110c0a6db'; font-family: 'Times New Roman'"&gt;&lt;span&gt;106,291&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;(&lt;/span&gt;&lt;span style="-aw-sdt-tag:'C_ba8b1931203d40b8b853f7cd33fb68a0'; font-family: 'Times New Roman'"&gt;&lt;span&gt;75,141&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.5pt"&gt;&lt;td style="width:76%; vertical-align:middle; background-color:#ccecff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_609bae755e8b4231bb1d4b943acee2ff'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;Intangible Assets, net&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#ccecff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ccecff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_bbacba70555c4d44a3ed2b95ac3cb5f3'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ccecff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_2fda802cc17945c78daa21dc34cb0e8e'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;152,383&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#ccecff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ccecff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_0f46f04104944ac794c1fcc3501b0184'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ccecff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_01b52cfeb567443aae2cc897f6e6903c'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;157,084&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedPatentsGross
      contextRef="I20250930"
      decimals="0"
      id="Tag78"
      unitRef="USD">152267</us-gaap:FiniteLivedPatentsGross>
    <us-gaap:FiniteLivedPatentsGross
      contextRef="I20241231"
      decimals="0"
      id="Tag82"
      unitRef="USD">127603</us-gaap:FiniteLivedPatentsGross>
    <sxtp:FiniteLivedWebsiteDevelopmentCostsGross
      contextRef="I20250930"
      decimals="0"
      id="Tag79"
      unitRef="USD">106407</sxtp:FiniteLivedWebsiteDevelopmentCostsGross>
    <sxtp:FiniteLivedWebsiteDevelopmentCostsGross
      contextRef="I20241231"
      decimals="0"
      id="Tag83"
      unitRef="USD">104622</sxtp:FiniteLivedWebsiteDevelopmentCostsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="I20250930"
      decimals="0"
      id="Tag80"
      unitRef="USD">258674</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="I20241231"
      decimals="0"
      id="Tag84"
      unitRef="USD">232225</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="I20250930" decimals="0" id="Tag3" unitRef="USD">106291</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="I20241231" decimals="0" id="Tag4" unitRef="USD">75141</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="I20250930"
      decimals="0"
      id="Tag81"
      unitRef="USD">152383</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="I20241231"
      decimals="0"
      id="Tag85"
      unitRef="USD">157084</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <sxtp:CapitalizedWebsiteDevelopmentrelatedCosts
      contextRef="D20250930"
      decimals="0"
      id="Tag817"
      unitRef="USD">1785</sxtp:CapitalizedWebsiteDevelopmentrelatedCosts>
    <sxtp:CapitalizedWebsiteDevelopmentrelatedCosts
      contextRef="D20240930"
      decimals="0"
      id="Tag747"
      unitRef="USD">3299</sxtp:CapitalizedWebsiteDevelopmentrelatedCosts>
    <sxtp:CapitalizedWebsiteDevelopmentrelatedCosts
      contextRef="D20250930_1"
      decimals="0"
      id="Tag748"
      unitRef="USD">1785</sxtp:CapitalizedWebsiteDevelopmentrelatedCosts>
    <sxtp:CapitalizedWebsiteDevelopmentrelatedCosts
      contextRef="D20240930_1"
      decimals="0"
      id="Tag749"
      unitRef="USD">25374</sxtp:CapitalizedWebsiteDevelopmentrelatedCosts>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="D20250930"
      decimals="0"
      id="Tag750"
      unitRef="USD">10605</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="D20240930"
      decimals="0"
      id="Tag751"
      unitRef="USD">10325</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="D20250930_1"
      decimals="0"
      id="Tag752"
      unitRef="USD">31150</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="D20240930_1"
      decimals="0"
      id="Tag753"
      unitRef="USD">28004</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="D20250930"
      decimals="0"
      id="Tag833"
      unitRef="USD">0</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="D20240930"
      decimals="0"
      id="Tag834"
      unitRef="USD">2922</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="D20250930_1"
      decimals="0"
      id="Tag820"
      unitRef="USD">0</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="D20240930_1"
      decimals="0"
      id="Tag754"
      unitRef="USD">11300</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock contextRef="D20250930_1" id="Tag931">&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;The following table summarizes the estimated future amortization expense for our patents and website development costs as of &lt;/span&gt;&lt;span style="-aw-sdt-tag:'ce96f421a46d06d458b3'; -aw-sdt-title:'Current_Period_P7'; font-family: 'Times New Roman'"&gt;&lt;span&gt;September 30, 2025&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;:&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="-aw-sdt-tag:'c0f2fdd191b23a42f69c'; -aw-sdt-title:'INTANGIBLE ASSETS T2'"&gt;&lt;table cellpadding="0" cellspacing="0" style="width:100%; border-collapse:collapse"&gt;&lt;tbody&gt;&lt;tr style="height:11.5pt"&gt;&lt;td style="width:76%; border-bottom:1.5pt solid #000000; vertical-align:bottom"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_174dcc19aadc45dcbec245e8e5590546'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;Period&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:bottom"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1.5pt solid #000000; vertical-align:bottom"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_2b4fd151a35e427f81944ed4aef3cd03'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;Patents&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:bottom"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1.5pt solid #000000; vertical-align:bottom"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_eac02702a1b6481292e04477eabff1f5'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;Website Development Costs&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.5pt"&gt;&lt;td style="width:76%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_bed21abb624848b39d25a0e5198a3eea'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;2025 (remaining three months)&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_0628bafa871b46b6b23c7839bac84a2b'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:10%; border-top:1.5pt solid #000000; padding-right:0.7pt; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_9ed72b1fc9a841678c6414ffa9250716'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;1,816&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_9971da9e37cf45c6965a560295ce2ee3'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_b86b8d6612d346b299a1f4e8b716937d'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;5,754&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.5pt"&gt;&lt;td style="width:76%; vertical-align:middle"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_98ee970e69c748c69cc8bbd0ed8e7995'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; padding-right:0.7pt; vertical-align:middle"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_29d81502a5fc40d6b3b22b749ae8c2cc'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;7,264&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; vertical-align:middle"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_d2022197ea7e432dad2b843e2cba5634'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;13,027&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.5pt"&gt;&lt;td style="width:76%; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_4130c067c39a40829ddaa2a81e97ae4b'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;2027&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; padding-right:0.7pt; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_4d3a475d713840deb210ba44e18e1f33'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;7,264&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_5fd36d2d7338473a98e0eaca4c3bb72e'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;3,689&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.5pt"&gt;&lt;td style="width:76%; vertical-align:middle"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_313ade7de15848e1805861fa9d495eb2'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;2028&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; padding-right:0.7pt; vertical-align:middle"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_9a518cad7b5f4600b17899e4df170f7e'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;7,264&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; vertical-align:middle"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_ba37da8a5d21434286c58831bdac112f'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;397&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.5pt"&gt;&lt;td style="width:76%; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_faf1ce39ee004fdbacf45816b0cd8e1b'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;2029&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; padding-right:0.7pt; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_1dbfcb6bede14893b1d590e5550007a7'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;7,264&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-tag:'C_4124ac0cb341498b8445cea7bd35d757'"&gt;&lt;span title="&amp;amp;#13;nil='true'"&gt;&lt;/span&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.5pt"&gt;&lt;td style="width:76%; vertical-align:middle"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_a93ca8f84d704c2685aef38dd6e616fb'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Thereafter&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; border-bottom:1.5pt solid #000000; padding-right:0.7pt; vertical-align:middle"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_6321783027ee42c18b71f36dd0941a2f'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;38,435&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle"&gt;&lt;div style="-aw-sdt-tag:'C_257cb67d346b4113ac890add634412f6'"&gt;&lt;span title="&amp;amp;#13;nil='true'"&gt;&lt;/span&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.5pt"&gt;&lt;td style="width:76%; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_d7c76dd6b9cc422d8a6b884dacaa3365'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_75767eb28a1d449ab596ff84732f7256'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; padding-right:0.7pt; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_2ee72c55a7204d64a57ac09c73611a03'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;69,307&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_6779a62c90a14cb8b35f588ce92d9296'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'e65-d56-30f-2c3-e9f3'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;22,867&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
      contextRef="I20250930_PatentsMember"
      decimals="0"
      id="Tag86"
      unitRef="USD">1816</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
      contextRef="I20250930_SoftwareAndSoftwareDevelopmentCostsMember"
      decimals="0"
      id="Tag93"
      unitRef="USD">5754</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="I20250930_PatentsMember"
      decimals="0"
      id="Tag87"
      unitRef="USD">7264</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="I20250930_SoftwareAndSoftwareDevelopmentCostsMember"
      decimals="0"
      id="Tag94"
      unitRef="USD">13027</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="I20250930_PatentsMember"
      decimals="0"
      id="Tag88"
      unitRef="USD">7264</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="I20250930_SoftwareAndSoftwareDevelopmentCostsMember"
      decimals="0"
      id="Tag95"
      unitRef="USD">3689</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="I20250930_PatentsMember"
      decimals="0"
      id="Tag89"
      unitRef="USD">7264</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="I20250930_SoftwareAndSoftwareDevelopmentCostsMember"
      decimals="0"
      id="Tag235"
      unitRef="USD">397</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="I20250930_PatentsMember"
      decimals="0"
      id="Tag90"
      unitRef="USD">7264</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="I20250930_SoftwareAndSoftwareDevelopmentCostsMember"
      id="Tag96"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
      contextRef="I20250930_PatentsMember"
      decimals="0"
      id="Tag91"
      unitRef="USD">38435</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
      contextRef="I20250930_SoftwareAndSoftwareDevelopmentCostsMember"
      id="Tag97"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="I20250930_PatentsMember"
      decimals="0"
      id="Tag92"
      unitRef="USD">69307</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="I20250930_SoftwareAndSoftwareDevelopmentCostsMember"
      decimals="0"
      id="Tag199"
      unitRef="USD">22867</us-gaap:FiniteLivedIntangibleAssetsNet>
    <sxtp:CapitalizedPatentExpenses
      contextRef="D20250930_1"
      decimals="0"
      id="Tag746"
      unitRef="USD">60209</sxtp:CapitalizedPatentExpenses>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="D20250930_1" id="Tag983">&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;6. STOCKHOLDERS&#x2019; EQUITY&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Pursuant to the Certificate of Incorporation of &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c00395ab615233e65b60'; font-family: 'Times New Roman'"&gt;&lt;span&gt;60&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; Degrees Pharmaceuticals, Inc., the Company&#x2019;s authorized shares consist of (a) &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c8256dca101917b93f72'; font-family: 'Times New Roman'"&gt;&lt;span&gt;150,000,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; shares of common stock, par value $&lt;/span&gt;&lt;span style="-aw-sdt-tag:'c3bf7f20ec7068739bfa'; font-family: 'Times New Roman'"&gt;&lt;span&gt;0.0001&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; per share and (b) &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c047a66335e6c7190382'; font-family: 'Times New Roman'"&gt;&lt;span&gt;1,000,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; shares of preferred stock, par value $&lt;/span&gt;&lt;span style="-aw-sdt-tag:'c911e740c0eb8459e49a'; font-family: 'Times New Roman'"&gt;&lt;span&gt;0.0001&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; per share, of which &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c8d91dff0ef3b8a20008'; -aw-sdt-title:'Series A Designated Shares'; font-family: 'Times New Roman'"&gt;&lt;span&gt;80,965&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; have been designated as Series A Non-Voting Convertible Preferred Stock (&#x201c;Series A Preferred Stock&#x201d;). As of &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c34ccecbf9d8ef0f5dec'; -aw-sdt-title:'Current_Period_P29'; font-family: 'Times New Roman'"&gt;&lt;span&gt;September 30, 2025&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;, &lt;/span&gt;&lt;span style="-aw-sdt-tag:'cf2aa1a6a0c77e7c2fd3'; -aw-sdt-title:'Current Common Shares Outstanding'; font-family: 'Times New Roman'"&gt;&lt;span&gt;4,104,469&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; shares of Common Stock and &lt;/span&gt;&lt;span style="-aw-sdt-tag:'ca0007fd29b564fc54fa'; -aw-sdt-title:'Current Series A Shares Outstanding'; font-family: 'Times New Roman'"&gt;&lt;span&gt;76,480&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; shares of Series A Preferred Stock are issued and outstanding.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Following stockholder approval in November &lt;/span&gt;&lt;span style="-aw-sdt-tag:'ce5446ee6a7ba063dc41'; font-family: 'Times New Roman'"&gt;&lt;span&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;, on February &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c208cdf92af8907a4aa6'; font-family: 'Times New Roman'"&gt;&lt;span&gt;18&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;, &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c37dc585619006d80d82'; font-family: 'Times New Roman'"&gt;&lt;span&gt;2025&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;, the Company filed an additional Amendment to the Certificate of Incorporation with the Secretary of State of Delaware to effect the &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c81652786d96c9a5557d'; font-family: 'Times New Roman'"&gt;&lt;span&gt;1:5&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; Reverse Stock Split of the issued and outstanding shares of the Company&#x2019;s common stock, which was effective as of February &lt;/span&gt;&lt;span style="-aw-sdt-tag:'cb3826fdc552899bbbcd'; font-family: 'Times New Roman'"&gt;&lt;span&gt;24&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;, &lt;/span&gt;&lt;span style="-aw-sdt-tag:'cbb3cb20b9a2ea915ff9'; font-family: 'Times New Roman'"&gt;&lt;span&gt;2025&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;. As of the effective time of the &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c0fc832f2594da84f996'; font-family: 'Times New Roman'"&gt;&lt;span&gt;1:5&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; Reverse Stock Split, every five (&lt;/span&gt;&lt;span style="-aw-sdt-tag:'c5da0431da494b8ec1a4'; font-family: 'Times New Roman'"&gt;&lt;span&gt;5&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;) issued and outstanding shares of the Company&#x2019;s common stock were automatically combined and converted into one (&lt;/span&gt;&lt;span style="-aw-sdt-tag:'c6f015b36370d0756173'; font-family: 'Times New Roman'"&gt;&lt;span&gt;1&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;) issued and outstanding share of the Company&#x2019;s common stock. &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;No fractional shares of common stock were issued in connection with the Reverse Stock Splits. All fractional shares were rounded up to the nearest whole share with respect to outstanding shares of common stock. The Reverse Stock Splits did not change the authorized number of shares of common stock or preferred stock, the par value of the common stock, or the number of issued and outstanding shares of Series A Preferred Stock. All references to numbers of shares of the Company&#x2019;s common stock and per share information in these consolidated condensed financial statements have been retroactively adjusted, as appropriate, to reflect the Reverse Stock Splits, including reclassifying an amount equal to the reduction in par value of common stock to additional paid-in capital.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-weight:bold; text-decoration:underline; font-family: 'Times New Roman'"&gt;Common Stock&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-style:italic; font-family: 'Times New Roman'"&gt;January &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c766051bc4fd2494d06a'; font-family: 'Times New Roman'"&gt;&lt;span style="font-style:italic"&gt;2025&lt;/span&gt;&lt;/span&gt;&lt;span style="font-style:italic; font-family: 'Times New Roman'"&gt; Offering&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-style:italic; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;On January &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c4b9a9512956ad47ecaf'; font-family: 'Times New Roman'"&gt;&lt;span&gt;28&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;, &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c6f16f1df2bab72eed3c'; font-family: 'Times New Roman'"&gt;&lt;span&gt;2025&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;, the Company entered into a securities purchase agreement with certain institutional investors pursuant to which the Company sold, in a registered direct offering priced at-the-market under the rules of Nasdaq, an aggregate of &lt;/span&gt;&lt;span style="-aw-sdt-tag:'34f-dfe-350-c12-0797'; -aw-sdt-title:'January 2025_Shares Sold'; font-family: 'Times New Roman'"&gt;&lt;span&gt;204,312&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; shares of common stock at a purchase price of $&lt;/span&gt;&lt;span style="-aw-sdt-tag:'c1872eac4741b1175066'; font-family: 'Times New Roman'"&gt;&lt;span&gt;5.105&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; per share. The shares were offered pursuant to a &#x201c;shelf&#x201d; registration statement on Form S-&lt;/span&gt;&lt;span style="-aw-sdt-tag:'cac83fd442a049f28577'; font-family: 'Times New Roman'"&gt;&lt;span&gt;3&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; (Registration No. &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c202eae5d68d3a899c77'; font-family: 'Times New Roman'"&gt;&lt;span&gt;333&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;-&lt;/span&gt;&lt;span style="-aw-sdt-tag:'c9a4b74ad6cb16c00e24'; font-family: 'Times New Roman'"&gt;&lt;span&gt;280796&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;). In a concurrent private placement, the Company also issued to the investors unregistered warrants (the &#x201c;January &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c0d7448c7d769ad24bc4'; font-family: 'Times New Roman'"&gt;&lt;span&gt;2025&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; Warrants&#x201d;) to purchase up to an aggregate of &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c906142c107a5541bca4'; -aw-sdt-title:'January 2025 Common Warrants'; font-family: 'Times New Roman'"&gt;&lt;span&gt;408,621&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; shares of common stock at an exercise price of $&lt;/span&gt;&lt;span style="-aw-sdt-tag:'c3c56402ae377ab0a7f9'; -aw-sdt-title:'January 2025 Common Warrants_Ex.Price'; font-family: 'Times New Roman'"&gt;&lt;span&gt;3.855&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; per share. The January &lt;/span&gt;&lt;span style="-aw-sdt-tag:'cfa07e0e67817e897454'; font-family: 'Times New Roman'"&gt;&lt;span&gt;2025&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; Warrants are exercisable upon issuance, or January &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c7e84c25b2f65bdff56b'; font-family: 'Times New Roman'"&gt;&lt;span&gt;30&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;, &lt;/span&gt;&lt;span style="-aw-sdt-tag:'cce83998a76b653b7691'; font-family: 'Times New Roman'"&gt;&lt;span&gt;2025&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;, and expire twenty-four months from the date of issuance, or January &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c57fd77fa1237d600805'; font-family: 'Times New Roman'"&gt;&lt;span&gt;30&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;, &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c7aaa60fc0eec6a0fd8c'; font-family: 'Times New Roman'"&gt;&lt;span&gt;2027&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;. The registered direct offering and concurrent private placement (together, the &#x201c;January &lt;/span&gt;&lt;span style="-aw-sdt-tag:'cd52d29afd3f5d2eccf7'; font-family: 'Times New Roman'"&gt;&lt;span&gt;2025&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; Offering&#x201d;) closed on January &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c494798979cbe56b695a'; font-family: 'Times New Roman'"&gt;&lt;span&gt;30&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;, &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c4016c0efa1198b21f27'; font-family: 'Times New Roman'"&gt;&lt;span&gt;2025&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;, resulting in net proceeds to the Company of approximately $&lt;/span&gt;&lt;span style="-aw-sdt-tag:'c580de3ddd57ac018e42'; font-family: 'Times New Roman'"&gt;&lt;span&gt;804,346&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;, after deducting the placement agent fees and other offering expenses paid by the Company.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;As compensation for acting as the placement agent for the January &lt;/span&gt;&lt;span style="-aw-sdt-tag:'cee7ccbe0d04fba82a6c'; font-family: 'Times New Roman'"&gt;&lt;span&gt;2025&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; Offering, in addition to certain cash fees, the Company issued H.C. Wainwright &amp;amp; Co., LLC (the &#x201c;Placement Agent&#x201d;) warrants to purchase up to &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c0f8089b6089330b6b04'; -aw-sdt-title:'January 2025 Agent Warrants'; font-family: 'Times New Roman'"&gt;&lt;span&gt;15,325&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; shares of common stock at an exercise price of $&lt;/span&gt;&lt;span style="-aw-sdt-tag:'c37edb8ca4f2c575ae63'; -aw-sdt-title:'January 2025 Agent Warrants_Ex.Price'; font-family: 'Times New Roman'"&gt;&lt;span&gt;6.382&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; (the &#x201c;January &lt;/span&gt;&lt;span style="-aw-sdt-tag:'cf18e7f7a6818d437bb7'; font-family: 'Times New Roman'"&gt;&lt;span&gt;2025&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; Agent Warrants&#x201d;). The January &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c31825f688b0d9e23238'; font-family: 'Times New Roman'"&gt;&lt;span&gt;2025&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; Agent Warrants were exercisable upon issuance and expire twenty-four months from the date of issuance.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-style:italic; font-family: 'Times New Roman'"&gt;February &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c5b0aa4c07ace5151d7d'; font-family: 'Times New Roman'"&gt;&lt;span style="font-style:italic"&gt;2025&lt;/span&gt;&lt;/span&gt;&lt;span style="font-style:italic; font-family: 'Times New Roman'"&gt; Offering&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-style:italic; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;On February &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c72b369793d8cb0663de'; font-family: 'Times New Roman'"&gt;&lt;span&gt;5&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;, &lt;/span&gt;&lt;span style="-aw-sdt-tag:'ccfae45335d3132329d8'; font-family: 'Times New Roman'"&gt;&lt;span&gt;2025&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;, the Company entered into a securities purchase agreement with certain institutional investors pursuant to which the Company sold, in a registered direct offering priced at-the-market under the rules of Nasdaq, an aggregate of &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c7a47a1b4a61568a79ee'; font-family: 'Times New Roman'"&gt;&lt;span&gt;300,700&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; shares of the Company&#x2019;s common stock at a purchase price of $&lt;/span&gt;&lt;span style="-aw-sdt-tag:'cd40fa8984cf91955d65'; -aw-sdt-title:'February 2025_Purchase Price'; font-family: 'Times New Roman'"&gt;&lt;span&gt;3.575&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; per share. In a concurrent private placement, the Company separately issued to the investors unregistered warrants to purchase up to an aggregate of &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c70410176c474a809bb6'; -aw-sdt-title:'February 2025 Warrants'; font-family: 'Times New Roman'"&gt;&lt;span&gt;300,700&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; shares of common stock at an exercise price of $&lt;/span&gt;&lt;span style="-aw-sdt-tag:'c9ab699f16e4535f6559'; -aw-sdt-title:'February 2025 Warrants_Ex.Price'; font-family: 'Times New Roman'"&gt;&lt;span&gt;2.95&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; per share (the &#x201c;February &lt;/span&gt;&lt;span style="-aw-sdt-tag:'ce612c83cf1f52410608'; font-family: 'Times New Roman'"&gt;&lt;span&gt;2025&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; Warrants&#x201d;). The February &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c94c89dae7699225143d'; font-family: 'Times New Roman'"&gt;&lt;span&gt;2025&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; Warrants were immediately exercisable upon issuance and expire twenty-four months from the date of issuance. The registered direct offering and concurrent private placement (together, the &#x201c;February &lt;/span&gt;&lt;span style="-aw-sdt-tag:'cb9faf62303c5603f05f'; font-family: 'Times New Roman'"&gt;&lt;span&gt;2025&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; Offering&#x201d;) closed on February &lt;/span&gt;&lt;span style="-aw-sdt-tag:'cab9c9f59f2aa9bdd2ea'; font-family: 'Times New Roman'"&gt;&lt;span&gt;6&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;, &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c02d9a9c7a98c7cb6b11'; font-family: 'Times New Roman'"&gt;&lt;span&gt;2025&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;, resulting in net proceeds to the Company of approximately $&lt;/span&gt;&lt;span style="-aw-sdt-tag:'cae17f4b26b5215dec57'; font-family: 'Times New Roman'"&gt;&lt;span&gt;908,627&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;, after deducting the placement agent fees and other offering expenses paid by the Company.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;As compensation for acting as the placement agent for the February &lt;/span&gt;&lt;span style="-aw-sdt-tag:'ca49d3c0f55aa58250b8'; font-family: 'Times New Roman'"&gt;&lt;span&gt;2025&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; Offering, in addition to certain cash fees, the Company issued the Placement Agent warrants to purchase up to &lt;/span&gt;&lt;span style="-aw-sdt-tag:'cdaf4a5d62e024e6958a'; -aw-sdt-title:'February 2025 Agent Warrants'; font-family: 'Times New Roman'"&gt;&lt;span&gt;22,554&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; shares of common stock at an exercise price of $&lt;/span&gt;&lt;span style="-aw-sdt-tag:'ca55514cbc775909ead5'; -aw-sdt-title:'February 2025 Agent Warrants_Ex.Price'; font-family: 'Times New Roman'"&gt;&lt;span&gt;4.469&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; (the &#x201c;February &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c33357b171c6a2bbe58b'; font-family: 'Times New Roman'"&gt;&lt;span&gt;2025&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; Agent Warrants&#x201d;). The February &lt;/span&gt;&lt;span style="-aw-sdt-tag:'cb0e922589e5ea34bfd9'; font-family: 'Times New Roman'"&gt;&lt;span&gt;2025&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; Agent Warrants were exercisable upon issuance and expire twenty-four months from the date of issuance.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-style:italic; font-family: 'Times New Roman'"&gt;July 2025 Offering&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;On July 15, 2025, the Company entered into a securities purchase agreement with certain institutional investors pursuant to which the Company sold, in a registered direct offering (the &#x201c;July 2025 Offering&#x201d;), &lt;/span&gt;&lt;span style="-aw-sdt-tag:'963-08e-7a4-81c-04b1'; -aw-sdt-title:'July 2025_Common Units'; font-family: 'Times New Roman'"&gt;&lt;span&gt;1,753,314&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; units at an offering price of $&lt;/span&gt;&lt;span style="-aw-sdt-tag:'35d-504-224-bc2-70b0'; -aw-sdt-title:'July 2025_Common Units Price'; font-family: 'Times New Roman'"&gt;&lt;span&gt;1.90&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; per unit and &lt;/span&gt;&lt;span style="-aw-sdt-tag:'0de-3a9-e49-e5f-bc0e'; -aw-sdt-title:'July 2025_Pre Funded Units'; font-family: 'Times New Roman'"&gt;&lt;span&gt;878,264&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; pre-funded units at an offering price of $&lt;/span&gt;&lt;span style="-aw-sdt-tag:'31f-af2-e74-9f4-4be5'; -aw-sdt-title:'July 2025_Pre Funded Units Price'; font-family: 'Times New Roman'"&gt;&lt;span&gt;1.899&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; per pre-funded unit. Each unit consisted of (i) one share of common stock, (ii) one series A-1 warrant exercisable for one share of common stock (the &#x201c;July 2025 A-1 Warrants&#x201d;), and (iii) one series A-2 warrant exercisable for one share of common stock (the &#x201c;July 2025 A-2 Warrants&#x201d; and together with the July 2025 A-1 Warrants, the &#x201c;July 2025 Warrants&#x201d;). Each pre-funded unit consists of one pre-funded warrant exercisable for one share of common stock (the &#x201c;July 2025 Pre-Funded Warrants&#x201d;) and warrants identical to the July 2025 Warrants included in the units. The July 2025 Pre-Funded Warrants have an exercise price of $&lt;/span&gt;&lt;span style="-aw-sdt-tag:'2e3-1e4-caf-c40-41a1'; -aw-sdt-title:'July 2025_Pre Funded Units Exercise Price'; font-family: 'Times New Roman'"&gt;&lt;span&gt;0.001&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; per share, and were immediately exercisable beginning on &lt;/span&gt;&lt;span style="-aw-sdt-tag:'270-92e-ea6-8c6-95e7'; -aw-sdt-title:'July 2025_Pre Funded Units Issue Date'; font-family: 'Times New Roman'"&gt;&lt;span&gt;July 16, 2025&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; until exercised in full. The July 2025 A-1 Warrants have an exercise price of $&lt;/span&gt;&lt;span style="-aw-sdt-tag:'85a-9a8-4d9-ee9-1793'; -aw-sdt-title:'July 2025_A-1 Exercise Price'; font-family: 'Times New Roman'"&gt;&lt;span&gt;1.90&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; per share and are exercisable beginning on &lt;/span&gt;&lt;span style="-aw-sdt-tag:'745-2b8-404-908-2d8c'; -aw-sdt-title:'July 2025_A-1 Issue Date'; font-family: 'Times New Roman'"&gt;&lt;span&gt;July 16, 2025&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; until &lt;/span&gt;&lt;span style="-aw-sdt-tag:'303-107-340-789-0138'; -aw-sdt-title:'July 2025_A-1 Expiry Date'; font-family: 'Times New Roman'"&gt;&lt;span&gt;July 15, 2030&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;. The July 2025 A-2 Warrants have an exercise price of $&lt;/span&gt;&lt;span style="-aw-sdt-tag:'7d7-395-569-007-7e21'; -aw-sdt-title:'July 2025_A-2 Exercise Price'; font-family: 'Times New Roman'"&gt;&lt;span&gt;1.90&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; per share and are exercisable beginning on &lt;/span&gt;&lt;span style="-aw-sdt-tag:'926-d02-8ee-91c-294d'; -aw-sdt-title:'July 2025_A-2 Issue Date'; font-family: 'Times New Roman'"&gt;&lt;span&gt;July 16, 2025&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; until &lt;/span&gt;&lt;span style="-aw-sdt-tag:'73a-95e-768-9a2-c4cc'; -aw-sdt-title:'July 2025_A-2 Expiry Date'; font-family: 'Times New Roman'"&gt;&lt;span&gt;January 15, 2027&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;As compensation for acting as the placement agent for the July 2025 Offering, the Company also issued to H.C. Wainwright &amp;amp; Co., LLC warrants (the &#x201c;July 2025 Placement Agent Warrants&#x201d;) to purchase up to &lt;/span&gt;&lt;span style="-aw-sdt-tag:'0b5-721-1f3-439-eaf1'; -aw-sdt-title:'July 2025 Placement Agent Warrants'; font-family: 'Times New Roman'"&gt;&lt;span&gt;197,368&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; shares of common stock. The July 2025 Placement Agent Warrants have an exercise price equal to $&lt;/span&gt;&lt;span style="-aw-sdt-tag:'8d1-309-84e-2ab-e8ac'; -aw-sdt-title:'July 2025_Agent Warrants Exercise Price'; font-family: 'Times New Roman'"&gt;&lt;span&gt;2.375&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; per share and are exercisable upon issuance, or &lt;/span&gt;&lt;span style="-aw-sdt-tag:'960-754-5c2-f81-ad5e'; -aw-sdt-title:'July 2025_Agent Warrants Issue Date'; font-family: 'Times New Roman'"&gt;&lt;span&gt;July 16, 2025&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;, and expire &lt;/span&gt;&lt;span style="-aw-sdt-tag:'295-24e-c09-37d-52db'; font-family: 'Times New Roman'"&gt;&lt;span&gt;five years&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; from the date of issuance, or &lt;/span&gt;&lt;span style="-aw-sdt-tag:'663-3e7-37e-91f-6134'; -aw-sdt-title:'July 2025_Agent Warrants Expiry Date'; font-family: 'Times New Roman'"&gt;&lt;span&gt;July 15, 2030&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;.&lt;/span&gt;&lt;span style="-aw-import:spaces; font-family: 'Times New Roman'"&gt;&#160; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="-aw-sdt-tag:'PG_6327b60d7f0da94a'"&gt;&lt;/div&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;The July 2025 Offering was made pursuant to the Company&#x2019;s registration statement on Form S-1 (File No. 333-288550), which was declared effective by the Securities and Exchange Commission (the &#x201c;SEC&#x201d;) on July 15, 2025, and the final prospectus, which was filed with the SEC on July 16, 2025. The Offering closed on July 16, 2025, resulting in net proceeds to the Company of approximately $&lt;/span&gt;&lt;span style="-aw-sdt-tag:'1ea-cd6-103-d88-c43a'; -aw-sdt-title:'July 2025_Net Proceeds'; font-family: 'Times New Roman'"&gt;&lt;span&gt;4,281,300&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;, after deducting placement agent fees and other offering expenses paid by the Company. &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-style:italic; font-family: 'Times New Roman'"&gt;2025 ATM Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="-aw-import:spaces; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;On September 5, 2025, the Company entered into an At-The-Market Sales Agreement (the &#x201c;2025 ATM Agreement&#x201d;) with H.C. Wainwright &amp;amp; Co., LLC (&#x201c;Wainwright&#x201d;) pursuant to which the Company may, from time to time, offer and sell shares of its common stock, having aggregate gross sales proceeds of up to $&lt;/span&gt;&lt;span style="-aw-sdt-tag:'5e1-86e-ff2-592-8db0'; font-family: 'Times New Roman'"&gt;&lt;span&gt;1,397,532&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; (the &#x201c;2025 ATM Offering&#x201d;). As compensation for acting as the sales agent for the 2025 ATM Offering, Wainwright will be entitled to a commission of &lt;/span&gt;&lt;span style="-aw-sdt-tag:'ec6-04e-04d-299-5b8e'; font-family: 'Times New Roman'"&gt;&lt;span&gt;3.0&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;% of the gross proceeds from sales of shares in the 2025 ATM Offering. &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;The common stock to be sold under the 2025 ATM Agreement, if any, will be issued and sold pursuant to the Company&#x2019;s shelf registration statement on Form S-3 and accompanying base prospectus (Registration Statement No. 333-280796), which was declared effective by the SEC on July 18, 2024, and a prospectus supplement dated September 5, 2025 relating to the offer and sale of the shares pursuant to the 2025 ATM Agreement. As of &lt;/span&gt;&lt;span style="-aw-sdt-tag:'1dd-95e-3f2-a00-31c0'; -aw-sdt-title:'Current_Period_P44'; font-family: 'Times New Roman'"&gt;&lt;span&gt;September 30, 2025&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;, &lt;/span&gt;&lt;span style="-aw-sdt-tag:'d31-fbf-141-727-882c'; font-family: 'Times New Roman'"&gt;&lt;span&gt;no&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; shares had been sold pursuant to the 2025 ATM Agreement. See Note 12 &#x2013; Subsequent Events. &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-style:italic; font-family: 'Times New Roman'"&gt;2024 ATM Offering&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-style:italic; -aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;On July 12, 2024, the Company entered into an At-the-Market Issuance Sales Agreement (the &#x201c;2024 ATM Agreement&#x201d;) with WallachBeth Capital LLC as sales agent, to sell shares of common stock having an aggregate offering price of up to $&lt;/span&gt;&lt;span style="-aw-sdt-tag:'f78-d1a-df1-988-f9d9'; font-family: 'Times New Roman'"&gt;&lt;span&gt;1,253,603&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; from time to time, through an &#x201c;at the market offering&#x201d; program (the &#x201c;2024 ATM Offering&#x201d;). The offer and sale of shares of common stock from the ATM Offering were made pursuant to the Company&#x2019;s shelf registration statement on Form S-3 and accompanying base prospectus (Registration Statement No. 333-280796) contained therein which became effective on July 18, 2024. The prospectus supplement was subsequently amended four times to increase the maximum aggregate offering price under the ATM Agreement. From July 19, 2024 to August 1, 2024, the Company sold a total of &lt;/span&gt;&lt;span style="-aw-sdt-tag:'215-287-a05-1c1-a884'; font-family: 'Times New Roman'"&gt;&lt;span&gt;135,568&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; shares in the ATM Offering for gross proceeds of $&lt;/span&gt;&lt;span style="-aw-sdt-tag:'596-827-921-65f-fb9d'; font-family: 'Times New Roman'"&gt;&lt;span&gt;1,994,583&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;. &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;On September 3, 2025, the Company and Wallachbeth Capital LLC entered into a Waiver and Termination Agreement, agreeing to terminate the 2024 ATM Agreement effective as of &lt;/span&gt;&lt;span style="-aw-sdt-tag:'613-61b-e90-595-df3c'; font-family: 'Times New Roman'"&gt;&lt;span&gt;September 3, 2025&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-style:italic; font-family: 'Times New Roman'"&gt;Preferred Stock Conversions&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-style:italic; -aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;On July 22, 2024 and July 26, 2024, the Company converted &lt;/span&gt;&lt;span style="-aw-sdt-tag:'ce3-ac4-d73-7d2-12d8'; font-family: 'Times New Roman'"&gt;&lt;span&gt;1,291&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; and &lt;/span&gt;&lt;span style="-aw-sdt-tag:'9a0-00a-e5a-a76-32bc'; font-family: 'Times New Roman'"&gt;&lt;span&gt;1,032&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; shares of Series A Preferred Stock, respectively, held by Knight Therapeutics Inc. into &lt;/span&gt;&lt;span style="-aw-sdt-tag:'93a-f5c-959-7bf-1e56'; font-family: 'Times New Roman'"&gt;&lt;span&gt;8,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; shares and &lt;/span&gt;&lt;span style="-aw-sdt-tag:'562-eef-59d-7f7-d8f5'; font-family: 'Times New Roman'"&gt;&lt;span&gt;6,667&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; shares of common stock, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-style:italic; font-family: 'Times New Roman'"&gt;Warrant Exercises&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-style:italic; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;During the &lt;/span&gt;&lt;span style="-aw-sdt-tag:'841-1ba-bd6-f3b-ce0b'; -aw-sdt-title:'Current_Quarter_P47'; font-family: 'Times New Roman'"&gt;&lt;span&gt;three months ended September 30, 2025&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; and &lt;/span&gt;&lt;span style="-aw-sdt-tag:'91c-dae-554-39a-2bb2'; -aw-sdt-title:'Previous_Year_P51'; font-family: 'Times New Roman'"&gt;&lt;span&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; the Company issued &lt;/span&gt;&lt;span style="-aw-sdt-tag:'645-280-92b-f86-2352'; -aw-sdt-title:'CQTD_Shares Issued for Warrant Exercises'; font-family: 'Times New Roman'"&gt;&lt;span&gt;878,264&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; and &lt;/span&gt;&lt;span style="-aw-sdt-tag:'d79-532-1f1-c9c-9b2d'; font-family: 'Times New Roman'"&gt;&lt;span&gt;0&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; shares of common stock upon the exercise of &lt;/span&gt;&lt;span style="-aw-sdt-tag:'7c5-227-e1d-0f7-eb4e'; -aw-sdt-title:'CQTD_Warrants Exercised'; font-family: 'Times New Roman'"&gt;&lt;span&gt;878,264&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; and &lt;/span&gt;&lt;span style="-aw-sdt-tag:'67f-ac0-19d-0e1-1c4f'; font-family: 'Times New Roman'"&gt;&lt;span&gt;0&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; pre-funded warrants, respectively, resulting in proceeds to the Company of $&lt;/span&gt;&lt;span style="-aw-sdt-tag:'2bc-7cc-b50-b2e-86ef'; -aw-sdt-title:'CQTD_Warrant Exercise Proceeds'; font-family: 'Times New Roman'"&gt;&lt;span&gt;878&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; and $&lt;/span&gt;&lt;span style="-aw-sdt-tag:'adb-c80-e7b-bbe-6898'; font-family: 'Times New Roman'"&gt;&lt;span&gt;0&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;, respectively. During the &lt;/span&gt;&lt;span style="-aw-sdt-tag:'7e7-2e9-110-4e9-daa7'; -aw-sdt-title:'Current_YTD_P55'; font-family: 'Times New Roman'"&gt;&lt;span&gt;nine months ended September 30, 2025&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; and &lt;/span&gt;&lt;span style="-aw-sdt-tag:'12b-9be-73b-065-6355'; -aw-sdt-title:'Previous_Year_P52'; font-family: 'Times New Roman'"&gt;&lt;span&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; the Company issued &lt;/span&gt;&lt;span style="-aw-sdt-tag:'bd7-fd5-83b-da2-1fa0'; font-family: 'Times New Roman'"&gt;&lt;span&gt;1,263,464&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; and &lt;/span&gt;&lt;span style="-aw-sdt-tag:'cf9c544cf94ba4b58a99'; -aw-sdt-title:'PYTD_CS issued for warrants'; font-family: 'Times New Roman'"&gt;&lt;span&gt;16,652&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; shares of common stock upon the exercise of &lt;/span&gt;&lt;span style="-aw-sdt-tag:'0ba-275-7d5-d83-6d9c'; font-family: 'Times New Roman'"&gt;&lt;span&gt;1,263,464&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; and &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c38e9982b4c14bef4cf7'; -aw-sdt-title:'PYTD_PFW Exercises'; font-family: 'Times New Roman'"&gt;&lt;span&gt;16,652&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; pre-funded warrants, respectively, resulting in proceeds to the Company of $&lt;/span&gt;&lt;span style="-aw-sdt-tag:'687-1b4-df6-4c3-39b0'; -aw-sdt-title:'CYTD_Warrant exercise proceeds'; font-family: 'Times New Roman'"&gt;&lt;span&gt;2,804&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; and $&lt;/span&gt;&lt;span style="-aw-sdt-tag:'cb9d9b63f679ae3cb8e1'; -aw-sdt-title:'PYTD_Warrant exercise proceeds'; font-family: 'Times New Roman'"&gt;&lt;span&gt;9,990&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-weight:bold; text-decoration:underline; font-family: 'Times New Roman'"&gt;Common Stock Warrants&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;As of &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c97818c1951368fe0e26'; -aw-sdt-title:'Current_Period_P19'; font-family: 'Times New Roman'"&gt;&lt;span&gt;September 30, 2025&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;, the Company accounts for all issued and outstanding warrants to purchase common stock as equity-classified instruments based on the guidance in ASC &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c0eabc92e2fa2c832655'; font-family: 'Times New Roman'"&gt;&lt;span&gt;480&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; and ASC &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c064d77ec2d1f973d46b'; font-family: 'Times New Roman'"&gt;&lt;span&gt;815&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;As compensation for acting as the placement agent for the Private Placement, the Company issued to H.C. Wainwright &amp;amp; Co., LLC warrants to purchase up to &lt;/span&gt;&lt;span style="-aw-sdt-tag:'cdf-796-b0c-6e9-ff08'; font-family: 'Times New Roman'"&gt;&lt;span&gt;43,479&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; shares of stock (the &#x201c;September 2024 Agent Warrants&#x201d;). The September 2024 Agent Warrants have substantially the same terms as the Series A Warrants, except that the September 2024 Agent Warrants have an exercise price equal to $&lt;/span&gt;&lt;span style="-aw-sdt-tag:'398-324-697-f50-ef44'; font-family: 'Times New Roman'"&gt;&lt;span&gt;8.63&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; per share.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="-aw-sdt-tag:'PG_79108baa3f2dac7d'"&gt;&lt;/div&gt;&lt;div style="-aw-sdt-tag:'0b9-32d-758-bbb-7d61'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;The following table presents a summary of the activity for the Company&#x2019;s equity-classified warrants during the &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c564d7f6835302971ae2'; -aw-sdt-title:'Current_Quarter_and_YTD_P11'; font-family: 'Times New Roman'"&gt;&lt;span&gt;three and nine months ended September 30, 2025&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;:&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="-aw-sdt-tag:'c03fb2d1c9552e699f9f'; -aw-sdt-title:'STOCKHOLDERS EQUITY T1'"&gt;&lt;table cellpadding="0" cellspacing="0" style="width:100%; border-collapse:collapse"&gt;&lt;tbody&gt;&lt;tr style="height:51pt"&gt;&lt;td style="width:65.32%; vertical-align:bottom"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1.02%; vertical-align:bottom"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10.2%; border-bottom:1.5pt solid #000000; vertical-align:bottom"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_255042d0e6a541a388b409c03b69aa6a'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;Number of Warrants&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1.02%; vertical-align:bottom"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"&gt;&lt;span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1.5pt solid #000000; vertical-align:bottom"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_1d3baab02d8c401b900003c44b2c7c3f'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;Weighted Average Exercise Price&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1.02%; vertical-align:bottom"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"&gt;&lt;span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10.2%; border-bottom:1.5pt solid #000000; vertical-align:bottom"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_d9d36dc13cae43cf8b651c83ff0751cb'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;Weighted Average Remaining Contractual Life (Years)&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12.75pt"&gt;&lt;td style="width:65.32%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_0df67d8471e9467a89ff88e0439581e5'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Total outstanding, December 31, 2024&lt;/span&gt;&lt;span style="font-size:6.67pt; vertical-align:super; font-family: 'Times New Roman'"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1.02%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10.2%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_cfd86fffd9a24a8681860699bbc5835a'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;1,765,070&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1.02%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1.02%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_018f691c6c554fcd9f2ea902cef36ea6'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:10.2%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_401143ee48e043d3b3536cd6cdf9c432'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;17.59&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1.02%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10.2%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_b26821ca78ac44ef92c209c2bc9c966d'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;3.26&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12.75pt"&gt;&lt;td style="width:65.32%; vertical-align:bottom; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_56484066bcc74bf8b3793fd9b87e4059'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1.02%; vertical-align:bottom; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10.2%; vertical-align:bottom; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_1e370c5c9b7142789405b4714e344dcf'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;747,200&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1.02%; vertical-align:bottom; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1.02%; vertical-align:bottom; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10.2%; vertical-align:bottom; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_49bb5b90dc4242be96236f035345724d'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;3.56&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1.02%; vertical-align:bottom; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10.2%; vertical-align:bottom; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_a636cf72eae548238b35fe47161c70e0'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;2.00&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12.75pt"&gt;&lt;td style="width:65.32%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_092740af605f4bc4a7ada8bdf5055958'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1.02%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10.2%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;(&lt;/span&gt;&lt;span style="-aw-sdt-tag:'C_be464264c8194207a861f4cab206040c'; font-family: 'Times New Roman'"&gt;&lt;span&gt;385,200&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1.02%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1.02%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10.2%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_9014c8bd62e048859509a2426149ef61'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;0.01&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1.02%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10.2%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_99814e762c194b82bf77fe18e9120666'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-import:spaces; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Indefinite &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12.75pt"&gt;&lt;td style="width:65.32%; vertical-align:bottom; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_96b027d191d3489eb4634d84c32b33bb'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Forfeited&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1.02%; vertical-align:bottom; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10.2%; vertical-align:bottom; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-tag:'C_ebc58888ed7e443eb0bed3fbb4e296cd'"&gt;&lt;span title="&amp;amp;#13;nil='true'"&gt;&lt;/span&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1.02%; vertical-align:bottom; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1.02%; vertical-align:bottom; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10.2%; vertical-align:bottom; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-tag:'C_1cbf9c8fae99456bb1db09f419f10e3b'"&gt;&lt;span title="&amp;amp;#13;nil='true'"&gt;&lt;/span&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1.02%; vertical-align:bottom; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10.2%; vertical-align:bottom; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-tag:'C_023e956011684a2e8efc0a2c95e7aafa'"&gt;&lt;span title="&amp;amp;#13;nil='true'"&gt;&lt;/span&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12.75pt"&gt;&lt;td style="width:65.32%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_3a9cd327c03648eabee6def9efeb8a16'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Expired&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1.02%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10.2%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-tag:'C_1b9506549baa4d28b730114acf607f9d'"&gt;&lt;span title="&amp;amp;#13;nil='true'"&gt;&lt;/span&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1.02%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1.02%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10.2%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-tag:'C_ceb7f15a6ff64d289ae12ddbd0b82690'"&gt;&lt;span title="&amp;amp;#13;nil='true'"&gt;&lt;/span&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1.02%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10.2%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-tag:'C_28fd827460b74eed914d939d69a18b99'"&gt;&lt;span title="&amp;amp;#13;nil='true'"&gt;&lt;/span&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:8.4pt"&gt;&lt;td style="width:65.32%; vertical-align:bottom; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_940a2249f6b3409bbd4cf1fd3bfef304'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Total outstanding, March 31, 2025&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1.02%; vertical-align:bottom; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10.2%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_dc623020fea849eba11ebc4bfb2db46b'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;2,127,070&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1.02%; vertical-align:bottom; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1.02%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_4a782ea234b64abda040b2705b8054db'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:10.2%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_6c6bbe87d4d04a50ba3802b29e13ca71'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;15.85&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1.02%; vertical-align:bottom; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10.2%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_13fb13eaf08b49a2b57074280816ad0b'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;2.60&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12.75pt"&gt;&lt;td style="width:65.32%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_ea5e3e245b884185986e713469cfdfa7'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1.02%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10.2%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-tag:'C_57e1c8a9723f46f5b83a7dc55783fee9'"&gt;&lt;span title="&amp;amp;#13;nil='true'"&gt;&lt;/span&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1.02%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1.02%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10.2%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-tag:'C_243d18f890714f9fa13c4b72d28af692'"&gt;&lt;span title="&amp;amp;#13;nil='true'"&gt;&lt;/span&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1.02%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10.2%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-tag:'C_f31c5abd07e34d559789feb6be7b30a9'"&gt;&lt;span title="&amp;amp;#13;nil='true'"&gt;&lt;/span&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12.75pt"&gt;&lt;td style="width:65.32%; vertical-align:bottom; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_5f1d9b909eb24eac860bae5956db20ff'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1.02%; vertical-align:bottom; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10.2%; vertical-align:bottom; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-tag:'C_c4963ba6c9714c2b848973d90745bbe7'"&gt;&lt;span title="&amp;amp;#13;nil='true'"&gt;&lt;/span&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1.02%; vertical-align:bottom; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1.02%; vertical-align:bottom; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10.2%; vertical-align:bottom; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-tag:'C_00ce71b2c5d1489abe5ef8882e6eb43b'"&gt;&lt;span title="&amp;amp;#13;nil='true'"&gt;&lt;/span&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1.02%; vertical-align:bottom; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10.2%; vertical-align:bottom; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-tag:'C_87370543a6f5422cb31f728fb2213f65'"&gt;&lt;span title="&amp;amp;#13;nil='true'"&gt;&lt;/span&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12.75pt"&gt;&lt;td style="width:65.32%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_de6f15e3ec76429fb39fe3cc06dcd0b4'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Forfeited&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1.02%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10.2%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-tag:'C_1226676f1bf44f8197d4965d8019abfa'"&gt;&lt;span title="&amp;amp;#13;nil='true'"&gt;&lt;/span&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1.02%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1.02%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10.2%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-tag:'C_38dc8b6b23e14f2fb10ac0aab43b0957'"&gt;&lt;span title="&amp;amp;#13;nil='true'"&gt;&lt;/span&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1.02%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10.2%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-tag:'C_71849749deae49b1affc3ffaa76a7bf6'"&gt;&lt;span title="&amp;amp;#13;nil='true'"&gt;&lt;/span&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12.75pt"&gt;&lt;td style="width:65.32%; vertical-align:bottom; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_8cdb6926b5124838a53f846006ffe4d5'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Expired&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1.02%; vertical-align:bottom; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10.2%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-tag:'C_85eba8ce16524c9c992ae58a76b43a52'"&gt;&lt;span title="&amp;amp;#13;nil='true'"&gt;&lt;/span&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1.02%; vertical-align:bottom; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1.02%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10.2%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-tag:'C_3fa373d813a84ebaac3667eead34d3c5'"&gt;&lt;span title="&amp;amp;#13;nil='true'"&gt;&lt;/span&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1.02%; vertical-align:bottom; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10.2%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-tag:'C_b9f06ff4ca7a45779ddab62a866d8364'"&gt;&lt;span title="&amp;amp;#13;nil='true'"&gt;&lt;/span&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:13.5pt"&gt;&lt;td style="width:65.32%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_c764316e0a5941d382adb9acefbbf02d'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Total outstanding, June 30, 2025&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1.02%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10.2%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_bd4af9854bee45f4a6e8551c9ffeab14'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;2,127,070&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1.02%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1.02%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_06b30492d24443dea9f922ac7c5991eb'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:10.2%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_dd5b51e6504c4fe485896034c4ab5aaf'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;15.85&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1.02%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10.2%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_8c4c3f1235014bbd826251d11d481ada'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;2.10&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:1.3pt"&gt;&lt;td style="width:65.32%; vertical-align:bottom; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_c64851bf815b4da8863747dd5755f707'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Granted&lt;/span&gt;&lt;span style="font-size:6.67pt; vertical-align:super; font-family: 'Times New Roman'"&gt;(2)&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1.02%; vertical-align:bottom; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10.2%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_807950b3ae924a2f975de95c2d052326'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;6,338,788&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1.02%; vertical-align:bottom; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1.02%; vertical-align:bottom; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10.2%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_4fd32df330bb4ce6a8e82401cf8bfee9'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;1.65&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1.02%; vertical-align:bottom; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10.2%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_ed4130eba4504c2992f76b5ad495c647'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;3.31&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:13.5pt"&gt;&lt;td style="width:65.32%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_d9b5d3e46cf0480dbe71aa1b85fd2730'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1.02%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10.2%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;(&lt;/span&gt;&lt;span style="-aw-sdt-tag:'C_453fa426afc145e39bde490d351be1d5'; font-family: 'Times New Roman'"&gt;&lt;span&gt;878,264&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1.02%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1.02%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10.2%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_b3cd337ad3c643b98646dee9eafdf4db'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;0.001&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1.02%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10.2%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_ebf6d0f4a79044b1a96cec392910afa3'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-import:spaces; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Indefinite &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:13.5pt"&gt;&lt;td style="width:65.32%; vertical-align:bottom; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_9941868f9f2b4eeb9ad1e9a0ec7731e5'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Forfeited&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1.02%; vertical-align:bottom; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10.2%; vertical-align:bottom; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-tag:'C_f6c86e35bf8044009a4b4a9ffa2be0b9'"&gt;&lt;span title="&amp;amp;#13;nil='true'"&gt;&lt;/span&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1.02%; vertical-align:bottom; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1.02%; vertical-align:bottom; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10.2%; vertical-align:bottom; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-tag:'C_5120de4eb07c46d1a887d6f33993bd48'"&gt;&lt;span title="&amp;amp;#13;nil='true'"&gt;&lt;/span&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1.02%; vertical-align:bottom; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10.2%; vertical-align:bottom; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-tag:'C_d16cd40451854e3c9422892d316527ed'"&gt;&lt;span title="&amp;amp;#13;nil='true'"&gt;&lt;/span&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:13.5pt"&gt;&lt;td style="width:65.32%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_d493e9ce3b6e44bcb5f236c8e5cf90bc'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Expired&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1.02%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10.2%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-tag:'C_5eee2f2968084f68bd96a105a2a456ba'"&gt;&lt;span title="&amp;amp;#13;nil='true'"&gt;&lt;/span&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1.02%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1.02%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10.2%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-tag:'C_351547f4bdc341548bd95be3a56c990b'"&gt;&lt;span title="&amp;amp;#13;nil='true'"&gt;&lt;/span&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1.02%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10.2%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-tag:'C_e5c3e7a2d1ea48788874fe6f1aaa160e'"&gt;&lt;span title="&amp;amp;#13;nil='true'"&gt;&lt;/span&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:13.5pt"&gt;&lt;td style="width:65.32%; vertical-align:bottom; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_a711a12f9677437590c66b5950b17bd5'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Total outstanding, September 30, 2025&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1.02%; vertical-align:bottom; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10.2%; border-top:0.75pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#ffffff; -aw-border-top:0.5pt single"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_8ea7f7a4e1d24d429c6f06db22b55e6d'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;7,587,594&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1.02%; vertical-align:bottom; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1.02%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_2d3b290467d343018ea51921f595758a'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:10.2%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_7047b295f89941d1bdfff27a2c97d2f6'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;5.82&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1.02%; vertical-align:bottom; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10.2%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_01e4caaff41844e1ae7feb1c2ae66d69'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;2.82&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:13.5pt"&gt;&lt;td style="width:65.32%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_d51b62342edd4404956c0bf1cb0b2079'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Total exercisable, September 30, 2025&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1.02%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10.2%; border-top:4.5pt double #000000; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_7b1ea82a944942ceb4546250d540a297'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;7,587,594&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1.02%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1.02%; border-top:4.5pt double #000000; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_f78db16daa4a48f09d41316116f43005'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:10.2%; border-top:4.5pt double #000000; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_f6c5be1b8d51432b8279c89401af163b'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;5.82&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1.02%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10.2%; border-top:4.5pt double #000000; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_28a537d0722b41f7ba4474c4041f1592'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;2.82&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman';  font-size: 12pt;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="width:100%"&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td style="width:3.3%; vertical-align:top"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:12.5pt"&gt;&lt;span style="font-size:8.33pt; vertical-align:super; font-family: 'Times New Roman'"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:96.7%; vertical-align:top"&gt;&lt;div style="-aw-sdt-tag:'cc60b45585da36d079a6'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Weighted average remaining contractual life at &lt;/span&gt;&lt;span style="-aw-sdt-tag:'cb7acd8bf727a3348920'; -aw-sdt-title:'Previous_Year_End_P16'; font-family: 'Times New Roman'"&gt;&lt;span&gt;December 31, 2024&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; excludes &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c9eaac2b3a02e0ecbfed'; font-family: 'Times New Roman'"&gt;&lt;span&gt;385,200&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; Pre-Funded Warrants issued September &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c084844e24a211ebd242'; font-family: 'Times New Roman'"&gt;&lt;span&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; that do not have a contractual expiration date, for which &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c6c65c3f0bb7343724f4'; font-family: 'Times New Roman'"&gt;&lt;span&gt;0&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; warrants remain outstanding and exercisable at March 31, 2025, June 30, 2025 and &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c3f8bf32fba6f0a28902'; -aw-sdt-title:'Current_Period_P16'; font-family: 'Times New Roman'"&gt;&lt;span&gt;September 30, 2025&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="width:100%; border-collapse:collapse"&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td style="width:3.3%; vertical-align:top"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:12.5pt"&gt;&lt;span style="font-size:8.33pt; vertical-align:super; font-family: 'Times New Roman'"&gt;(2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:96.7%; vertical-align:top"&gt;&lt;div style="-aw-sdt-tag:'4e2-557-131-530-ea28'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Weighted average remaining contractual life excludes &lt;/span&gt;&lt;span style="-aw-sdt-tag:'155-a3e-4e3-421-5e47'; font-family: 'Times New Roman'"&gt;&lt;span&gt;878,264&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; Pre-Funded Warrants issued July 2025 that do not have a contractual expiration date, for which &lt;/span&gt;&lt;span style="-aw-sdt-tag:'cfe-9a0-ea6-43f-4379'; font-family: 'Times New Roman'"&gt;&lt;span&gt;0&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; warrants remain outstanding and exercisable at &lt;/span&gt;&lt;span style="-aw-sdt-tag:'b56-24f-fd5-c1f-b53f'; -aw-sdt-title:'Current_Period_P43'; font-family: 'Times New Roman'"&gt;&lt;span&gt;September 30, 2025&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:3.3%; vertical-align:top"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:5pt"&gt;&lt;span style="font-size:3.33pt; vertical-align:super; -aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:96.7%; vertical-align:top"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:5pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="-aw-import:spaces; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="-aw-sdt-tag:'PG_2924caba445ee74c'"&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="-aw-sdt-tag:'0b9-32d-758-bbb-7d61'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;The following table presents a summary of the activity for the Company&#x2019;s equity-classified warrants during the &lt;/span&gt;&lt;span style="-aw-sdt-tag:'cb837e6a667bb2d8e81a'; -aw-sdt-title:'Previous_Quarter_and_YTD_P4'; font-family: 'Times New Roman'"&gt;&lt;span&gt;three and nine months ended September 30, 2024&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;:&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="-aw-sdt-tag:'5ef-bd1-660-949-dac4'; -aw-sdt-title:'PYTD Warrant Activity Table'"&gt;&lt;table cellpadding="0" cellspacing="0" style="width:100%; border-collapse:collapse"&gt;&lt;tbody&gt;&lt;tr style="height:66pt"&gt;&lt;td style="width:66%; vertical-align:bottom"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:bottom"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:bottom"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_2fe24833a44b41479778dfa15ea39d75'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;Number of Warrants&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:bottom"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1.5pt solid #000000; vertical-align:bottom"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_f18fecd537364a0f93431550cd6beb89'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;Weighted Average Exercise Price&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:bottom"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:bottom"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_46e2237dbc934f6b9426112c9d46cff7'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;Weighted Average Remaining Contractual Life (Years)&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:13.2pt"&gt;&lt;td style="width:66%; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_e3159a48c35a441588285bc5f08adbb5'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Total outstanding, December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_26c6e8ba5c4f437b898bce96847ea990'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;52,737&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_7932e86b6155416a856e4b9e3135e6a0'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_1e1cfe2fee02428fb18bed385db26f5b'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;369.98&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_0fdf3faee9384a09b6fb1053d73cd117'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;4.47&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:13.2pt"&gt;&lt;td style="width:66%; vertical-align:middle; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_d2f19f5220f34a67a6cf0ad536ecceaf'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; vertical-align:middle; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_ca72a78fc17a4df2b8b050de41cb1fb2'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;140,884&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; vertical-align:middle; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_03da05c614d4494ab5a425272003c87d'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;22.48&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; vertical-align:middle; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_1e23442a8f184d09a6640f316b286c13'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;5.00&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:13.2pt"&gt;&lt;td style="width:66%; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_5bc3ca100224454db31571d2f7b1902d'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; vertical-align:middle; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;(&lt;/span&gt;&lt;span style="-aw-sdt-tag:'C_947713b195ad4820bbb30058fc78b8f8'; font-family: 'Times New Roman'"&gt;&lt;span&gt;8,326&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_6653a7d365a745d882b7652b6ee003cf'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;0.60&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_d11cc3479bef4b49bb34a26fb81a3dab'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-import:spaces; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Indefinite &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:13.2pt"&gt;&lt;td style="width:66%; vertical-align:middle; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_036865088ae34687ad76ec0118f6c13a'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Forfeited&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; vertical-align:middle; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-tag:'C_0b98733a323540198451b82d59cb06fc'"&gt;&lt;span title="&amp;amp;#13;nil='true'"&gt;&lt;/span&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; vertical-align:middle; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-tag:'C_b095fd6b9be94bbc8c5bffe34783b7e9'"&gt;&lt;span title="&amp;amp;#13;nil='true'"&gt;&lt;/span&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; vertical-align:middle; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-tag:'C_62e43591234846379c4d980c1b569ce5'"&gt;&lt;span title="&amp;amp;#13;nil='true'"&gt;&lt;/span&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:13.2pt"&gt;&lt;td style="width:66%; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_ed4f3a89e25f4188a6c83db8976197d5'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Expired&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-tag:'C_e3ce5466c2be49d1857c06466db44631'"&gt;&lt;span title="&amp;amp;#13;nil='true'"&gt;&lt;/span&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-tag:'C_dfdbdd8338f8414d8f83aae99237906a'"&gt;&lt;span title="&amp;amp;#13;nil='true'"&gt;&lt;/span&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-tag:'C_fe44fba7b4ea4e7aa0021a9bccd19da2'"&gt;&lt;span title="&amp;amp;#13;nil='true'"&gt;&lt;/span&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:13.8pt"&gt;&lt;td style="width:66%; vertical-align:middle; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_3d817872bae142abb1bdde9aec1609a3'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Total outstanding, March 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_c163a2b7f7f04b69b4d13a118cc458f9'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;185,295&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_2b8349367e4e49bd8341592d5d525a88'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:10%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_f13c7faf7831462aab2cb911bc2f0dd6'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;122.36&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_0005a1e335884fc7ac7b8d95109bce26'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;4.67&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:13.8pt"&gt;&lt;td style="width:66%; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_dcc561ad8f5141e9ad4b5045a2890934'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-tag:'C_88de1f197d034065b9cd32ef1dcd9706'"&gt;&lt;span title="&amp;amp;#13;nil='true'"&gt;&lt;/span&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-tag:'C_f73d194d7c854624909dcf76b8ba5ce8'"&gt;&lt;span title="&amp;amp;#13;nil='true'"&gt;&lt;/span&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-tag:'C_fb1a4c504f914dc289bb53a1b30080ae'"&gt;&lt;span title="&amp;amp;#13;nil='true'"&gt;&lt;/span&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:13.2pt"&gt;&lt;td style="width:66%; vertical-align:middle; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_a977d41b2c174189a08b961656853a60'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;(&lt;/span&gt;&lt;span style="-aw-sdt-tag:'C_79bdaacfa9994fb2b69b6344f572705f'; font-family: 'Times New Roman'"&gt;&lt;span&gt;8,326&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; vertical-align:middle; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_31638e6c276c4f2fa99250fcb9843150'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;0.60&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; vertical-align:middle; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_f5cdcd321c28407aa89715dc54333513'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-import:spaces; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Indefinite &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:13.2pt"&gt;&lt;td style="width:66%; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_fa7dd320f8ff4aac96b933a7fbc11384'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Forfeited&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-tag:'C_110cf5dfc8bd4bc080a6b64cb16f3187'"&gt;&lt;span title="&amp;amp;#13;nil='true'"&gt;&lt;/span&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-tag:'C_4a2d3439c11443f6b2da01418ec74397'"&gt;&lt;span title="&amp;amp;#13;nil='true'"&gt;&lt;/span&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-tag:'C_0da9202225b040e19c3d69fa37a95f80'"&gt;&lt;span title="&amp;amp;#13;nil='true'"&gt;&lt;/span&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:13.2pt"&gt;&lt;td style="width:66%; vertical-align:middle; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_59813ff6f1844a788243218269af1e79'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Expired&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-tag:'C_9b5fd3e6aa1b4e4cb21d298ea65de0ea'"&gt;&lt;span title="&amp;amp;#13;nil='true'"&gt;&lt;/span&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-tag:'C_f2ddee167a494c22b7bd797d8ae1c6c2'"&gt;&lt;span title="&amp;amp;#13;nil='true'"&gt;&lt;/span&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-tag:'C_7a4c7af18d3f4f77813081f40c1d117a'"&gt;&lt;span title="&amp;amp;#13;nil='true'"&gt;&lt;/span&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:13.8pt"&gt;&lt;td style="width:66%; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_a82321d8724e48d9a9d4e5fea605470a'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Total outstanding, June 30, 2024&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_2a6ee883b436439caf9659428ef1344a'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;176,969&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_aa95f7f315f940a2a5739ae21aafd495'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_dedfd6de48f64fde8de26755f4cdd4e4'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;128.09&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_79c28b5186b7430280974bffea1c6e69'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;4.41&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:4.05pt"&gt;&lt;td style="width:66%; vertical-align:middle; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_1e54e27571a64e8887f09b7346aff7c4'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Granted&lt;/span&gt;&lt;span style="font-size:6.67pt; vertical-align:super; font-family: 'Times New Roman'"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; vertical-align:middle; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_adfe2fb2d65545cba64b8094d9c2cc08'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;1,782,612&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; vertical-align:middle; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_b0770c488b2d44c0b74d38914ce1a1f4'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;4.70&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; vertical-align:middle; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-tag:'C_8a1c8815f35841ef9b2cf22465a70cbd'"&gt;&lt;span title="&amp;amp;#13;nil='true'"&gt;&lt;/span&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:4.05pt"&gt;&lt;td style="width:66%; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_e4111cde5ebf4e2db2c6ef266cda76df'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-tag:'C_667abf06483d4e4aab4ecd254ca4fb4d'"&gt;&lt;span title="&amp;amp;#13;nil='true'"&gt;&lt;/span&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-tag:'C_1b9a47ca596e4271804077a0fce457bd'"&gt;&lt;span title="&amp;amp;#13;nil='true'"&gt;&lt;/span&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-tag:'C_c7fead391f1c4bedaf8cbd7c73bfcbf9'"&gt;&lt;span title="&amp;amp;#13;nil='true'"&gt;&lt;/span&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:4.05pt"&gt;&lt;td style="width:66%; vertical-align:middle; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_19cb9448efb54e7e898444eb0f2563a8'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Forfeited&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; vertical-align:middle; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-tag:'C_60dcc17070434c6ab1cafb9462e1e3d6'"&gt;&lt;span title="&amp;amp;#13;nil='true'"&gt;&lt;/span&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; vertical-align:middle; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-tag:'C_ba07f171b24f486fa792b6c7c3444cc7'"&gt;&lt;span title="&amp;amp;#13;nil='true'"&gt;&lt;/span&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; vertical-align:middle; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-tag:'C_1e57ce7e25864bb89046552a08c0e3fc'"&gt;&lt;span title="&amp;amp;#13;nil='true'"&gt;&lt;/span&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:4.05pt"&gt;&lt;td style="width:66%; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_350af71c0b4948a6a77dfcd4075ad433'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Expired&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-tag:'C_aedbe4e189824914abc8f3a4b2bda114'"&gt;&lt;span title="&amp;amp;#13;nil='true'"&gt;&lt;/span&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-tag:'C_9d6d068f7ee644de9a393925a4cbfc15'"&gt;&lt;span title="&amp;amp;#13;nil='true'"&gt;&lt;/span&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-tag:'C_bfabe0e863a542ac80153555a0367873'"&gt;&lt;span title="&amp;amp;#13;nil='true'"&gt;&lt;/span&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:4.05pt"&gt;&lt;td style="width:66%; vertical-align:middle; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_1de26c9af20040a29472d2ca9138d19f'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Total outstanding, September 30, 2024&lt;/span&gt;&lt;span style="font-size:6.67pt; vertical-align:super; font-family: 'Times New Roman'"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_f4d9856e21884f16b54c37b835a9f33a'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;1,959,581&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_f8d0824dee194343b9daffd0ef500eda'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_2419a538771d4014a0aa04299e82b736'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;15.84&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_7ddd3f67b2d74622afae5bc4f4059994'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;4.16&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:4.05pt"&gt;&lt;td style="width:66%; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_db4c1fd8ae924d69b46bdc6baf2841b1'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Total exercisable, September 30, 2024&lt;/span&gt;&lt;span style="font-size:6.67pt; vertical-align:super; font-family: 'Times New Roman'"&gt;(2)&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; border-top:4.5pt double #000000; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_8f538a18dc5c4b0789915e07028c8a3b'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;756,680&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; border-top:4.5pt double #000000; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_b445e814ada34f288326ca954e930c27'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:10%; border-top:4.5pt double #000000; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_e1118852385841f19496c5a949e0e0bb'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;29.96&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; border-top:4.5pt double #000000; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'a4f-f6d-3a4-587-6f95'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;4.16&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="width:100%; border-collapse:collapse"&gt;&lt;tbody&gt;&lt;tr style="height:11.5pt"&gt;&lt;td style="width:3.3%; vertical-align:top"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:12.5pt"&gt;&lt;span style="font-size:8.33pt; vertical-align:super; font-family: 'Times New Roman'"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:96.7%; vertical-align:top"&gt;&lt;div style="-aw-sdt-tag:'54e-de6-a74-b52-df70'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Weighted average remaining contractual life calculations exclude (i) &lt;/span&gt;&lt;span style="-aw-sdt-tag:'732-da0-de5-bf5-8dbb'; font-family: 'Times New Roman'"&gt;&lt;span&gt;579,711&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; Pre-Funded Warrants issued September 2024 that do not have a contractual expiration date, (ii) &lt;/span&gt;&lt;span style="-aw-sdt-tag:'f2c-5f7-8bf-af8-594f'; font-family: 'Times New Roman'"&gt;&lt;span&gt;43,479&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; September 2024 Agent Warrants and &lt;/span&gt;&lt;span style="-aw-sdt-tag:'e8a-7d2-dd0-c63-800f'; font-family: 'Times New Roman'"&gt;&lt;span&gt;579,711&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; Series A Warrants issued September 2024 that expire &lt;/span&gt;&lt;span style="-aw-sdt-tag:'316-f81-d28-80c-a600'; font-family: 'Times New Roman'"&gt;&lt;span&gt;five years&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; from the Stockholder Approval Date, defined above, and (iii) &lt;/span&gt;&lt;span style="-aw-sdt-tag:'051-85c-a14-d67-3f56'; font-family: 'Times New Roman'"&gt;&lt;span&gt;579,711&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; Series B Warrants issued September 2024 that expire &lt;/span&gt;&lt;span style="-aw-sdt-tag:'5a3-db5-072-293-bc68'; font-family: 'Times New Roman'"&gt;&lt;span&gt;eighteen months&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; from the Stockholder Approval Date, which had not yet occurred as of September 30, 2024.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.5pt"&gt;&lt;td style="width:3.3%; vertical-align:top"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:12.5pt"&gt;&lt;span style="font-size:8.33pt; vertical-align:super; font-family: 'Times New Roman'"&gt;(2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:96.7%; vertical-align:top"&gt;&lt;div style="-aw-sdt-tag:'f6b-c28-fc7-73a-bf3d'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Weighted average remaining contractual life calculation excludes &lt;/span&gt;&lt;span style="-aw-sdt-tag:'789-7d3-dde-216-e566'; font-family: 'Times New Roman'"&gt;&lt;span&gt;579,711&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; exercisable Pre-Funded Warrants issued September 2024 that do not have a contractual expiration date.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="-aw-sdt-tag:'PG_c093876e3a43e140a243'"&gt;&lt;/div&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-weight:bold; text-decoration:underline; font-family: 'Times New Roman'"&gt;Series A Preferred Stock&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;During the &lt;/span&gt;&lt;span style="-aw-sdt-tag:'5c9-2a4-edd-9b2-9f2b'; -aw-sdt-title:'Current_Quarter_and_YTD_P14'; font-family: 'Times New Roman'"&gt;&lt;span&gt;three and nine months ended September 30, 2025&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; and &lt;/span&gt;&lt;span style="-aw-sdt-tag:'30c-b61-ed7-5bc-836f'; -aw-sdt-title:'Previous_Year_P53'; font-family: 'Times New Roman'"&gt;&lt;span&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;, the Company converted &lt;/span&gt;&lt;span style="-aw-sdt-tag:'26e-8f7-c03-a34-5fdd'; font-family: 'Times New Roman'"&gt;&lt;span&gt;0&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; and &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c8c-9b4-436-87f-0fad'; -aw-sdt-title:'PY_Preferred Shares Converted'; font-family: 'Times New Roman'"&gt;&lt;span&gt;2,323&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; shares of Series A Preferred Stock, respectively, held by Knight Therapeutics Inc. into &lt;/span&gt;&lt;span style="-aw-sdt-tag:'46f-111-ec1-a22-3bfa'; font-family: 'Times New Roman'"&gt;&lt;span&gt;0&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; shares and &lt;/span&gt;&lt;span style="-aw-sdt-tag:'5d3-ac8-a1a-288-a527'; -aw-sdt-title:'PY_CS Issued for Preferred'; font-family: 'Times New Roman'"&gt;&lt;span&gt;14,667&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; shares of common stock, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;The holders of shares of Series A Preferred Stock have the rights, preferences, powers, restrictions, and limitations as set forth below.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-style:italic; font-family: 'Times New Roman'"&gt;Voting Rights&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; - The holders of shares of Series A Preferred Stock are not entitled to any voting rights.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-style:italic; font-family: 'Times New Roman'"&gt;Dividends&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; - From and after the date of issuance of any share of Series A Preferred Stock, cumulative dividends shall accrue, whether or not declared by the Board and whether or not there are funds legally available for the payment of dividends, on a daily basis in arrears at the rate of &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c892c80e3878c0cecf8e'; font-family: 'Times New Roman'"&gt;&lt;span&gt;6.0&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;% per annum on the sum of the Liquidation Value (as defined below). Accrued dividends shall be paid in cash only when, as and if declared by the Board out of funds legally available therefor or upon a liquidation or redemption of the Series A Preferred Stock. On March 31 of each calendar year, any accrued and unpaid dividends shall accumulate and compound on such date, and are cumulative until paid or converted. Holders of shares of Series A Preferred Stock are entitled to receive accrued and accumulated dividends prior to and in preference to any dividend, distribution, or redemption on shares of Common Stock or any other class of securities that is designated as junior to the Series A Preferred Stock. During the &lt;/span&gt;&lt;span style="-aw-sdt-tag:'cc911d4ba3e887d4a594'; -aw-sdt-title:'Current_Quarter_and_YTD_P12'; font-family: 'Times New Roman'"&gt;&lt;span&gt;three and nine months ended September 30, 2025&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;, dividends in the amount of $&lt;/span&gt;&lt;span style="-aw-sdt-tag:'c5d01b9ca1ecc7a2ced3'; -aw-sdt-title:'CQTD_Preferred Dividends Accrued'; font-family: 'Times New Roman'"&gt;&lt;span&gt;128,097&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; and $&lt;/span&gt;&lt;span style="-aw-sdt-tag:'c4dc3d0e64763e414812'; -aw-sdt-title:'CYTD_Preferred Dividends Accrued'; font-family: 'Times New Roman'"&gt;&lt;span&gt;372,960&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; accrued on outstanding shares of Series A Preferred Stock ($&lt;/span&gt;&lt;span style="-aw-sdt-tag:'cea75396bb906943a436'; -aw-sdt-title:'PQTD_Preferred Dividends Accrued'; font-family: 'Times New Roman'"&gt;&lt;span&gt;116,571&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; and $&lt;/span&gt;&lt;span style="-aw-sdt-tag:'ca40e5f7b0254ff2f7e6'; -aw-sdt-title:'PYTD_Preferred Dividends Accrued'; font-family: 'Times New Roman'"&gt;&lt;span&gt;352,333&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; during the &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c3c0fdc97672faa58e7e'; -aw-sdt-title:'Previous_Quarter_and_YTD_P5'; font-family: 'Times New Roman'"&gt;&lt;span&gt;three and nine months ended September 30, 2024&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;). As of &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c2299401c4c85264b52f'; -aw-sdt-title:'Current_Period_P18'; font-family: 'Times New Roman'"&gt;&lt;span&gt;September 30, 2025&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;, cumulative dividends on outstanding shares of Series A Preferred Stock amount to $&lt;/span&gt;&lt;span style="-aw-sdt-tag:'c813e72b0da56ce25468'; -aw-sdt-title:'Cumulative Preferred Dividends'; font-family: 'Times New Roman'"&gt;&lt;span&gt;1,076,975&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;. To date, the Company has not declared or paid any dividends.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-style:italic; font-family: 'Times New Roman'"&gt;Liquidation Rights - &lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;In the event of any voluntary or involuntary liquidation, dissolution or winding up of the Company, the holders of shares of Series A Preferred Stock then outstanding will share ratably in any distribution of the remaining assets and funds of the Company with all other stockholders as if each share of Series A Preferred Stock had been converted by the Company to Common Stock as described below.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-style:italic; font-family: 'Times New Roman'"&gt;Conversion Rights &lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;- The Company has the right, in its sole discretion, to convert all or any portion of the outstanding shares of Series A Preferred Stock (including any fraction of a share), plus the aggregate accrued or accumulated and unpaid dividends thereon into a number of shares of Common Stock determined by (i) multiplying the number of shares to be converted by $&lt;/span&gt;&lt;span style="-aw-sdt-tag:'c6021622cfc46b68553d'; font-family: 'Times New Roman'"&gt;&lt;span&gt;100&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; per share, as adjusted for any stock splits, stock dividends, recapitalizations or similar transactions with respect to the Series A Preferred Stock (but unchanged as a result of the Reverse Stock Splits impacting the common stock on August &lt;/span&gt;&lt;span style="-aw-sdt-tag:'cf52d7caefe8194001c1'; font-family: 'Times New Roman'"&gt;&lt;span&gt;12&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;, &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c75ba405cdf0dec60ee5'; font-family: 'Times New Roman'"&gt;&lt;span&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; and February &lt;/span&gt;&lt;span style="-aw-sdt-tag:'cc9a608cfc1faa48bbb2'; font-family: 'Times New Roman'"&gt;&lt;span&gt;24&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;, &lt;/span&gt;&lt;span style="-aw-sdt-tag:'cad67accf5f2bbc138d0'; font-family: 'Times New Roman'"&gt;&lt;span&gt;2025&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;) (the &#x201c;Liquidation Value&#x201d;), (ii) plus all accrued and accumulated and unpaid dividends on such shares to be converted, and then (ii) dividing the result by the then-effective Conversion Price in effect, provided that such conversion would not result in the holders of shares of Series A Preferred Stock owning more than &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c6205514cffce1e92bc3'; font-family: 'Times New Roman'"&gt;&lt;span&gt;19.9&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;% of the outstanding shares of common stock on an as-converted basis. The &#x201c;Conversion Price&#x201d; is equal to the lesser of (a) the Liquidation Value, (b) the offering price per share of Common Stock in the Company&#x2019;s IPO, &lt;/span&gt;&lt;span style="-aw-sdt-tag:'fc2-007-c74-683-0eb3'; font-family: 'Times New Roman'"&gt;&lt;span&gt;as adjusted for the 1:12 Reverse Stock Split after August 12, 2024 and the 1:5 Reverse Stock Split after February 24, 2025&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;, or $&lt;/span&gt;&lt;span style="-aw-sdt-tag:'c941adacc45bab52df52'; font-family: 'Times New Roman'"&gt;&lt;span&gt;300&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; per share, or (c) the &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c0d54e0a97864e25394d'; font-family: 'Times New Roman'"&gt;&lt;span&gt;10&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;-day volume weighted average price per share of Common Stock, as reasonably determined by the Company.&lt;/span&gt;&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="I20250930"
      decimals="0"
      id="Tag780"
      unitRef="Shares">150000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="I20250930"
      decimals="4"
      id="Tag781"
      unitRef="USDPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="I20250930_SeriesAPreferredStockMember"
      decimals="0"
      id="Tag808"
      unitRef="Shares">1000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="I20250930_SeriesAPreferredStockMember"
      decimals="4"
      id="Tag782"
      unitRef="USDPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:ExcessStockSharesAuthorized
      contextRef="I20250930_SeriesANonVotingConvertiblePreferredStockMember"
      decimals="0"
      id="Tag783"
      unitRef="Shares">80965</us-gaap:ExcessStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="I20250930"
      decimals="0"
      id="Tag903"
      unitRef="Shares">4104469</us-gaap:CommonStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="I20250930_SeriesAPreferredStockMember"
      decimals="0"
      id="Tag902"
      unitRef="Shares">76480</us-gaap:PreferredStockSharesIssued>
    <us-gaap:StockholdersEquityReverseStockSplit contextRef="D20250218" id="Tag784">1:5</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:StockholdersEquityReverseStockSplit contextRef="D20250930_1" id="Tag785">1:5</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="D20250128"
      decimals="0"
      id="Tag856"
      unitRef="Shares">204312</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="I20250128"
      decimals="3"
      id="Tag786"
      unitRef="USDPerShare">5.105</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="I20250128"
      decimals="0"
      id="Tag787"
      unitRef="Shares">408621</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="I20250128"
      decimals="3"
      id="Tag788"
      unitRef="USDPerShare">3.855</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="D20250130"
      decimals="0"
      id="Tag789"
      unitRef="USD">804346</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="I20250131_PlacementAgentWarrantsMember"
      decimals="0"
      id="Tag917"
      unitRef="Shares">15325</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="I20250131_PlacementAgentWarrantsMember"
      decimals="3"
      id="Tag790"
      unitRef="USDPerShare">6.382</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="D20250205"
      decimals="0"
      id="Tag791"
      unitRef="Shares">300700</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="I20250205"
      decimals="3"
      id="Tag792"
      unitRef="USDPerShare">3.575</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="D20250205_CommonStockMember_WarrantMember"
      decimals="0"
      id="Tag793"
      unitRef="Shares">300700</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="I20250205_WarrantMember"
      decimals="2"
      id="Tag794"
      unitRef="USDPerShare">2.95</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="D20250206"
      decimals="0"
      id="Tag795"
      unitRef="USD">908627</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="I20250205_PlacementAgentWarrantsMember"
      decimals="0"
      id="Tag796"
      unitRef="Shares">22554</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="I20250205_PlacementAgentWarrantsMember"
      decimals="3"
      id="Tag809"
      unitRef="USDPerShare">4.469</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <sxtp:UnitsIssuedDuringPeriodSharesNewIssues
      contextRef="D20250715_July2025OfferingMember"
      decimals="0"
      id="Tag822"
      unitRef="Shares">1753314</sxtp:UnitsIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="I20250715_July2025OfferingMember"
      decimals="2"
      id="Tag823"
      unitRef="USDPerShare">1.9</us-gaap:SaleOfStockPricePerShare>
    <sxtp:UnitsIssuedDuringPeriodSharesNewIssues
      contextRef="D20250715_PreFundedWarrantMember"
      decimals="0"
      id="Tag824"
      unitRef="Shares">878264</sxtp:UnitsIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="I20250715_PreFundedWarrantMember"
      decimals="3"
      id="Tag825"
      unitRef="USDPerShare">1.899</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="I20250715_JulyTwoThousandTwentyFivePreFundedWarrantsMember"
      decimals="3"
      id="Tag826"
      unitRef="USDPerShare">0.001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable
      contextRef="D20250715_JulyTwoThousandTwentyFivePreFundedWarrantsMember"
      id="Tag828">2025-07-16</us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="I20250715_JulyTwoThousandTwentyFiveAOneWarrantsMember"
      decimals="2"
      id="Tag827"
      unitRef="USDPerShare">1.9</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable
      contextRef="D20250715_JulyTwoThousandTwentyFiveAOneWarrantsMember"
      id="Tag829">2025-07-16</us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="I20250715_JulyTwoThousandTwentyFiveAOneWarrantsMember"
      id="Tag830">2030-07-15</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="I20250715_JulyTwoThousandTwentyFiveATwoWarrantsMember"
      decimals="2"
      id="Tag900"
      unitRef="USDPerShare">1.9</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable
      contextRef="D20250715_JulyTwoThousandTwentyFiveATwoWarrantsMember"
      id="Tag897">2025-07-16</us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="I20250715_JulyTwoThousandTwentyFiveATwoWarrantsMember"
      id="Tag898">2027-01-15</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="D20250715_MaximumMember_JulyTwoThousandTwentyFivePlacementAgentWarrantsMember"
      decimals="0"
      id="Tag894"
      unitRef="Shares">197368</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="I20250715_JulyTwoThousandTwentyFivePlacementAgentWarrantsMember"
      decimals="3"
      id="Tag895"
      unitRef="USDPerShare">2.375</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable
      contextRef="D20250715_JulyTwoThousandTwentyFivePlacementAgentWarrantsMember"
      id="Tag899">2025-07-16</us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="I20250715_JulyTwoThousandTwentyFivePlacementAgentWarrantsMember"
      id="Tag893">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate
      contextRef="I20250715_JulyTwoThousandTwentyFivePlacementAgentWarrantsMember"
      id="Tag896">2030-07-15</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="D20250716_July2025OfferingMember"
      decimals="0"
      id="Tag816"
      unitRef="USD">4281300</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <sxtp:CommonStockAggregateGrossSalesProceedAuthorized
      contextRef="I20250903_HCWainwrightAndCoLLCMember_AtTheMarket2025AgreementMember"
      decimals="0"
      id="Tag886"
      unitRef="USD">1397532</sxtp:CommonStockAggregateGrossSalesProceedAuthorized>
    <sxtp:SalesAgentCommissionPercentage
      contextRef="I20250903_HCWainwrightAndCoLLCMember_AtTheMarket2025AgreementMember"
      decimals="3"
      id="Tag885"
      unitRef="Pure">0.03</sxtp:SalesAgentCommissionPercentage>
    <sxtp:ATMOfferingShares
      contextRef="D20250930_HCWainwrightAndCoLLCMember_AtTheMarket2025AgreementMember"
      decimals="0"
      id="Tag887"
      unitRef="Shares">0</sxtp:ATMOfferingShares>
    <sxtp:CommonStockAggregateOfferingPrice
      contextRef="D20240712_WallachBethCapitalLLCMember"
      decimals="0"
      id="Tag848"
      unitRef="USD">1253603</sxtp:CommonStockAggregateOfferingPrice>
    <sxtp:ATMOfferingShares
      contextRef="D20240801_WallachBethCapitalLLCMember"
      decimals="0"
      id="Tag849"
      unitRef="Shares">135568</sxtp:ATMOfferingShares>
    <us-gaap:ProceedsFromOtherEquity
      contextRef="D20240801_WallachBethCapitalLLCMember"
      decimals="0"
      id="Tag850"
      unitRef="USD">1994583</us-gaap:ProceedsFromOtherEquity>
    <sxtp:SalesAgreementTerminationDate
      contextRef="D20250903_WallachBethCapitalLLCMember"
      id="Tag921">2025-09-03</sxtp:SalesAgreementTerminationDate>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="I20240722_SeriesAPreferredStockMember"
      decimals="0"
      id="Tag851"
      unitRef="Shares">1291</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="I20240726_SeriesAPreferredStockMember"
      decimals="0"
      id="Tag840"
      unitRef="Shares">1032</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="D20240722_CommonStockMember"
      decimals="0"
      id="Tag853"
      unitRef="Shares">8000</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="D20240726_CommonStockMember"
      decimals="0"
      id="Tag852"
      unitRef="Shares">6667</us-gaap:ConversionOfStockSharesConverted1>
    <sxtp:StockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfPreFundedWarrantsinShares
      contextRef="D20250930_PreFundedWarrantMember"
      decimals="0"
      id="Tag905"
      unitRef="Shares">878264</sxtp:StockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfPreFundedWarrantsinShares>
    <sxtp:StockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfPreFundedWarrantsinShares
      contextRef="D20240930_PreFundedWarrantMember_3"
      decimals="0"
      id="Tag906"
      unitRef="Shares">0</sxtp:StockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfPreFundedWarrantsinShares>
    <sxtp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfWarrantsExercised
      contextRef="D20250930_PreFundedWarrantMember"
      decimals="0"
      id="Tag909"
      unitRef="Shares">878264</sxtp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfWarrantsExercised>
    <sxtp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfWarrantsExercised
      contextRef="D20240930_PreFundedWarrantMember_3"
      decimals="0"
      id="Tag916"
      unitRef="Shares">0</sxtp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfWarrantsExercised>
    <sxtp:ProceedsFromExerciseOfPreFundedWarrants
      contextRef="D20250930_PreFundedWarrantMember"
      decimals="0"
      id="Tag912"
      unitRef="USD">878</sxtp:ProceedsFromExerciseOfPreFundedWarrants>
    <sxtp:ProceedsFromExerciseOfPreFundedWarrants
      contextRef="D20240930_PreFundedWarrantMember_3"
      decimals="0"
      id="Tag913"
      unitRef="USD">0</sxtp:ProceedsFromExerciseOfPreFundedWarrants>
    <sxtp:StockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfPreFundedWarrantsinShares
      contextRef="D20250930_PreFundedWarrantMember_1"
      decimals="0"
      id="Tag907"
      unitRef="Shares">1263464</sxtp:StockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfPreFundedWarrantsinShares>
    <sxtp:StockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfPreFundedWarrantsinShares
      contextRef="D20240930_PreFundedWarrantMember_1"
      decimals="0"
      id="Tag908"
      unitRef="Shares">16652</sxtp:StockIssuedDuringPeriodIssuanceOfCommonStockUponExerciseOfPreFundedWarrantsinShares>
    <sxtp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfWarrantsExercised
      contextRef="D20250930_PreFundedWarrantMember_1"
      decimals="0"
      id="Tag914"
      unitRef="Shares">1263464</sxtp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfWarrantsExercised>
    <sxtp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfWarrantsExercised
      contextRef="D20240930_PreFundedWarrantMember_1"
      decimals="0"
      id="Tag915"
      unitRef="Shares">16652</sxtp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfWarrantsExercised>
    <sxtp:ProceedsFromExerciseOfPreFundedWarrants
      contextRef="D20250930_PreFundedWarrantMember_1"
      decimals="0"
      id="Tag910"
      unitRef="USD">2804</sxtp:ProceedsFromExerciseOfPreFundedWarrants>
    <sxtp:ProceedsFromExerciseOfPreFundedWarrants
      contextRef="D20240930_PreFundedWarrantMember_1"
      decimals="0"
      id="Tag911"
      unitRef="USD">9990</sxtp:ProceedsFromExerciseOfPreFundedWarrants>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="I20250930_HCWainwrightAndCoLLCMember"
      decimals="0"
      id="Tag854"
      unitRef="Shares">43479</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="I20250930_HCWainwrightAndCoLLCMember"
      decimals="2"
      id="Tag855"
      unitRef="USDPerShare">8.63</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="D20250930_1" id="Tag963">&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;The following table presents a summary of the activity for the Company&#x2019;s equity-classified warrants during the &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c564d7f6835302971ae2'; -aw-sdt-title:'Current_Quarter_and_YTD_P11'; font-family: 'Times New Roman'"&gt;&lt;span&gt;three and nine months ended September 30, 2025&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;:&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="-aw-sdt-tag:'c03fb2d1c9552e699f9f'; -aw-sdt-title:'STOCKHOLDERS EQUITY T1'"&gt;&lt;table cellpadding="0" cellspacing="0" style="width:100%; border-collapse:collapse"&gt;&lt;tbody&gt;&lt;tr style="height:51pt"&gt;&lt;td style="width:65.32%; vertical-align:bottom"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1.02%; vertical-align:bottom"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10.2%; border-bottom:1.5pt solid #000000; vertical-align:bottom"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_255042d0e6a541a388b409c03b69aa6a'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;Number of Warrants&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1.02%; vertical-align:bottom"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"&gt;&lt;span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1.5pt solid #000000; vertical-align:bottom"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_1d3baab02d8c401b900003c44b2c7c3f'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;Weighted Average Exercise Price&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1.02%; vertical-align:bottom"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"&gt;&lt;span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10.2%; border-bottom:1.5pt solid #000000; vertical-align:bottom"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_d9d36dc13cae43cf8b651c83ff0751cb'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;Weighted Average Remaining Contractual Life (Years)&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12.75pt"&gt;&lt;td style="width:65.32%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_0df67d8471e9467a89ff88e0439581e5'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Total outstanding, December 31, 2024&lt;/span&gt;&lt;span style="font-size:6.67pt; vertical-align:super; font-family: 'Times New Roman'"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1.02%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10.2%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_cfd86fffd9a24a8681860699bbc5835a'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;1,765,070&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1.02%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1.02%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_018f691c6c554fcd9f2ea902cef36ea6'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:10.2%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_401143ee48e043d3b3536cd6cdf9c432'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;17.59&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1.02%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10.2%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_b26821ca78ac44ef92c209c2bc9c966d'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;3.26&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12.75pt"&gt;&lt;td style="width:65.32%; vertical-align:bottom; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_56484066bcc74bf8b3793fd9b87e4059'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1.02%; vertical-align:bottom; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10.2%; vertical-align:bottom; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_1e370c5c9b7142789405b4714e344dcf'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;747,200&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1.02%; vertical-align:bottom; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1.02%; vertical-align:bottom; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10.2%; vertical-align:bottom; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_49bb5b90dc4242be96236f035345724d'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;3.56&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1.02%; vertical-align:bottom; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10.2%; vertical-align:bottom; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_a636cf72eae548238b35fe47161c70e0'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;2.00&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12.75pt"&gt;&lt;td style="width:65.32%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_092740af605f4bc4a7ada8bdf5055958'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1.02%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10.2%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;(&lt;/span&gt;&lt;span style="-aw-sdt-tag:'C_be464264c8194207a861f4cab206040c'; font-family: 'Times New Roman'"&gt;&lt;span&gt;385,200&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1.02%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1.02%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10.2%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_9014c8bd62e048859509a2426149ef61'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;0.01&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1.02%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10.2%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_99814e762c194b82bf77fe18e9120666'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-import:spaces; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Indefinite &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12.75pt"&gt;&lt;td style="width:65.32%; vertical-align:bottom; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_96b027d191d3489eb4634d84c32b33bb'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Forfeited&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1.02%; vertical-align:bottom; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10.2%; vertical-align:bottom; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-tag:'C_ebc58888ed7e443eb0bed3fbb4e296cd'"&gt;&lt;span title="&amp;amp;#13;nil='true'"&gt;&lt;/span&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1.02%; vertical-align:bottom; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1.02%; vertical-align:bottom; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10.2%; vertical-align:bottom; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-tag:'C_1cbf9c8fae99456bb1db09f419f10e3b'"&gt;&lt;span title="&amp;amp;#13;nil='true'"&gt;&lt;/span&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1.02%; vertical-align:bottom; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10.2%; vertical-align:bottom; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-tag:'C_023e956011684a2e8efc0a2c95e7aafa'"&gt;&lt;span title="&amp;amp;#13;nil='true'"&gt;&lt;/span&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12.75pt"&gt;&lt;td style="width:65.32%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_3a9cd327c03648eabee6def9efeb8a16'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Expired&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1.02%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10.2%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-tag:'C_1b9506549baa4d28b730114acf607f9d'"&gt;&lt;span title="&amp;amp;#13;nil='true'"&gt;&lt;/span&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1.02%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1.02%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10.2%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-tag:'C_ceb7f15a6ff64d289ae12ddbd0b82690'"&gt;&lt;span title="&amp;amp;#13;nil='true'"&gt;&lt;/span&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1.02%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10.2%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-tag:'C_28fd827460b74eed914d939d69a18b99'"&gt;&lt;span title="&amp;amp;#13;nil='true'"&gt;&lt;/span&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:8.4pt"&gt;&lt;td style="width:65.32%; vertical-align:bottom; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_940a2249f6b3409bbd4cf1fd3bfef304'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Total outstanding, March 31, 2025&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1.02%; vertical-align:bottom; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10.2%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_dc623020fea849eba11ebc4bfb2db46b'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;2,127,070&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1.02%; vertical-align:bottom; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1.02%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_4a782ea234b64abda040b2705b8054db'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:10.2%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_6c6bbe87d4d04a50ba3802b29e13ca71'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;15.85&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1.02%; vertical-align:bottom; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10.2%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_13fb13eaf08b49a2b57074280816ad0b'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;2.60&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12.75pt"&gt;&lt;td style="width:65.32%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_ea5e3e245b884185986e713469cfdfa7'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1.02%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10.2%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-tag:'C_57e1c8a9723f46f5b83a7dc55783fee9'"&gt;&lt;span title="&amp;amp;#13;nil='true'"&gt;&lt;/span&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1.02%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1.02%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10.2%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-tag:'C_243d18f890714f9fa13c4b72d28af692'"&gt;&lt;span title="&amp;amp;#13;nil='true'"&gt;&lt;/span&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1.02%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10.2%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-tag:'C_f31c5abd07e34d559789feb6be7b30a9'"&gt;&lt;span title="&amp;amp;#13;nil='true'"&gt;&lt;/span&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12.75pt"&gt;&lt;td style="width:65.32%; vertical-align:bottom; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_5f1d9b909eb24eac860bae5956db20ff'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1.02%; vertical-align:bottom; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10.2%; vertical-align:bottom; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-tag:'C_c4963ba6c9714c2b848973d90745bbe7'"&gt;&lt;span title="&amp;amp;#13;nil='true'"&gt;&lt;/span&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1.02%; vertical-align:bottom; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1.02%; vertical-align:bottom; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10.2%; vertical-align:bottom; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-tag:'C_00ce71b2c5d1489abe5ef8882e6eb43b'"&gt;&lt;span title="&amp;amp;#13;nil='true'"&gt;&lt;/span&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1.02%; vertical-align:bottom; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10.2%; vertical-align:bottom; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-tag:'C_87370543a6f5422cb31f728fb2213f65'"&gt;&lt;span title="&amp;amp;#13;nil='true'"&gt;&lt;/span&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12.75pt"&gt;&lt;td style="width:65.32%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_de6f15e3ec76429fb39fe3cc06dcd0b4'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Forfeited&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1.02%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10.2%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-tag:'C_1226676f1bf44f8197d4965d8019abfa'"&gt;&lt;span title="&amp;amp;#13;nil='true'"&gt;&lt;/span&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1.02%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1.02%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10.2%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-tag:'C_38dc8b6b23e14f2fb10ac0aab43b0957'"&gt;&lt;span title="&amp;amp;#13;nil='true'"&gt;&lt;/span&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1.02%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10.2%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-tag:'C_71849749deae49b1affc3ffaa76a7bf6'"&gt;&lt;span title="&amp;amp;#13;nil='true'"&gt;&lt;/span&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12.75pt"&gt;&lt;td style="width:65.32%; vertical-align:bottom; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_8cdb6926b5124838a53f846006ffe4d5'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Expired&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1.02%; vertical-align:bottom; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10.2%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-tag:'C_85eba8ce16524c9c992ae58a76b43a52'"&gt;&lt;span title="&amp;amp;#13;nil='true'"&gt;&lt;/span&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1.02%; vertical-align:bottom; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1.02%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10.2%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-tag:'C_3fa373d813a84ebaac3667eead34d3c5'"&gt;&lt;span title="&amp;amp;#13;nil='true'"&gt;&lt;/span&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1.02%; vertical-align:bottom; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10.2%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-tag:'C_b9f06ff4ca7a45779ddab62a866d8364'"&gt;&lt;span title="&amp;amp;#13;nil='true'"&gt;&lt;/span&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:13.5pt"&gt;&lt;td style="width:65.32%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_c764316e0a5941d382adb9acefbbf02d'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Total outstanding, June 30, 2025&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1.02%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10.2%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_bd4af9854bee45f4a6e8551c9ffeab14'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;2,127,070&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1.02%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1.02%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_06b30492d24443dea9f922ac7c5991eb'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:10.2%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_dd5b51e6504c4fe485896034c4ab5aaf'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;15.85&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1.02%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10.2%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_8c4c3f1235014bbd826251d11d481ada'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;2.10&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:1.3pt"&gt;&lt;td style="width:65.32%; vertical-align:bottom; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_c64851bf815b4da8863747dd5755f707'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Granted&lt;/span&gt;&lt;span style="font-size:6.67pt; vertical-align:super; font-family: 'Times New Roman'"&gt;(2)&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1.02%; vertical-align:bottom; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10.2%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_807950b3ae924a2f975de95c2d052326'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;6,338,788&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1.02%; vertical-align:bottom; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1.02%; vertical-align:bottom; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10.2%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_4fd32df330bb4ce6a8e82401cf8bfee9'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;1.65&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1.02%; vertical-align:bottom; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10.2%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_ed4130eba4504c2992f76b5ad495c647'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;3.31&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:13.5pt"&gt;&lt;td style="width:65.32%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_d9b5d3e46cf0480dbe71aa1b85fd2730'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1.02%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10.2%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;(&lt;/span&gt;&lt;span style="-aw-sdt-tag:'C_453fa426afc145e39bde490d351be1d5'; font-family: 'Times New Roman'"&gt;&lt;span&gt;878,264&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1.02%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1.02%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10.2%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_b3cd337ad3c643b98646dee9eafdf4db'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;0.001&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1.02%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10.2%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_ebf6d0f4a79044b1a96cec392910afa3'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-import:spaces; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Indefinite &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:13.5pt"&gt;&lt;td style="width:65.32%; vertical-align:bottom; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_9941868f9f2b4eeb9ad1e9a0ec7731e5'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Forfeited&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1.02%; vertical-align:bottom; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10.2%; vertical-align:bottom; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-tag:'C_f6c86e35bf8044009a4b4a9ffa2be0b9'"&gt;&lt;span title="&amp;amp;#13;nil='true'"&gt;&lt;/span&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1.02%; vertical-align:bottom; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1.02%; vertical-align:bottom; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10.2%; vertical-align:bottom; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-tag:'C_5120de4eb07c46d1a887d6f33993bd48'"&gt;&lt;span title="&amp;amp;#13;nil='true'"&gt;&lt;/span&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1.02%; vertical-align:bottom; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10.2%; vertical-align:bottom; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-tag:'C_d16cd40451854e3c9422892d316527ed'"&gt;&lt;span title="&amp;amp;#13;nil='true'"&gt;&lt;/span&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:13.5pt"&gt;&lt;td style="width:65.32%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_d493e9ce3b6e44bcb5f236c8e5cf90bc'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Expired&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1.02%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10.2%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-tag:'C_5eee2f2968084f68bd96a105a2a456ba'"&gt;&lt;span title="&amp;amp;#13;nil='true'"&gt;&lt;/span&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1.02%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1.02%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10.2%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-tag:'C_351547f4bdc341548bd95be3a56c990b'"&gt;&lt;span title="&amp;amp;#13;nil='true'"&gt;&lt;/span&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1.02%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10.2%; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-tag:'C_e5c3e7a2d1ea48788874fe6f1aaa160e'"&gt;&lt;span title="&amp;amp;#13;nil='true'"&gt;&lt;/span&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:13.5pt"&gt;&lt;td style="width:65.32%; vertical-align:bottom; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_a711a12f9677437590c66b5950b17bd5'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Total outstanding, September 30, 2025&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1.02%; vertical-align:bottom; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10.2%; border-top:0.75pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#ffffff; -aw-border-top:0.5pt single"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_8ea7f7a4e1d24d429c6f06db22b55e6d'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;7,587,594&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1.02%; vertical-align:bottom; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1.02%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_2d3b290467d343018ea51921f595758a'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:10.2%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_7047b295f89941d1bdfff27a2c97d2f6'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;5.82&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1.02%; vertical-align:bottom; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10.2%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_01e4caaff41844e1ae7feb1c2ae66d69'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;2.82&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:13.5pt"&gt;&lt;td style="width:65.32%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_d51b62342edd4404956c0bf1cb0b2079'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Total exercisable, September 30, 2025&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1.02%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10.2%; border-top:4.5pt double #000000; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_7b1ea82a944942ceb4546250d540a297'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;7,587,594&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1.02%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1.02%; border-top:4.5pt double #000000; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_f78db16daa4a48f09d41316116f43005'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:10.2%; border-top:4.5pt double #000000; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_f6c5be1b8d51432b8279c89401af163b'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;5.82&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1.02%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10.2%; border-top:4.5pt double #000000; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_28a537d0722b41f7ba4474c4041f1592'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;2.82&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman';  font-size: 12pt;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="width:100%"&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td style="width:3.3%; vertical-align:top"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:12.5pt"&gt;&lt;span style="font-size:8.33pt; vertical-align:super; font-family: 'Times New Roman'"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:96.7%; vertical-align:top"&gt;&lt;div style="-aw-sdt-tag:'cc60b45585da36d079a6'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Weighted average remaining contractual life at &lt;/span&gt;&lt;span style="-aw-sdt-tag:'cb7acd8bf727a3348920'; -aw-sdt-title:'Previous_Year_End_P16'; font-family: 'Times New Roman'"&gt;&lt;span&gt;December 31, 2024&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; excludes &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c9eaac2b3a02e0ecbfed'; font-family: 'Times New Roman'"&gt;&lt;span&gt;385,200&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; Pre-Funded Warrants issued September &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c084844e24a211ebd242'; font-family: 'Times New Roman'"&gt;&lt;span&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; that do not have a contractual expiration date, for which &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c6c65c3f0bb7343724f4'; font-family: 'Times New Roman'"&gt;&lt;span&gt;0&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; warrants remain outstanding and exercisable at March 31, 2025, June 30, 2025 and &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c3f8bf32fba6f0a28902'; -aw-sdt-title:'Current_Period_P16'; font-family: 'Times New Roman'"&gt;&lt;span&gt;September 30, 2025&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="width:100%; border-collapse:collapse"&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td style="width:3.3%; vertical-align:top"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:12.5pt"&gt;&lt;span style="font-size:8.33pt; vertical-align:super; font-family: 'Times New Roman'"&gt;(2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:96.7%; vertical-align:top"&gt;&lt;div style="-aw-sdt-tag:'4e2-557-131-530-ea28'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Weighted average remaining contractual life excludes &lt;/span&gt;&lt;span style="-aw-sdt-tag:'155-a3e-4e3-421-5e47'; font-family: 'Times New Roman'"&gt;&lt;span&gt;878,264&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; Pre-Funded Warrants issued July 2025 that do not have a contractual expiration date, for which &lt;/span&gt;&lt;span style="-aw-sdt-tag:'cfe-9a0-ea6-43f-4379'; font-family: 'Times New Roman'"&gt;&lt;span&gt;0&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; warrants remain outstanding and exercisable at &lt;/span&gt;&lt;span style="-aw-sdt-tag:'b56-24f-fd5-c1f-b53f'; -aw-sdt-title:'Current_Period_P43'; font-family: 'Times New Roman'"&gt;&lt;span&gt;September 30, 2025&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:3.3%; vertical-align:top"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:5pt"&gt;&lt;span style="font-size:3.33pt; vertical-align:super; -aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:96.7%; vertical-align:top"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:5pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="-aw-import:spaces; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="-aw-sdt-tag:'PG_2924caba445ee74c'"&gt;&lt;/div&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;The following table presents a summary of the activity for the Company&#x2019;s equity-classified warrants during the &lt;/span&gt;&lt;span style="-aw-sdt-tag:'cb837e6a667bb2d8e81a'; -aw-sdt-title:'Previous_Quarter_and_YTD_P4'; font-family: 'Times New Roman'"&gt;&lt;span&gt;three and nine months ended September 30, 2024&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;:&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="-aw-sdt-tag:'5ef-bd1-660-949-dac4'; -aw-sdt-title:'PYTD Warrant Activity Table'"&gt;&lt;table cellpadding="0" cellspacing="0" style="width:100%; border-collapse:collapse"&gt;&lt;tbody&gt;&lt;tr style="height:66pt"&gt;&lt;td style="width:66%; vertical-align:bottom"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:bottom"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:bottom"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_2fe24833a44b41479778dfa15ea39d75'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;Number of Warrants&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:bottom"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1.5pt solid #000000; vertical-align:bottom"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_f18fecd537364a0f93431550cd6beb89'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;Weighted Average Exercise Price&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:bottom"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:bottom"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_46e2237dbc934f6b9426112c9d46cff7'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;Weighted Average Remaining Contractual Life (Years)&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:13.2pt"&gt;&lt;td style="width:66%; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_e3159a48c35a441588285bc5f08adbb5'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Total outstanding, December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_26c6e8ba5c4f437b898bce96847ea990'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;52,737&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_7932e86b6155416a856e4b9e3135e6a0'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_1e1cfe2fee02428fb18bed385db26f5b'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;369.98&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_0fdf3faee9384a09b6fb1053d73cd117'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;4.47&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:13.2pt"&gt;&lt;td style="width:66%; vertical-align:middle; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_d2f19f5220f34a67a6cf0ad536ecceaf'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; vertical-align:middle; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_ca72a78fc17a4df2b8b050de41cb1fb2'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;140,884&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; vertical-align:middle; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_03da05c614d4494ab5a425272003c87d'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;22.48&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; vertical-align:middle; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_1e23442a8f184d09a6640f316b286c13'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;5.00&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:13.2pt"&gt;&lt;td style="width:66%; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_5bc3ca100224454db31571d2f7b1902d'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; vertical-align:middle; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;(&lt;/span&gt;&lt;span style="-aw-sdt-tag:'C_947713b195ad4820bbb30058fc78b8f8'; font-family: 'Times New Roman'"&gt;&lt;span&gt;8,326&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_6653a7d365a745d882b7652b6ee003cf'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;0.60&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_d11cc3479bef4b49bb34a26fb81a3dab'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-import:spaces; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Indefinite &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:13.2pt"&gt;&lt;td style="width:66%; vertical-align:middle; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_036865088ae34687ad76ec0118f6c13a'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Forfeited&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; vertical-align:middle; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-tag:'C_0b98733a323540198451b82d59cb06fc'"&gt;&lt;span title="&amp;amp;#13;nil='true'"&gt;&lt;/span&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; vertical-align:middle; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-tag:'C_b095fd6b9be94bbc8c5bffe34783b7e9'"&gt;&lt;span title="&amp;amp;#13;nil='true'"&gt;&lt;/span&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; vertical-align:middle; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-tag:'C_62e43591234846379c4d980c1b569ce5'"&gt;&lt;span title="&amp;amp;#13;nil='true'"&gt;&lt;/span&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:13.2pt"&gt;&lt;td style="width:66%; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_ed4f3a89e25f4188a6c83db8976197d5'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Expired&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-tag:'C_e3ce5466c2be49d1857c06466db44631'"&gt;&lt;span title="&amp;amp;#13;nil='true'"&gt;&lt;/span&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-tag:'C_dfdbdd8338f8414d8f83aae99237906a'"&gt;&lt;span title="&amp;amp;#13;nil='true'"&gt;&lt;/span&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-tag:'C_fe44fba7b4ea4e7aa0021a9bccd19da2'"&gt;&lt;span title="&amp;amp;#13;nil='true'"&gt;&lt;/span&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:13.8pt"&gt;&lt;td style="width:66%; vertical-align:middle; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_3d817872bae142abb1bdde9aec1609a3'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Total outstanding, March 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_c163a2b7f7f04b69b4d13a118cc458f9'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;185,295&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_2b8349367e4e49bd8341592d5d525a88'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:10%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_f13c7faf7831462aab2cb911bc2f0dd6'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;122.36&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_0005a1e335884fc7ac7b8d95109bce26'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;4.67&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:13.8pt"&gt;&lt;td style="width:66%; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_dcc561ad8f5141e9ad4b5045a2890934'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-tag:'C_88de1f197d034065b9cd32ef1dcd9706'"&gt;&lt;span title="&amp;amp;#13;nil='true'"&gt;&lt;/span&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-tag:'C_f73d194d7c854624909dcf76b8ba5ce8'"&gt;&lt;span title="&amp;amp;#13;nil='true'"&gt;&lt;/span&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-tag:'C_fb1a4c504f914dc289bb53a1b30080ae'"&gt;&lt;span title="&amp;amp;#13;nil='true'"&gt;&lt;/span&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:13.2pt"&gt;&lt;td style="width:66%; vertical-align:middle; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_a977d41b2c174189a08b961656853a60'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;(&lt;/span&gt;&lt;span style="-aw-sdt-tag:'C_79bdaacfa9994fb2b69b6344f572705f'; font-family: 'Times New Roman'"&gt;&lt;span&gt;8,326&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; vertical-align:middle; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_31638e6c276c4f2fa99250fcb9843150'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;0.60&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; vertical-align:middle; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_f5cdcd321c28407aa89715dc54333513'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-import:spaces; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Indefinite &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:13.2pt"&gt;&lt;td style="width:66%; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_fa7dd320f8ff4aac96b933a7fbc11384'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Forfeited&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-tag:'C_110cf5dfc8bd4bc080a6b64cb16f3187'"&gt;&lt;span title="&amp;amp;#13;nil='true'"&gt;&lt;/span&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-tag:'C_4a2d3439c11443f6b2da01418ec74397'"&gt;&lt;span title="&amp;amp;#13;nil='true'"&gt;&lt;/span&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-tag:'C_0da9202225b040e19c3d69fa37a95f80'"&gt;&lt;span title="&amp;amp;#13;nil='true'"&gt;&lt;/span&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:13.2pt"&gt;&lt;td style="width:66%; vertical-align:middle; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_59813ff6f1844a788243218269af1e79'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Expired&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-tag:'C_9b5fd3e6aa1b4e4cb21d298ea65de0ea'"&gt;&lt;span title="&amp;amp;#13;nil='true'"&gt;&lt;/span&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-tag:'C_f2ddee167a494c22b7bd797d8ae1c6c2'"&gt;&lt;span title="&amp;amp;#13;nil='true'"&gt;&lt;/span&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-tag:'C_7a4c7af18d3f4f77813081f40c1d117a'"&gt;&lt;span title="&amp;amp;#13;nil='true'"&gt;&lt;/span&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:13.8pt"&gt;&lt;td style="width:66%; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_a82321d8724e48d9a9d4e5fea605470a'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Total outstanding, June 30, 2024&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_2a6ee883b436439caf9659428ef1344a'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;176,969&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_aa95f7f315f940a2a5739ae21aafd495'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_dedfd6de48f64fde8de26755f4cdd4e4'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;128.09&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_79c28b5186b7430280974bffea1c6e69'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;4.41&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:4.05pt"&gt;&lt;td style="width:66%; vertical-align:middle; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_1e54e27571a64e8887f09b7346aff7c4'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Granted&lt;/span&gt;&lt;span style="font-size:6.67pt; vertical-align:super; font-family: 'Times New Roman'"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; vertical-align:middle; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_adfe2fb2d65545cba64b8094d9c2cc08'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;1,782,612&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; vertical-align:middle; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_b0770c488b2d44c0b74d38914ce1a1f4'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;4.70&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; vertical-align:middle; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-tag:'C_8a1c8815f35841ef9b2cf22465a70cbd'"&gt;&lt;span title="&amp;amp;#13;nil='true'"&gt;&lt;/span&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:4.05pt"&gt;&lt;td style="width:66%; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_e4111cde5ebf4e2db2c6ef266cda76df'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-tag:'C_667abf06483d4e4aab4ecd254ca4fb4d'"&gt;&lt;span title="&amp;amp;#13;nil='true'"&gt;&lt;/span&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-tag:'C_1b9a47ca596e4271804077a0fce457bd'"&gt;&lt;span title="&amp;amp;#13;nil='true'"&gt;&lt;/span&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-tag:'C_c7fead391f1c4bedaf8cbd7c73bfcbf9'"&gt;&lt;span title="&amp;amp;#13;nil='true'"&gt;&lt;/span&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:4.05pt"&gt;&lt;td style="width:66%; vertical-align:middle; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_19cb9448efb54e7e898444eb0f2563a8'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Forfeited&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; vertical-align:middle; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-tag:'C_60dcc17070434c6ab1cafb9462e1e3d6'"&gt;&lt;span title="&amp;amp;#13;nil='true'"&gt;&lt;/span&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; vertical-align:middle; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-tag:'C_ba07f171b24f486fa792b6c7c3444cc7'"&gt;&lt;span title="&amp;amp;#13;nil='true'"&gt;&lt;/span&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; vertical-align:middle; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-tag:'C_1e57ce7e25864bb89046552a08c0e3fc'"&gt;&lt;span title="&amp;amp;#13;nil='true'"&gt;&lt;/span&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:4.05pt"&gt;&lt;td style="width:66%; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_350af71c0b4948a6a77dfcd4075ad433'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Expired&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-tag:'C_aedbe4e189824914abc8f3a4b2bda114'"&gt;&lt;span title="&amp;amp;#13;nil='true'"&gt;&lt;/span&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-tag:'C_9d6d068f7ee644de9a393925a4cbfc15'"&gt;&lt;span title="&amp;amp;#13;nil='true'"&gt;&lt;/span&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-tag:'C_bfabe0e863a542ac80153555a0367873'"&gt;&lt;span title="&amp;amp;#13;nil='true'"&gt;&lt;/span&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:4.05pt"&gt;&lt;td style="width:66%; vertical-align:middle; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_1de26c9af20040a29472d2ca9138d19f'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Total outstanding, September 30, 2024&lt;/span&gt;&lt;span style="font-size:6.67pt; vertical-align:super; font-family: 'Times New Roman'"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_f4d9856e21884f16b54c37b835a9f33a'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;1,959,581&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_f8d0824dee194343b9daffd0ef500eda'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_2419a538771d4014a0aa04299e82b736'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;15.84&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_7ddd3f67b2d74622afae5bc4f4059994'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;4.16&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:4.05pt"&gt;&lt;td style="width:66%; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_db4c1fd8ae924d69b46bdc6baf2841b1'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Total exercisable, September 30, 2024&lt;/span&gt;&lt;span style="font-size:6.67pt; vertical-align:super; font-family: 'Times New Roman'"&gt;(2)&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; border-top:4.5pt double #000000; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_8f538a18dc5c4b0789915e07028c8a3b'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;756,680&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; border-top:4.5pt double #000000; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_b445e814ada34f288326ca954e930c27'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:10%; border-top:4.5pt double #000000; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_e1118852385841f19496c5a949e0e0bb'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;29.96&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:middle; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; border-top:4.5pt double #000000; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'a4f-f6d-3a4-587-6f95'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;4.16&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="width:100%; border-collapse:collapse"&gt;&lt;tbody&gt;&lt;tr style="height:11.5pt"&gt;&lt;td style="width:3.3%; vertical-align:top"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:12.5pt"&gt;&lt;span style="font-size:8.33pt; vertical-align:super; font-family: 'Times New Roman'"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:96.7%; vertical-align:top"&gt;&lt;div style="-aw-sdt-tag:'54e-de6-a74-b52-df70'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Weighted average remaining contractual life calculations exclude (i) &lt;/span&gt;&lt;span style="-aw-sdt-tag:'732-da0-de5-bf5-8dbb'; font-family: 'Times New Roman'"&gt;&lt;span&gt;579,711&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; Pre-Funded Warrants issued September 2024 that do not have a contractual expiration date, (ii) &lt;/span&gt;&lt;span style="-aw-sdt-tag:'f2c-5f7-8bf-af8-594f'; font-family: 'Times New Roman'"&gt;&lt;span&gt;43,479&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; September 2024 Agent Warrants and &lt;/span&gt;&lt;span style="-aw-sdt-tag:'e8a-7d2-dd0-c63-800f'; font-family: 'Times New Roman'"&gt;&lt;span&gt;579,711&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; Series A Warrants issued September 2024 that expire &lt;/span&gt;&lt;span style="-aw-sdt-tag:'316-f81-d28-80c-a600'; font-family: 'Times New Roman'"&gt;&lt;span&gt;five years&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; from the Stockholder Approval Date, defined above, and (iii) &lt;/span&gt;&lt;span style="-aw-sdt-tag:'051-85c-a14-d67-3f56'; font-family: 'Times New Roman'"&gt;&lt;span&gt;579,711&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; Series B Warrants issued September 2024 that expire &lt;/span&gt;&lt;span style="-aw-sdt-tag:'5a3-db5-072-293-bc68'; font-family: 'Times New Roman'"&gt;&lt;span&gt;eighteen months&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; from the Stockholder Approval Date, which had not yet occurred as of September 30, 2024.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.5pt"&gt;&lt;td style="width:3.3%; vertical-align:top"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:12.5pt"&gt;&lt;span style="font-size:8.33pt; vertical-align:super; font-family: 'Times New Roman'"&gt;(2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:96.7%; vertical-align:top"&gt;&lt;div style="-aw-sdt-tag:'f6b-c28-fc7-73a-bf3d'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Weighted average remaining contractual life calculation excludes &lt;/span&gt;&lt;span style="-aw-sdt-tag:'789-7d3-dde-216-e566'; font-family: 'Times New Roman'"&gt;&lt;span&gt;579,711&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; exercisable Pre-Funded Warrants issued September 2024 that do not have a contractual expiration date.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="I20241231_WarrantMember"
      decimals="0"
      id="Tag232"
      unitRef="Shares">1765070</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="I20241231_WarrantMember"
      decimals="2"
      id="Tag233"
      unitRef="USDPerShare">17.59</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms contextRef="D20241231_WarrantMember" id="Tag234">P3Y3M3D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="D20250331_WarrantMember"
      decimals="0"
      id="Tag106"
      unitRef="Shares">747200</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="D20250331_WarrantMember"
      decimals="2"
      id="Tag108"
      unitRef="USDPerShare">3.56</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <sxtp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsGranted contextRef="D20250331_WarrantMember" id="Tag112">P2Y</sxtp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsGranted>
    <sxtp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfWarrantsExercised
      contextRef="D20250331_WarrantMember"
      decimals="0"
      id="Tag40"
      unitRef="Shares">-385200</sxtp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfWarrantsExercised>
    <sxtp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExercised
      contextRef="D20250331_WarrantMember"
      decimals="2"
      id="Tag109"
      unitRef="USDPerShare">0.01</sxtp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExercised>
    <sxtp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsExercised contextRef="D20250331_WarrantMember" id="Tag111">&#160;Indefinite </sxtp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="D20250331_WarrantMember"
      id="Tag116"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="D20250331_WarrantMember"
      id="Tag117"
      unitRef="USDPerShare"
      xsi:nil="true"/>
    <sxtp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsForfeited
      contextRef="D20250331_WarrantMember"
      id="Tag118"
      xsi:nil="true"/>
    <sxtp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfWarrantsExpired
      contextRef="D20250331_WarrantMember"
      id="Tag119"
      unitRef="Shares"
      xsi:nil="true"/>
    <sxtp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExpired
      contextRef="D20250331_WarrantMember"
      id="Tag120"
      unitRef="USDPerShare"
      xsi:nil="true"/>
    <sxtp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsExpired contextRef="D20250331" id="Tag236" xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="I20250331_WarrantMember"
      decimals="0"
      id="Tag107"
      unitRef="Shares">2127070</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="I20250331_WarrantMember"
      decimals="2"
      id="Tag110"
      unitRef="USDPerShare">15.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <sxtp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms1 contextRef="D20250331_WarrantMember" id="Tag113">P2Y7M6D</sxtp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="D20250630_WarrantMember"
      id="Tag145"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="D20250630_WarrantMember"
      id="Tag155"
      unitRef="USDPerShare"
      xsi:nil="true"/>
    <sxtp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsGranted
      contextRef="D20250630_WarrantMember"
      id="Tag156"
      xsi:nil="true"/>
    <sxtp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfWarrantsExercised
      contextRef="D20250630_WarrantMember"
      id="Tag146"
      unitRef="Shares"
      xsi:nil="true"/>
    <sxtp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExercised
      contextRef="D20250630_WarrantMember"
      id="Tag154"
      unitRef="USDPerShare"
      xsi:nil="true"/>
    <sxtp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsExercised
      contextRef="D20250630_WarrantMember"
      id="Tag157"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="D20250630_WarrantMember"
      id="Tag147"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="D20250630_WarrantMember"
      id="Tag153"
      unitRef="USDPerShare"
      xsi:nil="true"/>
    <sxtp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsForfeited
      contextRef="D20250630_WarrantMember"
      id="Tag158"
      xsi:nil="true"/>
    <sxtp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfWarrantsExpired
      contextRef="D20250630_WarrantMember"
      id="Tag148"
      unitRef="Shares"
      xsi:nil="true"/>
    <sxtp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExpired
      contextRef="D20250630_WarrantMember"
      id="Tag152"
      unitRef="USDPerShare"
      xsi:nil="true"/>
    <sxtp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsExpired
      contextRef="D20250630_WarrantMember"
      id="Tag198"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="I20250630_WarrantMember"
      decimals="0"
      id="Tag149"
      unitRef="Shares">2127070</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="I20250630_WarrantMember"
      decimals="2"
      id="Tag150"
      unitRef="USDPerShare">15.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <sxtp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms1 contextRef="D20250630_WarrantMember" id="Tag151">P2Y1M6D</sxtp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="D20250930_WarrantMember"
      decimals="0"
      id="Tag226"
      unitRef="Shares">6338788</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="D20250930_WarrantMember"
      decimals="2"
      id="Tag227"
      unitRef="USDPerShare">1.65</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <sxtp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsGranted contextRef="D20250930_WarrantMember" id="Tag228">P3Y3M21D</sxtp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsGranted>
    <sxtp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfWarrantsExercised
      contextRef="D20250930_WarrantMember"
      decimals="0"
      id="Tag25"
      unitRef="Shares">878264</sxtp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfWarrantsExercised>
    <sxtp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExercised
      contextRef="D20250930_WarrantMember"
      decimals="3"
      id="Tag142"
      unitRef="USDPerShare">0.001</sxtp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExercised>
    <sxtp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsExercised contextRef="D20250930_WarrantMember" id="Tag144">&#160;Indefinite </sxtp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="D20250930_WarrantMember"
      id="Tag192"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="D20250930_WarrantMember"
      id="Tag193"
      unitRef="USDPerShare"
      xsi:nil="true"/>
    <sxtp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsForfeited
      contextRef="D20250930_WarrantMember"
      id="Tag194"
      xsi:nil="true"/>
    <sxtp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfWarrantsExpired
      contextRef="D20250930_WarrantMember"
      id="Tag195"
      unitRef="Shares"
      xsi:nil="true"/>
    <sxtp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExpired
      contextRef="D20250930_WarrantMember"
      id="Tag196"
      unitRef="USDPerShare"
      xsi:nil="true"/>
    <sxtp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsExpired
      contextRef="D20250930_WarrantMember"
      id="Tag197"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="I20250930_WarrantMember"
      decimals="0"
      id="Tag141"
      unitRef="Shares">7587594</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="I20250930_WarrantMember"
      decimals="2"
      id="Tag143"
      unitRef="USDPerShare">5.82</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <sxtp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms1 contextRef="D20250930_WarrantMember" id="Tag245">P2Y9M25D</sxtp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms1>
    <sxtp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable
      contextRef="I20250930_WarrantMember"
      decimals="0"
      id="Tag219"
      unitRef="Shares">7587594</sxtp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable>
    <sxtp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageGrantDateFairValue
      contextRef="I20250930_WarrantMember"
      decimals="2"
      id="Tag218"
      unitRef="USDPerShare">5.82</sxtp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageGrantDateFairValue>
    <sxtp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableOutstandingWeightedAverageRemainingContractualTerms contextRef="D20250930_WarrantMember" id="Tag246">P2Y9M25D</sxtp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableOutstandingWeightedAverageRemainingContractualTerms>
    <sxtp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable
      contextRef="I20240930_PreFundedWarrantMember"
      decimals="0"
      id="Tag41"
      unitRef="Shares">385200</sxtp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="I20250630_PreFundedWarrantMember"
      decimals="0"
      id="Tag1034"
      unitRef="Shares">0</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="I20250930_PreFundedWarrantMember"
      decimals="0"
      id="Tag1035"
      unitRef="Shares">0</us-gaap:ClassOfWarrantOrRightOutstanding>
    <sxtp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable
      contextRef="I20250331_PreFundedWarrantMember"
      decimals="0"
      id="Tag1030"
      unitRef="Shares">0</sxtp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable>
    <sxtp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable
      contextRef="I20250630_PreFundedWarrantMember"
      decimals="0"
      id="Tag1031"
      unitRef="Shares">0</sxtp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable>
    <sxtp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable
      contextRef="I20250930_PreFundedWarrantMember"
      decimals="0"
      id="Tag1032"
      unitRef="Shares">0</sxtp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="I20250331_PreFundedWarrantMember"
      decimals="0"
      id="Tag46"
      unitRef="Shares">0</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="D20250731_PreFundedWarrantMember"
      decimals="0"
      id="Tag42"
      unitRef="Shares">878264</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <sxtp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable
      contextRef="I20250930_PreFundedWarrantMember"
      decimals="0"
      id="Tag1033"
      unitRef="Shares">0</sxtp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="I20250930_PreFundedWarrantMember"
      decimals="0"
      id="Tag47"
      unitRef="Shares">0</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="I20231231_WarrantMember"
      decimals="0"
      id="Tag122"
      unitRef="Shares">52737</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="I20231231_WarrantMember"
      decimals="2"
      id="Tag124"
      unitRef="USDPerShare">369.98</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms contextRef="D20231231_WarrantMember" id="Tag136">P4Y5M19D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="D20240331_WarrantMember"
      decimals="0"
      id="Tag123"
      unitRef="Shares">140884</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="D20240331_WarrantMember"
      decimals="2"
      id="Tag125"
      unitRef="USDPerShare">22.48</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <sxtp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsGranted contextRef="D20240331_WarrantMember" id="Tag137">P5Y</sxtp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsGranted>
    <sxtp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfWarrantsExercised
      contextRef="D20240331_WarrantMember"
      decimals="0"
      id="Tag24"
      unitRef="Shares">-8326</sxtp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfWarrantsExercised>
    <sxtp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExercised
      contextRef="D20240331_WarrantMember"
      decimals="2"
      id="Tag126"
      unitRef="USDPerShare">0.6</sxtp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExercised>
    <sxtp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsExercised contextRef="D20240331_WarrantMember" id="Tag138">&#160;Indefinite </sxtp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="D20240331_WarrantMember"
      id="Tag128"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="D20240331_WarrantMember"
      id="Tag130"
      unitRef="USDPerShare"
      xsi:nil="true"/>
    <sxtp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsForfeited
      contextRef="D20240331_WarrantMember"
      id="Tag132"
      xsi:nil="true"/>
    <sxtp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfWarrantsExpired
      contextRef="D20240331_WarrantMember"
      id="Tag134"
      unitRef="Shares"
      xsi:nil="true"/>
    <sxtp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExpired
      contextRef="D20240331_WarrantMember"
      id="Tag129"
      unitRef="USDPerShare"
      xsi:nil="true"/>
    <sxtp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsExpired
      contextRef="D20240331_WarrantMember"
      id="Tag133"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="I20240331_WarrantMember"
      decimals="0"
      id="Tag131"
      unitRef="Shares">185295</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="I20240331_WarrantMember"
      decimals="2"
      id="Tag127"
      unitRef="USDPerShare">122.36</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <sxtp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms1 contextRef="D20240331_WarrantMember" id="Tag135">P4Y8M1D</sxtp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="D20240630_WarrantMember"
      id="Tag172"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="D20240630_WarrantMember"
      id="Tag171"
      unitRef="USDPerShare"
      xsi:nil="true"/>
    <sxtp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsGranted
      contextRef="D20240630_WarrantMember"
      id="Tag170"
      xsi:nil="true"/>
    <sxtp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfWarrantsExercised
      contextRef="D20240630_WarrantMember"
      decimals="0"
      id="Tag26"
      unitRef="Shares">-8326</sxtp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfWarrantsExercised>
    <sxtp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExercised
      contextRef="D20240630_WarrantMember"
      decimals="2"
      id="Tag159"
      unitRef="USDPerShare">0.6</sxtp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExercised>
    <sxtp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsExercised contextRef="D20240630_WarrantMember" id="Tag160">&#160;Indefinite </sxtp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="D20240630_WarrantMember"
      id="Tag164"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="D20240630_WarrantMember"
      id="Tag166"
      unitRef="USDPerShare"
      xsi:nil="true"/>
    <sxtp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsForfeited
      contextRef="D20240630_WarrantMember"
      id="Tag168"
      xsi:nil="true"/>
    <sxtp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfWarrantsExpired
      contextRef="D20240630_WarrantMember"
      id="Tag165"
      unitRef="Shares"
      xsi:nil="true"/>
    <sxtp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExpired
      contextRef="D20240630_WarrantMember"
      id="Tag167"
      unitRef="USDPerShare"
      xsi:nil="true"/>
    <sxtp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsExpired
      contextRef="D20240630_WarrantMember"
      id="Tag169"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="I20240630_WarrantMember"
      decimals="0"
      id="Tag163"
      unitRef="Shares">176969</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="I20240630_WarrantMember"
      decimals="2"
      id="Tag162"
      unitRef="USDPerShare">128.09</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <sxtp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms1 contextRef="D20240630_WarrantMember" id="Tag161">P4Y4M28D</sxtp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="D20240930_WarrantMember"
      decimals="0"
      id="Tag183"
      unitRef="Shares">1782612</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="D20240930_WarrantMember"
      decimals="2"
      id="Tag181"
      unitRef="USDPerShare">4.7</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <sxtp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsGranted
      contextRef="D20240930_WarrantMember"
      id="Tag180"
      xsi:nil="true"/>
    <sxtp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfWarrantsExercised
      contextRef="D20240930_WarrantMember"
      id="Tag182"
      unitRef="Shares"
      xsi:nil="true"/>
    <sxtp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExercised
      contextRef="D20240930_WarrantMember"
      id="Tag174"
      unitRef="USDPerShare"
      xsi:nil="true"/>
    <sxtp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsExercised
      contextRef="D20240930_WarrantMember"
      id="Tag177"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="D20240930_WarrantMember"
      id="Tag184"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="D20240930_WarrantMember"
      id="Tag175"
      unitRef="USDPerShare"
      xsi:nil="true"/>
    <sxtp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsForfeited
      contextRef="D20240930_WarrantMember"
      id="Tag178"
      xsi:nil="true"/>
    <sxtp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNumberOfWarrantsExpired
      contextRef="D20240930_WarrantMember"
      id="Tag185"
      unitRef="Shares"
      xsi:nil="true"/>
    <sxtp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageExercisePriceExpired
      contextRef="D20240930_WarrantMember"
      id="Tag176"
      unitRef="USDPerShare"
      xsi:nil="true"/>
    <sxtp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageRemainingContractualLifeYearsExpired
      contextRef="D20240930_WarrantMember"
      id="Tag179"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="I20240930_WarrantMember"
      decimals="0"
      id="Tag216"
      unitRef="Shares">1959581</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="I20240930_WarrantMember"
      decimals="2"
      id="Tag215"
      unitRef="USDPerShare">15.84</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <sxtp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms1 contextRef="D20240930_WarrantMember" id="Tag217">P4Y1M28D</sxtp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms1>
    <sxtp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable
      contextRef="I20240930_WarrantMember"
      decimals="0"
      id="Tag231"
      unitRef="Shares">756680</sxtp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisable>
    <sxtp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageGrantDateFairValue
      contextRef="I20240930_WarrantMember"
      decimals="2"
      id="Tag230"
      unitRef="USDPerShare">29.96</sxtp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableWeightedAverageGrantDateFairValue>
    <sxtp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableOutstandingWeightedAverageRemainingContractualTerms contextRef="D20240930_WarrantMember_1" id="Tag229">P4Y1M28D</sxtp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisableOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="D20240930_PreFundedWarrantMember"
      decimals="0"
      id="Tag33"
      unitRef="Shares">579711</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="D20240930_SeptemberTwoThousandTwentyFourAgentWarrantsMember"
      decimals="0"
      id="Tag44"
      unitRef="Shares">43479</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="D20240930_SeriesAWarrantsMember"
      decimals="0"
      id="Tag43"
      unitRef="Shares">579711</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="I20240930_SeriesAPreferredStockMember"
      id="Tag48">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="D20240930_SeriesBWarrantsMember"
      decimals="0"
      id="Tag45"
      unitRef="Shares">579711</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="I20240930_SeriesBWarrantsMember" id="Tag28">P18M</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="D20240930_PreFundedWarrantMember"
      decimals="0"
      id="Tag34"
      unitRef="Shares">579711</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:PreferredStockConvertibleSharesIssuable
      contextRef="I20250930_SeriesAPreferredStockMember"
      decimals="0"
      id="Tag841"
      unitRef="Shares">0</us-gaap:PreferredStockConvertibleSharesIssuable>
    <us-gaap:PreferredStockConvertibleSharesIssuable
      contextRef="I20240930_SeriesAPreferredStockMember"
      decimals="0"
      id="Tag842"
      unitRef="Shares">2323</us-gaap:PreferredStockConvertibleSharesIssuable>
    <us-gaap:CommonStockSharesIssued
      contextRef="I20250930_ConvertibleCommonStockMember"
      decimals="0"
      id="Tag843"
      unitRef="Shares">0</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="I20240930_ConvertibleCommonStockMember"
      decimals="0"
      id="Tag844"
      unitRef="Shares">14667</us-gaap:CommonStockSharesIssued>
    <us-gaap:PreferredStockDividendRatePercentage
      contextRef="D20241231"
      decimals="3"
      id="Tag797"
      unitRef="Pure">0.06</us-gaap:PreferredStockDividendRatePercentage>
    <us-gaap:DividendsPreferredStock
      contextRef="D20250930_SeriesAPreferredStockMember_1"
      decimals="0"
      id="Tag802"
      unitRef="USD">128097</us-gaap:DividendsPreferredStock>
    <us-gaap:DividendsPreferredStock
      contextRef="D20250930_SeriesAPreferredStockMember"
      decimals="0"
      id="Tag803"
      unitRef="USD">372960</us-gaap:DividendsPreferredStock>
    <us-gaap:DividendsPreferredStock
      contextRef="D20240930_SeriesAPreferredStockMember_1"
      decimals="0"
      id="Tag804"
      unitRef="USD">116571</us-gaap:DividendsPreferredStock>
    <us-gaap:DividendsPreferredStock
      contextRef="D20240930_SeriesAPreferredStockMember"
      decimals="0"
      id="Tag805"
      unitRef="USD">352333</us-gaap:DividendsPreferredStock>
    <us-gaap:DividendsPreferredStock
      contextRef="D20250930_1"
      decimals="0"
      id="Tag798"
      unitRef="USD">1076975</us-gaap:DividendsPreferredStock>
    <us-gaap:CommonStockConvertibleConversionPriceIncrease
      contextRef="D20250930_SeriesAPreferredStockMember"
      decimals="0"
      id="Tag799"
      unitRef="USDPerShare">100</us-gaap:CommonStockConvertibleConversionPriceIncrease>
    <us-gaap:PreferredStockDividendRatePercentage
      contextRef="D20250930_SeriesAPreferredStockMember"
      decimals="3"
      id="Tag800"
      unitRef="Pure">0.199</us-gaap:PreferredStockDividendRatePercentage>
    <us-gaap:StockholdersEquityReverseStockSplit
      contextRef="D20250930_SeriesAPreferredStockMember"
      id="Tag819">as adjusted for the 1:12 Reverse Stock Split after August 12, 2024 and the 1:5 Reverse Stock Split after February 24, 2025</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="I20250930_IPOMember"
      decimals="0"
      id="Tag801"
      unitRef="USDPerShare">300</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:DebtDisclosureTextBlock contextRef="D20250930_1" id="Tag967">&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;7. DEBT&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;On May 14, 2020, the Company received COVID-19 EIDL lending from the U.S. Small Business Administration (SBA) in the amount of $&lt;/span&gt;&lt;span style="-aw-sdt-tag:'c48cb4c9162d422015d4'; font-family: 'Times New Roman'"&gt;&lt;span&gt;150,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;. The loan bears interest at an annual rate of &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c6f785f17e52ccfa7dc3'; font-family: 'Times New Roman'"&gt;&lt;span&gt;3.75&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;% calculated on a monthly basis. Monthly payments of $&lt;/span&gt;&lt;span style="-aw-sdt-tag:'ce8d5e1c3a4b0eab7645'; font-family: 'Times New Roman'"&gt;&lt;span&gt;731&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; were required beginning in November 2022, with a final balloon payment equal to the remaining principal due at the maturity date of &lt;/span&gt;&lt;span style="-aw-sdt-tag:'cc3ad40f0dbc4577a481'; font-family: 'Times New Roman'"&gt;&lt;span&gt;October 12, 2050&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;. The balance as of &lt;/span&gt;&lt;span style="-aw-sdt-tag:'cd38c0f163fbd87499cc'; -aw-sdt-title:'Current_Period_P8'; font-family: 'Times New Roman'"&gt;&lt;span&gt;September 30, 2025&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; and &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c5acf3df8535129173ae'; -aw-sdt-title:'Previous_Year_End_P10'; font-family: 'Times New Roman'"&gt;&lt;span&gt;December 31, 2024&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; was $&lt;/span&gt;&lt;span style="-aw-sdt-tag:'c87f7d68622df072b284'; -aw-sdt-title:'Total Maturity_CP'; font-family: 'Times New Roman'"&gt;&lt;span&gt;153,764&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; and $&lt;/span&gt;&lt;span style="-aw-sdt-tag:'cc7ee715ff42ce67d2e4'; -aw-sdt-title:'Total Maturity_PY'; font-family: 'Times New Roman'"&gt;&lt;span&gt;155,891&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;, respectively. The current maturity at &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c5a0ccdcf213162f587b'; -aw-sdt-title:'Current_Period_P9'; font-family: 'Times New Roman'"&gt;&lt;span&gt;September 30, 2025&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; is $&lt;/span&gt;&lt;span style="-aw-sdt-tag:'ce635aff7ad263800b94'; -aw-sdt-title:'Current maturity of SBA loan_CP'; font-family: 'Times New Roman'"&gt;&lt;span&gt;8,772&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; and the long-term liability is $&lt;/span&gt;&lt;span style="-aw-sdt-tag:'cfdb6cde5a192d0a563f'; -aw-sdt-title:'Long-term maturity of SBA loan_CP'; font-family: 'Times New Roman'"&gt;&lt;span&gt;144,992&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; ($&lt;/span&gt;&lt;span style="-aw-sdt-tag:'ce15e0c8eedcfdb512e2'; -aw-sdt-title:'Current maturity of SBA loan_PY'; font-family: 'Times New Roman'"&gt;&lt;span&gt;8,772&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; and $&lt;/span&gt;&lt;span style="-aw-sdt-tag:'c6ea72e7c7e452607500'; -aw-sdt-title:'Long-term maturity of SBA loan_PY'; font-family: 'Times New Roman'"&gt;&lt;span&gt;147,119&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; at &lt;/span&gt;&lt;span style="-aw-sdt-tag:'ce2f78b521ed062187e6'; -aw-sdt-title:'Previous_Year_End_P11'; font-family: 'Times New Roman'"&gt;&lt;span&gt;December 31, 2024&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;, respectively). The loan is collateralized by all tangible and intangible personal property of the Company. The Company is prohibited from accepting future advances under any superior liens on the collateral without the prior consent of SBA.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="-aw-sdt-tag:'PG_c57a1a7c3051a319b430'"&gt;&lt;/div&gt;&lt;div style="-aw-sdt-tag:'cd9aa1ed7e4867c19560'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;The current future payment obligations of the principal are as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="-aw-sdt-tag:'c317e04dae973ecfbe43'; -aw-sdt-title:'DEBT T1'"&gt;&lt;table cellpadding="0" cellspacing="0" style="width:100%; border-collapse:collapse"&gt;&lt;tbody&gt;&lt;tr style="height:11.5pt"&gt;&lt;td style="width:88%; border-bottom:1.5pt solid #000000; vertical-align:bottom"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_5c968b0016b149cfb1f12fa47b1bca41'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;Period&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; padding-bottom:1.75pt; vertical-align:bottom"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1.5pt solid #000000; vertical-align:bottom"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_5c764bbf41d64098a324b0fa0eee9c97'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;Principal Payments&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.5pt"&gt;&lt;td style="width:88%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_0bb61a42b37543a7b09da928c987f7ac'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;2025 (remaining three months)&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_ed70aeb871a64cbcae4e1e638cd44d8c'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:10%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-tag:'C_9cc5803ea7e44342b95a83be6a937207'"&gt;&lt;span title="&amp;amp;#13;nil='true'"&gt;&lt;/span&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.5pt"&gt;&lt;td style="width:88%; vertical-align:bottom"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_897e8cb5c5764f54bf36adbea961583d'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:bottom"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:bottom"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; vertical-align:bottom"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_11851a9e806d4f58b44ce574ad2a99ae'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;465&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.5pt"&gt;&lt;td style="width:88%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_bd218f23a8534654beb35d354f005013'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;2027&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_9e76a127fe434806b75dd7251717545a'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;3,220&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.5pt"&gt;&lt;td style="width:88%; vertical-align:bottom"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_5f57e987c26c48cb8368c698d86412c7'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;2028&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:bottom"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:bottom"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; vertical-align:bottom"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_a641af32d4f142d4896d4e72026bfbf6'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;3,333&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.5pt"&gt;&lt;td style="width:88%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_39e1010cfe6e4fc0b5e28f5cfced0432'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;2029&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_b3e786a7693a420dbcb23ba7b9111b35'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;3,470&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.5pt"&gt;&lt;td style="width:88%; padding-bottom:1.75pt; vertical-align:bottom"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_61dc3ec600314411bf83aaf42b0afb2c'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Thereafter&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; padding-bottom:1.75pt; vertical-align:bottom"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:bottom"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_d9ea3ec1cd2f4f809bcc21cdbccf2901'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;139,512&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.5pt"&gt;&lt;td style="width:88%; padding-bottom:4.25pt; vertical-align:bottom; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_5b82b081b0cd4cd7810fcd446de801b1'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; padding-bottom:4.25pt; vertical-align:bottom; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_0749ec546c48465eb63ec47c309b1dfa'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_cfd83dce046d4d62badcc6025377dc63'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;150,000&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="I20200514_SmallBusinessAdministrationMember"
      decimals="0"
      id="Tag770"
      unitRef="USD">150000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="I20200514_SmallBusinessAdministrationMember"
      decimals="4"
      id="Tag771"
      unitRef="Pure">0.0375</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid
      contextRef="I20200514_BalloonPaymentMember"
      decimals="0"
      id="Tag772"
      unitRef="USD">731</us-gaap:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid>
    <us-gaap:DebtInstrumentMaturityDate contextRef="D20200514_SBAMember" id="Tag773">2050-10-12</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="D20250930_1"
      decimals="0"
      id="Tag774"
      unitRef="USD">153764</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="D20241231"
      decimals="0"
      id="Tag775"
      unitRef="USD">155891</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:LongTermDebtCurrent
      contextRef="I20250930"
      decimals="0"
      id="Tag776"
      unitRef="USD">8772</us-gaap:LongTermDebtCurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="I20250930"
      decimals="0"
      id="Tag777"
      unitRef="USD">144992</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="I20241231"
      decimals="0"
      id="Tag778"
      unitRef="USD">8772</us-gaap:LongTermDebtCurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="I20241231"
      decimals="0"
      id="Tag779"
      unitRef="USD">147119</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock contextRef="D20250930_1" id="Tag922">&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;The current future payment obligations of the principal are as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="-aw-sdt-tag:'c317e04dae973ecfbe43'; -aw-sdt-title:'DEBT T1'"&gt;&lt;table cellpadding="0" cellspacing="0" style="width:100%; border-collapse:collapse"&gt;&lt;tbody&gt;&lt;tr style="height:11.5pt"&gt;&lt;td style="width:88%; border-bottom:1.5pt solid #000000; vertical-align:bottom"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_5c968b0016b149cfb1f12fa47b1bca41'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;Period&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; padding-bottom:1.75pt; vertical-align:bottom"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1.5pt solid #000000; vertical-align:bottom"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_5c764bbf41d64098a324b0fa0eee9c97'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;Principal Payments&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.5pt"&gt;&lt;td style="width:88%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_0bb61a42b37543a7b09da928c987f7ac'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;2025 (remaining three months)&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_ed70aeb871a64cbcae4e1e638cd44d8c'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:10%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-tag:'C_9cc5803ea7e44342b95a83be6a937207'"&gt;&lt;span title="&amp;amp;#13;nil='true'"&gt;&lt;/span&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.5pt"&gt;&lt;td style="width:88%; vertical-align:bottom"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_897e8cb5c5764f54bf36adbea961583d'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:bottom"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:bottom"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; vertical-align:bottom"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_11851a9e806d4f58b44ce574ad2a99ae'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;465&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.5pt"&gt;&lt;td style="width:88%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_bd218f23a8534654beb35d354f005013'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;2027&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_9e76a127fe434806b75dd7251717545a'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;3,220&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.5pt"&gt;&lt;td style="width:88%; vertical-align:bottom"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_5f57e987c26c48cb8368c698d86412c7'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;2028&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:bottom"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:bottom"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; vertical-align:bottom"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_a641af32d4f142d4896d4e72026bfbf6'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;3,333&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.5pt"&gt;&lt;td style="width:88%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_39e1010cfe6e4fc0b5e28f5cfced0432'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;2029&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_b3e786a7693a420dbcb23ba7b9111b35'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;3,470&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.5pt"&gt;&lt;td style="width:88%; padding-bottom:1.75pt; vertical-align:bottom"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_61dc3ec600314411bf83aaf42b0afb2c'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Thereafter&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; padding-bottom:1.75pt; vertical-align:bottom"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:bottom"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_d9ea3ec1cd2f4f809bcc21cdbccf2901'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;139,512&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.5pt"&gt;&lt;td style="width:88%; padding-bottom:4.25pt; vertical-align:bottom; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_5b82b081b0cd4cd7810fcd446de801b1'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; padding-bottom:4.25pt; vertical-align:bottom; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_0749ec546c48465eb63ec47c309b1dfa'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_cfd83dce046d4d62badcc6025377dc63'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;150,000&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
      contextRef="I20250930"
      id="Tag104"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
      contextRef="I20250930"
      decimals="0"
      id="Tag98"
      unitRef="USD">465</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
      contextRef="I20250930"
      decimals="0"
      id="Tag99"
      unitRef="USD">3220</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
      contextRef="I20250930"
      decimals="0"
      id="Tag100"
      unitRef="USD">3333</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
      contextRef="I20250930"
      decimals="0"
      id="Tag101"
      unitRef="USD">3470</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive
      contextRef="I20250930"
      decimals="0"
      id="Tag102"
      unitRef="USD">139512</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive>
    <us-gaap:LongTermDebt
      contextRef="I20250930"
      decimals="0"
      id="Tag103"
      unitRef="USD">150000</us-gaap:LongTermDebt>
    <us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock contextRef="D20250930_1" id="Tag971">&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;8. DERIVATIVE LIABILITIES&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;In accordance with the provisions of ASC 815, derivative liabilities are initially measured at fair value at the commitment date and subsequently remeasured at each reporting period, with any increase or decrease in the fair value recorded in the results of operations within other income/expense as the change in fair value of derivative liabilities.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;As of &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c5350c81469bdad05f66'; -aw-sdt-title:'Current_Period_P3'; font-family: 'Times New Roman'"&gt;&lt;span&gt;September 30, 2025&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; and &lt;/span&gt;&lt;span style="-aw-sdt-tag:'cc24fc16174c59980f1b'; -aw-sdt-title:'Previous_Year_End_P5'; font-family: 'Times New Roman'"&gt;&lt;span&gt;December 31, 2024&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;, derivative liabilities consist of the contingent milestone payment due to Knight Therapeutics, Inc. (&#x201c;Knight&#x201d;), a former lender of the Company, as required by the Debt Conversion Agreement executed between the Company and Knight on January 9, 2023, as subsequently amended (the &#x201c;Knight Debt Conversion Agreement&#x201d;). Key points of this agreement were as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="width:100%"&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td style="width:18pt; vertical-align:top"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:18pt; vertical-align:top"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#x25cf;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;The Parties agreed to fix Knight&#x2019;s cumulative debt to the value as it stood on March 31, 2022, which consisted of&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;principal and accumulated interest. As a result of the completion of the IPO, the cumulative outstanding principal as of March 31, 2022 converted to &lt;/span&gt;&lt;span style="-aw-sdt-tag:'fae-f38-9d2-e8b-9372'; font-family: 'Times New Roman'"&gt;&lt;span&gt;18,473&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; shares of common stock (representing &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c9be0aef95d1594431cf'; font-family: 'Times New Roman'"&gt;&lt;span&gt;19.9&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;% ownership of the Company&#x2019;s common stock after giving effect to the IPO), and the entirety of the accumulated interest as of March 31, 2022 converted into &lt;/span&gt;&lt;span style="-aw-sdt-tag:'b9a-c0f-a3d-679-5200'; font-family: 'Times New Roman'"&gt;&lt;span&gt;80,965&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; shares of Series A Preferred Stock, in full satisfaction of the Company&#x2019;s obligations with respect to the outstanding principal and accumulated interest.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="width:100%"&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td style="width:18pt; vertical-align:top"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:18pt; vertical-align:top"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#x25cf;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;The Parties agreed that the Company will make a milestone payment of $&lt;/span&gt;&lt;span style="-aw-sdt-tag:'327-c72-933-ea9-2221'; font-family: 'Times New Roman'"&gt;&lt;span&gt;10&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; million to Knight if, after the IPO, the Company sells Arakoda&#x2122; or if a Change of Control (as per the definition included in the original loan agreement dated on December 10, 2015) occurs, provided that the purchaser of Arakoda&#x2122; or individual or entity gaining control of the Borrower is not the Lender or an affiliate of the Lender.&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="width:100%"&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td style="width:18pt; vertical-align:top"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:18pt; vertical-align:top"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#x25cf;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="-aw-sdt-tag:'675-b6d-46f-99f-ad14'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;For the period ending upon the earlier of (i) &lt;/span&gt;&lt;span style="-aw-sdt-tag:'550-977-3ca-73c-4910'; font-family: 'Times New Roman'"&gt;&lt;span&gt;10 years&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; after the closing of the IPO, or (ii) the conversion or redemption in full of the Series A Preferred Stock, the Company will pay to Knight a royalty equal to &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c0b4d8ca01f4210c3db8'; font-family: 'Times New Roman'"&gt;&lt;span&gt;3.5&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;% of the Company&#x2019;s net sales (the &#x201c;Royalty&#x201d;) on a quarterly basis, where &#x201c;Net Sales&#x201d; has the same meaning as in the Company&#x2019;s license agreement with the U.S. Army for tafenoquine.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Upon consummation of the IPO, the Company concluded that the contingent milestone payment is a freestanding financial instrument that meets the definition of a derivative under ASC 815, and accordingly, the fair value of the derivative liability is marked to market each reporting period until settled. The Royalty due to Knight was determined to be an embedded component of the Series A Preferred Stock, however, is exempt from derivative accounting under the ASC 815 scope exception for specified volumes of sales or service revenues. Therefore, the Company accrues a royalty expense as sales are made.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;The valuation of the contingent milestone payment includes significant unobservable inputs such as the timing and probability of discrete potential exit scenarios, forward interest rate curves, and discount rates based on implied and market yields.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="-aw-sdt-tag:'c06f707a4f647dbf011d'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;A reconciliation of the beginning and ending balances for the derivative liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) is as follows for the &lt;/span&gt;&lt;span style="-aw-sdt-tag:'ca75fd2c5ebfac9ccdc1'; -aw-sdt-title:'Current_Quarter_and_YTD_P7'; font-family: 'Times New Roman'"&gt;&lt;span&gt;three and nine months ended September 30, 2025&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;:&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="-aw-sdt-tag:'c6639d815e653fadd5ae'; -aw-sdt-title:'DERIVATIVE LIABILITIES T1'"&gt;&lt;table cellpadding="0" cellspacing="0" style="width:100%; border-collapse:collapse"&gt;&lt;tbody&gt;&lt;tr style="height:11.5pt"&gt;&lt;td style="width:88%; vertical-align:bottom"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1.14%; vertical-align:bottom"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1.5pt solid #000000; vertical-align:bottom"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_fd577863c4914b8ea632e84e6f1d9eec'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;Contingent Milestone Payment&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.5pt"&gt;&lt;td style="width:88%; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_ff0051b243e64116bbf90efbe05a88e3'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Derivative&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;liabilities - December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1.14%; vertical-align:middle; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_ef378dbe0e17475fa21c77879bdff28f'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_c7aae7bfd1584e14a5a3a5d58fab1fd6'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;640,830&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.5pt"&gt;&lt;td style="width:88%; vertical-align:middle; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_4377246d44bb4cfc863de19c989a5202'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Change in fair value&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1.14%; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;(&lt;/span&gt;&lt;span style="-aw-sdt-tag:'C_c327358aecad485cba82f75897b00fec'; font-family: 'Times New Roman'"&gt;&lt;span&gt;5,105&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.5pt"&gt;&lt;td style="width:88%; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_5a97f90a3edd45afa8a36844a79b2ea4'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Derivative&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;liabilities - March 31, 2025&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1.14%; vertical-align:middle; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_9f633fdc6b9242d381ac51540e4153ee'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;635,725&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.5pt"&gt;&lt;td style="width:88%; vertical-align:middle; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_078e4af6f8af42d295052694ed2c2427'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Change in fair value&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1.14%; vertical-align:bottom; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_23198fd411e74a64b8eeef85300e3dcf'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;140,447&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.5pt"&gt;&lt;td style="width:88%; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_9462c6e0577448ed88294c1d0aae294c'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Derivative&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;liabilities - June 30, 2025&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1.14%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_a0832472ffb74935b23fb706f1e8f50b'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;776,172&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.5pt"&gt;&lt;td style="width:88%; vertical-align:middle; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_2150e1d56b154f04bf9d302078fa6006'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Change in fair value&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1.14%; vertical-align:bottom; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_ae80a322a7494033b888a0b4927f3dcd'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;21,103&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.5pt"&gt;&lt;td style="width:88%; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_adfe59ed6a5b4ce1ad247b7d83b2b16e'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Derivative&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;liabilities - September 30, 2025&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1.14%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_fc90d64ea50e4c308d229a9c947721a7'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_8c7042f142d54906ae51e9d2fb2300b4'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;797,275&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="-aw-sdt-tag:'PG_c50ece2c23a2dc4329b4'"&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="-aw-sdt-tag:'c06f707a4f647dbf011d'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;A reconciliation of the beginning and ending balances for the derivative liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) is as follows for the &lt;/span&gt;&lt;span style="-aw-sdt-tag:'cd848d58778f479d6fa9'; -aw-sdt-title:'Previous_Quarter_and_YTD_P3'; font-family: 'Times New Roman'"&gt;&lt;span&gt;three and nine months ended September 30, 2024&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;:&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="width:100%; border-collapse:collapse"&gt;&lt;tbody&gt;&lt;tr style="height:11.5pt"&gt;&lt;td style="width:88%; vertical-align:bottom"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1.14%; vertical-align:bottom"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1.5pt solid #000000; vertical-align:bottom"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_9b7bbdd2b0ad450593bb39fcb5204a2d'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;Contingent Milestone Payment&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.5pt"&gt;&lt;td style="width:88%; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_349fc0c506ae466a8afcdbfdf7eb138c'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Derivative&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;liabilities - December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1.14%; vertical-align:middle; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_e6028efd12ee4fa482ca3e0bf101af8e'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_7ab6157566fd406ba29b6922a10b9ec9'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;2,306,796&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.5pt"&gt;&lt;td style="width:88%; vertical-align:middle; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_c6bf1ed06ead4adf9f2296394e5d94fe'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Change in fair value&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1.14%; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;(&lt;/span&gt;&lt;span style="-aw-sdt-tag:'C_fd1f212ea84445ea8753de1b222fe7fa'; font-family: 'Times New Roman'"&gt;&lt;span&gt;1,740,847&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.5pt"&gt;&lt;td style="width:88%; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_ebba7a73ac5447149cff86376061747e'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Derivative&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;liabilities - March 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1.14%; vertical-align:middle; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_6c58f57330b54183b08d956ee1ecbd60'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;565,949&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.5pt"&gt;&lt;td style="width:88%; vertical-align:middle; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_a251d932ed0f4f349433c36d59e8d1c5'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Change in fair value&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1.14%; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_f59f8bc8d656446584c1334e2dc483b9'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;1,101&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.5pt"&gt;&lt;td style="width:88%; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_a2f0ff1379314111b76e648c5de945d5'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Derivative&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;liabilities - June 30, 2024&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1.14%; vertical-align:middle; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_2dbbcbe08cd646c49d4ad4090192625e'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;567,050&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.5pt"&gt;&lt;td style="width:88%; vertical-align:middle; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_97ca7a3e4491452f85dadb11644bd7ed'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Change in fair value&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1.14%; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_b81e163c70f24c44b27596e3b6f00f4d'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;56,712&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.5pt"&gt;&lt;td style="width:88%; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_2d719b55a9614add8a41b0e7dc9bd875'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Derivative&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;liabilities - September 30, 2024&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1.14%; vertical-align:middle; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_28189adff441454eb8ae6052808da967'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_1e958d79d6f442799205fed39a546989'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;623,762&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Changes in the fair value of derivative liabilities are included in &lt;/span&gt;&lt;span style="-aw-sdt-tag:'336-1f6-b4d-7ae-89fc'; -aw-sdt-title:'Other_income_(expense)_P1'; font-family: 'Times New Roman'"&gt;&lt;span&gt;other income (expense)&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; in the accompanying consolidated condensed statements of operations and comprehensive loss. During the &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c7a870c15245e746541a'; -aw-sdt-title:'Current_YTD_P10'; font-family: 'Times New Roman'"&gt;&lt;span&gt;nine months ended September 30, 2025&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; and &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c515be331bb8d4793eb8'; -aw-sdt-title:'Previous_Year_P12'; font-family: 'Times New Roman'"&gt;&lt;span&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;, the Company recorded a net (loss) gain on the change in the fair value of derivative liabilities of ($&lt;/span&gt;&lt;span style="-aw-sdt-tag:'c77e4e2e8d34f16dd511'; -aw-sdt-title:'CYTD_Change in FV Derivatives'; font-family: 'Times New Roman'"&gt;&lt;span&gt;156,445&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;) and $&lt;/span&gt;&lt;span style="-aw-sdt-tag:'c93e5c070ddcafae864d'; -aw-sdt-title:'PYTD_Change in FV Derivatives'; font-family: 'Times New Roman'"&gt;&lt;span&gt;1,683,034&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;, respectively.&lt;/span&gt;&lt;/p&gt;</us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="D20220331"
      decimals="0"
      id="Tag286"
      unitRef="Shares">18473</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:SaleOfStockPercentageOfOwnershipAfterTransaction
      contextRef="D20220331"
      decimals="3"
      id="Tag252"
      unitRef="Pure">0.199</us-gaap:SaleOfStockPercentageOfOwnershipAfterTransaction>
    <us-gaap:ExcessStockSharesAuthorized
      contextRef="I20220331_SeriesANonVotingConvertiblePreferredStockMember"
      decimals="0"
      id="Tag287"
      unitRef="Shares">80965</us-gaap:ExcessStockSharesAuthorized>
    <sxtp:MilestonePayment
      contextRef="D20250930_1"
      decimals="-6"
      id="Tag285"
      unitRef="USD">10000000</sxtp:MilestonePayment>
    <us-gaap:PreferredStockRedemptionTerms contextRef="D20250930_1" id="Tag638">For the period ending upon the earlier of (i) 10 years after the closing of the IPO, or (ii) the conversion or redemption in full of the Series A Preferred Stock, the Company will pay to Knight a royalty equal to 3.5% of the Company&#x2019;s net sales (the &#x201c;Royalty&#x201d;) on a quarterly basis, where &#x201c;Net Sales&#x201d; has the same meaning as in the Company&#x2019;s license agreement with the U.S. Army for tafenoquine.</us-gaap:PreferredStockRedemptionTerms>
    <sxtp:RoyaltyPercentage
      contextRef="D20250930_1"
      decimals="3"
      id="Tag105"
      unitRef="Pure">0.035</sxtp:RoyaltyPercentage>
    <us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock contextRef="D20250930_1" id="Tag934">&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;A reconciliation of the beginning and ending balances for the derivative liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) is as follows for the &lt;/span&gt;&lt;span style="-aw-sdt-tag:'ca75fd2c5ebfac9ccdc1'; -aw-sdt-title:'Current_Quarter_and_YTD_P7'; font-family: 'Times New Roman'"&gt;&lt;span&gt;three and nine months ended September 30, 2025&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;:&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="-aw-sdt-tag:'c6639d815e653fadd5ae'; -aw-sdt-title:'DERIVATIVE LIABILITIES T1'"&gt;&lt;table cellpadding="0" cellspacing="0" style="width:100%; border-collapse:collapse"&gt;&lt;tbody&gt;&lt;tr style="height:11.5pt"&gt;&lt;td style="width:88%; vertical-align:bottom"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1.14%; vertical-align:bottom"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1.5pt solid #000000; vertical-align:bottom"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_fd577863c4914b8ea632e84e6f1d9eec'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;Contingent Milestone Payment&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.5pt"&gt;&lt;td style="width:88%; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_ff0051b243e64116bbf90efbe05a88e3'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Derivative&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;liabilities - December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1.14%; vertical-align:middle; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_ef378dbe0e17475fa21c77879bdff28f'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_c7aae7bfd1584e14a5a3a5d58fab1fd6'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;640,830&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.5pt"&gt;&lt;td style="width:88%; vertical-align:middle; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_4377246d44bb4cfc863de19c989a5202'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Change in fair value&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1.14%; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;(&lt;/span&gt;&lt;span style="-aw-sdt-tag:'C_c327358aecad485cba82f75897b00fec'; font-family: 'Times New Roman'"&gt;&lt;span&gt;5,105&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.5pt"&gt;&lt;td style="width:88%; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_5a97f90a3edd45afa8a36844a79b2ea4'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Derivative&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;liabilities - March 31, 2025&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1.14%; vertical-align:middle; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_9f633fdc6b9242d381ac51540e4153ee'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;635,725&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.5pt"&gt;&lt;td style="width:88%; vertical-align:middle; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_078e4af6f8af42d295052694ed2c2427'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Change in fair value&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1.14%; vertical-align:bottom; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:bottom; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_23198fd411e74a64b8eeef85300e3dcf'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;140,447&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.5pt"&gt;&lt;td style="width:88%; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_9462c6e0577448ed88294c1d0aae294c'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Derivative&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;liabilities - June 30, 2025&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1.14%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_a0832472ffb74935b23fb706f1e8f50b'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;776,172&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.5pt"&gt;&lt;td style="width:88%; vertical-align:middle; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_2150e1d56b154f04bf9d302078fa6006'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Change in fair value&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1.14%; vertical-align:bottom; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_ae80a322a7494033b888a0b4927f3dcd'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;21,103&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.5pt"&gt;&lt;td style="width:88%; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_adfe59ed6a5b4ce1ad247b7d83b2b16e'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Derivative&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;liabilities - September 30, 2025&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1.14%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_fc90d64ea50e4c308d229a9c947721a7'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_8c7042f142d54906ae51e9d2fb2300b4'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;797,275&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="-aw-sdt-tag:'PG_c50ece2c23a2dc4329b4'"&gt;&lt;/div&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;A reconciliation of the beginning and ending balances for the derivative liabilities measured at fair value on a recurring basis using significant unobservable inputs (Level 3) is as follows for the &lt;/span&gt;&lt;span style="-aw-sdt-tag:'cd848d58778f479d6fa9'; -aw-sdt-title:'Previous_Quarter_and_YTD_P3'; font-family: 'Times New Roman'"&gt;&lt;span&gt;three and nine months ended September 30, 2024&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;:&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="width:100%; border-collapse:collapse"&gt;&lt;tbody&gt;&lt;tr style="height:11.5pt"&gt;&lt;td style="width:88%; vertical-align:bottom"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1.14%; vertical-align:bottom"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1.5pt solid #000000; vertical-align:bottom"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_9b7bbdd2b0ad450593bb39fcb5204a2d'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;Contingent Milestone Payment&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.5pt"&gt;&lt;td style="width:88%; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_349fc0c506ae466a8afcdbfdf7eb138c'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Derivative&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;liabilities - December 31, 2023&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1.14%; vertical-align:middle; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_e6028efd12ee4fa482ca3e0bf101af8e'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:10%; border-top:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_7ab6157566fd406ba29b6922a10b9ec9'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;2,306,796&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.5pt"&gt;&lt;td style="width:88%; vertical-align:middle; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_c6bf1ed06ead4adf9f2296394e5d94fe'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Change in fair value&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1.14%; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;(&lt;/span&gt;&lt;span style="-aw-sdt-tag:'C_fd1f212ea84445ea8753de1b222fe7fa'; font-family: 'Times New Roman'"&gt;&lt;span&gt;1,740,847&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.5pt"&gt;&lt;td style="width:88%; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_ebba7a73ac5447149cff86376061747e'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Derivative&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;liabilities - March 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1.14%; vertical-align:middle; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_6c58f57330b54183b08d956ee1ecbd60'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;565,949&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.5pt"&gt;&lt;td style="width:88%; vertical-align:middle; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_a251d932ed0f4f349433c36d59e8d1c5'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Change in fair value&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1.14%; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_f59f8bc8d656446584c1334e2dc483b9'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;1,101&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.5pt"&gt;&lt;td style="width:88%; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_a2f0ff1379314111b76e648c5de945d5'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Derivative&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;liabilities - June 30, 2024&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1.14%; vertical-align:middle; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_2dbbcbe08cd646c49d4ad4090192625e'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;567,050&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.5pt"&gt;&lt;td style="width:88%; vertical-align:middle; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_97ca7a3e4491452f85dadb11644bd7ed'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Change in fair value&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1.14%; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_b81e163c70f24c44b27596e3b6f00f4d'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;56,712&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.5pt"&gt;&lt;td style="width:88%; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_2d719b55a9614add8a41b0e7dc9bd875'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Derivative&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;liabilities - September 30, 2024&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1.14%; vertical-align:middle; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_28189adff441454eb8ae6052808da967'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:middle; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_1e958d79d6f442799205fed39a546989'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;623,762&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="I20241231_FairValueMeasurementsRecurringMember_ContingentMilestonePaymentMember_FairValueInputsLevel3Member"
      decimals="0"
      id="Tag114"
      unitRef="USD">640830</us-gaap:DerivativeLiabilitiesCurrent>
    <sxtp:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisMarkToMarketAdjustment
      contextRef="D20250331_FairValueMeasurementsRecurringMember_ContingentMilestonePaymentMember_FairValueInputsLevel3Member"
      decimals="0"
      id="Tag5"
      unitRef="USD">-5105</sxtp:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisMarkToMarketAdjustment>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="I20250331_FairValueMeasurementsRecurringMember_ContingentMilestonePaymentMember_FairValueInputsLevel3Member"
      decimals="0"
      id="Tag115"
      unitRef="USD">635725</us-gaap:DerivativeLiabilitiesCurrent>
    <sxtp:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisMarkToMarketAdjustment
      contextRef="D20250630_FairValueMeasurementsRecurringMember_ContingentMilestonePaymentMember_FairValueInputsLevel3Member"
      decimals="0"
      id="Tag140"
      unitRef="USD">140447</sxtp:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisMarkToMarketAdjustment>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="I20250630_FairValueMeasurementsRecurringMember_ContingentMilestonePaymentMember_FairValueInputsLevel3Member"
      decimals="0"
      id="Tag173"
      unitRef="USD">776172</us-gaap:DerivativeLiabilitiesCurrent>
    <sxtp:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisMarkToMarketAdjustment
      contextRef="D20250930_FairValueMeasurementsRecurringMember_ContingentMilestonePaymentMember_FairValueInputsLevel3Member"
      decimals="0"
      id="Tag186"
      unitRef="USD">21103</sxtp:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisMarkToMarketAdjustment>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="I20250930_FairValueMeasurementsRecurringMember_ContingentMilestonePaymentMember_FairValueInputsLevel3Member"
      decimals="0"
      id="Tag139"
      unitRef="USD">797275</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="I20231231_FairValueMeasurementsRecurringMember_FairValueInputsLevel3Member_ContingentMilestonePaymentMember"
      decimals="0"
      id="Tag253"
      unitRef="USD">2306796</us-gaap:DerivativeLiabilitiesCurrent>
    <sxtp:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisMarkToMarketAdjustment
      contextRef="D20240331_FairValueMeasurementsRecurringMember_ContingentMilestonePaymentMember_FairValueInputsLevel3Member"
      decimals="0"
      id="Tag121"
      unitRef="USD">-1740847</sxtp:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisMarkToMarketAdjustment>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="I20240331_FairValueMeasurementsRecurringMember_ContingentMilestonePaymentMember_FairValueInputsLevel3Member"
      decimals="0"
      id="Tag254"
      unitRef="USD">565949</us-gaap:DerivativeLiabilitiesCurrent>
    <sxtp:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisMarkToMarketAdjustment
      contextRef="D20240630_FairValueMeasurementsRecurringMember_ContingentMilestonePaymentMember_FairValueInputsLevel3Member"
      decimals="0"
      id="Tag327"
      unitRef="USD">1101</sxtp:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisMarkToMarketAdjustment>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="I20240630_FairValueMeasurementsRecurringMember_ContingentMilestonePaymentMember_FairValueInputsLevel3Member"
      decimals="0"
      id="Tag326"
      unitRef="USD">567050</us-gaap:DerivativeLiabilitiesCurrent>
    <sxtp:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisMarkToMarketAdjustment
      contextRef="D20240930_FairValueMeasurementsRecurringMember_ContingentMilestonePaymentMember_FairValueInputsLevel3Member"
      decimals="0"
      id="Tag325"
      unitRef="USD">56712</sxtp:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisMarkToMarketAdjustment>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="I20240930_FairValueMeasurementsRecurringMember_ContingentMilestonePaymentMember_FairValueInputsLevel3Member"
      decimals="0"
      id="Tag384"
      unitRef="USD">623762</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="D20250930_1"
      decimals="0"
      id="Tag815"
      unitRef="USD">-156445</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="D20240930_1"
      decimals="0"
      id="Tag814"
      unitRef="USD">1683034</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="D20250930_1" id="Tag966">&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;9. INCOME TAXES&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;The Company did not record a federal income tax provision or benefit for the &lt;/span&gt;&lt;span style="-aw-sdt-tag:'cd80ebf44dd4a49459a3'; -aw-sdt-title:'Current_Quarter_and_YTD_P8'; font-family: 'Times New Roman'"&gt;&lt;span&gt;three and nine months ended September 30, 2025&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; and &lt;/span&gt;&lt;span style="-aw-sdt-tag:'ca9a1d3291cee7dfe7d3'; -aw-sdt-title:'Previous_Year_P22'; font-family: 'Times New Roman'"&gt;&lt;span&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; due to taxable losses. The Company recorded a provision for income taxes for the District of Columbia of $&lt;/span&gt;&lt;span style="-aw-sdt-tag:'908-1ae-370-c57-56fb'; font-family: 'Times New Roman'"&gt;&lt;span&gt;250&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;and $&lt;/span&gt;&lt;span style="-aw-sdt-tag:'6f4-8fe-bb5-dd0-f075'; font-family: 'Times New Roman'"&gt;&lt;span&gt;250&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;for the &lt;/span&gt;&lt;span style="-aw-sdt-tag:'24f-910-caa-173-01a4'; -aw-sdt-title:'Current_Quarter_P45'; font-family: 'Times New Roman'"&gt;&lt;span&gt;three months ended September 30, 2025&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; and &lt;/span&gt;&lt;span style="-aw-sdt-tag:'1e7-2ec-a39-80f-df36'; -aw-sdt-title:'Previous_Year_P48'; font-family: 'Times New Roman'"&gt;&lt;span&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;, respectively, thereby reflecting the minimum statutory tax due ($&lt;/span&gt;&lt;span style="-aw-sdt-tag:'02d-fa8-465-f09-3ba2'; -aw-sdt-title:'DC_Taxes_CY_YTD'; font-family: 'Times New Roman'"&gt;&lt;span&gt;1,813&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;and $&lt;/span&gt;&lt;span style="-aw-sdt-tag:'d32-f75-fc1-36a-e6f0'; font-family: 'Times New Roman'"&gt;&lt;span&gt;751&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;for the &lt;/span&gt;&lt;span style="-aw-sdt-tag:'65b-b80-259-dec-ff1c'; -aw-sdt-title:'Current_YTD_P54'; font-family: 'Times New Roman'"&gt;&lt;span&gt;nine months ended September 30, 2025&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; and &lt;/span&gt;&lt;span style="-aw-sdt-tag:'679-3d3-4cd-809-ad81'; -aw-sdt-title:'Previous_Year_P49'; font-family: 'Times New Roman'"&gt;&lt;span&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;, respectively). &lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="D20250930"
      decimals="0"
      id="Tag835"
      unitRef="USD">250</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="D20240930"
      decimals="0"
      id="Tag836"
      unitRef="USD">250</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="D20250930_1"
      decimals="0"
      id="Tag837"
      unitRef="USD">1813</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="D20240930_1"
      decimals="0"
      id="Tag838"
      unitRef="USD">751</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="D20250930_1" id="Tag988">&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;10. SHARE-BASED COMPENSATION&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="-aw-sdt-tag:'c037fface987eb1f9566'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;The following is a summary of share-based compensation expenses reported in the &lt;/span&gt;&lt;span style="-aw-sdt-tag:'928-fd0-43f-33f-a583'; -aw-sdt-title:'PandL_title_P1'; font-family: 'Times New Roman'"&gt;&lt;span&gt;consolidated condensed statements of operations and comprehensive loss&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; for the &lt;/span&gt;&lt;span style="-aw-sdt-tag:'ce72a01889339805360e'; -aw-sdt-title:'Current_Quarter_and_YTD_P1'; font-family: 'Times New Roman'"&gt;&lt;span&gt;three and nine months ended September 30, 2025&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; and &lt;/span&gt;&lt;span style="-aw-sdt-tag:'cb6dccf48217e97e781f'; -aw-sdt-title:'Previous_Year_P14'; font-family: 'Times New Roman'"&gt;&lt;span&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;:&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="-aw-sdt-tag:'c13275b5451f7f9fa78e'; -aw-sdt-title:'SHARE-BASED COMPENSATION T1'"&gt;&lt;table cellpadding="0" cellspacing="0" style="width:100%; border-collapse:collapse"&gt;&lt;tbody&gt;&lt;tr style="height:11.5pt"&gt;&lt;td style="width:52%; vertical-align:bottom"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:bottom"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="border-bottom:1.5pt solid #000000; padding-right:3.6pt; padding-left:3.6pt; vertical-align:bottom"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_b793b7deaa5f4e1d950f54932847ec4e'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:bottom"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="border-bottom:1.5pt solid #000000; padding-left:11.5pt; vertical-align:bottom"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_537410e7812d486a9a1750abab377793'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.5pt"&gt;&lt;td style="width:52%; vertical-align:bottom"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:bottom"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:bottom"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_1c65bd1b721f4fdbb0598ff8d89de949'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; border-top:1.5pt solid #000000; vertical-align:bottom"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:bottom"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_e80ebe59c55b4da093ced29e2c908199'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:bottom"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1.5pt solid #000000; vertical-align:bottom"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_91ed7e22685d417984396bafa04be366'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; border-top:1.5pt solid #000000; vertical-align:bottom"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:bottom"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_df669bbe060d4fb4868590c39a9103dd'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.5pt"&gt;&lt;td style="width:52%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_1f65a7c0fbbf45a68b9646858ce371ce'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Research and Development&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_23d3849a725541999e62bbfea44aac84'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:10%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-tag:'C_11384fc8b65f4d7db353787823d55423'"&gt;&lt;span title="&amp;amp;#13;nil='true'"&gt;&lt;/span&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_025187fdcd654094abb16118f061da90'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:10%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_2b22ee8f24c54fa896add2668695efcb'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;600,000&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_b4c10c58c0314c169080c9c8b8fcbf8e'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:10%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-tag:'C_a08e3c8a4c6f4085aa8a9d31befcd057'"&gt;&lt;span title="&amp;amp;#13;nil='true'"&gt;&lt;/span&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_78842318fd574561a2884382a7738a2b'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:10%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_35eff82596e143da87976fe2e081d8ab'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;3,227,300&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.5pt"&gt;&lt;td style="width:52%; vertical-align:bottom"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_61c64308dfc6458ea1fbb4a8c7b703f2'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;General and Administrative Expenses&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:bottom"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:bottom"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_ddd5fe7024e34d6d8b4886992b4b418e'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;79,000&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:bottom"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:bottom"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_b1923603f0314dcc9f9dff054d6a03da'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;68,974&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:bottom"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:bottom"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_be2f81c4d0954142a92c2d69272f7316'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;344,383&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:bottom"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:bottom"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_62aa8b68d8d0491db7039e6b80dd5e0e'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;319,709&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.5pt"&gt;&lt;td style="width:52%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_bfa6fe246dec48e885d05f0057213748'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Total Share-Based Compensation Expense Included in Operating Expenses&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_f745775470c94315af299adf55367ded'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_74b13f97c0cf48dab5e62d86746dd071'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;79,000&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_f2f730e985d34774bbed0f63d2691b9d'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_40018e5c15e74eda9b9f7804866b0d19'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;668,974&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_6d7a61fde61344dc8721193a9a15d53c'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_04eded1abc4d4ad9aef27f111b48a590'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;344,383&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_9c2d8eda549747ef9ba345afb4170af9'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'761-c75-0e8-f8a-eee2'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;3,547,009&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-weight:bold; text-decoration:underline; font-family: 'Times New Roman'"&gt;Share-Based Compensation under &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c2cce9b34b4cce207dc3'; font-family: 'Times New Roman'"&gt;&lt;span style="font-weight:bold; text-decoration:underline"&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;span style="font-weight:bold; text-decoration:underline; font-family: 'Times New Roman'"&gt; Equity Incentive Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;On November &lt;/span&gt;&lt;span style="-aw-sdt-tag:'ce33ff49852d9b6cc9af'; font-family: 'Times New Roman'"&gt;&lt;span&gt;22&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;, &lt;/span&gt;&lt;span style="-aw-sdt-tag:'cd04e73f864219172e17'; font-family: 'Times New Roman'"&gt;&lt;span&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;, the Company adopted the &lt;/span&gt;&lt;span style="-aw-sdt-tag:'cc81a70adfa65fd8fe85'; font-family: 'Times New Roman'"&gt;&lt;span&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; Equity Incentive Plan (the &#x201c;&lt;/span&gt;&lt;span style="-aw-sdt-tag:'c84237e68151d396e260'; font-family: 'Times New Roman'"&gt;&lt;span&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; Plan&#x201d;), which provides for the grant of stock options, stock appreciation rights, restricted stock, restricted stock units and performance awards to eligible employees, directors and consultants, to be granted from time to time by the Board of Directors of the Company. To date, the Company has granted shares of common stock, restricted stock units, stock options to employees, non-employees, and directors under the &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c6469f80875469d8dcaa'; font-family: 'Times New Roman'"&gt;&lt;span&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; Plan. As of &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c119f5f4ee3e094a8aad'; -aw-sdt-title:'Current_Period_P17'; font-family: 'Times New Roman'"&gt;&lt;span&gt;September 30, 2025&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;, the number of remaining shares available for issuance under the 2022 Plan is equal to &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c0d4a4d9d67084ea6d66'; -aw-sdt-title:'2022 Plan _Shares Available for Issuance'; font-family: 'Times New Roman'"&gt;&lt;span&gt;57,068&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-style:italic; font-family: 'Times New Roman'"&gt;Stock Options&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-style:italic; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;The Company grants stock options to employees, non-employees, and directors with exercise prices equal to the closing price of the underlying shares of the Company&#x2019;s common stock on the Nasdaq Capital Market on the date that the options are granted. Options granted generally have a &lt;/span&gt;&lt;span style="-aw-sdt-tag:'e63-273-caa-f00-1383'; font-family: 'Times New Roman'"&gt;&lt;span&gt;term of five to ten years&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; from the grant date and are subject to vesting as determined in the individual award agreement. The Company estimates the fair value of stock options on the grant date by applying the Black-Scholes option pricing valuation model.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="-aw-sdt-tag:'PG_ccc01229426adb7fbfee'"&gt;&lt;/div&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;There were &lt;/span&gt;&lt;span style="-aw-sdt-tag:'5f1-2bf-683-a23-2ca7'; font-family: 'Times New Roman'"&gt;&lt;span&gt;no&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; stock options granted during the &lt;/span&gt;&lt;span style="-aw-sdt-tag:'9f5-d6b-c4e-520-d6a5'; -aw-sdt-title:'Current_Quarter_P46'; font-family: 'Times New Roman'"&gt;&lt;span&gt;three months ended September 30, 2025&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;. During the &lt;/span&gt;&lt;span style="-aw-sdt-tag:'918-ef8-5a7-218-1704'; -aw-sdt-title:'Current_YTD_P53'; font-family: 'Times New Roman'"&gt;&lt;span&gt;nine months ended September 30, 2025&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;, the Company granted a total of &lt;/span&gt;&lt;span style="-aw-sdt-tag:'cc4f82113885d00917ff'; -aw-sdt-title:'CYTD_Stock Options Granted'; font-family: 'Times New Roman'"&gt;&lt;span&gt;120,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; stock options to &lt;/span&gt;&lt;span style="-aw-sdt-tag:'2e4-092-32a-f6f-c96e'; font-family: 'Times New Roman'"&gt;&lt;span&gt;two&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; executives at a per share exercise price of $&lt;/span&gt;&lt;span style="-aw-sdt-tag:'c8fe171f9f46a4304c75'; -aw-sdt-title:'CYTD_Stock Options Ex.Price'; font-family: 'Times New Roman'"&gt;&lt;span&gt;6.55&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;. These options are subject to vesting annually in five equal tranches, with the first &lt;/span&gt;&lt;span style="-aw-sdt-tag:'cbd22998573814036f2e'; font-family: 'Times New Roman'"&gt;&lt;span&gt;20&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;% tranche fully vested on the date of grant and thereafter, vest on the last date of each fiscal year beginning December 31, 2025. The weighted average grant date fair value of options granted during the &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c6aa6012cf7103ba2a01'; -aw-sdt-title:'Current_YTD_P2'; font-family: 'Times New Roman'"&gt;&lt;span&gt;nine months ended September 30, 2025&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; was $&lt;/span&gt;&lt;span style="-aw-sdt-tag:'c2ff4eac22c6343b6acb'; -aw-sdt-title:'CYTD_Stock Options WA Grant Date FV'; font-family: 'Times New Roman'"&gt;&lt;span&gt;4.55&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;. &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;During the &lt;/span&gt;&lt;span style="-aw-sdt-tag:'0e2-2b6-e25-ec0-511e'; -aw-sdt-title:'Previous_Quarter_and_YTD_P6'; font-family: 'Times New Roman'"&gt;&lt;span&gt;three and nine months ended September 30, 2024&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;, Company granted a total of &lt;/span&gt;&lt;span style="-aw-sdt-tag:'844-d69-61d-665-d9fe'; -aw-sdt-title:'PYTD_Stock Options Granted'; font-family: 'Times New Roman'"&gt;&lt;span&gt;17,005&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; stock options at a weighted average per share exercise price of $&lt;/span&gt;&lt;span style="-aw-sdt-tag:'266-3e1-8af-307-25b7'; -aw-sdt-title:'PYTD_Stock Options_Avg Ex Price'; font-family: 'Times New Roman'"&gt;&lt;span&gt;54.62&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;. The weighted average grant date fair value of options granted during the &lt;/span&gt;&lt;span style="-aw-sdt-tag:'27d-ea8-614-ca9-2785'; -aw-sdt-title:'Previous_Quarter_and_YTD_P9'; font-family: 'Times New Roman'"&gt;&lt;span&gt;three and nine months ended September 30, 2024&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; was $&lt;/span&gt;&lt;span style="-aw-sdt-tag:'4bf-904-a4c-ccb-354e'; -aw-sdt-title:'PYTD_Options Granted_Avg. Grant Date Fair Value'; font-family: 'Times New Roman'"&gt;&lt;span&gt;8.78&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="-aw-sdt-tag:'2b8-829-358-045-27fb'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;The following table summarizes the significant assumptions used in determining the fair value of options granted during the &lt;/span&gt;&lt;span style="-aw-sdt-tag:'cb926b1bec8a5c9d7e88'; -aw-sdt-title:'Current_Quarter_and_YTD_P3'; font-family: 'Times New Roman'"&gt;&lt;span&gt;three and nine months ended September 30, 2025&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; and &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c208469c38a8aafffc4c'; -aw-sdt-title:'Previous_Year_P15'; font-family: 'Times New Roman'"&gt;&lt;span&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;:&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="-aw-sdt-tag:'c6b82afc388c401d9e30'; -aw-sdt-title:'SBC Table FMV Assumptions'"&gt;&lt;table cellpadding="0" cellspacing="0" style="width:100%; border-collapse:collapse"&gt;&lt;tbody&gt;&lt;tr style="height:11.5pt"&gt;&lt;td style="width:53%; vertical-align:bottom"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="border-bottom:1.5pt solid #000000; padding-right:3.6pt; padding-left:3.6pt; vertical-align:middle"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_371d5f2bfb054b0e8460d09bb59858a9'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:0.86%; vertical-align:middle"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="border-bottom:1.5pt solid #000000; padding-left:18.7pt; vertical-align:middle"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_e2d4b0f5404c484680abbbec2fbb1cd5'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.5pt"&gt;&lt;td style="width:53%; vertical-align:bottom"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_58cd0c9841254a3dac116deef4bcbc41'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_78c64d6266234af3b75e0972a6752883'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:0.86%; vertical-align:middle"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_4b5707f7e1f340fabeba896192704cbf'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_c0b54a2289c946b5b7a0a1ca7a79bae1'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.5pt"&gt;&lt;td style="width:53%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_bdbe21d861f54e598b6c2ebeaf8c95fe'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Weighted-average grant date fair value&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_7890dccaab874e7d92cb7b0e72fc317f'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:10%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_22b11df71f0d47098e6e2bded099c637'"&gt;&lt;span title="&amp;amp;#13;nil='true'"&gt;&lt;/span&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-import:spaces; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;N/A &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; padding-right:1.45pt; vertical-align:bottom; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_0a2dcde2664d42579b74f707d6505d93'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:10%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_37a0df27750945fc9b6899c1a6a047ca'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;8.78&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:0.86%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_f54f277a21d94c4cacdd010927e3433e'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:10%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_61461e1150e24180814adbbea8f0035f'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;4.55&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_7ea73308c7384caa83280f67a66a433e'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:10%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_2e5e3ada99254986ae82736208308e85'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;8.78&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.5pt"&gt;&lt;td style="width:53%; vertical-align:bottom; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_a86fcbd02d504a77b42500289cd5f9c5'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:bottom; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; vertical-align:bottom; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_422b919e53604b4d9b01e6a4ff8ae470'"&gt;&lt;span title="&amp;amp;#13;nil='true'"&gt;&lt;/span&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-import:spaces; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;N/A &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; padding-right:1.45pt; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:bottom; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; vertical-align:bottom; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-sdt-tag:'5c3-4af-63f-0a8-8170'; font-family: 'Times New Roman'"&gt;&lt;span&gt;3.62&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;% - &lt;/span&gt;&lt;span style="-aw-sdt-tag:'f97-3e4-a51-d60-5557'; font-family: 'Times New Roman'"&gt;&lt;span&gt;4.17&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:0.86%; vertical-align:bottom; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:bottom; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; vertical-align:bottom; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-sdt-tag:'C_a0a8c0c2864a4afbb105903f2b68b28b'; font-family: 'Times New Roman'"&gt;&lt;span&gt;4.36&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; padding-right:1.45pt; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:bottom; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; vertical-align:bottom; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-sdt-tag:'30e-490-8f8-814-d30e'; font-family: 'Times New Roman'"&gt;&lt;span&gt;3.62&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;% - &lt;/span&gt;&lt;span style="-aw-sdt-tag:'ee3-181-3dc-e8f-312d'; font-family: 'Times New Roman'"&gt;&lt;span&gt;4.17&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.5pt"&gt;&lt;td style="width:53%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_5fe58341b1494de19749b138fb5378ee'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_0c331ee129f64ed1b9fa50dc73136fcd'"&gt;&lt;span title="&amp;amp;#13;nil='true'"&gt;&lt;/span&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-import:spaces; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;N/A &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; padding-right:1.45pt; vertical-align:middle; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-sdt-tag:'bda-6e1-a52-5f0-7b06'; font-family: 'Times New Roman'"&gt;&lt;span&gt;86.00&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;% - &lt;/span&gt;&lt;span style="-aw-sdt-tag:'07d-67f-348-6f7-ba1e'; font-family: 'Times New Roman'"&gt;&lt;span&gt;87.00&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:0.86%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-sdt-tag:'C_3c6e0737f3d74b34934c2901d877dee2'; font-family: 'Times New Roman'"&gt;&lt;span&gt;90.00&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; padding-right:1.45pt; vertical-align:middle; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-sdt-tag:'64f-7fb-a1f-61b-8c23'; font-family: 'Times New Roman'"&gt;&lt;span&gt;86.00&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;% - &lt;/span&gt;&lt;span style="-aw-sdt-tag:'163-d0d-e3e-4ea-7923'; font-family: 'Times New Roman'"&gt;&lt;span&gt;87.00&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.5pt"&gt;&lt;td style="width:53%; vertical-align:bottom; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_f98e805c00b14edb84da40ce6346c721'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Expected term (years)&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:bottom; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; vertical-align:bottom; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_e4b5461f1a1746da98b836b10b7a794a'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-import:spaces; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;N/A &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; padding-right:1.45pt; vertical-align:bottom; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:bottom; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; vertical-align:bottom; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-sdt-tag:'9fd-a7d-dce-aee-b8d3'; font-family: 'Times New Roman'"&gt;&lt;span&gt;6.41&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; - &lt;/span&gt;&lt;span style="-aw-sdt-tag:'922-43a-fd5-af0-7c6d'; font-family: 'Times New Roman'"&gt;&lt;span&gt;10.00&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:0.86%; vertical-align:bottom; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:bottom; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; vertical-align:bottom; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_67fa179582ea40ab85e70f2d97a7168b'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;4.50&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; padding-right:1.45pt; vertical-align:bottom; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:bottom; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; vertical-align:bottom; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-sdt-tag:'39b-8fc-eba-917-6b4f'; font-family: 'Times New Roman'"&gt;&lt;span&gt;6.41&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; - &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c62-ee5-3a2-e98-0fdf'; font-family: 'Times New Roman'"&gt;&lt;span&gt;10.00&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.5pt"&gt;&lt;td style="width:53%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_04267cb0abf54990bdf4b71fb0d4b3f1'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Expected dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_3310313796d64fcca52c3a9e78c2bec2'"&gt;&lt;span title="&amp;amp;#13;nil='true'"&gt;&lt;/span&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-import:spaces; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;N/A &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; padding-right:1.45pt; vertical-align:bottom; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-sdt-tag:'C_d9ef82eb21d54263b8ca618d8d975456'; font-family: 'Times New Roman'"&gt;&lt;span&gt;0.00&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:0.86%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-sdt-tag:'C_555c1c1a0720497ba6cdc1357d20b8ce'; font-family: 'Times New Roman'"&gt;&lt;span&gt;0.00&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-sdt-tag:'bd0-9dc-c14-a77-e224'; font-family: 'Times New Roman'"&gt;&lt;span&gt;0.00&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;For the &lt;/span&gt;&lt;span style="-aw-sdt-tag:'e0c-27a-82f-8b3-9fea'; -aw-sdt-title:'Current_Quarter_P50'; font-family: 'Times New Roman'"&gt;&lt;span&gt;three months ended September 30, 2025&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; and &lt;/span&gt;&lt;span style="-aw-sdt-tag:'88b-dd6-6a9-1fd-8fb5'; -aw-sdt-title:'Previous_Year_P56'; font-family: 'Times New Roman'"&gt;&lt;span&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;, the Company recognized $&lt;/span&gt;&lt;span style="-aw-sdt-tag:'cfbc46a1a35c78396973'; -aw-sdt-title:'Option Expense CQ'; font-family: 'Times New Roman'"&gt;&lt;span&gt;34,882&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; and $&lt;/span&gt;&lt;span style="-aw-sdt-tag:'49b-c31-e1c-ca4-3665'; -aw-sdt-title:'Option Expense PQ'; font-family: 'Times New Roman'"&gt;&lt;span&gt;15,246&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; of compensation expense related to stock option awards, respectively ($&lt;/span&gt;&lt;span style="-aw-sdt-tag:'04d-477-46c-4d6-fb29'; -aw-sdt-title:'Option Expenses CYTD'; font-family: 'Times New Roman'"&gt;&lt;span&gt;212,030&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; and $&lt;/span&gt;&lt;span style="-aw-sdt-tag:'b15-7a6-d2f-027-2572'; -aw-sdt-title:'Option Expense PYTD'; font-family: 'Times New Roman'"&gt;&lt;span&gt;15,246&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; for the &lt;/span&gt;&lt;span style="-aw-sdt-tag:'d56-222-98b-71d-4fce'; -aw-sdt-title:'Current_YTD_P58'; font-family: 'Times New Roman'"&gt;&lt;span&gt;nine months ended September 30, 2025&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; and &lt;/span&gt;&lt;span style="-aw-sdt-tag:'147-551-d96-263-b55d'; -aw-sdt-title:'Previous_Year_P57'; font-family: 'Times New Roman'"&gt;&lt;span&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;, respectively). &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-style:italic; font-family: 'Times New Roman'"&gt;Restricted Stock Units&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-style:italic; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Compensation cost for service-based RSUs is based on the grant date fair value of the award, which is the closing market price of the Company&#x2019;s common stock on the grant date multiplied by the number of shares awarded.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;During the &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c8156768d3ede0db34bd'; -aw-sdt-title:'Current_Quarter_and_YTD_P5'; font-family: 'Times New Roman'"&gt;&lt;span&gt;three and nine months ended September 30, 2025&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; and &lt;/span&gt;&lt;span style="-aw-sdt-tag:'cf953a8ed1d8c57cfe06'; -aw-sdt-title:'Previous_Year_P16'; font-family: 'Times New Roman'"&gt;&lt;span&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;, &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c2d498a80f581c1e21a0'; font-family: 'Times New Roman'"&gt;&lt;span&gt;0&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; shares of common stock underlying RSUs vested and &lt;/span&gt;&lt;span style="-aw-sdt-tag:'f83-1f3-cda-5bd-ab74'; font-family: 'Times New Roman'"&gt;&lt;span&gt;no&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; RSUs were granted. The Company recognized $&lt;/span&gt;&lt;span style="-aw-sdt-tag:'cd379d5b42a143859706'; font-family: 'Times New Roman'"&gt;&lt;span&gt;0&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; of compensation expense related to vested RSUs for the &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c9e6e47e8d91295983e5'; -aw-sdt-title:'Current_Quarter_and_YTD_P6'; font-family: 'Times New Roman'"&gt;&lt;span&gt;three and nine months ended September 30, 2025&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; and &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c4363c78014d853fb341'; -aw-sdt-title:'Previous_Year_P17'; font-family: 'Times New Roman'"&gt;&lt;span&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-weight:bold; text-decoration:underline; font-family: 'Times New Roman'"&gt;Annual Performance Bonus&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;span style="width:360pt; display:inline-block; -aw-tabstop-align:left; -aw-tabstop-pos:362.5pt; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;In December &lt;/span&gt;&lt;span style="-aw-sdt-tag:'ca6d224b0a30d2bead97'; font-family: 'Times New Roman'"&gt;&lt;span&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;, the Board approved the payment of &lt;/span&gt;&lt;span style="-aw-sdt-tag:'cf9ad02c046ec83aca33'; font-family: 'Times New Roman'"&gt;&lt;span&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; performance bonuses to executives of the Company. Each executive was provided the option of receiving up to $&lt;/span&gt;&lt;span style="-aw-sdt-tag:'c4ee71f3aad053507c7f'; font-family: 'Times New Roman'"&gt;&lt;span&gt;20,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; in cash, with the remainder paid in shares of common stock determined based on the closing market price on January &lt;/span&gt;&lt;span style="-aw-sdt-tag:'ce3e6a83235437c0275c'; font-family: 'Times New Roman'"&gt;&lt;span&gt;2&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;, &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c1824d9e08acec6d5251'; font-family: 'Times New Roman'"&gt;&lt;span&gt;2025&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;. On January &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c8530f88525131331e3a'; font-family: 'Times New Roman'"&gt;&lt;span&gt;20&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;, &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c599c9f4b2e63ebb486c'; font-family: 'Times New Roman'"&gt;&lt;span&gt;2025&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;, the Company issued a total of &lt;/span&gt;&lt;span style="-aw-sdt-tag:'cfc988ccd41d40490852'; font-family: 'Times New Roman'"&gt;&lt;span&gt;15,809&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; shares of common stock to the executives in settlement of the share-based portion of the &lt;/span&gt;&lt;span style="-aw-sdt-tag:'cfa3618d6dccb054d4d7'; font-family: 'Times New Roman'"&gt;&lt;span&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; performance bonuses. Approximately &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c85caee2925573fd285e'; font-family: 'Times New Roman'"&gt;&lt;span&gt;2,748&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; shares were withheld to cover payroll tax withholdings.&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-weight:bold; text-decoration:underline; font-family: 'Times New Roman'"&gt;Share-Based Payments to Vendors for Services&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;In &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c70630d4e04440e9a333'; font-family: 'Times New Roman'"&gt;&lt;span&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;, the Company issued shares of common stock as share-based payments to certain vendors in exchange for services to be rendered to the Company in the future. For fully vested, nonforfeitable equity instruments that are granted at the date the Company and a nonemployee enter into an agreement for goods or services, the Company recognizes the fair value of the equity instruments as a prepaid asset on the grant date, as defined in ASC &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c7013a8e8550887fe160'; font-family: 'Times New Roman'"&gt;&lt;span&gt;718&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;. The corresponding cost is expensed over the service period depending on the specific facts and circumstances of the agreement with the nonemployee. As of &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c237df05d38456da6ce7'; -aw-sdt-title:'Current_Period_P6'; font-family: 'Times New Roman'"&gt;&lt;span&gt;September 30, 2025&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;, the remaining unamortized balance of prepaid assets related to these share-based payments for which the grant date criteria has been met and the services are expected to be rendered within one year is $&lt;/span&gt;&lt;span style="-aw-sdt-tag:'c3aab794da6a33ebaf3d'; -aw-sdt-title:'Current Unamortized Vendor SBC'; font-family: 'Times New Roman'"&gt;&lt;span&gt;240,004&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; ($&lt;/span&gt;&lt;span style="-aw-sdt-tag:'cf8ef19d090c64e5bbab'; -aw-sdt-title:'Prior Period Unamortized Vendor SBC'; font-family: 'Times New Roman'"&gt;&lt;span&gt;306,181&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; at &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c26c82bd0ee1b08b856a'; -aw-sdt-title:'Previous_Year_End_P8'; font-family: 'Times New Roman'"&gt;&lt;span&gt;December 31, 2024&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;), which is presented as a component of prepaid and other assets on the accompanying &lt;/span&gt;&lt;span style="-aw-sdt-tag:'be6-d2e-cb9-321-e328'; -aw-sdt-title:'Balance_Sheet_Title_P2'; font-family: 'Times New Roman'"&gt;&lt;span&gt;consolidated condensed balance sheets&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;. The unamortized balance of noncurrent prepaid assets related to these share-based payments for which the services are expected to be rendered beyond one year is $&lt;/span&gt;&lt;span style="-aw-sdt-tag:'c4028fc370a9695f41ea'; font-family: 'Times New Roman'"&gt;&lt;span&gt;0&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; ($&lt;/span&gt;&lt;span style="-aw-sdt-tag:'c8c2a095517ee623341c'; -aw-sdt-title:'Prior Period Long Term Unamortized Vendor SBC'; font-family: 'Times New Roman'"&gt;&lt;span&gt;66,176&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; at &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c43649c75076a44f9e67'; -aw-sdt-title:'Previous_Year_End_P9'; font-family: 'Times New Roman'"&gt;&lt;span&gt;December 31, 2024&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;), reported in long-term prepaid expense on the accompanying &lt;/span&gt;&lt;span style="-aw-sdt-tag:'8d3-6a2-4c1-ed7-7507'; -aw-sdt-title:'Balance_Sheet_Title_P3'; font-family: 'Times New Roman'"&gt;&lt;span&gt;consolidated condensed balance sheets&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;The agreements with the nonemployees do not include any provisions to claw back the share-based payments in the event of nonperformance by the nonemployees. Subject to applicable federal and state securities laws, the nonemployees can sell the received equity instruments.&lt;/span&gt;&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="D20250930_1" id="Tag955">&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;The following is a summary of share-based compensation expenses reported in the &lt;/span&gt;&lt;span style="-aw-sdt-tag:'928-fd0-43f-33f-a583'; -aw-sdt-title:'PandL_title_P1'; font-family: 'Times New Roman'"&gt;&lt;span&gt;consolidated condensed statements of operations and comprehensive loss&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; for the &lt;/span&gt;&lt;span style="-aw-sdt-tag:'ce72a01889339805360e'; -aw-sdt-title:'Current_Quarter_and_YTD_P1'; font-family: 'Times New Roman'"&gt;&lt;span&gt;three and nine months ended September 30, 2025&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; and &lt;/span&gt;&lt;span style="-aw-sdt-tag:'cb6dccf48217e97e781f'; -aw-sdt-title:'Previous_Year_P14'; font-family: 'Times New Roman'"&gt;&lt;span&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;:&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="-aw-sdt-tag:'c13275b5451f7f9fa78e'; -aw-sdt-title:'SHARE-BASED COMPENSATION T1'"&gt;&lt;table cellpadding="0" cellspacing="0" style="width:100%; border-collapse:collapse"&gt;&lt;tbody&gt;&lt;tr style="height:11.5pt"&gt;&lt;td style="width:52%; vertical-align:bottom"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:bottom"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="border-bottom:1.5pt solid #000000; padding-right:3.6pt; padding-left:3.6pt; vertical-align:bottom"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_b793b7deaa5f4e1d950f54932847ec4e'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:bottom"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="border-bottom:1.5pt solid #000000; padding-left:11.5pt; vertical-align:bottom"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_537410e7812d486a9a1750abab377793'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.5pt"&gt;&lt;td style="width:52%; vertical-align:bottom"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:bottom"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:bottom"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_1c65bd1b721f4fdbb0598ff8d89de949'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; border-top:1.5pt solid #000000; vertical-align:bottom"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:bottom"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_e80ebe59c55b4da093ced29e2c908199'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:bottom"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1.5pt solid #000000; vertical-align:bottom"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_91ed7e22685d417984396bafa04be366'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; border-top:1.5pt solid #000000; vertical-align:bottom"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:bottom"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_df669bbe060d4fb4868590c39a9103dd'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.5pt"&gt;&lt;td style="width:52%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_1f65a7c0fbbf45a68b9646858ce371ce'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Research and Development&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_23d3849a725541999e62bbfea44aac84'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:10%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-tag:'C_11384fc8b65f4d7db353787823d55423'"&gt;&lt;span title="&amp;amp;#13;nil='true'"&gt;&lt;/span&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_025187fdcd654094abb16118f061da90'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:10%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_2b22ee8f24c54fa896add2668695efcb'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;600,000&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_b4c10c58c0314c169080c9c8b8fcbf8e'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:10%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-tag:'C_a08e3c8a4c6f4085aa8a9d31befcd057'"&gt;&lt;span title="&amp;amp;#13;nil='true'"&gt;&lt;/span&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;-&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_78842318fd574561a2884382a7738a2b'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:10%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_35eff82596e143da87976fe2e081d8ab'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;3,227,300&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.5pt"&gt;&lt;td style="width:52%; vertical-align:bottom"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_61c64308dfc6458ea1fbb4a8c7b703f2'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;General and Administrative Expenses&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:bottom"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:bottom"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_ddd5fe7024e34d6d8b4886992b4b418e'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;79,000&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:bottom"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:bottom"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_b1923603f0314dcc9f9dff054d6a03da'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;68,974&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:bottom"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:bottom"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_be2f81c4d0954142a92c2d69272f7316'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;344,383&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:bottom"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; border-bottom:1.5pt solid #000000; vertical-align:bottom"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; border-bottom:1.5pt solid #000000; vertical-align:bottom"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_62aa8b68d8d0491db7039e6b80dd5e0e'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;319,709&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.5pt"&gt;&lt;td style="width:52%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_bfa6fe246dec48e885d05f0057213748'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Total Share-Based Compensation Expense Included in Operating Expenses&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_f745775470c94315af299adf55367ded'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_74b13f97c0cf48dab5e62d86746dd071'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;79,000&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_f2f730e985d34774bbed0f63d2691b9d'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_40018e5c15e74eda9b9f7804866b0d19'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;668,974&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_6d7a61fde61344dc8721193a9a15d53c'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_04eded1abc4d4ad9aef27f111b48a590'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;344,383&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_9c2d8eda549747ef9ba345afb4170af9'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:10%; border-top:1.5pt solid #000000; border-bottom:4.5pt double #000000; vertical-align:bottom; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'761-c75-0e8-f8a-eee2'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;3,547,009&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="D20250930_ResearchAndDevelopmentExpenseMember"
      id="Tag212"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="D20240930_ResearchAndDevelopmentExpenseMember"
      decimals="0"
      id="Tag202"
      unitRef="USD">600000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="D20250930_ResearchAndDevelopmentExpenseMember_1"
      id="Tag207"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="D20240930_ResearchAndDevelopmentExpenseMember_1"
      decimals="0"
      id="Tag203"
      unitRef="USD">3227300</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="D20250930_GeneralAndAdministrativeExpenseMember"
      decimals="0"
      id="Tag208"
      unitRef="USD">79000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="D20240930_GeneralAndAdministrativeExpenseMember_1"
      decimals="0"
      id="Tag206"
      unitRef="USD">68974</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="D20250930_GeneralAndAdministrativeExpenseMember_1"
      decimals="0"
      id="Tag204"
      unitRef="USD">344383</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="D20240930_GeneralAndAdministrativeExpenseMember"
      decimals="0"
      id="Tag205"
      unitRef="USD">319709</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="D20250930"
      decimals="0"
      id="Tag209"
      unitRef="USD">79000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="D20240930"
      decimals="0"
      id="Tag200"
      unitRef="USD">668974</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="D20250930_1"
      decimals="0"
      id="Tag201"
      unitRef="USD">344383</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="D20240930_1"
      decimals="0"
      id="Tag225"
      unitRef="USD">3547009</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="I20250930_TwoThousandTwentyTwoEquityIncentivePlanMember"
      decimals="0"
      id="Tag861"
      unitRef="Shares">57068</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward contextRef="D20250930_StockOptionsMember_1" id="Tag875">term of five to ten years</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="D20250930"
      decimals="0"
      id="Tag872"
      unitRef="Shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="D20250930_1"
      decimals="0"
      id="Tag873"
      unitRef="Shares">120000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <sxtp:NumberOfExecutives
      contextRef="I20250930"
      decimals="0"
      id="Tag871"
      unitRef="Number">2</sxtp:NumberOfExecutives>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="D20250930_1"
      decimals="2"
      id="Tag862"
      unitRef="USDPerShare">6.55</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="D20250930_ShareBasedCompensationAwardTrancheOneMember"
      decimals="2"
      id="Tag883"
      unitRef="Pure">0.20</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
      contextRef="D20250930_1"
      decimals="2"
      id="Tag863"
      unitRef="USDPerShare">4.55</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="D20240930"
      decimals="0"
      id="Tag1027"
      unitRef="Shares">17005</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="D20240930_1"
      decimals="0"
      id="Tag879"
      unitRef="Shares">17005</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="D20240930"
      decimals="2"
      id="Tag1028"
      unitRef="USDPerShare">54.62</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="D20240930_1"
      decimals="2"
      id="Tag880"
      unitRef="USDPerShare">54.62</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
      contextRef="D20240930"
      decimals="2"
      id="Tag1029"
      unitRef="USDPerShare">8.78</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
      contextRef="D20240930_1"
      decimals="2"
      id="Tag881"
      unitRef="USDPerShare">8.78</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock contextRef="D20250930_1" id="Tag956">&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;The following table summarizes the significant assumptions used in determining the fair value of options granted during the &lt;/span&gt;&lt;span style="-aw-sdt-tag:'cb926b1bec8a5c9d7e88'; -aw-sdt-title:'Current_Quarter_and_YTD_P3'; font-family: 'Times New Roman'"&gt;&lt;span&gt;three and nine months ended September 30, 2025&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; and &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c208469c38a8aafffc4c'; -aw-sdt-title:'Previous_Year_P15'; font-family: 'Times New Roman'"&gt;&lt;span&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;:&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="-aw-sdt-tag:'c6b82afc388c401d9e30'; -aw-sdt-title:'SBC Table FMV Assumptions'"&gt;&lt;table cellpadding="0" cellspacing="0" style="width:100%; border-collapse:collapse"&gt;&lt;tbody&gt;&lt;tr style="height:11.5pt"&gt;&lt;td style="width:53%; vertical-align:bottom"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="border-bottom:1.5pt solid #000000; padding-right:3.6pt; padding-left:3.6pt; vertical-align:middle"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_371d5f2bfb054b0e8460d09bb59858a9'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:0.86%; vertical-align:middle"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="border-bottom:1.5pt solid #000000; padding-left:18.7pt; vertical-align:middle"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_e2d4b0f5404c484680abbbec2fbb1cd5'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.5pt"&gt;&lt;td style="width:53%; vertical-align:bottom"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_58cd0c9841254a3dac116deef4bcbc41'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_78c64d6266234af3b75e0972a6752883'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:0.86%; vertical-align:middle"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_4b5707f7e1f340fabeba896192704cbf'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; border-top:1.5pt solid #000000; vertical-align:middle"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-weight:bold; -aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1.5pt solid #000000; border-bottom:1.5pt solid #000000; vertical-align:middle"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_c0b54a2289c946b5b7a0a1ca7a79bae1'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:center; font-size:10pt"&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.5pt"&gt;&lt;td style="width:53%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_bdbe21d861f54e598b6c2ebeaf8c95fe'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Weighted-average grant date fair value&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_7890dccaab874e7d92cb7b0e72fc317f'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:10%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_22b11df71f0d47098e6e2bded099c637'"&gt;&lt;span title="&amp;amp;#13;nil='true'"&gt;&lt;/span&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-import:spaces; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;N/A &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; padding-right:1.45pt; vertical-align:bottom; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_0a2dcde2664d42579b74f707d6505d93'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:10%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_37a0df27750945fc9b6899c1a6a047ca'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;8.78&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:0.86%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_f54f277a21d94c4cacdd010927e3433e'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:10%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_61461e1150e24180814adbbea8f0035f'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;4.55&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_7ea73308c7384caa83280f67a66a433e'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:10%; border-top:1.5pt solid #000000; vertical-align:bottom; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_2e5e3ada99254986ae82736208308e85'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;8.78&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.5pt"&gt;&lt;td style="width:53%; vertical-align:bottom; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_a86fcbd02d504a77b42500289cd5f9c5'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:bottom; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; vertical-align:bottom; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_422b919e53604b4d9b01e6a4ff8ae470'"&gt;&lt;span title="&amp;amp;#13;nil='true'"&gt;&lt;/span&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-import:spaces; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;N/A &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; padding-right:1.45pt; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:bottom; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; vertical-align:bottom; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-sdt-tag:'5c3-4af-63f-0a8-8170'; font-family: 'Times New Roman'"&gt;&lt;span&gt;3.62&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;% - &lt;/span&gt;&lt;span style="-aw-sdt-tag:'f97-3e4-a51-d60-5557'; font-family: 'Times New Roman'"&gt;&lt;span&gt;4.17&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:0.86%; vertical-align:bottom; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:bottom; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; vertical-align:bottom; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-sdt-tag:'C_a0a8c0c2864a4afbb105903f2b68b28b'; font-family: 'Times New Roman'"&gt;&lt;span&gt;4.36&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; padding-right:1.45pt; vertical-align:middle; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:bottom; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; vertical-align:bottom; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-sdt-tag:'30e-490-8f8-814-d30e'; font-family: 'Times New Roman'"&gt;&lt;span&gt;3.62&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;% - &lt;/span&gt;&lt;span style="-aw-sdt-tag:'ee3-181-3dc-e8f-312d'; font-family: 'Times New Roman'"&gt;&lt;span&gt;4.17&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.5pt"&gt;&lt;td style="width:53%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_5fe58341b1494de19749b138fb5378ee'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_0c331ee129f64ed1b9fa50dc73136fcd'"&gt;&lt;span title="&amp;amp;#13;nil='true'"&gt;&lt;/span&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-import:spaces; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;N/A &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; padding-right:1.45pt; vertical-align:middle; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-sdt-tag:'bda-6e1-a52-5f0-7b06'; font-family: 'Times New Roman'"&gt;&lt;span&gt;86.00&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;% - &lt;/span&gt;&lt;span style="-aw-sdt-tag:'07d-67f-348-6f7-ba1e'; font-family: 'Times New Roman'"&gt;&lt;span&gt;87.00&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:0.86%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-sdt-tag:'C_3c6e0737f3d74b34934c2901d877dee2'; font-family: 'Times New Roman'"&gt;&lt;span&gt;90.00&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; padding-right:1.45pt; vertical-align:middle; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-sdt-tag:'64f-7fb-a1f-61b-8c23'; font-family: 'Times New Roman'"&gt;&lt;span&gt;86.00&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;% - &lt;/span&gt;&lt;span style="-aw-sdt-tag:'163-d0d-e3e-4ea-7923'; font-family: 'Times New Roman'"&gt;&lt;span&gt;87.00&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.5pt"&gt;&lt;td style="width:53%; vertical-align:bottom; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_f98e805c00b14edb84da40ce6346c721'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Expected term (years)&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:bottom; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; vertical-align:bottom; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_e4b5461f1a1746da98b836b10b7a794a'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-import:spaces; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;N/A &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; padding-right:1.45pt; vertical-align:bottom; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:bottom; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; vertical-align:bottom; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-sdt-tag:'9fd-a7d-dce-aee-b8d3'; font-family: 'Times New Roman'"&gt;&lt;span&gt;6.41&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; - &lt;/span&gt;&lt;span style="-aw-sdt-tag:'922-43a-fd5-af0-7c6d'; font-family: 'Times New Roman'"&gt;&lt;span&gt;10.00&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:0.86%; vertical-align:bottom; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:bottom; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; vertical-align:bottom; background-color:#ffffff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_67fa179582ea40ab85e70f2d97a7168b'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;4.50&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; padding-right:1.45pt; vertical-align:bottom; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:bottom; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; vertical-align:bottom; background-color:#ffffff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-sdt-tag:'39b-8fc-eba-917-6b4f'; font-family: 'Times New Roman'"&gt;&lt;span&gt;6.41&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; - &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c62-ee5-3a2-e98-0fdf'; font-family: 'Times New Roman'"&gt;&lt;span&gt;10.00&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:11.5pt"&gt;&lt;td style="width:53%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_04267cb0abf54990bdf4b71fb0d4b3f1'"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Expected dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;div style="-aw-sdt-content:placeholder; -aw-sdt-tag:'C_3310313796d64fcca52c3a9e78c2bec2'"&gt;&lt;span title="&amp;amp;#13;nil='true'"&gt;&lt;/span&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-import:spaces; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;N/A &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="width:1%; padding-right:1.45pt; vertical-align:bottom; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-sdt-tag:'C_d9ef82eb21d54263b8ca618d8d975456'; font-family: 'Times New Roman'"&gt;&lt;span&gt;0.00&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:0.86%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-sdt-tag:'C_555c1c1a0720497ba6cdc1357d20b8ce'; font-family: 'Times New Roman'"&gt;&lt;span&gt;0.00&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:10%; vertical-align:bottom; background-color:#cceeff"&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:right; font-size:10pt"&gt;&lt;span style="-aw-sdt-tag:'bd0-9dc-c14-a77-e224'; font-family: 'Times New Roman'"&gt;&lt;span&gt;0.00&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="D20250930"
      id="Tag220"
      unitRef="USDPerShare"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="D20240930"
      decimals="2"
      id="Tag213"
      unitRef="USDPerShare">8.78</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="D20250930_1"
      decimals="2"
      id="Tag210"
      unitRef="USDPerShare">4.55</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="D20240930_1"
      decimals="2"
      id="Tag214"
      unitRef="USDPerShare">8.78</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="D20250930"
      id="Tag221"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="D20240930"
      decimals="4"
      id="Tag49"
      unitRef="Pure">0.0362</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="D20240930"
      decimals="4"
      id="Tag50"
      unitRef="Pure">0.0417</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="D20250930_1"
      decimals="4"
      id="Tag35"
      unitRef="Pure">0.0436</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="D20240930_1"
      decimals="4"
      id="Tag53"
      unitRef="Pure">0.0362</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="D20240930_1"
      decimals="4"
      id="Tag54"
      unitRef="Pure">0.0417</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="D20250930"
      id="Tag222"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="D20240930"
      decimals="4"
      id="Tag51"
      unitRef="Pure">0.86</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="D20240930"
      decimals="4"
      id="Tag52"
      unitRef="Pure">0.87</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="D20250930_1"
      decimals="4"
      id="Tag36"
      unitRef="Pure">0.90</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="D20240930_1"
      decimals="4"
      id="Tag55"
      unitRef="Pure">0.86</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="D20240930_1"
      decimals="4"
      id="Tag56"
      unitRef="Pure">0.87</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <sxtp:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1Minimum contextRef="D20240930" id="Tag59">P6Y4M28D</sxtp:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1Minimum>
    <sxtp:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1Maximum contextRef="D20240930" id="Tag60">P10Y</sxtp:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1Maximum>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="D20250930_1" id="Tag211">P4Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <sxtp:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1Minimum contextRef="D20240930_1" id="Tag57">P6Y4M28D</sxtp:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1Minimum>
    <sxtp:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1Maximum contextRef="D20240930_1" id="Tag58">P10Y</sxtp:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1Maximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="D20250930"
      id="Tag223"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="D20240930"
      decimals="4"
      id="Tag38"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="D20250930_1"
      decimals="4"
      id="Tag37"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="D20240930_1"
      decimals="4"
      id="Tag39"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="D20250930"
      decimals="0"
      id="Tag864"
      unitRef="USD">34882</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="D20240930"
      decimals="0"
      id="Tag901"
      unitRef="USD">15246</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="D20250930_1"
      decimals="0"
      id="Tag884"
      unitRef="USD">212030</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="D20240930_1"
      decimals="0"
      id="Tag882"
      unitRef="USD">15246</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="D20240930_CommonStockMember_RestrictedStockUnitsRSUMember"
      decimals="0"
      id="Tag1018"
      unitRef="Shares">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="D20250930_CommonStockMember_RestrictedStockUnitsRSUMember_1"
      decimals="0"
      id="Tag1020"
      unitRef="Shares">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="D20240930_CommonStockMember_RestrictedStockUnitsRSUMember_1"
      decimals="0"
      id="Tag1021"
      unitRef="Shares">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="D20250930_CommonStockMember_RestrictedStockUnitsRSUMember"
      decimals="0"
      id="Tag865"
      unitRef="Shares">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="D20240930_CommonStockMember_RestrictedStockUnitsRSUMember_4"
      decimals="0"
      id="Tag1026"
      unitRef="Shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="D20240930_CommonStockMember_RestrictedStockUnitsRSUMember_3"
      decimals="0"
      id="Tag1024"
      unitRef="Shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="D20250930_CommonStockMember_RestrictedStockUnitsRSUMember_3"
      decimals="0"
      id="Tag1025"
      unitRef="Shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="D20250930_CommonStockMember_RestrictedStockUnitsRSUMember_4"
      decimals="0"
      id="Tag876"
      unitRef="Shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="D20240930_RestrictedStockUnitsRSUMember"
      decimals="0"
      id="Tag1019"
      unitRef="USD">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="D20250930_RestrictedStockUnitsRSUMember_1"
      decimals="0"
      id="Tag1022"
      unitRef="USD">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="D20240930_RestrictedStockUnitsRSUMember_1"
      decimals="0"
      id="Tag1023"
      unitRef="USD">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="D20250930_RestrictedStockUnitsRSUMember"
      decimals="0"
      id="Tag874"
      unitRef="USD">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:Cash
      contextRef="I20241231"
      decimals="0"
      id="Tag866"
      unitRef="USD">20000</us-gaap:Cash>
    <sxtp:StockIssuedDuringPeriodIssuanceOfSharesForAnnualPerformanceBonusesNetOfSharesWithheldForTaxesinShares
      contextRef="D20250120_CommonStockMember_3"
      decimals="0"
      id="Tag878"
      unitRef="Shares">15809</sxtp:StockIssuedDuringPeriodIssuanceOfSharesForAnnualPerformanceBonusesNetOfSharesWithheldForTaxesinShares>
    <sxtp:SharesIssuedPayrollTaxesWithholdings
      contextRef="D20250120"
      decimals="0"
      id="Tag867"
      unitRef="Shares">2748</sxtp:SharesIssuedPayrollTaxesWithholdings>
    <sxtp:UnamortizedBalance
      contextRef="D20250930_1"
      decimals="0"
      id="Tag868"
      unitRef="USD">240004</sxtp:UnamortizedBalance>
    <sxtp:UnamortizedBalance
      contextRef="D20241231"
      decimals="0"
      id="Tag869"
      unitRef="USD">306181</sxtp:UnamortizedBalance>
    <us-gaap:PrepaidExpenseNoncurrent
      contextRef="I20250930"
      decimals="0"
      id="Tag877"
      unitRef="USD">0</us-gaap:PrepaidExpenseNoncurrent>
    <us-gaap:PrepaidExpenseNoncurrent
      contextRef="I20241231"
      decimals="0"
      id="Tag870"
      unitRef="USD">66176</us-gaap:PrepaidExpenseNoncurrent>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="D20250930_1" id="Tag973">&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="-aw-sdt-tag:'c7916e61a7bda9b51eb5'; font-family: 'Times New Roman'"&gt;&lt;span style="font-weight:bold"&gt;11&lt;/span&gt;&lt;/span&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;. COMMITMENTS AND CONTINGENCIES&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-weight:bold; text-decoration:underline; font-family: 'Times New Roman'"&gt;Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;The Company is a party to a single lease for its office space located in Washington, DC, which was most recently renewed for an additional &lt;/span&gt;&lt;span style="-sec-ix-hidden:Tag1013;-aw-sdt-tag:'471-47d-78e-0c2-c68d'; font-family: 'Times New Roman';"&gt;&lt;span&gt;one-year&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; term that expires March &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c8d35c399c9a3442b96c'; font-family: 'Times New Roman'"&gt;&lt;span&gt;31&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;, &lt;/span&gt;&lt;span style="-aw-sdt-tag:'ceb220ef0c9941bd9af2'; font-family: 'Times New Roman'"&gt;&lt;span&gt;2026&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;. As the term of the office lease is &lt;/span&gt;&lt;span style="-aw-sdt-tag:'cd0fb876e27f05507c99'; font-family: 'Times New Roman'"&gt;&lt;span&gt;12&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; months, the lease is not recorded on the balance sheet. The Company recognizes lease expense on this lease as short-term lease costs. Operating lease costs, including short-term leases, were in the amount of $&lt;/span&gt;&lt;span style="-aw-sdt-tag:'cd5c94b9c313d289b382'; -aw-sdt-title:'Operating lease costs_CQ'; font-family: 'Times New Roman'"&gt;&lt;span&gt;5,573&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;and $&lt;/span&gt;&lt;span style="-aw-sdt-tag:'c0db659496b5badf8a70'; -aw-sdt-title:'Operating lease costs_PQ'; font-family: 'Times New Roman'"&gt;&lt;span&gt;4,938&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;for the &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c00f68e43fb81f0a3a6f'; -aw-sdt-title:'Current_Quarter_P18'; font-family: 'Times New Roman'"&gt;&lt;span&gt;three months ended September 30, 2025&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; and &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c0544c7e1d672dd6a524'; -aw-sdt-title:'Previous_Year_P39'; font-family: 'Times New Roman'"&gt;&lt;span&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;, respectively ($&lt;/span&gt;&lt;span style="-aw-sdt-tag:'c19f05d774f689867aee'; -aw-sdt-title:'Operating lease costs_CYTD'; font-family: 'Times New Roman'"&gt;&lt;span&gt;15,340&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;and $&lt;/span&gt;&lt;span style="-aw-sdt-tag:'c323f9f24f97d741bebf'; -aw-sdt-title:'Operating lease costs_PYTD'; font-family: 'Times New Roman'"&gt;&lt;span&gt;24,067&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;for the &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c3eaf105153db479206c'; -aw-sdt-title:'Current_YTD_P17'; font-family: 'Times New Roman'"&gt;&lt;span&gt;nine months ended September 30, 2025&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; and &lt;/span&gt;&lt;span style="-aw-sdt-tag:'ccde6b94d63a3ed0d73b'; -aw-sdt-title:'Previous_Year_P40'; font-family: 'Times New Roman'"&gt;&lt;span&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;, respectively).&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-weight:bold; text-decoration:underline; font-family: 'Times New Roman'"&gt;Board of Directors&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;In November and December &lt;/span&gt;&lt;span style="-aw-sdt-tag:'ceded28c546cdff3103d'; font-family: 'Times New Roman'"&gt;&lt;span&gt;2022&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;, the Company signed agreements with &lt;/span&gt;&lt;span style="-aw-sdt-tag:'047-f50-789-ede-ed65'; font-family: 'Times New Roman'"&gt;&lt;span&gt;four&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; director nominees (Cheryl Xu, Paul Field, Charles Allen, and Stephen Toovey) which came into effect on July &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c5ebe60d064ae023bc98'; font-family: 'Times New Roman'"&gt;&lt;span&gt;11&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;, &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c0db6f79eaa785e55516'; font-family: 'Times New Roman'"&gt;&lt;span&gt;2023&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;, the date the Company&#x2019;s Registration Statement was declared effective. Each director is entitled to receive cash compensation of $&lt;/span&gt;&lt;span style="-aw-sdt-tag:'cead4e48e0e3dfb38324'; font-family: 'Times New Roman'"&gt;&lt;span&gt;11,250&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; quarterly. In addition, the &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c2b8816960a856041d4d'; font-family: 'Times New Roman'"&gt;&lt;span&gt;two&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; non-audit committee chairs (Toovey, Field) will receive $&lt;/span&gt;&lt;span style="-aw-sdt-tag:'cf60737ac055ebc86af7'; font-family: 'Times New Roman'"&gt;&lt;span&gt;1,250&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; per quarter and the audit committee chair (Allen) will receive an additional $&lt;/span&gt;&lt;span style="-aw-sdt-tag:'c678970b8b9f3d32b9e0'; font-family: 'Times New Roman'"&gt;&lt;span&gt;2,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; per quarter. In addition, each director is entitled to receive &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c45-3ff-244-abc-9e9e'; font-family: 'Times New Roman'"&gt;&lt;span&gt;annual&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; equity-based compensation awards, with the amounts and terms to be determined by the Compensation Committee.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-weight:bold; text-decoration:underline; font-family: 'Times New Roman'"&gt;Contingencies&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;The Company&#x2019;s operations are subject to a variety of local and state regulations. Failure to comply with one or more of those regulations could result in fines, restrictions on its operations, or losses of permits that could result in the Company ceasing operations.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-weight:bold; text-decoration:underline; font-family: 'Times New Roman'"&gt;Contingent Compensation &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Following the Company&#x2019;s IPO and the conversion of the outstanding debt pursuant to the Knight Debt Conversion Agreement as discussed in Note &lt;/span&gt;&lt;span style="-aw-sdt-tag:'cb6de7e290230b8a811a'; font-family: 'Times New Roman'"&gt;&lt;span&gt;8&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;, the Company is obligated to pay Knight a contingent milestone payment of $&lt;/span&gt;&lt;span style="-aw-sdt-tag:'c55651d68ed1749336c5'; font-family: 'Times New Roman'"&gt;&lt;span&gt;10&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; million if the Company sells Arakoda or if a Change of Control occurs. The Company accounts for the contingent milestone payment as a derivative liability (See Note &lt;/span&gt;&lt;span style="-aw-sdt-tag:'cb46d3d5eed43a8991ab'; font-family: 'Times New Roman'"&gt;&lt;span&gt;8&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;).&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;On July &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c9ddb49ff306b2e819bc'; font-family: 'Times New Roman'"&gt;&lt;span&gt;15&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;, &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c62eea5dde02cf11a936'; font-family: 'Times New Roman'"&gt;&lt;span&gt;2015&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;, the Company entered into the Exclusive License Agreement with the U.S. Army Medical Materiel Development Activity (the &#x201c;U.S. Army&#x201d;), which was subsequently amended (the &#x201c;U.S. Army Agreement&#x201d;), in which the Company obtained a license to develop and commercialize the licensed technology with respect to all therapeutic applications and uses excluding radical cure of symptomatic vivax malaria. The term of the U.S. Army Agreement will continue until the expiration of the last to expire of the patent application or valid claim of the licensed technology, or &lt;/span&gt;&lt;span style="-aw-sdt-tag:'cbf97d3e60b36d2a50b8'; font-family: 'Times New Roman'"&gt;&lt;span&gt;20&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; years from the start date of the U.S. Army Agreement, unless terminated earlier by the parties. The Company must make a minimum annual royalty payment of &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c0743d438ddf722d27fc'; font-family: 'Times New Roman'"&gt;&lt;span&gt;3&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;% of Net Sales (as defined in the U.S. Army Agreement) for Net Sales less than $&lt;/span&gt;&lt;span style="-aw-sdt-tag:'cf2e115de1723a0ed45f'; font-family: 'Times New Roman'"&gt;&lt;span&gt;35&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; million, and &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c4481b3b4d4093d568f0'; font-family: 'Times New Roman'"&gt;&lt;span&gt;5&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;% of Net Sales greater than $&lt;/span&gt;&lt;span style="-aw-sdt-tag:'cc31fd6e0a8dcfc322fa'; font-family: 'Times New Roman'"&gt;&lt;span&gt;35&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; million, with US government sales excluded from the definition of Net Sales. In addition, the Company must pay fees upon the achievement of certain milestones. The Company accrues the minimum annual royalty when the related sales occur. The achievement of the remaining milestones under the U.S. Army Agreement are not considered probable and thus no accruals for the related milestone payments have been made.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;On December &lt;/span&gt;&lt;span style="-aw-sdt-tag:'cbb240240b052d6f8172'; font-family: 'Times New Roman'"&gt;&lt;span&gt;20&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;, &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c027369bd0398d6eba8f'; font-family: 'Times New Roman'"&gt;&lt;span&gt;2024&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;, the Company entered into a Patent License Agreement with Tufts Medical Center (&#x201c;Tufts MC&#x201d;), in which the Company obtained a license to research and commercialize the licensed technology with respect to the use of tafenoquine for treatment and/or prevention of babesiosis (the &#x201c;Tufts MC Agreement&#x201d;). The term of the Tufts MC Agreement will continue until the expiration or final abandonment of the last patent application or issued patent for the use of tafenoquine for treatment and/or prevention of babesiosis, unless terminated earlier by the parties. On the earlier of (x) the date of patent issuance or (y) the date of regulatory approval for the use of tafenoquine product in treatment of babesiosis, the Company must make royalty payments equal to &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c54edac88924604315c8'; font-family: 'Times New Roman'"&gt;&lt;span&gt;4&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;% of Net Sales (as defined in the Tufts MC Agreement) for tafenoquine sold in a format labeled for use in the treatment of babesiosis or &lt;/span&gt;&lt;span style="-aw-sdt-tag:'cf88cbfc1ea21062cba6'; font-family: 'Times New Roman'"&gt;&lt;span&gt;2&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;% of Net Sales for &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c074caac69bf4612113a'; font-family: 'Times New Roman'"&gt;&lt;span&gt;60&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;P products that are not sold in a format labeled for use in the treatment of babesiosis. In addition, for all sublicense revenue received by &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c86ede9c1c4a486b5149'; font-family: 'Times New Roman'"&gt;&lt;span&gt;60&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;P from sales of sublicensed products, the Company must make royalty payments equal to &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c636764bc4488d0fba9e'; font-family: 'Times New Roman'"&gt;&lt;span&gt;20&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;% of the revenue received by the Company for sales of tafenoquine sold in a format labeled for use in the treatment of babesiosis or &lt;/span&gt;&lt;span style="-aw-sdt-tag:'cb710989fdd28cf064c7'; font-family: 'Times New Roman'"&gt;&lt;span&gt;10&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;% for sales of tafenoquine that are not sold in a format labeled for use in the treatment of babesiosis. As of &lt;/span&gt;&lt;span style="-aw-sdt-tag:'cce588c7b78411dd262d'; -aw-sdt-title:'Current_Period_P24'; font-family: 'Times New Roman'"&gt;&lt;span&gt;September 30, 2025&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;, the royalty period has not commenced, thus &lt;/span&gt;&lt;span style="-aw-sdt-tag:'1dc-6d9-7b7-ffb-8c04'; font-family: 'Times New Roman'"&gt;&lt;span&gt;no&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; accruals have been made.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-weight:bold; text-decoration:underline; font-family: 'Times New Roman'"&gt;Litigation, Claims and Assessments&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;From time to time, the Company may be involved in litigation relating to claims arising out of operations in the normal course of business. As of &lt;/span&gt;&lt;span style="-aw-sdt-tag:'c68a81d7a6d5e41ec529'; -aw-sdt-title:'Current_Period_P23'; font-family: 'Times New Roman'"&gt;&lt;span&gt;September 30, 2025&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;, there were &lt;/span&gt;&lt;span style="-aw-sdt-tag:'493-5d4-85c-584-67d2'; font-family: 'Times New Roman'"&gt;&lt;span&gt;no&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; pending or threatened lawsuits that could reasonably be expected to have a material effect on the results of the Company&#x2019;s operations.&lt;/span&gt;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="D20250930"
      decimals="0"
      id="Tag807"
      unitRef="USD">5573</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="D20240930"
      decimals="0"
      id="Tag755"
      unitRef="USD">4938</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="D20250930_1"
      decimals="0"
      id="Tag806"
      unitRef="USD">15340</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="D20240930_1"
      decimals="0"
      id="Tag756"
      unitRef="USD">24067</us-gaap:OperatingLeaseCost>
    <sxtp:NumberOfDirectors
      contextRef="I20250930_DirectorMember"
      decimals="0"
      id="Tag857"
      unitRef="Director">4</sxtp:NumberOfDirectors>
    <us-gaap:CompensationAndBenefitsTrust
      contextRef="I20250930_BoardOfDirectorsChairmanMember_StephenTooveyMember"
      decimals="0"
      id="Tag757"
      unitRef="USD">11250</us-gaap:CompensationAndBenefitsTrust>
    <sxtp:NumberOfNonAuditCommitteeChairs
      contextRef="I20250930"
      decimals="0"
      id="Tag758"
      unitRef="Pure">2</sxtp:NumberOfNonAuditCommitteeChairs>
    <us-gaap:CompensationAndBenefitsTrust
      contextRef="I20250930_PaulFieldMember"
      decimals="0"
      id="Tag759"
      unitRef="USD">1250</us-gaap:CompensationAndBenefitsTrust>
    <us-gaap:CompensationAndBenefitsTrust
      contextRef="I20250930_CharlesAllenMember"
      decimals="0"
      id="Tag760"
      unitRef="USD">2000</us-gaap:CompensationAndBenefitsTrust>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward contextRef="D20250930_DirectorMember" id="Tag858">annual</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="I20250930_IPOMember"
      decimals="-6"
      id="Tag818"
      unitRef="USD">10000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <sxtp:LicensedTechnologyTerm contextRef="D20150715" id="Tag761">P20Y</sxtp:LicensedTechnologyTerm>
    <sxtp:AnnualRoyaltyPaymentPercentage
      contextRef="D20150715_BoardOfDirectorsChairmanMember"
      decimals="2"
      id="Tag762"
      unitRef="Pure">0.03</sxtp:AnnualRoyaltyPaymentPercentage>
    <us-gaap:RoyaltyExpense
      contextRef="D20150715_USGovernmentSalesMember"
      decimals="-6"
      id="Tag763"
      unitRef="USD">35000000</us-gaap:RoyaltyExpense>
    <sxtp:AnnualRoyaltyPaymentPercentage
      contextRef="D20150715"
      decimals="2"
      id="Tag764"
      unitRef="Pure">0.05</sxtp:AnnualRoyaltyPaymentPercentage>
    <us-gaap:RoyaltyExpense
      contextRef="D20150715_USArmyAgreementMember"
      decimals="-6"
      id="Tag765"
      unitRef="USD">35000000</us-gaap:RoyaltyExpense>
    <sxtp:PercentageOfRoyaltyPaymentsOfNetSales
      contextRef="D20241220"
      decimals="2"
      id="Tag766"
      unitRef="Pure">0.04</sxtp:PercentageOfRoyaltyPaymentsOfNetSales>
    <sxtp:PercentageOfTreatmentOfBabesiosis
      contextRef="D20241220_MinimumMember"
      decimals="2"
      id="Tag767"
      unitRef="Pure">0.02</sxtp:PercentageOfTreatmentOfBabesiosis>
    <us-gaap:RevenueRemainingPerformanceObligationPercentage
      contextRef="I20241220"
      decimals="2"
      id="Tag768"
      unitRef="Pure">0.20</us-gaap:RevenueRemainingPerformanceObligationPercentage>
    <sxtp:PercentageOfTreatmentOfBabesiosis
      contextRef="D20241220_MaximumMember"
      decimals="2"
      id="Tag769"
      unitRef="Pure">0.10</sxtp:PercentageOfTreatmentOfBabesiosis>
    <us-gaap:RoyaltyExpense
      contextRef="D20250930_TuftsMedicalCenterAgreementMember"
      decimals="0"
      id="Tag860"
      unitRef="USD">0</us-gaap:RoyaltyExpense>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="I20250930"
      decimals="0"
      id="Tag859"
      unitRef="USD">0</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:SubsequentEventsTextBlock contextRef="D20250930_1" id="Tag990">&lt;p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt"&gt;&lt;span style="font-weight:bold; font-family: 'Times New Roman'"&gt;12. SUBSEQUENT EVENTS&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;&#160;&lt;/span&gt;&lt;span style="width:104.75pt; display:inline-block; -aw-tabstop-align:left; -aw-tabstop-pos:107.25pt; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;The Company has evaluated subsequent events through &lt;/span&gt;&lt;span style="-aw-sdt-tag:'e16-1c0-097-c46-bd43'; -aw-sdt-title:'Current_Period_Date_FS_Issued_P2'; font-family: 'Times New Roman'"&gt;&lt;span&gt;November 13, 2025&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;, which is the date the financial statements were issued. &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-style:italic; font-family: 'Times New Roman'"&gt;2025 Annual Meeting of Stockholders&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;On October 8, 2025, the Company conducted its virtual 2025 Annual Meeting of Stockholders (the &#x201c;2025 Annual Meeting&#x201d;). The Company&#x2019;s stockholders of record at the close of business on August 29, 2025, the record date for the determination of stockholders entitled to vote at the 2025 Annual Meeting, approved the proposals to (1) elect &lt;/span&gt;&lt;span style="-aw-sdt-tag:'454-79f-b5b-ad3-7921'; font-family: 'Times New Roman'"&gt;&lt;span&gt;five&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; directors to serve until the 2026 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified&#x37e; (2) approve an amendment to the 2022 Plan to increase the number of shares of common stock available for issuance by &lt;/span&gt;&lt;span style="-aw-sdt-tag:'ad1-9b9-eb6-e8c-4870'; font-family: 'Times New Roman'"&gt;&lt;span&gt;250,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; shares&#x37e; (3) approve an amendment to the Company&#x2019;s Certificate of Incorporation, to effect a reverse stock split of the common stock at a reverse stock split ratio ranging from &lt;/span&gt;&lt;span style="-aw-sdt-tag:'6e9-6db-b5f-c60-506b'; font-family: 'Times New Roman'"&gt;&lt;span&gt;1:3 to 1:10&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; inclusive, as may be determined at the appropriate time by the Board of Directors, in its sole discretion&#x37e; and (4) ratify the selection of RBSM LLP by the Board of Directors as the Company&#x2019;s independent registered public accounting firm for the fiscal year ending December 31, 2025.&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-style:italic; font-family: 'Times New Roman'"&gt;Option Grant&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;On October 21, 2025, the Company&#x2019;s Board of Directors approved the grant of &lt;/span&gt;&lt;span style="-aw-sdt-tag:'df3-cbb-b07-8bb-c693'; font-family: 'Times New Roman'"&gt;&lt;span&gt;32,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; stock options to each of the &lt;/span&gt;&lt;span style="-aw-sdt-tag:'705-e1a-464-35f-5940'; font-family: 'Times New Roman'"&gt;&lt;span&gt;four&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; directors (&lt;/span&gt;&lt;span style="-aw-sdt-tag:'50a-16a-20d-537-e8de'; font-family: 'Times New Roman'"&gt;&lt;span&gt;8,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; per director) at a per share exercise price of $&lt;/span&gt;&lt;span style="-aw-sdt-tag:'1ec-25c-5ee-eca-013d'; font-family: 'Times New Roman'"&gt;&lt;span&gt;1.46&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;. These stock options were fully vested on the date of grant and have a term of &lt;/span&gt;&lt;span style="-aw-sdt-tag:'71a-74e-77b-7dc-6383'; font-family: 'Times New Roman'"&gt;&lt;span&gt;seven years&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;. &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-style:italic; font-family: 'Times New Roman'"&gt;2025 ATM Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;Pursuant to the 2025 ATM Agreement described in Note 6, between &lt;/span&gt;&lt;span style="-aw-sdt-tag:'075-02e-67e-8cb-173b'; -aw-sdt-title:'ATM_Sales_Start Date'; font-family: 'Times New Roman'"&gt;&lt;span&gt;October 16, 2025&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; and &lt;/span&gt;&lt;span style="-aw-sdt-tag:'9c6-a68-8ff-273-4e9d'; -aw-sdt-title:'Signature_Date_P8'; font-family: 'Times New Roman'"&gt;&lt;span&gt;November 13, 2025&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;, the Company sold an aggregate of &lt;/span&gt;&lt;span style="-aw-sdt-tag:'3bd-c63-bbc-85b-e9a5'; -aw-sdt-title:'ATM_Shares_Sold'; font-family: 'Times New Roman'"&gt;&lt;span&gt;125,979&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt; shares at a weighted average price per share of $&lt;/span&gt;&lt;span style="-aw-sdt-tag:'88e-ea0-f71-977-3a31'; -aw-sdt-title:'ATM_Sales_WeightedAvgPrice'; font-family: 'Times New Roman'"&gt;&lt;span&gt;1.62&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;, generating net proceeds to the Company of $&lt;/span&gt;&lt;span style="-aw-sdt-tag:'63a-f84-1ca-24b-ad31'; -aw-sdt-title:'ATM_Sales_NetProceeds'; font-family: 'Times New Roman'"&gt;&lt;span&gt;196,356&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family: 'Times New Roman';"&gt;, after deducting commissions and certain other offering expenses. &lt;/span&gt;&lt;span style="-aw-import:spaces; font-family: 'Times New Roman'"&gt;&#160; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="-aw-import:ignore; font-family: 'Times New Roman'"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"&gt;&lt;span style="font-family: 'Times New Roman';"&gt;There have been no other events or transactions during this time which would have a material effect on these consolidated condensed financial statements.&lt;/span&gt;&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <sxtp:NumberOfDirectors
      contextRef="I20251008_SubsequentEventMember"
      decimals="0"
      id="Tag846"
      unitRef="Number">5</sxtp:NumberOfDirectors>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="I20251008_SubsequentEventMember"
      decimals="0"
      id="Tag845"
      unitRef="Shares">250000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:StockholdersEquityReverseStockSplit contextRef="D20251008_SubsequentEventMember" id="Tag847">1:3 to 1:10</us-gaap:StockholdersEquityReverseStockSplit>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="D20251021_SubsequentEventMember_StockOptionsMember_DirectorMember"
      decimals="0"
      id="Tag888"
      unitRef="Shares">32000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <sxtp:NumberOfDirectors
      contextRef="I20251021_SubsequentEventMember_StockOptionsMember_DirectorMember"
      decimals="0"
      id="Tag889"
      unitRef="Number">4</sxtp:NumberOfDirectors>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="D20251021_SubsequentEventMember_StockOptionsMember_DirectorOneMember"
      decimals="0"
      id="Tag890"
      unitRef="Shares">8000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="D20251021_SubsequentEventMember_StockOptionsMember_DirectorMember"
      decimals="2"
      id="Tag891"
      unitRef="USDPerShare">1.46</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="D20251021_SubsequentEventMember_StockOptionsMember_DirectorMember"
      id="Tag892">P7Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <sxtp:ATMOfferingShares
      contextRef="D20251113_SubsequentEventMember_HCWainwrightAndCoLLCMember_AtTheMarket2025AgreementMember"
      decimals="0"
      id="Tag918"
      unitRef="Shares">125979</sxtp:ATMOfferingShares>
    <sxtp:CommonStockSalesAgreementWeightedAveragePricePerShare
      contextRef="D20251113_SubsequentEventMember_HCWainwrightAndCoLLCMember_AtTheMarket2025AgreementMember"
      decimals="2"
      id="Tag919"
      unitRef="USDPerShare">1.62</sxtp:CommonStockSalesAgreementWeightedAveragePricePerShare>
    <sxtp:ProceedsFromCommonStockSalesAgreementNet
      contextRef="D20251113_SubsequentEventMember_HCWainwrightAndCoLLCMember_AtTheMarket2025AgreementMember"
      decimals="0"
      id="Tag920"
      unitRef="USD">196356</sxtp:ProceedsFromCommonStockSalesAgreementNet>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#Tag996"
          xlink:label="Tag996"
          xlink:type="locator"/>
        <link:footnote id="footnote0" xlink:label="footnote0" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="-aw-sdt-tag:'c13961dbf06a06abf874'"><xhtml:p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><xhtml:span style="font-family: 'Times New Roman';">Prior periods presented have been adjusted to reflect the 1:5 reverse stock split on February 24, 2025.</xhtml:span></xhtml:p></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tag996"
          xlink:to="footnote0"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tag997"
          xlink:label="Tag997"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tag997"
          xlink:to="footnote0"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tag998"
          xlink:label="Tag998"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tag998"
          xlink:to="footnote0"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tag1000"
          xlink:label="Tag1000"
          xlink:type="locator"/>
        <link:footnote id="footnote1" xlink:label="footnote1" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="-aw-sdt-tag:'c734aea3392f6a6b2ec2'"><xhtml:p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><xhtml:span style="font-family: 'Times New Roman';">Prior periods presented have been adjusted to reflect the 1:5 reverse stock split on February 24, 2025.</xhtml:span></xhtml:p></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tag1000"
          xlink:to="footnote1"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tag1001"
          xlink:label="Tag1001"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tag1001"
          xlink:to="footnote1"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tag1002"
          xlink:label="Tag1002"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tag1002"
          xlink:to="footnote1"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tag1003"
          xlink:label="Tag1003"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tag1003"
          xlink:to="footnote1"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tag1009"
          xlink:label="Tag1009"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tag1009"
          xlink:to="footnote0"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tag241"
          xlink:label="Tag241"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tag241"
          xlink:to="footnote0"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tag242"
          xlink:label="Tag242"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tag242"
          xlink:to="footnote0"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tag243"
          xlink:label="Tag243"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tag243"
          xlink:to="footnote0"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tag244"
          xlink:label="Tag244"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tag244"
          xlink:to="footnote0"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tag433"
          xlink:label="Tag433"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tag433"
          xlink:to="footnote0"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tag434"
          xlink:label="Tag434"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tag434"
          xlink:to="footnote0"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tag431"
          xlink:label="Tag431"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tag431"
          xlink:to="footnote0"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tag432"
          xlink:label="Tag432"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tag432"
          xlink:to="footnote0"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tag520"
          xlink:label="Tag520"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tag520"
          xlink:to="footnote1"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tag521"
          xlink:label="Tag521"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tag521"
          xlink:to="footnote1"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tag522"
          xlink:label="Tag522"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tag522"
          xlink:to="footnote1"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tag523"
          xlink:label="Tag523"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tag523"
          xlink:to="footnote1"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tag232"
          xlink:label="Tag232"
          xlink:type="locator"/>
        <link:footnote id="footnote2" xlink:label="footnote2" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="-aw-sdt-tag:'cc60b45585da36d079a6'"><xhtml:p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><xhtml:span style="font-family: 'Times New Roman';">Weighted average remaining contractual life at </xhtml:span><xhtml:span style="-aw-sdt-tag:'cb7acd8bf727a3348920'; -aw-sdt-title:'Previous_Year_End_P16'; font-family: 'Times New Roman'"><xhtml:span>December 31, 2024</xhtml:span></xhtml:span><xhtml:span style="font-family: 'Times New Roman';"> excludes </xhtml:span><xhtml:span style="-aw-sdt-tag:'c9eaac2b3a02e0ecbfed'; font-family: 'Times New Roman'"><xhtml:span>385,200</xhtml:span></xhtml:span><xhtml:span style="font-family: 'Times New Roman';"> Pre-Funded Warrants issued September </xhtml:span><xhtml:span style="-aw-sdt-tag:'c084844e24a211ebd242'; font-family: 'Times New Roman'"><xhtml:span>2024</xhtml:span></xhtml:span><xhtml:span style="font-family: 'Times New Roman';"> that do not have a contractual expiration date, for which </xhtml:span><xhtml:span style="-aw-sdt-tag:'c6c65c3f0bb7343724f4'; font-family: 'Times New Roman'"><xhtml:span>0</xhtml:span></xhtml:span><xhtml:span style="font-family: 'Times New Roman';"> warrants remain outstanding and exercisable at March 31, 2025, June 30, 2025 and </xhtml:span><xhtml:span style="-aw-sdt-tag:'c3f8bf32fba6f0a28902'; -aw-sdt-title:'Current_Period_P16'; font-family: 'Times New Roman'"><xhtml:span>September 30, 2025</xhtml:span></xhtml:span><xhtml:span style="font-family: 'Times New Roman';">.</xhtml:span></xhtml:p></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tag232"
          xlink:to="footnote2"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tag233"
          xlink:label="Tag233"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tag233"
          xlink:to="footnote2"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tag234"
          xlink:label="Tag234"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tag234"
          xlink:to="footnote2"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tag226"
          xlink:label="Tag226"
          xlink:type="locator"/>
        <link:footnote id="footnote3" xlink:label="footnote3" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="-aw-sdt-tag:'4e2-557-131-530-ea28'"><xhtml:p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><xhtml:span style="font-family: 'Times New Roman';">Weighted average remaining contractual life excludes </xhtml:span><xhtml:span style="-aw-sdt-tag:'155-a3e-4e3-421-5e47'; font-family: 'Times New Roman'"><xhtml:span>878,264</xhtml:span></xhtml:span><xhtml:span style="font-family: 'Times New Roman';"> Pre-Funded Warrants issued July 2025 that do not have a contractual expiration date, for which </xhtml:span><xhtml:span style="-aw-sdt-tag:'cfe-9a0-ea6-43f-4379'; font-family: 'Times New Roman'"><xhtml:span>0</xhtml:span></xhtml:span><xhtml:span style="font-family: 'Times New Roman';"> warrants remain outstanding and exercisable at </xhtml:span><xhtml:span style="-aw-sdt-tag:'b56-24f-fd5-c1f-b53f'; -aw-sdt-title:'Current_Period_P43'; font-family: 'Times New Roman'"><xhtml:span>September 30, 2025</xhtml:span></xhtml:span><xhtml:span style="font-family: 'Times New Roman';">.</xhtml:span></xhtml:p></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tag226"
          xlink:to="footnote3"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tag227"
          xlink:label="Tag227"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tag227"
          xlink:to="footnote3"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tag228"
          xlink:label="Tag228"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tag228"
          xlink:to="footnote3"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tag216"
          xlink:label="Tag216"
          xlink:type="locator"/>
        <link:footnote id="footnote4" xlink:label="footnote4" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="-aw-sdt-tag:'54e-de6-a74-b52-df70'"><xhtml:p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><xhtml:span style="font-family: 'Times New Roman';">Weighted average remaining contractual life calculations exclude (i) </xhtml:span><xhtml:span style="-aw-sdt-tag:'732-da0-de5-bf5-8dbb'; font-family: 'Times New Roman'"><xhtml:span>579,711</xhtml:span></xhtml:span><xhtml:span style="font-family: 'Times New Roman';"> Pre-Funded Warrants issued September 2024 that do not have a contractual expiration date, (ii) </xhtml:span><xhtml:span style="-aw-sdt-tag:'f2c-5f7-8bf-af8-594f'; font-family: 'Times New Roman'"><xhtml:span>43,479</xhtml:span></xhtml:span><xhtml:span style="font-family: 'Times New Roman';"> September 2024 Agent Warrants and </xhtml:span><xhtml:span style="-aw-sdt-tag:'e8a-7d2-dd0-c63-800f'; font-family: 'Times New Roman'"><xhtml:span>579,711</xhtml:span></xhtml:span><xhtml:span style="font-family: 'Times New Roman';"> Series A Warrants issued September 2024 that expire </xhtml:span><xhtml:span style="-aw-sdt-tag:'316-f81-d28-80c-a600'; font-family: 'Times New Roman'"><xhtml:span>five years</xhtml:span></xhtml:span><xhtml:span style="font-family: 'Times New Roman';"> from the Stockholder Approval Date, defined above, and (iii) </xhtml:span><xhtml:span style="-aw-sdt-tag:'051-85c-a14-d67-3f56'; font-family: 'Times New Roman'"><xhtml:span>579,711</xhtml:span></xhtml:span><xhtml:span style="font-family: 'Times New Roman';"> Series B Warrants issued September 2024 that expire </xhtml:span><xhtml:span style="-aw-sdt-tag:'5a3-db5-072-293-bc68'; font-family: 'Times New Roman'"><xhtml:span>eighteen months</xhtml:span></xhtml:span><xhtml:span style="font-family: 'Times New Roman';"> from the Stockholder Approval Date, which had not yet occurred as of September 30, 2024.</xhtml:span></xhtml:p></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tag216"
          xlink:to="footnote4"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tag215"
          xlink:label="Tag215"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tag215"
          xlink:to="footnote4"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tag217"
          xlink:label="Tag217"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tag217"
          xlink:to="footnote4"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tag231"
          xlink:label="Tag231"
          xlink:type="locator"/>
        <link:footnote id="footnote5" xlink:label="footnote5" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="-aw-sdt-tag:'f6b-c28-fc7-73a-bf3d'"><xhtml:p style="margin-top:0pt; margin-bottom:0pt; text-align:justify; font-size:10pt"><xhtml:span style="font-family: 'Times New Roman';">Weighted average remaining contractual life calculation excludes </xhtml:span><xhtml:span style="-aw-sdt-tag:'789-7d3-dde-216-e566'; font-family: 'Times New Roman'"><xhtml:span>579,711</xhtml:span></xhtml:span><xhtml:span style="font-family: 'Times New Roman';"> exercisable Pre-Funded Warrants issued September 2024 that do not have a contractual expiration date.</xhtml:span></xhtml:p></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tag231"
          xlink:to="footnote5"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tag230"
          xlink:label="Tag230"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tag230"
          xlink:to="footnote5"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tag229"
          xlink:label="Tag229"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tag229"
          xlink:to="footnote5"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
